

Adverse Renal Effects of Immune Checkpoint Inhibitors

American Journal of Nephrology

45, 160-169

DOI: [10.1159/000455014](https://doi.org/10.1159/000455014)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Facilitation of \hat{I}^2 Selection and Modification of Positive Selection in the Thymus of Pd-1â€“Deficient Mice. <i>Journal of Experimental Medicine</i> , 2000, 191, 891-898.	4.2	177
2	Regulatory function of in vivo anergized CD4+ T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 8738-8743.	3.3	60
3	Genetic remodeling of protein glycosylation in vivo induces autoimmune disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 1142-1147.	3.3	193
4	PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 13866-13871.	3.3	732
5	Genetic Modifiers of Systemic Lupus Erythematosus in FcÎ³RIIBâˆ“/âˆ“ Mice. <i>Journal of Experimental Medicine</i> , 2002, 195, 1167-1174.	4.2	238
6	Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 12293-12297.	3.3	2,563
7	Sustained Activation of Lyn Tyrosine Kinase In Vivo Leads to Autoimmunity. <i>Journal of Experimental Medicine</i> , 2002, 196, 1593-1604.	4.2	153
8	Susceptibility genes in the pathogenesis of murine lupus. <i>Arthritis Research</i> , 2002, 4, S255.	2.0	49
9	Interaction of B7RP-1 with ICOS negatively regulates antigen presentation by B cells. <i>Inflammation</i> , 2003, 27, 191-200.	1.7	3
10	Immunology of B7-H1 and Its Roles in Human Diseases. <i>International Journal of Hematology</i> , 2003, 78, 321-328.	0.7	34
11	B7-H1 pathway and its role in the evasion of tumor immunity. <i>Journal of Molecular Medicine</i> , 2003, 81, 281-287.	1.7	249
12	T-Helper Cell Tolerance to Ubiquitous Nuclear Antigens. <i>Scandinavian Journal of Immunology</i> , 2003, 58, 478-492.	1.3	6
13	B cell inhibitory receptors and autoimmunity. <i>Immunology</i> , 2003, 108, 263-273.	2.0	93
14	The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice. <i>Journal of Experimental Medicine</i> , 2003, 198, 63-69.	4.2	697
15	B7DC/PDL2 Promotes Tumor Immunity by a PD-1â€“independent Mechanism. <i>Journal of Experimental Medicine</i> , 2003, 197, 1721-1730.	4.2	130
16	A Role for Complement in Feedback Enhancement of Antibody Responses by IgG3. <i>Journal of Experimental Medicine</i> , 2003, 197, 1183-1190.	4.2	66
17	Molecular Modeling and Functional Mapping of B7-H1 and B7-DC Uncouple Costimulatory Function from PD-1 Interaction. <i>Journal of Experimental Medicine</i> , 2003, 197, 1083-1091.	4.2	259
18	PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 5336-5341.	3.3	536

#	ARTICLE	IF	CITATIONS
19	Costimulatory signals controlling regulatory T cells. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 15292-15293.	3.3	29
20	Cooperative B7-1/2 (CD80/CD86) and B7-DC Costimulation of CD4+ T Cells Independent of the PD-1 Receptor. Journal of Experimental Medicine, 2003, 198, 31-38.	4.2	144
21	Critical Role of the Programmed Death-1 (PD-1) Pathway in Regulation of Experimental Autoimmune Encephalomyelitis. Journal of Experimental Medicine, 2003, 198, 71-78.	4.2	461
22	PD-1 Inhibits Antiviral Immunity at the Effector Phase in the Liver. Journal of Experimental Medicine, 2003, 198, 39-50.	4.2	353
23	T Cell Costimulatory Molecules in Anti-Viral Immunity: Potential Role in Immunotherapeutic Vaccines. Canadian Journal of Infectious Diseases & Medical Microbiology, 2003, 14, 221-229.	0.3	5
24	Bruton's Tyrosine Kinase Is Essential for Human B Cell Tolerance. Journal of Experimental Medicine, 2004, 200, 927-934.	4.2	131
25	PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 10691-10696.	3.3	556
26	The candidate gene approach: have murine models informed the study of human SLE?. Clinical and Experimental Immunology, 2004, 137, 1-7.	1.1	12
27	Role of an intronic polymorphism in the PDCD1 gene with the risk of sporadic systemic lupus erythematosus and the occurrence of antiphospholipid antibodies. Human Genetics, 2004, 115, 393-8.	1.8	37
28	The role of ICOS and other costimulatory molecules in allergy and asthma. Seminars in Immunopathology, 2004, 25, 349-359.	4.0	53
29	Current advances in the human lupus genetics. Current Rheumatology Reports, 2004, 6, 391-398.	2.1	35
30	Immune Responses in Healthy and Allergic Individuals Are Characterized by a Fine Balance between Allergen-specific T Regulatory 1 and T Helper 2 Cells. Journal of Experimental Medicine, 2004, 199, 1567-1575.	4.2	960
31	A Deficiency in Drak2 Results in a T Cell Hypersensitivity and an Unexpected Resistance to Autoimmunity. Immunity, 2004, 21, 781-791.	6.6	67
32	Dendritic cell-mediated T cell polarization. Seminars in Immunopathology, 2005, 26, 289-307.	4.0	296
33	The balance of immune responses: costimulation verse coinhibition. Journal of Molecular Medicine, 2005, 83, 193-202.	1.7	69
34	T-helper cell intrinsic defects in lupus that break peripheral tolerance to nuclear autoantigens. Journal of Molecular Medicine, 2005, 83, 267-278.	1.7	30
35	Costimulation: critical pathways in the immunologic regulation of asthma. Current Allergy and Asthma Reports, 2005, 5, 149-154.	2.4	19
36	Bone marrow transplantation and approaches to avoid graft-versus-host disease (GVHD). Philosophical Transactions of the Royal Society B: Biological Sciences, 2005, 360, 1747-1767.	1.8	56

#	ARTICLE	IF	CITATIONS
37	Microglial Expression of the B7 Family Member B7 Homolog 1 Confers Strong Immune Inhibition: Implications for Immune Responses and Autoimmunity in the CNS. <i>Journal of Neuroscience</i> , 2005, 25, 2537-2546.	1.7	150
38	Establishment of NOD-Pdcd1 ^{-/-} mice as an efficient animal model of type I diabetes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 11823-11828.	3.3	380
39	Programmed Death-1 (PD-1):PD-Ligand 1 Interactions Inhibit TCR-Mediated Positive Selection of Thymocytes. <i>Journal of Immunology</i> , 2005, 175, 7372-7379.	0.4	122
40	Hydronephrosis associated with antiurothelial and antinuclear autoantibodies in BALB/c-Fcgr2b ^{+/+} /Pdcd1 ^{+/+} mice. <i>Journal of Experimental Medicine</i> , 2005, 202, 1643-1648.	4.2	47
41	Association of the programmed cell death 1 (PDCD1) gene polymorphism with ankylosing spondylitis in the Korean population. <i>Arthritis Research and Therapy</i> , 2006, 8, R163.	1.6	70
42	Checkpoint Blockade in Cancer Immunotherapy. <i>Advances in Immunology</i> , 2006, 90, 297-339.	1.1	498
43	Mechanisms of immune suppression by interleukin-10 and transforming growth factor-beta: the role of T regulatory cells. <i>Immunology</i> , 2006, 117, 433-442.	2.0	594
44	Activating and inhibitory Fcγ3Rs in autoimmune disorders. <i>Seminars in Immunopathology</i> , 2006, 28, 305-319.	4.0	53
45	Programmed Death-1 Gene Polymorphisms in Patients With Systemic Lupus Erythematosus in Taiwan. <i>Journal of Clinical Immunology</i> , 2006, 26, 506-511.	2.0	49
46	Modification of accessory molecule signaling. <i>Seminars in Immunopathology</i> , 2006, 27, 409-424.	4.0	31
47	Genetics of SLE in mice. <i>Seminars in Immunopathology</i> , 2006, 28, 83-96.	4.0	76
48	The genetics of systemic lupus erythematosus: understanding how SNPs confer disease susceptibility. <i>Seminars in Immunopathology</i> , 2006, 28, 109-117.	4.0	12
49	Unraveling the genetics of systemic lupus erythematosus. <i>Seminars in Immunopathology</i> , 2006, 28, 119-130.	4.0	127
50	Physiologic regulation of central and peripheral T cell tolerance: lessons for therapeutic applications. <i>Journal of Molecular Medicine</i> , 2006, 84, 887-899.	1.7	24
51	Putting T cells to sleep: A new paradigm for immune evasion by persistent viruses. <i>Journal of Biosciences</i> , 2006, 31, 497-501.	0.5	2
52	Generation and Characterization of B7-H4/B7S1/B7x-Deficient Mice. <i>Molecular and Cellular Biology</i> , 2006, 26, 6403-6411.	1.1	72
53	Regulation of T cell activation and tolerance by PDL2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 11695-11700.	3.3	151
54	BTNL2, a Butyrophilin-Like Molecule That Functions to Inhibit T Cell Activation. <i>Journal of Immunology</i> , 2006, 176, 7354-7360.	0.4	168

#	ARTICLE	IF	CITATIONS
55	Insulin-induced remission in new-onset NOD mice is maintained by the PD-1/PD-L1 pathway. <i>Journal of Experimental Medicine</i> , 2006, 203, 2737-2747.	4.2	280
56	Programmed death-1 (PD-1) defines a transient and dysfunctional oligoclonal T cell population in acute homeostatic proliferation. <i>Journal of Experimental Medicine</i> , 2007, 204, 2321-2333.	4.2	57
58	Distinct Cytokine-Driven Responses of Activated Blood β^1 T Cells: Insights into Unconventional T Cell Pleiotropy. <i>Journal of Immunology</i> , 2007, 178, 4304-4314.	0.4	128
59	Targeting Human β^1 T Cells with Zoledronate and Interleukin-2 for Immunotherapy of Hormone-Refractory Prostate Cancer. <i>Cancer Research</i> , 2007, 67, 7450-7457.	0.4	443
60	<i>In vivo</i> imaging of T cell delivery to tumors after adoptive transfer therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 12457-12461.	3.3	113
61	Molecular basis for checkpoints in the CD8 T cell response: Tolerance versus activation. <i>Seminars in Immunology</i> , 2007, 19, 153-161.	2.7	38
62	Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. <i>Journal of Clinical Investigation</i> , 2007, 117, 2570-2582.	3.9	698
63	Immunosuppressive Strategies that are Mediated by Tumor Cells. <i>Annual Review of Immunology</i> , 2007, 25, 267-296.	9.5	1,466
64	Impairment of organ-specific T cell negative selection by diabetes susceptibility genes: genomic analysis by mRNA profiling. <i>Genome Biology</i> , 2007, 8, R12.	13.9	37
65	Current state of immunotherapy for non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2007, 6, 196-211.	1.3	150
66	Immunotherapy and radiation therapy for operable early stage and locally advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2007, 6, 178-185.	1.3	21
67	Immune surveillance of tumors. <i>Journal of Clinical Investigation</i> , 2007, 117, 1137-1146.	3.9	1,198
68	Clinical experiences of combining immunotherapy and radiation therapy in non-small cell lung cancer: lessons from melanoma. <i>Translational Lung Cancer Research</i> , 2007, 6, 169-177.	1.3	4
69	Combining immunotherapy and radiation therapy for small cell lung cancer and thymic tumors. <i>Translational Lung Cancer Research</i> , 2007, 6, 186-195.	1.3	13
70	Mini-review of conventional and hypofractionated radiation therapy combined with immunotherapy for non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2007, 6, 220-229.	1.3	10
71	Preclinical rationale for combining radiation therapy and immunotherapy beyond checkpoint inhibitors (i.e., CART). <i>Translational Lung Cancer Research</i> , 2007, 6, 159-168.	1.3	32
72	Immunotherapy and radiation therapy for malignant pleural mesothelioma. <i>Translational Lung Cancer Research</i> , 2007, 6, 212-219.	1.3	31
73	Integrating immunotherapy into chemoradiation regimens for medically inoperable locally advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2007, 6, 113-118.	1.3	13

#	ARTICLE	IF	CITATIONS
74	Special topics in immunotherapy and radiation therapy: reirradiation and palliation. <i>Translational Lung Cancer Research</i> , 2007, 6, 119-130.	1.3	11
75	Association of PDCD1 genetic variation with risk and clinical manifestations of systemic lupus erythematosus in a multiethnic cohort. <i>Genes and Immunity</i> , 2007, 8, 279-287.	2.2	76
76	Interleukin-12- and interferon- γ -mediated natural killer cell activation by <i>Agaricus blazei</i> Murill. <i>Immunology</i> , 2007, 121, 197-206.	2.0	54
77	<i>Salmonella typhimurium</i> stimulation combined with tumour-derived heat shock proteins induces potent dendritic cell anti-tumour responses in a murine model. <i>Clinical and Experimental Immunology</i> , 2007, 149, 109-116.	1.1	16
78	Inhibitory costimulation and anti-tumor immunity. <i>Seminars in Cancer Biology</i> , 2007, 17, 288-298.	4.3	27
79	Potent Systemic Antitumor Immunity Induced by Vaccination with Chemotactic-Prostate Tumor Associated Antigen Gene-Modified Tumor Cell and Blockade of B7-H1. <i>Journal of Clinical Immunology</i> , 2007, 27, 117-130.	2.0	12
80	Polymorphisms of Genes for Programmed Cell Death 1 Ligands in Patients with Rheumatoid Arthritis. <i>Journal of Clinical Immunology</i> , 2007, 27, 563-567.	2.0	15
81	PD-1 gene haplotype is associated with the development of type 1 diabetes mellitus in Japanese children. <i>Human Genetics</i> , 2007, 121, 223-232.	1.8	63
82	Failure to confirm association between PDCD1 polymorphisms and rheumatoid arthritis in a Japanese population. <i>Journal of Human Genetics</i> , 2007, 52, 557-560.	1.1	27
83	Non-steroidal anti-inflammatory drugs-associated acute interstitial nephritis with granular tubular basement membrane deposits. <i>Pediatric Nephrology</i> , 2008, 23, 145-148.	0.9	17
84	Immunity, ageing and cancer. <i>Immunity and Ageing</i> , 2008, 5, 11.	1.8	131
85	PD-1 ligands expressed on myeloid-derived APC in the CNS regulate T cell responses in EAE. <i>European Journal of Immunology</i> , 2008, 38, 2706-2717.	1.6	103
86	The tumor microenvironment and its role in promoting tumor growth. <i>Oncogene</i> , 2008, 27, 5904-5912.	2.6	1,869
87	Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. <i>Nature Medicine</i> , 2008, 14, 1264-1270.	15.2	1,063
88	Special regulatory T cell review: The resurgence of the concept of contrasuppression in immunoregulation. <i>Immunology</i> , 2008, 123, 40-44.	2.0	68
89	NFATc1 Regulates PD-1 Expression upon T Cell Activation. <i>Journal of Immunology</i> , 2008, 181, 4832-4839.	0.4	311
90	Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 652-656.	3.3	270
91	Sunlight Triggers Cutaneous Lupus through a CSF-1-Dependent Mechanism in MRL- <i>lpr</i> Mice. <i>Journal of Immunology</i> , 2008, 181, 7367-7379.	0.4	60

#	ARTICLE	IF	CITATIONS
92	Intrarenal Antigens Activate CD4+ Cells via Co-stimulatory Signals from Dendritic Cells. <i>Journal of the American Society of Nephrology: JASN</i> , 2008, 19, 515-526.	3.0	28
93	Tumorigenesis and anti-tumor immune responses in <i>Xenopus</i> . <i>Frontiers in Bioscience - Landmark</i> , 2009, Volume, 167.	3.0	35
94	Dysregulation of CD8+ lymphocyte apoptosis, chronic disease, and immune regulation. <i>Frontiers in Bioscience - Landmark</i> , 2009, Volume, 3771.	3.0	55
95	The Addition of Tumor Necrosis Factor plus Beta Interferon Induces a Novel Synergistic Antiviral State against Poxviruses in Primary Human Fibroblasts. <i>Journal of Virology</i> , 2009, 83, 498-511.	1.5	77
96	Does chemotherapy modify the immune surveillance of hematological malignancies?. <i>Leukemia</i> , 2009, 23, 53-58.	3.3	39
97	Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates. <i>Journal of Clinical Oncology</i> , 2010, 28, 3167-3175.	0.8	2,667
98	Bridging Innate and Adaptive Antitumor Immunity Targeting Glycans. <i>Journal of Biomedicine and Biotechnology</i> , 2010, 2010, 1-19.	3.0	17
99	Tumor immunogenicity and responsiveness to cancer vaccine therapy: The state of the art. <i>Seminars in Immunology</i> , 2010, 22, 105-112.	2.7	44
100	Immunotherapy for Metastatic Solid Cancers. <i>Advances in Surgery</i> , 2011, 45, 341-360.	0.6	71
101	The role of co-inhibitory signals in spontaneous tolerance of weakly mismatched transplants. <i>Immunobiology</i> , 2011, 216, 918-924.	0.8	15
102	Costimulatory pathways in transplantation. <i>Seminars in Immunology</i> , 2011, 23, 293-303.	2.7	80
103	Targeting Lentiviral Vectors for Cancer Immunotherapy. <i>Current Cancer Therapy Reviews</i> , 2011, 7, 248-260.	0.2	13
104	Shifting the equilibrium in cancer immunoeediting: from tumor tolerance to eradication. <i>Immunological Reviews</i> , 2011, 241, 104-118.	2.8	229
105	Contribution of the immune system to the chemotherapeutic response. <i>Seminars in Immunopathology</i> , 2011, 33, 353-367.	2.8	30
106	A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. <i>EMBO Journal</i> , 2012, 31, 1062-1079.	3.5	641
107	Role of the PD-1 Pathway in the Immune Response. <i>American Journal of Transplantation</i> , 2012, 12, 2575-2587.	2.6	348
108	Immune response in melanoma: an in-depth analysis of the primary tumor and corresponding sentinel lymph node. <i>Modern Pathology</i> , 2012, 25, 1000-1010.	2.9	61
109	Novel Immunotherapies in GU Malignancies. <i>Current Oncology Reports</i> , 2013, 15, 224-231.	1.8	5

#	ARTICLE	IF	CITATIONS
110	Complement inhibition in cancer therapy. <i>Seminars in Immunology</i> , 2013, 25, 54-64.	2.7	121
111	Metastatic melanoma: New paradigms of treatment and new toxicities. <i>European Journal of Cancer, Supplement</i> , 2013, 11, 278-280.	2.2	1
112	Immunotherapy of melanoma. <i>European Journal of Cancer, Supplement</i> , 2013, 11, 97-105.	2.2	53
113	Challenges and approaches for the development of safer immunomodulatory biologics. <i>Nature Reviews Drug Discovery</i> , 2013, 12, 306-324.	21.5	138
114	PD-L2 modulates asthma severity by directly decreasing dendritic cell IL-12 production. <i>Mucosal Immunology</i> , 2013, 6, 728-739.	2.7	40
115	Beneficial and Detrimental Roles of NLRs in Carcinogenesis. <i>Frontiers in Immunology</i> , 2013, 4, 370.	2.2	53
116	Emerging treatments in management of prostate cancer: biomarker validation and endpoints for immunotherapy clinical trial design. <i>ImmunoTargets and Therapy</i> , 2013, 3, 1.	2.7	4
117	Rapamycin Augments Human DC IL-12p70 and IL-27 Secretion to Promote Allogeneic Type1 Polarization Modulated by NK Cells. <i>American Journal of Transplantation</i> , 2013, 13, 2322-2333.	2.6	33
118	The delicate balance of melanoma immunotherapy. <i>Clinical and Translational Immunology</i> , 2013, 2, e5.	1.7	22
119	Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer. <i>British Journal of Cancer</i> , 2013, 108, 1560-1565.	2.9	139
120	Update on the challenges and recent advances in cancer immunotherapy. <i>ImmunoTargets and Therapy</i> , 2013, 2, 39.	2.7	8
121	T cell immunoglobulin domain and mucin domain-3 as an emerging target for immunotherapy in cancer management. <i>ImmunoTargets and Therapy</i> , 2013, 2, 135.	2.7	5
122	The role of natural killer cells in pulmonary immunosurveillance. <i>Frontiers in Bioscience - Scholar</i> , 2013, S5, 575-587.	0.8	21
123	Therapeutic cancer vaccines and combination immunotherapies involving vaccination. <i>ImmunoTargets and Therapy</i> , 2014, 3, 135.	2.7	9
124	Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway. <i>Pharmacogenomics and Personalized Medicine</i> , 2014, 7, 357.	0.4	60
125	Targeting the NFκB Signaling Pathways for Breast Cancer Prevention and Therapy. <i>Current Medicinal Chemistry</i> , 2014, 22, 264-289.	1.2	178
126	Malignant Melanoma. <i>Healthcare (Switzerland)</i> , 2014, 2, 1-19.	1.0	39
127	Regulation of T-cell Tolerance by Lymphatic Endothelial Cells. <i>Journal of Clinical & Cellular Immunology</i> , 2014, 05, .	1.5	40

#	ARTICLE	IF	CITATIONS
128	The CD28-B7 Family in Anti-Tumor Immunity: Emerging Concepts in Cancer Immunotherapy. <i>Immune Network</i> , 2014, 14, 265.	1.6	78
129	Classification of current anticancer immunotherapies. <i>Oncotarget</i> , 2014, 5, 12472-12508.	0.8	395
130	Emerging options for the treatment of melanoma – focus on ipilimumab. <i>ImmunoTargets and Therapy</i> , 2014, 3, 67.	2.7	2
131	Victory and Defeat in the Induction of a Therapeutic Response through Vaccine Therapy for Human and Canine Brain Tumors: A Review of the State of the Art. <i>Critical Reviews in Immunology</i> , 2014, 34, 399-432.	1.0	13
132	Awareness and understanding of cancer immunotherapy in Europe. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 1828-1835.	1.4	6
133	Adding fuel to the fire: Immunogenic intensification. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 3306-3312.	1.4	4
134	PD-1 and PD-L1 antibodies for melanoma. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 3111-3116.	1.4	54
135	Biomarkers in melanoma: where are we now?. <i>Melanoma Management</i> , 2014, 1, 139-150.	0.1	1
136	Economic evaluation of therapeutic cancer vaccines and immunotherapy: A systematic review. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 3415-3424.	1.4	39
137	MÃ©nage Ã trois. <i>Oncolmmunology</i> , 2014, 3, e28927.	2.1	7
138	Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome. , 2014, 2, 40.		50
139	New antibody approaches to lymphoma therapy. <i>Journal of Hematology and Oncology</i> , 2014, 7, 58.	6.9	50
140	Intratumoral anti-HuD immunotoxin therapy for small cell lung cancer and neuroblastoma. <i>Journal of Hematology and Oncology</i> , 2014, 7, 91.	6.9	22
141	Immune checkpoint receptors in regulating immune reactivity in rheumatic disease. <i>Arthritis Research and Therapy</i> , 2014, 16, 469.	1.6	55
143	Functional expression cloning identifies COX-2 as a suppressor of antigen-specific cancer immunity. <i>Cell Death and Disease</i> , 2014, 5, e1568-e1568.	2.7	42
144	Exploiting Synergy: Immune-Based Combinations in the Treatment of Prostate Cancer. <i>Frontiers in Oncology</i> , 2014, 4, 351.	1.3	15
145	The inducible caspase-9 suicide gene system as a Ã¢â¬Åsafety switchÃ¢â¬Åto limit on-target, off-tumor toxicities of chimeric antigen receptor T cells. <i>Frontiers in Pharmacology</i> , 2014, 5, 235.	1.6	280
146	Is vaccine research still relevant for metastatic melanoma?. <i>Melanoma Management</i> , 2014, 1, 91-94.	0.1	5

#	ARTICLE	IF	CITATIONS
147	Immunotherapy for Lung Cancer: Has it Finally Arrived?. <i>Frontiers in Oncology</i> , 2014, 4, 288.	1.3	32
148	Melanoma stem cells and metastasis: mimicking hematopoietic cell trafficking?. <i>Laboratory Investigation</i> , 2014, 94, 13-30.	1.7	63
149	Tumor-Infiltrating T Lymphocytes: Pathogenic Role, Clinical Significance, and Differential Programming in the Tumor Microenvironment. <i>Frontiers in Immunology</i> , 2014, 5, 607.	2.2	89
150	Evolving toward a human-cell based and multiscale approach to drug discovery for CNS disorders. <i>Frontiers in Pharmacology</i> , 2014, 5, 252.	1.6	34
151	High-risk cutaneous melanoma follow-up: time for more intensive surveillance?. <i>Melanoma Management</i> , 2014, 1, 7-10.	0.1	1
153	Does vaccine-primed pancreatic cancer offer better candidates for immune-based therapies?. <i>Immunotherapy</i> , 2014, 6, 1017-1020.	1.0	10
154	To affinity and beyond: Harnessing the T Cell receptor for cancer immunotherapy. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 3313-3321.	1.4	29
155	Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma. <i>New England Journal of Medicine</i> , 2014, 371, 2189-2199.	13.9	3,753
156	Universes Collide: Combining Immunotherapy with Targeted Therapy for Cancer. <i>Cancer Discovery</i> , 2014, 4, 1377-1386.	7.7	76
157	PD-1 blockade induces responses by inhibiting adaptive immune resistance. <i>Nature</i> , 2014, 515, 568-571.	13.7	5,429
158	Antitumour immunity gets a boost. <i>Nature</i> , 2014, 515, 496-498.	13.7	90
159	Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. <i>Nature</i> , 2014, 515, 577-581.	13.7	1,705
160	The Immunological Synapse. <i>Cancer Immunology Research</i> , 2014, 2, 1023-1033.	1.6	330
161	Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies. <i>Annals of Oncology</i> , 2014, 25, 2277-2284.	0.6	119
162	PD-1 Blockade in Renal Cell Carcinoma: To Equilibrium and Beyond. <i>Cancer Immunology Research</i> , 2014, 2, 1132-1141.	1.6	42
163	Harnessing the PD-1 Pathway in Renal Cell Carcinoma: Current Evidence and Future Directions. <i>BioDrugs</i> , 2014, 28, 513-526.	2.2	7
164	Partial hepatectomy for primary hepatic melanoma: a report of two cases and review of the literature. <i>World Journal of Surgical Oncology</i> , 2014, 12, 362.	0.8	7
165	Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine. <i>Journal of Translational Medicine</i> , 2014, 12, 294.	1.8	144

#	ARTICLE	IF	CITATIONS
166	Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade. , 2014, 2, 42.		186
167	Potential for immunotherapy in soft tissue sarcoma. Human Vaccines and Immunotherapeutics, 2014, 10, 3117-3124.	1.4	26
168	The hepatitis B virus-associated tumor microenvironment in hepatocellular carcinoma. National Science Review, 2014, 1, 396-412.	4.6	72
169	Where to start with systemic melanoma therapy?. Melanoma Management, 2014, 1, 15-18.	0.1	0
170	Drug development: A chance of survival. Nature, 2014, 515, S118-S120.	13.7	8
171	Evaluating biomarkers in melanoma. Frontiers in Oncology, 2014, 4, 383.	1.3	38
172	A Role for Naturally Occurring Alleles of Endoplasmic Reticulum Aminopeptidases in Tumor Immunity and Cancer Pre-Disposition. Frontiers in Oncology, 2014, 4, 363.	1.3	56
173	Immunotherapy of hepatocellular carcinoma. Hepatic Oncology, 2014, 1, 433-446.	4.2	5
174	Inflammasomes in cancer: a double-edged sword. Protein and Cell, 2014, 5, 12-20.	4.8	221
175	Improved mouse models to assess tumour immunity and irAEs after combination cancer immunotherapies. Clinical and Translational Immunology, 2014, 3, e22.	1.7	64
176	Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia. Cancer Cell, 2014, 26, 605-622.	7.7	1,184
177	The melanoma revolution: From UV carcinogenesis to a new era in therapeutics. Science, 2014, 346, 945-949.	6.0	328
178	Immune approaches to the treatment of breast cancer, around the corner?. Breast Cancer Research, 2014, 16, 204.	2.2	38
179	Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors. Clinical Cancer Research, 2014, 20, 5290-5301.	3.2	500
180	Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab. Journal of Clinical Oncology, 2014, 32, 1020-1030.	0.8	2,015
181	Cancer immunotherapy: nanodelivery approaches for immune cell targeting and tracking. Frontiers in Chemistry, 2014, 2, 105.	1.8	147
182	The role of chemotherapy in the modern management of melanoma. Melanoma Management, 2014, 1, 173-184.	0.1	8
183	Potential of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer. Molecular Therapy - Oncolytics, 2014, 1, 14004.	2.0	33

#	ARTICLE	IF	CITATIONS
184	Antimelanoma CTL recognizes peptides derived from an ORF transcribed from the antisense strand of the 3' untranslated region of TRIT1. <i>Molecular Therapy - Oncolytics</i> , 2014, 1, 14009.	2.0	2
185	Combination therapies in advanced melanoma. <i>Melanoma Management</i> , 2014, 1, 47-56.	0.1	2
186	How anti-PD1 treatments are changing the management of melanoma. <i>Melanoma Management</i> , 2014, 1, 165-172.	0.1	5
187	Development of an Automated PD-L1 Immunohistochemistry (IHC) Assay for Non-Small Cell Lung Cancer. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2015, 23, 541-549.	0.6	171
188	Genetic Evidence for XPC-KRAS Interactions During Lung Cancer Development. <i>Journal of Genetics and Genomics</i> , 2015, 42, 589-596.	1.7	8
189	Long-term drug costs per life-month gained associated with first-line treatments for unresectable or metastatic melanoma. <i>Experimental Hematology and Oncology</i> , 2015, 5, 9.	2.0	1
190	Targeting immune checkpoints in melanoma: an update. <i>Melanoma Management</i> , 2015, 2, 339-352.	0.1	2
191	Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer. <i>Journal of Translational Medicine</i> , 2015, 13, 277.	1.8	186
192	Immune checkpoints: Cytotoxic T-lymphocyte antigen 4 and programmed cell death protein 1 in breast cancer surgery. <i>Oncology Letters</i> , 2015, 10, 1079-1086.	0.8	14
193	Combination immunotherapy with anti-CTLA-4 and anti-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma. <i>Journal of Translational Medicine</i> , 2015, 3, 21.		157
194	Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting. <i>Journal of Translational Medicine</i> , 2015, 13, 214.	1.8	84
195	Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes. <i>International Journal of Oncology</i> , 2015, 46, 28-36.	1.4	69
196	Treatment options for metastatic melanoma in solid organ transplant recipients. <i>JAAD Case Reports</i> , 2015, 1, S26-S28.	0.4	1
197	A phase II, multicenter, open-label study of sepantronium bromide (YM155) plus docetaxel in patients with stage III (unresectable) or stage IV melanoma. <i>Cancer Medicine</i> , 2015, 4, 643-650.	1.3	36
198	Cancer immunotherapy using novel tumor-associated antigenic peptides identified by genome-wide cDNA microarray analyses. <i>Cancer Science</i> , 2015, 106, 505-511.	1.7	40
199	Low programmed cell death-1 (PD-1) expression in peripheral CD4 ⁺ T cells in Japanese patients with autoimmune type 1 diabetes. <i>Clinical and Experimental Immunology</i> , 2015, 180, 452-457.	1.1	88
200	New clinical advances in immunotherapy for the treatment of solid tumours. <i>Immunology</i> , 2015, 145, 182-201.	2.0	35
201	Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy. <i>Cancer Science</i> , 2015, 106, 945-950.	1.7	78

#	ARTICLE	IF	CITATIONS
202	Contribution of dendritic cells to the autoimmune pathology of systemic lupus erythematosus. <i>Immunology</i> , 2015, 146, 497-507.	2.0	31
203	Long-term Outcomes of Helper Peptide Vaccination for Metastatic Melanoma. <i>Annals of Surgery</i> , 2015, 262, 456-464.	2.1	26
204	Elucidation of the molecular mechanisms underlying adverse reactions associated with a kinase inhibitor using systems toxicology. <i>Npj Systems Biology and Applications</i> , 2015, 1, 15005.	1.4	16
205	Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer. <i>Scientific Reports</i> , 2015, 5, 13110.	1.6	310
206	Development of 1-N-11C-Methyl-L- and -d-Tryptophan for pharmacokinetic imaging of the immune checkpoint inhibitor 1-Methyl-Tryptophan. <i>Scientific Reports</i> , 2015, 5, 16417.	1.6	15
207	Non-Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy. <i>Journal of Thoracic Oncology</i> , 2015, 10, 974-984.	0.5	127
208	Immune Checkpoint Blockade in Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2015, 4, 201-207.	4.2	40
209	A high-throughput RNAi screen for detection of immune checkpoint molecules that mediate tumor resistance to cytotoxic T lymphocytes. <i>EMBO Molecular Medicine</i> , 2015, 7, 450-463.	3.3	39
210	A novel IgM-H-Ficolin complement pathway to attack allogenic cancer cells in vitro. <i>Scientific Reports</i> , 2015, 5, 7824.	1.6	19
211	Network analysis of immunotherapy-induced regressing tumours identifies novel synergistic drug combinations. <i>Scientific Reports</i> , 2015, 5, 12298.	1.6	63
212	Molecular profiling of CD8 T cells in autochthonous melanoma identifies Maf as driver of exhaustion. <i>EMBO Journal</i> , 2015, 34, 2042-2058.	3.5	100
213	Oncolysis by paramyxoviruses: preclinical and clinical studies. <i>Molecular Therapy - Oncolytics</i> , 2015, 2, 15017.	2.0	33
214	FGFR1 inhibition in lung squamous cell carcinoma: questions and controversies. <i>Cell Death Discovery</i> , 2015, 1, 15049.	2.0	37
215	The wound inflammatory response exacerbates growth of pre-neoplastic cells and progression to cancer. <i>EMBO Journal</i> , 2015, 34, 2219-2236.	3.5	210
216	A Perspective of Immunotherapy for Breast Cancer: Lessons Learned and Forward Directions for All Cancers. <i>Breast Cancer: Basic and Clinical Research</i> , 2015, 9s2, BCBCR.S29425.	0.6	4
217	Human Cancer Immunotherapy with PD-1/PD-L1 Blockade. <i>Biomarkers in Cancer</i> , 2015, 7s2, BIC.S29325.	3.6	51
218	Current State of Animal (Mouse) Modeling in Melanoma Research. <i>Cancer Growth and Metastasis</i> , 2015, 8s1, CGM.S21214.	3.5	74
219	Current and Emerging Therapies for Bone Metastatic Castration-Resistant Prostate Cancer. <i>Cancer Control</i> , 2015, 22, 109-120.	0.7	41

#	ARTICLE	IF	CITATIONS
220	Novel melanoma therapy. <i>Experimental Hematology and Oncology</i> , 2015, 5, 23.	2.0	8
221	Tracheal squamous cell carcinoma (SCC) metastatic to the skin in a patient on a checkpoint inhibitor. <i>JAAD Case Reports</i> , 2015, 1, 308-309.	0.4	0
223	SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015. <i>Clinical and Translational Oncology</i> , 2015, 17, 1020-1029.	1.2	43
224	Tumor associated PD-L1 expression pattern in microscopically tumor positive sentinel lymph nodes in patients with melanoma. <i>Journal of Translational Medicine</i> , 2015, 13, 319.	1.8	27
225	Nivolumab plus ipilimumab in the treatment of advanced melanoma. <i>Journal of Hematology and Oncology</i> , 2015, 8, 123.	6.9	42
226	NK cells and CD8+ T cells cooperate to improve therapeutic responses in melanoma treated with interleukin-2 (IL-2) and CTLA-4 blockade. , 2015, 3, 18.		51
227	Enhancing the discovery and development of immunotherapies for cancer using quantitative and systems pharmacology: Interleukin-12 as a case study. , 2015, 3, 27.		17
228	Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what's new and what's enough. <i>Chinese Journal of Cancer</i> , 2015, 34, 310-9.	4.9	13
229	Primary pulmonary melanoma: a report of two cases. <i>World Journal of Surgical Oncology</i> , 2015, 13, 274.	0.8	9
230	JITC launches a new section: commentary and editorials. , 2015, 3, 28.		0
231	Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy. <i>The Cochrane Library</i> , 2015, 2015, CD010341.	1.5	32
232	Ipilimumab for the treatment of melanoma. <i>Melanoma Management</i> , 2015, 2, 33-39.	0.1	2
233	From personalized to patient-specific treatment of metastatic melanoma. <i>Melanoma Management</i> , 2015, 2, 193-197.	0.1	0
234	Increased circulating follicular helper T cells with decreased programmed death-1 in chronic renal allograft rejection. <i>BMC Nephrology</i> , 2015, 16, 182.	0.8	36
236	DNA methylation subgroups in melanoma are associated with proliferative and immunological processes. <i>BMC Medical Genomics</i> , 2015, 8, 73.	0.7	29
237	What's new in melanoma? Combination!. <i>Journal of Translational Medicine</i> , 2015, 13, 213.	1.8	38
238	Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma. <i>Journal of Translational Medicine</i> , 2015, 13, 351.	1.8	56
240	Near complete response after single dose of nivolumab in patient with advanced heavily pre-treated KRAS mutant pulmonary adenocarcinoma. <i>Experimental Hematology and Oncology</i> , 2015, 4, 34.	2.0	21

#	ARTICLE	IF	CITATIONS
241	Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation. , 2015, 3, 22.		95
242	Update on checkpoint blockade therapy for lymphoma. , 2015, 3, 33.		11
243	Targeting the indoleamine 2,3-dioxygenase pathway in cancer. , 2015, 3, 51.		280
244	Inhibitory receptors as targets for cancer immunotherapy. European Journal of Immunology, 2015, 45, 1892-1905.	1.6	116
245	Converting biology into clinical benefit: lessons learned from BRAF inhibitors. Melanoma Management, 2015, 2, 241-254.	0.1	10
246	Immune Checkpoint Inhibitor Therapy Associated Hypophysitis. Clinical Medicine Insights: Endocrinology and Diabetes, 2015, 8, CMED.S22469.	1.0	38
247	Ad-REIC Gene Therapy: Promising Results in a Patient with Metastatic CRPC following Chemotherapy. Clinical Medicine Insights: Oncology, 2015, 9, CMO.S23252.	0.6	27
248	Pembrolizumab in the management of metastatic melanoma. Melanoma Management, 2015, 2, 315-325.	0.1	4
249	Report of ipilimumab in a heart transplant patient with metastatic melanoma on tacrolimus. Melanoma Management, 2015, 2, 311-314.	0.1	22
250	<scp>RAC</scp>1 P29S regulates <scp>PD</scp>â€1 expression in melanoma. Pigment Cell and Melanoma Research, 2015, 28, 590-598.	1.5	69
251	Liver resection and ablation for metastatic melanoma: A single center experience. Journal of Surgical Oncology, 2015, 111, 962-968.	0.8	19
252	The end of the beginning: PD-1 inhibition as the new standard of care first-line immunotherapy in metastatic melanoma. Melanoma Management, 2015, 2, 305-309.	0.1	1
253	Immunotherapies for bladder cancer. Current Opinion in Urology, 2015, 25, 586-596.	0.9	17
254	Myeloid Cells as Targets for Therapy in Solid Tumors. Cancer Journal (Sudbury, Mass), 2015, 21, 343-350.	1.0	32
255	Interleukin-7 and Antiâ€Programmed Cell Death 1 Antibody Have Differing Effects to Reverse Sepsis-Induced Immunosuppression. Shock, 2015, 43, 334-343.	1.0	71
256	The Evolution of Therapies in Non-Small Cell Lung Cancer. Cancers, 2015, 7, 1815-1846.	1.7	107
257	Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice. Oncotarget, 2015, 6, 34221-34227.	0.8	198
258	Increased Treatment-Related Toxicity Subsequent to an Antiâ€PD-1 Agent. Current Oncology, 2015, 22, 320-322.	0.9	6

#	ARTICLE	IF	CITATIONS
259	Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. <i>Journal of Clinical Investigation</i> , 2015, 125, 3384-3391.	3.9	1,112
260	Targeting PD-1/PD-L1 in lung cancer: current perspectives. <i>Lung Cancer: Targets and Therapy</i> , 2015, 6, 55.	1.3	10
261	Lymphoma: Immune Evasion Strategies. <i>Cancers</i> , 2015, 7, 736-762.	1.7	35
262	Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. <i>Oncotarget</i> , 2015, 6, 42008-42018.	0.8	278
263	Ipilimumab was safe and effective in two patients with metastatic melanoma and end-stage renal disease. <i>Cancer Management and Research</i> , 2015, 7, 47.	0.9	29
264	Long-term survival in advanced melanoma patients using repeated therapies: successive immunomodulation improving the odds?. <i>Cancer Management and Research</i> , 2015, 7, 93.	0.9	10
265	The Quantum of Initial Transformed Cells Potentially Modulates the Type of Local Inflammation Mechanism Elicited by Surrounding Normal Epithelial Tissues and Systemic Immune Pattern for Tumor Arrest or Progression. <i>Journal of Cancer</i> , 2015, 6, 128-138.	1.2	0
266	PLX4032 Mediated Melanoma Associated Antigen Potentiation in Patient Derived Primary Melanoma Cells. <i>Journal of Cancer</i> , 2015, 6, 1320-1330.	1.2	6
267	The distinctive nature of adenocarcinoma of the lung. <i>OncoTargets and Therapy</i> , 2015, 8, 2399.	1.0	16
268	Systemic Chemotherapy for Advanced Hepatocellular Carcinoma: Past, Present, and Future. <i>Diseases (Basel, Switzerland)</i> , 2015, 3, 360-381.	1.0	41
269	The role of mast cells in cancers. <i>F1000prime Reports</i> , 2015, 7, 09.	5.9	91
270	Cancer immunotherapy: harnessing the immune system to battle cancer. <i>Journal of Clinical Investigation</i> , 2015, 125, 3335-3337.	3.9	1,016
271	Nivolumab in the treatment of malignant melanoma: review of the literature. <i>OncoTargets and Therapy</i> , 2015, 8, 2045.	1.0	21
272	Epidemiology of Melanoma in the South of Brazil: study of a city in the Vale do Itajaí from 1999 to 2013. <i>Anais Brasileiros De Dermatologia</i> , 2015, 90, 185-189.	0.5	10
273	The expression status and prognostic significance of programmed cell death 1 ligand 1 in gastro-intestinal tract cancer: a systematic review and meta-analysis. <i>OncoTargets and Therapy</i> , 2015, 8, 2617.	1.0	28
274	CD28 co-stimulation in T-cell homeostasis: a recent perspective. <i>ImmunoTargets and Therapy</i> , 2015, 4, 111.	2.7	97
275	PD-1 blockade attenuates immunosuppressive myeloid cells due to inhibition of CD47/SIRP1 α axis in HPV negative head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2015, 6, 42067-42080.	0.8	95
276	Immunotherapy and Radiation – A New Combined Treatment Approach for Bladder Cancer?. <i>Bladder Cancer</i> , 2015, 1, 15-27.	0.2	19

#	ARTICLE	IF	CITATIONS
277	New developments in the management of advanced melanoma – role of pembrolizumab. <i>OncoTargets and Therapy</i> , 2015, 8, 2535.	1.0	16
278	Therapeutic cancer vaccines. <i>Journal of Clinical Investigation</i> , 2015, 125, 3401-3412.	3.9	640
279	Anti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic Approaches. <i>Cancers</i> , 2015, 7, 2397-2414.	1.7	61
280	Adenoid cystic carcinoma: current therapy and potential therapeutic advances based on genomic profiling. <i>Oncotarget</i> , 2015, 6, 37117-37134.	0.8	80
281	Drug Development for Metastasis Prevention. <i>Critical Reviews in Oncogenesis</i> , 2015, 20, 449-473.	0.2	48
282	Anti-HBV Drugs: Progress, Unmet Needs, and New Hope. <i>Viruses</i> , 2015, 7, 4960-4977.	1.5	38
283	Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?. <i>Viruses</i> , 2015, 7, 6291-6312.	1.5	48
284	Signaling Circuits and Regulation of Immune Suppression by Ovarian Tumor-Associated Macrophages. <i>Vaccines</i> , 2015, 3, 448-466.	2.1	19
285	The Promise of Preventive Cancer Vaccines. <i>Vaccines</i> , 2015, 3, 467-489.	2.1	38
286	Cancer Dormancy: A Regulatory Role for Endogenous Immunity in Establishing and Maintaining the Tumor Dormant State. <i>Vaccines</i> , 2015, 3, 597-619.	2.1	46
287	Dendritic Cell-Based Adjuvant Vaccination Targeting Wilmsâ€™ Tumor 1 in Patients with Advanced Colorectal Cancer. <i>Vaccines</i> , 2015, 3, 1004-1018.	2.1	34
288	Nanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and Immunotherapy. <i>Vaccines</i> , 2015, 3, 662-685.	2.1	225
289	Establishing the pig as a large animal model for vaccine development against human cancer. <i>Frontiers in Genetics</i> , 2015, 6, 286.	1.1	24
290	SOCS1 Mimetics and Antagonists: A Complementary Approach to Positive and Negative Regulation of Immune Function. <i>Frontiers in Immunology</i> , 2015, 6, 183.	2.2	65
291	Therapeutic Potential and Challenges of Natural Killer Cells in Treatment of Solid Tumors. <i>Frontiers in Immunology</i> , 2015, 6, 202.	2.2	130
292	Impaired T-Cell Function in B-Cell Lymphoma: A Direct Consequence of Events at the Immunological Synapse?. <i>Frontiers in Immunology</i> , 2015, 6, 258.	2.2	16
293	Inhibitory Receptors Beyond T Cell Exhaustion. <i>Frontiers in Immunology</i> , 2015, 6, 310.	2.2	188
294	Editorial: â€œCancer Immunotherapy: Lights and Shadowsâ€ Frontiers in Immunology, 2015, 6, 350.	2.2	2

#	ARTICLE	IF	CITATIONS
295	Prognostic and Predictive Value of DAMPs and DAMP-Associated Processes in Cancer. <i>Frontiers in Immunology</i> , 2015, 6, 402.	2.2	135
296	Targeting C-Type Lectin Receptors for Cancer Immunity. <i>Frontiers in Immunology</i> , 2015, 6, 408.	2.2	80
297	Beyond CTLA-4 and PD-1, the Generation Z of Negative Checkpoint Regulators. <i>Frontiers in Immunology</i> , 2015, 6, 418.	2.2	158
298	Novel Immune Check-Point Regulators in Tolerance Maintenance. <i>Frontiers in Immunology</i> , 2015, 6, 421.	2.2	37
299	Immune Reactivation by Cell-Free Fetal DNA in Healthy Pregnancies Re-Purposed to Target Tumors: Novel Checkpoint Inhibition in Cancer Therapeutics. <i>Frontiers in Immunology</i> , 2015, 6, 424.	2.2	12
300	Lymphoma Immunotherapy: Current Status. <i>Frontiers in Immunology</i> , 2015, 6, 448.	2.2	36
301	Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2015, 6, 516.	2.2	79
302	Identifying Individual T Cell Receptors of Optimal Avidity for Tumor Antigens. <i>Frontiers in Immunology</i> , 2015, 6, 582.	2.2	73
303	Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death. <i>Frontiers in Immunology</i> , 2015, 6, 588.	2.2	317
304	T Lymphocyte-Endothelial Interactions: Emerging Understanding of Trafficking and Antigen-Specific Immunity. <i>Frontiers in Immunology</i> , 2015, 6, 603.	2.2	156
305	The Role of Chemokines in Shaping the Balance Between CD4+ T Cell Subsets and Its Therapeutic Implications in Autoimmune and Cancer Diseases. <i>Frontiers in Immunology</i> , 2015, 6, 609.	2.2	46
306	Rapid Response of Advanced Squamous Non-Small Cell Lung Cancer with Thrombocytopenia after First-Line Treatment with Pembrolizumab Plus Autologous Cytokine-Induced Killer Cells. <i>Frontiers in Immunology</i> , 2015, 6, 633.	2.2	12
307	Melanoma: From Incurable Beast to a Curable Bet. The Success of Immunotherapy. <i>Frontiers in Oncology</i> , 2015, 5, 152.	1.3	26
308	Intracardiac Metastasis From Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2015, 5, 168.	1.3	3
309	Immunotherapy of Childhood Sarcomas. <i>Frontiers in Oncology</i> , 2015, 5, 181.	1.3	54
310	Editorial: Advances in Combination Tumor Immunotherapy. <i>Frontiers in Oncology</i> , 2015, 5, 198.	1.3	0
311	Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data. <i>Frontiers in Oncology</i> , 2015, 5, 202.	1.3	201
312	Resection Followed by Involved-Field Fractionated Radiotherapy in the Management of Single Brain Metastasis. <i>Frontiers in Oncology</i> , 2015, 5, 206.	1.3	13

#	ARTICLE	IF	CITATIONS
313	Using MRI to evaluate and predict therapeutic success from depot-based cancer vaccines. <i>Molecular Therapy - Methods and Clinical Development</i> , 2015, 2, 15048.	1.8	7
314	Dacomitinib in lung cancer: a “lost generation” EGFR tyrosine-kinase inhibitor from a bygone era?. <i>Drug Design, Development and Therapy</i> , 2015, 9, 5641.	2.0	24
315	Clinical applications of PD-1-based therapy: a focus on pembrolizumab (MK-3475) in the management of melanoma and other tumor types. <i>OncoTargets and Therapy</i> , 2015, 8, 929.	1.0	27
316	Crizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancer. <i>Drug Design, Development and Therapy</i> , 2015, 9, 5491.	2.0	1
317	Update on use of aldesleukin for treatment of high-risk metastatic melanoma. <i>ImmunoTargets and Therapy</i> , 2015, 4, 79.	2.7	21
318	Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors. <i>Viruses</i> , 2015, 7, 5889-5901.	1.5	19
319	Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma. <i>Oncotarget</i> , 2015, 6, 4704-4716.	0.8	127
320	TIGIT and PD-1 impair tumor antigen-specific CD8+ T cells in melanoma patients. <i>Journal of Clinical Investigation</i> , 2015, 125, 2046-2058.	3.9	603
321	Reinvigorating Exhausted T Cells by Blockade of the PD-1 Pathway. <i>Forum on Immunopathological Diseases and Therapeutics</i> , 2015, 6, 7-17.	0.1	82
322	Targeting Transcriptional Regulators of CD8+ T Cell Dysfunction to Boost Anti-Tumor Immunity. <i>Vaccines</i> , 2015, 3, 771-802.	2.1	11
323	Evolution of Gastric Cancer Treatment: From the Golden Age of Surgery to an Era of Precision Medicine. <i>Yonsei Medical Journal</i> , 2015, 56, 1177.	0.9	49
324	Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma. <i>PLoS ONE</i> , 2015, 10, e0118564.	1.1	197
325	An Exhaustion-Like Phenotype Constrains the Activity of CD4+ T Cells Specific for a Self and Melanoma Antigen. <i>PLoS ONE</i> , 2015, 10, e0123332.	1.1	10
326	Inducible but Not Constitutive Expression of PD-L1 in Human Melanoma Cells Is Dependent on Activation of NF- κ B. <i>PLoS ONE</i> , 2015, 10, e0123410.	1.1	181
327	Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers. <i>PLoS ONE</i> , 2015, 10, e0130142.	1.1	390
328	PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups. <i>PLoS ONE</i> , 2015, 10, e0136023.	1.1	202
329	PD-1 Blockade Can Restore Functions of T-Cells in Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma In Vitro. <i>PLoS ONE</i> , 2015, 10, e0136476.	1.1	59
330	Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?. <i>PLoS ONE</i> , 2015, 10, e0139438.	1.1	27

#	ARTICLE	IF	CITATIONS
331	PDL1 Expression on Plasma and Dendritic Cells in Myeloma Bone Marrow Suggests Benefit of Targeted anti PD1-PDL1 Therapy. PLoS ONE, 2015, 10, e0139867.	1.1	67
332	Novel Humoral Prognostic Markers in Small-Cell Lung Carcinoma: A Prospective Study. PLoS ONE, 2015, 10, e0143558.	1.1	28
333	TIGIT predominantly regulates the immune response via regulatory T cells. Journal of Clinical Investigation, 2015, 125, 4053-4062.	3.9	470
334	Enhancement of antibody-dependent cell mediated cytotoxicity: a new era in cancer treatment. ImmunoTargets and Therapy, 2015, 4, 91.	2.7	47
335	Molecular profiling in the treatment of colorectal cancer: focus on regorafenib. OncoTargets and Therapy, 2015, 8, 2949.	1.0	7
336	Bladder cancer in the elderly patient: challenges and solutions. Clinical Interventions in Aging, 2015, 10, 939.	1.3	44
337	Targeting the NLRP3 inflammasome in chronic inflammatory diseases: current perspectives. Journal of Inflammation Research, 2015, 8, 15.	1.6	263
338	Mechanistic insights into the oncolytic activity of vesicular stomatitis virus in cancer immunotherapy. Oncolytic Virotherapy, 2015, 4, 157.	6.0	14
339	Nanotechnology-Based Drug Delivery Systems for Melanoma Antitumoral Therapy: A Review. BioMed Research International, 2015, 2015, 1-22.	0.9	60
340	Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy. BioMed Research International, 2015, 2015, 1-16.	0.9	111
341	Analysis of the Intratumoral Adaptive Immune Response in Well Differentiated and Dedifferentiated Retroperitoneal Liposarcoma. Sarcoma, 2015, 2015, 1-9.	0.7	48
342	The Immune System in Hepatocellular Carcinoma and Potential New Immunotherapeutic Strategies. BioMed Research International, 2015, 2015, 1-12.	0.9	25
343	Immunotherapy for Bone and Soft Tissue Sarcomas. BioMed Research International, 2015, 2015, 1-11.	0.9	16
344	Bone-Immune Cell Crosstalk: Bone Diseases. Journal of Immunology Research, 2015, 2015, 1-11.	0.9	60
345	Immunosuppression and Multiple Primary Malignancies in Kidney-Transplanted Patients: A Single-Institute Study. BioMed Research International, 2015, 2015, 1-8.	0.9	20
346	Immunotherapy of Ovarian Cancer: The Role of Checkpoint Inhibitors. Journal of Immunology Research, 2015, 2015, 1-7.	0.9	49
347	Research Progress on Regulatory T Cells in Acute Kidney Injury. Journal of Immunology Research, 2015, 2015, 1-9.	0.9	11
348	Effect and Molecular Mechanisms of Traditional Chinese Medicine on Regulating Tumor Immunosuppressive Microenvironment. BioMed Research International, 2015, 2015, 1-12.	0.9	59

#	ARTICLE	IF	CITATIONS
349	Anticytotoxic T-Lymphocyte Antigen-4 Induced Autoimmune Hypophysitis: A Case Report and Literature Review. <i>Case Reports in Endocrinology</i> , 2015, 2015, 1-6.	0.2	7
350	Clinical Development of Immune Checkpoint Inhibitors. <i>BioMed Research International</i> , 2015, 2015, 1-12.	0.9	51
351	Immunotherapy in Metastatic Renal Cell Carcinoma: A Comprehensive Review. <i>BioMed Research International</i> , 2015, 2015, 1-8.	0.9	43
352	Immunotherapy in Tumors. <i>Deutsches A&#x0308;rztblatt International</i> , 2015, 112, 809-15.	0.6	31
353	Adverse Events of Monoclonal Antibodies Used for Cancer Therapy. <i>BioMed Research International</i> , 2015, 2015, 1-13.	0.9	59
354	Interferon- γ -Mediated Natural Killer Cell Activation by an Aqueous <i>Panax ginseng</i> Extract. <i>Evidence-based Complementary and Alternative Medicine</i> , 2015, 2015, 1-11.	0.5	13
355	RNA-Based Vaccines in Cancer Immunotherapy. <i>Journal of Immunology Research</i> , 2015, 2015, 1-9.	0.9	169
356	Human Tumor Antigens and Cancer Immunotherapy. <i>BioMed Research International</i> , 2015, 2015, 1-17.	0.9	173
357	Clinical Neuropathology mini-review 6-2015: PD-L1: emerging biomarker in glioblastoma?. , 2015, 34, 313-321.		31
358	Oncogenic cancer/testis antigens: prime candidates for immunotherapy. <i>Oncotarget</i> , 2015, 6, 15772-15787.	0.8	265
359	Programmed death-1/programmed death-L1 signaling pathway and its blockade in hepatitis C virus immunotherapy. <i>World Journal of Hepatology</i> , 2015, 7, 2449.	0.8	32
360	Targeted massively parallel sequencing of angiosarcomas reveals frequent activation of the mitogen activated protein kinase pathway. <i>Oncotarget</i> , 2015, 6, 36041-36052.	0.8	103
361	LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model. <i>Oncotarget</i> , 2015, 6, 27359-27377.	0.8	242
362	Histone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune Therapy. <i>Cancers</i> , 2015, 7, 1959-1982.	1.7	32
363	PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. <i>New England Journal of Medicine</i> , 2015, 372, 2509-2520.	13.9	7,696
364	Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2015, 373, 123-135.	13.9	7,261
365	Genetically engineered lymphocytes and adoptive cell therapy: cancer immunotherapy's smart bombs. <i>Cancer Gene Therapy</i> , 2015, 22, 63-63.	2.2	5
366	Myeloid-Derived Suppressor Cells Impair Alveolar Macrophages through PD-1 Receptor Ligation during <i>Pneumocystis Pneumonia</i> . <i>Infection and Immunity</i> , 2015, 83, 572-582.	1.0	37

#	ARTICLE	IF	CITATIONS
367	Bilateral Choroidopathy and Serous Retinal Detachments During Ipilimumab Treatment for Cutaneous Melanoma. <i>JAMA Ophthalmology</i> , 2015, 133, 965.	1.4	56
368	Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens. <i>Nature Reviews Drug Discovery</i> , 2015, 14, 487-498.	21.5	203
369	Rethinking Clinical Response and Outcome Assessment in a Biologic Age. <i>Current Oncology Reports</i> , 2015, 17, 27.	1.8	3
370	Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study. , 2015, 3, 3.		76
371	Monoclonal antibodies specific to human $\hat{I}^{*}42PD1$: A novel immunoregulator potentially involved in HIV-1 and tumor pathogenesis. <i>MAbs</i> , 2015, 7, 620-629.	2.6	6
372	Severe Acute Orthopnea: Ipilimumab-Induced Bilateral Phrenic Nerve Neuropathy. <i>Lung</i> , 2015, 193, 611-613.	1.4	16
373	Building better monoclonal antibody-based therapeutics. <i>Nature Reviews Cancer</i> , 2015, 15, 361-370.	12.8	558
374	Combinatorial Strategies for the Induction of Immunogenic Cell Death. <i>Frontiers in Immunology</i> , 2015, 6, 187.	2.2	289
375	Cutting Edge: PD-1 Regulates Imiquimod-Induced Psoriasiform Dermatitis through Inhibition of IL-17A Expression by Innate $\hat{I}^{*}1$ -Low T Cells. <i>Journal of Immunology</i> , 2015, 195, 421-425.	0.4	62
376	Programmed death-1 checkpoint blockade in acute myeloid leukemia. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 1191-1203.	1.4	75
377	PD-1/PD-L1 inhibitors. <i>Current Opinion in Pharmacology</i> , 2015, 23, 32-38.	1.7	483
378	Blinded by the light: why the treatment of metastatic melanoma has created a new paradigm for the management of cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2015, 7, 107-121.	1.4	8
379	Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen. <i>Cancer Immunology Research</i> , 2015, 3, 345-355.	1.6	520
380	Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. <i>New England Journal of Medicine</i> , 2015, 373, 23-34.	13.9	6,773
381	Differential control of CD4 ⁺ T _H cell subsets by the PD-1/PD-L1 axis in a mouse model of allergic asthma. <i>European Journal of Immunology</i> , 2015, 45, 1019-1029.	1.6	62
382	6-Thioguanine-loaded polymeric micelles deplete myeloid-derived suppressor cells and enhance the efficacy of T cell immunotherapy in tumor-bearing mice. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1033-1046.	2.0	56
383	Regulation of viability, differentiation and death of human melanoma cells carrying neural stem cell biomarkers: a possibility for neural trans-differentiation. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2015, 20, 996-1015.	2.2	5
384	Decreased PD-1/PD-L1 Expression Is Associated with the Reduction in Mucosal Immunoglobulin A in Mice with Intestinal Ischemia Reperfusion. <i>Digestive Diseases and Sciences</i> , 2015, 60, 2662-2669.	1.1	12

#	ARTICLE	IF	CITATIONS
385	Renal Toxicities of Targeted Therapies. <i>Targeted Oncology</i> , 2015, 10, 487-499.	1.7	66
386	Novel Immunologic Approaches in Lymphoma: Unleashing the Brakes on the Immune System. <i>Current Oncology Reports</i> , 2015, 17, 30.	1.8	9
387	The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. <i>Clinical Therapeutics</i> , 2015, 37, 764-782.	1.1	469
388	C-Reactive Protein As a Marker of Melanoma Progression. <i>Journal of Clinical Oncology</i> , 2015, 33, 1389-1396.	0.8	71
389	Safety, Correlative Markers, and Clinical Results of Adjuvant Nivolumab in Combination with Vaccine in Resected High-Risk Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2015, 21, 712-720.	3.2	225
390	Lung Cancer in the Era of Precision Medicine. <i>Clinical Cancer Research</i> , 2015, 21, 2213-2220.	3.2	148
391	Does It MEK a Difference? Understanding Immune Effects of Targeted Therapy. <i>Clinical Cancer Research</i> , 2015, 21, 3102-3104.	3.2	27
392	Programmed Death-1 Controls T Cell Survival by Regulating Oxidative Metabolism. <i>Journal of Immunology</i> , 2015, 194, 5789-5800.	0.4	104
393	Transcriptional repression of IFN γ by ATF2 confers melanoma resistance to therapy. <i>Oncogene</i> , 2015, 34, 5739-5748.	2.6	23
394	Beyond adjuvants: Immunomodulation strategies to enhance T cell immunity. <i>Vaccine</i> , 2015, 33, B21-B28.	1.7	28
395	Anti-PD-L1 prolongs survival and triggers T cell but not humoral anti-tumor immune responses in a human MUC1-expressing preclinical ovarian cancer model. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1095-1108.	2.0	19
396	Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells. <i>Cancer Immunology Research</i> , 2015, 3, 1148-1157.	1.6	391
397	CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic. <i>Frontiers in Oncology</i> , 2014, 4, 385.	1.3	175
398	Immunotherapeutic Advancements for Glioblastoma. <i>Frontiers in Oncology</i> , 2015, 5, 12.	1.3	37
400	Challenges and Opportunities for Quantitative Clinical Pharmacology in Cancer Immunotherapy: Something Old, Something New, Something Borrowed, and Something Blue. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2015, 4, 495-497.	1.3	15
401	Therapeutic interventions to disrupt the protein synthetic machinery in melanoma. <i>Pigment Cell and Melanoma Research</i> , 2015, 28, 501-519.	1.5	3
402	Pseudoprogression and Immune-Related Response in Solid Tumors. <i>Journal of Clinical Oncology</i> , 2015, 33, 3541-3543.	0.8	720
403	PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells. <i>Cancer Immunology Research</i> , 2015, 3, 1308-1315.	1.6	114

#	ARTICLE	IF	CITATIONS
404	Photodynamic Therapy of Non-â€“Small Cell Lung Cancer. Narrative Review and Future Directions. <i>Annals of the American Thoracic Society</i> , 2016, 13, 265-275.	1.5	103
405	Characterising the immune profile of the kidney biopsy at lupus nephritis flare differentiates early treatment responders from non-responders. <i>Lupus Science and Medicine</i> , 2015, 2, e000112-e000112.	1.1	38
406	The potential complementary role of targeted alpha therapy in the management of metastatic melanoma. <i>Melanoma Management</i> , 2015, 2, 353-366.	0.1	1
407	Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. <i>BMC Medicine</i> , 2015, 13, 211.	2.3	570
408	Advances in the treatment of newly diagnosed glioblastoma. <i>BMC Medicine</i> , 2015, 13, 293.	2.3	36
409	A â€“fitâ€“ microbiota to potentiate cancer immunotherapy. <i>Genome Medicine</i> , 2015, 7, 131.	3.6	10
410	Development of a radiofrequency ablation platform in a clinically relevant murine model of hepatocellular cancer. <i>Cancer Biology and Therapy</i> , 2015, 16, 1812-1819.	1.5	9
411	Advancing Clinical Trials to Streamline Drug Development. <i>Clinical Cancer Research</i> , 2015, 21, 4527-4535.	3.2	29
412	T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment. <i>Journal of Hematology and Oncology</i> , 2015, 8, 93.	6.9	127
413	Intratumoral talimogene laherparepvec therapy in melanoma. <i>Melanoma Management</i> , 2015, 2, 297-300.	0.1	2
414	ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development. <i>Journal of Hematology and Oncology</i> , 2015, 8, 129.	6.9	223
415	IL-1 in Colon Inflammation, Colon Carcinogenesis and Invasiveness of Colon Cancer. <i>Cancer Microenvironment</i> , 2015, 8, 187-200.	3.1	97
416	Long-term survival as a treatment benchmark in melanoma: latest results and clinical implications. <i>Therapeutic Advances in Medical Oncology</i> , 2015, 7, 181-191.	1.4	20
417	Phase II study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 969-975.	1.1	38
418	Bowel perforation associated with robust response to BRAF/MEK inhibitor therapy for BRAF-mutant melanoma: a case report. <i>Melanoma Management</i> , 2015, 2, 115-120.	0.1	4
419	Granulomatous interstitial nephritis: a chameleon in a globalized world. <i>CKJ: Clinical Kidney Journal</i> , 2015, 8, 511-515.	1.4	8
420	Pretreatment neutrophil-to-lymphocyte ratio predicts prognosis in patients with locoregionally advanced laryngeal carcinoma treated with chemoradiotherapy. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, hv175.	0.6	30
421	Soluble PD-1 aggravates progression of collagen-induced arthritis through Th1 and Th17 pathways. <i>Arthritis Research and Therapy</i> , 2015, 17, 340.	1.6	80

#	ARTICLE	IF	CITATIONS
422	The Wnts of change: How Wnts regulate phenotype switching in melanoma. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2015, 1856, 244-251.	3.3	52
423	Mismatch repair deficiency associated with complete remission to combination programmed cell death ligand immune therapy in a patient with sporadic urothelial carcinoma: immunotheranostic considerations. , 2015, 3, 58.		26
424	Second-line combination therapies in nonsmall cell lung cancer without known driver mutations. <i>European Respiratory Review</i> , 2015, 24, 582-593.	3.0	22
425	Pathologic and immunohistochemical characterization of tumoral inflammatory cell infiltrate in invasive penile squamous cell carcinomas: Fox-P3 expression is an independent predictor of recurrence. <i>Tumor Biology</i> , 2015, 36, 2509-2516.	0.8	28
426	Therapeutic targeting of tumor suppressor genes. <i>Cancer</i> , 2015, 121, 1357-1368.	2.0	132
427	Checkpoint inhibitors in immunotherapy of ovarian cancer. <i>Tumor Biology</i> , 2015, 36, 33-39.	0.8	19
428	Checkpoint Blockade Immunotherapy Relies on T-bet but Not Eomes to Induce Effector Function in Tumor-Infiltrating CD8+ T Cells. <i>Cancer Immunology Research</i> , 2015, 3, 116-124.	1.6	32
429	Immunotherapy for the Treatment of Breast Cancer. <i>Current Oncology Reports</i> , 2015, 17, 5.	1.8	59
430	CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations. <i>Cancer Medicine</i> , 2015, 4, 661-672.	1.3	100
431	Targeting drivers of melanoma with synthetic small molecules and phytochemicals. <i>Cancer Letters</i> , 2015, 359, 20-35.	3.2	67
432	Overexpression of Programmed Death Ligands in Naturally Occurring Postweaning Multisystemic Wasting Syndrome. <i>Viral Immunology</i> , 2015, 28, 101-106.	0.6	9
433	Immunogenic peptide discovery in cancer genomes. <i>Current Opinion in Genetics and Development</i> , 2015, 30, 7-16.	1.5	63
434	Immune Escape Mechanisms as a Guide for Cancer Immunotherapy. <i>Clinical Cancer Research</i> , 2015, 21, 687-692.	3.2	801
435	Akt Inhibition Enhances Expansion of Potent Tumor-Specific Lymphocytes with Memory Cell Characteristics. <i>Cancer Research</i> , 2015, 75, 296-305.	0.4	283
436	Immune Checkpoint Blockade in Cancer Therapy. <i>Journal of Clinical Oncology</i> , 2015, 33, 1974-1982.	0.8	2,220
437	Anti-programmed death receptor 1 immunotherapy in melanoma: rationale, evidence and clinical potential. <i>Therapeutic Advances in Medical Oncology</i> , 2015, 7, 12-21.	1.4	22
438	Understanding the complexity and malleability of T cell recognition. <i>Immunology and Cell Biology</i> , 2015, 93, 433-441.	1.0	44
439	Combination Therapy with Anti-CTLA-4 and Anti-PD-1 Leads to Distinct Immunologic Changes In Vivo. <i>Journal of Immunology</i> , 2015, 194, 950-959.	0.4	362

#	ARTICLE	IF	CITATIONS
440	HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL). Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E166-75.	3.3	150
441	Current challenges in designing GBM trials for immunotherapy. Journal of Neuro-Oncology, 2015, 123, 331-337.	1.4	34
442	Chitosan hydrogel vaccine generates protective CD8 T cell memory against mouse melanoma. Immunology and Cell Biology, 2015, 93, 634-640.	1.0	30
443	Impact of NRAS Mutations for Patients with Advanced Melanoma Treated with Immune Therapies. Cancer Immunology Research, 2015, 3, 288-295.	1.6	145
444	Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma. , 2015, 3, 2.		93
446	Both PD-1 Ligands Protect the Kidney from Ischemia Reperfusion Injury. Journal of Immunology, 2015, 194, 325-333.	0.4	70
447	Requirement for Innate Immunity and CD90+ NK1.1 ⁺ Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy. Cancer Immunology Research, 2015, 3, 296-304.	1.6	25
448	PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation. Journal of Translational Medicine, 2015, 13, 5.	1.8	73
450	Increased Numbers of Circulating ICOS+ Follicular Helper T and CD38+ Plasma Cells in Patients with Newly Diagnosed Primary Biliary Cirrhosis. Digestive Diseases and Sciences, 2015, 60, 405-413.	1.1	19
451	Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience. Oncogene, 2015, 34, 5411-5417.	2.6	48
452	Apoptosis and anergy of T cell induced by pancreatic stellate cells-derived galectin-1 in pancreatic cancer. Tumor Biology, 2015, 36, 5617-5626.	0.8	51
453	Nivolumab in NSCLC: latest evidence and clinical potential. Therapeutic Advances in Medical Oncology, 2015, 7, 85-96.	1.4	196
454	Renal effects of targeted anticancer therapies. Nature Reviews Nephrology, 2015, 11, 354-370.	4.1	95
455	Overcoming tumor immune evasion with an unique arbovirus. Journal of Translational Medicine, 2015, 13, 3.	1.8	3
456	Nivolumab in melanoma: latest evidence and clinical potential. Therapeutic Advances in Medical Oncology, 2015, 7, 97-106.	1.4	124
457	Association between PDCD1 Gene Polymorphisms and Risk of Systemic Lupus Erythematosus in Three Main Ethnic Groups of the Malaysian Population. International Journal of Molecular Sciences, 2015, 16, 9794-9803.	1.8	20
458	Nivolumab and Olaparib. Hospital Pharmacy, 2015, 50, 356-366.	0.4	4
459	Genomic Classification of Cutaneous Melanoma. Cell, 2015, 161, 1681-1696.	13.5	2,562

#	ARTICLE	IF	CITATIONS
460	Lesion human leukocyte antigen-F expression is associated with a poor prognosis in patients with hepatocellular carcinoma. <i>Oncology Letters</i> , 2015, 9, 300-304.	0.8	21
461	Spotlight on pembrolizumab in the treatment of advanced melanoma. <i>Drug Design, Development and Therapy</i> , 2015, 9, 2883.	2.0	7
462	Evolving Concepts: Immunity in Oncology from Targets to Treatments. <i>Journal of Oncology</i> , 2015, 2015, 1-15.	0.6	23
463	Combination cancer immunotherapy and new immunomodulatory targets. <i>Nature Reviews Drug Discovery</i> , 2015, 14, 561-584.	21.5	1,058
464	DRESS syndrome: cerebral vasculitic-like presentation. <i>Neuroradiology</i> , 2015, 57, 1015-1021.	1.1	11
465	CD4 T Cell Depletion Substantially Augments the Rescue Potential of PD-L1 Blockade for Deeply Exhausted CD8 T Cells. <i>Journal of Immunology</i> , 2015, 195, 1054-1063.	0.4	34
466	Update in Lung Cancer 2014. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 192, 283-294.	2.5	36
467	PD-1hiTIM-3+ T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation. <i>Blood Cancer Journal</i> , 2015, 5, e330-e330.	2.8	124
468	Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression. <i>JAMA Dermatology</i> , 2015, 151, 1206.	2.0	385
469	Tumor Microenvironment Remodeling by 4-Methylumbelliferone Boosts the Antitumor Effect of Combined Immunotherapy in Murine Colorectal Carcinoma. <i>Molecular Therapy</i> , 2015, 23, 1444-1455.	3.7	18
470	Managing teenage/young adult (TYA) brain tumors: a UK perspective. <i>CNS Oncology</i> , 2015, 4, 235-246.	1.2	6
471	BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies. <i>OncoTargets and Therapy</i> , 2015, 8, 157.	1.0	134
472	In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment. <i>Vaccine</i> , 2015, 33, 7415-7422.	1.7	142
473	New immunotherapies targeting the PD-1 pathway. <i>Trends in Pharmacological Sciences</i> , 2015, 36, 587-595.	4.0	158
474	Blinatumomab and Pembrolizumab. <i>Hospital Pharmacy</i> , 2015, 50, 269-273.	0.4	4
475	T-cell exhaustion in the tumor microenvironment. <i>Cell Death and Disease</i> , 2015, 6, e1792-e1792.	2.7	743
476	Therapeutic DNA vaccination against colorectal cancer by targeting the MYB oncoprotein. <i>Clinical and Translational Immunology</i> , 2015, 4, e30.	1.7	39
477	Combined immunotherapyâ€”a new standard in metastatic melanoma?. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 439-440.	12.5	8

#	ARTICLE	IF	CITATIONS
478	Immunotherapy in Cancer: A Combat between Tumors and the Immune System; You Win Some, You Lose Some. <i>Frontiers in Immunology</i> , 2015, 6, 127.	2.2	51
479	The Role of Merkel Cell Polyomavirus and Other Human Polyomaviruses in Emerging Hallmarks of Cancer. <i>Viruses</i> , 2015, 7, 1871-1901.	1.5	41
480	Engineering CAR-T cells: Design concepts. <i>Trends in Immunology</i> , 2015, 36, 494-502.	2.9	354
481	Association of Common Genetic Polymorphisms with Melanoma Patient IL-12p40 Blood Levels, Risk, and Outcomes. <i>Journal of Investigative Dermatology</i> , 2015, 135, 2266-2272.	0.3	7
482	Antigen-specific T cell therapies for cancer: Figure 1.. <i>Human Molecular Genetics</i> , 2015, 24, R67-R73.	1.4	32
483	Milestone Survival: A Potential Intermediate Endpoint for Immune Checkpoint Inhibitors. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv156.	3.0	62
484	Chemotherapy-related complications in the kidneys and collecting system: an imaging perspective. <i>Insights Into Imaging</i> , 2015, 6, 479-487.	1.6	27
485	Evolving synergistic combinations of targeted immunotherapies to combat cancer. <i>Nature Reviews Cancer</i> , 2015, 15, 457-472.	12.8	576
486	Molecular and cellular insights into T cell exhaustion. <i>Nature Reviews Immunology</i> , 2015, 15, 486-499.	10.6	3,159
487	Clinical Management of Multiple Melanoma Brain Metastases. <i>JAMA Oncology</i> , 2015, 1, 668.	3.4	70
488	Engineered materials for cancer immunotherapy. <i>Nano Today</i> , 2015, 10, 511-531.	6.2	96
489	Concepts of immunotherapy for glioma. <i>Journal of Neuro-Oncology</i> , 2015, 123, 323-330.	1.4	12
490	Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy. <i>Seminars in Oncology</i> , 2015, 42, 601-616.	0.8	139
491	Immune Modulation in Hematologic Malignancies. <i>Seminars in Oncology</i> , 2015, 42, 617-625.	0.8	22
492	The Place of Targeted Agents in the Treatment of Elderly Patients with Metastatic Colorectal Cancer. <i>Cancers</i> , 2015, 7, 439-449.	1.7	2
493	Primary malignant melanoma of the trachea: A case report. <i>Oncology Letters</i> , 2015, 9, 657-660.	0.8	6
494	In-situ tumor vaccination: Bringing the fight to the tumor. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 1901-1909.	1.4	60
495	Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. <i>Lancet Oncology</i> , The, 2015, 16, 908-918.	5.1	1,419

#	ARTICLE	IF	CITATIONS
496	In vivo RNAi screens: concepts and applications. <i>Trends in Immunology</i> , 2015, 36, 315-322.	2.9	18
497	2015: The Year of Anti-PD-1/PD-L1s Against Melanoma and Beyond. <i>EBioMedicine</i> , 2015, 2, 92-93.	2.7	51
498	Squiring immunotherapy to CheckMate. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 436-436.	12.5	7
499	CheckMate 067â€”frontline nivolumab improves PFS alone or in combination with ipilimumab. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 435-435.	12.5	18
500	OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal. <i>Frontiers in Oncology</i> , 2015, 5, 34.	1.3	193
501	The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment. <i>Oncologist</i> , 2015, 20, 812-822.	1.9	198
502	IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. <i>Nature Medicine</i> , 2015, 21, 719-729.	15.2	658
503	Inflammation and cancer: advances and new agents. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 584-596.	12.5	901
504	The pharmacology of second-generation chimeric antigen receptors. <i>Nature Reviews Drug Discovery</i> , 2015, 14, 499-509.	21.5	411
505	Antagonists of PD-1 and PD-L1 in Cancer Treatment. <i>Seminars in Oncology</i> , 2015, 42, 587-600.	0.8	259
506	Combining Immunotherapy with Oncogene-Targeted Therapy: A New Road for Melanoma Treatment. <i>Frontiers in Immunology</i> , 2015, 6, 46.	2.2	69
507	Are Macrophages in Tumors Good Targets for Novel Therapeutic Approaches?. <i>Molecules and Cells</i> , 2015, 38, 95-104.	1.0	9
508	Targeting the Innate Immune System as Immunotherapy for Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2015, 5, 83.	1.3	33
509	Tumor infiltrating lymphocytes in ovarian cancer. <i>Cancer Biology and Therapy</i> , 2015, 16, 807-820.	1.5	257
510	Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy. <i>Cancer Biology and Therapy</i> , 2015, 16, 662-670.	1.5	27
511	Murine lung cancer induces generalized T-cellâ€”exhaustion. <i>Journal of Surgical Research</i> , 2015, 195, 541-549.	0.8	25
512	Advancing the Minimal Residual Disease Concept in Acute Myeloid Leukemia. <i>Seminars in Hematology</i> , 2015, 52, 184-192.	1.8	32
513	Mechanisms of action of therapeutic antibodies for cancer. <i>Molecular Immunology</i> , 2015, 67, 28-45.	1.0	136

#	ARTICLE	IF	CITATIONS
514	Î³Î´ T Cell Immunotherapyâ€™A Review. Pharmaceuticals, 2015, 8, 40-61.	1.7	50
515	Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. Human Pathology, 2015, 46, 357-365.	1.1	252
516	Toxicities of Immunotherapy for the Practitioner. Journal of Clinical Oncology, 2015, 33, 2092-2099.	0.8	521
517	Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. Journal of Clinical Oncology, 2015, 33, 2013-2020.	0.8	385
518	Chimeric Antigen Receptor-Engineered T Cells for the Treatment of Metastatic Prostate Cancer. BioDrugs, 2015, 29, 75-89.	2.2	57
519	T cell metabolic fitness in antitumor immunity. Trends in Immunology, 2015, 36, 257-264.	2.9	237
522	Broadening the repertoire of melanoma-associated T-cell epitopes. Cancer Immunology, Immunotherapy, 2015, 64, 609-620.	2.0	8
523	Clinical outcomes in 66 patients with advanced gastric cancer treated in phase I trials: the NCCHE experience. Investigational New Drugs, 2015, 33, 664-670.	1.2	3
524	The role of checkpoints in the treatment of GBM. Journal of Neuro-Oncology, 2015, 123, 413-423.	1.4	15
525	Re-defining response and treatment effects for neuro-oncology immunotherapy clinical trials. Journal of Neuro-Oncology, 2015, 123, 339-346.	1.4	10
526	The TLR2 agonist in polysaccharide-K is a structurally distinct lipid which acts synergistically with the protein-bound Î²-glucan. Journal of Natural Medicines, 2015, 69, 198-208.	1.1	13
527	Treatment of NRAS-Mutant Melanoma. Current Treatment Options in Oncology, 2015, 16, 15.	1.3	110
528	Immunotherapy for lung cancer: for whom the bell tolls?. Tumor Biology, 2015, 36, 1411-1422.	0.8	17
529	Effect of TLR Agonists on the Differentiation and Function of Human Monocytic Myeloid-Derived Suppressor Cells. Journal of Immunology, 2015, 194, 4215-4221.	0.4	60
530	Targeting cancer-specific mutations by T cell receptor gene therapy. Current Opinion in Immunology, 2015, 33, 112-119.	2.4	82
531	Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma. New England Journal of Medicine, 2015, 372, 2006-2017.	13.9	2,489
532	Role of PD-1 co-inhibitory pathway in HIV infection and potential therapeutic options. Retrovirology, 2015, 12, 14.	0.9	119
533	Immunotherapeutic approaches to ovarian cancer treatment. , 2015, 3, 7.		63

#	ARTICLE	IF	CITATIONS
534	Recovery from experimental autoimmune uveitis promotes induction of antiuveitic inducible Tregs. <i>Journal of Leukocyte Biology</i> , 2015, 97, 1101-1109.	1.5	36
535	The Role of Anti-PD-1/PD-L1 Agents in Melanoma: Progress to Date. <i>Drugs</i> , 2015, 75, 563-575.	4.9	18
536	IFN- γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. <i>British Journal of Cancer</i> , 2015, 112, 1501-1509.	2.9	533
537	CpG Oligonucleotides as Cancer Vaccine Adjuvants. <i>Vaccines</i> , 2015, 3, 390-407.	2.1	108
538	Pembrolizumab "is the writing on the wall for cancer?". <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 371-371.	12.5	0
539	From humble beginnings to success in the clinic: Chimeric antigen receptor-modified T-cells and implications for immunotherapy. <i>Experimental Biology and Medicine</i> , 2015, 240, 1087-1098.	1.1	52
540	Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma. <i>Cancer Immunology Research</i> , 2015, 3, 399-411.	1.6	387
541	Clinically feasible approaches to potentiating cancer cell-based immunotherapies. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 851-869.	1.4	67
542	Alternative Treatments For Melanoma: Targeting BCL-2 Family Members to De-Bulk and Kill Cancer Stem Cells. <i>Journal of Investigative Dermatology</i> , 2015, 135, 2155-2161.	0.3	38
543	FGL2 as a Multimodality Regulator of Tumor-Mediated Immune Suppression and Therapeutic Target in Gliomas. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	80
544	Classifying Cancers Based on T-cell Infiltration and PD-L1. <i>Cancer Research</i> , 2015, 75, 2139-2145.	0.4	1,167
545	Targeting Nodal in Conjunction with Dacarbazine Induces Synergistic Anticancer Effects in Metastatic Melanoma. <i>Molecular Cancer Research</i> , 2015, 13, 670-680.	1.5	22
546	Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. <i>Cell Reports</i> , 2015, 11, 1018-1030.	2.9	1,083
547	Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model. <i>Journal of Visualized Experiments</i> , 2015, , .	0.2	14
548	Immunotherapeutic Approaches to Sarcoma. <i>Current Treatment Options in Oncology</i> , 2015, 16, 26.	1.3	48
549	Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. , 2015, 3, 11.		274
550	Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. <i>Science</i> , 2015, 348, 124-128.	6.0	6,756
551	Small Cell Lung Cancer: Will Recent Progress Lead to Improved Outcomes?. <i>Clinical Cancer Research</i> , 2015, 21, 2244-2255.	3.2	179

#	ARTICLE	IF	CITATIONS
552	Overcoming T cell exhaustion in infection and cancer. Trends in Immunology, 2015, 36, 265-276.	2.9	856
553	TLR5 Ligand- Secreting T Cells Reshape the Tumor Microenvironment and Enhance Antitumor Activity. Cancer Research, 2015, 75, 1959-1971.	0.4	33
554	Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature, 2015, 520, 373-377.	13.7	1,955
555	Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites. Clinical Cancer Research, 2015, 21, 3052-3060.	3.2	198
556	The development of immunotherapy in urothelial bladder cancer. Nature Reviews Clinical Oncology, 2015, 12, 193-194.	12.5	8
557	Haematological malignancies: at the forefront of immunotherapeutic innovation. Nature Reviews Cancer, 2015, 15, 201-215.	12.8	63
558	Elevating the Horizon: Emerging Molecular and Genomic Targets in the Treatment of Advanced Urothelial Carcinoma. Clinical Genitourinary Cancer, 2015, 13, 410-420.	0.9	17
559	Repurposing Drugs in Oncology (ReDO)- clarithromycin as an anti-cancer agent. Ecancermedicalscience, 2015, 9, 513.	0.6	62
560	Melanoma-intrinsic β -catenin signalling prevents anti-tumour immunity. Nature, 2015, 523, 231-235.	13.7	2,130
561	IL2 Inducible T-cell Kinase, a Novel Therapeutic Target in Melanoma. Clinical Cancer Research, 2015, 21, 2167-2176.	3.2	16
562	Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558,) Tj ETQq0 0 0 rgBT /Overlock Clinical Oncology, 2015, 33, 2004-2012.	0.8	1,035
563	Molecular Biology and Immunology of Head and Neck Cancer. Surgical Oncology Clinics of North America, 2015, 24, 397-407.	0.6	32
564	Ipilimumab-induced hypophysitis: review of the literature. Journal of Endocrinological Investigation, 2015, 38, 1159-1166.	1.8	56
565	The therapeutic promise of disrupting the PD-1/PD-L1 immune checkpoint in cancer: unleashing the CD8 T cell mediated anti-tumor activity results in significant, unprecedented clinical efficacy in various solid tumors. , 2015, 3, 15.		57
566	Evaluation of ⁶⁸ Ga- and ¹⁷⁷ Lu-DOTA-PEG ₄ -LLP2A for VLA-4-Targeted PET Imaging and Treatment of Metastatic Melanoma. Molecular Pharmaceutics, 2015, 12, 1929-1938.	2.3	39
567	The New Deal: A Potential Role for Secreted Vesicles in Innate Immunity and Tumor Progression. Frontiers in Immunology, 2015, 6, 66.	2.2	92
568	T-cell exhaustion in allograft rejection and tolerance. Current Opinion in Organ Transplantation, 2015, 20, 37-42.	0.8	34
569	Kinetics of microRNA Expression in Bronchoalveolar Lavage Fluid Samples. Lung, 2015, 193, 381-385.	1.4	5

#	ARTICLE	IF	CITATIONS
570	Diffuse High Intensity PD-L1 Staining in Thymic Epithelial Tumors. <i>Journal of Thoracic Oncology</i> , 2015, 10, 500-508.	0.5	129
571	Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 1889-1894.	0.8	1,809
572	Genetics and immunotherapy: using the genetic landscape of gliomas to inform management strategies. <i>Journal of Neuro-Oncology</i> , 2015, 123, 373-383.	1.4	14
573	Enhanced T-Cell Immunity to Osteosarcoma Through Antibody Blockade of PD-1/PD-L1 Interactions. <i>Journal of Immunotherapy</i> , 2015, 38, 96-106.	1.2	171
574	Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. <i>British Journal of Cancer</i> , 2015, 112, 1421-1427.	2.9	215
575	CheckMate® has nivolumab beaten melanoma?. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 310-310.	12.5	0
576	Cancer immunotherapy and immune-related response assessment: The role of radiologists in the new arena of cancer treatment. <i>European Journal of Radiology</i> , 2015, 84, 1259-1268.	1.2	105
577	Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy. <i>Cancer Cell</i> , 2015, 27, 450-461.	7.7	3,266
578	Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential. <i>Cell</i> , 2015, 161, 205-214.	13.5	1,872
579	Trametinib in the treatment of melanoma. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 735-747.	1.4	23
580	NF- κ B Regulates PD-1 Expression in Macrophages. <i>Journal of Immunology</i> , 2015, 194, 4545-4554.	0.4	134
581	Oncolytic Virus Immunotherapy for Melanoma. <i>Current Treatment Options in Oncology</i> , 2015, 16, 326.	1.3	40
582	TLR2/6 agonists and interferon-gamma induce human melanoma cells to produce CXCL10. <i>International Journal of Cancer</i> , 2015, 137, 1386-1396.	2.3	25
583	Beyond consolidation: auto-SCT and immunotherapy for plasma cell myeloma. <i>Bone Marrow Transplantation</i> , 2015, 50, 770-780.	1.3	9
584	TGF β 2 Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity. <i>Cancer Research</i> , 2015, 75, 2232-2242.	0.4	429
585	Novel strategies for inhibiting PD-1 pathway-mediated immune suppression while simultaneously delivering activating signals to tumor-reactive T cells. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1287-1293.	2.0	18
586	Monitoring for Extra-Intestinal Cancers in IBD. <i>Current Gastroenterology Reports</i> , 2015, 17, 42.	1.1	17
587	Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2015, 373, 1627-1639.	13.9	7,973

#	ARTICLE	IF	CITATIONS
588	A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma. <i>Annals of Oncology</i> , 2015, 26, 2267-2274.	0.6	67
589	Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. <i>Annals of Oncology</i> , 2015, 26, 2375-2391.	0.6	1,136
590	Predictive biomarkers in precision medicine and drug development against lung cancer. <i>Chinese Journal of Cancer</i> , 2015, 34, 295-309.	4.9	34
591	Nivolumab in combination with ipilimumab for the treatment of melanoma. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 1135-1141.	1.1	22
592	Identification of tumour-reactive lymphatic endothelial cells capable of inducing progression of gastric cancer. <i>British Journal of Cancer</i> , 2015, 113, 1046-1054.	2.9	17
593	Interleukin-2, Ipilimumab, and Anti-PD-1: clinical management and the evolving role of immunotherapy for the treatment of patients with metastatic melanoma. <i>Cancer Biology and Therapy</i> , 2021, 22, 513-526.	1.5	24
594	PD-L1 Expression in Melanocytic Lesions Does Not Correlate with the BRAF V600E Mutation. <i>Cancer Immunology Research</i> , 2015, 3, 110-115.	1.6	45
595	Clinical Activity of Ipilimumab in Acral Melanoma: A Retrospective Review. <i>Oncologist</i> , 2015, 20, 648-652.	1.9	38
596	Adaptive Immunity to Leukemia Is Inhibited by Cross-Reactive Induced Regulatory T Cells. <i>Journal of Immunology</i> , 2015, 195, 4028-4037.	0.4	26
597	Predictors of clinical response to immunotherapy with or without radiotherapy. <i>Journal of Radiation Oncology</i> , 2015, 4, 339-345.	0.7	17
598	The Rapid Emergence of Novel Therapeutics in Advanced Malignant Melanoma. <i>Dermatology and Therapy</i> , 2015, 5, 151-169.	1.4	19
599	Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2015, 373, 1803-1813.	13.9	4,889
600	Immune checkpoints and immunotherapy for colorectal cancer. <i>Gastroenterology Report</i> , 2015, 3, gov053.	0.6	80
601	Immunosuppressive mechanisms in glioblastoma: Fig. 1.. <i>Neuro-Oncology</i> , 2015, 17, vii9-vii14.	0.6	275
602	Immunomodulation: checkpoint blockade etc.: Fig. 1.. <i>Neuro-Oncology</i> , 2015, 17, vii26-vii31.	0.6	26
603	Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. <i>Lancet Oncology</i> , The, 2015, 16, e534-e542.	5.1	582
604	Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 997-1004.	1.1	58
605	Immunotherapy for neuro-oncology: the critical rationale for combinatorial therapy. <i>Neuro-Oncology</i> , 2015, 17, vii32-vii40.	0.6	21

#	ARTICLE	IF	CITATIONS
606	Pan-cancer analysis of TCGA data reveals notable signaling pathways. <i>BMC Cancer</i> , 2015, 15, 516.	1.1	33
608	Nivolumabâ€”an effective second-line treatment for NSCLC. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 685-685.	12.5	5
610	Nivolumab: A Review in Advanced Squamous Non-Small Cell Lung Cancer. <i>Drugs</i> , 2015, 75, 1925-1934.	4.9	23
611	Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1. <i>Structure</i> , 2015, 23, 2341-2348.	1.6	399
612	Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy. <i>Clinical Cancer Research</i> , 2015, 21, 5427-5433.	3.2	254
613	Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab. <i>Cancer Immunology Research</i> , 2015, 3, 1185-1192.	1.6	227
614	Pilot Trial of Selecting Molecularly Guided Therapy for Patients with Nonâ€”V600 BRAF-Mutant Metastatic Melanoma: Experience of the SU2C/MRA Melanoma Dream Team. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1962-1971.	1.9	25
615	Nivolumab: A Review in Advanced Melanoma. <i>Drugs</i> , 2015, 75, 1413-1424.	4.9	44
616	Transfer of the IL-37b gene elicits anti-tumor responses in mice bearing 4T1 breast cancer. <i>Acta Pharmacologica Sinica</i> , 2015, 36, 528-534.	2.8	21
617	Prospects of immune checkpoint modulators in the treatment of glioblastoma. <i>Nature Reviews Neurology</i> , 2015, 11, 504-514.	4.9	307
618	The Next Hurdle in Cancer Immunotherapy: Overcoming the Nonâ€”T-Cellâ€”Inflamed Tumor Microenvironment. <i>Seminars in Oncology</i> , 2015, 42, 663-671.	0.8	388
619	Why has active immunotherapy not worked in lung cancer?. <i>Annals of Oncology</i> , 2015, 26, 2213-2220.	0.6	35
620	Frequent PD-L1 expression in testicular germ cell tumors. <i>British Journal of Cancer</i> , 2015, 113, 411-413.	2.9	126
621	AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy. <i>Journal of Hematology and Oncology</i> , 2015, 8, 96.	6.9	84
622	Immunological landscape and immunotherapy of hepatocellular carcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015, 12, 681-700.	8.2	478
623	NKT cell-dependent glycolipidâ€”peptide vaccines with potent anti-tumour activity. <i>Chemical Science</i> , 2015, 6, 5120-5127.	3.7	64
624	Epigenetic and Immune Regulation of Colorectal Cancer Stem Cells. <i>Current Colorectal Cancer Reports</i> , 2015, 11, 414-421.	1.0	5
625	Major histocompatibility complex class I expression impacts on patient survival and type and density of immune cells in biliary tract cancer. <i>British Journal of Cancer</i> , 2015, 113, 1343-1349.	2.9	54

#	ARTICLE	IF	CITATIONS
626	Immunotherapy in Sarcoma: Future Horizons. <i>Current Oncology Reports</i> , 2015, 17, 52.	1.8	16
627	Unique potential of 4-1BB agonist antibody to promote durable regression of HPV ⁺ tumors when combined with an E6/E7 peptide vaccine. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E5290-9.	3.3	79
628	U.S. Food and Drug Administration Approval Summary: Ramucirumab for the Treatment of Metastatic Non-Small Cell Lung Cancer Following Disease Progression On or After Platinum-Based Chemotherapy. <i>Oncologist</i> , 2015, 20, 1320-1325.	1.9	27
629	The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma. <i>Oncologist</i> , 2015, 20, 1253-1260.	1.9	40
631	An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors. <i>Current Treatment Options in Oncology</i> , 2015, 16, 54.	1.3	44
632	Novel Therapies for Metastatic Melanoma: An Update on Their Use in Older Patients. <i>Drugs and Aging</i> , 2015, 32, 821-834.	1.3	12
633	Immune Response to Cancer Therapy: Mounting an Effective Antitumor Response and Mechanisms of Resistance. <i>Trends in Cancer</i> , 2015, 1, 66-75.	3.8	101
634	HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade. <i>Cancer Immunology Research</i> , 2015, 3, 1375-1385.	1.6	342
635	Current position of TNF- α in melanomagenesis. <i>Tumor Biology</i> , 2015, 36, 6589-6602.	0.8	13
636	Lung cancer: Biology and treatment options. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2015, 1856, 189-210.	3.3	526
637	Melanoma Risk and Survival among Organ Transplant Recipients. <i>Journal of Investigative Dermatology</i> , 2015, 135, 2657-2665.	0.3	108
638	Strategies for combining immunotherapy with radiation for anticancer therapy. <i>Immunotherapy</i> , 2015, 7, 967-980.	1.0	83
639	Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2015, 33, 3488-3515.	0.8	606
640	IL-36 β Transforms the Tumor Microenvironment and Promotes Type 1 Lymphocyte-Mediated Antitumor Immune Responses. <i>Cancer Cell</i> , 2015, 28, 296-306.	7.7	93
641	Immune-mediated adverse events of anticytotoxic T lymphocyte-associated antigen 4 antibody therapy in metastatic melanoma. <i>Translational Research</i> , 2015, 166, 412-424.	2.2	65
642	Comparison of biomarkers for systemic juvenile idiopathic arthritis. <i>Pediatric Research</i> , 2015, 78, 554-559.	1.1	25
643	Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy. <i>New England Journal of Medicine</i> , 2015, 373, 288-290.	13.9	339
644	Dendritic Versus Tumor Cell Presentation of Autologous Tumor Antigens for Active Specific Immunotherapy in Metastatic Melanoma: Impact on Long-Term Survival by Extent of Disease at the Time of Treatment. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2015, 30, 187-194.	0.7	20

#	ARTICLE	IF	CITATIONS
645	Adaptive Immune Resistance: How Cancer Protects from Immune Attack. <i>Cancer Discovery</i> , 2015, 5, 915-919.	7.7	495
646	Are Cancer Outcomes Worse in the Presence of HIV Infection?. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1165-1166.	1.1	4
647	Immune Mechanisms Are Major Players in Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 3581-3583.	3.2	1
648	Pembrolizumab. , 2015, 3, 36.		171
649	Checkpoint modulation - A new way to direct the immune system against renal cell carcinoma. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 1201-1208.	1.4	11
650	Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. <i>Cell</i> , 2015, 162, 974-986.	13.5	1,408
651	Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. <i>Cell</i> , 2015, 162, 1229-1241.	13.5	2,158
652	Management of Dermatologic Complications of Lung Cancer Therapies. <i>Current Treatment Options in Oncology</i> , 2015, 16, 50.	1.3	13
653	Genetic Landscape of Human Papillomavirus-Associated Head and Neck Cancer and Comparison to Tobacco-Related Tumors. <i>Journal of Clinical Oncology</i> , 2015, 33, 3227-3234.	0.8	125
654	Immune checkpoint inhibitors in melanoma. <i>Melanoma Management</i> , 2015, 2, 267-284.	0.1	6
655	Targeting Chromatin-Mediated Transcriptional Control of Gene Expression in Non-Small Cell Lung Cancer Therapy: Preclinical Rationale and Clinical Results. <i>Drugs</i> , 2015, 75, 1757-1771.	4.9	11
656	Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth. <i>Cell</i> , 2015, 162, 1242-1256.	13.5	507
657	Nutrient Competition: A New Axis of Tumor Immunosuppression. <i>Cell</i> , 2015, 162, 1206-1208.	13.5	102
658	An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression. <i>Cancer Gene Therapy</i> , 2015, 22, 454-462.	2.2	62
659	Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. <i>Science</i> , 2015, 350, 207-211.	6.0	2,275
660	Two heads better than one? Ipilimumab immunotherapy and radiation therapy for melanoma brain metastases. <i>Neuro-Oncology</i> , 2015, 17, 1312-1321.	0.6	57
661	Anti-PD1 and anti-PD-L1 in the treatment of metastatic melanoma. <i>Melanoma Management</i> , 2015, 2, 41-50.	0.1	7
662	The kynurenine to tryptophan ratio as a prognostic tool for glioblastoma patients enrolling in immunotherapy. <i>Journal of Clinical Neuroscience</i> , 2015, 22, 1964-1968.	0.8	61

#	ARTICLE	IF	CITATIONS
663	New Treatment Options for ALK-Rearranged Non-Small Cell Lung Cancer. <i>Current Treatment Options in Oncology</i> , 2015, 16, 49.	1.3	28
664	Immunotherapy for Multiple Myeloma, Past, Present, and Future: Monoclonal Antibodies, Vaccines, and Cellular Therapies. <i>Current Hematologic Malignancy Reports</i> , 2015, 10, 395-404.	1.2	13
665	Multiplying therapies and reducing toxicity in metastatic melanoma. <i>Cancer Biology and Therapy</i> , 2015, 16, 1014-1018.	1.5	9
666	Promise of cancer stem cell vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 2796-2799.	1.4	14
667	Neopeptides of Cancers: Looking Back, Looking Ahead. <i>Cancer Immunology Research</i> , 2015, 3, 969-977.	1.6	59
668	Antibody-based immunotherapy of solid cancers: progress and possibilities. <i>Immunotherapy</i> , 2015, 7, 923-939.	1.0	24
669	Enhancing Cancer Immunotherapy Via Activation of Innate Immunity. <i>Seminars in Oncology</i> , 2015, 42, 562-572.	0.8	30
670	Engineering opportunities in cancer immunotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 14467-14472.	3.3	111
671	IL15 and T-cell Stemness in T-cell-Based Cancer Immunotherapy. <i>Cancer Research</i> , 2015, 75, 5187-5193.	0.4	86
672	Management of melanoma brain metastases. <i>Melanoma Management</i> , 2015, 2, 225-239.	0.1	2
673	Landscape of Tumor Antigens in T Cell Immunotherapy. <i>Journal of Immunology</i> , 2015, 195, 5117-5122.	0.4	124
674	Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1. <i>Immunotherapy</i> , 2015, 7, 1169-1186.	1.0	45
675	STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 15408-15413.	3.3	404
676	Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia. <i>Journal of Hematology and Oncology</i> , 2015, 8, 104.	6.9	139
677	Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy. <i>Molecular Oncology</i> , 2015, 9, 1936-1965.	2.1	64
678	Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E6506-14.	3.3	299
679	Microenvironmental regulation of therapeutic response in cancer. <i>Trends in Cell Biology</i> , 2015, 25, 198-213.	3.6	604
680	Novel immunotherapies for hematologic malignancies. <i>Immunological Reviews</i> , 2015, 263, 90-105.	2.8	44

#	ARTICLE	IF	CITATIONS
681	Clinical blockade of PD1 and LAG3 " potential mechanisms of action. Nature Reviews Immunology, 2015, 15, 45-56.	10.6	524
682	Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. Journal of Clinical Oncology, 2015, 33, 1430-1437.	0.8	914
683	B7H1/CD80 Interaction Augments PD-1-Dependent T Cell Apoptosis and Ameliorates Graft-versus-Host Disease. Journal of Immunology, 2015, 194, 560-574.	0.4	61
684	Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends in Molecular Medicine, 2015, 21, 24-33.	3.5	628
685	Tumoral Expression of IL-33 Inhibits Tumor Growth and Modifies the Tumor Microenvironment through CD8+ T and NK Cells. Journal of Immunology, 2015, 194, 438-445.	0.4	185
686	The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints. Cancer Discovery, 2015, 5, 43-51.	7.7	1,180
687	Association between a PD-1 gene polymorphism and antisperm antibody-related infertility in Iranian men. Journal of Assisted Reproduction and Genetics, 2015, 32, 103-106.	1.2	16
688	Battling regional (stage III) lung cancer: bumpy road of a cancer survivor in the immunotherapy age. BMJ Case Reports, 2016, 2016, bcr2016215304.	0.2	2
689	PD-1+ and Foxp3+ T cell reduction correlates with survival of HCC patients after sorafenib therapy. JCI Insight, 2016, 1, .	2.3	60
690	Systemic sarcoidosis first manifesting in a tattoo in the setting of immune checkpoint inhibition. BMJ Case Reports, 2016, 2016, bcr2016216217.	0.2	28
691	Partial Remission of Hepatic Metastatic Lesion but Complicated with Secondary and Refractory Fever Lead by Nivolumab in a Patient with Lung Adenocarcinoma Presenting Gefitinib Acquired Resistance. Chinese Medical Journal, 2016, 129, 879-880.	0.9	4
692	Safety and efficacy of pembrolizumab in a patient with advanced melanoma on haemodialysis. BMJ Case Reports, 2016, 2016, bcr2016216426.	0.2	20
693	Challenges in the use of immunotherapy in metastatic melanoma. BMJ Case Reports, 2016, 2016, bcr2016216681.	0.2	1
694	Vedolizumab: a novel treatment for ipilimumab-induced colitis. BMJ Case Reports, 2016, 2016, bcr2016216641.	0.2	39
695	Genetic analysis of B-cell lymphomas associated with hemophagocytic lymphohistiocytosis. Blood Advances, 2016, 1, 205-207.	2.5	5
696	Immunotherapy and lung cancer: from therapeutic cancer vaccination to novel approaches. Journal of Thoracic Disease, 2016, 8, E1348-E1350.	0.6	6
697	The steady progress of targeted therapies, promising advances for lung cancer. Ecancermedicalscience, 2016, 10, 638.	0.6	6
698	Expression of PD-1 on CD4+ T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancer. Oncotarget, 2016, 7, 56233-56240.	0.8	48

#	ARTICLE	IF	CITATIONS
699	Metastatic Renal Cell Carcinoma Presenting as Painful Chewing Successfully Treated with Combined Nivolumab and Sunitinib. , 2016, 20, 15-149.		2
700	Prognostic value of PD-L1 and PD-1 expression in pulmonary neuroendocrine tumors. OncoTargets and Therapy, 2016, Volume 9, 6075-6082.	1.0	47
701	Immuno-oncology combinations: raising the tail of the survival curve. Cancer Biology and Medicine, 2016, 13, 171-193.	1.4	98
702	Targeted therapies in gastric cancer and future perspectives. World Journal of Gastroenterology, 2016, 22, 471.	1.4	35
703	Strengthening the case that elevated levels of programmed death ligand 1 predict poor prognosis in hepatocellular carcinoma patients. Journal of Hepatocellular Carcinoma, 2017, Volume 4, 11-13.	1.8	9
704	Contemporary treatment of metastatic renal cell carcinoma. Oncology Reviews, 2016, 10, 295.	0.8	32
705	Role of metabolism during viral infections, and crosstalk with the innate immune system. Intractable and Rare Diseases Research, 2016, 5, 90-96.	0.3	52
706	The positive prognostic effect of stromal CD8+ tumor-infiltrating T cells is restrained by the expression of HLA-E in non-small cell lung carcinoma. Oncotarget, 2016, 7, 3477-3488.	0.8	73
707	Clinical significance of <i>PD-L1</i> and <i>PD-L2</i> copy number gains in non-small-cell lung cancer. Oncotarget, 2016, 7, 32113-32128.	0.8	100
708	Immune checkpoint inhibition in patients with brain metastases. Annals of Translational Medicine, 2016, 4, S9-S9.	0.7	29
709	Spotlight on talimogene laherparepvec for the treatment of melanoma lesions in the skin and lymph nodes. Oncolytic Virotherapy, 2016, Volume 5, 91-98.	6.0	13
710	Fundamental effects of PD-1 antibody on the body: a brief report. OncoTargets and Therapy, 2016, Volume 9, 4137-4141.	1.0	4
711	A case report and literature review of primary resistant Hodgkin lymphoma: a response to anti-PD-1 after failure of autologous stem cell transplantation and brentuximab vedotin. OncoTargets and Therapy, 2016, Volume 9, 5781-5789.	1.0	2
712	Spotlight on pembrolizumab in non-small cell lung cancer: the evidence to date. OncoTargets and Therapy, 2016, Volume 9, 5855-5866.	1.0	11
713	Data Interoperability of Whole Exome Sequencing (WES) Based Mutational Burden Estimates from Different Laboratories. International Journal of Molecular Sciences, 2016, 17, 651.	1.8	20
714	Dermal Delivery of Constructs Encoding Cre Recombinase to Induce Skin Tumors in PtenLoxP/LoxP;BrafCA/+ Mice. International Journal of Molecular Sciences, 2016, 17, 2149.	1.8	2
715	Phenylethanoid Glycosides from <i>Cistanche tubulosa</i> <i>Inhibits the Growth of B16-F10 Cells both</i> <i>in Vitro</i> and <i>in Vivo</i> by Induction of Apoptosis via Mitochondria-dependent Pathway. Journal of Cancer, 2016, 7, 1877-1887.	1.2	21
716	Inflammatory bowel disease and cancer: The role of inflammation, immunosuppression, and cancer treatment. World Journal of Gastroenterology, 2016, 22, 4794.	1.4	356

#	ARTICLE	IF	CITATIONS
717	A rare case of thyroid storm. <i>BMJ Case Reports</i> , 2016, 2016, bcr2016214603.	0.2	50
718	Insight to drug delivery aspects for colorectal cancer. <i>World Journal of Gastroenterology</i> , 2016, 22, 582.	1.4	101
719	Regulatory Roles of Dclk1 in Epithelial Mesenchymal Transition and Cancer Stem Cells. <i>Journal of Carcinogenesis & Mutagenesis</i> , 2016, 07, .	0.3	28
720	Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 7081-7093.	1.0	83
721	Limbic encephalitis following immunotherapy against metastatic malignant melanoma. <i>BMJ Case Reports</i> , 2016, 2016, bcr2016215012.	0.2	56
722	Repurposing Drugs in Oncology (ReDO)â€”diclofenac as an anti-cancer agent. <i>Ecancermedicalsecience</i> , 2016, 10, 610.	0.6	80
723	A randomized Phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 7275-7283.	1.0	49
724	Immune checkpoint inhibitors and prostate cancer: a new frontier?. <i>Oncology Reviews</i> , 2016, 10, 293.	0.8	47
725	Effects of lung cancer cell-associated B7-H1 on T-cell proliferation in vitro and in vivo. <i>Brazilian Journal of Medical and Biological Research</i> , 2016, 49, .	0.7	2
726	Aptamers: A promising chemical antibody for cancer therapy. <i>Oncotarget</i> , 2016, 7, 13446-13463.	0.8	82
727	Targeting melanoma with immunoliposomes coupled to anti-MAGE A1 TCR-like single-chain antibody. <i>International Journal of Nanomedicine</i> , 2016, 11, 955.	3.3	27
728	Association of <i>Fusobacterium nucleatum</i> with immunity and molecular alterations in colorectal cancer. <i>World Journal of Gastroenterology</i> , 2016, 22, 557.	1.4	278
729	Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. <i>Journal of Clinical Investigation</i> , 2016, 126, 3447-3452.	3.9	439
730	Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer?. <i>Cancer Biology and Medicine</i> , 2016, 13, 157-170.	1.4	86
731	Genetic alteration profiling of patients with resected squamous cell lung carcinomas. <i>Oncotarget</i> , 2016, 7, 36590-36601.	0.8	20
732	Targeted therapies and immunotherapy in non-small-cell lung cancer. <i>Ecancermedicalsecience</i> , 2016, 10, 648.	0.6	29
733	Clinicopathological and immunohistochemical features of lung invasive mucinous adenocarcinoma based on computed tomography findings. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 153-163.	1.0	28
734	>nab-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 101-112.	1.0	60

#	ARTICLE	IF	CITATIONS
735	Prognostic value of tumor infiltrating NK cells and macrophages in stage II+III esophageal cancer patients. <i>Oncotarget</i> , 2016, 7, 74904-74916.	0.8	55
736	Profile of nivolumab in the treatment of metastatic squamous non-small-cell lung cancer. <i>OncoTargets and Therapy</i> , 2016, 9, 3187.	1.0	11
737	New targeted treatments for non-small-cell lung cancer – role of nivolumab. <i>Biologics: Targets and Therapy</i> , 2016, Volume 10, 103-117.	3.0	23
738	Cancer of the Pancreas: Molecular Pathways and Current Advancement in Treatment. <i>Journal of Cancer</i> , 2016, 7, 1497-1514.	1.2	71
739	Follicular Helper T Cells in Systemic Lupus Erythematosus: Why Should They Be Considered as Interesting Therapeutic Targets?. <i>Journal of Immunology Research</i> , 2016, 2016, 1-13.	0.9	24
740	Lung cancer in Brazil: epidemiology and treatment challenges. <i>Lung Cancer: Targets and Therapy</i> , 2016, Volume 7, 141-148.	1.3	16
741	Enhanced Anti-tumor Reactivity of Cytotoxic T Lymphocytes Expressing PD-1 Decoy. <i>Immune Network</i> , 2016, 16, 134.	1.6	8
742	microRNA-7-5p inhibits melanoma cell proliferation and metastasis by suppressing RelA/NF- κ B. <i>Oncotarget</i> , 2016, 7, 31663-31680.	0.8	71
743	T cell Bim levels reflect responses to anti- α PD-1 cancer therapy. <i>JCI Insight</i> , 2016, 1, .	2.3	68
744	Immunological battlefield in gastric cancer and role of immunotherapies. <i>World Journal of Gastroenterology</i> , 2016, 22, 6373.	1.4	33
745	The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability vs. PD-L1. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 771-788.	0.6	84
746	Multiplatform molecular profiling identifies potentially targetable biomarkers in malignant phyllodes tumors of the breast. <i>Oncotarget</i> , 2016, 7, 1707-1716.	0.8	25
747	Improving the clinical impact of biomaterials in cancer immunotherapy. <i>Oncotarget</i> , 2016, 7, 15421-15443.	0.8	56
748	Repeated observation of immune gene sets enrichment in women with non-small cell lung cancer. <i>Oncotarget</i> , 2016, 7, 20282-20292.	0.8	28
749	The head and neck cancer immune landscape and its immunotherapeutic implications. <i>JCI Insight</i> , 2016, 1, e89829.	2.3	569
750	Merkel Cell Carcinoma: An Unusually Immunogenic Cancer Proves Ripe for Immune Therapy. <i>Journal of Oncology Practice</i> , 2016, 12, 649-650.	2.5	8
751	MDSC-decreasing chemotherapy increases the efficacy of cytokine-induced killer cell immunotherapy in metastatic renal cell carcinoma and pancreatic cancer. <i>Oncotarget</i> , 2016, 7, 4760-4769.	0.8	56
752	Immunoproteasomes and immunotherapyâ€”a smoking gun for lung cancer?. <i>Journal of Thoracic Disease</i> , 2016, 8, E558-E563.	0.6	7

#	ARTICLE	IF	CITATIONS
753	Adjuvant immunotherapy in resected early non-small cell lung cancerâ€”battle lost, hopefully not the war!. <i>Journal of Thoracic Disease</i> , 2016, 8, 1886-1890.	0.6	2
754	PD-L1 expression in lung cancer. <i>Journal of Thoracic Disease</i> , 2016, 8, 3053-3055.	0.6	2
755	Are immune checkpoint blockade monoclonal antibodies active against CNS metastases from NSCLC?â€”current evidence and future perspectives. <i>Translational Lung Cancer Research</i> , 2016, 5, 628-636.	1.3	15
756	Pembrolizumab as first-line treatment for non-small cell lung cancerâ€”a game changer?. <i>Translational Lung Cancer Research</i> , 2016, 5, 538-542.	1.3	4
757	Metastatic lymphoepithelioma-like carcinoma of the lung treated with nivolumab: a case report and focused review of literature. <i>Translational Lung Cancer Research</i> , 2016, 5, 720-726.	1.3	32
758	Molecularly targeted therapy for advanced hepatocellular carcinoma - a drug development crisis?. <i>World Journal of Gastrointestinal Oncology</i> , 2016, 8, 173.	0.8	28
759	Beyond RAS and BRAF: a target rich disease that is ripe for picking. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 705-712.	0.6	2
760	Dramatic response to anti-PD-1 therapy in a patient of squamous cell carcinoma of thymus with multiple lung metastases. <i>Journal of Thoracic Disease</i> , 2016, 8, E535-E537.	0.6	21
761	Tackling ALK in non-small cell lung cancer: the role of novel inhibitors. <i>Translational Lung Cancer Research</i> , 2016, 5, 301-321.	1.3	37
762	Summary of emerging personalized medicine in neuroendocrine tumors: are we on track?. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 804-818.	0.6	9
763	Cocktails for cancer with a measure of immunotherapy. <i>Nature</i> , 2016, 532, 162-164.	13.7	53
764	Stereotactic body radiotherapy for the pancreas: a critical review for the medical oncologist. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 479-486.	0.6	21
765	The role of surgical intervention in lung cancer with carcinomatous pleuritis. <i>Journal of Thoracic Disease</i> , 2016, 8, S901-S907.	0.6	10
766	Efficacy and safety of nivolumab combined with standard therapies for first-line therapy of advanced non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2016, 8, E1254-E1256.	0.6	0
767	Immune checkpoint therapy for pancreatic cancer. <i>World Journal of Gastroenterology</i> , 2016, 22, 9457.	1.4	73
768	Dendritic cell-based vaccine for pancreatic cancer in Japan. <i>World Journal of Gastrointestinal Pharmacology and Therapeutics</i> , 2016, 7, 133.	0.6	22
769	The Kynurenine/Tryptophan Ratio and Glioblastoma Patients Treated with Hsppc-96 Vaccine. <i>Immunotherapy (Los Angeles, Calif)</i> , 2016, 2, .	0.1	5
770	Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy. <i>Oncotarget</i> , 2016, 7, 77404-77415.	0.8	139

#	ARTICLE	IF	CITATIONS
771	Melatonin as a potential anticarcinogen for non-small-cell lung cancer. <i>Oncotarget</i> , 2016, 7, 46768-46784.	0.8	85
772	Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors. <i>Oncotarget</i> , 2016, 7, 76565-76576.	0.8	100
773	Targeting microenvironment in cancer therapeutics. <i>Oncotarget</i> , 2016, 7, 52575-52583.	0.8	52
774	TGF- β^2 and VEGF cooperatively control the immunotolerant tumor environment and the efficacy of cancer immunotherapies. <i>JCI Insight</i> , 2016, 1, e85974.	2.3	91
775	Interplay between Cellular and Molecular Inflammatory Mediators in Lung Cancer. <i>Mediators of Inflammation</i> , 2016, 2016, 1-11.	1.4	29
776	Current Immunotherapies for Sarcoma: Clinical Trials and Rationale. <i>Sarcoma</i> , 2016, 2016, 1-6.	0.7	20
777	A Case of Non-Small Cell Lung Cancer with Possible "Disease Flare" on Nivolumab Treatment. <i>Case Reports in Oncological Medicine</i> , 2016, 2016, 1-3.	0.2	28
778	Randomized Phase II Study of Docetaxel plus Personalized Peptide Vaccination versus Docetaxel plus Placebo for Patients with Previously Treated Advanced Wild Type EGFR Non-Small-Cell Lung Cancer. <i>Journal of Immunology Research</i> , 2016, 2016, 1-7.	0.9	17
779	The Immune System in Cancer Pathogenesis: Potential Therapeutic Approaches. <i>Journal of Immunology Research</i> , 2016, 2016, 1-13.	0.9	153
780	Pathogen-Associated Molecular Patterns Induced Crosstalk between Dendritic Cells, T Helper Cells, and Natural Killer Helper Cells Can Improve Dendritic Cell Vaccination. <i>Mediators of Inflammation</i> , 2016, 2016, 1-12.	1.4	25
781	Can the Neutrophil to Lymphocyte Ratio Be Used to Determine Gastric Cancer Treatment Outcomes? A Systematic Review and Meta-Analysis. <i>Disease Markers</i> , 2016, 2016, 1-10.	0.6	72
782	Evaluation of PD-L1 Expression in Tumor Tissue of Patients with Lung Carcinoma and Correlation with Clinical and Demographic Data. <i>Journal of Immunology Research</i> , 2016, 2016, 1-12.	0.9	17
783	Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium. <i>Journal of Immunology Research</i> , 2016, 2016, 1-14.	0.9	36
784	Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational Modifications. <i>Journal of Immunology Research</i> , 2016, 2016, 1-18.	0.9	154
785	Proteomic-Based Approaches for the Study of Cytokines in Lung Cancer. <i>Disease Markers</i> , 2016, 2016, 1-12.	0.6	26
786	From Inflammation to Prostate Cancer: The Role of Inflammasomes. <i>Advances in Urology</i> , 2016, 2016, 1-5.	0.6	50
787	PD-1 blockade enhances the vaccination-induced immune response in glioma. <i>JCI Insight</i> , 2016, 1, .	2.3	128
788	PD1 blockade enhances cytotoxicity of <i>in vitro</i> expanded natural killer cells towards myeloma cells. <i>Oncotarget</i> , 2016, 7, 48360-48374.	0.8	57

#	ARTICLE	IF	CITATIONS
789	AKT-STAT3 Pathway as a Downstream Target of EGFR Signaling to Regulate PD-L1 Expression on NSCLC cells. <i>Journal of Cancer</i> , 2016, 7, 1579-1586.	1.2	90
790	Enhanced Anti-Tumor Efficacy through a Combination of Integrin $\alpha_6\beta_4$ -Targeted Photodynamic Therapy and Immune Checkpoint Inhibition. <i>Theranostics</i> , 2016, 6, 627-637.	4.6	92
791	Toxicity management of immunotherapy for patients with metastatic melanoma. <i>Annals of Translational Medicine</i> , 2016, 4, 272-272.	0.7	92
792	Potential role of immunotherapy in advanced non-small-cell lung cancer. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 21-30.	1.0	46
793	Advances in targeted and immunobased therapies for colorectal cancer in the genomic era. <i>OncoTargets and Therapy</i> , 2016, 9, 1899.	1.0	44
794	Current Status and Perspective of Immunotherapy in Gastrointestinal Cancers. <i>Journal of Cancer</i> , 2016, 7, 1599-1604.	1.2	8
795	The multifaceted role of autophagy in tumor evasion from immune surveillance. <i>Oncotarget</i> , 2016, 7, 17591-17607.	0.8	53
796	Repurposing metformin for cancer treatment: current clinical studies. <i>Oncotarget</i> , 2016, 7, 40767-40780.	0.8	252
797	Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model. <i>Oncotarget</i> , 2016, 7, 34341-34355.	0.8	258
798	High-Resolution PET Imaging with Therapeutic Antibody-based PD-1/PD-L1 Checkpoint Tracers. <i>Theranostics</i> , 2016, 6, 1629-1640.	4.6	167
799	An update on clinical oncology for the non-oncologist. <i>Einstein (Sao Paulo, Brazil)</i> , 2016, 14, 294-299.	0.3	2
800	Clinical utility of nivolumab in the treatment of advanced melanoma. <i>Therapeutics and Clinical Risk Management</i> , 2016, 12, 313.	0.9	16
801	High-Grade Glioma Management and Response Assessment—Recent Advances and Current Challenges. <i>Current Oncology</i> , 2016, 23, 383-391.	0.9	33
802	Neither the maximum tumor size nor solid component size is prognostic in part-solid lung cancer: to be ground-glass opacity or not to be, is that really the question?. <i>Journal of Thoracic Disease</i> , 2016, 8, 2334-2336.	0.6	3
803	The emerging role of immunotherapy in colorectal cancer. <i>Annals of Translational Medicine</i> , 2016, 4, 305-305.	0.7	63
804	Overcoming Hypoxia-Mediated Tumor Progression: Combinatorial Approaches Targeting pH Regulation, Angiogenesis and Immune Dysfunction. <i>Frontiers in Cell and Developmental Biology</i> , 2016, 4, 27.	1.8	107
805	Monitoring of the Immune Dysfunction in Cancer Patients. <i>Vaccines</i> , 2016, 4, 29.	2.1	15
806	Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors. <i>Vaccines</i> , 2016, 4, 37.	2.1	63

#	ARTICLE	IF	CITATIONS
807	Comparative Aspects of Canine Melanoma. <i>Veterinary Sciences</i> , 2016, 3, 7.	0.6	78
808	Non-small cell lung cancer: current treatment and future advances. <i>Translational Lung Cancer Research</i> , 2016, 5, 288-300.	1.3	1,256
809	SÅ©zary Syndrome and Atopic Dermatitis: Comparison of Immunological Aspects and Targets. <i>BioMed Research International</i> , 2016, 2016, 1-15.	0.9	33
810	Harnessing the immune system to improve cancer therapy. <i>Annals of Translational Medicine</i> , 2016, 4, 261-261.	0.7	225
811	Improving the efficiency of image guided brachytherapy in cervical cancer. <i>Journal of Contemporary Brachytherapy</i> , 2016, 6, 557-565.	0.4	15
812	Natural Killer Cell Recognition of Melanoma: New Clues for a More Effective Immunotherapy. <i>Frontiers in Immunology</i> , 2015, 6, 649.	2.2	35
813	Inducing and Administering Tregs to Treat Human Disease. <i>Frontiers in Immunology</i> , 2015, 6, 654.	2.2	40
814	Exploiting the Immunogenic Potential of Cancer Cells for Improved Dendritic Cell Vaccines. <i>Frontiers in Immunology</i> , 2015, 6, 663.	2.2	74
815	Differential Expression of Immune Checkpoint Modulators on In Vitro Primed CD4+ and CD8+ T Cells. <i>Frontiers in Immunology</i> , 2016, 7, 221.	2.2	20
816	A Well-Controlled Experimental System to Study Interactions of Cytotoxic T Lymphocytes with Tumor Cells. <i>Frontiers in Immunology</i> , 2016, 7, 326.	2.2	22
817	Glatiramer Acetate, Dimethyl Fumarate, and Monomethyl Fumarate Upregulate the Expression of CCR10 on the Surface of Natural Killer Cells and Enhance Their Chemotaxis and Cytotoxicity. <i>Frontiers in Immunology</i> , 2016, 7, 437.	2.2	17
818	IL-1Î², But Not Programed Death-1 and Programed Death Ligand Pathway, Is Critical for the Human Th17 Response to <i>Mycobacterium tuberculosis</i> . <i>Frontiers in Immunology</i> , 2016, 7, 465.	2.2	16
819	The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation. <i>Frontiers in Immunology</i> , 2016, 7, 550.	2.2	409
820	PD-L1 Is Not Constitutively Expressed on Tasmanian Devil Facial Tumor Cells but Is Strongly Upregulated in Response to IFN-Î³ and Can Be Expressed in the Tumor Microenvironment. <i>Frontiers in Immunology</i> , 2016, 7, 581.	2.2	41
821	Chemoradiation Increases PD-L1 Expression in Certain Melanoma and Glioblastoma Cells. <i>Frontiers in Immunology</i> , 2016, 7, 610.	2.2	111
822	The Role of the Tumor Vasculature in the Host Immune Response: Implications for Therapeutic Strategies Targeting the Tumor Microenvironment. <i>Frontiers in Immunology</i> , 2016, 7, 621.	2.2	132
823	Focus on Alectinib and Competitor Compounds for Second-Line Therapy in ALK-Rearranged NSCLC. <i>Frontiers in Medicine</i> , 2016, 3, 65.	1.2	8
824	Focus on Nivolumab in NSCLC. <i>Frontiers in Medicine</i> , 2016, 3, 67.	1.2	7

#	ARTICLE	IF	CITATIONS
825	Quercetin as an Emerging Anti-Melanoma Agent: A Four-Focus Area Therapeutic Development Strategy. <i>Frontiers in Nutrition</i> , 2016, 3, 48.	1.6	41
826	Systemic Immunotherapy for the Treatment of Brain Metastases. <i>Frontiers in Oncology</i> , 2016, 6, 49.	1.3	66
827	Cytokine-Induced Modulation of Colorectal Cancer. <i>Frontiers in Oncology</i> , 2016, 6, 96.	1.3	181
828	Bone Marrow Immunity and Myelodysplasia. <i>Frontiers in Oncology</i> , 2016, 6, 172.	1.3	32
829	Are We Making Personalized Cancer Care Less Personalized?. <i>Frontiers in Oncology</i> , 2016, 6, 220.	1.3	0
830	Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy. <i>Frontiers in Oncology</i> , 2016, 6, 233.	1.3	148
831	Recent Advances in Immunotherapy in Metastatic NSCLC. <i>Frontiers in Oncology</i> , 2016, 6, 239.	1.3	29
832	Hijacker of the Antitumor Immune Response: Autophagy Is Showing Its Worst Facet. <i>Frontiers in Oncology</i> , 2016, 6, 246.	1.3	22
833	Long-term Response to Nivolumab and Acute Renal Failure in a Patient with Metastatic Papillary Renal Cell Carcinoma and a PD-L1 Tumor Expression Increased with Sunitinib Therapy: A Case Report. <i>Frontiers in Oncology</i> , 2016, 6, 250.	1.3	17
834	Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?. <i>Frontiers in Oncology</i> , 2016, 6, 256.	1.3	39
835	Dissecting the Biology of Menstrual Cycle-Associated Breast Cancer Risk. <i>Frontiers in Oncology</i> , 2016, 6, 267.	1.3	37
836	Biomarkers for immune therapy in colorectal cancer: mismatch-repair deficiency and others. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 713-720.	0.6	45
837	Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward?. <i>Antibodies</i> , 2016, 5, 1.	1.2	34
838	Capitalizing on Cancer Specific Replication: Oncolytic Viruses as a Versatile Platform for the Enhancement of Cancer Immunotherapy Strategies. <i>Biomedicines</i> , 2016, 4, 21.	1.4	11
839	Updates in Therapy for Advanced Melanoma. <i>Cancers</i> , 2016, 8, 17.	1.7	37
840	Targeted Therapy in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (LA-R/M HNSCC). <i>Cancers</i> , 2016, 8, 27.	1.7	42
841	A Perspective of Immunotherapy for Prostate Cancer. <i>Cancers</i> , 2016, 8, 64.	1.7	28
842	Novel Immunotherapeutic Approaches for Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2016, 8, 87.	1.7	30

#	ARTICLE	IF	CITATIONS
843	Advances in Cancer Immunotherapy in Solid Tumors. <i>Cancers</i> , 2016, 8, 106.	1.7	131
844	First- and Second-Line Targeted Systemic Therapy in Hepatocellular Carcinoma—An Update on Patient Selection and Response Evaluation. <i>Diagnostics</i> , 2016, 6, 44.	1.3	11
845	The Utilization of the Immune System in Lung Cancer Treatment: Beyond Chemotherapy. <i>International Journal of Molecular Sciences</i> , 2016, 17, 286.	1.8	7
846	Case Characterization, Clinical Features and Risk Factors in Drug-Induced Liver Injury. <i>International Journal of Molecular Sciences</i> , 2016, 17, 714.	1.8	69
847	Immune Mechanisms in Myelodysplastic Syndrome. <i>International Journal of Molecular Sciences</i> , 2016, 17, 944.	1.8	48
848	The Immunogenicity of Colorectal Cancer in Relation to Tumor Development and Treatment. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1030.	1.8	33
849	A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1151.	1.8	134
850	Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1169.	1.8	53
851	Role of Oxidative Stress in Drug-Induced Kidney Injury. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1826.	1.8	131
852	Immunotherapy for Gastroesophageal Cancer. <i>Journal of Clinical Medicine</i> , 2016, 5, 84.	1.0	41
853	Immunoregulation in Fungal Diseases. <i>Microorganisms</i> , 2016, 4, 47.	1.6	14
854	Cytotoxic and Pro-Apoptotic Effects of Cassane Diterpenoids from the Seeds of <i>Caesalpinia sappan</i> in Cancer Cells. <i>Molecules</i> , 2016, 21, 791.	1.7	30
855	Impact of aging on host immune response and survival in melanoma: an analysis of 3 patient cohorts. <i>Journal of Translational Medicine</i> , 2016, 14, 299.	1.8	26
856	Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors—an autopsy study. , 2016, 4, 13.		162
857	PD-1/CTLA-4 Blockade Inhibits Epstein-Barr Virus-Induced Lymphoma Growth in a Cord Blood Humanized-Mouse Model. <i>PLoS Pathogens</i> , 2016, 12, e1005642.	2.1	87
858	PD-1 Antibody Monotherapy for Malignant Melanoma: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2016, 11, e0160485.	1.1	33
859	Evaluation of Costimulatory Molecules in Peripheral Blood Lymphocytes of Canine Patients with Histiocytic Sarcoma. <i>PLoS ONE</i> , 2016, 11, e0150030.	1.1	25
860	PD-L1 and Tumor Infiltrating Lymphocytes as Prognostic Markers in Resected NSCLC. <i>PLoS ONE</i> , 2016, 11, e0153954.	1.1	73

#	ARTICLE	IF	CITATIONS
861	Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology. PLoS ONE, 2016, 11, e0161779.	1.1	172
862	Efficient Killing of High Risk Neuroblastoma Using Natural Killer Cells Activated by Plasmacytoid Dendritic Cells. PLoS ONE, 2016, 11, e0164401.	1.1	20
863	A Stromal Immune Module Correlated with the Response to Neoadjuvant Chemotherapy, Prognosis and Lymphocyte Infiltration in HER2-Positive Breast Carcinoma Is Inversely Correlated with Hormonal Pathways. PLoS ONE, 2016, 11, e0167397.	1.1	9
864	A retrospective analysis of safety and efficacy of weekly nab-paclitaxel as second-line chemotherapy in elderly patients with advanced squamous non-small-cell lung carcinoma. Clinical Interventions in Aging, 2016, 11, 167.	1.3	15
865	Incidence and risk of hepatic toxicities with PD-1 inhibitors in cancer patients: a meta-analysis. Drug Design, Development and Therapy, 2016, Volume 10, 3153-3161.	2.0	29
866	The efficacy and safety of nivolumab in previously treated advanced non-small-cell lung cancer: a meta-analysis of prospective clinical trials. OncoTargets and Therapy, 2016, Volume 9, 5867-5874.	1.0	22
867	The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs. Journal of Cancer, 2016, 7, 484-489.	1.2	106
868	PD-L1 expression in human cancers and its association with clinical outcomes. OncoTargets and Therapy, 2016, Volume 9, 5023-5039.	1.0	558
869	Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting. Vaccines, 2016, 4, 28.	2.1	372
870	Immune checkpoint inhibitors: the new frontier in non-small cell lung cancer treatment. OncoTargets and Therapy, 2016, Volume 9, 5101-5116.	1.0	27
871	Spotlight on afatinib and its potential in the treatment of squamous cell lung cancer: the evidence so far. Therapeutics and Clinical Risk Management, 2016, 12, 807.	0.9	10
872	Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations. OncoTargets and Therapy, 2016, 9, 3711.	1.0	98
873	PD-1/PD-L1 blockades in non-small-cell lung cancer therapy. OncoTargets and Therapy, 2016, 9, 489.	1.0	43
874	Inhibiting Immune Checkpoints for the Treatment of Bladder Cancer. Bladder Cancer, 2016, 2, 15-25.	0.2	29
875	The efficacy and potential predictive factors of PD-1/PD-L1 blockades in epithelial carcinoma patients: a systematic review and meta analysis. Oncotarget, 2016, 7, 74350-74361.	0.8	35
876	The efficacy and safety of nivolumab in the treatment of advanced melanoma: a meta-analysis of clinical trials. OncoTargets and Therapy, 2016, 9, 1571.	1.0	7
877	Current classification, treatment options, and new perspectives in the management of adipocytic sarcomas. OncoTargets and Therapy, 2016, Volume 9, 6233-6246.	1.0	65
878	Combination therapy for metastatic renal cell carcinoma. Annals of Translational Medicine, 2016, 4, 100-100.	0.7	22

#	ARTICLE	IF	CITATIONS
879	Radiation therapy and the abscopal effect: a concept comes of age. <i>Annals of Translational Medicine</i> , 2016, 4, 118-118.	0.7	61
880	The role of pembrolizumab in the treatment of advanced non-small cell lung cancer. <i>Annals of Translational Medicine</i> , 2016, 4, 215-215.	0.7	13
881	Immunotherapy in non-small cell lung cancer: the clinical impact of immune response and targeting. <i>Annals of Translational Medicine</i> , 2016, 4, 268-268.	0.7	16
882	The Role of the Transcription Factor Ets1 in Lupus and Other Autoimmune Diseases. <i>Critical Reviews in Immunology</i> , 2016, 36, 485-510.	1.0	36
883	Methylation of RAD51B, XRCC3 and other homologous recombination genes is associated with expression of immune checkpoints and an inflammatory signature in squamous cell carcinoma of the head and neck, lung and cervix. <i>Oncotarget</i> , 2016, 7, 75379-75393.	0.8	27
884	Suspected autoimmune myocarditis and cardiac conduction abnormalities with nivolumab therapy for non-small cell lung cancer. <i>BMJ Case Reports</i> , 2016, 2016, bcr2016216228.	0.2	61
885	A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors. <i>Oncotarget</i> , 2016, 7, 10215-10227.	0.8	158
886	The challenge of developmental therapeutics for adrenocortical carcinoma. <i>Oncotarget</i> , 2016, 7, 46734-46749.	0.8	17
887	The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis. <i>Oncotarget</i> , 2016, 7, 73068-73079.	0.8	76
888	Distinct genetic profiles of extracranial and intracranial acral melanoma metastases. <i>Journal of Cutaneous Pathology</i> , 2016, 43, 884-891.	0.7	2
889	Residual inflammation and viral reservoirs. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 234-241.	1.5	107
890	Fasting-Mimicking Diet Reduces HO-1 to Promote TÂCell-Mediated Tumor Cytotoxicity. <i>Cancer Cell</i> , 2016, 30, 136-146.	7.7	289
891	Pembrolizumab (Keytruda). <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 2777-2789.	1.4	237
892	Combination immunotherapy for cancer. <i>Journal of Experimental Medicine</i> , 2016, 213, 1115-1115.	4.2	4
893	Benefit-Risk Summary of Crizotinib for the Treatment of Patients With ROS1 Alteration-Positive, Metastatic Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2016, 21, 974-980.	1.9	64
894	Immune checkpoint blockade in human cancer therapy: lung cancer and hematologic malignancies. <i>Immunotherapy</i> , 2016, 8, 809-819.	1.0	44
895	Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges. <i>Immunotherapy</i> , 2016, 8, 821-837.	1.0	139
896	Rationale for immune-based therapies in Merkel polyomavirus-positive and -negative Merkel cell carcinomas. <i>Immunotherapy</i> , 2016, 8, 907-921.	1.0	20

#	ARTICLE	IF	CITATIONS
897	Mechanisms of adaptation and progression in idiosyncratic drug induced liver injury, clinical implications. <i>Liver International</i> , 2016, 36, 158-165.	1.9	103
898	Rendomab B4, a monoclonal antibody that discriminates the human endothelin B receptor of melanoma cells and inhibits their migration. <i>MAbs</i> , 2016, 8, 1371-1385.	2.6	7
899	Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery. <i>Cancer</i> , 2016, 122, 3051-3058.	2.0	182
900	Genetically Engineered Mouse Models of Pancreatic Cancer: The KPC Model (<i>LSL^{Kras}G12D/+</sup>;LSL^{Trp53}R172H/+</sup>;Pdx¹Cre</i>), Its Variants, and Their Application in Immunology and Oncology Drug Discovery. <i>Current Protocols in Pharmacology</i> , 2016, 73, 14.39.1-14.39.20.	4.0	141
901	Ischemia as a factor affecting innate immune responses in kidney transplantation. <i>Current Opinion in Nephrology and Hypertension</i> , 2016, 25, 3-11.	1.0	12
902	Future directions in the treatment of osteosarcoma. <i>Current Opinion in Pediatrics</i> , 2016, 28, 26-33.	1.0	228
903	Immune Checkpoint Therapy and the Search for Predictive Biomarkers. <i>Cancer Journal (Sudbury, Mass)</i> 2016, 22, 107-114.	1.0	31
904	Targeting microRNAs as key modulators of tumor immune response. <i>Journal of Experimental and Clinical Cancer Research</i> , 2016, 35, 103.	3.5	160
905	Prolonged Benefit from Ipilimumab Correlates with Improved Outcomes from Subsequent Pembrolizumab. <i>Cancer Immunology Research</i> , 2016, 4, 569-573.	1.6	20
906	Multispectral Imaging of T and B Cells in Murine Spleen and Tumor. <i>Journal of Immunology</i> , 2016, 196, 3943-3950.	0.4	63
907	Comprehensive Immunohistochemical Study of Programmed Cell Death Ligand 1 (PD-L1). <i>American Journal of Surgical Pathology</i> , 2016, 40, 1133-1142.	2.1	85
908	Targeted Therapies Combined With Immune Checkpoint Therapy. <i>Cancer Journal (Sudbury, Mass)</i> , 2016, 22, 138-146.	1.0	36
909	Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2016, 34, 596-603.	1.2	43
910	Pembrolizumab: first experience with recurrent primary central nervous system (CNS) tumors. <i>Journal of Neuro-Oncology</i> , 2016, 129, 453-460.	1.4	82
911	Advanced Hepatocellular Cancer: the Current State of Future Research. <i>Current Treatment Options in Oncology</i> , 2016, 17, 43.	1.3	50
912	Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 1484-1499.	1.0	75
913	The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints. <i>Haematologica</i> , 2016, 101, 794-802.	1.7	94
914	Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model. <i>Journal of Immunology</i> , 2016, 197, 1477-1488.	0.4	42

#	ARTICLE	IF	CITATIONS
915	Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2969-2979.	0.8	397
916	Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2980-2987.	0.8	444
917	Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas. <i>Modern Pathology</i> , 2016, 29, 1165-1172.	2.9	340
918	Immune Checkpoint Therapies in Prostate Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2016, 22, 117-120.	1.0	46
919	The current status of checkpoint inhibitors in metastatic bladder cancer. <i>Clinical and Experimental Metastasis</i> , 2016, 33, 629-635.	1.7	11
920	Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer. <i>British Journal of Cancer</i> , 2016, 115, 252-260.	2.9	66
921	Stimulatory versus suppressive effects of GM-CSF on tumor progression in multiple cancer types. <i>Experimental and Molecular Medicine</i> , 2016, 48, e242-e242.	3.2	167
922	Nonoverlapping roles of PD-1 and FoxP3 in maintaining immune tolerance in a novel autoimmune pancreatitis mouse model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 8490-8495.	3.3	140
923	Updates in the management of brain metastases. <i>Neuro-Oncology</i> , 2016, 18, 1043-1065.	0.6	209
924	The clinical utility of PD-L1 testing in selecting non-small cell lung cancer patients for PD1/PD-L1-directed therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 100, 212-214.	2.3	20
925	NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 255-264.	2.3	335
926	NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 1213-1224.	2.3	93
927	Measurement of quality of life in second-line patients with advanced NSCLC without targetable mutations: a review. <i>Lung Cancer Management</i> , 2016, 5, 105-116.	1.5	1
928	A stochastic model for immunotherapy of cancer. <i>Scientific Reports</i> , 2016, 6, 24169.	1.6	42
929	Metastatic Merkel cell carcinoma response to nivolumab. , 2016, 4, 79.		40
930	Pin1-FoxM1 inhibitors: a potential therapeutic for metastatic melanoma?. <i>Melanoma Management</i> , 2016, 3, 161-164.	0.1	2
931	What does PD-L1 positive or negative mean?. <i>Journal of Experimental Medicine</i> , 2016, 213, 2835-2840.	4.2	263
932	Filling the Tank: Keeping Antitumor T Cells Metabolically Fit for the Long Haul. <i>Cancer Immunology Research</i> , 2016, 4, 1001-1006.	1.6	22

#	ARTICLE	IF	CITATIONS
933	Validation of biomarkers to predict response to immunotherapy in cancer: Volume I “pre-analytical and analytical validation. , 2016, 4, 76.		155
934	The role of immune checkpoint inhibition in the treatment of ovarian cancer. <i>Gynecologic Oncology Research and Practice</i> , 2016, 3, 11.	3.6	118
935	Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy. <i>Npj Genomic Medicine</i> , 2016, 1, .	1.7	103
936	Aldehyde reductase participates in the downregulation of T cell functions due to suppressor macrophages. <i>Scientific Reports</i> , 2016, 6, 21093.	1.6	5
937	Responses to immune checkpoint inhibitors in nonagenarians. <i>Oncolmmunology</i> , 2016, 5, e1234572.	2.1	24
938	Predictive biomarkers for checkpoint inhibitor-based immunotherapy. <i>Lancet Oncology</i> , The, 2016, 17, e542-e551.	5.1	1,274
939	The cost and value of cancer drugs “are new innovations outpacing our ability to pay?. <i>Israel Journal of Health Policy Research</i> , 2016, 5, 40.	1.4	18
940	PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer. <i>Breast Care</i> , 2016, 11, 385-390.	0.8	20,872
941	Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: a case report & review of the literature. , 2016, 4, 94.		91
942	Enhancing the treatment effect on melanoma by heat shock protein 70-peptide complexes purified from human melanoma cell lines. <i>Oncology Reports</i> , 2016, 36, 1243-1250.	1.2	7
943	Cancer immunotherapy trials: leading a paradigm shift in drug development. , 2016, 4, 42.		35
944	Vitamin D3 pretreatment regulates renal inflammatory responses during lipopolysaccharide-induced acute kidney injury. <i>Scientific Reports</i> , 2016, 5, 18687.	1.6	62
945	High expression levels of egfl7 correlate with low endothelial cell activation in peritumoral vessels of human breast cancer. <i>Oncology Letters</i> , 2016, 12, 1422-1428.	0.8	12
946	Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma. , 2016, 4, 44.		54
947	Canine cancer immunotherapy studies: linking mouse and human. , 2016, 4, 97.		86
948	Distinct phenotypic subpopulations of circulating CD4+CXCR5+ follicular helper T cells in children with active IgA vasculitis. <i>BMC Immunology</i> , 2016, 17, 40.	0.9	9
949	A New VISTA on combination therapy for negative checkpoint regulator blockade. , 2016, 4, 86.		36
950	Emerging roles of T helper 17 and regulatory T cells in lung cancer progression and metastasis. <i>Molecular Cancer</i> , 2016, 15, 67.	7.9	141

#	ARTICLE	IF	CITATIONS
951	Immune checkpoint inhibitors for hepatocellular carcinoma. <i>Hepatic Oncology</i> , 2016, 3, 201-211.	4.2	5
952	Nivolumab-associated acute glomerulonephritis: a case report and literature review. <i>BMC Nephrology</i> , 2016, 17, 188.	0.8	91
953	PD-L1 is upregulated by EBV-driven LMP1 through NF- κ B pathway and correlates with poor prognosis in natural killer/T-cell lymphoma. <i>Journal of Hematology and Oncology</i> , 2016, 9, 109.	6.9	217
954	Genomic landscape of colorectal cancer in Japan: clinical implications of comprehensive genomic sequencing for precision medicine. <i>Genome Medicine</i> , 2016, 8, 136.	3.6	64
955	Patient-derived xenograft (PDX) models in basic and translational breast cancer research. <i>Cancer and Metastasis Reviews</i> , 2016, 35, 547-573.	2.7	189
956	Development of bullous pemphigoid during nivolumab therapy. <i>JAAD Case Reports</i> , 2016, 2, 442-444.	0.4	60
957	Non-small cell lung cancer is characterised by a distinct inflammatory signature in serum compared with chronic obstructive pulmonary disease. <i>Clinical and Translational Immunology</i> , 2016, 5, e109.	1.7	26
958	The PD-1/PD-L1 inhibitory pathway is altered in pre-eclampsia and regulates T cell responses in pre-eclamptic rats. <i>Scientific Reports</i> , 2016, 6, 27683.	1.6	69
959	Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab. <i>Scientific Reports</i> , 2016, 6, 31726.	1.6	232
960	Emerging therapeutic agents for lung cancer. <i>Journal of Hematology and Oncology</i> , 2016, 9, 138.	6.9	77
961	Advancements in unresectable melanoma: a multidisciplinary perspective. <i>Melanoma Management</i> , 2016, 3, 171-175.	0.1	0
962	Dendritic cell vaccines for melanoma: past, present and future. <i>Melanoma Management</i> , 2016, 3, 273-289.	0.1	20
963	Vaccine therapy + dasatinib for the treatment of patients with stage IIIb-IV melanoma. <i>Melanoma Management</i> , 2016, 3, 251-254.	0.1	4
964	The cutting edge of metastatic melanoma therapy. <i>Melanoma Management</i> , 2016, 3, 217-229.	0.1	1
965	A review of drugs in development for the personalized treatment of head and neck squamous cell carcinoma. <i>Expert Review of Precision Medicine and Drug Development</i> , 2016, 1, 379-385.	0.4	5
966	B Lymphocytes and Cancer: A Love-Hate Relationship. <i>Trends in Cancer</i> , 2016, 2, 747-757.	3.8	284
967	Cancer Prevention: Lessons Learned and Future Directions. <i>Trends in Cancer</i> , 2016, 2, 713-722.	3.8	15
968	Endogenous programmed death ligand-1 restrains the development and onset of Sjögren's syndrome in non-obese diabetic mice. <i>Scientific Reports</i> , 2016, 6, 39105.	1.6	27

#	ARTICLE	IF	CITATIONS
969	Variations in DNA methylation of interferon gamma and programmed death 1 in allograft rejection after kidney transplantation. <i>Clinical Epigenetics</i> , 2016, 8, 116.	1.8	22
970	Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies. <i>Journal of Translational Medicine</i> , 2016, 14, 173.	1.8	103
971	Diversity and collaboration for effective immunotherapy. <i>Nature Medicine</i> , 2016, 22, 1390-1391.	15.2	8
972	PD-L1 polymorphism can predict clinical outcomes of non-small cell lung cancer patients treated with first-line paclitaxel-cisplatin chemotherapy. <i>Scientific Reports</i> , 2016, 6, 25952.	1.6	36
973	Checkpoint inhibition in myeloma. <i>Hematology American Society of Hematology Education Program</i> , 2016, 2016, 528-533.	0.9	10
974	Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment. <i>European Respiratory Review</i> , 2016, 25, 472-486.	3.0	225
975	A meta-analysis of efficacy and safety of antibodies targeting PD-1/PD-L1 in treatment of advanced nonsmall cell lung cancer. <i>Medicine (United States)</i> , 2016, 95, e5539.	0.4	37
976	Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non-small-cell Lung Cancer. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2016, 24, 392-397.	0.6	261
977	Impact of Immune-Modulatory Drugs on Regulatory T Cell. <i>Transplantation</i> , 2016, 100, 2288-2300.	0.5	99
978	A phase I study of TPI 287 in combination with temozolomide for patients with metastatic melanoma. <i>Melanoma Research</i> , 2016, 26, 604-608.	0.6	17
979	Radiotherapy to Control Limited Melanoma Progression Following Ipilimumab. <i>Journal of Immunotherapy</i> , 2016, 39, 373-378.	1.2	19
980	Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma. <i>BMC Cancer</i> , 2016, 16, 434.	1.1	124
981	Challenges in the Delivery of Therapies to Melanoma Brain Metastases. <i>Current Pharmacology Reports</i> , 2016, 2, 309-325.	1.5	18
982	Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma. , 2016, 4, 81.		79
983	Immune Therapy for Prostate Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2016, 22, 334-341.	1.0	16
984	Long-term Consequences of the Acute Neural-Inflammatory Stress Response in the Cancer Surgical Patient: New Findings and Perspectives. <i>International Anesthesiology Clinics</i> , 2016, 54, 58-71.	0.3	4
985	Role of immune cells in pancreatic cancer from bench to clinical application. <i>Medicine (United States)</i> , 2016, 95, e5541.	0.4	118
986	Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients. , 2016, 4, 84.		94

#	ARTICLE	IF	CITATIONS
987	Third-generation CD28/4-1BB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute lymphoblastic leukaemia: a non-randomised, open-label phase I trial protocol. <i>BMJ Open</i> , 2016, 6, e013904.	0.8	63
988	Programmed death-ligand 1 expression in rectal cancer. <i>European Surgery - Acta Chirurgica Austriaca</i> , 2016, 48, 352-356.	0.3	15
989	Immune-related endocrine disorders in novel immune checkpoint inhibition therapy. <i>Genes and Diseases</i> , 2016, 3, 252-256.	1.5	17
990	The rationale for including immune checkpoint inhibition into multimodal primary treatment concepts of head and neck cancer. <i>Cancers of the Head & Neck</i> , 2016, 1, 8.	6.2	22
991	Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients. <i>Journal of Translational Medicine</i> , 2016, 14, 232.	1.8	27
992	Recurrent pleural effusions and cardiac tamponade as possible manifestations of pseudoprogression associated with nivolumab therapy – a report of two cases. , 2016, 4, 80.		80
993	Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2016, 34, 347-354.	1.2	57
994	Targeting persistent androgen receptor signaling in castration-resistant prostate cancer. <i>Medical Oncology</i> , 2016, 33, 44.	1.2	40
995	Considerations for the combination of anticancer vaccines and immune checkpoint inhibitors. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 895-901.	1.4	20
996	Monitoring immune responses in the tumor microenvironment. <i>Current Opinion in Immunology</i> , 2016, 41, 23-31.	2.4	96
997	Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. <i>Journal of Hematology and Oncology</i> , 2016, 9, 47.	6.9	271
998	Neoadjuvant treatment for melanoma: current challenges and future perspectives. <i>Melanoma Management</i> , 2016, 3, 149-159.	0.1	1
999	Adjuvant treatment for stage III melanoma in the era of targeted medicine and immunotherapy. <i>Melanoma Management</i> , 2016, 3, 137-147.	0.1	1
1000	Repeat courses of SRS in patients initially treated with SRS alone for brain-metastatic melanoma. <i>Melanoma Management</i> , 2016, 3, 97-104.	0.1	5
1001	Targeting neoantigens for cancer immunotherapy: Table 1.. <i>International Immunology</i> , 2016, 28, 365-370.	1.8	42
1002	Intralesional treatment for advanced melanoma: what's on the horizon?. <i>Melanoma Management</i> , 2016, 3, 113-123.	0.1	0
1003	Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?. <i>Drugs</i> , 2016, 76, 925-945.	4.9	123
1004	<i>EGFR</i> Mutations and <i>ALK</i> Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis. <i>Clinical Cancer Research</i> , 2016, 22, 4585-4593.	3.2	977

#	ARTICLE	IF	CITATIONS
1005	Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 2389-2397.	0.8	293
1006	Lymph nodes and the melanoma surgeon: re-defining a long-term relationship. <i>Melanoma Management</i> , 2016, 3, 73-82.	0.1	0
1007	Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches. <i>Annals of Oncology</i> , 2016, 27, 1706-1712.	0.6	113
1008	PDL1: The Illusion of an Ideal Biomarker. <i>European Urology Focus</i> , 2016, 1, 269-271.	1.6	11
1009	Emerging molecular classifications and therapeutic implications for gastric cancer. <i>Chinese Journal of Cancer</i> , 2016, 35, 49.	4.9	35
1010	Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma. <i>Current Treatment Options in Oncology</i> , 2016, 17, 31.	1.3	57
1011	Influences of BRAF Inhibitors on the Immune Microenvironment and the Rationale for Combined Molecular and Immune Targeted Therapy. <i>Current Oncology Reports</i> , 2016, 18, 42.	1.8	54
1012	PD-L1 Expression in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 964-975.	0.5	329
1013	Concomitant targeting of programmed death-1 (PD-1) and CD137 improves the efficacy of radiotherapy in a mouse model of human BRAFV600-mutant melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 753-763.	2.0	32
1014	Therapeutic Application of Pharmacogenomics in Oncology. <i>AAPS Journal</i> , 2016, 18, 819-829.	2.2	7
1016	Nivolumab: A Review in Advanced Nonsquamous Non-Small Cell Lung Cancer. <i>Drugs</i> , 2016, 76, 969-978.	4.9	34
1017	PSGL-1 Is an Immune Checkpoint Regulator that Promotes T Cell Exhaustion. <i>Immunity</i> , 2016, 44, 1190-1203.	6.6	116
1018	Co-stimulatory and Co-inhibitory Pathways in Autoimmunity. <i>Immunity</i> , 2016, 44, 1034-1051.	6.6	232
1019	Costimulatory and Coinhibitory Receptor Pathways in Infectious Disease. <i>Immunity</i> , 2016, 44, 1052-1068.	6.6	213
1020	Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation. <i>Immunity</i> , 2016, 44, 989-1004.	6.6	1,538
1021	Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 674-690.	12.5	1,938
1022	The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following?. <i>Targeted Oncology</i> , 2016, 11, 593-603.	1.7	14
1023	Folate-conjugated immunoglobulin targets melanoma tumor cells for NK cell effector functions. <i>Melanoma Research</i> , 2016, 26, 329-337.	0.6	11

#	ARTICLE	IF	CITATIONS
1024	Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab. <i>Clinical Cancer Research</i> , 2016, 22, 5487-5496.	3.2	480
1025	Molecular Drivers of the Non- α -T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer. <i>Cancer Immunology Research</i> , 2016, 4, 563-568.	1.6	293
1026	Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors. <i>Immunotherapy</i> , 2016, 8, 705-719.	1.0	61
1027	Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression. <i>JAMA Oncology</i> , 2016, 2, 1179.	3.4	154
1028	Combined immunotherapy and radiation for treatment of mucosal melanomas of the lower genital tract. <i>Gynecologic Oncology Reports</i> , 2016, 16, 42-46.	0.3	40
1029	PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes. <i>Modern Pathology</i> , 2016, 29, 1104-1112.	2.9	210
1030	Burden of Nonsynonymous Mutations among TCGA Cancers and Candidate Immune Checkpoint Inhibitor Responses. <i>Cancer Research</i> , 2016, 76, 3767-3772.	0.4	124
1031	Phase I study to evaluate toxicity and feasibility of intratumoral injection of β -gal glycolipids in patients with advanced melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 897-907.	2.0	11
1032	CIS is a potent checkpoint in NK cell-mediated tumor immunity. <i>Nature Immunology</i> , 2016, 17, 816-824.	7.0	289
1033	Pembrolizumab for the treatment of advanced melanoma. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 867-873.	0.5	10
1034	Novel therapeutics in metastatic colorectal cancer: molecular insights and pharmacogenomic implications. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 1091-1108.	1.3	9
1035	FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1. <i>Oncologist</i> , 2016, 21, 643-650.	1.9	302
1036	Predictive and Prognostic Clinical Variables in Cancer Patients Treated With Adenoviral Oncolytic Immunotherapy. <i>Molecular Therapy</i> , 2016, 24, 1323-1332.	3.7	28
1037	Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. <i>Science</i> , 2016, 352, 189-196.	6.0	3,421
1038	The Face of the Next Generation in China. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 193, 1090-1091.	2.5	4
1039	PD-L1 Expression and Survival among Patients with Advanced Non-Small Cell Lung Cancer Treated with Chemotherapy. <i>Translational Oncology</i> , 2016, 9, 64-69.	1.7	77
1040	PD-1 Blockade Boosts Radiofrequency Ablation-Elicited Adaptive Immune Responses against Tumor. <i>Clinical Cancer Research</i> , 2016, 22, 1173-1184.	3.2	207
1041	Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1. <i>Cancer Immunology Research</i> , 2016, 4, 383-389.	1.6	247

#	ARTICLE	IF	CITATIONS
1042	Novel targets in the treatment of advanced gastric cancer: a perspective review. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 113-125.	1.4	54
1043	Molecular Pathways: Breaking the Epithelial Cancer Barrier for Chimeric Antigen Receptor and T-cell Receptor Gene Therapy. <i>Clinical Cancer Research</i> , 2016, 22, 1559-1564.	3.2	28
1044	Into the Clinic With Nivolumab and Pembrolizumab. <i>Oncologist</i> , 2016, 21, 527-528.	1.9	17
1045	Zinc-Induced Polymerization of Killer-Cell Ig-like Receptor into Filaments Promotes Its Inhibitory Function at Cytotoxic Immunological Synapses. <i>Molecular Cell</i> , 2016, 62, 21-33.	4.5	23
1046	What are the options for hepatocellular carcinoma patients who progress under sorafenib?. <i>Hepatic Oncology</i> , 2016, 3, 105-108.	4.2	1
1047	Severe Hyponatremia and Immune Nephritis Following an Initial Infusion of Nivolumab. <i>Targeted Oncology</i> , 2016, 11, 553-556.	1.7	32
1048	Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. <i>Nature Reviews Cancer</i> , 2016, 16, 275-287.	12.8	2,133
1049	Characterization of alanine to valine sequence variants in the Fc region of nivolumab biosimilar produced in Chinese hamster ovary cells. <i>MAbs</i> , 2016, 8, 951-960.	2.6	12
1050	The role of neoantigens in response to immune checkpoint blockade. <i>International Immunology</i> , 2016, 28, 411-419.	1.8	148
1051	MicroRNAs provide a novel pathway toward combinatorial immune checkpoint blockade. <i>Neuro-Oncology</i> , 2016, 18, 601-602.	0.6	2
1052	Epithelial to Mesenchymal Transition and Immune Evasion during Lung Cancer Progression: The Chicken or the Egg?. <i>Clinical Cancer Research</i> , 2016, 22, 3422-3424.	3.2	65
1053	Emerging Opportunities and Challenges in Cancer Immunotherapy. <i>Clinical Cancer Research</i> , 2016, 22, 1845-1855.	3.2	242
1054	Programmed death 1 expression in the peritumoral microenvironment is associated with a poorer prognosis in classical Hodgkin lymphoma. <i>Tumor Biology</i> , 2016, 37, 7507-7514.	0.8	40
1055	The Efficacy and Safety of Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors for Advanced Melanoma. <i>Medicine (United States)</i> , 2016, 95, e3134.	0.4	13
1056	Advances in immunotherapy for melanoma. <i>BMC Medicine</i> , 2016, 14, 20.	2.3	111
1057	Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. <i>European Journal of Cancer</i> , 2016, 60, 12-25.	1.3	321
1058	Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers. <i>Annals of Oncology</i> , 2016, 27, 1286-1291.	0.6	92
1059	Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer. <i>Journal of Hematology and Oncology</i> , 2016, 9, 34.	6.9	231

#	ARTICLE	IF	CITATIONS
1060	FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy. <i>Oncologist</i> , 2016, 21, 634-642.	1.9	379
1061	Novel Treatment Strategies for Brain Metastases in Non-small-cell Lung Cancer. <i>Current Treatment Options in Oncology</i> , 2016, 17, 25.	1.3	15
1062	PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2016, 374, 2542-2552.	13.9	1,048
1063	Carfilzomib alters the HLA-presented peptidome of myeloma cells and impairs presentation of peptides with aromatic C-termini. <i>Blood Cancer Journal</i> , 2016, 6, e411-e411.	2.8	20
1064	The presence of intraepithelial CD45RO+ cells in resected lymph nodes with metastases from NSCLC patients is an independent predictor of disease-specific survival. <i>British Journal of Cancer</i> , 2016, 114, 1145-1151.	2.9	25
1065	Taxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast cancer—a systematic review. <i>Supportive Care in Cancer</i> , 2016, 24, 3633-3650.	1.0	33
1066	Cancer immunotherapy: the beginning of the end of cancer?. <i>BMC Medicine</i> , 2016, 14, 73.	2.3	908
1067	Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. <i>Nature Genetics</i> , 2016, 48, 607-616.	9.4	933
1068	Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis. <i>Breast Cancer Research</i> , 2016, 18, 43.	2.2	90
1069	Role of the tumor microenvironment in mature B-cell lymphoid malignancies. <i>Haematologica</i> , 2016, 101, 531-540.	1.7	75
1070	Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy. <i>British Journal of Cancer</i> , 2016, 114, 1084-1089.	2.9	113
1071	Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 2460-2467.	0.8	1,185
1072	Real-world efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanoma. <i>Oncology Letters</i> , 2016, 11, 1581-1585.	0.8	34
1073	Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 473-486.	12.5	831
1074	Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 2219-2231.	1.4	49
1075	Quantifying Treatment Benefit in Molecular Subgroups to Assess a Predictive Biomarker. <i>Clinical Cancer Research</i> , 2016, 22, 2114-2120.	3.2	6
1076	Planes, Trains, and Automobiles: Perspectives on CAR T Cells and Other Cellular Therapies for Hematologic Malignancies. <i>Current Hematologic Malignancy Reports</i> , 2016, 11, 318-325.	1.2	2
1077	Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer. <i>Annals of Oncology</i> , 2016, 27, 1291-1298.	0.6	129

#	ARTICLE	IF	CITATIONS
1079	A framework for understanding and targeting residual disease in oncogene-driven solid cancers. <i>Nature Medicine</i> , 2016, 22, 472-478.	15.2	145
1080	Isolation of Pancreatic Cancer Cells from a Patient-Derived Xenograft Model Allows for Practical Expansion and Preserved Heterogeneity in Culture. <i>American Journal of Pathology</i> , 2016, 186, 1537-1546.	1.9	31
1081	Fatal GvHD induced by PD-1 inhibitor pembrolizumab in a patient with Hodgkin's lymphoma. <i>Bone Marrow Transplantation</i> , 2016, 51, 1268-1270.	1.3	68
1083	CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia. <i>Current Treatment Options in Oncology</i> , 2016, 17, 28.	1.3	60
1084	Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy. <i>Cancer Discovery</i> , 2016, 6, 703-713.	7.7	92
1085	Tumor control with PD-1 inhibition in a patient with concurrent metastatic melanoma and renal cell carcinoma. , 2016, 4, 26.		10
1086	Adapting Cancer Immunotherapy Models for the Real World. <i>Trends in Immunology</i> , 2016, 37, 354-363.	2.9	77
1087	Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients. <i>International Immunology</i> , 2016, 28, 373-382.	1.8	143
1088	Roles of regulatory T cells in cancer immunity. <i>International Immunology</i> , 2016, 28, 401-409.	1.8	412
1089	Do programmed death 1 (PD-1) and its ligand (PD-L1) play a role in patients with non-clear cell renal cell carcinoma?. <i>Medical Oncology</i> , 2016, 33, 59.	1.2	22
1091	Survival Analysis of Advanced Non-Small Cell Lung Cancer Patients Treated by Using Wheel Balance Cancer Therapy. <i>Integrative Cancer Therapies</i> , 2016, 15, 467-477.	0.8	10
1092	Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 5461-5471.	3.2	234
1093	Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab. <i>Clinical Cancer Research</i> , 2016, 22, 4848-4858.	3.2	146
1094	Tumor-Infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 2863-2873.	1.8	137
1095	Biology and treatment of BRAF mutant metastatic melanoma. <i>Melanoma Management</i> , 2016, 3, 33-45.	0.1	28
1096	Utilization of ancillary studies in the cytologic diagnosis of respiratory lesions: The papanicolaou society of cytopathology consensus recommendations for respiratory cytology. <i>Diagnostic Cytopathology</i> , 2016, 44, 1000-1009.	0.5	55
1097	Optimal Use of BRAF Targeting Therapy in the Immunotherapy Era. <i>Current Oncology Reports</i> , 2016, 18, 67.	1.8	10
1098	NETs in cancer. <i>Tumor Biology</i> , 2016, 37, 14355-14361.	0.8	52

#	ARTICLE	IF	CITATIONS
1099	PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?. , 2016, 4, 48.		178
1100	Investigation of PD-L1 Biomarker Testing Methods for PD-1 Axis Inhibition in Non-squamous Non-small Cell Lung Cancer. <i>Journal of Histochemistry and Cytochemistry</i> , 2016, 64, 587-600.	1.3	30
1101	Demethylation of the PD-1 Promoter Is Imprinted during the Effector Phase of CD8 T Cell Exhaustion. <i>Journal of Virology</i> , 2016, 90, 8934-8946.	1.5	69
1102	Treatment of malignant melanoma with nivolumab and vemurafenib combined with hypofractionated radiation therapy. <i>International Cancer Conference Journal</i> , 2016, 5, 214-218.	0.2	1
1103	Integrating the escalation and dose expansion studies into a unified Phase I clinical trial. <i>Contemporary Clinical Trials</i> , 2016, 50, 124-134.	0.8	13
1105	Reevaluating stereotactic radiosurgery for glioblastoma: new potential for targeted dose-escalation. <i>Journal of Neuro-Oncology</i> , 2016, 130, 397-411.	1.4	11
1106	A multicentre phase II trial of cabazitaxel in patients with advanced non-small-cell lung cancer progressing after docetaxel-based chemotherapy. <i>British Journal of Cancer</i> , 2016, 115, 784-788.	2.9	18
1107	Combination therapeutics in complex diseases. <i>Journal of Cellular and Molecular Medicine</i> , 2016, 20, 2231-2240.	1.6	76
1108	Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study. <i>Annals of Oncology</i> , 2016, 27, 1940-1946.	0.6	94
1109	Radiotherapy: Changing the Game in Immunotherapy. <i>Trends in Cancer</i> , 2016, 2, 286-294.	3.8	270
1110	Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1590-1598.	5.1	594
1111	Novel immunotherapy approaches for metastatic urothelial and renal cell carcinoma. <i>Asian Journal of Urology</i> , 2016, 3, 268-277.	0.5	4
1112	Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy. <i>Nature Genetics</i> , 2016, 48, 1327-1329.	9.4	115
1113	Emerging roles of p53 and other tumour-suppressor genes in immune regulation. <i>Nature Reviews Immunology</i> , 2016, 16, 741-750.	10.6	262
1114	Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade. <i>Cancer Immunology Research</i> , 2016, 4, 959-967.	1.6	428
1115	Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort. <i>Journal of Clinical Oncology</i> , 2016, 34, 3838-3845.	0.8	715
1116	Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 4431-4439.	1.8	187
1117	Short-term EGFR blockade enhances immune-mediated cytotoxicity of EGFR mutant lung cancer cells: rationale for combination therapies. <i>Cell Death and Disease</i> , 2016, 7, e2380-e2380.	2.7	38

#	ARTICLE	IF	CITATIONS
1118	Focal lung infiltrate complicating PD-1 inhibitor use: A new pattern of drug-associated lung toxicity?. <i>Respiratory Medicine Case Reports</i> , 2016, 19, 118-120.	0.2	10
1119	Gemcitabine reduces MDSCs, tregs and TGF β -1 while restoring the teff/treg ratio in patients with pancreatic cancer. <i>Journal of Translational Medicine</i> , 2016, 14, 282.	1.8	152
1120	Trends and advances in tumor immunology and lung cancer immunotherapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2016, 35, 157.	3.5	50
1122	Insights into significance of combined inhibition of MEK and m-TOR signalling output in KRAS mutant non-small-cell lung cancer. <i>British Journal of Cancer</i> , 2016, 115, 549-552.	2.9	11
1123	Autoimmune Diseases in Children and Adults With Type 1 Diabetes From the T1D Exchange Clinic Registry. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 4931-4937.	1.8	75
1124	Catching up with solid tumor oncology: what is the evidence for a prognostic role of programmed cell death-ligand 1/programmed cell death-1 expression in B-cell lymphomas?. <i>Haematologica</i> , 2016, 101, 1144-1158.	1.7	6
1125	Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. <i>Lancet Oncology</i> , The, 2016, 17, 1497-1508.	5.1	1,279
1126	Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients. <i>BMC Cancer</i> , 2016, 16, 744.	1.1	94
1127	The Long and Winding Road. <i>Advances in Pharmacology</i> , 2016, 76, 147-173.	1.2	2
1128	Rationale and Design of the Genetic Contribution to Drug Induced Renal Injury (DIRECT) Study. <i>Kidney International Reports</i> , 2016, 1, 288-298.	0.4	13
1129	PD-1/PD-L1 expression in chromophobe renal cell carcinoma: An immunological exception?. <i>Medical Oncology</i> , 2016, 33, 120.	1.2	23
1130	Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients. <i>British Journal of Cancer</i> , 2016, 115, 1186-1192.	2.9	50
1131	Genomic Approaches to Understanding Response and Resistance to Immunotherapy. <i>Clinical Cancer Research</i> , 2016, 22, 5642-5650.	3.2	134
1132	Costimulatory and coinhibitory immune checkpoint receptors in head and neck cancer: unleashing immune responses through therapeutic combinations. <i>Cancers of the Head & Neck</i> , 2016, 1, 12.	6.2	17
1133	Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series. <i>British Journal of Cancer</i> , 2016, 115, 1280-1284.	2.9	36
1134	Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 11919-11924.	3.3	197
1135	Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 1533-1544.	2.0	89
1136	Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma. <i>Diagnostic Pathology</i> , 2016, 11, 95.	0.9	149

#	ARTICLE	IF	CITATIONS
1137	Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. <i>New England Journal of Medicine</i> , 2016, 375, 1856-1867.	13.9	3,845
1138	Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 4102-4109.	0.8	528
1139	Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy. <i>Cancer Discovery</i> , 2016, 6, 1090-1105.	7.7	217
1140	Genomic insights into head and neck cancer. <i>Cancers of the Head & Neck</i> , 2016, 1, .	6.2	65
1141	Immunotherapy as a Potential Treatment for Chordoma: a Review. <i>Current Oncology Reports</i> , 2016, 18, 55.	1.8	16
1142	The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 3638-3647.	0.8	140
1143	Molecular Imaging of Immunotherapy Targets in Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1487-1492.	2.8	77
1144	Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer. <i>Lung Cancer</i> , 2016, 99, 79-87.	0.9	108
1145	Metastatic melanoma and immunotherapy. <i>Clinical Immunology</i> , 2016, 172, 105-110.	1.4	43
1146	Nivolumab in the treatment of metastatic squamous non-small cell lung cancer: a review of the evidence. <i>Therapeutic Advances in Respiratory Disease</i> , 2016, 10, 444-454.	1.0	26
1147	Immune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer. <i>Current Oncology Reports</i> , 2016, 18, 59.	1.8	35
1148	An <i>In Vivo</i> Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma. <i>Cancer Research</i> , 2016, 76, 5455-5466.	0.4	24
1149	Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy. <i>Cancer Immunology Research</i> , 2016, 4, 755-765.	1.6	36
1150	Platinum-induced hearing loss after treatment for childhood cancer. <i>The Cochrane Library</i> , 2019, 2019, CD010181.	1.5	38
1151	Oncolytic viruses-immunotherapeutics on the rise. <i>Journal of Molecular Medicine</i> , 2016, 94, 979-991.	1.7	43
1152	Immunotherapy of advanced renal cell carcinoma: Current and future therapies. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 2997-3004.	1.4	12
1153	Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry. <i>Investigational New Drugs</i> , 2016, 34, 677-684.	1.2	30
1154	Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 1247-1253.	1.5	50

#	ARTICLE	IF	CITATIONS
1155	The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of Melanoma. <i>Clinical Infectious Diseases</i> , 2016, 63, 1490-1493.	2.9	226
1156	Spatial Heterogeneity in the Tumor Microenvironment. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2016, 6, a026583.	2.9	194
1157	The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer. <i>Oncologist</i> , 2016, 21, 910-921.	1.9	58
1158	Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy. <i>JAAD Case Reports</i> , 2016, 2, 264-268.	0.4	86
1159	Revisitation of autoimmune hypophysitis: knowledge and uncertainties on pathophysiological and clinical aspects. <i>Pituitary</i> , 2016, 19, 625-642.	1.6	94
1160	The Role of Molecular Diagnostics in the Management of Patients with Gliomas. <i>Current Treatment Options in Oncology</i> , 2016, 17, 51.	1.3	32
1161	Adaptive NK Cells with Low TIGIT Expression Are Inherently Resistant to Myeloid-Derived Suppressor Cells. <i>Cancer Research</i> , 2016, 76, 5696-5706.	0.4	146
1163	Relationship between Overall Survival and Response or Progression-Free Survival in Advanced Non-Small Cell Lung Cancer Patients Treated with Anti-PD-1/PD-L1 Antibodies. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1927-1939.	0.5	63
1164	Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents. <i>Oncologist</i> , 2016, 21, 1230-1240.	1.9	212
1165	The Promise of Molecularly Targeted and Immunotherapy for Advanced Melanoma. <i>Current Treatment Options in Oncology</i> , 2016, 17, 48.	1.3	36
1166	PD-1 Axis Inhibitors in EGFR- and ALK-Driven Lung Cancer: Lost Cause?. <i>Clinical Cancer Research</i> , 2016, 22, 4539-4541.	3.2	39
1167	Immunotherapy: A promising approach to reverse sepsis-induced immunosuppression. <i>Pharmacological Research</i> , 2016, 111, 688-702.	3.1	113
1168	Chemotherapy remains an essential element of personalized care for persons with lung cancers. <i>Annals of Oncology</i> , 2016, 27, 1829-1835.	0.6	83
1169	Pembrolizumab in classical Hodgkin's lymphoma. <i>European Journal of Haematology</i> , 2016, 97, 219-227.	1.1	22
1170	Therapeutic implications of melanoma heterogeneity. <i>Experimental Dermatology</i> , 2016, 25, 497-500.	1.4	28
1171	Biomodulatory metronomic therapy in stage IV melanoma is well-tolerated and may induce prolonged progression-free survival, a phase I trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, e119-e121.	1.3	14
1172	PD-1 Pathway Inhibitors: Immunotherapy Agents for Restoring Antitumor Immune Responses. <i>Pharmacotherapy</i> , 2016, 36, 317-334.	1.2	82
1173	Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You. <i>Current Hematologic Malignancy Reports</i> , 2016, 11, 368-384.	1.2	60

#	ARTICLE	IF	CITATIONS
1174	Evolving Immunotherapy Approaches for Renal Cell Carcinoma. <i>Current Oncology Reports</i> , 2016, 18, 57.	1.8	24
1175	Medical treatment of renal cancer: new horizons. <i>British Journal of Cancer</i> , 2016, 115, 505-516.	2.9	83
1176	A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling. <i>Clinical Cancer Research</i> , 2016, 22, 5729-5737.	3.2	175
1177	EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer. <i>Journal of Hematology and Oncology</i> , 2016, 9, 59.	6.9	143
1178	Combination or single-agent ipilimumab as immunotherapy of advanced melanoma: a critical review. <i>Melanoma Management</i> , 2016, 3, 231-243.	0.1	4
1179	Adding checkpoint inhibitors to tyrosine kinase inhibitors targeting EGFR/ALK in non-small cell lung cancer: a new therapeutic strategy. <i>Investigational New Drugs</i> , 2016, 34, 794-796.	1.2	17
1180	Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. , 2016, 4, 50.		413
1181	Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy. <i>Annals of Oncology</i> , 2016, 27, 1966-1969.	0.6	22
1182	Complementing T-cell Function: An Inhibitory Role of the Complement System in T-cell-Mediated Antitumor Immunity. <i>Cancer Discovery</i> , 2016, 6, 953-955.	7.7	9
1183	Tumor Mutational Load and Immune Parameters across Metastatic Renal Cell Carcinoma Risk Groups. <i>Cancer Immunology Research</i> , 2016, 4, 820-822.	1.6	63
1184	Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody. , 2016, 4, 36.		90
1185	T-cell exhaustion: understanding the interface of chronic viral and autoinflammatory diseases. <i>Immunology and Cell Biology</i> , 2016, 94, 935-942.	1.0	29
1186	Current Progress in Immunotherapy for the Treatment of Biliary Cancers. <i>Journal of Gastrointestinal Cancer</i> , 2016, 47, 351-357.	0.6	8
1187	A Prospective Clinical Trial Combining Radiation Therapy With Systemic Immunotherapy in Metastatic Melanoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 578-588.	0.4	190
1188	New insights in melanoma biomarkers: long-noncoding RNAs. <i>Melanoma Management</i> , 2016, 3, 195-205.	0.1	0
1189	Second-Line Treatment of Non-Small Cell Lung Cancer: New Developments for Tumours Not Harboring Targetable Oncogenic Driver Mutations. <i>Drugs</i> , 2016, 76, 1321-1336.	4.9	17
1190	Clinician Perspectives on Current Issues in Lung Cancer Drug Development. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1387-1396.	0.5	6
1191	Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. <i>Genome Biology</i> , 2016, 17, 174.	3.8	1,768

#	ARTICLE	IF	CITATIONS
1192	State of the science on prevention and screening to reduce melanoma incidence and mortality: The time is now. <i>Ca-A Cancer Journal for Clinicians</i> , 2016, 66, 460-480.	157.7	140
1193	Inflammationâ€”Triggered Cancer Immunotherapy by Programmed Delivery of CpG and Antiâ€”PD1 Antibody. <i>Advanced Materials</i> , 2016, 28, 8912-8920.	11.1	286
1194	Crosstalk in skin: melanocytes, keratinocytes, stem cells, and melanoma. <i>Journal of Cell Communication and Signaling</i> , 2016, 10, 191-196.	1.8	49
1195	PD-L1 expression in basaloid squamous cell lung carcinoma: Relationship to PD-1+ and CD8+ tumor-infiltrating T cells and outcome. <i>Modern Pathology</i> , 2016, 29, 1552-1564.	2.9	25
1196	Stereotactic ablative radiotherapy and immunotherapy combinations: turning the future into systemic therapy?. <i>British Journal of Radiology</i> , 2016, 89, 20160472.	1.0	32
1197	Suppression of Glut1 and Glucose Metabolism by Decreased Akt/mTORC1 Signaling Drives T Cell Impairment in B Cell Leukemia. <i>Journal of Immunology</i> , 2016, 197, 2532-2540.	0.4	110
1198	Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2016, 34, 3562-3569.	0.8	175
1199	Sequencing of New and Old Therapies for Metastatic Melanoma. <i>Current Treatment Options in Oncology</i> , 2016, 17, 52.	1.3	7
1200	Regulatory circuits of T cell function in cancer. <i>Nature Reviews Immunology</i> , 2016, 16, 599-611.	10.6	445
1201	Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer. <i>Annals of Oncology</i> , 2016, 27, 1953-1958.	0.6	289
1202	How Many Lymph Nodes Are Enough? Assessing the Adequacy of Lymph Node Yield for Papillary Thyroid Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 3434-3439.	0.8	85
1203	Adjuvant Therapy of Resected Non-small Cell Lung Cancer: can We Move Forward?. <i>Current Treatment Options in Oncology</i> , 2016, 17, 54.	1.3	18
1204	Clinical outcomes in metastatic uveal melanoma treated with PDâ€”1 and PDâ€”L1 antibodies. <i>Cancer</i> , 2016, 122, 3344-3353.	2.0	288
1205	The efficacy of antiâ€”PDâ€”1 agents in acral and mucosal melanoma. <i>Cancer</i> , 2016, 122, 3354-3362.	2.0	236
1206	PD-1 Inhibitorâ€”Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course. <i>Clinical Cancer Research</i> , 2016, 22, 6051-6060.	3.2	393
1207	Immunotherapy in Lung Cancer. <i>Cancer Treatment and Research</i> , 2016, 170, 203-223.	0.2	8
1208	Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyond. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 360-374.	1.4	37
1209	Costâ€”effectiveness of immune checkpoint inhibitors in NSCLC according to PD-L1 expression. <i>Lung Cancer Management</i> , 2016, 5, 119-122.	1.5	5

#	ARTICLE	IF	CITATIONS
1210	Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy. , 2016, 4, 72.		156
1211	Direct identification of clinically relevant neopeptides presented on native human melanoma tissue by mass spectrometry. Nature Communications, 2016, 7, 13404.	5.8	613
1212	Validation of biomarkers to predict response to immunotherapy in cancer: Volume II " clinical validation and regulatory considerations. , 2016, 4, 77.		87
1213	Hyperglycemia Associated With Targeted Oncologic Treatment: Mechanisms and Management. Oncologist, 2016, 21, 1326-1336.	1.9	49
1214	Epigenetic therapy approaches in non-small cell lung cancer: Update and perspectives. Epigenetics, 2016, 11, 858-870.	1.3	60
1216	Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncology, The, 2016, 17, 1558-1568.	5.1	827
1217	BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression. Cell Reports, 2016, 16, 2829-2837.	2.9	331
1218	Varicella-Zoster Virus Downregulates Programmed Death Ligand 1 and Major Histocompatibility Complex Class I in Human Brain Vascular Adventitial Fibroblasts, Perineurial Cells, and Lung Fibroblasts. Journal of Virology, 2016, 90, 10527-10534.	1.5	21
1219	Update in Lung Cancer 2015. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 661-671.	2.5	13
1220	Immunotherapy for prostate cancer: False promises or true hope?. Cancer, 2016, 122, 3598-3607.	2.0	22
1221	Current management and future directions in metastatic pancreatic adenocarcinoma. Cancer, 2016, 122, 3765-3775.	2.0	18
1222	Rapid bone repair in a patient with lung cancer metastases to the spine using a novel herbal medicine: A case report. Oncology Letters, 2016, 12, 2023-2027.	0.8	4
1223	Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy. Annals of Oncology, 2016, 27, 2288-2294.	0.6	117
1224	Clinical Response of a Patient to Anti-PD-1 Immunotherapy and the Immune Landscape of Testicular Germ Cell Tumors. Cancer Immunology Research, 2016, 4, 903-909.	1.6	45
1225	Melanoma central nervous system metastases: current approaches, challenges, and opportunities. Pigment Cell and Melanoma Research, 2016, 29, 627-642.	1.5	102
1226	Checkpoint inhibitors in lung cancer: latest developments and clinical potential. Therapeutic Advances in Medical Oncology, 2016, 8, 460-473.	1.4	30
1227	First-line immunotherapy in lung cancer " taking the first step. Nature Reviews Clinical Oncology, 2016, 13, 595-596.	12.5	5
1228	Sneaky side effects and ineffectiveness of an immunotherapy with ipilimumab in a case of metastatic melanoma. Dermato-Endocrinology, 2016, 8, e1199307.	1.9	4

#	ARTICLE	IF	CITATIONS
1229	PD-L1 in melanoma: facts and myths. <i>Melanoma Management</i> , 2016, 3, 187-194.	0.1	11
1230	Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma. <i>Journal of Neuro-Oncology</i> , 2016, 130, 543-552.	1.4	90
1231	Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Immunotherapy. <i>JAMA Dermatology</i> , 2016, 152, 1128.	2.0	188
1232	PD-L1 expression is associated with advanced non-small cell lung cancer. <i>Oncology Letters</i> , 2016, 12, 921-927.	0.8	18
1233	Expression of PD-1, PD-L1 and PD-L2 is associated with differentiation status and histological type of endometrial cancer. <i>Oncology Letters</i> , 2016, 12, 944-950.	0.8	75
1234	Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1283-1294.	5.1	818
1235	Advances in immunotherapy for melanoma management. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 2501-2511.	1.4	15
1236	Immunotherapy and Novel Combinations in Oncology: Current Landscape, Challenges, and Opportunities. <i>Clinical and Translational Science</i> , 2016, 9, 89-104.	1.5	144
1237	Releasing the brakes to fight cancer. <i>EMBO Reports</i> , 2016, 17, 1257-1260.	2.0	4
1238	Surgical immune interventions for solid malignancies. <i>American Journal of Surgery</i> , 2016, 212, 682-690.e5.	0.9	9
1239	Prognostic Role of Programmed Death Ligand-1 Expression in Breast Cancer: A Systematic Review and Meta-Analysis. <i>Targeted Oncology</i> , 2016, 11, 753-761.	1.7	73
1240	Checkpoint inhibitors for renal cell carcinoma: current landscape and future directions. <i>Immunotherapy</i> , 2016, 8, 785-798.	1.0	7
1241	Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC). <i>Journal of Neuro-Oncology</i> , 2016, 130, 19-29.	1.4	107
1242	Immunotherapy for head and neck squamous cell carcinoma. <i>Memo - Magazine of European Medical Oncology</i> , 2016, 9, 66-69.	0.3	24
1243	Cellular immunotherapy for malignant gliomas. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1265-1275.	1.4	37
1244	Co-Managing Patients with Type 1 Diabetes and Cancer. <i>Current Diabetes Reports</i> , 2016, 16, 73.	1.7	1
1245	Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma. <i>Modern Pathology</i> , 2016, 29, 1433-1442.	2.9	144
1246	Drug discovery in advanced prostate cancer: translating biology into therapy. <i>Nature Reviews Drug Discovery</i> , 2016, 15, 699-718.	21.5	111

#	ARTICLE	IF	CITATIONS
1247	Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. <i>New England Journal of Medicine</i> , 2016, 375, 819-829.	13.9	2,430
1248	Recent advances and future of immunotherapy for glioblastoma. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1245-1264.	1.4	57
1249	Systemic therapy for bladder cancer finally comes into a new age. <i>Future Oncology</i> , 2016, 12, 2227-2242.	1.1	6
1250	Current status and future prospects of chemotherapy for advanced hepatocellular carcinoma. <i>Clinical Journal of Gastroenterology</i> , 2016, 9, 184-190.	0.4	31
1251	Squamous cell carcinoma associated with chronic graft versus host disease-like/lichen planus-like lesion of the oral cavity in a patient managed for metastatic melanoma with a PD-1 inhibitor pembrolizumab. <i>Oral Oncology</i> , 2016, 63, e1-e3.	0.8	11
1252	MicroRNA-491 regulates the proliferation and apoptosis of CD8+ T cells. <i>Scientific Reports</i> , 2016, 6, 30923.	1.6	34
1253	Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes. <i>Science Immunology</i> , 2016, 1, .	5.6	169
1254	Talimogene laherparepvec: overview, combination therapy and current practices. <i>Melanoma Management</i> , 2016, 3, 267-272.	0.1	8
1255	Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. <i>Nature Communications</i> , 2016, 7, 10582.	5.8	412
1256	A Case of Nivolumab-Induced Myositis. <i>Oncologist</i> , 2016, 21, e3-e3.	1.9	28
1257	FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer. <i>World Journal of Surgical Oncology</i> , 2016, 14, 238.	0.8	25
1258	Overcoming resistance to checkpoint blockade therapy by targeting PI3K ^{Î³} in myeloid cells. <i>Nature</i> , 2016, 539, 443-447.	13.7	661
1259	The Treatment of Melanoma Brain Metastases. <i>Current Oncology Reports</i> , 2016, 18, 73.	1.8	16
1260	Non-oncogenic Acute Viral Infections Disrupt Anti-cancer Responses and Lead to Accelerated Cancer-Specific Host Death. <i>Cell Reports</i> , 2016, 17, 957-965.	2.9	22
1261	IL-2 in the tumor microenvironment is necessary for Wiskott-Aldrich syndrome protein deficient NK cells to respond to tumors in vivo. <i>Scientific Reports</i> , 2016, 6, 30636.	1.6	22
1262	Acute interstitial nephritis related to immune checkpoint inhibitors. <i>British Journal of Cancer</i> , 2016, 115, 1457-1461.	2.9	88
1263	Density of immunogenic antigens does not explain the presence or absence of the T-cellâ€inflamed tumor microenvironment in melanoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E7759-E7768.	3.3	328
1264	Combination approaches in NSCLC involving immune checkpoint inhibitors. <i>Lung Cancer Management</i> , 2016, 5, 163-171.	1.5	1

#	ARTICLE	IF	CITATIONS
1265	Neurological and Neuropsychiatric Adverse Effects of Dermatologic Medications. <i>CNS Drugs</i> , 2016, 30, 1149-1168.	2.7	3
1266	Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E7769-E7777.	3.3	145
1267	Emerging role of immunotherapy in urothelial carcinoma. <i>Immunobiology/biomarkers. Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 556-565.	0.8	23
1268	Making urothelial carcinomas less immune to immunotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 534-537.	0.8	2
1269	Programmed Death-1 Culls Peripheral Accumulation of High-Affinity Autoreactive CD4 ⁺ T Cells to Protect against Autoimmunity. <i>Cell Reports</i> , 2016, 17, 1783-1794.	2.9	35
1270	PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. <i>Science Translational Medicine</i> , 2016, 8, 328rv4.	5.8	1,844
1272	Ubiquitin-specific Protease-7 Inhibition Impairs Tip60-dependent Foxp3 + T-regulatory Cell Function and Promotes Antitumor Immunity. <i>EBioMedicine</i> , 2016, 13, 99-112.	2.7	86
1273	In-silico insights on the prognostic potential of immune cell infiltration patterns in the breast lobular epithelium. <i>Scientific Reports</i> , 2016, 6, 33322.	1.6	21
1274	High-resolution crystal structure of the therapeutic antibody pembrolizumab bound to the human PD-1. <i>Scientific Reports</i> , 2016, 6, 35297.	1.6	77
1275	Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide. , 2016, 4, 68.		27
1276	Hepatocellular carcinoma and immune therapy, from a clinical perspective; where are we?. <i>Hepatic Oncology</i> , 2016, 3, 183-185.	4.2	2
1277	Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients. <i>Cell Death Discovery</i> , 2016, 2, 16025.	2.0	68
1278	Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with PDL1 amplification. <i>Journal of Physical Education and Sports Management</i> , 2016, 2, a001180.	0.5	57
1279	Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. <i>BMC Medicine</i> , 2016, 14, 168.	2.3	106
1280	Immune biomarkers of treatment failure for a patient on a phase I clinical trial of pembrolizumab plus radiotherapy. <i>Journal of Hematology and Oncology</i> , 2016, 9, 96.	6.9	21
1281	Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction. , 2016, 4, 60.		60
1282	Antitumor activity of nivolumab on hemodialysis after renal allograft rejection. , 2016, 4, 64.		75
1283	Interdependent IL-7 and IFN- γ signalling in T-cell controls tumour eradication by combined CTLA-4+PD-1 therapy. <i>Nature Communications</i> , 2016, 7, 12335.	5.8	93

#	ARTICLE	IF	CITATIONS
1284	Cabozantinib in patients with advanced RET -rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial. <i>Lancet Oncology</i> , The, 2016, 17, 1653-1660.	5.1	365
1285	Cell-Intrinsic Barriers of T Cell-Based Immunotherapy. <i>Trends in Molecular Medicine</i> , 2016, 22, 1000-1011.	3.5	60
1286	The efficacy and safety of immunotherapy in patients with advanced NSCLC: a systematic review and meta-analysis. <i>Scientific Reports</i> , 2016, 6, 32020.	1.6	18
1287	Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies. <i>Protein and Cell</i> , 2016, 7, 866-877.	4.8	44
1288	Network Meta-analysis of Progression-Free Survival and Overall Survival in First-Line Treatment of BRAF Mutation-Positive Metastatic Melanoma. <i>Oncology and Therapy</i> , 2016, 4, 239-256.	1.0	8
1289	Targeting the KRAS Pathway in Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2016, 21, 1450-1460.	1.9	101
1290	PD-L1 testing, fit for routine evaluation? From a pathologist's point of view. <i>Memo - Magazine of European Medical Oncology</i> , 2016, 9, 201-206.	0.3	38
1291	Induction of IL-25 secretion from tumour-associated fibroblasts suppresses mammary tumour metastasis. <i>Nature Communications</i> , 2016, 7, 11311.	5.8	32
1292	Crizotinib resistance: implications for therapeutic strategies. <i>Annals of Oncology</i> , 2016, 27, iii42-iii50.	0.6	109
1293	CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients. <i>Scientific Reports</i> , 2016, 6, 20070.	1.6	237
1294	Fine needle aspirate flow cytometric phenotyping characterizes immunosuppressive nature of the mesothelioma microenvironment. <i>Scientific Reports</i> , 2016, 6, 31745.	1.6	22
1295	From 2000 to 2016: Which Second-Line Treatment in Advanced Non-Small Cell Lung Cancer?. <i>Current Treatment Options in Oncology</i> , 2016, 17, 59.	1.3	3
1296	Targeting VEGF-A in myeloid cells enhances natural killer cell responses to chemotherapy and ameliorates cachexia. <i>Nature Communications</i> , 2016, 7, 12528.	5.8	25
1297	Role of multimodality therapy in cIIIA-N2 non-small cell lung cancer: perspective. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 1174-1178.	0.6	4
1298	Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosis. <i>BMC Medicine</i> , 2016, 14, 89.	2.3	57
1299	Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors. <i>Frontiers of Medicine</i> , 2016, 10, 383-388.	1.5	76
1300	Drug Combinations as the New Standard for Melanoma Treatment. <i>Current Treatment Options in Oncology</i> , 2016, 17, 61.	1.3	16
1301	Prevention of allograft rejection in heart transplantation through concurrent gene silencing of TLR and Kinase signaling pathways. <i>Scientific Reports</i> , 2016, 6, 33869.	1.6	13

#	ARTICLE	IF	CITATIONS
1302	Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study. <i>Annals of Oncology</i> , 2016, 27, 2242-2250.	0.6	84
1303	In-depth tissue profiling using multiplexed immunohistochemical consecutive staining on single slide. <i>Science Immunology</i> , 2016, 1, aaf6925.	5.6	142
1304	Antagonizing programmed death-1 and programmed death ligand-1 as a therapeutic approach for gastric cancer. <i>Therapeutic Advances in Gastroenterology</i> , 2016, 9, 853-860.	1.4	13
1305	The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials. <i>Lung Cancer</i> , 2016, 102, 21-27.	0.9	11
1306	Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy. <i>Nature Communications</i> , 2016, 7, 13354.	5.8	224
1307	Establishment and characterization of HROC69â€™s Crohn's related colonic carcinoma cell line and its matched patient-derived xenograft. <i>Scientific Reports</i> , 2016, 6, 24671.	1.6	12
1308	Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapse. <i>Cancer Biology and Therapy</i> , 2016, 17, 1213-1220.	1.5	52
1309	Approaches to modernize the combination drug development paradigm. <i>Genome Medicine</i> , 2016, 8, 115.	3.6	64
1310	Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma. <i>Scientific Reports</i> , 2016, 6, 30093.	1.6	213
1311	Fulminant Myocarditis with Combination Immune Checkpoint Blockade. <i>New England Journal of Medicine</i> , 2016, 375, 1749-1755.	13.9	1,668
1312	Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway. <i>New England Journal of Medicine</i> , 2016, 375, 1767-1778.	13.9	1,025
1313	Eph Receptor Tyrosine Kinases in Tumor Immunity. <i>Cancer Research</i> , 2016, 76, 6452-6457.	0.4	55
1314	Successful Treatment of a Patient with Glioblastoma and a Germline <i>POLE</i> Mutation: Where Next?. <i>Cancer Discovery</i> , 2016, 6, 1210-1211.	7.7	14
1315	Lung Cancer Subtypes Generate Unique Immune Responses. <i>Journal of Immunology</i> , 2016, 197, 4493-4503.	0.4	115
1316	Immune checkpoint therapy and type 1 diabetes. <i>Diabetology International</i> , 2016, 7, 221-227.	0.7	12
1317	Imaging Biomarkers in Immunotherapy. <i>Biomarkers in Cancer</i> , 2016, 8s2, BIC.S31805.	3.6	31
1318	T cells in multiple myeloma display features of exhaustion and senescence at the tumor site. <i>Journal of Hematology and Oncology</i> , 2016, 9, 116.	6.9	201
1319	Acute visual loss after ipilimumab treatment for metastatic melanoma. , 2016, 4, 66.		59

#	ARTICLE	IF	CITATIONS
1320	Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810. , 2016, 4, 70.		132
1321	Pseudo-Meigsâ€™ syndrome due to ovarian metastases from colon cancer: a case report and review of the literature. Surgical Case Reports, 2016, 2, 112.	0.2	7
1322	Society for immunotherapy of cancer (SITC) statement on the proposed changes to the common rule. , 2016, 4, 37.		1
1323	Itâ€™s TIME for a biomarker-driven approach to cancer immunotherapy. , 2016, 4, 43.		6
1324	A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma. , 2016, 4, 52.		37
1325	Imaging in Advanced Nonâ€™Small Cell Lung Cancer. Journal of Thoracic Imaging, 2016, 31, 238-242.	0.8	3
1326	Innate Immune System for Diagnostics and Therapy: Progress in Fundamental Knowledge and Clinical Application. Transfusion Medicine and Hemotherapy, 2016, 43, 63-64.	0.7	2
1327	Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors. BMC Cancer, 2016, 16, 868.	1.1	15
1328	Clinical outcomes of patients with gastrointestinal stromal tumor in phase I clinical trials. BMC Cancer, 2016, 16, 889.	1.1	2
1329	Oral mucosal melanoma treated with carbon ion radiotherapy: a case report. Journal of Medical Case Reports, 2016, 10, 284.	0.4	1
1330	Progression-free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial. , 2016, 4, 34.		34
1331	A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma. , 2016, 4, 85.		18
1332	Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy. , 2016, 4, 89.		81
1333	A case report of using nivolumab for a malignant melanoma patient with rheumatoid arthritis. International Cancer Conference Journal, 2016, 5, 192-196.	0.2	6
1334	Cancer immunotherapy-induced rheumatic diseases emerge as new clinical entities. RMD Open, 2016, 2, e000321.	1.8	37
1335	Early analysis of surrogate endpoints for metastatic melanoma in immune checkpoint inhibitor trials. Medicine (United States), 2016, 95, e3997.	0.4	12
1336	Current status of alloimmunity. Current Opinion in Nephrology and Hypertension, 2016, 25, 556-562.	1.0	3
1337	Stereotactic Ablative Radiation Therapy Combined With Immunotherapy for Solid Tumors. Cancer Journal (Sudbury, Mass), 2016, 22, 257-266.	1.0	38

#	ARTICLE	IF	CITATIONS
1338	Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 2698-2704.	0.8	868
1340	Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1954-1961.	3.3	122
1341	Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1727-1738.	1.2	73
1342	Dabrafenib plus Trametinib: a Review in Advanced Melanoma with a BRAF V600 Mutation. <i>Targeted Oncology</i> , 2016, 11, 417-428.	1.7	37
1343	Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. <i>Kidney International</i> , 2016, 90, 638-647.	2.6	524
1344	Case report: mismatch repair proficiency and microsatellite stability in gastric cancer may not predict programmed death-1 blockade resistance. <i>Journal of Hematology and Oncology</i> , 2016, 9, 29.	6.9	21
1345	Multiple Inhibitory Pathways Contribute to Lung CD8+ T Cell Impairment and Protect against Immunopathology during Acute Viral Respiratory Infection. <i>Journal of Immunology</i> , 2016, 197, 233-243.	0.4	26
1347	Management of High-Risk Squamous Cell Carcinoma of the Skin. <i>Current Treatment Options in Oncology</i> , 2016, 17, 34.	1.3	46
1348	Merkel Cell Carcinoma Therapeutic Update. <i>Current Treatment Options in Oncology</i> , 2016, 17, 36.	1.3	88
1349	Neutrophils in cancer: neutral no more. <i>Nature Reviews Cancer</i> , 2016, 16, 431-446.	12.8	1,296
1350	Isolation and identification of <i>Candida</i> species in patients with orogastric cancer: susceptibility to antifungal drugs, attributes of virulence in vitro and immune response phenotype. <i>BMC Infectious Diseases</i> , 2016, 16, 86.	1.3	16
1351	Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma. <i>CKJ: Clinical Kidney Journal</i> , 2016, 9, 411-417.	1.4	98
1352	Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens. <i>Cancer Immunology Research</i> , 2016, 4, 669-678.	1.6	117
1353	Emerging targets for radioprotection and radiosensitization in radiotherapy. <i>Tumor Biology</i> , 2016, 37, 11589-11609.	0.8	23
1354	Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype. <i>Modern Pathology</i> , 2016, 29, 1028-1037.	2.9	84
1355	Acid-induced aggregation propensity of nivolumab is dependent on the Fc. <i>MAbs</i> , 2016, 8, 1107-1117.	2.6	41
1356	Checkpoint Inhibitors in Head and Neck Cancer: Rationale, Clinical Activity, and Potential Biomarkers. <i>Current Treatment Options in Oncology</i> , 2016, 17, 40.	1.3	34
1357	Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 3119-3125.	0.8	755

#	ARTICLE	IF	CITATIONS
1358	Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events. <i>Oncologist</i> , 2016, 21, 804-816.	1.9	208
1359	Intratumoral expression of programmed death ligand 1 (PD-L1) in patients with clear cell renal cell carcinoma (ccRCC). <i>Medical Oncology</i> , 2016, 33, 80.	1.2	32
1360	Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma. <i>Nature Reviews Urology</i> , 2016, 13, 420-431.	1.9	78
1361	Recent results of immunotherapy and perspectives for advanced NSCLC. <i>Lung Cancer Management</i> , 2016, 5, 57-60.	1.5	0
1362	Molecular characterisation of cutaneous melanoma: creating a framework for targeted and immune therapies. <i>British Journal of Cancer</i> , 2016, 115, 145-155.	2.9	50
1363	Molecular assessment of disease states in kidney transplant biopsy samples. <i>Nature Reviews Nephrology</i> , 2016, 12, 534-548.	4.1	129
1364	Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer. <i>Current Treatment Options in Oncology</i> , 2016, 17, 41.	1.3	33
1365	Autophagy is not uniformly cytoprotective: a personalized medicine approach for autophagy inhibition as a therapeutic strategy in non-small cell lung cancer. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2016, 1860, 2130-2136.	1.1	25
1366	Gamma-interferon-inducible lysosomal thiol reductase is upregulated in human melanoma. <i>Melanoma Research</i> , 2016, 26, 125-137.	0.6	18
1367	Dendritic cell vaccination in melanoma patients: From promising results to future perspectives. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 2523-2528.	1.4	15
1368	Use of big data in drug development for precision medicine. <i>Expert Review of Precision Medicine and Drug Development</i> , 2016, 1, 245-253.	0.4	28
1369	Combinatorial approach to cancer immunotherapy: strength in numbers. <i>Journal of Leukocyte Biology</i> , 2016, 100, 275-290.	1.5	90
1370	Cellular Immune Responses and Immune Escape Mechanisms in Breast Cancer: Determinants of Immunotherapy. <i>Breast Care</i> , 2016, 11, 102-107.	0.8	35
1371	Prevalence of Autoimmune Disease Among Patients With Lung Cancer. <i>JAMA Oncology</i> , 2016, 2, 1507.	3.4	121
1373	Identifying and Targeting the Cause of Cancer is Needed to Cure Cancer. <i>Oncology and Therapy</i> , 2016, 4, 17-33.	1.0	19
1374	Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 976-983.	5.1	846
1375	Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 943-955.	5.1	293
1376	Checkpoint Inhibitors and Their Application in Breast Cancer. <i>Breast Care</i> , 2016, 11, 108-115.	0.8	45

#	ARTICLE	IF	CITATIONS
1377	DNMT3b Modulates Melanoma Growth by Controlling Levels of mTORC2 Component RICTOR. Cell Reports, 2016, 14, 2180-2192.	2.9	60
1378	Nintedanib in NSCLC: evidence to date and place in therapy. Therapeutic Advances in Medical Oncology, 2016, 8, 188-197.	1.4	19
1379	Quantitative CD3 PET Imaging Predicts Tumor Growth Response to Anti-CTLA-4 Therapy. Journal of Nuclear Medicine, 2016, 57, 1607-1611.	2.8	105
1380	The Utility of Exercise Testing in Patients with Lung Cancer. Journal of Thoracic Oncology, 2016, 11, 1397-1410.	0.5	62
1381	Epigenetic therapy in gastrointestinal cancer: the right combination. Therapeutic Advances in Gastroenterology, 2016, 9, 560-579.	1.4	81
1382	Bilateral neuroretinitis and anterior uveitis following ipilimumab treatment for metastatic melanoma. Journal of Ophthalmic Inflammation and Infection, 2016, 6, 14.	1.2	44
1383	Predicting analysis times in randomized clinical trials with cancer immunotherapy. BMC Medical Research Methodology, 2016, 16, 12.	1.4	17
1384	Second- and third-generation ALK inhibitors for non-small cell lung cancer. Journal of Hematology and Oncology, 2016, 9, 19.	6.9	116
1385	Buccal injection of synthetic HPV long peptide vaccine induces local and systemic antigen-specific CD8+ T-cell immune responses and antitumor effects without adjuvant. Cell and Bioscience, 2016, 6, 17.	2.1	15
1386	Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study. , 2016, 4, 12.		79
1387	Disease stabilization with pembrolizumab for metastatic acral melanoma in the setting of autoimmune bullous pemphigoid. , 2016, 4, 20.		32
1388	Targetless T cells in cancer immunotherapy. , 2016, 4, 23.		26
1389	The State of Cancer Care in America, 2016: A Report by the American Society of Clinical Oncology. Journal of Oncology Practice, 2016, 12, 339-383.	2.5	115
1390	T-Cell Therapy Using Interleukin-21-Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression. Journal of Clinical Oncology, 2016, 34, 3787-3795.	0.8	98
1391	Immune Checkpoint Inhibitors in Older Adults. Current Oncology Reports, 2016, 18, 47.	1.8	49
1392	Exacerbation of Autoimmune Thyroiditis by CTLA-4 Blockade: A Role for IFN γ -Induced Indoleamine 2, 3-Dioxygenase. Thyroid, 2016, 26, 1117-1124.	2.4	19
1393	Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discovery, 2016, 6, 827-837.	7.7	785
1394	Programmed cell death-1 blockade in recurrent disseminated Ewing sarcoma. Journal of Hematology and Oncology, 2016, 9, 48.	6.9	28

#	ARTICLE	IF	CITATIONS
1395	Molecular and genetic inflammation networks in major human diseases. <i>Molecular BioSystems</i> , 2016, 12, 2318-2341.	2.9	49
1396	Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1511-1521.	0.5	95
1397	Ovarian cancer patients' and their family members' perspectives on novel vaccine and virotherapy trials. <i>Clinical Trials</i> , 2016, 13, 660-664.	0.7	1
1398	Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure. <i>Journal of Clinical Oncology</i> , 2016, 34, 3733-3739.	0.8	586
1399	Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial. <i>Annals of Surgical Oncology</i> , 2016, 23, 4169-4177.	0.7	236
1400	IL-15 temporally reorients IL-10 biased B-1a cells toward IL-12 expression. <i>Cellular and Molecular Immunology</i> , 2016, 13, 229-239.	4.8	7
1401	Novel technologies and emerging biomarkers for personalized cancer immunotherapy. , 2016, 4, 3.		183
1402	The role of microbiota in cancer therapy. <i>Current Opinion in Immunology</i> , 2016, 39, 75-81.	2.4	74
1403	Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma. <i>British Journal of Cancer</i> , 2016, 114, 256-261.	2.9	256
1404	Bt2a2, a T cell immunomodulatory molecule coregulated with MHC class II genes. <i>Journal of Experimental Medicine</i> , 2016, 213, 177-187.	4.2	49
1405	Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies. <i>Cellular and Molecular Life Sciences</i> , 2016, 73, 1569-1589.	2.4	100
1406	Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-Analysis. <i>Targeted Oncology</i> , 2016, 11, 143-148.	1.7	152
1407	IL-15/sIL-15 gene transfer suppresses Lewis lung cancer growth in the lungs, liver and kidneys. <i>Cancer Gene Therapy</i> , 2016, 23, 54-60.	2.2	11
1408	Potential biomarker for checkpoint blockade immunotherapy and treatment strategy. <i>Tumor Biology</i> , 2016, 37, 4251-4261.	0.8	78
1409	Synthetic ROR γ t Agonists Enhance Protective Immunity. <i>ACS Chemical Biology</i> , 2016, 11, 1012-1018.	1.6	48
1410	Metastatic colonization by circulating tumour cells. <i>Nature</i> , 2016, 529, 298-306.	13.7	1,498
1411	Immune-checkpoint blockade " durable cancer control. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 77-78.	12.5	71
1412	Acquired resistance to immunotherapy and future challenges. <i>Nature Reviews Cancer</i> , 2016, 16, 121-126.	12.8	353

#	ARTICLE	IF	CITATIONS
1413	Ligand-targeted theranostic nanomedicines against cancer. <i>Journal of Controlled Release</i> , 2016, 240, 267-286.	4.8	154
1414	Neutralization of Tumor Acidity Improves Antitumor Responses to Immunotherapy. <i>Cancer Research</i> , 2016, 76, 1381-1390.	0.4	451
1415	Treatment of recurrent and platinum-refractory stage IV non-small cell lung cancer with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as a single agent. <i>Medical Oncology</i> , 2016, 33, 13.	1.2	12
1416	Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab. <i>Clinical Cancer Research</i> , 2016, 22, 2908-2918.	3.2	459
1417	PD-1 Blockade Expands Intratumoral Memory T Cells. <i>Cancer Immunology Research</i> , 2016, 4, 194-203.	1.6	321
1418	Epigenetic Therapeutics: A New Weapon in the War Against Cancer. <i>Annual Review of Medicine</i> , 2016, 67, 73-89.	5.0	285
1419	Heterogeneity of Programmed Cell Death Ligand 1 Expression in Multifocal Lung Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 2177-2182.	3.2	119
1420	Doublet BRAF/MEK inhibition versus single-agent BRAF inhibition in the management of BRAF-mutant advanced melanoma, biological rationale and meta-analysis of published data. <i>Clinical and Translational Oncology</i> , 2016, 18, 848-858.	1.2	21
1421	Regulatory T cells in the immunotherapy of melanoma. <i>Tumor Biology</i> , 2016, 37, 77-85.	0.8	17
1422	Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer. <i>JAMA Oncology</i> , 2016, 2, 46.	3.4	693
1423	Identification of a Novel Pathogenic Germline KDR Variant in Melanoma. <i>Clinical Cancer Research</i> , 2016, 22, 2377-2385.	3.2	34
1424	Clinical relevance of host immunity in breast cancer: from TILs to the clinic. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 228-241.	12.5	679
1425	MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints. <i>Neuro-Oncology</i> , 2016, 18, 639-648.	0.6	161
1426	Circulating tumor-associated neutrophils (cTAN) contribute to circulating tumor cell survival by suppressing peripheral leukocyte activation. <i>Tumor Biology</i> , 2016, 37, 5397-5404.	0.8	48
1427	Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. <i>Cancer Discovery</i> , 2016, 6, 202-216.	7.7	1,158
1428	Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv362.	3.0	71
1429	Circulating Tumor Cells, DNA, and mRNA: Potential for Clinical Utility in Patients With Melanoma. <i>Oncologist</i> , 2016, 21, 84-94.	1.9	20
1430	Recognizing that the microbiome is part of the human immune system will advance treatment of both cancer and infections. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 772-774.	0.6	5

#	ARTICLE	IF	CITATIONS
1431	CNS demyelination and enhanced myelin-reactive responses after ipilimumab treatment. <i>Neurology</i> , 2016, 86, 1553-1556.	1.5	65
1432	CTLA-4 and PD-1 Pathways. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016, 39, 98-106.	0.6	1,644
1433	Epidermal Growth Factor Receptor Inhibition in the Management of Squamous Cell Carcinoma of the Lung. <i>Oncologist</i> , 2016, 21, 205-213.	1.9	22
1434	How Cancers Escape Immune Destruction and Mechanisms of Action for the New Significantly Active Immune Therapies: Helping Nonimmunologists Decipher Recent Advances. <i>Oncologist</i> , 2016, 21, 233-243.	1.9	71
1436	Combining Epigenetic and Immunotherapy to Combat Cancer. <i>Cancer Research</i> , 2016, 76, 1683-1689.	0.4	251
1437	Blocking Indolamine-2,3-Dioxygenase Rebound Immune Suppression Boosts Antitumor Effects of Radio-Immunotherapy in Murine Models and Spontaneous Canine Malignancies. <i>Clinical Cancer Research</i> , 2016, 22, 4328-4340.	3.2	94
1438	B7-H3 increases thymidylate synthase expression via the PI3k-Akt pathway. <i>Tumor Biology</i> , 2016, 37, 9465-9472.	0.8	29
1439	Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting. <i>Oncologist</i> , 2016, 21, 283-291.	1.9	45
1440	Enhanced local and systemic anti-melanoma CD8+ T cell responses after memory T cell-based adoptive immunotherapy in mice. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 601-611.	2.0	13
1441	Cobimetinib Plus Vemurafenib: A Review in BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma. <i>Drugs</i> , 2016, 76, 605-615.	4.9	16
1442	Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment. <i>International Immunology</i> , 2016, 28, 383-391.	1.8	223
1443	Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine. <i>Gynecologic Oncology</i> , 2016, 141, 86-94.	0.6	26
1444	Rational selection of biomarker driven therapies for gynecologic cancers: The more we know, the more we know we don't know. <i>Gynecologic Oncology</i> , 2016, 141, 65-71.	0.6	11
1445	Immunotherapy for head and neck cancer: latest developments and clinical potential. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 168-175.	1.4	18
1447	The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer. <i>Advances in Immunology</i> , 2016, 130, 25-74.	1.1	181
1448	The role of tumor microenvironment in melanoma therapy resistance. <i>Melanoma Management</i> , 2016, 3, 23-32.	0.1	18
1449	Basics of PD-1 in self-tolerance, infection, and cancer immunity. <i>International Journal of Clinical Oncology</i> , 2016, 21, 448-455.	1.0	74
1450	Combination Therapies for Melanoma: A New Standard of Care?. <i>American Journal of Clinical Dermatology</i> , 2016, 17, 99-105.	3.3	23

#	ARTICLE	IF	CITATIONS
1451	STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. <i>Cancer Research</i> , 2016, 76, 999-1008.	0.4	451
1452	CD44+ Cells in Head and Neck Squamous Cell Carcinoma Suppress T-Cell-Mediated Immunity by Selective Constitutive and Inducible Expression of PD-L1. <i>Clinical Cancer Research</i> , 2016, 22, 3571-3581.	3.2	177
1453	Enhancement of tumor cell susceptibility to natural killer cell activity through inhibition of the PI3K signaling pathway. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 355-366.	2.0	13
1454	<i>NRAS</i> mutant melanoma: an overview for the clinician for melanoma management. <i>Melanoma Management</i> , 2016, 3, 47-59.	0.1	12
1455	Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 655-674.	1.4	21
1456	Current treatment options of brain metastases and outcomes in patients with malignant melanoma. <i>Reports of Practical Oncology and Radiotherapy</i> , 2016, 21, 271-277.	0.3	15
1457	The Herpes Simplex Virus Latency-Associated Transcript Gene Is Associated with a Broader Repertoire of Virus-Specific Exhausted CD8 ⁺ T Cells Retained within the Trigeminal Ganglia of Latently Infected HLA Transgenic Rabbits. <i>Journal of Virology</i> , 2016, 90, 3913-3928.	1.5	32
1458	Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2?. <i>Seminars in Immunology</i> , 2016, 28, 73-80.	2.7	56
1459	Variation in Cancer Incidence among Patients with ESRD during Kidney Function and Nonfunction Intervals. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 1495-1504.	3.0	91
1460	Comprehensive molecular tumor profiling in radiation oncology: How it could be used for precision medicine. <i>Cancer Letters</i> , 2016, 382, 118-126.	3.2	15
1461	Moving towards personalised therapy in head and neck squamous cell carcinoma through analysis of next generation sequencing data. <i>European Journal of Cancer</i> , 2016, 55, 147-157.	1.3	28
1462	Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab. <i>Cancer Immunology Research</i> , 2016, 4, 345-353.	1.6	214
1463	Immunotherapy for Gastric Cancer: A Focus on Immune Checkpoints. <i>Targeted Oncology</i> , 2016, 11, 469-477.	1.7	34
1464	Significance of Programmed Death Ligand 1 (PD-L1) Immunohistochemical Expression in Colorectal Cancer. <i>Molecular Diagnosis and Therapy</i> , 2016, 20, 175-181.	1.6	30
1465	Glycogen Synthase Kinase 3 Inactivation Drives T-bet-Mediated Downregulation of Co-receptor PD-1 to Enhance CD8 ⁺ Cytolytic T Cell Responses. <i>Immunity</i> , 2016, 44, 274-286.	6.6	144
1466	Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. <i>Nature Communications</i> , 2016, 7, 10501.	5.8	1,163
1467	Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 1092-1101.	1.4	37
1468	Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2016, 34, 987-1011.	0.8	141

#	ARTICLE	IF	CITATIONS
1469	Pembrolizumab: A Review in Advanced Melanoma. <i>Drugs</i> , 2016, 76, 375-386.	4.9	39
1470	Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 3630-3642.	3.2	353
1471	Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy. <i>Immunity</i> , 2016, 44, 343-354.	6.6	767
1472	Exploiting IL-17-producing CD4+ and CD8+ T cells to improve cancer immunotherapy in the clinic. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 247-259.	2.0	35
1473	Ongoing Response in BRAF V600E-Mutant Melanoma After Cessation of Intermittent Vemurafenib Therapy: A Case Report. <i>Targeted Oncology</i> , 2016, 11, 557-563.	1.7	16
1475	The development of adult innate lymphoid cells. <i>Current Opinion in Immunology</i> , 2016, 39, 114-120.	2.4	40
1476	Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. <i>Nature Communications</i> , 2016, 7, 10391.	5.8	784
1477	Immunotherapy for pancreatic cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1795-1805.	1.2	27
1478	Immunotherapy and Oncogenic Pathways: The PTEN Connection. <i>Cancer Discovery</i> , 2016, 6, 128-129.	7.7	17
1479	Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. <i>Lancet Oncology</i> , The, 2016, 17, 299-308.	5.1	556
1480	Analysis of Immune Cells from Human Mammary Ductal Epithelial Organoids Reveals $\gamma\delta$ T Cells That Efficiently Target Breast Carcinoma Cells in the Presence of Bisphosphonate. <i>Cancer Prevention Research</i> , 2016, 9, 305-316.	0.7	58
1481	Major clinical response to nivolumab in relapsed/refractory Hodgkin lymphoma after allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2016, 51, 850-852.	1.3	51
1482	Personalized treatment of advanced non-small-cell lung cancer in routine clinical practice. <i>Cancer and Metastasis Reviews</i> , 2016, 35, 141-150.	2.7	25
1483	The Use of EGFR Tyrosine Kinase Inhibitors in EGFR Wild-Type Non-Small-Cell Lung Cancer. <i>Current Treatment Options in Oncology</i> , 2016, 17, 18.	1.3	18
1484	Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade. <i>Cancer Cell</i> , 2016, 29, 285-296.	7.7	349
1485	Anti-Programmed Cell Death (PD)-1 Immunotherapy for Malignant Tumor: A Systematic Review and Meta-Analysis. <i>Translational Oncology</i> , 2016, 9, 32-40.	1.7	17
1486	PD-1/PD-L1 blockade in cancer treatment: perspectives and issues. <i>International Journal of Clinical Oncology</i> , 2016, 21, 462-473.	1.0	255
1487	Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 468, 511-525.	1.4	212

#	ARTICLE	IF	CITATIONS
1488	High immunosuppressive burden in cancer patients: a major hurdle for cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 813-819.	2.0	53
1489	An increased number of PD-1+ and Tim-3+ CD8+ T cells is involved in immune evasion in gastric cancer. <i>Surgery Today</i> , 2016, 46, 1341-1347.	0.7	34
1490	Antibody engineering & therapeutics, the annual meeting of the antibody society December 7-10, 2015, San Diego, CA, USA. <i>MAbs</i> , 2016, 8, 617-652.	2.6	7
1491	Bringing Model-Based Prediction to Oncology Clinical Practice: A Review of Pharmacometrics Principles and Applications. <i>Oncologist</i> , 2016, 21, 220-232.	1.9	35
1492	The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 273-290.	12.5	909
1493	Low temperature plasmas as emerging cancer therapeutics: the state of play and thoughts for the future. <i>Tumor Biology</i> , 2016, 37, 7021-7031.	0.8	122
1494	Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition. <i>Current Oncology Reports</i> , 2016, 18, 21.	1.8	39
1495	Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma. <i>Neuro-Oncology</i> , 2016, 18, 1137-1145.	0.6	126
1496	Vaccination with Irradiated Autologous Tumor Cells Mixed with Irradiated GM-K562 Cells Stimulates Antitumor Immunity and T Lymphocyte Activation in Patients with Recurrent Malignant Glioma. <i>Clinical Cancer Research</i> , 2016, 22, 2885-2896.	3.2	45
1497	Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overview. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 171-181.	0.8	38
1498	Evolving molecularly targeted therapies for advanced-stage thyroid cancers. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 403-416.	12.5	80
1499	Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. <i>Lancet, The</i> , 2016, 387, 1909-1920.	6.3	3,077
1500	Tumor and Host Factors Controlling Antitumor Immunity and Efficacy of Cancer Immunotherapy. <i>Advances in Immunology</i> , 2016, 130, 75-93.	1.1	74
1501	Tumor Regression and Allograft Rejection after Administration of Anti-PD-1. <i>New England Journal of Medicine</i> , 2016, 374, 896-898.	13.9	244
1502	Genetic and Epigenetic Regulation of PD-1 Expression. <i>Journal of Immunology</i> , 2016, 196, 2431-2437.	0.4	181
1503	Predictive Markers for the Efficacy of Anti-PD-1/PD-L1 Antibodies in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 976-988.	0.5	197
1504	Anti-PD-1 Inhibitor-Related Pneumonitis in Non-Small Cell Lung Cancer. <i>Cancer Immunology Research</i> , 2016, 4, 289-293.	1.6	135
1505	Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. <i>Journal of Clinical Oncology</i> , 2016, 34, 1510-1517.	0.8	627

#	ARTICLE	IF	CITATIONS
1506	A high number of IgG4-positive cells in gastric cancer tissue is associated with tumor progression and poor prognosis. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 468, 549-557.	1.4	22
1507	The Impact of Genomic Profiling for Novel Cancer Therapy – Recent Progress in Non-Small Cell Lung Cancer. <i>Journal of Genetics and Genomics</i> , 2016, 43, 3-10.	1.7	8
1508	Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2016, 22, 1364-1370.	3.2	251
1509	Adoptive T-Cell Therapy for Cancer. <i>Advances in Immunology</i> , 2016, 130, 279-294.	1.1	168
1510	The Basis of Oncoimmunology. <i>Cell</i> , 2016, 164, 1233-1247.	13.5	671
1511	Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors. <i>EBioMedicine</i> , 2016, 6, 50-58.	2.7	113
1512	Development of immuno-oncology drugs – from CTLA4 to PD1 to the next generations. <i>Nature Reviews Drug Discovery</i> , 2016, 15, 235-247.	21.5	503
1513	Predictive Biomarkers for PD-1 Axis Therapies: The Hidden Treasure or a Call for Research. <i>Clinical Cancer Research</i> , 2016, 22, 2102-2104.	3.2	31
1514	Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. <i>Therapeutic Advances in Respiratory Disease</i> , 2016, 10, 183-193.	1.0	112
1515	Medullary carcinoma of the colon: a distinct morphology reveals a distinctive immunoregulatory microenvironment. <i>Modern Pathology</i> , 2016, 29, 528-541.	2.9	60
1516	Vaccines for established cancer: overcoming the challenges posed by immune evasion. <i>Nature Reviews Cancer</i> , 2016, 16, 219-233.	12.8	580
1517	HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 4119-4132.	3.2	266
1518	Myelodysplastic Syndrome Revealed by Systems Immunology in a Melanoma Patient Undergoing Anti-PD-1 Therapy. <i>Cancer Immunology Research</i> , 2016, 4, 474-480.	1.6	17
1519	Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 4-31.	1.4	40
1520	STAT3 Establishes an Immunosuppressive Microenvironment during the Early Stages of Breast Carcinogenesis to Promote Tumor Growth and Metastasis. <i>Cancer Research</i> , 2016, 76, 1416-1428.	0.4	87
1521	Bypassing checkpoints, overcoming resistance, and honing in on new targets. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 75-76.	12.5	9
1522	A vaccine from plant virus proteins. <i>Nature Nanotechnology</i> , 2016, 11, 214-215.	15.6	21
1523	New Strategies in Bladder Cancer: A Second Coming for Immunotherapy. <i>Clinical Cancer Research</i> , 2016, 22, 793-801.	3.2	60

#	ARTICLE	IF	CITATIONS
1524	Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies. <i>Clinical Cancer Research</i> , 2016, 22, 1592-1602.	3.2	108
1525	Biomaterials and emerging anticancer therapeutics: engineering the microenvironment. <i>Nature Reviews Cancer</i> , 2016, 16, 56-66.	12.8	341
1526	Molecular Targeted Therapy Approaches for BRAF Wild-Type Melanoma. <i>Current Oncology Reports</i> , 2016, 18, 6.	1.8	26
1527	Opportunities and challenges in combination gene cancer therapy. <i>Advanced Drug Delivery Reviews</i> , 2016, 98, 35-40.	6.6	64
1528	Systemic Immune Activity Predicts Overall Survival in Treatment-Naïve Patients with Metastatic Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 2565-2574.	3.2	80
1529	Current progress in immunotherapy for pancreatic cancer. <i>Cancer Letters</i> , 2016, 381, 244-251.	3.2	149
1530	Immunosuppressive cells in tumor immune escape and metastasis. <i>Journal of Molecular Medicine</i> , 2016, 94, 509-522.	1.7	270
1531	Stemming the Rising Incidence of Melanoma: Calling Prevention to Action. <i>Journal of the National Cancer Institute</i> , 2016, 108, .	3.0	61
1532	Take two: Combining immunotherapy with epigenetic drugs to tackle cancer. <i>Nature Medicine</i> , 2016, 22, 8-10.	15.2	57
1533	The Role of Adaptive Immunity in the Efficacy of Targeted Cancer Therapies. <i>Trends in Immunology</i> , 2016, 37, 141-153.	2.9	24
1534	The changing landscape of phase I trials in oncology. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 106-117.	12.5	84
1535	Immune suppressive mechanisms in the tumor microenvironment. <i>Current Opinion in Immunology</i> , 2016, 39, 1-6.	2.4	407
1536	The TGF- β /SMAD pathway is an important mechanism for NK cell immune evasion in childhood B-acute lymphoblastic leukemia. <i>Leukemia</i> , 2016, 30, 800-811.	3.3	109
1537	Prospective immunotherapies in childhood sarcomas: PD1/PDL1 blockade in combination with tumor vaccines. <i>Pediatric Research</i> , 2016, 79, 371-377.	1.1	12
1538	PD-1 Blunts the Function of Ovarian Tumor-Infiltrating Dendritic Cells by Inactivating NF- κ B. <i>Cancer Research</i> , 2016, 76, 239-250.	0.4	84
1539	Anti-PD-1/PD-L1 Therapy as a Promising Option for Non-Small Cell Lung Cancer: a Single arm Meta-Analysis. <i>Pathology and Oncology Research</i> , 2016, 22, 331-339.	0.9	13
1540	Combination cancer immunotherapies tailored to the tumour microenvironment. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 143-158.	12.5	753
1541	Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 13-20.	1.1	81

#	ARTICLE	IF	CITATIONS
1542	The intersection of cancer, cancer stem cells, and the immune system: therapeutic opportunities. <i>Neuro-Oncology</i> , 2016, 18, 153-159.	0.6	86
1543	Immunotherapy for cancer in the central nervous system: Current and future directions. <i>OncImmunology</i> , 2016, 5, e1082027.	2.1	72
1544	The clinical significance of systemic inflammation score in esophageal squamous cell carcinoma. <i>Tumor Biology</i> , 2016, 37, 3081-3090.	0.8	28
1545	RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors. <i>Clinical Cancer Research</i> , 2016, 22, 1499-1509.	3.2	428
1546	Immune checkpoint inhibitors: a new frontier in bladder cancer. <i>World Journal of Urology</i> , 2016, 34, 49-55.	1.2	15
1547	Immunotherapy for non-small cell lung cancer: current concepts and clinical trials. <i>European Journal of Cardio-thoracic Surgery</i> , 2016, 49, 1324-1333.	0.6	33
1548	Novel immunotherapies in lymphoid malignancies. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 25-40.	12.5	224
1549	Tolerance induction using nanoparticles bearing HY peptides in bone marrow transplantation. <i>Biomaterials</i> , 2016, 76, 1-10.	5.7	46
1550	Fast Cars and No Brakes: Autologous Stem Cell Transplantation as a Platform for Novel Immunotherapies. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 17-22.	2.0	16
1551	Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes. <i>Clinical Cancer Research</i> , 2016, 22, 886-894.	3.2	705
1552	Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2016, 1865, 58-71.	3.3	49
1553	Immunotherapy and tumor microenvironment. <i>Cancer Letters</i> , 2016, 370, 85-90.	3.2	242
1554	PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 470-478.	3.2	168
1555	Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine. <i>Gastroenterology</i> , 2016, 150, 48-63.	0.6	90
1556	Repeated stereotactic radiosurgery for patients with progressive brain metastases. <i>Journal of Neuro-Oncology</i> , 2016, 126, 91-97.	1.4	65
1558	PD-L1 expression and prognostic impact in glioblastoma. <i>Neuro-Oncology</i> , 2016, 18, 195-205.	0.6	463
1559	The Immunotherapy Roadmap. <i>Clinical Cancer Research</i> , 2016, 22, 275-276.	3.2	2
1560	The continuing evolution of targeted therapy for inflammatory skin disease. <i>Seminars in Immunopathology</i> , 2016, 38, 123-133.	2.8	12

#	ARTICLE	IF	CITATIONS
1561	Therapeutic efficacy of PD-L1 blockade in a breast cancer model is enhanced by cellular vaccines expressing B7-1 and glycolipid-anchored IL-12. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 421-430.	1.4	18
1562	Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism. <i>Leukemia</i> , 2016, 30, 484-491.	3.3	201
1563	Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer. <i>Clinical Cancer Research</i> , 2016, 22, 436-447.	3.2	107
1564	Endogenous Toll-Like Receptor 9 Regulates AKI by Promoting Regulatory T Cell Recruitment. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 706-714.	3.0	24
1565	Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights. <i>Pituitary</i> , 2016, 19, 82-92.	1.6	259
1566	Retrospective analysis of second-line chemotherapy outcomes with paclitaxel or docetaxel in correlation with STMN1 polymorphism in advanced non-small cell lung cancer patients. <i>Clinical and Translational Oncology</i> , 2016, 18, 33-39.	1.2	11
1567	Lectin microarray technology identifies specific lectins related to lymph node metastasis of advanced gastric cancer. <i>Gastric Cancer</i> , 2016, 19, 531-542.	2.7	33
1568	Hyperthermic intraperitoneal chemotherapy leads to an anticancer immune response via exposure of cell surface heat shock protein 90. <i>Oncogene</i> , 2016, 35, 261-268.	2.6	54
1569	Precision oncology: A new era of cancer clinical trials. <i>Cancer Letters</i> , 2017, 387, 121-126.	3.2	53
1570	CTLA-4 Limits Anti-CD20-Mediated Tumor Regression. <i>Clinical Cancer Research</i> , 2017, 23, 193-203.	3.2	35
1571	Integration of multiple "OMIC" biomarkers: A precision medicine strategy for lung cancer. <i>Lung Cancer</i> , 2017, 107, 50-58.	0.9	45
1572	Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer. <i>Oncogene</i> , 2017, 36, 439-445.	2.6	277
1573	Translational aspects in targeting the stromal tumour microenvironment: From bench to bedside. <i>European Journal of Molecular and Clinical Medicine</i> , 2017, 3, 9.	0.5	18
1574	A second chance for telomerase reverse transcriptase in anticancer immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 115-128.	12.5	95
1575	Targeted therapy combined with radiotherapy in non-small-cell lung cancer: a review of the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society). <i>Clinical and Translational Oncology</i> , 2017, 19, 31-43.	1.2	19
1576	Altered expression of major immune regulatory molecules in peripheral blood immune cells associated with breast cancer. <i>Breast Cancer</i> , 2017, 24, 111-120.	1.3	21
1577	Sequential treatment with immunotherapy and BRAF inhibitors in BRAF-mutant advanced melanoma. <i>Clinical and Translational Oncology</i> , 2017, 19, 119-124.	1.2	23
1578	Principles of Kinase Inhibitor Therapy for Solid Tumors. <i>Annals of Surgery</i> , 2017, 265, 311-319.	2.1	10

#	ARTICLE	IF	CITATIONS
1579	Combine and conquer: challenges for targeted therapy combinations in early phase trials. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 57-66.	12.5	239
1580	Coevolution of Leukemia and Host Immune Cells in Chronic Lymphocytic Leukemia. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2017, 7, a026740.	2.9	25
1581	Elements of cancer immunity and the cancerâ€œimmune set point. <i>Nature</i> , 2017, 541, 321-330.	13.7	3,558
1582	COX2/mPGES1/PGE ₂ pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 1117-1122.	3.3	378
1583	Inflammasomes and Cancer. <i>Cancer Immunology Research</i> , 2017, 5, 94-99.	1.6	290
1584	Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora?. <i>Seminars in Immunopathology</i> , 2017, 39, 327-331.	2.8	22
1585	Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma. <i>British Journal of Cancer</i> , 2017, 116, 432-440.	2.9	59
1586	Cancer immunotherapy â€œ immune checkpoint blockade and associated endocrinopathies. <i>Nature Reviews Endocrinology</i> , 2017, 13, 195-207.	4.3	515
1587	Successful Treatment of an Aggressive Tracheal Malignancy With Immunotherapy. <i>Annals of Thoracic Surgery</i> , 2017, 103, e123-e125.	0.7	4
1588	Strategies to overcome therapeutic resistance in renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 102-110.	0.8	35
1589	Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E970-E979.	3.3	172
1590	Inverse lichenoid drug eruption associated with nivolumab. <i>JAAD Case Reports</i> , 2017, 3, 7-9.	0.4	13
1591	Aptamers for CD Antigens: From Cell Profiling to Activity Modulation. <i>Molecular Therapy - Nucleic Acids</i> , 2017, 6, 29-44.	2.3	33
1592	A current perspective on cancer immune therapy: stepâ€œbyâ€œstep approach to constructing the magic bullet. <i>Clinical and Translational Medicine</i> , 2017, 6, 3.	1.7	58
1593	Heterogeneous expression of PD-L1 in pulmonary squamous cell carcinoma and adenocarcinoma: implications for assessment by small biopsy. <i>Modern Pathology</i> , 2017, 30, 530-538.	2.9	92
1594	Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer. <i>Modern Pathology</i> , 2017, 30, 577-586.	2.9	132
1595	Death receptor 6 contributes to autoimmunity in lupus-prone mice. <i>Nature Communications</i> , 2017, 8, 13957.	5.8	38
1596	Public primary and secondary skin cancer prevention, perceptions and knowledge: an international crossâ€œsectional survey. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 815-820.	1.3	51

#	ARTICLE	IF	CITATIONS
1597	Metastatic Melanoma Patient Had a Complete Response with Clonal Expansion after Whole Brain Radiation and PD-1 Blockade. <i>Cancer Immunology Research</i> , 2017, 5, 100-105.	1.6	46
1598	Clinical Impact of Frequent Surveillance Imaging in the First Year Following Chemoradiation for Locally Advanced Non-small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, 410-414.	1.1	7
1599	Renal complications of immune checkpoint blockade. <i>Current Problems in Cancer</i> , 2017, 41, 100-110.	1.0	81
1600	Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis. <i>Journal of Clinical Oncology</i> , 2017, 35, 226-235.	0.8	458
1601	Liposomal Delivery Enhances Immune Activation by STING Agonists for Cancer Immunotherapy. <i>Advanced Biology</i> , 2017, 1, 1600013.	3.0	175
1602	Current Status of Companion and Complementary Diagnostics: Strategic Considerations for Development and Launch. <i>Clinical and Translational Science</i> , 2017, 10, 84-92.	1.5	92
1603	The development of dendritic cell vaccine-based immunotherapies for glioblastoma. <i>Seminars in Immunopathology</i> , 2017, 39, 225-239.	2.8	42
1604	Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of Afatinib. <i>Current Oncology Reports</i> , 2017, 19, 4.	1.8	15
1605	The Exportin-1 Inhibitor Selinexor Exerts Superior Antitumor Activity when Combined with T-Cell Checkpoint Inhibitors. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 417-427.	1.9	16
1606	Clinical Dosing Regimen of Selinexor Maintains Normal Immune Homeostasis and T-cell Effector Function in Mice: Implications for Combination with Immunotherapy. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 428-439.	1.9	25
1607	Effect of cryopreservation on delineation of immune cell subpopulations in tumor specimens as determined by multiparametric single cell mass cytometry analysis. <i>BMC Immunology</i> , 2017, 18, 6.	0.9	31
1608	Phase I/II study of docetaxel combined with resminostat, an oral hydroxamic acid HDAC inhibitor, for advanced non-small cell lung cancer in patients previously treated with platinum-based chemotherapy. <i>Investigational New Drugs</i> , 2017, 35, 217-226.	1.2	12
1609	Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program. <i>Clinical and Translational Oncology</i> , 2017, 19, 761-768.	1.2	12
1610	Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape. <i>Cancer Immunology Research</i> , 2017, 5, 106-117.	1.6	236
1611	Perioperative chemotherapy in upper tract urothelial carcinoma: a comprehensive review. <i>World Journal of Urology</i> , 2017, 35, 1401-1407.	1.2	29
1612	Radiation-Induced Enhancement of Antitumor T-cell Immunity by VEGF-Targeted 4-1BB Costimulation. <i>Cancer Research</i> , 2017, 77, 1310-1321.	0.4	32
1613	Is CD47 an innate immune checkpoint for tumor evasion?. <i>Journal of Hematology and Oncology</i> , 2017, 10, 12.	6.9	139
1614	Accuracy of transbronchial biopsy as a rebiopsy method for patients with relapse of advanced non-small-cell lung cancer after systemic chemotherapy. <i>BMJ Open Respiratory Research</i> , 2017, 4, e000163.	1.2	7

#	ARTICLE	IF	CITATIONS
1615	Is there still a role for cytotoxic chemotherapy after targeted therapy and immunotherapy in metastatic melanoma? A case report and literature review. <i>Chinese Journal of Cancer</i> , 2017, 36, 10.	4.9	38
1616	Advanced MRI assessment to predict benefit of anti-programmed cell death 1 protein immunotherapy response in patients with recurrent glioblastoma. <i>Neuroradiology</i> , 2017, 59, 135-145.	1.1	57
1617	Correlation between Classic Driver Oncogene Mutations in EGFR , ALK , or ROS1 and PD-L1 Expression in Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2017, 12, 878-883.	0.5	109
1618	Radiotherapy and immunotherapy: a beneficial liaison?. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 365-379.	12.5	760
1619	Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma. <i>Neuro-Oncology</i> , 2017, 19, now287.	0.6	128
1620	Gastrointestinal and Hepatic Complications of Immune Checkpoint Inhibitors. <i>Current Gastroenterology Reports</i> , 2017, 19, 3.	1.1	141
1621	Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL. <i>Leukemia</i> , 2017, 31, 2181-2190.	3.3	188
1622	Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 157-165.	0.8	345
1623	Targeting ALK: Precision Medicine Takes on Drug Resistance. <i>Cancer Discovery</i> , 2017, 7, 137-155.	7.7	405
1624	PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective. <i>Journal of Hematology and Oncology</i> , 2017, 10, 34.	6.9	82
1625	Redirecting the focus of cancer immunotherapy to premalignant conditions. <i>Cancer Letters</i> , 2017, 391, 83-88.	3.2	24
1626	Medication-associated gastrointestinal tract injury. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 470, 245-266.	1.4	22
1627	Comparison of Five Different Assays for the Detection of BRAF Mutations in Formalin-Fixed Paraffin Embedded Tissues of Patients with Metastatic Melanoma. <i>Molecular Diagnosis and Therapy</i> , 2017, 21, 209-216.	1.6	8
1628	Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 581-592.	2.0	189
1629	Chemotherapy induces tumor immune evasion by upregulation of programmed cell death ligand 1 expression in bone marrow stromal cells. <i>Molecular Oncology</i> , 2017, 11, 358-372.	2.1	43
1630	Cardiovascular Toxicities Associated with Cancer Immunotherapies. <i>Current Cardiology Reports</i> , 2017, 19, 21.	1.3	126
1631	Anticancer Drug-Induced Acute Kidney Injury. <i>Kidney International Reports</i> , 2017, 2, 504-514.	0.4	81
1632	A first reported case of metastatic anorectal amelanotic melanoma with a marked response to anti-PD-1 antibody nivolumab: A case report. <i>International Journal of Surgery Case Reports</i> , 2017, 31, 188-192.	0.2	21

#	ARTICLE	IF	CITATIONS
1633	Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice. <i>Nature Communications</i> , 2017, 8, 14572.	5.8	279
1634	PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors. <i>Clinical Cancer Research</i> , 2017, 23, 4270-4279.	3.2	117
1635	Development of Cancer Vaccines Targeting Brachyury, a Transcription Factor Associated with Tumor Epithelial-Mesenchymal Transition. <i>Cells Tissues Organs</i> , 2017, 203, 128-138.	1.3	20
1636	Emerging role of checkpoint blockade therapy in lymphoma. <i>Therapeutic Advances in Hematology</i> , 2017, 8, 81-90.	1.1	32
1637	Cost-Effectiveness of Immune Checkpoint Inhibition in <i>BRAF</i> Wild-Type Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 1194-1202.	0.8	89
1638	Dependence of Glomerulonephritis Induction on Novel Intraglomerular Alternatively Activated Bone Marrow-Derived Macrophages and Mac-1 and PD-L1 in Lupus-Prone NZM2328 Mice. <i>Journal of Immunology</i> , 2017, 198, 2589-2601.	0.4	32
1639	Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors. <i>Supportive Care in Cancer</i> , 2017, 25, 1713-1739.	1.0	125
1640	The biology of uveal melanoma. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 109-140.	2.7	160
1641	Oncolytic Adenoviruses Armed with Tumor Necrosis Factor Alpha and Interleukin-2 Enable Successful Adoptive Cell Therapy. <i>Molecular Therapy - Oncolytics</i> , 2017, 4, 77-86.	2.0	88
1642	Human peripheral blood mononuclear cells (PBMCs) from smokers release higher levels of IL-1-like cytokines after exposure to combustion-generated ultrafine particles. <i>Scientific Reports</i> , 2017, 7, 43016.	1.6	35
1643	Immune Checkpoint Blockade Biology in Mouse Models of Glioblastoma. <i>Journal of Cellular Biochemistry</i> , 2017, 118, 2516-2527.	1.2	15
1644	Targeting neoantigens to augment antitumour immunity. <i>Nature Reviews Cancer</i> , 2017, 17, 209-222.	12.8	724
1645	The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy. <i>Endocrine-Related Cancer</i> , 2017, 24, R123-R144.	1.6	64
1646	NLRC5/CITA: A Key Player in Cancer Immune Surveillance. <i>Trends in Cancer</i> , 2017, 3, 28-38.	3.8	59
1647	Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. <i>New England Journal of Medicine</i> , 2017, 376, 1015-1026.	13.9	2,677
1648	Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma. <i>Current Treatment Options in Oncology</i> , 2017, 18, 7.	1.3	46
1649	Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2017, 18, 446-453.	5.1	322
1650	Transient Cannabinoid Receptor 2 Blockade during Immunization Heightens Intensity and Breadth of Antigen-specific Antibody Responses in Young and Aged mice. <i>Scientific Reports</i> , 2017, 7, 42584.	1.6	21

#	ARTICLE	IF	CITATIONS
1651	Economic burden of patients affected by non-small cell lung cancer (NSCLC): the LIFE study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 783-791.	1.2	36
1652	A human programmed death-ligand 1-expressing mouse tumor model for evaluating the therapeutic efficacy of anti-human PD-L1 antibodies. <i>Scientific Reports</i> , 2017, 7, 42687.	1.6	22
1653	Mouse genomic screen reveals novel host regulator of metastasis. <i>Genome Biology</i> , 2017, 18, 31.	3.8	3
1654	PD-1 inhibitors increase the incidence and risk of pneumonitis in cancer patients in a dose-independent manner: a meta-analysis. <i>Scientific Reports</i> , 2017, 7, 44173.	1.6	70
1655	Standard of care in immunotherapy trials: Challenges and considerations. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 2164-2178.	1.4	4
1656	A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2017, 3, 1051.	3.4	658
1657	Precision medicine driven by cancer systems biology. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 91-108.	2.7	38
1658	Expanding the B Cell-Centric View of Systemic Lupus Erythematosus. <i>Trends in Immunology</i> , 2017, 38, 373-382.	2.9	40
1659	The Shc1 adaptor simultaneously balances Stat1 and Stat3 activity to promote breast cancer immune suppression. <i>Nature Communications</i> , 2017, 8, 14638.	5.8	52
1660	T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. <i>Science</i> , 2017, 355, 1428-1433.	6.0	1,229
1661	Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis. <i>Oncologist</i> , 2017, 22, 470-479.	1.9	244
1662	Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041). <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 651-660.	1.1	76
1663	Structure-guided development of a high-affinity human Programmed Cell Death-1: Implications for tumor immunotherapy. <i>EBioMedicine</i> , 2017, 17, 30-44.	2.7	52
1664	A Novel DNA Vaccine Platform Enhances Neo-antigen-like T Cell Responses against WT1 to Break Tolerance and Induce Anti-tumor Immunity. <i>Molecular Therapy</i> , 2017, 25, 976-988.	3.7	29
1665	COX-2 expression positively correlates with PD-L1 expression in human melanoma cells. <i>Journal of Translational Medicine</i> , 2017, 15, 46.	1.8	85
1666	Immune checkpoint inhibitors in challenging populations. <i>Cancer</i> , 2017, 123, 1904-1911.	2.0	266
1667	Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 683-695.	2.0	53
1668	Immune modulation by dendritic-cell-based cancer vaccines. <i>Journal of Biosciences</i> , 2017, 42, 161-173.	0.5	15

#	ARTICLE	IF	CITATIONS
1669	Inhibitory Receptors Induced by VSV Viroimmunotherapy Are Not Necessarily Targets for Improving Treatment Efficacy. <i>Molecular Therapy</i> , 2017, 25, 962-975.	3.7	22
1670	Inflammatory cytokines compromise programmed cell death-1 (PD-1)-mediated T cell suppression in inflammatory arthritis through up-regulation of soluble PD-1. <i>Clinical and Experimental Immunology</i> , 2017, 188, 455-466.	1.1	55
1671	FAK-inhibition opens the door to checkpoint immunotherapy in Pancreatic Cancer. , 2017, 5, 17.		24
1672	Combination immunotherapy: a road map. , 2017, 5, 16.		325
1673	Targeting the programmed death-1 pathway in lymphoid neoplasms. <i>Cancer Treatment Reviews</i> , 2017, 54, 99-109.	3.4	27
1674	Autologous bone marrow Th cells can support multiple myeloma cell proliferation in vitro and in xenografted mice. <i>Leukemia</i> , 2017, 31, 2114-2121.	3.3	13
1675	Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	689
1676	Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients. <i>Cancer Immunology Research</i> , 2017, 5, 312-318.	1.6	354
1677	Survival Gains from First-Line Systemic Therapy in Metastatic Non-Small Cell Lung Cancer in the U.S., 1990â€“2015: Progress and Opportunities. <i>Oncologist</i> , 2017, 22, 304-310.	1.9	8
1678	The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry. <i>Clinical Epigenetics</i> , 2017, 9, 4.	1.8	33
1679	An unexpected N-terminal loop in PD-1 dominates binding by nivolumab. <i>Nature Communications</i> , 2017, 8, 14369.	5.8	192
1680	Integrated genomic analysis of recurrence-associated small non-coding RNAs in oesophageal cancer. <i>Gut</i> , 2017, 66, 215-225.	6.1	34
1681	Reactivation of dormant anti-tumor immunity â€“ a clinical perspective of therapeutic immune checkpoint modulation. <i>Cell Communication and Signaling</i> , 2017, 15, 5.	2.7	34
1682	Immune Checkpoint Blockade and Hematopoietic Stem Cell Transplant. <i>Current Hematologic Malignancy Reports</i> , 2017, 12, 44-50.	1.2	12
1683	DNA vaccines for prostate cancer. , 2017, 174, 27-42.		36
1684	Precision medicine needs randomized clinical trials. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 317-323.	12.5	60
1685	Metastatic disease from uveal melanoma: treatment options and future prospects. <i>British Journal of Ophthalmology</i> , 2017, 101, 38-44.	2.1	287
1686	PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression. <i>Clinical Cancer Research</i> , 2017, 23, 3711-3720.	3.2	710

#	ARTICLE	IF	CITATIONS
1687	Routine Computer Tomography Imaging for the Detection of Recurrences in High-Risk Melanoma Patients. <i>Annals of Surgical Oncology</i> , 2017, 24, 947-951.	0.7	26
1688	Genetically engineered mouse models in oncology research and cancer medicine. <i>EMBO Molecular Medicine</i> , 2017, 9, 137-153.	3.3	356
1689	Applications of Immunogenomics to Cancer. <i>Cell</i> , 2017, 168, 600-612.	13.5	198
1690	Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. <i>Cell</i> , 2017, 168, 707-723.	13.5	3,483
1691	Strategies for Translating Evidence-Based Medicine in Lung Cancer into Community Practice. <i>Current Oncology Reports</i> , 2017, 19, 5.	1.8	0
1692	Risk of tumor flare after nivolumab treatment in patients with irradiated field recurrence. <i>Medical Oncology</i> , 2017, 34, 34.	1.2	25
1693	Non-tumor cell IDO1 predominantly contributes to enzyme activity and response to CTLA-4/PD-L1 inhibition in mouse glioblastoma. <i>Brain, Behavior, and Immunity</i> , 2017, 62, 24-29.	2.0	46
1694	Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report. <i>Journal of Hematology and Oncology</i> , 2017, 10, 64.	6.9	30
1696	The Role of Surgery for Melanoma in an Era of Effective Systemic Therapy. <i>Current Oncology Reports</i> , 2017, 19, 17.	1.8	30
1697	Development of Novel ImmunoPET Tracers to Image Human PD-1 Checkpoint Expression on Tumor-Infiltrating Lymphocytes in a Humanized Mouse Model. <i>Molecular Imaging and Biology</i> , 2017, 19, 903-914.	1.3	91
1698	TIM-3 and its role in regulating anti-tumor immunity. <i>Immunological Reviews</i> , 2017, 276, 97-111.	2.8	599
1699	TAM receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy. <i>Immunological Reviews</i> , 2017, 276, 165-177.	2.8	125
1700	Introduction to checkpoint inhibitors and cancer immunotherapy. <i>Immunological Reviews</i> , 2017, 276, 5-8.	2.8	151
1701	Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells. <i>Cancer Immunology Research</i> , 2017, 5, 319-329.	1.6	25
1702	The Role of Immune Checkpoint Inhibition in the Treatment of Brain Tumors. <i>Neurotherapeutics</i> , 2017, 14, 1049-1065.	2.1	20
1703	LAG-3 (CD223) as a cancer immunotherapy target. <i>Immunological Reviews</i> , 2017, 276, 80-96.	2.8	664
1704	Immunoregulatory functions of VISTA. <i>Immunological Reviews</i> , 2017, 276, 66-79.	2.8	154
1705	Co-inhibitory blockade while preserving tolerance: checkpoint inhibitors for glioblastoma. <i>Immunological Reviews</i> , 2017, 276, 9-25.	2.8	13

#	ARTICLE	IF	CITATIONS
1706	Outcomes of postoperative stereotactic radiosurgery to the resection cavity versus stereotactic radiosurgery alone for melanoma brain metastases. <i>Journal of Neuro-Oncology</i> , 2017, 132, 455-462.	1.4	38
1707	Anti-PD-L1 atezolizumab-Induced Autoimmune Diabetes: a Case Report and Review of the Literature. <i>Targeted Oncology</i> , 2017, 12, 235-241.	1.7	40
1708	Nivolumab treatment for advanced renal cell carcinoma: Considerations for clinical practice. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 142-148.	0.8	16
1709	INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology. <i>ACS Medicinal Chemistry Letters</i> , 2017, 8, 486-491.	1.3	235
1710	Immunotherapy in pancreatic cancer treatment: a new frontier. <i>Therapeutic Advances in Gastroenterology</i> , 2017, 10, 168-194.	1.4	73
1711	The master role of microphthalmia-associated transcription factor in melanocyte and melanoma biology. <i>Laboratory Investigation</i> , 2017, 97, 649-656.	1.7	197
1712	The clinical evidence for targeting human myeloid-derived suppressor cells in cancer patients. <i>Journal of Leukocyte Biology</i> , 2017, 102, 381-391.	1.5	50
1713	Treatment Options for EGFR T790M-Negative EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer. <i>Targeted Oncology</i> , 2017, 12, 153-161.	1.7	31
1714	Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer: a randomized Phase I study. <i>Breast Cancer Research and Treatment</i> , 2017, 162, 479-488.	1.1	14
1715	Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients. <i>European Journal of Cancer</i> , 2017, 73, 61-70.	1.3	88
1716	Cancer treatment and the KIR-HLA system: an overview. <i>Clinical and Experimental Medicine</i> , 2017, 17, 419-429.	1.9	21
1717	Interferon- γ -inducible Dendritic Cells Matured with OK-432 Exhibit TRAIL and Fas Ligand Pathway-mediated Killer Activity. <i>Scientific Reports</i> , 2017, 7, 42145.	1.6	12
1718	Smac mimetics synergize with immune checkpoint inhibitors to promote tumour immunity against glioblastoma. <i>Nature Communications</i> , 2017, 8, .	5.8	103
1719	'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations. <i>Nature Immunology</i> , 2017, 18, 255-262.	7.0	361
1720	Targeting the programmed cell death 1 pathway in Hodgkin lymphoma: the place of nivolumab. <i>Therapeutic Advances in Hematology</i> , 2017, 8, 175-180.	1.1	4
1721	Blocking the PD-1/PD-L1 pathway in glioma: a potential new treatment strategy. <i>Journal of Hematology and Oncology</i> , 2017, 10, 81.	6.9	114
1722	Genetic evolution of uveal melanoma guides the development of an inflammatory microenvironment. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 903-912.	2.0	92
1723	Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment. <i>EBioMedicine</i> , 2017, 18, 56-61.	2.7	83

#	ARTICLE	IF	CITATIONS
1724	The Prognostic Value of BRAF , C-KIT , and NRAS Mutations in Melanoma Patients With Brain Metastases. International Journal of Radiation Oncology Biology Physics, 2017, 98, 1069-1077.	0.4	58
1725	T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature, 2017, 545, 60-65.	13.7	1,280
1726	From the Guest Editors. Cancer Journal (Sudbury, Mass), 2017, 23, 1-2.	1.0	0
1727	Clinical Features of Acquired Resistance to Anti-PD-1 Therapy in Advanced Melanoma. Cancer Immunology Research, 2017, 5, 357-362.	1.6	40
1728	Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors. Immunity, 2017, 46, 577-586.	6.6	323
1729	Elevated serum autoantibodies against co-inhibitory PD-1 facilitate T cell proliferation and correlate with disease activity in new-onset systemic lupus erythematosus patients. Arthritis Research and Therapy, 2017, 19, 52.	1.6	25
1730	Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 41-54.	3.3	55
1731	An antivascular vaccine to boost self-immunity and strike the tumor. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E3164-E3165.	3.3	1
1732	End points and statistical considerations in immuno-oncology trials: impact on multiple myeloma. Future Oncology, 2017, 13, 1181-1193.	1.1	25
1733	Sarcopenic overweight is associated with early acute limiting toxicity of anti-PD1 checkpoint inhibitors in melanoma patients. Investigational New Drugs, 2017, 35, 436-441.	1.2	73
1734	Selective blockade of B7-3 enhances antitumour immune activity by reducing immature myeloid cells in head and neck squamous cell carcinoma. Journal of Cellular and Molecular Medicine, 2017, 21, 2199-2210.	1.6	43
1735	Prediction of optimal gene functions for osteosarcoma using gene ontology and microarray profiles. Journal of Bone Oncology, 2017, 7, 18-22.	1.0	6
1736	Update on Chemotherapy-Induced Peripheral Neuropathy. Current Neurology and Neuroscience Reports, 2017, 17, 47.	2.0	63
1737	Immune Checkpoint Inhibitors for Brain Metastases. Current Oncology Reports, 2017, 19, 38.	1.8	18
1738	Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet, The, 2017, 389, 2492-2502.	6.3	3,224
1739	PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison. Clinical Cancer Research, 2017, 23, 4938-4944.	3.2	120
1740	Small cell lung cancer transformation during immunotherapy with nivolumab: A case report. Respiratory Medicine Case Reports, 2017, 21, 52-55.	0.2	27
1741	Immunotherapy and targeted therapy in brain metastases: emerging options in precision medicine. CNS Oncology, 2017, 6, 139-151.	1.2	12

#	ARTICLE	IF	CITATIONS
1742	Response to the treatment immediately before nivolumab monotherapy may predict clinical response to nivolumab in patients with non-small cell lung cancer. <i>International Journal of Clinical Oncology</i> , 2017, 22, 690-697.	1.0	20
1743	Prognostic impact of PD-1 and its ligands in renal cell carcinoma. <i>Medical Oncology</i> , 2017, 34, 99.	1.2	19
1744	Repolarizing macrophages improves breast cancer therapy. <i>Cell Research</i> , 2017, 27, 963-964.	5.7	40
1745	Cancer in Solid Organ Transplant Recipients: There Is Still Much to Learn and Do. <i>American Journal of Transplantation</i> , 2017, 17, 1967-1969.	2.6	15
1746	Increasing the safety and efficacy of chimeric antigen receptor T cell therapy. <i>Protein and Cell</i> , 2017, 8, 573-589.	4.8	67
1747	Expression of Programmed Cell Death Protein 1 by Tumor-Infiltrating Lymphocytes and Tumor Cells is Associated with Advanced Tumor Stage in Patients with Esophageal Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2017, 24, 2698-2706.	0.7	24
1748	Dendritic cell based vaccination strategy: an evolving paradigm. <i>Journal of Neuro-Oncology</i> , 2017, 133, 223-235.	1.4	39
1749	Renal cell carcinoma: molecular characterization and evolving treatment paradigms. <i>Current Opinion in Oncology</i> , 2017, 29, 201-209.	1.1	12
1750	Nivolumab induced myxedema crisis. , 2017, 5, 13.		48
1751	New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management. <i>Critical Care</i> , 2017, 21, 89.	2.5	340
1752	Treatment Paradigms for Advanced Non-Small Cell Lung Cancer at Academic Medical Centers: Involvement in Clinical Trial Endpoint Design. <i>Oncologist</i> , 2017, 22, 700-708.	1.9	11
1753	Indicators of responsiveness to immune checkpoint inhibitors. <i>Scientific Reports</i> , 2017, 7, 807.	1.6	70
1754	Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC. <i>Cancer Immunology Research</i> , 2017, 5, 417-424.	1.6	400
1755	Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic. <i>Annals of Oncology</i> , 2017, 28, 1388-1398.	0.6	70
1756	Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells. <i>Lung Cancer</i> , 2017, 109, 1-8.	0.9	27
1757	Adjuvant Therapy for Melanoma. <i>Current Oncology Reports</i> , 2017, 19, 36.	1.8	26
1758	Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial. <i>Annals of Oncology</i> , 2017, 28, 874-881.	0.6	197
1759	Current status of research and treatment for non-small cell lung cancer in never-smoking females. <i>Cancer Biology and Therapy</i> , 2017, 18, 359-368.	1.5	66

#	ARTICLE	IF	CITATIONS
1760	Post-chemotherapy PD-L1 expression correlates with clinical outcomes in Japanese bladder cancer patients treated with total cystectomy. <i>Medical Oncology</i> , 2017, 34, 117.	1.2	7
1761	Glycolysis regulates the expansion of myeloid-derived suppressor cells in tumor-bearing hosts through prevention of ROS-mediated apoptosis. <i>Cell Death and Disease</i> , 2017, 8, e2779-e2779.	2.7	114
1762	Vaccine-based immunotherapeutic approaches to gliomas and beyond. <i>Nature Reviews Neurology</i> , 2017, 13, 363-374.	4.9	125
1763	Mechanisms of Immune Tolerance in Leukemia and Lymphoma. <i>Trends in Immunology</i> , 2017, 38, 513-525.	2.9	86
1764	Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer. <i>Journal of Hematology and Oncology</i> , 2017, 10, 105.	6.9	129
1765	Nivolumab for patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series. <i>Journal of Neuro-Oncology</i> , 2017, 133, 561-569.	1.4	43
1766	Checkpoint inhibition and melanoma: Considerations in treating the older adult. <i>Journal of Geriatric Oncology</i> , 2017, 8, 237-241.	0.5	27
1767	Focus on cutaneous and uveal melanoma specificities. <i>Genes and Development</i> , 2017, 31, 724-743.	2.7	75
1768	Emerging therapies for breast cancer. <i>Journal of Hematology and Oncology</i> , 2017, 10, 98.	6.9	60
1769	Antiangiogenics and immunotherapies in cervical cancer: an update and future's view. <i>Medical Oncology</i> , 2017, 34, 115.	1.2	14
1770	Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. <i>Annals of Oncology</i> , 2017, 28, 1631-1639.	0.6	549
1771	A Dose-Volume Response Model for Brain Metastases Treated With Frameless Single-Fraction Robotic Radiosurgery: Seeking to Better Predict Response to Treatment. <i>Technology in Cancer Research and Treatment</i> , 2017, 16, 344-351.	0.8	6
1772	Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1268-1279.	0.5	152
1773	Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E4223-E4232.	3.3	121
1774	A Case Report of Drug-Induced Myopathy Involving Extraocular Muscles after Combination Therapy with Tremelimumab and Durvalumab for Non-Small Cell Lung Cancer. <i>Neuro-Ophthalmology</i> , 2017, 41, 140-143.	0.4	24
1775	Chemotherapy-induced peripheral neuropathy: A current review. <i>Annals of Neurology</i> , 2017, 81, 772-781.	2.8	506
1776	Exploiting Synthetic Lethality and Network Biology to Overcome EGFR Inhibitor Resistance in Lung Cancer. <i>Journal of Molecular Biology</i> , 2017, 429, 1767-1786.	2.0	14
1777	A new frontier in treatment of advanced melanoma: Redefining clinical management in the era of immune checkpoint inhibitors. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 1765-1767.	1.4	3

#	ARTICLE	IF	CITATIONS
1778	In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	466
1779	Checkpoint inhibitors in hematological malignancies. <i>Journal of Hematology and Oncology</i> , 2017, 10, 103.	6.9	106
1780	Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 1844.	3.8	281
1781	Current status of chimeric antigen receptor engineered T cell-based and immune checkpoint blockade-based cancer immunotherapies. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1113-1121.	2.0	29
1782	The Potential of Cellular- and Viral-Based Immunotherapies for Malignant Glioma-Dendritic Cell Vaccines, Adoptive Cell Transfer, and Oncolytic Viruses. <i>Current Neurology and Neuroscience Reports</i> , 2017, 17, 50.	2.0	10
1783	Multivalent bi-specific nanobioconjugate engager for targeted cancer immunotherapy. <i>Nature Nanotechnology</i> , 2017, 12, 763-769.	15.6	136
1784	AJRCCM: 100-Year Anniversary. The Shifting Landscape for Lung Cancer: Past, Present, and Future. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 1150-1160.	2.5	75
1785	Harnessing antitumor immunity: Employment of tumor recall antigens to optimize the inflammatory response to cancer. <i>Oncology Letters</i> , 2017, 13, 2015-2020.	0.8	3
1786	Epigenetic Remodeling in Exhausted T Cells. <i>Transplantation</i> , 2017, 101, 894-895.	0.5	3
1787	Granzyme B PET Imaging as a Predictive Biomarker of Immunotherapy Response. <i>Cancer Research</i> , 2017, 77, 2318-2327.	0.4	235
1788	Programmed cell death ligand 1 as a biomarker in head and neck cancer. <i>Cancer Cytopathology</i> , 2017, 125, 529-533.	1.4	1
1789	Outcomes targeting the PD-1/PD-L1 axis in conjunction with stereotactic radiation for patients with non-small cell lung cancer brain metastases. <i>Journal of Neuro-Oncology</i> , 2017, 133, 331-338.	1.4	107
1790	CXCL10/CXCR3-Dependent Mobilization of Herpes Simplex Virus-Specific CD8 + T EM and CD8 + T RM Cells within Infected Tissues Allows Efficient Protection against Recurrent Herpesvirus Infection and Disease. <i>Journal of Virology</i> , 2017, 91, .	1.5	40
1791	Phase I Trial of Intratumoral Injection of CCL21-Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8+ T-cell Infiltration. <i>Clinical Cancer Research</i> , 2017, 23, 4556-4568.	3.2	149
1792	Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study. <i>Cancer</i> , 2017, 123, 3285-3290.	2.0	170
1793	Progress and opportunities for enhancing the delivery and efficacy of checkpoint inhibitors for cancer immunotherapy. <i>Advanced Drug Delivery Reviews</i> , 2017, 114, 33-42.	6.6	81
1794	Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 4993-4998.	3.3	614
1795	Signaling by Antibodies: Recent Progress. <i>Annual Review of Immunology</i> , 2017, 35, 285-311.	9.5	167

#	ARTICLE	IF	CITATIONS
1796	The use of immunotherapy in the treatment of melanoma. <i>Journal of Hematology and Oncology</i> , 2017, 10, 88.	6.9	89
1798	Comment on "Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy". <i>British Journal of Cancer</i> , 2017, 116, e14-e14.	2.9	4
1799	Cellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is Associated with Worse Survival. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1139-1145.	1.1	63
1800	Assessment of PD-1 positive cells on initial and secondary resected tumor specimens of newly diagnosed glioblastoma and its implications on patient outcome. <i>Journal of Neuro-Oncology</i> , 2017, 133, 277-285.	1.4	39
1801	KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1175-1187.	2.0	211
1802	Dysfunctional T cell metabolism in the tumor microenvironment. <i>Cytokine and Growth Factor Reviews</i> , 2017, 35, 7-14.	3.2	101
1803	The next generation of immunotherapy: keeping lung cancer in check. <i>Journal of Hematology and Oncology</i> , 2017, 10, 87.	6.9	84
1804	Population Pharmacokinetic/Pharmacodynamic Modeling of Tumor Size Dynamics in Pembrolizumab-Treated Advanced Melanoma. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017, 6, 29-39.	1.3	66
1805	Conserved Region C Functions To Regulate PD-1 Expression and Subsequent CD8 T Cell Memory. <i>Journal of Immunology</i> , 2017, 198, 205-217.	0.4	24
1806	Immunological and infectious risk factors for lung cancer in US veterans with HIV: a longitudinal cohort study. <i>Lancet HIV</i> , 2017, 4, e67-e73.	2.1	80
1807	Immunosuppression in liver tumors: opening the portal to effective immunotherapy. <i>Cancer Gene Therapy</i> , 2017, 24, 114-120.	2.2	15
1808	Primary Resistance to PD-1 Blockade Mediated by <i>JAK1/2</i> Mutations. <i>Cancer Discovery</i> , 2017, 7, 188-201.	7.7	997
1809	T-cell programming in pancreatic adenocarcinoma: a review. <i>Cancer Gene Therapy</i> , 2017, 24, 106-113.	2.2	45
1810	Gene Targeting Meets Cell-Based Therapy: Raising the Tail, or Merely a Whimper?. <i>Clinical Cancer Research</i> , 2017, 23, 327-329.	3.2	1
1811	CXCL12 expression and PD-L1 expression serve as prognostic biomarkers in HCC and are induced by hypoxia. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 470, 185-196.	1.4	71
1812	Transient immunological and clinical effectiveness of treating mice bearing premalignant oral lesions with PD-1 antibodies. <i>International Journal of Cancer</i> , 2017, 140, 1609-1619.	2.3	16
1813	Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. <i>Lancet Oncology</i> , 2017, 18, 31-41.	5.1	845
1814	Evasion of host immune defenses by human papillomavirus. <i>Virus Research</i> , 2017, 231, 21-33.	1.1	142

#	ARTICLE	IF	CITATIONS
1815	Cancer therapies in HIV cure research. <i>Current Opinion in HIV and AIDS</i> , 2017, 12, 96-104.	1.5	19
1816	Transcriptional and epigenetic regulation of T cell hyporesponsiveness. <i>Journal of Leukocyte Biology</i> , 2017, 102, 601-615.	1.5	39
1817	Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non-Small Cell Lung Cancer Trials. <i>JAMA Oncology</i> , 2017, 3, e171029.	3.4	70
1818	Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1977-1984.	1.2	14
1819	Sequencing Treatment in BRAF V600 Mutant Melanoma: Anti-PD-1 Before and After BRAF Inhibition. <i>Journal of Immunotherapy</i> , 2017, 40, 31-35.	1.2	85
1820	PD-L1 Assessment for Targeted Therapy Testing in Cancer: Urgent Need For Realistic Economic and Practice Expectations. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2017, 25, 1-3.	0.6	9
1821	Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. <i>Hepatology International</i> , 2017, 11, 317-370.	1.9	1,537
1822	Granuloma-forming interstitial pneumonia induced by nivolumab: a possible immune-related adverse event of the lung. <i>International Cancer Conference Journal</i> , 2017, 6, 131-134.	0.2	3
1823	PD-L1 Expression in Pancreatic Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw304.	3.0	43
1824	Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer. <i>Targeted Oncology</i> , 2017, 12, 563-569.	1.7	71
1825	A reconstructed melanoma data set for evaluating differential treatment benefit according to biomarker subgroups. <i>Data in Brief</i> , 2017, 12, 667-675.	0.5	12
1826	Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies. <i>Current Oncology Reports</i> , 2017, 19, 45.	1.8	70
1827	Antibody-mediated neutralization of soluble MIC significantly enhances CTLA4 blockade therapy. <i>Science Advances</i> , 2017, 3, e1602133.	4.7	27
1828	Immunotherapy for Head and Neck Squamous Cell Carcinoma: A Review of Current and Emerging Therapeutic Options. <i>Oncologist</i> , 2017, 22, 680-693.	1.9	23
1829	Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis. <i>Oncologist</i> , 2017, 22, 709-718.	1.9	221
1830	Immune surveillance in melanoma: From immune attack to melanoma escape and even counterattack. <i>Cancer Biology and Therapy</i> , 2017, 18, 451-469.	1.5	35
1831	Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma. <i>Oncologist</i> , 2017, 22, 963-971.	1.9	145
1832	Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases. <i>British Journal of Cancer</i> , 2017, 116, 1558-1563.	2.9	91

#	ARTICLE	IF	CITATIONS
1833	Preclinical immunoPET/CT imaging using Zr-89-labeled anti-PD-L1 monoclonal antibody for assessing radiation-induced PD-L1 upregulation in head and neck cancer and melanoma. <i>Oncolimmunology</i> , 2017, 6, e1329071.	2.1	85
1834	Assessment of nivolumab benefitâ€“risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors. <i>Annals of Oncology</i> , 2017, 28, 2002-2008.	0.6	152
1835	Evaluation of dosing strategy for pembrolizumab for oncology indications. , 2017, 5, 43.		189
1836	Imaging of Programmed Cell Death Ligand 1: Impact of Protein Concentration on Distribution of Anti-PD-L1 SPECT Agents in an Immunocompetent Murine Model of Melanoma. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1560-1566.	2.8	73
1837	Immunogenomics: using genomics to personalize cancer immunotherapy. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 209-219.	1.4	7
1838	Hallmarks of response to immune checkpoint blockade. <i>British Journal of Cancer</i> , 2017, 117, 1-7.	2.9	194
1839	Advancing Immunotherapy in Metastatic Breast Cancer. <i>Current Treatment Options in Oncology</i> , 2017, 18, 35.	1.3	13
1840	Delivering safer immunotherapies for cancer. <i>Advanced Drug Delivery Reviews</i> , 2017, 114, 79-101.	6.6	233
1841	Combinatorial drug delivery approaches for immunomodulation. <i>Advanced Drug Delivery Reviews</i> , 2017, 114, 161-174.	6.6	42
1842	Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 2770-2780.	1.8	210
1843	Case Report: Encephalitis, with Brainstem Involvement, Following Checkpoint Inhibitor Therapy in Metastatic Melanoma. <i>Oncologist</i> , 2017, 22, 749-753.	1.9	38
1844	Neutrophil-Lymphocyte Ratio Is a Prognostic Marker in Patients with Locally Advanced (Stage IIIA and) Tj ETQq1 1 0,784314 rgBT /Over	1.9	82
1845	First-Line Nivolumab in Stage IV or Recurrent Nonâ€“Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2017, 376, 2415-2426.	13.9	2,145
1846	DNA Damage and Repair Biomarkers of Immunotherapy Response. <i>Cancer Discovery</i> , 2017, 7, 675-693.	7.7	519
1847	PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer. <i>Annals of Oncology</i> , 2017, 28, 882-889.	0.6	105
1848	Immune Checkpoint Inhibitor-Induced Colitis: Diagnosis and Management. <i>Targeted Oncology</i> , 2017, 12, 301-308.	1.7	66
1849	Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. <i>Lancet Oncology, The</i> , 2017, 18, 863-873.	5.1	561
1850	Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies. <i>Cancer Treatment Reviews</i> , 2017, 58, 22-33.	3.4	76

#	ARTICLE	IF	CITATIONS
1851	Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy. <i>Molecular Therapy</i> , 2017, 25, 1917-1932.	3.7	50
1852	A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus). <i>British Journal of Cancer</i> , 2017, 117, 33-40.	2.9	104
1853	Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. <i>Science</i> , 2017, 357, 409-413.	6.0	4,945
1854	Combined immune checkpoint blockade as a therapeutic strategy for <i>BRCA1</i> -mutated breast cancer. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	227
1855	Immune-Related Tumor Response Dynamics in Melanoma Patients Treated with Pembrolizumab: Identifying Markers for Clinical Outcome and Treatment Decisions. <i>Clinical Cancer Research</i> , 2017, 23, 4671-4679.	3.2	110
1856	Cancer immunotherapy by targeting immune checkpoints: mechanism of T cell dysfunction in cancer immunity and new therapeutic targets. <i>Journal of Biomedical Science</i> , 2017, 24, 35.	2.6	88
1857	Immunological effect of local ablation combined with immunotherapy on solid malignancies. <i>Chinese Journal of Cancer</i> , 2017, 36, 49.	4.9	23
1858	Autophagy in natural and therapy-driven anticancer immunosurveillance. <i>Autophagy</i> , 2017, 13, 2163-2170.	4.3	52
1859	PD-L1 inhibits acute and chronic pain by suppressing nociceptive neuron activity via PD-1. <i>Nature Neuroscience</i> , 2017, 20, 917-926.	7.1	148
1860	Combining drugs and extending treatment â€” a PFS end point is not sufficient. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 521-522.	12.5	16
1861	Better VISTAs ahead? Potential and pitfalls of immunotherapy. <i>Nature Reviews Urology</i> , 2017, 14, 455-456.	1.9	9
1862	PD-L1 expression in Xp11.2 translocation renal cell carcinoma: Indicator of tumor aggressiveness. <i>Scientific Reports</i> , 2017, 7, 2074.	1.6	21
1863	Immune Checkpoint Inhibitor Therapy: What Line of Therapy and How to Choose?. <i>Current Treatment Options in Oncology</i> , 2017, 18, 33.	1.3	13
1864	Sequencing of ALK Inhibitors in ALK+ Non-Small Cell Lung Cancer. <i>Current Treatment Options in Oncology</i> , 2017, 18, 36.	1.3	14
1865	A case of cystitis after administration of nivolumab. <i>International Cancer Conference Journal</i> , 2017, 6, 164-166.	0.2	22
1866	Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. <i>Lancet Oncology</i> , 2017, 18, 895-903.	5.1	872
1867	B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes. <i>Clinical Cancer Research</i> , 2017, 23, 5202-5209.	3.2	99
1868	Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland. <i>Melanoma Research</i> , 2017, 27, 358-368.	0.6	20

#	ARTICLE	IF	CITATIONS
1869	Clinical applications of PD-L1 bioassays for cancer immunotherapy. <i>Journal of Hematology and Oncology</i> , 2017, 10, 110.	6.9	66
1870	Myeloid-derived suppressor cells—a new therapeutic target to overcome resistance to cancer immunotherapy. <i>Journal of Leukocyte Biology</i> , 2017, 102, 727-740.	1.5	88
1871	Interaction of molecular alterations with immune response in melanoma. <i>Cancer</i> , 2017, 123, 2130-2142.	2.0	24
1872	Combining radiotherapy with immunotherapy: the past, the present and the future. <i>British Journal of Radiology</i> , 2017, 90, 20170157.	1.0	99
1873	Quantitative Mass Spectrometry Analysis of PD-L1 Protein Expression, N-glycosylation and Expression Stoichiometry with PD-1 and PD-L2 in Human Melanoma. <i>Molecular and Cellular Proteomics</i> , 2017, 16, 1705-1717.	2.5	56
1874	Positive Expression of Programmed Death Ligand 1 in Peritumoral Liver Tissue is Associated with Poor Survival after Curative Resection of Hepatocellular Carcinoma. <i>Translational Oncology</i> , 2017, 10, 511-517.	1.7	47
1875	Acquired IFN γ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions. <i>Nature Communications</i> , 2017, 8, 15440.	5.8	195
1876	Skin Cancers in Organ Transplant Recipients. <i>American Journal of Transplantation</i> , 2017, 17, 2509-2530.	2.6	151
1877	High PD-1 expression on regulatory and effector T-cells in lung cancer draining lymph nodes. <i>ERJ Open Research</i> , 2017, 3, 00110-2016.	1.1	20
1878	Paradigm shift of therapeutic management of brain metastases in EGFR-mutant non-small cell lung cancer in the era of targeted therapy. <i>Medical Oncology</i> , 2017, 34, 121.	1.2	12
1879	Toward Molecularly Driven Precision Medicine in Lung Adenocarcinoma. <i>Cancer Discovery</i> , 2017, 7, 555-557.	7.7	11
1880	Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2017, 44, 403-414.	0.8	103
1881	Primary malignant melanoma of esophagus following chemoradiotherapy for esophageal squamous cell carcinoma: report of a case. <i>Clinical Journal of Gastroenterology</i> , 2017, 10, 336-341.	0.4	8
1882	Targeting the programmed cell death-1 pathway in rheumatoid arthritis. <i>Autoimmunity Reviews</i> , 2017, 16, 767-773.	2.5	16
1883	Osimertinib reactivated immune-related colitis after treatment with anti-PD1 antibody for non-small cell lung cancer. <i>Investigational New Drugs</i> , 2017, 35, 848-850.	1.2	12
1884	Glioblastoma targeted therapy: updated approaches from recent biological insights. <i>Annals of Oncology</i> , 2017, 28, 1457-1472.	0.6	314
1885	Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients. <i>Annals of Oncology</i> , 2017, 28, 1988-1995.	0.6	326
1886	Pembrolizumab-induced pneumonitis. <i>ERJ Open Research</i> , 2017, 3, 00081-2016.	1.1	35

#	ARTICLE	IF	CITATIONS
1887	Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade. <i>Oncologist</i> , 2017, 22, 627-630.	1.9	74
1888	Pembrolizumab in cervical cancer: latest evidence and clinical usefulness. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 431-439.	1.4	73
1889	New insights into the role of <sc>EMT</sc> in tumor immune escape. <i>Molecular Oncology</i> , 2017, 11, 824-846.	2.1	332
1890	Advancing Immune and Cell-Based Therapies Through Imaging. <i>Molecular Imaging and Biology</i> , 2017, 19, 379-384.	1.3	20
1891	Immunotherapy for Esophageal Squamous Cell Carcinoma. <i>Current Oncology Reports</i> , 2017, 19, 33.	1.8	53
1892	Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial. <i>Lancet Oncology</i> , 2017, 18, 599-610.	5.1	257
1893	Targeted Therapies for Melanoma Brain Metastases. <i>Current Treatment Options in Neurology</i> , 2017, 19, 13.	0.7	28
1894	Targeted agents and immunotherapies: optimizing outcomes in melanoma. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 463-482.	12.5	945
1895	Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy. <i>Neuro-Oncology</i> , 2017, 19, 1047-1057.	0.6	325
1896	Delayed pseudoprogression of lung adenocarcinoma accompanied with interstitial lung disease during chemotherapy after <sc>nivolumab</sc> treatment. <i>Thoracic Cancer</i> , 2017, 8, 275-277.	0.8	17
1897	Association of Surgical Treatment, Systemic Therapy, and Survival in Patients With Abdominal Visceral Melanoma Metastases, 1965-2014. <i>JAMA Surgery</i> , 2017, 152, 672.	2.2	57
1899	Milestones in the systemic treatment of lung cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2017, 10, 22-26.	0.3	8
1900	Targeted Therapy in Head and Neck Cancer: An Update on Current Clinical Developments in Epidermal Growth Factor Receptor-Targeted Therapy and Immunotherapies. <i>Drugs</i> , 2017, 77, 843-857.	4.9	40
1901	Clinical Determinants of Durable Clinical Benefit of Pembrolizumab in Veterans With Advanced Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, 559-564.	1.1	12
1902	Beyond checkpoint inhibition – Immunotherapeutic strategies in combination with radiation. <i>Clinical and Translational Radiation Oncology</i> , 2017, 2, 29-35.	0.9	27
1903	Organizing pneumonia following treatment with pembrolizumab for metastatic malignant melanoma – A case report. <i>Respiratory Medicine Case Reports</i> , 2017, 20, 95-97.	0.2	11
1904	Diagnosis and Treatment of Kaposi Sarcoma. <i>American Journal of Clinical Dermatology</i> , 2017, 18, 529-539.	3.3	98
1905	Immune engineering: From systems immunology to engineering immunity. <i>Current Opinion in Biomedical Engineering</i> , 2017, 1, 54-62.	1.8	7

#	ARTICLE	IF	CITATIONS
1906	Mechanistic and pharmacologic insights on immune checkpoint inhibitors. <i>Pharmacological Research</i> , 2017, 120, 1-9.	3.1	46
1907	Emerging and investigational therapies for neuroblastoma. <i>Expert Opinion on Orphan Drugs</i> , 2017, 5, 355-368.	0.5	27
1908	Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?. <i>BMC Medicine</i> , 2017, 15, 55.	2.3	65
1909	Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma. <i>JAMA Oncology</i> , 2017, 3, 974.	3.4	65
1910	Development of CAR T cells designed to improve antitumor efficacy and safety. , 2017, 178, 83-91.		90
1911	Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients. <i>Scientific Reports</i> , 2017, 7, 45124.	1.6	72
1912	Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor. , 2017, 5, 3.		44
1913	Systematic evaluation of immune regulation and modulation. , 2017, 5, 21.		20
1914	A quantitative method for screening and identifying molecular targets for nanomedicine. <i>Journal of Controlled Release</i> , 2017, 263, 57-67.	4.8	9
1915	Immunotherapy in malignant melanoma: recent approaches and new perspectives. <i>Melanoma Management</i> , 2017, 4, 39-48.	0.1	7
1916	Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy. <i>British Journal of Cancer</i> , 2017, 116, 1141-1147.	2.9	112
1917	Evaluating the significance of density, localization, and PD-1/PD-L1 immunopositivity of mononuclear cells in the clinical course of lung adenocarcinoma patients with brain metastasis. <i>Neuro-Oncology</i> , 2017, 19, 1058-1067.	0.6	38
1918	CD8 T cell regulation by T regulatory cells and the programmed cell death protein 1 pathway. <i>Immunology</i> , 2017, 151, 146-153.	2.0	12
1919	Strategies for Increasing Pancreatic Tumor Immunogenicity. <i>Clinical Cancer Research</i> , 2017, 23, 1656-1669.	3.2	131
1920	Cancer immunotherapies targeting the PD-1 signaling pathway. <i>Journal of Biomedical Science</i> , 2017, 24, 26.	2.6	501
1921	Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal. <i>Annals of Oncology</i> , 2017, 28, 1036-1041.	0.6	207
1922	UV-induced somatic mutations elicit a functional T cell response in the YUMMER1.7 mouse melanoma model. <i>Pigment Cell and Melanoma Research</i> , 2017, 30, 428-435.	1.5	143
1923	Renal cell carcinoma: new insights and challenges for a clinician scientist. <i>American Journal of Physiology - Renal Physiology</i> , 2017, 313, F145-F154.	1.3	46

#	ARTICLE	IF	CITATIONS
1924	PD-L1 expression in lung adenosquamous carcinomas compared with the more common variants of non-small cell lung cancer. <i>Scientific Reports</i> , 2017, 7, 46209.	1.6	41
1925	High number of kinase mutations in non-small cell lung cancer is associated with reduced immune response and poor relapse-free survival. <i>International Journal of Cancer</i> , 2017, 141, 184-190.	2.3	14
1926	The Advantages and Challenges of Using FDG PET/CT for Response Assessment in Melanoma in the Era of Targeted Agents and Immunotherapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 67-77.	3.3	112
1927	Immune checkpoint dysfunction in large and medium vessel vasculitis. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2017, 312, H1052-H1059.	1.5	85
1928	Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts. <i>Drugs and Aging</i> , 2017, 34, 331-357.	1.3	7
1929	An Anti-Programmed Death-1 Antibody (±PD-1) Fusion Protein That Self-Assembles into a Multivalent and Functional ±PD-1 Nanoparticle. <i>Molecular Pharmaceutics</i> , 2017, 14, 1494-1500.	2.3	26
1930	Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate. <i>Clinical Cancer Research</i> , 2017, 23, 4242-4250.	3.2	704
1931	PD-L2: A prognostic marker in chromophobe renal cell carcinoma?. <i>Medical Oncology</i> , 2017, 34, 71.	1.2	17
1932	Talimogene Laherparepvec for Treating Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2017, 35, 1035-1046.	1.7	7
1933	Reply to "Comment on "Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy". <i>British Journal of Cancer</i> , 2017, 116, e15-e15.	2.9	1
1934	Cancer Immunotherapy: Whence and Whither. <i>Molecular Cancer Research</i> , 2017, 15, 635-650.	1.5	30
1935	Molecular genetic and immunotherapeutic targets in metastatic melanoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 281-293.	1.4	16
1936	Role of TIM-3 in ovarian cancer. <i>Clinical and Translational Oncology</i> , 2017, 19, 1079-1083.	1.2	20
1937	Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancer. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 573-585.	1.0	21
1938	Induction of T-Cell Infiltration and Programmed Death Ligand 2 Expression by Adeno-Associated Virus in Rhesus Macaque Skeletal Muscle and Modulation by Prednisone. <i>Human Gene Therapy</i> , 2017, 28, 493-509.	1.4	17
1939	Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma. <i>Future Oncology</i> , 2017, 13, 1263-1279.	1.1	113
1940	Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point ¹⁸ F-FDG PET/CT Imaging in Patients with Advanced Melanoma. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1421-1428.	2.8	209
1941	Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?. <i>Angiogenesis</i> , 2017, 20, 185-204.	3.7	482

#	ARTICLE	IF	CITATIONS
1942	Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. <i>Lancet Oncology</i> , The, 2017, 18, 587-598.	5.1	261
1943	ATVB Distinguished Scientist Award. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 764-777.	1.1	38
1944	The Microenvironmental Landscape of Brain Tumors. <i>Cancer Cell</i> , 2017, 31, 326-341.	7.7	1,163
1945	Digoxin Plus Trametinib Therapy Achieves Disease Control in BRAF Wild-Type Metastatic Melanoma Patients. <i>Neoplasia</i> , 2017, 19, 255-260.	2.3	35
1946	Single vs. combination immunotherapeutic strategies for glioma. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 543-554.	1.4	17
1947	Treatment Strategies for Metastatic Neuroendocrine Tumors of the Gastrointestinal Tract. <i>Current Treatment Options in Oncology</i> , 2017, 18, 14.	1.3	52
1948	The high price of anticancer drugs: origins, implications, barriers, solutions. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 381-390.	12.5	289
1949	Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy. , 2017, 5, 8.		111
1950	Immune checkpoint inhibition and its relationship with hypermutation phenotype as a potential treatment for Glioblastoma. <i>Journal of Neuro-Oncology</i> , 2017, 132, 359-372.	1.4	8
1951	Multiscale Modeling of Complex Formation and CD80 Depletion during Immune Synapse Development. <i>Biophysical Journal</i> , 2017, 112, 997-1009.	0.2	11
1952	The Host Microbiome Regulates and Maintains Human Health: A Primer and Perspective for Non-Microbiologists. <i>Cancer Research</i> , 2017, 77, 1783-1812.	0.4	270
1954	Clinical value of monoclonal antibodies and tyrosine kinase inhibitors in the treatment of head and neck squamous cell carcinoma. <i>Medical Oncology</i> , 2017, 34, 60.	1.2	18
1955	Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines. , 2017, 178, 31-47.		89
1956	Current Management Strategy for Metastatic Renal Cell Carcinoma and Future Directions. <i>Current Oncology Reports</i> , 2017, 19, 27.	1.8	16
1957	Immune Checkpoint Inhibitors in Gliomas. <i>Current Oncology Reports</i> , 2017, 19, 23.	1.8	27
1958	Control of immune cell entry through the tumour vasculature: a missing link in optimising melanoma immunotherapy?. <i>Clinical and Translational Immunology</i> , 2017, 6, e134.	1.7	32
1959	Tumor-Localized Secretion of Soluble PD1 Enhances Oncolytic Virotherapy. <i>Cancer Research</i> , 2017, 77, 2952-2963.	0.4	86
1960	Preclinical evaluation of the efficacy, pharmacokinetics and immunogenicity of JS-001, a programmed cell death protein-1 (PD-1) monoclonal antibody. <i>Acta Pharmacologica Sinica</i> , 2017, 38, 710-718.	2.8	38

#	ARTICLE	IF	CITATIONS
1961	PD-L1 expression in pancreatic ductal adenocarcinoma is a poor prognostic factor in patients with high CD8+ tumor-infiltrating lymphocytes: highly sensitive detection using phosphor-integrated dot staining. <i>International Journal of Clinical Oncology</i> , 2017, 22, 726-733.	1.0	47
1962	In Situ Activation of Pituitary-Infiltrating T Lymphocytes in Autoimmune Hypophysitis. <i>Scientific Reports</i> , 2017, 7, 43492.	1.6	23
1963	Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response. <i>Biomarker Research</i> , 2017, 5, 12.	2.8	149
1964	Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer. <i>Investigational New Drugs</i> , 2017, 35, 529-536.	1.2	128
1965	Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma. <i>European Journal of Cancer</i> , 2017, 76, 152-166.	1.3	82
1966	Lung Adenocarcinoma and Squamous Cell Carcinoma Gene Expression Subtypes Demonstrate Significant Differences in Tumor Immune Landscape. <i>Journal of Thoracic Oncology</i> , 2017, 12, 943-953.	0.5	136
1967	Model-Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti-PD-1 Monoclonal Antibody in Advanced Solid Tumors. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017, 6, 49-57.	1.3	121
1968	Improved survival and complete response rates in patients with advanced melanoma treated with concurrent ipilimumab and radiotherapy versus ipilimumab alone. <i>Cancer Biology and Therapy</i> , 2017, 18, 36-42.	1.5	123
1969	Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. <i>Lancet Oncology</i> , The, 2017, 18, 52-62.	5.1	225
1970	The emerging role of immune checkpoint inhibition in malignant lymphoma. <i>Haematologica</i> , 2017, 102, 30-42.	1.7	101
1971	Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. <i>Annals of Oncology</i> , 2017, 28, 583-589.	0.6	510
1972	The role of the immune system in neurofibromatosis type 1-associated nervous system tumors. <i>CNS Oncology</i> , 2017, 6, 45-60.	1.2	24
1973	Immuno-Oncology: The Third Paradigm in Early Drug Development. <i>Targeted Oncology</i> , 2017, 12, 125-138.	1.7	22
1974	Patterns and Timing of Initial Relapse in Pathologic Stage II Melanoma Patients. <i>Annals of Surgical Oncology</i> , 2017, 24, 939-946.	0.7	41
1975	Driving gene-engineered T cell immunotherapy of cancer. <i>Cell Research</i> , 2017, 27, 38-58.	5.7	232
1976	Quantitative Characterization of the Exposure-Response Relationship for Cancer Immunotherapy: A Case Study of Nivolumab in Patients With Advanced Melanoma. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017, 6, 40-48.	1.3	71
1977	Systemic therapy of brain metastases: non-“small cell lung cancer, breast cancer, and melanoma. <i>Neuro-Oncology</i> , 2017, 19, i1-i24.	0.6	171
1978	Advances in the molecular genetics of gliomas “ implications for classification and therapy. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 434-452.	12.5	497

#	ARTICLE	IF	CITATIONS
1979	Immune Toxicities Elicited by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire. <i>Cancer Research</i> , 2017, 77, 1322-1330.	0.4	188
1980	Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Nonâ€“Small Cell Lung Cancer. <i>Cancer Discovery</i> , 2017, 7, 264-276.	7.7	706
1981	Treatment Design and Rationale for a Randomized Trial of Cisplatin and Etoposide Plus Thoracic Radiotherapy Followed by Nivolumab or Placebo for Locally Advanced Nonâ€“Small-Cell Lung Cancer (RTOG 3505). <i>Clinical Lung Cancer</i> , 2017, 18, 333-339.	1.1	47
1982	Molecular Pathways: The Necrosomeâ€“A Target for Cancer Therapy. <i>Clinical Cancer Research</i> , 2017, 23, 1132-1136.	3.2	35
1983	Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors. <i>Investigational New Drugs</i> , 2017, 35, 207-216.	1.2	70
1984	Rapid and partial remission of primary lesion but complicated by secondary fibrosis after treatment with nivolumab in a lung squamous carcinoma. <i>Therapeutic Advances in Respiratory Disease</i> , 2017, 11, 129-132.	1.0	2
1985	Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 46-58.	1.4	27
1986	Pharmacological and immunological targeting of tumor mesenchymalization. , 2017, 170, 212-225.		14
1987	Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIM SM. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 31-41.e4.	0.9	31
1988	Infiltration of CD8 T Cells and Expression of PD-1 and PD-L1 in Synovial Sarcoma. <i>Cancer Immunology Research</i> , 2017, 5, 118-126.	1.6	56
1989	Thinking Critically About Classifying Adverse Events: Incidence of Pancreatitis in Patients Treated With Nivolumab + Ipilimumab. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw260.	3.0	56
1990	Immune Checkpoint Blockade in Hepatocellular Carcinoma: 2017 Update. <i>Liver Cancer</i> , 2017, 6, 1-12.	4.2	60
1991	Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity. <i>Nature Reviews Drug Discovery</i> , 2017, 16, 264-272.	21.5	204
1992	Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 43-50.	0.5	317
1993	Practical Immuno-PET Radiotracer Design Considerations for Human Immune Checkpoint Imaging. <i>Journal of Nuclear Medicine</i> , 2017, 58, 538-546.	2.8	102
1994	Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma. <i>American Journal of Clinical Dermatology</i> , 2017, 18, 1-15.	3.3	215
1995	Rheumatic and Musculoskeletal Immuneâ€“Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature. <i>Arthritis Care and Research</i> , 2017, 69, 1751-1763.	1.5	292
1996	Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm. <i>Annals of Oncology</i> , 2017, 28, 673-675.	0.6	87

#	ARTICLE	IF	CITATIONS
1997	Angiotensin-2 as a Biomarker and Target for Immune Checkpoint Therapy. <i>Cancer Immunology Research</i> , 2017, 5, 17-28.	1.6	130
1998	Cytokines and metabolic factors regulate tumoricidal T-cell function during cancer immunotherapy. <i>Immunotherapy</i> , 2017, 9, 71-82.	1.0	5
1999	Cancer and inflammation. <i>Wiley Interdisciplinary Reviews: Systems Biology and Medicine</i> , 2017, 9, e1370.	6.6	166
2000	Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. <i>Lancet</i> , The, 2017, 389, 255-265.	6.3	3,872
2001	Regulation of PD-L1 expression in a high-grade invasive human oral squamous cell carcinoma microenvironment. <i>International Journal of Oncology</i> , 2017, 50, 41-48.	1.4	65
2002	Innate immune signaling and regulation in cancer immunotherapy. <i>Cell Research</i> , 2017, 27, 96-108.	5.7	291
2003	Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade. <i>Cancer Immunology Research</i> , 2017, 5, 84-91.	1.6	126
2004	Clinical trials of CAR-T cells in China. <i>Journal of Hematology and Oncology</i> , 2017, 10, 166.	6.9	62
2005	Resistance to checkpoint blockade therapy through inactivation of antigen presentation. <i>Nature Communications</i> , 2017, 8, 1136.	5.8	686
2006	Recurrence of Melanoma after Starting Apremilast for Psoriasis. <i>Case Reports in Dermatology</i> , 2017, 9, 108-111.	0.3	12
2007	Aviscumine, a recombinant ribosomal inhibitor, increases the antitumor activity of natural killer cells. <i>Oncology Letters</i> , 2017, 14, 5563-5568.	0.8	3
2008	Klotho expression is correlated to molecules associated with epithelial-mesenchymal transition in lung squamous cell carcinoma. <i>Oncology Letters</i> , 2017, 14, 5526-5532.	0.8	13
2009	Metastatic melanoma imaging using a novel Tc-99m-labeled lactam-cyclized alpha-MSH peptide. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 4952-4955.	1.0	5
2010	Combined immunotherapy with anti-PDL-1/PD-1 and anti-CD4 antibodies cures syngeneic disseminated neuroblastoma. <i>Scientific Reports</i> , 2017, 7, 14049.	1.6	37
2011	Estimating Survival in Melanoma Patients With Brain Metastases: An Update of the Graded Prognostic Assessment for Melanoma Using Molecular Markers (Melanoma-molGPA). <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 812-816.	0.4	163
2012	Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy. <i>Cancer Immunology Research</i> , 2017, 5, 1133-1140.	1.6	114
2013	Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC. <i>Lung Cancer</i> , 2017, 111, 108-115.	0.9	11
2014	Ipilimumab-Induced Enteritis without Colitis: A New Challenge. <i>Case Reports in Oncology</i> , 2017, 9, 705-713.	0.3	41

#	ARTICLE	IF	CITATIONS
2015	Future cancer research priorities in the USA: a Lancet Oncology Commission. <i>Lancet Oncology</i> , The, 2017, 18, e653-e706.	5.1	153
2016	Obstruction of BRAFV600E transcription by complementary PNA oligomers as a means to inhibit BRAF-mutant melanoma growth. <i>Cancer Gene Therapy</i> , 2017, 24, 401-408.	2.2	1
2017	PD-L1 expression in squamous-cell carcinoma and adenocarcinoma of the lung. <i>Radiology and Oncology</i> , 2017, 51, 357-362.	0.6	40
2018	A preliminary study for the assessment of PD-L1 and PD-L2 on circulating tumor cells by microfluidic-based chipcytometry. <i>Future Science OA</i> , 2017, 3, FSO244.	0.9	24
2019	Evaluation of the toxicity of iron-ion irradiation in murine bone marrow dendritic cells via increasing the expression of indoleamine 2,3-dioxygenase 1. <i>Toxicology Research</i> , 2017, 6, 958-968.	0.9	3
2020	Anti-PD-1/anti-PD-L1 immunotherapy versus docetaxel for previously treated advanced non-small cell lung cancer: a systematic review and meta-analysis of randomised clinical trials. <i>ESMO Open</i> , 2017, 2, e000236.	2.0	30
2021	Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based Immunotherapy. <i>Clinical Cancer Research</i> , 2017, 23, 5729-5736.	3.2	172
2022	Immune-related adverse events during anticancer immunotherapy: Pathogenesis and management (Review). <i>Oncology Letters</i> , 2017, 14, 5671-5680.	0.8	54
2023	Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio. <i>JAMA Oncology</i> , 2017, 3, 1692.	3.4	179
2024	Radiomics: the bridge between medical imaging and personalized medicine. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 749-762.	12.5	3,216
2025	Nanoparticulate Delivery of Cancer Cell Membrane Elicits Multiantigenic Antitumor Immunity. <i>Advanced Materials</i> , 2017, 29, 1703969.	11.1	392
2026	The abundance of metabolites related to protein methylation correlates with the metastatic capacity of human melanoma xenografts. <i>Science Advances</i> , 2017, 3, eaao5268.	4.7	38
2027	Current challenges in the management of follicular lymphoma. <i>International Journal of Hematologic Oncology</i> , 2017, 6, 13-24.	0.7	1
2028	Immune checkpoint inhibitors in renal cell carcinoma. <i>Clinical Science</i> , 2017, 131, 2627-2642.	1.8	62
2029	Has the melanoma information tsunami become a maelstrom?. <i>Melanoma Management</i> , 2017, 4, 179-182.	0.1	0
2030	Genomics and advances towards precision medicine for head and neck squamous cell carcinoma. <i>Laryngoscope Investigative Otolaryngology</i> , 2017, 2, 310-319.	0.6	12
2031	Distant intracranial failure in melanoma brain metastases treated with stereotactic radiosurgery in the era of immunotherapy and targeted agents. <i>Advances in Radiation Oncology</i> , 2017, 2, 572-580.	0.6	63
2032	Cancer Immunotherapy Getting Brainy: Visualizing the Distinctive CNS Metastatic Niche to Illuminate Therapeutic Resistance. <i>Drug Resistance Updates</i> , 2017, 33-35, 23-35.	6.5	16

#	ARTICLE	IF	CITATIONS
2033	Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	232
2034	Programmed Cell Death Protein Ligand-1 Silencing with Polyethylenimine- α -Dermatan Sulfate Complex for Dual Inhibition of Melanoma Growth. <i>ACS Nano</i> , 2017, 11, 10135-10146.	7.3	84
2035	A Case Report of Steroid Responsive Nivolumab-Induced Encephalitis. <i>Cancer Control</i> , 2017, 24, 107327481772906.	0.7	20
2036	The changing landscape of dermatology practice: melanoma and pump-probe laser microscopy. <i>Lasers in Medical Science</i> , 2017, 32, 1935-1939.	1.0	2
2037	4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 7263-7275.	3.2	41
2038	PD-1 Expression in Head and Neck Squamous Cell Carcinomas Derives Primarily from Functionally Anergic CD4+ TILs in the Presence of PD-L1+ TAMs. <i>Cancer Research</i> , 2017, 77, 6365-6374.	0.4	77
2039	Immune Activation in Early-Stage Non-Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab. <i>Clinical Cancer Research</i> , 2017, 23, 7474-7482.	3.2	65
2040	Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. <i>Cancer Discovery</i> , 2017, 7, 1420-1435.	7.7	507
2041	Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. <i>Cell</i> , 2017, 171, 934-949.e16.	13.5	1,515
2043	Immunotherapy for Breast Cancer: Current and Future Strategies. <i>Current Surgery Reports</i> , 2017, 5, 1.	0.4	31
2044	PD-1 Blockade Prevents the Development and Progression of Carcinogen-Induced Oral Premalignant Lesions. <i>Cancer Prevention Research</i> , 2017, 10, 684-693.	0.7	53
2045	Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. <i>Ca-A Cancer Journal for Clinicians</i> , 2017, 67, 472-492.	157.7	1,662
2046	The Prognostic Value of Tumor-infiltrating Lymphocytes in Hepatocellular Carcinoma: a Systematic Review and Meta-analysis. <i>Scientific Reports</i> , 2017, 7, 7525.	1.6	105
2047	Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program. <i>Journal of Immunotherapy</i> , 2017, 40, 334-340.	1.2	16
2049	Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers. <i>Nature Communications</i> , 2017, 8, 1050.	5.8	115
2050	Validation of multiplex immunofluorescence panels using multispectral microscopy for immune-profiling of formalin-fixed and paraffin-embedded human tumor tissues. <i>Scientific Reports</i> , 2017, 7, 13380.	1.6	208
2051	A conduit to metastasis: circulating tumor cell biology. <i>Genes and Development</i> , 2017, 31, 1827-1840.	2.7	330
2052	Expression of PD-1 and PD-L1 in poorly differentiated neuroendocrine carcinomas of the digestive system: a potential target for anti-PD-1/PD-L1 therapy. <i>Human Pathology</i> , 2017, 70, 49-54.	1.1	38

#	ARTICLE	IF	CITATIONS
2053	MAGT1-mediated disturbance of Mg ²⁺ homeostasis lead to exhausted of HBV-infected NK and CD8+ T cells. <i>Scientific Reports</i> , 2017, 7, 13594.	1.6	11
2054	Epigenetic Therapeutics and Their Impact in Immunotherapy of Lung Cancer. <i>Current Pharmacology Reports</i> , 2017, 3, 360-373.	1.5	10
2055	Identification and Validation of a PD-L1 Binding Peptide for Determination of PDL1 Expression in Tumors. <i>Scientific Reports</i> , 2017, 7, 13682.	1.6	37
2056	Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer). <i>Annals of Oncology</i> , 2017, 28, 2698-2706.	0.6	77
2057	Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity?. <i>Annals of Oncology</i> , 2017, 28, 2950-2961.	0.6	78
2058	Clinical and molecular characterization of patients with cancer of unknown primary in the modern era. <i>Annals of Oncology</i> , 2017, 28, 3015-3021.	0.6	79
2059	Checkpoint immunotherapy in head and neck cancers. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 475-489.	2.7	33
2060	Pembrolizumab as second-line therapy in non-small cell lung cancer in northern Norway: budget impact and expected gain—a model-based analysis. <i>ESMO Open</i> , 2017, 2, e000222.	2.0	11
2061	Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2598-2608.	1.9	1,779
2062	FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond. <i>Oncologist</i> , 2017, 22, 1392-1399.	1.9	235
2063	Immunotherapy in Gynecologic Cancers: Are We There Yet?. <i>Current Treatment Options in Oncology</i> , 2017, 18, 59.	1.3	45
2064	Initial Experience With Lung Cancer Resection After Treatment With T-Cell Checkpoint Inhibitors. <i>Annals of Thoracic Surgery</i> , 2017, 104, e217-e218.	0.7	69
2065	Novel Immunotherapies for Multiple Myeloma. <i>Current Hematologic Malignancy Reports</i> , 2017, 12, 344-357.	1.2	30
2066	Anti-PD-1 Antibodies as a Therapeutic Strategy in Classical Hodgkin Lymphoma. <i>Drugs</i> , 2017, 77, 1645-1655.	4.9	5
2067	Pembrolizumab in the treatment of metastatic non-small cell lung cancer: a review of current evidence. <i>Therapeutic Advances in Respiratory Disease</i> , 2017, 11, 353-373.	1.0	28
2068	mTOR co-targeting strategies for head and neck cancer therapy. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 491-502.	2.7	46
2069	Immune Dysfunction in Non-Hodgkin Lymphoma: Avenues for New Immunotherapy-Based Strategies. <i>Current Hematologic Malignancy Reports</i> , 2017, 12, 484-494.	1.2	4
2071	Immunotherapy for metastatic prostate cancer. <i>Current Opinion in Urology</i> , 2017, 27, 566-571.	0.9	18

#	ARTICLE	IF	CITATIONS
2072	Optimizing tumor immune response through combination of radiation and immunotherapy. <i>Medical Oncology</i> , 2017, 34, 165.	1.2	14
2073	Multiple treatment comparison of seven new drugs for patients with advanced malignant melanoma: a systematic review and health economic decision model in a Norwegian setting. <i>BMJ Open</i> , 2017, 7, e014880.	0.8	18
2074	Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40. <i>Clinical Cancer Research</i> , 2017, 23, 6165-6177.	3.2	249
2075	Antigen-Presenting Intratumoral B Cells Affect CD4+ TIL Phenotypes in Non-Small Cell Lung Cancer Patients. <i>Cancer Immunology Research</i> , 2017, 5, 898-907.	1.6	184
2077	Nivolumab infusion reaction manifesting as plantar erythema and pulmonary infiltrate in a lung cancer patient. <i>Thoracic Cancer</i> , 2017, 8, 706-709.	0.8	8
2078	The colorectal cancer immune microenvironment and approach to immunotherapies. <i>Future Oncology</i> , 2017, 13, 1633-1647.	1.1	76
2079	Tubulointerstitial nephritis as adverse effect of programmed cell death 1 inhibitor, nivolumab, showed distinct histological findings. <i>CEN Case Reports</i> , 2017, 6, 169-174.	0.5	17
2080	Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers. <i>British Journal of Cancer</i> , 2017, 117, 913-920.	2.9	145
2081	The Current Landscape of Anaplastic Lymphoma Kinase (ALK) in Non-Small Cell Lung Cancer: Emerging Treatment Paradigms and Future Directions. <i>Targeted Oncology</i> , 2017, 12, 709-718.	1.7	17
2082	Tumour radiosensitivity is associated with immune activation in solid tumours. <i>European Journal of Cancer</i> , 2017, 84, 304-314.	1.3	44
2083	Cancer vaccines: Enhanced immunogenic modulation through therapeutic combinations. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 2561-2574.	1.4	91
2084	Challenges and Opportunities in Adapting Clinical Trial Design for Immunotherapies. <i>Clinical Cancer Research</i> , 2017, 23, 4950-4958.	3.2	46
2085	Programmed death-ligand 1 (PD-L1) expression in tumour cell and tumour infiltrating lymphocytes of HER2-positive breast cancer and its prognostic value. <i>Scientific Reports</i> , 2017, 7, 11671.	1.6	57
2086	Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy. <i>Immunotherapy</i> , 2017, 9, 913-927.	1.0	44
2087	Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 902-910.e2.	0.6	56
2088	Nanomaterials for cancer immunotherapy. <i>Biomaterials</i> , 2017, 148, 16-30.	5.7	226
2089	Predictors of responses to immune checkpoint blockade in advanced melanoma. <i>Nature Communications</i> , 2017, 8, 592.	5.8	166
2090	Immune cell profiling in cancer: molecular approaches to cell-specific identification. <i>Npj Precision Oncology</i> , 2017, 1, 26.	2.3	73

#	ARTICLE	IF	CITATIONS
2091	Patent trend and competitive analysis of cancer immunotherapy in the United States. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 2583-2593.	1.4	6
2092	Enhancing CD8+ T Cell Fatty Acid Catabolism within a Metabolically Challenging Tumor Microenvironment Increases the Efficacy of Melanoma Immunotherapy. <i>Cancer Cell</i> , 2017, 32, 377-391.e9.	7.7	419
2093	PD-1 checkpoint inhibition: Toxicities and management. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 701-707.	0.8	57
2094	De novo induction of intratumoral lymphoid structures and vessel normalization enhances immunotherapy in resistant tumors. <i>Nature Immunology</i> , 2017, 18, 1207-1217.	7.0	190
2095	Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2017, 377, 1345-1356.	13.9	3,589
2096	Thoracic Complications of Precision Cancer Therapies: A Practical Guide for Radiologists in the New Era of Cancer Care. <i>Radiographics</i> , 2017, 37, 1371-1387.	1.4	56
2097	Tim-3, Lag-3, and TIGIT. <i>Current Topics in Microbiology and Immunology</i> , 2017, 410, 127-156.	0.7	109
2098	Alteration of PD-L1 expression and its prognostic impact after concurrent chemoradiation therapy in non-small cell lung cancer patients. <i>Scientific Reports</i> , 2017, 7, 11373.	1.6	70
2099	PD-1 Status in CD8+ T Cells Associates with Survival and Anti-PD-1 Therapeutic Outcomes in Head and Neck Cancer. <i>Cancer Research</i> , 2017, 77, 6353-6364.	0.4	161
2100	Immunotherapies for advanced melanoma: as promising as they are expensive?. <i>Journal of the Royal Society of Medicine</i> , 2017, 110, 395-399.	1.1	2
2101	A computational multiscale agent-based model for simulating spatio-temporal tumour immune response to PD1 and PDL1 inhibition. <i>Journal of the Royal Society Interface</i> , 2017, 14, 20170320.	1.5	118
2102	CNS side effects of immune checkpoint inhibitors: preclinical models, genetics and multimodality therapy. <i>Immunotherapy</i> , 2017, 9, 929-941.	1.0	34
2103	Metagenomic Shotgun Sequencing and Unbiased Metabolomic Profiling Identify Specific Human Gut Microbiota and Metabolites Associated with Immune Checkpoint Therapy Efficacy in Melanoma Patients. <i>Neoplasia</i> , 2017, 19, 848-855.	2.3	475
2104	Tailoring Natural Killer cell immunotherapy to the tumour microenvironment. <i>Seminars in Immunology</i> , 2017, 31, 30-36.	2.7	30
2105	PD-L1 is an activation-independent marker of brown adipocytes. <i>Nature Communications</i> , 2017, 8, 647.	5.8	97
2106	Mutations in BRAF codons 594 and 596 predict good prognosis in melanoma. <i>Oncology Letters</i> , 2017, 14, 3601-3605.	0.8	25
2107	Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer. <i>Medical Molecular Morphology</i> , 2017, 50, 185-194.	0.4	31
2108	Economic Considerations in the Use of Novel Targeted Therapies for Lung Cancer: Review of Current Literature. <i>Pharmacoeconomics</i> , 2017, 35, 1195-1209.	1.7	16

#	ARTICLE	IF	CITATIONS
2109	The Challenge for Development of Valuable Immuno-oncology Biomarkers. <i>Clinical Cancer Research</i> , 2017, 23, 4970-4979.	3.2	76
2110	Safety and efficacy of carboplatin plus nab-paclitaxel for treating advanced non-small-cell lung cancer with interstitial lung disease. <i>Molecular and Clinical Oncology</i> , 2017, 7, 604-608.	0.4	21
2111	CXorf48 is a potential therapeutic target for achieving treatment-free remission in CML patients. <i>Blood Cancer Journal</i> , 2017, 7, e601-e601.	2.8	10
2112	A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma. <i>Scientific Reports</i> , 2017, 7, 8951.	1.6	111
2113	Smac mimetics and oncolytic viruses synergize in driving anticancer T-cell responses through complementary mechanisms. <i>Nature Communications</i> , 2017, 8, 344.	5.8	61
2114	PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis. <i>Scientific Reports</i> , 2017, 7, 10255.	1.6	160
2115	Systemic BRAF/MEK Inhibitors as a Potential Treatment Option in Metastatic Conjunctival Melanoma. <i>Ocular Oncology and Pathology</i> , 2017, 3, 133-141.	0.5	44
2117	Modelling the Survival Outcomes of Immuno-Oncology Drugs in Economic Evaluations: A Systematic Approach to Data Analysis and Extrapolation. <i>Pharmacoeconomics</i> , 2017, 35, 1257-1270.	1.7	49
2118	A single neonatal administration of Bisphenol A induces higher tumour weight associated to changes in tumour microenvironment in the adulthood. <i>Scientific Reports</i> , 2017, 7, 10573.	1.6	21
2119	Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells. <i>Acta Pharmacologica Sinica</i> , 2017, 38, 1512-1520.	2.8	56
2120	Case series of pleomorphic carcinomas of the lung treated with nivolumab. <i>Thoracic Cancer</i> , 2017, 8, 724-728.	0.8	39
2121	Atezolizumab for the treatment of non-small cell lung cancer. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 935-945.	1.3	34
2122	In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. <i>Nature</i> , 2017, 547, 413-418.	18.7	792
2123	Nutrition, inflammation and cancer. <i>Nature Immunology</i> , 2017, 18, 843-850.	7.0	313
2124	PD-L1 Expression in Human Placentas and Gestational Trophoblastic Diseases. <i>International Journal of Gynecological Pathology</i> , 2017, 36, 146-153.	0.9	145
2126	Immune Surveillance Plays a Role in Locally Aggressive Giant Cell Lesions of Bone. <i>Clinical Orthopaedics and Related Research</i> , 2017, 475, 3071-3081.	0.7	14
2127	Lung cancer as a paradigm for precision oncology in solid tumours. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 221-233.	1.4	14
2128	TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. <i>Cancer Discovery</i> , 2017, 7, 1088-1097.	7.7	160

#	ARTICLE	IF	CITATIONS
2130	Comparative beneficiary effects of immunotherapy against chemotherapy in patients with advanced NSCLC: Meta-analysis and systematic review. <i>Oncology Letters</i> , 2017, 14, 1568-1580.	0.8	18
2131	Polymorphisms in the hepatitis C virus core and its association with development of hepatocellular carcinoma. <i>Journal of Biosciences</i> , 2017, 42, 509-521.	0.5	2
2132	Melanoma subtypes demonstrate distinct PD-L1 expression profiles. <i>Laboratory Investigation</i> , 2017, 97, 1063-1071.	1.7	156
2133	The immune contexture in cancer prognosis and treatment. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 717-734.	12.5	1,590
2134	PD-L1 inhibitors in haematological malignancies: update 2017. <i>Immunology</i> , 2017, 152, 357-371.	2.0	108
2135	Nivolumab, a new immunomodulatory drug, a new adverse effect; adrenal crisis. <i>Turkish Journal of Emergency Medicine</i> , 2017, 17, 157-159.	0.3	16
2136	Nivolumab-induced myasthenia gravis in a patient with squamous cell lung carcinoma. <i>Medicine (United States)</i> , 2017, 96, e7350.	0.4	44
2137	Japanese Kampo medicine ninjin'yoeito synergistically enhances tumor vaccine effects mediated by CD8+ T cells. <i>Oncology Letters</i> , 2017, 13, 3471-3478.	0.8	13
2138	CTLA-4 expression in the non-small cell lung cancer patient tumor microenvironment: diverging prognostic impact in primary tumors and lymph node metastases. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1449-1461.	2.0	69
2139	Divergent Function of Programmed Death-Ligand 1 in Donor Tissue versus Recipient Immune System in a Murine Model of Bronchiolitis Obliterans. <i>American Journal of Pathology</i> , 2017, 187, 1368-1379.	1.9	2
2140	Precision Medicine and PET/Computed Tomography in Melanoma. <i>PET Clinics</i> , 2017, 12, 449-458.	1.5	11
2142	Cancer Immunotherapies: Are They as Effective in the Elderly?. <i>Drugs and Aging</i> , 2017, 34, 567-581.	1.3	31
2143	Is Disease-Specific Immunotherapy a Potential Reality for MDS?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S26-S30.	0.2	5
2144	Immunotherapy. <i>Otolaryngologic Clinics of North America</i> , 2017, 50, 867-874.	0.5	4
2145	Mismatch repair status and PD-L1 expression in clear cell carcinomas of the ovary and endometrium. <i>Modern Pathology</i> , 2017, 30, 1622-1632.	2.9	62
2146	Oesophageal cancer. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17048.	18.1	671
2147	Infiltrating T Cells Increase IDO1 Expression in Glioblastoma and Contribute to Decreased Patient Survival. <i>Clinical Cancer Research</i> , 2017, 23, 6650-6660.	3.2	141
2148	Checkpoint Inhibitors for Non-Small Cell Lung Cancer Among Older Adults. <i>Current Oncology Reports</i> , 2017, 19, 62.	1.8	20

#	ARTICLE	IF	CITATIONS
2149	Tools to define the melanoma-associated immunopeptidome. <i>Immunology</i> , 2017, 152, 536-544.	2.0	14
2151	Pan-urolologic cancer genomic subtypes that transcend tissue of origin. <i>Nature Communications</i> , 2017, 8, 199.	5.8	49
2152	Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab. <i>Scientific Reports</i> , 2017, 7, 5532.	1.6	166
2153	Long-term outcomes after carbon-ion radiotherapy for oral mucosal malignant melanoma. <i>Journal of Radiation Research</i> , 2017, 58, 517-522.	0.8	27
2154	Intravenous dendritic cell administration enhances suppression of lung metastasis induced by carbon-ion irradiation. <i>Journal of Radiation Research</i> , 2017, 58, 446-455.	0.8	44
2155	Quantitative Proteomic Analysis of Optimal Cutting Temperature (OCT) Embedded Core-Needle Biopsy of Lung Cancer. <i>Journal of the American Society for Mass Spectrometry</i> , 2017, 28, 2078-2089.	1.2	15
2156	Immunosuppressive Agents and Their Role in Managing Immunotherapy Toxicities in Melanoma. <i>Clinical Skin Cancer</i> , 2017, 2, 18-23.	0.1	5
2157	The genetic landscape of programmed death ligand-1 (PD-L1) alterations in head and neck cancer. <i>Laryngoscope Investigative Otolaryngology</i> , 2017, 2, 99-103.	0.6	14
2158	Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study. <i>Annals of Oncology</i> , 2017, 28, 2581-2587.	0.6	201
2160	A Multikinase and DNA-PK Inhibitor Combination Immunomodulates Melanomas, Suppresses Tumor Progression, and Enhances Immunotherapies. <i>Cancer Immunology Research</i> , 2017, 5, 790-803.	1.6	38
2161	An unbiased in vivo functional genomics screening approach in mice identifies novel tumor cell-based regulators of immune rejection. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1529-1544.	2.0	12
2162	Not only for melanoma. Subcutaneous pseudoprogression in lung squamous-cell carcinoma treated with nivolumab. <i>Medicine (United States)</i> , 2017, 96, e5951.	0.4	15
2163	New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification. <i>Endocrine Reviews</i> , 2017, 38, 489-515.	8.9	241
2164	Targeting Immune System Alterations in Hodgkin Lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2017, 12, 358-369.	1.2	5
2165	Lung cancer as a cardiotoxic state: a review. <i>Medical Oncology</i> , 2017, 34, 159.	1.2	12
2166	Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade. <i>Cell</i> , 2017, 170, 1120-1133.e17.	13.5	960
2167	Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy. <i>British Journal of Cancer</i> , 2017, 117, 921-924.	2.9	81
2168	Cancer Clonal Theory, Immune Escape, and Their Evolving Roles in Cancer Multi-Agent Therapeutics. <i>Current Oncology Reports</i> , 2017, 19, 66.	1.8	10

#	ARTICLE	IF	CITATIONS
2169	Treatment Outcomes for Metastatic Melanoma of Unknown Primary in the New Era: A Single-Institution Study and Review of the Literature. <i>Oncology</i> , 2017, 93, 249-258.	0.9	19
2170	Tropomyosin Receptor Kinase A Expression on Merkel Cell Carcinoma Cells. <i>JAMA Dermatology</i> , 2017, 153, 1166.	2.0	7
2171	Clinical characteristics of patient selection and imaging predictors of outcome in solid tumors treated with checkpoint-inhibitors. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 2310-2325.	3.3	46
2172	Recent Advances in Targeting ROS1 in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1611-1625.	0.5	194
2173	Identification of CMTM6 and CMTM4 as PD-L1 protein regulators. <i>Nature</i> , 2017, 549, 106-110.	13.7	501
2174	Osimertinib-induced interstitial lung disease in a patient with non-small cell lung cancer pretreated with nivolumab: A case report. <i>Molecular and Clinical Oncology</i> , 2017, 7, 383-385.	0.4	19
2175	The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade. <i>Cancer Immunology Research</i> , 2017, 5, 767-777.	1.6	120
2176	Opportunities and challenges in the immunological therapy of pediatric malignancy: a concise snapshot. <i>European Journal of Pediatrics</i> , 2017, 176, 1163-1172.	1.3	11
2177	Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies. <i>Targeted Oncology</i> , 2017, 12, 571-597.	1.7	135
2178	Neurological Complications of Therapeutic Monoclonal Antibodies: Trends from Oncology to Rheumatology. <i>Current Neurology and Neuroscience Reports</i> , 2017, 17, 75.	2.0	15
2179	Mechanisms of Mixed Chimerism-Based Transplant Tolerance. <i>Trends in Immunology</i> , 2017, 38, 829-843.	2.9	66
2180	Cutaneous Eruptions in Patients Receiving Immune Checkpoint Blockade. <i>American Journal of Surgical Pathology</i> , 2017, 41, 1381-1389.	2.1	54
2181	Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. <i>European Respiratory Journal</i> , 2017, 50, 1700050.	3.1	301
2182	BET bromodomain inhibitors synergize with ATR inhibitors in melanoma. <i>Cell Death and Disease</i> , 2017, 8, e2982-e2982.	2.7	17
2183	Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1. <i>Current Oncology Reports</i> , 2017, 19, 64.	1.8	106
2184	Exposure-Response Analysis of Nivolumab in Patients With Previously Treated or Untreated Advanced Melanoma. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 1527-1533.	1.0	28
2185	Is immunity in cancer the key to improving clinical outcome?: Report on the International Symposium on Immunotherapy, The Royal Society, London, UK, 12-13 May 2017. <i>Therapeutic Advances in Vaccines</i> , 2017, 5, 55-68.	2.7	3
2186	EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice. <i>European Respiratory Journal</i> , 2017, 50, 1700514.	3.1	20

#	ARTICLE	IF	CITATIONS
2187	Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade. <i>Cancer Cell</i> , 2017, 32, 253-267.e5.	7.7	430
2188	Fatty Acid Uptake in T Cell Subsets Using a Quantum Dot Fatty Acid Conjugate. <i>Scientific Reports</i> , 2017, 7, 5790.	1.6	26
2189	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. <i>Advances in Anatomic Pathology</i> , 2017, 24, 211-239.	2.4	530
2190	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. <i>Advances in Anatomic Pathology</i> , 2017, 24, 225-251.	2.4	469
2191	Development of an intervention to support patients and clinicians with advanced lung cancer when considering systematic anticancer therapy: protocol for the PACT study. <i>BMJ Open</i> , 2017, 7, e015277.	0.8	4
2192	Expression of programmed death ligand-1 predicts poor outcome in nasopharyngeal carcinoma. <i>Molecular and Clinical Oncology</i> , 2017, 7, 378-382.	0.4	24
2193	Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma. <i>Current Treatment Options in Oncology</i> , 2017, 18, 51.	1.3	69
2194	Impact of the Tumor Microenvironment on Tumor-Infiltrating Lymphocytes: Focus on Breast Cancer. <i>Breast Cancer: Basic and Clinical Research</i> , 2017, 11, 117822341773156.	0.6	36
2195	Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data. <i>Clinical Trials</i> , 2017, 14, 611-620.	0.7	7
2196	The effect of tumor-derived exosomes on immune regulation and cancer immunotherapy. <i>Future Oncology</i> , 2017, 13, 2583-2592.	1.1	113
2197	Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy. <i>Cell</i> , 2017, 171, 1678-1691.e13.	13.5	467
2198	Ablation of Transcription Factor IRF4 Promotes Transplant Acceptance by Driving Allogenic CD4+ T Cell Dysfunction. <i>Immunity</i> , 2017, 47, 1114-1128.e6.	6.6	76
2199	Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence. <i>Cell Reports</i> , 2017, 21, 2796-2812.	2.9	77
2200	MELK Promotes Melanoma Growth by Stimulating the NF- κ B Pathway. <i>Cell Reports</i> , 2017, 21, 2829-2841.	2.9	61
2201	Preserved Liver Transplant After PD-1 Pathway Inhibitor for Hepatocellular Carcinoma. <i>American Journal of Gastroenterology</i> , 2017, 112, 1895-1896.	0.2	52
2202	Oncolytic virotherapy as an immunotherapeutic strategy for multiple myeloma. <i>Blood Cancer Journal</i> , 2017, 7, 640.	2.8	19
2203	Human CD26 ^{high} T cells elicit tumor immunity against multiple malignancies via enhanced migration and persistence. <i>Nature Communications</i> , 2017, 8, 1961.	5.8	67
2204	Multiplex three-dimensional optical mapping of tumor immune microenvironment. <i>Scientific Reports</i> , 2017, 7, 17031.	1.6	41

#	ARTICLE	IF	CITATIONS
2205	QuPath: Open source software for digital pathology image analysis. <i>Scientific Reports</i> , 2017, 7, 16878.	1.6	3,854
2206	Assessment of Concordance between 22C3 and SP142 Immunohistochemistry Assays regarding PD-L1 Expression in Non-Small Cell Lung Cancer. <i>Scientific Reports</i> , 2017, 7, 16956.	1.6	29
2207	T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity. <i>Nature Communications</i> , 2017, 8, 1747.	5.8	336
2208	DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells. <i>Nature Communications</i> , 2017, 8, 1751.	5.8	497
2209	Combined inhibition of MEK and nuclear ERK translocation has synergistic antitumor activity in melanoma cells. <i>Scientific Reports</i> , 2017, 7, 16345.	1.6	16
2210	Real-Time Reverse-Transcription Quantitative Polymerase Chain Reaction Assay Is a Feasible Method for the Relative Quantification of Heregulin Expression in Non-Small Cell Lung Cancer Tissue. <i>Biomarker Insights</i> , 2017, 12, 117727191769985.	1.0	3
2211	Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer. <i>Cell</i> , 2017, 171, 1284-1300.e21.	13.5	366
2212	Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines. <i>Cell Reports</i> , 2017, 21, 1936-1952.	2.9	72
2213	Harnessing BET Inhibitor Sensitivity Reveals AMIGO2 as a Melanoma Survival Gene. <i>Molecular Cell</i> , 2017, 68, 731-744.e9.	4.5	90
2214	Immunogenic Cell Death Amplified by Co-localized Adjuvant Delivery for Cancer Immunotherapy. <i>Nano Letters</i> , 2017, 17, 7387-7393.	4.5	184
2215	Update in the Therapy of Advanced Neuroendocrine Tumors. <i>Current Treatment Options in Oncology</i> , 2017, 18, 72.	1.3	18
2216	Personalised medicine for nonsmall cell lung cancer. <i>European Respiratory Review</i> , 2017, 26, 170066.	3.0	37
2217	Role of Adjuvant Treatment in Sinonasal Mucosal Melanoma. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2017, 78, 512-518.	0.4	31
2218	Primary malignant melanoma of the lung. <i>Medicine (United States)</i> , 2017, 96, e8772.	0.4	10
2219	Cure in Advanced Renal Cell Cancer: Is It an Achievable Goal?. <i>Oncologist</i> , 2017, 22, 1470-1477.	1.9	10
2220	Anti-SIRP α antibody immunotherapy enhances neutrophil and macrophage antitumor activity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E10578-E10585.	3.3	223
2221	Non-small cell lung cancer clinical trials requiring biopsies with biomarker-specific results for enrollment provide unique challenges. <i>Cancer</i> , 2017, 123, 4800-4807.	2.0	19
2222	Surgical resection of metastatic melanoma in the era of immunotherapy and targeted therapy. <i>Melanoma Management</i> , 2017, 4, 61-68.	0.1	20

#	ARTICLE	IF	CITATIONS
2223	Immunotherapy â€œShockâ€ with vitiligo due to nivolumab administration as third line therapy in lung adenocarcinoma. <i>Respiratory Medicine Case Reports</i> , 2017, 22, 283-286.	0.2	19
2224	Combining immunotherapies for the treatment of prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 694-700.	0.8	36
2225	Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain. <i>Nature Communications</i> , 2017, 8, 1447.	5.8	67
2227	Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives. <i>Nature Reviews Neurology</i> , 2017, 13, 755-763.	4.9	139
2228	Acuteâ€onset type 1 diabetes mellitus caused by nivolumab in a patient with advanced pulmonary adenocarcinoma. <i>Journal of Diabetes Investigation</i> , 2017, 8, 798-799.	1.1	22
2229	CD27-Mediated Regulatory T Cell Depletion and Effector T Cell Costimulation Both Contribute to Antitumor Efficacy. <i>Journal of Immunology</i> , 2017, 199, 4110-4123.	0.4	37
2230	Histopathological and genotypic characterization of metastatic colorectal carcinoma with PDâ€L1 (CD274)â€expression: Possible roles of tumour micro environmental factors for CD274 expression. <i>Journal of Pathology: Clinical Research</i> , 2017, 3, 268-278.	1.3	18
2231	Live Cell Labeling with Terpyridine Derivative Proligands to Measure Cytotoxicity Mediated by Immune Cells. <i>ChemMedChem</i> , 2017, 12, 2006-2013.	1.6	9
2232	Association between B7â€H1 and cervical cancer: B7â€H1 impairs the immune response in human cervical cancer cells. <i>Experimental and Therapeutic Medicine</i> , 2017, 14, 4125-4133.	0.8	5
2233	Fine and Predictable Tuning of TALEN Gene Editing Targeting for Improved T Cell Adoptive Immunotherapy. <i>Molecular Therapy - Nucleic Acids</i> , 2017, 9, 312-321.	2.3	36
2234	Immune-related adverse events associated with PD-1 and PD-L1 inhibitors for nonsmall cell lung cancer. <i>Medicine (United States)</i> , 2017, 96, e8407.	0.4	8
2235	Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2017, 18, 1104-1115.	5.1	325
2236	Immunotherapy and Targeted Therapy for Small Cell Lung Cancer: There Is Hope. <i>Current Oncology Reports</i> , 2017, 19, 49.	1.8	23
2237	An abscopal effect in a case of concomitant treatment of locally and peritoneally recurrent gastric cancer using adoptive Tâ€cell immunotherapy and radiotherapy. <i>Clinical Case Reports (discontinued)</i> , 2017, 5, 380-384.	0.2	26
2238	New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a Backbone. <i>Cancer Journal (Sudbury, Mass)</i> , 2017, 23, 10-22.	1.0	45
2239	Recurrent natalizumab-related aseptic meningitis in a patient with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1424-1427.	1.4	7
2240	Overall survival and prognostic factors in patients with spinal metastases from lung cancer treated with and without epidermal growth factor receptor tyrosine kinase inhibitors. <i>International Journal of Clinical Oncology</i> , 2017, 22, 698-705.	1.0	12
2241	Targeted therapies for renal cell carcinoma. <i>Nature Reviews Nephrology</i> , 2017, 13, 496-511.	4.1	185

#	ARTICLE	IF	CITATIONS
2242	Hair Repigmentation During Immunotherapy Treatment With an Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Agent for Lung Cancer. <i>JAMA Dermatology</i> , 2017, 153, 1162.	2.0	69
2243	Successful Treatment of Sudden Hepatitis Induced by Long-Term Nivolumab Administration. <i>Case Reports in Oncology</i> , 2017, 10, 368-371.	0.3	21
2244	Genomic analysis of 220 CTLs identifies a novel recurrent gain-of-function alteration in RLTPR (p.Q575E). <i>Blood</i> , 2017, 130, 1430-1440.	0.6	131
2245	Predictive and prognostic significance of CD8+ tumor-infiltrating lymphocytes in patients with luminal B/HER 2 negative breast cancer treated with neoadjuvant chemotherapy. <i>Oncology Letters</i> , 2017, 14, 337-344.	0.8	33
2246	Efficacy and Safety of Nintedanib Plus Docetaxel in Patients with Advanced Lung Adenocarcinoma: Complementary and Exploratory Analyses of the Phase III LUME-Lung 1 Study. <i>Targeted Oncology</i> , 2017, 12, 475-485.	1.7	30
2247	Stem cell-released oncolytic herpes simplex virus has therapeutic efficacy in brain metastatic melanomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E6157-E6165.	3.3	90
2248	Expression of CD70 (CD27L) Is Associated With Epithelioid and Sarcomatous Features in IDH-Wild-Type Glioblastoma. <i>Journal of Neuropathology and Experimental Neurology</i> , 2017, 76, 697-708.	0.9	16
2249	The role for chemotherapy in the modern management of melanoma. <i>Melanoma Management</i> , 2017, 4, 125-136.	0.1	26
2250	Combining Local Immunotoxins Targeting Mesothelin with CTLA-4 Blockade Synergistically Eradicates Murine Cancer by Promoting Anticancer Immunity. <i>Cancer Immunology Research</i> , 2017, 5, 685-694.	1.6	37
2251	Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity. <i>Cancer Immunology Research</i> , 2017, 5, 676-684.	1.6	130
2252	A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab. <i>Seminars in Oncology</i> , 2017, 44, 136-140.	0.8	183
2253	Tumor Response Dynamics of Advanced Non-small Cell Lung Cancer Patients Treated with PD-1 Inhibitors: Imaging Markers for Treatment Outcome. <i>Clinical Cancer Research</i> , 2017, 23, 5737-5744.	3.2	69
2254	Inhibition of the HDAC/Suv39/G9a pathway restores the expression of DNA damage-dependent major histocompatibility complex class I-related chain A and B in cancer cells. <i>Oncology Reports</i> , 2017, 38, 693-702.	1.2	25
2255	Pharmacotherapy of Glioblastoma: Established Treatments and Emerging Concepts. <i>CNS Drugs</i> , 2017, 31, 675-684.	2.7	24
2257	Immunotheranostic Polymersomes Modularly Assembled from Tetrablock and Diblock Copolymers with Oxidation-Responsive Fluorescence. <i>Cellular and Molecular Bioengineering</i> , 2017, 10, 357-370.	1.0	21
2258	Patient Reported Outcomes (PROs) as Part of Value-Based Care Can Shape Therapy Guidelines: Impact on Emerging Targeted Agents and Immunotherapy Protocols in Resource-Limited Regions. <i>Oncology and Therapy</i> , 2017, 5, 69-74.	1.0	5
2259	Rapid decrease of circulating tumor DNA predicted the treatment effect of nivolumab in a lung cancer patient within only 5 days. <i>Respiratory Medicine Case Reports</i> , 2017, 22, 31-33.	0.2	6
2260	Monitoring immune-checkpoint blockade: response evaluation and biomarker development. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 655-668.	12.5	787

#	ARTICLE	IF	CITATIONS
2261	Dual PI3K and Wnt pathway inhibition is a synergistic combination against triple negative breast cancer. <i>Npj Breast Cancer</i> , 2017, 3, 17.	2.3	41
2262	Assessing treatment efficacy in the subset of responders in a randomized clinical trial. <i>Annals of Oncology</i> , 2017, 28, 1640-1647.	0.6	7
2263	New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31st Annual Meeting of the Society for Immunotherapy of Cancer, 2016. , 2017, 5, 50.		10
2264	Spotlight on landmark oncology trials: the latest evidence and novel trial designs. <i>BMC Medicine</i> , 2017, 15, 111.	2.3	3
2265	Morphologic and molecular study of lung cancers associated with idiopathic pulmonary fibrosis and other pulmonary fibroses. <i>Respiratory Research</i> , 2017, 18, 120.	1.4	41
2266	Precision medicine in breast cancer: reality or utopia?. <i>Journal of Translational Medicine</i> , 2017, 15, 139.	1.8	56
2267	Molecular imaging biomarkers for cell-based immunotherapies. <i>Journal of Translational Medicine</i> , 2017, 15, 140.	1.8	11
2268	Programmed death-ligand 1 (PD-L1) is expressed in a significant number of the uterine cervical carcinomas. <i>Diagnostic Pathology</i> , 2017, 12, 45.	0.9	93
2269	Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy. <i>Clinical Epigenetics</i> , 2017, 9, 59.	1.8	118
2270	Pembrolizumab for metastatic melanoma in a renal allograft recipient with subsequent graft rejection and treatment response failure: a case report. <i>Journal of Medical Case Reports</i> , 2017, 11, 73.	0.4	47
2271	Nuclear IRF-1 expression as a mechanism to assess "Capability" to express PD-L1 and response to PD-1 therapy in metastatic melanoma. , 2017, 5, 25.		35
2272	Long-term complete remission with ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients. , 2017, 5, 31.		45
2273	Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. , 2017, 5, 44.		181
2274	Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer. , 2017, 5, 40.		99
2275	Cerebral vasculitis mimicking intracranial metastatic progression of lung cancer during PD-1 blockade. , 2017, 5, 46.		64
2276	Safe and effective administration of T-VEC in a patient with heart transplantation and recurrent locally advanced melanoma. , 2017, 5, 45.		20
2277	Nivolumab as salvage treatment in a patient with HIV-related relapsed/refractory Hodgkin lymphoma and liver failure with encephalopathy. , 2017, 5, 49.		29
2278	Immune-Related Adverse Events as a Biomarker in Non-Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors. <i>Oncologist</i> , 2017, 22, 1232-1237.	1.9	109

#	ARTICLE	IF	CITATIONS
2279	Primary malignant melanoma of the lung: A case report. <i>Molecular and Clinical Oncology</i> , 2017, 7, 39-41.	0.4	8
2280	Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression. <i>JAMA Oncology</i> , 2017, 3, 1511.	3.4	131
2281	Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock?. <i>Targeted Oncology</i> , 2017, 12, 413-447.	1.7	19
2282	Dendritic cell-based immunotherapy: a basic review and recent advances. <i>Immunologic Research</i> , 2017, 65, 798-810.	1.3	158
2283	Health-related quality of life results from the phase III CheckMate 067 study. <i>European Journal of Cancer</i> , 2017, 82, 80-91.	1.3	76
2284	PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability. <i>Modern Pathology</i> , 2017, 30, 1411-1421.	2.9	151
2285	Predicting the response to CTLA-4 blockade by longitudinal noninvasive monitoring of CD8 T cells. <i>Journal of Experimental Medicine</i> , 2017, 214, 2243-2255.	4.2	187
2286	Radiotherapy and Immune Checkpoint Blockade for Melanoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2017, 23, 32-39.	1.0	28
2287	Immunotherapeutic Approaches to Biliary Cancer. <i>Current Treatment Options in Oncology</i> , 2017, 18, 44.	1.3	8
2288	PD-L1 and IAPs co-operate to protect tumors from cytotoxic lymphocyte-derived TNF. <i>Cell Death and Differentiation</i> , 2017, 24, 1705-1716.	5.0	64
2289	Nonsmall cell lung carcinoma: diagnostic difficulties in small biopsies and cytological specimens. <i>European Respiratory Review</i> , 2017, 26, 170007.	3.0	74
2290	Successful immune checkpoint blockade in a patient with advanced stage microsatellite-unstable biliary tract cancer. <i>Journal of Physical Education and Sports Management</i> , 2017, 3, a001974.	0.5	54
2291	Comprehensive treatment with Chinese medicine in patients with advanced non-small cell lung cancer: A multicenter, prospective, cohort study. <i>Chinese Journal of Integrative Medicine</i> , 2017, 23, 733-739.	0.7	17
2292	PD-1/PD-L1 immune-checkpoint blockade in B-cell lymphomas. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 203-220.	12.5	358
2293	Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2017, 20, 28-35.	2.0	120
2294	Programmed Death-Ligand 1 Expression, Microsatellite Instability, Epstein-Barr Virus, and Human Papillomavirus in Nasopharyngeal Carcinomas of Patients from the Philippines. <i>Head and Neck Pathology</i> , 2017, 11, 203-211.	1.3	23
2295	Understanding Mechanisms of Resistance in the Epithelial Growth Factor Receptor in Non-Small Cell Lung Cancer and the Role of Biopsy at Progression. <i>Oncologist</i> , 2017, 22, 3-11.	1.9	34
2296	Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer. <i>Modern Pathology</i> , 2017, 30, 340-349.	2.9	138

#	ARTICLE	IF	CITATIONS
2297	Targeted therapies for the treatment of non-small-cell lung cancer: Monoclonal antibodies and biological inhibitors. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 843-853.	1.4	51
2298	Combinatorial immunotherapy for melanoma. <i>Cancer Gene Therapy</i> , 2017, 24, 141-147.	2.2	24
2299	Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples. <i>Annals of Oncology</i> , 2017, 28, 34-43.	0.6	198
2300	Fulminant type I diabetes mellitus associated with nivolumab in a patient with relapsed classical Hodgkin lymphoma. <i>International Journal of Hematology</i> , 2017, 105, 383-386.	0.7	59
2301	Cancer immunotherapy in patients with preexisting autoimmune disorders. <i>Seminars in Immunopathology</i> , 2017, 39, 333-337.	2.8	31
2302	Phenotype-based variation as a biomarker of sensitivity to molecularly targeted therapy in melanoma. <i>MedChemComm</i> , 2017, 8, 88-95.	3.5	4
2303	Basis for molecular diagnostics and immunotherapy for esophageal cancer. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 33-45.	1.1	23
2304	Translational Pharmacokinetic/Pharmacodynamic Modeling of Tumor Growth Inhibition Supports Dose-Range Selection of the Anti-PD-1 Antibody Pembrolizumab. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017, 6, 11-20.	1.3	88
2305	Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 119-128.	2.0	89
2306	Preclinical Advances with Multiphoton Microscopy in Live Imaging of Skin Cancers. <i>Journal of Investigative Dermatology</i> , 2017, 137, 282-287.	0.3	22
2307	Resistance to anticancer immunity in cancer patients: potential strategies to reverse resistance. <i>Annals of Oncology</i> , 2017, 28, 457-467.	0.6	27
2308	Using Model-Based "Learn and Confirm" to Reveal the Pharmacokinetics-Pharmacodynamics Relationship of Pembrolizumab in the KEYNOTE-001 Trial. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017, 6, 21-28.	1.3	85
2309	Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies. <i>Annals of Oncology</i> , 2017, 28, 57-74.	0.6	45
2310	Combining MPDL3280A with adoptive cell immunotherapy exerts better antitumor effects against cervical cancer. <i>Bioengineered</i> , 2017, 8, 367-373.	1.4	7
2311	Lymphocytic hypophysitis: modern day management with limited role for surgery. <i>Pituitary</i> , 2017, 20, 241-250.	1.6	30
2312	Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non-small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, 60-67.	1.1	6
2313	Clinicopathologic profile, immunophenotype, and genotype of CD274 (PD-L1)-positive colorectal carcinomas. <i>Modern Pathology</i> , 2017, 30, 278-285.	2.9	77
2314	Cardiac allograft rejection as a complication of PD-1 checkpoint blockade for cancer immunotherapy: a case report. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 45-50.	2.0	55

#	ARTICLE	IF	CITATIONS
2315	Is there a role for therapeutic cancer vaccines in the age of checkpoint inhibitors?. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 528-532.	1.4	30
2316	A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1. <i>JAMA Oncology</i> , 2017, 3, 256.	3.4	164
2317	Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2017, 22, 81-88.	1.9	128
2318	HHLA2, a New Immune Checkpoint Member of the B7 Family, Is Widely Expressed in Human Lung Cancer and Associated with EGFR Mutational Status. <i>Clinical Cancer Research</i> , 2017, 23, 825-832.	3.2	78
2319	PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors. <i>Clinical Cancer Research</i> , 2017, 23, 454-465.	3.2	126
2320	CD137â€™CRDI is not necessary in the role of contacting its natural ligand. <i>Immunology and Cell Biology</i> , 2017, 95, 24-32.	1.0	4
2321	Osimertinib-induced interstitial lung disease after treatment with anti-PD1 antibody. <i>Investigational New Drugs</i> , 2017, 35, 105-107.	1.2	45
2322	Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 176-189.	2.2	44
2323	Systemic inflammation is associated with the density of immune cells in the tumor microenvironment of gastric cancer. <i>Gastric Cancer</i> , 2017, 20, 602-611.	2.7	76
2324	Local delivery of checkpoints antibodies. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 245-248.	1.4	16
2325	Adverse Renal Effects of Novel Molecular Oncologic Targeted Therapies: A Narrative Review. <i>Kidney International Reports</i> , 2017, 2, 108-123.	0.4	72
2326	Developmental therapeutics for patients with breast cancer and central nervous system metastasis: current landscape and future perspectives. <i>Annals of Oncology</i> , 2017, 28, 44-56.	0.6	43
2327	Global chemotherapy development for gastric cancer. <i>Gastric Cancer</i> , 2017, 20, 92-101.	2.7	38
2328	Pembrolizumab: Role of Modeling and Simulation in Bringing a Novel Immunotherapy to Patients With Melanoma. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017, 6, 5-7.	1.3	23
2329	Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations. <i>Nature Reviews Urology</i> , 2017, 14, 15-25.	1.9	210
2330	PD-1/PD-L1 blockade in renal cell cancer. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 77-84.	1.3	27
2331	Potential applications of nanoparticles in cancer immunotherapy. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 63-74.	1.4	35
2332	Genomic Evolution after Chemoradiotherapy in Anal Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2017, 23, 3214-3222.	3.2	44

#	ARTICLE	IF	CITATIONS
2333	Estimating Survival in Patients With Lung Cancer and Brain Metastases. <i>JAMA Oncology</i> , 2017, 3, 827.	3.4	543
2334	Comparison of exome-based HLA class I genotyping tools: identification of platform-specific genotyping errors. <i>Journal of Human Genetics</i> , 2017, 62, 397-405.	1.1	55
2335	Predictive biomarkers and effectiveness of MUC1-targeted dendritic-cell-based vaccine in patients with refractory non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 147-157.	1.4	17
2336	Ipilimumab: from preclinical development to future clinical perspectives in melanoma. <i>Future Oncology</i> , 2017, 13, 625-636.	1.1	31
2337	The role of B7 family costimulatory molecules and indoleamine 2,3-dioxygenase in primary Sjögren's syndrome and systemic sclerosis. <i>Immunologic Research</i> , 2017, 65, 622-629.	1.3	16
2338	A consensus statement on the gender perspective in lung cancer. <i>Clinical and Translational Oncology</i> , 2017, 19, 527-535.	1.2	26
2339	Next generation predictive biomarkers for immune checkpoint inhibition. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 179-190.	2.7	84
2340	Immune-Related Adverse Effects of Cancer Immunotherapy—Implications for Rheumatology. <i>Rheumatic Disease Clinics of North America</i> , 2017, 43, 65-78.	0.8	101
2341	Genomic Amplification of <i>CD274</i> (PD-L1) in Small-Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 1220-1226.	3.2	92
2342	Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients. <i>Gastric Cancer</i> , 2017, 20, 407-415.	2.7	189
2343	The role of dendritic cells in cancer. <i>Seminars in Immunopathology</i> , 2017, 39, 307-316.	2.8	76
2344	Wnt signaling in cancer. <i>Oncogene</i> , 2017, 36, 1461-1473.	2.6	1,975
2345	PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 110-120.	0.5	108
2346	Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells. <i>Clinical Cancer Research</i> , 2017, 23, 1388-1396.	3.2	261
2347	A state-of-the-art review and guidelines for tumor treating fields treatment planning and patient follow-up in glioblastoma. <i>CNS Oncology</i> , 2017, 6, 29-43.	1.2	34
2348	Metastasectomy Following Immunotherapy with Adoptive Cell Transfer for Patients with Advanced Melanoma. <i>Annals of Surgical Oncology</i> , 2017, 24, 135-141.	0.7	24
2349	Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer. <i>Oncologist</i> , 2017, 22, 70-80.	1.9	58
2350	Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	139

#	ARTICLE	IF	CITATIONS
2351	Are we entering the era of combination therapy for melanoma?. <i>Melanoma Management</i> , 2017, 4, 5-8.	0.1	0
2352	Ex Vivo Imaging of Resident CD8 T Lymphocytes in Human Lung Tumor Slices Using Confocal Microscopy. <i>Journal of Visualized Experiments</i> , 2017, , .	0.2	14
2353	Development of Ocular Rosacea following Combined Ipilimumab and Nivolumab Treatment for Metastatic Malignant Skin Melanoma. <i>Ocular Oncology and Pathology</i> , 2017, 3, 188-192.	0.5	19
2354	Acute Angle Closure Precipitated by Hemorrhage and Necrosis of a Large Uveal Melanoma in the Setting of Systemic Immunomodulatory Therapy. <i>Ocular Oncology and Pathology</i> , 2017, 3, 254-258.	0.5	4
2355	A Case of Immune Thrombocytopenia as a Rare Side Effect of an Immunotherapy with PD1-Blocking Agents for Metastatic Melanoma. <i>Transfusion Medicine and Hemotherapy</i> , 2017, 44, 426-428.	0.7	35
2356	Brain metastasis in a patient with melanoma receiving Pembrolizumab therapy. <i>Medicine (United States)</i> , 2017, 96, e9431.	0.4	36
2357	Acute liver failure caused by pembrolizumab in a patient with pulmonary metastatic liver cancer. <i>Medicine (United States)</i> , 2017, 96, e9431.	0.4	36
2358	Efficacy and safety of nanoparticle albumin-bound paclitaxel monotherapy as second-line therapy of cytotoxic anticancer drugs in patients with advanced non-small cell lung cancer. <i>Medicine (United States)</i> , 2017, 96, e8931.	0.4	21
2359	Risk of gastrointestinal toxicities with PD-1 inhibitors in cancer patients. <i>Medicine (United States)</i> , 2017, 96, e8931.	0.4	21
2360	Targeted therapy of brain metastases: latest evidence and clinical implications. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 781-796.	1.4	46
2361	Characterization of Tumor Cells Using a Medical Wire for Capturing Circulating Tumor Cells: A 3D Approach Based on Immunofluorescence and DNA FISH. <i>Journal of Visualized Experiments</i> , 2017, , .	0.2	4
2362	The Successful Treatment of Pulmonary Pleomorphic Carcinoma with Pembrolizumab: A Case Report. <i>Case Reports in Oncology</i> , 2017, 10, 752-757.	0.3	31
2363	Inhibition of IL-18-mediated myeloid derived suppressor cell accumulation enhances anti-PD1 efficacy against osteosarcoma cancer. <i>Journal of Bone Oncology</i> , 2017, 9, 59-64.	1.0	32
2364	Informatics for cancer immunotherapy. <i>Annals of Oncology</i> , 2017, 28, xii56-xii73.	0.6	19
2365	Bayesian adaptive clinical trials of combination treatments. <i>Contemporary Clinical Trials Communications</i> , 2017, 8, 227-233.	0.5	6
2366	Identification of candidate responders for anti-PD-L1/PD-1 immunotherapy, Rova-T therapy, or EZH2 inhibitory therapy in small-cell lung cancer. <i>Molecular and Clinical Oncology</i> , 2017, 8, 310-314.	0.4	22
2367	Preclinical and clinical development of neoantigen vaccines. <i>Annals of Oncology</i> , 2017, 28, xii11-xii17.	0.6	160
2368	Atezolizumab: feasible second-line therapy for patients with non-small cell lung cancer? A review of efficacy, safety and place in therapy. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 769-779.	1.4	11

#	ARTICLE	IF	CITATIONS
2369	Response to nivolumab in metastatic collecting duct carcinoma expressing PD-L1: A case report. <i>Molecular and Clinical Oncology</i> , 2017, 7, 988-990.	0.4	19
2370	TNF \pm blockade overcomes resistance to anti-PD-1 in experimental melanoma. <i>Nature Communications</i> , 2017, 8, 2256.	5.8	284
2371	Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1036, 19-31.	0.8	212
2372	Immune checkpoint inhibitors in the treatment of advanced mucosal melanoma. <i>Melanoma Management</i> , 2017, 4, 161-167.	0.1	7
2373	Awakening immunity against cancer: a 2017 primer for clinicians. <i>Chinese Journal of Cancer</i> , 2017, 36, 67.	4.9	12
2374	An update on the relevance of vaccine research for the treatment of metastatic melanoma. <i>Melanoma Management</i> , 2017, 4, 203-215.	0.1	8
2375	Cancer Immunotherapy with Chimeric Antigen Receptor (CAR) T Cells. <i>Journal of Onco-Nephrology</i> , 2017, 1, 151-155.	0.3	4
2376	Treatment advances and prognosis for patients with adult T-cell leukemia-lymphoma. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2017, 57, 87-97.	0.3	26
2378	Advanced squamous lung cancer: therapeutic options, future directions, unmet needs and results of a monocentric survey. <i>Lung Cancer Management</i> , 2017, 6, 93-107.	1.5	5
2379	“Lazarus response” of nivolumab in a frail patient with non-small-cell lung cancer. <i>Respirology Case Reports</i> , 2017, 5, e00247.	0.3	4
2380	Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study. <i>Chinese Journal of Cancer</i> , 2017, 36, 94.	4.9	47
2381	Imaging Features of Toxicities by Immune Checkpoint Inhibitors in Cancer Therapy. <i>Current Radiology Reports</i> , 2017, 5, 59.	0.4	69
2383	Combined checkpoint inhibitor therapy causing diabetic ketoacidosis in metastatic melanoma. , 2017, 5, 97.		23
2384	Life expectancy difference and life expectancy ratio: two measures of treatment effects in randomised trials with non-proportional hazards. <i>BMJ: British Medical Journal</i> , 2017, 357, j2250.	2.4	67
2385	Serial pseudoprogression of metastatic malignant melanoma in a patient treated with nivolumab: a case report. <i>BMC Cancer</i> , 2017, 17, 778.	1.1	22
2386	Family with sequence similarity 83, member A $\frac{1}{2}$ B is a predictor of poor prognosis and a potential therapeutic target for lung adenocarcinoma expressing wild-type epidermal growth factor receptor. <i>Oncology Letters</i> , 2017, 15, 1549-1558.	0.8	8
2387	Why cure, why now?. <i>Journal of Medical Ethics</i> , 2017, 43, 67-70.	1.0	17
2388	The use of baseline biomarkers to predict outcome in melanoma patients treated with pembrolizumab. <i>Annals of Research Hospitals</i> , 2017, 1, 1-1.	0.0	1

#	ARTICLE	IF	CITATIONS
2389	PD-L1 expression as poor prognostic factor in patients with non-squamous non-small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 58457-58468.	0.8	42
2390	Decreased Serum Concentration of Total IgG Is Related to Tumor Progression in Gastric Cancer Patients. <i>Yonago Acta Medica</i> , 2017, 60, 119-125.	0.3	11
2391	Meta-analysis of programmed cell death 1 polymorphisms with systemic lupus erythematosus risk. <i>Oncotarget</i> , 2017, 8, 36885-36897.	0.8	20
2392	Transcriptional response profiles of paired tumor-normal samples offer novel perspectives in pan-cancer analysis. <i>Oncotarget</i> , 2017, 8, 41334-41347.	0.8	22
2393	Phenotypic and clinical characterization of low density neutrophils in patients with advanced lung adenocarcinoma. <i>Oncotarget</i> , 2017, 8, 90969-90978.	0.8	28
2394	PD-L1 up-regulation in melanoma increases disease aggressiveness and is mediated through miR-17-5p. <i>Oncotarget</i> , 2017, 8, 15894-15911.	0.8	84
2395	High proportions of PD-1+ and PD-L1+ leukocytes in classical Hodgkin lymphoma microenvironment are associated with inferior outcome. <i>Blood Advances</i> , 2017, 1, 1427-1439.	2.5	37
2396	PD-L1 and c-MET expression and survival in patients with small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 53978-53988.	0.8	32
2397	Clinical Response to Anti-Programmed Death 1 After Response and Subsequent Progression on Anti-Programmed Death Ligand 1 Therapy. <i>JCO Precision Oncology</i> , 2017, 1, 1-9.	1.5	3
2398	Unusual case of immune-related colitis. <i>BMJ Case Reports</i> , 2017, 2017, bcr-2017-221319.	0.2	3
2399	A case of autosplenectomy associated with T-cell checkpoint inhibitor treatment. <i>BMJ Case Reports</i> , 2017, 2017, bcr-2017-220775.	0.2	2
2400	Aftermath of induced inflammation: acute periaortitis due to nivolumab therapy. <i>BMJ Case Reports</i> , 2017, 2017, bcr-2017-221852.	0.2	16
2401	Proteomic identification of the oncoprotein STAT3 as a target of a novel Skp1 inhibitor. <i>Oncotarget</i> , 2017, 8, 2681-2693.	0.8	22
2402	Programmed Cell Death-1/Programmed Death-ligand 1 Pathway. <i>Chinese Medical Journal</i> , 2017, 130, 986-992.	0.9	15
2403	High-grade neutropenia in a patient successfully treated with nivolumab for refractory primary mediastinal B-cell lymphoma. <i>Blood Advances</i> , 2017, 1, 1306-1308.	2.5	20
2404	HDAC inhibition potentiates immunotherapy in triple negative breast cancer. <i>Oncotarget</i> , 2017, 8, 114156-114172.	0.8	139
2405	Checkpoint inhibitors for malignant melanoma: a systematic review and meta-analysis. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2017, Volume 10, 325-339.	0.8	52
2406	Prognostic value of Cox-2 and PD-L1 expression and its relationship with tumor-infiltrating lymphocytes in resected lung adenocarcinoma. <i>Cancer Management and Research</i> , 2017, Volume 9, 741-750.	0.9	19

#	ARTICLE	IF	CITATIONS
2407	Update on targeted therapies for advanced non-small cell lung cancer: nivolumab in context. <i>Therapeutics and Clinical Risk Management</i> , 2017, Volume 13, 223-236.	0.9	16
2408	Non-small cell lung cancer treatment (r)evolution: ten years of advances and more to come. <i>Ecancermedalscience</i> , 2017, 11, 787.	0.6	34
2409	Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy. <i>Frontiers in Pharmacology</i> , 2017, 8, 49.	1.6	459
2410	Immune Checkpoint in Glioblastoma: Promising and Challenging. <i>Frontiers in Pharmacology</i> , 2017, 8, 242.	1.6	133
2411	Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2017, 8, 730.	1.6	350
2412	Cancer Immunoprevention and Public Health. <i>Frontiers in Public Health</i> , 2017, 5, 101.	1.3	10
2413	Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor. <i>Journal of Cancer</i> , 2017, 8, 410-416.	1.2	176
2414	Targeting immune checkpoints in malignant glioma. <i>Oncotarget</i> , 2017, 8, 7157-7174.	0.8	42
2415	Pneumonitis and pneumonitis-related death in cancer patients treated with programmed cell death-1 inhibitors: a systematic review and meta-analysis. <i>Therapeutics and Clinical Risk Management</i> , 2017, Volume 13, 1259-1271.	0.9	16
2416	Treating & EGFR mutation resistance in non-small cell lung cancer role of osimertinib. <i>The Application of Clinical Genetics</i> , 2017, Volume 10, 49-56.	1.4	25
2417	Immune Checkpoint Inhibitors in Melanoma and HIV Infection. <i>Open AIDS Journal</i> , 2017, 11, 91-100.	0.1	12
2418	Immune Modulation by Androgen Deprivation and Radiation Therapy: Implications for Prostate Cancer Immunotherapy. <i>Cancers</i> , 2017, 9, 13.	1.7	40
2419	Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma. <i>Blood Advances</i> , 2017, 1, 2643-2654.	2.5	91
2420	Bevacizumab in the treatment of NSCLC: patient selection and perspectives. <i>Lung Cancer: Targets and Therapy</i> , 2017, Volume 8, 259-269.	1.3	37
2421	New PD-L1 inhibitors in non-small cell lung cancer impact of atezolizumab. <i>Lung Cancer: Targets and Therapy</i> , 2017, Volume 8, 67-78.	1.3	27
2422	Targeting the PD-1 pathway in pediatric solid tumors and brain tumors. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 2097-2106.	1.0	45
2423	Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 2349-2363.	1.0	35
2424	Immunotherapy for Non-small-cell Lung Cancer: Current Status and Future Obstacles. <i>Immune Network</i> , 2017, 17, 378.	1.6	70

#	ARTICLE	IF	CITATIONS
2425	Tumor cell PD-L1 predicts poor local control for rectal cancer patients following neoadjuvant radiotherapy. <i>Cancer Management and Research</i> , 2017, Volume 9, 249-258.	0.9	11
2426	The efficacy of anti-PD-1/PD-L1 therapy and its comparison with EGFR-TKIs for advanced non-small-cell lung cancer. <i>Oncotarget</i> , 2017, 8, 57826-57835.	0.8	24
2427	Beyond chemotherapy for advanced disease—the role of EGFR and PD-1 inhibitors. <i>Translational Andrology and Urology</i> , 2017, 6, 848-854.	0.6	12
2428	Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events. <i>ImmunoTargets and Therapy</i> , 2017, Volume 6, 51-71.	2.7	101
2429	Immune-Checkpoint Inhibitors in the Era of Precision Medicine: What Radiologists Should Know. <i>Korean Journal of Radiology</i> , 2017, 18, 42.	1.5	33
2430	Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells. <i>Medical Sciences (Basel, Switzerland)</i> , 2017, 5, 28.	1.3	22
2431	Pembrolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives. <i>Lung Cancer: Targets and Therapy</i> , 2017, Volume 8, 1-11.	1.3	6
2432	Patient and oncologist preferences for attributes of treatments in advanced melanoma: a discrete choice experiment. <i>Patient Preference and Adherence</i> , 2017, Volume 11, 1389-1399.	0.8	23
2433	Immune Checkpoints as a Target for Colorectal Cancer Treatment. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1324.	1.8	112
2434	Cancer immunology and melanoma immunotherapy. <i>Anais Brasileiros De Dermatologia</i> , 2017, 92, 830-835.	0.5	8
2435	>NRAS-mutant melanoma: current challenges and future prospect. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 3941-3947.	1.0	122
2436	Pembrolizumab-Induced Pancytopenia: A Case Report. , 2017, 21, 17-004.		33
2437	Cost analysis of adverse events associated with non-small cell lung cancer management in France. <i>ClinicoEconomics and Outcomes Research</i> , 2017, Volume 9, 443-449.	0.7	9
2438	Profile of pembrolizumab in the treatment of head and neck squamous cell carcinoma: design development and place in therapy. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 2537-2549.	2.0	6
2439	Baseline relative eosinophil count as a predictive biomarker for ipilimumab treatment in advanced melanoma. <i>Oncotarget</i> , 2017, 8, 79809-79815.	0.8	27
2440	Role of tumor microenvironment in tumorigenesis. <i>Journal of Cancer</i> , 2017, 8, 761-773.	1.2	1,048
2441	PD-1 and PD-L1 as emerging therapeutic targets in gastric cancer: current evidence. <i>Gastrointestinal Cancer: Targets and Therapy</i> , 2017, Volume 7, 1-11.	5.5	49
2442	Clinical features, predictive correlates, and pathophysiology of immune-related adverse events in immune checkpoint inhibitor treatments in cancer: a short review. <i>ImmunoTargets and Therapy</i> , 2017, Volume 6, 73-82.	2.7	121

#	ARTICLE	IF	CITATIONS
2443	Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer. <i>Journal of Gynecologic Oncology</i> , 2017, 28, e64.	1.0	45
2444	Markers of T Cell Senescence in Humans. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1742.	1.8	162
2445	PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic Drugs. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2111.	1.8	53
2446	Control of NK Cell Activation by Immune Checkpoint Molecules. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2129.	1.8	64
2447	miRNAs, Melanoma and Microenvironment: An Intricate Network. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2354.	1.8	43
2448	Does Locoregional Chemotherapy Still Matter in the Treatment of Advanced Pelvic Melanoma?. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2382.	1.8	8
2449	Targeting Immune Cell Checkpoints during Sepsis. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2413.	1.8	125
2450	Newly Emerging Immune Checkpoints: Promises for Future Cancer Therapy. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2642.	1.8	72
2451	New Immunotherapy Strategies in Breast Cancer. <i>International Journal of Environmental Research and Public Health</i> , 2017, 14, 68.	1.2	76
2452	Programmed Cell Death 1 (PD-1) and Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA-4) in Viral Hepatitis. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1517.	1.8	69
2453	Systemic Immunotherapy for Urothelial Cancer: Current Trends and Future Directions. <i>Cancers</i> , 2017, 9, 15.	1.7	30
2454	PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome. <i>Frontiers in Pharmacology</i> , 2017, 8, 561.	1.6	1,276
2455	TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action. <i>International Journal of Molecular Sciences</i> , 2017, 18, 645.	1.8	193
2456	CIMAvax-EGF: A New Therapeutic Vaccine for Advanced Non-Small Cell Lung Cancer Patients. <i>Frontiers in Immunology</i> , 2017, 8, 269.	2.2	56
2457	Immunoregulatory Role of NK Cells in Tissue Inflammation and Regeneration. <i>Frontiers in Immunology</i> , 2017, 8, 301.	2.2	114
2458	PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?. <i>Frontiers in Immunology</i> , 2017, 8, 1597.	2.2	225
2459	Genomic Analysis of Tumor Microenvironment Immune Types across 14 Solid Cancer Types: Immunotherapeutic Implications. <i>Theranostics</i> , 2017, 7, 3585-3594.	4.6	214
2460	PD-L1 Promotes Self-Renewal and Tumorigenicity of Malignant Melanoma Initiating Cells. <i>BioMed Research International</i> , 2017, 2017, 1-8.	0.9	13

#	ARTICLE	IF	CITATIONS
2461	Biologic therapy in esophageal and gastric malignancies: current therapies and future directions. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 418-429.	0.6	20
2462	Immunotherapy for Pediatric Brain Tumors. <i>Brain Sciences</i> , 2017, 7, 137.	1.1	24
2463	Diagnostic and Therapeutic Potential of MicroRNAs in Lung Cancer. <i>Cancers</i> , 2017, 9, 49.	1.7	53
2464	Local Immune Responsiveness of Mice Bearing Premalignant Oral Lesions to PD-1 Antibody Treatment. <i>Cancers</i> , 2017, 9, 62.	1.7	9
2465	Acute and Late Toxicities of Concurrent Chemoradiotherapy for Locally-Advanced Non-Small Cell Lung Cancer. <i>Cancers</i> , 2017, 9, 120.	1.7	55
2466	Non-Canonical Thinking for Targeting ALK-Fusion Onco-Proteins in Lung Cancer. <i>Cancers</i> , 2017, 9, 164.	1.7	26
2467	Major Tumor Suppressor and Oncogenic Non-Coding RNAs: Clinical Relevance in Lung Cancer. <i>Cells</i> , 2017, 6, 12.	1.8	75
2468	Function and Clinical Implications of Long Non-Coding RNAs in Melanoma. <i>International Journal of Molecular Sciences</i> , 2017, 18, 715.	1.8	37
2469	The between Now and Then of Lung Cancer Chemotherapy and Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1374.	1.8	47
2470	Immunotherapeutic Concepts to Target Acute Myeloid Leukemia: Focusing on the Role of Monoclonal Antibodies, Hypomethylating Agents and the Leukemic Microenvironment. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1660.	1.8	33
2471	Tumor-Associated Lymphatic Vessels Upregulate PDL1 to Inhibit T-Cell Activation. <i>Frontiers in Immunology</i> , 2017, 8, 66.	2.2	102
2472	Bidirectional Crosstalk between Lymphatic Endothelial Cell and T Cell and Its Implications in Tumor Immunity. <i>Frontiers in Immunology</i> , 2017, 8, 83.	2.2	38
2473	Human Tumor-Infiltrating Myeloid Cells: Phenotypic and Functional Diversity. <i>Frontiers in Immunology</i> , 2017, 8, 86.	2.2	167
2474	Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the Fuel. <i>Frontiers in Immunology</i> , 2017, 8, 267.	2.2	61
2475	Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study. <i>Frontiers in Immunology</i> , 2017, 8, 386.	2.2	27
2476	Comparative Analysis of Immune Checkpoint Molecules and Their Potential Role in the Transmissible Tasmanian Devil Facial Tumor Disease. <i>Frontiers in Immunology</i> , 2017, 8, 513.	2.2	19
2477	PD-1 Blockade Promotes Emerging Checkpoint Inhibitors in Enhancing T Cell Responses to Allogeneic Dendritic Cells. <i>Frontiers in Immunology</i> , 2017, 8, 572.	2.2	59
2478	Intratumoral FoxP3+Helios+ Regulatory T Cells Upregulating Immunosuppressive Molecules Are Expanded in Human Colorectal Cancer. <i>Frontiers in Immunology</i> , 2017, 8, 619.	2.2	69

#	ARTICLE	IF	CITATIONS
2479	Phase II Study of Adjuvant Immunotherapy with the CSF-470 Vaccine Plus Bacillus Calmette-Guérin Plus Recombinant Human Granulocyte Macrophage-Colony Stimulating Factor vs Medium-Dose Interferon Alpha 2B in Stages IIB, IIC, and III Cutaneous Melanoma Patients: A Single Institution, Randomized Study. <i>Frontiers in Immunology</i> , 2017, 8, 625.	2.2	56
2480	Cancer Immunotherapy: Historical Perspective of a Clinical Revolution and Emerging Preclinical Animal Models. <i>Frontiers in Immunology</i> , 2017, 8, 829.	2.2	159
2481	Tertiary Lymphoid Structures: An Anti-tumor School for Adaptive Immune Cells and an Antibody Factory to Fight Cancer?. <i>Frontiers in Immunology</i> , 2017, 8, 830.	2.2	54
2482	In Vitro Culture with Interleukin-15 Leads to Expression of Activating Receptors and Recovery of Natural Killer Cell Function in Acute Myeloid Leukemia Patients. <i>Frontiers in Immunology</i> , 2017, 8, 931.	2.2	31
2483	Immunological Properties of Murine Parthenogenetic Stem Cell-Derived Cardiomyocytes and Engineered Heart Muscle. <i>Frontiers in Immunology</i> , 2017, 8, 955.	2.2	7
2484	Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells. <i>Frontiers in Immunology</i> , 2017, 8, 961.	2.2	93
2485	Immunomodulatory Monoclonal Antibodies in Combined Immunotherapy Trials for Cutaneous Melanoma. <i>Frontiers in Immunology</i> , 2017, 8, 1024.	2.2	29
2486	Inflammasomes and Cancer: The Dynamic Role of the Inflammasome in Tumor Development. <i>Frontiers in Immunology</i> , 2017, 8, 1132.	2.2	101
2487	Natural Killer T Cell-Targeted Immunotherapy Mediating Long-term Memory Responses and Strong Antitumor Activity. <i>Frontiers in Immunology</i> , 2017, 8, 1206.	2.2	16
2488	Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic Viral Infections and Cancer. <i>Frontiers in Immunology</i> , 2017, 8, 1215.	2.2	80
2489	PD-1 Controls Tonic Signaling and Lymphopenia-Induced Proliferation of T Lymphocytes. <i>Frontiers in Immunology</i> , 2017, 8, 1289.	2.2	20
2490	Dynamics of Heat Shock Protein 70 Serum Levels As a Predictor of Clinical Response in Non-Small-Cell Lung Cancer and Correlation with the Hypoxia-Related Marker Osteopontin. <i>Frontiers in Immunology</i> , 2017, 8, 1305.	2.2	35
2491	Early Events of the Reaction Elicited by CSF-470 Melanoma Vaccine Plus Adjuvants: An In Vitro Analysis of Immune Recruitment and Cytokine Release. <i>Frontiers in Immunology</i> , 2017, 8, 1342.	2.2	22
2492	Current Advances in \checkmark T Cell-Based Tumor Immunotherapy. <i>Frontiers in Immunology</i> , 2017, 8, 1401.	2.2	74
2493	Chronic NKG2D Engagement In Vivo Differentially Impacts NK Cell Responsiveness by Activating NK Receptors. <i>Frontiers in Immunology</i> , 2017, 8, 1466.	2.2	20
2494	Iron Induces Anti-tumor Activity in Tumor-Associated Macrophages. <i>Frontiers in Immunology</i> , 2017, 8, 1479.	2.2	121
2495	T Follicular Helper Cells As a New Target for Immunosuppressive Therapies. <i>Frontiers in Immunology</i> , 2017, 8, 1510.	2.2	41
2496	Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract. <i>Frontiers in Immunology</i> , 2017, 8, 1547.	2.2	125

#	ARTICLE	IF	CITATIONS
2497	Tregs: Where We Are and What Comes Next?. <i>Frontiers in Immunology</i> , 2017, 8, 1578.	2.2	142
2498	Strategies to Improve the Efficacy of Dendritic Cell-Based Immunotherapy for Melanoma. <i>Frontiers in Immunology</i> , 2017, 8, 1594.	2.2	48
2499	Recent Successes and Future Directions in Immunotherapy of Cutaneous Melanoma. <i>Frontiers in Immunology</i> , 2017, 8, 1617.	2.2	43
2500	The Future of Immunotherapy: A 20-Year Perspective. <i>Frontiers in Immunology</i> , 2017, 8, 1668.	2.2	76
2501	Transplantation Tolerance through Hematopoietic Chimerism: Progress and Challenges for Clinical Translation. <i>Frontiers in Immunology</i> , 2017, 8, 1762.	2.2	39
2502	The CD40-CD40L Dyad in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2017, 8, 1791.	2.2	56
2503	New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness. <i>Frontiers in Immunology</i> , 2017, 8, 1804.	2.2	54
2504	Neoantigen Targeting—Dawn of a New Era in Cancer Immunotherapy?. <i>Frontiers in Immunology</i> , 2017, 8, 1848.	2.2	73
2505	Historical Evolution of Second-Line Therapy in Non-Small Cell Lung Cancer. <i>Frontiers in Medicine</i> , 2017, 4, 4.	1.2	27
2506	Second-Line Treatment of NSCLC—The Pan-ErbB Inhibitor Afatinib in Times of Shifting Paradigms. <i>Frontiers in Medicine</i> , 2017, 4, 9.	1.2	14
2507	Second-line Treatment of Non-Small Cell Lung Cancer: Focus on the Clinical Development of Dacomitinib. <i>Frontiers in Medicine</i> , 2017, 4, 36.	1.2	11
2508	The Emerging Role of Targeted Therapy and Immunotherapy in the Management of Brain Metastases in Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2017, 7, 33.	1.3	14
2509	Current Treatment Algorithms for Patients with Metastatic Non-Small Cell, Non-Squamous Lung Cancer. <i>Frontiers in Oncology</i> , 2017, 7, 38.	1.3	14
2510	Update on the Treatment of Metastatic Squamous Non-Small Cell Lung Cancer in New Era of Personalized Medicine. <i>Frontiers in Oncology</i> , 2017, 7, 50.	1.3	30
2511	Antiangiogenesis for Advanced Non-Small-Cell Lung Cancer in the Era of Immunotherapy and Personalized Medicine. <i>Frontiers in Oncology</i> , 2017, 7, 52.	1.3	26
2512	Targeted Chemotherapy for Esophageal Cancer. <i>Frontiers in Oncology</i> , 2017, 7, 63.	1.3	22
2513	Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2017, 7, 67.	1.3	28
2514	Histone Deacetylase Inhibitor Treatment Increases the Expression of the Plasma Membrane Ca ²⁺ Pump PMCA4b and Inhibits the Migration of Melanoma Cells Independent of ERK. <i>Frontiers in Oncology</i> , 2017, 7, 95.	1.3	22

#	ARTICLE	IF	CITATIONS
2515	Genetically Engineered Vaccinia Viruses As Agents for Cancer Treatment, Imaging, and Transgene Delivery. <i>Frontiers in Oncology</i> , 2017, 7, 96.	1.3	61
2516	Current Immunotherapeutic Strategies to Enhance Oncolytic Virotherapy. <i>Frontiers in Oncology</i> , 2017, 7, 114.	1.3	22
2517	Presentation, Treatment, and Prognosis of Secondary Melanoma within the Orbit. <i>Frontiers in Oncology</i> , 2017, 7, 125.	1.3	20
2518	Current Advances in Checkpoint Inhibitors: Lessons from Non-Central Nervous System Cancers and Potential for Glioblastoma. <i>Frontiers in Oncology</i> , 2017, 7, 141.	1.3	16
2519	The Oncopig Cancer Model: An Innovative Large Animal Translational Oncology Platform. <i>Frontiers in Oncology</i> , 2017, 7, 190.	1.3	92
2520	Emerging Therapies for Stage III Non-Small Cell Lung Cancer: Stereotactic Body Radiation Therapy and Immunotherapy. <i>Frontiers in Oncology</i> , 2017, 7, 197.	1.3	18
2521	Radiotherapy Dosing for Locally Advanced Non-Small Cell Lung Carcinoma: "MTD" or "ALARA"? <i>Frontiers in Oncology</i> , 2017, 7, 205.	1.3	9
2522	Radiotherapy for Oligometastatic Lung Cancer. <i>Frontiers in Oncology</i> , 2017, 7, 210.	1.3	38
2523	Genetic Characterization of Brain Metastases in the Era of Targeted Therapy. <i>Frontiers in Oncology</i> , 2017, 7, 230.	1.3	43
2524	Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review. <i>Frontiers in Oncology</i> , 2017, 7, 233.	1.3	61
2525	Clinical Applications of Immunotherapy Combination Methods and New Opportunities for the Future. <i>BioMed Research International</i> , 2017, 2017, 1-10.	0.9	6
2526	A Case of Nivolumab-Induced Severe Mononeuropathy Multiplex and Rhabdomyolysis. <i>Case Reports in Medicine</i> , 2017, 2017, 1-4.	0.3	17
2527	Manipulation of Innate and Adaptive Immunity through Cancer Vaccines. <i>Journal of Immunology Research</i> , 2017, 2017, 1-7.	0.9	31
2528	Dual Roles of IL-27 in Cancer Biology and Immunotherapy. <i>Mediators of Inflammation</i> , 2017, 2017, 1-14.	1.4	90
2529	Targeting Cancer Stem Cells and Their Niche: Current Therapeutic Implications and Challenges in Pancreatic Cancer. <i>Stem Cells International</i> , 2017, 2017, 1-9.	1.2	11
2530	Increased EGFR Phosphorylation Correlates with Higher Programmed Death Ligand-1 Expression: Analysis of TKI-Resistant Lung Cancer Cell Lines. <i>BioMed Research International</i> , 2017, 2017, 1-7.	0.9	13
2531	Mismatch Repair Deficiency as a Predictive Biomarker for Immunotherapy Efficacy. <i>BioMed Research International</i> , 2017, 2017, 1-7.	0.9	65
2532	CD8 ⁺ T Cells Expressed by CD8 ⁺ T Cells Contributes to PD-L1-Induced Apoptosis of Activated CD8 ⁺ T Cells. <i>Journal of Immunology Research</i> , 2017, 2017, 1-6.	0.9	33

#	ARTICLE	IF	CITATIONS
2533	Are PD-1 antibodies safe for use in metastatic uveal melanoma?. <i>Melanoma Management</i> , 2017, 4, 79-82.	0.1	0
2534	Management of the cutaneous adverse effects of antimelanoma therapy. <i>Melanoma Management</i> , 2017, 4, 187-202.	0.1	5
2535	Immunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives. <i>BioMed Research International</i> , 2017, 2017, 1-13.	0.9	10
2536	Plasma Levels of High-Mobility Group Box 1 during Peptide Vaccination in Patients with Recurrent Ovarian Cancer. <i>Journal of Immunology Research</i> , 2017, 2017, 1-8.	0.9	9
2537	Advances in Immunotherapy for Glioblastoma Multiforme. <i>Journal of Immunology Research</i> , 2017, 2017, 1-11.	0.9	73
2538	Systemic Treatment of Metastatic Conjunctival Melanoma. <i>Case Reports in Oncological Medicine</i> , 2017, 2017, 1-3.	0.2	26
2539	Phenotypic and Functional Properties of Tumor-Infiltrating Regulatory T Cells. <i>Mediators of Inflammation</i> , 2017, 2017, 1-9.	1.4	33
2540	Advances and Current Concepts in the Medical Management of Gastroenteropancreatic Neuroendocrine Neoplasms. <i>BioMed Research International</i> , 2017, 2017, 1-12.	0.9	25
2541	Gastric and Rectal Metastases from Malignant Melanoma Presenting with Hypochromic Anemia and Treated with Immunotherapy. <i>Case Reports in Oncological Medicine</i> , 2017, 2017, 1-4.	0.2	12
2542	Hypokalemic Paralysis Secondary to Immune Checkpoint Inhibitor Therapy. <i>Case Reports in Oncological Medicine</i> , 2017, 2017, 1-4.	0.2	11
2543	Efficacy of Juzentaihoto for Tumor Immunotherapy in B16 Melanoma Metastasis Model. <i>Evidence-based Complementary and Alternative Medicine</i> , 2017, 2017, 1-8.	0.5	25
2544	Immunotherapy of Nivolumab with Dendritic Cell Vaccination Is Effective against Intractable Recurrent Primary Central Nervous System Lymphoma: A Case Report. <i>Neurologia Medico-Chirurgica</i> , 2017, 57, 191-197.	1.0	18
2545	Anti-PD-1 and PD-L1 antibodies in metastatic melanoma. <i>Melanoma Management</i> , 2017, 4, 175-178.	0.1	24
2546	A population of innate myelolymphoblastoid effector cell expanded by inactivation of mTOR complex 1 in mice. <i>ELife</i> , 2017, 6, .	2.8	5
2547	Cost-Effectiveness of Nivolumab-Ipilimumab Combination Therapy Compared with Monotherapy for First-Line Treatment of Metastatic Melanoma in the United States. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2017, 23, 653-664.	0.5	61
2548	Evaluating the cost-effectiveness of afatinib after platinum-based therapy for the treatment of squamous non-small-cell lung cancer in France. <i>ClinicoEconomics and Outcomes Research</i> , 2017, Volume 9, 655-668.	0.7	11
2549	The current status of immunobased therapies for metastatic renal-cell carcinoma. <i>ImmunoTargets and Therapy</i> , 2017, Volume 6, 83-93.	2.7	14
2550	Melanoma: tumor microenvironment and new treatments. <i>Anais Brasileiros De Dermatologia</i> , 2017, 92, 156-166.	0.5	35

#	ARTICLE	IF	CITATIONS
2551	New developments in the treatment of advanced squamous cell lung cancer: focus on afatinib. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 2513-2526.	1.0	33
2552	PD-L1: a novel prognostic biomarker in head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2017, 8, 52889-52900.	0.8	82
2553	Do we have biomarkers to predict response to neoadjuvant and adjuvant chemotherapy and immunotherapy in bladder cancer?. <i>Translational Andrology and Urology</i> , 2017, 6, 1067-1080.	0.6	19
2554	Overexpression of PD-L2 is associated with shorter relapse-free survival in patients with malignant salivary gland tumors. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 2983-2992.	1.0	46
2555	High expression of carcinoembryonic antigen and telomerase reverse transcriptase in circulating tumor cells is associated with poor clinical response to the immune checkpoint inhibitor nivolumab. <i>Oncology Letters</i> , 2018, 15, 3061-3067.	0.8	16
2556	Current Status of Immune Checkpoint Inhibitors in Gastrointestinal Cancers. <i>Journal of Cancer</i> , 2017, 8, 1460-1465.	1.2	13
2557	Acute Hyperglycemia Associated with Anti-Cancer Medication. <i>Endocrinology and Metabolism</i> , 2017, 32, 23.	1.3	48
2558	Cytokine-induced killer cells/dendritic cells and cytokine-induced killer cells immunotherapy for the treatment of esophageal cancer in China: a meta-analysis. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 1897-1908.	1.0	9
2559	Retinal Pigment Epithelial Cells are a Potential Reservoir for Ebola Virus in the Human Eye. <i>Translational Vision Science and Technology</i> , 2017, 6, 12.	1.1	53
2560	Potential role of radiation therapy in augmenting the activity of immunotherapy for gynecologic cancers. <i>Cancer Management and Research</i> , 2017, Volume 9, 553-563.	0.9	14
2561	Role of afatinib in the treatment of advanced lung squamous cell carcinoma. <i>Clinical Pharmacology: Advances and Applications</i> , 2017, Volume 9, 147-157.	0.8	7
2562	Induction of PD-L1 expression by epidermal growth factor receptor–mediated signaling in esophageal squamous cell carcinoma. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 763-771.	1.0	39
2563	Spotlight on ramucirumab in the treatment of nonsmall cell lung cancer: design, development, and clinical activity. <i>Lung Cancer: Targets and Therapy</i> , 2017, Volume 8, 57-66.	1.3	5
2564	Challenging the standard of care in advanced melanoma: focus on pembrolizumab. <i>Cancer Management and Research</i> , 2017, Volume 9, 433-442.	0.9	15
2565	Development of Papulopustular Rosacea during Nivolumab Therapy for Metastatic Cancer. <i>Acta Dermato-Venereologica</i> , 2017, 97, 539-540.	0.6	18
2566	Update on immune checkpoint inhibitors in gynecological cancers. <i>Journal of Gynecologic Oncology</i> , 2017, 28, e20.	1.0	49
2567	Association between PD-L1 Expression on Tumour-Infiltrating Lymphocytes and Overall Survival in Patients with Gastric Cancer. <i>Journal of Cancer</i> , 2017, 8, 1579-1585.	1.2	26
2568	Novel Therapies in Platinum-refractory Metastatic Germ Cell Tumor: A Case Report with a Focus on a PD-1 Inhibitor. <i>Rare Tumors</i> , 2017, 9, 47-49.	0.3	14

#	ARTICLE	IF	CITATIONS
2569	Checkpoint blockade in solid tumors and B-cell malignancies, with special consideration of the role of CD200. <i>Cancer Management and Research</i> , 2017, Volume 9, 601-609.	0.9	21
2570	PD-L1 is a Prognostic Biomarker in Resected NSCLC Patients with Moderate/high Smoking History and Elevated Serum SCCA Level. <i>Journal of Cancer</i> , 2017, 8, 3251-3260.	1.2	21
2571	AURA 3: the last word on chemotherapy as a control arm in EGFR mutant NSCLC?. <i>Annals of Translational Medicine</i> , 2017, 5, S14-S14.	0.7	5
2572	Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis. <i>Cancer Management and Research</i> , 2017, Volume 9, 207-213.	0.9	128
2573	Improved resection and prolonged overall survival with PD-1-IRDye800CW fluorescence probe-guided surgery and PD-1 adjuvant immunotherapy in 4T1 mouse model. <i>International Journal of Nanomedicine</i> , 2017, Volume 12, 8337-8351.	3.3	19
2574	Autoimmune Diabetes and Thyroiditis Complicating Treatment with Nivolumab. <i>Case Reports in Oncology</i> , 2017, 10, 230-234.	0.3	35
2575	Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 1487-1502.	1.0	12
2576	Emerging role of nivolumab in the management of patients with non-small-cell lung cancer: current data and future perspectives. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 3697-3708.	1.0	6
2577	Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review. <i>Oncotarget</i> , 2017, 8, 48248-48252.	0.8	97
2578	Prognostic value of smoking status in non-small-cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis. <i>Oncotarget</i> , 2017, 8, 93149-93155.	0.8	58
2579	Which treatment is preferred for advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor in second-line therapy? A meta-analysis comparing immune checkpoint inhibitor, tyrosine kinase inhibitor and chemotherapy. <i>Oncotarget</i> , 2017, 8, 66491-66503.	0.8	2
2580	A systematic and genome-wide correlation meta-analysis of PD-L1 expression and targetable NSCLC driver genes. <i>Journal of Thoracic Disease</i> , 2017, 9, 2560-2571.	0.6	25
2581	Targeted therapy for soft tissue sarcomas in adolescents and young adults. <i>Adolescent Health, Medicine and Therapeutics</i> , 2017, Volume 8, 41-55.	0.7	11
2582	Soluble B and T Lymphocyte Attenuator Correlates to Disease Severity in Sepsis and High Levels Are Associated with an Increased Risk of Mortality. <i>PLoS ONE</i> , 2017, 12, e0169176.	1.1	37
2583	Development of a versatile oncolytic virus platform for local intra-tumoural expression of therapeutic transgenes. <i>PLoS ONE</i> , 2017, 12, e0177810.	1.1	23
2584	Mass spectrometry-based serum peptidome profiling accurately and reliably predicts outcomes of pemetrexed plus platinum chemotherapy in patients with advanced lung adenocarcinoma. <i>PLoS ONE</i> , 2017, 12, e0179000.	1.1	3
2585	Clinical implications of the novel cytokine IL-38 expressed in lung adenocarcinoma: Possible association with PD-L1 expression. <i>PLoS ONE</i> , 2017, 12, e0181598.	1.1	31
2586	Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms. <i>PLoS ONE</i> , 2017, 12, e0183023.	1.1	73

#	ARTICLE	IF	CITATIONS
2587	Assessing the relationship between toxicity and economic cost of oncological target agents: A systematic review of clinical trials. PLoS ONE, 2017, 12, e0183639.	1.1	2
2588	Forced expression of IL-7R promotes CD8 T cell cytotoxicity to self antigen. PLoS ONE, 2017, 12, e0188112.	1.1	8
2589	Radiation enhanced the local and distant anti-tumor efficacy in dual immune checkpoint blockade therapy in osteosarcoma. PLoS ONE, 2017, 12, e0189697.	1.1	40
2590	Isolated Adrenocorticotrophic Hormone Deficiency Caused by Nivolumab in a Patient with Metastatic Lung Cancer. Internal Medicine, 2017, 56, 2463-2469.	0.3	34
2591	Radiologic criteria of response to systemic treatments for hepatocellular carcinoma. Hepatic Oncology, 2017, 4, 129-137.	4.2	16
2592	Utility of ipilimumab in melanoma patients who progress on anti-PD-1 therapy. Melanoma Management, 2017, 4, 143-145.	0.1	8
2593	Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis. Oncoimmunology, 2017, 6, e1344805.	2.1	142
2594	Immune profiles and clinical outcomes between sepsis patients with or without active cancer requiring admission to intensive care units. PLoS ONE, 2017, 12, e0179749.	1.1	18
2595	Intratumoral heterogeneity of programmed cell death ligand-1 expression is common in lung cancer. PLoS ONE, 2017, 12, e0186192.	1.1	49
2596	In vitro and in vivo antiviral activity of an anti-programmed death-ligand 1 (PD-L1) rat-bovine chimeric antibody against bovine leukemia virus infection. PLoS ONE, 2017, 12, e0174916.	1.1	33
2597	Elevated frequencies of CD8 T cells expressing PD-1, CTLA-4 and Tim-3 within tumour from perineural squamous cell carcinoma patients. PLoS ONE, 2017, 12, e0175755.	1.1	30
2598	When to consider alternatives to front-line immune therapies in metastatic melanoma. Melanoma Management, 2017, 4, 71-74.	0.1	0
2599	Pathogenesis, Clinical Manifestations and Management of Immune Checkpoint Inhibitors Toxicity. Tumori, 2017, 103, 405-421.	0.6	52
2600	Anti-PD-1 monotherapy versus anti-PD1 plus anti-CTLA4 in advanced melanoma: how do we decide?. Melanoma Management, 2017, 4, 151-155.	0.1	2
2601	Addressing the challenges of applying precision oncology. Npj Precision Oncology, 2017, 1, 28.	2.3	43
2602	Lymphocyte count or percentage: which can better predict the prognosis of advanced cancer patients following palliative care?. BMC Cancer, 2017, 17, 514.	1.1	34
2603	Presence of immune cells, low tumor proliferation and wild type BRAF mutation status is associated with a favourable clinical outcome in stage III cutaneous melanoma. BMC Cancer, 2017, 17, 584.	1.1	11
2604	The values of neutrophil-lymphocyte ratio and/or prostate-specific antigen in discriminating real Gleason score ≥ 7 prostate cancer from group of biopsy-based Gleason score ≤ 6 . BMC Cancer, 2017, 17, 11629.	1.1	7

#	ARTICLE	IF	CITATIONS
2605	Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma. <i>BMC Cancer</i> , 2017, 17, 618.	1.1	42
2606	Clinicopathological and prognostic significance of programmed death ligand-1 expression in breast cancer: a meta-analysis. <i>BMC Cancer</i> , 2017, 17, 690.	1.1	41
2607	A single-arm phase II study of nab-paclitaxel for patients with chemorefractory non-small cell lung cancer. <i>BMC Cancer</i> , 2017, 17, 683.	1.1	11
2608	Hospitalisation costs of metastatic melanoma in France; the MELISSA study (MELanoma In hoSpital) Tj ETQq1 1 0.784314 rgBT /Over	0.9	4
2609	Combination therapy for melanoma with BRAF/MEK inhibitor and immune checkpoint inhibitor: a mathematical model. <i>BMC Systems Biology</i> , 2017, 11, 70.	3.0	37
2610	Role of microRNA-33a in regulating the expression of PD-1 in lung adenocarcinoma. <i>Cancer Cell International</i> , 2017, 17, 105.	1.8	38
2611	The biology of Hepatocellular carcinoma: implications for genomic and immune therapies. <i>Molecular Cancer</i> , 2017, 16, 149.	7.9	338
2612	Checkpoint inhibitors in melanoma and early phase development in solid tumors: whatâ€™s the future?. <i>Journal of Translational Medicine</i> , 2017, 15, 173.	1.8	36
2613	Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab. <i>Journal of Translational Medicine</i> , 2017, 15, 244.	1.8	73
2614	Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China. <i>Journal of Hematology and Oncology</i> , 2017, 10, 136.	6.9	42
2615	PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy. <i>Journal of Hematology and Oncology</i> , 2017, 10, 146.	6.9	77
2616	Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy. <i>Journal of Hematology and Oncology</i> , 2017, 10, 174.	6.9	92
2617	IL-27 mediates HLA class I up-regulation, which can be inhibited by the IL-6 pathway, in HLA-deficient Small Cell Lung Cancer cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 140.	3.5	19
2618	Cancer gene profiling in non-small cell lung cancers reveals activating mutations in JAK2 and JAK3 with therapeutic implications. <i>Genome Medicine</i> , 2017, 9, 89.	3.6	39
2619	Partial response of pulmonary adenocarcinoma with symptomatic brain metastasis to nivolumab plus high-dose oral corticosteroid: a case report. <i>Journal of Medical Case Reports</i> , 2017, 11, 183.	0.4	7
2620	Pharmacokinetics, microscale distribution, and dosimetry of alpha-emitter-labeled anti-PD-L1 antibodies in an immune competent transgenic breast cancer model. <i>EJNMMI Research</i> , 2017, 7, 57.	1.1	35
2621	Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. , 2017, 5, 53.		688
2622	Progressive hypoventilation due to mixed CD8+ and CD4+ lymphocytic polymyositis following tremelimumab - durvalumab treatment. , 2017, 5, 54.		30

#	ARTICLE	IF	CITATIONS
2623	Pretreatment antigen-specific immunity and regulation - association with subsequent immune response to anti-tumor DNA vaccination. , 2017, 5, 56.		9
2624	Acute interstitial nephritis after sequential ipilimumab - nivolumab therapy of metastatic melanoma. , 2017, 5, 57.		29
2625	Tumor-derived exosomes induce CD8+ T cell suppressors. , 2017, 5, 65.		133
2626	Whole-blood RNA transcript-based models can predict clinical response in two large independent clinical studies of patients with advanced melanoma treated with the checkpoint inhibitor, tremelimumab. , 2017, 5, 67.		28
2627	Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series. , 2017, 5, 66.		37
2628	High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute. , 2017, 5, 74.		45
2629	Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment. , 2017, 5, 76.		96
2630	Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma. , 2017, 5, 83.		46
2631	Smoldering myocarditis following immune checkpoint blockade. , 2017, 5, 91.		147
2632	Safety in treatment of hepatocellular carcinoma with immune checkpoint inhibitors as compared to melanoma and non-small cell lung cancer. , 2017, 5, 93.		56
2633	Biomarkers for immunotherapy in bladder cancer: a moving target. , 2017, 5, 94.		144
2634	Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. , 2017, 5, 95.		1,460
2635	A pilot study of an autologous tumor-derived autophagosome vaccine with docetaxel in patients with stage IV non-small cell lung cancer. , 2017, 5, 103.		8
2636	Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry. , 2017, 5, 102.		31
2637	Intestinal perforation after nivolumab immunotherapy for a malignant melanoma: a case report. Surgical Case Reports, 2017, 3, 94.	0.2	14
2638	Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma. Chinese Journal of Cancer, 2017, 36, 61.	4.9	42
2639	Prospect of Immunotherapy for Glioblastoma: Tumor Vaccine, Immune Checkpoint Inhibitors and Combination Therapy. Neurologia Medico-Chirurgica, 2017, 57, 321-330.	1.0	16
2640	Clinical parameters associated with anti-programmed death-1 (PD-1) inhibitors-induced tumor response in melanoma patients. Investigational New Drugs, 2017, 35, 842-847.	1.2	13

#	ARTICLE	IF	CITATIONS
2641	Clinical safety of combined therapy of immune checkpoint inhibitors and Viscum album L. therapy in patients with advanced or metastatic cancer. BMC Complementary and Alternative Medicine, 2017, 17, 534.	3.7	31
2642	Impressive response to immunotherapy in a metastatic gastric cancer patient: could somatic copy number alterations help patient selection?. , 2017, 5, 84.		5
2643	Nivolumab-induced Acute Fibrinous and Organizing Pneumonia (AFOP). Internal Medicine, 2017, 56, 2311-2315.	0.3	23
2644	Nivolumab Therapy for Synchronous ALK-Positive Lung Cancer and Gastric Cancer. Case Reports in Oncology, 2017, 10, 361-367.	0.3	9
2645	Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity. Oncotarget, 2017, 8, 90532-90544.	0.8	89
2646	Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a meta-analysis. Translational Lung Cancer Research, 2017, 6, S8-S20.	1.3	97
2647	Harnessing the immune system through programmed death-1 blockade in the management of Hodgkin lymphoma. Blood and Lymphatic Cancer: Targets and Therapy, 2017, Volume 7, 1-7.	1.2	1
2648	High PD-L1 expression is associated with stage IV disease and poorer overall survival in 186 cases of small cell lung cancers. Oncotarget, 2017, 8, 18021-18030.	0.8	46
2649	Live, Learn, Pass It on. Journal of Patient Experience, 2017, 4, 162-168.	0.4	7
2650	Highlights from the eancer Future Horizons in Lung Cancer conference, 1â€²2 September 2016: Focusing on the future of treatment for NSCLC and SCLC. Eancermedicalscience, 2017, 11, 729.	0.6	2
2651	The combination of checkpoint immunotherapy and targeted therapy in cancer. Annals of Translational Medicine, 2017, 5, 388-388.	0.7	54
2652	Severe Esophagitis and Gastritis from Nivolumab Therapy. ACG Case Reports Journal, 2017, 4, e57.	0.2	67
2653	On the origin of myeloid-derived suppressor cells. Oncotarget, 2017, 8, 3649-3665.	0.8	156
2654	Relationship between expression of PD-L1 and tumor angiogenesis, proliferation, and invasion in glioma. Oncotarget, 2017, 8, 49702-49712.	0.8	84
2655	Atezolizumab in advanced non-small cell lung cancer. Journal of Thoracic Disease, 2017, 9, 3603-3606.	0.6	7
2656	Programmed cell death-ligand 1 expression and immunoscore in stage II and III non-small cell lung cancer patients receiving adjuvant chemotherapy. Oncotarget, 2017, 8, 61618-61625.	0.8	13
2657	Preferential accumulation of regulatory T cells with highly immunosuppressive characteristics in breast tumor microenvironment. Oncotarget, 2017, 8, 33159-33171.	0.8	96
2658	Lung cancer prognosis: can histological patterns and morphological features have a role in the management of lung cancer patients?. Annals of Translational Medicine, 2017, 5, 353-353.	0.7	11

#	ARTICLE	IF	CITATIONS
2659	Initial experience of anti-PD1 therapy with nivolumab in advanced hepatocellular carcinoma. <i>Oncotarget</i> , 2017, 8, 96649-96655.	0.8	22
2660	Differentiated tumor immune microenvironment of Epstein-Barr virus-associated and negative gastric cancer: implication in prognosis and immunotherapy. <i>Oncotarget</i> , 2017, 8, 67094-67103.	0.8	47
2661	Improving Molecular Testing and Personalized Medicine in Non-Small-Cell Lung Cancer in Ontario. <i>Current Oncology</i> , 2017, 24, 103-110.	0.9	30
2662	Sequential Therapy with Nivolumab Followed by Ipilimumab Induces Complete Response in Metastatic Melanoma of the Lung but with Severe Hepatotoxicities. <i>Case Reports in Oncology</i> , 2017, 9, 644-649.	0.3	13
2663	Development and validation of a targeted next generation DNA sequencing panel outperforming whole exome sequencing for the identification of clinically relevant genetic variants. <i>Oncotarget</i> , 2017, 8, 102033-102045.	0.8	25
2664	Editorial (Thematic Issue: Targets for Immunotherapy in Acute Leukemia). <i>Current Drug Targets</i> , 2017, 18, 256-256.	1.0	2
2665	EGFR or HER2 inhibition modulates the tumor microenvironment by suppression of PD-L1 and cytokines release. <i>Oncotarget</i> , 2017, 8, 63901-63910.	0.8	30
2666	A rare case of lung carcinoma acquires multidrug-resistant Klebsiella pneumoniae; pneumonia radiologically mimicking metastasis caused by nivolumab therapy-associated neutropenia. <i>Therapeutics and Clinical Risk Management</i> , 2017, Volume 13, 1375-1377.	0.9	9
2667	IFN- γ -related mRNA profile predicts clinical response to PD-1 blockade. <i>Journal of Clinical Investigation</i> , 2017, 127, 2930-2940.	3.9	2,560
2668	Therapeutic Sequencing in Metastatic Renal Cell Carcinoma. <i>Kidney Cancer</i> , 2017, 1, 15-29.	0.2	4
2669	BPTF inhibits NK cell activity and the abundance of natural cytotoxicity receptor co-ligands. <i>Oncotarget</i> , 2017, 8, 64344-64357.	0.8	24
2670	PD-L1 immunohistochemical assays for assessment of therapeutic strategies involving immune checkpoint inhibitors in non-small cell lung cancer: a comparative study. <i>Oncotarget</i> , 2017, 8, 98524-98532.	0.8	40
2671	A Case Report of Severe Type B Lactic Acidosis Following First Dose of Nivolumab in a VHL-Mutated Metastatic Renal Cell Carcinoma. <i>Kidney Cancer</i> , 2017, 1, 83-88.	0.2	4
2672	Driver genes in non-small cell lung cancer: Characteristics, detection methods, and targeted therapies. <i>Oncotarget</i> , 2017, 8, 57680-57692.	0.8	62
2673	Toxicity of Checkpoint Inhibition in Advanced RCC: A Systematic Review. <i>Kidney Cancer</i> , 2017, 1, 133-141.	0.2	9
2674	Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer. <i>Oncotarget</i> , 2017, 8, 8738-8751.	0.8	129
2675	PD-1 targeted Immunotherapy as first-line therapy for advanced non-small-cell lung cancer patients. <i>Journal of Thoracic Disease</i> , 2017, 9, E384-E386.	0.6	17
2676	Correlation of cancer stem cell markers and immune cell markers in resected non-small cell lung cancer. <i>Journal of Cancer</i> , 2017, 8, 3190-3197.	1.2	11

#	ARTICLE	IF	CITATIONS
2677	Comparative effectiveness and safety of nab-paclitaxel plus carboplatin vs gemcitabine plus carboplatin in first-line treatment of advanced squamous cell non-small cell lung cancer in a US community oncology setting. <i>Lung Cancer: Targets and Therapy</i> , 2017, Volume 8, 179-190.	1.3	6
2678	PD-L1 Expression Is Associated with FOXP3+ Regulatory T-Cell Infiltration of Soft Tissue Sarcoma and Poor Patient Prognosis. <i>Journal of Cancer</i> , 2017, 8, 2018-2025.	1.2	80
2679	Primary pancreatic lymphoma: two case reports and a literature review. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 1687-1694.	1.0	17
2680	PD1 signal transduction pathways in T cells. <i>Oncotarget</i> , 2017, 8, 51936-51945.	0.8	191
2681	The coexpression of multi-immune inhibitory receptors on T lymphocytes in primary non-small-cell lung cancer. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 3367-3376.	2.0	6
2682	Safety and efficacy profile of pembrolizumab in solid cancer: pooled reanalysis based on randomized controlled trials. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 2851-2860.	2.0	34
2683	Spotlight on nivolumab in the treatment of renal cell carcinoma: design, development, and place in therapy. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 1175-1182.	2.0	14
2684	Altered status of programmed death-ligand 1 after recurrence in resected lung adenocarcinoma patients. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 2003-2007.	1.0	5
2685	Fc&gamma;RIIA and III A polymorphisms predict clinical outcome of trastuzumab-treated metastatic gastric cancer. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 5065-5076.	1.0	11
2686	PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1331.	1.8	60
2687	Tumor location impacts immune response in mouse models of colon cancer. <i>Oncotarget</i> , 2017, 8, 54775-54787.	0.8	75
2688	Overcoming Oncogenic Mediated Tumor Immunity in Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1542.	1.8	25
2689	Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies. <i>Oncotarget</i> , 2017, 8, 44960-44975.	0.8	82
2690	New prognostic biomarkers and therapeutic effect of bevacizumab for patients with non-small-cell lung cancer. <i>Lung Cancer: Targets and Therapy</i> , 2017, Volume 8, 91-99.	1.3	14
2691	Structural basis of the therapeutic anti-PD-L1 antibody atezolizumab. <i>Oncotarget</i> , 2017, 8, 90215-90224.	0.8	68
2692	NANOG as an adverse predictive marker in advanced non-small cell lung cancer treated with platinum-based chemotherapy. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 4625-4633.	1.0	20
2693	Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma. <i>Oncolytic Virotherapy</i> , 2017, Volume 6, 11-18.	6.0	32
2694	An Archaeosome-Adjuvanted Vaccine and Checkpoint Inhibitor Therapy Combination Significantly Enhances Protection from Murine Melanoma. <i>Vaccines</i> , 2017, 5, 38.	2.1	14

#	ARTICLE	IF	CITATIONS
2695	PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes. <i>Medical Science Monitor</i> , 2017, 23, 1208-1216.	0.5	49
2696	Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials. <i>Oncotarget</i> , 2017, 8, 8910-8920.	0.8	108
2697	Immune Checkpoint Inhibition and the Prevalence of Autoimmune Disorders Among Patients With Lung and Renal Cancer. <i>Cancer Informatics</i> , 2017, 16, 117693511771252.	0.9	13
2698	Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells. <i>Oncotarget</i> , 2017, 8, 72167-72181.	0.8	221
2699	Locoregional and systemic therapy for hepatocellular carcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 215-228.	0.6	64
2700	Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence <i>in situ</i> hybridization (FISH) to select the optimal patients for matched therapy?. <i>Oncotarget</i> , 2017, 8, 100863-100898.	0.8	16
2701	Development and Application of Cancer Stem Cell-Targeted Vaccine in Cancer Immunotherapy. <i>Journal of Vaccines & Vaccination</i> , 2017, 08, .	0.3	7
2702	Evidence from a meta-analysis: is nivolumab neurotoxic in cancer patients?. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 1335-1344.	1.0	3
2703	Survival significance of epidermal growth factor receptor tyrosine kinase inhibitors and current staging system for survival after recurrence in patients with completely resected lung adenocarcinoma. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 4135-4141.	1.0	1
2704	Plasma fibrinogen and serum albumin levels (FA score) act as a promising prognostic indicator in non-small cell lung cancer. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 3107-3118.	1.0	21
2705	First-line treatment of metastatic melanoma: role of nivolumab. <i>ImmunoTargets and Therapy</i> , 2017, Volume 6, 1-10.	2.7	26
2706	Nuclear Molecular Imaging Strategies in Immune Checkpoint Inhibitor Therapy. <i>Diagnostics</i> , 2017, 7, 23.	1.3	13
2707	Reasons for Lack of Referral to Medical Oncology for Systemic Therapy in Stage Iv Non-small-cell Lung Cancer: Comparison of 2003â€“2006 with 2010â€“2011. <i>Current Oncology</i> , 2017, 24, 486-493.	0.9	13
2708	Hepatocyte Growth Factor, a Key Tumor-Promoting Factor in the Tumor Microenvironment. <i>Cancers</i> , 2017, 9, 35.	1.7	85
2709	Programmed cell death ligand 1 protein levels predicted survival of non-small cell lung cancer. <i>Journal of Cancer</i> , 2017, 8, 4075-4082.	1.2	7
2710	Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade. <i>Oncotarget</i> , 2017, 8, 110693-110707.	0.8	115
2711	PD-1 blockade restores impaired function of ex vivo expanded CD8⁺ T cells and enhances apoptosis in mismatch repair deficient EpCAM⁺PD-L1⁺ cancer cells. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 3453-3465.	1.0	24
2712	Programmed cell death 1 checkpoint inhibitors in the treatment of patients with advanced melanoma. <i>Wspolczesna Onkologia</i> , 2017, 1, 1-5.	0.7	12

#	ARTICLE	IF	CITATIONS
2713	Management of intracranial melanomas in the era of precision medicine. <i>Oncotarget</i> , 2017, 8, 89326-89347.	0.8	16
2714	Mental Health Services Use by Melanoma Patients Receiving Adjuvant Interferon: Association of Pre-treatment Mental Health Care with Early Discontinuation. <i>Current Oncology</i> , 2017, 24, 503-512.	0.9	2
2715	Real-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: A systematic review of recently published studies. <i>PLoS ONE</i> , 2017, 12, e0175679.	1.1	68
2716	PD-1 and its ligands are important immune checkpoints in cancer. <i>Oncotarget</i> , 2017, 8, 2171-2186.	0.8	234
2717	Immune Checkpoint Inhibitors in the Cancer Patient with An Organ Transplant. <i>Journal of Onco-Nephrology</i> , 2017, 1, 42-48.	0.3	21
2718	Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors. <i>Oncotarget</i> , 2017, 8, 41641-41669.	0.8	15
2719	Case Report. Extracorporeal Membrane Oxygenation in Nivolumab Associated Pneumonitis. <i>The Journal of Critical Care Medicine</i> , 2017, 3, 84-88.	0.3	0
2720	Comparative efficacy and safety of immune checkpoint inhibitor-related therapies for advanced melanoma: a Bayesian network analysis. <i>Oncotarget</i> , 2017, 8, 83637-83649.	0.8	7
2721	From targeting the tumor to targeting the immune system: Transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis. <i>World Journal of Clinical Oncology</i> , 2017, 8, 37.	0.9	64
2722	Recurrent glioma clinical trial, CheckMate-143: the game is not over yet. <i>Oncotarget</i> , 2017, 8, 91779-91794.	0.8	298
2723	Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment. <i>Oncotarget</i> , 2017, 8, 8890-8899.	0.8	48
2724	Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers. <i>Oncotarget</i> , 2017, 8, 41932-41946.	0.8	95
2725	NLRP3 inflammasome activation plays a carcinogenic role through effector cytokine IL-18 in lymphoma. <i>Oncotarget</i> , 2017, 8, 108571-108583.	0.8	47
2726	Association between PD-L1 expression combined with tumor-infiltrating lymphocytes and the prognosis of patients with advanced hypopharyngeal squamous cell carcinoma. <i>Oncotarget</i> , 2017, 8, 92699-92714.	0.8	29
2727	Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3. <i>Journal of Clinical Oncology</i> , 2017, 35, 3322-3329.	0.8	204
2728	Potential Risk Factors for Nivolumab-induced Thyroid Dysfunction. <i>In Vivo</i> , 2017, 31, 1225-1228.	0.6	14
2729	Drug-Related Pneumonitis in the Era of Precision Cancer Therapy. <i>JCO Precision Oncology</i> , 2017, 1, 1-12.	1.5	35
2730	Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 3851-3858.	0.8	384

#	ARTICLE	IF	CITATIONS
2731	Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials. <i>Journal of Clinical Oncology</i> , 2017, 35, 3807-3814.	0.8	364
2732	Hypermutation and microsatellite instability in gastrointestinal cancers. <i>Oncotarget</i> , 2017, 8, 112103-112115.	0.8	69
2733	Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). <i>Journal of Clinical Oncology</i> , 2017, 35, 2781-2789.	0.8	348
2734	Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and Tj ETQq1 1 0784314 rgt /Over	0.8	341
2735	Microenvironmental regulation of the progression of oral potentially malignant disorders towards malignancy. <i>Oncotarget</i> , 2017, 8, 81617-81635.	0.8	17
2736	Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 1542-1549.	0.8	527
2737	Overcoming resistance to targeted therapy with immunotherapy and combination therapy for metastatic melanoma. <i>Oncotarget</i> , 2017, 8, 75675-75686.	0.8	42
2738	Reaffirming and Clarifying the American Society of Clinical Oncology's Policy Statement on the Critical Role of Phase I Trials in Cancer Research and Treatment. <i>Journal of Clinical Oncology</i> , 2017, 35, 139-140.	0.8	22
2739	South African Breast Cancer and HIV Outcomes Study: Methods and Baseline Assessment. <i>Journal of Global Oncology</i> , 2017, 3, 114-124.	0.5	32
2740	Developmental therapeutics for inflammatory breast cancer: Biology and translational directions. <i>Oncotarget</i> , 2017, 8, 12417-12432.	0.8	24
2741	The role of novel immunotherapies in non-Hodgkin lymphoma. <i>Translational Cancer Research</i> , 2017, 6, 93-103.	0.4	26
2742	Positive PD-L1 Expression Predicts Worse Outcome in Cutaneous Angiosarcoma. <i>Journal of Global Oncology</i> , 2017, 3, 360-369.	0.5	34
2743	Risk of cumulative toxicity after complete melanoma response with pembrolizumab. <i>BMJ Case Reports</i> , 2017, 2017, bcr2016218308.	0.2	5
2744	PD-1/PD-L1 interaction up-regulates MDR1/P-gp expression in breast cancer cells via PI3K/AKT and MAPK/ERK pathways. <i>Oncotarget</i> , 2017, 8, 99901-99912.	0.8	78
2745	Improving anti-melanoma effect of curcumin by biodegradable nanoparticles. <i>Oncotarget</i> , 2017, 8, 108624-108642.	0.8	23
2746	Platelet-lymphocyte ratio acts as an indicator of poor prognosis in patients with breast cancer. <i>Oncotarget</i> , 2017, 8, 1023-1030.	0.8	58
2747	Therapeutic management options for stage III non-small cell lung cancer. <i>World Journal of Clinical Oncology</i> , 2017, 8, 1.	0.9	188
2748	EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer. <i>Oncotarget</i> , 2017, 8, 75712-75726.	0.8	119

#	ARTICLE	IF	CITATIONS
2749	Case Report of Extended Survival and Quality of Life in a Melanoma Patient with Multiple Brain Metastases and Review of Literature. <i>Cureus</i> , 2017, 9, e1947.	0.2	9
2750	Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies. <i>Oncotarget</i> , 2017, 8, 67129-67139.	0.8	65
2751	Predictive relevance of PD-L1 expression with pre-existing TILs in gastric cancer. <i>Oncotarget</i> , 2017, 8, 99372-99381.	0.8	22
2752	Immune system and melanoma biology: a balance between immunosurveillance and immune escape. <i>Oncotarget</i> , 2017, 8, 106132-106142.	0.8	174
2753	Altered follicular helper T cell impaired antibody production in a murine model of myelodysplastic syndromes. <i>Oncotarget</i> , 2017, 8, 98270-98279.	0.8	5
2754	The significance of programmed cell death ligand 1 expression in resected lung adenocarcinoma. <i>Oncotarget</i> , 2017, 8, 16421-16429.	0.8	50
2755	Emerging treatment options for the management of Hodgkin's lymphoma: clinical utility of Nivolumab. <i>Journal of Blood Medicine</i> , 2017, Volume 8, 41-54.	0.7	5
2756	CD207+/langerin positive dendritic cells in invasive and in situ cutaneous malignant melanoma. <i>Postepy Dermatologii i Alergologii</i> , 2017, 3, 233-239.	0.4	3
2757	Increased PD-L1 expression in erlotinib-resistant NSCLC cells with <i>MET</i> gene amplification is reversed upon MET-TKI treatment. <i>Oncotarget</i> , 2017, 8, 68221-68229.	0.8	31
2758	Biological agents in gastrointestinal cancers: adverse effects and their management. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 485-498.	0.6	24
2759	A mighty oak in the rapidly expanding field of checkpoint inhibition for NSCLC. <i>Journal of Thoracic Disease</i> , 2017, 9, E292-E294.	0.6	0
2760	Anti-PD-1/PD-L1 antibody versus conventional chemotherapy for previously-treated, advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials. <i>Journal of Thoracic Disease</i> , 2017, 9, 655-665.	0.6	15
2761	PD-L1 protein expression in non-small cell lung cancer based on different immunohistochemical antibodies. <i>Journal of Thoracic Disease</i> , 2017, 9, E470-E473.	0.6	3
2762	Durable complete response to nivolumab in a patient with HIV and metastatic non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2017, 9, E540-E542.	0.6	28
2763	Prognostic significance of sites of extrathoracic metastasis in patients with non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2017, 9, 1903-1910.	0.6	25
2764	Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy. <i>Journal of Thoracic Disease</i> , 2017, 9, 2142-2158.	0.6	92
2765	Unique distribution of programmed death ligand 1 (PD-L1) expression in East Asian non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2017, 9, 2579-2586.	0.6	51
2766	Anti-cancer activity of dose-fractioned mPE +/â bevacizumab regimen is paralleled by immune-modulation in advanced squamous NSLC patients. <i>Journal of Thoracic Disease</i> , 2017, 9, 3123-3131.	0.6	18

#	ARTICLE	IF	CITATIONS
2767	The role of an immune checkpoint score in resected non-small cell lung cancer patients's prognosis. <i>Journal of Thoracic Disease</i> , 2017, 9, 3480-3482.	0.6	1
2768	KEYNOTE-010: flash of a supernova (immune-checkpoint inhibitors) in second-line non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2017, 9, 4187-4190.	0.6	4
2769	Tumor-associated macrophages' additional effectors at anti-PD-1/PD-L1 therapy?. <i>Journal of Thoracic Disease</i> , 2017, 9, 4197-4200.	0.6	5
2770	Complete resection of the primary lesion improves survival of certain patients with stage IV non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2017, 9, 5278-5287.	0.6	15
2771	Predictive biomarkers of immunotherapy for non-small cell lung cancer: results from an Experts Panel Meeting of the Italian Association of Thoracic Oncology. <i>Translational Lung Cancer Research</i> , 2017, 6, 373-386.	1.3	45
2772	Biology and clinical significance of circulating tumor cell subpopulations in lung cancer. <i>Translational Lung Cancer Research</i> , 2017, 6, 431-443.	1.3	25
2773	Immunohistochemistry for predictive biomarkers in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2017, 6, 570-587.	1.3	42
2774	Epidermal growth factor tyrosine kinase inhibitor therapy inferior to second-line chemotherapy in EGFR wild-type non-small cell lung cancer patients: results of French nationwide observational study. <i>Translational Lung Cancer Research</i> , 2017, 6, S39-S40.	1.3	5
2775	Immunotherapy for malignant pleural mesothelioma: current status and future directions. <i>Translational Lung Cancer Research</i> , 2017, 6, 315-324.	1.3	30
2776	Prognostic significance of PD-L1 expression and tumor infiltrating lymphocyte in surgically resectable non-small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 83986-83994.	0.8	69
2777	Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progression. <i>Oncotarget</i> , 2017, 8, 24031-24044.	0.8	77
2778	Genetic and immune features of resectable malignant brainstem gliomas. <i>Oncotarget</i> , 2017, 8, 82571-82582.	0.8	12
2779	Immune checkpoint blockade for hematologic malignancies: a review. <i>Stem Cell Investigation</i> , 2017, 4, 32-32.	1.3	59
2780	Next generation sequencing identifies 'interactome' signatures in relapsed and refractory metastatic colorectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 20-31.	0.6	14
2781	An elderly man with remote history of metastatic melanoma now with localized pancreas cancer and new liver masses. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 596-602.	0.6	0
2782	Checkpoint inhibitors in metastatic epidermal growth factor receptor-mutated non-small cell lung cancer patients: where we treating the wrong cancer?. <i>Journal of Thoracic Disease</i> , 2017, 9, 2771-2773.	0.6	3
2783	Moving more potent and less toxic options to the frontline in the management of advanced lung cancer. <i>Journal of Thoracic Disease</i> , 2017, 9, 2812-2818.	0.6	1
2784	Comments on the trial of cisplatin and etoposide plus thoracic radiotherapy followed by nivolumab or placebo for locally advanced non-small cell lung cancer (RTOG 3505). <i>Journal of Thoracic Disease</i> , 2017, 9, 3525-3528.	0.6	0

#	ARTICLE	IF	CITATIONS
2785	Optimal pembrolizumab dosing for non-small cell lung cancer: further studies still needed. <i>Journal of Thoracic Disease</i> , 2017, 9, 4821-4824.	0.6	13
2786	Locally advanced non-small cell lung cancer treatment: another step forward. <i>Journal of Thoracic Disease</i> , 2017, 9, 4908-4911.	0.6	4
2787	Pembrolizumab in advanced pretreated small cell lung cancer patients with PD-L1 expression: data from the KEYNOTE-028 trial: a reason for hope?. <i>Translational Lung Cancer Research</i> , 2017, 6, S78-S83.	1.3	9
2788	Reproducibility of PD-L1 assessment in non-small cell lung cancer—know your limits but never stop trying to exceed them. <i>Translational Lung Cancer Research</i> , 2017, 6, S51-S54.	1.3	12
2789	Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed/refractory patients. <i>Blood Advances</i> , 2017, 1, 455-466.	2.5	54
2790	Avelumab: another active immune checkpoint inhibitor in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2017, 6, S41-S43.	1.3	2
2791	Atorvastatin downregulates co-inhibitory receptor expression by targeting Ras-activated mTOR signalling. <i>Oncotarget</i> , 2017, 8, 98215-98232.	0.8	30
2792	Bilateral uveitis associated with nivolumab therapy for metastatic melanoma: a case report. <i>International Journal of Ophthalmology</i> , 2017, 10, 1183-1186.	0.5	22
2793	PD-L1 expression heterogeneity in non-small cell lung cancer: evaluation of small biopsies reliability. <i>Oncotarget</i> , 2017, 8, 90123-90131.	0.8	89
2794	Robust detection of immune transcripts in FFPE samples using targeted RNA sequencing. <i>Oncotarget</i> , 2017, 8, 3197-3205.	0.8	53
2795	Combined prognostic effect of PD-L1 expression and immunoscore in microsatellite-unstable advanced gastric cancers. <i>Oncotarget</i> , 2017, 8, 58887-58902.	0.8	22
2796	Targeting Melanoma with Cancer-Killing Viruses. <i>The Open Virology Journal</i> , 2017, 11, 28-47.	1.8	8
2797	A novel bispecific c-MET/PD-1 antibody with therapeutic potential in solid cancer. <i>Oncotarget</i> , 2017, 8, 29067-29079.	0.8	29
2798	High-affinity human PD-L1 variants attenuate the suppression of T cell activation. <i>Oncotarget</i> , 2017, 8, 88360-88375.	0.8	30
2799	Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy. <i>Oncotarget</i> , 2017, 8, 77415-77423.	0.8	68
2800	Genotypic and phenotypic signatures to predict immune checkpoint blockade therapy response in patients with colorectal cancer. <i>Translational Research</i> , 2018, 196, 62-70.	2.2	9
2801	Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials. <i>British Journal of Cancer</i> , 2018, 118, 763-769.	2.9	28
2802	Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice. <i>Cell Research</i> , 2018, 28, 433-447.	5.7	91

#	ARTICLE	IF	CITATIONS
2803	Immunohistochemical analysis and prognostic significance of PD-L1, PD-1, and CD8+ tumor-infiltrating lymphocytes in Ewing's sarcoma family of tumors (ESFT). <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 472, 815-824.	1.4	53
2804	The concentration of programmed cell death-ligand 1 in the peripheral blood is a useful biomarker for esophageal squamous cell carcinoma. <i>Esophagus</i> , 2018, 15, 103-108.	1.0	14
2805	Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1-Specific VHHs. <i>Cancer Immunology Research</i> , 2018, 6, 389-401.	1.6	68
2806	Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers. <i>JAMA Oncology</i> , 2018, 4, 522.	3.4	92
2807	Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGF β 2 enhance the efficacy of cancer immunotherapy. <i>Nature Communications</i> , 2018, 9, 741.	5.8	238
2808	Antitumor activity of kinetochore-associated protein 2 siRNA against lung cancer patient-derived tumor xenografts. <i>Oncology Letters</i> , 2018, 15, 4676-4682.	0.8	2
2809	Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy. <i>Cancer Letters</i> , 2018, 419, 210-221.	3.2	251
2810	ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint) <i>Trends Microbiol</i> , 2018, 26, 103-114.	2.8	96
2811	Immune Checkpoint Inhibition in Hodgkin Lymphoma. <i>HemaSphere</i> , 2018, 2, e20.	1.2	15
2812	Combined laparoscopic abdomino-endoscopic perineal total mesorectal excision for anorectal malignant melanoma: A case report. <i>International Journal of Surgery Case Reports</i> , 2018, 44, 135-138.	0.2	4
2813	Higher than reported adolescent and young adult clinical trial enrollment during the "Golden Age" of melanoma clinical trials. <i>Cancer Medicine</i> , 2018, 7, 991-996.	1.3	12
2814	Incidence and Management of Immune-Related Adverse Events in Patients Undergoing Treatment with Immune Checkpoint Inhibitors. <i>Current Oncology Reports</i> , 2018, 20, 24.	1.8	35
2815	PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC. <i>British Journal of Cancer</i> , 2018, 118, 820-824.	2.9	190
2816	Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma. <i>Cancer Medicine</i> , 2018, 7, 690-697.	1.3	90
2817	Prognostic Significance of Platelet-Based Inflammatory Indicators in Patients with Gastric Cancer. <i>World Journal of Surgery</i> , 2018, 42, 2542-2550.	0.8	22
2818	Cutaneous Manifestations of Reactions to Biologics. <i>Current Allergy and Asthma Reports</i> , 2018, 18, 12.	2.4	6
2819	PD-1 is required to maintain stem cell properties in human dental pulp stem cells. <i>Cell Death and Differentiation</i> , 2018, 25, 1350-1360.	5.0	31
2820	Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials. <i>Cancer</i> , 2018, 124, 2010-2017.	2.0	81

#	ARTICLE	IF	CITATIONS
2821	Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer. <i>Molecular Cancer</i> , 2018, 17, 38.	7.9	489
2822	Analysis of middle- and long-term efficacy of thoracoscope-assisted segmental resection of the lung on non-small cell lung cancer in the early stage. <i>Oncology Letters</i> , 2018, 15, 3662-3668.	0.8	1
2823	Checkpoint Inhibitors in Breast Cancer - Current Status and Future Directions. <i>Breast Care</i> , 2018, 13, 27-31.	0.8	8
2824	Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1 ⁺ Tim-3 ⁺ CD8 ⁺ T Cells. <i>Journal of Visualized Experiments</i> , 2018, , .	0.2	14
2825	Systemic immune-inflammation index in germ-cell tumours. <i>British Journal of Cancer</i> , 2018, 118, 831-838.	2.9	70
2826	PD-L1 inhibition with avelumab for metastatic Merkel cell carcinoma. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 345-359.	1.3	27
2827	Imaging in neuro-oncology. <i>Therapeutic Advances in Neurological Disorders</i> , 2018, 11, 175628641875986.	1.5	41
2828	Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update. <i>International Journal of Clinical Oncology</i> , 2018, 23, 410-420.	1.0	50
2829	Development of Molecularly Targeted Agents and Immunotherapies in Glioblastoma: A Personalized Approach. <i>Clinical Medicine Insights: Oncology</i> , 2018, 12, 117955491875907.	0.6	4
2830	Differentially expressed and survival-related proteins of lung adenocarcinoma with bone metastasis. <i>Cancer Medicine</i> , 2018, 7, 1081-1092.	1.3	37
2831	Successful Treatment of Nivolumab-Resistant Multiple In-Transit Melanomas with Ipilimumab and Topical Imiquimod. <i>Case Reports in Oncology</i> , 2018, 11, 1-5.	0.3	9
2832	Sustained Persistence of IL2 Signaling Enhances the Antitumor Effect of Peptide Vaccines through T-cell Expansion and Preventing PD-1 Inhibition. <i>Cancer Immunology Research</i> , 2018, 6, 617-627.	1.6	13
2833	Combination Cancer Immunotherapy in Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2018, 7, 20-27.	4.2	55
2834	ERK5 is activated by oncogenic BRAF and promotes melanoma growth. <i>Oncogene</i> , 2018, 37, 2601-2614.	2.6	50
2835	Prostaglandin E ₂ Induction Suppresses the Th1 Immune Responses in Cattle with Johne's Disease. <i>Infection and Immunity</i> , 2018, 86, .	1.0	26
2836	Recent progress in Lynch syndrome and other familial colorectal cancer syndromes. <i>Ca-A Cancer Journal for Clinicians</i> , 2018, 68, 217-231.	157.7	117
2837	BET proteins in abnormal metabolism, inflammation, and the breast cancer microenvironment. <i>Journal of Leukocyte Biology</i> , 2018, 104, 265-274.	1.5	29
2838	Tumor Immunology and Immunotherapy for Head and Neck Squamous Cell Carcinoma. <i>Journal of Dental Research</i> , 2018, 97, 622-626.	2.5	16

#	ARTICLE	IF	CITATIONS
2839	Second-Line Treatment Landscape for Renal Cell Carcinoma: A Comprehensive Review. <i>Oncologist</i> , 2018, 23, 540-555.	1.9	57
2840	Fall in thyroid stimulating hormone (TSH) may be an early marker of ipilimumab-induced hypophysitis. <i>Pituitary</i> , 2018, 21, 274-282.	1.6	25
2841	Improving immunotherapy for colorectal cancer using dendritic cells combined with anti-programmed death-ligand in vitro. <i>Oncology Letters</i> , 2018, 15, 5345-5351.	0.8	10
2842	Combination nivolumab with transcatheter arterial chemoembolization for clinical remission of small cell lung cancer: A case report. <i>Thoracic Cancer</i> , 2018, 9, 646-651.	0.8	4
2843	Melanoma Immunotherapy in the Elderly. <i>Current Oncology Reports</i> , 2018, 20, 20.	1.8	16
2844	Computationally-Guided Development of a Stromal Inflammation Histologic Biomarker in Lung Squamous Cell Carcinoma. <i>Scientific Reports</i> , 2018, 8, 3941.	1.6	11
2845	The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression. <i>Clinical Cancer Research</i> , 2018, 24, 3366-3376.	3.2	73
2846	IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma. <i>Clinical Cancer Research</i> , 2018, 24, 2559-2573.	3.2	147
2847	Immunotherapy for Head and Neck Squamous Cell Carcinoma. <i>Current Oncology Reports</i> , 2018, 20, 22.	1.8	131
2848	PD-L1 testing using the clone 22C3 pharmDx kit for selection of patients with non-small cell lung cancer to receive immune checkpoint inhibitor therapy: are cytology cell blocks a viable option?. <i>Journal of the American Society of Cytopathology</i> , 2018, 7, 133-141.	0.2	56
2849	Toxic epidermal necrolysis (TEN) associated with the use of nivolumab (PD-1 inhibitor) for lymphoma. <i>JAAD Case Reports</i> , 2018, 4, 229-231.	0.4	41
2850	Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy. <i>Journal of Immunotherapy</i> , 2018, 41, 284-291.	1.2	11
2851	Analysis of PD-1 and Tim-3 expression on CD4+ T cells of patients with rheumatoid arthritis; negative association with DAS28. <i>Clinical Rheumatology</i> , 2018, 37, 2063-2071.	1.0	14
2852	Association between programmed cell death ligand-1 expression and extracranial metastasis in intracranial solitary fibrous tumor/hemangiopericytoma. <i>Journal of Neuro-Oncology</i> , 2018, 139, 251-259.	1.4	16
2853	Pitfalls in the radiological response assessment of immunotherapy. <i>Memo - Magazine of European Medical Oncology</i> , 2018, 11, 138-143.	0.3	59
2854	Outcomes of Adoptive Cell Transfer With Tumor-infiltrating Lymphocytes for Metastatic Melanoma Patients With and Without Brain Metastases. <i>Journal of Immunotherapy</i> , 2018, 41, 241-247.	1.2	40
2855	Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials. <i>Lung Cancer</i> , 2018, 120, 137-141.	0.9	29
2856	New Therapies in Head and Neck Cancer. <i>Trends in Cancer</i> , 2018, 4, 385-396.	3.8	50

#	ARTICLE	IF	CITATIONS
2857	A Dual Immunotherapy Nanoparticle Improves Tâ€Cell Activation and Cancer Immunotherapy. <i>Advanced Materials</i> , 2018, 30, e1706098.	11.1	130
2858	The expression profile of PD-L1 and CD8+ lymphocyte in pituitary adenomas indicating for immunotherapy. <i>Journal of Neuro-Oncology</i> , 2018, 139, 89-95.	1.4	69
2859	Generalization and representativeness of phase III immune checkpoint blockade trials in nonâ€small cell lung cancer. <i>Thoracic Cancer</i> , 2018, 9, 736-744.	0.8	31
2860	Gender and outcomes in non-small cell lung cancer: an old prognostic variable comes back for targeted therapy and immunotherapy?. <i>ESMO Open</i> , 2018, 3, e000344.	2.0	105
2861	Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab. <i>Clinical Cancer Research</i> , 2018, 24, 4960-4967.	3.2	222
2862	Relapsed Myasthenia Gravis after Nivolumab Treatment. <i>Internal Medicine</i> , 2018, 57, 1893-1897.	0.3	32
2863	Adjuvant immunotherapy for cancer: both dendritic cell-priming and check-point inhibitor blockade are required for immunotherapy. <i>Proceedings of the Japan Academy Series B: Physical and Biological Sciences</i> , 2018, 94, 153-160.	1.6	25
2864	Emerging Systemic Therapies for Colorectal Cancer. <i>Clinics in Colon and Rectal Surgery</i> , 2018, 31, 179-191.	0.5	26
2865	Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. <i>New England Journal of Medicine</i> , 2018, 378, 1976-1986.	13.9	1,495
2866	Tumor molecular profiling of responders and non-responders following pembrolizumab monotherapy in chemotherapy resistant advanced cervical cancer. <i>Gynecologic Oncology Reports</i> , 2018, 24, 1-5.	0.3	10
2867	Next generation antibody drugs: pursuit of the 'high-hanging fruit'. <i>Nature Reviews Drug Discovery</i> , 2018, 17, 197-223.	21.5	595
2868	Tumour necrosis factor, interferon-gamma and interleukins as predictive markers of antiprogrammed cell-death protein-1 treatment in advanced non-small cell lung cancer: a pragmatic approach in clinical practice. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591876823.	1.4	78
2869	Melanoma: What do all the mutations mean?. <i>Cancer</i> , 2018, 124, 3490-3499.	2.0	131
2870	Elimination of established tumors with nanodisc-based combination chemoimmunotherapy. <i>Science Advances</i> , 2018, 4, eaao1736.	4.7	269
2871	Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer?. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591876209.	1.4	102
2872	PD-L1 expression testing in non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591876349.	1.4	120
2873	Radiotherapy and checkpoint inhibitors: a winning new combination?. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591876824.	1.4	87
2874	Quo Vadisâ€Do Immunotherapies Have a Role in Glioblastoma?. <i>Current Treatment Options in Neurology</i> , 2018, 20, 14.	0.7	22

#	ARTICLE	IF	CITATIONS
2875	Association of Immune-Mediated Cerebellitis With Immune Checkpoint Inhibitor Therapy. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2018, 2, 74-77.	1.2	30
2876	Skin Diseases in the Immunosuppressed. , 2018, , .		2
2877	Concordance measure and discriminatory accuracy in transformation cure models. <i>Biostatistics</i> , 2018, 19, 14-26.	0.9	20
2878	ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. <i>Lancet Oncology, The</i> , 2018, 19, 694-704.	5.1	310
2879	Baricitinib-induced blockade of interferon gamma receptor and interleukin-6 receptor for the prevention and treatment of graft-versus-host disease. <i>Leukemia</i> , 2018, 32, 2483-2494.	3.3	61
2880	Cutaneous Malignancies in Solid Organ Transplant Recipients. , 2018, , 91-116.		0
2881	Nivolumab-induced acute granulomatous tubulointerstitial nephritis in a patient with gastric cancer. <i>Investigational New Drugs</i> , 2018, 36, 726-731.	1.2	17
2882	Antitumor activity of CD56-chimeric antigen receptor T cells in neuroblastoma and SCLC models. <i>Oncogene</i> , 2018, 37, 3686-3697.	2.6	45
2883	Clinical assessment of immune-related adverse events. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591876462.	1.4	101
2884	Pembrolizumab and its role in relapsed/refractory classical Hodgkinâ€™s lymphoma: evidence to date and clinical utility. <i>Therapeutic Advances in Hematology</i> , 2018, 9, 89-105.	1.1	13
2885	Pharmacology behind Common Drug Nephrotoxicities. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 1897-1908.	2.2	148
2886	Science and biology drives the immune system to cure lung cancer patients: a revolution but not without challenges. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591876372.	1.4	3
2887	Bispecific antibodies in cancer immunotherapy. , 2018, 6, 3-17.	1.4	157
2888	Tumor lysate-based vaccines: on the road to immunotherapy for gallbladder cancer. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1897-1910.	2.0	42
2889	MicroRNA-374b inhibits liver cancer progression via down regulating programmed cell death-1 expression on cytokine-induced killer cells. <i>Oncology Letters</i> , 2018, 15, 4797-4804.	0.8	29
2890	Overcoming Tumor-Induced Immune Suppression: From Relieving Inhibition to Providing Costimulation with T Cell Agonists. <i>BioDrugs</i> , 2018, 32, 221-231.	2.2	22
2891	Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. <i>Cancer Cell</i> , 2018, 33, 843-852.e4.	7.7	827
2892	PD-1/PD-L1 pathway inhibitors in advanced prostate cancer. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 475-486.	1.3	83

#	ARTICLE	IF	CITATIONS
2893	STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591876374.	1.4	30
2894	Cardiotoxicity of Immunotherapy: Incidence, Diagnosis, and Management. <i>Current Oncology Reports</i> , 2018, 20, 44.	1.8	53
2895	Role of PD-1 during effector CD8 T cell differentiation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 4749-4754.	3.3	327
2896	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Central Nervous System Metastases from Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2018, 23, 1199-1209.	1.9	42
2897	Tumor cell-intrinsic Tim-3 promotes liver cancer via NF- κ B/IL-6/STAT3 axis. <i>Oncogene</i> , 2018, 37, 2456-2468.	2.6	54
2898	Nab-paclitaxel plus carboplatin as an effective and safe chemotherapy regimen for pulmonary carcinosarcoma with interstitial lung disease: A case report. <i>Respiratory Medicine Case Reports</i> , 2018, 23, 131-135.	0.2	2
2899	Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 2467-2472.	3.3	131
2900	Cloning and expansion of antigen-specific T cells using iPS cell technology: development of "off-the-shelf" T cells for the use in allogeneic transfusion settings. <i>International Journal of Hematology</i> , 2018, 107, 271-277.	0.7	21
2901	Unleashing the tiger "iatrogenic autoimmunity from cancer immunotherapy drugs. <i>JRSM Open</i> , 2018, 9, 205427041774690.	0.2	3
2902	Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and Management. <i>Current Neurology and Neuroscience Reports</i> , 2018, 18, 3.	2.0	83
2903	Blockade of CCL2 enhances immunotherapeutic effect of anti-PD1 in lung cancer. <i>Journal of Bone Oncology</i> , 2018, 11, 27-32.	1.0	63
2904	Inhibition of the checkpoint protein PD-1 by the therapeutic antibody pembrolizumab outlined by quantum chemistry. <i>Scientific Reports</i> , 2018, 8, 1840.	1.6	33
2905	Systemic treatments for metastatic cutaneous melanoma. <i>The Cochrane Library</i> , 2020, 2020, CD011123.	1.5	136
2906	Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection. <i>British Journal of Cancer</i> , 2018, 118, 679-697.	2.9	17
2907	Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302). <i>British Journal of Cancer</i> , 2018, 118, 654-661.	2.9	192
2908	Temozolomide-associated hypermutation in gliomas. <i>Neuro-Oncology</i> , 2018, 20, 1300-1309.	0.6	130
2909	Current state and future prospects of immunotherapy for glioma. <i>Immunotherapy</i> , 2018, 10, 317-339.	1.0	60
2910	Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab. <i>International Journal of Clinical Oncology</i> , 2018, 23, 634-640.	1.0	103

#	ARTICLE	IF	CITATIONS
2911	Immune Checkpoint Blockade: The New Frontier in Cancer Treatment. <i>Targeted Oncology</i> , 2018, 13, 1-20.	1.7	31
2912	Chemotherapy and immunotherapy for recurrent and metastatic head and neck cancer: a systematic review. <i>Medical Oncology</i> , 2018, 35, 37.	1.2	52
2913	IL-2 and Beyond in Cancer Immunotherapy. <i>Journal of Interferon and Cytokine Research</i> , 2018, 38, 45-68.	0.5	83
2914	A Correlative Analysis of PD-L1, PD-1, PD-L2, EGFR, HER2, and HER3 Expression in Oropharyngeal Squamous Cell Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 710-716.	1.9	25
2915	Dextran Enhances the Lentiviral Transduction Efficiency of Murine and Human Primary NK Cells. <i>Journal of Visualized Experiments</i> , 2018, , .	0.2	7
2916	Cell death-based treatments of melanoma:conventional treatments and new therapeutic strategies. <i>Cell Death and Disease</i> , 2018, 9, 112.	2.7	94
2918	Cell death-based treatment of lung adenocarcinoma. <i>Cell Death and Disease</i> , 2018, 9, 117.	2.7	434
2919	Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2. <i>ESMO Open</i> , 2018, 3, e000283.	2.0	45
2920	Wide Expression and Significance of Alternative Immune Checkpoint Molecules, B7x and HHLA2, in PD-L1 ⁺ Negative Human Lung Cancers. <i>Clinical Cancer Research</i> , 2018, 24, 1954-1964.	3.2	64
2921	Current challenges for cancer vaccine adjuvant development. <i>Expert Review of Vaccines</i> , 2018, 17, 207-215.	2.0	111
2922	Acute Kidney Injury in Cancer Patients. <i>Contributions To Nephrology</i> , 2018, 193, 137-148.	1.1	18
2923	IDO1 in cancer: a Gemini of immune checkpoints. <i>Cellular and Molecular Immunology</i> , 2018, 15, 447-457.	4.8	266
2924	Unwrapping the genomic characteristics of urothelial bladder cancer and successes with immune checkpoint blockade therapy. <i>Oncogenesis</i> , 2018, 7, 2.	2.1	68
2925	Clinical Development of PD-1 in Advanced Melanoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2018, 24, 7-14.	1.0	37
2926	The structure, expression, and multifaceted role of immune-checkpoint protein VISTA as a critical regulator of anti-tumor immunity, autoimmunity, and inflammation. <i>Cellular and Molecular Immunology</i> , 2018, 15, 438-446.	4.8	88
2927	The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma. <i>Medical Oncology</i> , 2018, 35, 25.	1.2	124
2928	HER kinase inhibition in patients with HER2- and HER3-mutant cancers. <i>Nature</i> , 2018, 554, 189-194.	13.7	572
2929	Transcriptomic alterations during ageing reflect the shift from cancer to degenerative diseases in the elderly. <i>Nature Communications</i> , 2018, 9, 327.	5.8	94

#	ARTICLE	IF	CITATIONS
2930	Development of an Immune-Pathology Informed Radiomics Model for Non-Small Cell Lung Cancer. <i>Scientific Reports</i> , 2018, 8, 1922.	1.6	108
2931	Anti-“PD-1/anti-“CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8 ⁺ T cell trafficking. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E1540-E1549.	3.3	165
2932	Eradication of spontaneous malignancy by local immunotherapy. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	289
2933	Radiation effects on antitumor immune responses: current perspectives and challenges. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883401774257.	1.4	185
2934	Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883401774974.	1.4	200
2935	Evaluation of PD-L1/PD-1 on circulating tumor cells in patients with advanced non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883401775012.	1.4	61
2936	Treatment-Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE-001 at a Single Center. <i>Cancer Immunology Research</i> , 2018, 6, 288-294.	1.6	70
2937	Diverse cutaneous adverse eruptions caused by anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) immunotherapies: clinical features and management. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883401775163.	1.4	29
2938	Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management. <i>ESMO Open</i> , 2018, 3, e000278.	2.0	197
2939	Antitumor T-cell Reconditioning: Improving Metabolic Fitness for Optimal Cancer Immunotherapy. <i>Clinical Cancer Research</i> , 2018, 24, 2473-2481.	3.2	49
2940	Role of immune-checkpoint inhibitors in lung cancer. <i>Therapeutic Advances in Respiratory Disease</i> , 2018, 12, 175346581775007.	1.0	88
2941	Percentages of PD-1 ⁺ CD4 ⁺ T cells and PD-L1 ⁺ DCs are increased and sPD-1 level is elevated in patients with immune thrombocytopenia. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 832-838.	1.4	15
2943	Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis. <i>Lancet Oncology</i> , The, 2018, 19, 229-239.	5.1	111
2944	TUSC2 Immunogene Therapy Synergizes with Anti-“PD-1 through Enhanced Proliferation and Infiltration of Natural Killer Cells in Syngeneic <i>Kras</i> -Mutant Mouse Lung Cancer Models. <i>Cancer Immunology Research</i> , 2018, 6, 163-177.	1.6	30
2945	Established, emerging and elusive molecular targets in the treatment of lung cancer. <i>Journal of Pathology</i> , 2018, 244, 565-577.	2.1	15
2946	Modeling of Interactions between Cancer Stem Cells and their Microenvironment: Predicting Clinical Response. <i>Methods in Molecular Biology</i> , 2018, 1711, 333-349.	0.4	8
2947	A potential biomarker for anti-PD-1 immunotherapy. <i>Nature Medicine</i> , 2018, 24, 123-124.	15.2	23
2948	Myeloid-targeted immunotherapies act in synergy to induce inflammation and antitumor immunity. <i>Journal of Experimental Medicine</i> , 2018, 215, 877-893.	4.2	111

#	ARTICLE	IF	CITATIONS
2949	The Role of Immune Escape and Immune Cell Infiltration in Breast Cancer. <i>Breast Care</i> , 2018, 13, 16-21.	0.8	135
2950	Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies. <i>JAMA Oncology</i> , 2018, 4, 717.	3.4	229
2951	From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?. <i>Current Oncology Reports</i> , 2018, 20, 8.	1.8	20
2952	Emerging Biomarkers in Cutaneous Melanoma. <i>Molecular Diagnosis and Therapy</i> , 2018, 22, 203-218.	1.6	35
2953	Decitabine improve the efficiency of anti-PD-1 therapy via activating the response to IFN/PD-L1 signal of lung cancer cells. <i>Oncogene</i> , 2018, 37, 2302-2312.	2.6	57
2954	Anti-PD-L1 Treatment Induced Central Diabetes Insipidus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 365-369.	1.8	88
2955	Melanoma Brain Metastases: Local Therapies, Targeted Therapies, Immune Checkpoint Inhibitors and Their Combinations—Chances and Challenges. <i>American Journal of Clinical Dermatology</i> , 2018, 19, 529-541.	3.3	11
2956	Cancer Immunotherapy: Factors Important for the Evaluation of Safety in Nonclinical Studies. <i>AAPS Journal</i> , 2018, 20, 28.	2.2	13
2957	Regulatory T cells in renal disease. <i>Clinical and Translational Immunology</i> , 2018, 7, e1004.	1.7	42
2958	Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial. <i>Lancet Oncology</i> , The, 2018, 19, 405-415.	5.1	305
2959	Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer. <i>Scientific Reports</i> , 2018, 8, 2592.	1.6	81
2960	Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients. <i>Cancer Medicine</i> , 2018, 7, 746-756.	1.3	348
2961	Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. <i>Lancet Oncology</i> , The, 2018, 19, 310-322.	5.1	486
2962	Hypermutated Tumors and Immune Checkpoint Inhibition. <i>Drugs</i> , 2018, 78, 155-162.	4.9	22
2963	Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. <i>Lancet Oncology</i> , The, 2018, 19, 416-426.	5.1	517
2964	Increased diversity with reduced diversity evenness of tumor infiltrating T-cells for the successful cancer immunotherapy. <i>Scientific Reports</i> , 2018, 8, 1058.	1.6	51
2965	TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma. <i>ESMO Open</i> , 2018, 3, e000257.	2.0	62
2966	Checkpoint Inhibitors, Palliative Care, or Hospice. <i>Current Oncology Reports</i> , 2018, 20, 2.	1.8	8

#	ARTICLE	IF	CITATIONS
2967	Overexpression of adhesion molecules and barrier molecules is associated with differential infiltration of immune cells in non-small cell lung cancer. <i>Scientific Reports</i> , 2018, 8, 1023.	1.6	33
2968	Most medical practices are not parachutes: a citation analysis of practices felt by biomedical authors to be analogous to parachutes. <i>CMAJ Open</i> , 2018, 6, E31-E38.	1.1	27
2969	Exacerbation of autoimmune hemolytic anemia induced by the first dose of programmed death-1 inhibitor pembrolizumab: a case report. <i>Investigational New Drugs</i> , 2018, 36, 509-512.	1.2	24
2970	The differences in the assessments of side effects at an oncology outpatient clinic. <i>International Journal of Clinical Pharmacy</i> , 2018, 40, 386-393.	1.0	7
2971	Mechanisms of Resistance to PD-1 and PD-L1 Blockade. <i>Cancer Journal (Sudbury, Mass)</i> , 2018, 24, 47-53.	1.0	287
2972	Toxicities Associated With PD-1/PD-L1 Blockade. <i>Cancer Journal (Sudbury, Mass)</i> , 2018, 24, 36-40.	1.0	72
2973	PD-1/PD-L1 Axis in Lung Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2018, 24, 15-19.	1.0	61
2974	Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients. <i>Clinical and Translational Oncology</i> , 2018, 20, 1072-1079.	1.2	43
2975	The biology and management of non-small cell lung cancer. <i>Nature</i> , 2018, 553, 446-454.	13.7	2,877
2976	Immune-Active Microenvironment in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Rationale for Immune Checkpoint Blockade. <i>Journal of the National Cancer Institute</i> , 2018, 110, 787-790.	3.0	123
2977	Refractory thyroid carcinoma: which systemic treatment to use?. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883401775285.	1.4	18
2978	Ipilimumab for the treatment of metastatic prostate cancer. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 205-213.	1.4	14
2979	CD8+ T cells and NK cells: parallel and complementary soldiers of immunotherapy. <i>Current Opinion in Chemical Engineering</i> , 2018, 19, 9-20.	3.8	100
2980	Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions. <i>Future Oncology</i> , 2018, 14, 907-917.	1.1	112
2981	Combining radiotherapy and ipilimumab induces clinically relevant radiation-induced abscopal effects in metastatic melanoma patients: A systematic review. <i>Clinical and Translational Radiation Oncology</i> , 2018, 9, 5-11.	0.9	76
2982	Unique cytologic features of thyroiditis caused by immune checkpoint inhibitor therapy for malignant melanoma. <i>Genes and Diseases</i> , 2018, 5, 46-48.	1.5	53
2983	Diffuse granulomatous panniculitis associated with anti PD-1 antibody therapy. <i>JAAD Case Reports</i> , 2018, 4, 13-16.	0.4	13
2984	PD-1 Modulates Radiation-Induced Cardiac Toxicity through Cytotoxic T Lymphocytes. <i>Journal of Thoracic Oncology</i> , 2018, 13, 510-520.	0.5	77

#	ARTICLE	IF	CITATIONS
2985	Instrumented Spinal Stabilization without Fusion for Spinal Metastatic Disease. <i>World Neurosurgery</i> , 2018, 111, e403-e409.	0.7	16
2986	Affinity purification mass spectrometry analysis of PD-1 uncovers SAP as a new checkpoint inhibitor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E468-E477.	3.3	72
2987	Maturation of hematopoietic stem cells from prehematopoietic stem cells is accompanied by up-regulation of PD-L1. <i>Journal of Experimental Medicine</i> , 2018, 215, 645-659.	4.2	19
2988	Immune Checkpoint Inhibitor-Associated Type 1 Diabetes Mellitus: Case Series, Review of the Literature, and Optimal Management. <i>Case Reports in Oncology</i> , 2018, 10, 897-909.	0.3	57
2989	Durable Near-Complete Response to Anti-PD-1 Checkpoint Immunotherapy in a Refractory Malignant Solitary Fibrous Tumor of the Pleura. <i>Case Reports in Oncology</i> , 2018, 10, 998-1005.	0.3	10
2990	Association of Immunotherapy With Durable Survival as Defined by Value Frameworks for Cancer Care. <i>JAMA Oncology</i> , 2018, 4, 326.	3.4	43
2991	Inflammatory Reprogramming with IDO1 Inhibitors: Turning Immunologically Unresponsive "Cold" Tumors "Hot". <i>Trends in Cancer</i> , 2018, 4, 38-58.	3.8	130
2992	Anti-PD-1-induced high-grade hepatitis associated with corticosteroid-resistant T cells: a case report. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 563-573.	2.0	50
2993	Generating the Abscopal Effect by Combining Proapoptotic Peptides With IL-12-Based Immunotherapy. <i>Neoplasia</i> , 2018, 20, 193-196.	2.3	2
2994	Molecular Biomarkers of Primary and Acquired Resistance to T-Cell-Mediated Immunotherapy in Cancer: Landscape, Clinical Implications, and Future Directions. <i>Oncologist</i> , 2018, 23, 410-421.	1.9	23
2995	Emerging biomarkers for the combination of radiotherapy and immune checkpoint blockers. <i>Seminars in Cancer Biology</i> , 2018, 52, 125-134.	4.3	51
2996	<i>Bifidobacterium</i> can mitigate intestinal immunopathology in the context of CTLA-4 blockade. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 157-161.	3.3	152
2997	Critical research gaps and recommendations to inform research prioritisation for more effective prevention and improved outcomes in colorectal cancer. <i>Gut</i> , 2018, 67, 179-193.	6.1	73
2998	Feasibility and Safety of Intrathoracic Biopsy and Repeat Biopsy for Evaluation of Programmed Cell Death Ligand-1 Expression for Immunotherapy in Non-Small Cell Lung Cancer. <i>Radiology</i> , 2018, 287, 326-332.	3.6	24
2999	Understanding preanalytical variables and their effects on clinical biomarkers of oncology and immunotherapy. <i>Seminars in Cancer Biology</i> , 2018, 52, 26-38.	4.3	49
3000	Is It Possible to Develop Cancer Vaccines to Neoantigens, What Are the Major Challenges, and How Can These Be Overcome?. <i>Cold Spring Harbor Perspectives in Biology</i> , 2018, 10, a033704.	2.3	10
3001	Phase I Pharmacokinetic Study of Nivolumab in Korean Patients with Advanced Solid Tumors. <i>Oncologist</i> , 2018, 23, 155-e17.	1.9	21
3002	Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma. <i>JAMA Oncology</i> , 2018, 4, 210.	3.4	437

#	ARTICLE	IF	CITATIONS
3003	Pembrolizumab Utilization and Outcomes for Advanced Melanoma in US Community Oncology Practices. <i>Journal of Immunotherapy</i> , 2018, 41, 86-95.	1.2	28
3004	Impact of oncogenic pathways on evasion of antitumour immune responses. <i>Nature Reviews Cancer</i> , 2018, 18, 139-147.	12.8	506
3005	Modeling tumor immunity of mouse glioblastoma by exhausted CD8+ T cells. <i>Scientific Reports</i> , 2018, 8, 208.	1.6	24
3006	Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC). <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883401774501.	1.4	101
3007	Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval. <i>Oncologist</i> , 2018, 23, 328-336.	1.9	87
3008	Population-level effect of molecular testing and targeted therapy in patients with advanced pulmonary adenocarcinoma: a prospective cohort study. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 472, 581-588.	1.4	5
3009	Combined SEP and anti-PD-L1 antibody produces a synergistic antitumor effect in B16-F10 melanoma-bearing mice. <i>Scientific Reports</i> , 2018, 8, 217.	1.6	15
3010	Thyroid dysfunctions secondary to cancer immunotherapy. <i>Journal of Endocrinological Investigation</i> , 2018, 41, 625-638.	1.8	59
3011	Improving immune-vascular crosstalk for cancer immunotherapy. <i>Nature Reviews Immunology</i> , 2018, 18, 195-203.	10.6	340
3012	Dosimetry Prediction for Clinical Translation of 64Cu-Pembrolizumab ImmunoPET Targeting Human PD-1 Expression. <i>Scientific Reports</i> , 2018, 8, 633.	1.6	41
3013	Neurologic complications of immune checkpoint inhibitors. <i>Journal of Neuro-Oncology</i> , 2018, 137, 601-609.	1.4	126
3014	Mechanisms of resistance to immune checkpoint inhibitors. <i>British Journal of Cancer</i> , 2018, 118, 9-16.	2.9	944
3015	Severe Inflammatory Ophthalmopathy in a Euthyroid Patient during Nivolumab Treatment. <i>European Thyroid Journal</i> , 2018, 7, 84-87.	1.2	31
3016	High macrophage PD-L1 expression not responsible for T cell suppression. <i>Cellular Immunology</i> , 2018, 324, 50-58.	1.4	5
3017	Association Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Outcome of Patients With Metastatic Renal-Cell Carcinoma Treated With Nivolumab. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e563-e575.	0.9	72
3018	High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy. <i>Nature Medicine</i> , 2018, 24, 144-153.	15.2	564
3019	Inhibitors of the PD-1 Pathway in Tumor Therapy. <i>Journal of Immunology</i> , 2018, 200, 375-383.	0.4	112
3020	A Believer's Overview of Cancer Immunosurveillance and Immunotherapy. <i>Journal of Immunology</i> , 2018, 200, 385-391.	0.4	103

#	ARTICLE	IF	CITATIONS
3021	Hitting the Target: How T Cells Detect and Eliminate Tumors. <i>Journal of Immunology</i> , 2018, 200, 392-399.	0.4	67
3022	<i>Mycoplasma bovis</i> -Induced Inhibition of Bovine Peripheral Blood Mononuclear Cell Proliferation Is Ameliorated after Blocking the Immune-Inhibitory Programmed Death 1 Receptor. <i>Infection and Immunity</i> , 2018, 86, .	1.0	19
3023	EGFR-TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2018, 4, 1112.	3.4	205
3024	Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2018, 4, 351.	3.4	599
3025	A novel biologic platform elicits profound T cell costimulatory activity and antitumor immunity in mice. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 605-613.	2.0	4
3026	Nanoparticle anchoring targets immune agonists to tumors enabling anti-cancer immunity without systemic toxicity. <i>Nature Communications</i> , 2018, 9, 6.	5.8	184
3027	The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy. <i>Journal of the National Cancer Institute</i> , 2018, 110, 777-786.	3.0	58
3028	Modulating Tumor Immunology by Inhibiting Indoleamine 2,3-Dioxygenase (IDO): Recent Developments and First Clinical Experiences. <i>Targeted Oncology</i> , 2018, 13, 125-140.	1.7	19
3029	Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. <i>BMJ: British Medical Journal</i> , 2018, 360, k793.	2.4	438
3030	Immune checkpoint inhibitor (nivolumab)-associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis: a case report. <i>BMC Nephrology</i> , 2018, 19, 48.	0.8	66
3031	Re-challenging immune checkpoint inhibitor in a patient with advanced non-small cell lung cancer: a case report. <i>BMC Cancer</i> , 2018, 18, 302.	1.1	17
3032	Radiotherapy-induced anti-tumor immune response and immune-related adverse events in a case of recurrent nasopharyngeal carcinoma undergoing anti-PD-1 immunotherapy. <i>BMC Cancer</i> , 2018, 18, 395.	1.1	15
3033	Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade. <i>Journal of Translational Medicine</i> , 2018, 16, 94.	1.8	132
3034	Lessons learned from the blockade of immune checkpoints in cancer immunotherapy. <i>Journal of Hematology and Oncology</i> , 2018, 11, 31.	6.9	256
3035	Gut microbiome modulates efficacy of immune checkpoint inhibitors. <i>Journal of Hematology and Oncology</i> , 2018, 11, 47.	6.9	138
3036	CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial. <i>Trials</i> , 2018, 19, 233.	0.7	41
3037	Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis. , 2018, 6, 26.		150
3038	Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors. <i>Journal of Translational Medicine</i> , 2018, 16, 82.	1.8	98

#	ARTICLE	IF	CITATIONS
3039	Prediction of treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer by analysis of immune checkpoint protein expression. <i>Journal of Translational Medicine</i> , 2018, 16, 87.	1.8	35
3040	PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics. <i>Diagnostic Pathology</i> , 2018, 13, 12.	0.9	175
3041	The impact of PD-L1 on survival and value of the immune check point inhibitors in non-small-cell lung cancer; proposal, policies and perspective. , 2018, 6, 15.		22
3042	Ipilimumab induced digital vasculitis. , 2018, 6, 12.		37
3043	Immunotherapy for Merkel cell carcinoma: a turning point in patient care. , 2018, 6, 23.		34
3044	CD74 regulates complexity of tumor cell HLA class II peptidome in brain metastasis and is a positive prognostic marker for patient survival. <i>Acta Neuropathologica Communications</i> , 2018, 6, 18.	2.4	26
3045	Temozolomide for immunomodulation in the treatment of glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 1566-1572.	0.6	166
3046	Intensity-Modulated Radiotherapy Triggers Onset of Bullous Pemphigoid in a Patient with Advanced Melanoma Treated with Nivolumab. <i>Case Reports in Oncology</i> , 2018, 11, 114-118.	0.3	17
3047	The importance of greater speed in drug development for advanced malignancies. <i>Cancer Medicine</i> , 2018, 7, 1824-1836.	1.3	23
3048	The binding of an anti-PD-1 antibody to Fc γ R1 TM has a profound impact on its biological functions. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1079-1090.	2.0	162
3049	APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer. <i>Oncogene</i> , 2018, 37, 3924-3936.	2.6	204
3050	Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients. <i>British Journal of Cancer</i> , 2018, 118, 1296-1301.	2.9	49
3051	Can early palliative care with anticancer treatment improve overall survival and patient-related outcomes in advanced lung cancer patients? A review of the literature. <i>Supportive Care in Cancer</i> , 2018, 26, 2945-2953.	1.0	51
3052	Integrative Pharmacology: Advancing Development of Effective Immunotherapies. <i>AAPS Journal</i> , 2018, 20, 66.	2.2	10
3053	Checkpoint Inhibitors in the Treatment of Breast Cancer. <i>Current Oncology Reports</i> , 2018, 20, 51.	1.8	10
3054	Short- and long-term evolution in our arms race with cancer: Why the war on cancer is winnable. <i>Evolutionary Applications</i> , 2018, 11, 845-852.	1.5	1
3055	The opposing roles of CD4 ⁺ T cells in anti-tumour immunity. <i>Immunology</i> , 2018, 154, 582-592.	2.0	92
3056	Recent advances in the management of lung cancer. <i>Clinical Medicine</i> , 2018, 18, s41-s46.	0.8	274

#	ARTICLE	IF	CITATIONS
3057	Safety and Feasibility of Lung Resection After Immunotherapy for Metastatic or Unresectable Tumors. <i>Annals of Thoracic Surgery</i> , 2018, 106, 178-183.	0.7	96
3058	Clinical Features and Management of Acquired Resistance to PD-1 Axis Inhibitors in 26 Patients With Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 831-839.	0.5	94
3059	Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models. <i>Clinical Cancer Research</i> , 2018, 24, 3409-3422.	3.2	44
3060	Cutaneous melanoma: From pathogenesis to therapy (Review). <i>International Journal of Oncology</i> , 2018, 52, 1071-1080.	1.4	281
3061	Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer. <i>JAMA Oncology</i> , 2018, 4, e180013.	3.4	1,350
3062	Neoplastic meningitis in solid tumors: from diagnosis to personalized treatments. <i>Therapeutic Advances in Neurological Disorders</i> , 2018, 11, 175628641875961.	1.5	17
3063	Anti-CTLA-4 therapy requires an Fc domain for efficacy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 3912-3917.	3.3	121
3064	Acute tubulointerstitial nephritis associated with atezolizumab, an anti-programmed death-ligand 1 (pd-1) antibody therapy. <i>Oncolmunology</i> , 2018, 7, e1445952.	2.1	16
3065	Armed oncolytic viruses: A kick-start for anti-tumor immunity. <i>Cytokine and Growth Factor Reviews</i> , 2018, 41, 28-39.	3.2	110
3066	Aplastic anemia secondary to nivolumab and ipilimumab in a patient with metastatic melanoma: a case report. <i>Experimental Hematology and Oncology</i> , 2018, 7, 6.	2.0	32
3067	Management of gastrointestinal adverse events induced by immune-checkpoint inhibitors. <i>Chronic Diseases and Translational Medicine</i> , 2018, 4, 1-7.	0.9	6
3068	Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies. <i>Immunity</i> , 2018, 48, 417-433.	6.6	416
3069	Adverse Events Associated with Immune Checkpoint Blockade. <i>New England Journal of Medicine</i> , 2018, 378, 1163-1165.	13.9	79
3070	Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2018, 378, 1277-1290.	13.9	3,334
3071	Autoimmune Polyendocrine Syndromes. <i>New England Journal of Medicine</i> , 2018, 378, 1132-1141.	13.9	311
3072	Cancer immunotherapy using checkpoint blockade. <i>Science</i> , 2018, 359, 1350-1355.	6.0	4,274
3073	Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma. <i>Clinical Cancer Research</i> , 2018, 24, 4771-4784.	3.2	29
3074	Post-operative unadjuvanted therapeutic xenovaccination with chicken whole embryo vaccine suppresses distant micrometastases and prolongs survival in a murine Lewis lung carcinoma model. <i>Oncology Letters</i> , 2018, 15, 5098-5104.	0.8	1

#	ARTICLE	IF	CITATIONS
3075	Taxane acute pain syndrome (TAPS) in patients receiving chemotherapy for breast or prostate cancer: a prospective multi-center study. <i>Supportive Care in Cancer</i> , 2018, 26, 3073-3081.	1.0	12
3076	Indoleamine 2,3-Dioxygenase and Its Therapeutic Inhibition in Cancer. <i>International Review of Cell and Molecular Biology</i> , 2018, 336, 175-203.	1.6	204
3077	Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies. <i>Cancer Cell</i> , 2018, 33, 649-663.e4.	7.7	448
3078	When worlds collide: Th17 and Treg cells in cancer and autoimmunity. <i>Cellular and Molecular Immunology</i> , 2018, 15, 458-469.	4.8	331
3079	Melanoma and Immune Checkpoint Inhibitors. <i>Current Oncology Reports</i> , 2018, 20, 29.	1.8	54
3080	Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non-Small Cell Lung Cancer Patients. <i>Oncologist</i> , 2018, 23, 936-942.	1.9	69
3081	The benefit and risk of nivolumab in non-small cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized controlled trials. <i>Cancer Medicine</i> , 2018, 7, 1642-1659.	1.3	15
3082	NF1 mutations in conjunctival melanoma. <i>British Journal of Cancer</i> , 2018, 118, 1243-1247.	2.9	59
3083	Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2. <i>Onc Immunology</i> , 2018, 7, e1438106.	2.1	54
3084	Enhanced expression of PD-1 and other activation markers by CD4+ T cells of young but not old patients with metastatic melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 925-933.	2.0	8
3085	Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study. <i>Journal of the Endocrine Society</i> , 2018, 2, 241-251.	0.1	146
3086	The role of programmed death ligand-1 and tumor-infiltrating lymphocytes in breast cancer overexpressing HER2 gene. <i>Breast Cancer Research and Treatment</i> , 2018, 170, 293-302.	1.1	16
3087	Two cases of nonbacterial cystitis associated with nivolumab, the anti-programmed-death-receptor-1 inhibitor. <i>Urology Case Reports</i> , 2018, 17, 97-99.	0.1	22
3088	Late renal toxicity of treatment for childhood malignancy: risk factors, long-term outcomes, and surveillance. <i>Pediatric Nephrology</i> , 2018, 33, 215-225.	0.9	53
3089	The expanding repertoire of targets for immune checkpoint inhibition in bladder cancer: What lies beneath the tip of the iceberg, PD-L1. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 459-468.	0.8	8
3090	CD103+ lung dendritic cells (LDCs) induce stronger Th1/Th17 immunity to a bacterial lung infection than CD11bhi LDCs. <i>Cellular and Molecular Immunology</i> , 2018, 15, 377-387.	4.8	33
3091	Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy. <i>Surgery Today</i> , 2018, 48, 1-8.	0.7	88
3092	A case of nivolumab-related cholangitis and literature review: how to look for the right tools for a correct diagnosis of this rare immune-related adverse event. <i>Investigational New Drugs</i> , 2018, 36, 144-146.	1.2	42

#	ARTICLE	IF	CITATIONS
3093	PD-1 and cancer: molecular mechanisms and polymorphisms. <i>Immunogenetics</i> , 2018, 70, 73-86.	1.2	100
3094	The emerging role of immune checkpoint based approaches in AML and MDS. <i>Leukemia and Lymphoma</i> , 2018, 59, 790-802.	0.6	90
3095	Toward Precision Radiotherapy for Use with Immune Checkpoint Blockers. <i>Clinical Cancer Research</i> , 2018, 24, 259-265.	3.2	137
3096	Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 225-235.	0.6	61
3097	The Autophagy Receptor Adaptor p62 is Upregulated by UVA Radiation in Melanocytes and in Melanoma Cells. <i>Photochemistry and Photobiology</i> , 2018, 94, 432-437.	1.3	25
3098	Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non-Small Cell Lung Carcinoma. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2018, 26, 83-93.	0.6	124
3099	Evolutionary basis of a new gene- and immune-therapeutic approach for the treatment of malignant brain tumors: from mice to clinical trials for glioma patients. <i>Clinical Immunology</i> , 2018, 189, 43-51.	1.4	27
3100	NCCTG N0879 (Alliance): A randomized phase 2 cooperative group trial of carboplatin, paclitaxel, and bevacizumab ± everolimus for metastatic melanoma. <i>Cancer</i> , 2018, 124, 537-545.	2.0	27
3101	A Comprehensive Review of Sequencing and Combination Strategies of Targeted Agents in Metastatic Colorectal Cancer. <i>Oncologist</i> , 2018, 23, 25-34.	1.9	63
3102	Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 311-325.	2.0	40
3103	Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. <i>Annals of Oncology</i> , 2018, 29, 250-255.	0.6	304
3104	The anti-PD-1 era – an opportunity to enhance radiotherapy for patients with bladder cancer. <i>Nature Reviews Urology</i> , 2018, 15, 251-259.	1.9	27
3105	Remarkable response of nivolumab-refractory lung cancer to salvage chemotherapy. <i>Thoracic Cancer</i> , 2018, 9, 175-180.	0.8	34
3106	Checkpoint inhibitor-induced uveitis: a case series. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2018, 256, 187-191.	1.0	59
3107	Different Response to Nivolumab in a Patient with Synchronous Double Primary Carcinomas of Hypopharyngeal Cancer and Non-Small-Cell Lung Cancer. <i>Case Reports in Oncology</i> , 2018, 10, 802-808.	0.3	5
3108	Radiomics to predict immunotherapy-induced pneumonitis: proof of concept. <i>Investigational New Drugs</i> , 2018, 36, 601-607.	1.2	90
3109	Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 334-340.	3.2	323
3110	Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature. <i>Cancer</i> , 2018, 124, 271-277.	2.0	265

#	ARTICLE	IF	CITATIONS
3111	<i>In-vitro</i> effect of pembrolizumab on different T regulatory cell subsets. <i>Clinical and Experimental Immunology</i> , 2018, 191, 189-197.	1.1	42
3112	Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens. <i>JAMA Oncology</i> , 2018, 4, 173.	3.4	753
3113	Clinical Outcomes in Patients With Metastatic Lung Cancer Treated With PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy. <i>JAMA Oncology</i> , 2018, 4, 253.	3.4	76
3114	Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer. <i>JAMA Oncology</i> , 2018, 4, 374.	3.4	735
3115	Overcoming resistance to anti-PD immunotherapy in a syngeneic mouse lung cancer model using locoregional virotherapy. <i>Oncolmmunology</i> , 2018, 7, e1376156.	2.1	14
3116	CD4 and CD8 T lymphocyte interplay in controlling tumor growth. <i>Cellular and Molecular Life Sciences</i> , 2018, 75, 689-713.	2.4	351
3117	Homo- and Heterodimerization of Proteins in Cell Signaling: Inhibition and Drug Design. <i>Advances in Protein Chemistry and Structural Biology</i> , 2018, 111, 1-59.	1.0	14
3118	Afatinib treatment of a squamous lung cancer after tumor progression of nivolumab. <i>Thoracic Cancer</i> , 2018, 9, 164-166.	0.8	2
3119	The diverse functions of the PD1 inhibitory pathway. <i>Nature Reviews Immunology</i> , 2018, 18, 153-167.	10.6	1,210
3120	Immune checkpoint blockade in infectious diseases. <i>Nature Reviews Immunology</i> , 2018, 18, 91-104.	10.6	407
3121	Analysis of the immune infiltrate in undifferentiated pleomorphic sarcoma of the extremity and trunk in response to radiotherapy: Rationale for combination neoadjuvant immune checkpoint inhibition and radiotherapy. <i>Oncolmmunology</i> , 2018, 7, e1385689.	2.1	46
3122	Cholangiocarcinoma – evolving concepts and therapeutic strategies. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 95-111.	12.5	1,051
3123	Phase I study of the combination of quinacrine and erlotinib in patients with locally advanced or metastatic non small cell lung cancer. <i>Investigational New Drugs</i> , 2018, 36, 435-441.	1.2	15
3124	Endocrinopathies with use of cancer immunotherapies. <i>Clinical Endocrinology</i> , 2018, 88, 327-332.	1.2	20
3125	Beyond the Percentages of PD-L1-Positive Tumor Cells: Induced Versus Constitutive PD-L1 Expression in Primary and Metastatic Head and Neck Squamous Cell Carcinoma. <i>Head and Neck Pathology</i> , 2018, 12, 221-229.	1.3	27
3126	Combinatorial Therapies in Melanoma: MAPK Inhibitors and Beyond. <i>American Journal of Clinical Dermatology</i> , 2018, 19, 181-193.	3.3	18
3127	Synthetic immune niches for cancer immunotherapy. <i>Nature Reviews Immunology</i> , 2018, 18, 212-219.	10.6	141
3128	Oncolytic reovirus sensitizes multiple myeloma cells to anti-PD-L1 therapy. <i>Leukemia</i> , 2018, 32, 230-233.	3.3	49

#	ARTICLE	IF	CITATIONS
3129	Agonist OX40 immunotherapy improves survival in glioma-bearing mice and is complementary with vaccination with irradiated GM-CSF-expressing tumor cells. <i>Neuro-Oncology</i> , 2018, 20, 44-54.	0.6	51
3130	89Zr-labeled nivolumab for imaging of T-cell infiltration in a humanized murine model of lung cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i>, 2018, 45, 110-120.	3.3	100
3131	Metabolic activity by ¹⁸ F-FDG-PET/CT is predictive of early response after nivolumab in previously treated NSCLC. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 56-66.	3.3	166
3132	18F-FDG-PET detects complete response to PD1-therapy in melanoma patients two weeks after therapy start. <i>European Journal of Nuclear Medicine and Molecular Imaging</i>, 2018, 45, 95-101.	3.3	46
3133	Sequential, Multiple Assignment, Randomized Trial Designs in Immuno-oncology Research. <i>Clinical Cancer Research</i> , 2018, 24, 730-736.	3.2	16
3134	Chronic Obstructive Pulmonary Disease Alters Immune Cell Composition and Immune Checkpoint Inhibitor Efficacy in Non-Small Cell Lung Cancer. <i>American Journal of Respiratory and Critical Care Medicine</i>, 2018, 197, 325-336.	2.5	77
3135	Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas. <i>Oncologist</i> , 2018, 23, 71-83.	1.9	45
3136	Therapeutic Implications of the Molecular and Immune Landscape of Triple-Negative Breast Cancer. <i>Pathology and Oncology Research</i>, 2018, 24, 701-716.	0.9	17
3137	Emerging biomarkers for cancer immunotherapy in melanoma. <i>Seminars in Cancer Biology</i> , 2018, 52, 207-215.	4.3	42
3138	Targets for immunotherapy of liver cancer. <i>Journal of Hepatology</i>, 2018, 68, 157-166.	1.8	129
3139	Regulatory T cells in acute and chronic kidney diseases. <i>American Journal of Physiology - Renal Physiology</i> , 2018, 314, F679-F698.	1.3	46
3140	Adverse prognostic value of PD-L1 expression in primary resected pulmonary squamous cell carcinomas and paired mediastinal lymph node metastases. <i>Modern Pathology</i>, 2018, 31, 101-110.	2.9	38
3141	Intratumoral CD8+ T-cell Apoptosis Is a Major Component of T-cell Dysfunction and Impedes Antitumor Immunity. <i>Cancer Immunology Research</i> , 2018, 6, 14-24.	1.6	129
3142	Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma. <i>Future Oncology</i>, 2018, 14, 417-430.	1.1	55
3143	Can checkpoint inhibitor therapy improve response to chemotherapy?. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 183-185.	1.2	1
3144	Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer. <i>Expert Review of Anticancer Therapy</i>, 2018, 18, 63-70.	1.1	172
3145	Development of a Diagnostic Programmed Cell Death 1-Ligand 1 Immunohistochemistry Assay for Nivolumab Therapy in Melanoma. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2018, 26, 6-12.	0.6	25
3146	Evolution of early phase clinical trials in oncology. <i>Journal of Molecular Medicine</i>, 2018, 96, 31-38.	1.7	13

#	ARTICLE	IF	CITATIONS
3147	Immune-related tumour response assessment criteria: a comprehensive review. <i>British Journal of Radiology</i> , 2018, 91, 20170457.	1.0	58
3148	Current status of cancer immunotherapy for esophageal squamous cell carcinoma. <i>Esophagus</i> , 2018, 15, 1-9.	1.0	19
3149	Immunotherapy as a treatment for biliary tract cancers: A review of approaches with an eye to the future. <i>Current Problems in Cancer</i> , 2018, 42, 49-58.	1.0	25
3150	Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses. <i>MAbs</i> , 2018, 10, 315-324.	2.6	72
3151	Trastuzumab combined with doublet or single-agent chemotherapy as first-line therapy for HER2-positive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 337-348.	1.1	6
3152	T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling. <i>Clinical Cancer Research</i> , 2018, 24, 870-881.	3.2	75
3153	Towards personalized, tumour-specific, therapeutic vaccines for cancer. <i>Nature Reviews Immunology</i> , 2018, 18, 168-182.	10.6	736
3154	Emerging trends in the immunotherapy of pancreatic cancer. <i>Cancer Letters</i> , 2018, 417, 35-46.	3.2	77
3155	Investigational PD-1 inhibitors in HL and NHL and biomarkers for predictors of response and outcome. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 55-70.	1.9	5
3156	Phase I Dose-Escalation Study of Anti-CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 671-676.	1.9	33
3157	Synergy of Immune Checkpoint Blockade with a Novel Synthetic Consensus DNA Vaccine Targeting TERT. <i>Molecular Therapy</i> , 2018, 26, 435-445.	3.7	39
3158	Implications of the tumor immune microenvironment for staging and therapeutics. <i>Modern Pathology</i> , 2018, 31, 214-234.	2.9	278
3159	Advances in targeted therapy for acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2018, 180, 484-500.	1.2	91
3160	Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation. <i>Cancer Treatment Reviews</i> , 2018, 63, 48-60.	3.4	134
3161	PD-L1, inflammation, non-coding RNAs, and neuroblastoma: Immuno-oncology perspective. <i>Seminars in Cancer Biology</i> , 2018, 52, 53-65.	4.3	58
3162	Product review on the Anti-PD-L1 antibody atezolizumab. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 269-276.	1.4	41
3163	Metastasectomy for Tumor-Infiltrating Lymphocytes: An Emerging Operative Indication in Surgical Oncology. <i>Annals of Surgical Oncology</i> , 2018, 25, 565-572.	0.7	14
3164	Relative efficiency of precision medicine designs for clinical trials with predictive biomarkers. <i>Statistics in Medicine</i> , 2018, 37, 687-709.	0.8	8

#	ARTICLE	IF	CITATIONS
3165	A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2018, 24, 1525-1535.	3.2	153
3166	Association of Immunotherapy With Overall Survival in Elderly Patients With Melanoma. <i>JAMA Dermatology</i> , 2018, 154, 82.	2.0	51
3167	Molecular classification and precision therapy of cancer: immune checkpoint inhibitors. <i>Frontiers of Medicine</i> , 2018, 12, 229-235.	1.5	53
3168	Moving treatments earlier to move further forwards. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 75-76.	12.5	7
3169	Drug development in the era of precision medicine. <i>Nature Reviews Drug Discovery</i> , 2018, 17, 183-196.	21.5	294
3170	Immunotherapy in metastatic urothelial carcinoma: focus on immune checkpoint inhibition. <i>Nature Reviews Urology</i> , 2018, 15, 112-124.	1.9	73
3171	Aberrant SIRT6 expression contributes to melanoma growth: Role of the autophagy paradox and IGF-AKT signaling. <i>Autophagy</i> , 2018, 14, 518-533.	4.3	45
3172	Analysis of Drug Development Paradigms for Immune Checkpoint Inhibitors. <i>Clinical Cancer Research</i> , 2018, 24, 1785-1794.	3.2	42
3173	Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 1562-1573.	3.2	150
3174	CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation. <i>Cancer Discovery</i> , 2018, 8, 216-233.	7.7	503
3175	BRAF peptide vaccine facilitates therapy of murine BRAF-mutant melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 299-310.	2.0	48
3176	The inflammatory microenvironment and microbiome in prostate cancer development. <i>Nature Reviews Urology</i> , 2018, 15, 11-24.	1.9	311
3177	Clinical Factors as a Component of the Personalized Treatment Approach to Advanced Pancreatic Cancer: a Systematic Literature Review. <i>Journal of Gastrointestinal Cancer</i> , 2018, 49, 1-8.	0.6	11
3178	CTLA-4: a moving target in immunotherapy. <i>Blood</i> , 2018, 131, 58-67.	0.6	704
3179	Prognostic relevance of programmed cell death ligand 1 expression in glioblastoma. <i>Journal of Neuro-Oncology</i> , 2018, 136, 453-461.	1.4	34
3180	Japan Society of Gynecologic Oncology guidelines 2015 for the treatment of vulvar cancer and vaginal cancer. <i>International Journal of Clinical Oncology</i> , 2018, 23, 201-234.	1.0	47
3181	Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. <i>Investigational New Drugs</i> , 2018, 36, 638-646.	1.2	149
3182	PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer. <i>Molecular Diagnosis and Therapy</i> , 2018, 22, 1-10.	1.6	139

#	ARTICLE	IF	CITATIONS
3183	Complement Activation via a C3a Receptor Pathway Alters CD4+ T Lymphocytes and Mediates Lung Cancer Progression. <i>Cancer Research</i> , 2018, 78, 143-156.	0.4	94
3184	Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma. <i>Investigational New Drugs</i> , 2018, 36, 96-102.	1.2	150
3185	SEOM clinical guideline for the management of malignant melanoma (2017). <i>Clinical and Translational Oncology</i> , 2018, 20, 69-74.	1.2	16
3186	Combining DNA damaging therapeutics with immunotherapy: more haste, less speed. <i>British Journal of Cancer</i> , 2018, 118, 312-324.	2.9	184
3187	A phase 2 study of ontuxizumab, a monoclonal antibody targeting endosialin, in metastatic melanoma. <i>Investigational New Drugs</i> , 2018, 36, 103-113.	1.2	19
3188	Ceritinib Enhances the Efficacy of Trametinib in <i>BRAF/NRAS</i> -Wild-Type Melanoma Cell Lines. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 73-83.	1.9	18
3189	Targeted Therapies: Immunologic Effects and Potential Applications Outside of Cancer. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 7-24.	1.0	23
3190	The PD-1/PD-L1 Inhibitory Pathway is Altered in Primary Glomerulonephritides. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2018, 66, 133-143.	1.0	13
3191	Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma. <i>JAMA Oncology</i> , 2018, 4, 98.	3.4	125
3192	Breast Cancer Immunotherapy: Facts and Hopes. <i>Clinical Cancer Research</i> , 2018, 24, 511-520.	3.2	567
3193	Tumor-associated macrophage infiltration is highly associated with PD-L1 expression in gastric adenocarcinoma. <i>Gastric Cancer</i> , 2018, 21, 31-40.	2.7	75
3194	Potential Influence of Endothelial Adsorption on the Delayed Time to Maximum Concentration of Biopharmaceuticals. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2018, 43, 103-113.	0.6	4
3195	Toxicities with targeted therapies after immunotherapy in metastatic melanoma. <i>Melanoma Research</i> , 2018, 28, 600-604.	0.6	10
3196	Immune blockade inhibitors and the radiation abscopal effect in gastrointestinal cancers. <i>World Journal of Gastrointestinal Oncology</i> , 2018, 10, 221-227.	0.8	6
3197	Tubulitis in a patient treated with nivolumab: Case report and literature review. <i>Journal of Onco-Nephrology</i> , 2018, 2, 107-112.	0.3	1
3198	T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma. <i>JCI Insight</i> , 2018, 3, .	2.3	206
3199	Urothelial cancer: Once there were urologists, now oncologists joined, what about nephrologists?. <i>Journal of Onco-Nephrology</i> , 2018, 2, 3-5.	0.3	3
3200	Harnessing the immune system in the battle against breast cancer. <i>Drugs in Context</i> , 2018, 7, 1-21.	1.0	19

#	ARTICLE	IF	CITATIONS
3201	Immune checkpoint inhibitors of CTLA4 and PD-1 for malignant melanoma arising in ovarian cystic teratoma. <i>Medicine (United States)</i> , 2018, 97, e12937.	0.4	4
3202	Real world data of nivolumab for previously treated non-small cell lung cancer patients: a Galician lung cancer group clinical experience. <i>Translational Lung Cancer Research</i> , 2018, 7, 404-415.	1.3	54
3203	Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study. <i>Oncotarget</i> , 2018, 9, 15542-15551.	0.8	80
3204	Immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival. <i>JCI Insight</i> , 2018, 3, .	2.3	49
3205	Novel Quantitative Imaging for Predicting Response to Therapy: Techniques and Clinical Applications. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 1008-1018.	1.8	52
3206	Immunomodulatory Bonds of the Partnership between Dendritic Cells and T Cells. <i>Critical Reviews in Immunology</i> , 2018, 38, 379-401.	1.0	58
3207	Treatment With Tumor-infiltrating Lymphocytes in Advanced Melanoma: Evaluation of Early Clinical Implementation of an Advanced Therapy Medicinal Product. <i>Journal of Immunotherapy</i> , 2018, 41, 413-425.	1.2	10
3208	ClinicalTrials.gov for Facilitating Rapid Understanding of Potential Harms of New Drugs: The Case of Checkpoint Inhibitors. <i>Journal of Oncology Practice</i> , 2018, 14, 72-76.	2.5	8
3209	HLA class I loss and PD-L1 expression in lung cancer: impact on T-cell infiltration and immune escape. <i>Oncotarget</i> , 2018, 9, 4120-4133.	0.8	66
3210	Direct costs associated with adverse events of systemic therapies for advanced melanoma. <i>Medicine (United States)</i> , 2018, 97, e11736.	0.4	19
3211	Spatial and phenotypic immune profiling of metastatic colon cancer. <i>JCI Insight</i> , 2018, 3, .	2.3	73
3212	Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 610-617.	0.6	192
3213	Vol-PACT: A Foundation for the NIH Public-Private Partnership That Supports Sharing of Clinical Trial Data for the Development of Improved Imaging Biomarkers in Oncology. <i>JCO Clinical Cancer Informatics</i> , 2018, 2, 1-12.	1.0	14
3214	Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 391-398.	0.8	156
3215	Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders. <i>Journal of Clinical Oncology</i> , 2018, 36, 1905-1912.	0.8	268
3216	Interim Futility Monitoring Assessing Immune Therapies With a Potentially Delayed Treatment Effect. <i>Journal of Clinical Oncology</i> , 2018, 36, 2444-2449.	0.8	17
3217	Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma. <i>Journal of Clinical Oncology</i> , 2018, 36, 1419-1427.	0.8	477
3218	Positive Tumor Response to Combined Checkpoint Inhibitors in a Patient With Refractory Alveolar Soft Part Sarcoma: A Case Report. <i>Journal of Global Oncology</i> , 2018, 4, 1-6.	0.5	24

#	ARTICLE	IF	CITATIONS
3219	Clinical and molecular characteristics of pulmonary sarcomatoid carcinoma. Korean Journal of Internal Medicine, 2018, 33, 737-744.	0.7	21
3220	Anti-tumor roles of both strands of the miR-455 duplex: their targets SKA1 and SKA3 are involved in the pathogenesis of renal cell carcinoma. Oncotarget, 2018, 9, 26638-26658.	0.8	22
3221	Improved sensitivity for detection of breast cancer by combination of miR-34a and tumor markers CA 15-3 or CEA. Oncotarget, 2018, 9, 22523-22536.	0.8	40
3222	Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. Journal of Clinical Oncology, 2018, 36, 383-390.	0.8	431
3223	Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2018, 36, 1714-1768.	0.8	2,691
3224	Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. Journal of Clinical Oncology, 2018, 36, 633-641.	0.8	1,109
3225	Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037). Journal of Clinical Oncology, 2018, 36, 3223-3230.	0.8	267
3226	Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma. Journal of Clinical Oncology, 2018, 36, 3450-3458.	0.8	55
3227	Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma. Journal of Clinical Oncology, 2018, 36, 1658-1667.	0.8	483
3228	CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer. Journal of Clinical Oncology, 2018, 36, 2836-2844.	0.8	459
3229	Successful use of adalimumab in immune checkpoint inhibitor-associated inflammatory arthritis. Rheumatology Advances in Practice, 2018, 2, rky001.	0.3	5
3230	Nivolumab Treatment for Cancers in the HIV-infected Population. Journal of Immunotherapy, 2018, 41, 379-383.	1.2	32
3231	Immunotherapy after chemoradiotherapy in stage III non-small cell lung cancer: a new standard of care?. Journal of Thoracic Disease, 2018, 10, 1198-1200.	0.6	6
3232	A tertiary care cancer center experience with carboplatin and pemetrexed in combination with pembrolizumab in comparison with carboplatin and pemetrexed alone in non-squamous non-small cell lung cancer. Journal of Thoracic Disease, 2018, 10, 3575-3584.	0.6	36
3233	Neoadjuvant immunotherapy for non-small cell lung cancer: can early intervention result in durable clinical benefit?. Journal of Thoracic Disease, 2018, 10, S3203-S3206.	0.6	6
3234	Lung cancer in never smokers—the East Asian experience. Translational Lung Cancer Research, 2018, 7, 450-463.	1.3	104
3235	Measuring tumor mutation burden in non-small cell lung cancer: tissue versus liquid biopsy. Translational Lung Cancer Research, 2018, 7, 668-677.	1.3	56
3236	PD-L1 expression and its effect on clinical outcomes of EGFR-mutant NSCLC patients treated with EGFR-TKIs. Cancer Biology and Medicine, 2018, 15, 434.	1.4	19

#	ARTICLE	IF	CITATIONS
3237	Cardio-toxicity of checkpoint inhibitors. <i>Journal of Thoracic Disease</i> , 2018, 10, S4400-S4404.	0.6	19
3238	Predictive markers for anti-PD-1/PD-L1 therapy in non-small cell lung cancer—where are we?. <i>Translational Lung Cancer Research</i> , 2018, 7, 682-690.	1.3	29
3239	Immunotherapy in treatment naïve advanced non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, S412-S421.	0.6	13
3240	Consolidation of immunotherapy becomes new standard of care in unresectable stage III non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, 1205-1206.	0.6	2
3241	The current state of oligometastatic and oligoprogressive non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, S2537-S2544.	0.6	26
3242	Neoadjuvant PD-1 blockade in non-small cell lung cancer: what else do we need to do?. <i>Journal of Thoracic Disease</i> , 2018, 10, S3162-S3165.	0.6	0
3243	Modern concepts in cardio-oncology. <i>Journal of Thoracic Disease</i> , 2018, 10, S4386-S4390.	0.6	13
3244	Clinical utility of tumor mutational burden in patients with non-small cell lung cancer treated with immunotherapy. <i>Translational Lung Cancer Research</i> , 2018, 7, 647-660.	1.3	66
3245	Effects of mdig on proliferation and apoptosis of lung cancer cells. <i>Oncology Letters</i> , 2018, 16, 7146-7151.	0.8	0
3246	Gut microbiome: a key player in cancer immunotherapy. <i>Hepatobiliary Surgery and Nutrition</i> , 2018, 7, 479-480.	0.7	10
3247	Atezolizumab for first-line treatment of metastatic nonsquamous non-small cell lung cancer: what makes the difference?. <i>Journal of Thoracic Disease</i> , 2018, 10, S3241-S3243.	0.6	2
3248	PD-1 and PD-L1 inhibitor toxicities in non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, S4034-S4037.	0.6	5
3249	Role of immune checkpoint blockers in patients with EGFR mutation. <i>Translational Lung Cancer Research</i> , 2018, 7, S385-S387.	1.3	2
3250	Immunotherapy in tyrosine kinase inhibitor-naïve advanced epidermal growth factor receptor-mutant non-small cell lung cancer—driving down a precarious road in driver-mutated lung cancer. <i>Translational Lung Cancer Research</i> , 2018, 7, S377-S380.	1.3	3
3251	Immunotherapies in the management of epidermal growth factor receptor mutated non-small cell lung cancer: a role will be found?. <i>Translational Lung Cancer Research</i> , 2018, 7, S370-S372.	1.3	2
3252	Circulating programmed death ligand-1 (cPD-L1) in non-small-cell lung cancer (NSCLC). <i>Oncotarget</i> , 2018, 9, 17554-17563.	0.8	21
3253	Immunomodulation in hepatocellular cancer. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 208-219.	0.6	22
3254	Developing rational combinations of immune checkpoint inhibitors and radiation therapy for gastrointestinal cancers. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 225-230.	0.6	2

#	ARTICLE	IF	CITATIONS
3255	Approach and management of checkpoint inhibitor-related immune hepatitis. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 220-224.	0.6	28
3256	Immunotherapy in pancreatic adenocarcinoma—overcoming barriers to response. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 143-159.	0.6	42
3257	Stereotactic ablative radiotherapy for oligometastatic non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, 21-24.	0.6	1
3258	Square peg, round hole? Programmed death-1 inhibitors in epidermal growth factor receptor-mutant non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, 25-29.	0.6	3
3259	A pooled analysis of advanced nonsquamous non-small cell lung cancer patients with stable treated brain metastases in two phase II trials receiving bevacizumab and pemetrexed as second-line therapy. <i>Journal of Thoracic Disease</i> , 2018, 10, 219-227.	0.6	6
3260	Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients. <i>Journal of Thoracic Disease</i> , 2018, 10, S1516-S1533.	0.6	57
3261	Locally-advanced non-small cell lung cancer: shall immunotherapy be a new chance?. <i>Journal of Thoracic Disease</i> , 2018, 10, S1461-S1467.	0.6	25
3262	Immunotherapy in surgically resectable non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, S404-S411.	0.6	53
3263	Neoadjuvant and consolidation immuno-oncology therapy in stage III non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, S451-S459.	0.6	34
3264	Assessment of programmed cell death ligand-1 expression with multiple immunohistochemistry antibody clones in non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, 816-824.	0.6	9
3265	Do immune checkpoint inhibitors need new studies methodology?. <i>Journal of Thoracic Disease</i> , 2018, 10, S1564-S1580.	0.6	58
3266	Immunotherapy in previously treated non-small cell lung cancer (NSCLC). <i>Journal of Thoracic Disease</i> , 2018, 10, S422-S432.	0.6	9
3267	Immune checkpoint blockade for advanced non-small cell lung cancer: challenging clinical scenarios. <i>Journal of Thoracic Disease</i> , 2018, 10, S1494-S1502.	0.6	12
3268	Oncogene-addicted non-small cell lung cancer and immunotherapy. <i>Journal of Thoracic Disease</i> , 2018, 10, S1547-S1555.	0.6	25
3269	Modeling the relationship between baseline lactate dehydrogenase and prognosis in patients with extensive-disease small cell lung cancer: a retrospective cohort study. <i>Journal of Thoracic Disease</i> , 2018, 10, 1043-1049.	0.6	5
3270	Early radiological response as predictor of overall survival in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor mutations. <i>Journal of Thoracic Disease</i> , 2018, 10, 1386-1393.	0.6	4
3271	Immune checkpoint blockade in esophageal squamous cell carcinoma: is it ready for prime time?. <i>Journal of Thoracic Disease</i> , 2018, 10, 1276-1279.	0.6	4
3272	Personalized medicine in immuno-oncology: a novel prognostic index in non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, S995-S998.	0.6	1

#	ARTICLE	IF	CITATIONS
3273	The evolving understanding of immunoeediting and the clinical impact of immune escape. Journal of Thoracic Disease, 2018, 10, 1248-1252.	0.6	10
3274	Shining light on advanced NSCLC in 2017: combining immune checkpoint inhibitors. Journal of Thoracic Disease, 2018, 10, S1534-S1546.	0.6	7
3275	Nivolumab induced vitiligo-like lesions in a patient with metastatic squamous cell carcinoma of the lung. Journal of Thoracic Disease, 2018, 10, E481-E484.	0.6	12
3276	Immunotherapy in the Asiatic population: any differences from Caucasian population?. Journal of Thoracic Disease, 2018, 10, S1482-S1493.	0.6	42
3277	Efficacy and immune activation of ipilimumab in early-stage lung cancer patients. Journal of Thoracic Disease, 2018, 10, S1945-S1948.	0.6	1
3278	Vaccine and immune cell therapy in non-small cell lung cancer. Journal of Thoracic Disease, 2018, 10, S1602-S1614.	0.6	30
3279	Radiologic presentation of non-small cell lung cancer treated with anti-PD-1 therapy. Journal of Thoracic Disease, 2018, 10, S3930-S3932.	0.6	1
3280	Heart failure in cancer: role of checkpoint inhibitors. Journal of Thoracic Disease, 2018, 10, S4323-S4334.	0.6	15
3281	Do EGFR tyrosine kinase inhibitors (TKIs) still have a role in EGFR wild-type pre-treated advanced non-small cell lung cancer (NSCLC)?â€”the shifting paradigm of therapeutics. Translational Lung Cancer Research, 2018, 7, S39-S45.	1.3	11
3282	Nivolumab in pretreated non-small cell lung cancer: continuing the immunolution. Translational Lung Cancer Research, 2018, 7, S91-S94.	1.3	16
3283	Durvalumab for non-resectable stage IIIB non-small cell lung cancerâ€”a small step or a big leap?. Translational Lung Cancer Research, 2018, 7, S153-S157.	1.3	1
3284	Proton beam therapy and immunotherapy: an emerging partnership for immune activation in non-small cell lung cancer. Translational Lung Cancer Research, 2018, 7, 180-188.	1.3	28
3285	Autochthonous murine models for the study of smoker and never-smoker associated lung cancers. Translational Lung Cancer Research, 2018, 7, 464-486.	1.3	11
3286	MicroRNA-204 inhibits the proliferation, migration and invasion of human lung cancer cells by targeting PCNA-1 and inhibits tumor growth in vivo. International Journal of Molecular Medicine, 2018, 43, 1149-1156.	1.8	13
3287	Reirradiation for locoregionally recurrent non-small cell lung cancer. Journal of Thoracic Disease, 2018, 10, S2522-S2536.	0.6	20
3288	Moving away (finally) from doublet therapy in lung cancer: immunotherapy and KEYNOTE-189. Journal of Thoracic Disease, 2018, 10, 5186-5189.	0.6	1
3289	Evaluation of combined anti-PD-1 immunotherapy and radiation therapy in a preclinical mouse model of pneumonitis and fibrosis. Journal of Thoracic Disease, 2018, 10, 6254-6260.	0.6	6
3290	Implementing tumor mutational burden (TMB) analysis in routine diagnosticsâ€”a primer for molecular pathologists and clinicians. Translational Lung Cancer Research, 2018, 7, 703-715.	1.3	152

#	ARTICLE	IF	CITATIONS
3291	Real-World Benefit of Nivolumab in A Canadian Non-Small-Cell Lung Cancer Cohort. <i>Current Oncology</i> , 2018, 25, 384-392.	0.9	48
3292	Predictive biomarkers for immune checkpoint inhibitor therapy: we need to keep searching. <i>Journal of Thoracic Disease</i> , 2018, 10, S2195-S2197.	0.6	3
3293	Combination chemotherapy and immunotherapy in metastatic non-small cell lung cancer: a setback for personalized medicine?. <i>Translational Lung Cancer Research</i> , 2018, 7, S208-S210.	1.3	9
3294	Prognostic significance of the fibrinogen-to-albumin ratio in gallbladder cancer patients. <i>World Journal of Gastroenterology</i> , 2018, 24, 3281-3292.	1.4	56
3295	Pulmonary sarcomatoid carcinoma: University of Cincinnati experience. <i>Oncotarget</i> , 2018, 9, 4102-4108.	0.8	47
3296	Immunotherapy in colorectal cancer: for the select few or all?. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 170-179.	0.6	51
3297	Immunotherapy combination strategies (non-chemotherapy) in non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, S433-S450.	0.6	15
3298	Immune checkpoint inhibitors in small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, S460-S467.	0.6	46
3299	Identifying and managing the adverse effects of immune checkpoint blockade. <i>Journal of Thoracic Disease</i> , 2018, 10, S480-S489.	0.6	78
3300	Immune checkpoint inhibitors and small cell lung cancer: what's new?. <i>Journal of Thoracic Disease</i> , 2018, 10, S1503-S1508.	0.6	18
3301	Is there a room for immune checkpoint inhibitors in early stage non-small cell lung cancer?. <i>Journal of Thoracic Disease</i> , 2018, 10, S1427-S1437.	0.6	11
3302	Single nucleotide polymorphisms of casitas B-lineage lymphoma proto-oncogene-b predict outcomes of patients with advanced non-small cell lung cancer after first-line platinum based doublet chemotherapy. <i>Journal of Thoracic Disease</i> , 2018, 10, 1635-1647.	0.6	2
3303	Durvalumab showed long and durable effects after chemoradiotherapy in stage III non-small cell lung cancer: results of the PACIFIC study. <i>Journal of Thoracic Disease</i> , 2018, 10, S1108-S1112.	0.6	15
3304	Biomarkers for the detection of apparent and subclinical cancer therapy-related cardiotoxicity. <i>Journal of Thoracic Disease</i> , 2018, 10, S4282-S4295.	0.6	69
3305	VISTA/PD-1H: a potential target for non-small cell lung cancer immunotherapy. <i>Journal of Thoracic Disease</i> , 2018, 10, 6378-6382.	0.6	13
3306	Nivolumab as first-line treatment in non-small cell lung cancer patients's key factors: tumor mutation burden and PD-L1 ≥50%. <i>Translational Lung Cancer Research</i> , 2018, 7, S28-S30.	1.3	11
3307	Putting the brakes on CTLA-4 inhibition in lung cancer?. <i>Translational Lung Cancer Research</i> , 2018, 7, S35-S38.	1.3	7
3308	Methods of measurement for tumor mutational burden in tumor tissue. <i>Translational Lung Cancer Research</i> , 2018, 7, 661-667.	1.3	166

#	ARTICLE	IF	CITATIONS
3309	Microbial marauders: pancreatic microbiota and its impact on carcinogenesis. <i>Annals of Translational Medicine</i> , 2018, 6, S63-S63.	0.7	2
3310	PD-L1 immunohistochemistry in patients with non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, S2127-S2129.	0.6	7
3311	Harmonization study of antibodies and platforms for programmed death ligand 1 immunostaining in non-small cell lung cancer: does shuffling couples settle the troubles?. <i>Journal of Thoracic Disease</i> , 2018, 10, S2124-S2126.	0.6	1
3312	Clinical relevance of PD-L1 and PD-L2 overexpression in patients with esophageal squamous cell carcinoma. <i>Journal of Thoracic Disease</i> , 2018, 10, 4433-4444.	0.6	24
3313	Atezolizumab in non-squamous non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, S3155-S3159.	0.6	4
3315	Cytology versus histology for programmed death-ligand 1 expression evaluation in the landscape of non-small cell lung cancer patients selection for immunotherapy. <i>Translational Lung Cancer Research</i> , 2018, 7, S221-S224.	1.3	2
3316	The evolving toxicity profile of SBRT for lung cancer. <i>Translational Lung Cancer Research</i> , 2018, 8, 48-57.	1.3	39
3317	Complete response to pembrolizumab in a patient with metastatic colon cancer with microsatellite instability and a history of Guillain-Barre syndrome. <i>Journal of Gastrointestinal Oncology</i> , 2018, 10, 161-165.	0.6	12
3318	Approaches to stereotactic body radiation therapy for large (≥5 centimeter) non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2018, 8, 70-77.	1.3	11
3319	Development of biomarkers for real precision medicine. <i>Translational Lung Cancer Research</i> , 2018, 7, S228-S231.	1.3	0
3320	Combining immunotherapy with radiation therapy in thoracic oncology. <i>Journal of Thoracic Disease</i> , 2018, 10, S2492-S2507.	0.6	16
3321	Programmed death ligand-1 inhibitors potentially carry a lower risk of pneumonitis compared with programmed death-1 inhibitors in patients with non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, S4082-S4084.	0.6	1
3322	Strategies for first-line immunotherapy in squamous cell lung cancer: are combinations a game changer?. <i>Translational Lung Cancer Research</i> , 2018, 7, S198-S201.	1.3	8
3323	PROS: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?. <i>Translational Lung Cancer Research</i> , 2018, 7, S283-S286.	1.3	1
3324	Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: the Mayo Clinic experience. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 1054-1062.	0.6	110
3325	Reversal of resistance to chemotherapy following anti-programmed cell death-1 immunotherapy in metastatic lung adenocarcinoma. <i>Medicine (United States)</i> , 2018, 97, e13427.	0.4	1
3326	Inflammation: A key process in skin tumorigenesis (Review). <i>Oncology Letters</i> , 2018, 17, 4068-4084.	0.8	77
3327	NIBIT-MESO-1: limitations and clinical perspectives in MPM treatment testing an immune checkpoint blockade combination in a single-arm study. <i>Journal of Thoracic Disease</i> , 2018, 10, S3878-S3881.	0.6	0

#	ARTICLE	IF	CITATIONS
3328	A leopard canâ€™t change its spots: can a T790M mutation-positive cancer change its spots after epidermal growth factor receptor-tyrosine kinase inhibitor therapy?. <i>Journal of Thoracic Disease</i> , 2018, 10, S4113-S4113.	0.6	1
3329	Predictive factors of postoperative survival among patients with pulmonary neuroendocrine tumor. <i>Journal of Thoracic Disease</i> , 2018, 10, 6912-6920.	0.6	13
3330	Histology versus cytology: PD-L1 testing in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2018, 7, S225-S227.	1.3	7
3331	Do toxicity patterns vary between programmed death-1 and programmed death ligand-1 inhibitors?. <i>Journal of Thoracic Disease</i> , 2018, 10, S4069-S4072.	0.6	3
3332	Quality of life for non-small cell lung cancer patients in the age of immunotherapy. <i>Translational Lung Cancer Research</i> , 2018, 7, S149-S152.	1.3	17
3333	Tumor Regression and Cure Depends on Sustained Th1 Responses. <i>Journal of Immunotherapy</i> , 2018, 41, 369-378.	1.2	26
3334	Evaluation of T cell infiltration in matched biopsy and nephrectomy samples in renal cell carcinoma. <i>Medicine (United States)</i> , 2018, 97, e12344.	0.4	4
3335	The growing role of precision and personalized medicine for cancer treatment. <i>Technology</i> , 2018, 06, 79-100.	1.4	237
3336	Cutaneous Side Effects of Targeted Therapy and Immunotherapy for Advanced Melanoma. <i>Scientifica</i> , 2018, 2018, 1-7.	0.6	14
3337	Oncolytic viruses and checkpoint inhibitors: combination therapy in clinical trials. <i>Clinical and Translational Medicine</i> , 2018, 7, 35.	1.7	96
3338	Lung cancer and interstitial lung disease: a literature review. <i>Journal of Thoracic Disease</i> , 2018, 10, 3829-3844.	0.6	126
3339	Cons: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?. <i>Translational Lung Cancer Research</i> , 2018, 7, S290-S293.	1.3	2
3340	Companion and complementary diagnostics for first-line immune checkpoint inhibitor treatment in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2018, 7, S95-S99.	1.3	7
3341	The importance of PD-L1 diagnostic assay harmonization for the selection of lung cancer immunotherapy. <i>Journal of Thoracic Disease</i> , 2018, 10, S4096-S4100.	0.6	4
3342	The clinical utility of tumor mutational burden in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2018, 7, 639-646.	1.3	98
3343	Circulating immune biomarkers as predictors of the response to pembrolizumab and weekly low dose carboplatin and paclitaxel in NSCLC and poor PS: An interim analysis. <i>Oncology Letters</i> , 2019, 17, 1349-1356.	0.8	27
3344	The Pattern of Malignancies in Down Syndrome and Its Potential Context With the Immune System. <i>Frontiers in Immunology</i> , 2018, 9, 3058.	2.2	41
3345	Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer. <i>Oncotarget</i> , 2018, 9, 28561-28571.	0.8	129

#	ARTICLE	IF	CITATIONS
3346	Systemic immunological biomarkers of clinical responses in immune checkpoint blockade therapies. Lung Cancer Management, 2018, 7, LMT07.	1.5	1
3347	Ig-Like Transcript 2 (ILT2) Blockade and Lenalidomide Restore NK Cell Function in Chronic Lymphocytic Leukemia. Frontiers in Immunology, 2018, 9, 2917.	2.2	35
3348	ROS1-rearranged high-PD-L1-expressing lung adenocarcinoma manifesting as mediastinal tumor: A case report. Oncology Letters, 2019, 17, 488-491.	0.8	2
3349	Combining immunotherapy and radiotherapy in lung cancer. Journal of Thoracic Disease, 2018, 10, S1447-S1460.	0.6	54
3350	Tumor microenvironment classification based on T-cell infiltration and PD-L1 in patients with mismatch repair-proficient and -deficient colorectal cancer. Oncology Letters, 2018, 17, 2335-2343.	0.8	8
3351	Thrombotic Thrombocytopenic Purpura due to Checkpoint Inhibitors. Case Reports in Hematology, 2018, 2018, 1-4.	0.3	24
3352	Increased serum levels of Galectin-9 in patients with chronic lymphocytic leukemia. Oncology Letters, 2019, 17, 1019-1029.	0.8	10
3353	New drugs and new toxicities: pembrolizumab-induced myocarditis. BMJ Case Reports, 2018, 2018, bcr-2017-223252.	0.2	19
3354	Severe inflammatory ileitis resulting in ileal perforation in association with combination immune checkpoint blockade for metastatic malignant melanoma. BMJ Case Reports, 2018, 2018, bcr-2018-224913.	0.2	10
3355	Severe thromboembolic phenomenon in the setting of pseudoprogression of melanoma brain metastases in response to combination immunotherapy. BMJ Case Reports, 2018, 2018, bcr-2018-226089.	0.2	0
3356	Metastatic primary pulmonary melanoma successfully treated with checkpoint inhibitors. BMJ Case Reports, 2018, 2018, bcr-2017-223025.	0.2	1
3357	Delayed Presentation of Isolated Adrenocorticotropin Insufficiency after Nivolumab Therapy for Advanced Non-small-cell lung carcinoma (NSCLC). BMJ Case Reports, 2018, 2018, bcr-2018-225048.	0.2	14
3358	Personalized Clinical Decision Making Through Implementation of a Molecular Tumor Board: A German Single-Center Experience. JCO Precision Oncology, 2018, 2, 1-16.	1.5	41
3359	Disparities in the Use of Programmed Death 1 Immune Checkpoint Inhibitors. Oncologist, 2018, 23, 1388-1390.	1.9	17
3360	The effectiveness of PD-1 inhibitors in non-small cell lung cancer (NSCLC) patients of different ages. Oncotarget, 2018, 9, 7942-7948.	0.8	27
3361	The efficacy and safety of anti-PD-1/PD-L1 antibody therapy versus docetaxel for pretreated advanced NSCLC: a meta-analysis. Oncotarget, 2018, 9, 4239-4248.	0.8	14
3362	Immune RECIST criteria and symptomatic pseudoprogression in non-small cell lung cancer patients treated with immunotherapy. Radiology and Oncology, 2018, 52, 365-369.	0.6	36
3363	An engineered PD-1-based and MMP-2/9-oriented fusion protein exerts potent antitumor effects against melanoma. BMB Reports, 2018, 51, 572-577.	1.1	4

#	ARTICLE	IF	CITATIONS
3364	Exosomes in melanoma: a role in tumor progression, metastasis and impaired immune system activity. <i>Oncotarget</i> , 2018, 9, 20826-20837.	0.8	97
3365	Future of anti-PD-1/PD-L1 applications: Combinations with other therapeutic regimens. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2018, 30, 157-172.	0.7	40
3366	Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single-agent checkpoint blockade. <i>Clinical and Translational Medicine</i> , 2018, 7, 32.	1.7	29
3367	Actionable Gene Alterations in an Asian Population With Triple-Negative Breast Cancer. <i>JCO Precision Oncology</i> , 2018, 2, 1-13.	1.5	3
3368	Multidisciplinary approach for post-liver transplant recurrence of hepatocellular carcinoma: A proposed management algorithm. <i>World Journal of Gastroenterology</i> , 2018, 24, 5081-5094.	1.4	58
3369	Nivolumab-induced fulminant diabetic ketoacidosis followed by thyroiditis. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2018, 2018, .	0.2	19
3370	The Adaptive Complexity of Cancer. <i>BioMed Research International</i> , 2018, 2018, 1-14.	0.9	17
3371	Regulation of GVHD and GVL Activity via PD-L1 Interaction With PD-1 and CD80. <i>Frontiers in Immunology</i> , 2018, 9, 3061.	2.2	28
3372	Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer. <i>Frontiers in Immunology</i> , 2018, 9, 3081.	2.2	116
3373	A multicenter round robin test of PD-L1 expression assessment in urothelial bladder cancer by immunohistochemistry and RT-qPCR with emphasis on prognosis prediction after radical cystectomy. <i>Oncotarget</i> , 2018, 9, 15001-15014.	0.8	33
3374	Immune Checkpoint Inhibitors in Pediatric Solid Tumors: Status in 2018. <i>Ochsner Journal</i> , 2018, 18, 370-376.	0.5	33
3375	Anti-Inflammatory Biologics and Anti-Tumoral Immune Therapies-Associated Colitis: A Focused Review of Literature. <i>Gastroenterology Research</i> , 2018, 11, 174-188.	0.4	19
3376	Targeting Interleukin-6 (IL-6) Sensitizes Anti-PD-L1 Treatment in a Colorectal Cancer Preclinical Model. <i>Medical Science Monitor</i> , 2018, 24, 5501-5508.	0.5	59
3377	Nivolumab therapy for lung cancer with tracheo-parenchymal fistula. <i>Medicine (United States)</i> , 2018, 97, e13739.	0.4	6
3378	Combination therapy for metastatic melanoma: a pharmacist's role, drug interactions & complementary alternative therapies. <i>Melanoma Management</i> , 2018, 5, MMT07.	0.1	15
3379	Combined intra-arterial and intravenous chemotherapy for unresectable, advanced gastric cancer has an improved curative effect compared with intravenous chemotherapy only. <i>Oncology Letters</i> , 2018, 15, 5662-5670.	0.8	5
3380	Real-world PD-L1 testing and distribution of PD-L1 tumor expression by immunohistochemistry assay type among patients with metastatic non-small cell lung cancer in the United States. <i>PLoS ONE</i> , 2018, 13, e0206370.	1.1	58
3381	Emerging Role of Immune Checkpoint Blockade in Pancreatic Cancer. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3505.	1.8	69

#	ARTICLE	IF	CITATIONS
3382	Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. <i>BMJ: British Medical Journal</i> , 2018, 363, k4226.	2.4	362
3383	Whatever happened to the Shwartzman phenomenon?. <i>Innate Immunity</i> , 2018, 24, 466-479.	1.1	17
3384	The Role of Melanoma Cell-Stroma Interaction in Cell Motility, Invasion, and Metastasis. <i>Frontiers in Medicine</i> , 2018, 5, 307.	1.2	27
3385	Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma. <i>Frontiers in Immunology</i> , 2018, 9, 2431.	2.2	85
3386	The Evolving Understanding of the Molecular and Therapeutic Landscape of Pancreatic Ductal Adenocarcinoma. <i>Diseases (Basel, Switzerland)</i> , 2018, 6, 103.	1.0	7
3387	From Friend to Enemy: Dissecting the Functional Alteration of Immunoregulatory Components during Pancreatic Tumorigenesis. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3584.	1.8	10
3388	Carbohydrate Targets for CAR T Cells in Solid Childhood Cancers. <i>Frontiers in Oncology</i> , 2018, 8, 513.	1.3	29
3389	T-Cell Exhaustion in Chronic Infections: Reversing the State of Exhaustion and Reinvigorating Optimal Protective Immune Responses. <i>Frontiers in Immunology</i> , 2018, 9, 2569.	2.2	241
3390	Resistance to anti-PD-1-based immunotherapy in basal cell carcinoma: a case report and review of the literature. , 2018, 6, 126.		40
3391	Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma. , 2018, 6, 124.		89
3392	Combatting mucosal melanoma: recent advances and future perspectives. <i>Melanoma Management</i> , 2018, 5, MMT11.	0.1	75
3393	CAR T Cell Therapy for Neuroblastoma. <i>Frontiers in Immunology</i> , 2018, 9, 2380.	2.2	107
3394	Mutations in DNA repair genes are associated with increased neo-antigen load and activated T cell infiltration in lung adenocarcinoma. <i>Oncotarget</i> , 2018, 9, 7949-7960.	0.8	49
3395	The impact of immunosenescence on the efficacy of immune checkpoint inhibitors in melanoma patients: a meta-analysis. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 7521-7527.	1.0	21
3396	Clinical and molecular characteristics associated with the efficacy of PD-1/PD-L1 inhibitors for solid tumors: a meta-analysis. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 7529-7542.	1.0	29
3397	A meta-analysis of nivolumab for the treatment of advanced non-small-cell lung cancer. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 7691-7697.	1.0	6
3398	Clinical efficacy of immune checkpoint inhibitors in the treatment of unresectable advanced or recurrent gastric cancer: an evidence-based review of therapies. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 8239-8250.	1.0	32
3399	Checkpoint inhibitor use in two heart transplant patients with metastatic melanoma and review of high-risk populations. <i>Melanoma Management</i> , 2018, 5, MMT10.	0.1	19

#	ARTICLE	IF	CITATIONS
3400	Radiation Therapy and Immunotherapyâ€”A Potential Combination in Cancer Treatment. <i>Current Oncology</i> , 2018, 25, 454-460.	0.9	29
3401	Predictors of Immunotherapy-Induced Immune-Related Adverse Events. <i>Current Oncology</i> , 2018, 25, 403-410.	0.9	77
3402	Immune-Related Adverse Events of Immune Checkpoint Inhibitors: A Brief Review. <i>Current Oncology</i> , 2018, 25, 342-347.	0.9	98
3403	Nivolumabâ€”induced severe acute kidney injury with a long latent phase in a patient with nonâ€”smallâ€”cell lung cancer: A case report. <i>Clinical Case Reports (discontinued)</i> , 2018, 6, 2185-2188.	0.2	9
3404	A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors. , 2018, 6, 128.		233
3405	Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies. , 2018, 6, 129.		95
3406	Non-small cell to small cell lung cancer on PD-1 inhibitors: two cases on potential histologic transformation. <i>Lung Cancer: Targets and Therapy</i> , 2018, Volume 9, 85-90.	1.3	20
3407	How Does an Anti-CTLA-4 Antibody Promote Cancer Immunity?. <i>Trends in Immunology</i> , 2018, 39, 953-956.	2.9	55
3408	Lung cancer, elderly and immune checkpoint inhibitors. <i>Journal of Thoracic Disease</i> , 2018, 10, S1474-S1481.	0.6	25
3409	Serum Level of Soluble CD163 May Be a Predictive Marker of the Effectiveness of Nivolumab in Patients With Advanced Cutaneous Melanoma. <i>Frontiers in Oncology</i> , 2018, 8, 530.	1.3	27
3410	Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. <i>Lancet Oncology, The</i> , 2018, 19, 1579-1589.	5.1	742
3411	Immune checkpoint inhibitors in the management of malignancies in transplant recipients. <i>Postgraduate Medical Journal</i> , 2018, 94, 704-708.	0.9	10
3412	The Central Role of Inflammation Associated with Checkpoint Inhibitor Treatments. <i>Journal of Immunology Research</i> , 2018, 2018, 1-10.	0.9	26
3413	Combination Immune Checkpoint Blockade Strategies to Maximize Immune Response in Gynecological Cancers. <i>Current Oncology Reports</i> , 2018, 20, 94.	1.8	43
3414	Assessment of proportional hazard assumption in aggregate data: a systematic review on statistical methodology in clinical trials using time-to-event endpoint. <i>British Journal of Cancer</i> , 2018, 119, 1456-1463.	2.9	43
3415	Successful response to the combination of immunotherapy and chemotherapy in cholangiocarcinoma with high tumour mutational burden and PD-L1 expression: a case report. <i>BMC Cancer</i> , 2018, 18, 1105.	1.1	48
3416	Updates on immunotherapy for colorectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 160-169.	0.6	126
3417	Tucum-do-cerrado (<i>Bactris setosa</i> Mart.) modulates oxidative stress, inflammation, and apoptosis-related proteins in rats treated with azoxymethane. <i>PLoS ONE</i> , 2018, 13, e0206670.	1.1	6

#	ARTICLE	IF	CITATIONS
3418	Predictive Factors of Nivolumab-induced Hypothyroidism in Patients with Non-small Cell Lung Cancer. <i>In Vivo</i> , 2018, 31, 1035-1039.	0.6	32
3419	Mathematical modeling identifies Lck as a potential mediator for PD-1 induced inhibition of early TCR signaling. <i>PLoS ONE</i> , 2018, 13, e0206232.	1.1	22
3420	Are Clinical Trial Eligibility Criteria an Accurate Reflection of a Real-World Population of Advanced Non-Small-Cell Lung Cancer Patients?. <i>Current Oncology</i> , 2018, 25, 291-297.	0.9	37
3421	β-catenin is a marker of poor clinical characteristics and suppressed immune infiltration in testicular germ cell tumors. <i>BMC Cancer</i> , 2018, 18, 1062.	1.1	20
3422	Current Landscape of Immunotherapy in the Treatment of Solid Tumours, with Future Opportunities and Challenges. <i>Current Oncology</i> , 2018, 25, 373-384.	0.9	109
3423	Chemoresistance of Cancer Cells: Requirements of Tumor Microenvironment-mimicking <i>In Vitro</i> Models in Anti-Cancer Drug Development. <i>Theranostics</i> , 2018, 8, 5259-5275.	4.6	138
3424	The Role of PD-1 Checkpoint Inhibition in Gynecologic Malignancies. <i>Current Treatment Options in Oncology</i> , 2018, 19, 70.	1.3	17
3425	Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer. <i>Nature Communications</i> , 2018, 9, 4664.	5.8	331
3426	Criticality in tumor evolution and clinical outcome. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E11101-E11110.	3.3	23
3427	⁶⁸ Ga-DOTA-GGNle-CycMSH _{hex} targets the melanocortin-1 receptor for melanoma imaging. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	30
3428	The Role of Co-Stimulatory Molecules in Chagas Disease. <i>Cells</i> , 2018, 7, 200.	1.8	6
3429	Analysis of PD-1 related immune transcriptional profile in different cancer types. <i>Cancer Cell International</i> , 2018, 18, 218.	1.8	15
3430	T-cell functionality testing is highly relevant to developing novel immuno-tracers monitoring T cells in the context of immunotherapies and revealed CD7 as an attractive target. <i>Theranostics</i> , 2018, 8, 6070-6087.	4.6	28
3431	How to Increase the Efficacy of Immunotherapy in NSCLC and HNSCC: Role of Radiation Therapy, Chemotherapy, and Other Strategies. <i>Frontiers in Immunology</i> , 2018, 9, 2941.	2.2	20
3432	Effects of mir-128a on the invasion and proliferation of glioma U251 cells. <i>Oncology Letters</i> , 2018, 17, 891-896.	0.8	3
3433	Assembly 11: thoracic oncology. <i>Breathe</i> , 2018, 14, 163-164.	0.6	0
3434	A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy. , 2018, 6, 156.		58
3435	Anorectal mucosal melanoma. <i>Oncotarget</i> , 2018, 9, 8785-8800.	0.8	68

#	ARTICLE	IF	CITATIONS
3454	Comparative Transcriptomics Unravels Prodigiosin's Potential Cancer-Specific Activity Between Human Small Airway Epithelial Cells and Lung Adenocarcinoma Cells. <i>Frontiers in Oncology</i> , 2018, 8, 573.	1.3	11
3455	Isolated adrenocorticotrophic hormone deficiency potentially induced by nivolumab following pseudo-progression in clear cell renal cell carcinoma: A case report. <i>Molecular and Clinical Oncology</i> , 2018, 10, 304-308.	0.4	10
3456	Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer. <i>Npj Breast Cancer</i> , 2018, 4, 40.	2.3	36
3457	A phase II trial of recombinant MAGE-A3 protein with immunostimulant AS15 in combination with high-dose Interleukin-2 (HDIL2) induction therapy in metastatic melanoma. <i>BMC Cancer</i> , 2018, 18, 1274.	1.1	31
3458	The clinical promise of immunotherapy in triple-negative breast cancer. <i>Cancer Management and Research</i> , 2018, Volume 10, 6823-6833.	0.9	113
3459	Local ablative therapy with or without chemotherapy for non-small-cell lung cancer patients with postoperative oligometastases. <i>Cancer Management and Research</i> , 2018, Volume 10, 6421-6429.	0.9	3
3460	Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 8565-8573.	1.0	8
3461	Artificial T Cell Mimetics to Combat Melanoma Tumor Growth. <i>American Journal of Advanced Drug Delivery</i> , 2018, 06, .	0.1	2
3462	Analysis of expression of the PD-1/PD-L1 immune checkpoint system and its prognostic impact in gastroenteropancreatic neuroendocrine tumors. <i>Scientific Reports</i> , 2018, 8, 17812.	1.6	39
3463	The Increase of Circulating PD-1- and PD-L1-Expressing Lymphocytes in Endometriosis: Correlation with Clinical and Laboratory Parameters. <i>Mediators of Inflammation</i> , 2018, 2018, 1-12.	1.4	23
3464	The Relative Risk and Incidence of Immune Checkpoint Inhibitors Related Pneumonitis in Patients With Advanced Cancer: A Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2018, 9, 1430.	1.6	88
3465	Two-Round Mixed Lymphocyte Reaction for Evaluation of the Functional Activities of Anti-PD-1 and Immunomodulators. <i>Immune Network</i> , 2018, 18, e45.	1.6	10
3466	Neoadjuvant PD-1 blockade in lung cancer: we're not in Kansas anymore. <i>Journal of Thoracic Disease</i> , 2018, 10, 4686-4688.	0.6	0
3467	Orchestration of immune checkpoints in tumor immune contexture and their prognostic significance in esophageal squamous cell carcinoma. <i>Cancer Management and Research</i> , 2018, Volume 10, 6457-6468.	0.9	23
3468	The Era of Immune Checkpoint Therapy: From Cancer to Viral Infection—A Mini Comment on the 2018 Medicine Nobel Prize. <i>Virologica Sinica</i> , 2018, 33, 467-471.	1.2	9
3469	Targeted radiotherapy of pigmented melanoma with 131I-IPN. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 306.	3.5	12
3470	The Role of Yes-Associated Protein (YAP) in Regulating Programmed Death-Ligand 1 (PD-L1) in Thoracic Cancer. <i>Biomedicines</i> , 2018, 6, 114.	1.4	28
3471	Gene code CD274/PD-L1: from molecular basis toward cancer immunotherapy. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591881559.	1.4	38

#	ARTICLE	IF	CITATIONS
3472	Recent updates in cancer immunotherapy: a comprehensive review and perspective of the 2018 China Cancer Immunotherapy Workshop in Beijing. <i>Journal of Hematology and Oncology</i> , 2018, 11, 142.	6.9	95
3473	PD-L1 monoclonal antibody-conjugated nanoparticles enhance drug delivery level and chemotherapy efficacy in gastric cancer cells. <i>International Journal of Nanomedicine</i> , 2019, Volume 14, 17-32.	3.3	72
3474	MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	97
3475	Association of PD-1 and PD-L1 Genetic Polymorphisms with Type 1 Diabetes Susceptibility. <i>Journal of Diabetes Research</i> , 2018, 2018, 1-7.	1.0	27
3476	Clinical evaluation of the utility of a flexible 19-gauge EBUS-TBNA needle. <i>Journal of Thoracic Disease</i> , 2018, 10, 2388-2396.	0.6	23
3477	Tumor mutational burden (TMB) as a biomarker of response to immunotherapy in small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, 4689-4693.	0.6	57
3478	Organoid Modeling of the Tumor Immune Microenvironment. <i>Cell</i> , 2018, 175, 1972-1988.e16.	13.5	870
3479	Programmed cell death ligand-1 (PD-L1) as a biomarker for non-small cell lung cancer (NSCLC) treatment—are we barking up the wrong tree?. <i>Translational Lung Cancer Research</i> , 2018, 7, S275-S279.	1.3	36
3480	Promises and Pitfalls in the Use of PD-1/PD-L1 Inhibitors in Multiple Myeloma. <i>Frontiers in Immunology</i> , 2018, 9, 2749.	2.2	41
3481	Immune checkpoint inhibitors in cancer therapy. <i>Journal of Biomedical Research</i> , 2018, 32, 317.	0.7	101
3482	Systematic review and meta-analysis of third-line salvage therapy for the treatment of advanced non-small-cell lung cancer: A meta-analysis of randomized controlled trials. <i>Oncotarget</i> , 2018, 9, 35439-35447.	0.8	2
3483	Real-world evaluation of carboplatin plus a weekly dose of nab-paclitaxel for patients with advanced non-small-cell lung cancer with interstitial lung disease. <i>Cancer Management and Research</i> , 2018, Volume 10, 7013-7019.	0.9	10
3484	Renal Cell Carcinoma (RCC) Tumors Display Large Expansion of Double Positive (DP) CD4+CD8+ T Cells With Expression of Exhaustion Markers. <i>Frontiers in Immunology</i> , 2018, 9, 2728.	2.2	39
3485	Progresses and Perspectives of Anti-PD-1/PD-L1 Antibody Therapy in Head and Neck Cancers. <i>Frontiers in Oncology</i> , 2018, 8, 563.	1.3	35
3486	Current Status and Future Opportunities in Lung Precision Medicine Research with a Focus on Biomarkers. An American Thoracic Society/National Heart, Lung, and Blood Institute Research Statement. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, e116-e136.	2.5	49
3487	Association between PD-L1 expression and driver gene status in non-small-cell lung cancer: a meta-analysis. <i>Oncotarget</i> , 2018, 9, 7684-7699.	0.8	62
3488	Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials. <i>Journal of Clinical Medicine</i> , 2018, 7, 542.	1.0	64
3489	Immune checkpoint inhibitors in the onset of myasthenia gravis with hyperkalemia. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 1421-1427.	1.7	31

#	ARTICLE	IF	CITATIONS
3490	2018 Nobel Prize in medicine awarded to cancer immunotherapy: Immune checkpoint blockade â€“ A personal account. <i>Genes and Diseases</i> , 2018, 5, 302-303.	1.5	32
3491	Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations. , 2018, 6, 141.		214
3492	Genomic Characteristics of Invasive Mucinous Adenocarcinomas of the Lung and Potential Therapeutic Targets of B7-H3. <i>Cancers</i> , 2018, 10, 478.	1.7	30
3493	Combination of chemotherapy and physical plasma elicits melanoma cell death via upregulation of SLC22A16. <i>Cell Death and Disease</i> , 2018, 9, 1179.	2.7	88
3494	The BET-bromodomain inhibitor JQ1 mitigates vemurafenib drug resistance in melanoma. <i>Melanoma Research</i> , 2018, 28, 521-526.	0.6	13
3495	Deep Semi Supervised Generative Learning for Automated Tumor Proportion Scoring on NSCLC Tissue Needle Biopsies. <i>Scientific Reports</i> , 2018, 8, 17343.	1.6	75
3496	Expression of the immune checkpoint receptor TIGIT in Hodgkinâ€™s lymphoma. <i>BMC Cancer</i> , 2018, 18, 1209.	1.1	28
3497	Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitorâ€“induced colitis: a multi-center study. , 2018, 6, 142.		146
3498	Prognostic Value of Lymphocyte Activation Gene-3 (LAG-3) Expression in Esophageal Squamous Cell Carcinoma. <i>Journal of Cancer</i> , 2018, 9, 4287-4293.	1.2	34
3499	The Clinical and Biomarker Association of Programmed Death Ligand 1 and its Spatial Heterogeneous Expression in Colorectal Cancer. <i>Journal of Cancer</i> , 2018, 9, 4325-4333.	1.2	16
3500	Does the Immunocompetent Status of Cancer Patients Have an Impact on Therapeutic DC Vaccination Strategies?. <i>Vaccines</i> , 2018, 6, 79.	2.1	7
3501	Atypical response with bone pseudoprogression in a patient receiving nivolumab for advanced cutaneous squamous cell carcinoma. , 2018, 6, 130.		10
3502	Immunological targets for cancer therapy: new recognition. <i>ImmunoTargets and Therapy</i> , 2018, Volume 7, 83-85.	2.7	13
3503	Liver Allograft Failure After Nivolumab Treatmentâ€“A Case Report With Systematic Literature Research. <i>Transplantation Direct</i> , 2018, 4, e376.	0.8	98
3504	Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine. <i>Genome Medicine</i> , 2018, 10, 93.	3.6	121
3505	Human preprocalcitonin self-antigen generates TAP-dependent and -independent epitopes triggering optimised T-cell responses toward immune-escaped tumours. <i>Nature Communications</i> , 2018, 9, 5097.	5.8	21
3506	The Balancing Act between Cancer Immunity and Autoimmunity in Response to Immunotherapy. <i>Cancer Immunology Research</i> , 2018, 6, 1445-1452.	1.6	132
3507	Successful Use of Pembrolizumab to Treat Refractory Thymic Carcinoma with High PD-L1 Expression. <i>Case Reports in Oncology</i> , 2018, 11, 688-692.	0.3	7

#	ARTICLE	IF	CITATIONS
3508	Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatment. <i>Cancer Management and Research</i> , 2018, Volume 10, 5537-5544.	0.9	1
3509	Crosstalk Between PD-1/PD-L1 Blockade and Its Combinatorial Therapies in Tumor Immune Microenvironment: A Focus on HNSCC. <i>Frontiers in Oncology</i> , 2018, 8, 532.	1.3	27
3510	Statins improve survival in patients previously treated with nivolumab for advanced non-small cell lung cancer: An observational study. <i>Molecular and Clinical Oncology</i> , 2018, 10, 137-143.	0.4	39
3511	Durable Clinical Responses and Long-Term Follow-Up of Stage III-IV Non-Small-Cell Lung Cancer (NSCLC) Patients Treated With IDO Peptide Vaccine in a Phase I Study—A Brief Research Report. <i>Frontiers in Immunology</i> , 2018, 9, 2145.	2.2	37
3512	The systemic immune-inflammation index is an independent predictor of survival for metastatic colorectal cancer and its association with the lymphocytic response to the tumor. <i>Journal of Translational Medicine</i> , 2018, 16, 273.	1.8	73
3513	PD-1 Inhibitor Immune-Related Adverse Events in Patients With Preexisting Endocrine Autoimmunity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 3589-3592.	1.8	35
3514	Distribution of CD4 ⁺ and CD8 ⁺ exhausted tumor-infiltrating lymphocytes in molecular subtypes of Chinese breast cancer patients. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 6139-6145.	1.0	6
3515	Immunotherapy combined with epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer treatment. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 6189-6196.	1.0	47
3516	Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. <i>Nature Medicine</i> , 2018, 24, 1649-1654.	15.2	592
3517	A review of guidelines for lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, S1556-S1563.	0.6	64
3518	Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer. <i>Chest</i> , 2018, 154, 1416-1423.	0.4	230
3519	Diffuse alveolar hemorrhage with pseudoprogression during nivolumab therapy in a patient with malignant melanoma. <i>Thoracic Cancer</i> , 2018, 9, 1522-1524.	0.8	9
3520	Pleural or pericardial metastasis: A significant factor affecting efficacy and adverse events in lung cancer patients treated with PD-1/PD-L1 inhibitors. <i>Thoracic Cancer</i> , 2018, 9, 1500-1508.	0.8	18
3521	Genomic Characterization of Six Virus-Associated Cancers Identifies Changes in the Tumor Immune Microenvironment and Altered Genetic Programs. <i>Cancer Research</i> , 2018, 78, 6413-6423.	0.4	33
3522	Nivolumab for the treatment of Japanese patients with advanced metastatic non-small cell lung cancer: a review of clinical trial evidence for efficacy and safety. <i>Therapeutic Advances in Respiratory Disease</i> , 2018, 12, 175346661880116.	1.0	5
3523	Early Detection and Chemoprevention of Lung Cancer. <i>F1000Research</i> , 2018, 7, 61.	0.8	19
3524	The role of radiology in the evaluation of the immunotherapy efficacy. <i>Journal of Thoracic Disease</i> , 2018, 10, S1438-S1446.	0.6	22
3525	The role of cancer stem cells in the modulation of anti-tumor immune responses. <i>Seminars in Cancer Biology</i> , 2018, 53, 189-200.	4.3	80

#	ARTICLE	IF	CITATIONS
3526	Response to PD1 inhibition in conventional chondrosarcoma. , 2018, 6, 94.		26
3527	Clinical observation of immune checkpoint inhibitors in the treatment of advanced pancreatic cancer: a real-world study in Chinese cohort. Therapeutics and Clinical Risk Management, 2018, Volume 14, 1691-1700.	0.9	8
3528	IgA Nephropathy after Nivolumab Therapy for Postoperative Recurrence of Lung Squamous Cell Carcinoma. Internal Medicine, 2018, 57, 1259-1263.	0.3	53
3529	Increased Risk for Malignancies in 131 Affected CTLA4 Mutation Carriers. Frontiers in Immunology, 2018, 9, 2012.	2.2	79
3530	Cancer/testis antigens (CTAs) expression in resected lung cancer. OncoTargets and Therapy, 2018, Volume 11, 4491-4499.	1.0	20
3531	Cancer Immunotherapy in Diffuse Large B-Cell Lymphoma. Frontiers in Oncology, 2018, 8, 351.	1.3	71
3532	Not All Immune Checkpoints Are Created Equal. Frontiers in Immunology, 2018, 9, 1909.	2.2	114
3533	Thyroid disorders induced by checkpoint inhibitors. Reviews in Endocrine and Metabolic Disorders, 2018, 19, 325-333.	2.6	87
3534	Immunotherapy for Merkel Cell Carcinoma. Current Treatment Options in Oncology, 2018, 19, 57.	1.3	12
3535	A High-Throughput Immune-Oncology Screen Identifies EGFR Inhibitors as Potent Enhancers of Antigen-Specific Cytotoxic T-lymphocyte Tumor Cell Killing. Cancer Immunology Research, 2018, 6, 1511-1523.	1.6	59
3536	Profile of atezolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives. Drug Design, Development and Therapy, 2018, Volume 12, 2857-2873.	2.0	10
3537	Pembrolizumab and salvage chemotherapy in EGFR T790M-positive non-small-cell lung cancer with high PD-L1 expression. OncoTargets and Therapy, 2018, Volume 11, 5601-5605.	1.0	7
3538	Comparison of Protein and Peptide Targeting for the Development of a CD169-Based Vaccination Strategy Against Melanoma. Frontiers in Immunology, 2018, 9, 1997.	2.2	16
3539	Systemic treatment for hepatocellular carcinoma. Chronic Diseases and Translational Medicine, 2018, 4, 148-155.	0.9	8
3540	CD8+ T cells modulate autosomal dominant polycystic kidney disease progression. Kidney International, 2018, 94, 1127-1140.	2.6	54
3541	Single-cell transcriptomics reveal that PD-1 mediates immune tolerance by regulating proliferation of regulatory T cells. Genome Medicine, 2018, 10, 71.	3.6	30
3542	Establishment of a prospective multicenter cohort for advanced non-small cell lung cancer in China (CAPTRA-Lung study). Thoracic Cancer, 2018, 9, 1795-1800.	0.8	3
3543	Immune-related adverse events and atypical radiological response with checkpoint inhibitor immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma. Oncotarget, 2018, 9, 33043-33049.	0.8	13

#	ARTICLE	IF	CITATIONS
3544	Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy. Trends in Biochemical Sciences, 2018, 43, 1014-1032.	3.7	151
3545	Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes and Development, 2018, 32, 1267-1284.	2.7	1,326
3546	EF Hand Domain Family Member D2 Is Required for T Cell Cytotoxicity. Journal of Immunology, 2018, 201, 2824-2831.	0.4	13
3547	Programmed Cell Death-1/Programmed Death-Ligand 1 Blockade Improves Survival of Animals with Sepsis: A Systematic Review and Meta-Analysis. BioMed Research International, 2018, 2018, 1-8.	0.9	7
3548	Body mass index may predict the response to ipilimumab in metastatic melanoma: An observational multi-centre study. PLoS ONE, 2018, 13, e0204729.	1.1	83
3549	PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer. OncoTargets and Therapy, 2018, Volume 11, 5973-5989.	1.0	94
3550	A real-world, comparative study of FDA-approved diagnostic assays PD-L1 IHC 28-8 and 22C3 in lung cancer and other malignancies. Journal of Clinical Pathology, 2018, 71, 1078-1083.	1.0	33
3551	Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences. Frontiers in Pharmacology, 2018, 9, 1050.	1.6	48
3552	A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell, 2018, 175, 313-326.	13.5	985
3553	Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients. , 2018, 6, 101.		31
3554	PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy. Cancer Biology and Medicine, 2018, 15, 116.	1.4	52
3555	Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316). BMC Cancer, 2018, 18, 946.	1.1	32
3556	PD-L1/PD-1 crosstalk in colorectal cancer: are we targeting the right cells?. BMC Cancer, 2018, 18, 945.	1.1	19
3557	Durable response to anti-PD-1 immunotherapy in epithelioid angiomyolipoma: a report on the successful treatment of a rare malignancy. , 2018, 6, 97.		19
3558	A nomogram-based immunoprofile predicts overall survival for previously untreated patients with esophageal squamous cell carcinoma after esophagectomy. , 2018, 6, 100.		53
3559	Improved Cancer Immunochemotherapy via Optimal Co-delivery of Chemotherapeutic and Immunomodulatory Agents. Molecular Pharmaceutics, 2018, 15, 5162-5173.	2.3	20
3560	T Cell Calcium Signaling Regulation by the Co-Receptor CD5. International Journal of Molecular Sciences, 2018, 19, 1295.	1.8	20
3561	The World of Melanoma: Epidemiologic, Genetic, and Anatomic Differences of Melanoma Across the Globe. Current Oncology Reports, 2018, 20, 87.	1.8	119

#	ARTICLE	IF	CITATIONS
3562	Key questions about the checkpoint blockade-are microRNAs an answer?. <i>Cancer Biology and Medicine</i> , 2018, 15, 103.	1.4	36
3563	Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients. <i>Journal of Visualized Experiments</i> , 2018, , .	0.2	1
3564	Expression of the Immune Checkpoint Modulator OX40 in Acute Lymphoblastic Leukemia Is Associated with BCR-ABL Positivity. <i>Neoplasia</i> , 2018, 20, 1150-1160.	2.3	14
3565	Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1). <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E10119-E10126.	3.3	180
3566	Positive & Negative Roles of Innate Effector Cells in Controlling Cancer Progression. <i>Frontiers in Immunology</i> , 2018, 9, 1990.	2.2	29
3567	On the Road to Immunotherapy—Prospects for Treating Head and Neck Cancers With Checkpoint Inhibitor Antibodies. <i>Frontiers in Immunology</i> , 2018, 9, 2182.	2.2	15
3568	Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. <i>Science</i> , 2018, 362, .	6.0	1,575
3569	A case of interstitial lung disease with alveolar hemorrhage induced by pembrolizumab. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 5879-5883.	1.0	10
3570	Stereotactic Radiosurgery and Immune Checkpoint Inhibitors in the Management of Brain Metastases. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3054.	1.8	44
3571	Low Baseline Serum Sodium Concentration Is Associated with Poor Clinical Outcomes in Metastatic Non-Small Cell Lung Cancer Patients Treated with Immunotherapy. <i>Targeted Oncology</i> , 2018, 13, 795-800.	1.7	15
3572	Post-treatment changes in hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patients. <i>PLoS ONE</i> , 2018, 13, e0197743.	1.1	50
3573	Experimental animal study of docetaxel combined with carboplatin in the treatment of retinoblastoma. <i>Oncology Letters</i> , 2018, 16, 235-238.	0.8	0
3574	Clinical significance of programmed death 1 ligand-1 (CD274/PD-L1) and intra-tumoral CD8+ T-cell infiltration in stage II–III colorectal cancer. <i>Scientific Reports</i> , 2018, 8, 15658.	1.6	49
3575	Combination of immune checkpoint blockade with DNA cancer vaccine induces potent antitumor immunity against P815 mastocytoma. <i>Scientific Reports</i> , 2018, 8, 15732.	1.6	23
3576	Characteristics and outcomes of patients with recurrent ovarian cancer undergoing early phase immune checkpoint inhibitor clinical trials. <i>Gynecologic Oncology</i> , 2018, 151, 407-413.	0.6	17
3578	Checkpoint Inhibition: Will Combination with Radiotherapy and Nanoparticle-Mediated Delivery Improve Efficacy?. <i>Medicines (Basel, Switzerland)</i> , 2018, 5, 114.	0.7	17
3579	Effect of anesthetic methods on postoperative CD3+, CD4+ and CD4+CD25+ in patients with lung cancer undergoing radical operation. <i>Oncology Letters</i> , 2018, 16, 6547-6551.	0.8	5
3580	Current frontline approaches in the management of hepatocellular carcinoma: the evolving role of immunotherapy. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 175628481880808.	1.4	10

#	ARTICLE	IF	CITATIONS
3581	Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again. <i>Genome Medicine</i> , 2018, 10, 79.	3.6	36
3582	Toxicity of radiation and immunotherapy combinations. <i>Advances in Radiation Oncology</i> , 2018, 3, 506-511.	0.6	42
3583	Generating antitumor immunity by targeted radiation therapy: Role of dose and fractionation. <i>Advances in Radiation Oncology</i> , 2018, 3, 486-493.	0.6	48
3584	Next generation immune-checkpoints for cancer therapy. <i>Journal of Thoracic Disease</i> , 2018, 10, S1581-S1601.	0.6	50
3585	Efficacy and safety of apatinib in patients with advanced nonsmall cell lung cancer that failed prior chemotherapy or EGFR-TKIs. <i>Medicine (United States)</i> , 2018, 97, e12083.	0.4	12
3586	Inhibitory Receptors and Pathways of Lymphocytes: The Role of PD-1 in Treg Development and Their Involvement in Autoimmunity Onset and Cancer Progression. <i>Frontiers in Immunology</i> , 2018, 9, 2374.	2.2	150
3587	Retrospective Side Effect Profiling of the Metastatic Melanoma Combination Therapy Ipilimumab-Nivolumab Using Adverse Event Data. <i>Diagnostics</i> , 2018, 8, 76.	1.3	23
3588	Chronic Obstructive Pulmonary Disease and Lung Cancer: Underlying Pathophysiology and New Therapeutic Modalities. <i>Drugs</i> , 2018, 78, 1717-1740.	4.9	62
3589	Association of Inflammatory Markers with Disease Progression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors. , 2018, 22, 17-149.		11
3590	2018 Nobel Prize in physiology or medicine. <i>Clinical and Translational Immunology</i> , 2018, 7, e1041.	1.7	41
3592	Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection. <i>European Journal of Cancer</i> , 2018, 104, 137-144.	1.3	97
3593	The immunologic constant of rejection classification refines the prognostic value of conventional prognostic signatures in breast cancer. <i>British Journal of Cancer</i> , 2018, 119, 1383-1391.	2.9	54
3594	Anti-PD-1/PD-L1 Antibody Therapy for Pretreated Advanced or Metastatic Nonsmall Cell Lung Carcinomas and the Correlation between PD-L1 Expression and Treatment Effectiveness: An Update Meta-Analysis of Randomized Clinical Trials. <i>BioMed Research International</i> , 2018, 2018, 1-9.	0.9	16
3595	Durvalumab in NSCLC: latest evidence and clinical potential. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591880415.	1.4	22
3596	Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study. , 2018, 6, 109.		151
3597	Trial Reporting in Immuno-Oncology (TRIO): An American Society of Clinical Oncology-Society for Immunotherapy of Cancer Statement. , 2018, 6, 108.		16
3598	Predictive biomarkers for tumor immune checkpoint blockade. <i>Cancer Management and Research</i> , 2018, Volume 10, 4501-4507.	0.9	18
3599	Somatic mutation profiling of liver and biliary cancer by targeted next generation sequencing. <i>Oncology Letters</i> , 2018, 16, 6003-6012.	0.8	8

#	ARTICLE	IF	CITATIONS
3600	FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients With NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1733-1742.	0.5	120
3601	Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1884-1896.	0.5	78
3602	Tubulointerstitial and intraglomerular metastasis with subsequent development of tumor lysis syndrome in a patient with advanced metastatic melanoma. <i>Journal of Onco-Nephrology</i> , 2018, 2, 24-30.	0.3	2
3603	A case report of eyelid Merkel cell carcinoma occurring under treatment with nivolumab for a lung adenocarcinoma. <i>BMC Cancer</i> , 2018, 18, 1024.	1.1	3
3604	Radiological Features of Programmed Cell Death-Ligand 2-positive Lung Adenocarcinoma: A Single-institution Retrospective Study. <i>In Vivo</i> , 2018, 32, 1541-1550.	0.6	4
3605	Tobacco smoking and cessation and PD-L1 inhibitors in non-small cell lung cancer (NSCLC): a review of the literature. <i>ESMO Open</i> , 2018, 3, e000406.	2.0	84
3606	The Protein Expression of PDL1 Is Highly Correlated with Those of eIF2 α and ATF4 in Lung Cancer. <i>Disease Markers</i> , 2018, 2018, 1-9.	0.6	13
3607	Management of Persistent Pruritus and Lichenoid Reaction Secondary to Nivolumab With Narrowband Ultraviolet B Phototherapy. <i>Frontiers in Oncology</i> , 2018, 8, 405.	1.3	14
3609	Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment. , 2018, 6, 106.		138
3610	Predictive value of LDH kinetics in bevacizumab treatment and survival of patients with advanced NSCLC. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 6287-6294.	1.0	17
3611	Targeted Intracellular Delivery of Antibodies: The State of the Art. <i>Frontiers in Pharmacology</i> , 2018, 9, 1208.	1.6	144
3612	Tumor Type-Agnostic Treatment and the Future of Cancer Therapy. <i>Targeted Oncology</i> , 2018, 13, 541-544.	1.7	7
3613	Checkpoint-inhibition in ovarian cancer: rising star or just a dream?. <i>Journal of Gynecologic Oncology</i> , 2018, 29, e93.	1.0	37
3614	Prognostic value of PD-L1 expression in resected lung adenocarcinoma and potential molecular mechanisms. <i>Journal of Cancer</i> , 2018, 9, 3489-3499.	1.2	12
3615	Treatment of metastatic non-small cell lung cancer with NY-ESO-1 specific TCR engineered T cells in a phase I clinical trial: A case report. <i>Oncology Letters</i> , 2018, 16, 6998-7007.	0.8	29
3616	Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy. <i>British Journal of Cancer</i> , 2018, 119, 950-960.	2.9	133
3617	Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. , 2018, 6, 103.		130
3618	Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials. <i>Oncotarget</i> , 2018, 9, 8706-8715.	0.8	75

#	ARTICLE	IF	CITATIONS
3619	Immune-checkpoint inhibitors for combating T-cell dysfunction in cancer. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 6505-6524.	1.0	47
3620	Mucous Membrane Pemphigoid, Bullous Pemphigoid, and Anti-programmed Death-1/ Programmed Death-Ligand 1: A Case Report of an Elderly Woman With Mucous Membrane Pemphigoid Developing After Pembrolizumab Therapy for Metastatic Melanoma and Review of the Literature. <i>Frontiers in Medicine</i> , 2018, 5, 268.	1.2	49
3621	Pembrolizumab for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction cancer: an evidence-based review of place in therapy. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 6525-6537.	1.0	10
3623	Hyperprogressive disease in patients with non-small cell lung cancer treated with nivolumab: A case series. <i>Thoracic Cancer</i> , 2018, 9, 1782-1787.	0.8	23
3624	Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time. <i>Frontiers in Immunology</i> , 2018, 9, 2265.	2.2	107
3625	Disruption of PD-1 Enhanced the Anti-tumor Activity of Chimeric Antigen Receptor T Cells Against Hepatocellular Carcinoma. <i>Frontiers in Pharmacology</i> , 2018, 9, 1118.	1.6	126
3626	TIM-3, a promising target for cancer immunotherapy. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 7005-7009.	1.0	172
3627	Exploring optimal sequencing of radiation and immunotherapy combinations. <i>Advances in Radiation Oncology</i> , 2018, 3, 494-505.	0.6	26
3628	Immune regulation of metastasis: mechanistic insights and therapeutic opportunities. <i>DMM Disease Models and Mechanisms</i> , 2018, 11, .	1.2	102
3629	IFN γ -activated dermal lymphatic vessels inhibit cytotoxic T cells in melanoma and inflamed skin. <i>Journal of Experimental Medicine</i> , 2018, 215, 3057-3074.	4.2	134
3630	Pembrolizumab-induced agranulocytosis in a pulmonary pleomorphic carcinoma patient who developed interstitial lung disease and ocular myasthenia gravis. <i>Oxford Medical Case Reports</i> , 2018, 2018, omy094.	0.2	23
3631	Stereotactic Body Radiation Therapy for Spinal Malignancies. <i>Technology in Cancer Research and Treatment</i> , 2018, 17, 153303381880230.	0.8	24
3632	Predominance of triple wild-type and IGF2R mutations in mucosal melanomas. <i>BMC Cancer</i> , 2018, 18, 1054.	1.1	15
3633	SwissMTB: establishing comprehensive molecular cancer diagnostics in Swiss clinics. <i>BMC Medical Informatics and Decision Making</i> , 2018, 18, 89.	1.5	18
3634	Oncolytic Viruses for Canine Cancer Treatment. <i>Cancers</i> , 2018, 10, 404.	1.7	31
3635	A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. <i>Cell</i> , 2018, 175, 984-997.e24.	13.5	892
3636	Killer immunoglobulin-like receptor genotype did not correlate with response to anti-PD-1 antibody treatment in a Japanese cohort. <i>Scientific Reports</i> , 2018, 8, 15962.	1.6	4
3637	An update: emerging drugs to treat squamous cell carcinomas of the head and neck. <i>Expert Opinion on Emerging Drugs</i> , 2018, 23, 283-299.	1.0	44

#	ARTICLE	IF	CITATIONS
3638	The IFN- γ /PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy. <i>Journal of Neuroinflammation</i> , 2018, 15, 290.	3.1	177
3639	Antitumor effects of the silencing of programmed cell death ligand 1 in colorectal cancer via immunoregulation. <i>Oncology Reports</i> , 2018, 40, 3370-3380.	1.2	6
3640	Checkpoint Inhibitors Hodgkin Lymphoma and Non-Hodgkin Lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2018, 13, 543-554.	1.2	31
3641	Updates in the Clinical Development of Epacadostat and Other Indoleamine 2,3-Dioxygenase 1 Inhibitors (IDO1) for Human Cancers. <i>Frontiers in Oncology</i> , 2018, 8, 423.	1.3	136
3642	Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs. <i>Cancer Immunology Research</i> , 2018, 6, 1561-1577.	1.6	151
3643	Local angiotensin II contributes to tumor resistance to checkpoint immunotherapy. , 2018, 6, 88.		41
3644	A phase I/randomized phase II study of GM.CD40L vaccine in combination with CCL21 in patients with advanced lung adenocarcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1853-1862.	2.0	21
3646	Comparable immunoreactivity rates of PD-L1 in archival and recent specimens from non-small cell lung cancer. <i>Thoracic Cancer</i> , 2018, 9, 1476-1482.	0.8	9
3647	PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma. <i>Frontiers in Immunology</i> , 2018, 9, 1955.	2.2	24
3648	Indoximod: An Immunometabolic Adjuvant That Empowers T Cell Activity in Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 370.	1.3	91
3649	Definitive radiotherapy for hilar and/or mediastinal lymph node metastases after stereotactic body radiotherapy or surgery for stage I non-small cell lung cancer: 5-year results. <i>Japanese Journal of Radiology</i> , 2018, 36, 719-725.	1.0	17
3650	Molecular Recalibration of PD-1+ Antigen-Specific T Cells from Blood and Liver. <i>Molecular Therapy</i> , 2018, 26, 2553-2566.	3.7	20
3651	New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1. <i>Therapeutic Advances in Respiratory Disease</i> , 2018, 12, 175346661879413.	1.0	35
3652	Alterations of Signaling Pathways Related to the Immune System in Breast Cancer: New Perspectives in Patient Management. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2733.	1.8	9
3653	Nivolumab induced encephalopathy in a man with metastatic renal cell cancer: a case report. <i>Journal of Medical Case Reports</i> , 2018, 12, 262.	0.4	44
3654	Efficacy and safety of Nivolumab in non-small cell lung cancer patients in Tel-Aviv tertiary medical center: Facing the reality. <i>Molecular and Clinical Oncology</i> , 2018, 9, 419-422.	0.4	7
3655	High expression of programmed cell death protein 1 on peripheral blood T cell subsets is associated with poor prognosis in metastatic gastric cancer. <i>Oncology Letters</i> , 2018, 16, 4448-4454.	0.8	4
3657	The characteristics of nivolumab-induced colitis: an evaluation of three cases and a literature review. <i>BMC Gastroenterology</i> , 2018, 18, 135.	0.8	44

#	ARTICLE	IF	CITATIONS
3658	Magnetic resonance imaging and molecular features associated with tumor-infiltrating lymphocytes in breast cancer. <i>Breast Cancer Research</i> , 2018, 20, 101.	2.2	44
3659	Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: a case report. , 2018, 6, 82.		30
3660	Proton therapy for thoracic reirradiation of non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2018, 7, 153-159.	1.3	5
3661	Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy. <i>JAMA Oncology</i> , 2018, 4, 1543.	3.4	567
3662	Management of metastatic melanoma: improved survival in a national cohort following the approvals of checkpoint blockade immunotherapies and targeted therapies. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1833-1844.	2.0	52
3663	A Structured Tumor-Immune Microenvironment in Triple Negative Breast Cancer Revealed by Multiplexed Ion Beam Imaging. <i>Cell</i> , 2018, 174, 1373-1387.e19.	13.5	729
3664	Interplay between interferon regulatory factor 1 and BRD4 in the regulation of PD-L1 in pancreatic stellate cells. <i>Scientific Reports</i> , 2018, 8, 13225.	1.6	32
3665	Development of shellfish allergy after exposure to dual immune checkpoint blockade. <i>Hepatic Oncology</i> , 2018, 5, HEP02.	4.2	3
3666	Immune Checkpoint Inhibitors: Toward New Paradigms in Renal Cell Carcinoma. <i>Drugs</i> , 2018, 78, 1443-1457.	4.9	70
3667	The nephrotoxicity of immune checkpoint inhibitor-based combinations. <i>European Journal of Cancer</i> , 2018, 103, 274-278.	1.3	5
3668	New drugs in thoracic oncology: needs and knowledge – an online ERS Lung Cancer Assembly survey. <i>ERJ Open Research</i> , 2018, 4, 00040-2018.	1.1	2
3669	Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models. <i>Breast Cancer Research</i> , 2018, 20, 108.	2.2	81
3670	Long-term remission in advanced stage hepatocellular carcinoma? A chance for cure?. <i>Memo - Magazine of European Medical Oncology</i> , 2018, 11, 185-192.	0.3	6
3671	Long-Term Outcomes of a Phase 2 Trial of Chemotherapy With Consolidative Radiation Therapy for Oligometastatic Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 527-535.	0.4	47
3672	UBE2N Promotes Melanoma Growth via MEK/FRA1/SOX10 Signaling. <i>Cancer Research</i> , 2018, 78, 6462-6472.	0.4	56
3673	The influence of acute kidney injury on the outcome of Stevens-Johnson syndrome and toxic epidermal necrolysis: The prognostic value of KDIGO staging. <i>PLoS ONE</i> , 2018, 13, e0203642.	1.1	17
3674	Clinical utility of reflex testing using focused next-generation sequencing for management of patients with advanced lung adenocarcinoma. <i>Journal of Clinical Pathology</i> , 2018, 71, 1108-1115.	1.0	33
3675	A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab. , 2018, 6, 90.		32

#	ARTICLE	IF	CITATIONS
3676	Circulating HLA-DR+CD4+ effector memory T cells resistant to CCR5 and PD-L1 mediated suppression compromise regulatory T cell function in tuberculosis. <i>PLoS Pathogens</i> , 2018, 14, e1007289.	2.1	34
3677	Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006. <i>British Journal of Cancer</i> , 2018, 119, 670-674.	2.9	114
3678	Establishment of peripheral blood mononuclear cell-derived humanized lung cancer mouse models for studying efficacy of PD-L1/PD-1 targeted immunotherapy. <i>MAbs</i> , 2018, 10, 1301-1311.	2.6	57
3679	Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis. <i>BMJ: British Medical Journal</i> , 2018, 362, k3529.	2.4	354
3680	Nivolumab-Induced Impressive Response of Refractory Pulmonary Sarcomatoid Carcinoma with Brain Metastasis. <i>Case Reports in Oncology</i> , 2018, 11, 615-621.	0.3	25
3681	New developments in immunotherapy for lymphoma. <i>Cancer Biology and Medicine</i> , 2018, 15, 189.	1.4	24
3682	Genetic contribution to mesenchymal stem cell dysfunction in systemic lupus erythematosus. <i>Stem Cell Research and Therapy</i> , 2018, 9, 149.	2.4	30
3683	Characterization of neutralizing antibodies reacting with the 213-224 amino-acid segment of human galectin-9. <i>PLoS ONE</i> , 2018, 13, e0202512.	1.1	12
3684	PD-L1 expression in colorectal cancer defines three subsets of tumor immune microenvironments. <i>Oncotarget</i> , 2018, 9, 8584-8596.	0.8	53
3685	Real-world experience with pembrolizumab toxicities in advanced melanoma patients: a single-center experience in the UK. <i>Melanoma Management</i> , 2018, 5, MMT05.	0.1	25
3686	Regulation of Ovarian Cancer Prognosis by Immune Cells in the Tumor Microenvironment. <i>Cancers</i> , 2018, 10, 302.	1.7	94
3687	Activation of PD-1 Protects Intestinal Immune Defense Through IL-10/miR-155 Pathway After Intestinal Ischemia Reperfusion. <i>Digestive Diseases and Sciences</i> , 2018, 63, 3307-3316.	1.1	11
3688	Reirradiation and PD-1 inhibition with nivolumab for the treatment of recurrent diffuse intrinsic pontine glioma: a single-institution experience. <i>Journal of Neuro-Oncology</i> , 2018, 140, 629-638.	1.4	44
3689	Combined radiotherapy with nivolumab for extracranial metastatic malignant melanoma. <i>Japanese Journal of Radiology</i> , 2018, 36, 712-718.	1.0	3
3690	Robotic Stereotactic Radiosurgery in Melanoma Patients with Brain Metastases under Simultaneous Anti-PD-1 Treatment. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2653.	1.8	32
3691	Roles of intestinal microbiota in response to cancer immunotherapy. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2018, 37, 2235-2240.	1.3	13
3692	Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer. <i>Oncolmmunology</i> , 2018, 7, e1500107.	2.1	66
3693	Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications. <i>Drugs in Context</i> , 2018, 7, 1-10.	1.0	34

#	ARTICLE	IF	CITATIONS
3694	Immune-Related Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitors. <i>Current Rheumatology Reports</i> , 2018, 20, 65.	2.1	39
3695	Expression of the Vesicular Monoamine Transporter Gene Solute Carrier Family 18 Member 1 (<i>SLC18A1</i>) in Lung Cancer. <i>Cancer Genomics and Proteomics</i> , 2018, 15, 387-393.	1.0	4
3696	Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells. <i>Frontiers in Immunology</i> , 2018, 9, 2041.	2.2	93
3697	Incidence, Risk Factors, and Effect on Survival of Immune-related Adverse Events in Patients With Non-Small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2018, 19, e893-e900.	1.1	98
3698	MEK inhibitors for the treatment of NRAS mutant melanoma. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 2553-2565.	2.0	37
3699	Bevacizumab with Single-agent Chemotherapy in Previously Treated Non-squamous Non-small-cell Lung Cancer: Phase II Study. <i>In Vivo</i> , 2018, 32, 1155-1160.	0.6	5
3700	Immune Checkpoint Inhibition in Head and Neck Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 310.	1.3	103
3701	A Longitudinal Investigation of Internalized Stigma, Constrained Disclosure, and Quality of Life Across 12 Weeks in Lung Cancer Patients on Active Oncologic Treatment. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1284-1293.	0.5	30
3702	Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody. <i>PLoS ONE</i> , 2018, 13, e0191926.	1.1	17
3703	Modeling the economic outcomes of immuno-oncology drugs: alternative model frameworks to capture clinical outcomes. <i>ClinicoEconomics and Outcomes Research</i> , 2018, Volume 10, 139-154.	0.7	13
3704	Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options. <i>Frontiers in Immunology</i> , 2018, 9, 1878.	2.2	127
3705	Acute Kidney Injury after Pembrolizumab-Induced Adrenalitis and Adrenal Insufficiency. <i>Case Reports in Nephrology and Dialysis</i> , 2018, 8, 171-177.	0.3	21
3706	Tissue-Resident Lymphocytes Across Innate and Adaptive Lineages. <i>Frontiers in Immunology</i> , 2018, 9, 2104.	2.2	38
3707			

#	ARTICLE	IF	CITATIONS
3712	Treatment of mycophenolate-resistant immune-related organizing pneumonia with infliximab. , 2018, 6, 85.		19
3713	Antibody targeting of phosphatidylserine for the detection and immunotherapy of cancer. ImmunoTargets and Therapy, 2018, Volume 7, 1-14.	2.7	34
3714	Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy, a real-world observational multicenter analysis. PLoS ONE, 2018, 13, e0203058.	1.1	43
3715	sLAG-3 in non-small-cell lung cancer patients’ serum. OncoTargets and Therapy, 2018, Volume 11, 4781-4784.	1.0	25
3716	The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent. Frontiers in Immunology, 2018, 9, 2100.	2.2	94
3717	Cure in metastatic breast cancer. Memo - Magazine of European Medical Oncology, 2018, 11, 172-179.	0.3	23
3718	Post-progression survival after cessation of treatment with nivolumab for advanced non-small cell lung cancer: A retrospective study. PLoS ONE, 2018, 13, e0203070.	1.1	7
3719	Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma. Drug Design, Development and Therapy, 2018, Volume 12, 209-215.	2.0	29
3720	Strategies for Predicting Response to Checkpoint Inhibitors. Current Hematologic Malignancy Reports, 2018, 13, 383-395.	1.2	23
3721	A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity. Journal of Autoimmunity, 2018, 95, 77-99.	3.0	141
3722	Exploring major signaling cascades in melanomagenesis: a rationale route for targetted skin cancer therapy. Bioscience Reports, 2018, 38, .	1.1	28
3723	Durable response to nivolumab in a lung adenocarcinoma patient with idiopathic pulmonary fibrosis. Thoracic Cancer, 2018, 9, 1519-1521.	0.8	17
3724	Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies. Journal of Immunology Research, 2018, 2018, 1-17.	0.9	147
3725	Application of dynamic modeling for survival estimation in advanced renal cell carcinoma. PLoS ONE, 2018, 13, e0203406.	1.1	1
3726	Role of Anti-PD-1 Antibodies in Advanced Melanoma: The Era of Immunotherapy. Cureus, 2018, 10, e3700.	0.2	25
3727	Novel immunotherapy approaches to follicular lymphoma. Hematology American Society of Hematology Education Program, 2018, 2018, 194-199.	0.9	8
3728	Effectiveness and safety of PD-1/PD-L1 or CTLA4 inhibitors combined with chemotherapy as a first-line treatment for lung cancer: A meta-analysis. Journal of Thoracic Disease, 2018, 10, 6636-6652.	0.6	33
3729	Systemic Therapy of Lung Cancer CNS Metastases Using Molecularly Targeted Agents and Immune Checkpoint Inhibitors. CNS Drugs, 2018, 32, 527-542.	2.7	10

#	ARTICLE	IF	CITATIONS
3730	Multidisciplinary therapy for metastatic primary malignant melanoma of the esophagus: A case report. <i>Molecular and Clinical Oncology</i> , 2018, 8, 528-532.	0.4	22
3731	Hepatocellular Carcinoma: Review of Targeted and Immune Therapies. <i>Journal of Gastrointestinal Cancer</i> , 2018, 49, 227-236.	0.6	28
3732	Checkpoint blockade in the treatment of breast cancer: current status and future directions. <i>British Journal of Cancer</i> , 2018, 119, 4-11.	2.9	82
3733	Persistent inflammation, immunosuppression, and catabolism and the development of chronic critical illness after surgery. <i>Surgery</i> , 2018, 164, 178-184.	1.0	75
3734	Constrained Combinatorial Libraries of Gp2 Proteins Enhance Discovery of PD-L1 Binders. <i>ACS Combinatorial Science</i> , 2018, 20, 423-435.	3.8	16
3735	Interferon-gamma drives programmed death-ligand 1 expression on islet β^2 cells to limit T cell function during autoimmune diabetes. <i>Scientific Reports</i> , 2018, 8, 8295.	1.6	100
3736	Feasibility of reâ€biopsy and <i>EGFR</i> mutation analysis in patients with nonâ€small cell lung cancer. <i>Thoracic Cancer</i> , 2018, 9, 856-864.	0.8	21
3737	<i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i> -Mutant Lung Adenocarcinoma. <i>Cancer Discovery</i> , 2018, 8, 822-835.	7.7	1,108
3738	Targeting the upstream transcriptional activator of PD-L1 as an alternative strategy in melanoma therapy. <i>Oncogene</i> , 2018, 37, 4941-4954.	2.6	83
3739	Defining and Understanding Adaptive Resistance in Cancer Immunotherapy. <i>Trends in Immunology</i> , 2018, 39, 624-631.	2.9	153
3740	Efficacy and safety of nivolumab in nonâ€small cell lung cancer with preexisting interstitial lung disease. <i>Thoracic Cancer</i> , 2018, 9, 847-855.	0.8	103
3741	Clinically Relevant Cytotoxic Immune Cell Signatures and Clonal Expansion of T-Cell Receptors in High-Risk <i>MYCN</i> -Not-Amplified Human Neuroblastoma. <i>Clinical Cancer Research</i> , 2018, 24, 5673-5684.	3.2	92
3742	Immune Checkpoint Inhibitor Toxicity Review for the Palliative Care Clinician. <i>Journal of Pain and Symptom Management</i> , 2018, 56, 460-472.	0.6	14
3743	Imm<sc>TAC</sc>/Antiâ€<sc>PD</sc>â€1 antibody combination to enhance killing of cancer cells by reversing regulatory Tâ€cellâ€mediated immunosuppression. <i>Immunology</i> , 2018, 155, 238-250.	2.0	8
3744	Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in Cancer. <i>Journal of Molecular Biology</i> , 2018, 430, 2014-2029.	2.0	42
3745	In Situ Vaccination with Cowpea vs Tobacco Mosaic Virus against Melanoma. <i>Molecular Pharmaceutics</i> , 2018, 15, 3700-3716.	2.3	79
3746	Goodpastureâ€™s disease in a patient with advanced lung cancer treated with nivolumab: An autopsy case report. <i>Lung Cancer</i> , 2018, 122, 22-24.	0.9	29
3747	Immunotherapy in non-metastatic non-small cell lung cancer: Can the benefits of stage IV therapy be translated into earlier stages?. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591877281.	1.4	18

#	ARTICLE	IF	CITATIONS
3748	Incidence of Thyroid Function Test Abnormalities in Patients Receiving Immune Checkpoint Inhibitors for Cancer Treatment. <i>Oncologist</i> , 2018, 23, 1236-1241.	1.9	20
3749	Advanced Lung Adenocarcinoma with Nivolumab-associated Dermatomyositis. <i>Internal Medicine</i> , 2018, 57, 2217-2221.	0.3	34
3750	Factor XIII ^A -expressing inflammatory monocytes promote lung squamous cancer through fibrin cross-linking. <i>Nature Communications</i> , 2018, 9, 1988.	5.8	69
3751	Immuno-Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD-L1 Testing May Not Be Enough. <i>Oncologist</i> , 2018, 23, 1171-1177.	1.9	29
3752	The potential importance of myeloid-derived suppressor cells (MDSCs) in the pathogenesis of Alzheimer's disease. <i>Cellular and Molecular Life Sciences</i> , 2018, 75, 3099-3120.	2.4	24
3753	Retrospective study of nivolumab for patients with recurrent high grade gliomas. <i>Journal of Neuro-Oncology</i> , 2018, 139, 625-631.	1.4	25
3754	Survivin knockdown induces senescence in TTF ¹ -expressing, KRAS-mutant lung adenocarcinomas. <i>International Journal of Oncology</i> , 2018, 53, 33-46.	1.4	10
3755	Cutaneous toxicities of new treatments for melanoma. <i>Clinical and Translational Oncology</i> , 2018, 20, 1373-1384.	1.2	24
3756	Menace Elbow: Disseminated Nocardiosis. <i>American Journal of Medicine</i> , 2018, 131, 1307-1309.	0.6	3
3757	Regulation of innate and adaptive antitumor immunity by IAP antagonists. <i>Immunotherapy</i> , 2018, 10, 787-796.	1.0	51
3758	Rapid expansion in the WAVE bioreactor of clinical scale cells for tumor immunotherapy. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 2516-2526.	1.4	16
3759	Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome. <i>Clinical Cancer Research</i> , 2018, 24, 4416-4428.	3.2	89
3760	Survival analysis and pathological features of advanced non-small cell lung cancer with miliary pulmonary metastases in patients harboring epidermal growth factor receptor mutations. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1601-1611.	1.2	8
3761	Multi-institutional report on toxicities of concurrent nivolumab and radiation therapy. <i>Advances in Radiation Oncology</i> , 2018, 3, 399-404.	0.6	22
3762	A Convergence-Based Framework for Cancer Drug Resistance. <i>Cancer Cell</i> , 2018, 33, 801-815.	7.7	181
3763	The GSK3 Signaling Axis Regulates Adaptive Glutamine Metabolism in Lung Squamous Cell Carcinoma. <i>Cancer Cell</i> , 2018, 33, 905-921.e5.	7.7	135
3764	Regulated intratumoral expression of IL-12 using a RheoSwitch Therapeutic System [®] (RTS [®]) gene switch as gene therapy for the treatment of glioma. <i>Cancer Gene Therapy</i> , 2018, 25, 106-116.	2.2	69
3765	Severe neurologic complications of immune checkpoint inhibitors: a single-center review. <i>Journal of Neurology</i> , 2018, 265, 1636-1642.	1.8	49

#	ARTICLE	IF	CITATIONS
3766	Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations. <i>Oncogene</i> , 2018, 37, 4639-4661.	2.6	219
3767	Effective Immunotherapy in Bone Marrow Metastatic Melanoma Presenting with Disseminated Intravascular Coagulopathy. <i>Case Reports in Immunology</i> , 2018, 2018, 1-8.	0.2	5
3768	Irradiation enhanced the effects of PD-1 blockade in brain metastatic osteosarcoma. <i>Journal of Bone Oncology</i> , 2018, 12, 61-64.	1.0	12
3769	Chemotherapy plus nivolumab-associated acute kidney injury in a patient with non-oropharyngeal head and neck squamous cell carcinoma with renal metastasis. <i>Journal of Cancer Research and Practice</i> , 2018, 5, 116-118.	0.2	1
3770	Nivolumab-induced systemic vasculitis. <i>JAAD Case Reports</i> , 2018, 4, 606-608.	0.4	19
3771	Clinical, histological and molecular predictors of metastatic melanoma responses to anti-PD-1 immunotherapy. <i>British Journal of Cancer</i> , 2018, 119, 193-199.	2.9	21
3772	Risk of Immune-Related Pancreatitis in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors: Systematic Assessment with Meta-Analysis. <i>Journal of Immunology Research</i> , 2018, 2018, 1-9.	0.9	40
3773	Cancer Immune Therapy: Prognostic Significance and Implications for Therapy of PD-1 in BCG-Relapsing Bladder Cancer. <i>Annals of Surgical Oncology</i> , 2018, 25, 2498-2499.	0.7	5
3774	PD-1/PD-L1 expression in a series of intracranial germinoma and its association with Foxp3+ and CD8+ infiltrating lymphocytes. <i>PLoS ONE</i> , 2018, 13, e0194594.	1.1	19
3775	CD4 T Cells Reactive to Hybrid Insulin Peptides Are Indicators of Disease Activity in the NOD Mouse. <i>Diabetes</i> , 2018, 67, 1836-1846.	0.3	52
3776	Why do women with melanoma do better than men?. <i>ELife</i> , 2018, 7, .	2.8	21
3777	An Extremely Rapid Case of Pneumonitis with the Use of Nivolumab for Pancreatic Adenocarcinoma. <i>Case Reports in Oncological Medicine</i> , 2018, 2018, 1-5.	0.2	4
3778	Prognostic Value of Combination of Pretreatment Red Cell Distribution Width and Neutrophil-to-Lymphocyte Ratio in Patients with Gastric Cancer. <i>Gastroenterology Research and Practice</i> , 2018, 2018, 1-8.	0.7	13
3779	Novel tumour antigens and the development of optimal vaccine design. , 2018, 6, 31-47.	1.4	11
3780	Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab. <i>Oncologist</i> , 2018, 23, 1358-1365.	1.9	196
3781	Natural Killer Cells from Malignant Pleural Effusion Are Endowed with a Decidual-Like Proangiogenic Polarization. <i>Journal of Immunology Research</i> , 2018, 2018, 1-18.	0.9	43
3782	Safe Administration of Ipilimumab, Pembrolizumab, and Nivolumab in a Patient with Metastatic Melanoma, Psoriasis, and a Previous Guillain-Barré Syndrome. <i>Case Reports in Oncological Medicine</i> , 2018, 2018, 1-4.	0.2	6
3783	Advanced Non-Small-Cell Lung Cancer in Elderly Patients: Patient Features and Therapeutic Management. <i>BioMed Research International</i> , 2018, 2018, 1-8.	0.9	24

#	ARTICLE	IF	CITATIONS
3784	Renal Tubular Acidosis an Adverse Effect of PD-1 Inhibitor Immunotherapy. Case Reports in Oncological Medicine, 2018, 2018, 1-3.	0.2	26
3785	CD8+ T-Cell Density Imaging with ⁶⁴ Cu-Labeled Cys-Diabody Informs Immunotherapy Protocols. Clinical Cancer Research, 2018, 24, 4976-4987.	3.2	79
3786	CUP Syndrome. Deutsches Ärzteblatt International, 2018, 115, 157-162.	0.6	25
3787	Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer. ESMO Open, 2018, 3, e000375.	2.0	43
3788	Clinicopathological analysis and prognostic significance of programmed cell death-ligand 1 protein and mRNA expression in non-small cell lung cancer. PLoS ONE, 2018, 13, e0198634.	1.1	25
3789	Fulminant Type 1 Diabetes Mellitus Accompanied by Positive Conversion of Anti-insulin Antibody after the Administration of Anti-CTLA-4 Antibody Following the Discontinuation of Anti-PD-1 Antibody. Internal Medicine, 2018, 57, 2029-2034.	0.3	35
3790	Gastrointestinal adverse events with combination of checkpoint inhibitors in advanced melanoma: a systematic review. Melanoma Management, 2018, 5, MMT01.	0.1	11
3791	Indirect comparison of efficacy and safety between immune checkpoint inhibitors and antiangiogenic therapy in advanced non-â€œsmall-cell lung cancer. Scientific Reports, 2018, 8, 9686.	1.6	5
3792	Clinical factors associated with early progression and grade 3&â€œ4 toxicity in patients with advanced non-small-cell lung cancers treated with nivolumab. PLoS ONE, 2018, 13, e0195945.	1.1	46
3793	Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors. Diabetes, 2018, 67, 1471-1480.	0.3	386
3794	Phase II study of pazopanib in combination with paclitaxel in patients with metastatic melanoma. Cancer Chemotherapy and Pharmacology, 2018, 82, 353-360.	1.1	15
3795	Seeking Convergence and Cure with New Myeloma Therapies. Trends in Cancer, 2018, 4, 567-582.	3.8	8
3796	Pediatric Cancer Immunotherapy: Opportunities and Challenges. Paediatric Drugs, 2018, 20, 395-408.	1.3	76
3797	Association Between Imaging Findings of Airway Obstruction Adjacent to Lung Tumors and the Onset of Interstitial Lung Disease After Nivolumab. In Vivo, 2018, 32, 887-891.	0.6	11
3798	Management of KRAS-Mutant Non-Small Cell Lung Cancer in the Era of Precision Medicine. Current Treatment Options in Oncology, 2018, 19, 43.	1.3	10
3799	Systemically Administered Sindbis Virus in Combination with Immune Checkpoint Blockade Induces Curative Anti-tumor Immunity. Molecular Therapy - Oncolytics, 2018, 9, 51-63.	2.0	22
3800	S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies. British Journal of Cancer, 2018, 119, 339-346.	2.9	83
3801	Recent Advances in the Clinical Development of Immune Checkpoint Blockade Therapy for Mismatch Repair Proficient (pMMR)/non-MSI-H Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2018, 17, 258-273.	1.0	41

#	ARTICLE	IF	CITATIONS
3802	Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer. <i>Lung Cancer</i> , 2018, 123, 91-98.	0.9	35
3803	Expression ratio of the TGF β 2-inducible gene MYO10 is prognostic for overall survival of squamous cell lung cancer patients and predicts chemotherapy response. <i>Scientific Reports</i> , 2018, 8, 9517.	1.6	11
3804	Lipid Accumulation in Peripheral Blood Dendritic Cells and Anticancer Immunity in Patients with Lung Cancer. <i>Journal of Immunology Research</i> , 2018, 2018, 1-8.	0.9	24
3805	Immunotherapies: Exploiting the Immune System for Cancer Treatment. <i>Journal of Immunology Research</i> , 2018, 2018, 1-16.	0.9	89
3806	Immune Toxicity with Checkpoint Inhibition for Metastatic Melanoma: Case Series and Clinical Management. <i>Journal of Skin Cancer</i> , 2018, 2018, 1-13.	0.5	21
3807	Anti-PD-1 Therapy-Associated Perforating Colitis. <i>Case Reports in Gastrointestinal Medicine</i> , 2018, 2018, 1-3.	0.2	24
3808	Melanoma & nuclear medicine: new insights & advances. <i>Melanoma Management</i> , 2018, 5, MMT06.	0.1	23
3809	Merkel Cell Carcinoma Masquerading As Cellulitis: A Case Report and Review of the Literature. <i>Current Oncology</i> , 2018, 25, 106-112.	0.9	1
3810	Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. <i>British Journal of Cancer</i> , 2018, 119, 153-159.	2.9	329
3811	CEACAM1 promotes CD8+ T cell responses and improves control of a chronic viral infection. <i>Nature Communications</i> , 2018, 9, 2561.	5.8	41
3812	Induction of oligoclonal CD8 T cell responses against pulmonary metastatic cancer by a phospholipid-conjugated TLR7 agonist. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E6836-E6844.	3.3	17
3813	PD-L1, TIM-3, and CTLA-4 Blockade Fails To Promote Resistance to Secondary Infection with Virulent Strains of <i>Toxoplasma gondii</i> . <i>Infection and Immunity</i> , 2018, 86, .	1.0	14
3814	Nephrotoxicity of Cancer Immunotherapies: Past, Present and Future. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 2039-2052.	3.0	121
3815	Antiphospholipid Antibody Induced by Nivolumab. <i>Case Reports in Hematology</i> , 2018, 2018, 1-3.	0.3	6
3816	Immunobiology of Solid Cancers: Cellular and Molecular Pathways as Potential Diagnostic and Therapeutic Targets. <i>BioMed Research International</i> , 2018, 2018, 1-2.	0.9	0
3817	Fulminant Diabetes in a Patient with Advanced Melanoma on Nivolumab. <i>Case Reports in Oncological Medicine</i> , 2018, 2018, 1-4.	0.2	12
3818	New developments in brain metastases. <i>Therapeutic Advances in Neurological Disorders</i> , 2018, 11, 175628641878550.	1.5	25
3819	Expression and clinical significance of PD β 1 in hepatocellular carcinoma tissues detected by a novel mouse anti-human PD β 1 monoclonal antibody. <i>International Journal of Oncology</i> , 2018, 52, 2079-2092.	1.4	10

#	ARTICLE	IF	CITATIONS
3820	Increased tumor vascularization is associated with the amount of immune competent PD-1 positive cells in testicular germ cell tumors. <i>Oncology Letters</i> , 2018, 15, 9852-9860.	0.8	13
3821	Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1305-1315.	2.0	93
3822	Oral Metronomic Vinorelbine (OMV) in elderly or pretreated patients with advanced non small cell lung cancer: outcome and pharmacokinetics in the real world. <i>Investigational New Drugs</i> , 2018, 36, 927-932.	1.2	13
3823	A Comparison of Response Patterns for Progression-Free Survival and Overall Survival Following Treatment for Cancer With PD-1 Inhibitors. <i>JAMA Network Open</i> , 2018, 1, e180416.	2.8	45
3824	Immune Checkpoint Inhibitors in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer. <i>Current Treatment Options in Oncology</i> , 2018, 19, 39.	1.3	18
3825	The Puzzle of Predicting Response to Immune Checkpoint Blockade. <i>EBioMedicine</i> , 2018, 33, 18-19.	2.7	10
3826	DNA damage response signaling as a predictive biomarker and synergistic therapeutic target for anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer. <i>Thoracic Cancer</i> , 2018, 9, 901-903.	0.8	3
3827	Successful Treatment of Pulmonary Pleomorphic Carcinoma with Nivolumab: A Case Report. <i>Case Reports in Oncology</i> , 2018, 11, 336-340.	0.3	11
3828	Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death-ligand 1 (PD-L1), in female breast carcinomas. <i>PLoS ONE</i> , 2018, 13, e0195958.	1.1	51
3829	Safety and Efficacy of Apatinib Combined with Temozolomide in Advanced Melanoma Patients after Conventional Treatment Failure. <i>Translational Oncology</i> , 2018, 11, 1155-1159.	1.7	8
3830	Minimal change disease associated with anti-PD1 immunotherapy: a case report. <i>BMC Nephrology</i> , 2018, 19, 156.	0.8	24
3831	Classification of gallbladder cancer by assessment of CD8+ TIL and PD-L1 expression. <i>BMC Cancer</i> , 2018, 18, 766.	1.1	42
3832	Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events. , 2018, 6, 40.		110
3833	Latest development of liquid biopsy. <i>Journal of Thoracic Disease</i> , 2018, 10, S1645-S1651.	0.6	62
3834	Musculoskeletal and Rheumatic Diseases Induced by Immune Checkpoint Inhibitors: A Review of the Literature. <i>Current Drug Safety</i> , 2018, 13, 150-164.	0.3	55
3835	Management of Leptomeningeal Metastases in Non-oncogene Addicted Non-small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 278.	1.3	15
3836	Improved Induction of Anti-Melanoma T Cells by Adenovirus-5/3 Fiber Modification to Target Human DCs. <i>Vaccines</i> , 2018, 6, 42.	2.1	8
3837	Current Landscape of Immunotherapy for the Treatment of Metastatic Non-Small-Cell Lung Cancer. <i>Current Oncology</i> , 2018, 25, 94-102.	0.9	39

#	ARTICLE	IF	CITATIONS
3838	Rapidly Changing Treatment Algorithms for Metastatic Nonsquamous Non-Small-Cell Lung Cancer. <i>Current Oncology</i> , 2018, 25, 68-76.	0.9	11
3839	Effects of zoledronic acid and ibandronate in the treatment of cancer pain in rats with lung cancer combined with bone metastases. <i>Oncology Letters</i> , 2018, 16, 1696-1700.	0.8	5
3840	Tumor Immunology and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. <i>Tuberculosis and Respiratory Diseases</i> , 2018, 81, 29.	0.7	24
3841	The Current Understanding of the Endocrine Effects From Immune Checkpoint Inhibitors and Recommendations for Management. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky021.	1.4	92
3842	PD-L1 assessment in pediatric rhabdomyosarcoma: a pilot study. <i>BMC Cancer</i> , 2018, 18, 652.	1.1	13
3843	Monitoring Immune Checkpoint Regulators as Predictive Biomarkers in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2018, 8, 269.	1.3	106
3844	Role of Immunotherapy for Oncogene-Driven Non-Small Cell Lung Cancer. <i>Cancers</i> , 2018, 10, 245.	1.7	34
3845	Immunotherapy for esophageal squamous cell carcinoma: a review. <i>Fukushima Journal of Medical Sciences</i> , 2018, 64, 46-53.	0.1	36
3846	Therapies Targeting the Tumor Stroma and the VEGF/VEGFR Axis in Pancreatic Ductal Adenocarcinoma: a Systematic Review and Meta-Analysis. <i>Targeted Oncology</i> , 2018, 13, 447-459.	1.7	13
3847	Activation of phagocytosis by immune checkpoint blockade. <i>Frontiers of Medicine</i> , 2018, 12, 473-480.	1.5	15
3848	A case of pulmonary adenocarcinoma showing rapid progression of peritoneal dissemination after immune checkpoint inhibitor therapy. <i>BMC Cancer</i> , 2018, 18, 620.	1.1	8
3849	Risk of hematologic toxicities with programmed cell death-1 inhibitors in cancer patients: a meta-analysis of current studies. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 1645-1657.	2.0	19
3850	Glyco-Engineered Anti-Human Programmed Death-Ligand 1 Antibody Mediates Stronger CD8 T Cell Activation Than Its Normal Glycosylated and Non-Glycosylated Counterparts. <i>Frontiers in Immunology</i> , 2018, 9, 1614.	2.2	23
3851	Immune Checkpoint-Mediated Interactions Between Cancer and Immune Cells in Prostate Adenocarcinoma and Melanoma. <i>Frontiers in Immunology</i> , 2018, 9, 1786.	2.2	29
3852	Immunotherapy for Gastric Cancer: Time for a Personalized Approach?. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1602.	1.8	48
3853	Immune Checkpoint Inhibitor Toxicity. <i>Current Oncology Reports</i> , 2018, 20, 72.	1.8	91
3854	Nivolumab-induced thyroid dysfunction lacking antithyroid antibody is frequently evoked in Japanese patients with malignant melanoma. <i>BMC Endocrine Disorders</i> , 2018, 18, 36.	0.9	12
3855	Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease. , 2018, 6, 35.		172

#	ARTICLE	IF	CITATIONS
3856	An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0. , 2018, 6, 44.		59
3857	Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy. , 2018, 6, 77.		36
3858	A mathematical modelling tool for unravelling the antibody-mediated effects on CTLA-4 interactions. BMC Medical Informatics and Decision Making, 2018, 18, 37.	1.5	5
3859	The Significant Antitumor Activity of Nivolumab in Lung Adenocarcinoma with Choriocarcinomatous Features. Internal Medicine, 2018, 57, 1773-1777.	0.3	6
3860	Oncolytic virus and PD-1/PD-L1 blockade combination therapy. Oncolytic Virotherapy, 2018, Volume 7, 65-77.	6.0	57
3861	Clinical Remission of Cutaneous Squamous Cell Carcinoma of the Auricle with Cetuximab and Nivolumab. Journal of Clinical Medicine, 2018, 7, 10.	1.0	41
3862	Pemetrexed Continuation Maintenance versus Conventional Platinum-Based Doublet Chemotherapy in EGFR-Negative Lung Adenocarcinoma: Retrospective Analysis. Tuberculosis and Respiratory Diseases, 2018, 81, 148.	0.7	4
3863	Brain Metastases in Non-Small-Cell Lung Cancer: Are Tyrosine Kinase Inhibitors and Checkpoint Inhibitors Now Viable Options?. Current Oncology, 2018, 25, 103-114.	0.9	42
3864	Mesenchymal stem cells expressing interleukin-18 inhibit breast cancer in a mouse model. Oncology Letters, 2018, 15, 6265-6274.	0.8	20
3865	Current status and future directions of cancer immunotherapy. Journal of Cancer, 2018, 9, 1773-1781.	1.2	273
3866	Tumor PD-L1 Expression and Clinical Outcomes in Advanced-stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab or Pembrolizumab: Real-World Data in Taiwan. Journal of Cancer, 2018, 9, 1813-1820.	1.2	41
3867	Noninvasive imaging of the PD-1:PD-L1 immune checkpoint: Embracing nuclear medicine for the benefit of personalized immunotherapy. Theranostics, 2018, 8, 3559-3570.	4.6	85
3868	Radiotherapy, tumor mutational burden, and immune checkpoint inhibitors: time to do the math. Strahlentherapie Und Onkologie, 2018, 194, 873-875.	1.0	11
3869	A Network Meta-analysis Comparing the Efficacy and Safety of Anti-PD-1 with Anti-PD-L1 in Non-small Cell Lung Cancer. Journal of Cancer, 2018, 9, 1200-1206.	1.2	31
3870	Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay. Diagnostic Pathology, 2018, 13, 47.	0.9	29
3871	In-field and abscopal response after short-course radiation therapy in patients with metastatic Merkel cell carcinoma progressing on PD-1 checkpoint blockade: a case series. , 2018, 6, 43.		37
3872	Durvalumab: a potential maintenance therapy in surgery-ineligible non-small-cell lung cancer. Cancer Management and Research, 2018, Volume 10, 931-940.	0.9	10
3873	Reply to "Challenging PD-L1 expressing cytotoxic T cells as a predictor for response to immunotherapy in melanoma". Nature Communications, 2018, 9, 2922.	5.8	3

#	ARTICLE	IF	CITATIONS
3874	Thoracic and cutaneous sarcoid-like reaction associated with anti-PD-1 therapy: longitudinal monitoring of PD-1 and PD-L1 expression after stopping treatment. , 2018, 6, 52.		27
3875	Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies. Cancer Management and Research, 2018, Volume 10, 1259-1273.	0.9	109
3876	Incorporation of Immune Checkpoint Blockade into Chimeric Antigen Receptor T Cells (CAR-Ts): Combination or Built-In CAR-T. International Journal of Molecular Sciences, 2018, 19, 340.	1.8	157
3877	Individual results may vary: Inequality-probability bounds for some health-outcome treatment effects. Journal of Health Economics, 2018, 61, 151-162.	1.3	9
3878	Deciphering mechanisms of brain metastasis in melanoma - the gist of the matter. Molecular Cancer, 2018, 17, 106.	7.9	46
3879	Rhabdomyolysis during high dose interleukin-2 treatment of metastatic melanoma after sequential immunotherapies: a case report. , 2018, 6, 53.		2
3880	A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma. , 2018, 6, 76.		14
3881	Comparisons of therapeutic efficacy and safety of ipilimumab plus GM-CSF versus ipilimumab alone in patients with cancer: a meta-analysis of outcomes. Drug Design, Development and Therapy, 2018, Volume 12, 2025-2038.	2.0	8
3882	Impact of smoking on efficacy of PD-1/PD-L1 inhibitors in non-small cell lung cancer patients: a meta-analysis. OncoTargets and Therapy, 2018, Volume 11, 3691-3696.	1.0	50
3883	Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook. Therapeutics and Clinical Risk Management, 2018, Volume 14, 1019-1040.	0.9	55
3884	Immuno-Oncology: Emerging Targets and Combination Therapies. Frontiers in Oncology, 2018, 8, 315.	1.3	244
3885	The evolving immunotherapeutic landscape in advanced oesophagogastric cancer. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591878622.	1.4	5
3886	Biomarkers for Immune Checkpoint Inhibitors in Melanoma. Frontiers in Oncology, 2018, 8, 270.	1.3	47
3887	Construction of an anti- ϵ programmed death-1 chimeric antigen receptor and determination of its antitumor function with transduced cells. Oncology Letters, 2018, 16, 157-166.	0.8	9
3888	AKR1C1 Activates STAT3 to Promote the Metastasis of Non-Small Cell Lung Cancer. Theranostics, 2018, 8, 676-692.	4.6	69
3889	Melanoma treatment in review. ImmunoTargets and Therapy, 2018, Volume 7, 35-49.	2.7	483
3890	New PDL1 inhibitors for non-small cell lung cancer: focus on pembrolizumab. OncoTargets and Therapy, 2018, Volume 11, 4051-4064.	1.0	15
3891	Simvastatin Suppresses Proliferation and Migration in Non-small Cell Lung Cancer via Pyroptosis. International Journal of Biological Sciences, 2018, 14, 406-417.	2.6	85

#	ARTICLE	IF	CITATIONS
3892	Ex vivo expanded tumour-infiltrating lymphocytes from ovarian cancer patients release anti-tumour cytokines in response to autologous primary ovarian cancer cells. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1519-1531.	2.0	21
3893	Comparative efficacy and safety of licensed treatments for previously treated non-small cell lung cancer: A systematic review and network meta-analysis. <i>PLoS ONE</i> , 2018, 13, e0199575.	1.1	9
3894	Efficacy of pemetrexed-based regimens in advanced non–small cell lung cancer patients with activating epidermal growth factor receptor mutations after tyrosine kinase inhibitor failure: a systematic review. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 2121-2129.	1.0	15
3895	PD-L1 Expression On tumor Cells Was Associated With Unfavorable Prognosis In Esophageal Squamous Cell Carcinoma. <i>Journal of Cancer</i> , 2018, 9, 2224-2231.	1.2	17
3896	Efficacy of Pemetrexed-based Chemotherapy in Comparison to Non-Pemetrexed-based Chemotherapy in Advanced, ALK+ Non-Small Cell Lung Cancer. <i>Yonsei Medical Journal</i> , 2018, 59, 202.	0.9	7
3897	Current views on molecularly targeted therapy for lung cancer â€“ aÂreview of literature from the last five years. <i>Kardiochirurgia I Torakochirurgia Polska</i> , 2018, 15, 119-124.	0.1	6
3898	Activity and Immune Correlates of a Programmed Death-1 Blockade Antibody in the treatment of Refractory Solid Tumors. <i>Journal of Cancer</i> , 2018, 9, 205-212.	1.2	9
3899	Treatment of Advanced Merkel Cell Carcinoma: Current Therapeutic Options and Novel Immunotherapy Approaches. <i>Targeted Oncology</i> , 2018, 13, 567-582.	1.7	12
3900	Neuromuscular Complications of Programmed Cell Death-1 (PD-1) Inhibitors. <i>Current Neurology and Neuroscience Reports</i> , 2018, 18, 63.	2.0	88
3901	Cardiotoxicity of Anticancer Therapeutics. <i>Frontiers in Cardiovascular Medicine</i> , 2018, 5, 9.	1.1	68
3902	Prior to Peripheral Tolerance, Newly Generated CD4 T Cells Maintain Dangerous Autoimmune Potential: Fas- and Perforin-Independent Autoimmunity Controlled by Programmed Death-1. <i>Frontiers in Immunology</i> , 2018, 9, 12.	2.2	17
3903	Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2018, 9, 14.	2.2	356
3904	Tissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy Responses. <i>Frontiers in Immunology</i> , 2018, 9, 70.	2.2	120
3905	Fatal Necrotizing Encephalopathy after Treatment with Nivolumab for Squamous Non-Small Cell Lung Cancer: Case Report and Review of the Literature. <i>Frontiers in Immunology</i> , 2018, 9, 108.	2.2	51
3906	Unique Immune Gene Expression Patterns in Bronchoalveolar Lavage and Tumor Adjacent Non-Neoplastic Lung Tissue in Non-Small Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2018, 9, 232.	2.2	10
3907	Acquired Natural Killer Cell Dysfunction in the Tumor Microenvironment of Classic Hodgkin Lymphoma. <i>Frontiers in Immunology</i> , 2018, 9, 267.	2.2	57
3908	Features of Effective T Cell-Inducing Vaccines against Chronic Viral Infections. <i>Frontiers in Immunology</i> , 2018, 9, 276.	2.2	91
3909	Checks and Balances in Autoimmune Vasculitis. <i>Frontiers in Immunology</i> , 2018, 9, 315.	2.2	31

#	ARTICLE	IF	CITATIONS
3910	Modulation of Gut Microbiota: A Novel Paradigm of Enhancing the Efficacy of Programmed Death-1 and Programmed Death Ligand-1 Blockade Therapy. <i>Frontiers in Immunology</i> , 2018, 9, 374.	2.2	51
3911	Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer. <i>Frontiers in Immunology</i> , 2018, 9, 394.	2.2	84
3912	Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional <i>Bacillus Calmette-Guérin</i> followed by Ipilimumab in Patients with Advanced Metastatic Melanoma. <i>Frontiers in Immunology</i> , 2018, 9, 411.	2.2	49
3913	Characterizing the Role of Monocytes in T Cell Cancer Immunotherapy Using a 3D Microfluidic Model. <i>Frontiers in Immunology</i> , 2018, 9, 416.	2.2	91
3914	Exhaustion of the CD8+ T Cell Compartment in Patients with Mutations in Phosphoinositide 3-Kinase Delta. <i>Frontiers in Immunology</i> , 2018, 9, 446.	2.2	52
3915	Tailoring Immune Responses toward Autoimmunity: Transcriptional Regulators That Drive the Creation and Collusion of Autoreactive Lymphocytes. <i>Frontiers in Immunology</i> , 2018, 9, 482.	2.2	7
3916	Sexual Dimorphism of Immune Responses: A New Perspective in Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2018, 9, 552.	2.2	74
3917	Combination Immunotherapy: Taking Cancer Vaccines to the Next Level. <i>Frontiers in Immunology</i> , 2018, 9, 610.	2.2	46
3918	Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme. <i>Frontiers in Immunology</i> , 2018, 9, 727.	2.2	55
3919	Genetically Induced Tumors in the Oncopig Model Invoke an Antitumor Immune Response Dominated by Cytotoxic CD8 ⁺ T Cells and Differentiated $\gamma\delta$ T Cells Alongside a Regulatory Response Mediated by FOXP3+ T Cells and Immunoregulatory Molecules. <i>Frontiers in Immunology</i> , 2018, 9, 1301.	2.2	15
3920	Glioblastoma Stem-Like Cells Are More Susceptible Than Differentiated Cells to Natural Killer Cell Lysis Mediated Through Killer Immunoglobulin-Like Receptors-Human Leukocyte Antigen Ligand Mismatch and Activation Receptor-Ligand Interactions. <i>Frontiers in Immunology</i> , 2018, 9, 1345.	2.2	52
3921	Lenalidomide and Programmed Death-1 Blockade Synergistically Enhances the Effects of Dendritic Cell Vaccination in a Model of Murine Myeloma. <i>Frontiers in Immunology</i> , 2018, 9, 1370.	2.2	49
3922	Interferon Signaling Is Frequently Downregulated in Melanoma. <i>Frontiers in Immunology</i> , 2018, 9, 1414.	2.2	28
3923	Dendritic Cells Actively Limit Interleukin-10 Production Under Inflammatory Conditions via DC-SCRIPT and Dual-Specificity Phosphatase 4. <i>Frontiers in Immunology</i> , 2018, 9, 1420.	2.2	16
3924	Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment-A Review From the Melanoma Perspective and Beyond. <i>Frontiers in Immunology</i> , 2018, 9, 1474.	2.2	174
3925	Perspective on Translating Biomaterials Into Glioma Therapy: Lessons From in Vitro Models. <i>Frontiers in Materials</i> , 2018, 5, .	1.2	9
3926	Myasthenia Gravis Induced by Ipilimumab in a Patient With Metastatic Melanoma. <i>Frontiers in Neurology</i> , 2018, 9, 150.	1.1	28
3927	Targeted Therapy and Immunotherapy Response Assessment with F-18 Fluorothymidine Positron-Emission Tomography/Magnetic Resonance Imaging in Melanoma Brain Metastasis: A Pilot Study. <i>Frontiers in Oncology</i> , 2018, 8, 18.	1.3	34

#	ARTICLE	IF	CITATIONS
3928	Metastatic Extramammary Paget's Disease: Pathogenesis and Novel Therapeutic Approach. <i>Frontiers in Oncology</i> , 2018, 8, 38.	1.3	54
3929	Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma. <i>Frontiers in Oncology</i> , 2018, 8, 44.	1.3	67
3930	Cutaneous Angiosarcoma: The Possibility of New Treatment Options Especially for Patients with Large Primary Tumor. <i>Frontiers in Oncology</i> , 2018, 8, 46.	1.3	68
3931	Immune Dysregulation in Cancer Patients Undergoing Immune Checkpoint Inhibitor Treatment and Potential Predictive Strategies for Future Clinical Practice. <i>Frontiers in Oncology</i> , 2018, 8, 80.	1.3	40
3932	Immunotherapy Plus Cryotherapy: Potential Augmented Abscopal Effect for Advanced Cancers. <i>Frontiers in Oncology</i> , 2018, 8, 85.	1.3	83
3933	Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations. <i>Frontiers in Oncology</i> , 2018, 8, 86.	1.3	926
3934	Attenuated Bacteria as Immunotherapeutic Tools for Cancer Treatment. <i>Frontiers in Oncology</i> , 2018, 8, 136.	1.3	50
3935	Mechanisms and Therapy for Cancer Metastasis to the Brain. <i>Frontiers in Oncology</i> , 2018, 8, 161.	1.3	123
3936	Expression of the Circadian Clock Gene BMAL1 Positively Correlates With Antitumor Immunity and Patient Survival in Metastatic Melanoma. <i>Frontiers in Oncology</i> , 2018, 8, 185.	1.3	60
3937	Personalized Medicine in Malignant Melanoma: Towards Patient Tailored Treatment. <i>Frontiers in Oncology</i> , 2018, 8, 202.	1.3	35
3938	Editorial: Controversies in the Local Management of Lung Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 233.	1.3	1
3939	Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers. , 2018, 6, 65.		118
3940	Next Generation Immunotherapy for Pancreatic Cancer: DNA Vaccination is Seeking New Combo Partners. <i>Cancers</i> , 2018, 10, 51.	1.7	21
3941	Coronary Toxicities of Anti-PD-1 and Anti-PD-L1 Immunotherapies: a Case Report and Review of the Literature and International Registries. <i>Targeted Oncology</i> , 2018, 13, 509-515.	1.7	30
3942	The association of genomic lesions and PD-1/PD-L1 expression in resected triple-negative breast cancers. <i>Breast Cancer Research</i> , 2018, 20, 71.	2.2	55
3943	Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination. , 2018, 6, 46.		135
3944	Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches. , 2018, 6, 48.		126
3945	Intravital microscopy in the study of the tumor microenvironment: from bench to human application. <i>Oncotarget</i> , 2018, 9, 20165-20178.	0.8	31

#	ARTICLE	IF	CITATIONS
3946	Immune Monitoring of Cancer Patients Prior to and During CTLA-4 or PD-1/PD-L1 Inhibitor Treatment. <i>Biomedicines</i> , 2018, 6, 26.	1.4	16
3947	Colorectal Cancers: An Update on Their Molecular Pathology. <i>Cancers</i> , 2018, 10, 26.	1.7	128
3948	Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors. <i>Cancers</i> , 2018, 10, 32.	1.7	54
3949	Precision Immuno-Oncology: Prospects of Individualized Immunotherapy for Pancreatic Cancer. <i>Cancers</i> , 2018, 10, 39.	1.7	44
3950	Update on Immunohistochemistry for the Diagnosis of Lung Cancer. <i>Cancers</i> , 2018, 10, 72.	1.7	94
3951	Clinical Importance of Epstein-Barr Virus-Associated Gastric Cancer. <i>Cancers</i> , 2018, 10, 167.	1.7	63
3952	Tune Up In Situ Autovaccination against Solid Tumors with Oncolytic Viruses. <i>Cancers</i> , 2018, 10, 171.	1.7	11
3953	TGF- β 2 in T Cell Biology: Implications for Cancer Immunotherapy. <i>Cancers</i> , 2018, 10, 194.	1.7	132
3954	Oncolytic Reovirus and Immune Checkpoint Inhibition as a Novel Immunotherapeutic Strategy for Breast Cancer. <i>Cancers</i> , 2018, 10, 205.	1.7	49
3955	Well-controlled pleural effusion indicated pseudoprogression after immunotherapy in lung cancer: A case report. <i>Thoracic Cancer</i> , 2018, 9, 1190-1193.	0.8	13
3956	Immunotherapy of melanoma. <i>Wspolczesna Onkologia</i> , 2018, 2018, 61-67.	0.7	78
3957	Nivolumab Induces Sustained Liver Injury in a Patient with Malignant Melanoma. <i>Internal Medicine</i> , 2018, 57, 1789-1792.	0.3	26
3958	The Significance of MMP-1 in EGFR-TKI-Resistant Lung Adenocarcinoma: Potential for Therapeutic Targeting. <i>International Journal of Molecular Sciences</i> , 2018, 19, 609.	1.8	21
3959	The Role of the Estrogen Pathway in the Tumor Microenvironment. <i>International Journal of Molecular Sciences</i> , 2018, 19, 611.	1.8	145
3960	Strengths and Weaknesses of Pre-Clinical Models for Human Melanoma Treatment: Dawn of Dogs TM Revolution for Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2018, 19, 799.	1.8	33
3961	A Developed NK-92MI Cell Line with Siglec-7 ^{neg} Phenotype Exhibits High and Sustainable Cytotoxicity against Leukemia Cells. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1073.	1.8	13
3962	Human Cancer and Platelet Interaction, a Potential Therapeutic Target. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1246.	1.8	52
3963	The Costimulatory Pathways and T Regulatory Cells in Ischemia-Reperfusion Injury: A Strong Arm in the Inflammatory Response?. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1283.	1.8	6

#	ARTICLE	IF	CITATIONS
3964	Mechanisms of Intrinsic Tumor Resistance to Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1340.	1.8	61
3965	Cancer Immunotherapy: A Focus on the Regulation of Immune Checkpoints. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1389.	1.8	77
3966	Microsatellite Instability Occurs Rarely in Patients with Cholangiocarcinoma: A Retrospective Study from a German Tertiary Care Hospital. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1421.	1.8	46
3967	PD-L1 Nanobody Competitively Inhibits the Formation of the PD-1/PD-L1 Complex: Comparative Molecular Dynamics Simulations. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1984.	1.8	31
3968	Current and Future Molecular Testing in NSCLC, What Can We Expect from New Sequencing Technologies?. <i>Journal of Clinical Medicine</i> , 2018, 7, 144.	1.0	54
3969	Immunotherapy in Non-Small Cell Lung Cancer: Shifting Prognostic Paradigms. <i>Journal of Clinical Medicine</i> , 2018, 7, 151.	1.0	11
3970	An Update on Predictive Biomarkers for Treatment Selection in Non-Small Cell Lung Cancer. <i>Journal of Clinical Medicine</i> , 2018, 7, 153.	1.0	47
3971	Diagnosing Lung Cancer: The Complexities of Obtaining a Tissue Diagnosis in the Era of Minimally Invasive and Personalised Medicine. <i>Journal of Clinical Medicine</i> , 2018, 7, 163.	1.0	50
3972	Marine Bacterial Polysaccharide EPS11 Inhibits Cancer Cell Growth via Blocking Cell Adhesion and Stimulating Anoikis. <i>Marine Drugs</i> , 2018, 16, 85.	2.2	17
3973	The Oncolytic Virus VSV-GP Is Effective against Malignant Melanoma. <i>Viruses</i> , 2018, 10, 108.	1.5	43
3974	Advances in cancer immunotherapy for gastroenterological malignancy. <i>Annals of Gastroenterological Surgery</i> , 2018, 2, 244-245.	1.2	19
3975	Pulmonary pleomorphic carcinoma with pseudoprogression during nivolumab therapy and the usefulness of tumor markers: A case report. <i>Clinical Case Reports (discontinued)</i> , 2018, 6, 1338-1341.	0.2	8
3976	An Adaptive Dose-Finding Design Based on Both Safety and Immunologic Responses in Cancer Clinical Trials. <i>Statistics in Biopharmaceutical Research</i> , 2018, 10, 185-195.	0.6	11
3977	Ineffective anti PD-1 therapy after BRAF inhibitor failure in advanced melanoma. <i>BMC Cancer</i> , 2018, 18, 705.	1.1	23
3978	Comparison of immunological characteristics between paired mismatch repair-proficient and -deficient colorectal cancer patients. <i>Journal of Translational Medicine</i> , 2018, 16, 195.	1.8	13
3979	Immunohistochemical expression and prognostic value of PD-L1 in Extrapulmonary small cell carcinoma: a single institution experience. , 2018, 6, 42.		15
3980	Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes. <i>Cancers</i> , 2018, 10, 62.	1.7	73
3981	Comparison of chemotherapy plus bevacizumab vs. chemotherapy alone as third-line treatment or beyond for advanced non-small cell lung cancer: A propensity score-matched analysis. <i>Oncology Letters</i> , 2018, 15, 5671-5679.	0.8	4

#	ARTICLE	IF	CITATIONS
3982	Cytokines Produced by Dendritic Cells Administered Intratumorally Correlate with Clinical Outcome in Patients with Diverse Cancers. <i>Clinical Cancer Research</i> , 2018, 24, 3845-3856.	3.2	35
3983	Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC). , 2018, 6, 39.		329
3984	Current treatment strategies for patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). <i>Clinical Diabetes and Endocrinology</i> , 2018, 4, 16.	1.3	51
3985	Expected advances in human fertility treatments and their likely translational consequences. <i>Journal of Translational Medicine</i> , 2018, 16, 149.	1.8	8
3986	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC). , 2018, 6, 75.		188
3987	Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab. , 2018, 6, 74.		292
3988	Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab. , 2018, 6, 73.		46
3989	A Case of Nivolumab-Induced Bullous Pemphigoid: Review of Dermatologic Toxicity Associated with Programmed Cell Death Protein-1/Programmed Death Ligand-1 Inhibitors and Recommendations for Diagnosis and Management. <i>Oncologist</i> , 2018, 23, 1119-1126.	1.9	72
3990	Primary malignant melanoma of the uterine cervix treated with pembrolizumab after radical surgery: a case report and literature review. <i>Obstetrics and Gynecology Science</i> , 2018, 61, 524.	0.6	9
3991	Systemic treatment of advanced non-small cell lung cancer: controversies and perspectives. <i>Memo - Magazine of European Medical Oncology</i> , 2018, 11, 112-115.	0.3	2
3992	Management of adverse events related to checkpoint inhibition therapy. <i>Memo - Magazine of European Medical Oncology</i> , 2018, 11, 132-137.	0.3	22
3993	Cancer immune checkpoint blockade therapy and its associated autoimmune cardiotoxicity. <i>Acta Pharmacologica Sinica</i> , 2018, 39, 1693-1698.	2.8	39
3994	Improved Risk-Adjusted Survival for Melanoma Brain Metastases in the Era of Checkpoint Blockade Immunotherapies: Results from a National Cohort. <i>Cancer Immunology Research</i> , 2018, 6, 1039-1045.	1.6	60
3995	Immune-checkpoint inhibitors in melanoma and kidney cancer: from sequencing to rational selection. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591877742.	1.4	7
3996	Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer). <i>The Cochrane Library</i> , 2018, 7, CD012556.	1.5	13
3997	Microbial biomarkers for immune checkpoint blockade therapy against cancer. <i>Journal of Gastroenterology</i> , 2018, 53, 999-1005.	2.3	15
3998	Safety and tolerability of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: a meta-analysis of randomized controlled trials. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1851-1859.	1.2	55
3999	Update on systemic therapy for advanced cutaneous melanoma and recent development of novel drugs. <i>Clinical and Experimental Metastasis</i> , 2018, 35, 503-520.	1.7	9

#	ARTICLE	IF	CITATIONS
4000	Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC). <i>Journal of Thoracic Oncology</i> , 2018, 13, 1393-1399.	0.5	169
4001	Molecular and clinical characterization of PTPN2 expression from RNA-seq data of 996 brain gliomas. <i>Journal of Neuroinflammation</i> , 2018, 15, 145.	3.1	15
4002	RNA-sequencing in non-small cell lung cancer shows gene downregulation of therapeutic targets in tumor tissue compared to non-malignant lung tissue. <i>Radiation Oncology</i> , 2018, 13, 131.	1.2	8
4003	Towards Molecular Profiling in Multiple Myeloma: A Literature Review and Early Indications of Its Efficacy for Informing Treatment Strategies. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2087.	1.8	14
4004	Radiation Pneumonitis: Old Problem, New Tricks. <i>Cancers</i> , 2018, 10, 222.	1.7	109
4005	A Review of Recent Advances in the Treatment of Elderly and Poor Performance NSCLC. <i>Cancers</i> , 2018, 10, 236.	1.7	31
4006	Antiangiogenic Therapies in Non-Small-Cell Lung Cancer. <i>Current Oncology</i> , 2018, 25, 45-58.	0.9	38
4007	Combination Strategies Using EGFR-TKi in NSCLC Therapy: Learning from the Gap between Pre-Clinical Results and Clinical Outcomes. <i>International Journal of Biological Sciences</i> , 2018, 14, 204-216.	2.6	75
4008	Continuing and new roles for surgery in the management of patients with stage IV melanoma. <i>Melanoma Management</i> , 2018, 5, MMT03.	0.1	4
4009	Combining Immunotherapy and Radiotherapy for Cancer Treatment: Current Challenges and Future Directions. <i>Frontiers in Pharmacology</i> , 2018, 9, 185.	1.6	277
4010	Advances in the Systemic Treatment of Triple-Negative Breast Cancer. <i>Current Oncology</i> , 2018, 25, 142-150.	0.9	241
4011	Novel Systemic Therapies for Advanced Gastric Cancer. <i>Journal of Gastric Cancer</i> , 2018, 18, 1.	0.9	33
4012	Combination therapy of ipilimumab and nivolumab induced thyroid storm in a patient with Hashimoto's disease and diabetes mellitus: a case report. <i>Journal of Medical Case Reports</i> , 2018, 12, 171.	0.4	25
4013	Significant response to nivolumab for metastatic chromophobe renal cell carcinoma with sarcomatoid differentiation: a case report. <i>BMC Urology</i> , 2018, 18, 26.	0.6	15
4014	Second-line treatment for advanced NSCLC without actionable mutations: is immunotherapy the "panacea" for all patients?. <i>BMC Medicine</i> , 2018, 16, 24.	2.3	11
4015	Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone. , 2018, 6, 13.		29
4016	Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab. , 2018, 6, 22.		45
4017	Emerging Trends in the Management of Brain Metastases from Non-small Cell Lung Cancer. <i>Current Oncology Reports</i> , 2018, 20, 54.	1.8	19

#	ARTICLE	IF	CITATIONS
4018	Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study. <i>British Journal of Cancer</i> , 2018, 119, 538-545.	2.9	111
4019	Efficacy of next treatment received after nivolumab progression in patients with advanced nonsmall cell lung cancer. <i>ERJ Open Research</i> , 2018, 4, 00120-2017.	1.1	19
4020	Readministration of Nivolumab after Persistent Immune-related Colitis in a Patient with Recurrent Melanoma. <i>Internal Medicine</i> , 2018, 57, 1173-1176.	0.3	10
4021	Immune checkpoint receptors: homeostatic regulators of immunity. <i>Hepatology International</i> , 2018, 12, 223-236.	1.9	43
4022	Monitoring the responsiveness of T and antigen presenting cell compartments in breast cancer patients is useful to predict clinical tumor response to neoadjuvant chemotherapy. <i>BMC Cancer</i> , 2018, 18, 77.	1.1	10
4023	Neuromyelitis optica spectrum disorder secondary to treatment with anti-PD-1 antibody nivolumab: the first report. <i>BMC Cancer</i> , 2018, 18, 95.	1.1	51
4024	Autoimmune comorbidities in patients with metastatic melanoma: a retrospective analysis of us claims data. <i>BMC Cancer</i> , 2018, 18, 145.	1.1	16
4025	Contrasting roles of H3K4me3 and H3K9me3 in regulation of apoptosis and gemcitabine resistance in human pancreatic cancer cells. <i>BMC Cancer</i> , 2018, 18, 149.	1.1	36
4026	PD-L1 expression in malignant salivary gland tumors. <i>BMC Cancer</i> , 2018, 18, 156.	1.1	38
4027	High incidence and early onset of nivolumab-induced pneumonitis: four case reports and literature review. <i>BMC Pulmonary Medicine</i> , 2018, 18, 23.	0.8	21
4028	Liquid biomarkers in melanoma: detection and discovery. <i>Molecular Cancer</i> , 2018, 17, 8.	7.9	74
4029	Physical basis of the "magnification rule"™ for standardized Immunohistochemical scoring of HER2 in breast and gastric cancer. <i>Diagnostic Pathology</i> , 2018, 13, 19.	0.9	15
4030	Clinical results of multidisciplinary therapy including palliative posterior spinal stabilization surgery and postoperative adjuvant therapy for metastatic spinal tumor. <i>Journal of Orthopaedic Surgery and Research</i> , 2018, 13, 30.	0.9	21
4031	Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma. <i>Journal of Hematology and Oncology</i> , 2018, 11, 15.	6.9	155
4032	PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse. <i>Journal of Hematology and Oncology</i> , 2018, 11, 16.	6.9	96
4033	Concealed complete response in melanoma patients under therapy with immune checkpoint inhibitors: two case reports. , 2018, 6, 2.		11
4034	Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. , 2018, 6, 8.		936
4035	Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients. , 2018, 6, 18.		153

#	ARTICLE	IF	CITATIONS
4036	Complete intracranial response to talimogene laherparepvec (T-Vec), pembrolizumab and whole brain radiotherapy in a patient with melanoma brain metastases refractory to dual checkpoint-inhibition. , 2018, 6, 25.		26
4037	Clinical decision making in the era of immunotherapy for high grade-glioma: report of four cases. BMC Cancer, 2018, 18, 239.	1.1	38
4038	Erlotinib treatment after platinum-based therapy in elderly patients with non-small-cell lung cancer in routine clinical practice “ results from the ElderTac study. BMC Cancer, 2018, 18, 333.	1.1	10
4039	Survival and clinical outcomes of patients with melanoma brain metastasis in the era of checkpoint inhibitors and targeted therapies. BMC Cancer, 2018, 18, 490.	1.1	73
4040	Randomized phase II trial of autologous dendritic cell vaccines versus autologous tumor cell vaccines in metastatic melanoma: 5-year follow up and additional analyses. , 2018, 6, 19.		45
4041	Pharmacometric Applications and Challenges in the Development of Therapeutic Antibodies in Immuno-Oncology. Current Pharmacology Reports, 2018, 4, 285-291.	1.5	7
4042	Personalized medicine in non-small cell lung cancer: a review from a pharmacogenomics perspective. Acta Pharmaceutica Sinica B, 2018, 8, 530-538.	5.7	43
4043	Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials. JAMA Oncology, 2018, 4, e180798.	3.4	86
4044	Egr2-independent, Klf1-mediated induction of PD-L1 in CD4+ T cells. Scientific Reports, 2018, 8, 7021.	1.6	10
4045	Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism. Endocrine Connections, 2018, 7, R196-R211.	0.8	10
4046	Co-expression of NGF and PD-L1 on tumor-associated immune cells in the microenvironment of Merkel cell carcinoma. Journal of Cancer Research and Clinical Oncology, 2018, 144, 1301-1308.	1.2	12
4047	Indoleamine 2,3-dioxygenase 1 inhibition targets anti-PD1-resistant lung tumors by blocking myeloid-derived suppressor cells. Cancer Letters, 2018, 431, 54-63.	3.2	50
4048	Programmed cell death-1 contributes to the establishment and maintenance of HIV-1 latency. Aids, 2018, 32, 1491-1497.	1.0	136
4049	Tumor-Specific Inhibition of <i>In Situ</i> Vaccination by Distant Untreated Tumor Sites. Cancer Immunology Research, 2018, 6, 825-834.	1.6	61
4050	The Safety and Efficacy of Treatment with Nab-paclitaxel and Carboplatin for Patients with Advanced Squamous Non-small Cell Lung Cancer Concurrent with Idiopathic Interstitial Pneumonias. Internal Medicine, 2018, 57, 1827-1832.	0.3	16
4051	Recent Advances in the Histopathology of Drug-Induced Liver Injury. Surgical Pathology Clinics, 2018, 11, 297-311.	0.7	23
4052	Pathway-based dissection of the genomic heterogeneity of cancer hallmarks’™ acquisition with SLAPenrich. Scientific Reports, 2018, 8, 6713.	1.6	24
4053	The search for a melanoma-tailored chemotherapy in the new era of personalized therapy: a phase II study of chemo-modulating temozolomide followed by fotemustine and a cooperative study of GOIM (Gruppo Oncologico Italia Meridionale). BMC Cancer, 2018, 18, 552.	1.1	14

#	ARTICLE	IF	CITATIONS
4054	Conservative management of nivolumab-induced pericardial effusion: a case report and review of literature. <i>Experimental Hematology and Oncology</i> , 2018, 7, 11.	2.0	38
4055	Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden. , 2018, 6, 32.		111
4056	Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson. , 2018, 6, 37.		174
4057	Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 653-664.	1.4	26
4058	Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer. <i>BMC Cancer</i> , 2018, 18, 6.	1.1	7
4059	Combination Immunotherapy in Non-small Cell Lung Cancer. <i>Current Oncology Reports</i> , 2018, 20, 55.	1.8	25
4060	Immunotherapy for pulmonary squamous cell carcinoma and colon carcinoma with pembrolizumab. <i>Medicine (United States)</i> , 2018, 97, e0718.	0.4	6
4061	ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma. <i>Cancer Research</i> , 2018, 78, 5680-5693.	0.4	19
4062	Abscopal effect of radiotherapy combined with immune checkpoint inhibitors. <i>Journal of Hematology and Oncology</i> , 2018, 11, 104.	6.9	303
4063	Aptamer-based targeted therapy. <i>Advanced Drug Delivery Reviews</i> , 2018, 134, 65-78.	6.6	314
4064	Clinical and Molecular Characteristics Associated with Survival in Advanced Melanoma Treated with Checkpoint Inhibitors. <i>Journal of Oncology</i> , 2018, 2018, 1-13.	0.6	3
4065	New Directions in the Study and Treatment of Metastatic Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 258.	1.3	14
4066	Family A and B DNA Polymerases in Cancer: Opportunities for Therapeutic Interventions. <i>Biology</i> , 2018, 7, 5.	1.3	3
4067	Management of Brain Metastases in the New Era of Checkpoint Inhibition. <i>Current Neurology and Neuroscience Reports</i> , 2018, 18, 70.	2.0	25
4068	Immunotherapy in Prostate Cancer: Teaching an Old Dog New Tricks. <i>Current Oncology Reports</i> , 2018, 20, 75.	1.8	55
4069	Anti-PD-1/PD-L1 antibodies versus docetaxel in patients with previously treated non-small-cell lung cancer. <i>Oncotarget</i> , 2018, 9, 7672-7683.	0.8	14
4070	Impact of antibiotic treatment on immune-checkpoint blockade efficacy in advanced non-squamous non-small cell lung cancer. <i>Oncotarget</i> , 2018, 9, 16512-16520.	0.8	71
4071	Implementation of immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). <i>Annals of Translational Medicine</i> , 2018, 6, 144-144.	0.7	19

#	ARTICLE	IF	CITATIONS
4072	Isolated Adrenocorticotropin Deficiency due to Nivolumab-induced Hypophysitis in a Patient with Advanced Lung Adenocarcinoma: A Case Report and Literature Review. <i>Internal Medicine</i> , 2018, 57, 527-535.	0.3	40
4073	Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer Therapy. <i>Frontiers in Oncology</i> , 2018, 8, 285.	1.3	89
4074	Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going. <i>Cancer Management and Research</i> , 2018, Volume 10, 91-103.	0.9	53
4075	Immune Checkpoint Inhibitor-related Pneumonitis. Incidence, Risk Factors, and Clinical and Radiographic Features. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 951-953.	2.5	8
4076	CNS cancer immunity cycle and strategies to target this for glioblastoma. <i>Oncotarget</i> , 2018, 9, 22802-22816.	0.8	11
4077	Classifying Non-Small Cell Lung Cancer by Status of Programmed Cell Death Ligand 1 and Tumor-Infiltrating Lymphocytes on Tumor Cells. <i>Journal of Cancer</i> , 2018, 9, 129-134.	1.2	11
4078	A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers. <i>Nature Communications</i> , 2018, 9, 3196.	5.8	145
4079	Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicity. <i>ESMO Open</i> , 2018, 3, e000332.	2.0	55
4080	Phase II study assessing the benefit of cisplatin re-introduction (stop-and-go strategy) in patients with advanced non-squamous non-small cell lung cancer: the IFCT-1102 BUCiL study (a Better Use of) <i>TJ ETQq0 0 0 rgBTz/Overlock 1.10 Tf 50 4</i>	0.0	0
4081	High mammographic density in women is associated with protumor inflammation. <i>Breast Cancer Research</i> , 2018, 20, 92.	2.2	26
4082	Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy. <i>Frontiers in Immunology</i> , 2018, 9, 1739.	2.2	174
4083	Targeting the Microenvironment in High Grade Serous Ovarian Cancer. <i>Cancers</i> , 2018, 10, 266.	1.7	30
4084	Algorithm for the Treatment of Advanced or Metastatic Squamous Non-Small-Cell Lung Cancer: An Evidence-Based Overview. <i>Current Oncology</i> , 2018, 25, 77-85.	0.9	9
4085	Prognostic models for patients with brain metastases after stereotactic radiosurgery with or without whole brain radiotherapy: a validation study. <i>Journal of Neuro-Oncology</i> , 2018, 140, 341-349.	1.4	12
4086	Immune-Related Thyroiditis with Immune Checkpoint Inhibitors. <i>Thyroid</i> , 2018, 28, 1243-1251.	2.4	160
4087	Design considerations for early-phase clinical trials of immune-oncology agents. , 2018, 6, 81.		44
4088	Immune-related Colitis Induced by the Long-term Use of Nivolumab in a Patient with Non-small Cell Lung Cancer. <i>Internal Medicine</i> , 2018, 57, 1269-1272.	0.3	27
4089	Expression Analysis of Autophagy Related Markers LC3B, p62 and HMGB1 Indicate an Autophagy-Independent Negative Prognostic Impact of High p62 Expression in Pulmonary Squamous Cell Carcinomas. <i>Cancers</i> , 2018, 10, 281.	1.7	15

#	ARTICLE	IF	CITATIONS
4090	Implementation of cell-free tumor DNA sequencing from the cerebrospinal fluid to guide treatment in a patient with primary leptomeningeal melanoma: A case report. <i>Molecular and Clinical Oncology</i> , 2018, 9, 58-61.	0.4	8
4091	Subacute cutaneous lupus erythematosus and systemic lupus erythematosus associated with abatacept. <i>JAAD Case Reports</i> , 2018, 4, 698-700.	0.4	15
4092	The age of enlightenment in melanoma immunotherapy. , 2018, 6, 80.		25
4093	Epigenetic mechanisms of tumor resistance to immunotherapy. <i>Cellular and Molecular Life Sciences</i> , 2018, 75, 4163-4176.	2.4	27
4094	Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors. <i>Molecular Cancer</i> , 2018, 17, 129.	7.9	536
4095	Effectiveness and safety of immune checkpoint inhibitors: A retrospective study in Taiwan. <i>PLoS ONE</i> , 2018, 13, e0202725.	1.1	15
4096	OX40 Stimulation Enhances Protective Immune Responses Induced After Vaccination With Attenuated Malaria Parasites. <i>Frontiers in Cellular and Infection Microbiology</i> , 2018, 8, 247.	1.8	21
4097	Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study. <i>Lung Cancer</i> , 2018, 125, 273-281.	0.9	69
4098	Targeting the PD-1/PD-L1 Axis for the Treatment of Non-Small-Cell Lung Cancer. <i>Current Oncology</i> , 2018, 25, 324-334.	0.9	56
4099	The role of automated cytometry in the new era of cancer immunotherapy (Review). <i>Molecular and Clinical Oncology</i> , 2018, 9, 355-361.	0.4	12
4100	Present and future of cancer immunotherapy: A tumor microenvironmental perspective (Review). <i>Oncology Letters</i> , 2018, 16, 4105-4113.	0.8	58
4101	Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. <i>Nature Genetics</i> , 2018, 50, 1271-1281.	9.4	438
4102	Adjuvant effect of the novel TLR1/TLR2 agonist Diprovocim synergizes with anti-PD-L1 to eliminate melanoma in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E8698-E8706.	3.3	77
4103	Mouse models in the era of large human tumour sequencing studies. <i>Open Biology</i> , 2018, 8, .	1.5	7
4104	Treatment of Complications from Immune Checkpoint Inhibition in Patients with Lung Cancer. <i>Current Treatment Options in Oncology</i> , 2018, 19, 46.	1.3	16
4105	Dendritic cell vaccines for high-grade gliomas. <i>Therapeutics and Clinical Risk Management</i> , 2018, Volume 14, 1299-1313.	0.9	42
4106	Risk of immune-related colitis with PD-1/PD-L1 inhibitors vs chemotherapy in solid tumors: systems assessment. <i>Journal of Cancer</i> , 2018, 9, 1614-1622.	1.2	17
4107	The Role of Targeted Agents and Immunotherapy in Older Patients with Non-small Cell Lung Cancer. <i>Drugs and Aging</i> , 2018, 35, 819-834.	1.3	16

#	ARTICLE	IF	CITATIONS
4108	Review of checkpoint immunotherapy for the management of non-small cell lung cancer. <i>ImmunoTargets and Therapy</i> , 2018, Volume 7, 63-75.	2.7	48
4109	New developments in the management of head and neck cancer – impact of pembrolizumab. <i>Therapeutics and Clinical Risk Management</i> , 2018, Volume 14, 295-303.	0.9	55
4110	Cancer Cell-Intrinsic PD-1 and Implications in Combinatorial Immunotherapy. <i>Frontiers in Immunology</i> , 2018, 9, 1774.	2.2	125
4111	New Development of Biomarkers for Gastrointestinal Cancers: From Neoplastic Cells to Tumor Microenvironment. <i>Biomedicines</i> , 2018, 6, 87.	1.4	8
4112	Cost-effectiveness and safety of the molecular targeted drugs afatinib, gefitinib and erlotinib as first-line treatments for patients with advanced EGFR mutation-positive non-small-cell lung cancer. <i>Molecular and Clinical Oncology</i> , 2018, 9, 201-206.	0.4	18
4113	Enhanced effect of checkpoint inhibitors when given after or together with IMM-101: significant responses in four advanced melanoma patients with no additional major toxicity. <i>Journal of Translational Medicine</i> , 2018, 16, 227.	1.8	18
4114	The Expanding Role of Radiosurgery for Brain Metastases. <i>Medicines (Basel, Switzerland)</i> , 2018, 5, 90.	0.7	32
4115	Relative Efficacy of Checkpoint Inhibitors for Advanced NSCLC According to Programmed Death-Ligand-1 Expression: A Systematic Review and Network Meta-Analysis. <i>Scientific Reports</i> , 2018, 8, 11738.	1.6	21
4116	Integrated Genomic Comparison of Mouse Models Reveals Their Clinical Resemblance to Human Liver Cancer. <i>Molecular Cancer Research</i> , 2018, 16, 1713-1723.	1.5	14
4117	Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?. <i>Journal of Translational Medicine</i> , 2018, 16, 219.	1.8	96
4118	Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Gastric Adenocarcinoma. <i>Oncologist</i> , 2018, 23, 1319-1327.	1.9	131
4119	Complementary vaccination protocol with dendritic cells pulsed with autologous tumour lysate in patients with resected stage III or IV melanoma: protocol for a phase II randomised trial (ACDC) Tj ETQq1 1 0.7843 t48gBT /Overlock 10		
4120	Overexpression of Romo1 is an unfavorable prognostic biomarker and a predictor of lymphatic metastasis in non-small cell lung cancer patients. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 4233-4246.	1.0	17
4121	The Cancer Omics Atlas: an integrative resource for cancer omics annotations. <i>BMC Medical Genomics</i> , 2018, 11, 63.	0.7	20
4122	Current landscape and future directions of biomarkers for predicting responses to immune checkpoint inhibitors. <i>Cancer Management and Research</i> , 2018, Volume 10, 2475-2488.	0.9	22
4123	The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 981-986.	2.0	27
4124	Effective nivolumab sequential thoracic radiotherapy in elderly patients with advanced squamous cell lung cancer: did radiation therapy play a role? A case report. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 4621-4629.	1.0	6
4125	Patient performance status and cancer immunotherapy efficacy: a meta-analysis. <i>Medical Oncology</i> , 2018, 35, 132.	1.2	52

#	ARTICLE	IF	CITATIONS
4126	Ipilimumab in combination with nivolumab for the treatment of renal cell carcinoma. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 947-957.	1.4	46
4127	Neutrophil-to-lymphocyte ratio after four weeks of nivolumab administration as a predictive marker in patients with pretreated non-small-cell lung cancer. <i>Thoracic Cancer</i> , 2018, 9, 1291-1299.	0.8	47
4128	Drug response to PD-1/PD-L1 blockade: based on biomarkers. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 4673-4683.	1.0	55
4129	Dynamic Macrophages: Understanding Mechanisms of Activation as Guide to Therapy for Atherosclerotic Vascular Disease. <i>Frontiers in Cardiovascular Medicine</i> , 2018, 5, 97.	1.1	21
4130	Personalized cancer neoantigen vaccines come of age. <i>Theranostics</i> , 2018, 8, 4238-4246.	4.6	51
4131	PD 1 checkpoint inhibition in solid organ transplants: 2 sides of a coin – case report. <i>BMC Nephrology</i> , 2018, 19, 210.	0.8	30
4132	Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer. <i>Journal of Ovarian Research</i> , 2018, 11, 43.	1.3	60
4133	Biological effects of radiation on cancer cells. <i>Military Medical Research</i> , 2018, 5, 20.	1.9	110
4134	Upregulation of PD-L1 expression by resveratrol and piceatannol in breast and colorectal cancer cells occurs via HDAC3/p300-mediated NF- κ B signaling. <i>International Journal of Oncology</i> , 2018, 53, 1469-1480.	1.4	63
4135	Molecular imaging of T cell co-regulator factor B7-H3 with ⁸⁹ Zr-DS-5573a. <i>Theranostics</i> , 2018, 8, 4199-4209.	4.6	32
4136	Carcinogenesis as a Result of Multiple Inflammatory and Oxidative Hits: a Comprehensive Review from Tumor Microenvironment to Gut Microbiota. <i>Neoplasia</i> , 2018, 20, 721-733.	2.3	65
4137	Diagnosis and Management of Hepatitis in Patients on Checkpoint Blockade. <i>Oncologist</i> , 2018, 23, 991-997.	1.9	86
4138	Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. <i>Nature Medicine</i> , 2018, 24, 724-730.	15.2	637
4139	Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. <i>Nature Medicine</i> , 2018, 24, 749-757.	15.2	900
4140	Emerging Trends in Clinical Research With Implications for Population Health and Health Policy. <i>Milbank Quarterly</i> , 2018, 96, 369-401.	2.1	5
4141	Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations. <i>Clinical Cancer Research</i> , 2018, 24, 5347-5356.	3.2	253
4142	Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma. <i>JAMA Oncology</i> , 2018, 4, 1189.	3.4	53
4143	Adipocyte-Derived Lipids Mediate Melanoma Progression via FATP Proteins. <i>Cancer Discovery</i> , 2018, 8, 1006-1025.	7.7	248

#	ARTICLE	IF	CITATIONS
4144	Intracranial Response to Nivolumab in a Patient with PD-L1-negative Lung Adenocarcinoma. <i>Internal Medicine</i> , 2018, 57, 3149-3152.	0.3	1
4145	Merkel Cell Carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 742-774.	2.3	202
4146	Safety and efficacy of anti-PD-L1 therapy in the woodchuck model of HBV infection. <i>PLoS ONE</i> , 2018, 13, e0190058.	1.1	37
4147	Metastatic site as a predictor of nivolumab efficacy in patients with advanced non-small cell lung cancer: A retrospective multicenter trial. <i>PLoS ONE</i> , 2018, 13, e0192227.	1.1	78
4148	Investigation of single and synergic effects of NLRC5 and PD-L1 variants on the risk of colorectal cancer. <i>PLoS ONE</i> , 2018, 13, e0192385.	1.1	20
4149	The time-series behavior of neutrophil-to-lymphocyte ratio is useful as a predictive marker in non-small cell lung cancer. <i>PLoS ONE</i> , 2018, 13, e0193018.	1.1	64
4150	Cancer immunotherapy: broadening the scope of targetable tumours. <i>Open Biology</i> , 2018, 8, .	1.5	162
4151	Complete Atrioventricular Block Associated with Pembrolizumab-induced Acute Myocarditis: The Need for Close Cardiac Monitoring. <i>Internal Medicine</i> , 2018, 57, 3157-3162.	0.3	31
4152	Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap. <i>Nature Communications</i> , 2018, 9, 2237.	5.8	329
4153	Non-conventional Inhibitory CD4 ⁺ Foxp3 ⁺ PD-1 ^{hi} T Cells as a Biomarker of Immune Checkpoint Blockade Activity. <i>Cancer Cell</i> , 2018, 33, 1017-1032.e7.	7.7	112
4154	Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259T Cells in Synovial Sarcoma. <i>Cancer Discovery</i> , 2018, 8, 944-957.	7.7	313
4155	Dying cells expose a nuclear antigen cross-reacting with anti-PD-1 monoclonal antibodies. <i>Scientific Reports</i> , 2018, 8, 8810.	1.6	13
4156	The Analysis of Renal Infiltrating Cells in Acute Tubulointerstitial Nephritis Induced by Anti-PD-1 Antibodies: A Case Report and Review of the Literature. <i>Internal Medicine</i> , 2018, 57, 3135-3139.	0.3	23
4157	PD-L1 checkpoint inhibition and anti-CTLA-4 whole tumor cell vaccination counter adaptive immune resistance: A mouse neuroblastoma model that mimics human disease. <i>PLoS Medicine</i> , 2018, 15, e1002497.	3.9	49
4158	Observational study of chemotherapy-induced <i>Clostridium difficile</i> infection in patients with lung cancer. <i>International Journal of Clinical Oncology</i> , 2018, 23, 1046-1051.	1.0	2
4159	Immune checkpoint inhibitors and radiosurgery for newly diagnosed melanoma brain metastases. <i>Journal of Neuro-Oncology</i> , 2018, 140, 55-62.	1.4	25
4160	Immunogenic effects of chemotherapy-induced tumor cell death. <i>Genes and Diseases</i> , 2018, 5, 194-203.	1.5	219
4161	Expression of multiple immune checkpoint molecules on T _H 1/2 cells in malignant ascites from epithelial ovarian carcinoma. <i>Oncology Letters</i> , 2018, 15, 6457-6468.	0.8	37

#	ARTICLE	IF	CITATIONS
4162	Changes in programmed death ligand 1 expression in non-small cell lung cancer patients who received anticancer treatments. <i>International Journal of Clinical Oncology</i> , 2018, 23, 1052-1059.	1.0	27
4163	Myocarditis with tremelimumab plus durvalumab combination therapy for endometrial cancer: A case report. <i>Gynecologic Oncology Reports</i> , 2018, 25, 74-77.	0.3	42
4164	Development of a radionuclide-labeled monoclonal anti-CD55 antibody with theranostic potential in pleural metastatic lung cancer. <i>Scientific Reports</i> , 2018, 8, 8960.	1.6	14
4165	Profiles of brain metastases: Prioritization of therapeutic targets. <i>International Journal of Cancer</i> , 2018, 143, 3019-3026.	2.3	31
4166	Clinical outcomes of African American patients with advanced or metastatic non-small cell lung cancer on Nivolumab in a single community-based cancer center. <i>Medical Oncology</i> , 2018, 35, 109.	1.2	10
4167	Targeting EGFR in Lung Cancer: Current Standards and Developments. <i>Drugs</i> , 2018, 78, 893-911.	4.9	61
4168	The absolute lymphocyte count can predict the overall survival of patients with non-small cell lung cancer on nivolumab: a clinical study. <i>Clinical and Translational Oncology</i> , 2019, 21, 206-212.	1.2	59
4169	Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment. <i>Liver Cancer</i> , 2019, 8, 110-120.	4.2	46
4171	A PK/PD Analysis of Circulating Biomarkers and Their Relationship to Tumor Response in Atezolizumab-treated non-small Cell Lung Cancer Patients. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 486-495.	2.3	23
4172	Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England. <i>Pharmacoeconomics - Open</i> , 2019, 3, 43-54.	0.9	15
4173	Functional genomics: paving the way for more successful cancer immunotherapy. <i>Briefings in Functional Genomics</i> , 2019, 18, 86-98.	1.3	6
4174	Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 108-117.	0.4	137
4175	Discordancy and changes in the pattern of programmed death ligand 1 expression before and after platinum-based chemotherapy in metastatic gastric cancer. <i>Gastric Cancer</i> , 2019, 22, 147-154.	2.7	16
4176	Clinicopathological features of 22C3 PD-L1 expression with mismatch repair, Epstein-Barr virus status, and cancer genome alterations in metastatic gastric cancer. <i>Gastric Cancer</i> , 2019, 22, 69-76.	2.7	45
4177	Development of a PD-L1-Expressing Orthotopic Liver Cancer Model: Implications for Immunotherapy for Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2019, 8, 155-171.	4.2	25
4178	<i>Onconephrology</i> , 2019, , 251-262.		0
4179	Acquired resistance to cancer immunotherapy. <i>Seminars in Immunopathology</i> , 2019, 41, 31-40.	2.8	34
4180	Evaluation of safety and efficacy of p53MVA vaccine combined with pembrolizumab in patients with advanced solid cancers. <i>Clinical and Translational Oncology</i> , 2019, 21, 363-372.	1.2	57

#	ARTICLE	IF	CITATIONS
4181	Global trends in the distribution of cancer types among patients in oncology phase I trials, 1991â€“2015. <i>Investigational New Drugs</i> , 2019, 37, 166-174.	1.2	4
4182	Strategies for Recognizing and Managing Immune-Mediated Adverse Events in the Treatment of Hodgkin Lymphoma with Checkpoint Inhibitors. <i>Oncologist</i> , 2019, 24, 86-95.	1.9	11
4183	Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade. <i>Oncogene</i> , 2019, 38, 390-405.	2.6	149
4184	Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy. <i>Cellular and Molecular Immunology</i> , 2019, 16, 28-39.	4.8	57
4185	Does patient age influence anti-cancer immunity?. <i>Seminars in Immunopathology</i> , 2019, 41, 125-131.	2.8	60
4186	Programmed Death Ligand 1 Is a Negative Prognostic Marker in Recurrent Isocitrate Dehydrogenase-Wildtype Glioblastoma. <i>Neurosurgery</i> , 2019, 85, 280-289.	0.6	22
4187	Essential preanalytics in <sc>PD</sc>â€“1 immunocytochemistry. <i>Histopathology</i> , 2019, 74, 362-364.	1.6	6
4188	Clinical features of immuneâ€“related thyroid dysfunction and its association with outcomes in patients with advanced malignancies treated by PDâ€“1 blockade. <i>Oncology Letters</i> , 2019, 18, 2140-2147.	0.8	35
4189	Functional and Phenotypic Characterization of Tumor-Infiltrating Leukocyte Subsets and Their Contribution to the Pathogenesis of Hepatocellular Carcinoma and Cholangiocarcinoma. <i>Translational Oncology</i> , 2019, 12, 1468-1479.	1.7	9
4190	Severe arthritis and tenosynovitis caused by immune checkpoint blockade therapy with pembrolizumab (anti-PD-1 antibody). <i>Baylor University Medical Center Proceedings</i> , 2019, 32, 419-421.	0.2	3
4191	Imaging of Precision Therapy for Lung Cancer: Current State of the Art. <i>Radiology</i> , 2019, 293, 15-29.	3.6	45
4192	A Case of Immunotherapy-Induced Colitis Complicated by Perforation and Treated with Infliximab Postoperatively. <i>Case Reports in Oncological Medicine</i> , 2019, 2019, 1-6.	0.2	8
4193	DNA Methylation Biomarkers Predict Objective Responses to PD-1/PD-L1 Inhibition Blockade. <i>Frontiers in Genetics</i> , 2019, 10, 724.	1.1	12
4194	TLR9 Mediated Tumor-Stroma Interactions in Human Papilloma Virus (HPV)-Positive Head and Neck Squamous Cell Carcinoma Up-Regulate PD-L1 and PD-L2. <i>Frontiers in Immunology</i> , 2019, 10, 1644.	2.2	24
4195	Biomarkers for Predicting Efficacies of Anti-PD1 Antibodies. <i>Frontiers in Medicine</i> , 2019, 6, 174.	1.2	49
4196	Tuberculosis Infection in a Patient Treated With Nivolumab for Non-small Cell Lung Cancer: Case Report and Literature Review. <i>Frontiers in Oncology</i> , 2019, 9, 659.	1.3	38
4197	Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC). <i>International Journal of Molecular Sciences</i> , 2019, 20, 3821.	1.8	116
4198	The Stage IV Shuffle: Elusiveness of Straight Talk About Advanced Cancer. <i>Journal of General Internal Medicine</i> , 2019, 34, 2637-2642.	1.3	2

#	ARTICLE	IF	CITATIONS
4199	Assessment of kidney transplant suitability for patients with prior cancers: is it time for a rethink?. <i>Transplant International</i> , 2019, 32, 1223-1240.	0.8	11
4200	Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches. <i>Radiation Oncology</i> , 2019, 14, 141.	1.2	285
4201	Exosomal PD-L1 promotes tumor growth through immune escape in non-small cell lung cancer. <i>Experimental and Molecular Medicine</i> , 2019, 51, 1-13.	3.2	194
4202	Immunogenicity of pembrolizumab in patients with advanced tumors. , 2019, 7, 212.		27
4203	<p>Relative value assessment: characterizing the benefit of oncology therapies through diverse survival metrics from a US perspective</p>. <i>ClinicoEconomics and Outcomes Research</i> , 2019, Volume 11, 199-219.	0.7	1
4204	Pneumonitis as a complication of immune system targeting drugs?â€”a meta-analysis of anti-PD/PD-L1 immunotherapy randomized clinical trials. <i>Journal of Thoracic Disease</i> , 2019, 11, 521-534.	0.6	16
4205	Management of non-small cell lung cancer harboring epidermal growth factor receptor mutations in the era of first-line osimertinib. <i>Journal of Thoracic Disease</i> , 2019, 11, 2664-2668.	0.6	3
4206	Immunotherapy for non-small cell lung cancer: from clinical trials to real-world practice. <i>Translational Lung Cancer Research</i> , 2019, 8, 202-207.	1.3	12
4207	Tumor mutation burden: from comprehensive mutational screening to the clinic. <i>Cancer Cell International</i> , 2019, 19, 209.	1.8	116
4208	The Immune Landscape of Thyroid Cancer in the Context of Immune Checkpoint Inhibition. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3934.	1.8	69
4209	LINKâ€™A lncRNA is upregulated in metastatic nonâ€™small cell lung cancer and is associated with poor prognosis. <i>Oncology Letters</i> , 2019, 18, 3049-3057.	0.8	5
4210	Mankind and the machine: A relationship of symbiosis or conflict?. <i>Cancer Cytopathology</i> , 2019, 127, 622-624.	1.4	0
4211	Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors. <i>Advances in Therapy</i> , 2019, 36, 2638-2678.	1.3	145
4212	B7-H3 participates in human salivary gland epithelial cells apoptosis through NF-Î³B pathway in primary SjÃ¶grenâ€™s syndrome. <i>Journal of Translational Medicine</i> , 2019, 17, 268.	1.8	27
4213	Immune microenvironment modulation unmask therapeutic benefit of radiotherapy and checkpoint inhibition. , 2019, 7, 216.		56
4214	The neurotoxic effects of immune checkpoint inhibitor therapy for melanoma. <i>Melanoma Management</i> , 2019, 6, MMT16.	0.1	2
4215	PD-L1 Distribution and Perspective for Cancer Immunotherapyâ€™Blockade, Knockdown, or Inhibition. <i>Frontiers in Immunology</i> , 2019, 10, 2022.	2.2	270
4216	The Clinical Efficacy and Safety of Four-Weekly Docetaxel as First-Line Therapy in Elderly Lung Cancer Patients with Squamous Cell Carcinoma. <i>Tuberculosis and Respiratory Diseases</i> , 2019, 82, 211.	0.7	3

#	ARTICLE	IF	CITATIONS
4217	Therapeutic vaccination immunomodulation: forming the basis of all cancer immunotherapy. , 2019, 7, 251513551986223.	1.4	28
4218	Peripheral PD-1+CD56+ T-cell frequencies correlate with outcome in stage IV melanoma under PD-1 blockade. PLoS ONE, 2019, 14, e0221301.	1.1	16
4219	The influence of the microbiota on immune development, chronic inflammation, and cancer in the context of aging. Microbial Cell, 2019, 6, 324-334.	1.4	46
4220	Examining Peripheral and Tumor Cellular Immune in Patients With Cancer. Frontiers in Immunology, 2019, 10, 1767.	2.2	44
4221	Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. Lancet Oncology, The, 2019, 20, 1395-1408.	5.1	247
4222	Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy. Nature Reviews Cancer, 2019, 19, 495-509.	12.8	573
4223	A Review of Immune-Mediated Adverse Events in Melanoma. Oncology and Therapy, 2019, 7, 101-120.	1.0	23
4224	Immuno-Oncology Therapy for Hepatocellular Carcinoma: Current Status and Ongoing Trials. Liver Cancer, 2019, 8, 221-238.	4.2	51
4225	Immune Checkpoint Inhibitor Dosing: Can We Go Lower Without Compromising Clinical Efficacy?. Journal of Global Oncology, 2019, 5, 1-5.	0.5	36
4226	Clinical outcomes in non-small cell lung cancer patients with an ultra-high expression of programmed death ligand-1 treated using pembrolizumab as a first-line therapy: A retrospective multicenter cohort study in Japan. PLoS ONE, 2019, 14, e0220570.	1.1	20
4227	Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatment. Translational Lung Cancer Research, 2019, 8, 302-316.	1.3	91
4228	A tumor-targeted immune checkpoint blocker. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 15889-15894.	3.3	21
4229	Therapeutic outcomes in non-small cell lung cancer with BRAF mutations: a single institution, retrospective cohort study. Translational Lung Cancer Research, 2019, 8, 258-267.	1.3	17
4230	Circulating Tumor Cell PD-L1 Expression as Biomarker for Therapeutic Efficacy of Immune Checkpoint Inhibition in NSCLC. Cells, 2019, 8, 809.	1.8	76
4231	Dedifferentiated Endometrial Carcinoma Could be A Target for Immune Checkpoint Inhibitors (Anti) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	1.8	22
4232	Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer. Clinical and Experimental Metastasis, 2019, 36, 449-456.	1.7	15
4233	Mechanisms of immunotherapy resistance: lessons from glioblastoma. Nature Immunology, 2019, 20, 1100-1109.	7.0	421
4234	Immunotherapy for acute myeloid leukemia: from allogeneic stem cell transplant to novel therapeutics. Leukemia and Lymphoma, 2019, 60, 3350-3362.	0.6	1

#	ARTICLE	IF	CITATIONS
4235	Organization of the Skin Immune System and Compartmentalized Immune Responses in Infectious Diseases. <i>Clinical Microbiology Reviews</i> , 2019, 32, .	5.7	74
4236	Phase I clinical trial of decitabine (5-aza-2'-deoxycytidine) administered by hepatic arterial infusion in patients with unresectable liver-predominant metastases. <i>ESMO Open</i> , 2019, 4, e000464.	2.0	21
4237	Exclusive Cutaneous and Subcutaneous Sarcoidal Granulomatous Inflammation due to Immune Checkpoint Inhibitors: Report of Two Cases with Unusual Manifestations and Review of the Literature. <i>Case Reports in Dermatological Medicine</i> , 2019, 2019, 1-7.	0.1	17
4238	Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma. , 2019, 7, 196.		62
4239	CA-170 " A Potent Small-Molecule PD-L1 Inhibitor or Not?. <i>Molecules</i> , 2019, 24, 2804.	1.7	103
4240	Cutaneous Squamous Cell Carcinoma in Immunosuppressed Patients. <i>Current Oncology Reports</i> , 2019, 21, 82.	1.8	8
4241	Neoadjuvant therapy of locally/regionally advanced melanoma. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591986695.	1.4	21
4242	Perioperative change in lymphocyte count and prognosis in esophageal squamous cell carcinoma. <i>Journal of Thoracic Disease</i> , 2019, 11, 2332-2339.	0.6	5
4243	Real-world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non-small cell lung cancer. <i>Cancer</i> , 2019, 125, 4019-4032.	2.0	115
4244	Does Industry-Conducted All-Case Surveillance of Newly Approved Oncology Drugs Contribute to the Revision of Package Inserts in Japan?. <i>Clinical and Translational Science</i> , 2019, 12, 505-512.	1.5	4
4245	Upregulation of PD-1 follows tumour development in the AOM/DSS model of inflammation-induced colorectal cancer in mice. <i>Immunology</i> , 2019, 158, 35-46.	2.0	32
4246	Comparison of tumor cell numbers and 22C3 PD-L1 expression between cryobiopsy and transbronchial biopsy with endobronchial ultrasonography-guide sheath for lung cancer. <i>Respiratory Research</i> , 2019, 20, 185.	1.4	21
4247	Expression of the immune checkpoint receptor TIGIT in seminoma. <i>Oncology Letters</i> , 2019, 18, 1497-1502.	0.8	7
4248	Clinicopathological characteristics and survival of primary malignant melanoma of the esophagus. <i>Oncology Letters</i> , 2019, 18, 1872-1880.	0.8	12
4249	Programmed Death-1 Restrains the Germinal Center in Type 1 Diabetes. <i>Journal of Immunology</i> , 2019, 203, 844-852.	0.4	15
4250	A Case of Advanced Gastric Cancer with Peritoneal Metastasis Treated Successfully with Nivolumab. <i>Case Reports in Oncology</i> , 2019, 12, 523-528.	0.3	3
4251	An individual patient-data meta-analysis of metronomic oral vinorelbine in metastatic non-small cell lung cancer. <i>PLoS ONE</i> , 2019, 14, e0220988.	1.1	17
4252	<p><p>Prospect of immunotherapy combined with anti-angiogenic agents in patients with advanced non-small cell lung cancer</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 7707-7719.	0.9	45

#	ARTICLE	IF	CITATIONS
4253	Systematic Immunotherapy Target Discovery Using Genome-Scale In Vivo CRISPR Screens in CD8 ⁺ Cells. <i>Cell</i> , 2019, 178, 1189-1204.e23.	13.5	189
4254	Single pembrolizumab treatment causing profound durable response in a patient with pulmonary pleomorphic carcinoma. <i>Respiratory Medicine Case Reports</i> , 2019, 28, 100879.	0.2	6
4255	Phase II study of nedaplatin and amrubicin as first-line treatment for advanced squamous cell lung cancer. <i>Thoracic Cancer</i> , 2019, 10, 1764-1769.	0.8	3
4256	Hyperprogression after immunotherapy in patients with malignant tumors of digestive system. <i>BMC Cancer</i> , 2019, 19, 705.	1.1	27
4257	Tumor mutational burden quantification from targeted gene panels: major advancements and challenges. , 2019, 7, 183.		231
4258	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). , 2019, 7, 184.		413
4259	M2 macrophage infiltration into tumor islets leads to poor prognosis in non-small-cell lung cancer. <i>Cancer Management and Research</i> , 2019, Volume 11, 6125-6138.	0.9	96
4260	Management of Adverse Events in Cancer Patients Treated With PD-1/PD-L1 Blockade: Focus on Asian Populations. <i>Frontiers in Pharmacology</i> , 2019, 10, 726.	1.6	20
4261	Liquid Biopsy for the Detection of Resistance Mechanisms in NSCLC: Comparison of Different Blood Biomarkers. <i>Journal of Clinical Medicine</i> , 2019, 8, 998.	1.0	28
4262	Novel Delivery Systems for Checkpoint Inhibitors. <i>Medicines (Basel, Switzerland)</i> , 2019, 6, 74.	0.7	24
4263	Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy. <i>Cancer Cell</i> , 2019, 36, 168-178.e4.	7.7	240
4264	Immunotherapy in Dialysis-Dependent Cancer Patients: Our Experience in Patients With Metastatic Renal Cell Carcinoma and a Review of the Literature. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e903-e908.	0.9	30
4265	Neutrophil-to-lymphocyte ratio evolution is an independent predictor of early progression of second-line nivolumab-treated patients with advanced non-small-cell lung cancers. <i>PLoS ONE</i> , 2019, 14, e0219060.	1.1	30
4266	How Do the Accrual Pattern and Follow-Up Duration Affect the Hazard Ratio Estimate When the Proportional Hazards Assumption Is Violated?. <i>Oncologist</i> , 2019, 24, 867-871.	1.9	11
4267	Prognostic role of pretreatment neutrophil-to-lymphocyte ratio in non-small cell lung cancer patients treated with systemic therapy: a meta-analysis. <i>Translational Lung Cancer Research</i> , 2019, 8, 214-226.	1.3	66
4268	Clinical genetic features and related survival implications in patients with surgically resected large-cell lung cancer. <i>Cancer Management and Research</i> , 2019, Volume 11, 5489-5499.	0.9	5
4269	Quantitation of Super Basic Peptides in Biological Matrices by a Generic Perfluoropentanoic Acid-Based Liquid Chromatography-Mass Spectrometry Method. <i>Journal of the American Society for Mass Spectrometry</i> , 2019, 30, 1779-1789.	1.2	3
4270	Surgery for stage IIIA-N2 non-small cell lung cancer: the jury is still out!. <i>Journal of Thoracic Disease</i> , 2019, 11, S1153-S1156.	0.6	3

#	ARTICLE	IF	CITATIONS
4271	<p>Completely resolved advanced biliary tract cancer after treatment by pembrolizumab: a report of two cases</p>. OncoTargets and Therapy, 2019, Volume 12, 5293-5298.	1.0	20
4272	Immune checkpoint inhibitor-induced sarcoidosis-like granulomas. International Journal of Clinical Oncology, 2019, 24, 1171-1181.	1.0	42
4273	Kidney Complications of Immune Checkpoint Inhibitors: A Review. American Journal of Kidney Diseases, 2019, 74, 529-537.	2.1	55
4274	Role of tumor gene mutations in treatment response to immune checkpoint blockades. Precision Clinical Medicine, 2019, 2, 100-109.	1.3	11
4275	The Three Pâ€™s: Parotid, PD-L1, and Pembrolizumab. Case Reports in Oncological Medicine, 2019, 2019, 1-3.	0.2	1
4276	MYC Expression and Metabolic Redox Changes in Cancer Cells: A Synergy Able to Induce Chemoresistance. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-9.	1.9	17
4277	Smoking history influences the prognostic value of peripheral naïve CD4+ T cells in advanced non-small cell lung cancer. Cancer Cell International, 2019, 19, 176.	1.8	8
4278	Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma. Experimental Hematology and Oncology, 2019, 8, 14.	2.0	10
4279	Characterizing responsive and refractory orthotopic mouse models of hepatocellular carcinoma in cancer immunotherapy. PLoS ONE, 2019, 14, e0219517.	1.1	11
4280	Correlation between thyroid transcription factor-1 expression, immune-related thyroid dysfunction, and efficacy of anti-programmed cell death protein-1 treatment in non-small cell lung cancer. Journal of Thoracic Disease, 2019, 11, 1919-1928.	0.6	13
4281	The Inhibition of Caspase-1- Does Not Revert Particulate Matter (PM)-Induced Lung Immunesuppression in Mice. Frontiers in Immunology, 2019, 10, 1329.	2.2	11
4282	A Phase I Comparative Pharmacokinetic and Safety Study of Two Intravenous Formulations of Vinorelbine in Patients With Advanced Non-Small Cell Lung Cancer. Frontiers in Pharmacology, 2019, 10, 774.	1.6	0
4283	Positive PDâ€™L1 expression is predictive for patients with advanced EGFR wildâ€™type nonâ€™small cell lung cancer treated with gemcitabine and cisplatin. Oncology Letters, 2019, 18, 161-168.	0.8	2
4284	Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumors. , 2019, 7, 172.		26
4285	Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitors. , 2019, 7, 173.		76
4286	Baseline Absolute Lymphocyte Count and ECOG Performance Score Are Associated with Survival in Advanced Non-Small Cell Lung Cancer Undergoing PD-1/PD-L1 Blockade. Journal of Clinical Medicine, 2019, 8, 1014.	1.0	41
4287	Role of antibiotic use, plasma citrulline and blood microbiome in advanced non-small cell lung cancer patients treated with nivolumab. , 2019, 7, 176.		62
4288	Genomic landscape and its correlations with tumor mutational burden, PD-L1 expression, and immune cells infiltration in Chinese lung squamous cell carcinoma. Journal of Hematology and Oncology, 2019, 12, 75.	6.9	84

#	ARTICLE	IF	CITATIONS
4289	Donor-derived cell-free DNA detects kidney transplant rejection during nivolumab treatment. , 2019, 7, 182.		29
4290	Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy. , 2019, 7, 181.		15
4291	Immune cell concentrations among the primary tumor microenvironment in colorectal cancer patients predicted by clinicopathologic characteristics and blood indexes. , 2019, 7, 179.		58
4292	Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma – results of a prospective biomarker study. , 2019, 7, 180.		137
4293	Successful Treatment of Unresectable Advanced Melanoma by Administration of Nivolumab With Ipilimumab Before Primary Tumor Resection. <i>Frontiers in Medicine</i> , 2019, 6, 140.	1.2	9
4294	Immune-Related Adverse Events: A Case-Based Approach. <i>Frontiers in Oncology</i> , 2019, 9, 530.	1.3	31
4295	Prognostic Relevance of Circulating Tumor Cells and Circulating Cell-Free DNA Association in Metastatic Non-Small Cell Lung Cancer Treated with Nivolumab. <i>Journal of Clinical Medicine</i> , 2019, 8, 1011.	1.0	45
4296	Extra-Adrenal Glucocorticoid Synthesis in the Intestinal Mucosa: Between Immune Homeostasis and Immune Escape. <i>Frontiers in Immunology</i> , 2019, 10, 1438.	2.2	46
4297	<p>>A pooled meta-analysis of PD-1/L1 inhibitors incorporation therapy for advanced non-small cell lung cancer</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 4955-4973.	1.0	9
4298	Prognostic Impact of Adenosine Receptor 2 (A2aR) and Programmed Cell Death Ligand 1 (PD-L1) Expression in Colorectal Cancer. <i>BioMed Research International</i> , 2019, 2019, 1-10.	0.9	23
4299	Cytotoxic Chemotherapy as an Immune Stimulus: A Molecular Perspective on Turning Up the Immunological Heat on Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 1654.	2.2	101
4300	Possible Biomarkers for Cancer Immunotherapy. <i>Cancers</i> , 2019, 11, 935.	1.7	35
4302	Aristolochic Acid and Immunotherapy for Urothelial Carcinoma: Directions for unmet Needs. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3162.	1.8	10
4303	Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance. , 2019, 7, 165.		135
4304	Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer. <i>JAMA Network Open</i> , 2019, 2, e196879.	2.8	161
4305	Systemic immune-inflammatory index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small cell lung cancer treated with nivolumab. <i>Journal of Clinical Laboratory Analysis</i> , 2019, 33, e22964.	0.9	171
4306	Challenges for real-time intraoperative diagnosis of high risk histology in lung adenocarcinoma: A necessity for sublobar resection. <i>Thoracic Cancer</i> , 2019, 10, 1663-1668.	0.8	23
4307	Diabetic ketoacidosis caused by fulminant type 1 diabetes during adjuvant chemotherapy for colon cancer: A case report. <i>Molecular and Clinical Oncology</i> , 2019, 11, 189-191.	0.4	3

#	ARTICLE	IF	CITATIONS
4308	Pseudoprogression presenting as intestinal perforation in non- \checkmark small cell lung cancer treated with anti- \checkmark PD-1: A case report. <i>Molecular and Clinical Oncology</i> , 2019, 11, 132-134.	0.4	9
4309	The Role of Checkpoint Inhibitors in Glioblastoma. <i>Targeted Oncology</i> , 2019, 14, 375-394.	1.7	30
4310	A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients. , 2019, 7, 192.		60
4311	A phase I/II study of pemetrexed with sirolimus in advanced, previously treated non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2019, 8, 247-257.	1.3	13
4312	Integrative Approaches to Cancer Immunotherapy. <i>Trends in Cancer</i> , 2019, 5, 400-410.	3.8	64
4313	Increased expression of core-fucosylated glycans in human lung squamous cell carcinoma. <i>RSC Advances</i> , 2019, 9, 22064-22073.	1.7	4
4314	Discontinuation due to immune-related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non- \checkmark small cell lung cancer. <i>Thoracic Cancer</i> , 2019, 10, 1798-1804.	0.8	37
4315	Hyperprogressive Disease in Lung Cancer with Transformation of Adenocarcinoma to Small-cell Carcinoma during Pembrolizumab Therapy. <i>Internal Medicine</i> , 2019, 58, 3295-3298.	0.3	12
4316	Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing. <i>Frontiers in Immunology</i> , 2019, 10, 1505.	2.2	34
4317	Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology. <i>Journal of Cancer</i> , 2019, 10, 3717-3727.	1.2	46
4318	Immunotherapy for hepatocellular carcinoma: recent advances and future perspectives. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591986269.	1.4	75
4319	Effectiveness of First-Line Treatments in Metastatic Squamous Non-Small-Cell Lung Cancer. <i>Current Oncology</i> , 2019, 26, 300-308.	0.9	4
4320	Serological Markers Associated With Response to Immune Checkpoint Blockade in Metastatic Gastrointestinal Tract Cancer. <i>JAMA Network Open</i> , 2019, 2, e197621.	2.8	25
4321	PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin \checkmark), Both Plus Paclitaxel and Carboplatin, as First-Line Treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Study. <i>BioDrugs</i> , 2019, 33, 555-570.	2.2	36
4322	Multiplex quantitative analysis of cancer-associated fibroblasts and immunotherapy outcome in metastatic melanoma. , 2019, 7, 194.		47
4323	PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences Are Emerging. A Literature Review. <i>Cancers</i> , 2019, 11, 1033.	1.7	160
4324	Strategies to Augment Natural Killer (NK) Cell Activity against Solid Tumors. <i>Cancers</i> , 2019, 11, 1040.	1.7	40
4325	CTLA-4 antibody ipilimumab negatively affects CD4+ T-cell responses in vitro. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1359-1368.	2.0	23

#	ARTICLE	IF	CITATIONS
4326	First-in-human phase 1 study of IT1208, a defucosylated humanized anti-CD4 depleting antibody, in patients with advanced solid tumors. , 2019, 7, 195.		32
4327	Small-Molecule Poly(ADP-ribose) Polymerase and PD-L1 Inhibitor Conjugates as Dual-Action Anticancer Agents. ACS Omega, 2019, 4, 12584-12597.	1.6	19
4328	Practical Application of Real-World Evidence in Developing Cancer Therapies. JCO Clinical Cancer Informatics, 2019, 3, 1-2.	1.0	6
4329	AP-1 Transcription Factors as Regulators of Immune Responses in Cancer. Cancers, 2019, 11, 1037.	1.7	166
4330	The biological functions and clinical applications of exosomes in lung cancer. Cellular and Molecular Life Sciences, 2019, 76, 4613-4633.	2.4	90
4331	Phase I Trial of Targeted EGFR or ALK Therapy with Ipilimumab in Metastatic NSCLC with Long-Term Follow-Up. Targeted Oncology, 2019, 14, 417-421.	1.7	34
4332	Epigenetic alterations are associated with tumor mutation burden in non-small cell lung cancer. , 2019, 7, 198.		28
4333	Circulating tumor cells in pulmonary vein and peripheral arterial provide a metric for PD-L1 diagnosis and prognosis of patients with non-small cell lung cancer. PLoS ONE, 2019, 14, e0220306.	1.1	21
4334	PD-L1 Blockade by Atezolizumab Downregulates Signaling Pathways Associated with Tumor Growth, Metastasis, and Hypoxia in Human Triple Negative Breast Cancer. Cancers, 2019, 11, 1050.	1.7	50
4335	The Role of BRAF-Targeted Therapy for Advanced Melanoma in the Immunotherapy Era. Current Oncology Reports, 2019, 21, 76.	1.8	18
4336	T-cell-receptor cross-recognition and strategies to select safe T-cell receptors for clinical translation. Immuno-Oncology Technology, 2019, 2, 1-10.	0.2	18
4337	T Cell Dysfunction in Cancer Immunity and Immunotherapy. Frontiers in Immunology, 2019, 10, 1719.	2.2	219
4338	BH3 mimetic ABT-263 enhances the anticancer effects of apigenin in tumor cells with activating EGFR mutation. Cell and Bioscience, 2019, 9, 60.	2.1	9
4339	<p></p>Clinical utility of ramucirumab in non-small-cell lung cancer</p>. Biologics: Targets and Therapy, 2019, Volume 13, 133-137.	3.0	6
4340	<p></p>Significant benefit of nivolumab combining radiotherapy in metastatic gallbladder cancer patient with strong PD-L1 expression: a case report</p>. OncoTargets and Therapy, 2019, Volume 12, 5389-5393.	1.0	10
4341	Immunological Backbone of Uveal Melanoma: Is There a Rationale for Immunotherapy?. Cancers, 2019, 11, 1055.	1.7	40
4342	The influence of microenvironment on tumor immunotherapy. FEBS Journal, 2019, 286, 4160-4175.	2.2	64
4343	Characterization and Comparison of GITR Expression in Solid Tumors. Clinical Cancer Research, 2019, 25, 6501-6510.	3.2	37

#	ARTICLE	IF	CITATIONS
4344	Comprehensive Clinical Trial Data Summation for BRAF-MEK Inhibition and Checkpoint Immunotherapy in Metastatic Melanoma. <i>Oncologist</i> , 2019, 24, e1197-e1211.	1.9	15
4345	Bilateral Testicular Metastases from Lung Adenocarcinoma Showing an Objective Response to Nivolumab: A Case Report and Review of the Literature. <i>Internal Medicine</i> , 2019, 58, 3277-3282.	0.3	6
4346	Acute Interstitial Nephritis With Karyomegalic Epithelial Cells After Nivolumab Treatment—Two Case Reports. <i>Clinical Medicine Insights: Case Reports</i> , 2019, 12, 117954761985364.	0.3	11
4347	A Computational Model of Neoadjuvant PD-1 Inhibition in Non-Small Cell Lung Cancer. <i>AAPS Journal</i> , 2019, 21, 79.	2.2	53
4348	Combination pembrolizumab plus chemotherapy: a new standard of care for patients with advanced non-small-cell lung cancer. <i>Lung Cancer: Targets and Therapy</i> , 2019, Volume 10, 47-56.	1.3	12
4349	Granulomatosis With Polyangiitis in a Patient on Programmed Death-1 Inhibitor for Advanced Non-small-cell Lung Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 478.	1.3	15
4350	Evaluating a Single Domain Antibody Targeting Human PD-L1 as a Nuclear Imaging and Therapeutic Agent. <i>Cancers</i> , 2019, 11, 872.	1.7	50
4351	Immunomodulatory and immunotherapeutic implications of tobacco smoking in squamous cell carcinomas and normal airway epithelium. <i>Oncotarget</i> , 2019, 10, 3835-3839.	0.8	8
4352	Anti-CD40 mAb enhanced efficacy of anti-PD1 against osteosarcoma. <i>Journal of Bone Oncology</i> , 2019, 17, 100245.	1.0	17
4353	Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small cell lung cancer. <i>Journal of Hematology and Oncology</i> , 2019, 12, 67.	6.9	54
4354	Cost-effectiveness Analysis of Pembrolizumab Plus Axitinib Versus Sunitinib in First-line Advanced Renal Cell Carcinoma in China. <i>Clinical Drug Investigation</i> , 2019, 39, 931-938.	1.1	27
4355	Dabrafenib Plus Trametinib for BRAF V600E-Mutant Non-small Cell Lung Cancer: A Patient Case Report. <i>Clinical Drug Investigation</i> , 2019, 39, 1003-1007.	1.1	6
4356	Metastasis manners and the underlying mechanisms of ALK and ROS1 rearrangement lung cancer and current possible therapeutic strategies. <i>RSC Advances</i> , 2019, 9, 17921-17932.	1.7	2
4357	L-Selectin Enhanced T Cells Improve the Efficacy of Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2019, 10, 1321.	2.2	50
4358	Recent Findings in the Regulation of Programmed Death Ligand 1 Expression. <i>Frontiers in Immunology</i> , 2019, 10, 1337.	2.2	85
4359	Molecular background of skin melanoma development and progression: therapeutic implications. <i>Postepy Dermatologii i Alergologii</i> , 2019, 36, 129-138.	0.4	22
4360	Modifiable Host Factors in Melanoma: Emerging Evidence for Obesity, Diet, Exercise, and the Microbiome. <i>Current Oncology Reports</i> , 2019, 21, 72.	1.8	29
4361	Next-generation sequencing and biomarkers for gastric cancer: what is the future?. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591984818.	1.4	9

#	ARTICLE	IF	CITATIONS
4362	Association Between Tumor Mutation Burden (TMB) and Outcomes of Cancer Patients Treated With PD-1/PD-L1 Inhibitions: A Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2019, 10, 673.	1.6	52
4363	Efficacy and Safety of Nivolumab in Patients with Advanced Non-small-cell Lung Cancer and Poor Performance Status. <i>Journal of Cancer</i> , 2019, 10, 2139-2144.	1.2	17
4364	Correlates of response and outcomes with talimogene laherperpvec. <i>Journal of Surgical Oncology</i> , 2019, 120, 558-564.	0.8	17
4365	Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy. <i>Cell Research</i> , 2019, 29, 609-627.	5.7	74
4366	NK cells switch from granzyme B to death receptor-mediated cytotoxicity during serial killing. <i>Journal of Experimental Medicine</i> , 2019, 216, 2113-2127.	4.2	210
4367	The PD-1/PD-L1 Axis and Virus Infections: A Delicate Balance. <i>Frontiers in Cellular and Infection Microbiology</i> , 2019, 9, 207.	1.8	194
4368	Renal Vasculitis and Pauci-immune Glomerulonephritis Associated With Immune Checkpoint Inhibitors. <i>American Journal of Kidney Diseases</i> , 2019, 74, 853-856.	2.1	61
4369	Is the Blood an Alternative for Programmed Cell Death Ligand 1 Assessment in Non-Small Cell Lung Cancer?. <i>Cancers</i> , 2019, 11, 920.	1.7	10
4370	ARID1A Mutations Are Associated with Increased Immune Activity in Gastrointestinal Cancer. <i>Cells</i> , 2019, 8, 678.	1.8	73
4371	Chemotherapy for Lung Cancer in the Era of Personalized Medicine. <i>Tuberculosis and Respiratory Diseases</i> , 2019, 82, 179.	0.7	48
4372	Immune Checkpoint Inhibitor Toxicities. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1321-1329.	1.4	105
4373	In Vitro Assessment of Putative PD-1/PD-L1 Inhibitors: Suggestions of an Alternative Mode of Action. <i>ACS Medicinal Chemistry Letters</i> , 2019, 10, 1187-1192.	1.3	22
4374	The macrophage checkpoint CD47 : SIRP1 α for recognition of "self" cells: from clinical trials of blocking antibodies to mechanobiological fundamentals. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2019, 374, 20180217.	1.8	32
4375	Genetic and genomic basis of the mismatch repair system involved in Lynch syndrome. <i>International Journal of Clinical Oncology</i> , 2019, 24, 999-1011.	1.0	57
4376	Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma. <i>Cancers</i> , 2019, 11, 1489.	1.7	37
4377	Relationship between Microsatellite Instability, Immune Cells Infiltration, and Expression of Immune Checkpoint Molecules in Ovarian Carcinoma: Immunotherapeutic Strategies for the Future. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5129.	1.8	19
4378	Programmed Death Ligand 1 Indicates Pre-Existing Adaptive Immune Response by Tumor-Infiltrating CD8+ T Cells in Non-Small Cell Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5138.	1.8	14
4379	Pembrolizumab-Induced Obstructive Bronchiolitis in a Patient With Stage IV Non-Small-Cell Lung Cancer. <i>Current Oncology</i> , 2019, 26, 571-573.	0.9	13

#	ARTICLE	IF	CITATIONS
4380	Pericardial effusion under nivolumab: case-reports and review of the literature. , 2019, 7, 266.		35
4381	The Management of Oligoprogression in the Landscape of New Therapies for Metastatic Melanoma. Cancers, 2019, 11, 1559.	1.7	20
4382	SWOG S1400C (NCT02154490)â€”A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alterationâ€”Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy). Journal of Thoracic Oncology, 2019, 14, 1853-1859.	0.5	58
4383	Challenges and Opportunities for Childhood Cancer Drug Development. Pharmacological Reviews, 2019, 71, 671-697.	7.1	13
4384	Elevated CRP levels indicate poor progression-free and overall survival on cancer patients treated with PD-1 inhibitors. ESMO Open, 2019, 4, e000531.	2.0	60
4385	Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events. ESMO Open, 2019, 4, e000472.	2.0	26
4386	Checkpoint inhibitors plus chemotherapy for first-line treatment of advanced non-small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials. Future Science OA, 2019, 5, FSO421.	0.9	26
4387	CEACAM1 structure and function in immunity and its therapeutic implications. Seminars in Immunology, 2019, 42, 101296.	2.7	62
4388	Syndrome of inappropriate anti-diuretic hormone secretion in cancer patients: results of the first multicenter Italian study. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591987772.	1.4	16
4389	<p></p>Prognostic significance of FA score based on plasma fibrinogen and serum albumin in patients with epithelial ovarian cancer</p>. Cancer Management and Research, 2019, Volume 11, 7697-7705.	0.9	8
4390	<p></p>PD-1 inhibitors dependent CD8+</sup> T cells inhibit mouse colon cancer cell metastasis</p>. OncoTargets and Therapy, 2019, Volume 12, 6961-6971.	1.0	11
4391	<p></p>The Role Of PD-1/PD-L1 Axis In Treg Development And Function: Implications For Cancer Immunotherapy</p>. OncoTargets and Therapy, 2019, Volume 12, 8437-8445.	1.0	141
4392	Seronegative autoimmune autonomic ganglionopathy from dual immune checkpoint inhibition in a patient with metastatic melanoma. , 2019, 7, 262.		12
4393	Survival Comparison between Melanoma Patients Treated with Patient-Specific Dendritic Cell Vaccines and Other Immunotherapies Based on Extent of Disease at the Time of Treatment. Biomedicines, 2019, 7, 80.	1.4	0
4394	Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4+ T Cells. Vaccines, 2019, 7, 149.	2.1	63
4395	Principles of prophylactic and therapeutic management of skin toxicity during treatment with checkpoint inhibitors. Postepy Dermatologii I Alergologii, 2019, 36, 382-391.	0.4	24
4396	Programmed death ligandâ€”1/programmed deathâ€”1 inhibition therapy and programmed death ligandâ€”1 expression in urothelial bladder carcinoma. Chronic Diseases and Translational Medicine, 2019, 5, 170-177.	0.9	3
4397	The mechanisms of acute interstitial nephritis in the era of immune checkpoint inhibitors in melanoma. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591987554.	1.4	21

#	ARTICLE	IF	CITATIONS
4398	Rebalancing Immune Homeostasis to Treat Autoimmune Diseases. <i>Trends in Immunology</i> , 2019, 40, 888-908.	2.9	83
4399	Prognostic Nutritional Index and Neutrophil-to-Lymphocyte Ratio Are Respectively Associated with Prognosis of Gastric Cancer with Liver Metastasis Undergoing and without Hepatectomy. <i>BioMed Research International</i> , 2019, 2019, 1-7.	0.9	9
4400	Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm. <i>Journal of Translational Medicine</i> , 2019, 17, 338.	1.8	16
4401	Comparative Safety of PD-1/PD-L1 Inhibitors for Cancer Patients: Systematic Review and Network Meta-Analysis. <i>Frontiers in Oncology</i> , 2019, 9, 972.	1.3	17
4402	Monoclonal Antibodies in Dermatoonologyâ€™State of the Art and Future Perspectives. <i>Cancers</i> , 2019, 11, 1420.	1.7	9
4403	The Role of Immune Checkpoint Receptors in Regulating Immune Reactivity in Lupus. <i>Cells</i> , 2019, 8, 1213.	1.8	14
4404	Potential clinical application of tumor-infiltrating lymphocyte therapy for ovarian epithelial cancer prior or post-resistance to chemotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1747-1757.	2.0	16
4405	Liver graft rejection following immune checkpoint inhibitors treatment: a review. <i>Medical Oncology</i> , 2019, 36, 94.	1.2	27
4406	Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor. <i>Seminars in Immunology</i> , 2019, 42, 101305.	2.7	189
4407	Delivery rate of patients with advanced gastric cancer to third-line chemotherapy and those patientsâ€™ characteristics: an analysis in real-world setting. <i>Journal of Gastrointestinal Oncology</i> , 2019, 10, 957-964.	0.6	4
4408	Ipilimumab-induced renal granulomatous arteritis: a case report. <i>BMC Nephrology</i> , 2019, 20, 366.	0.8	11
4409	Pembrolizumab-Induced Seronegative Arthritis and Fasciitis in a Patient with Lung Adenocarcinoma. <i>Current Drug Safety</i> , 2019, 14, 225-229.	0.3	5
4410	Patient-specific dendritic cell vaccines with autologous tumor antigens in 72 patients with metastatic melanoma. <i>Melanoma Management</i> , 2019, 6, MMT20.	0.1	9
4411	Pembrolizumab Induced Ocular Hypotony With Near Complete Vision Loss, Interstitial Pulmonary Fibrosis and Arthritis. <i>Frontiers in Oncology</i> , 2019, 9, 944.	1.3	17
4412	The Relative Risk of Immune-Related Liver Dysfunction of PD-1/PD-L1 Inhibitors Versus Chemotherapy in Solid Tumors: A Meta-Analysis of Randomized Controlled Trials. <i>Frontiers in Pharmacology</i> , 2019, 10, 1063.	1.6	7
4413	Factors Influencing the Efficacy of Anti-PD-1 Therapy in Chinese Patients with Advanced Melanoma. <i>Journal of Oncology</i> , 2019, 2019, 1-8.	0.6	9
4414	Inflammatory Biomarkers as Predictors of Response to Immunotherapy in Urological Tumors. <i>Journal of Oncology</i> , 2019, 2019, 1-11.	0.6	6
4415	Expansion of effector and memory T cells is associated with increased survival in recurrent glioblastomas treated with dendritic cell immunotherapy. <i>Neuro-Oncology Advances</i> , 2019, 1, vdz022.	0.4	16

#	ARTICLE	IF	CITATIONS
4416	Foxp3+Helios+ regulatory T cells are associated with monocyte subsets and their PD-1 expression during acute HIV-1 infection. <i>BMC Immunology</i> , 2019, 20, 38.	0.9	7
4417	Adverse Effects of Immune Checkpoint Inhibitors (Programmed Death-1 Inhibitors and Cytotoxic) Tj ETQq1 1 0.784314 rgBT /Overloc <i>Medicine Research</i> , 2019, 11, 225-236.	0.6	133
4418	Intermittent hypoxia enhances the tumor programmed death ligand 1 expression in a mouse model of sleep apnea. <i>Annals of Translational Medicine</i> , 2019, 7, 97-97.	0.7	18
4419	Impact of clinicopathological features on the efficacy of immune checkpoint inhibitors plus conventional treatment in patients with advanced lung cancer. <i>Journal of Thoracic Disease</i> , 2019, 11, 3794-3807.	0.6	3
4420	Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients. <i>Journal of Translational Medicine</i> , 2019, 17, 355.	1.8	150
4421	Recent advances in nanotheranostics for triple negative breast cancer treatment. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 430.	3.5	121
4422	<p>Genetic Biomarkers For Hepatocellular Carcinoma In The Era Of Precision Medicine</p>. <i>Journal of Hepatocellular Carcinoma</i> , 2019, Volume 6, 151-166.	1.8	25
4423	The Activity of Immune Checkpoint Inhibition in KRAS Mutated Non-small Cell Lung Cancer: A Single Centre Experience. <i>Cancer Genomics and Proteomics</i> , 2019, 16, 577-582.	1.0	52
4424	Granulation Tissue-induced Pseudo-relapse During Nivolumab Treatment in Advanced Non-small Cell Lung Cancer. <i>In Vivo</i> , 2019, 33, 2113-2115.	0.6	4
4425	Artificial Intelligence in Lung Cancer Pathology Image Analysis. <i>Cancers</i> , 2019, 11, 1673.	1.7	152
4426	Intra-Patient Heterogeneity of Circulating Tumor Cells and Circulating Tumor DNA in Blood of Melanoma Patients. <i>Cancers</i> , 2019, 11, 1685.	1.7	23
4427	Overview of Immune Checkpoint Inhibitors Therapy for Hepatocellular Carcinoma, and The ITA.LI.CA Cohort Derived Estimate of Amenability Rate to Immune Checkpoint Inhibitors in Clinical Practice. <i>Cancers</i> , 2019, 11, 1689.	1.7	44
4428	PD-L1/PD-1 Axis in Glioblastoma Multiforme. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5347.	1.8	115
4429	Peptide-based materials for cancer immunotherapy. <i>Theranostics</i> , 2019, 9, 7807-7825.	4.6	77
4430	Surgery for Metastatic Melanoma: an Evolving Concept. <i>Current Oncology Reports</i> , 2019, 21, 98.	1.8	11
4431	Immune regulation and cytotoxic T cell activation of IL-10 agonists â€“ Preclinical and clinical experience. <i>Seminars in Immunology</i> , 2019, 44, 101325.	2.7	30
4432	The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 892-901.	3.2	80
4433	Nanoparticle Delivery and Tumor Vascular Normalization: The Chicken or The Egg?. <i>Frontiers in Oncology</i> , 2019, 9, 1227.	1.3	47

#	ARTICLE	IF	CITATIONS
4434	Hyperprogressive Disease during Anti-PD-1 (PDCD1) / PD-L1 (CD274) Therapy: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2019, 11, 1699.	1.7	81
4435	Targeting Immune-Related Biological Processes in Solid Tumors: We do Need Biomarkers. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5452.	1.8	53
4436	Advances in Engineering Cells for Cancer Immunotherapy. <i>Theranostics</i> , 2019, 9, 7889-7905.	4.6	44
4437	Pemetrexed Plus Platinum for Patients With Advanced Non-small Cell Lung Cancer and Interstitial Lung Disease. <i>In Vivo</i> , 2019, 33, 2059-2064.	0.6	13
4438	Acute kidney injury from immune checkpoint inhibitor use. <i>BMJ Case Reports</i> , 2019, 12, e231211.	0.2	6
4439	Vitiligo Adverse Event Observed in a Patient With Durable Complete Response After Nivolumab for Metastatic Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2019, 9, 1033.	1.3	15
4440	Role of Focal Adhesion Kinase in Small-Cell Lung Cancer and Its Potential as a Therapeutic Target. <i>Cancers</i> , 2019, 11, 1683.	1.7	38
4441	Immune-Related Adverse Events Requiring Hospitalization: Spectrum of Toxicity, Treatment, and Outcomes. <i>Journal of Oncology Practice</i> , 2019, 15, e825-e834.	2.5	37
4442	The Common Costimulatory and Coinhibitory Signaling Molecules in Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Immunology</i> , 2019, 10, 2457.	2.2	16
4443	Recent advances and challenges of repurposing nanoparticle-based drug delivery systems to enhance cancer immunotherapy. <i>Theranostics</i> , 2019, 9, 7906-7923.	4.6	100
4444	Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial. <i>BMC Cancer</i> , 2019, 19, 1074.	1.1	30
4445	Immune Checkpoint Inhibitor Toxicity in Head and Neck Cancer: From Identification to Management. <i>Frontiers in Pharmacology</i> , 2019, 10, 1254.	1.6	21
4446	The Differences in the Safety and Tolerability of Immune Checkpoint Inhibitors as Treatment for Non-Small Cell Lung Cancer and Melanoma: Network Meta-Analysis and Systematic Review. <i>Frontiers in Pharmacology</i> , 2019, 10, 1260.	1.6	18
4447	Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors. <i>Cancer Cell</i> , 2019, 36, 471-482.	7.7	280
4448	Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports. <i>BMC Cancer</i> , 2019, 19, 1019.	1.1	48
4449	Leveraging transcriptional dynamics to improve BRAF inhibitor responses in melanoma. <i>EBioMedicine</i> , 2019, 48, 178-190.	2.7	66
4450	The Landscape of Tumor Fusion Neoantigens: A Pan-Cancer Analysis. <i>IScience</i> , 2019, 21, 249-260.	1.9	39
4451	The Rise of NK Cell Checkpoints as Promising Therapeutic Targets in Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2019, 10, 2354.	2.2	70

#	ARTICLE	IF	CITATIONS
4452	Prognostic Value of Lymphocyte-Activation Gene 3 (LAG3) in Cancer: A Meta-Analysis. <i>Frontiers in Oncology</i> , 2019, 9, 1040.	1.3	38
4453	Clinicopathologic Significance and Immunogenomic Analysis of Programmed Death-Ligand 1 (PD-L1) and Programmed Death 1 (PD-1) Expression in Thymic Epithelial Tumors. <i>Frontiers in Oncology</i> , 2019, 9, 1055.	1.3	18
4454	Adverse Events of Concurrent Immune Checkpoint Inhibitors and Antiangiogenic Agents: A Systematic Review. <i>Frontiers in Pharmacology</i> , 2019, 10, 1173.	1.6	35
4455	The Lung Immune Prognostic Index Discriminates Survival Outcomes in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors. <i>Cancers</i> , 2019, 11, 1713.	1.7	56
4456	Novel Immunotherapy Combinations. <i>Current Oncology Reports</i> , 2019, 21, 96.	1.8	12
4457	PD-L1 Expression and Tumor-Infiltrating Lymphocytes in Thymic Epithelial Neoplasms. <i>Journal of Clinical Medicine</i> , 2019, 8, 1833.	1.0	19
4458	Intratumoral Cytotoxic T-Lymphocyte Density and PD-L1 Expression Are Prognostic Biomarkers for Patients with Colorectal Cancer. <i>Medicina (Lithuania)</i> , 2019, 55, 723.	0.8	18
4459	Immune Responses in Bladder Cancer-Role of Immune Cell Populations, Prognostic Factors and Therapeutic Implications. <i>Frontiers in Oncology</i> , 2019, 9, 1270.	1.3	76
4460	Incidence of Immune Checkpoint Inhibitor-Associated Diabetes: A Meta-Analysis of Randomized Controlled Studies. <i>Frontiers in Pharmacology</i> , 2019, 10, 1453.	1.6	24
4462	Dual checkpoint inhibitor-associated eosinophilic enteritis. , 2019, 7, 310.		16
4463	Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study. , 2019, 7, 299.		108
4464	Therapeutic Monoclonal Antibodies Targeting Immune Checkpoints for the Treatment of Solid Tumors. <i>Antibodies</i> , 2019, 8, 51.	1.2	32
4465	Cold Atmospheric Plasma-Treated PBS Eliminates Immunosuppressive Pancreatic Stellate Cells and Induces Immunogenic Cell Death of Pancreatic Cancer Cells. <i>Cancers</i> , 2019, 11, 1597.	1.7	77
4466	PD-1-Targeted Discovery of Peptide Inhibitors by Virtual Screening, Molecular Dynamics Simulation, and Surface Plasmon Resonance. <i>Molecules</i> , 2019, 24, 3784.	1.7	26
4467	Vascular endothelial growth factor and programmed death-1 pathway inhibitors in renal cell carcinoma. <i>Cancer</i> , 2019, 125, 4148-4157.	2.0	21
4468	The role and therapeutic implications of T cells in cancer of the lung. <i>Clinical and Translational Immunology</i> , 2019, 8, e1076.	1.7	25
4469	Quantitative Assessment of CMTM6 in the Tumor Microenvironment and Association with Response to PD-1 Pathway Blockade in Advanced-Stage Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, 2084-2096.	0.5	48
4470	Pembrolizumab-induced interstitial lung disease following thoracic surgery in a patient with non-small cell lung cancer. <i>Thoracic Cancer</i> , 2019, 10, 2179-2182.	0.8	6

#	ARTICLE	IF	CITATIONS
4471	Autoreactive B cells in SLE, villains or innocent bystanders?. Immunological Reviews, 2019, 292, 120-138.	2.8	40
4472	The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors. , 2019, 7, 278.		586
4473	KEYNOTE-042 and the role for single agent pembrolizumab in patients with PD-L1 tumor proportion score 1â€“49%. Journal of Thoracic Disease, 2019, 11, S1963-S1965.	0.6	6
4474	A modified recursive partitioning analysis for predicting overall survival in patients with non-small cell lung cancer and central nervous system metastases. Journal of Thoracic Disease, 2019, 11, 3909-3919.	0.6	2
4475	Prognostic impact of the Controlling Nutritional Status score in patients with non-small cell lung cancer treated with pembrolizumab. Journal of Thoracic Disease, 2019, 11, 3757-3768.	0.6	29
4476	Present Scenario of Bioconjugates in Cancer Therapy: A Review. International Journal of Molecular Sciences, 2019, 20, 5243.	1.8	37
4477	Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 22246-22251.	3.3	142
4478	Survival in Early Phase Immuno-Oncology Trials: Development and Validation of a Prognostic Index. JNCI Cancer Spectrum, 2019, 3, pkz071.	1.4	4
4479	Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab. BMC Cancer, 2019, 19, 974.	1.1	104
4480	PACIFIC: shifting tides in the treatment of locally advanced non-small cell lung cancer. Translational Lung Cancer Research, 2019, 8, S139-S146.	1.3	11
4481	Treatment effect and safety profile of salvage chemotherapy following immune checkpoint inhibitors in lung cancer. Lung Cancer Management, 2019, 8, LMT12.	1.5	10
4482	Three discipline collaborative radiation therapy (3DCRT) special debate: The single most important factor in determining the future of SBRT is immune response. Journal of Applied Clinical Medical Physics, 2019, 20, 6-12.	0.8	1
4483	The Targeted Therapies Era Beyond the Surgical Point of View: What Spine Surgeons Should Know Before Approaching Spinal Metastases. Cancer Control, 2019, 26, 107327481987054.	0.7	16
4484	Evolution of the nonsense-mediated decay pathway is associated with decreased cytolytic immune infiltration. PLoS Computational Biology, 2019, 15, e1007467.	1.5	15
4485	Comparative efficacy and safety of combination therapies for advanced melanoma: a network meta-analysis. BMC Cancer, 2019, 19, 43.	1.1	31
4486	Theoretical and Practical Implications of Treating Cachexia in Advanced Lung Cancer Patients. Cancers, 2019, 11, 1619.	1.7	9
4487	Targeting Multiple Receptors to Increase Checkpoint Blockade Efficacy. International Journal of Molecular Sciences, 2019, 20, 158.	1.8	29
4488	Neurological Immune Related Adverse Events Associated with Nivolumab, Ipilimumab, and Pembrolizumab Therapyâ€”Review of the Literature and Future Outlook. Journal of Clinical Medicine, 2019, 8, 1777.	1.0	87

#	ARTICLE	IF	CITATIONS
4489	Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 22699-22709.	3.3	226
4490	Sustained Response and Rationale of Programmed Cell Death-1-Targeting for Progressive Multifocal Leukoencephalopathy. Open Forum Infectious Diseases, 2019, 6, ofz374.	0.4	17
4491	High mortality and poor treatment efficacy of immune checkpoint inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in non-small cell lung cancer. Thoracic Cancer, 2019, 10, 2006-2012.	0.8	52
4492	The efficacy of immune checkpoint inhibitors in anaplastic lymphoma kinase-positive non-small cell lung cancer. Thoracic Cancer, 2019, 10, 2117-2123.	0.8	9
4493	Nivolumab-related severe thrombocytopenia in a patient with relapsed lung adenocarcinoma: a case report and review of the literature. Journal of Medical Case Reports, 2019, 13, 316.	0.4	19
4494	A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma—A Proof of Antigen Discovery Feasibility in Three Patients. Frontiers in Immunology, 2019, 10, 1832.	2.2	73
4495	Invariant NKT Cell-Mediated Modulation of ILC1s as a Tool for Mucosal Immune Intervention. Frontiers in Immunology, 2019, 10, 1849.	2.2	6
4496	Novel Biomarkers for Personalized Cancer Immunotherapy. Cancers, 2019, 11, 1223.	1.7	36
4497	Association of miR-100 expression with clinicopathological features and prognosis of patients with lung cancer. Oncology Letters, 2019, 18, 1318-1322.	0.8	5
4498	Differential expression of efferocytosis and phagocytosis associated genes in tumor associated macrophages exposed to African American patient derived prostate cancer microenvironment. Journal of Solid Tumors, 2019, 9, 22.	0.1	5
4499	Integrated Transcriptome Analysis Reveals KLK5 and L1CAM Predict Response to Anlotinib in NSCLC at 3rd Line. Frontiers in Oncology, 2019, 9, 886.	1.3	20
4500	Tumor microenvironment immune types in gastric cancer are associated with mismatch repair however, not HER2 status. Oncology Letters, 2019, 18, 1775-1785.	0.8	8
4501	Impressive response to nivolumab of non-small cell lung cancer containing sarcomatoid components. Respirology Case Reports, 2019, 7, e00477.	0.3	8
4502	Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies. Genes and Diseases, 2019, 6, 232-246.	1.5	44
4503	Phagocytosis checkpoints as new targets for cancer immunotherapy. Nature Reviews Cancer, 2019, 19, 568-586.	12.8	557
4504	The Prognostic Landscape of Tumor-Infiltrating Immune Cells and Immune Checkpoints in Glioblastoma. Technology in Cancer Research and Treatment, 2019, 18, 153303381986994.	0.8	29
4505	Immune Heterogeneity Between Primary Tumors and Corresponding Metastatic Lesions and Response to Platinum Therapy in Primary Ovarian Cancer. Cancers, 2019, 11, 1250.	1.7	18
4506	Gut Microbiome: A Promising Biomarker for Immunotherapy in Colorectal Cancer. International Journal of Molecular Sciences, 2019, 20, 4155.	1.8	83

#	ARTICLE	IF	CITATIONS
4507	Long non-coding RNA OECC promotes cell proliferation and metastasis through the PI3K/Akt/mTOR signaling pathway in human lung cancer. <i>Oncology Letters</i> , 2019, 18, 3017-3024.	0.8	7
4508	Successful Resection of Cisplatin-Resistant Renal Pelvic Cancer after the Administration of Pembrolizumab as Second-Line Therapy. <i>Case Reports in Oncology</i> , 2019, 12, 548-553.	0.3	1
4509	Radiation as an In Situ Auto-Vaccination: Current Perspectives and Challenges. <i>Vaccines</i> , 2019, 7, 100.	2.1	30
4510	Genomics meets immunity in pancreatic cancer: Current research and future directions for pancreatic adenocarcinoma immunotherapy. <i>Oncology Reviews</i> , 2019, 13, 430.	0.8	9
4511	Validation of prognostic impact of number of extrathoracic metastases according to the eighth TNM classification: a single-institution retrospective study in Japan. <i>International Journal of Clinical Oncology</i> , 2019, 24, 1549-1557.	1.0	4
4512	Selection of patient reported outcomes questions reflecting symptoms for patients with metastatic melanoma receiving immunotherapy. <i>Journal of Patient-Reported Outcomes</i> , 2019, 3, 19.	0.9	17
4513	Anti-PD-1 Immunotherapy May Induce Interstitial Nephritis With Increased Tubular Epithelial Expression of PD-L1. <i>Kidney International Reports</i> , 2019, 4, 1152-1160.	0.4	44
4514	Myasthenia gravis and myopathy after nivolumab treatment for non-small cell lung carcinoma: A case report. <i>Thoracic Cancer</i> , 2019, 10, 2045-2049.	0.8	12
4515	Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape. , 2019, 7, 224.		154
4516	Synchronous Occurrence of Bazex Syndrome and Remitting Seronegative Symmetrical Synovitis with Pitting Edema Syndrome in a Patient with Lung Cancer. <i>Internal Medicine</i> , 2019, 58, 3267-3271.	0.3	5
4517	Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC). <i>Advances in Therapy</i> , 2019, 36, 2600-2617.	1.3	80
4518	Lipid accumulation impairs natural killer cell cytotoxicity and tumor control in the postoperative period. <i>BMC Cancer</i> , 2019, 19, 823.	1.1	54
4519	Severe toxicity from checkpoint protein inhibitors: What intensive care physicians need to know?. <i>Annals of Intensive Care</i> , 2019, 9, 25.	2.2	46
4520	Nanoparticle Encapsulation of Synergistic Immune Agonists Enables Systemic Codelivery to Tumor Sites and IFN γ -Driven Antitumor Immunity. <i>Cancer Research</i> , 2019, 79, 5394-5406.	0.4	55
4521	Inhibition of lung cancer cells and Ras/Raf/MEK/ERK signal transduction by ectonucleoside triphosphate phosphohydrolase-7 (ENTPD7). <i>Respiratory Research</i> , 2019, 20, 194.	1.4	12
4522	Neoantigen vaccine: an emerging tumor immunotherapy. <i>Molecular Cancer</i> , 2019, 18, 128.	7.9	398
4523	Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies. , 2019, 7, 225.		16
4524	Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200. , 2019, 7, 227.		58

#	ARTICLE	IF	CITATIONS
4525	Pembrolizumab in a Patient With a Metastatic CASTLE Tumor of the Parotid. <i>Frontiers in Oncology</i> , 2019, 9, 734.	1.3	15
4526	Expression of Programmed Cell Death-Ligands in Hepatocellular Carcinoma: Correlation With Immune Microenvironment and Survival Outcomes. <i>Frontiers in Oncology</i> , 2019, 9, 883.	1.3	40
4527	Programmed Death-Ligand-1 Expression in Non-Small Cell Lung Cancer and Prognosis. <i>Balkan Medical Journal</i> , 2019, 36, 184-189.	0.3	7
4528	Cancer immunotherapy and its renal effects. <i>Journal of Onco-Nephrology</i> , 2019, 3, 151-159.	0.3	3
4529	Tumor Metabolism as a Regulator of Tumor-Host Interactions in the B-Cell Lymphoma Microenvironment—Fueling Progression and Novel Brakes for Therapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4158.	1.8	14
4530	Diagnosis and Treatment of ALK Aberrations in Metastatic NSCLC. <i>Current Treatment Options in Oncology</i> , 2019, 20, 79.	1.3	34
4531	Immunopathologic Stratification of Colorectal Cancer for Checkpoint Blockade Immunotherapy. <i>Cancer Immunology Research</i> , 2019, 7, 1574-1579.	1.6	33
4532	PD-L1, FGFR1, PIK3CA, PTEN, and p16 expression in pulmonary emphysema and chronic obstructive pulmonary disease with resected lung squamous cell carcinoma. <i>BMC Pulmonary Medicine</i> , 2019, 19, 169.	0.8	4
4533	Prediction of PD-L1 Expression in Neuroblastoma via Computational Modeling. <i>Brain Sciences</i> , 2019, 9, 221.	1.1	22
4534	The impact of EGFR-TKI use on clinical outcomes of lung adenocarcinoma patients with brain metastases after Gamma Knife radiosurgery: a propensity score-matched analysis based on extended JLGK0901 dataset (JLGK0901-EGFR-TKI). <i>Journal of Neuro-Oncology</i> , 2019, 145, 151-157.	1.4	16
4535	Immune Microenvironment of Brain Metastases—Are Microglia and Other Brain Macrophages Little Helpers?. <i>Frontiers in Immunology</i> , 2019, 10, 1941.	2.2	41
4536	Tumor-induced peripheral immunosuppression promotes brain metastasis in patients with non-small cell lung cancer. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1501-1513.	2.0	39
4537	Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy. <i>Journal of Translational Medicine</i> , 2019, 17, 303.	1.8	89
4538	Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. <i>Journal of Hematology and Oncology</i> , 2019, 12, 92.	6.9	485
4539	Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapy. , 2019, 7, 237.		88
4540	PD-1 expression and its significance in tumour microenvironment of hepatocellular carcinoma. <i>Translational Gastroenterology and Hepatology</i> , 2019, 4, 51-51.	1.5	16
4541	Neutrophil Heterogeneity in Cancer: From Biology to Therapies. <i>Frontiers in Immunology</i> , 2019, 10, 2155.	2.2	110
4542	Nivolumab-Induced Recurrence of Rheumatoid Arthritis in a Patient with Metastatic Gastric Adenocarcinoma. <i>Clinical Drug Investigation</i> , 2019, 39, 1251-1254.	1.1	3

#	ARTICLE	IF	CITATIONS
4543	Irreversible Electroporation Combined with Checkpoint Blockade and TLR7 Stimulation Induces Antitumor Immunity in a Murine Pancreatic Cancer Model. <i>Cancer Immunology Research</i> , 2019, 7, 1714-1726.	1.6	72
4544	Immunotherapy in inoperable stage III non-small cell lung cancer: a review. <i>Drugs in Context</i> , 2019, 8, 1-6.	1.0	9
4545	Oncolytic Viruses Engineered to Enforce Leptin Expression Reprogram Tumor-Infiltrating T Cell Metabolism and Promote Tumor Clearance. <i>Immunity</i> , 2019, 51, 548-560.e4.	6.6	88
4546	Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors. <i>Journal of Clinical Investigation</i> , 2019, 129, 2056-2070.	3.9	159
4547	Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer. <i>Experimental Hematology and Oncology</i> , 2019, 8, 19.	2.0	30
4548	PD-L1 Induction by Cancer-Associated Fibroblast-Derived Factors in Lung Adenocarcinoma Cells. <i>Cancers</i> , 2019, 11, 1257.	1.7	52
4549	Glycan-Modified Melanoma-Derived Apoptotic Extracellular Vesicles as Antigen Source for Anti-Tumor Vaccination. <i>Cancers</i> , 2019, 11, 1266.	1.7	47
4550	Plasma Biomarkers and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: New Tools for Better Patient Selection?. <i>Cancers</i> , 2019, 11, 1269.	1.7	25
4551	The Association Between the Incidence Risk of Peripheral Neuropathy and PD-1/PD-L1 Inhibitors in the Treatment for Solid Tumor Patients: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2019, 9, 866.	1.3	25
4552	Sex Differences in Cancer Immunotherapy Efficacy, Biomarkers, and Therapeutic Strategy. <i>Molecules</i> , 2019, 24, 3214.	1.7	106
4553	Loss of Scribble confers cisplatin resistance during NSCLC chemotherapy via Nox2/ROS and Nrf2/PD-L1 signaling. <i>EBioMedicine</i> , 2019, 47, 65-77.	2.7	36
4554	The Reproducibility of the Immunohistochemical PD-L1 Testing in Non-Small-Cell Lung Cancer: A Multicentric Italian Experience. <i>BioMed Research International</i> , 2019, 2019, 1-7.	0.9	20
4555	The evolving immuno-oncology landscape in advanced lung cancer: first-line treatment of non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591987036.	1.4	45
4556	Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition—A Pooled Analysis of Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 3350-3358.	0.8	52
4557	Fatal encephalopathy after pembrolizumab treatment for advanced non-small cell lung carcinoma. <i>Journal of Neuro-Oncology</i> , 2019, 145, 399-402.	1.4	1
4558	Anti-programmed cell death protein 1 (anti-PD1) immunotherapy induced autoimmune polyendocrine syndrome type II (APS-2): a case report and review of the literature. , 2019, 7, 241.		19
4559	<p>Effect of PD-1 inhibitor on exhaled nitric oxide and pulmonary function in non-small cell lung cancer patients with and without COPD</p>. <i>International Journal of COPD</i> , 2019, Volume 14, 1867-1877.	0.9	12
4560	Toward T Cell-Mediated Control or Elimination of HIV Reservoirs: Lessons From Cancer Immunology. <i>Frontiers in Immunology</i> , 2019, 10, 2109.	2.2	32

#	ARTICLE	IF	CITATIONS
4561	Comparison of PD-L1 Expression Status between Pure-Solid Versus Part-Solid Lung Adenocarcinomas. <i>Biomolecules</i> , 2019, 9, 456.	1.8	11
4562	Real-World Outcomes and Prognostic Factors in Patients Receiving Nivolumab Therapy for Recurrent or Metastatic Head and Neck Carcinoma. <i>Cancers</i> , 2019, 11, 1317.	1.7	28
4563	IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 397.	3.5	111
4564	Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma. , 2019, 7, 254.		14
4565	Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Nonâ€“Small Cell Lung Cancer. <i>JAMA Network Open</i> , 2019, 2, e1911895.	2.8	55
4566	Down Regulation of c-FLIPL Enhance PD-1 Blockade Efficacy in B16 Melanoma. <i>Frontiers in Oncology</i> , 2019, 9, 857.	1.3	12
4567	RAS: Striking at the Core of the Oncogenic Circuitry. <i>Frontiers in Oncology</i> , 2019, 9, 965.	1.3	106
4568	Development and Evaluation of Multifunctional Poly(Lactic-co-glycolic acid) Nanoparticles Embedded in Carboxymethyl Î²-Glucan Porous Microcapsules as a Novel Drug Delivery System for Gefitinib. <i>Pharmaceutics</i> , 2019, 11, 469.	2.0	16
4569	Robust Iterative Stimulation with Self-Antigens Overcomes CD8+ T Cell Tolerance to Self- and Tumor Antigens. <i>Cell Reports</i> , 2019, 28, 3092-3104.e5.	2.9	18
4570	Transperineal abdominoperineal resection for anorectal melanoma: A case report. <i>International Journal of Surgery Case Reports</i> , 2019, 61, 214-217.	0.2	1
4571	Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis. , 2019, 7, 248.		18
4572	Analysis of Predictive Biomarkers in Patients With Lung Adenocarcinoma From Southern Brazil Reveals a Distinct Profile From Other Regions of the Country. <i>Journal of Global Oncology</i> , 2019, 5, 1-9.	0.5	13
4573	Risk of major autoimmune diseases in female breast cancer patients: A nationwide, population-based cohort study. <i>PLoS ONE</i> , 2019, 14, e0222860.	1.1	12
4574	Improving Cancer Immunotherapy by Targeting the Hypoxic Tumor Microenvironment: New Opportunities and Challenges. <i>Cells</i> , 2019, 8, 1083.	1.8	153
4575	Germline genetic host factors as predictive biomarkers in immuno-oncology. <i>Immuno-Oncology Technology</i> , 2019, 2, 14-21.	0.2	2
4576	The role of pembrolizumab in the treatment of PD-L1 expressing gastric and gastroesophageal junction adenocarcinoma. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481986976.	1.4	31
4577	Niclosamide, an antihelminthic drug, enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer. , 2019, 7, 245.		66
4578	Immune checkpoint inhibitor therapy for pediatric cancers: A mini review of endocrine adverse events. <i>Clinical Pediatric Endocrinology</i> , 2019, 28, 59-68.	0.4	15

#	ARTICLE	IF	CITATIONS
4579	Cardiotoxicity from immune checkpoint inhibitors. <i>IJC Heart and Vasculature</i> , 2019, 25, 100420.	0.6	79
4580	Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitor-related Pneumonitis. An Official American Thoracic Society Research Statement. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, e31-e43.	2.5	97
4581	Autoimmune rhabdomyolysis and a multiorgan display of PD-1 inhibitor induced immune related adverse events during treatment of metastatic melanoma. <i>Experimental Hematology and Oncology</i> , 2019, 8, 20.	2.0	4
4582	Clinical and immune profiling for cancer of unknown primary site. , 2019, 7, 251.		26
4583	PD-L1 and CD47 co-expression in pulmonary sarcomatoid carcinoma: a predictor of poor prognosis and potential targets of future combined immunotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 3055-3065.	1.2	24
4584	VCAM-1 Density and Tumor Perfusion Predict T-cell Infiltration and Treatment Response in Preclinical Models. <i>Neoplasia</i> , 2019, 21, 1036-1050.	2.3	17
4585	TCR-like antibodies in cancer immunotherapy. <i>Journal of Hematology and Oncology</i> , 2019, 12, 99.	6.9	39
4586	Patients with BRCA mutated ovarian cancer may have fewer circulating MDSC and more peripheral CD8+ T cells compared with women with BRCA wild-type disease during the early disease course. <i>Oncology Letters</i> , 2019, 18, 3914-3924.	0.8	5
4587	Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations. <i>Molecular Cancer</i> , 2019, 18, 139.	7.9	156
4588	The Diverse Function of PD-1/PD-L Pathway Beyond Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 2298.	2.2	244
4589	Qualifying antibodies for image-based immune profiling and multiplexed tissue imaging. <i>Nature Protocols</i> , 2019, 14, 2900-2930.	5.5	92
4590	Checkpoint inhibition in advanced gastroesophageal cancer: clinical trial data, molecular subtyping, predictive biomarkers, and the potential of combination therapies. <i>Translational Gastroenterology and Hepatology</i> , 2019, 4, 63-63.	1.5	12
4591	The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy. <i>Journal of Clinical Medicine</i> , 2019, 8, 1534.	1.0	41
4592	Association with PD-L1 Expression and Clinicopathological Features in 1000 Lung Cancers: A Large Single-Institution Study of Surgically Resected Lung Cancers with a High Prevalence of EGFR Mutation. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4794.	1.8	29
4593	Immune Checkpoints as Promising Targets for the Treatment of Idiopathic Pulmonary Fibrosis?. <i>Journal of Clinical Medicine</i> , 2019, 8, 1547.	1.0	30
4594	<p></p>Correlation of body composition by computerized tomography and metabolic parameters with survival of nivolumab-treated lung cancer patients</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 8201-8207.	0.9	34
4595	<p></p>Major histocompatibility complex class II molecule in non-small cell lung cancer diagnosis, prognosis and treatment</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 7281-7288.	1.0	11
4596	<p></p>Durable Response After Combination Of Concurrent Chemoradiotherapy And Anti-PD-1 Therapy In HER2-Negative Advanced Gastric Adenocarcinoma: A Case Report</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 7691-7698.	1.0	5

#	ARTICLE	IF	CITATIONS
4597	Safety and Efficacy of Therapeutic Cancer Vaccines Alone or in Combination With Immune Checkpoint Inhibitors in Cancer Treatment. <i>Frontiers in Pharmacology</i> , 2019, 10, 1184.	1.6	50
4598	Current Perspectives in Cancer Immunotherapy. <i>Cancers</i> , 2019, 11, 1472.	1.7	149
4599	Immune checkpoint inhibition in sepsis: a Phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab. <i>Intensive Care Medicine</i> , 2019, 45, 1360-1371.	3.9	117
4600	<p>A retrospective study evaluating the pretreatment tumor volume (PTV) in non-small cell lung cancer (NSCLC) as a predictor of response to program death-1 (PD-1) inhibitors</p>. <i>Lung Cancer: Targets and Therapy</i> , 2019, Volume 10, 95-105.	1.3	3
4601	Gastrin vaccine improves response to immune checkpoint antibody in murine pancreatic cancer by altering the tumor microenvironment. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1635-1648.	2.0	13
4602	Effect of Radiotherapy Combined With Pembrolizumab on Local Tumor Control in Mucosal Melanoma Patients. <i>Frontiers in Oncology</i> , 2019, 9, 835.	1.3	32
4603	Nitric Oxide-Mediated Enhancement and Reversal of Resistance of Anticancer Therapies. <i>Antioxidants</i> , 2019, 8, 407.	2.2	40
4604	Programmed Deathâ€“Ligand 1 and Vimentin: A Tandem Marker as Prognostic Factor in NSCLC. <i>Cancers</i> , 2019, 11, 1411.	1.7	14
4605	Current Possibilities of Gynecologic Cancer Treatment with the Use of Immune Checkpoint Inhibitors. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4705.	1.8	48
4606	Astragalus polysaccharides (PG2) Enhances the M1 Polarization of Macrophages, Functional Maturation of Dendritic Cells, and T Cell-Mediated Anticancer Immune Responses in Patients with Lung Cancer. <i>Nutrients</i> , 2019, 11, 2264.	1.7	85
4607	Viral Infections and Autoimmune Disease: Roles of LCMV in Delineating Mechanisms of Immune Tolerance. <i>Viruses</i> , 2019, 11, 885.	1.5	5
4608	In Vivo Administration of Recombinant Human Granulocyte Colony-Stimulating Factor Increases the Immune Effectiveness of Dendritic Cell-Based Cancer Vaccination. <i>Vaccines</i> , 2019, 7, 120.	2.1	9
4609	Measuring tumor mutation burden in cell-free DNA: advantages and limits. <i>Translational Lung Cancer Research</i> , 2019, 8, 553-555.	1.3	4
4610	Dramatic Response of Leptomeningeal Carcinomatosis to Nivolumab in PD-L1 Highly Expressive Non-small Cell Lung Cancer: A Case Report. <i>Frontiers in Oncology</i> , 2019, 9, 819.	1.3	12
4611	Molecular Modeling Studies on the Binding Mode of the PD-1/PD-L1 Complex Inhibitors. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4654.	1.8	29
4612	The clinicopathological and prognostic significance of PD-L1 expression assessed by immunohistochemistry in lung cancer: a meta-analysis of 50 studies with 11,383 patients. <i>Translational Lung Cancer Research</i> , 2019, 8, 429-449.	1.3	54
4613	Retrospective analysis of docetaxel in combination with ramucirumab for previously treated non-small cell lung cancer patients. <i>Translational Lung Cancer Research</i> , 2019, 8, 450-460.	1.3	18
4614	The association of PD-L1 expression with the efficacy of anti-PD-1/PD-L1 immunotherapy and survival of non-small cell lung cancer patients: a meta-analysis of randomized controlled trials. <i>Translational Lung Cancer Research</i> , 2019, 8, 413-428.	1.3	95

#	ARTICLE	IF	CITATIONS
4615	Tumour Microenvironment and Immune Evasion in EGFR Addicted NSCLC: Hurdles and Possibilities. <i>Cancers</i> , 2019, 11, 1419.	1.7	54
4616	Classical Hodgkin's Lymphoma in the Era of Immune Checkpoint Inhibition. <i>Journal of Clinical Medicine</i> , 2019, 8, 1596.	1.0	15
4617	Tumor-Infiltrating Immunosuppressive Cells in Cancer-Cell Plasticity, Tumor Progression and Therapy Response. <i>Cancer Microenvironment</i> , 2019, 12, 119-132.	3.1	46
4618	SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study). <i>Journal of Thoracic Oncology</i> , 2019, 14, 1839-1846.	0.5	53
4619	Correlation between B7-H4 and Survival of Non-Small-Cell Lung Cancer Patients Treated with Nivolumab. <i>Journal of Clinical Medicine</i> , 2019, 8, 1566.	1.0	26
4620	Sinonasal Melanoma: A Single Institutional Analysis and Future Directions. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2019, 80, 484-492.	0.4	6
4621	In vivo CRISPR screening in CD8 T cells with AAV's "Sleeping Beauty hybrid vectors identifies membrane targets for improving immunotherapy for glioblastoma. <i>Nature Biotechnology</i> , 2019, 37, 1302-1313.	9.4	123
4622	Conceptual Development of Immunotherapeutic Approaches to Gastrointestinal Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4624.	1.8	5
4623	Impact of the gut microbiota on immune checkpoint inhibitor-associated toxicities. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481987091.	1.4	35
4624	OX40 and OX40L protein expression of tumor infiltrating lymphocytes in non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers. <i>Translational Lung Cancer Research</i> , 2019, 8, 352-366.	1.3	38
4625	<p>Review and perspective on adjuvant and neoadjuvant immunotherapies in NSCLC</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 7329-7336.	1.0	19
4626	Screening responsive or resistant biomarkers of immune checkpoint inhibitors based on online databases. <i>Frontiers of Medicine</i> , 2019, 13, 24-31.	1.5	4
4627	Immunotherapeutic Approaches for Multiple Myeloma: Where Are We Now?. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 1-10.	1.2	0
4628	Indoleamine Dioxygenase Inhibitors: Clinical Rationale and Current Development. <i>Current Oncology Reports</i> , 2019, 21, 2.	1.8	42
4629	Patterns of treatment and BRAF testing with immune checkpoint inhibitors and targeted therapy in patients with metastatic melanoma presumed to be BRAF positive. <i>Melanoma Research</i> , 2019, 29, 301-310.	0.6	7
4630	Questionnaire survey on patient awareness of invasive rebiopsy in advanced non-small cell lung cancer. <i>Thoracic Cancer</i> , 2019, 10, 501-507.	0.8	6
4631	Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors. , 2019, 7, 18.		72
4632	Blockade of the PD-1 axis alone is not sufficient to activate HIV-1 virion production from CD4+ T cells of individuals on suppressive ART. <i>PLoS ONE</i> , 2019, 14, e0211112.	1.1	16

#	ARTICLE	IF	CITATIONS
4633	The Risks and Benefits of Immune Checkpoint Blockade in Anti-AChR Antibody-Seropositive Non-Small Cell Lung Cancer Patients. <i>Cancers</i> , 2019, 11, 140.	1.7	18
4634	The Tumor Microenvironment in Post-Transplant Lymphoproliferative Disorders. <i>Cancer Microenvironment</i> , 2019, 12, 3-16.	3.1	20
4635	Local Delivery of α 401, α Cd80, and α Cd86 mRNA Kindles Global Anticancer Immunity. <i>Cancer Research</i> , 2019, 79, 1624-1634.	0.4	85
4636	A brief report of toxicity end points of HER2 vaccines for the treatment of patients with HER2 ⁺ breast cancer. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 309-316.	2.0	15
4637	The evolving role of immunooncology for the treatment of head and neck cancer. <i>Laryngoscope Investigative Otolaryngology</i> , 2019, 4, 62-69.	0.6	3
4638	The Evolving Landscape of Immunotherapy-Based Combinations for Frontline Treatment of Advanced Renal Cell Carcinoma. <i>Frontiers in Immunology</i> , 2018, 9, 3120.	2.2	28
4639	Treatment of Advanced Prostate Cancer. <i>Annual Review of Medicine</i> , 2019, 70, 479-499.	5.0	417
4640	Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer: a National Cancer Database analysis. <i>Radiation Oncology</i> , 2019, 14, 18.	1.2	41
4641	Involvement of the PD-1/PD-L1 Co-Inhibitory Pathway in the Pathogenesis of the Inflammatory Stage of Early-Onset Preeclampsia. <i>International Journal of Molecular Sciences</i> , 2019, 20, 583.	1.8	16
4642	Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL). <i>Leukemia</i> , 2019, 33, 844-862.	3.3	131
4643	On the Other Side: Manipulating the Immune Checkpoint Landscape of Dendritic Cells to Enhance Cancer Immunotherapy. <i>Frontiers in Oncology</i> , 2019, 9, 50.	1.3	11
4644	Rapid and Long-term Response of Pulmonary Pleomorphic Carcinoma to Nivolumab. <i>Internal Medicine</i> , 2019, 58, 985-989.	0.3	25
4645	Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients. <i>Antibodies</i> , 2019, 8, 3.	1.2	22
4646	Novel Immunoregulatory Functions of IL-18, an Accomplice of TGF- β 1. <i>Cancers</i> , 2019, 11, 75.	1.7	16
4647	<i>Pseudomonas</i> Exotoxin Immunotoxins and Anti-Tumor Immunity: From Observations at the Patient's Bedside to Evaluation in Preclinical Models. <i>Toxins</i> , 2019, 11, 20.	1.5	37
4648	Deciphering Microenvironment of NSCLC based on CD8 ⁺ TIL Density and PD-1/PD-L1 Expression. <i>Journal of Cancer</i> , 2019, 10, 211-222.	1.2	29
4649	High Expression of Indoleamine 2, 3-Dioxygenase in Adenosquamous Lung Carcinoma Correlates with Favorable Patient Outcome. <i>Journal of Cancer</i> , 2019, 10, 267-276.	1.2	9
4650	Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma. <i>Cancer Research</i> , 2019, 79, 1113-1123.	0.4	45

#	ARTICLE	IF	CITATIONS
4651	Hyperprogression after anti-programmed cell death ligand-1 therapy in a patient with recurrent metastatic urothelial bladder carcinoma following first-line cisplatin-based chemotherapy: a case report. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 291-300.	2.0	14
4652	Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer. <i>JAMA Oncology</i> , 2019, 5, 393.	3.4	303
4653	ePROs in the follow-up of cancer patients treated with immune checkpoint inhibitors: a retrospective study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 765-774.	1.2	35
4654	Adverse Event Profiles of Anti-CTLA-4 and Anti-PD-1 Monoclonal Antibodies Alone or in Combination: Analysis of Spontaneous Reports Submitted to FAERS. <i>Clinical Drug Investigation</i> , 2019, 39, 319-330.	1.1	78
4655	Reprogramming responsiveness to checkpoint blockade in dysfunctional CD8 T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 2640-2645.	3.3	22
4656	Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition. <i>Neuro-Oncology</i> , 2019, 21, 730-741.	0.6	63
4657	Combination Cancer Immunotherapy with Molecular Targeted Agents/Anti-CTLA-4 Antibody for Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2019, 8, 1-11.	4.2	48
4658	Programmed Death-ligand 1 Expression With Clone 22C3 in Non-small Cell Lung Cancer: A Single Institution Experience. <i>Clinical Medicine Insights: Oncology</i> , 2019, 13, 117955491882131.	0.6	7
4659	The Clinicopathologic and Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1) Expression in Patients With Prostate Cancer: A Systematic Review and Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2018, 9, 1494.	1.6	24
4660	Targeted Therapy and Immunotherapy for Melanoma in Japan. <i>Current Treatment Options in Oncology</i> , 2019, 20, 7.	1.3	79
4661	PD-L1 Expression in Circulating Tumor Cells Increases during Radio(chemo)therapy and Indicates Poor Prognosis in Non-small Cell Lung Cancer. <i>Scientific Reports</i> , 2019, 9, 566.	1.6	90
4662	Impact of bowel movement condition on immune checkpoint inhibitor efficacy in patients with advanced non-small cell lung cancer. <i>Thoracic Cancer</i> , 2019, 10, 526-532.	0.8	13
4663	Human double negative T cells target lung cancer via ligand-dependent mechanisms that can be enhanced by IL-15. , 2019, 7, 17.		38
4664	<p>Efficacy and safety of nivolumab for metastatic biliary tract cancer</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 861-867.	1.0	31
4665	Fragment-based screening of programmed death ligand 1 (PD-L1). <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 786-790.	1.0	48
4666	Outcomes of Programmed Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1(PD-L1) Inhibitor Therapy in HIV Patients with Advanced Cancer. <i>Journal of Oncology</i> , 2019, 2019, 1-5.	0.6	17
4667	Safe and effective use of nivolumab for treating lung adenocarcinoma associated with sporadic lymphangioleiomyomatosis: a rare case report. <i>BMC Pulmonary Medicine</i> , 2019, 19, 12.	0.8	4
4668	Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports. <i>Clinical Diabetes and Endocrinology</i> , 2019, 5, 1.	1.3	125

#	ARTICLE	IF	CITATIONS
4669	Monitoring checkpoint inhibitors: predictive biomarkers in immunotherapy. <i>Frontiers of Medicine</i> , 2019, 13, 32-44.	1.5	25
4670	Novel clinical and radiomic predictors of rapid disease progression phenotypes among lung cancer patients treated with immunotherapy: An early report. <i>Lung Cancer</i> , 2019, 129, 75-79.	0.9	113
4671	SA-49, a novel aloperine derivative, induces MITF-dependent lysosomal degradation of PD-L1. <i>EBioMedicine</i> , 2019, 40, 151-162.	2.7	53
4672	Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer. , 2019, 7, 24.		114
4673	Bispecific anti-CD3×anti-B7-H3 antibody mediates T cell cytotoxic ability to human melanoma in vitro and in vivo. <i>Investigational New Drugs</i> , 2019, 37, 1036-1043.	1.2	19
4674	Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients. , 2019, 7, 27.		66
4675	GITR ligation enhances functionality of tumor-infiltrating T cells in hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2019, 145, 1111-1124.	2.3	42
4676	Clonal Deletion of Tumor-Specific T Cells by Interferon- γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade. <i>Immunity</i> , 2019, 50, 477-492.e8.	6.6	93
4677	Cardiovascular toxicities associated with immune checkpoint inhibitors. <i>Cardiovascular Research</i> , 2019, 115, 854-868.	1.8	311
4678	<p>Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new data</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 4297-4312.	0.9	47
4679	<p>Refinement of diagnosis and supporting evidence for the use of immunotherapy through sequential biopsies in a case of EML4-ALK positive lung cancer</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 2943-2948.	1.0	3
4680	<p>Comparative study of the PD-L1 expression and CD8+ tumor-infiltrating lymphocyte between surgically resected and matched re-biopsy specimens in recurrent non-small cell lung cancer</p>. <i>Therapeutics and Clinical Risk Management</i> , 2019, Volume 15, 605-612.	0.9	2
4681	Acute Tubulointerstitial Nephritis: A Case Report on Rare Adverse Effect of Pembrolizumab. <i>Medicina (Lithuania)</i> , 2019, 55, 176.	0.8	11
4682	<p>Lenvatinib, a molecule with versatile application: from preclinical evidence to future development in anti-cancer treatment</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 3847-3860.	0.9	78
4683	Safety and Efficacy of Anti-PD-1 Monoclonal Antibodies in Patients With Relapsed or Refractory Lymphoma: A Meta-Analysis of Prospective Clinic Trails. <i>Frontiers in Pharmacology</i> , 2019, 10, 387.	1.6	15
4684	Nivolumab and Ipilimumab in the Treatment of Metastatic Uveal Melanoma: A Single-Center Experience. <i>Case Reports in Oncological Medicine</i> , 2019, 2019, 1-8.	0.2	15
4685	<p>Incidence risk of PD-1/PD-L1 related diarrhea in non-small cell lung cancer (NSCLC) patients: a systematic review and meta-analysis</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 3957-3969.	0.9	5
4686	<p>Prognostic and clinicopathological value of PD-L1 in colorectal cancer: a systematic review and meta-analysis</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 3671-3682.	1.0	40

#	ARTICLE	IF	CITATIONS
4687	<p>Poor prognosis of pulmonary sarcomatoid carcinoma with KRAS mutation and ALK fusion</p>. OncoTargets and Therapy, 2019, Volume 12, 3321-3325.	1.0	4
4688	Intrinsic Control of Surface Immune and Epithelial Homeostasis by Tissue-Resident Gut Stromal Cells. Frontiers in Immunology, 2019, 10, 1281.	2.2	9
4689	Liquid biopsy for lung cancer immunotherapy (Review). Oncology Letters, 2019, 17, 4751-4760.	0.8	14
4690	The Tolerogenic Function of Regulatory T Cells in Pregnancy and Cancer. Frontiers in Immunology, 2019, 10, 911.	2.2	90
4691	Targeting the Complement Pathway as a Therapeutic Strategy in Lung Cancer. Frontiers in Immunology, 2019, 10, 954.	2.2	89
4692	Targeting Immune-Mediated Dormancy: A Promising Treatment of Cancer. Frontiers in Oncology, 2019, 9, 498.	1.3	33
4693	PD-L1 testing of non-small cell lung cancer using different antibodies and platforms: a Swiss cross-validation study. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 475, 67-76.	1.4	13
4694	PD-L1 is a double-edged sword in colorectal cancer: the prognostic value of PD-L1 depends on the cell type expressing PD-L1. Journal of Cancer Research and Clinical Oncology, 2019, 145, 1785-1794.	1.2	20
4695	Potential Influence on Clinical Trials of Long-Term Survivors of Stage IV Non-small cell Lung Cancer. JNCI Cancer Spectrum, 2019, 3, pkz010.	1.4	8
4696	Recent advances in the clinical development of immune checkpoint blockade therapy. Cellular Oncology (Dordrecht), 2019, 42, 609-626.	2.1	76
4697	Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures. Journal of Experimental and Clinical Cancer Research, 2019, 38, 253.	3.5	58
4698	Can Immunogenic Chemotherapies Relieve Cancer Cell Resistance to Immune Checkpoint Inhibitors?. Frontiers in Immunology, 2019, 10, 1181.	2.2	20
4699	Phenotype plasticity as enabler of melanoma progression and therapy resistance. Nature Reviews Cancer, 2019, 19, 377-391.	12.8	262
4700	Differentiating Acute Interstitial Nephritis from Acute Tubular Injury: A Challenge for Clinicians. Nephron, 2019, 143, 211-216.	0.9	23
4701	Clonality of CD4+ Blood T Cells Predicts Longer Survival With CTLA4 or PD-1 Checkpoint Inhibition in Advanced Melanoma. Frontiers in Immunology, 2019, 10, 1336.	2.2	57
4702	CD27 Promotes CD4+ Effector T Cell Survival in Response to Tissue Self-Antigen. Journal of Immunology, 2019, 203, 639-646.	0.4	8
4703	Molecular Mechanisms and Countermeasures of Immunotherapy Resistance in Malignant Tumor. Journal of Cancer, 2019, 10, 1764-1771.	1.2	11
4704	Management of metastatic cutaneous melanoma: updates in clinical practice. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591985166.	1.4	29

#	ARTICLE	IF	CITATIONS
4705	Circulating Lymphocytes, PD-L1 Expression on Tumor-infiltrating Lymphocytes, and Survival of Colorectal Cancer Patients with Different Mismatch Repair Gene Status. <i>Journal of Cancer</i> , 2019, 10, 1745-1754.	1.2	19
4706	Cowpea Mosaic Virus Immunotherapy Combined with Cyclophosphamide Reduces Breast Cancer Tumor Burden and Inhibits Lung Metastasis. <i>Advanced Science</i> , 2019, 6, 1802281.	5.6	50
4707	Comparison of Immune Checkpoint Inhibitors between Older and Younger Patients with Advanced or Metastatic Lung Cancer: A Systematic Review and Meta-Analysis. <i>BioMed Research International</i> , 2019, 2019, 1-13.	0.9	21
4708	CD8 ⁺ PD-1 ⁺ T-cells and PD-L1 ⁺ circulating tumor cells in chemotherapy-naïve non-small cell lung cancer: towards their clinical relevance?. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591985319.	1.4	13
4709	PD-L1 expression on stromal tumor-infiltrating lymphocytes is a favorable prognostic factor in ovarian serous carcinoma. <i>Journal of Ovarian Research</i> , 2019, 12, 56.	1.3	30
4710	Tumor-targeted IL-12 combined with tumor resection yields a survival-favorable immune profile. , 2019, 7, 154.		16
4711	Treatment Outcomes of Immune-Related Cutaneous Adverse Events. <i>Journal of Clinical Oncology</i> , 2019, 37, 2746-2758.	0.8	160
4712	Probiotics <i>Lactobacillus reuteri</i> Abrogates Immune Checkpoint Blockade-Associated Colitis by Inhibiting Group 3 Innate Lymphoid Cells. <i>Frontiers in Immunology</i> , 2019, 10, 1235.	2.2	83
4713	PD-1/PD-Ls Checkpoint: Insight on the Potential Role of NK Cells. <i>Frontiers in Immunology</i> , 2019, 10, 1242.	2.2	130
4714	Overview of Targeted Drugs for Mature B-Cell Non-hodgkin Lymphomas. <i>Frontiers in Oncology</i> , 2019, 9, 443.	1.3	25
4715	PD-L1 Expression with Epithelial Mesenchymal Transition of Circulating Tumor Cells Is Associated with Poor Survival in Curatively Resected Non-Small Cell Lung Cancer. <i>Cancers</i> , 2019, 11, 806.	1.7	66
4716	Immunopotentiator Aikejia improves the therapeutic efficacy of PD-1/PD-L1 immunosuppressive pathway in CT26.WT cancer cell. <i>Journal of Cancer</i> , 2019, 10, 3472-3480.	1.2	4
4717	Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors. <i>Cancers</i> , 2019, 11, 835.	1.7	109
4718	Constitutive reduction in the checkpoint inhibitor, CTLA-4, does not accelerate SLE in NZM 2328 mice. <i>Lupus Science and Medicine</i> , 2019, 6, e000313.	1.1	3
4719	PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma. <i>Journal of Translational Medicine</i> , 2019, 17, 207.	1.8	13
4720	Off-label use of common predictive biomarkers in gastrointestinal malignancies: a critical appraisal. <i>Diagnostic Pathology</i> , 2019, 14, 62.	0.9	4
4721	Checkpoint Inhibitors. <i>Deutsches A&#x0308;rztblatt International</i> , 2019, 116, 119-126.	0.6	83
4722	Who will suffer from hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors. <i>Journal of Thoracic Disease</i> , 2019, 11, S1289-S1291.	0.6	6

#	ARTICLE	IF	CITATIONS
4723	Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019. <i>European Urology</i> , 2019, 76, 368-380.	0.9	48
4724	Mucosal Injury during Anti-Cancer Treatment: From Pathobiology to Bedside. <i>Cancers</i> , 2019, 11, 857.	1.7	77
4725	Magnetic iron oxide nanoparticles for disease detection and therapy. <i>Materials Today</i> , 2019, 31, 86-99.	8.3	114
4726	Hyperprogressive disease during nivolumab or irinotecan treatment in patients with advanced gastric cancer. <i>ESMO Open</i> , 2019, 4, e000488.	2.0	39
4727	IL-1 Family Members in Cancer; Two Sides to Every Story. <i>Frontiers in Immunology</i> , 2019, 10, 1197.	2.2	190
4728	Stability and survival analysis of elderly patients with osteolytic spinal bone metastases after palliative radiotherapy. <i>Strahlentherapie Und Onkologie</i> , 2019, 195, 1074-1085.	1.0	10
4729	A review of eligibility for patients with central nervous system (CNS) metastases from non-small cell lung cancer (NSCLC) in immunotherapy clinical trials. <i>Journal of Neuro-Oncology</i> , 2019, 144, 235-237.	1.4	4
4730	Immune evasion before tumour invasion in early lung squamous carcinogenesis. <i>Nature</i> , 2019, 571, 570-575.	13.7	227
4731	Characterization of a novel anti-human lymphocyte activation gene 3 (LAG-3) antibody for cancer immunotherapy. <i>MAbs</i> , 2019, 11, 1139-1148.	2.6	74
4732	Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination. , 2019, 7, 160.		132
4733	<p>Neutrophil"lymphocyte ratio (NLR) predicted prognosis for advanced non-small-cell lung cancer (NSCLC) patients who received immune checkpoint blockade (ICB)<p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 4235-4244.	1.0	53
4734	Tumor-Derived Extracellular Vesicles Inhibit Natural Killer Cell Function in Pancreatic Cancer. <i>Cancers</i> , 2019, 11, 874.	1.7	85
4735	A tumor"targeting nanomedicine carrying the p53 gene crosses the blood"brain barrier and enhances anti"PD"1 immunotherapy in mouse models of glioblastoma. <i>International Journal of Cancer</i> , 2019, 145, 2535-2546.	2.3	48
4736	Adjuvant Therapy for Melanoma. <i>Current Treatment Options in Oncology</i> , 2019, 20, 63.	1.3	38
4737	Management of Gastrointestinal Toxicity from Immune Checkpoint Inhibitor. <i>GE Portuguese Journal of Gastroenterology</i> , 2019, 26, 268-274.	0.3	17
4738	Molecular profile of non-small cell lung cancer in northeastern Brazil. <i>Jornal Brasileiro De Pneumologia</i> , 2019, 45, e20180181.	0.4	12
4739	Association of LRP1B Mutation With Tumor Mutation Burden and Outcomes in Melanoma and Non-small Cell Lung Cancer Patients Treated With Immune Check-Point Blockades. <i>Frontiers in Immunology</i> , 2019, 10, 1113.	2.2	128
4740	When to Consider Immune Checkpoint Inhibitors in Oncogene-Driven Non-Small Cell Lung Cancer?. <i>Current Treatment Options in Oncology</i> , 2019, 20, 60.	1.3	30

#	ARTICLE	IF	CITATIONS
4741	Protein 4.1B Suppresses Tumor Metastasis by Regulating Epithelial-mesenchymal Transition Progression in Melanoma Cells. <i>International Journal of Medical Sciences</i> , 2019, 16, 529-536.	1.1	5
4742	Immune Checkpoint Inhibitors in Melanoma: A Review of Pharmacokinetics and Exposure-Response Relationships. <i>Clinical Pharmacokinetics</i> , 2019, 58, 1393-1405.	1.6	24
4743	A prospective observational study to assess PD-L1 expression in small biopsy samples for non-small-cell lung cancer. <i>BMC Cancer</i> , 2019, 19, 546.	1.1	30
4744	Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma. , 2019, 7, 145.		261
4745	A Review of Efficacy and Safety of Checkpoint Inhibitor for the Treatment of Acute Myeloid Leukemia. <i>Frontiers in Pharmacology</i> , 2019, 10, 609.	1.6	60
4746	Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors. <i>Cancer Cell</i> , 2019, 35, 885-900.e10.	7.7	475
4747	The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1046-1060.	0.5	52
4748	CD45RA+CCR7 ^{hi} CD8 T cells lacking co-stimulatory receptors demonstrate enhanced frequency in peripheral blood of NSCLC patients responding to nivolumab. , 2019, 7, 149.		44
4749	Immunosuppressive Tumor Microenvironment Status and Histological Grading of Endometrial Carcinoma. <i>Cancer Microenvironment</i> , 2019, 12, 169-179.	3.1	21
4750	Application of PD-1 Blockade in Cancer Immunotherapy. <i>Computational and Structural Biotechnology Journal</i> , 2019, 17, 661-674.	1.9	333
4751	Cold atmospheric plasma and silymarin nanoemulsion synergistically inhibits human melanoma tumorigenesis via targeting HGF/c-MET downstream pathway. <i>Cell Communication and Signaling</i> , 2019, 17, 52.	2.7	58
4752	Blood Levels of Co-inhibitory-Receptors: A Biomarker of Disease Prognosis in Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2019, 10, 835.	2.2	25
4753	Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma. <i>Frontiers in Immunology</i> , 2019, 10, 990.	2.2	86
4754	MicroRNAs aid the assessment of programmed death ligand 1 expression in patients with non-small cell lung cancer. <i>Oncology Letters</i> , 2019, 17, 5193-5200.	0.8	14
4755	Absence of PD-L1 expression on tumor cells in the context of an activated immune infiltrate may indicate impaired IFN γ signaling in non-small cell lung cancer. <i>PLoS ONE</i> , 2019, 14, e0216864.	1.1	11
4756	Assessment of Subcutaneous vs Intravenous Administration of Anti-PD-1 Antibody PF-06801591 in Patients With Advanced Solid Tumors. <i>JAMA Oncology</i> , 2019, 5, 999.	3.4	47
4757	Regulatory characteristics and pivotal study design of US Food and Drug Administration approval of drugs for major vs. minor cancer. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 1193-1200.	0.8	6
4758	The Immune Contexture Associates with the Genomic Landscape in Lung Adenomatous Premalignancy. <i>Cancer Research</i> , 2019, 79, 5022-5033.	0.4	37

#	ARTICLE	IF	CITATIONS
4759	PD-1 Dynamically Regulates Inflammation and Development of Brain-Resident Memory CD8 T Cells During Persistent Viral Encephalitis. <i>Frontiers in Immunology</i> , 2019, 10, 783.	2.2	33
4760	Molecular targeted therapy-related life-threatening toxicity in patients with malignancies. A systematic review of published cases. <i>Intensive Care Medicine</i> , 2019, 45, 988-997.	3.9	18
4761	The prognostic significance of the comprehensive complication index in patients with gastric cancer. <i>Surgery Today</i> , 2019, 49, 913-920.	0.7	10
4762	Prognostic and Predictive Values of Metabolic Parameters of ¹⁸ F-FDG PET/CT in Patients With Non-Small Cell Lung Cancer Treated With Chemotherapy. <i>Molecular Imaging</i> , 2019, 18, 153601211984602.	0.7	13
4763	Intracranial antitumor responses of nivolumab and ipilimumab: a pharmacodynamic and pharmacokinetic perspective, a scoping systematic review. <i>BMC Cancer</i> , 2019, 19, 519.	1.1	37
4764	Treatment-duration is related to changes in peripheral lymphocyte counts during definitive radiotherapy for unresectable stage III NSCLC. <i>Radiation Oncology</i> , 2019, 14, 86.	1.2	30
4765	Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations. , 2019, 7, 142.		31
4766	Long-Term Outcomes of Carbon-Ion Radiotherapy for Malignant Gynecological Melanoma. <i>Cancers</i> , 2019, 11, 482.	1.7	13
4767	Expression of PD-1 and PD-L1 in Extramammary Paget Disease: Implications for Immune-Targeted Therapy. <i>Cancers</i> , 2019, 11, 754.	1.7	21
4768	Autoimmune Endocrine Dysfunctions Associated with Cancer Immunotherapies. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2560.	1.8	72
4769	MALDI Mass Spectrometry Imaging Linked with Top-Down Proteomics as a Tool to Study the Non-Small-Cell Lung Cancer Tumor Microenvironment. <i>Methods and Protocols</i> , 2019, 2, 44.	0.9	19
4770	Changes in critically ill cancer patients'™ short-term outcome over the last decades: results of systematic review with meta-analysis on individual data. <i>Intensive Care Medicine</i> , 2019, 45, 977-987.	3.9	100
4771	Organizing pneumonia after thoracic radiotherapy followed by anti- PD-1 antibody treatment for patients with lung cancer: Three case reports. <i>Thoracic Cancer</i> , 2019, 10, 1503-1507.	0.8	2
4772	Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE) Tj ETQq1 1 0.784214 rgBTi/0verlock	1.2	10
4773	<p>Nivolumab plus ipilimumab combination therapy for the first-line treatment NSCLC: evidence to date</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 4893-4904.	0.9	10
4774	Disorder of Coagulation-Fibrinolysis System: An Emerging Toxicity of Anti-PD-1/PD-L1 Monoclonal Antibodies. <i>Journal of Clinical Medicine</i> , 2019, 8, 762.	1.0	53
4775	From Hope to Reality: Durable Overall Survival With Immune Checkpoint Inhibitors for Advanced Lung Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 2511-2513.	0.8	22
4776	Comparative safety analysis of immunotherapy combined with chemotherapy versus monotherapy in solid tumors: a meta-analysis of randomized clinical trials. <i>Oncotarget</i> , 2019, 10, 3294-3301.	0.8	13

#	ARTICLE	IF	CITATIONS
4777	Exceptional pemetrexed sensitivity can predict therapeutic benefit from subsequent chemotherapy in metastatic non-squamous non-small cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1897-1905.	1.2	4
4778	<p></p>Functionalized docetaxel-loaded lipid-based-nanosuspensions to enhance antitumor efficacy in vivo</p>. <i>International Journal of Nanomedicine</i> , 2019, Volume 14, 2543-2555.	3.3	8
4779	Development of the Inhibitors That Target the PD-1/PD-L1 Interactionâ€”A Brief Look at Progress on Small Molecules, Peptides and Macrocycles. <i>Molecules</i> , 2019, 24, 2071.	1.7	106
4780	Acute Renal Failure in Critically Ill Cancer Patients. , 2019, , 1-16.		0
4781	Pulling RANK on Cancer: Blocking Aire-Mediated Central Tolerance to Enhance Immunotherapy. <i>Cancer Immunology Research</i> , 2019, 7, 854-859.	1.6	8
4782	Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy. <i>Journal of Hematology and Oncology</i> , 2019, 12, 54.	6.9	416
4783	<i>PD</i></i>â€<i>L1</i> and <i>PD</i></i>â€<i>L2</i> expression correlated genes in nonâ€smallâ€cell lung cancer. <i>Cancer Communications</i> , 2019, 39, 1-14.	3.7	66
4784	Intradermal DNA vaccination combined with dual CTLA-4 and PD-1 blockade provides robust tumor immunity in murine melanoma. <i>PLoS ONE</i> , 2019, 14, e0217762.	1.1	18
4785	Phase II study of avelumab in multiple relapsed/refractory germ cell cancer. <i>Investigational New Drugs</i> , 2019, 37, 748-754.	1.2	48
4786	The survivorship experience for patients with metastatic melanoma on immune checkpoint and BRAF-MEK inhibitors. <i>Journal of Cancer Survivorship</i> , 2019, 13, 503-511.	1.5	31
4787	Pathogenesis of fulminant type1 diabetes: Genes, viruses and the immune mechanism, and usefulness of patientâ€derived induced pluripotent stem cells for future research. <i>Journal of Diabetes Investigation</i> , 2019, 10, 1158-1164.	1.1	30
4788	Inhibition of the Nkp44-PCNA Immune Checkpoint Using a mAb to PCNA. <i>Cancer Immunology Research</i> , 2019, 7, 1120-1134.	1.6	26
4789	Differential Kinase Activation in Peripheral Blood Mononuclear Cells from Non-Small-Cell Lung Cancer Patients Treated with Nivolumab. <i>Cancers</i> , 2019, 11, 762.	1.7	5
4790	Salvage treatment with anlotinib for advanced nonâ€small cell lung cancer. <i>Thoracic Cancer</i> , 2019, 10, 1590-1596.	0.8	25
4791	Long-Term Survival, Quality of Life, and Psychosocial Outcomes in Advanced Melanoma Patients Treated with Immune Checkpoint Inhibitors. <i>Journal of Oncology</i> , 2019, 2019, 1-17.	0.6	55
4792	Dissecting the Stromal Signaling and Regulation of Myeloid Cells and Memory Effector T Cells in Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 5351-5363.	3.2	57
4793	Î2-Catenin Activation Promotes Immune Escape and Resistance to Antiâ€PD-1 Therapy in Hepatocellular Carcinoma. <i>Cancer Discovery</i> , 2019, 9, 1124-1141.	7.7	498
4794	An Improved Patient-Derived Xenograft Humanized Mouse Model for Evaluation of Lung Cancer Immune Responses. <i>Cancer Immunology Research</i> , 2019, 7, 1267-1279.	1.6	92

#	ARTICLE	IF	CITATIONS
4795	The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/PD-L1 plus anti-CTLA-4): a systematic review and meta-analysis. <i>BMC Cancer</i> , 2019, 19, 559.	1.1	62
4796	Hyperprogression under Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2674.	1.8	96
4797	The Novel Combination of Nitroxoline and PD-1 Blockade, Exerts a Potent Antitumor Effect in a Mouse Model of Prostate Cancer. <i>International Journal of Biological Sciences</i> , 2019, 15, 919-928.	2.6	21
4798	In vivo liquid biopsy using Cytophone platform for photoacoustic detection of circulating tumor cells in patients with melanoma. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	108
4799	Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis. <i>BMC Cancer</i> , 2019, 19, 558.	1.1	106
4800	Characteristics of Brazilian melanomas: real-world results before and after the introduction of new therapies. <i>BMC Research Notes</i> , 2019, 12, 296.	0.6	6
4801	Efficacy and safety of programmed death 1 inhibitors in patients with advanced non-small cell lung cancer: a meta-analysis. <i>Cancer Management and Research</i> , 2019, Volume 11, 4619-4630.	0.9	5
4802	Novel and Future Therapeutic Drugs for Advanced Mycosis Fungoides and SÅ©zary Syndrome. <i>Frontiers in Medicine</i> , 2019, 6, 116.	1.2	28
4803	Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events. <i>Frontiers in Medicine</i> , 2019, 6, 119.	1.2	145
4804	Targeting ERK beyond the boundaries of the kinase active site in melanoma. <i>Molecular Carcinogenesis</i> , 2019, 58, 1551-1570.	1.3	26
4805	Pembrolizumab-associated bronchiolitis in an elderly lung cancer patient required the treatment with an inhaled corticosteroid, erythromycin and bronchodilators. <i>Respiratory Medicine Case Reports</i> , 2019, 28, 100866.	0.2	6
4806	Immune checkpoint inhibitorâ€­induced Type 1 diabetes: a systematic review and metaâ€­analysis. <i>Diabetic Medicine</i> , 2019, 36, 1075-1081.	1.2	124
4807	Combination of CTLA-4 and PD-1 blockers for treatment of cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 255.	3.5	577
4808	Immune targeting of the microenvironment in classical Hodgkinâ€™s lymphoma: insights for the hematologist. <i>Therapeutic Advances in Hematology</i> , 2019, 10, 204062071984645.	1.1	10
4809	Inhibition of immune checkpoints PD-1, CTLA-4, and IDO1 coordinately induces immune-mediated liver injury in mice. <i>PLoS ONE</i> , 2019, 14, e0217276.	1.1	34
4810	Future Options of Molecular-Targeted Therapy in Small Cell Lung Cancer. <i>Cancers</i> , 2019, 11, 690.	1.7	57
4811	The next decade of clinical trials in locoregionally advanced nasopharyngeal carcinoma. <i>British Journal of Radiology</i> , 2019, 92, 20181031.	1.0	20
4812	The current state of molecular testing in the treatment of patients with solid tumors, 2019. <i>Ca-A Cancer Journal for Clinicians</i> , 2019, 69, 305-343.	157.7	203

#	ARTICLE	IF	CITATIONS
4813	New Insights into Molecular Oncogenesis and Therapy of Uveal Melanoma. <i>Cancers</i> , 2019, 11, 694.	1.7	23
4814	PD1/PD-L1 Expression in Blastic Plasmacytoid Dendritic Cell Neoplasm. <i>Cancers</i> , 2019, 11, 695.	1.7	12
4815	Rapidly progressing programmed cell death 1 inhibitor-related pneumonitis in a hemodialytic patient with metastatic renal cell carcinoma. <i>IJU Case Reports</i> , 2019, 2, 155-157.	0.1	0
4816	Model-Based Population Pharmacokinetic Analysis of Nivolumab in Chinese Patients With Previously Treated Advanced Solid Tumors, Including Non-Small Cell Lung Cancer. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 1415-1424.	1.0	12
4817	Infliximab for the treatment of refractory immune-related hepatitis secondary to checkpoint inhibitors: A case report. <i>JHEP Reports</i> , 2019, 1, 66-69.	2.6	23
4818	Tumor suppression of novel anti-PD-1 antibodies mediated through CD28 costimulatory pathway. <i>Journal of Experimental Medicine</i> , 2019, 216, 1525-1541.	4.2	23
4819	Challenge of immune-mediated adverse reactions in the emergency department. <i>Emergency Medicine Journal</i> , 2019, 36, 369-377.	0.4	10
4820	Programmed Cell Death 1 (PD-1) Inhibitors in Renal Transplant Patients with Advanced Cancer: A Double-Edged Sword?. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2194.	1.8	28
4821	Development of immune checkpoint therapy for cancer. <i>Journal of Experimental Medicine</i> , 2019, 216, 1244-1254.	4.2	125
4822	Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy. , 2019, 7, 121.		71
4823	PD1 pathway in immune-mediated myopathies. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, e558.	3.1	42
4824	Harnessing immunotherapy for liver recipients with hepatocellular carcinoma: a review from a transplant oncology perspective. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591984346.	1.4	19
4825	Immune Checkpoint Blockade for Advanced NSCLC: A New Landscape for Elderly Patients. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2258.	1.8	31
4826	Prognostic factors of advanced or postoperative recurrent non-small cell lung cancer targeted with immune check point inhibitors. <i>Journal of Thoracic Disease</i> , 2019, 11, 1117-1123.	0.6	46
4827	Myocarditis in Humans and in Experimental Animal Models. <i>Frontiers in Cardiovascular Medicine</i> , 2019, 6, 64.	1.1	99
4828	Current Status of Immunotherapies for Treating Pancreatic Cancer. <i>Current Oncology Reports</i> , 2019, 21, 60.	1.8	38
4829	Electrophysiological findings in immune checkpoint inhibitor-related peripheral neuropathy. <i>Clinical Neurophysiology</i> , 2019, 130, 1440-1445.	0.7	44
4830	The emerging roles of inflammasome-dependent cytokines in cancer development. <i>EMBO Reports</i> , 2019, 20, .	2.0	77

#	ARTICLE	IF	CITATIONS
4831	The promise of Immuno-oncology: implications for defining the value of cancer treatment. , 2019, 7, 129.		66
4832	Recurrent Pneumonitis in Patients with Melanoma Treated with Immune Checkpoint Inhibitors. <i>Oncologist</i> , 2019, 24, 640-647.	1.9	32
4833	Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosis. , 2019, 7, 119.		35
4834	Oncolytic Viruses and Immune Checkpoint Inhibition: The Best of Both Worlds. <i>Molecular Therapy - Oncolytics</i> , 2019, 13, 93-106.	2.0	107
4835	The Impact of High-Dose Glucocorticoids on the Outcome of Immune-Checkpoint Inhibitor-Related Thyroid Disorders. <i>Cancer Immunology Research</i> , 2019, 7, 1214-1220.	1.6	44
4836	Association of Baseline Serum Levels of CXCL5 With the Efficacy of Nivolumab in Advanced Melanoma. <i>Frontiers in Medicine</i> , 2019, 6, 86.	1.2	18
4837	A Novel Paradigm Between Leukocytosis, G-CSF Secretion, Neutrophil-to-Lymphocyte Ratio, Myeloid-Derived Suppressor Cells, and Prognosis in Non-small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 295.	1.3	47
4838	Editorial: Management of Immune-Related Adverse Events for Patients Undergoing Treatment With Checkpoint Inhibitors. <i>Frontiers in Oncology</i> , 2019, 9, 365.	1.3	2
4839	Antitumor activity of ginsenoside Rg3 in melanoma through downregulation of the ERK and Akt pathways. <i>International Journal of Oncology</i> , 2019, 54, 2069-2079.	1.4	27
4840	Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 563-580.	12.5	1,235
4841	Pembrolizumab-induced necrotizing myositis in a patient with metastatic non-small-cell lung cancer: a case report. <i>Lung Cancer Management</i> , 2019, 8, LMT10.	1.5	5
4842	Atezolizumab and Bevacizumab Attenuate Cisplatin Resistant Ovarian Cancer Cells Progression Synergistically via Suppressing Epithelial-Mesenchymal Transition. <i>Frontiers in Immunology</i> , 2019, 10, 867.	2.2	36
4843	Novel circulating tumor cell-based blood test for the assessment of PD-L1 protein expression in treatment-naïve, newly diagnosed patients with non-small cell lung cancer. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1087-1094.	2.0	22
4844	Low frequency of positive antithyroid antibodies is observed in patients with thyroid dysfunction related to immune check point inhibitors. <i>Journal of Endocrinological Investigation</i> , 2019, 42, 1443-1450.	1.8	40
4845	TLR1/2 ligand enhances antitumor efficacy of CTLA-4 blockade by increasing intratumoral Treg depletion. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 10453-10462.	3.3	53
4846	Clinical outcomes in non-small-cell lung cancer patients receiving concurrent metformin and immune checkpoint inhibitors. <i>Lung Cancer Management</i> , 2019, 8, LMT11.	1.5	58
4847	Therapy with CD4+CD25+ T regulatory cells “ should we be afraid of cancer?. <i>Wspolczesna Onkologia</i> , 2019, 23, 1-6.	0.7	7
4848	AVAILABLE NIS “ AVASTIN® in lung cancer treatment in routine oncology practice in Germany. <i>BMC Cancer</i> , 2019, 19, 433.	1.1	9

#	ARTICLE	IF	CITATIONS
4849	Abscopal Effects in Radio-Immunotherapy—Response Analysis of Metastatic Cancer Patients With Progressive Disease Under Anti-PD-1 Immune Checkpoint Inhibition. <i>Frontiers in Pharmacology</i> , 2019, 10, 511.	1.6	56
4850	Immune Checkpoint Ligand Reverse Signaling: Looking Back to Go Forward in Cancer Therapy. <i>Cancers</i> , 2019, 11, 624.	1.7	32
4851	Phospho-STAT1 expression as a potential biomarker for anti-PD-1/anti-PD-L1 immunotherapy for breast cancer. <i>International Journal of Oncology</i> , 2019, 54, 2030-2038.	1.4	34
4852	High expression of DLC family proteins predicts better prognosis and inhibits tumor progression in NSCLC. <i>Molecular Medicine Reports</i> , 2019, 19, 4881-4889.	1.1	9
4853	Prediction of response to pemetrexed in non-small-cell lung cancer with immunohistochemical phenotyping based on gene expression profiles. <i>BMC Cancer</i> , 2019, 19, 440.	1.1	7
4854	PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 193.	3.5	61
4855	LPA5 Is an Inhibitory Receptor That Suppresses CD8 T-Cell Cytotoxic Function via Disruption of Early TCR Signaling. <i>Frontiers in Immunology</i> , 2019, 10, 1159.	2.2	58
4856	Prognostic significance of tumour-infiltrating lymphocytes for oestrogen receptor-negative breast cancer without lymph node metastasis. <i>Oncology Letters</i> , 2019, 17, 2647-2656.	0.8	56
4857	Posterior reversible encephalopathy syndrome induced by nivolumab immunotherapy for non-small-cell lung cancer. <i>Clinical Case Reports (discontinued)</i> , 2019, 7, 935-938.	0.2	27
4858	Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker. <i>BioMed Research International</i> , 2019, 2019, 1-15.	0.9	37
4859	High glucose promotes pancreatic cancer cells to escape from immune surveillance via AMPK-Bmi1-GATA2-MICA/B pathway. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 192.	3.5	33
4860	Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches. <i>Journal of Pathology</i> , 2019, 249, 151-165.	2.1	80
4861	Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCR β diversity. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1095-1106.	2.0	5
4862	Targeted Therapies for the Treatment of Glioblastoma in Adults. <i>Current Oncology Reports</i> , 2019, 21, 61.	1.8	15
4863	CheckMate-032 Study: promising efficacy with nivolumab-based immunotherapy in pretreated esophagogastric cancer. <i>Journal of Thoracic Disease</i> , 2019, 11, S394-S395.	0.6	6
4864	Immuno-checkpoint inhibitors in metastatic esophago-gastric cancer. <i>Journal of Thoracic Disease</i> , 2019, 11, S376-S380.	0.6	1
4865	Nivolumab and immune-mediated colitis. <i>Clinical Case Reports (discontinued)</i> , 2019, 7, 644-647.	0.2	3
4866	Severe pulmonary toxicity from immune checkpoint inhibitor treated successfully with intravenous immunoglobulin: Case report and review of the literature. <i>Respiratory Medicine Case Reports</i> , 2019, 27, 100834.	0.2	25

#	ARTICLE	IF	CITATIONS
4867	Molecular characterization of clinical responses to PD-1/PD-L1 inhibitors in non-small cell lung cancer: Predictive value of multidimensional immunomarker detection for the efficacy of PD-1 inhibitors in Chinese patients. <i>Thoracic Cancer</i> , 2019, 10, 1303-1309.	0.8	12
4868	Lactate dehydrogenase and baseline markers associated with clinical outcomes of advanced esophageal squamous cell carcinoma patients treated with camrelizumab (SHR-1210), a novel anti-PD-1 antibody. <i>Thoracic Cancer</i> , 2019, 10, 1395-1401.	0.8	33
4869	Unlike PD-L1, PD-1 Is Downregulated on Partial Immune Cells in Type 2 Diabetes. <i>Journal of Diabetes Research</i> , 2019, 2019, 1-8.	1.0	16
4870	The ABCs of preventing hyperprogressive disease after immunotherapy: awareness, biomarkers, and combination. <i>Journal of Thoracic Disease</i> , 2019, 11, S347-S351.	0.6	6
4871	Combinatorial Approaches With Checkpoint Inhibitors to Enhance Anti-tumor Immunity. <i>Frontiers in Immunology</i> , 2019, 10, 999.	2.2	47
4872	Immunophenotype of T Cells Expressing Programmed Death-1 and Cytotoxic T Cell Antigen-4 in Early Lung Cancer: Local vs. Systemic Immune Response. <i>Cancers</i> , 2019, 11, 567.	1.7	17
4873	Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2019, 5, 1043.	3.4	266
4874	A single-arm phase II trial of weekly nanoparticle albumin-bound paclitaxel (nab-paclitaxel) monotherapy after standard of chemotherapy for previously treated advanced non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 351-358.	1.1	8
4875	Managing cardiotoxicity associated with immune checkpoint inhibitors. <i>Chronic Diseases and Translational Medicine</i> , 2019, 5, 6-14.	0.9	52
4876	Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature. , 2019, 7, 106.		203
4877	Strategies to Improve Cancer Immune Checkpoint Inhibitors Efficacy, Other Than Abscopal Effect: A Systematic Review. <i>Cancers</i> , 2019, 11, 539.	1.7	45
4878	LKB1 and Tumor Metabolism: The Interplay of Immune and Angiogenic Microenvironment in Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1874.	1.8	39
4879	Phenotypic and Genomic Determinants of Immunotherapy Response Associated with Squamousness. <i>Cancer Immunology Research</i> , 2019, 7, 866-873.	1.6	23
4880	Understanding the mechanisms of immune-evasion by lung cancer in the context of chronic inflammation in emphysema. <i>Journal of Thoracic Disease</i> , 2019, 11, 382-385.	0.6	2
4881	Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-Analysis. <i>Frontiers in Oncology</i> , 2019, 9, 264.	1.3	87
4882	PD-L1 Expression and Immune Cell Infiltration in Gastroenteropancreatic (GEP) and Non-GEP Neuroendocrine Neoplasms With High Proliferative Activity. <i>Frontiers in Oncology</i> , 2019, 9, 343.	1.3	47
4883	Beyond PD-L1 Markers for Lung Cancer Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1915.	1.8	61
4884	A Phase I/II Open-Label Study of Nivolumab in Previously Treated Advanced or Recurrent Nasopharyngeal Carcinoma and Other Solid Tumors. <i>Oncologist</i> , 2019, 24, 891-e431.	1.9	25

#	ARTICLE	IF	CITATIONS
4885	Stereotactic Ablative Radiotherapy Combined with Immune Checkpoint Inhibitors Reboots the Immune Response Assisted by Immunotherapy in Metastatic Lung Cancer: A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2173.	1.8	68
4886	Lazarus-Type Tumour Response to Therapy with Nivolumab for Sarcomatoid Carcinomas of the Lung. <i>Current Oncology</i> , 2019, 26, 270-273.	0.9	17
4887	Malignant Melanoma: Autoimmunity and Supracellular Messaging as New Therapeutic Approaches. <i>Current Treatment Options in Oncology</i> , 2019, 20, 45.	1.3	20
4888	The role of pembrolizumab in relapsed/refractory primary mediastinal large B-cell lymphoma. <i>Therapeutic Advances in Hematology</i> , 2019, 10, 204062071984159.	1.1	23
4889	Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma. <i>Genome Medicine</i> , 2019, 11, 28.	3.6	107
4890	<p>Durvalumab for the management of urothelial carcinoma: a short review on the emerging data and therapeutic potential</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 2505-2512.	1.0	17
4891	<p>Clinical outcome of osteosarcoma and its correlation with programmed death-ligand 1 and T cell activation markers</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 2513-2518.	1.0	25
4892	Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial. <i>BMC Cancer</i> , 2019, 19, 413.	1.1	57
4893	Emerging therapies for small cell lung cancer. <i>Journal of Hematology and Oncology</i> , 2019, 12, 47.	6.9	273
4894	Correlation of Milestone Restricted Mean Survival Time Ratio With Overall Survival Hazard Ratio in Randomized Clinical Trials of Immune Checkpoint Inhibitors. <i>JAMA Network Open</i> , 2019, 2, e193433.	2.8	8
4895	The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV. <i>International Journal of Clinical Oncology</i> , 2019, 24, 731-770.	1.0	100
4896	A Network Approach to Developing Immuno-Oncology Combinations in Canada. <i>Current Oncology</i> , 2019, 26, 73-79.	0.9	1
4897	Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials. <i>JAMA Oncology</i> , 2019, 5, 1008.	3.4	526
4898	The Need to Prioritize and Re-prioritize Palliative Care Options: Smoking Cessation as a Case-in-Point. <i>Current Treatment Options in Oncology</i> , 2019, 20, 33.	1.3	0
4899	The nephrotoxicity of new immunotherapies. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 513-521.	1.3	12
4900	Sym021, a promising anti-PD1 clinical candidate antibody derived from a new chicken antibody discovery platform. <i>MAbs</i> , 2019, 11, 666-680.	2.6	25
4901	Systematic review and case series: flexible sigmoidoscopy identifies most cases of checkpoint inhibitor–induced colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1474-1483.	1.9	38
4902	Clinicopathologic characteristics, tumor infiltrating lymphocytes and progamed cell death ligand-1 expression in 162 endometrial carcinomas with deficient mismatch repair function. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 113-118.	1.2	8

#	ARTICLE	IF	CITATIONS
4903	Rational design of anti-GITR-based combination immunotherapy. <i>Nature Medicine</i> , 2019, 25, 759-766.	15.2	180
4904	The multidisciplinary lung cancer team meeting: increasing evidence that it should be considered a medical intervention in its own right. <i>Journal of Thoracic Disease</i> , 2019, 11, S311-S314.	0.6	11
4905	Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities. <i>Trends in Immunology</i> , 2019, 40, 511-523.	2.9	180
4906	PD-L1 (B7-H1) Competes with the RNA Exosome to Regulate the DNA Damage Response and Can Be Targeted to Sensitize to Radiation or Chemotherapy. <i>Molecular Cell</i> , 2019, 74, 1215-1226.e4.	4.5	144
4907	The efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer harboring driver mutations. <i>Molecular and Clinical Oncology</i> , 2019, 10, 610-614.	0.4	4
4908	The relationship between the PD-L1 expression of surgically resected and fine-needle aspiration specimens for patients with pancreatic cancer. <i>Journal of Gastroenterology</i> , 2019, 54, 1019-1028.	2.3	6
4909	Management of immune related adverse events induced by immune checkpoint inhibition. <i>Cancer Letters</i> , 2019, 456, 80-87.	3.2	36
4910	<p>Monoclonal antibody therapy of solid tumors: clinical limitations and novel strategies to enhance treatment efficacy</p>. <i>Biologics: Targets and Therapy</i> , 2019, Volume 13, 33-51.	3.0	115
4911	Trial Reporting in Immuno-Oncology (TRIO): An American Society of Clinical Oncology-Society for Immunotherapy of Cancer Statement. <i>Journal of Clinical Oncology</i> , 2019, 37, 72-80.	0.8	17
4912	Second-line erlotinib after failure of pemetrexed-containing chemotherapy in advanced non-small cell lung cancer (NSCLC): Real-world effectiveness, safety and tolerability. <i>PLoS ONE</i> , 2019, 14, e0215135.	1.1	6
4913	CD8+ T cell exhaustion. <i>Seminars in Immunopathology</i> , 2019, 41, 327-337.	2.8	169
4914	Relative efficacy of interventions in the treatment of second-line non-small cell lung cancer: a systematic review and network meta-analysis. <i>BMC Cancer</i> , 2019, 19, 353.	1.1	27
4915	Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 162.	3.5	116
4916	Ntrk1 Promotes Resistance to PD-1 Checkpoint Blockade in Mesenchymal Kras/p53 Mutant Lung Cancer. <i>Cancers</i> , 2019, 11, 462.	1.7	20
4917	PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1631.	1.8	59
4918	Targeting the PD-1/PD-L1 Pathway in Renal Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1692.	1.8	61
4919	Impact of the microbiome on cancer progression and response to anti-cancer therapies. <i>Advances in Cancer Research</i> , 2019, 143, 255-294.	1.9	23
4920	Early assessment with 18F-2-fluoro-2-deoxyglucose positron emission tomography/computed tomography to predict short-term outcome in clear cell renal carcinoma treated with nivolumab. <i>BMC Cancer</i> , 2019, 19, 298.	1.1	24

#	ARTICLE	IF	CITATIONS
4921	Differential expressions of PD-1, PD-L1 and PD-L2 between primary and metastatic sites in renal cell carcinoma. <i>BMC Cancer</i> , 2019, 19, 360.	1.1	52
4922	Selecting treatment options in refractory metastatic colorectal cancer. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 2271-2278.	1.0	20
4923	Multiple antigen-engineered DC vaccines with or without IFN γ to promote antitumor immunity in melanoma. , 2019, 7, 113.		31
4924	Enhancing Dendritic Cell Therapy in Solid Tumors with Immunomodulating Conventional Treatment. <i>Molecular Therapy - Oncolytics</i> , 2019, 13, 67-81.	2.0	44
4925	Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies. <i>Journal of Hematology and Oncology</i> , 2019, 12, 42.	6.9	58
4926	Association of BRCA1- and BRCA2-deficiency with mutation burden, expression of PD-L1/PD-1, immune infiltrates, and T cell-inflamed signature in breast cancer. <i>PLoS ONE</i> , 2019, 14, e0215381.	1.1	73
4927	Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591983992.	1.4	48
4928	Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: a systematic review and secondary analysis of trials. <i>BMC Cancer</i> , 2019, 19, 392.	1.1	7
4929	Case report: reinitiating pembrolizumab treatment after small bowel perforation. <i>BMC Cancer</i> , 2019, 19, 379.	1.1	14
4930	Emerging therapies for non-small cell lung cancer. <i>Journal of Hematology and Oncology</i> , 2019, 12, 45.	6.9	111
4931	KEYNOTE-024: goodbye to chemotherapy?. <i>Journal of Thoracic Disease</i> , 2019, 11, S428-S432.	0.6	3
4932	Sequential Blockade of PD-1 and PD-L1 Causes Fulminant Cardiotoxicity—From Case Report to Mouse Model Validation. <i>Cancers</i> , 2019, 11, 580.	1.7	28
4933	The Role of the Immune System in Cutaneous Squamous Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2009.	1.8	81
4934	Programmed cell death ligand 1 expression in cytologic and surgical non-small cell lung carcinoma specimens from a single institution: Association with clinicopathologic features and molecular alterations. <i>Cancer Cytopathology</i> , 2019, 127, 447-457.	1.4	12
4935	Systemic and local immunosuppression in patients with high-grade meningiomas. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 999-1009.	2.0	28
4936	Tumor expression and usefulness as a biomarker of programmed death ligand 1 in advanced non-small cell lung cancer patients with preexisting interstitial lung disease. <i>Medical Oncology</i> , 2019, 36, 49.	1.2	16
4937	Immune checkpoint-based therapy in myeloid malignancies: a promise yet to be fulfilled. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 393-404.	1.1	26
4938	Novel Approaches to Improve the Efficacy of Immuno-Radiotherapy. <i>Frontiers in Oncology</i> , 2019, 9, 156.	1.3	119

#	ARTICLE	IF	CITATIONS
4939	Surgical removal of the index node marked using magnetic seed localization to assess response to neoadjuvant immunotherapy in patients with stage III melanoma. <i>British Journal of Surgery</i> , 2019, 106, 519-522.	0.1	35
4940	Impact of EGFR mutation on the clinical efficacy of PD-1 inhibitors in patients with pulmonary adenocarcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1341-1349.	1.2	19
4941	Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes. <i>BMJ Open Diabetes Research and Care</i> , 2019, 7, e000591.	1.2	137
4942	CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function. <i>Cancer Immunology Research</i> , 2019, 7, 559-571.	1.6	79
4943	Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma. , 2019, 7, 80.		65
4944	<p>Mismatch repair status and high expression of PD-L1 in nasopharyngeal carcinoma</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 1631-1640.	0.9	9
4945	Phenotypic Characterization of Circulating Lung Cancer Cells for Clinically Actionable Targets. <i>Cancers</i> , 2019, 11, 380.	1.7	33
4946	Clinical protein science in translational medicine targeting malignant melanoma. <i>Cell Biology and Toxicology</i> , 2019, 35, 293-332.	2.4	33
4947	Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy. , 2019, 7, 82.		76
4948	Antigen Targets for the Development of Immunotherapies in Leukemia. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1397.	1.8	10
4949	PD-1 Ligand Expression in Epithelial Thyroid Cancers: Potential Clinical Implications. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1405.	1.8	36
4950	Immune Checkpoint Inhibitors in Acute Myeloid Leukemia: Novel Combinations and Therapeutic Targets. <i>Current Oncology Reports</i> , 2019, 21, 37.	1.8	72
4951	Consensus on the use of immune-related response criteria to evaluate the efficacy of immunotherapy in non-small cell lung cancer. <i>Clinical and Translational Oncology</i> , 2019, 21, 1464-1471.	1.2	1
4952	Innate lymphoid cells: A potential link between microbiota and immune responses against cancer. <i>Seminars in Immunology</i> , 2019, 41, 101271.	2.7	13
4953	<p>A meta-analysis of the efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors as treatments for metastatic bladder cancer</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 1791-1801.	1.0	20
4954	Next Generation Sequencing and Genetic Alterations in Squamous Cell Lung Carcinoma: Where Are We Today?. <i>Frontiers in Oncology</i> , 2019, 9, 166.	1.3	61
4955	Cat and Mouse: HIV Transcription in Latency, Immune Evasion and Cure/Remission Strategies. <i>Viruses</i> , 2019, 11, 269.	1.5	26
4956	Immunotherapy in colorectal cancer: rationale, challenges and potential. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 361-375.	8.2	1,039

#	ARTICLE	IF	CITATIONS
4957	PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 1111-1122.	1.4	297
4958	MHC Class 1 and PDL-1 Status of Primary Tumor and Lymph Node Metastatic Tumor Tissue in Gastric Cancers. <i>Gastroenterology Research and Practice</i> , 2019, 2019, 1-7.	0.7	21
4959	Metastatic renal cell carcinoma regains sensitivity to tyrosine kinase inhibitor after nivolumab treatment: A case report. <i>Oncology Letters</i> , 2019, 17, 4011-4015.	0.8	8
4960	Radiotherapy is an independent prognostic marker of favorable prognosis in non-small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumab. <i>Thoracic Cancer</i> , 2019, 10, 992-1000.	0.8	44
4961	Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCIST. <i>EJNMMI Research</i> , 2019, 9, 8.	1.1	121
4962	Identification of a Robust Methylation Classifier for Cutaneous Melanoma Diagnosis. <i>Journal of Investigative Dermatology</i> , 2019, 139, 1349-1361.	0.3	23
4963	Vogt-Koyanagi-Harada Disease-Like Uveitis during Nivolumab (Anti-PD-1 Antibody) Treatment for Metastatic Cutaneous Malignant Melanoma. <i>Case Reports in Ophthalmology</i> , 2019, 10, 67-74.	0.3	46
4964	Immunotherapy: Pancreatic Cancer and Extrahepatic Biliary Tract Cancer. <i>Visceral Medicine</i> , 2019, 35, 28-37.	0.5	7
4965	Successful Treatment of Myasthenia Gravis Following PD-1/CTLA-4 Combination Checkpoint Blockade in a Patient With Metastatic Melanoma. <i>Frontiers in Oncology</i> , 2019, 9, 84.	1.3	18
4966	Genomic correlates of response to immune checkpoint blockade. <i>Nature Medicine</i> , 2019, 25, 389-402.	15.2	346
4967	Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591982771.	1.4	38
4968	The neoepitope landscape of breast cancer: implications for immunotherapy. <i>BMC Cancer</i> , 2019, 19, 200.	1.1	68
4969	Use of the Response Assessment in Neuro-Oncology (RANO) criteria in clinical trials and clinical practice. <i>CNS Oncology</i> , 2019, 8, CNS28.	1.2	169
4970	PD-1 Inhibitors-Related Neurological Toxicities in Patients with Non-Small-Cell Lung Cancer: A Literature Review. <i>Cancers</i> , 2019, 11, 296.	1.7	33
4971	Macrophage Origin, Metabolic Reprogramming and IL-1 Signaling: Promises and Pitfalls in Lung Cancer. <i>Cancers</i> , 2019, 11, 298.	1.7	10
4972	CDK7 inhibition as a promising therapeutic strategy for lung squamous cell carcinomas with a SOX2 amplification. <i>Cellular Oncology (Dordrecht)</i> , 2019, 42, 449-458.	2.1	13
4973	Radiotherapy enhances responses of lung cancer to CTLA-4 blockade. , 2019, 7, 64.		16
4974	Immunotherapy Associated Pulmonary Toxicity: Biology Behind Clinical and Radiological Features. <i>Cancers</i> , 2019, 11, 305.	1.7	51

#	ARTICLE	IF	CITATIONS
4975	Recent treatment strategy for advanced squamous cell carcinoma of the lung in Japan. <i>International Journal of Clinical Oncology</i> , 2019, 24, 461-467.	1.0	7
4976	EGFR exon 21 L858R as an acquired resistance mechanism to nivolumab in a lung cancer patient originally driver gene-negative. <i>Thoracic Cancer</i> , 2019, 10, 1256-1259.	0.8	5
4977	Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes. <i>Clinical Cancer Research</i> , 2019, 25, 4592-4602.	3.2	447
4978	Glioblastoma-Derived IL6 Induces Immunosuppressive Peripheral Myeloid Cell PD-L1 and Promotes Tumor Growth. <i>Clinical Cancer Research</i> , 2019, 25, 3643-3657.	3.2	128
4979	Combined targeted therapy and immunotherapy in melanoma: a review of the impact on the tumor microenvironment and outcomes of early clinical trials. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591983082.	1.4	107
4980	Intralymphatic histiocytosis in a patient with lung adenocarcinoma treated with pembrolizumab: a case report. , 2019, 7, 59.		9
4981	Retrospect and Prospect for Lung Cancer in China: Clinical Advances of Immune Checkpoint Inhibitors. <i>Oncologist</i> , 2019, 24, S21-S30.	1.9	22
4982	Ongoing Phase I Studies of Immune Checkpoint Inhibitors in China. <i>Oncologist</i> , 2019, 24, S11-S20.	1.9	2
4983	Are Conventional Type 1 Dendritic Cells Critical for Protective Antitumor Immunity and How?. <i>Frontiers in Immunology</i> , 2019, 10, 9.	2.2	126
4984	CD56dim CD16 ⁺ Natural Killer Cell Profiling in Melanoma Patients Receiving a Cancer Vaccine and Interferon- γ . <i>Frontiers in Immunology</i> , 2019, 10, 14.	2.2	41
4985	Impact of early inflammatory cytokine elevation after commencement of PD-1 inhibitors to predict efficacy in patients with non-small cell lung cancer. <i>Medical Oncology</i> , 2019, 36, 33.	1.2	66
4986	Nivolumab-associated DRESS syndrome: A case report. <i>JAAD Case Reports</i> , 2019, 5, 216-218.	0.4	34
4987	Mutations in DNA repair genes are associated with increased neoantigen burden and a distinct immunophenotype in lung squamous cell carcinoma. <i>Scientific Reports</i> , 2019, 9, 3235.	1.6	60
4988	Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma. <i>Clinical and Experimental Immunology</i> , 2019, 197, 74-82.	1.1	32
4989	Divergent <i>SATB1</i> expression across human life span and tissue compartments. <i>Immunology and Cell Biology</i> , 2019, 97, 498-511.	1.0	20
4990	Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges. <i>Oncologist</i> , 2019, 24, S3-S10.	1.9	108
4991	The Role of Radiation Oncology in Immuno-Oncology. <i>Oncologist</i> , 2019, 24, S42-S52.	1.9	23
4992	PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions. <i>Oncologist</i> , 2019, 24, S31-S41.	1.9	239

#	ARTICLE	IF	CITATIONS
4993	PD-1/PD-L1 blockade in cervical cancer: current studies and perspectives. <i>Frontiers of Medicine</i> , 2019, 13, 438-450.	1.5	32
4994	Depletion of PD-1-positive cells ameliorates autoimmune disease. <i>Nature Biomedical Engineering</i> , 2019, 3, 292-305.	11.6	48
4995	The Immune Subtypes and Landscape of Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 3528-3537.	3.2	136
4996	Treatment Strategies and Survival Trends for Anorectal Melanoma: Is it Time for a Change?. <i>World Journal of Surgery</i> , 2019, 43, 1809-1819.	0.8	28
4997	Japanese subgroup analysis of a phase III study of S-1 versus docetaxel in non-small cell lung cancer patients after platinum-based treatment: EAST-LC. <i>International Journal of Clinical Oncology</i> , 2019, 24, 485-493.	1.0	4
4998	Immunotherapy: Current Status and Future Perspectives. <i>Digestive Diseases and Sciences</i> , 2019, 64, 1030-1040.	1.1	24
4999	Adverse Events Associated With Immune Checkpoint Inhibitors. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1218.	3.8	3
5000	Negative Co-stimulation Constrains T Cell Differentiation by Imposing Boundaries on Possible Cell States. <i>Immunity</i> , 2019, 50, 1084-1098.e10.	6.6	75
5001	CCL22 controls immunity by promoting regulatory T cell communication with dendritic cells in lymph nodes. <i>Journal of Experimental Medicine</i> , 2019, 216, 1170-1181.	4.2	145
5002	Efficacy of subsequent docetaxel + ramucirumab and S-1 after nivolumab for patients with advanced non-small cell lung cancer. <i>Thoracic Cancer</i> , 2019, 10, 1141-1148.	0.8	11
5003	Immunotherapy-related hepatitis: real-world experience from a tertiary centre. <i>Frontline Gastroenterology</i> , 2019, 10, 364-371.	0.9	65
5004	Checkpoint inhibition immunotherapy for advanced local and systemic conjunctival melanoma: a clinical case series. , 2019, 7, 83.		55
5005	Targeting FER Kinase Inhibits Melanoma Growth and Metastasis. <i>Cancers</i> , 2019, 11, 419.	1.7	15
5006	Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1613-1623.	1.2	66
5007	Combined Checkpoint Inhibition and Chemotherapy: New Era of 1st-Line Treatment for Non-Small-Cell Lung Cancer. <i>Molecular Therapy - Oncolytics</i> , 2019, 13, 1-6.	2.0	26
5008	Immunotherapy is associated with improved survival and decreased neurologic death after SRS for brain metastases from lung and melanoma primaries. <i>Neuro-Oncology Practice</i> , 2019, 6, 402-409.	1.0	43
5009	Immunotherapy of Melanoma: Facts and Hopes. <i>Clinical Cancer Research</i> , 2019, 25, 5191-5201.	3.2	181
5010	Effector Functions of CD4+ T Cells at the Site of Local Autoimmune Inflammation—Lessons From Rheumatoid Arthritis. <i>Frontiers in Immunology</i> , 2019, 10, 353.	2.2	144

#	ARTICLE	IF	CITATIONS
5011	The Aryl hydrocarbon receptor mediates tobacco-induced PD-L1 expression and is associated with response to immunotherapy. <i>Nature Communications</i> , 2019, 10, 1125.	5.8	131
5012	Teriflunomide induces a tolerogenic bias in blood immune cells of MS patients. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 355-363.	1.7	21
5013	KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition. <i>EBioMedicine</i> , 2019, 41, 711-716.	2.7	142
5014	Development of an Interleukin-12 Fusion Protein That Is Activated by Cleavage with Matrix Metalloproteinase 9. <i>Journal of Interferon and Cytokine Research</i> , 2019, 39, 233-245.	0.5	21
5015	Nivolumab-induced interstitial lung disease in a patient with gastric cancer. <i>Oxford Medical Case Reports</i> , 2019, 2019, omz007.	0.2	3
5016	The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients. <i>Journal of Translational Medicine</i> , 2019, 17, 74.	1.8	103
5017	Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC). , 2019, 7, 65.		108
5018	From Whole-Brain Radiotherapy to Immunotherapy: A Multidisciplinary Approach for Patients with Brain Metastases from NSCLC. <i>Journal of Oncology</i> , 2019, 2019, 1-12.	0.6	12
5019	Non-immunological complications following kidney transplantation. <i>F1000Research</i> , 2019, 8, 194.	0.8	26
5020	Harnessing Radiation Biology to Augment Immunotherapy for Glioblastoma. <i>Frontiers in Oncology</i> , 2019, 8, 656.	1.3	32
5021	Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. <i>Frontiers in Oncology</i> , 2019, 9, 179.	1.3	34
5022	Canadian Consensus: Oligoprogressive, Pseudoprogressive, and Oligometastatic Non-Small-Cell Lung Cancer. <i>Current Oncology</i> , 2019, 26, 81-93.	0.9	38
5023	Impact of prior antibiotic use on the efficacy of nivolumab for non-small cell lung cancer. <i>Oncology Letters</i> , 2019, 17, 2946-2952.	0.8	82
5024	The immune microenvironment in non-small cell lung cancer is predictive of prognosis after surgery. <i>Molecular Oncology</i> , 2019, 13, 1166-1179.	2.1	57
5025	Renal toxicities associated with pembrolizumab. <i>CKJ: Clinical Kidney Journal</i> , 2019, 12, 81-88.	1.4	101
5026	Safe Administration of anti-PD-L1 Atezolizumab in a Patient with Metastatic Urothelial Cell Carcinoma and End-Stage Renal Disease on Dialysis. <i>Case Reports in Oncological Medicine</i> , 2019, 2019, 1-3.	0.2	8
5027	Targeting the Antibody Checkpoints to Enhance Cancer Immunotherapy—Focus on Fcγ3RIIB. <i>Frontiers in Immunology</i> , 2019, 10, 481.	2.2	33
5028	Beyond CAR T Cells: Other Cell-Based Immunotherapeutic Strategies Against Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 196.	1.3	44

#	ARTICLE	IF	CITATIONS
5029	A Case of Nivolumab-Induced Acute-Onset Type 1 Diabetes Mellitus in Melanoma. <i>Current Oncology</i> , 2019, 26, 115-118.	0.9	20
5030	Diabetes Mellitus Secondary to Treatment with Immune Checkpoint Inhibitors. <i>Current Oncology</i> , 2019, 26, 111-114.	0.9	23
5031	Autoimmune genetic risk variants as germline biomarkers of response to melanoma immune-checkpoint inhibition. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 897-905.	2.0	38
5032	Strong CD8+ lymphocyte infiltration in combination with expression of HLA class I is associated with better tumor control in breast cancer patients treated with neoadjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 605-615.	1.1	13
5033	A novel immunogenic mouse model of melanoma for the preclinical assessment of combination targeted and immune-based therapy. <i>Scientific Reports</i> , 2019, 9, 1225.	1.6	16
5034	Whole transcriptome targeted gene quantification provides new insights on pulmonary sarcomatoid carcinomas. <i>Scientific Reports</i> , 2019, 9, 3536.	1.6	11
5035	The new <i>Clinical Kidney Journal</i> , 4 years later. <i>CKJ: Clinical Kidney Journal</i> , 2019, 12, 1-5.	1.4	3
5036	Exceptional response and multisystem autoimmune-like toxicities associated with the same T cell clone in a patient with uveal melanoma treated with immune checkpoint inhibitors. , 2019, 7, 61.		40
5037	<p>Complete response associated with immune checkpoint inhibitors in advanced non-small-cell lung cancer: a meta-analysis of nine randomized controlled trials</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 1623-1629.	0.9	19
5038	<p>Development of treatment options for Chinese patients with advanced squamous cell lung cancer: focus on afatinib</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 1521-1538.	1.0	3
5039	<p>Risk and incidence of fatal adverse events associated with immune checkpoint inhibitors: a systematic review and meta-analysis</p>. <i>Therapeutics and Clinical Risk Management</i> , 2019, Volume 15, 293-302.	0.9	27
5040	Quantitative immunohistochemical assay with novel digital immunostaining for comparisons of PDéL1 antibodies. <i>Molecular and Clinical Oncology</i> , 2019, 10, 391-396.	0.4	3
5041	Significance of PDéL1 in the diagnosis and treatment of Bécell malignant lymphoma. <i>Oncology Letters</i> , 2019, 17, 3382-3386.	0.8	4
5042	Clinical Pharmacokinetic and Pharmacodynamic Considerations in the (Modern) Treatment of Melanoma. <i>Clinical Pharmacokinetics</i> , 2019, 58, 1029-1043.	1.6	6
5043	The Position of Inhaled Chemotherapy in the Care of Patients with Lung Tumors: Clinical Feasibility and Indications According to Recent Pharmaceutical Progresses. <i>Cancers</i> , 2019, 11, 329.	1.7	37
5044	Molecular classification of IDH-mutant glioblastomas based on gene expression profiles. <i>Carcinogenesis</i> , 2019, 40, 853-860.	1.3	37
5045	A multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA). <i>BMC Cancer</i> , 2019, 19, 231.	1.1	19
5046	Rapid effects of benralizumab on severe asthma during surgery for residual tumor after advanced lung squamous cell carcinoma treatment with pembrolizumab. <i>Respiratory Medicine Case Reports</i> , 2019, 26, 292-295.	0.2	6

#	ARTICLE	IF	CITATIONS
5047	Adipocytes: A Novel Target for IL-15/IL-15R α Cancer Gene Therapy. <i>Molecular Therapy</i> , 2019, 27, 922-932.	3.7	25
5048	Systemic Immunotherapy for Advanced Cutaneous Squamous Cell Carcinoma. <i>Current Treatment Options in Oncology</i> , 2019, 20, 30.	1.3	24
5049	Association of Sarcopenia with and Efficacy of Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer. <i>Journal of Clinical Medicine</i> , 2019, 8, 450.	1.0	72
5050	Expression of LDH and CEA in serum in the process of targeted therapy of lung adenocarcinoma and the association between them and prognosis. <i>Oncology Letters</i> , 2019, 17, 4550-4556.	0.8	7
5051	First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers. <i>Journal of Clinical Oncology</i> , 2019, 37, 992-1000.	0.8	457
5052	Ex vivo Hsp70-Activated NK Cells in Combination With PD-1 Inhibition Significantly Increase Overall Survival in Preclinical Models of Glioblastoma and Lung Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 454.	2.2	48
5053	The FG Loop of PD-1 Serves as a "Hotspot" for Therapeutic Monoclonal Antibodies in Tumor Immune Checkpoint Therapy. <i>IScience</i> , 2019, 14, 113-124.	1.9	34
5054	Enhancement of Cytomegalovirus-Specific Cytokine Production after Modulation of the Costimulation in Kidney Transplant Patients. <i>Journal of Immunology Research</i> , 2019, 2019, 1-8.	0.9	5
5055	Continued administration of pembrolizumab for adenocarcinoma of the lung after the onset of fulminant type 1 diabetes mellitus as an immune-related adverse effect: A case report. <i>Thoracic Cancer</i> , 2019, 10, 1276-1279.	0.8	11
5056	The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation. , 2019, 7, 103.		79
5057	Dawn of precision medicine on gastric cancer. <i>International Journal of Clinical Oncology</i> , 2019, 24, 779-788.	1.0	15
5058	Controversies in the management of hepatocellular carcinoma. <i>JHEP Reports</i> , 2019, 1, 17-29.	2.6	45
5059	Bowel obstruction caused by colonic metastasis of lung adenocarcinoma: a case report and literature review. <i>World Journal of Surgical Oncology</i> , 2019, 17, 63.	0.8	12
5060	Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program. , 2019, 7, 99.		110
5061	Role of Targeted Therapy and Immune Checkpoint Blockers in Advanced Non-Small Cell Lung Cancer: A Review. <i>Oncologist</i> , 2019, 24, 1270-1284.	1.9	21
5062	<p>Anti-PD1 up-regulates PD-L1 expression and inhibits T-cell lymphoma progression: possible involvement of an IFN- γ -associated JAK-STAT pathway</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 2079-2088.	1.0	24
5063	Tumor-Associated Lymphatic Vessel Features and Immunomodulatory Functions. <i>Frontiers in Immunology</i> , 2019, 10, 720.	2.2	72
5064	Lentiviral Vector-Based Dendritic Cell Vaccine Suppresses HIV Replication in Humanized Mice. <i>Molecular Therapy</i> , 2019, 27, 960-973.	3.7	24

#	ARTICLE	IF	CITATIONS
5065	Efficacy of PD-1/PD-L1 inhibitors in patients with advanced non-small cell lung cancer: A meta-analysis of randomized clinical trials. <i>Thoracic Cancer</i> , 2019, 10, 1176-1181.	0.8	8
5066	Targeted antibody and cytokine cancer immunotherapies through collagen affinity. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	134
5067	Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors. <i>ESMO Open</i> , 2019, 4, e000457.	2.0	151
5068	Retrospective analysis of antitumor effects and biomarkers for nivolumab in NSCLC patients with EGFR mutations. <i>PLoS ONE</i> , 2019, 14, e0215292.	1.1	12
5069	Clinical development of targeted and immune based anti-cancer therapies. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 156.	3.5	170
5070	PD-L1 Expression Is Associated With VEGFA and LADC Patients' Survival. <i>Frontiers in Oncology</i> , 2019, 9, 189.	1.3	21
5071	Glial Cell Expression of PD-L1. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1677.	1.8	21
5072	Telomerase-Targeted Cancer Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1823.	1.8	80
5073	MAPK pathway activity plays a key role in PD-L1 expression of lung adenocarcinoma cells. <i>Journal of Pathology</i> , 2019, 249, 52-64.	2.1	117
5074	Clinical impact of PD-L1 and PD-1 expression in squamous cell cancer of the vulva. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1651-1660.	1.2	31
5075	Multi-region sequencing unveils novel actionable targets and spatial heterogeneity in esophageal squamous cell carcinoma. <i>Nature Communications</i> , 2019, 10, 1670.	5.8	110
5076	A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab. <i>Journal of Translational Medicine</i> , 2019, 17, 99.	1.8	52
5077	Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology. <i>Molecules</i> , 2019, 24, 1190.	1.7	163
5078	Role of the tumor microenvironment in pancreatic cancer. <i>Annals of Gastroenterological Surgery</i> , 2019, 3, 130-137.	1.2	114
5079	Cutaneous toxicities of antineoplastic agents: data from a large cohort of Greek patients. <i>Supportive Care in Cancer</i> , 2019, 27, 4535-4542.	1.0	10
5080	Medical Options for the Adjuvant Treatment and Management of Pediatric Melanoma. <i>Paediatric Drugs</i> , 2019, 21, 71-79.	1.3	4
5081	Dual-Sized Microparticle System for Generating Suppressive Dendritic Cells Prevents and Reverses Type 1 Diabetes in the Nonobese Diabetic Mouse Model. <i>ACS Biomaterials Science and Engineering</i> , 2019, 5, 2631-2646.	2.6	58
5082	PD-L1 promotes head and neck squamous cell carcinoma cell growth through mTOR signaling. <i>Oncology Reports</i> , 2019, 41, 2833-2843.	1.2	15

#	ARTICLE	IF	CITATIONS
5083	Clinicopathologic Correlation With Expression of PD-L1 on Both Tumor Cells and Tumor-infiltrating Immune Cells in Patients With Non-Small Cell Lung Cancer. <i>Journal of Immunotherapy</i> , 2019, 42, 23-28.	1.2	22
5084	Rationale for Combining Radiotherapy and Immune Checkpoint Inhibition for Patients With Hypoxic Tumors. <i>Frontiers in Immunology</i> , 2019, 10, 407.	2.2	44
5085	Efficacy of immunotherapy in sarcomatoid lung cancer, a case report and literature review. <i>Respiratory Medicine Case Reports</i> , 2019, 26, 310-314.	0.2	24
5086	–Road map for fibrolamellar carcinoma: progress and goals of a diversified approach–. <i>Journal of Hepatocellular Carcinoma</i> , 2019, Volume 6, 41-48.	1.8	5
5087	Co-existing of Neuromyelitis Optica and Fulminant Type 1 Diabetes. <i>Internal Medicine</i> , 2019, 58, 1913-1916.	0.3	1
5088	Immune Cell Infiltration of the Primary Tumor, Not PD-L1 Status, Is Associated With Improved Response to Checkpoint Inhibition in Metastatic Melanoma. <i>Frontiers in Medicine</i> , 2019, 6, 27.	1.2	54
5089	A Threshold Model for T-Cell Activation in the Era of Checkpoint Blockade Immunotherapy. <i>Frontiers in Immunology</i> , 2019, 10, 491.	2.2	23
5090	Efficacy and Tolerance of Post-operative Hypo-Fractionated Stereotactic Radiotherapy in a Large Series of Patients With Brain Metastases. <i>Frontiers in Oncology</i> , 2019, 9, 184.	1.3	15
5091	Tolerizing CTL by Sustained Hepatic PD-L1 Expression Provides a New Therapy Approach in Mouse Sepsis. <i>Theranostics</i> , 2019, 9, 2003-2016.	4.6	13
5092	Could the menagerie of the gut microbiome really cure cancer? Hope or hype. , 2019, 7, 92.		16
5093	–Growth and differentiation factor 15 regulates PD-L1 expression in glioblastoma–. <i>Cancer Management and Research</i> , 2019, Volume 11, 2653-2661.	0.9	20
5094	Immunological Agents Used in Cancer Treatment. <i>Eurasian Journal of Medicine</i> , 2019, 51, 90-94.	0.2	32
5095	Korean Practice Guideline for Gastric Cancer 2018: an Evidence-based, Multi-disciplinary Approach. <i>Journal of Gastric Cancer</i> , 2019, 19, 1.	0.9	328
5096	Computational Redesign of PD-1 Interface for PD-L1 Ligand Selectivity. <i>Structure</i> , 2019, 27, 829-836.e3.	1.6	13
5097	Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 481-489.	0.8	265
5098	Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 867-875.	0.8	258
5099	Comparison of a combination of chemotherapy and immune checkpoint inhibitors and immune checkpoint inhibitors alone for the treatment of advanced and metastatic non-small cell lung cancer. <i>Thoracic Cancer</i> , 2019, 10, 1158-1166.	0.8	17
5100	Lycopene improves the efficiency of anti-PD-1 therapy via activating IFN signaling of lung cancer cells. <i>Cancer Cell International</i> , 2019, 19, 68.	1.8	22

#	ARTICLE	IF	CITATIONS
5101	Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 52-60.	0.8	218
5102	The Inhibitory T Cell Receptors PD1 and 2B4 Are Differentially Regulated on CD4 and CD8 T Cells in a Mouse Model of Non-alcoholic Steatohepatitis. <i>Frontiers in Pharmacology</i> , 2019, 10, 244.	1.6	6
5103	Bevacizumab as a steroid-sparing agent during immunotherapy for melanoma brain metastases: A case series. <i>Health Science Reports</i> , 2019, 2, e115.	0.6	29
5104	Immunotherapy for High-Grade Gliomas: A Clinical Update and Practical Considerations for Neurosurgeons. <i>World Neurosurgery</i> , 2019, 124, 397-409.	0.7	19
5105	Early Phase I Study of a ^{99m} Tc-Labeled Anti-Programmed Death Ligand-1 (PD-L1) Single-Domain Antibody in SPECT/CT Assessment of PD-L1 Expression in Non-Small Cell Lung Cancer. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1213-1220.	2.8	111
5106	Current State of Immunotherapy for Treatment of Glioblastoma. <i>Current Treatment Options in Oncology</i> , 2019, 20, 24.	1.3	215
5107	Pegylated Interleukin-10: Clinical Development of an Immunoregulatory Cytokine for Use in Cancer Therapeutics. <i>Current Oncology Reports</i> , 2019, 21, 19.	1.8	34
5108	Immune Check Point Inhibitor-Associated Glomerulonephritis. <i>Kidney International Reports</i> , 2019, 4, 355-359.	0.4	22
5109	Impact of sarcopenia in patients with advanced non-small cell lung cancer treated with PD-1 inhibitors: A preliminary retrospective study. <i>Scientific Reports</i> , 2019, 9, 2447.	1.6	116
5110	Peripheral T cell cytotoxicity predicts T cell function in the tumor microenvironment. <i>Scientific Reports</i> , 2019, 9, 2636.	1.6	38
5111	Magnetic aerosol drug targeting in lung cancer therapy using permanent magnet. <i>Drug Delivery</i> , 2019, 26, 120-128.	2.5	37
5112	Immunotherapy of Cancer: Developments and Reference Points, an Unorthodox Approach. <i>Integrative Cancer Therapies</i> , 2019, 18, 153473541982709.	0.8	2
5113	Switch maintenance therapy with S-1 after induction therapy with carboplatin and nanoparticle albumin-bound paclitaxel in advanced lung squamous cell carcinoma. <i>Investigational New Drugs</i> , 2019, 37, 531-537.	1.2	3
5114	Immunotherapy-based combination strategies for treatment of gastrointestinal cancers: current status and future prospects. <i>Frontiers of Medicine</i> , 2019, 13, 12-23.	1.5	14
5115	Irreversible electroporation reverses resistance to immune checkpoint blockade in pancreatic cancer. <i>Nature Communications</i> , 2019, 10, 899.	5.8	169
5116	The immunomodulatory potential of natural compounds in tumor-bearing mice and humans. <i>Critical Reviews in Food Science and Nutrition</i> , 2019, 59, 992-1007.	5.4	52
5117	Charge variants characterization and release assay development for co-formulated antibodies as a combination therapy. <i>MAbs</i> , 2019, 11, 489-499.	2.6	26
5118	Late-onset isolated adrenocorticotrophic hormone deficiency caused by nivolumab: a case report. <i>BMC Endocrine Disorders</i> , 2019, 19, 25.	0.9	27

#	ARTICLE	IF	CITATIONS
5119	Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients. , 2019, 7, 50.		44
5120	Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors. , 2019, 7, 53.		59
5121	Programmed death ligand 1 expression in early stage, resectable non-small cell lung cancer. Oncotarget, 2019, 10, 561-572.	0.8	15
5122	<p>Safety and efficacy of atezolizumab in the treatment of cancers: a systematic review and pooled-analysis</p>. Drug Design, Development and Therapy, 2019, Volume 13, 523-538.	2.0	23
5123	TCR Repertoire Analysis Reveals Mobilization of Novel CD8+ T Cell Clones Into the Cancer-Immunity Cycle Following Anti-CD4 Antibody Administration. Frontiers in Immunology, 2018, 9, 3185.	2.2	33
5124	Emerging Nanoµapproaches for Cancer Immunotherapy. Advanced Science, 2019, 6, 1801847.	5.6	136
5125	A pilot study of interferon-alpha-2b dose reduction in the adjuvant therapy of high-risk melanoma. Cancer Immunology, Immunotherapy, 2019, 68, 619-629.	2.0	7
5126	The Changing Landscape of Systemic Treatment of Advanced Hepatocellular Carcinoma: New Targeted Agents and Immunotherapies. Targeted Oncology, 2019, 14, 115-123.	1.7	19
5127	Thyroid dysfunction induced by nivolumab: searching for disease patterns and outcomes. Endocrine, 2019, 64, 605-613.	1.1	46
5128	Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non&small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2019, 158, 269-276.	0.4	218
5129	Met inhibition revokes IFN³-induction of PD-1 ligands in MET-amplified tumours. British Journal of Cancer, 2019, 120, 527-536.	2.9	34
5130	Therapeutic modulation of autophagy: which disease comes first?. Cell Death and Differentiation, 2019, 26, 680-689.	5.0	48
5131	Incidence of Ipilimumab-Related Serious Adverse Events in Patients with Advanced Cancer: A Meta-Analysis. Journal of Cancer, 2019, 10, 120-130.	1.2	5
5132	Tumoral EHF predicts the efficacy of anti-PD1 therapy in pancreatic ductal adenocarcinoma. Journal of Experimental Medicine, 2019, 216, 656-673.	4.2	31
5133	Cardiac Complications in Immune Checkpoint Inhibition Therapy. Frontiers in Cardiovascular Medicine, 2019, 6, 3.	1.1	65
5134	Comparative efficacy and safety of first&line treatments for advanced non&small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta&analysis. Thoracic Cancer, 2019, 10, 607-623.	0.8	22
5135	Immune-Checkpoint Blockade Opposes CD8+ T-cell Suppression in Human and Murine Cancer. Cancer Immunology Research, 2019, 7, 510-525.	1.6	47
5136	Prognostic value of CD8&+&PD-1+ immune infiltrates and PDCD1 gene expression in triple negative breast cancer. , 2019, 7, 34.		75

#	ARTICLE	IF	CITATIONS
5137	Suppression of Myeloid Cell Arginase Activity leads to Therapeutic Response in a NSCLC Mouse Model by Activating Anti-Tumor Immunity. , 2019, 7, 32.		92
5138	Immunomagnetic isolation of circulating melanoma cells and detection of PD-L1 status. PLoS ONE, 2019, 14, e0211866.	1.1	16
5139	Combinatorial therapy of immune checkpoint and cancer pathways provides a novel perspective on ovarian cancer treatment (Review). Oncology Letters, 2019, 17, 2583-2591.	0.8	16
5140	Programmed Death Ligand-1 expression in stage II colon cancer - experiences from a nationwide populationbased cohort. BMC Cancer, 2019, 19, 142.	1.1	24
5141	Efficacy of PD-1 blockade in cervical cancer is related to a CD8+FoxP3+CD25+ T-cell subset with operational effector functions despite high immune checkpoint levels. , 2019, 7, 43.		42
5142	2020 vision or myopia? A personal perspective on the future of cancer imaging and an introduction to the sequels to the "How I Read Series" Cancer Imaging, 2019, 19, 7.	1.2	0
5143	Programmed death ligand 1 immunohistochemistry in non-small cell lung carcinoma. Journal of Thoracic Disease, 2019, 11, S89-S101.	0.6	52
5144	Fcγ3R-Binding Is an Important Functional Attribute for Immune Checkpoint Antibodies in Cancer Immunotherapy. Frontiers in Immunology, 2019, 10, 292.	2.2	111
5145	Nanobody Engineering: Toward Next Generation Immunotherapies and Immunoimaging of Cancer. Antibodies, 2019, 8, 13.	1.2	100
5146	The co-inhibitory molecule PD-L1 contributes to regulatory T cell-mediated protection in murine crescentic glomerulonephritis. Scientific Reports, 2019, 9, 2038.	1.6	25
5147	Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies. Pigment Cell and Melanoma Research, 2019, 32, 553-563.	1.5	28
5148	Combinatorial Approach to Improve Cancer Immunotherapy: Rational Drug Design Strategy to Simultaneously Hit Multiple Targets to Kill Tumor Cells and to Activate the Immune System. Journal of Oncology, 2019, 2019, 1-18.	0.6	76
5149	Efficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib NPU program. Clinical and Translational Oncology, 2019, 21, 1270-1279.	1.2	38
5150	Combination of Baseline LDH, Performance Status and Age as Integrated Algorithm to Identify Solid Tumor Patients with Higher Probability of Response to Anti PD-1 and PD-L1 Monoclonal Antibodies. Cancers, 2019, 11, 223.	1.7	18
5151	Balancing the Checkpoint: Managing Colitis Associated with Dual Checkpoint Inhibitors and High-Dose Aspirin. Digestive Diseases and Sciences, 2019, 64, 685-688.	1.1	1
5152	A mathematical solution to Peto's paradox using Polya's urn model: implications for the aetiology of cancer in general. Theory in Biosciences, 2019, 138, 241-250.	0.6	3
5153	Targeting Immune Checkpoints in Lung Cancer: Current Landscape and Future Prospects. Clinical Drug Investigation, 2019, 39, 341-353.	1.1	28
5154	Advances in immune checkpoint inhibitors for bone sarcoma therapy. Journal of Bone Oncology, 2019, 15, 100221.	1.0	122

#	ARTICLE	IF	CITATIONS
5155	Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 990-997.	0.6	130
5156	Turning the corner on therapeutic cancer vaccines. <i>Npj Vaccines</i> , 2019, 4, 7.	2.9	490
5157	Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts. , 2019, 7, 37.		123
5158	Accumulation of exhausted CD8+ T cells in extramammary Paget's disease. <i>PLoS ONE</i> , 2019, 14, e0211135.	1.1	12
5159	Adjuvant Ipilimumab in High-Risk Uveal Melanoma. <i>Cancers</i> , 2019, 11, 152.	1.7	27
5160	Efficacy of nivolumab as checkpoint inhibitor drug on survival rate of patients with relapsed/refractory classical Hodgkin lymphoma: a meta-analysis of prospective clinical study. <i>Clinical and Translational Oncology</i> , 2019, 21, 1093-1103.	1.2	7
5161	Prognostic impact of CD8 and programmed death-ligand 1 expression in patients with resectable non-small cell lung cancer. <i>British Journal of Cancer</i> , 2019, 120, 547-554.	2.9	42
5162	The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. <i>Nature Reviews Cancer</i> , 2019, 19, 133-150.	12.8	1,657
5163	Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. <i>Nature Medicine</i> , 2019, 25, 477-486.	15.2	932
5164	Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. <i>Nature Medicine</i> , 2019, 25, 462-469.	15.2	569
5165	Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?. , 2019, 7, 39.		14
5166	Immune Checkpoint Blockade Anti-PD-L1 as a Trigger for Autoimmune Polyendocrine Syndrome. <i>Journal of the Endocrine Society</i> , 2019, 3, 496-503.	0.1	50
5167	Cannabis Impacts Tumor Response Rate to Nivolumab in Patients with Advanced Malignancies. <i>Oncologist</i> , 2019, 24, 549-554.	1.9	105
5168	Immune checkpoint inhibitors in EGFR-mutation positive TKI-treated patients with advanced non-small-cell lung cancer network meta-analysis. <i>Oncotarget</i> , 2019, 10, 209-215.	0.8	33
5169	LAYN Is a Prognostic Biomarker and Correlated With Immune Infiltrates in Gastric and Colon Cancers. <i>Frontiers in Immunology</i> , 2019, 10, 6.	2.2	280
5170	Analysis of Pleiotropic Effects of Nivolumab in Pretreated Advanced or Recurrent Non-small Cell Lung Cancer Cases. <i>In Vivo</i> , 2019, 33, 507-514.	0.6	8
5171	The Coincidence Between Increasing Age, Immunosuppression, and the Incidence of Patients With Glioblastoma. <i>Frontiers in Pharmacology</i> , 2019, 10, 200.	1.6	82
5172	Inhibition of the adenosinergic pathway: the indispensable part of oncological therapy in the future. <i>Purinergic Signalling</i> , 2019, 15, 53-67.	1.1	10

#	ARTICLE	IF	CITATIONS
5173	Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non-small cell lung cancer patients. <i>Thoracic Cancer</i> , 2019, 10, 775-781.	0.8	64
5174	Conventional transbronchial needle aspiration is promising for identifying EGFR mutations in lung adenocarcinoma. <i>Thoracic Cancer</i> , 2019, 10, 856-863.	0.8	1
5175	Successful Treatment of Nivolumab-related Cholangitis with Prednisolone: A Case Report and Review of the Literature. <i>Internal Medicine</i> , 2019, 58, 1747-1752.	0.3	23
5176	T-cell exhaustion correlates with improved outcomes in kidney transplant recipients. <i>Kidney International</i> , 2019, 96, 436-449.	2.6	49
5177	Cancer associated fibroblasts sculpt tumour microenvironment by recruiting monocytes and inducing immunosuppressive PD-1+ TAMs. <i>Scientific Reports</i> , 2019, 9, 3172.	1.6	178
5178	Human NK cells: surface receptors, inhibitory checkpoints, and translational applications. <i>Cellular and Molecular Immunology</i> , 2019, 16, 430-441.	4.8	327
5179	Cancer immunotherapies repurposed for use in autoimmunity. <i>Nature Biomedical Engineering</i> , 2019, 3, 259-263.	11.6	28
5180	Talimogene laherparepvec (TÂ€•<sc>VEC</sc>) in advanced melanoma: complete response in a heart and kidney transplant patient. A case report. <i>British Journal of Dermatology</i> , 2019, 181, 186-189.	1.4	19
5181	Atypical patterns of response to immune checkpoint inhibitors: interpreting pseudoprogression and hyperprogression in decision making for patientsâ€™ treatment. <i>Journal of Thoracic Disease</i> , 2019, 11, 35-38.	0.6	28
5182	Molecular markers and prediction of response to immunotherapy in non-small cell lung cancer, an update. <i>Journal of Thoracic Disease</i> , 2019, 11, S25-S36.	0.6	51
5183	<p>Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients</p>. <i>Therapeutics and Clinical Risk Management</i> , 2019, Volume 15, 211-221.	0.9	42
5184	Dendritic Cell Regulation of Graft-Vs.-Host Disease: Immunostimulation and Tolerance. <i>Frontiers in Immunology</i> , 2019, 10, 93.	2.2	41
5185	Nonâ€™Thermal Plasma as a Unique Delivery System of Shortâ€™Lived Reactive Oxygen and Nitrogen Species for Immunogenic Cell Death in Melanoma Cells. <i>Advanced Science</i> , 2019, 6, 1802062.	5.6	177
5186	The Role of Angiogenesis Inhibitors in the Era of Immune Checkpoint Inhibitors and Targeted Therapy in Metastatic Non-Small Cell Lung Cancer. <i>Current Treatment Options in Oncology</i> , 2019, 20, 21.	1.3	27
5187	Curative effect assessment of immunotherapy for non-small cell lung cancer: The â€™ceblind areaâ€™ of Immune Response Evaluation Criteria in Solid Tumors (IRECIST). <i>Thoracic Cancer</i> , 2019, 10, 587-592.	0.8	14
5188	Acute Interstitial Nephritis in a Patient with Non-Small Cell Lung Cancer under Immunotherapy with Nivolumab. <i>Case Reports in Nephrology</i> , 2019, 2019, 1-5.	0.2	8
5189	Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 87.	3.5	213
5190	Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition. , 2019, 7, 49.		102

#	ARTICLE	IF	CITATIONS
5191	Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis. <i>Frontiers in Immunology</i> , 2019, 10, 108.	2.2	117
5192	Decidua Basalis Mesenchymal Stem Cells Favor Inflammatory M1 Macrophage Differentiation In Vitro. <i>Cells</i> , 2019, 8, 173.	1.8	17
5193	Immune Exhaustion: Past Lessons and New Insights from Lymphocytic Choriomeningitis Virus. <i>Viruses</i> , 2019, 11, 156.	1.5	32
5194	Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors. <i>American Journal of Hematology</i> , 2019, 94, 563-574.	2.0	51
5195	Stand by me(mory): Chronic infection diminishes memory pool via IL-6/STAT1. <i>Journal of Experimental Medicine</i> , 2019, 216, 474-475.	4.2	0
5196	The importance of the PD-1/PD-L1 pathway at the maternal-fetal interface. <i>BMC Pregnancy and Childbirth</i> , 2019, 19, 74.	0.9	58
5197	Radiochemotherapy combined with NK cell transfer followed by second-line PD-1 inhibition in a patient with NSCLC stage IIIb inducing long-term tumor control: a case study. <i>Strahlentherapie Und Onkologie</i> , 2019, 195, 352-361.	1.0	32
5198	Recent success and limitations of immune checkpoint inhibitors for cancer: a lesson from melanoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 474, 421-432.	1.4	45
5199	Advances in immunotherapy delivery from implantable and injectable biomaterials. <i>Acta Biomaterialia</i> , 2019, 88, 15-31.	4.1	127
5200	Immunohistochemical detection of PD-L1 among diverse human neoplasms in a reference laboratory: observations based upon 62,896 cases. <i>Modern Pathology</i> , 2019, 32, 929-942.	2.9	67
5201	Base excision repair regulates PD-L1 expression in cancer cells. <i>Oncogene</i> , 2019, 38, 4452-4466.	2.6	70
5202	Microsatellite Instability Occurs in a Subset of Follicular Thyroid Cancers. <i>Thyroid</i> , 2019, 29, 523-529.	2.4	31
5203	Immunotherapy for skin cancer. <i>International Immunology</i> , 2019, 31, 465-475.	1.8	47
5204	Human tumor-associated monocytes/macrophages and their regulation of T cell responses in early-stage lung cancer. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	169
5205	Immunotherapy in extensive small cell lung cancer. <i>Experimental Hematology and Oncology</i> , 2019, 8, 5.	2.0	32
5206	The Role of Molecular Profiling to Predict the Response to Immune Checkpoint Inhibitors in Lung Cancer. <i>Cancers</i> , 2019, 11, 201.	1.7	49
5207	NLRP3 inflammasome inactivation driven by miR-223-3p reduces tumor growth and increases anticancer immunity in breast cancer. <i>Molecular Medicine Reports</i> , 2019, 19, 2180-2188.	1.1	26
5208	Blockade of the programmed death ligand 1 (PD-L1) as potential therapy for anaplastic thyroid cancer. <i>Endocrine</i> , 2019, 64, 122-129.	1.1	39

#	ARTICLE	IF	CITATIONS
5209	Evaluation of a Novel Pb-203-Labeled Lactam-Cyclized Alpha-Melanocyte-Stimulating Hormone Peptide for Melanoma Targeting. <i>Molecular Pharmaceutics</i> , 2019, 16, 1694-1702.	2.3	26
5210	T cell co-stimulation and co-inhibition in cardiovascular disease: a double-edged sword. <i>Nature Reviews Cardiology</i> , 2019, 16, 325-343.	6.1	65
5211	Malignant pleural effusion as a predictor of the efficacy of anti-PD-L1 antibody in patients with non-small cell lung cancer. <i>Thoracic Cancer</i> , 2019, 10, 815-822.	0.8	20
5212	Blood tumor mutational burden: are we ready for clinical implementation?. <i>Journal of Thoracic Disease</i> , 2019, 11, S1906-S1908.	0.6	6
5213	The local immune landscape determines tumor PD-L1 heterogeneity and sensitivity to therapy. <i>Journal of Clinical Investigation</i> , 2019, 129, 3347-3360.	3.9	82
5214	Acute kidney injury in the patient with cancer. <i>Kidney Research and Clinical Practice</i> , 2019, 38, 295-308.	0.9	41
5215	Interobserver Reproducibility of PD-L1 Biomarker in Non-small Cell Lung Cancer: A Multi-Institutional Study by 27 Pathologists. <i>Journal of Pathology and Translational Medicine</i> , 2019, 53, 347-353.	0.4	24
5216	Unique pathological findings of lung adenocarcinoma after unexpected nivolumab treatment, possible different effects on the primary lesion and metastatic lymph nodes: case report. <i>AME Case Reports</i> , 2019, 3, 45-45.	0.2	1
5217	Elderly patients and PD-L1-positive advanced non-small cell lung cancer: is pembrolizumab monotherapy effective and safe?. <i>Annals of Translational Medicine</i> , 2019, 7, S282-S282.	0.7	4
5218	Broad-based genomic sequencing in advanced non-small cell lung cancer in the dock. <i>Translational Lung Cancer Research</i> , 2019, 8, S360-S363.	1.3	3
5219	Is first-line pembrolizumab appropriate for all patients with metastatic non-squamous histology non-small cell lung cancer patients?. <i>Translational Lung Cancer Research</i> , 2019, 8, S327-S330.	1.3	3
5220	Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?. <i>Oncologist</i> , 2019, 24, 1469-1478.	1.9	25
5221	Targeted next-generation sequencing to assess tumor mutation burden: ready for prime-time in non-small cell lung cancer?. <i>Translational Lung Cancer Research</i> , 2019, 8, S323-S326.	1.3	6
5222	Spontaneous Regression of Recurrent Undifferentiated Carcinoma of the Endometrium. <i>Internal Medicine</i> , 2019, 58, 1649-1653.	0.3	3
5223	The Current and Evolving Landscape of First-Line Treatments for Advanced Renal Cell Carcinoma. <i>Oncologist</i> , 2019, 24, 338-348.	1.9	34
5224	Rapid Affinity Maturation of Novel Anti-PD-L1 Antibodies by a Fast Drop of the Antigen Concentration and FACS Selection of Yeast Libraries. <i>BioMed Research International</i> , 2019, 2019, 1-22.	0.9	9
5225	Clinical Features of Liver Injury Induced by Immune Checkpoint Inhibitors in Japanese Patients. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2019, 2019, 1-12.	0.8	43
5226	Evaluation of the lung immune prognostic index in advanced non-small cell lung cancer patients under nivolumab monotherapy. <i>Translational Lung Cancer Research</i> , 2019, 8, 1078-1085.	1.3	34

#	ARTICLE	IF	CITATIONS
5227	Cancer immunotherapy experience in the Integral Oncology Centre "Diana Laura Riojas de Colosio", Mdica Sur Hospital. <i>Wspolczesna Onkologia</i> , 2019, 23, 239-246.	0.7	0
5228	Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors. <i>Oncologist</i> , 2019, 24, 1128-1136.	1.9	156
5229	Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy. <i>Oncologist</i> , 2019, 24, 1259-1269.	1.9	127
5230	Thoracic Radiotherapy Benefits Elderly Extensive-Stage Small Cell Lung Cancer Patients with Distant Metastasis. <i>Cancer Management and Research</i> , 2019, Volume 11, 10767-10775.	0.9	5
5231	PD-1 Inhibitors in the Advanced Esophageal Cancer. <i>Frontiers in Pharmacology</i> , 2019, 10, 1418.	1.6	22
5232	Knockdown of PTGS2 by CRISPR/CAS9 System Designates a New Potential Gene Target for Melanoma Treatment. <i>Frontiers in Pharmacology</i> , 2019, 10, 1456.	1.6	16
5233	T-Regulatory Cells In Tumor Progression And Therapy. <i>Cancer Management and Research</i> , 2019, Volume 11, 10731-10747.	0.9	57
5234	Current and Future Treatment Strategies for Rhabdomyosarcoma. <i>Frontiers in Oncology</i> , 2019, 9, 1458.	1.3	100
5235	Real-World Outcomes of Patients with Metastatic Non-Small Cell Lung Cancer Treated with Programmed Cell Death Protein 1 Inhibitors in the Year Following U.S. Regulatory Approval. <i>Oncologist</i> , 2019, 24, 648-656.	1.9	60
5236	Immune checkpoints inhibitors rechallenge in non-small-cell lung cancer: different scenarios with different solutions?. <i>Lung Cancer Management</i> , 2019, 8, LMT18.	1.5	17
5237	Toxicity of tumor immune checkpoint inhibitors"more attention should be paid. <i>Translational Lung Cancer Research</i> , 2019, 8, 1125-1133.	1.3	7
5238	Variation of Programmed Death Ligand 1 Expression After Platinum-based Neoadjuvant Chemotherapy in Lung Cancer. <i>Journal of Immunotherapy</i> , 2019, 42, 215-220.	1.2	47
5239	Managing Pulmonary Toxicities Associated with Immunotherapy: A Case Discussion. <i>Oncologist</i> , 2019, 24, 730-734.	1.9	9
5240	Upfront Surgical Resection of Melanoma Brain Metastases Provides a Bridge Toward Immunotherapy-Mediated Systemic Control. <i>Oncologist</i> , 2019, 24, 671-679.	1.9	36
5241	Somatic genetic aberrations in gallbladder cancer: comparison between Chinese and US patients. <i>Hepatobiliary Surgery and Nutrition</i> , 2019, 8, 604-614.	0.7	34
5242	MYD88 L265P mutation and CDKN2A loss are early mutational events in primary central nervous system diffuse large B-cell lymphomas. <i>Blood Advances</i> , 2019, 3, 375-383.	2.5	77
5243	The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4- positive T-cells that are PD-1-negative. <i>Blood</i> , 2019, 134, 2059-2069.	0.6	66
5244	Ex vivo lung cancer spheroids resemble treatment response of a patient with NSCLC to chemotherapy and immunotherapy: case report and translational study. <i>ESMO Open</i> , 2019, 4, e000536.	2.0	26

#	ARTICLE	IF	CITATIONS
5245	Epigenomic Profiling Discovers Trans-lineage SOX2 Partnerships Driving Tumor Heterogeneity in Lung Squamous Cell Carcinoma. <i>Cancer Research</i> , 2019, 79, 6084-6100.	0.4	24
5246	Interdisciplinary multimodality management of stage III nonsmall cell lung cancer. <i>European Respiratory Review</i> , 2019, 28, 190024.	3.0	47
5247	The role of the gut microbiome on the efficacy of immune checkpoint inhibitors in Japanese responder patients with advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2019, 8, 847-853.	1.3	52
5248	Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population. <i>Oncologist</i> , 2019, 24, e1165-e1171.	1.9	35
5249	Characterization of Comorbidities Limiting the Recruitment of Patients in Early Phase Clinical Trials. <i>Oncologist</i> , 2019, 24, 96-102.	1.9	35
5250	Balancing the Hype with Reality: What Do Patients with Advanced Melanoma Consider When Making the Decision to Have Immunotherapy?. <i>Oncologist</i> , 2019, 24, e1190-e1196.	1.9	24
5251	Inter-tumor heterogeneity of PD-L1 expression in non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2019, 11, 4982-4991.	0.6	33
5252	KEYNOTE-042 rolls back programmed cell death ligand 1 threshold for non-small cell lung cancer pembrolizumab monotherapy without new insight into those deriving benefit. <i>Translational Lung Cancer Research</i> , 2019, 8, S403-S406.	1.3	2
5253	Impact of pre-therapy glioblastoma multiforme microenvironment on clinical response to autologous CMV-specific T cell therapy. <i>Clinical and Translational Immunology</i> , 2019, 8, e01088.	1.7	10
5254	EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression. <i>Molecular Cancer</i> , 2019, 18, 165.	7.9	160
5255	Retrospective Evaluation of Lung Adenocarcinoma Patients Progressing on 1st Line Chemotherapy. <i>Medicina (Lithuania)</i> , 2019, 55, 743.	0.8	1
5256	Management of V600E and V600K BRAF-Mutant Melanoma. <i>Current Treatment Options in Oncology</i> , 2019, 20, 81.	1.3	28
5257	Immunotherapy in EGFR mutant non-small cell lung cancer: when, who and how?. <i>Translational Lung Cancer Research</i> , 2019, 8, 710-714.	1.3	11
5258	Paraneoplastic Pemphigus Revealed by Anti-programmed Death-1 Pembrolizumab Therapy for Cutaneous Squamous Cell Carcinoma Complicating Hidradenitis Suppurativa. <i>Frontiers in Medicine</i> , 2019, 6, 249.	1.2	18
5259	Nanotopography-based lymphatic delivery for improved anti-tumor responses to checkpoint blockade immunotherapy. <i>Theranostics</i> , 2019, 9, 8332-8343.	4.6	31
5260	Impaired B cell tolerance checkpoints promote the development of autoimmune diseases and pathogenic autoantibodies. <i>Immunological Reviews</i> , 2019, 292, 90-101.	2.8	86
5261	The effect of antibiotics on the clinical outcomes of patients with solid cancers undergoing immune checkpoint inhibitor treatment: a retrospective study. <i>BMC Cancer</i> , 2019, 19, 1100.	1.1	40
5262	Neoadjuvant treatment with tyrosine kinase inhibitors in patients with resectable non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2019, 11, 4092-4095.	0.6	5

#	ARTICLE	IF	CITATIONS
5263	KEYNOTE-021 cohorts D and H suggest modest benefit in combining ipilimumab with pembrolizumab in second-line or later advanced non-small cell lung cancer treatment. <i>Translational Lung Cancer Research</i> , 2019, 8, 706-709.	1.3	5
5264	Immune checkpoint inhibitors win the 2018 Nobel Prize. <i>Biomedical Journal</i> , 2019, 42, 299-306.	1.4	62
5265	KEYNOTE-042: is lowering the PD-L1 threshold for first-line pembrolizumab monotherapy a good idea?. <i>Translational Lung Cancer Research</i> , 2019, 8, 723-727.	1.3	4
5266	Immunization With the CSF-470 Vaccine Plus BCG and rhGM-CSF Induced in a Cutaneous Melanoma Patient a TCR β Repertoire Found at Vaccination Site and Tumor Infiltrating Lymphocytes That Persisted in Blood. <i>Frontiers in Immunology</i> , 2019, 10, 2213.	2.2	9
5267	Induction of Tolerance and Immunity by Dendritic Cells: Mechanisms and Clinical Applications. <i>Frontiers in Immunology</i> , 2019, 10, 2393.	2.2	92
5268	Immune checkpoint inhibitor-associated gastrointestinal and hepatic adverse events and their management. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481988419.	1.4	62
5269	Immunotherapy of Hepatocellular Carcinoma with Magnetic PD-1 Peptide-Imprinted Polymer Nanocomposite and Natural Killer Cells. <i>Biomolecules</i> , 2019, 9, 651.	1.8	17
5270	Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2019, 11, 1798.	1.7	99
5271	Melanoma and Vitiligo: In Good Company. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5731.	1.8	40
5272	Interleukin-18 Is a Prognostic Biomarker Correlated with CD8+ T Cell and Natural Killer Cell Infiltration in Skin Cutaneous Melanoma. <i>Journal of Clinical Medicine</i> , 2019, 8, 1993.	1.0	31
5273	Atezolizumab First-Line Combination Therapy: A Review in Metastatic Nonsquamous NSCLC. <i>Targeted Oncology</i> , 2019, 14, 759-768.	1.7	21
5274	Dendritic Cell-Activating Magnetic Nanoparticles Enable Early Prediction of Antitumor Response with Magnetic Resonance Imaging. <i>ACS Nano</i> , 2019, 13, 13884-13898.	7.3	66
5275	Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NF κ B ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN). <i>Trials</i> , 2019, 20, 753.	0.7	20
5276	Immunotherapy-induced endocrinopathies: assessment, management and monitoring. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2019, 10, 204201881989618.	1.4	29
5277	Classifying Stage IV Lung Cancer From Health Care Claims: A Comparison of Multiple Analytic Approaches. <i>JCO Clinical Cancer Informatics</i> , 2019, 3, 1-19.	1.0	8
5278	Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-12.	1.5	58
5279	Immune Checkpoint Inhibitor-Related Adverse Cardiovascular Events in Patients With Lung Cancer. <i>JACC: CardioOncology</i> , 2019, 1, 182-192.	1.7	47
5280	Odds ratio of programmed cell death-1 or ligand 1 inhibitor-related endocrine dysfunction in patients with lung cancer. <i>Medicine (United States)</i> , 2019, 98, e18310.	0.4	2

#	ARTICLE	IF	CITATIONS
5281	Long-term efficacy of afatinib in a patient with squamous cell carcinoma of the lung and multiple ERBB family aberrations. <i>Anti-Cancer Drugs</i> , 2019, 30, 873-878.	0.7	6
5282	Reliability of PD-L1 assays using small tissue samples compared with surgical specimens. <i>Medicine (United States)</i> , 2019, 98, e14972.	0.4	15
5283	Real-world experience with pembrolizumab in patients with advanced melanoma. <i>Medicine (United States)</i> , 2019, 98, e14972.	0.4	26
5284	Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection. <i>Journal of Clinical Oncology</i> , 2019, 37, 353.		91
5285	Humanized Mice as an Effective Evaluation System for Peptide Vaccines and Immune Checkpoint Inhibitors. <i>International Journal of Molecular Sciences</i> , 2019, 20, 6337.	1.8	23
5286	The past, present, and future of costimulation blockade in organ transplantation. <i>Current Opinion in Organ Transplantation</i> , 2019, 24, 391-401.	0.8	36
5287	Ramsay-Hunt syndrome and subsequent sensory neuropathy as potential immune-related adverse events of nivolumab: a case report. <i>BMC Cancer</i> , 2019, 19, 1220.	1.1	8
5288	High OX-40 expression in the tumor immune infiltrate is a favorable prognostic factor of overall survival in non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2019, 7, 351.		39
5289	The effect of PD-L1/PD-1 immunotherapy in the treatment of squamous non-small-cell lung cancer: a meta-analysis of randomized controlled clinical trials. <i>Journal of Thoracic Disease</i> , 2019, 11, 4453-4463.	0.6	5
5290	Maximum Somatic Allele Frequency in Combination With Blood-Based Tumor Mutational Burden to Predict the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer: A Pooled Analysis of the Randomized POPLAR and OAK Studies. <i>Frontiers in Oncology</i> , 2019, 9, 1432.	1.3	27
5291	An Exceptional Responder to Nivolumab in Metastatic Non-Small-Cell Lung Cancer: A Case Report and Literature Review of Long-Term Survivors. <i>Case Reports in Oncological Medicine</i> , 2019, 2019, 1-7.	0.2	3
5292	Phase I/II Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 6623-6632.	3.2	96
5293	Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 316.		102
5294	Blocking TGF- β Signaling To Enhance The Efficacy Of Immune Checkpoint Inhibitor. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 9527-9538.	1.0	93
5295	Is there an Exposure-Response Relationship for Nivolumab in Real-World NSCLC Patients?. <i>Cancers</i> , 2019, 11, 1784.	1.7	28
5296	Combination of PD-L1 expression and NLR as prognostic marker in patients with surgically resected non-small cell lung cancer. <i>Journal of Cancer</i> , 2019, 10, 6703-6710.	1.2	16
5297	Immune-Checkpoint Inhibitors as the First Line Treatment of Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials. <i>Journal of Cancer</i> , 2019, 10, 6261-6268.	1.2	22
5298	KIAA1211 plays an oncogenic role in human non-small cell lung cancer. <i>Journal of Cancer</i> , 2019, 10, 6747-6753.	1.2	5

#	ARTICLE	IF	CITATIONS
5299	Combination with Stereotactic Body Radiotherapy Offers a Promising Strategy to Overcome Resistance to Immunotherapy in Advanced Renal Cell Cancer. <i>Journal of Oncology</i> , 2019, 2019, 1-12.	0.6	17
5300	Beyond T Cells: Understanding the Role of PD-1/PD-L1 in Tumor-Associated Macrophages. <i>Journal of Immunology Research</i> , 2019, 2019, 1-7.	0.9	93
5301	Immune Checkpoint Inhibitor Induced Diabetes Mellitus Treated with Insulin and Metformin: Evolution of Diabetes Management in the Era of Immunotherapy. <i>Case Reports in Oncological Medicine</i> , 2019, 2019, 1-3.	0.2	9
5302	Immunotherapy response evaluation with magnetic resonance elastography (MRE) in advanced HCC. , 2019, 7, 329.		33
5303	Tumor PD-L1 Induction by Resveratrol/Piceatannol May Function as a Search, Enhance, and Engage (â€œSEEâ€) Signal to Facilitate the Elimination of â€œCold, Non-Responsiveâ€ Low PD-L1-Expressing Tumors by PD-L1 Blockade. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5969.	1.8	9
5304	High hopes and high honours for cancer immunotherapy. <i>Biomedical Journal</i> , 2019, 42, 293-298.	1.4	2
5305	Anti-programmed Death-1 Immunotherapy for Endometrial Cancer with Microsatellite Instabilityâ€“High Tumors. <i>Current Treatment Options in Oncology</i> , 2019, 20, 83.	1.3	11
5306	Immune-Mediated Colitis. <i>Current Treatment Options in Gastroenterology</i> , 2019, 17, 506-523.	0.3	6
5307	Is the game over for PD-1 inhibitors in EGFR mutant non-small cell lung cancer?. <i>Translational Lung Cancer Research</i> , 2019, 8, S339-S342.	1.3	13
5308	The Predictive Value of Tumor Mutation Burden on Efficacy of Immune Checkpoint Inhibitors in Cancers: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2019, 9, 1161.	1.3	96
5309	Racial Differences in Immunological Landscape Modifiers Contributing to Disparity in Prostate Cancer. <i>Cancers</i> , 2019, 11, 1857.	1.7	26
5310	Enhanced Therapeutic Efficacy of a Novel Oncolytic Herpes Simplex Virus Type 2 Encoding an Antibody Against Programmed Cell Death 1. <i>Molecular Therapy - Oncolytics</i> , 2019, 15, 201-213.	2.0	20
5311	Multiple nivolumab-induced CNS demyelination with spontaneous resolution in an asymptomatic metastatic melanoma patient. , 2019, 7, 336.		21
5312	Harnessing NK Cells for Cancer Treatment. <i>Frontiers in Immunology</i> , 2019, 10, 2836.	2.2	66
5313	Reprioritizing Risk and Benefit: The Future of Study Design in Earlyâ€Phase Cancer Research. <i>Ethics & Human Research</i> , 2019, 41, 2-11.	0.5	8
5314	KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591988554.	1.4	25
5315	Long-lasting responses after discontinuation of nivolumab treatment for reasons other than tumor progression in patients with previously treated, advanced non-small cell lung cancer. <i>Cancer Communications</i> , 2019, 39, 78.	3.7	19
5316	Immune checkpoint inhibitors in gastrointestinal malignancies: what can we learn from experience with other tumors?. <i>Translational Gastroenterology and Hepatology</i> , 2019, 4, 73-73.	1.5	4

#	ARTICLE	IF	CITATIONS
5317	Indirect comparison between immune checkpoint inhibitors and targeted therapies for the treatment of melanoma. <i>Journal of Cancer</i> , 2019, 10, 6114-6123.	1.2	3
5318	The Evolution of Adjuvant Therapy for Melanoma. <i>Current Oncology Reports</i> , 2019, 21, 106.	1.8	23
5319	Understanding and measuring human Bâ€cell tolerance and its breakdown in autoimmune disease. <i>Immunological Reviews</i> , 2019, 292, 76-89.	2.8	34
5320	Analysis of key clinical features for achieving complete remission in stage III and IV non-small cell lung cancer patients. <i>Respiratory Research</i> , 2019, 20, 263.	1.4	5
5321	Cancer biomarkers for targeted therapy. <i>Biomarker Research</i> , 2019, 7, 25.	2.8	72
5322	Antitumor Activity and Treatment-Related Toxicity Associated With Nivolumab Plus Ipilimumab in Advanced Malignancies: A Systematic Review and Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2019, 10, 1300.	1.6	12
5323	Differential impact of classical and non-canonical NF-ÎB pathway-related gene expression on the survival of breast cancer patients. <i>Journal of Cancer</i> , 2019, 10, 5191-5211.	1.2	11
5324	CD4⁺ and CD8a⁺ PET imaging predicts response to novel PD-1 checkpoint inhibitor: studies of Sym021 in syngeneic mouse cancer models. <i>Theranostics</i> , 2019, 9, 8221-8238.	4.6	59
5325	Can PD-L1 tumor proportion score be used as the key to unlocking the KEYNOTE studies of pembrolizumab in advanced lung cancer?. <i>Translational Lung Cancer Research</i> , 2019, 8, 715-722.	1.3	5
5326	Neurologic Immune-Related Adverse Events Associated with Immune Checkpoint Inhibition. <i>Current Oncology Reports</i> , 2019, 21, 108.	1.8	46
5327	Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer. <i>Mediators of Inflammation</i> , 2019, 2019, 1-10.	1.4	39
5328	Silencing Fc Domains in T cellâ€Engaging Bispecific Antibodies Improves T-cell Trafficking and Antitumor Potency. <i>Cancer Immunology Research</i> , 2019, 7, 2013-2024.	1.6	37
5329	Identification of recurrence marker associated with immune infiltration in prostate cancer with radical resection and build prognostic nomogram. <i>BMC Cancer</i> , 2019, 19, 1179.	1.1	45
5330	Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway. <i>Journal of Biomedical Science</i> , 2019, 26, 96.	2.6	26
5331	Role of the microbiome in occurrence, development and treatment of pancreatic cancer. <i>Molecular Cancer</i> , 2019, 18, 173.	7.9	67
5332	Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis. , 2019, 7, 341.		126
5333	Tumor microenvironment dictates regulatory T cell phenotype: Upregulated immune checkpoints reinforce suppressive function. , 2019, 7, 339.		65
5334	Clinical Correlates of Response to Anti-PD-1â€based Therapy in Patients With Metastatic Melanoma. <i>Journal of Immunotherapy</i> , 2019, 42, 221-227.	1.2	20

#	ARTICLE	IF	CITATIONS
5335	Immunotargeted therapy in melanoma: patient, provider preferences, and willingness to pay at an academic cancer center. <i>Melanoma Research</i> , 2019, 29, 626-634.	0.6	15
5336	Role of programmed cell death ligand-1 expression on prognostic and overall survival of breast cancer. <i>Medicine (United States)</i> , 2019, 98, e15201.	0.4	28
5337	Evaluating the tumor biology of lung adenocarcinoma: A multimodal analysis. <i>Medicine (United States)</i> , 2019, 98, e15201.	0.4	10
5338	The overall safety evaluation of programmed cell death/programmed cell death ligand 1 (PD-1/PD-L1) treatment for lung cancer patients. <i>Medicine (United States)</i> , 2019, 98, e16439.	0.4	1
5339	The usefulness of stereotactic radiosurgery for recursive partitioning analysis class II/III lung cancer patients with brain metastases in the modern treatment era. <i>Medicine (United States)</i> , 2019, 98, e17390.	0.4	1
5340	Correlation between PD-L1 expression and clinicopathological characteristics of non-small cell lung cancer: A real-world study of a large Chinese cohort. <i>Journal of Thoracic Disease</i> , 2019, 11, 4591-4601.	0.6	35
5341	Biomarker for personalized immunotherapy. <i>Translational Lung Cancer Research</i> , 2019, 8, S308-S317.	1.3	7
5342	Immunotherapy in metastatic melanoma: a novel scenario of new toxicities and their management. <i>Melanoma Management</i> , 2019, 6, MMT30.	0.1	19
5343	Treatment patterns of melanoma by <i>BRAF</i> mutation status in the USA from 2011 to 2017: a retrospective cohort study. <i>Melanoma Management</i> , 2019, 6, MMT31.	0.1	3
5344	Role of Tumor-Mediated Dendritic Cell Tolerization in Immune Evasion. <i>Frontiers in Immunology</i> , 2019, 10, 2876.	2.2	60
5345	New Frontiers for Molecular Pathology. <i>Frontiers in Medicine</i> , 2019, 6, 284.	1.2	21
5346	The Role of Long Non-coding RNAs in Immunotherapy Resistance. <i>Frontiers in Oncology</i> , 2019, 9, 1292.	1.3	45
5347	Isolation and Identification of Cancer Stem-Like Cells in Adenocarcinoma and Squamous Cell Carcinoma of the Lung: A Pilot Study. <i>Frontiers in Oncology</i> , 2019, 9, 1394.	1.3	35
5348	Immune Checkpoint Inhibitor-Associated Cardiotoxicity: Current Understanding on Its Mechanism, Diagnosis and Management. <i>Frontiers in Pharmacology</i> , 2019, 10, 1350.	1.6	75
5349	A Review of Key Biological and Molecular Events Underpinning Transformation of Melanocytes to Primary and Metastatic Melanoma. <i>Cancers</i> , 2019, 11, 2041.	1.7	17
5350	Evolving management of positive regional lymph nodes in melanoma: Past, present and future directions. <i>Oncology Reviews</i> , 2019, 13, 433.	0.8	9
5351	MicroRNAs in non-small cell lung cancer: Gene regulation, impact on cancer cellular processes, and therapeutic potential. <i>Pharmacology Research and Perspectives</i> , 2019, 7, e00528.	1.1	58
5352	A case of sustained ventricular tachycardia due to pembrolizumab. <i>HeartRhythm Case Reports</i> , 2019, 5, 570-572.	0.2	0

#	ARTICLE	IF	CITATIONS
5353	Combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab causing acute-onset type 1 diabetes mellitus following a single administration: two case reports. <i>BMC Endocrine Disorders</i> , 2019, 19, 144.	0.9	24
5354	Rapid Progression of Tracheoesophageal Fistula Caused by Immunotherapy Administered after Tracheal Stent Placement. <i>Biomedicine Hub</i> , 2019, 4, 1-5.	0.4	4
5355	Scientific Rationale for Combination Immunotherapy of Hepatocellular Carcinoma with Anti-PD-1/PD-L1 and Anti-CTLA-4 Antibodies. <i>Liver Cancer</i> , 2019, 8, 413-426.	4.2	40
5356	An update on adjuvant systemic therapies in melanoma. <i>Melanoma Management</i> , 2019, 6, MMT28.	0.1	10
5357	Metabolic Remodelling: An Accomplice for New Therapeutic Strategies to Fight Lung Cancer. <i>Antioxidants</i> , 2019, 8, 603.	2.2	12
5358	Hypophysitis induced by immune checkpoint inhibitors: a 10-year assessment. <i>Expert Review of Endocrinology and Metabolism</i> , 2019, 14, 381-398.	1.2	54
5359	Postoperative adjuvant therapy for resectable esophageal cancer. <i>Medicine (United States)</i> , 2019, 98, e15485.	0.4	6
5360	Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer. <i>European Respiratory Review</i> , 2019, 28, 190058.	3.0	73
5361	A systematic analysis of immune genes and overall survival in cancer patients. <i>BMC Cancer</i> , 2019, 19, 1225.	1.1	30
5362	Immune biomarkers in thymic epithelial tumors: expression patterns, prognostic value and comparison of diagnostic tests for PD-L1. <i>Biomarker Research</i> , 2019, 7, 28.	2.8	22
5363	Recruitment of CD103 ⁺ dendritic cells via tumor-targeted chemokine delivery enhances efficacy of checkpoint inhibitor immunotherapy. <i>Science Advances</i> , 2019, 5, eaay1357.	4.7	87
5364	Current Clinical Progress of PD-1/PD-L1 Immunotherapy and Potential Combination Treatment in Non-Small Cell Lung Cancer. <i>Integrative Cancer Therapies</i> , 2019, 18, 153473541989002.	0.8	33
5365	Pathology of immune-mediated tissue lesions following treatment with immune checkpoint inhibitors. <i>Rheumatology</i> , 2019, 58, vii17-vii28.	0.9	39
5366	The KEY to the end of the chemotherapy in advanced non-small cell lung cancer, or not yet?. <i>Translational Lung Cancer Research</i> , 2019, 8, 731-737.	1.3	1
5367	MHC-II neoantigens shape tumour immunity and response to immunotherapy. <i>Nature</i> , 2019, 574, 696-701.	13.7	563
5368	Multiplexed activation of endogenous genes by CRISPRa elicits potent antitumor immunity. <i>Nature Immunology</i> , 2019, 20, 1494-1505.	7.0	83
5369	Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups. <i>Nature Immunology</i> , 2019, 20, 1425-1434.	7.0	336
5370	Tumour flare reaction in cancer treatments. <i>Anti-Cancer Drugs</i> , 2019, 30, 953-958.	0.7	17

#	ARTICLE	IF	CITATIONS
5371	Biomarkers, measured during therapy, for response of melanoma patients to immune checkpoint inhibitors: a systematic review. <i>Melanoma Research</i> , 2019, 29, 453-464.	0.6	26
5372	Real-world treatment patterns and clinical outcomes among patients with advanced melanoma. <i>Medicine (United States)</i> , 2019, 98, e16328.	0.4	30
5373	Prediction of response to immune checkpoint inhibitor therapy using 18F-FDG PET/CT in patients with melanoma. <i>Medicine (United States)</i> , 2019, 98, e16417.	0.4	28
5374	Significant response to anti-PD-1 based immunotherapy plus lenvatinib for recurrent intrahepatic cholangiocarcinoma with bone metastasis. <i>Medicine (United States)</i> , 2019, 98, e17832.	0.4	37
5375	Enforcing the checkpoints. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2019, 26, 213-218.	1.2	25
5376	A Celiac Disease Phenotype After Checkpoint Inhibitor Exposure: An Example of Immune Dysregulation After Immunotherapy. <i>ACG Case Reports Journal</i> , 2019, 6, e00158.	0.2	12
5377	<p>Primary Pulmonary Lymphoepithelioma-Like Carcinoma Response Favorably To Nivolumab: A Case Report</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 8595-8600.	1.0	23
5378	Acute Kidney Injury with Immune Checkpoint Inhibitors. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 1679-1681.	2.2	4
5379	Multiple Targets of the Canonical WNT/β-Catenin Signaling in Cancers. <i>Frontiers in Oncology</i> , 2019, 9, 1248.	1.3	135
5380	Switching to Immune Checkpoint Inhibitors upon Response to Targeted Therapy; The Road to Long-Term Survival in Advanced Melanoma Patients with Highly Elevated Serum LDH?. <i>Cancers</i> , 2019, 11, 1940.	1.7	29
5381	Enhancing the abscopal effect of radiation and immune checkpoint inhibitor therapies with magnetic nanoparticle hyperthermia in a model of metastatic breast cancer. <i>International Journal of Hyperthermia</i> , 2019, 36, 47-63.	1.1	35
5382	Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy. <i>Rheumatology</i> , 2019, 58, vii68-vii74.	0.9	31
5383	Impact of initial stage on metastatic melanoma survival. <i>Melanoma Research</i> , 2019, 29, 281-288.	0.6	12
5384	Integrative cancer treatment may have a survival benefit in patients with lung cancer. <i>Medicine (United States)</i> , 2019, 98, e16048.	0.4	7
5385	Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association Canadienne Des Pathologistes (CAP-ACP). <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2019, 27, 699-714.	0.6	36
5386	DHA-SBT-1214 Taxoid Nanoemulsion and Anti-“PD-L1 Antibody Combination Therapy Enhances Antitumor Efficacy in a Syngeneic Pancreatic Adenocarcinoma Model. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1961-1972.	1.9	14
5387	<p>Pseudo-Progression and the Neutrophil-to-Lymphocyte Ratio in Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors: A Case-“Control Study</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 10559-10568.	1.0	15
5388	Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers. <i>Cancers</i> , 2019, 11, 1926.	1.7	27

#	ARTICLE	IF	CITATIONS
5389	Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy. <i>Rheumatology</i> , 2019, 58, vii40-vii48.	0.9	49
5390	Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors. <i>Rheumatology</i> , 2019, 58, vii59-vii67.	0.9	137
5391	Management of rheumatic complications of ICI therapy: a rheumatology viewpoint. <i>Rheumatology</i> , 2019, 58, vii49-vii58.	0.9	24
5392	Toxicities associated with checkpoint inhibitors—an overview. <i>Rheumatology</i> , 2019, 58, vii7-vii16.	0.9	80
5393	<p><p>>Approaches to Tumor Classification in Pulmonary Sarcomatoid Carcinoma</p></p>. Lung Cancer: Targets and Therapy, 2019, Volume 10, 131-149.	1.3	31
5394	<p>A Molecular Epidemiological Analysis Of Programmed Cell Death Ligand-1 (PD-L1) Protein Expression, Mutations And Survival In Non-Small Cell Lung Cancer</p>. Cancer Management and Research, 2019, Volume 11, 9469-9481.	0.9	1
5395	EPSILoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation Cohort. <i>Cancers</i> , 2019, 11, 1954.	1.7	57
5396	Metastatic Colorectal Cancer: Therapeutic Options for Treating Refractory Disease. <i>Current Oncology</i> , 2019, 26, 24-32.	0.9	11
5397	Setting the scene — a future “epidemic” of immune-related adverse events in association with checkpoint inhibitor therapy. <i>Rheumatology</i> , 2019, 58, vii1-vii6.	0.9	3
5398	Management of rheumatic complications of immune checkpoint inhibitor therapy — an oncological perspective. <i>Rheumatology</i> , 2019, 58, vii29-vii39.	0.9	22
5399	Immunotherapies for pediatric cancer: current landscape and future perspectives. <i>Cancer and Metastasis Reviews</i> , 2019, 38, 573-594.	2.7	20
5400	Acute kidney injury in interstitial nephritis. <i>Current Opinion in Critical Care</i> , 2019, 25, 558-564.	1.6	19
5401	Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies. , 2019, 7, 343.		56
5402	Cholestatic Liver Injury Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma. <i>Internal Medicine</i> , 2019, 58, 3283-3287.	0.3	17
5403	Safe Transition to Pembrolizumab following Ipilimumab-Induced Guillain-Barré Syndrome: A Case Report and Review of the Literature. <i>Case Reports in Oncological Medicine</i> , 2019, 2019, 1-5.	0.2	6
5404	Long Non-Coding RNA in Drug Resistance of Non-Small Cell Lung Cancer: A Mini Review. <i>Frontiers in Pharmacology</i> , 2019, 10, 1457.	1.6	20
5405	<p><p>>Conformance Assessment of PD-L1 Expression Between Primary Tumour and Nodal Metastases in Non-Small-Cell Lung Cancer</p></p>. OncoTargets and Therapy, 2019, Volume 12, 11541-11547.	1.0	13
5406	Impact of the Gut Microbiome on Immune Checkpoint Inhibitor Efficacy—A Systematic Review. <i>Current Oncology</i> , 2019, 26, 395-403.	0.9	44

#	ARTICLE	IF	CITATIONS
5407	Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature. <i>Oncologist</i> , 2019, 24, 435-443.	1.9	80
5408	Current Treatment Options in Gastroenteropancreatic Neuroendocrine Carcinoma. <i>Oncologist</i> , 2019, 24, 1076-1088.	1.9	18
5409	Immune Checkpoint Inhibitors and the Risk of Allograft Rejection: A Comprehensive Analysis on an Emerging Issue. <i>Oncologist</i> , 2019, 24, 394-401.	1.9	48
5410	Pulmonary function is implicated in the prognosis of metastatic non-small cell lung cancer but not in extended disease small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2019, 11, 4562-4572.	0.6	12
5411	Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Renal Toxicity: Illustrative Case and Review. <i>Oncologist</i> , 2019, 24, 735-742.	1.9	43
5412	An Accurate and Comprehensive Clinical Sequencing Assay for Cancer Targeted and Immunotherapies. <i>Oncologist</i> , 2019, 24, e1294-e1302.	1.9	67
5413	Significance of re-biopsy of histological tumor samples in advanced non-small-cell lung cancer in clinical practice. <i>International Journal of Clinical Oncology</i> , 2019, 24, 41-45.	1.0	5
5414	Predicting marker for early progression in unresectable melanoma treated with nivolumab. <i>International Journal of Clinical Oncology</i> , 2019, 24, 323-327.	1.0	17
5415	Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer. <i>Oncogene</i> , 2019, 38, 656-670.	2.6	140
5416	Bad company: Microenvironmentally mediated resistance to targeted therapy in melanoma. <i>Pigment Cell and Melanoma Research</i> , 2019, 32, 237-247.	1.5	35
5417	JAK2, PD-L1, and PD-L2 (9p24.1) amplification in metastatic mucosal and cutaneous melanomas with durable response to immunotherapy. <i>Human Pathology</i> , 2019, 88, 87-91.	1.1	20
5418	<scp>VSIG</scp> as a ligand of <scp>VISTA</scp> inhibits human T cell function. <i>Immunology</i> , 2019, 156, 74-85.	2.0	171
5419	Principles of adoptive T cell therapy in cancer. <i>Seminars in Immunopathology</i> , 2019, 41, 49-58.	2.8	141
5420	Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade. <i>Neurosurgery</i> , 2019, 84, 945-953.	0.6	24
5421	A multicentre observational study of the effectiveness, safety and economic impact of nivolumab on non-small-cell lung cancer in real clinical practice. <i>International Journal of Clinical Pharmacy</i> , 2019, 41, 272-279.	1.0	22
5422	Combined γ -programmed death-1 monoclonal antibody blockade and fractionated radiation therapy reduces tumor growth in mouse EL4 lymphoma. <i>Cancer Biology and Therapy</i> , 2019, 20, 666-679.	1.5	6
5423	Dynamic metrics-based biomarkers to predict responders to anti-PD-1 immunotherapy. <i>British Journal of Cancer</i> , 2019, 120, 346-355.	2.9	16
5424	Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2019, 5, 376.	3.4	235

#	ARTICLE	IF	CITATIONS
5425	Neutrophil-to-Lymphocyte Ratio Predicts Survival After Whole-brain Radiotherapy in Non-small Cell Lung Cancer. <i>In Vivo</i> , 2019, 33, 195-201.	0.6	16
5426	Association of Patient Sex With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers. <i>JAMA Oncology</i> , 2019, 5, 529.	3.4	192
5427	Autoimmunity and Cancer, the Paradox Comorbidities Challenging Therapy in the Context of Preexisting Autoimmunity. <i>Journal of Interferon and Cytokine Research</i> , 2019, 39, 72-84.	0.5	31
5428	Ushering in Integrated T Cell Repertoire Profiling in Cancer. <i>Trends in Cancer</i> , 2019, 5, 85-94.	3.8	19
5429	Krüppel like factor 6 splice variant 1 (KLF6-SV1) overexpression recruits macrophages to participate in lung cancer metastasis by up-regulating TWIST1. <i>Cancer Biology and Therapy</i> , 2019, 20, 680-691.	1.5	13
5430	Prognostic Value of Red Blood Cell Distribution Width in Non-small Cell Lung Cancer Treated With Anti-programmed Cell Death-1 Antibody. <i>In Vivo</i> , 2019, 33, 213-220.	0.6	15
5431	PDL1 Fusion Protein Protects Against Experimental Cerebral Malaria via Repressing Over-Reactive CD8+ T Cell Responses. <i>Frontiers in Immunology</i> , 2019, 9, 3157.	2.2	11
5432	NK Cell-Based Immunotherapy in Cancer Metastasis. <i>Cancers</i> , 2019, 11, 29.	1.7	82
5433	Pembrolizumab-induced pneumonitis with a perilymphatic nodular pattern in a lung cancer patient: A radio-pathologic correlation. <i>Respiratory Medicine Case Reports</i> , 2019, 26, 168-170.	0.2	8
5434	Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus. <i>JAMA Oncology</i> , 2019, 5, 546.	3.4	366
5435	Benefit of ablative versus palliative-only radiotherapy in combination with nivolumab in patients affected by metastatic kidney and lung cancer. <i>Clinical and Translational Oncology</i> , 2019, 21, 933-938.	1.2	19
5436	Tumor regression after combination of radiation and PD-1 antibody nivolumab treatment in a patient with metastatic mediastinal leiomyosarcoma: a case report. <i>Cancer Biology and Therapy</i> , 2019, 20, 408-412.	1.5	7
5437	Nondestructive, multiplex three-dimensional mapping of immune infiltrates in core needle biopsy. <i>Laboratory Investigation</i> , 2019, 99, 1400-1413.	1.7	18
5438	T cell-inflamed phenotype and increased Foxp3 expression in infiltrating T-cells of mismatch-repair deficient endometrial cancers. <i>Modern Pathology</i> , 2019, 32, 576-584.	2.9	29
5439	Novel Cancer Therapeutics in Geriatrics: What is Unique to the Aging Patient?. <i>Drugs and Aging</i> , 2019, 36, 1-11.	1.3	10
5440	Product review: avelumab, an anti-PD-L1 antibody. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 891-908.	1.4	50
5441	PD-L1 expression in ROS1-rearranged non-small cell lung cancer: A study using simultaneous genotypic screening of EGFR, ALK, and ROS1. <i>Thoracic Cancer</i> , 2019, 10, 103-110.	0.8	36
5442	Teaching an old dog new tricks: next-generation CAR T cells. <i>British Journal of Cancer</i> , 2019, 120, 26-37.	2.9	240

#	ARTICLE	IF	CITATIONS
5443	Monocytes show immunoregulatory capacity on CD4+ T cells in a human in-vitro model of extracorporeal photopheresis. <i>Clinical and Experimental Immunology</i> , 2019, 195, 369-380.	1.1	8
5444	¹⁸ F-FDG PET/CT for Monitoring of Ipilimumab Therapy in Patients with Metastatic Melanoma. <i>Journal of Nuclear Medicine</i> , 2019, 60, 335-341.	2.8	123
5445	Class II MHC antigen processing in immune tolerance and inflammation. <i>Immunogenetics</i> , 2019, 71, 171-187.	1.2	77
5446	Intratumoral delivery of antigen with complement C3-bound liposomes reduces tumor growth in mice. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2019, 18, 326-335.	1.7	14
5447	SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018). <i>Clinical and Translational Oncology</i> , 2019, 21, 3-17.	1.2	110
5448	Cancer immunotherapy of patients with HIV infection. <i>Clinical and Translational Oncology</i> , 2019, 21, 713-720.	1.2	22
5449	Anti PD-1 immunotherapy related interstitial lung disease presenting as respiratory failure - A review with case series. <i>Respiratory Medicine Case Reports</i> , 2019, 26, 17-22.	0.2	21
5450	The requirement for immune infiltration and organization in the tumor microenvironment for successful immunotherapy in prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 543-555.	0.8	21
5451	Circulating miR-320a promotes immunosuppressive macrophages M2 phenotype associated with lung cancer risk. <i>International Journal of Cancer</i> , 2019, 144, 2746-2761.	2.3	56
5452	miR-146a Controls Immune Response in the Melanoma Microenvironment. <i>Cancer Research</i> , 2019, 79, 183-195.	0.4	69
5453	Nivolumab-induced Hypophysitis, Secondary Adrenal Insufficiency and Destructive Thyroiditis in a Patient with Lung Adenocarcinoma. <i>Internal Medicine</i> , 2019, 58, 693-697.	0.3	13
5454	Endocrine and metabolic adverse effects of immune checkpoint inhibitors: an overview (what) Tj ETQq1 1 0.784314 ggBT /Overlock 10 T	1.8	51
5455	Ablation of interferon regulatory factor 4 in T cells induces "memory" of transplant tolerance that is irreversible by immune checkpoint blockade. <i>American Journal of Transplantation</i> , 2019, 19, 884-893.	2.6	21
5456	Imaging of Cancer Immunotherapy: Current Approaches and Future Directions. <i>Radiology</i> , 2019, 290, 9-22.	3.6	147
5457	A novel role for programmed cell death receptor ligand 2 in sepsis-induced hepatic dysfunction. <i>American Journal of Physiology - Renal Physiology</i> , 2019, 316, G106-G114.	1.6	7
5458	Bicytopenia in Primary Lung Melanoma Treated with Nivolumab. <i>Internal Medicine</i> , 2019, 58, 827-831.	0.3	10
5459	Biological Consequences of MHC-II Expression by Tumor Cells in Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 2392-2402.	3.2	282
5460	Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant Melanoma. <i>Clinical Cancer Research</i> , 2019, 25, 1272-1279.	3.2	57

#	ARTICLE	IF	CITATIONS
5461	WNT/ β 2-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers. <i>Clinical Cancer Research</i> , 2019, 25, 3074-3083.	3.2	435
5462	Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes and Immunotherapy Outcome in Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2019, 25, 2442-2449.	3.2	106
5463	A CD40 Agonist and PD-1 Antagonist Antibody Reprogram the Microenvironment of Nonimmunogenic Tumors to Allow T-cell-Mediated Anticancer Activity. <i>Cancer Immunology Research</i> , 2019, 7, 428-442.	1.6	92
5464	Association of Tumor Microenvironment T-cell Repertoire and Mutational Load with Clinical Outcome after Sequential Checkpoint Blockade in Melanoma. <i>Cancer Immunology Research</i> , 2019, 7, 458-465.	1.6	43
5465	Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors. <i>BMC Cancer</i> , 2019, 19, 19.	1.1	66
5466	Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients. <i>Journal of Hematology and Oncology</i> , 2019, 12, 7.	6.9	113
5467	Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer. <i>Drug Safety</i> , 2019, 42, 281-294.	1.4	69
5468	Humanized anti-CD123 antibody facilitates NK cell antibody-dependent cell-mediated cytotoxicity (ADCC) of Hodgkin lymphoma targets via ARF6/PLD-1. <i>Blood Cancer Journal</i> , 2019, 9, 6.	2.8	13
5469	Nivolumab to pembrolizumab switch induced a durable melanoma response. <i>Medicine (United States)</i> , 2019, 98, e13804.	0.4	14
5470	Liver damage related to immune checkpoint inhibitors. <i>Hepatology International</i> , 2019, 13, 248-252.	1.9	36
5471	Efficacy of pembrolizumab for patients with both high PD-L1 expression and an <i>MET</i> exon 14 skipping mutation: A case report. <i>Thoracic Cancer</i> , 2019, 10, 369-372.	0.8	12
5472	Delivery technologies for cancer immunotherapy. <i>Nature Reviews Drug Discovery</i> , 2019, 18, 175-196.	21.5	1,562
5473	Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience. , 2019, 7, 2.		213
5474	Programmed cell death ligand 1 (PD-L1, CD274) in cholangiocarcinoma – correlation with clinicopathological data and comparison of antibodies. <i>BMC Cancer</i> , 2019, 19, 72.	1.1	32
5475	Preferential Localization of MUC1 Glycoprotein in Exosomes Secreted by Non-Small Cell Lung Carcinoma Cells. <i>International Journal of Molecular Sciences</i> , 2019, 20, 323.	1.8	71
5476	Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial. , 2019, 7, 12.		67
5477	Hyperspectral cell sociology reveals spatial tumor-immune cell interactions associated with lung cancer recurrence. , 2019, 7, 13.		37
5478	Roles, function and relevance of LAG3 in HIV infection. <i>PLoS Pathogens</i> , 2019, 15, e1007429.	2.1	27

#	ARTICLE	IF	CITATIONS
5479	The route of administration dictates the immunogenicity of peptide-based cancer vaccines in mice. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 455-466.	2.0	31
5480	Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer. <i>Gastric Cancer</i> , 2019, 22, 793-802.	2.7	124
5481	Time for radioimmunotherapy: an overview to bring improvements in clinical practice. <i>Clinical and Translational Oncology</i> , 2019, 21, 992-1004.	1.2	13
5482	Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada. <i>PharmacoEconomics - Open</i> , 2019, 3, 321-331.	0.9	9
5483	Measurement and immunophenotyping of pleural fluid EpCAM-positive cells and clusters for the management of non-small cell lung cancer patients. <i>Lung Cancer</i> , 2019, 127, 25-33.	0.9	13
5484	Lipoxidation and cancer immunity. <i>Redox Biology</i> , 2019, 23, 101103.	3.9	17
5485	Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 1692-1697.	3.3	237
5486	Practical guidance for the management of inflammatory bowel disease in patients with cancer. Which treatment?. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481881729.	1.4	23
5487	Correlate tumor mutation burden with immune signatures in human cancers. <i>BMC Immunology</i> , 2019, 20, 4.	0.9	149
5488	Differential expression of TIM-3 between primary and metastatic sites in renal cell carcinoma. <i>BMC Cancer</i> , 2019, 19, 49.	1.1	21
5489	Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 16.	3.5	27
5490	Tumor-Targeted Chemoimmunotherapy with Immune-Checkpoint Blockade for Enhanced Anti-Melanoma Efficacy. <i>AAPS Journal</i> , 2019, 21, 18.	2.2	8
5491	Efficacy, safety, and resistance profile of osimertinib in T790M mutation-positive non-small cell lung cancer in real-world practice. <i>PLoS ONE</i> , 2019, 14, e0210225.	1.1	19
5492	Adverse events associated with immune checkpoint inhibitor treatment for cancer. <i>Cmaj</i> , 2019, 191, E40-E46.	0.9	36
5493	Activation and Proliferation of PD-1+ Kidney Double-Negative T Cells Is Dependent on Nonclassical MHC Proteins and IL-2. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 277-292.	3.0	27
5494	Non-Invasive Fluorescent Monitoring of Ovarian Cancer in an Immunocompetent Mouse Model. <i>Cancers</i> , 2019, 11, 32.	1.7	16
5495	Therapeutic Targets for Bone and Soft-Tissue Sarcomas. <i>International Journal of Molecular Sciences</i> , 2019, 20, 170.	1.8	52
5496	Drug-Induced Liver Injury: Highlights of the Recent Literature. <i>Drug Safety</i> , 2019, 42, 365-387.	1.4	82

#	ARTICLE	IF	CITATIONS
5497	Autoimmune hemolytic anemia associated with the use of immune checkpoint inhibitors for cancer: 68 cases from the Food and Drug Administration database and review. <i>European Journal of Haematology</i> , 2019, 102, 157-162.	1.1	73
5498	PD-1 methylation regulates PD-1 expression and is associated with melanoma survival. <i>Pigment Cell and Melanoma Research</i> , 2019, 32, 435-440.	1.5	54
5499	T-cell trafficking plays an essential role in tumor immunity. <i>Laboratory Investigation</i> , 2019, 99, 85-92.	1.7	11
5500	Spermidine reduces cancer-related mortality in humans. <i>Autophagy</i> , 2019, 15, 362-365.	4.3	31
5501	Survival Outcomes in Patients With Previously Untreated <i>BRAF</i> Wild-Type Advanced Melanoma Treated With Nivolumab Therapy. <i>JAMA Oncology</i> , 2019, 5, 187.	3.4	295
5502	Engineering Precision Medicine. <i>Advanced Science</i> , 2019, 6, 1801039.	5.6	55
5503	FUT4 is involved in PD-1-related immunosuppression and leads to worse survival in patients with operable lung adenocarcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 65-76.	1.2	18
5504	A novel humanized anti-PD-1 monoclonal antibody potentiates therapy in oral squamous cell carcinoma. <i>Investigational New Drugs</i> , 2019, 37, 799-809.	1.2	4
5505	Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints. <i>Endocrine Reviews</i> , 2019, 40, 17-65.	8.9	349
5506	Cancer diagnosis and immunotherapy in the age of CRISPR. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 233-243.	1.5	4
5507	First experience and clinical results using a new non-coplanar mono-isocenter technique (HyperArc [®]) for Linac-based VMAT radiosurgery in brain metastases. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 193-200.	1.2	50
5508	Aldehyde dehydrogenase in regulatory T cell development, immunity and cancer. <i>Immunology</i> , 2019, 156, 47-55.	2.0	38
5509	PD-1 immunobiology in systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , 2019, 97, 1-9.	3.0	68
5510	Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan-Kynurenine-Aryl Hydrocarbon Axis. <i>Clinical Cancer Research</i> , 2019, 25, 1462-1471.	3.2	271
5511	Developing combination strategies using PD-1 checkpoint inhibitors to treat cancer. <i>Seminars in Immunopathology</i> , 2019, 41, 21-30.	2.8	49
5512	Feasibility and safety of nivolumab in advanced hepatocellular carcinoma: real-life experience from three German centers. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 253-259.	1.2	44
5513	Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1 Low/Negative Recurrent or Metastatic HNSCC. <i>JAMA Oncology</i> , 2019, 5, 195.	3.4	235
5514	Locus-specific concordance of genomic alterations between tissue and plasma circulating tumor DNA in metastatic melanoma. <i>Molecular Oncology</i> , 2019, 13, 171-184.	2.1	44

#	ARTICLE	IF	CITATIONS
5515	The Impact of Early-Phase Trial Design in the Drug Development Process. <i>Clinical Cancer Research</i> , 2019, 25, 819-827.	3.2	38
5516	The Effectiveness of Checkpoint Inhibitor Combinations and Administration Timing Can Be Measured by Granzyme B PET Imaging. <i>Clinical Cancer Research</i> , 2019, 25, 1196-1205.	3.2	85
5517	The lung microenvironment: an important regulator of tumour growth and metastasis. <i>Nature Reviews Cancer</i> , 2019, 19, 9-31.	12.8	692
5518	Clinical significance of $\geq 50\%$ PD-L1 expression with the SP263 monoclonal antibody in non-small cell lung cancer patients. <i>Thoracic Cancer</i> , 2019, 10, 175-182.	0.8	4
5519	Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 511-521.	1.2	153
5520	Q-TWiST Analysis to Assess Benefit-Risk of Pembrolizumab in Patients with PD-L1-Positive Advanced or Metastatic Non-small Cell Lung Cancer. <i>Pharmacoeconomics</i> , 2019, 37, 105-116.	1.7	13
5521	Modulating the Tumor Microenvironment via Oncolytic Viruses and CSF-1R Inhibition Synergistically Enhances Anti-PD-1 Immunotherapy. <i>Molecular Therapy</i> , 2019, 27, 244-260.	3.7	67
5522	Next-generation sequencing-based clinical sequencing: toward precision medicine in solid tumors. <i>International Journal of Clinical Oncology</i> , 2019, 24, 115-122.	1.0	35
5523	Cancer immunoeediting and resistance to T cell-based immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 151-167.	12.5	1,093
5524	Pembrolizumab-related renal toxicities: diagnosis first, treatment later. <i>CKJ: Clinical Kidney Journal</i> , 2019, 12, 78-80.	1.4	7
5525	Tipping the balance: inhibitory checkpoints in intestinal homeostasis. <i>Mucosal Immunology</i> , 2019, 12, 21-35.	2.7	13
5526	Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 278-288.	1.9	24
5527	Interplay between small and long non-coding RNAs in cutaneous melanoma: a complex jigsaw puzzle with missing pieces. <i>Molecular Oncology</i> , 2019, 13, 74-98.	2.1	29
5528	Prognostic value of baseline metabolic tumor volume measured on 18F-fluorodeoxyglucose positron emission tomography/computed tomography in melanoma patients treated with ipilimumab therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 930-939.	3.3	75
5529	Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 479-485.	1.2	253
5530	IL-10 producing CD8+ CD122+ PD-1+ regulatory T cells are expanded by dendritic cells silenced for Allograft Inflammatory Factor-1. <i>Journal of Leukocyte Biology</i> , 2018, 105, 123-130.	1.5	26
5531	Decreased RORC expression and downstream signaling in HTLV-1-associated adult T-cell lymphoma/leukemia uncovers an antiproliferative IL17 link: A potential target for immunotherapy?. <i>International Journal of Cancer</i> , 2019, 144, 1664-1675.	2.3	13
5532	PD-L1 Expression in Non-Small-Cell Lung Cancer Including Various Adenocarcinoma Subtypes. <i>Annals of Thoracic and Cardiovascular Surgery</i> , 2019, 25, 1-9.	0.3	69

#	ARTICLE	IF	CITATIONS
5533	Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology. <i>Clinical and Translational Oncology</i> , 2019, 21, 556-571.	1.2	29
5534	EBV-associated gastric cancer evades T-cell immunity by PD-1/PD-L1 interactions. <i>Gastric Cancer</i> , 2019, 22, 486-496.	2.7	72
5535	Mechanisms of Resistance to Immune Checkpoint Blockade. <i>American Journal of Clinical Dermatology</i> , 2019, 20, 41-54.	3.3	83
5536	Predictive value of angiogenic proteins in patients with metastatic melanoma treated with bevacizumab monotherapy. <i>Journal of Pathology: Clinical Research</i> , 2019, 5, 53-62.	1.3	7
5537	Association between inflammatory potential of diet and risk of lung cancer among smokers in a prospective study in Singapore. <i>European Journal of Nutrition</i> , 2019, 58, 2755-2766.	1.8	16
5538	Rheumatic diseases associated with immune checkpoint inhibitors in cancer immunotherapy. <i>Modern Rheumatology</i> , 2019, 29, 721-732.	0.9	10
5539	A novel bispecific c-MET/CTLA-4 antibody targetting lung cancer stem cell-like cells with therapeutic potential in human non-small-cell lung cancer. <i>Bioscience Reports</i> , 2019, 39, .	1.1	17
5540	Mutational Diversity of Lung Cancer and Associated Lymph Nodes. An Exploratory Prospective Study of 4 Resected cIIIA-N2. <i>Pathology and Oncology Research</i> , 2019, 25, 319-325.	0.9	2
5541	Erlotinib for Patients with EGFR Wild-Type Metastatic NSCLC: a Retrospective Biomarkers Analysis. <i>Pathology and Oncology Research</i> , 2019, 25, 513-520.	0.9	5
5542	Recent advances in therapeutic strategies for unresectable or metastatic melanoma and real-world data in Japan. <i>International Journal of Clinical Oncology</i> , 2019, 24, 1508-1514.	1.0	13
5543	Update on advanced melanoma treatments: small molecule targeted therapy, immunotherapy, and future combination therapies. <i>Wiener Medizinische Wochenschrift</i> , 2019, 169, 314-322.	0.5	5
5544	From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational Overview. <i>Antioxidants and Redox Signaling</i> , 2019, 30, 2110-2153.	2.5	96
5545	Overview on the role of preoperative therapy in the management of kidney cancer. <i>Clinical and Translational Oncology</i> , 2020, 22, 11-20.	1.2	3
5546	Managing Lung Cancer with Comorbid Interstitial Pneumonia. <i>Internal Medicine</i> , 2020, 59, 163-167.	0.3	14
5547	The emerging role of epigenetic therapeutics in immuno-oncology. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 75-90.	12.5	260
5548	The Immune Microenvironment and Cancer Metastasis. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2020, 10, a037424.	2.9	57
5549	C-reactive protein and the neutrophil-to-lymphocyte ratio are prognostic biomarkers in metastatic renal cell carcinoma patients treated with nivolumab. <i>International Journal of Clinical Oncology</i> , 2020, 25, 135-144.	1.0	38
5550	¹⁸ F-Sodium fluoride PET/CT predicts overall survival in patients with advanced genitourinary malignancies treated with cabozantinib and nivolumab with or without ipilimumab. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 178-184.	3.3	11

#	ARTICLE	IF	CITATIONS
5551	Albuminâ€“globulin ratio is a predictive biomarker of antitumor effect of anti-PD-1 antibody in patients with non-small cell lung cancer. <i>International Journal of Clinical Oncology</i> , 2020, 25, 74-81.	1.0	25
5552	Use of Immunotherapy and Radiation Treatment in the Management of Metastatic Melanoma With Rhabdomyosarcomatous Differentiation. <i>Advances in Radiation Oncology</i> , 2020, 5, 134-139.	0.6	6
5553	Cdk5 knocking out mediated by CRISPR-Cas9 genome editing for PD-L1 attenuation and enhanced antitumor immunity. <i>Acta Pharmaceutica Sinica B</i> , 2020, 10, 358-373.	5.7	61
5554	CIMT 2019: report on the 17th Annual Meeting of the Association for Cancer Immunotherapy. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 808-815.	1.4	2
5555	Cost Effectiveness of PD-L1-Based Test-and-Treat Strategy with Pembrolizumab as the First-Line Treatment for Metastatic NSCLC in Hong Kong. <i>Pharmacoeconomics - Open</i> , 2020, 4, 235-247.	0.9	19
5556	Giant cell myocarditis with central diabetes insipidus: A case report. <i>Journal of Cardiology Cases</i> , 2020, 21, 8-11.	0.2	2
5557	Brain Metastasis Organotropism. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2020, 10, a037242.	2.9	26
5558	Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses. <i>Acta Pharmaceutica Sinica B</i> , 2020, 10, 723-733.	5.7	102
5559	Histologic patterns of liver injury induced by anti-PD-1 therapy. <i>Gastroenterology Report</i> , 2020, 8, 50-55.	0.6	24
5560	Pharmacogenomics, biomarker network, and allele frequencies in colorectal cancer. <i>Pharmacogenomics Journal</i> , 2020, 20, 136-158.	0.9	15
5561	Fracaso renal agudo asociado a inhibidores check-point. <i>Nefrologia</i> , 2020, 40, 206-208.	0.2	1
5562	A new expression of immune checkpoint inhibitorsâ€™ renal toxicity: when distal tubular acidosis precedes creatinine elevation. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 42-45.	1.4	24
5563	Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy. <i>Clinical Cancer Research</i> , 2020, 26, 970-977.	3.2	200
5564	High-Intensity Focused Ultrasound (HIFU) Triggers Immune Sensitization of Refractory Murine Neuroblastoma to Checkpoint Inhibitor Therapy. <i>Clinical Cancer Research</i> , 2020, 26, 1152-1161.	3.2	94
5565	Oncolysis without viruses â€” inducing systemic anticancer immune responses with local therapies. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 49-64.	12.5	92
5566	Acute tubulointerstitial nephritis and IgM deposits on glomerular capillary walls after immunotherapy with nivolumab for metastatic renal cell carcinoma. <i>CEN Case Reports</i> , 2020, 9, 48-54.	0.5	9
5568	Comparison of PD-L1 expression between paired cytologic and histologic specimens from non-small cell lung cancer patients. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 476, 261-271.	1.4	15
5569	The postoperative platelet distribution width is useful for predicting the prognosis in patients with esophageal squamous cell carcinoma. <i>Surgery Today</i> , 2020, 50, 123-133.	0.7	8

#	ARTICLE	IF	CITATIONS
5570	Interchangeability of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy. <i>Modern Pathology</i> , 2020, 33, 4-17.	2.9	135
5571	The prevalence of programmed death ligand-1 (PD-L1) expression in non-small cell lung cancer in an unselected, consecutive population. <i>Modern Pathology</i> , 2020, 33, 109-117.	2.9	40
5572	Predictive biomarkers and tumor microenvironment in female genital melanomas: a multi-institutional study of 55 cases. <i>Modern Pathology</i> , 2020, 33, 138-152.	2.9	12
5573	To treat or not to treat? Managing comorbidities in cancer patients under immune checkpoint inhibition. <i>Acta Clinica Belgica</i> , 2020, 75, 434-441.	0.5	1
5574	Quantitative assessment of PD-L1 as an analyte in immunohistochemistry diagnostic assays using a standardized cell line tissue microarray. <i>Laboratory Investigation</i> , 2020, 100, 4-15.	1.7	52
5575	PD-L1 expression in gastric cancer determined by digital image analyses: pitfalls and correlation with pathologist interpretation. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 476, 243-250.	1.4	16
5576	Efficacy of anti-PD-1 therapy for recurrence after chemoradiotherapy in locally advanced NSC LC. <i>International Journal of Clinical Oncology</i> , 2020, 25, 67-73.	1.0	6
5577	Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do?. <i>Kidney International</i> , 2020, 97, 62-74.	2.6	121
5578	The Role of Pharmacists in Managing Adverse Events Related to Immune Checkpoint Inhibitor Therapy. <i>Journal of Pharmacy Practice</i> , 2020, 33, 338-349.	0.5	9
5579	Platinum complexes of curcumin delivered by dual-responsive polymeric nanoparticles improve chemotherapeutic efficacy based on the enhanced anti-metastasis activity and reduce side effects. <i>Acta Pharmaceutica Sinica B</i> , 2020, 10, 1106-1121.	5.7	58
5580	The Journey of an EGFR-Mutant Lung Adenocarcinoma through Erlotinib, Osimertinib and ABCP Immunotherapy Regimens: Sensitivity and Resistance. <i>Case Reports in Oncology</i> , 2020, 12, 765-776.	0.3	9
5581	Neuropsychiatric Immune-related Adverse Events Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma and Systemic Lupus Erythematosus. <i>Internal Medicine</i> , 2020, 59, 569-572.	0.3	8
5582	First-line PD-1/PD-L1 inhibitor plus chemotherapy vs chemotherapy alone for negative or PD-L1-expressing metastatic non-small-cell lung cancers. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 441-448.	1.2	8
5583	Risk of immune-related diarrhea with PD-1/PD-L1 inhibitors in different cancer types and treatment regimens. <i>Journal of Cancer</i> , 2020, 11, 41-50.	1.2	3
5584	Health care utilization and steroid-refractory toxicities from immune checkpoint inhibitors. <i>Cancer</i> , 2020, 126, 322-328.	2.0	13
5585	Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer. <i>Journal of Pathology</i> , 2020, 250, 19-29.	2.1	92
5586	CD70 expression correlates with a worse prognosis in malignant pleural mesothelioma patients via immune evasion and enhanced invasiveness. <i>Journal of Pathology</i> , 2020, 250, 205-216.	2.1	34
5587	Immunotherapy for the Treatment of Breast Cancer: Emerging New Data. <i>Breast Cancer: Targets and Therapy</i> , 2019, Volume 11, 321-328.	1.0	25

#	ARTICLE	IF	CITATIONS
5588	Current issues and perspectives in PD-1 blockade cancer immunotherapy. <i>International Journal of Clinical Oncology</i> , 2020, 25, 790-800.	1.0	120
5589	Retrospective Efficacy Analysis of Immune Checkpoint Inhibitor Rechallenge in Patients with Non-Small Cell Lung Cancer. <i>Journal of Clinical Medicine</i> , 2020, 9, 102.	1.0	42
5590	CTLA-4 correlates with immune and clinical characteristics of glioma. <i>Cancer Cell International</i> , 2020, 20, 7.	1.8	74
5591	Development of therapeutic antibodies for the treatment of diseases. <i>Journal of Biomedical Science</i> , 2020, 27, 1.	2.6	1,277
5592	iRECIST: how to do it. <i>Cancer Imaging</i> , 2020, 20, 2.	1.2	41
5593	Exosomal PD-L1 functions as an immunosuppressant to promote wound healing. <i>Journal of Extracellular Vesicles</i> , 2020, 9, 1709262.	5.5	67
5594	Considering adjuvant therapy for stage II melanoma. <i>Cancer</i> , 2020, 126, 1166-1174.	2.0	32
5595	Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥ 75 years) with non-small cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 457-466.	1.2	21
5596	Multiple lung cancers including squamous cell carcinoma with strong PD-L1 expression and adenocarcinoma with EGFR exon 19 deletion: A case report. <i>Respiratory Medicine Case Reports</i> , 2020, 29, 100976.	0.2	2
5597	Bone Metastasis: Current State of Play. <i>Translational Oncology</i> , 2020, 13, 308-320.	1.7	30
5598	Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma. <i>Nature Medicine</i> , 2020, 26, 39-46.	15.2	236
5599	Molecular Classification and Emerging Targeted Therapy in Endometrial Cancer. <i>International Journal of Gynecological Pathology</i> , 2020, 39, 26-35.	0.9	69
5600	Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial. <i>International Journal of Clinical Oncology</i> , 2020, 25, 165-174.	1.0	27
5601	Targeting the interleukin-17 immune axis for cancer immunotherapy. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	105
5602	Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines. <i>Journal of Virology</i> , 2020, 94, .	1.5	54
5603	Changes in CT Radiomic Features Associated with Lymphocyte Distribution Predict Overall Survival and Response to Immunotherapy in Non-Small Cell Lung Cancer. <i>Cancer Immunology Research</i> , 2020, 8, 108-119.	1.6	187
5604	Harnessing big "omics" data and AI for drug discovery in hepatocellular carcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 238-251.	8.2	90
5605	Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy. <i>Radiation Oncology</i> , 2020, 15, 5.	1.2	28

#	ARTICLE	IF	CITATIONS
5606	A case of non-small cell lung cancer with long-term response after re-challenge with nivolumab. Respiratory Medicine Case Reports, 2020, 29, 100979.	0.2	4
5607	Renal cell cancer. , 2020, , 229-243.e4.		0
5608	Acute kidney injury incidence, pathogenesis, and outcomes. , 2020, , 269-274.e3.		0
5609	Systematic Review of the Safety of Immune Checkpoint Inhibitors Among Kidney Transplant Patients. Kidney International Reports, 2020, 5, 149-158.	0.4	52
5610	Preserving the CTLA-4 Checkpoint for Safer and More Effective Cancer Immunotherapy. Trends in Pharmacological Sciences, 2020, 41, 4-12.	4.0	82
5611	Modulation of SRSF2 expression reverses the exhaustion of TILs via the epigenetic regulation of immune checkpoint molecules. Cellular and Molecular Life Sciences, 2020, 77, 3441-3452.	2.4	22
5612	Mechanisms of immune evasion in bladder cancer. Cancer Immunology, Immunotherapy, 2020, 69, 3-14.	2.0	127
5614	CT and MRI findings in leptomeningeal melanocytosis. Radiology Case Reports, 2020, 15, 186-189.	0.2	4
5615	Targeting innate sensing in the tumor microenvironment to improve immunotherapy. Cellular and Molecular Immunology, 2020, 17, 13-26.	4.8	76
5616	Critical Care Management of Toxicities Associated With Targeted Agents and Immunotherapies for Cancer. Critical Care Medicine, 2020, 48, 10-21.	0.4	42
5617	The Cytosolic DNA-Sensing cGASâ€‘STING Pathway in Cancer. Cancer Discovery, 2020, 10, 26-39.	7.7	558
5618	Hyponatremia in a Patient With Cancer. American Journal of Kidney Diseases, 2020, 75, A15-A18.	2.1	9
5619	Identifying Predictive Factors of Recurrence after Radical Resection in Gastric Cancer by RNA Immune-oncology Panel. Journal of Cancer, 2020, 11, 638-647.	1.2	9
5620	Immunotherapy for Gynecologic Cancer: Current Applications and Future Directions. Clinical Obstetrics and Gynecology, 2020, 63, 48-63.	0.6	27
5622	Checkpoint inhibitors in AML: are we there yet?. British Journal of Haematology, 2020, 188, 159-167.	1.2	31
5623	Rapid evolution of acute kidney injury after initial infusion of pembrolizumab in a melanoma patient concurrently treated with RAF/MEK inhibitors. Melanoma Research, 2020, 30, 219-222.	0.6	3
5624	Pharmacokinetics, Pharmacodynamics, and Safety of Nivolumab in Patients With Sepsis-Induced Immunosuppression: A Multicenter, Open-Label Phase 1/2 Study. Shock, 2020, 53, 686-694.	1.0	27
5625	<scp>PTPN</scp> 2 phosphatase deletion in T cells promotes antiâ€‘tumour immunity and <scp>CAR</scp> Tâ€‘cell efficacy in solid tumours. EMBO Journal, 2020, 39, e103637.	3.5	79

#	ARTICLE	IF	CITATIONS
5626	Separating or combining immune checkpoint inhibitors (ICIs) and radiotherapy in the treatment of NSCLC brain metastases. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 137-152.	1.2	17
5627	The efficacy of immune checkpoint inhibitors in advanced non-small-cell lung cancer with liver metastases. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 777-785.	1.2	40
5628	PD-L1 Expression in Pediatric Low-Grade Gliomas Is Independent of BRAF V600E Mutational Status. <i>Journal of Neuropathology and Experimental Neurology</i> , 2020, 79, 74-85.	0.9	10
5629	Nivolumab-induced small bowel obstruction and perforation: a rare but life-threatening side effect of immunotherapy. <i>Emergency Radiology</i> , 2020, 27, 107-110.	1.0	8
5630	Combination of Local Ablative Therapy and Continuation of Immune Checkpoint Inhibitor (ICI) Therapy Provides Durable Treatment Response Past Oligometastatic Progression in NSCLC: A Case Report. <i>Case Reports in Oncology</i> , 2020, 12, 866-871.	0.3	7
5631	Midkine (MDK) growth factor: a key player in cancer progression and a promising therapeutic target. <i>Oncogene</i> , 2020, 39, 2040-2054.	2.6	141
5632	Brain immunology and immunotherapy in brain tumours. <i>Nature Reviews Cancer</i> , 2020, 20, 12-25.	12.8	389
5633	Recombinant Dual-target MDM2/MDMX Inhibitor Reverses Doxorubicin Resistance through Activation of the TAB1/TAK1/p38 MAPK Pathway in Wild-type p53 Multidrug-resistant Breast Cancer Cells. <i>Journal of Cancer</i> , 2020, 11, 25-40.	1.2	13
5634	Immune Checkpoint Inhibition in Colorectal Cancer: Microsatellite Instability and Beyond. <i>Targeted Oncology</i> , 2020, 15, 11-24.	1.7	65
5635	Tumor immune microenvironment is associated with the growth of intracranial germinomas. <i>Journal of Neuro-Oncology</i> , 2020, 146, 139-146.	1.4	6
5636	Evaluation of the Metastatic Spine Disease Multidisciplinary Working Group Algorithms as Part of a Multidisciplinary Spine Tumor Conference. <i>Global Spine Journal</i> , 2020, 10, 888-895.	1.2	1
5637	PD-L1 Expression Correlates With Young Age and CD8+ TIL Density in Poorly Differentiated Cervical Squamous Cell Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2020, 39, 428-435.	0.9	14
5638	Chemotherapy and Tyrosine Kinase Inhibitors in the last month of life in patients with metastatic lung cancer: A patient file study in the Netherlands. <i>European Journal of Cancer Care</i> , 2020, 29, e13210.	0.7	3
5639	Inhibition of Haspin Kinase Promotes Cell-Intrinsic and Extrinsic Antitumor Activity. <i>Cancer Research</i> , 2020, 80, 798-810.	0.4	22
5640	Renal Effects after Pembrolizumab Treatment for Non-small Cell Lung Carcinoma. <i>Internal Medicine</i> , 2020, 59, 977-981.	0.3	14
5641	Structure and Optimization of Checkpoint Inhibitors. <i>Cancers</i> , 2020, 12, 38.	1.7	37
5642	Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients. <i>Cancers</i> , 2020, 12, 67.	1.7	39
5643	The Roles of CD38 and CD157 in the Solid Tumor Microenvironment and Cancer Immunotherapy. <i>Cells</i> , 2020, 9, 26.	1.8	29

#	ARTICLE	IF	CITATIONS
5644	Anti-PD-1 Therapy plus Chemotherapy and/or Bevacizumab as Second Line or later Treatment for Patients with Advanced Non-Small Cell Lung Cancer. <i>Journal of Cancer</i> , 2020, 11, 741-749.	1.2	21
5645	Benign lymph node microenvironment is associated with response to immunotherapy. <i>Precision Clinical Medicine</i> , 2020, 3, 44-53.	1.3	10
5646	Granzyme B nanoreporter for early monitoring of tumor response to immunotherapy. <i>Science Advances</i> , 2020, 6, .	4.7	49
5647	Critical roles of super-enhancers in the pathogenesis of autoimmune diseases. <i>Inflammation and Regeneration</i> , 2020, 40, 16.	1.5	12
5648	NLRP3 Inflammasome From Bench to Bedside: New Perspectives for Triple Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1587.	1.3	19
5649	Inflammasome Deletion Promotes Anti-tumor NK Cell Function in an IL-1/IL-18 Independent Way in Murine Invasive Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1683.	1.3	8
5650	Understanding Esophageal Cancer: The Challenges and Opportunities for the Next Decade. <i>Frontiers in Oncology</i> , 2020, 10, 1727.	1.3	97
5651	Molecular Insights and Emerging Strategies for Treatment of Metastatic Uveal Melanoma. <i>Cancers</i> , 2020, 12, 2761.	1.7	24
5652	The Tumor and Host Immune Signature, and the Gut Microbiota as Predictive Biomarkers for Immune Checkpoint Inhibitor Response in Melanoma Patients. <i>Life</i> , 2020, 10, 219.	1.1	11
5653	Severe combined cardiac and neuromuscular toxicity from immune checkpoint blockade: an institutional case series. <i>Cardio-Oncology</i> , 2020, 6, 21.	0.8	14
5654	Real-world treatment practice in patients with advanced melanoma. <i>Wspolczesna Onkologia</i> , 2020, 24, 118-124.	0.7	6
5655	Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab vs. Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1649.	1.3	32
5656	Impact of age-related T-cell dynamics on the identification of biomarkers predictive of immunotherapy discontinuation: A prospective cohort study. <i>Aging and Cancer</i> , 2020, 1, 58-70.	0.5	1
5657	Efficacy and Safety of First-Line Immunotherapy in Combination with Chemotherapy for Patients with Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis. <i>Journal of Oncology</i> , 2020, 2020, 1-10.	0.6	9
5658	<p>Application and Prospects of Molecular Imaging in Immunotherapy</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 9389-9403.	0.9	8
5659	Manipulation of Glucose Availability to Boost Cancer Immunotherapies. <i>Cancers</i> , 2020, 12, 2940.	1.7	15
5660	Augmenting the Effectiveness of CAR-T Cells by Enhanced Self-Delivery of PD-1-Neutralizing scFv. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 803.	1.8	30
5661	Does Pemetrexed Work in Targetable, Nonsquamous Non-Small-Cell Lung Cancer? A Narrative Review. <i>Cancers</i> , 2020, 12, 2658.	1.7	10

#	ARTICLE	IF	CITATIONS
5662	A CT-derived deep neural network predicts for programmed death ligand-1 expression status in advanced lung adenocarcinomas. <i>Annals of Translational Medicine</i> , 2020, 8, 930-930.	0.7	13
5663	Clinical management of lung cancer patients during the outbreak of COVID-19 epidemic. <i>Infectious Agents and Cancer</i> , 2020, 15, 56.	1.2	5
5664	Immune Checkpoint Blockade Improves Chemotherapy in the PyMT Mammary Carcinoma Mouse Model. <i>Frontiers in Oncology</i> , 2020, 10, 1771.	1.3	7
5665	From Conventional Therapies to Immunotherapy: Melanoma Treatment in Review. <i>Cancers</i> , 2020, 12, 3057.	1.7	50
5666	Good response with durvalumab after chemoradiotherapy for epidermal growth factor receptor exon 20 insertion adenocarcinoma: A case report. <i>Respiratory Medicine Case Reports</i> , 2020, 31, 101236.	0.2	1
5667	<p>Management of Immune Checkpoint Inhibitor Toxicities</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 9139-9158.	0.9	18
5668	<p>Managing Ipilimumab-Induced Hypophysitis: Challenges and Current Therapeutic Strategies</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 9551-9561.	0.9	21
5669	High PD-L1/CD274 Expression of Monocytes and Blood Dendritic Cells Is a Risk Factor in Lung Cancer Patients Undergoing Treatment with PD1 Inhibitor Therapy. <i>Cancers</i> , 2020, 12, 2966.	1.7	16
5670	Immune checkpoint inhibitorâ€œinduced bullous pemphigoid: Towards a new class of drug-drug interaction?. <i>European Journal of Cancer</i> , 2020, 138, 122-124.	1.3	3
5671	Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade. <i>IScience</i> , 2020, 23, 101580.	1.9	22
5672	The incidence risk of programmed cell death-1/programmed cell death ligand 1 inhibitor-related alopecia for cancer patients. <i>Medicine (United States)</i> , 2020, 99, e22555.	0.4	2
5673	Efficacy and safety of combination PDâ€œ1/PDâ€œL1 checkpoint inhibitors for malignant solid tumours: A systematic review. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 13494-13506.	1.6	4
5674	Risk of non-infectious uveitis or myasthenia gravis in patients on checkpoint inhibitors in a large healthcare claims database. <i>British Journal of Ophthalmology</i> , 2022, 106, 87-90.	2.1	7
5675	Analyses of Intermediate-Stage Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization prior to Designing Clinical Trials. <i>Liver Cancer</i> , 2020, 9, 596-612.	4.2	10
5676	The Confounders of Cancer Immunotherapy: Roles of Lifestyle, Metabolic Disorders and Sociological Factors. <i>Cancers</i> , 2020, 12, 2983.	1.7	56
5677	Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma. <i>Vaccines</i> , 2020, 8, 616.	2.1	47
5678	Unresectable Hepatic Metastasis of Uveal Melanoma: Hepatic Chemosaturation with High-Dose Melphalanâ€œLong-Term Overall Survival Negatively Correlates with Tumor Burden. <i>Radiology Research and Practice</i> , 2020, 2020, 1-7.	0.6	9
5679	Understanding PD-L1 Testing in Breast Cancer: A Practical Approach. <i>Breast Care</i> , 2020, 15, 481-490.	0.8	34

#	ARTICLE	IF	CITATIONS
5680	Is the neutrophil-to-lymphocyte ratio a useful prognostic indicator in melanoma patients?. <i>Melanoma Management</i> , 2020, 7, MMT47.	0.1	24
5681	Harmonization of Molecular Testing for Non-Small Cell Lung Cancer: Emphasis on PD-L1. <i>Frontiers in Oncology</i> , 2020, 10, 549198.	1.3	2
5682	Senescent Tumor CD8+ T Cells: Mechanisms of Induction and Challenges to Immunotherapy. <i>Cancers</i> , 2020, 12, 2828.	1.7	10
5683	The relationship between pneumonitis and programmed cell death-1/programmed cell death ligand 1 inhibitors among cancer patients. <i>Medicine (United States)</i> , 2020, 99, e22567.	0.4	5
5684	Prognostic Value of the Lung Immune Prognostic Index May Differ in Patients Treated With Immune Checkpoint Inhibitor Monotherapy or Combined With Chemotherapy for Non-small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 572853.	1.3	15
5685	The impact of immunotherapy on the survival of pancreatic adenocarcinoma patients who do not receive definitive surgery of the tumor. <i>Clinical and Translational Radiation Oncology</i> , 2020, 24, 34-40.	0.9	11
5686	Clinical Efficacy of Immune Checkpoint Inhibitors in Older Non-small-Cell Lung Cancer Patients: A Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 558454.	1.3	14
5687	Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors. <i>JHEP Reports</i> , 2020, 2, 100170.	2.6	86
5688	Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. <i>Nature Medicine</i> , 2020, 26, 1845-1851.	15.2	193
5689	Identification of molecular features correlating with tumor immunity in gastric cancer by multi-omics data analysis. <i>Annals of Translational Medicine</i> , 2020, 8, 1050-1050.	0.7	31
5690	The prospect of combination therapy with immune checkpoint inhibitors and chemotherapy for squamous cell carcinoma of the lung. <i>Translational Lung Cancer Research</i> , 2020, 9, 811-815.	1.3	3
5691	Dissociated Response in Metastatic Cancer: An Atypical Pattern Brought Into the Spotlight With Immunotherapy. <i>Frontiers in Oncology</i> , 2020, 10, 566297.	1.3	39
5692	Tumor Microenvironment: Implications in Melanoma Resistance to Targeted Therapy and Immunotherapy. <i>Cancers</i> , 2020, 12, 2870.	1.7	64
5693	Effect of interleukins (IL-2, IL-15, IL-18) on receptors activation and cytotoxic activity of natural killer cells in breast cancer cell. <i>African Health Sciences</i> , 2020, 20, 822-832.	0.3	25
5694	Pneumonitis Induced by Immune Checkpoint Inhibitors: From Clinical Data to Translational Investigation. <i>Frontiers in Oncology</i> , 2020, 10, 1785.	1.3	35
5695	From the Infection to the Immunotherapy in Cervical Cancer: Can We Stop the Natural Course of the Disease?. <i>Vaccines</i> , 2020, 8, 597.	2.1	8
5696	Sequential therapy with INCAGN01949 followed by ipilimumab and nivolumab in two patients with advanced ovarian carcinoma. <i>Gynecologic Oncology Reports</i> , 2020, 34, 100655.	0.3	3
5697	Human T Cells Expressing a CD19 CAR-T Receptor Provide Insights into Mechanisms of Human CD19-Positive \hat{I}^2 Cell Destruction. <i>Cell Reports Medicine</i> , 2020, 1, 100097.	3.3	16

#	ARTICLE	IF	CITATIONS
5698	PD-1 Expression by Lymph Node and Intratumoral Regulatory T Cells Is Associated with Lymph Node Metastasis in Pancreatic Cancer. <i>Cancers</i> , 2020, 12, 2756.	1.7	15
5699	p.P476S mutation of RBPJL inhibits the efficacy of anti-PD-1 therapy in oesophageal squamous cell carcinoma by blunting T-cell responses. <i>Clinical and Translational Immunology</i> , 2020, 9, e1172.	1.7	1
5700	Characterization of the Immune Cell Infiltration Landscape in Head and Neck Squamous Cell Carcinoma to Aid Immunotherapy. <i>Molecular Therapy - Nucleic Acids</i> , 2020, 22, 298-309.	2.3	181
5701	Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i. <i>Nature Medicine</i> , 2020, 26, 1557-1563.	15.2	78
5702	Metastatic pulmonary adenocarcinoma to the nasopharynx at first clinical presentation: A case report and review of literature. <i>SAGE Open Medical Case Reports</i> , 2020, 8, 2050313X2093982.	0.2	4
5703	Nivolumab plus Ipilimumab versus Existing Immunotherapies in Patients with PD-L1-Positive Advanced Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis. <i>Cancers</i> , 2020, 12, 1905.	1.7	14
5704	Chemotherapy but Not the Tumor Draining Lymph Nodes Determine the Immunotherapy Response in Secondary Tumors. <i>IScience</i> , 2020, 23, 101056.	1.9	15
5705	Analysis of real-world PD-L1 IHC 28-8 and 22C3 pharmDx assay utilisation, turnaround times and analytical concordance across multiple tumour types. <i>Journal of Clinical Pathology</i> , 2020, 73, 656-664.	1.0	37
5706	Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients. <i>Melanoma Research</i> , 2020, 30, 364-375.	0.6	42
5707	Bronchoscopic tissue yield for advanced molecular testing: are we getting enough?. <i>Journal of Thoracic Disease</i> , 2020, 12, 3287-3295.	0.6	9
5708	Novel treatment strategies for early-stage lung cancer: the oncologist's perspective. <i>Journal of Thoracic Disease</i> , 2020, 12, 3390-3398.	0.6	22
5709	Combination of apatinib and docetaxel in treating advanced non-squamous non-small cell lung cancer patients with wild-type EGFR: a multi-center, phase II trial. <i>Journal of Thoracic Disease</i> , 2020, 12, 2450-2458.	0.6	6
5710	Minimal change disease in a patient receiving checkpoint inhibition: Another possible manifestation of kidney autoimmunity?. <i>Cancer Reports</i> , 2020, 3, e1250.	0.6	9
5711	Durvalumab and tremelimumab combination therapy versus durvalumab or tremelimumab monotherapy for patients with solid tumors. <i>Medicine (United States)</i> , 2020, 99, e21273.	0.4	9
5712	Immune reaction and regulation in transplantation based on pluripotent stem cell technology. <i>Inflammation and Regeneration</i> , 2020, 40, 12.	1.5	20
5713	Development of Antibody Immuno-PET/SPECT Radiopharmaceuticals for Imaging of Oncological Disorders—An Update. <i>Cancers</i> , 2020, 12, 1868.	1.7	33
5714	Molecular Mechanisms and Potential Therapeutic Reversal of Pancreatic Cancer-Induced Immune Evasion. <i>Cancers</i> , 2020, 12, 1872.	1.7	18
5715	Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions. <i>Journal of Immunology Research</i> , 2020, 2020, 1-12.	0.9	127

#	ARTICLE	IF	CITATIONS
5716	Resistance to immune checkpoint inhibitors in non-small cell lung cancer: biomarkers and therapeutic strategies. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592093790.	1.4	49
5717	Efficacy and safety of PD-1/PD-L1 inhibitors plus nab-paclitaxel for patients with non-small cell lung cancer who have progressed after platinum-based chemotherapy. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592093688.	1.4	17
5718	Integrating clinical and biological prognostic biomarkers in patients with advanced NSCLC treated with immunotherapy: the DEMo score system. <i>Translational Lung Cancer Research</i> , 2020, 9, 617-628.	1.3	8
5719	Pembrolizumab—the “KEY” to an evolving landscape in treatment of squamous non-small cell lung cancer (NSCLC). <i>Translational Lung Cancer Research</i> , 2020, 9, 824-827.	1.3	0
5720	Cancer Risk in Pediatric-Onset Inflammatory Bowel Disease. <i>Frontiers in Pediatrics</i> , 2020, 8, 400.	0.9	10
5721	Early T cell infiltration is modulated by programmed cell death-1 protein and its ligand (PD-1/PD-L1) interactions in murine kidney transplants. <i>Kidney International</i> , 2020, 98, 897-905.	2.6	12
5722	Selected highlights of the 2019 Pulmonary Pathology Society Biennial Meeting: PD-L1 test harmonization studies. <i>Translational Lung Cancer Research</i> , 2020, 9, 906-916.	1.3	3
5723	Harnessing the Complete Repertoire of Conventional Dendritic Cell Functions for Cancer Immunotherapy. <i>Pharmaceutics</i> , 2020, 12, 663.	2.0	24
5724	A new chapter in immune checkpoint inhibitor therapy: starting with advanced lung squamous cell carcinoma. <i>Translational Lung Cancer Research</i> , 2020, 9, 833-836.	1.3	0
5725	The Association between Leukocyte and Its Subtypes and Benign Breast Disease: The TCLSIH Cohort Study. <i>Journal of Oncology</i> , 2020, 2020, 1-7.	0.6	0
5726	Retrospective Analysis of Treatment and Complications of Immune Checkpoint Inhibitor-Associated Colitis: Histological Ulcerations as Potential Predictor for a Steroid-Refractory Disease Course. <i>Inflammatory Intestinal Diseases</i> , 2020, 5, 109-116.	0.8	17
5727	Immunotherapy in Gastrointestinal Cancers. <i>Visceral Medicine</i> , 2020, 36, 231-237.	0.5	7
5728	Implementation of PD-L1 22C3 IHC pharmDx™&TM™ in Cell Block Preparations of Lung Cancer: Concordance with Surgical Resections and Technical Validation of Cytolyt® Prefixation. <i>Acta Cytologica</i> , 2020, 64, 577-587.	0.7	14
5729	Correlation of immune-related adverse events and response from immune checkpoint inhibitors in patients with advanced non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2020, 12, 2706-2712.	0.6	10
5730	Programmed death ligand-1 expression in gastrointestinal cancer: Clinical significance and future challenges. <i>Annals of Gastroenterological Surgery</i> , 2020, 4, 369-378.	1.2	10
5731	Prognostic Implications of Novel Ten-Gene Signature in Uveal Melanoma. <i>Frontiers in Oncology</i> , 2020, 10, 567512.	1.3	27
5732	Current Perspectives on Immunotherapy in the Peri-Operative Setting of Muscle-Infiltrating Bladder Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 568279.	1.3	11
5733	Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee. , 2020, 8, e001583.		15

#	ARTICLE	IF	CITATIONS
5734	Effect of age and sex on immune checkpoint expression and kinetics in human T cells. <i>Immunity and Ageing</i> , 2020, 17, 32.	1.8	8
5735	Immune Microenvironment Related Competitive Endogenous RNA Network as Powerful Predictors for Melanoma Prognosis Based on WGCNA Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 577072.	1.3	21
5736	Cardiomyopathies and Arrhythmias Induced by Cancer Therapies. <i>Biomedicines</i> , 2020, 8, 496.	1.4	10
5737	The Landscape of Novel Therapeutics and Challenges in Glioblastoma Multiforme: Contemporary State and Future Directions. <i>Pharmaceuticals</i> , 2020, 13, 389.	1.7	36
5738	Radiotherapy for non-small cell lung cancer in the immunotherapy era: the opportunity and challenge—a narrative review. <i>Translational Lung Cancer Research</i> , 2020, 9, 2120-2136.	1.3	16
5739	<p>Emerging Targets of Immunotherapy in Gynecologic Cancer</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 11869-11882.	1.0	6
5740	Tumor MHC Expression Guides First-Line Immunotherapy Selection in Melanoma. <i>Cancers</i> , 2020, 12, 3374.	1.7	27
5741	Will Next-Generation Immunotherapy Overcome the Intrinsic Diversity and Low Immunogenicity of Sarcomas to Improve Clinical Benefit?. <i>Cancers</i> , 2020, 12, 3392.	1.7	5
5742	Multidisciplinary Clinical Approach to Cancer Patients with Immune-Related Adverse Events Induced by Checkpoint Inhibitors. <i>Cancers</i> , 2020, 12, 3446.	1.7	19
5743	A prognostic risk model based on immune-related genes predicts overall survival of patients with hepatocellular carcinoma. <i>Health Science Reports</i> , 2020, 3, e202.	0.6	2
5744	Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets. <i>Nature Cancer</i> , 2020, 1, 1204-1217.	5.7	58
5745	Radiotherapy for unresectable locally advanced non-small cell lung cancer: a narrative review of the current landscape and future prospects in the era of immunotherapy. <i>Translational Lung Cancer Research</i> , 2020, 9, 2097-2112.	1.3	5
5746	Cancer and Immune Checkpoint Inhibitor Treatment in the Era of SARS-CoV-2 Infection. <i>Cancers</i> , 2020, 12, 3383.	1.7	11
5747	Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma. <i>Cell Reports Medicine</i> , 2020, 1, 100139.	3.3	45
5748	High-throughput single-EV liquid biopsy: Rapid, simultaneous, and multiplexed detection of nucleic acids, proteins, and their combinations. <i>Science Advances</i> , 2020, 6, .	4.7	73
5749	Using Machine Learning Modeling to Explore New Immune-Related Prognostic Markers in Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 550002.	1.3	10
5750	Mutational landscape influences immunotherapy outcomes among patients with non-small-cell lung cancer with human leukocyte antigen supertype B44. <i>Nature Cancer</i> , 2020, 1, 1167-1175.	5.7	22
5751	Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma. , 2020, 8, e001681.		57

#	ARTICLE	IF	CITATIONS
5752	FLAURA strikes again: efficacy of osimertinib is independent of PD-L1 expression. <i>Translational Lung Cancer Research</i> , 2020, 9, 2165-2172.	1.3	0
5753	Treatment of stage III non-small cell lung cancer in the era of immunotherapy: pathological complete response to neoadjuvant pembrolizumab and chemotherapy. <i>Translational Lung Cancer Research</i> , 2020, 9, 2059-2073.	1.3	9
5754	Durable Complete Response in a Melanoma Patient With Unknown Primary, Associated With Sequential and Severe Multi-Organ Toxicity After a Single Dose of CTLA-4 Plus PD-1 Blockade: A Case Report. <i>Frontiers in Oncology</i> , 2020, 10, 592609.	1.3	6
5755	Discovery Strategies to Maximize the Clinical Potential of T-Cell Engaging Antibodies for the Treatment of Solid Tumors. <i>Antibodies</i> , 2020, 9, 65.	1.2	13
5756	Durvalumab-associated vasculitis presenting as "the blue toe syndrome". <i>BMJ Case Reports</i> , 2020, 13, e235886.	0.2	9
5757	Patient-derived cell line, xenograft and organoid models in lung cancer therapy. <i>Translational Lung Cancer Research</i> , 2020, 9, 2214-2232.	1.3	51
5758	A narrative review of synergistic drug administration in unresectable locally advanced non-small cell lung cancer: current landscape and future prospects in the era of immunotherapy. <i>Translational Lung Cancer Research</i> , 2020, 9, 2082-2096.	1.3	4
5759	Integration of the Tumor Mutational Burden and Tumor Heterogeneity Identify an Immunological Subtype of Melanoma With Favorable Survival. <i>Frontiers in Oncology</i> , 2020, 10, 571545.	1.3	12
5760	Prognostic Value of the Pretreatment Systemic Immune-Inflammation Index in Patients with Colorectal Cancer. <i>Gastroenterology Research and Practice</i> , 2020, 2020, 1-8.	0.7	5
5761	Expression of AKT and p-AKT protein in lung adenocarcinoma and its correlation with PD-L1 protein and prognosis. <i>Annals of Translational Medicine</i> , 2020, 8, 1172-1172.	0.7	8
5762	A pathological complete response to neoadjuvant chemotherapy and immunotherapy in a non-small cell lung cancer patient. <i>Translational Lung Cancer Research</i> , 2020, 9, 2157-2160.	1.3	5
5763	Prognostic Role of Tumor Mutation Burden Combined With Immune Infiltrates in Skin Cutaneous Melanoma Based on Multi-Omics Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 570654.	1.3	16
5764	Circulating Tumour DNA in Advanced Melanoma Patients Ceasing PD1 Inhibition in the Absence of Disease Progression. <i>Cancers</i> , 2020, 12, 3486.	1.7	10
5765	Eventos adversos menos frecuentes. , 2020, , .		0
5766	<p>Pretreatment CT-Based Radiomics Signature as a Potential Imaging Biomarker for Predicting the Expression of PD-L1 and CD8+TILs in ESCC</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 12003-12013.	1.0	29
5767	Safety and Efficacy of Immune Checkpoint Inhibitors for Patients With Metastatic Urothelial Carcinoma and End-Stage Renal Disease: Experiences From Real-World Practice. <i>Frontiers in Oncology</i> , 2020, 10, 584834.	1.3	12
5768	Pediatric onco-nephrology: time to spread the word. <i>Pediatric Nephrology</i> , 2021, 36, 2227-2255.	0.9	3
5769	Targeted nanobody complex enhanced photodynamic therapy for lung cancer by overcoming tumor microenvironment. <i>Cancer Cell International</i> , 2020, 20, 570.	1.8	19

#	ARTICLE	IF	CITATIONS
5770	The optimal timing and courses of bevacizumab added to chemotherapy for non-squamous non-small cell lung cancer: revelations from the real-world experience in a single Chinese cancer center. <i>Annals of Translational Medicine</i> , 2020, 8, 1311-1311.	0.7	1
5771	Enhancing Combined Immunotherapy and Radiotherapy through Nanomedicine. <i>Bioconjugate Chemistry</i> , 2020, 31, 2668-2678.	1.8	13
5772	Unique genomic features and prognostic value of COSMIC mutational signature 4 in lung adenocarcinoma and lung squamous cell carcinoma. <i>Annals of Translational Medicine</i> , 2020, 8, 1176-1176.	0.7	8
5773	Hyperprogression on immunotherapy with complete response to chemotherapy in a NSCLC patient with high PD-L1 and STK11. <i>Medicine (United States)</i> , 2020, 99, e22323.	0.4	12
5774	PD-1 Regulates GABAergic Neurotransmission and GABA-Mediated Analgesia and Anesthesia. <i>IScience</i> , 2020, 23, 101570.	1.9	23
5775	Iodine-125 radioactive particles antagonize hyperprogressive disease following immunotherapy. <i>Medicine (United States)</i> , 2020, 99, e22933.	0.4	3
5776	Targeting novel inhibitory receptors in cancer immunotherapy. <i>Seminars in Immunology</i> , 2020, 49, 101436.	2.7	8
5777	Inhibition of the CCL2 receptor, CCR2, enhances tumor response to immune checkpoint therapy. <i>Communications Biology</i> , 2020, 3, 720.	2.0	82
5778	Pembrolizumab for the treatment of uveal melanoma: A case series. <i>Rare Tumors</i> , 2020, 12, 203636132097198.	0.3	8
5779	TGF- β 2 is a Prognostic Biomarker Correlated with Immune Cell Infiltration in Colorectal Cancer. <i>Medicine (United States)</i> , 2020, 99, e23024.	0.4	8
5780	SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery. , 2020, 8, e000705.		20
5781	<p>Neuro-ophthalmic Complications of Immune Checkpoint Inhibitors: A Systematic Review</p>. <i>Eye and Brain</i> , 2020, Volume 12, 139-167.	3.8	28
5782	The Immune Checkpoint PD-1 in Natural Killer Cells: Expression, Function and Targeting in Tumour Immunotherapy. <i>Cancers</i> , 2020, 12, 3285.	1.7	85
5783	First line Immunotherapy for Non-Small Cell Lung Cancer. <i>Pharmaceuticals</i> , 2020, 13, 373.	1.7	49
5784	Pretreatment hemoglobin level as a predictor to evaluate the efficacy of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592097004.	1.4	22
5785	Induction of Durable Antitumor Response by a Novel Oncolytic Herpesvirus Expressing Multiple Immunomodulatory Transgenes. <i>Biomedicines</i> , 2020, 8, 484.	1.4	28
5786	Intratumoral Combinatorial Administration of CD1c (BDCA-1)+ Myeloid Dendritic Cells Plus Ipilimumab and Avelumab in Combination with Intravenous Low-Dose Nivolumab in Patients with Advanced Solid Tumors: A Phase IB Clinical Trial. <i>Vaccines</i> , 2020, 8, 670.	2.1	17
5787	CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592095299.	1.4	23

#	ARTICLE	IF	CITATIONS
5788	<p></p>Thyroid Dysfunctions Due to Immune Checkpoint Inhibitors: A Review<p></p>. International Journal of General Medicine, 2020, Volume 13, 1003-1009.	0.8	21
5789	Ceramide Pathway Regulators Predict Clinical Prognostic Risk and Affect the Tumor Immune Microenvironment in Lung Adenocarcinoma. Frontiers in Oncology, 2020, 10, 562574.	1.3	4
5790	Systematic Assessment of Risk of Fever in Solid Tumor Patients Treated With PD-1/PD-L1 Inhibitors: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2020, 10, 570080.	1.3	5
5791	Cold-Inducible RNA Binding Protein as a Vaccination Platform to Enhance Immunotherapeutic Responses against Hepatocellular Carcinoma. Cancers, 2020, 12, 3397.	1.7	17
5792	Clinical Characteristics Correlate With Outcomes of Immunotherapy in Advanced Non-Small Cell Lung Cancer. Journal of Cancer, 2020, 11, 7137-7145.	1.2	14
5793	Innovative Therapeutic Approaches in Primary Cutaneous B Cell Lymphoma. Frontiers in Oncology, 2020, 10, 1163.	1.3	7
5794	<p></p>Tumor-Associated CD163<p></p>+<p></p>M2 Macrophage Infiltration is Highly Associated with PD-L1 Expression in Cervical Cancer<p></p>. Cancer Management and Research, 2020, Volume 12, 5831-5843.	0.9	8
5795	Radiobiology of stereotactic ablative radiotherapy (SABR): perspectives of clinical oncologists. Journal of Cancer, 2020, 11, 5056-5068.	1.2	6
5796	Atezolizumab in a Cohort of pretreated, advanced, non-small cell lung cancer patients with rare Histological Subtypes (CHANCE trial). Therapeutic Advances in Medical Oncology, 2020, 12, 175883592091598.	1.4	5
5797	Comparative risk of serious and fatal treatment-related adverse events caused by 19 immune checkpoint inhibitors used in cancer treatment: a network meta-analysis. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592094092.	1.4	11
5798	<p></p>Past, Present, and Future of Anticancer Nanomedicine<p></p>. International Journal of Nanomedicine, 2020, Volume 15, 5719-5743.	3.3	23
5799	<p></p>Prognostic Significance of PD-L1 Expression and Its Tumor-Intrinsic Functions in Hypopharyngeal Squamous Cell Carcinoma<p></p>. Cancer Management and Research, 2020, Volume 12, 5893-5902.	0.9	13
5800	Immunoradiotherapy as an Effective Therapeutic Strategy in Lung Cancer: From Palliative Care to Curative Intent. Cancers, 2020, 12, 2178.	1.7	25
5801	Recent and Current Advances in FDG-PET Imaging within the Field of Clinical Oncology in NSCLC: A Review of the Literature. Diagnostics, 2020, 10, 561.	1.3	22
5802	Complete response to immunotherapy in a nonagenarian patient with metastatic melanoma. BMJ Case Reports, 2020, 13, e235472.	0.2	0
5803	Monoclonal Antibodies in Cancer Therapy. Antibodies, 2020, 9, 34.	1.2	325
5804	Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors. Frontiers in Cell and Developmental Biology, 2020, 8, 672.	1.8	205
5805	Tumor Primary Location May Affect Metastasis Pattern for Patients with Stage IV NSCLC: A Population-Based Study. Journal of Oncology, 2020, 2020, 1-8.	0.6	6

#	ARTICLE	IF	CITATIONS
5806	Identification of Prognostic Immune-Related Genes by Integrating mRNA Expression and Methylation in Lung Adenocarcinoma. <i>International Journal of Genomics</i> , 2020, 2020, 1-20.	0.8	11
5807	Nivolumab-Induced Autoimmune-Like Cholestatic Hepatitis in a Liver Transplant Recipient. <i>ACG Case Reports Journal</i> , 2020, 7, e00416.	0.2	17
5808	T Cells and Acute Kidney Injury: A Two-Way Relationship. <i>Frontiers in Immunology</i> , 2020, 11, 1546.	2.2	30
5809	Recent Advances in Nanotechnology for Dendritic Cell-Based Immunotherapy. <i>Frontiers in Pharmacology</i> , 2020, 11, 960.	1.6	15
5810	Immunotherapy in older patients with non-small cell lung cancer: Young International Society of Geriatric Oncology position paper. <i>British Journal of Cancer</i> , 2020, 123, 874-884.	2.9	15
5811	The Third Generation Anti-HER2 Chimeric Antigen Receptor Mouse T Cells Alone or Together With Anti-PD1 Antibody Inhibits the Growth of Mouse Breast Tumor Cells Expressing HER2 in vitro and in Immune Competent Mice. <i>Frontiers in Oncology</i> , 2020, 10, 1143.	1.3	25
5812	Extended-Interval Dosing Strategy of Immune Checkpoint Inhibitors in Lung Cancer: Will it Outlast the COVID-19 Pandemic?. <i>Frontiers in Oncology</i> , 2020, 10, 1193.	1.3	13
5813	Genetic and Molecular Basis of Heterogeneous NK Cell Responses against Acute Leukemia. <i>Cancers</i> , 2020, 12, 1927.	1.7	15
5814	Do Elderly Lung Cancer Patients Aged ≥75 Years Benefit from Immune Checkpoint Inhibitors?. <i>Cancers</i> , 2020, 12, 1995.	1.7	8
5815	Identification and Validation of the Immune Subtypes of Lung Adenocarcinoma: Implications for Immunotherapy. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 550.	1.8	14
5816	Renal adverse effects following the use of different immune checkpoint inhibitor regimens: A real-world pharmacoepidemiology study of post-marketing surveillance data. <i>Cancer Medicine</i> , 2020, 9, 6576-6585.	1.3	21
5817	Nivolumab-induced immune thrombocytopenia in a patient with malignant pleural mesothelioma. <i>Respiratory Medicine Case Reports</i> , 2020, 31, 101170.	0.2	2
5818	Pimasertib Versus Dacarbazine in Patients With Unresectable NRAS-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover. <i>Cancers</i> , 2020, 12, 1727.	1.7	36
5819	EKG Changes in Melanoma Patients Undergoing Cancer Therapy—Data from the ECoR Registry. <i>Journal of Clinical Medicine</i> , 2020, 9, 2060.	1.0	6
5820	Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592093761.	1.4	78
5821	Deep learning-based image analysis methods for brightfield-acquired multiplex immunohistochemistry images. <i>Diagnostic Pathology</i> , 2020, 15, 100.	0.9	35
5822	Progress in Neoantigen Targeted Cancer Immunotherapies. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 728.	1.8	28
5823	Methylation-Induced Silencing of ALDH2 Facilitates Lung Adenocarcinoma Bone Metastasis by Activating the MAPK Pathway. <i>Frontiers in Oncology</i> , 2020, 10, 1141.	1.3	16

#	ARTICLE	IF	CITATIONS
5824	The Potential of Five Immune-Related Prognostic Genes to Predict Survival and Response to Immune Checkpoint Inhibitors for Soft Tissue Sarcomas Based on Multi-Omic Study. <i>Frontiers in Oncology</i> , 2020, 10, 1317.	1.3	18
5825	Autophagy-lysosome inhibitor chloroquine prevents CTLA-4 degradation of T cells and attenuates acute rejection in murine skin and heart transplantation. <i>Theranostics</i> , 2020, 10, 8051-8060.	4.6	22
5826	High Expression of Programmed Death Ligand 1 and Programmed Death Ligand 2 in Ophthalmic Sebaceous Carcinoma: The Case for a Clinical Trial of Checkpoint Inhibitors. <i>American Journal of Ophthalmology</i> , 2020, 220, 128-139.	1.7	8
5827	Plasmacytoid Dendritic Cell Impairment in Metastatic Melanoma by Lactic Acidosis. <i>Cancers</i> , 2020, 12, 2085.	1.7	17
5828	The interplay between immunosenescence and age-related diseases. <i>Seminars in Immunopathology</i> , 2020, 42, 545-557.	2.8	150
5829	Is pembrolizumab monotherapy the optimal treatment for elderly patients with PD-L1 positive advanced non-small cell lung cancer?. <i>Annals of Translational Medicine</i> , 2020, 8, 778-778.	0.7	1
5830	<p>Update on Targeted Therapies for Advanced Non-Small Cell Lung Cancer: Durvalumab in Context</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 6885-6896.	1.0	1
5831	Prognostic significance of the neutrophil/lymphocyte ratio in patients undergoing treatment with nivolumab for recurrent non-small-cell lung cancer. <i>Lung Cancer Management</i> , 2020, 9, LMT37.	1.5	6
5832	Next-Generation Sequencing at High Sequencing Depth as a Tool to Study the Evolution of Metastasis Driven by Genetic Change Events of Lung Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 1215.	1.3	7
5833	Optimizing Sequential Systemic Therapies for Advanced Hepatocellular Carcinoma: A Decision Analysis. <i>Cancers</i> , 2020, 12, 2132.	1.7	18
5834	A brief review concerning Chimeric Antigen Receptors T cell therapy. <i>Journal of Cancer</i> , 2020, 11, 5424-5431.	1.2	4
5835	The role of gut microbiota in cancer treatment: friend or foe?. <i>Gut</i> , 2020, 69, 1867-1876.	6.1	189
5836	<p>Effective Treatment with PD-1 Antibody, Chidamide, Etoposide, and Thalidomide (PCET) for Relapsed/Refractory Natural Killer/T-Cell Lymphoma: A Report of Three Cases</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 7189-7197.	1.0	13
5837	Novel Targeted Therapies for Metastatic Thyroid Cancerâ€™A Comprehensive Review. <i>Cancers</i> , 2020, 12, 2104.	1.7	50
5838	The Value of PD-L1 Expression as Predictive Biomarker in Metastatic Renal Cell Carcinoma Patients: A Meta-Analysis of Randomized Clinical Trials. <i>Cancers</i> , 2020, 12, 1945.	1.7	49
5839	Therapeutic Strategies for Overcoming Immunotherapy Resistance Mediated by Immunosuppressive Factors of the Glioblastoma Microenvironment. <i>Cancers</i> , 2020, 12, 1960.	1.7	20
5840	Nivolumab for Previously Treated Patients with Non-Small-Cell Lung Cancerâ€™Daily Practice versus Clinical Trials. <i>Journal of Clinical Medicine</i> , 2020, 9, 2273.	1.0	3
5841	Adverse cardiac events in the treatment of non-small cell lung cancer with programmed death-1and programmed death-ligand 1 inhibitors. <i>Medicine (United States)</i> , 2020, 99, e21613.	0.4	0

#	ARTICLE	IF	CITATIONS
5842	Renal injury in the setting of immune checkpoint inhibitor: Report of a case of hypothyroidism and the role of positron emission tomography. <i>Journal of Onco-Nephrology</i> , 2020, 4, 112-116.	0.3	4
5843	The frequency and inter-relationship of PD-L1 expression and tumour mutational burden across multiple types of advanced solid tumours in China. <i>Experimental Hematology and Oncology</i> , 2020, 9, 17.	2.0	21
5844	Selective Upregulation of CTLA-4 on CD8+ T Cells Restricted by HLA-B*35Px Renders them to an Exhausted Phenotype in HIV-1 infection. <i>PLoS Pathogens</i> , 2020, 16, e1008696.	2.1	27
5845	Molecular and Immunological Characterization of Biliary Tract Cancers: A Paradigm Shift Towards a Personalized Medicine. <i>Cancers</i> , 2020, 12, 2190.	1.7	38
5846	Mechanisms of Cancer Resistance to Immunotherapy. <i>Frontiers in Oncology</i> , 2020, 10, 1290.	1.3	159
5847	A Prognostic Nomogram Combining Immune-Related Gene Signature and Clinical Factors Predicts Survival in Patients With Lung Adenocarcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 1300.	1.3	54
5848	Screening Cancer Immunotherapy: When Engineering Approaches Meet Artificial Intelligence. <i>Advanced Science</i> , 2020, 7, 2001447.	5.6	30
5849	Immune Cytolytic Activity as an Indicator of Immune Checkpoint Inhibitors Treatment for Prostate Cancer. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 930.	2.0	17
5850	Medical management of brain metastases. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa015.	0.4	15
5851	Hyperprogressive disease in advanced cancer patients with liver metastasis treated with PD-1 inhibitors: two case reports. <i>Annals of Translational Medicine</i> , 2020, 8, 1100-1100.	0.7	4
5852	First-Line Immune-Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Landscape and Future Progress. <i>Frontiers in Pharmacology</i> , 2020, 11, 578091.	1.6	51
5853	Opportunities for Subspecialization in Nephrology. <i>Advances in Chronic Kidney Disease</i> , 2020, 27, 320-327.e1.	0.6	11
5854	Radiation therapy for augmenting the efficacy of immunotherapy in advanced non-small cell lung cancer: a case-controlled study. <i>ERJ Open Research</i> , 2020, 6, 00189-2019.	1.1	2
5855	Organ Dysfunction in Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors. <i>Oncologist</i> , 2020, 25, e1753-e1762.	1.9	6
5856	DNA Repair and Signaling in Immune-Related Cancer Therapy. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 205.	1.6	20
5857	Adoptive transfer of TILs plus anti-PD1 therapy: An alternative combination therapy for treating metastatic osteosarcoma. <i>Journal of Bone Oncology</i> , 2020, 25, 100332.	1.0	19
5858	A Phase 2 Study of Nivolumab Using a Fixed Dose of 40mg (Nivo40) in Patients With Relapsed/Refractory Hodgkin Lymphoma. <i>HemaSphere</i> , 2020, 4, e480.	1.2	19
5859	New Verse for a Familiar Song: Small Molecule Inhibitors for MET exon 14 Skipping Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2020, 25, 822-825.	1.9	9

#	ARTICLE	IF	CITATIONS
5860	Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP) Tj ETQq0 0 0 rgBTj/Overlock 10 Tf 50	5.1	68
5861	Incidence and Clinical Features of Immune-Related Acute Kidney Injury in Patients Receiving Programmed Cell Death Ligand-1 Inhibitors. <i>Kidney International Reports</i> , 2020, 5, 1700-1705.	0.4	47
5862	Clinical Outcomes for PD-1 Inhibitor Plus Chemotherapy as Second-Line or Later Therapy Compared to PD-1/PD-L1 Inhibitor Alone in Advanced Non-small-cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 556275.	1.3	6
5863	Targeted Molecular Therapies in the Treatment of Esophageal Adenocarcinoma, Are We There Yet?. <i>Cancers</i> , 2020, 12, 3077.	1.7	4
5864	<p>Clinical Investigation of the Efficacy and Safety of Anlotinib with Immunotherapy in Advanced Non-Small Cell Lung Cancer as Third-Line Therapy: A Retrospective Study</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 10333-10340.	0.9	12
5865	The Impact of Liver Metastasis on Anti-PD-1 Monoclonal Antibody Monotherapy in Advanced Melanoma: Analysis of Five Clinical Studies. <i>Frontiers in Oncology</i> , 2020, 10, 546604.	1.3	15
5866	Microbiota and Lung Cancer. Opportunities and Challenges for Improving Immunotherapy Efficacy. <i>Frontiers in Oncology</i> , 2020, 10, 568939.	1.3	15
5867	Implementing ctDNA Analysis in the Clinic: Challenges and Opportunities in Non-Small Cell Lung Cancer. <i>Cancers</i> , 2020, 12, 3112.	1.7	23
5868	Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-“Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2020, 6, 1952.	3.4	241
5869	Novel Prognostic Model Based on Immune Signature for Head and Neck Squamous Cell Carcinoma. <i>BioMed Research International</i> , 2020, 2020, 1-9.	0.9	7
5870	Lipopolysaccharide-Mediated Chronic Inflammation Promotes Tobacco Carcinogen-“Induced Lung Cancer and Determines the Efficacy of Immunotherapy. <i>Cancer Research</i> , 2021, 81, 144-157.	0.4	52
5871	<p>CBX3 Promotes Gastric Cancer Progression and Affects Factors Related to Immunotherapeutic Responses</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 10113-10125.	0.9	23
5872	The Mechanisms of PD-L1 Regulation in Non-Small-Cell Lung Cancer (NSCLC): Which Are the Involved Players?. <i>Cancers</i> , 2020, 12, 3129.	1.7	29
5873	The Innate Immune Signalling Pathways: Turning RIG-I Sensor Activation against Cancer. <i>Cancers</i> , 2020, 12, 3158.	1.7	29
5874	Application and development of aptamer in cancer: from clinical diagnosis to cancer therapy. <i>Journal of Cancer</i> , 2020, 11, 6902-6915.	1.2	37
5875	Id1 and PD-1 Combined Blockade Impairs Tumor Growth and Survival of KRAS-mutant Lung Cancer by Stimulating PD-L1 Expression and Tumor Infiltrating CD8+ T Cells. <i>Cancers</i> , 2020, 12, 3169.	1.7	10
5876	Plasma soluble PD-L1 and STAT3 predict the prognosis in diffuse large B cell lymphoma patients. <i>Journal of Cancer</i> , 2020, 11, 7001-7008.	1.2	17
5877	A Methylation-Based Reclassification of Bladder Cancer Based on Immune Cell Genes. <i>Cancers</i> , 2020, 12, 3054.	1.7	28

#	ARTICLE	IF	CITATIONS
5878	Efficacy and safety of immune checkpoint blockade in self-identified Black patients with advanced non-small cell lung cancer. <i>Cancer</i> , 2020, 126, 5040-5049.	2.0	12
5879	Preliminary analysis of distinct clinical and biologic features of bone metastases in melanoma. <i>Melanoma Research</i> , 2020, 30, 492-499.	0.6	3
5880	Immunotherapy via PD-L1-presenting biomaterials leads to long-term islet graft survival. <i>Science Advances</i> , 2020, 6, eaba5573.	4.7	54
5881	Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors. <i>Biomarker Research</i> , 2020, 8, 34.	2.8	266
5882	Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives. <i>Biomarker Research</i> , 2020, 8, 35.	2.8	122
5883	Addition of Radiotherapy to Immunotherapy: Effects on Outcome of Different Subgroups Using a Propensity Score Matching. <i>Cancers</i> , 2020, 12, 2429.	1.7	5
5884	Clinical Outcomes and Prognosis Factors of Nivolumab Plus Chemotherapy or Multitarget Tyrosine Kinase Inhibitor in Multi-Line Therapy for Recurrent Hepatitis B Virus-Related Hepatocellular Carcinoma: A Retrospective Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 1404.	1.3	8
5885	Low ARID1A Expression is Associated with Poor Prognosis in Hepatocellular Carcinoma. <i>Cells</i> , 2020, 9, 2002.	1.8	25
5886	Impact of PD-L1 Scores and Changes on Clinical Outcome in Rectal Cancer Patients Undergoing Neoadjuvant Chemoradiotherapy. <i>Journal of Clinical Medicine</i> , 2020, 9, 2775.	1.0	10
5887	First-line treatments for advanced renal-cell carcinoma with immune checkpoint inhibitors: systematic review, network meta-analysis and cost-effectiveness analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592095019.	1.4	21
5888	STK11(LKB1) mutations in metastatic NSCLC: Prognostic value in the real world. <i>PLoS ONE</i> , 2020, 15, e0238358.	1.1	44
5889	Compare the efficacy and safety of programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) inhibitors for advanced non-small cell lung cancer: a Bayesian analysis. <i>Translational Lung Cancer Research</i> , 2020, 9, 1302-1323.	1.3	16
5890	Cancer-associated changes of emotional brain network in non-nervous system metastatic non-small cell lung cancer patients: a structural connectomic diffusion tensor imaging study. <i>Translational Lung Cancer Research</i> , 2020, 9, 1101-1111.	1.3	10
5891	Genetic and microenvironmental differences in non-smoking lung adenocarcinoma patients compared with smoking patients. <i>Translational Lung Cancer Research</i> , 2020, 9, 1407-1421.	1.3	17
5892	A meta-analysis on immune checkpoint inhibitor efficacy for advanced non-small cell lung cancer between East Asians versus non-East Asians. <i>Translational Lung Cancer Research</i> , 2020, 9, 1124-1137.	1.3	6
5893	Pilot Study of CT-Based Radiomics Model for Early Evaluation of Response to Immunotherapy in Patients With Metastatic Melanoma. <i>Frontiers in Oncology</i> , 2020, 10, 1524.	1.3	24
5894	Immunogenic Cell Death and Elimination of Immunosuppressive Cells: A Double-Edged Sword of Chemotherapy. <i>Cancers</i> , 2020, 12, 2637.	1.7	40
5895	Metabolic and epigenetic regulation of T-cell exhaustion. <i>Nature Metabolism</i> , 2020, 2, 1001-1012.	5.1	167

#	ARTICLE	IF	CITATIONS
5896	Immunotherapy in prostate cancer: current state and future perspectives. <i>Therapeutic Advances in Urology</i> , 2020, 12, 175628722095140.	0.9	24
5897	Predictive and prognostic significance of M descriptors of the 8th TNM classification for advanced NSCLC patients treated with immune checkpoint inhibitors. <i>Translational Lung Cancer Research</i> , 2020, 9, 1053-1066.	1.3	7
5898	Mass spectrometry-based serum proteomic signature as a potential biomarker for survival in patients with non-small cell lung cancer receiving immunotherapy. <i>Translational Lung Cancer Research</i> , 2020, 9, 1015-1028.	1.3	15
5899	Obesity, Sarcopenia, and Outcomes in Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors. <i>Frontiers in Oncology</i> , 2020, 10, 576314.	1.3	17
5900	Immunotherapy Breakthroughs in the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2020, 12, 2691.	1.7	39
5901	Brain metastases: lessons and challenges in the targeted therapy and immunotherapy era. <i>Journal of Thoracic Disease</i> , 2020, 12, 4527-4530.	0.6	3
5902	Innovative approaches to immunotherapy in breast cancer. <i>Journal of Thoracic Disease</i> , 2020, 12, 4536-4540.	0.6	4
5903	Microbiota and Cancer: The Emerging Beneficial Role of Bifidobacteria in Cancer Immunotherapy. <i>Frontiers in Microbiology</i> , 2020, 11, 575072.	1.5	40
5904	Design for immuno-oncology clinical trials enrolling both responders and nonresponders. <i>Statistics in Medicine</i> , 2020, 39, 3914-3936.	0.8	2
5905	KRAS ^{G12C} Inhibition with Sotorasib in Advanced Solid Tumors. <i>New England Journal of Medicine</i> , 2020, 383, 1207-1217.	13.9	1,049
5906	Acute kidney injury in patients treated with anti-programmed death receptor-1 for advanced melanoma: a real-life study in a single-centre cohort. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1664-1674.	0.4	41
5907	Combining immunotherapy and radiotherapy in lung cancer: a promising future?. <i>Journal of Thoracic Disease</i> , 2020, 12, 4498-4503.	0.6	7
5908	Beyond Chemotherapies: Recent Strategies in Breast Cancer Treatment. <i>Cancers</i> , 2020, 12, 2634.	1.7	7
5909	Treatment of Advanced Melanoma: Past, Present and Future. <i>Life</i> , 2020, 10, 208.	1.1	18
5910	Use of Immune Checkpoint Inhibitors in End Stage Kidney Disease Patients, Single Center Experience and Review of the Literature. <i>Kidney360</i> , 2020, 1, 399-402.	0.9	26
5911	<p>High PD-L1 Expression is Associated with Unfavorable Clinical Outcome in EGFR-Mutated Lung Adenocarcinomas Treated with Targeted Therapy</p><p>OncoTargets and Therapy, 2020, Volume 13, 8273-8285.</p>	1.0	19
5912	Clinical and radiological features of immune checkpoint inhibitor-related pneumonitis in lung cancer and non-lung cancers. <i>British Journal of Radiology</i> , 2020, 93, 20200409.	1.0	28
5913	Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma. <i>JAMA Oncology</i> , 2020, 6, 1563.	3.4	198

#	ARTICLE	IF	CITATIONS
5914	Pediatric pan-central nervous system tumor analysis of immune-cell infiltration identifies correlates of antitumor immunity. <i>Nature Communications</i> , 2020, 11, 4324.	5.8	75
5915	Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies. <i>Cancers</i> , 2020, 12, 2392.	1.7	171
5916	Resumption of anti- $\text{CD}137$ programmed cell death 1 monotherapy for severe immune-related adverse events experienced patient with renal cell carcinoma. <i>IJU Case Reports</i> , 2020, 3, 176-179.	0.1	1
5917	Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer. <i>Nature Communications</i> , 2020, 11, 4607.	5.8	69
5918	Evolutionary dynamics of neoantigens in growing tumors. <i>Nature Genetics</i> , 2020, 52, 1057-1066.	9.4	68
5919	Immunotherapy use in kidney transplant recipients: Immune checkpoint inhibitors and CAR-T cell therapy. <i>Journal of Onco-Nephrology</i> , 2020, 4, 165-170.	0.3	0
5920	Primary Resistance to Immune Checkpoint Blockade in an STK11/TP53/KRAS -Mutant Lung Adenocarcinoma with High PD-L1 Expression. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 8901-8905.	1.0	7
5922	ctDNA Concentration, MIK167 Mutations and Hyper-Progressive Disease Related Gene Mutations Are Prognostic Markers for Camrelizumab and Apatinib Combined Multiline Treatment in Advanced NSCLC. <i>Frontiers in Oncology</i> , 2020, 10, 1706.	1.3	17
5923	Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives. <i>Frontiers in Pharmacology</i> , 2020, 11, 572870.	1.6	72
5924	CD19-CAR-T Cells Bearing a KIR/PD-1-Based Inhibitory CAR Eradicate CD19+HLA-C1 ^{hi} Malignant B Cells While Sparing CD19+HLA-C1 ⁺ Healthy B Cells. <i>Cancers</i> , 2020, 12, 2612.	1.7	22
5925	Revisiting the PD-1 pathway. <i>Science Advances</i> , 2020, 6, .	4.7	277
5926	Lung cancer in women in 21th century. <i>Journal of Thoracic Disease</i> , 2020, 12, 4398-4410.	0.6	20
5927	VEGF-A Is Associated With the Degree of TILs and PD-L1 Expression in Primary Breast Cancer. <i>In Vivo</i> , 2020, 34, 2641-2646.	0.6	15
5928	Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 554313.	1.3	32
5929	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicity. <i>Supportive Care in Cancer</i> , 2020, 28, 6145-6157.	1.0	14
5930	Efficacy of Docetaxel Plus Ramucirumab as Palliative Third-Line Therapy Following Second-Line Immune-Checkpoint-Inhibitor Treatment in Patients With Non-Small-Cell Lung Cancer Stage IV. <i>Clinical Medicine Insights: Oncology</i> , 2020, 14, 117955492095135.	0.6	24
5931	Excision Repair Cross Complementation Group 1 Single Nucleotide Polymorphisms and Nivolumab in Advanced Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1167.	1.3	8
5932	Immune-Related Adverse Events and Corticosteroid Use for Cancer-Related Symptoms Are Associated With Efficacy in Patients With Non-small Cell Lung Cancer Receiving Anti-PD-(L)1 Blockade Agents. <i>Frontiers in Oncology</i> , 2020, 10, 1677.	1.3	32

#	ARTICLE	IF	CITATIONS
5933	Integrative clinical and molecular analysis of advanced biliary tract cancers on immune checkpoint blockade reveals potential markers of response. <i>Clinical and Translational Medicine</i> , 2020, 10, e118.	1.7	15
5934	Translational Considerations to Improve Response and Overcome Therapy Resistance in Immunotherapy for Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 2495.	1.7	12
5935	Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8+ T cell exhaustion. <i>Nature Communications</i> , 2020, 11, 4520.	5.8	218
5936	Prognosis of Lung Adenocarcinoma Patients With NTRK3 Mutations to Immune Checkpoint Inhibitors. <i>Frontiers in Pharmacology</i> , 2020, 11, 1213.	1.6	28
5937	Humanized Rodent Models for Cancer Research. <i>Frontiers in Oncology</i> , 2020, 10, 1696.	1.3	68
5938	Primary orbital melanoma: A report of a case and comprehensive review of the literature. <i>Orbit</i> , 2021, 40, 461-469.	0.5	6
5939	Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative. <i>BMC Pulmonary Medicine</i> , 2020, 20, 240.	0.8	16
5940	Diagnosis and management of immune-related adverse effects of immune checkpoint therapy in the emergency department. <i>Journal of the American College of Emergency Physicians Open</i> , 2020, 1, 1637-1659.	0.4	17
5941	<p></p>Prognostic Value of Cumulative Score Based on Preoperative Fibrinogen and Albumin Level in Skull Base Chordoma</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 8337-8346.	1.0	9
5942	18F-FDG PET/CT to predict tumor PD-L1 expression and response to PD-(L)1 blockade in patients with non-small-cell lung cancer. <i>Journal of Thoracic Disease</i> , 2020, 12, 3883-3885.	0.6	0
5943	<p></p>A Review About Pembrolizumab in First-Line Treatment of Advanced NSCLC: Focus on KEYNOTE Studies</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 6493-6509.	0.9	19
5944	Genomic Mapping Identifies Mutations in RYR2 and AHNAK as Associated with Favorable Outcome in Basal-Like Breast Tumors Expressing PD1/PD-L1. <i>Cancers</i> , 2020, 12, 2243.	1.7	22
5945	Development of Mannose-Modified Carboxylated Curdlan-Coated Liposomes for Antigen Presenting Cell Targeted Antigen Delivery. <i>Pharmaceutics</i> , 2020, 12, 754.	2.0	12
5946	Interface of cancer stem cells and cancer immunity. <i>Annals of Translational Medicine</i> , 2020, 8, 810-810.	0.7	0
5947	<p></p>Encapsulated Checkpoint Blocker Before Chemotherapy: The Optimal Sequence of Anti-CTLA-4 and Doxil Combination Therapy</p>. <i>International Journal of Nanomedicine</i> , 2020, Volume 15, 5279-5288.	3.3	18
5948	<p></p>Combination of Immune Checkpoint Inhibitors with Chemotherapy in Lung Cancer</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 7229-7241.	1.0	12
5949	Computed tomography texture analysis of response to second-line nivolumab in metastatic non-small cell lung cancer. <i>Lung Cancer Management</i> , 2020, 9, LMT38.	1.5	9
5950	Synthesis and Evaluation of Biphenyl-1,2,3-Triazol-Benzonitrile Derivatives as PD-1/PD-L1 Inhibitors. <i>ACS Omega</i> , 2020, 5, 21181-21190.	1.6	9

#	ARTICLE	IF	CITATIONS
5951	Are there any ethnic differences in the efficacy and safety of immune checkpoint inhibitors for treatment of lung cancer?. <i>Journal of Thoracic Disease</i> , 2020, 12, 3796-3803.	0.6	19
5952	Immunotherapy for Glioblastoma: Current State, Challenges, and Future Perspectives. <i>Cancers</i> , 2020, 12, 2334.	1.7	15
5953	LncRNA KCNQ1OT1 sponges miR-15a to promote immune evasion and malignant progression of prostate cancer via up-regulating PD-L1. <i>Cancer Cell International</i> , 2020, 20, 394.	1.8	53
5954	Filtering Data About Treatment-Induced Renal Injury: From Biology to Practice. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1389-1391.	0.5	2
5955	Endocrine Adverse Events of Nivolumab in Non-Small Cell Lung Cancer Patientsâ€”Literature Review. <i>Cancers</i> , 2020, 12, 2314.	1.7	13
5956	C-Reactive Protein (CRP) Levels in Immune Checkpoint Inhibitor Response and Progression in Advanced Non-Small Cell Lung Cancer: A Bi-Center Study. <i>Cancers</i> , 2020, 12, 2319.	1.7	52
5957	Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma. <i>Cancers</i> , 2020, 12, 2329.	1.7	45
5958	Targeted and Checkpoint Inhibitor Therapy of Metastatic Malignant Melanoma in Germany, 2000â€”2016. <i>Cancers</i> , 2020, 12, 2354.	1.7	8
5959	Uncommon Subtypes of Malignant Melanomas: A Review Based on Clinical and Molecular Perspectives. <i>Cancers</i> , 2020, 12, 2362.	1.7	22
5960	The challenge of primary gastric melanoma: a systematic review. <i>Melanoma Management</i> , 2020, 7, MMT51.	0.1	9
5961	Real-World Safety and Efficacy of Nivolumab in Advanced Squamous and Nonsquamous Non-Small-Cell Lung Cancer: A Retrospective Cohort Study in Croatia, Hungary, and Malta. <i>Journal of Oncology</i> , 2020, 2020, 1-9.	0.6	2
5962	Factors Associated With Efficacy and Nivolumab-Related Interstitial Pneumonia in Non-Small Cell Lung Cancer: A Retrospective Survey. <i>Cancer Control</i> , 2020, 27, 107327482097720.	0.7	5
5963	PD-L1 expression with respect to driver mutations in non-small cell lung cancer in an Asian population: a large study of 1370 cases in China. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592096584.	1.4	13
5964	Nivolumab treatment in advanced non-small cell lung cancer: real-world long-term outcomes within overall and special populations (the UNIVOC study). <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592096723.	1.4	13
5965	Gastrointestinal side effects of cancer treatments. <i>Therapeutic Advances in Chronic Disease</i> , 2020, 11, 204062232097035.	1.1	41
5966	The real-world experience with nivolumab in previously treated patients with advanced non-small cell lung cancer from a cancer center in India. <i>South Asian Journal of Cancer</i> , 2020, 09, 50-52.	0.2	4
5967	Quality of CD8 ⁺ T cell immunity evoked in lymph nodes is compartmentalized by route of antigen transport and functional in tumor context. <i>Science Advances</i> , 2020, 6, .	4.7	24
5968	Genotyping Squamous Cell Lung Carcinoma in Colombia (Geno1.1-CLICaP). <i>Frontiers in Oncology</i> , 2020, 10, 588932.	1.3	4

#	ARTICLE	IF	CITATIONS
5969	The Value of PD-L1 Expression in Predicting the Efficacy of Anti-PD-1 or Anti-PD-L1 Therapy in Patients with Cancer: A Systematic Review and Meta-Analysis. <i>Disease Markers</i> , 2020, 2020, 1-14.	0.6	13
5970	Hyperacute Onset of Immune Checkpoint Inhibitor-Related Acute Interstitial Nephritis. <i>Kidney International Reports</i> , 2020, 5, 2084-2088.	0.4	3
5971	Understanding the Targeting Mechanisms of Multi-Specific Biologics in Immunotherapy with Multiscale Modeling. <i>IScience</i> , 2020, 23, 101835.	1.9	6
5972	Patients With BRAF-Mutant NSCLC May Not Benefit From Immune Checkpoint Inhibitors: A Population-Based Study. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100006.	0.6	8
5973	A case of large-cell lung carcinoma successfully treated with pembrolizumab but complicated with cholangitis. <i>Respiratory Medicine Case Reports</i> , 2020, 31, 101197.	0.2	4
5974	Retreatment with immune checkpoint inhibitors in solid tumors: a systematic review. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592097535.	1.4	18
5975	The present and future of systemic and microenvironment-targeted therapy for pancreatic adenocarcinoma. <i>Annals of Pancreatic Cancer</i> , 2020, 3, 3-3.	1.2	2
5976	Changing paradigm in advanced and metastatic non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2020, 12, 6992-7001.	0.6	3
5977	Radiation and immunotherapy: emerging mechanisms of synergy. <i>Journal of Thoracic Disease</i> , 2020, 12, 7011-7023.	0.6	28
5978	<p>Review of Adjuvant Therapies in Renal Cell Carcinoma: Evidence to Date</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 12301-12316.	1.0	22
5979	Lung Adenocarcinoma Harboring EGFR Kinase Domain Duplication (EGFR-KDD) Confers Sensitivity to Osimertinib and Nivolumab: A Case Report. <i>Frontiers in Oncology</i> , 2020, 10, 575739.	1.3	3
5980	â€œGiant cell arteritis manifesting as retinal arterial occlusion and paracentral acute middle maculopathy in a patient on pembrolizumab for metastatic uveal melanomaâ€. <i>American Journal of Ophthalmology Case Reports</i> , 2020, 20, 100891.	0.4	14
5981	Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. <i>The Cochrane Library</i> , 2020, 12, CD013257.	1.5	30
5982	Perspectives From an Onconeurology Interest Group: Conference Report. <i>Canadian Journal of Kidney Health and Disease</i> , 2020, 7, 205435812096258.	0.6	1
5983	Complement System: Promoter or Suppressor of Cancer Progression?. <i>Antibodies</i> , 2020, 9, 57.	1.2	58
5984	Unveiling the Hidden Treasury: CIITA-Driven MHC Class II Expression in Tumor Cells to Dig up the Relevant Repertoire of Tumor Antigens for Optimal Stimulation of Tumor Specific CD4+ T Helper Cells. <i>Cancers</i> , 2020, 12, 3181.	1.7	9
5985	<p>The Value of Hope: Patientsâ€™ and Physiciansâ€™ Preferences for Survival in Advanced Non-Small Cell Lung Cancer</p>. <i>Patient Preference and Adherence</i> , 2020, Volume 14, 2093-2104.	0.8	9
5986	The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?. <i>Frontiers in Immunology</i> , 2020, 11, 574271.	2.2	112

#	ARTICLE	IF	CITATIONS
5987	Immune Checkpoint Inhibitors and Survival Outcomes in Brain Metastasis: A Time Series-Based Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 564382.	1.3	9
5988	Comparative Risks of High-Grade Adverse Events Among FDA-Approved Systemic Therapies in Advanced Melanoma: Systematic Review and Network Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 571135.	1.3	2
5989	Extramedullary malignant melanotic schwannoma of the spine: Case report and an up to date systematic review of the literature. <i>Annals of Medicine and Surgery</i> , 2020, 59, 217-223.	0.5	12
5990	PD-L1 Immunohistochemistry Comparability and Their Correlation with Clinical Characteristics in NSCLC. <i>Analytical Cellular Pathology</i> , 2020, 2020, 1-7.	0.7	3
5991	Co-inhibitory Receptor Signaling in T-Cell-Mediated Autoimmune Glomerulonephritis. <i>Frontiers in Medicine</i> , 2020, 7, 584382.	1.2	3
5992	Rapid progression of disease from immunotherapy following targeted therapy: insights into treatment management and sequence. <i>Journal of Thoracic Disease</i> , 2020, 12, 5096-5103.	0.6	0
5993	Nivolumab in pre-treated advanced non-small cell lung cancer: long term follow up data from the Dutch expanded access program and routine clinical care. <i>Translational Lung Cancer Research</i> , 2020, 9, 1736-1748.	1.3	9
5994	Case Report: Low-Dose Decitabine Plus Anti-PD-1 Inhibitor Camrelizumab for Previously Treated Advanced Metastatic Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 558572.	1.3	12
5995	ZMYND8 Expression in Breast Cancer Cells Blocks T-Lymphocyte Surveillance to Promote Tumor Growth. <i>Cancer Research</i> , 2021, 81, 174-186.	0.4	12
5996	Immune Responses and Risk of Triple-negative Breast Cancer: Implications for Higher Rates among African American Women. <i>Cancer Prevention Research</i> , 2020, 13, 901-910.	0.7	10
5997	Prognostic nomogram on clinicopathologic features and serum indicators for advanced non-small cell lung cancer patients treated with anti-PD-1 inhibitors. <i>Annals of Translational Medicine</i> , 2020, 8, 1078-1078.	0.7	9
5998	Tumor density is associated with response to endobronchial ultrasound-guided transbronchial needle injection of cisplatin. <i>Journal of Thoracic Disease</i> , 2020, 12, 4825-4832.	0.6	6
5999	Biomarkers in immunotherapy: literature review and future directions. <i>Journal of Thoracic Disease</i> , 2020, 12, 5119-5127.	0.6	7
6000	A Holistic Perspective: Exosomes Shuttle between Nerves and Immune Cells in the Tumor Microenvironment. <i>Journal of Clinical Medicine</i> , 2020, 9, 3529.	1.0	10
6001	Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors. <i>Cancer Discovery</i> , 2020, 10, 1808-1825.	7.7	388
6002	Radiomics of ¹⁸ F Fluorodeoxyglucose PET/CT Images Predicts Severe Immune-related Adverse Events in Patients with NSCLC. <i>Radiology: Artificial Intelligence</i> , 2020, 2, e190063.	3.0	24
6004	Clinical Data on Immunotherapy in Breast Cancer. <i>Breast Care</i> , 2020, 15, 450-469.	0.8	12
6005	Future of immune checkpoint inhibitors: focus on tumor immune microenvironment. <i>Annals of Translational Medicine</i> , 2020, 8, 1095-1095.	0.7	27

#	ARTICLE	IF	CITATIONS
6006	Exosomal PD-L1: New Insights Into Tumor Immune Escape Mechanisms and Therapeutic Strategies. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 569219.	1.8	59
6007	Development of Extragenital Lichen Sclerosus in Malignant Melanoma Patients Treated With Ipilimumab in Combination With Nivolumab. <i>Frontiers in Oncology</i> , 2020, 10, 573527.	1.3	6
6008	Osteosarcoma and soft-tissue sarcomas with an immune infiltrate express PD-L1: relation to clinical outcome and Th1 pathway activation. <i>Oncolimmunology</i> , 2020, 9, 1737385.	2.1	23
6009	A Case of Nivolumab-Induced Cutaneous Toxicity with Multiple Morphologies. <i>Dermatopathology (Basel, Switzerland)</i> , 2019, 6, 255-259.	0.7	9
6010	Mathematical prediction of clinical outcomes in advanced cancer patients treated with checkpoint inhibitor immunotherapy. <i>Science Advances</i> , 2020, 6, eaay6298.	4.7	41
6011	Bullous pemphigoid secondary to pembrolizumab mimicking toxic epidermal necrolysis. <i>JAAD Case Reports</i> , 2020, 6, 400-402.	0.4	13
6012	Renal Toxicity From Pemetrexed and Pembrolizumab in the Era of Combination Therapy in Patients With Metastatic Nonsquamous Cell NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1472-1483.	0.5	32
6013	The Long Half-Life of Programmed Cell Death Protein 1 Inhibitors May Increase the Frequency of Immune-Related Adverse Events After Subsequent EGFR Tyrosine Kinase Inhibitor Therapy. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100008.	0.6	4
6014	ADAM10 and ADAM17 cleave PD-L1 to mediate PD-(L)1 inhibitor resistance. <i>Oncolimmunology</i> , 2020, 9, 1744980.	2.1	77
6015	Targeting PD-L1 Initiates Effective Antitumor Immunity in a Murine Model of Cushing Disease. <i>Clinical Cancer Research</i> , 2020, 26, 1141-1151.	3.2	43
6016	Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy. <i>Annals of Oncology</i> , 2020, 31, 1075-1082.	0.6	62
6017	Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1130-1143.	0.6	89
6018	Stereotactic body radiation therapy (SBRT) in the management of pulmonary spindle cell carcinoma. <i>BMJ Case Reports</i> , 2020, 13, e234779.	0.2	3
6019	Breakthrough 5-year survival with pembrolizumab in Keynote-001 study: horizon shifting in advanced non-small cell lung cancer with immune check point inhibition. <i>Annals of Translational Medicine</i> , 2020, 8, 555-555.	0.7	8
6020	Opportunities for using in silico-based extended dosing regimens for monoclonal antibody immune checkpoint inhibitors. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1769-1777.	1.1	25
6021	Anti PD-1 monoclonal antibody induced autoimmune diabetes mellitus: a case report and brief review. <i>Translational Lung Cancer Research</i> , 2020, 9, 379-388.	1.3	4
6022	Pretreatment nutritional status and response to checkpoint inhibitors in lung cancer. <i>Lung Cancer Management</i> , 2020, 9, LMT31.	1.5	19
6023	Association of immune-related pneumonitis with the efficacy of PD-1/PD-L1 inhibitors in non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092203.	1.4	26

#	ARTICLE	IF	CITATIONS
6024	Chemotherapy and immune checkpoint inhibitor combination, a new standard in squamous non-small cell lung cancer?. <i>Translational Lung Cancer Research</i> , 2020, 9, 401-405.	1.3	1
6025	A Simple Model Established by Blood Markers Predicting Overall Survival After Radical Resection of Pancreatic Ductal Adenocarcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 583.	1.3	9
6026	The Effects of Obesity on Anti-Cancer Immunity and Cancer Immunotherapy. <i>Cancers</i> , 2020, 12, 1230.	1.7	74
6027	Oncologic Emergencies: Immune-Based Cancer Therapies and Complications. <i>Western Journal of Emergency Medicine</i> , 2020, 21, 566-580.	0.6	13
6028	Intervention strategies for microbial therapeutics in cancer immunotherapy. <i>Immuno-Oncology Technology</i> , 2020, 6, 9-17.	0.2	8
6029	A guide to cancer immunotherapy: from T cell basic science to clinical practice. <i>Nature Reviews Immunology</i> , 2020, 20, 651-668.	10.6	2,160
6030	The KEY for chemo-immunotherapy combination: taking NOTES from squamous cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 410-413.	1.3	0
6031	Construction of Biocompatible Dual-Drug Loaded Complicated Nanoparticles for in vivo Improvement of Synergistic Chemotherapy in Esophageal Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 622.	1.3	12
6032	PIOS (Patras Immunotherapy Score) Score Is Associated with Best Overall Response, Progression-Free Survival, and Post-Immunotherapy Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated with Anti-Program Cell Death-1 (PD-1) Inhibitors. <i>Cancers</i> , 2020, 12, 1257.	1.7	8
6033	Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient. <i>Cancers</i> , 2020, 12, 1125.	1.7	43
6034	Surgery for Unresectable Stage IIIC and IV Melanoma in the Era of New Systemic Therapy. <i>Cancers</i> , 2020, 12, 1176.	1.7	11
6035	Immune-related adverse events of checkpoint inhibitors. <i>Nature Reviews Disease Primers</i> , 2020, 6, 38.	18.1	684
6036	Lactate dehydrogenase-elevating virus enhances natural killer cell-mediated immunosurveillance of mouse mesothelioma development. <i>Infectious Agents and Cancer</i> , 2020, 15, 30.	1.2	3
6037	Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib. <i>Oncologist</i> , 2020, 25, 702-711.	1.9	17
6038	Immune Checkpoint Inhibitors for Lung Cancer Treatment: A Review. <i>Journal of Clinical Medicine</i> , 2020, 9, 1362.	1.0	102
6039	Rational Design of Polyglutamic Acid Delivering an Optimized Combination of Drugs Targeting Mutated BRAF and MEK in Melanoma. <i>Advanced Therapeutics</i> , 2020, 3, 2000028.	1.6	9
6040	Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis. , 2020, 8, e000146.		49
6041	Blocking interaction between SHP2 and PD-1 denotes a novel opportunity for developing PD-1 inhibitors. <i>EMBO Molecular Medicine</i> , 2020, 12, e11571.	3.3	40

#	ARTICLE	IF	CITATIONS
6042	Keynote 42: Pembrolizumab, PD-L1, and where to draw the line. <i>Annals of Translational Medicine</i> , 2020, 8, 517-517.	0.7	2
6043	The impact of immune-inflammation-nutritional parameters on the prognosis of non-small cell lung cancer patients treated with atezolizumab. <i>Journal of Thoracic Disease</i> , 2020, 12, 1520-1528.	0.6	52
6044	Opportunities for Conventional and In Situ Cancer Vaccine Strategies and Combination with Immunotherapy for Gastrointestinal Cancers, A Review. <i>Cancers</i> , 2020, 12, 1121.	1.7	31
6045	Tumor aggression among hepatitis-C related hepatocellular carcinoma patients: an observational study regarding the impact of anti-HCV therapy. <i>Infectious Agents and Cancer</i> , 2020, 15, 35.	1.2	5
6046	Hyponatremia in the cancer patient. <i>Kidney International</i> , 2020, 98, 870-882.	2.6	25
6047	PD-1/PD-L1 Based Combinational Cancer Therapy: Icing on the Cake. <i>Frontiers in Pharmacology</i> , 2020, 11, 722.	1.6	65
6048	Nivolumab-induced IgA nephropathy in a patient with advanced gastric cancer. <i>Medicine (United Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50</i>	0.4	11
6049	Immune checkpoint inhibitor-mediated myasthenia gravis with focal subclinical myocarditis progressing to symptomatic cardiac disease. <i>BMJ Case Reports</i> , 2020, 13, e232920.	0.2	9
6050	Acquired Resistance to Immune Checkpoint Blockade Therapies. <i>Cancers</i> , 2020, 12, 1161.	1.7	9
6051	Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives. <i>Cancers</i> , 2020, 12, 1196.	1.7	65
6052	CAR T cell therapy: newer approaches to counter resistance and cost. <i>Heliyon</i> , 2020, 6, e03779.	1.4	19
6053	Pulmonary Complications Secondary to Immune Checkpoint Inhibitors. <i>International Journal of Chronic Diseases</i> , 2020, 2020, 1-5.	1.9	1
6054	<p>Recurrent Metastatic Penile Cancer Patient with Positive PD-L1 Expression Obtained Significant Benefit from Immunotherapy: A Case Report and Literature Review</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 3319-3324.	1.0	15
6055	Identification and Analysis of Dysfunctional Genes and Pathways in CD8+ T Cells of Non-Small Cell Lung Cancer Based on RNA Sequencing. <i>Frontiers in Genetics</i> , 2020, 11, 352.	1.1	6
6056	Chemotherapy Reverses Anti-PD-1 Resistance in One Patient With Advanced Non-small Lung Cell Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 507.	1.3	6
6057	Metabolism and Immune Modulation in Patients with Solid Tumors: Systematic Review of Preclinical and Clinical Evidence. <i>Cancers</i> , 2020, 12, 1153.	1.7	4
6058	HIP1R Expression and Its Association with PD-1 Pathway Blockade Response in Refractory Advanced NonSmall Cell Lung Cancer: A Gene Set Enrichment Analysis. <i>Journal of Clinical Medicine</i> , 2020, 9, 1425.	1.0	6
6059	18F-FDG PET/CT based spleen to liver ratio associates with clinical outcome to ipilimumab in patients with metastatic melanoma. <i>Cancer Imaging</i> , 2020, 20, 36.	1.2	46

#	ARTICLE	IF	CITATIONS
6060	Low Expression of Programmed Death 1 (PD-1), PD-1 Ligand 1 (PD-L1), and Low CD8+ T Lymphocyte Infiltration Identify a Subgroup of Patients With Gastric and Esophageal Adenocarcinoma With Severe Prognosis. <i>Frontiers in Medicine</i> , 2020, 7, 144.	1.2	15
6061	Clinical Characteristics and Treatment Outcomes of 65 Patients With BRAF-Mutated Non-small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 603.	1.3	26
6062	PD-L1 expression in malignant pleural effusion samples and its correlation with oncogene mutations in non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2020, 12, 1385-1392.	0.6	12
6063	Autologously Humanized Mice for Immune-Oncologic Studies. <i>Current Protocols in Pharmacology</i> , 2020, 89, e76.	4.0	4
6064	Immune checkpoint inhibitor-related dermatologic adverse events. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1255-1268.	0.6	221
6065	An Episode of Pseudothrombocytopenia during Pembrolizumab Therapy in NSCLC Patient. <i>Case Reports in Oncological Medicine</i> , 2020, 2020, 1-4.	0.2	3
6066	Neoadjuvant rituximab modulates the tumor immune environment in patients with high risk prostate cancer. <i>Journal of Translational Medicine</i> , 2020, 18, 214.	1.8	23
6067	Microenvironment characterization and multi-omics signatures related to prognosis and immunotherapy response of hepatocellular carcinoma. <i>Experimental Hematology and Oncology</i> , 2020, 9, 10.	2.0	48
6068	Bad Neighborhood: Fibrotic Stroma as a New Player in Melanoma Resistance to Targeted Therapies. <i>Cancers</i> , 2020, 12, 1364.	1.7	19
6069	Soluble PD-L1 in NSCLC Patients Treated with Checkpoint Inhibitors and Its Correlation with Metabolic Parameters. <i>Cancers</i> , 2020, 12, 1373.	1.7	24
6070	Diffuse pneumonitis from coronavirus HKU1 on checkpoint inhibitor therapy. , 2020, 8, e000898.		3
6071	The Efficacy and Safety of PD-1/PD-L1 Inhibitors in Combination with Conventional Therapies for Advanced Solid Tumors: A Meta-Analysis. <i>BioMed Research International</i> , 2020, 2020, 1-10.	0.9	8
6072	Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2020, 6, 1606.	3.4	79
6073	The speed of adoption of new drugs and prescription volume after the amendments in reimbursement coverage: the case of non-vitamin K antagonist oral anticoagulants in South Korea. <i>BMC Public Health</i> , 2020, 20, 797.	1.2	4
6074	Much has changed in the last decade except overall survival: A Swiss single center analysis of treatment and survival in patients with stage IV non-small cell lung cancer. <i>PLoS ONE</i> , 2020, 15, e0233768.	1.1	6
6075	PD-L1 siRNA-mediated silencing in acute myeloid leukemia enhances anti-leukemic T cell reactivity. <i>Bone Marrow Transplantation</i> , 2020, 55, 2308-2318.	1.3	12
6076	Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy. <i>Journal of Hematology and Oncology</i> , 2020, 13, 74.	6.9	17
6077	Triple-negative breast cancer molecular subtyping and treatment progress. <i>Breast Cancer Research</i> , 2020, 22, 61.	2.2	1,022

#	ARTICLE	IF	CITATIONS
6078	Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors. <i>Cancers</i> , 2020, 12, 1502.	1.7	145
6079	Combination Therapy and Nanoparticulate Systems: Smart Approaches for the Effective Treatment of Breast Cancer. <i>Pharmaceutics</i> , 2020, 12, 524.	2.0	22
6080	The cancer immunotherapy environment may confound the utility of anti-TIF-1 β in differentiating between paraneoplastic and treatment-related dermatomyositis. Report of a case and review of the literature. <i>Wspolczesna Onkologia</i> , 2020, 24, 75-78.	0.7	4
6081	Application of immune checkpoint inhibitors in EGFR-mutant non-small-cell lung cancer: from bed to bench. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592093033.	1.4	25
6082	<p>Ipilimumab and Nivolumab as First-Line Treatment of Patients with Renal Cell Carcinoma: The Evidence to Date</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 4871-4881.	0.9	29
6083	Real-world outcomes of advanced melanoma patients not represented in phase <scp>III</scp> trials. <i>International Journal of Cancer</i> , 2020, 147, 3461-3470.	2.3	27
6084	IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy. <i>Nature</i> , 2020, 583, 609-614.	13.7	195
6085	Imaging-Based Prediction of Molecular Therapy Targets in NSCLC by Radiogenomics and AI Approaches: A Systematic Review. <i>Diagnostics</i> , 2020, 10, 359.	1.3	51
6086	Intrahepatic Cholangiocarcinoma: Genomic Heterogeneity Between Eastern and Western Patients. <i>JCO Precision Oncology</i> , 2020, 4, 557-569.	1.5	35
6087	Mechanistic dissection of the PD-L1:B7-1 co-inhibitory immune complex. <i>PLoS ONE</i> , 2020, 15, e0233578.	1.1	23
6088	Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma. <i>Cancers</i> , 2020, 12, 1449.	1.7	72
6089	Real-world treatment efficacy of anti-programmed death-1 combined with anti-angiogenesis therapy in non-small cell lung cancer patients. <i>Medicine (United States)</i> , 2020, 99, e20545.	0.4	18
6090	Racial differences in CD8+ T cell infiltration in breast tumors from Black and White women. <i>Breast Cancer Research</i> , 2020, 22, 62.	2.2	24
6091	Evolving insights into the mechanisms of toxicity associated with immune checkpoint inhibitor therapy. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1778-1789.	1.1	34
6092	Immune Checkpoint Inhibitors and Immune-Related Adverse Renal Events. <i>Kidney International Reports</i> , 2020, 5, 1139-1148.	0.4	71
6093	Non-“Small Cell Lung Cancer Patient Preferences for First-Line Treatment: A Discrete Choice Experiment. <i>MDM Policy and Practice</i> , 2020, 5, 238146832092220.	0.5	2
6094	Targeting KRAS Mutant Non-Small-Cell Lung Cancer: Past, Present and Future. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4325.	1.8	84
6095	Programmed Death Ligand 1: A Poor Prognostic Marker in Endometrial Carcinoma. <i>Diagnostics</i> , 2020, 10, 394.	1.3	4

#	ARTICLE	IF	CITATIONS
6096	A microsimulation model to assess the economic impact of immunotherapy in non-small cell lung cancer. <i>ERJ Open Research</i> , 2020, 6, 00174-2019.	1.1	3
6097	Inflammatory Cytokines and ctDNA Are Biomarkers for Progression in Advanced-Stage Melanoma Patients Receiving Checkpoint Inhibitors. <i>Cancers</i> , 2020, 12, 1414.	1.7	15
6098	Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis. , 2020, 8, e000451.		39
6099	Immunocheckpoint Inhibitor- (Nivolumab-) Associated Hypereosinophilia in Non-Small-Cell Lung Carcinoma. <i>Case Reports in Oncological Medicine</i> , 2020, 2020, 1-5.	0.2	3
6100	Electrolyte Disorders Induced by Antineoplastic Drugs. <i>Frontiers in Oncology</i> , 2020, 10, 779.	1.3	39
6101	Over-Expression and Prognostic Significance of HHLA2, a New Immune Checkpoint Molecule, in Human Clear Cell Renal Cell Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 280.	1.8	28
6102	The top 100 cited articles in lung cancer – a bibliometric analysis. <i>Wspolczesna Onkologia</i> , 2020, 24, 17-28.	0.7	7
6103	Analysis of Gene Signatures of Tumor Microenvironment Yields Insight Into Mechanisms of Resistance to Immunotherapy. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 348.	2.0	4
6104	Molecular Mechanisms of Cardiomyocyte Death in Drug-Induced Cardiotoxicity. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 434.	1.8	89
6105	Higher Tumor Mutation Burden and Higher PD-L1 Activity Predicts the Efficacy of Immune Checkpoint Inhibitor Treatment in a Patient With Four Lung Cancers. A Case Report. <i>Frontiers in Oncology</i> , 2020, 10, 689.	1.3	2
6106	Anti-PD-1 Therapy Response Predicted by the Combination of Exosomal PD-L1 and CD28. <i>Frontiers in Oncology</i> , 2020, 10, 760.	1.3	33
6107	Targeting Autophagy Facilitates T Lymphocyte Migration by Inducing the Expression of CXCL10 in Gastric Cancer Cell Lines. <i>Frontiers in Oncology</i> , 2020, 10, 886.	1.3	4
6108	Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2020, 6, 1039.	3.4	70
6109	Metabolism in tumor microenvironment: Implications for cancer immunotherapy. <i>MedComm</i> , 2020, 1, 47-68.	3.1	93
6110	Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion. <i>Cancer Cell</i> , 2020, 38, 79-96.e11.	7.7	389
6111	Importance of methodology in the evaluation of renal mononuclear phagocytes and analysis of a model of experimental nephritis with Shp1 conditional knockout mice. <i>Biochemistry and Biophysics Reports</i> , 2020, 22, 100741.	0.7	0
6112	The Risk Ratio of Immune-Related Colitis, Hepatitis, and Pancreatitis in Patients With Solid Tumors Caused by PD-1/PD-L1 Inhibitors: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 261.	1.3	11
6113	Clinical characteristics of adrenal insufficiency as an immune-related adverse event in non-small-cell lung cancer. <i>Medical Oncology</i> , 2020, 37, 30.	1.2	11

#	ARTICLE	IF	CITATIONS
6114	Lymphocyte Activation Gene (LAG)-3 Is Associated With Mucosal Inflammation and Disease Activity in Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1446-1461.	0.6	25
6115	Kidney retransplantation after anti-“programmed cell death-1 (PD-1)“related allograft rejection. <i>American Journal of Transplantation</i> , 2020, 20, 2264-2268.	2.6	20
6116	The role of T cell trafficking in CTLA-4 blockades-induced gut immunopathology. <i>BMC Biology</i> , 2020, 18, 29.	1.7	6
6117	Natural Compounds with Potential to Modulate Cancer Therapies and Self-Reactive Immune Cells. <i>Cancers</i> , 2020, 12, 673.	1.7	24
6118	Viral Vector-Based Melanoma Gene Therapy. <i>Biomedicines</i> , 2020, 8, 60.	1.4	16
6119	Cancer Vaccines and Oncolytic Viruses Exert Profoundly Lower Side Effects in Cancer Patients than Other Systemic Therapies: A Comparative Analysis. <i>Biomedicines</i> , 2020, 8, 61.	1.4	36
6120	“The same old story“™: thoughts on authorized doses of anticancer drugs. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592090541.	1.4	5
6121	Immunotherapy utilization for hepatobiliary cancer in the United States: disparities among patients with different socioeconomic status. <i>Hepatobiliary Surgery and Nutrition</i> , 2020, 9, 13-24.	0.7	11
6122	Immunotherapy, Inflammation and Colorectal Cancer. <i>Cells</i> , 2020, 9, 618.	1.8	167
6123	Nephrotoxic Chemotherapy Agents: Old and New. <i>Advances in Chronic Kidney Disease</i> , 2020, 27, 38-49.	0.6	11
6124	Tumor cell-intrinsic PD-1 receptor is a tumor suppressor and mediates resistance to PD-1 blockade therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 6640-6650.	3.3	141
6125	Refractory solitary cervical lymph node metastasis after esophageal squamous cell carcinoma surgery and its successful treatment with immune checkpoint inhibitor. <i>Medicine (United States)</i> , 2020, 99, e19440.	0.4	3
6126	Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF- β 2 and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1210-1222.	0.5	119
6127	Leukemia-induced dysfunctional TIM-3+CD4+ bone marrow T cells increase risk of relapse in pediatric B-precursor ALL patients. <i>Leukemia</i> , 2020, 34, 2607-2620.	3.3	31
6128	Neurologic complications of immune checkpoint inhibitors. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 479-488.	1.0	82
6129	The Current Status of Immune Checkpoint Inhibitors in Neuro-Oncology: A Systematic Review. <i>Cancers</i> , 2020, 12, 586.	1.7	48
6130	Immune Checkpoint Inhibitors in Esophageal Cancers: Are We Finally Finding the Right Path in the Mist?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1658.	1.8	22
6131	Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents. <i>Journal of Clinical Medicine</i> , 2020, 9, 675.	1.0	57

#	ARTICLE	IF	CITATIONS
6132	Pulmonary Administration: Strengthening the Value of Therapeutic Proximity. <i>Frontiers in Medicine</i> , 2020, 7, 50.	1.2	11
6133	Primary pulmonary lymphoepithelioma-like carcinoma. <i>Medical Oncology</i> , 2020, 37, 20.	1.2	7
6134	Stanford type IV venous collateral blood flow following complete chronic occlusion of the superior vena cava in a patient with lung cancer. <i>Radiology Case Reports</i> , 2020, 15, 254-258.	0.2	1
6135	Risk of Gastrointestinal Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitor Plus Chemotherapy: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 197.	1.3	9
6136	The effect of MEK1/2 inhibitors on cisplatin-induced acute kidney injury (AKI) and cancer growth in mice. <i>Cellular Signalling</i> , 2020, 71, 109605.	1.7	3
6137	Primary CNS lymphoma commonly expresses immune response biomarkers. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa018.	0.4	24
6138	A detailed smoking history and determination of MYC status predict response to checkpoint inhibitors in advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 55-60.	1.3	18
6139	Overexpression of Murine Rnaset2 in a Colon Syngeneic Mouse Carcinoma Model Leads to Rebalance of Intra-Tumor M1/M2 Macrophage Ratio, Activation of T Cells, Delayed Tumor Growth, and Rejection. <i>Cancers</i> , 2020, 12, 717.	1.7	16
6140	Case of small bowel perforation secondary to nivolumab and ipilimumab related tumour regression. <i>BMJ Case Reports</i> , 2020, 13, e232304.	0.2	4
6141	Immunotherapy: From Advanced NSCLC to Early Stages, an Evolving Concept. <i>Frontiers in Medicine</i> , 2020, 7, 90.	1.2	31
6142	Frontiers of ctDNA, targeted therapies, and immunotherapy in non-small-cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 111-138.	1.3	27
6143	KEYNOTE-407: changing the way we treat stage IV squamous non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 148-153.	1.3	5
6144	Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls. <i>Current Oncology Reports</i> , 2020, 22, 39.	1.8	199
6145	Safety and Pharmacokinetics of CXCR4 Peptide Antagonist, LY2510924, in Combination with Durvalumab in Advanced Refractory Solid Tumors. <i>Journal of Pancreatic Cancer</i> , 2020, 6, 21-31.	1.6	31
6146	<p>Novel Alternatively Spliced Variants of Smad4 Expressed in TGF-Î²-Induced EMT Regulating Proliferation and Migration of A549 Cells</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 2203-2213.	1.0	10
6147	Integrative Analysis of Breast Cancer Cells Reveals an Epithelial-Mesenchymal Transition Role in Adaptation to Acidic Microenvironment. <i>Frontiers in Oncology</i> , 2020, 10, 304.	1.3	28
6148	Suppression of age-related salivary gland autoimmunity by glycosylation-dependent galectin-1-driven immune inhibitory circuits. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 6630-6639.	3.3	37
6149	<p>Contemporary Multidisciplinary Management of Sinonasal Mucosal Melanoma</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 2289-2298.	1.0	21

#	ARTICLE	IF	CITATIONS
6150	Protein Expression in Metastatic Melanoma and the Link to Disease Presentation in a Range of Tumor Phenotypes. <i>Cancers</i> , 2020, 12, 767.	1.7	2
6151	<p>A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia</p>. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 1177-1189.	2.0	21
6152	Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. <i>Nature Reviews Cardiology</i> , 2020, 17, 474-502.	6.1	332
6153	Immune checkpoint inhibitor-associated renal amyloid A amyloidosis: A case series and review of the literature. <i>Journal of Onco-Nephrology</i> , 2020, 4, 52-58.	0.3	10
6154	Bilateral murine tumor models for characterizing the response to immune checkpoint blockade. <i>Nature Protocols</i> , 2020, 15, 1628-1648.	5.5	19
6155	Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors. <i>Immune Network</i> , 2020, 20, e9.	1.6	143
6156	Dissociated responses at initial computed tomography evaluation is a good prognostic factor in non-small cell lung cancer patients treated with anti-programmed cell death-1/ligand 1 inhibitors. <i>BMC Cancer</i> , 2020, 20, 207.	1.1	26
6157	Inflammatory Mechanisms of HCC Development. <i>Cancers</i> , 2020, 12, 641.	1.7	114
6158	Potential of FDG-PET as Prognostic Significance after anti-PD-1 Antibody against Patients with Previously Treated Non-Small Cell Lung Cancer. <i>Journal of Clinical Medicine</i> , 2020, 9, 725.	1.0	46
6159	How to assess kidney function in oncology patients. <i>Kidney International</i> , 2020, 97, 894-903.	2.6	9
6160	Rapidly Progressive Acute Kidney Injury Associated with Nivolumab Treatment. <i>Case Reports in Oncology</i> , 2020, 13, 85-90.	0.3	9
6161	MMR Deficiency is Homogeneous in Pancreatic Carcinoma and Associated with High Density of Cd8-Positive Lymphocytes. <i>Annals of Surgical Oncology</i> , 2020, 27, 3997-4006.	0.7	20
6162	<p>The lncRNA NORAD/miR-520a-3p Facilitates Malignancy in Non-Small Cell Lung Cancer via PI3k/Akt/mTOR Signaling Pathway</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 1533-1544.	1.0	37
6163	Circulating Tumor DNA-Based Detection of Microsatellite Instability and Response to Immunotherapy in Pancreatic Cancer. <i>Frontiers in Pharmacology</i> , 2020, 11, 23.	1.6	6
6164	Comparative Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Advanced Cancer: A Systematic Review and Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2020, 11, 40.	1.6	31
6165	MDM2, MDM4 and EGFR Amplifications and Hyperprogression in Metastatic Acral and Mucosal Melanoma. <i>Cancers</i> , 2020, 12, 540.	1.7	55
6166	Cardiovascular immune-related adverse events: Evaluation, diagnosis and management. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, 232-240.	0.7	16
6167	Localized cocktail chemoimmunotherapy after in situ gelation to trigger robust systemic antitumor immune responses. <i>Science Advances</i> , 2020, 6, eaaz4204.	4.7	136

#	ARTICLE	IF	CITATIONS
6168	Influence of Estrogen on the NSCLC Microenvironment: A Comprehensive Picture and Clinical Implications. <i>Frontiers in Oncology</i> , 2020, 10, 137.	1.3	53
6169	Development of an Immune Infiltration-Related Prognostic Scoring System Based on the Genomic Landscape Analysis of Glioblastoma Multiforme. <i>Frontiers in Oncology</i> , 2020, 10, 154.	1.3	20
6170	<p>Analysis of Patient Preferences in Lung Cancer â€“ Estimating Acceptable Tradeoffs Between Treatment Benefit and Side Effects</p>. <i>Patient Preference and Adherence</i> , 2020, Volume 14, 927-937.	0.8	39
6171	Case-based discussions in onco-nephrology. <i>Journal of Onco-Nephrology</i> , 2020, 4, 135-144.	0.3	1
6172	Peripheral Blood Biomarkers Associated With Outcome in Non-small Cell Lung Cancer Patients Treated With Nivolumab and Durvalumab Monotherapy. <i>Frontiers in Oncology</i> , 2020, 10, 913.	1.3	29
6173	Integration of Tumor Mutation Burden and PD-L1 Testing in Routine Laboratory Diagnostics in Non-Small Cell Lung Cancer. <i>Cancers</i> , 2020, 12, 1685.	1.7	10
6174	Case report: Minimal change disease and acute interstitial nephritis in a patient with Hodgkinâ€™s lymphoma treated with nivolumab. <i>Journal of Onco-Nephrology</i> , 2020, 4, 81-86.	0.3	1
6175	The effects of B cell depletion on immune related adverse events associated with immune checkpoint inhibition. <i>Experimental Hematology and Oncology</i> , 2020, 9, 9.	2.0	9
6176	Immune and Clinical Features of CD96 Expression in Glioma by in silico Analysis. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 592.	2.0	23
6177	Independent Prognostic Value of Intratumoral Heterogeneity and Immune Response Features by Automated Digital Immunohistochemistry Analysis in Early Hormone Receptor-Positive Breast Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 950.	1.3	15
6178	Ultraviolet Radiation and Melanomagenesis: From Mechanism to Immunotherapy. <i>Frontiers in Oncology</i> , 2020, 10, 951.	1.3	35
6179	Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes. , 2020, 8, e000467.		106
6180	Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092958.	1.4	1
6181	Role of DNA repair defects in predicting immunotherapy response. <i>Biomarker Research</i> , 2020, 8, 23.	2.8	47
6182	<p>Multiple Immune-Related Adverse Events and Anti-Tumor Efficacy: Real-World Data on Various Solid Tumors</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 4585-4593.	0.9	37
6183	<p>Economic Evaluations of Immune Checkpoint Inhibitors for Patients with Non-Small Cell Lung Cancer: A Systematic Review</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 4503-4518.	0.9	5
6184	Immune Checkpoint Inhibitor Nephrotoxicity: Update 2020. <i>Kidney360</i> , 2020, 1, 130-140.	0.9	62
6185	Tumor evolution in epidermal growth factor receptor mutated non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2020, 12, 2896-2909.	0.6	5

#	ARTICLE	IF	CITATIONS
6186	The safety of first and subsequent lines of PD-1/PD-L1 inhibitors monotherapy in non-small cell lung cancer patients: a meta-analysis. <i>Translational Cancer Research</i> , 2020, 9, 3231-3241.	0.4	5
6187	Immunotherapy For Ovarian Cancer: Recent Advances And Combination Therapeutic Approaches. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 6109-6129.	1.0	54
6188	Tumor Mutational Burden and PD-L1 Expression in Non-Small-Cell Lung Cancer (NSCLC) in Southwestern China. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 5191-5198.	1.0	3
6189	Nanomedicine and Onco-Immunotherapy: From the Bench to Bedside to Biomarkers. <i>Nanomaterials</i> , 2020, 10, 1274.	1.9	26
6190	CMV coinfection in treatment refractory immune checkpoint inhibitor colitis. <i>BMJ Case Reports</i> , 2020, 13, e233519.	0.2	4
6191	Clinical and prognostic value of tumor volumetric parameters in melanoma patients undergoing 18F-FDG-PET/CT: a comparison with serologic markers of tumor burden and inflammation. <i>Cancer Imaging</i> , 2020, 20, 44.	1.2	13
6192	Recent Advances and Challenges in the Treatment of Rhabdomyosarcoma. <i>Cancers</i> , 2020, 12, 1758.	1.7	30
6193	Cancer Immune Therapy for Philadelphia Chromosome-Negative Chronic Myeloproliferative Neoplasms. <i>Cancers</i> , 2020, 12, 1763.	1.7	17
6194	Reactive Oxygen Species and Antitumor Immunity—From Surveillance to Evasion. <i>Cancers</i> , 2020, 12, 1748.	1.7	79
6195	Immunotherapy discontinuation—how, and when? Data from melanoma as a paradigm. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 707-715.	12.5	57
6196	Downregulation of PD-L1 via FKBP5 by celecoxib augments antitumor effects of PD-1 blockade in a malignant glioma model. <i>Neuro-Oncology Advances</i> , 2020, 2, vdz058.	0.4	12
6197	Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives. <i>Immune Network</i> , 2020, 20, e10.	1.6	86
6198	Review of the Agnostic-Type Treatment Approach: Treating Cancer by Mutations, Not by Location. <i>Oncology and Therapy</i> , 2020, 8, 59-66.	1.0	4
6199	Renal immune-related adverse events of immune checkpoint inhibitor. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, 305-311.	0.7	6
6200	Balancing Cancer Immunotherapy Efficacy and Toxicity. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 2898-2906.	2.0	28
6201	How to Monitor Cardiac Complications of Immune Checkpoint Inhibitor Therapy. <i>Frontiers in Pharmacology</i> , 2020, 11, 972.	1.6	26
6202	Combined Therapy with Anti-PD1 and BRAF and/or MEK Inhibitor for Advanced Melanoma: A Multicenter Cohort Study. <i>Cancers</i> , 2020, 12, 1666.	1.7	17
6203	Anti-PDL1 effect in squamous non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 406-409.	1.3	2

#	ARTICLE	IF	CITATIONS
6204	Advances in Anti-Cancer Immunotherapy: Car-T Cell, Checkpoint Inhibitors, Dendritic Cell Vaccines, and Oncolytic Viruses, and Emerging Cellular and Molecular Targets. <i>Cancers</i> , 2020, 12, 1826.	1.7	46
6205	Renal damage secondary to checkpoint inhibitors. <i>Nefrologia</i> , 2020, 40, 206-208.	0.2	1
6206	Optimal treatment strategy for metastatic melanoma patients harboring <i>BRAF-V600</i> mutations. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092521.	1.4	31
6207	ICON: a randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer. <i>Journal of Translational Medicine</i> , 2020, 18, 269.	1.8	26
6208	Is there hope in improving 5-year overall survival?—review of 5-year overall survival data from KEYNOTE-001. <i>Annals of Translational Medicine</i> , 2020, 8, 728-728.	0.7	0
6209	GL261 luciferase-expressing cells elicit an anti-tumor immune response: an evaluation of murine glioma models. <i>Scientific Reports</i> , 2020, 10, 11003.	1.6	24
6210	Transgenic T-cell receptor immunotherapy for cancer: building on clinical success. , 2020, 8, 251513552093350.	1.4	10
6211	Acute Kidney Injury in Oncology Patients. <i>Journal of Cancer</i> , 2020, 11, 4700-4708.	1.2	6
6212	Low-dose oncolytic adenovirus therapy overcomes tumor-induced immune suppression and sensitizes intracranial gliomas to anti-PD-1 therapy. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa011.	0.4	22
6213	Fatal adverse events associated with programmed cell death protein 1 or programmed cell death-ligand 1 monotherapy in cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883591989575.	1.4	8
6214	KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures. <i>Cancer Treatment Reviews</i> , 2020, 85, 101978.	3.4	85
6215	A Genomic Profile of Local Immunity in the Melanoma Microenvironment Following Treatment with \pm Particle-Emitting Ultrasmall Silica Nanoparticles. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2020, 35, 459-473.	0.7	13
6216	Early Detection of Hyperprogressive Disease in Non-Small Cell Lung Cancer by Monitoring of Systemic T Cell Dynamics. <i>Cancers</i> , 2020, 12, 344.	1.7	60
6217	Reverting Immune Suppression to Enhance Cancer Immunotherapy. <i>Frontiers in Oncology</i> , 2019, 9, 1554.	1.3	49
6218	Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study. <i>Cancers</i> , 2020, 12, 473.	1.7	72
6219	The Co-Expression of Programmed Death-Ligand 1 (PD-L1) in Untreated EGFR-Mutated Metastatic Lung Adenocarcinoma. <i>Biomedicines</i> , 2020, 8, 36.	1.4	14
6220	<p>Use of Programmed Death Receptor-1 and/or Programmed Death Ligand 1 Inhibitors for the Treatment of Brain Metastasis of Lung Cancer</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 667-683.	1.0	24
6221	<p>Immune Checkpoint Inhibitors for the Treatment of Unresectable Stage III Non"Small Cell Lung Cancer: Emerging Mechanisms and Perspectives</p>. <i>Lung Cancer: Targets and Therapy</i> , 2020, Volume 10, 161-170.	1.3	7

#	ARTICLE	IF	CITATIONS
6222	Current Advances in the Treatment of BRAF-Mutant Melanoma. <i>Cancers</i> , 2020, 12, 482.	1.7	112
6223	The Inflammatory Milieu of Adamantinomatous Craniopharyngioma and Its Implications for Treatment. <i>Journal of Clinical Medicine</i> , 2020, 9, 519.	1.0	26
6224	Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas. <i>Annals of Oncology</i> , 2020, 31, 599-608.	0.6	183
6225	Combination of chemotherapy and PD-1 blockade induces T cell responses to tumor non-mutated neoantigens. <i>Communications Biology</i> , 2020, 3, 85.	2.0	36
6226	Recent Progress of Potentiating Immune Checkpoint Blockade with External Stimuli—An Industry Perspective. <i>Advanced Science</i> , 2020, 7, 1903394.	5.6	40
6227	Modeling clear cell renal cell carcinoma and therapeutic implications. <i>Oncogene</i> , 2020, 39, 3413-3426.	2.6	86
6228	Oncolytic poxvirus CF33-hNIS-I ^h F14.5 favorably modulates tumor immune microenvironment and works synergistically with anti-PD-L1 antibody in a triple-negative breast cancer model. <i>Oncolimmunology</i> , 2020, 9, 1729300.	2.1	29
6229	Skeletal muscle mass predicts the outcome of nivolumab treatment for non-small cell lung cancer. <i>Medicine (United States)</i> , 2020, 99, e19059.	0.4	30
6230	Immunogenomic pathways associated with cytotoxic lymphocyte infiltration and survival in colorectal cancer. <i>BMC Cancer</i> , 2020, 20, 124.	1.1	8
6231	Revisiting Immunotherapy: A Focus on Prostate Cancer. <i>Cancer Research</i> , 2020, 80, 1615-1623.	0.4	120
6232	Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression ≥50%. <i>Annals of Oncology</i> , 2020, 31, 404-411.	0.6	79
6233	VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or Tj ETQq1 1 0.784314 rgrBT /Over	0.7	13
6234	Inhibition of SHP-1 Expands the Repertoire of Antitumor T Cells Available to Respond to Immune Checkpoint Blockade. <i>Cancer Immunology Research</i> , 2020, 8, 506-517.	1.6	23
6235	Organ-Specific Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitor Monotherapy Versus Combination Therapy in Cancer: A Meta-Analysis of Randomized Controlled Trials. <i>Frontiers in Pharmacology</i> , 2019, 10, 1671.	1.6	40
6236	Correlation of PD-L1 Expression Tested by 22C3 and SP263 in Non-Small Cell Lung Cancer and Its Prognostic Effect on EGFR Mutation-Positive Lung Adenocarcinoma. <i>Tuberculosis and Respiratory Diseases</i> , 2020, 83, 51.	0.7	13
6237	Severe hepatotoxicity due to osimertinib after nivolumab therapy in patients with non-small cell lung cancer harboring EGFR mutation. <i>Thoracic Cancer</i> , 2020, 11, 1045-1051.	0.8	14
6238	Immunotherapy with immune checkpoint inhibitors in colorectal cancer: what is the future beyond deficient mismatch-repair tumours?. <i>Gastroenterology Report</i> , 2020, 8, 11-24.	0.6	68
6239	Potential Immune-Related Adverse Events Associated With Monotherapy and Combination Therapy of Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 91.	1.3	112

#	ARTICLE	IF	CITATIONS
6240	Mass Spectrometry-Based Identification of MHC-Associated Peptides. <i>Cancers</i> , 2020, 12, 535.	1.7	29
6241	Regulatory T Cells Induced by Single-Peptide Liposome Immunotherapy Suppress Islet-Specific T Cell Responses to Multiple Antigens and Protect from Autoimmune Diabetes. <i>Journal of Immunology</i> , 2020, 204, 1787-1797.	0.4	30
6242	Age-associated changes in the immune system may influence the response to anti-PD1 therapy in metastatic melanoma patients. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 717-730.	2.0	18
6243	Safe Use of Nivolumab in a Patient with Epipharyngeal Carcinoma and Preexisting Ulcerative Colitis: A Histologically Proven Case Report. <i>Internal Medicine</i> , 2020, 59, 1105-1109.	0.3	6
6244	Inhibition Mechanism of Indoleamine 2, 3-Dioxygenase 1 (IDO1) by Amidoxime Derivatives and Its Revelation in Drug Design: Comparative Molecular Dynamics Simulations. <i>Frontiers in Molecular Biosciences</i> , 2019, 6, 164.	1.6	5
6245	Oncological outcomes of addition of anti-PD1/PD-L1 to chemotherapy in the therapy of patients with advanced gastric or gastro-oesophageal junction cancer. <i>Medicine (United States)</i> , 2020, 99, e18332.	0.4	1
6246	Tumor Mutation Burden as a Potential Biomarker for PD-1/PD-L1 Inhibition in Advanced Non-small Cell Lung Cancer. <i>Targeted Oncology</i> , 2020, 15, 93-100.	1.7	27
6247	The balancing act: Immunology of leishmaniosis. <i>Research in Veterinary Science</i> , 2020, 130, 19-25.	0.9	44
6248	Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 332-338.	0.5	140
6249	Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells. <i>BMC Cancer</i> , 2020, 20, 25.	1.1	75
6250	Complement C3 overexpression activates JAK2/STAT3 pathway and correlates with gastric cancer progression. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 9.	3.5	60
6251	Real-world use and survival outcomes of immune checkpoint inhibitors in older adults with non-small cell lung cancer. <i>Cancer</i> , 2020, 126, 978-985.	2.0	52
6252	Cancer Cell-derived Secretory Factors in Breast Cancer-associated Lung Metastasis: Their Mechanism and Future Prospects. <i>Current Cancer Drug Targets</i> , 2020, 20, 168-186.	0.8	25
6253	A review of cancer immunotherapy toxicity. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 86-104.	157.7	753
6254	Immune profile and immunosurveillance in treatment-naïve and neoadjuvantly treated esophageal adenocarcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 523-533.	2.0	19
6255	Molecular analysis of primary melanoma T cells identifies patients at risk for metastatic recurrence. <i>Nature Cancer</i> , 2020, 1, 197-209.	5.7	30
6256	Toxicity of Immune Checkpoint Inhibitors: Considerations for the Surgeon. <i>Annals of Surgical Oncology</i> , 2020, 27, 1533-1545.	0.7	6
6257	Immune Suppression Mediated by STAT4 Deficiency Promotes Lymphatic Metastasis in HNSCC. <i>Frontiers in Immunology</i> , 2019, 10, 3095.	2.2	22

#	ARTICLE	IF	CITATIONS
6258	Immunosurveillance and Immunoediting of Lung Cancer: Current Perspectives and Challenges. <i>International Journal of Molecular Sciences</i> , 2020, 21, 597.	1.8	58
6259	Health-related quality of life in cancer patients treated with immune checkpoint inhibitors: A systematic review on reporting of methods in randomized controlled trials. <i>PLoS ONE</i> , 2020, 15, e0227344.	1.1	26
6260	Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020, 72, 320-341.	1.8	165
6261	Anti-PD-1 and Novel Combinations in the Treatment of Melanoma—An Update. <i>Journal of Clinical Medicine</i> , 2020, 9, 223.	1.0	95
6262	Possibilities of Improving the Clinical Value of Immune Checkpoint Inhibitor Therapies in Cancer Care by Optimizing Patient Selection. <i>International Journal of Molecular Sciences</i> , 2020, 21, 556.	1.8	21
6263	Phase I Study of a B Cell-Based and Monocyte-Based Immunotherapeutic Vaccine, BVAC-C in Human Papillomavirus Type 16- or 18-Positive Recurrent Cervical Cancer. <i>Journal of Clinical Medicine</i> , 2020, 9, 147.	1.0	14
6264	PD-1/PD-L1 expression and tumor-infiltrating lymphocytes are prognostically favorable in advanced high-grade serous ovarian carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 477, 83-91.	1.4	41
6265	Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis. <i>Cancer Discovery</i> , 2020, 10, 254-269.	7.7	275
6266	Assessment of Tumor Mutational Burden in Pediatric Tumors by Real-Life Whole-Exome Sequencing and In Silico Simulation of Targeted Gene Panels: How the Choice of Method Could Affect the Clinical Decision?. <i>Cancers</i> , 2020, 12, 230.	1.7	9
6267	A pipeline for identification and validation of tumor-specific antigens in a mouse model of metastatic breast cancer. <i>Oncimmunology</i> , 2020, 9, 1685300.	2.1	8
6268	NK Cell-Based Immunotherapy in Renal Cell Carcinoma. <i>Cancers</i> , 2020, 12, 316.	1.7	20
6269	The miRNAs Role in Melanoma and in Its Resistance to Therapy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 878.	1.8	50
6270	Mesenchymal stem cells derived from iPSCs expressing interleukin-24 inhibit the growth of melanoma in the tumor-bearing mouse model. <i>Cancer Cell International</i> , 2020, 20, 33.	1.8	14
6271	Contributions of Age-Related Thymic Involution to Immunosenescence and Inflammaging. <i>Immunity and Ageing</i> , 2020, 17, 2.	1.8	211
6272	Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment. <i>Diagnostic Pathology</i> , 2020, 15, 6.	0.9	55
6273	Bone decalcification to assess programmed cell death ligand 1 expression in bone metastases of non-small cell lung cancers. <i>Journal of Bone Oncology</i> , 2020, 21, 100275.	1.0	8
6274	Biostimulating Gut Microbiome with Bilberry Anthocyanin Combo to Enhance Anti-PD-L1 Efficiency against Murine Colon Cancer. <i>Microorganisms</i> , 2020, 8, 175.	1.6	37
6275	Recalling the Biological Significance of Immune Checkpoints on NK Cells: A Chance to Overcome LAG3, PD1, and CTLA4 Inhibitory Pathways by Adoptive NK Cell Transfer?. <i>Frontiers in Immunology</i> , 2019, 10, 3010.	2.2	48

#	ARTICLE	IF	CITATIONS
6276	Modulation of Vaccine-Induced HIV-1-Specific Immune Responses by Co-Electroporation of PD-L1 Encoding DNA. <i>Vaccines</i> , 2020, 8, 27.	2.1	11
6277	Consistency Analysis of Programmed Death-Ligand 1 Expression between Primary and Metastatic Non-Small Cell Lung Cancer: A Retrospective Study. <i>Journal of Cancer</i> , 2020, 11, 974-982.	1.2	10
6278	The value of immunotherapy for survivors of stage IV non-small cell lung cancer: patient perspectives on quality of life. <i>Journal of Cancer Survivorship</i> , 2020, 14, 363-376.	1.5	22
6279	Smokers or non-smokers: who benefits more from immune checkpoint inhibitors in treatment of malignancies? An up-to-date meta-analysis. <i>World Journal of Surgical Oncology</i> , 2020, 18, 15.	0.8	58
6280	Anti-Metastatic Effects on Melanoma via Intravenous Administration of Anti-NF- κ B siRNA Complexed with Functional Peptide-Modified Nano-Micelles. <i>Pharmaceutics</i> , 2020, 12, 64.	2.0	21
6281	Predictors of Response and Survival in Immune Checkpoint Inhibitor-Treated Unresectable Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 182.	1.7	74
6282	Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response. <i>Journal of Clinical Medicine</i> , 2020, 9, 286.	1.0	50
6283	Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab. <i>JAMA Oncology</i> , 2020, 6, 402.	3.4	125
6284	Myosin II Reactivation and Cytoskeletal Remodeling as a Hallmark and a Vulnerability in Melanoma Therapy Resistance. <i>Cancer Cell</i> , 2020, 37, 85-103.e9.	7.7	91
6285	Potential role of the PD-L1 expression and tumor-infiltrating lymphocytes on neuroblastoma. <i>Pediatric Surgery International</i> , 2020, 36, 137-143.	0.6	14
6286	Predictive biomarkers of response to immune checkpoint inhibitors in melanoma. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 137-145.	1.1	16
6287	Cardiac adverse events of PD-1 and PD-L1 inhibitors in cancer protocol for a systematic review and network meta-analysis. <i>Medicine (United States)</i> , 2020, 99, e18701.	0.4	1
6288	Expanding the Scope of Immunotherapy in Colorectal Cancer: Current Clinical Approaches and Future Directions. <i>BioMed Research International</i> , 2020, 2020, 1-24.	0.9	38
6289	Safety and efficacy of immune checkpoint inhibitors in patients with HBV/HCV infection and advanced-stage cancer. <i>Medicine (United States)</i> , 2020, 99, e19013.	0.4	64
6290	Current status of the clinical use of PD-1/PD-L1 inhibitors: a questionnaire survey of oncologists in China. <i>BMC Cancer</i> , 2020, 20, 86.	1.1	13
6291	Comprehensive Survey of Clinical Trials Registration for Melanoma Immunotherapy in the ClinicalTrials.gov. <i>Frontiers in Pharmacology</i> , 2019, 10, 1539.	1.6	5
6293	Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 435-446.	3.0	247
6294	<p>Circulating Tumor Cells as a Biomarker to Assist Molecular Diagnosis for Early Stage Non-Small Cell Lung Cancer</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 841-854.	0.9	26

#	ARTICLE	IF	CITATIONS
6295	Neurotoxicities associated with checkpoint inhibitors: Two case reports and a review of the literature. <i>Clinical Case Reports (discontinued)</i> , 2020, 8, 24-32.	0.2	8
6296	Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pretreated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adenocarcinoma. <i>Medicine (United States)</i> , 2020, 99, e18726.	0.4	23
6297	Prediction of patients with a tumor proportion score > 50% who do not respond to first-line monotherapy with pembrolizumab. <i>BMC Cancer</i> , 2020, 20, 93.	1.1	15
6298	Cross-Cancer Pleiotropic Analysis Reveals Novel Susceptibility Loci for Lung Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 1492.	1.3	6
6299	Targeting CD47 as a Novel Immunotherapy for Multiple Myeloma. <i>Cancers</i> , 2020, 12, 305.	1.7	56
6300	Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 29.	3.5	45
6301	Sub-acute Toxicity in Non-cancerous Tissue and Immune-Related Adverse Events of a Novel Combination Therapy for Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 1504.	1.3	4
6302	Long Non-coding RNAs: Emerging Roles in the Immunosuppressive Tumor Microenvironment. <i>Frontiers in Oncology</i> , 2020, 10, 48.	1.3	63
6303	Cell Block as a Surrogate for Programmed Death-Ligand 1 Staining Testing in Patients of Non-Small Cell Lung Cancer. <i>Journal of Cancer</i> , 2020, 11, 551-558.	1.2	7
6304	TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials. <i>Cancer Gene Therapy</i> , 2020, 27, 841-853.	2.2	94
6305	Impact of Immunometabolism on Cancer Metastasis: A Focus on T Cells and Macrophages. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2020, 10, a037044.	2.9	10
6306	Clinical recommendations on diagnosis and treatment of immune checkpoint inhibitor-induced renal immune-related adverse events. <i>Thoracic Cancer</i> , 2020, 11, 1746-1751.	0.8	11
6307	Long-term efficacy and predictive correlates of response to nivolumab in Japanese patients with esophageal cancer. <i>Cancer Science</i> , 2020, 111, 1676-1684.	1.7	21
6308	Bilateral uveitis associated with nivolumab therapy for metastatic non-small cell lung cancer. <i>American Journal of Ophthalmology Case Reports</i> , 2020, 18, 100691.	0.4	9
6309	Status of correlation between BMI and response to immunocheck-point inhibitor in advanced non-small-cell lung cancer. <i>Lung Cancer Management</i> , 2020, 9, LMT26.	1.5	9
6310	Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway. <i>Frontiers in Microbiology</i> , 2020, 11, 814.	1.5	94
6311	5-FU-Induced Upregulation of Exosomal PD-L1 Causes Immunosuppression in Advanced Gastric Cancer Patients. <i>Frontiers in Oncology</i> , 2020, 10, 492.	1.3	33
6312	HPV Involvement in the Tumor Microenvironment and Immune Treatment in Head and Neck Squamous Cell Carcinomas. <i>Cancers</i> , 2020, 12, 1060.	1.7	40

#	ARTICLE	IF	CITATIONS
6313	eIF5B drives integrated stress response-dependent translation of PD-L1 in lung cancer. <i>Nature Cancer</i> , 2020, 1, 533-545.	5.7	73
6314	Intratumor Heterogeneity in Early Lung Adenocarcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 349.	1.3	41
6315	Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence. <i>Cancers</i> , 2020, 12, 738.	1.7	826
6316	Immunotherapy in Glioblastoma: Current Shortcomings and Future Perspectives. <i>Cancers</i> , 2020, 12, 751.	1.7	66
6317	The landscape of immune cell infiltration and its clinical implications of pancreatic ductal adenocarcinoma. <i>Journal of Advanced Research</i> , 2020, 24, 139-148.	4.4	50
6318	Retrospective analysis of the prognostic value of PD-L1 expression and 18F-FDG PET/CT metabolic parameters in colorectal cancer. <i>Journal of Cancer</i> , 2020, 11, 2864-2873.	1.2	15
6319	Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma. <i>JAMA Network Open</i> , 2020, 3, e201611.	2.8	70
6320	Assessment of the Feasibility and Safety of Durvalumab for Treatment of Solid Tumors in Patients With HIV-1 Infection. <i>JAMA Oncology</i> , 2020, 6, 1063.	3.4	70
6321	Drug-Induced Liver Injury in GI Practice. <i>Hepatology Communications</i> , 2020, 4, 631-645.	2.0	47
6322	Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment. <i>International Journal of Clinical Oncology</i> , 2020, 25, 801-809.	1.0	115
6324	Pembrolizumab-associated nephrotic syndrome recovered from transient hemodialysis in a patient with lung cancer. <i>CEN Case Reports</i> , 2020, 9, 215-219.	0.5	6
6325	Tumour mutational burden as a biomarker for immunotherapy: Current data and emerging concepts. <i>European Journal of Cancer</i> , 2020, 131, 40-50.	1.3	143
6326	Temporal activation of WNT/ β -catenin signaling is sufficient to inhibit SOX10 expression and block melanoma growth. <i>Oncogene</i> , 2020, 39, 4132-4154.	2.6	23
6327	Response and outcomes after anti-CTLA4 versus anti-PD1 combined with stereotactic body radiation therapy for metastatic non-small cell lung cancer: retrospective analysis of two single-institution prospective trials. , 2020, 8, e000492.		55
6328	BTK Has Potential to Be a Prognostic Factor for Lung Adenocarcinoma and an Indicator for Tumor Microenvironment Remodeling: A Study Based on TCGA Data Mining. <i>Frontiers in Oncology</i> , 2020, 10, 424.	1.3	93
6329	TCMIO: A Comprehensive Database of Traditional Chinese Medicine on Immuno-Oncology. <i>Frontiers in Pharmacology</i> , 2020, 11, 439.	1.6	34
6330	Future Challenges in Cancer Resistance to Immunotherapy. <i>Cancers</i> , 2020, 12, 935.	1.7	41
6331	Imaging of Adverse Events Related to Checkpoint Inhibitor Therapy. <i>Diagnostics</i> , 2020, 10, 216.	1.3	13

#	ARTICLE	IF	CITATIONS
6332	Dendritic Cells Pre-Pulsed with Wilmsâ€™ Tumor 1 in Optimized Culture for Cancer Vaccination. <i>Pharmaceutics</i> , 2020, 12, 305.	2.0	7
6333	Determination of the Expression of PD-L1 in the Morphologic Spectrum of Renal Cell Carcinoma. <i>Journal of Cancer</i> , 2020, 11, 3596-3603.	1.2	17
6334	Prognostic Inflammasome-Related Signature Construction in Kidney Renal Clear Cell Carcinoma Based on a Pan-Cancer Landscape. <i>Evidence-based Complementary and Alternative Medicine</i> , 2020, 2020, 1-13.	0.5	3
6335	A Case of Isolated Adrenocorticotrophic Hormone Deficiency Caused by Pembrolizumab. <i>Case Reports in Oncology</i> , 2020, 13, 200-206.	0.3	15
6336	Successful Treatment of a Patient with anti-PD1 Antibody-Resistant Advanced Mucosal Melanoma with Nivolumab, Ipilimumab plus Denosumab Combination Therapy. <i>Case Reports in Oncology</i> , 2020, 13, 271-275.	0.3	3
6337	Contribution of Macrophages and T Cells in Skeletal Metastasis. <i>Cancers</i> , 2020, 12, 1014.	1.7	19
6338	Recent and Emerging Therapies for Cutaneous Squamous Cell Carcinomas of the Head and Neck. <i>Current Treatment Options in Oncology</i> , 2020, 21, 37.	1.3	12
6339	Public Adverse Event Data Insights into the Safety of Pembrolizumab in Melanoma Patients. <i>Cancers</i> , 2020, 12, 1008.	1.7	3
6340	Primary Resistance to PD-1-Based Immunotherapyâ€™ A Study in 319 Patients with Stage IV Melanoma. <i>Cancers</i> , 2020, 12, 1027.	1.7	17
6342	Cytomegalovirus Enterocolitis in a Patient with Refractory Immune-Related Colitis. <i>Case Reports in Gastroenterology</i> , 2020, 14, 103-109.	0.3	14
6343	EBUS-FNA cytologic-histologic correlation of PD-L1 immunohistochemistry in nonâ€™small cell lung cancer. <i>Journal of the American Society of Cytopathology</i> , 2020, 9, 485-493.	0.2	9
6344	In Situ Immune Profiling of Heartâ€™Transplant Biopsies Improves Diagnostic Accuracy and Rejection Risk Stratification. <i>JACC Basic To Translational Science</i> , 2020, 5, 328-340.	1.9	13
6345	Checkpoint inhibitors: Better outcomes among advanced cutaneous head and neck melanoma patients. <i>PLoS ONE</i> , 2020, 15, e0231038.	1.1	3
6346	<p>Rationale for Lung Adenocarcinoma Prevention and Drug Development Based on Molecular Biology During Carcinogenesis</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 3085-3091.	1.0	25
6347	Tumor Mutational Burden Determined by Panel Sequencing Predicts Survival After Immunotherapy in Patients With Advanced Gastric Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 314.	1.3	62
6348	Chronic kidney disease as a complication of cancer, with special focus on kidney and urothelial tumors. , 2020, , 299-306.e1.		0
6349	<p>Ultrasound-Mediated Co-Delivery of miR-34a and sPD-1 Complexed with Microbubbles for Synergistic Cancer Therapy</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 2459-2469.	0.9	16
6350	How Non-invasive in vivo Cell Tracking Supports the Development and Translation of Cancer Immunotherapies. <i>Frontiers in Physiology</i> , 2020, 11, 154.	1.3	27

#	ARTICLE	IF	CITATIONS
6351	Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer. <i>JAMA Oncology</i> , 2020, 6, 865.	3.4	295
6352	Overview of multiplex immunohistochemistry/immunofluorescence techniques in the era of cancer immunotherapy. <i>Cancer Communications</i> , 2020, 40, 135-153.	3.7	339
6354	Desensitizing Effect of Cancer Cachexia on Immune Checkpoint Inhibitors in Patients With Advanced NSCLC. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100020.	0.6	23
6355	Immune Checkpoint Inhibitors for Brain Metastases: A Primer for Neurosurgeons. <i>Neurosurgery</i> , 2020, 87, E281-E288.	0.6	22
6356	A case report of fulminant cytokine release syndrome complicated by dermatomyositis after the combination therapy with immune checkpoint inhibitors. <i>Medicine (United States)</i> , 2020, 99, e19741.	0.4	19
6357	Epigenetic Mechanisms in Leukemias and Lymphomas. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2020, 10, a034959.	2.9	14
6358	Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma. , 2020, 8, e000144.		56
6359	SHP-2 and PD-L1 Inhibition Combined with Radiotherapy Enhances Systemic Antitumor Effects in an Anti-“PD-1”-Resistant Model of Non-“Small Cell Lung Cancer. <i>Cancer Immunology Research</i> , 2020, 8, 883-894.	1.6	48
6360	Prevalence of PD-L1 expression in matched recurrent and/or metastatic sarcoma samples and in a range of selected sarcomas subtypes. <i>PLoS ONE</i> , 2020, 15, e0222551.	1.1	26
6361	TNF- \pm inhibitor reduces drug-resistance to anti-PD-1: A mathematical model. <i>PLoS ONE</i> , 2020, 15, e0231499.	1.1	9
6362	<p>Combination Strategies of Checkpoint Immunotherapy in Metastatic Breast Cancer</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 2657-2666.	1.0	9
6363	Successful Treatment of Non-small-cell Lung Cancer with Atezolizumab Following Tubulointerstitial Nephritis Due to Pembrolizumab. <i>Internal Medicine</i> , 2020, 59, 1639-1642.	0.3	6
6364	Membranoproliferative Glomerulonephritis Associated with Nivolumab Therapy. <i>Case Reports in Nephrology</i> , 2020, 2020, 1-4.	0.2	10
6365	Critical Care Admission of an HIV Patient with Diabetic Ketoacidosis Secondary to Pembrolizumab. <i>Case Reports in Critical Care</i> , 2020, 2020, 1-3.	0.2	6
6366	Rapid Expansion of Highly Functional Antigen-Specific T Cells from Patients with Melanoma by Nanoscale Artificial Antigen-Presenting Cells. <i>Clinical Cancer Research</i> , 2020, 26, 3384-3396.	3.2	24
6367	PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation. <i>Blood Advances</i> , 2020, 4, 122-126.	2.5	46
6368	Pembrolizumab-induced hypothyroidism caused reversible increased serum creatinine levels: a case report. <i>BMC Nephrology</i> , 2020, 21, 113.	0.8	5
6369	A pooled analysis of the prognostic value of PD-L1 in melanoma: evidence from 1062 patients. <i>Cancer Cell International</i> , 2020, 20, 96.	1.8	21

#	ARTICLE	IF	CITATIONS
6370	Circulating PD-1 mRNA in Peripheral Blood is a Potential Biomarker for Predicting Survival of Breast Cancer Patients. <i>Annals of Surgical Oncology</i> , 2020, 27, 4035-4043.	0.7	7
6371	Deciphering the tumor microenvironment through radiomics in non-small cell lung cancer: Correlation with immune profiles. <i>PLoS ONE</i> , 2020, 15, e0231227.	1.1	43
6372	Combination immunotherapy with anti-PD-L1 antibody and depletion of regulatory T cells during acute viral infections results in improved virus control but lethal immunopathology. <i>PLoS Pathogens</i> , 2020, 16, e1008340.	2.1	11
6373	Pretreatment Geriatric Assessments of Elderly Patients with Glioma: Development and Implications. , 2020, 11, 448.		15
6374	Immune regulatory markers of lepidic-pattern adenocarcinomas presenting as ground glass opacities. <i>Journal of Thoracic Disease</i> , 2020, 12, 329-337.	0.6	4
6375	<p>Detection of PD-L1 Expression and Its Clinical Significance in Circulating Tumor Cells from Patients with Non-Small-Cell Lung Cancer</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 2069-2078.	0.9	25
6376	Immuno-Oncology Biomarkers for Personalized Immunotherapy in Breast Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 162.	1.8	21
6377	Pharmacologic Blockade of 15-PGDH Protects Against Acute Renal Injury Induced by LPS in Mice. <i>Frontiers in Physiology</i> , 2020, 11, 138.	1.3	23
6378	Hyperprogression Under Immune Checkpoint-Based Immunotherapyâ€™Current Understanding, The Role of PD-1/PD-L1 Tumour-Intrinsic Signalling, Future Directions and a Potential Large Animal Model. <i>Cancers</i> , 2020, 12, 804.	1.7	19
6379	An Organotypic Microcosm for the Pancreatic Tumor Microenvironment. <i>Cancers</i> , 2020, 12, 811.	1.7	7
6380	Landscape and Future Perspectives of Immunotherapy in Neuroendocrine Neoplasia. <i>Cancers</i> , 2020, 12, 832.	1.7	27
6381	Mass Spectrometry Imaging Reveals Neutrophil Defensins as Additional Biomarkers for Anti-PD-(L)1 Immunotherapy Response in NSCLC Patients. <i>Cancers</i> , 2020, 12, 863.	1.7	18
6382	RAD51Bme Levels as a Potential Predictive Biomarker for PD-1 Blockade Response in Non-Small Cell Lung Cancer. <i>Journal of Clinical Medicine</i> , 2020, 9, 1000.	1.0	6
6383	Immunization against ROS1 by DNA Electroporation Impairs K-Ras-Driven Lung Adenocarcinomas. <i>Vaccines</i> , 2020, 8, 166.	2.1	1
6384	Analysis of lncRNA, miRNA and mRNA-associated ceRNA networks and identification of potential drug targets for drug-resistant non-small cell lung cancer. <i>Journal of Cancer</i> , 2020, 11, 3357-3368.	1.2	26
6385	Evaluating Mismatch Repair/Microsatellite Instability Status Using Cytology Effusion Specimens to Determine Eligibility for Immunotherapy. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 46-54.	1.2	12
6386	A review of glioblastoma immunotherapy. <i>Journal of Neuro-Oncology</i> , 2021, 151, 41-53.	1.4	159
6387	EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 36-48.	0.5	153

#	ARTICLE	IF	CITATIONS
6388	Comprehensive assessment of multiple tryptophan metabolites as potential biomarkers for immune checkpoint inhibitors in patients with non-small cell lung cancer. <i>Clinical and Translational Oncology</i> , 2021, 23, 418-423.	1.2	31
6389	Advances in Small-Cell Lung Cancer (SCLC) Translational Research. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2021, 11, a038240.	2.9	34
6390	PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 546-553.	1.4	49
6391	Acute interstitial nephritis associated with immune checkpoint inhibitors: a single-centre experience. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 1364-1370.	1.4	30
6392	Cancer immunotherapy in patients with new or recurrent malignancies after liver transplantation. <i>International Journal of Surgery Oncology</i> , 2021, 2, 49.	0.2	4
6393	Autologous cytokine-induced killer (CIK) cells enhance the clinical response to PD-1 blocking antibodies in patients with advanced non-small cell lung cancer: A preliminary study. <i>Thoracic Cancer</i> , 2021, 12, 145-152.	0.8	12
6394	Efficacy of immune checkpoint inhibitors in elderly patients aged ≥ 75 years. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1777-1780.	2.0	8
6395	Changes in cancer incidence and outcomes among kidney transplant recipients in the United States over a thirty-year period. <i>Kidney International</i> , 2021, 99, 1430-1438.	2.6	21
6396	Metabolic interventions: A new insight into the cancer immunotherapy. <i>Archives of Biochemistry and Biophysics</i> , 2021, 697, 108659.	1.4	8
6397	Antibiotics and steroids, the double enemies of anticancer immunotherapy: a review of the literature. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1511-1517.	2.0	16
6398	Nivolumab treatment beyond progressive disease in advanced non-small cell lung cancer. <i>Clinical and Translational Oncology</i> , 2021, 23, 582-590.	1.2	5
6399	Proof-of-principle Phase I results of combining nivolumab with brachytherapy and external beam radiation therapy for Grade Group 5 prostate cancer: safety, feasibility, and exploratory analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 140-149.	2.0	15
6400	Comparing RECIST 1.1 and iRECIST in advanced melanoma patients treated with pembrolizumab in a phase II clinical trial. <i>European Radiology</i> , 2021, 31, 1853-1862.	2.3	10
6401	Treatment of rheumatic immune-related adverse events due to cancer immunotherapy with immune checkpoint inhibitors: is it time for a paradigm shift?. <i>Clinical Rheumatology</i> , 2021, 40, 1687-1695.	1.0	15
6402	Recurrent acute interstitial nephritis: what lies beneath. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 197-204.	1.4	6
6403	Acute tubulointerstitial nephritis induced by checkpoint inhibitors versus classical acute tubulointerstitial nephritis: are they the same disease?. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 884-890.	1.4	13
6404	Molecular characterization of HLA class II binding to the LAG-3 T cell co-inhibitory receptor. <i>European Journal of Immunology</i> , 2021, 51, 331-341.	1.6	13
6405	Neoadjuvant immunotherapy for melanoma. <i>Journal of Surgical Oncology</i> , 2021, 123, 782-788.	0.8	26

#	ARTICLE	IF	CITATIONS
6406	Morphology of tumor and nontumor tissue in liver resection specimens for hepatocellular carcinoma following nivolumab therapy. <i>Modern Pathology</i> , 2021, 34, 823-833.	2.9	6
6407	Implications of metabolism-driven myeloid dysfunctions in cancer therapy. <i>Cellular and Molecular Immunology</i> , 2021, 18, 829-841.	4.8	21
6408	Overcoming T-cell exhaustion in LCH: PD-1 blockade and targeted MAPK inhibition are synergistic in a mouse model of LCH. <i>Blood</i> , 2021, 137, 1777-1791.	0.6	25
6409	Inorganic Nanomaterial-Mediated Gene Therapy in Combination with Other Antitumor Treatment Modalities. <i>Advanced Functional Materials</i> , 2021, 31, 2007096.	7.8	32
6410	Dicarbonyl Electrophiles Mediate Inflammation-Induced Gastrointestinal Carcinogenesis. <i>Gastroenterology</i> , 2021, 160, 1256-1268.e9.	0.6	17
6411	Novel human immunomodulatory T cell receptors and their double-edged potential in autoimmunity, cardiovascular disease and cancer. <i>Cellular and Molecular Immunology</i> , 2021, 18, 919-935.	4.8	11
6412	Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti-PD-(L)1 Therapy. <i>Clinical Cancer Research</i> , 2021, 27, 1019-1028.	3.2	58
6413	A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor-Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention. <i>Cancer Discovery</i> , 2021, 11, 614-625.	7.7	145
6414	Exploring the knowledge gap of immune checkpoint inhibitors in chronic renal failure: A systematic review of the literature. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103169.	2.0	14
6415	Advances in bladder cancer biology and therapy. <i>Nature Reviews Cancer</i> , 2021, 21, 104-121.	12.8	320
6416	CD137 agonist-based combination immunotherapy enhances activated, effector memory T cells and prolongs survival in pancreatic adenocarcinoma. <i>Cancer Letters</i> , 2021, 499, 99-108.	3.2	22
6417	SWOG S1400A (NCT02154490): A Phase II Study of Durvalumab for Patients With Previously Treated Stage IV or Recurrent Squamous Cell Lung Cancer (Lung-MAP Sub-study). <i>Clinical Lung Cancer</i> , 2021, 22, 178-186.	1.1	6
6418	Advanced Melanoma. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 111-128.	0.9	5
6419	Immune checkpoint inhibitor use, multimorbidity and healthcare expenditures among older adults with late-stage melanoma. <i>Immunotherapy</i> , 2021, 13, 103-112.	1.0	1
6420	Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory FoRECATT study. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1583-1592.	2.0	12
6421	The cutting-edge progress of immune-checkpoint blockade in lung cancer. <i>Cellular and Molecular Immunology</i> , 2021, 18, 279-293.	4.8	102
6422	Outcome and risk factor of immune-related adverse events and pneumonitis in patients with advanced or postoperative recurrent non-small cell lung cancer treated with immune checkpoint inhibitors. <i>Thoracic Cancer</i> , 2021, 12, 153-164.	0.8	28
6423	Tumor Mutational Burden as a Predictor of Immunotherapy Response: Is More Always Better?. <i>Clinical Cancer Research</i> , 2021, 27, 1236-1241.	3.2	222

#	ARTICLE	IF	CITATIONS
6424	microRNA expression patterns in tumor infiltrating lymphocytes are strongly associated with response to adoptive cell transfer therapy. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1541-1555.	2.0	4
6425	IL-17A/F enable cholangiocytes to restrict T cell-driven experimental cholangitis by upregulating PD-L1 expression. <i>Journal of Hepatology</i> , 2021, 74, 919-930.	1.8	18
6426	Immune microenvironment features and efficacy of <sc>PD-1/PD-L1</sc> blockade in non-small cell lung cancer patients with <sc>EGFR</sc> or <sc>HER2</sc> exon 20 insertions. <i>Thoracic Cancer</i> , 2021, 12, 218-226.	0.8	44
6427	Life and Death Decision-Making by p53 and Implications for Cancer Immunotherapy. <i>Trends in Cancer</i> , 2021, 7, 226-239.	3.8	34
6428	Immunostimulatory nanoparticle incorporating two immune agonists for the treatment of pancreatic tumors. <i>Journal of Controlled Release</i> , 2021, 330, 1095-1105.	4.8	34
6429	Distinct roles of programmed death ligand 1 alternative splicing isoforms in colorectal cancer. <i>Cancer Science</i> , 2021, 112, 178-193.	1.7	24
6430	A Gene Mutation Signature Predicting Immunotherapy Benefits in Patients With NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 419-427.	0.5	33
6431	Complete response of squamous cell carcinoma of the lung following treatment with pembrolizumab in an elderly patient: A case report. <i>Thoracic Cancer</i> , 2021, 12, 259-263.	0.8	6
6432	Solid organ transplantation worsens the prognosis of patients with cutaneous squamous cell carcinoma of the head and neck region—Comparison between solid organ transplant recipients and immunocompetent patients. <i>Head and Neck</i> , 2021, 43, 884-894.	0.9	7
6433	SMAD4 mutation correlates with poor prognosis in non-small cell lung cancer. <i>Laboratory Investigation</i> , 2021, 101, 463-476.	1.7	16
6434	Immune imitation of tumor progression after anti-CD19 chimeric antigen receptor T cells treatment in aggressive B-cell lymphoma. <i>Bone Marrow Transplantation</i> , 2021, 56, 1134-1143.	1.3	17
6435	A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1667-1678.	2.0	27
6436	Relationship between immune checkpoint proteins, tumour microenvironment characteristics, and prognosis in primary operable colorectal cancer. <i>Journal of Pathology: Clinical Research</i> , 2021, 7, 121-134.	1.3	17
6437	Institutional-Level Differences in Quality and Outcomes of Lung Cancer Resections in the United States. <i>Chest</i> , 2021, 159, 1630-1641.	0.4	10
6438	Expression of Human Epidermal Growth Factor Receptor-2 Status and Programmed Cell Death Protein-1 Ligand Is Associated With Prognosis in Gastric Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 580045.	1.3	2
6439	A Systematic Review of Immune Checkpoint Inhibitor-Associated Glomerular Disease. <i>Kidney International Reports</i> , 2021, 6, 66-77.	0.4	84
6440	CD24, not CD47, negatively impacts upon response to PD-1/L1 inhibitors in non-small cell lung cancer with PD-L1 tumor proportion score ≥ 50. <i>Cancer Science</i> , 2021, 112, 72-80.	1.7	9
6441	Hemagglutinating virus of Japan envelope containing programmed cell death ligand 1 siRNA inhibits immunosuppressive activities and elicits antitumor immune responses in glioma. <i>Cancer Science</i> , 2021, 112, 81-90.	1.7	9

#	ARTICLE	IF	CITATIONS
6442	Expression of human leukocyte antigen class I and Î²2-microglobulin in colorectal cancer and its prognostic impact. <i>Cancer Science</i> , 2021, 112, 91-100.	1.7	8
6443	The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker. <i>Cancer Cell</i> , 2021, 39, 154-173.	7.7	491
6444	Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 599-607.	0.8	156
6445	Disease Response to Pazopanib in Follicular Dendritic Cell Sarcoma. <i>Case Reports in Oncology</i> , 2021, 13, 1131-1135.	0.3	5
6446	SMARCA4 mutations in KRAS-mutant lung adenocarcinoma: a multi-cohort analysis. <i>Molecular Oncology</i> , 2021, 15, 462-472.	2.1	29
6447	Combinatorial Approaches to the Treatment of Advanced Melanoma. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 145-158.	0.9	5
6448	The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers. <i>Annals of Oncology</i> , 2021, 32, 269-278.	0.6	14
6449	A balance score between immune stimulatory and suppressive microenvironments identifies mediators of tumour immunity and predicts pan-cancer survival. <i>British Journal of Cancer</i> , 2021, 124, 760-769.	2.9	13
6450	Abdominal immune-related adverse events: detection on ultrasonography, CT, MRI and 18F-Fluorodeoxyglucose positron emission tomography. <i>British Journal of Radiology</i> , 2021, 94, 20200663.	1.0	13
6451	Network-based survival analysis to discover target genes for developing cancer immunotherapies and predicting patient survival. <i>Journal of Applied Statistics</i> , 2021, 48, 1352-1373.	0.6	3
6452	Organized immune cell interactions within tumors sustain a productive T-cell response. <i>International Immunology</i> , 2021, 33, 27-37.	1.8	8
6453	Treatment Monitoring of Immunotherapy and Targeted Therapy Using ¹⁸ F-FET PET in Patients with Melanoma and Lung Cancer Brain Metastases: Initial Experiences. <i>Journal of Nuclear Medicine</i> , 2021, 62, 464-470.	2.8	25
6454	Patient-Specific Lymphocyte Loss Kinetics as Biomarker of Spleen Dose in Patients Undergoing Radiation Therapy for Upper Abdominal Malignancies. <i>Advances in Radiation Oncology</i> , 2021, 6, 100545.	0.6	10
6455	Current status and future perspectives of immunotherapy in bladder cancer treatment. <i>Science China Life Sciences</i> , 2021, 64, 512-533.	2.3	21
6456	Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC). <i>Investigational New Drugs</i> , 2021, 39, 182-192.	1.2	8
6457	Relapse of membranous nephropathy with cancer immunotherapy. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 418-420.	1.4	10
6458	PD-1 and LAG-3 blockade improve anti-tumor vaccine efficacy. <i>Oncolimmunology</i> , 2021, 10, 1912892.	2.1	25
6459	Real-world experience with elective discontinuation of PD-1 inhibitors at 1 year in patients with metastatic melanoma. , 2021, 9, e001781.		15

#	ARTICLE	IF	CITATIONS
6460	Expanded Tumor-infiltrating Lymphocytes From Soft Tissue Sarcoma Have Tumor-specific Function. <i>Journal of Immunotherapy</i> , 2021, 44, 63-70.	1.2	22
6461	Hybridoma technology: is it still useful?. <i>Current Research in Immunology</i> , 2021, 2, 32-40.	1.2	17
6462	Immunotherapy-induced pneumonitis in non-small cell lung cancer patients: current concern in treatment with immune-check-point inhibitors. <i>Investigational New Drugs</i> , 2021, 39, 891-898.	1.2	7
6463	Proteogenomic Analysis Unveils the HLA Class I-Presented Immunopeptidome in Melanoma and EGFR-Mutant Lung Adenocarcinoma. <i>Molecular and Cellular Proteomics</i> , 2021, 20, 100136.	2.5	19
6464	Management of Immunotherapy Adverse Events in Oncological Patients: Anti-CTLA-4, Anti-PD-1/PD-L1. <i>Reviews on Recent Clinical Trials</i> , 2021, 15, 339-346.	0.4	5
6465	Effectiveness of steroid therapy in a patient with a pembrolizumab-associated acute kidney injury. <i>Nihon Toseki Igakkai Zasshi</i> , 2021, 54, 481-488.	0.2	0
6466	Response Rate and Survival at Key Timepoints With PD-1 Blockade vs Chemotherapy in PD-L1 Subgroups: Meta-Analysis of Metastatic NSCLC Trials. <i>JNCI Cancer Spectrum</i> , 2021, 5, pKab012.	1.4	16
6467	Addition of anti-TIM3 or anti-TIGIT Antibodies to anti-PD1 Blockade Augments Human T cell Adoptive Cell Transfer. <i>Oncimmunology</i> , 2021, 10, 1873607.	2.1	20
6468	Dendritic cell-based immunotherapies and their potential use in colorectal cancer immunotherapy. <i>Journal of Microscopy and Ultrastructure</i> , 2022, 10, 107.	0.1	4
6469	An integrated epigenomic-transcriptomic landscape of lung cancer reveals novel methylation driver genes of diagnostic and therapeutic relevance. <i>Theranostics</i> , 2021, 11, 5346-5364.	4.6	23
6470	Smoking history and the efficacy of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer: a systematic review and meta-analysis. <i>Journal of Thoracic Disease</i> , 2021, 13, 220-231.	0.6	9
6471	Impact of the corticosteroid indication and administration route on overall survival and the tumor response after immune checkpoint inhibitor initiation. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592199665.	1.4	18
6472	Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome. <i>Translational Lung Cancer Research</i> , 2021, 10, 202-220.	1.3	29
6473	Programmed cell death-1 rs11568821 and interleukin-28B rs12979860 polymorphisms in autoimmune hepatitis. <i>Journal of Translational Autoimmunity</i> , 2021, 4, 100126.	2.0	2
6474	Bioinformatic analysis of PLOD family member expression and prognostic value in non-small cell lung cancer. <i>Translational Cancer Research</i> , 2021, 10, 2707-2724.	0.4	7
6475	Real-World Outcomes and Clinical Predictors of Immune Checkpoint Inhibitor Monotherapy in Advanced Lung Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2021, 15, 117955492110044.	0.6	13
6476	Prognostic value of Thyroid Transcription Factor-1 expression in lung adenocarcinoma in patients treated with anti PD-1/PD-L1. <i>Oncimmunology</i> , 2021, 10, 1957603.	2.1	10
6477	Novel Kras-mutant murine models of non-small cell lung cancer possessing co-occurring oncogenic mutations and increased tumor mutational burden. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2389-2400.	2.0	11

#	ARTICLE	IF	CITATIONS
6478	Identification of chemical compounds regulating PD-L1 by introducing HiBiT-tagged cells. <i>FEBS Letters</i> , 2021, 595, 563-576.	1.3	8
6479	The Anti-PD-1/PD-L1 Immunotherapy for Gastric Esophageal Cancer: A Systematic Review and Meta-Analysis and Literature Review. <i>Cancer Control</i> , 2021, 28, 107327482199743.	0.7	30
6480	Hallmarks of cancer—the new testament. <i>Open Biology</i> , 2021, 11, 200358.	1.5	104
6481	Prognostic value of LRRC4C in Colon and Gastric Cancers correlates with Tumour Microenvironment Immunity. <i>International Journal of Biological Sciences</i> , 2021, 17, 1413-1427.	2.6	6
6482	Immune Checkpoint Inhibitors in Special Populations. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382110365.	0.8	4
6483	Emerging roles for lymphatics in acute kidney injury: Beneficial or maleficent?. <i>Experimental Biology and Medicine</i> , 2021, 246, 845-850.	1.1	6
6484	Old but gold: the role of drug combinations in improving response to immune check-point inhibitors in thoracic malignancies beyond NSCLC. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , .	0.5	0
6485	Clinical pattern of failure after a durable response to immune checkpoint inhibitors in non-small cell lung cancer patients. <i>Scientific Reports</i> , 2021, 11, 2514.	1.6	17
6486	The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC). <i>Cell Reports Medicine</i> , 2021, 2, 100186.	3.3	90
6487	Effect of Systemic Corticosteroid Therapy on the Efficacy and Safety of Nivolumab in the Treatment of Non-Small-Cell Lung Cancer. <i>Cancer Control</i> , 2021, 28, 107327482098579.	0.7	4
6488	The role of endoscopic tumor length in resected esophageal squamous cell carcinoma: a retrospective study. <i>Journal of Thoracic Disease</i> , 2021, 13, 353-361.	0.6	1
6489	Incidence, predictors, and survival impact of acute kidney injury in patients with melanoma treated with immune checkpoint inhibitors: a 10-year single-institution analysis. <i>Oncology</i> , 2021, 10, 1927313.	2.1	27
6490	Circulating leukocyte-platelet complexes as a predictive biomarker for the development of immune-related adverse events in advanced non-small cell lung cancer patients receiving anti-PD-(L)1 blocking agents. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1691-1704.	2.0	6
6491	Designing Dose-Finding Phase I Clinical Trials: Top 10 Questions That Should Be Discussed With Your Statistician. <i>JCO Precision Oncology</i> , 2021, 5, 317-324.	1.5	9
6492	Plasma cytokines interleukin-18 and C-X-C motif chemokine ligand 10 are indicative of the anti-programmed cell death protein-1 treatment response in lung cancer patients. <i>Annals of Translational Medicine</i> , 2021, 9, 33-33.	0.7	16
6493	Immune-related adverse event profile of combination treatment of PD-(L)1 checkpoint inhibitors and bevacizumab in non-small cell lung cancer patients: data from the FDA adverse event reporting system. <i>Translational Lung Cancer Research</i> , 2021, 10, 2614-2624.	1.3	11
6494	High indoleamine-2,3-dioxygenase 1 (IDO) activity is linked to primary resistance to immunotherapy in non-small cell lung cancer (NSCLC). <i>Translational Lung Cancer Research</i> , 2021, 10, 304-313.	1.3	23
6495	The predictive value of body mass index on prognosis and adverse events of cancers treated with immunotherapy: a systematic review and meta-analysis. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2323-2335.	2.0	4

#	ARTICLE	IF	CITATIONS
6496	Efficacy of immune-checkpoint inhibitors in advanced non-small cell lung cancer patients with different metastases. <i>Annals of Translational Medicine</i> , 2021, 9, 34-34.	0.7	22
6497	Transcriptomic and Network Analysis of Minor Salivary Glands of Patients With Primary Sjögren's Syndrome. <i>Frontiers in Immunology</i> , 2020, 11, 606268.	2.2	21
6498	Phase I study of pucotenlimab (HX008), an anti-PD-1 antibody, for patients with advanced solid tumors. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110205.	1.4	9
6499	Prevalence, therapy and tumour response in patients with rheumatic immune-related adverse events following immune checkpoint inhibitor therapy: a single-centre analysis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110069.	1.2	13
6500	B16 melanoma control by anti-PD-L1 requires CD8+ T cells and NK cells: application of anti-PD-L1 Abs and Trp2 peptide vaccines. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 1910-1922.	1.4	9
6501	TGFB2 mutation predicts resistance to immune checkpoint inhibitors in patients with non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110384.	1.4	15
6502	Turning cold tumors into hot tumors by improving T-cell infiltration. <i>Theranostics</i> , 2021, 11, 5365-5386.	4.6	324
6503	A phase III study on neoadjuvant chemotherapy versus neoadjuvant toripalimab plus chemotherapy for locally advanced esophageal squamous cell carcinoma: Henan Cancer Hospital Thoracic Oncology Group 1909 (HCHTOG1909). <i>Annals of Translational Medicine</i> , 2021, 9, 73-73.	0.7	32
6504	Pan-Cancer Molecular Characterization of m6A Regulators and Immunogenomic Perspective on the Tumor Microenvironment. <i>Frontiers in Oncology</i> , 2020, 10, 618374.	1.3	28
6505	Integrative evaluation of primary and metastatic lesion spectrum to guide anti-PD-L1 therapy of non-small cell lung cancer: results from two randomized studies. <i>Oncimmunology</i> , 2021, 10, 1909296.	2.1	13
6506	Prevalence of programmed death ligand-1 in patients diagnosed with non-small cell lung cancer in Lebanon. <i>SAGE Open Medicine</i> , 2021, 9, 2050312121110437.	0.7	1
6507	Hepatitis B Virus Reactivation in Cancer Patients Treated With Immune Checkpoint Inhibitors. <i>Journal of Immunotherapy</i> , 2021, 44, 132-139.	1.2	19
6508	Recent applications and strategies in nanotechnology for lung diseases. <i>Nano Research</i> , 2021, 14, 2067-2089.	5.8	49
6509	Geographic heterogeneity in the outcomes of patients receiving immune checkpoint inhibitors for advanced solid tumors: a meta-analysis. <i>Translational Cancer Research</i> , 2021, 10, 310-326.	0.4	1
6510	Peripheral CD4+ T cell signatures in predicting the responses to anti-PD-1/PD-L1 monotherapy for Chinese advanced non-small cell lung cancer. <i>Science China Life Sciences</i> , 2021, 64, 1590-1601.	2.3	9
6511	KCTD12 is a prognostic marker of breast cancer and correlates with tumor immune cell infiltration. <i>Translational Cancer Research</i> , 2021, 10, 261-272.	0.4	1
6512	Magnetic Forces Enable Control of Biological Processes In Vivo. <i>Journal of Applied Mechanics, Transactions ASME</i> , 2021, 88, 030801.	1.1	2
6513	Acute Tubulointerstitial Nephritis in a Patient on Anti-Programmed Death-Ligand 1 Triggered by COVID-19: A Case Report. <i>Canadian Journal of Kidney Health and Disease</i> , 2021, 8, 205435812110147.	0.6	5

#	ARTICLE	IF	CITATIONS
6514	A modular framework for early-phase seamless oncology trials. <i>Clinical Trials</i> , 2021, 18, 303-313.	0.7	4
6515	Immune-Related Adverse Events in the Older Adult with Cancer Receiving Immune Checkpoint Inhibitor Therapy. <i>Asia-Pacific Journal of Oncology Nursing</i> , 2021, 8, 18.	0.7	3
6516	Utility of Serial Donor-derived Cell-free DNA Measurements for Detecting Allograft Rejection in a Kidney Transplant Recipient After PD-1 Checkpoint Inhibitor Administration. <i>Transplantation Direct</i> , 2021, 7, e656.	0.8	8
6518	Correlation between PD-L1 expression ON CTCs and prognosis of patients with cancer: a systematic review and meta-analysis. <i>Oncolmmunology</i> , 2021, 10, 1938476.	2.1	14
6519	Prognostic significance of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for advanced non-small cell lung cancer patients with high PD-L1 tumor expression receiving pembrolizumab. <i>Translational Lung Cancer Research</i> , 2021, 10, 355-367.	1.3	26
6520	Distinct difference in tumor-infiltrating immune cells between Wilmsâ€™ tumor gene 1 peptide vaccine and anti-programmed cell death-1 antibody therapies. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab091.	0.4	2
6521	Surgery after neoadjuvant immunotherapy in patients with resectable non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 563-580.	1.3	14
6522	Nephrotoxicity in patients with solid tumors treated with anti-PD-1/PD-L1 monoclonal antibodies: a systematic review and meta-analysis. <i>Investigational New Drugs</i> , 2021, 39, 860-870.	1.2	12
6523	PD-1 inhibition in patient derived tissue cultures of human gastric and gastroesophageal adenocarcinoma. <i>Oncolmmunology</i> , 2021, 10, 1960729.	2.1	8
6524	Toll-like receptor 7 deficiency suppresses type 1 diabetes development by modulating B-cell differentiation and function. <i>Cellular and Molecular Immunology</i> , 2021, 18, 328-338.	4.8	13
6525	Predictive factors for dental inflammation with exacerbation during cancer therapy with FDG-PET/CT imaging. <i>Supportive Care in Cancer</i> , 2021, 29, 4277-4284.	1.0	0
6526	Association between incidental statin use and skeletal myopathies in patients treated with immune checkpoint inhibitors. <i>Immunotherapy Advances</i> , 2021, 1, ltab014.	1.2	10
6527	Lung Adenocarcinoma with Paraneoplastic Hyper-Eosinophilia Not Responding To Pembrolizumab. <i>Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine</i> , 2021, 15, 117954842110301.	0.5	3
6528	Pretreatment neutrophil-to-lymphocyte ratio predicts treatment efficacy and prognosis of cytotoxic anticancer drugs, molecular targeted drugs, and immune checkpoint inhibitors in patients with advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 221-232.	1.3	7
6529	VISTA and PD-L1 synergistically predict poor prognosis in patients with extranodal natural killer/T-cell lymphoma. <i>Oncolmmunology</i> , 2021, 10, 1907059.	2.1	20
6530	Cardiovascular Toxicity of Immune Checkpoint Inhibitors: Clinical Risk Factors. <i>Current Oncology Reports</i> , 2021, 23, 13.	1.8	38
6531	Durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis following concurrent chemoradiotherapy: a multicenter prospective cohort study. <i>Investigational New Drugs</i> , 2021, 39, 853-859.	1.2	4
6532	Association of immune-checkpoint inhibitors and the risk of immune-related colitis among elderly patients with advanced melanoma: real-world evidence from the SEERâ€™ Medicare database. <i>Therapeutic Advances in Drug Safety</i> , 2021, 12, 204209862199127.	1.0	1

#	ARTICLE	IF	CITATIONS
6533	Research Interest and Public Interest in Melanoma: A Bibliometric and Google Trends Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 629687.	1.3	15
6534	The Impact of Programmed Death-Ligand 1 Expression on the Prognosis of Early Stage Resected Non-Small Cell Lung Cancer: A Meta-Analysis of Literatures. <i>Frontiers in Oncology</i> , 2021, 11, 567978.	1.3	6
6535	Combinatorial sympathetic and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) blockades inhibit the murine melanoma growth by targeting infiltrating T cells. <i>Translational Cancer Research</i> , 2021, 10, 899-913.	0.4	5
6536	Real Impact of Novel Immunotherapy Drugs in Cancer. The Experience of 10 Last Years. <i>Toxins</i> , 2021, 13, 149.	1.5	6
6537	The Efficacy and Safety of Anlotinib Combined With PD-1 Antibody for Third-Line or Further-Line Treatment of Patients With Advanced Non-Small-Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 619010.	1.3	16
6538	A CT-Based Radiomics Approach to Predict Nivolumab Response in Advanced Non-Small-Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 544339.	1.3	18
6539	Nivolumab plus ipilimumab, with or without enzalutamide, in AR α -expressing metastatic castration-resistant prostate cancer: A phase 2 nonrandomized clinical trial. <i>Prostate</i> , 2021, 81, 326-338.	1.2	35
6540	Ratio of the interferon- γ signature to the immunosuppression signature predicts anti-PD-1 therapy response in melanoma. <i>Npj Genomic Medicine</i> , 2021, 6, 7.	1.7	41
6541	From antibodies to living drugs: Quo vadis cancer immunotherapy?. <i>Biologia Futura</i> , 2021, 72, 85-99.	0.6	2
6542	Identifying the prognostic significance of B3GNT3 with PD-L1 expression in lung adenocarcinoma. <i>Translational Lung Cancer Research</i> , 2021, 10, 965-980.	1.3	12
6543	Novel risk scoring system for immune checkpoint inhibitors treatment in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 776-789.	1.3	6
6544	Pembrolizumab in the adjuvant treatment of melanoma: efficacy and safety. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 583-590.	1.1	4
6545	Identification of an Immune-Related Signature for Predicting Prognosis in Patients With Pancreatic Ductal Adenocarcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 618215.	1.3	15
6546	The evolving landscape of immunotherapy in solid tumors. <i>Journal of Surgical Oncology</i> , 2021, 123, 798-806.	0.8	17
6547	Impact of cancer evolution on immune surveillance and checkpoint inhibitor response. <i>Seminars in Cancer Biology</i> , 2022, 84, 89-102.	4.3	21
6548	Clinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental Signatures. <i>Cancer Discovery</i> , 2021, 11, 1468-1489.	7.7	119
6549	Acute renal transplant rejection following nivolumab therapy for metastatic melanoma. <i>BMJ Case Reports</i> , 2021, 14, e238037.	0.2	9
6550	Low-density PD-1 expression on resting human natural killer cells is functional and upregulated after transplantation. <i>Blood Advances</i> , 2021, 5, 1069-1080.	2.5	20

#	ARTICLE	IF	CITATIONS
6551	FDA Approval Summary: Nivolumab with Ipilimumab and Chemotherapy for Metastatic Non-small Cell Lung Cancer, A Collaborative Project Orbis Review. <i>Clinical Cancer Research</i> , 2021, 27, 3522-3527.	3.2	32
6552	Modulation of intratumoural myeloid cells, the hallmark of the anti-tumour efficacy induced by a triple combination: tumour-associated peptide, TLR-3 ligand and \pm -PD-1. <i>British Journal of Cancer</i> , 2021, 124, 1275-1285.	2.9	5
6553	Systemic Immune-Inflammation Index Is a Prognostic Predictor in Patients with Intrahepatic Cholangiocarcinoma Undergoing Liver Transplantation. <i>Mediators of Inflammation</i> , 2021, 2021, 1-7.	1.4	11
6554	Relevance of PD-L1 Non-Coding Polymorphisms on the Prognosis of a Genetically Admixed NSCLC Cohort. <i>Pharmacogenomics and Personalized Medicine</i> , 2021, Volume 14, 239-252.	0.4	3
6555	The landscape of immune checkpoints expression in non-small cell lung cancer: a narrative review. <i>Translational Lung Cancer Research</i> , 2021, 10, 1029-1038.	1.3	12
6556	Cancer therapy-induced hyponatremia: A case-illustrated review. <i>Journal of Onco-Nephrology</i> , 2021, 5, 70-78.	0.3	7
6557	PD-L1 as a biomarker of response to immune-checkpoint inhibitors. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 345-362.	12.5	646
6558	Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial. <i>Cancer Discovery</i> , 2021, 11, 1688-1699.	7.7	154
6559	Acute kidney injury as a risk factor for mortality in oncological patients receiving checkpoint inhibitors. <i>Nephrology Dialysis Transplantation</i> , 2021, , .	0.4	23
6560	Phospholipase A2 receptor antibody mediated membranous nephropathy associated with cemiplimab. <i>Journal of Onco-Nephrology</i> , 2021, 5, 27-30.	0.3	4
6561	Immune classification of clear cell renal cell carcinoma. <i>Scientific Reports</i> , 2021, 11, 4338.	1.6	18
6562	Correlations Between Tumor Mutation Burden and Immunocyte Infiltration and Their Prognostic Value in Colon Cancer. <i>Frontiers in Genetics</i> , 2021, 12, 623424.	1.1	20
6563	The Top 100 Most Frequently Cited Publications Concerning Anti-PD-1/PD-L1 Therapy for Lung Cancer: A Bibliometric Analysis. <i>Cancer Management and Research</i> , 2021, Volume 13, 1383-1393.	0.9	5
6564	A case of pembrolizumab induced distal renal tubular acidosis. <i>Journal of Onco-Nephrology</i> , 2021, 5, 23-26.	0.3	8
6565	Ubiquitin-Specific Protease 6 Functions as a Tumor Suppressor in Ewing Sarcoma through Immune Activation. <i>Cancer Research</i> , 2021, 81, 2171-2183.	0.4	14
6566	Murine cancer cachexia models replicate elevated catabolic pembrolizumab clearance in humans. <i>JCSM Rapid Communications</i> , 2021, 4, 232-244.	0.6	6
6567	Differential expression of PD-L1 between primary and metastatic epithelial ovarian cancer and its clinico-pathological correlation. <i>Scientific Reports</i> , 2021, 11, 3750.	1.6	22
6568	Targeted drug delivery strategies for precision medicines. <i>Nature Reviews Materials</i> , 2021, 6, 351-370.	23.3	388

#	ARTICLE	IF	CITATIONS
6569	DNA Damage Repair Gene Mutations Are Indicative of a Favorable Prognosis in Colorectal Cancer Treated With Immune Checkpoint Inhibitors. <i>Frontiers in Oncology</i> , 2020, 10, 549777.	1.3	26
6570	Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. <i>Science</i> , 2021, 371, 595-602.	6.0	746
6571	Immune checkpoint blockade in renal cell carcinoma. <i>Journal of Surgical Oncology</i> , 2021, 123, 739-750.	0.8	13
6572	Real-world experience with pembrolizumab in patients with advanced soft tissue sarcoma. <i>Annals of Translational Medicine</i> , 2021, 9, 339-339.	0.7	12
6573	Dampening antiviral immunity can protect the host. <i>FEBS Journal</i> , 2022, 289, 634-646.	2.2	5
6574	Prognostic Characteristics and Immunotherapy Response of Patients With Nonsquamous NSCLC With Kras Mutation in East Asian Populations: A Single-Center Cohort Study in Taiwan. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100140.	0.6	11
6575	The Reproducibility of Histopathologic Assessments of Programmed Cell Death-Ligand 1 Using Companion Diagnostics in NSCLC. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100102.	0.6	2
6576	ERK Inhibitor LY3214996-Based Treatment Strategies for RAS-Driven Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 641-654.	1.9	16
6577	Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 72.	7.1	191
6578	Dynamics of thymus function and T cell receptor repertoire breadth in health and disease. <i>Seminars in Immunopathology</i> , 2021, 43, 119-134.	2.8	29
6579	Non-canonical PD-1 signaling in cancer and its potential implications in clinic. , 2021, 9, e001230.		15
6580	PD-1 restrains IL-17A production from $\gamma\delta$ T cells to modulate acute radiation-induced lung injury. <i>Translational Lung Cancer Research</i> , 2021, 10, 685-698.	1.3	7
6581	Pembrolizumab in Patients with Advanced Metastatic Germ Cell Tumors. <i>Oncologist</i> , 2021, 26, 558-e1098.	1.9	18
6582	BAP1-Altered Malignant Pleural Mesothelioma: Outcomes With Chemotherapy, Immune Check-Point Inhibitors and Poly(ADP-Ribose) Polymerase Inhibitors. <i>Frontiers in Oncology</i> , 2021, 11, 603223.	1.3	9
6583	Tumor Response Dynamics During First-Line Pembrolizumab Therapy in Patients With Advanced Non-Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 501-509.	1.5	4
6584	Efficacy and Safety of S-1 Compared With Docetaxel in Elderly Patients With Advanced NSCLC Previously Treated With Platinum-Based Chemotherapy: A Subgroup Analysis of the EAST-LC Trial. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100142.	0.6	1
6585	High numbers of programmed cell death-1-positive tumor infiltrating lymphocytes correlate with early onset of post-transplant lymphoproliferative disorder. <i>International Journal of Hematology</i> , 2021, 114, 53-64.	0.7	1
6586	An emerging role for cellular crosstalk in the cancer stem cell niche. <i>Journal of Pathology</i> , 2021, 254, 384-394.	2.1	31

#	ARTICLE	IF	CITATIONS
6587	Refractory Acute Interstitial Nephritis in the Setting of Nivolumab Therapy. Case Reports in Nephrology, 2021, 2021, 1-4.	0.2	4
6588	The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy. Molecular Cancer Therapeutics, 2021, 20, 975-985.	1.9	79
6589	Resident and circulating memory T cells persist for years in melanoma patients with durable responses to immunotherapy. Nature Cancer, 2021, 2, 300-311.	5.7	70
6590	Melanoma brain metastasis presentation, treatment, and outcomes in the age of targeted and immunotherapies. Cancer, 2021, 127, 2062-2073.	2.0	40
6591	Low-dose pembrolizumab in the treatment of advanced non-small cell lung cancer. International Journal of Cancer, 2021, 149, 169-176.	2.3	24
6592	Upregulating hsa-miR-128a Increased the Effects of Pembrolizumab on Laryngeal Cancer Cells via the p53 Pathway. BioMed Research International, 2021, 2021, 1-6.	0.9	4
6593	Risk Prediction Using Bayesian Networks: An Immunotherapy Case Study in Patients With Metastatic Renal Cell Carcinoma. JCO Clinical Cancer Informatics, 2021, 5, 326-337.	1.0	4
6594	Multimodal Non-Surgical Treatments of Aggressive Pituitary Tumors. Frontiers in Endocrinology, 2021, 12, 624686.	1.5	13
6595	Pharmacological Interventions for the Prevention and Treatment of Immune Checkpoint Inhibitor-Associated Enterocolitis: A Systematic Review. Digestive Diseases and Sciences, 2022, 67, 1128-1155.	1.1	4
6596	ITGA5 is a prognostic biomarker and correlated with immune infiltration in gastrointestinal tumors. BMC Cancer, 2021, 21, 269.	1.1	33
6597	Progression Patterns, Treatment, and Prognosis Beyond Resistance of Responders to Immunotherapy in Advanced Non-Small Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 642883.	1.3	21
6598	Targeted Therapy Given after Anti-PD-1 Leads to Prolonged Responses in Mouse Melanoma Models through Sustained Antitumor Immunity. Cancer Immunology Research, 2021, 9, 554-567.	1.6	15
6599	Patients With Short PFS to EGFR-TKIs Predicted Better Response to Subsequent Anti-PD-1/PD-L1 Based Immunotherapy in EGFR Common Mutation NSCLC. Frontiers in Oncology, 2021, 11, 639947.	1.3	24
6600	Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer. , 2021, 9, e001865.		31
6601	Renal Cell Carcinoma and Kidney Transplantation: A Narrative Review. Transplantation, 2022, 106, e52-e63.	0.5	25
6602	Comprehensive molecular analysis of genomic profiles and PD-L1 expression in lung adenocarcinoma with a high-grade fetal adenocarcinoma component. Translational Lung Cancer Research, 2021, 10, 1292-1304.	1.3	7
6603	Molecular Subtypes and CD4+ Memory T Cell-Based Signature Associated With Clinical Outcomes in Gastric Cancer. Frontiers in Oncology, 2020, 10, 626912.	1.3	15
6604	Tumor-derived ILT4 induces T cell senescence and suppresses tumor immunity. , 2021, 9, e001536.		23

#	ARTICLE	IF	CITATIONS
6605	Discovery of Diaminopyrimidine Carboxamide HPK1 Inhibitors as Preclinical Immunotherapy Tool Compounds. <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 653-661.	1.3	18
6606	Promises and challenges of adoptive T-cell therapies for solid tumours. <i>British Journal of Cancer</i> , 2021, 124, 1759-1776.	2.9	113
6607	Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 723-733.	0.8	329
6608	Kidney injury and disease in patients with haematological malignancies. <i>Nature Reviews Nephrology</i> , 2021, 17, 386-401.	4.1	20
6609	STK1p as a prognostic biomarker for overall survival in non-small-cell lung carcinoma, based on real-world data. <i>Future Science OA</i> , 2021, 7, FSO661.	0.9	3
6610	Virus-specific memory T cell responses unmasked by immune checkpoint blockade cause hepatitis. <i>Nature Communications</i> , 2021, 12, 1439.	5.8	39
6611	Distinct prognostic values of programmed death-ligand 1 and programmed cell death protein 1 in lung adenocarcinoma and squamous cell carcinoma patients. <i>Annals of Translational Medicine</i> , 2021, 9, 397-397.	0.7	0
6612	Primary malignant melanoma of uterine cervix treated with pembrolizumab as adjuvant immunotherapy. <i>International Cancer Conference Journal</i> , 2021, 10, 254-258.	0.2	3
6613	Recent advances in preclinical models for lung squamous cell carcinoma. <i>Oncogene</i> , 2021, 40, 2817-2829.	2.6	26
6614	Ocular Toxicity of Targeted Anticancer Agents. <i>Drugs</i> , 2021, 81, 771-823.	4.9	22
6615	Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions. <i>Clinical Cancer Research</i> , 2021, 27, 2920-2927.	3.2	42
6616	Lipid presentation by the protein C receptor links coagulation with autoimmunity. <i>Science</i> , 2021, 371, .	6.0	66
6617	Pembrolizumab Utilization and Clinical Outcomes Among Patients With Advanced Melanoma in the US Community Oncology Setting: An Updated Analysis. <i>Journal of Immunotherapy</i> , 2021, 44, 224-233.	1.2	3
6618	Neoadjuvant pembrolizumab with chemotherapy for the treatment of stage IIB-IIIB resectable lung squamous cell carcinoma. <i>Journal of Thoracic Disease</i> , 2021, 13, 1760-1768.	0.6	36
6619	Sex- and Gender-Based Pharmacological Response to Drugs. <i>Pharmacological Reviews</i> , 2021, 73, 730-762.	7.1	80
6620	Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Anti-PD-1 Therapy Efficacy. <i>Cancer Immunology Research</i> , 2021, 9, 568-582.	1.6	30
6621	Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	84
6622	Efficacy and Feasibility of Programmed Death-1/Programmed Death Ligand-1 Blockade Therapy in Non-Small Cell Lung Cancer Patients With High Antinuclear Antibody Titers. <i>Frontiers in Oncology</i> , 2021, 11, 610952.	1.3	10

#	ARTICLE	IF	CITATIONS
6623	Checkpoint inhibitor therapy-associated acute kidney injury: time to move on to evidence-based recommendations. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 1301-1306.	1.4	12
6624	Integration of radiotherapy with anti-PD-1 antibody for the treatment of intrahepatic or hilar cholangiocarcinoma: reflection from four cases. <i>Cancer Biology and Therapy</i> , 2021, 22, 175-183.	1.5	13
6625	Renal toxicity of targeted therapies for renal cell carcinoma in patients with normal and impaired kidney function. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 723-742.	1.1	13
6626	Use of checkpoint inhibitors in patients with lymphoid malignancies receiving allogeneic cell transplantation: a review. <i>Bone Marrow Transplantation</i> , 2021, 56, 1784-1793.	1.3	5
6627	Anti-PD-1 Monotherapy for Advanced NSCLC Patients with Older Age or Those with Poor Performance Status. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 1961-1968.	1.0	10
6628	Integration of cancer registry and electronic health record data to construct a childhood cancer survivorship cohort, facilitate risk stratification for late effects, and assess appropriate follow-up care. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29014.	0.8	5
6629	Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM). , 2021, 9, e001664.		11
6630	Improvement of urinary symptoms after bladder biopsy: A case of pathologically proven allergy-related cystitis during administration of nivolumab. <i>IJU Case Reports</i> , 2021, 4, 213-215.	0.1	7
6631	Prognostic Value of Deep Learning-Mediated Treatment Monitoring in Lung Cancer Patients Receiving Immunotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 609054.	1.3	23
6632	Detect it so you can treat it: A case series and proposed checklist to detect neurotoxicity in checkpoint therapy. <i>ENeurologicalSci</i> , 2021, 22, 100324.	0.5	9
6633	A novel prognosis prediction model, including cytotoxic T lymphocyte-associated antigen 4, ischemia-modified albumin, lipoprotein-associated phospholipase A2, glial fibrillary acidic protein, and homocysteine, for ischemic stroke in the Chinese hypertensive population. <i>Journal of Clinical Laboratory Analysis</i> , 2021, 35, e23756.	0.9	8
6634	Immune Checkpoint Inhibition as a Strategy in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer. <i>Journal of Immunotherapy and Precision Oncology</i> , 2021, 4, 86-104.	0.6	0
6635	Ageing, cancer, and antitumor immunity. <i>International Journal of Clinical Oncology</i> , 2022, 27, 316-322.	1.0	29
6636	Recurrent Myocarditis Induced by Immune-Checkpoint Inhibitor Treatment Is Accompanied by Persistent Inflammatory Markers Despite Immunosuppressive Treatment. <i>JCO Precision Oncology</i> , 2021, 5, 485-491.	1.5	5
6637	An unexpected role for p53 in regulating cancer cell-intrinsic PD-1 by acetylation. <i>Science Advances</i> , 2021, 7, .	4.7	32
6638	PD-L1 Expression and Outcome in Patients with Metastatic Non-Small Cell Lung Cancer and EGFR Mutations Receiving EGFR-TKI as Frontline Treatment. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 2301-2309.	1.0	6
6639	Pyroptosis: mechanisms and diseases. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 128.	7.1	821
6640	Population-level changes in outcomes and Medicare cost following the introduction of new cancer therapies. <i>Health Services Research</i> , 2021, 56, 486-496.	1.0	3

#	ARTICLE	IF	CITATIONS
6641	Clinical outcome of patients with metastatic melanoma of unknown primary in the era of novel therapy. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3123-3135.	2.0	6
6642	Population pharmacokinetic characteristics of cemiplimab in patients with advanced malignancies. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2021, 48, 479-494.	0.8	15
6643	KRAS G12C inhibition and innate immune targeting. <i>Expert Opinion on Therapeutic Targets</i> , 2021, 25, 1-8.	1.5	6
6644	Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based Therapy. <i>JCO Precision Oncology</i> , 2021, 5, 510-524.	1.5	36
6645	Efficacy and Safety of Anti-PD-1 Plus Anlotinib in Patients With Advanced Non-Small-Cell Lung Cancer After Previous Systemic Treatment Failure: A Retrospective Study. <i>Frontiers in Oncology</i> , 2021, 11, 628124.	1.3	39
6646	Imaging Biomarkers to Predict and Evaluate the Effectiveness of Immunotherapy in Advanced Non-Small-Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 657615.	1.3	29
6647	Immune-Related Adverse Events Are Associated With Clinical Benefit in Patients With Non-Small-Cell Lung Cancer Treated With Immunotherapy Plus Chemotherapy: A Retrospective Study. <i>Frontiers in Oncology</i> , 2021, 11, 630136.	1.3	17
6648	Beyond immune checkpoint blockade: emerging immunological strategies. <i>Nature Reviews Drug Discovery</i> , 2021, 20, 899-919.	21.5	208
6649	Emerging strategies for treating metastasis. <i>Nature Cancer</i> , 2021, 2, 258-270.	5.7	71
6650	Hedgehog-induced PD-L1 on tumor-associated macrophages is critical for suppression of tumor-infiltrating CD8+ T cell function. <i>JCI Insight</i> , 2021, 6, .	2.3	47
6651	Tumor Microenvironment in Oral Cancer Following Neoadjuvant Pembrolizumab: Preliminary Analysis of the Histopathologic Findings. <i>Frontiers in Oral Health</i> , 2021, 2, 653104.	1.2	2
6652	Mesenchymal Stem Cell Transplantation for Ischemic Diseases: Mechanisms and Challenges. <i>Tissue Engineering and Regenerative Medicine</i> , 2021, 18, 587-611.	1.6	24
6653	Epidermal Growth Factor Receptor Mutation Status and Response to Tyrosine Kinase Inhibitors in Advanced Chinese Female Lung Squamous Cell Carcinoma: A Retrospective Study. <i>Frontiers in Oncology</i> , 2021, 11, 652560.	1.3	8
6654	PD-1 Inhibitor for a Non-Small-Cell Lung Cancer Patient With Paraneoplastic Nephropathy. <i>Archivos De Bronconeumologia</i> , 2021, 57, 311-312.	0.4	0
6655	Immune Checkpoints, a Novel Class of Therapeutic Targets for Autoimmune Diseases. <i>Frontiers in Immunology</i> , 2021, 12, 645699.	2.2	18
6656	Efficacy of Combination Docetaxel and Nintedanib in Advanced Non-Small Cell Lung Cancer in Thailand: A Multicenter Study. <i>Frontiers in Oncology</i> , 2021, 11, 572740.	1.3	4
6657	Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA). <i>Journal of Clinical Oncology</i> , 2021, 39, 1108-1118.	0.8	67
6658	Overcoming therapy resistance in EGFR-mutant lung cancer. <i>Nature Cancer</i> , 2021, 2, 377-391.	5.7	198

#	ARTICLE	IF	CITATIONS
6659	Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 562315.	1.3	38
6660	Nivolumab and Hypofractionated Radiotherapy in Patients With Advanced Lung Cancer: ABSCOPAL-1 Clinical Trial. <i>Frontiers in Oncology</i> , 2021, 11, 657024.	1.3	17
6661	Consolidation With Pembrolizumab and Nab-Paclitaxel After Induction Platinum-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 666691.	1.3	2
6662	Trials and tribulations of pancreatic cancer immunotherapy. <i>Cancer Letters</i> , 2021, 504, 1-14.	3.2	37
6663	Brief Report on the Efficacy of Nivolumab in Patients With Previously Treated Advanced Large-Cell Neuroendocrine Cancer of the Lung. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100129.	0.6	5
6664	Anti-angiogenic agents "overcoming tumour endothelial cell anergy and improving immunotherapy outcomes. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 527-540.	12.5	162
6665	Development of Immunotherapy Combination Strategies in Cancer. <i>Cancer Discovery</i> , 2021, 11, 1368-1397.	7.7	130
6666	A Review of Cancer Immunotherapy Toxicity: Immune Checkpoint Inhibitors. <i>Journal of Medical Toxicology</i> , 2021, 17, 411-424.	0.8	54
6667	Inhibition of Granulocytic Myeloid-Derived Suppressor Cells Overcomes Resistance to Immune Checkpoint Inhibition in LKB1-Deficient Non-Small Cell Lung Cancer. <i>Cancer Research</i> , 2021, 81, 3295-3308.	0.4	51
6668	The International Association for the Study of Lung Cancer Global Survey on Programmed Death-Ligand 1 Testing for NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 686-696.	0.5	13
6669	Molecular Biomarkers for Melanoma Screening, Diagnosis and Prognosis: Current State and Future Prospects. <i>Frontiers in Medicine</i> , 2021, 8, 642380.	1.2	28
6670	Tumor resident regulatory T cells. <i>Seminars in Immunology</i> , 2021, 52, 101476.	2.7	18
6671	CD200 Immune-Checkpoint Peptide Elicits an Anti-glioma Response Through the DAP10 Signaling Pathway. <i>Neurotherapeutics</i> , 2021, 18, 1980-1994.	2.1	6
6672	Renal adverse effects of immune checkpoints inhibitors in clinical practice: ImmuNoTox study. <i>European Journal of Cancer</i> , 2021, 147, 29-39.	1.3	46
6673	Emerging Role of PD-1 in the Central Nervous System and Brain Diseases. <i>Neuroscience Bulletin</i> , 2021, 37, 1188-1202.	1.5	30
6674	Use of amantadine in the evaluation of response to chemotherapy in lung cancer: a pilot study. <i>Future Science OA</i> , 2021, 7, FSO679.	0.9	3
6675	Personal Neoantigens From Patients With NSCLC Induce Efficient Antitumor Responses. <i>Frontiers in Oncology</i> , 2021, 11, 628456.	1.3	14
6676	Atypical anti-glomerular basement membrane glomerulonephritis in a patient with metastatic melanoma treated with mitogen-activated protein kinase and immune checkpoint inhibitors: a case report. <i>Journal of Medical Case Reports</i> , 2021, 15, 186.	0.4	9

#	ARTICLE	IF	CITATIONS
6677	Evolving Role of Oncolytic Virotherapy: Challenges and Prospects in Clinical Practice. <i>JCO Precision Oncology</i> , 2021, 5, 432-441.	1.5	16
6678	Gastrointestinal disorders as immune-related adverse events. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , .	0.5	2
6679	Adrenal insufficiency development during chemotherapy plus anti-programmed death receptor-1 monoclonal antibody (tislelizumab) therapy in patients with advanced gastric cancer: two case reports. <i>Yeungnam University Journal of Medicine</i> , 2022, 39, 62-66.	0.7	3
6680	Abnormal spindle-like microcephaly-associated protein enhances cell invasion through Wnt/ β 2-catenin-dependent regulation of epithelial-mesenchymal transition in non-small cell lung cancer cells. <i>Journal of Thoracic Disease</i> , 2021, 13, 2460-2474.	0.6	5
6681	Stereotactic radiotherapy for early stage non-small cell lung cancer: current standards and ongoing research. <i>Translational Lung Cancer Research</i> , 2021, 10, 1930-1949.	1.3	10
6682	IL-7 coupled with IL-12 increases intratumoral T cell clonality, leading to complete regression of non-immunogenic tumors. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3557-3571.	2.0	11
6683	Acute pancreatitis without abdominal pain induced by administration of nivolumab and ipilimumab. <i>Modern Rheumatology Case Reports</i> , 2021, 5, 425-430.	0.3	6
6684	Multimodal Molecular Imaging Detects Early Responses to Immune Checkpoint Blockade. <i>Cancer Research</i> , 2021, 81, 3693-3705.	0.4	15
6685	Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. <i>The Cochrane Library</i> , 2021, 2021, CD013257.	1.5	35
6686	The Pattern of Time to Onset and Resolution of Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors in Cancer: A Pooled Analysis of 23 Clinical Trials and 8,436 Patients. <i>Cancer Research and Treatment</i> , 2021, 53, 339-354.	1.3	63
6687	Perioperative safety and feasibility outcomes of stage IIIA-N2 non-small cell lung cancer following neoadjuvant immunotherapy or neoadjuvant chemotherapy: a retrospective study. <i>Annals of Translational Medicine</i> , 2021, 9, 685-685.	0.7	10
6688	Response durability after cessation of immune checkpoint inhibitors in patients with metastatic Merkel cell carcinoma: a retrospective multicenter DeCOG study. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3313-3322.	2.0	17
6689	Tumour neoantigen mimicry by microbial species in cancer immunotherapy. <i>British Journal of Cancer</i> , 2021, 125, 313-323.	2.9	29
6690	Distinct Biomarker Profiles and TCR Sequence Diversity Characterize the Response to PD-L1 Blockade in a Mouse Melanoma Model. <i>Molecular Cancer Research</i> , 2021, 19, 1422-1436.	1.5	3
6691	Overview of Ocular Side Effects of Selinexor. <i>Oncologist</i> , 2021, 26, 619-623.	1.9	5
6692	Factors affecting survival after palliative radiotherapy in patients with lung cancer. <i>Reports of Practical Oncology and Radiotherapy</i> , 2021, 26, 674-682.	0.3	0
6693	Adverse events induced by immune checkpoint inhibitors. <i>Current Opinion in Immunology</i> , 2021, 69, 29-38.	2.4	25
6694	Immune Checkpoint Inhibitor Associated Hepatotoxicity in Primary Liver Cancer Versus Other Cancers: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 650292.	1.3	22

#	ARTICLE	IF	CITATIONS
6695	Cost-Effectiveness Analysis of Atezolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer With Different PD-L1 Expression Status. <i>Frontiers in Oncology</i> , 2021, 11, 669195.	1.3	19
6696	Targeting the IL-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activity (NCI9922). <i>Melanoma Research</i> , 2021, 31, 162-172.	0.6	6
6697	PD-1 Inhibitor for a Non-Small-Cell Lung Cancer Patient With Paraneoplastic Nephropathy. <i>Archivos De Bronconeumologia</i> , 2021, 57, 311-312.	0.4	0
6698	Biomarkers, Clinical Features, and Rechallenge for Immune Checkpoint Inhibitor Renal Immune-Related Adverse Events. <i>Kidney International Reports</i> , 2021, 6, 1022-1031.	0.4	54
6699	Pembrolizumab Plus Chemotherapy or Anlotinib vs. Pembrolizumab Alone in Patients With Previously Treated EGFR-Mutant NSCLC. <i>Frontiers in Oncology</i> , 2021, 11, 671228.	1.3	13
6700	Serum Levels of Soluble Urokinase Plasminogen Activator Receptor Predict Tumor Response and Outcome to Immune Checkpoint Inhibitor Therapy. <i>Frontiers in Oncology</i> , 2021, 11, 646883.	1.3	7
6701	Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma. , 2021, 9, e002478.		59
6702	Growth arrest of a refractory vestibular schwannoma after anti-PD-1 antibody treatment. <i>BMJ Case Reports</i> , 2021, 14, e241834.	0.2	0
6703	Immune checkpoint inhibitors combined with chemotherapy/bevacizumab therapy for patients with advanced lung cancer and heavily treated with EGFR mutation: a retrospective analysis. <i>Journal of Thoracic Disease</i> , 2021, 13, 2959-2967.	0.6	2
6704	Absolute Lymphocyte Count Predicts Immune-Related Adverse Events in Patients With Non-Small-Cell Lung Cancer Treated With Nivolumab Monotherapy: A Multicenter Retrospective Study. <i>Frontiers in Oncology</i> , 2021, 11, 618570.	1.3	12
6705	Nivolumab-associated glomerular endothelial injury in a patient with gastric cancer. <i>CEN Case Reports</i> , 2021, 10, 576-581.	0.5	1
6706	Post-transcriptional control of cell cytokine production: Implications for cancer therapy. <i>Immunology</i> , 2021, 164, 57-72.	2.0	3
6707	Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy. <i>European Journal of Cancer</i> , 2021, 149, 153-164.	1.3	79
6708	Genomic profiling of advanced cervical cancer to predict response to programmed death-1 inhibitor combination therapy: a secondary analysis of the CLAP trial. , 2021, 9, e002223.		23
6709	Cardiotoxicity of Immune Checkpoint Inhibitors. <i>Current Oncology Reports</i> , 2021, 23, 79.	1.8	85
6711	Outcomes after stereotactic radiosurgery of brain metastases in patients with malignant melanoma and validation of the melanoma molGPA. <i>Clinical and Translational Oncology</i> , 2021, 23, 2020-2029.	1.2	0
6712	Ginseng polysaccharides alter the gut microbiota and kynurenine/tryptophan ratio, potentiating the antitumour effect of anti-programmed cell death 1/programmed cell death ligand 1 (anti-PD-1/PD-L1) immunotherapy. <i>Gut</i> , 2022, 71, 734-745.	6.1	177
6713	Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure. <i>Frontiers in Oncology</i> , 2021, 11, 683341.	1.3	13

#	ARTICLE	IF	CITATIONS
6714	Emerging concepts in PD-1 checkpoint biology. <i>Seminars in Immunology</i> , 2021, 52, 101480.	2.7	84
6715	Treatment-Related Serious Adverse Events of Immune Checkpoint Inhibitors in Clinical Trials: A Systematic Review. <i>Frontiers in Oncology</i> , 2021, 11, 621639.	1.3	12
6716	The Role of Programmed Death-1 in Type 1 Diabetes. <i>Current Diabetes Reports</i> , 2021, 21, 20.	1.7	11
6717	Cutaneous innate immune tolerance is mediated by epigenetic control of MAP2K3 by HDAC8/9. <i>Science Immunology</i> , 2021, 6, .	5.6	33
6718	Immune-related genes and gene sets for predicting the response to anti-programmed death 1 therapy in patients with primary or metastatic non-small cell lung cancer. <i>Oncology Letters</i> , 2021, 22, 540.	0.8	8
6719	Emerging Next-Generation Target for Cancer Immunotherapy Research: The Orphan Nuclear Receptor NR2F6. <i>Cancers</i> , 2021, 13, 2600.	1.7	11
6720	Immunotherapy and radiation for high-grade glioma: a narrative review. <i>Translational Cancer Research</i> , 2021, 10, 2537-2570.	0.4	6
6721	The Interplay Between Programmed Death Ligand 1 and Vimentin in Advanced Non-Small-Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 669839.	1.3	4
6722	Cancer microenvironment and genomics: evolution in process. <i>Clinical and Experimental Metastasis</i> , 2022, 39, 85-99.	1.7	11
6723	Intracranial complete response for non-small-cell lung cancer patient with negative PD-L1 expression of the lung using nivolumab. <i>Cancer Reports</i> , 2021, , e1460.	0.6	3
6724	The genomic characteristics of different progression patterns in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors. <i>Annals of Translational Medicine</i> , 2021, 9, 779-779.	0.7	4
6725	Epidemiology and Survival Outcomes for Patients With NSCLC in Scandinavia in the Preimmunotherapy Era: A SCAN-LEAF Retrospective Analysis From the I-O Optimise Initiative. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100165.	0.6	6
6726	Silylation of deoxynucleotide analog yields an orally available drug with anti-leukemia effects. <i>Molecular Cancer Therapeutics</i> , 2021, 20, molcanther.1125.2020.	1.9	6
6727	The Impact of VEGF Inhibition on Clinical Outcomes in Patients With Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy: A Retrospective Cohort Study. <i>Frontiers in Oncology</i> , 2021, 11, 663612.	1.3	8
6728	Correlation of Peripheral Blood Parameters and Immune-Related Adverse Events with the Efficacy of Immune Checkpoint Inhibitors. <i>Journal of Oncology</i> , 2021, 2021, 1-15.	0.6	8
6729	Imaging of T-cell Responses in the Context of Cancer Immunotherapy. <i>Cancer Immunology Research</i> , 2021, 9, 490-502.	1.6	8
6730	Single-cell Analysis Technologies for Immuno-oncology Research: from Mechanistic Delineation to Biomarker Discovery. <i>Genomics, Proteomics and Bioinformatics</i> , 2021, 19, 191-207.	3.0	5
6731	Immune checkpoint inhibitors for unresectable malignant pleural mesothelioma. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 2972-2980.	1.4	5

#	ARTICLE	IF	CITATIONS
6732	Tumor Mutation Burden and Differentially Mutated Genes Among Immune Phenotypes in Patients with Lung Adenocarcinoma. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 2953-2965.	1.0	6
6733	Sintilimab induced diabetic ketoacidosis in a patient with small cell lung cancer. <i>Medicine (United States)</i> , 2021, 100(14), e024314.	0.4	9
6734	Combinatorial Therapies to Overcome BRAF/MEK Inhibitors Resistance in Melanoma Cells: An in vitro Study. <i>Journal of Experimental Pharmacology</i> , 2021, Volume 13, 521-535.	1.5	5
6735	MicroRNA-1: Diverse role of a small player in multiple cancers. <i>Seminars in Cell and Developmental Biology</i> , 2022, 124, 114-126.	2.3	14
6736	Mechanisms of primary and acquired resistance to PD-1/PD-L1 blockade and the emerging role of gut microbiome. <i>Clinical and Translational Oncology</i> , 2021, 23, 2237-2252.	1.2	7
6737	Reduced frequency of cytotoxic CD56dim CD16+ NK cells leads to impaired antibody-dependent degranulation in EBV-positive classical Hodgkin lymphoma. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 13-24.	2.0	7
6738	Comprehensive analysis of blood-based biomarkers for predicting immunotherapy benefits in patients with advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 2103-2117.	1.3	12
6739	Experiences of cancer immunotherapy with immune checkpoint inhibitors (ExCI) – insights of people affected by cancer and healthcare professionals: a qualitative study protocol. <i>BMJ Open</i> , 2021, 11, e043750.	0.8	3
6740	The utilization of immunotherapy with radiation therapy in lung cancer: a narrative review. <i>Translational Cancer Research</i> , 2021, 10, 2596-2608.	0.4	8
6741	Melanoma models for the next generation of therapies. <i>Cancer Cell</i> , 2021, 39, 610-631.	7.7	90
6742	Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases. <i>Clinical Cancer Research</i> , 2021, 27, 4109-4125.	3.2	65
6743	Endocrine-related adverse events in a large series of cancer patients treated with anti-PD1 therapy. <i>Endocrine</i> , 2021, 74, 172-179.	1.1	19
6744	Prognostic and therapeutic role of tumor-infiltrating lymphocyte subtypes in breast cancer. <i>Cancer and Metastasis Reviews</i> , 2021, 40, 519-536.	2.7	56
6745	Chromatin accessibility governs the differential response of cancer and T cells to arginine starvation. <i>Cell Reports</i> , 2021, 35, 109101.	2.9	20
6746	Role of immunotherapy in oligometastatic nonsmall cell lung cancer. <i>BMJ Case Reports</i> , 2021, 14, e241070.	0.2	1
6747	Prognostic Value of ctDNA Mutation in Melanoma: A Meta-Analysis. <i>Journal of Oncology</i> , 2021, 2021, 1-13.	0.6	6
6748	Case Report: THSD7A-Positive Membranous Nephropathy Caused by Tislelizumab in a Lung Cancer Patient. <i>Frontiers in Immunology</i> , 2021, 12, 619147.	2.2	18
6749	Tumor-related stress regulates functional plasticity of MDSCs. <i>Cellular Immunology</i> , 2021, 363, 104312.	1.4	10

#	ARTICLE	IF	CITATIONS
6750	Tumor burden as possible biomarker of outcome in advanced NSCLC patients treated with immunotherapy: a single center, retrospective, real-world analysis. Exploration of Targeted Anti-tumor Therapy, 0, , .	0.5	1
6751	Assessment of the Clinical Trials Safety Profile of PD-1/PD-L1 Inhibitors Among Patients With Cancer: An Updated Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 662392.	1.3	3
6752	Salvage Immunotherapy With Pembrolizumab in Patients Hospitalized for Life-Threatening Complications of NSCLC. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100147.	0.6	3
6753	Organ-Specific Immune-Related Adverse Events for PD-1 Antibodies in Lung Cancer Treatment. <i>Frontiers in Oncology</i> , 2021, 11, 628243.	1.3	1
6754	PD-L1 combined with HDAC9 is a useful prognostic predictor in hepatocellular carcinoma. <i>Translational Cancer Research</i> , 2021, 10, 2305-2317.	0.4	3
6755	Nephrotoxicity of immune checkpoint inhibitor therapy: a pharmacovigilance study. <i>Nephrology Dialysis Transplantation</i> , 2021, , .	0.4	1
6756	Weighting tumor-specific TCR repertoires as a classifier to stratify the immunotherapy delivery in non-â€small cell lung cancers. <i>Science Advances</i> , 2021, 7, .	4.7	12
6757	Relationship between microsatellite status and immune microenvironment of colorectal cancer and its application to diagnosis and treatment. <i>Journal of Clinical Laboratory Analysis</i> , 2021, 35, e23810.	0.9	20
6758	Immunotherapy in association with stereotactic radiotherapy for non-small cell lung cancer brain metastases: results from a multicentric retrospective study on behalf of AIRO. <i>Neuro-Oncology</i> , 2021, 23, 1750-1764.	0.6	28
6759	Current management of melanoma patients with nodal metastases. <i>Clinical and Experimental Metastasis</i> , 2022, 39, 181-199.	1.7	8
6760	Pharmacological Wnt ligand inhibition overcomes key tumor-mediated resistance pathways to anti-PD-1 immunotherapy. <i>Cell Reports</i> , 2021, 35, 109071.	2.9	35
6761	Efficacy and safety of immune checkpoint inhibitors in patients with non-â€small cell lung cancer aged 80-â€%years or older. <i>Cancer Reports</i> , 2021, 4, e1405.	0.6	8
6762	Genome profiling of mismatch repair genes in eight types of tumors. <i>Cell Cycle</i> , 2021, 20, 1-16.	1.3	0
6763	Analysis of Real-World Data to Investigate the Impact of Race and Ethnicity on Response to Programmed Cell Death-1 and Programmed Cell Death-Ligand 1 Inhibitors in Advanced Non-Small Cell Lung Cancers. <i>Oncologist</i> , 2021, 26, e1226-e1239.	1.9	17
6764	The immunotherapeutic role of indoleamine 2,3-â€dioxygenase in head and neck squamous cell carcinoma: A systematic review. <i>Clinical Otolaryngology</i> , 2021, 46, 919-934.	0.6	17
6765	Risk of Cardiac Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 645245.	1.3	9
6766	M5C regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in lung adenocarcinoma. <i>Translational Lung Cancer Research</i> , 2021, 10, 2172-2192.	1.3	15
6767	Predictability of early changes in derived neutrophil-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors. <i>Journal of Thoracic Disease</i> , 2021, 13, 2824-2832.	0.6	9

#	ARTICLE	IF	CITATIONS
6768	The prognostic landscape of tumor-infiltrating immune cells in lung squamous cell carcinoma. <i>Annals of Translational Medicine</i> , 2021, 9, 799-799.	0.7	2
6769	Hypoxia-Related Radiomics and Immunotherapy Response: A Multicohort Study of Non-Small Cell Lung Cancer. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab048.	1.4	23
6770	Neutralization of PD-L2 is Essential for Overcoming Immune Checkpoint Blockade Resistance in Ovarian Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4435-4448.	3.2	35
6771	Anti-PD-1 elicits regression of undifferentiated pleomorphic sarcomas with UV-mutation signatures. , 2021, 9, e002345.		7
6772	Nanotechnology synergized immunoengineering for cancer. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2021, 163, 72-101.	2.0	8
6773	Immunotherapy in AML: a brief review on emerging strategies. <i>Clinical and Translational Oncology</i> , 2021, 23, 2431-2447.	1.2	4
6774	N 6-methyladenosine (m 6 A) RNA modification of G protein-coupled receptor 133 increases proliferation of lung adenocarcinoma. <i>FEBS Open Bio</i> , 2021, , .	1.0	3
6775	Clinical benefit of continuing pembrolizumab treatment beyond progression in patients with metastatic urothelial carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 229-236.	2.0	8
6776	Prognostic significance of cachexia in advanced non-small cell lung cancer patients treated with pembrolizumab. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 387-398.	2.0	16
6777	Correlation of peripheral blood biomarkers with clinical outcomes in NSCLC patients with high PD-L1 expression treated with pembrolizumab. <i>Translational Lung Cancer Research</i> , 2021, 10, 2509-2522.	1.3	13
6778	Correlation Between 18F-FDG Uptake and Immune Cell Infiltration in Metastatic Brain Lesions. <i>Frontiers in Oncology</i> , 2021, 11, 618705.	1.3	5
6779	Hepatectomy and immune checkpoint inhibitor treatment for liver metastasis originating from non-cutaneous melanoma: a report of three cases. <i>International Cancer Conference Journal</i> , 2021, 10, 274-279.	0.2	2
6780	Current approach and novel perspectives in nasopharyngeal carcinoma: the role of targeting proteasome dysregulation as a molecular landmark in nasopharyngeal cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 202.	3.5	14
6781	CALD1 is a prognostic biomarker and correlated with immune infiltrates in gastric cancers. <i>Heliyon</i> , 2021, 7, e07257.	1.4	11
6782	Simple parameters to solve a complex issue: predicting response to checkpoint inhibitor therapy in lung cancer. <i>Lung Cancer Management</i> , 2021, 10, LMT44.	1.5	3
6783	Imaging Assessment of Tumor Response in the Era of Immunotherapy. <i>Diagnostics</i> , 2021, 11, 1041.	1.3	3
6784	Managing side effects of immune checkpoint inhibitors in breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 162, 103354.	2.0	15
6785	Genetic Alterations in Gliomas Remodel the Tumor Immune Microenvironment and Impact Immune-Mediated Therapies. <i>Frontiers in Oncology</i> , 2021, 11, 631037.	1.3	10

#	ARTICLE	IF	CITATIONS
6786	Emerging New Approaches in Desensitization: Targeted Therapies for HLA Sensitization. <i>Frontiers in Immunology</i> , 2021, 12, 694763.	2.2	16
6787	Role of the intestinal microbiome and microbial-derived metabolites in immune checkpoint blockade immunotherapy of cancer. <i>Genome Medicine</i> , 2021, 13, 107.	3.6	74
6788	Inhibition of Polyamine Biosynthesis Using Difluoromethylornithine Acts as a Potent Immune Modulator and Displays Therapeutic Synergy With PD-1-blockade. <i>Journal of Immunotherapy</i> , 2021, 44, 283-291.	1.2	6
6789	Sociodemographic disparities in the management of advanced lung cancer: a narrative review. <i>Journal of Thoracic Disease</i> , 2021, 13, 3772-3800.	0.6	14
6790	Vulvar Melanoma: Molecular Characteristics, Diagnosis, Surgical Management, and Medical Treatment. <i>American Journal of Clinical Dermatology</i> , 2021, 22, 639-651.	3.3	15
6791	Targeting regulator of G protein signaling 1 in tumor-specific T cells enhances their trafficking to breast cancer. <i>Nature Immunology</i> , 2021, 22, 865-879.	7.0	41
6792	Immunotherapy in oncogene addicted non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 2736-2751.	1.3	7
6793	PD-L1 detection on circulating tumor-derived extracellular vesicles (T-EVs) from patients with lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 2441-2451.	1.3	19
6794	The dark side of immunotherapy. <i>Annals of Translational Medicine</i> , 2021, 9, 1041-1041.	0.7	12
6795	Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation. <i>New England Journal of Medicine</i> , 2021, 384, 2371-2381.	13.9	833
6796	PD-1 Inhibitors Could Improve the Efficacy of Chemotherapy as First-Line Treatment in Biliary Tract Cancers: A Propensity Score Matching Based Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 648068.	1.3	13
6797	Not-so-opposite ends of the spectrum: CD8+ T cell dysfunction across chronic infection, cancer and autoimmunity. <i>Nature Immunology</i> , 2021, 22, 809-819.	7.0	113
6798	Fibroblasts Influence the Efficacy, Resistance, and Future Use of Vaccines and Immunotherapy in Cancer Treatment. <i>Vaccines</i> , 2021, 9, 634.	2.1	8
6799	The roles of PD-1/PD-L1 in the prognosis and immunotherapy of prostate cancer. <i>Molecular Therapy</i> , 2021, 29, 1958-1969.	3.7	41
6800	The Application of Combined Immune Checkpoint Inhibitor Modalities in Previously Treated Non-Small Cell Lung Cancer Patients and the Associations Thereof With the Lung Immune Prognostic Index. <i>Frontiers in Oncology</i> , 2021, 11, 690093.	1.3	5
6801	De Novo Mutation in Non-Tyrosine Kinase Domain of ROS1 as a Potential Predictor of Immune Checkpoint Inhibitors in Melanoma. <i>Frontiers in Oncology</i> , 2021, 11, 666145.	1.3	2
6802	Durable Response to the Combination of Atezolizumab With Platinum-Based Chemotherapy in an Untreated Non-Smoking Lung Adenocarcinoma Patient With BRAF V600E Mutation: A Case Report. <i>Frontiers in Oncology</i> , 2021, 11, 634920.	1.3	7
6803	The Position of EGF Deprivation in the Management of Advanced Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 639745.	1.3	9

#	ARTICLE	IF	CITATIONS
6804	Pembrolizumab Alone or Combined With Chemotherapy in Advanced NSCLC With PD-L1 ≥50%: Results of a Retrospective Study. <i>Frontiers in Oncology</i> , 2021, 11, 691519.	1.3	4
6805	Current and future biomarkers for outcomes with immunotherapy in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 2937-2954.	1.3	19
6806	Safety of immune checkpoint inhibitors in patients with cancer and pre-existing autoimmune disease. <i>Annals of Translational Medicine</i> , 2021, 9, 1033-1033.	0.7	23
6807	The Evolution of STING Signaling and Its Involvement in Cancer. <i>Trends in Biochemical Sciences</i> , 2021, 46, 446-460.	3.7	38
6808	Memory-like Differentiation Enhances NK Cell Responses to Melanoma. <i>Clinical Cancer Research</i> , 2021, 27, 4859-4869.	3.2	33
6809	Triple Combination Therapy With PD-1/PD-L1, BRAF, and MEK Inhibitor for Stage III-IV Melanoma: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 693655.	1.3	16
6810	Renal Complications Related to Checkpoint Inhibitors: Diagnostic and Therapeutic Strategies. <i>Diagnostics</i> , 2021, 11, 1187.	1.3	10
6811	Evaluation of efficacy and toxicity of nivolumab combined with or without docetaxel in patients with advanced NSCLC. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 267-276.	2.0	2
6812	The Prognostic Value of Pre-treatment Hemoglobin (Hb) in Patients With Advanced or Metastatic Gastric Cancer Treated With Immunotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 655716.	1.3	13
6813	Acquired Resistance to Immune Checkpoint Blockades: The Underlying Mechanisms and Potential Strategies. <i>Frontiers in Immunology</i> , 2021, 12, 693609.	2.2	21
6814	Comprehensive Analysis of Regulatory Network for LINC00472 in Clear Cell Renal Cell Carcinoma. <i>Journal of Healthcare Engineering</i> , 2021, 2021, 1-20.	1.1	8
6815	Electronic patient-reported outcomes and machine learning in predicting immune-related adverse events of immune checkpoint inhibitor therapies. <i>BMC Medical Informatics and Decision Making</i> , 2021, 21, 205.	1.5	15
6816	Immune Checkpoint Inhibitors and Cardiotoxicity: An Analysis of Spontaneous Reports in Eudravigilance. <i>Drug Safety</i> , 2021, 44, 957-971.	1.4	38
6817	The Prognostic Value of Preoperative Serum Tumor Markers in Non-Small Cell Lung Cancer Varies With Radiological Features and Histological Types. <i>Frontiers in Oncology</i> , 2021, 11, 645159.	1.3	10
6818	Energy status dictates PD-L1 protein abundance and anti-tumor immunity to enable checkpoint blockade. <i>Molecular Cell</i> , 2021, 81, 2317-2331.e6.	4.5	97
6819	Novel patterns of progression upon immunotherapy in other thoracic malignancies and uncommon populations. <i>Translational Lung Cancer Research</i> , 2021, 10, 2955-2969.	1.3	2
6820	Cancer-specific immune evasion and substantial heterogeneity within cancer types provide evidence for personalized immunotherapy. <i>Npj Precision Oncology</i> , 2021, 5, 52.	2.3	24
6821	Cancer immunotherapy: it's time to better predict patients' response. <i>British Journal of Cancer</i> , 2021, 125, 927-938.	2.9	63

#	ARTICLE	IF	CITATIONS
6822	Kidney injury associated with antitumor therapy: focus on the adverse events of modern immuno-oncological drugs. <i>Terapevticheskii Arkhiv</i> , 2021, 93, 649-660.	0.2	0
6823	Real-world experience of nivolumab in the treatment of poor performance status patients with advanced non-small cell lung cancer. <i>Cancer Reports</i> , 2021, , e1487.	0.6	2
6824	Molecular and Clinical Characterization of LAG3 in Breast Cancer Through 2994 Samples. <i>Frontiers in Immunology</i> , 2021, 12, 599207.	2.2	18
6825	Biomarkers of therapeutic response with immune checkpoint inhibitors. <i>Annals of Translational Medicine</i> , 2021, 9, 1040-1040.	0.7	3
6826	First-line immunotherapy in non-small cell lung cancer patients with poor performance status: a systematic review and meta-analysis. <i>Translational Lung Cancer Research</i> , 2021, 10, 2917-2936.	1.3	18
6827	Differences in treatment effect size between progression-free survival and overall survival in anti-PD-1/PD-L1 inhibitors-based trials in advanced NSCLC: a systematic review and meta-analysis. <i>Translational Lung Cancer Research</i> , 2021, 10, 2562-2572.	1.3	0
6828	Challenges and Opportunities in the Statistical Analysis of Multiplex Immunofluorescence Data. <i>Cancers</i> , 2021, 13, 3031.	1.7	21
6829	Immune Checkpoint Inhibitor Uptake in Real-World Patients With Malignant Pleural Mesothelioma. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100188.	0.6	0
6830	ICI plus chemotherapy prolonged survival over ICI alone in patients with previously treated advanced NSCLC. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 219-228.	2.0	5
6831	Hyperprogressive Disease Caused by PD-1 Inhibitors for the Treatment of Pan-Cancer. <i>Disease Markers</i> , 2021, 2021, 1-10.	0.6	13
6832	First line immunotherapy extends brain metastasis free survival, improves overall survival, and reduces the incidence of brain metastasis in patients with advanced melanoma. <i>Cancer Reports</i> , 2021, 4, e1419.	0.6	4
6833	Overall survival in metastatic melanoma correlates with pembrolizumab exposure and T cell exhaustion markers. <i>Pharmacology Research and Perspectives</i> , 2021, 9, e00808.	1.1	6
6834	Multiplexed digital spatial profiling of invasive breast tumors from Black and White women. <i>Molecular Oncology</i> , 2022, 16, 54-68.	2.1	12
6835	Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 625-644.	12.5	148
6836	Development and validation of an individualized immune prognostic model in stage III lung squamous cell carcinoma. <i>Scientific Reports</i> , 2021, 11, 12727.	1.6	12
6837	Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy. <i>Annals of Allergy, Asthma and Immunology</i> , 2021, 126, 630-638.	0.5	23
6838	Increased serum cholesterol and long-chain fatty acid levels are associated with the efficacy of nivolumab in patients with non-small cell lung cancer. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 203-217.	2.0	16
6839	Checkpoint inhibitor immunotherapy toxicity and overall survival among older adults with advanced cancer. <i>Journal of Geriatric Oncology</i> , 2021, 12, 813-819.	0.5	23

#	ARTICLE	IF	CITATIONS
6840	Comparative Risk of Renal Adverse Events in Patients Receiving Immune Checkpoint Inhibitors: A Bayesian Network Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 662731.	1.3	10
6841	Integrated Analysis of Genomic and Immunological Features in Lung Adenocarcinoma With Micropapillary Component. <i>Frontiers in Oncology</i> , 2021, 11, 652193.	1.3	12
6842	The Effect of Asymptomatic and/or Treated Brain Metastases on Efficacy of Immune Checkpoint Inhibitors in Metastatic Non-Small Cell Lung Cancer: A Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 702924.	1.3	6
6843	A Comparative Retrospective Study of Immunotherapy RANO Versus Standard RANO Criteria in Glioblastoma Patients Receiving Immune Checkpoint Inhibitor Therapy. <i>Frontiers in Oncology</i> , 2021, 11, 679331.	1.3	4
6844	Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: a systematic review and meta-analysis. <i>Translational Lung Cancer Research</i> , 2021, 10, 2890-2916.	1.3	21
6845	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. , 2021, 9, e002435.		298
6846	Low Infiltration of CD8+ PD-L1+ T Cells and M2 Macrophages Predicts Improved Clinical Outcomes After Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 658690.	1.3	15
6847	Inhibition of host <i>Ogr1</i> enhances effector CD8+ T-cell function by modulating acidic microenvironment. <i>Cancer Gene Therapy</i> , 2021, 28, 1213-1224.	2.2	13
6848	Immune checkpoint blockade reprograms systemic immune landscape and tumor microenvironment in obesity-associated breast cancer. <i>Cell Reports</i> , 2021, 35, 109285.	2.9	38
6849	Thromboembolic risk in patients with lung cancer receiving systemic therapy. <i>British Journal of Haematology</i> , 2021, 194, 179-190.	1.2	9
6850	A new biological triangle in cancer: intestinal microbiota, immune checkpoint inhibitors and antibiotics. <i>Clinical and Translational Oncology</i> , 2021, 23, 2415-2430.	1.2	8
6851	The clinical impact of three validated PD-L1 immunohistochemistry assays as a prognostic factor in small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 2539-2550.	1.3	6
6852	Increase in tumour PD-L1 expression in non-small cell lung cancer following bronchoscopic thermal vapour ablation. <i>Translational Lung Cancer Research</i> , 2021, 10, 2858-2864.	1.3	12
6853	Exploring the immune-checkpoint inhibitors' efficacy/tolerability in special non-small cell lung cancer (NSCLC) populations: focus on steroids and autoimmune disease. <i>Translational Lung Cancer Research</i> , 2021, 10, 2876-2889.	1.3	2
6854	Artificial intelligence-based analysis for immunohistochemistry staining of immune checkpoints to predict resected non-small cell lung cancer survival and relapse. <i>Translational Lung Cancer Research</i> , 2021, 10, 2452-2474.	1.3	11
6855	Expansion of tumor-associated Treg cells upon disruption of a CTLA-4-dependent feedback loop. <i>Cell</i> , 2021, 184, 3998-4015.e19.	13.5	92
6856	Interleukins in cancer: from biology to therapy. <i>Nature Reviews Cancer</i> , 2021, 21, 481-499.	12.8	318
6857	Nivolumab in Non-Small Cell Lung Cancer: Real World Long-Term Survival Results and Blood-Based Efficacy Biomarkers. <i>Frontiers in Oncology</i> , 2021, 11, 625668.	1.3	9

#	ARTICLE	IF	CITATIONS
6858	PD-L1 expression in non-small cell lung cancer: heterogeneity by pathologic types, tissue sampling and metastasis. <i>Journal of Thoracic Disease</i> , 2021, 13, 4360-4370.	0.6	3
6859	The incidence of gastrointestinal adverse events in patients with advanced non-small cell lung cancer (NSCLC) treated with PD-1 inhibitors: a meta-analysis. <i>Translational Cancer Research</i> , 2021, 10, 3389-3403.	0.4	1
6860	Retrospective Analysis of Rechallenge with Ipilimumab in Patients with Metastatic Melanoma. <i>Journal of Skin Cancer</i> , 2021, 2021, 1-3.	0.5	2
6861	Intrapulmonic Cavity or Necrosis on Baseline CT Scan Serves as an Efficacy Predictor of Anti-PD-(L)1 Inhibitor in Advanced Lung Squamous Cell Carcinoma. <i>Cancer Management and Research</i> , 2021, Volume 13, 5931-5939.	0.9	2
6862	Hepatocellular carcinoma in patients with renal dysfunction: Pathophysiology, prognosis, and treatment challenges. <i>World Journal of Gastroenterology</i> , 2021, 27, 4104-4142.	1.4	15
6863	Predictive factors of neoadjuvant immune checkpoint blockade in melanoma. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-9.	1.4	3
6864	A phase I study of IMC-001, a PD-L1 blocker, in patients with metastatic or locally advanced solid tumors. <i>Investigational New Drugs</i> , 2021, 39, 1624-1632.	1.2	0
6865	Novel strategies for immuno-oncology breakthroughs with cell therapy. <i>Biomarker Research</i> , 2021, 9, 62.	2.8	18
6866	Real-World Efficacy and Safety of Anlotinib With and Without Immunotherapy in Advanced Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 659380.	1.3	10
6867	Prognostic Significance of Gene Signature of Tertiary Lymphoid Structures in Patients With Lung Adenocarcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 693234.	1.3	18
6868	Immunotherapy use outside clinical trial populations: never say never?. <i>Annals of Oncology</i> , 2021, 32, 866-880.	0.6	22
6869	Risk of Infection with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. <i>Targeted Oncology</i> , 2021, 16, 553-568.	1.7	13
6870	Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. <i>Nature Medicine</i> , 2021, 27, 1432-1441.	15.2	216
6871	CX-072 (pacmilimab), a Probody^{Å®} PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study. , 2021, 9, e002447.		26
6872	Down-regulation of A20 promotes immune escape of lung adenocarcinomas. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	10
6873	Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 495-508.	21.5	120
6874	RBM10 Deficiency Is Associated With Increased Immune Activity in Lung Adenocarcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 677826.	1.3	7
6876	Efficacy of docetaxel plus ramucirumab as palliative second-line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with non-small cell lung cancer (NSCLC) UICC stage IV. <i>Translational Lung Cancer Research</i> , 2021, 10, 3093-3105.	1.3	23

#	ARTICLE	IF	CITATIONS
6877	Oncolytic Viruses for Malignant Glioma: On the Verge of Success?. <i>Viruses</i> , 2021, 13, 1294.	1.5	28
6878	CD8+ T cell differentiation and dysfunction in cancer. <i>Nature Reviews Immunology</i> , 2022, 22, 209-223.	10.6	345
6879	Targeting the spectrum of immune checkpoints in prostate cancer. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 1253-1266.	1.3	13
6880	Inhibition of lung tumorigenesis by a small molecule CA170 targeting the immune checkpoint protein VISTA. <i>Communications Biology</i> , 2021, 4, 906.	2.0	12
6881	Endogenous retrovirus envelope as a tumor-associated immunotherapeutic target in murine osteosarcoma. <i>IScience</i> , 2021, 24, 102759.	1.9	1
6882	Immunotherapy in Older Adults With Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 2115-2127.	0.8	33
6883	The role of PD-L1 in the immune dysfunction that mediates hypoxia-induced multiple organ injury. <i>Cell Communication and Signaling</i> , 2021, 19, 76.	2.7	14
6884	Clinical Course and Treatment Implications of Combination Immune Checkpoint Inhibitor-Mediated Hepatitis: A Multicentre Cohort. <i>Journal of the Canadian Association of Gastroenterology</i> , 2022, 5, 39-47.	0.1	3
6885	Integrative analysis of gut microbiome and host transcriptomes reveals associations between treatment outcomes and immunotherapy-induced colitis. <i>Molecular Oncology</i> , 2022, 16, 1493-1507.	2.1	17
6886	First-in-Humans Evaluation of a PD-L1-Binding Peptide PET Radiotracer in Non-Small Cell Lung Cancer Patients. <i>Journal of Nuclear Medicine</i> , 2022, 63, 536-542.	2.8	56
6887	Intraoperative opioid exposure, tumour genomic alterations, and survival differences in people with lung adenocarcinoma. <i>British Journal of Anaesthesia</i> , 2021, 127, 75-84.	1.5	33
6888	Immune checkpoint inhibitor related hypophysitis: diagnostic criteria and recovery patterns. <i>Endocrine-Related Cancer</i> , 2021, 28, 419-431.	1.6	29
6889	The therapeutic implications of immunosuppressive tumor aerobic glycolysis. <i>Cellular and Molecular Immunology</i> , 2022, 19, 46-58.	4.8	39
6890	Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic ROS1-Rearranged Lung Cancers. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100187.	0.6	11
6891	Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximab. , 2021, 9, e002742.		16
6892	The Expression of PD-L1 and B7-H4 in Thymic Epithelial Tumor and Its Relationship With Tumor Immune-Infiltrating Cells. <i>Frontiers in Oncology</i> , 2021, 11, 662010.	1.3	4
6893	Tumor PD-L1 expression is associated with outcomes in stage III non-small cell lung cancer (NSCLC) patients treated with consolidation durvalumab. <i>Translational Lung Cancer Research</i> , 2021, 10, 3071-3078.	1.3	11
6894	The detection value of PD-L1 expression in biopsy specimens and surgical resection specimens in non-small cell lung cancer: a meta-analysis. <i>Journal of Thoracic Disease</i> , 2021, 13, 4301-4310.	0.6	6

#	ARTICLE	IF	CITATIONS
6895	First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 417-431.	2.0	6
6896	Association of hepatitis B virus infection status with outcomes of non-small cell lung cancer patients undergoing anti-PD-1/PD-L1 therapy. <i>Translational Lung Cancer Research</i> , 2021, 10, 3191-3202.	1.3	10
6897	Immunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes with PD-1 Blockade in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5131-5140.	3.2	40
6898	The Risk of Immune-Related Thyroid Dysfunction Induced by PD-1/PD-L1 Inhibitors in Cancer Patients: An Updated Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 667650.	1.3	8
6899	Polymeric microneedle-mediated sustained release systems: Design strategies and promising applications for drug delivery. <i>Asian Journal of Pharmaceutical Sciences</i> , 2022, 17, 70-86.	4.3	38
6900	A clinical variable-based nomogram could predict the survival for advanced NSCLC patients receiving second-line atezolizumab. <i>Cancer Medicine</i> , 2021, 10, 6218-6226.	1.3	2
6901	Intratumour microbiome associated with the infiltration of cytotoxic CD8+ T cells and patient survival in cutaneous melanoma. <i>European Journal of Cancer</i> , 2021, 151, 25-34.	1.3	59
6902	Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score \geq 50%. <i>Journal of Clinical Oncology</i> , 2021, 39, 2339-2349.	0.8	468
6903	Identification of a class of non-conventional ER-stress-response-derived immunogenic peptides. <i>Cell Reports</i> , 2021, 36, 109312.	2.9	13
6904	Anti-tumour effect of neo-antigen-reactive T cells induced by RNA mutanome vaccine in mouse lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3255-3268.	1.2	8
6905	Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules. <i>Clinical Cancer Research</i> , 2021, 27, 5280-5288.	3.2	21
6906	Sensitive detection of tumor mutations from blood and its application to immunotherapy prognosis. <i>Nature Communications</i> , 2021, 12, 4172.	5.8	16
6907	Global mapping of cancers: The Cancer Genome Atlas and beyond. <i>Molecular Oncology</i> , 2021, 15, 2823-2840.	2.1	55
6908	Recruitment, outcomes, and toxicity trends in phase I oncology trials: Six-year experience in a large institution. <i>Cancer Reports</i> , 2021, , e1465.	0.6	1
6909	Comparison of the Predictive Power of a Combination versus Individual Biomarker Testing in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors. <i>Cancer Research and Treatment</i> , 2022, 54, 424-433.	1.3	11
6910	Malignant melanoma: evolving practice management in an era of increasingly effective systemic therapies. <i>Current Problems in Surgery</i> , 2022, 59, 101030.	0.6	4
6911	Hypoxia-related lncRNAs to build prognostic classifier and reveal the immune characteristics of EGFR wild type and low expression of PD-L1 squamous and adenocarcinoma NSCLC. <i>Cancer Medicine</i> , 2021, 10, 6099-6113.	1.3	4
6912	A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant. <i>Kidney International</i> , 2021, 100, 196-205.	2.6	95

#	ARTICLE	IF	CITATIONS
6913	CT-Based Hand-crafted Radiomic Signatures Can Predict PD-L1 Expression Levels in Non-small Cell Lung Cancer: a Two-Center Study. <i>Journal of Digital Imaging</i> , 2021, 34, 1073-1085.	1.6	17
6914	Genotoxic Treatment Enhances Immune Response in a Genetic Model of Lung Cancer. <i>Cancers</i> , 2021, 13, 3595.	1.7	1
6915	Subsequent systemic therapy for non-small cell lung cancer patients with immune checkpoint inhibitor-related interstitial lung disease. <i>Translational Lung Cancer Research</i> , 2021, 10, 3132-3143.	1.3	1
6916	Update on recent key publications in lung oncology: picking up speed. <i>European Respiratory Review</i> , 2021, 30, 200300.	3.0	1
6917	Circulating regulatory T cells predict efficacy and atypical responses in lung cancer patients treated with PD-1/PD-L1 inhibitors. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 579-588.	2.0	27
6918	Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung 8 trial. <i>EClinicalMedicine</i> , 2021, 37, 100940.	3.2	11
6919	Combining nanomedicine and immune checkpoint therapy for cancer immunotherapy. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2022, 14, e1739.	3.3	19
6920	Inhibitors of immune checkpoints—PD-1, PD-L1, CTLA-4—new opportunities for cancer patients and a new challenge for internists and general practitioners. <i>Cancer and Metastasis Reviews</i> , 2021, 40, 949-982.	2.7	72
6921	Detection of Immune Checkpoint Receptors — A Current Challenge in Clinical Flow Cytometry. <i>Frontiers in Immunology</i> , 2021, 12, 694055.	2.2	22
6922	JAML promotes CD8 and $\gamma\delta$ T cell antitumor immunity and is a novel target for cancer immunotherapy. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	11
6923	Clinical Significance of the HHLA2 Protein in Hepatocellular Carcinoma and the Tumor Microenvironment. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 4217-4228.	1.6	20
6924	Cancer immunotherapy from biology to nanomedicine. <i>Journal of Controlled Release</i> , 2021, 336, 410-432.	4.8	12
6925	Plasmonic gold nanostars for synergistic photoimmunotherapy to treat cancer. <i>Nanophotonics</i> , 2021, 10, 3295-3302.	2.9	8
6926	Aggressive pituitary neuroendocrine tumors: current practices, controversies, and perspectives, on behalf of the EANS skull base section. <i>Acta Neurochirurgica</i> , 2021, 163, 3131-3142.	0.9	9
6927	Case Report: Dual Checkpoint Inhibition in Advanced Metastatic Osteosarcoma Results in Remission of All Tumor Manifestations—A Report of a Stunning Success in a 37-Year-Old Patient. <i>Frontiers in Oncology</i> , 2021, 11, 684733.	1.3	7
6928	Association Between Efficacy of Immune Checkpoint Inhibitors and Sex: An Updated Meta-Analysis on 21 Trials and 12,675 Non-Small Cell Lung Cancer Patients. <i>Frontiers in Oncology</i> , 2021, 11, 627016.	1.3	7
6929	FGF-Receptors and PD-L1 in Anaplastic and Poorly Differentiated Thyroid Cancer: Evaluation of the Preclinical Rationale. <i>Frontiers in Endocrinology</i> , 2021, 12, 712107.	1.5	16
6930	Immune Checkpoint Inhibitors in the Aged. <i>Current Oncology Reports</i> , 2021, 23, 115.	1.8	3

#	ARTICLE	IF	CITATIONS
6931	Identification of a Five-Gene Prognostic Signature Related to B Cells Infiltration in Pancreatic Adenocarcinoma. <i>International Journal of General Medicine</i> , 2021, Volume 14, 5051-5068.	0.8	6
6932	Use and Toxicity of Checkpoint Inhibitors for Solid Tumor Treatment in a Veteran Population. , 2021, 38, S46-S51.		0
6933	The effect of smoking status on efficacy of immune checkpoint inhibitors in metastatic non-small cell lung cancer: A systematic review and meta-analysis. <i>EClinicalMedicine</i> , 2021, 38, 100990.	3.2	34
6934	Which factors matter the most? Revisiting and dissecting antibody therapeutic doses. <i>Drug Discovery Today</i> , 2021, 26, 1980-1990.	3.2	3
6935	Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 3633-3644.	0.8	27
6936	Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 Monotherapy. <i>Clinical Cancer Research</i> , 2021, 27, 5993-6000.	3.2	70
6937	Activation or exhaustion of CD8+ T cells in patients with COVID-19. <i>Cellular and Molecular Immunology</i> , 2021, 18, 2325-2333.	4.8	106
6938	Prognostic significance of programmed cell death ligand 1 expression on circulating tumor cells in various cancers: A systematic review and meta-analysis. <i>Cancer Medicine</i> , 2021, 10, 7021-7039.	1.3	13
6939	Vaccination with Polyclonal Antibody Stimulator (PAS) Prevents Pancreatic Carcinogenesis in the KRAS Mouse Model. <i>Cancer Prevention Research</i> , 2021, 14, 933-944.	0.7	1
6940	The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3,) Tj ETQq1 1 0.784314 rg3T 1.8 36		
6941	Toward personalized treatment approaches for non-small-cell lung cancer. <i>Nature Medicine</i> , 2021, 27, 1345-1356.	15.2	338
6942	Radiomics Study for Predicting the Expression of PD-L1 and Tumor Mutation Burden in Non-Small Cell Lung Cancer Based on CT Images and Clinicopathological Features. <i>Frontiers in Oncology</i> , 2021, 11, 620246.	1.3	38
6943	PD-1 preferentially inhibits the activation of low-affinity T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	9
6944	Immunotherapy Treatment for Triple Negative Breast Cancer. <i>Pharmaceuticals</i> , 2021, 14, 763.	1.7	30
6945	Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2656-2666.	0.8	145
6946	Myocarditis occurrence with cancer immunotherapy across indications in clinical trial and post-marketing data. <i>Scientific Reports</i> , 2021, 11, 17324.	1.6	24
6947	Enhanced antitumor immune response in melanoma tumor model by anti-PD-1 small interference RNA encapsulated in nanoliposomes. <i>Cancer Gene Therapy</i> , 2022, 29, 814-824.	2.2	12
6948	Intestinal Regulatory T Cells as Specialized Tissue-Restricted Immune Cells in Intestinal Immune Homeostasis and Disease. <i>Frontiers in Immunology</i> , 2021, 12, 716499.	2.2	34

#	ARTICLE	IF	CITATIONS
6949	PD-L1 degradation is regulated by electrostatic membrane association of its cytoplasmic domain. <i>Nature Communications</i> , 2021, 12, 5106.	5.8	38
6950	Comprehensive Pan-Cancer Analysis and the Regulatory Mechanism of ASF1B, a Gene Associated With Thyroid Cancer Prognosis in the Tumor Micro-Environment. <i>Frontiers in Oncology</i> , 2021, 11, 711756.	1.3	11
6951	TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma. <i>Cancer Immunology Research</i> , 2021, 9, 1202-1213.	1.6	71
6952	Tumor-mutation burden as a marker for immunotherapy of pancreatic cancer. <i>Anti-Cancer Drugs</i> , 2021, Publish Ahead of Print, .	0.7	1
6953	Engineering a High-Affinity PD-1 Peptide for Optimized Immune Cell-Mediated Tumor Therapy. <i>Cancer Research and Treatment</i> , 2022, 54, 362-374.	1.3	5
6954	Survival benefit of immune checkpoint inhibitor monotherapy in patients with non-small cell lung cancer recurrence after completely pulmonary resection. <i>Annals of Translational Medicine</i> , 2021, 9, 1225-1225.	0.7	2
6955	Does denosumab offer survival benefits? "Our experience with denosumab in metastatic non-small cell lung cancer patients treated with immune-checkpoint inhibitors. <i>Journal of Thoracic Disease</i> , 2021, 13, 4668-4677.	0.6	8
6956	Alliance Foundation Trial 09: A Randomized, Multicenter, Phase 2 Trial Evaluating Two Sequences of Pembrolizumab and Standard Platinum-Based Chemotherapy in Patients With Metastatic NSCLC. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100208.	0.6	0
6957	Programmed Death-Ligand 1 Tumor Proportion Score and Overall Survival From First-Line Pembrolizumab in Patients With Nonsquamous Versus Squamous NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 2139-2143.	0.5	15
6958	Inhibitors Targeting CDK9 Show High Efficacy against Osimertinib and AMG510 Resistant Lung Adenocarcinoma Cells. <i>Cancers</i> , 2021, 13, 3906.	1.7	8
6959	Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC. <i>Cancer Discovery</i> , 2022, 12, 47-61.	7.7	58
6960	Tumour-infiltrating CD4+, CD8- and FOXP3-positive immune cells as predictive markers of mortality in BRCA1- and BRCA2-associated breast cancer. <i>British Journal of Cancer</i> , 2021, 125, 1388-1398.	2.9	11
6961	Real-world efficacy of osimertinib in previously EGFR-TKI treated NSCLC patients without identification of T790M mutation. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, , 1.	1.2	3
6962	Implantable optical fibers for immunotherapeutics delivery and tumor impedance measurement. <i>Nature Communications</i> , 2021, 12, 5138.	5.8	28
6963	Determining the optimal PD-1/PD-L1 inhibitors for the first-line treatment of non-small cell lung cancer with high-level PD-L1 expression in China. <i>Cancer Medicine</i> , 2021, 10, 6344-6353.	1.3	9
6964	An analysis of the immunological tumor microenvironment of primary tumors and regional lymph nodes in squamous cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 3520-3537.	1.3	3
6965	Early Cost Effectiveness of Whole-Genome Sequencing as a Clinical Diagnostic Test for Patients with Inoperable Stage IIIB,C/IV Non-squamous Non-small-Cell Lung Cancer. <i>Pharmacoeconomics</i> , 2021, 39, 1429-1442.	1.7	10
6966	Predictors of Rheumatic <sc>Immune-Related</sc> Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer. <i>Arthritis and Rheumatology</i> , 2022, 74, 527-540.	2.9	21

#	ARTICLE	IF	CITATIONS
6967	NF- κ B: At the Borders of Autoimmunity and Inflammation. <i>Frontiers in Immunology</i> , 2021, 12, 716469.	2.2	214
6968	Apoptotic Gastritis in Melanoma Patients Treated With PD-1-Based Immune Checkpoint Inhibition – Clinical and Histopathological Findings Including the Diagnostic Value of Anti-Caspase-3 Immunohistochemistry. <i>Frontiers in Oncology</i> , 2021, 11, 725549.	1.3	6
6969	Proautoimmune Allele of Tyrosine Phosphatase, PTPN22, Enhances Tumor Immunity. <i>Journal of Immunology</i> , 2021, 207, 1662-1671.	0.4	9
6970	Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)., 2021, 9, e002973.		26
6971	MERTK on mononuclear phagocytes regulates T cell antigen recognition at autoimmune and tumor sites. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	15
6972	Immune Checkpoint Inhibitor-Related Pneumonitis in Lung Cancer. <i>Chest</i> , 2021, 160, 731-742.	0.4	64
6973	Three models that predict the efficacy of immunotherapy in Chinese patients with advanced non-small cell lung cancer. <i>Cancer Medicine</i> , 2021, 10, 6291-6303.	1.3	11
6974	The Molecular Context of Vulnerability for CDK9 Suppression in Triple Wild-Type Melanoma. <i>Journal of Investigative Dermatology</i> , 2021, 141, 2018-2027.e4.	0.3	8
6975	Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1–Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100205.	0.6	32
6976	Immune Checkpoint Inhibitors and Neurotoxicity. <i>Current Neuropharmacology</i> , 2021, 19, 1246-1263.	1.4	10
6977	Validation of a claims-based algorithm for identifying non-infectious pneumonitis in patients diagnosed with lung cancer. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 1624-1629.	0.9	1
6978	Initial rapidity of tumor growth as a prognostic factor for the therapeutic effect of immune-checkpoint inhibitors in patients with non-small cell lung cancer: evaluation for linear and non-linear correlation. <i>Journal of Thoracic Disease</i> , 2021, 13, 4903-4914.	0.6	0
6979	Novel and Promising Systemic Treatment Approaches in Mesothelioma. <i>Current Treatment Options in Oncology</i> , 2021, 22, 89.	1.3	2
6980	Impact of Smoking History on Response to Immunotherapy in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 703143.	1.3	23
6981	Schrödinger’s T Cells: Molecular Insights Into Stemness and Exhaustion. <i>Frontiers in Immunology</i> , 2021, 12, 725618.	2.2	22
6982	Immunotherapy for Non-melanoma Skin Cancer. <i>Current Oncology Reports</i> , 2021, 23, 125.	1.8	49
6983	Prognostic value of blood cell count-derived ratios in BRAF-mutated metastatic melanoma. <i>Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia</i> , 2022, 166, 393-404.	0.2	2
6984	Dendrimers for cancer immunotherapy: Avidity-based drug delivery vehicles for effective anti-tumor immune response. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2022, 14, e1752.	3.3	13

#	ARTICLE	IF	CITATIONS
6985	Impact of tumor programmed death ligand-1 expression on osimertinib efficacy in untreated EGFR-mutated advanced non-small cell lung cancer: a prospective observational study. <i>Translational Lung Cancer Research</i> , 2021, 10, 3582-3593.	1.3	12
6986	Immune-mediated adverse events in immune checkpoint inhibitors therapy: literature review. <i>Journal of Modern Oncology</i> , 2021, 23, 319-326.	0.1	4
6987	EBV+ lymphoproliferative diseases: opportunities for leveraging EBV as a therapeutic target. <i>Blood</i> , 2022, 139, 983-994.	0.6	17
6988	Immunotherapy in Hepatocellular Carcinoma. <i>Current Treatment Options in Oncology</i> , 2021, 22, 87.	1.3	25
6989	Current Trends of Immunotherapy in the Treatment of Cutaneous Melanoma: A Review. <i>Dermatology and Therapy</i> , 2021, 11, 1481-1496.	1.4	12
6990	A Preliminary Study of the Complement Component 1q Levels in Predicting the Efficacy of Combined Immunotherapy in Patients with Lung Cancer. <i>Cancer Management and Research</i> , 2021, Volume 13, 7131-7137.	0.9	7
6991	Prior Exposure to Coxsackievirus A21 Does Not Mitigate Oncolytic Therapeutic Efficacy. <i>Cancers</i> , 2021, 13, 4462.	1.7	2
6992	Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2914-2925.	0.8	55
6993	The Predictive Value of Clinical and Molecular Characteristics of Immunotherapy in Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials. <i>Frontiers in Oncology</i> , 2021, 11, 732214.	1.3	11
6994	Early discontinuation of induction therapy in chemoimmunotherapy as an effective alternative to the standard regimen in patients with non-small cell lung cancer: a retrospective study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 2437-2446.	1.2	4
6995	Molecular Alterations in Lung Adenocarcinoma With Ground-Glass Nodules: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 724692.	1.3	2
6996	Correlation between LRP1B Mutations and Tumor Mutation Burden in Gastric Cancer. <i>Computational and Mathematical Methods in Medicine</i> , 2021, 2021, 1-6.	0.7	13
6997	Radiation-activated secretory proteins of Scgb1a1+ club cells increase the efficacy of immune checkpoint blockade in lung cancer. <i>Nature Cancer</i> , 2021, 2, 919-931.	5.7	26
6998	Anti-VEGF antibody protects against alveolar exudate leakage caused by vascular hyperpermeability, resulting in mitigation of pneumonitis induced by immunotherapy. <i>Molecular Cancer Therapeutics</i> , 2021, 20, molcanther.MCT-21-0031-E.2021.	1.9	6
6999	Tumor-derived exosomes drive immunosuppressive macrophages in a pre-metastatic niche through glycolytic dominant metabolic reprogramming. <i>Cell Metabolism</i> , 2021, 33, 2040-2058.e10.	7.2	200
7000	Immune-Related Adverse Events Associated With Outcomes in Patients With NSCLC Treated With Anti-PD-1 Inhibitors: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 708195.	1.3	16
7001	Pembrolizumab plus platinum-based chemotherapy for squamous non-small cell lung cancer: the new kid on the block. <i>Translational Lung Cancer Research</i> , 2021, 10, 3850-3854.	1.3	1
7002	Expression, prognostic significance and therapeutic implications of PD-L1 in gliomas. <i>Neuropathology and Applied Neurobiology</i> , 2022, 48, .	1.8	8

#	ARTICLE	IF	CITATIONS
7003	Vitiligo-like leukoderma as an indicator of clinical response to immune checkpoint inhibitors in late-stage melanoma patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, , 1.	1.2	2
7004	Image intensity histograms as imaging biomarkers: application to immune-related colitis. <i>Biomedical Physics and Engineering Express</i> , 2021, 7, 065019.	0.6	3
7005	Dynamic changes in the T cell receptor repertoire during treatment with radiotherapy combined with an immune checkpoint inhibitor. <i>Molecular Oncology</i> , 2021, 15, 2958-2968.	2.1	5
7006	A comparative study of immunotherapy as second-line treatment and beyond in patients with advanced non-small-cell lung carcinoma. <i>Lung Cancer Management</i> , 2021, 10, LMT47.	1.5	1
7007	Development of Nivolumab/Ipilimumab-Associated Autoimmune Nephritis during Steroid Therapy. <i>Case Reports in Nephrology and Dialysis</i> , 2021, 11, 270-274.	0.3	6
7008	Macrophage-Based Combination Therapies as a New Strategy for Cancer Immunotherapy. <i>Kidney Diseases (Basel, Switzerland)</i> , 2022, 8, 26-43.	1.2	16
7009	A Novel Prognostic Biomarker LPAR6 in Hepatocellular Carcinoma via Associating with Immune Infiltrates. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 10, 90-103.	0.7	9
7010	Imaging evaluation of lung cancer treated with PD-1/PD-L1 inhibitors. <i>British Journal of Radiology</i> , 2021, 94, 20210228.	1.0	2
7011	Characterization of m6A-Related Genes Landscape in Skin Cutaneous Melanoma to Aid Immunotherapy and Assess Prognosis. <i>International Journal of General Medicine</i> , 2021, Volume 14, 5345-5361.	0.8	7
7012	A CLDN18.2-Targeting Bispecific T Cell Co-Stimulatory Activator for Cancer Immunotherapy. <i>Cancer Management and Research</i> , 2021, Volume 13, 6977-6987.	0.9	8
7013	The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 2427-2435.	1.2	5
7014	Immunotherapy in Gastroesophageal Cancers: Current Evidence and Ongoing Trials. <i>Current Treatment Options in Oncology</i> , 2021, 22, 100.	1.3	11
7015	Modulating Tumor Microenvironment: A Review on STK11 Immune Properties and Predictive vs Prognostic Role for Non-small-cell Lung Cancer Immunotherapy. <i>Current Treatment Options in Oncology</i> , 2021, 22, 96.	1.3	5
7016	Case Report: Long Progression-Free Survival of Immunotherapy for Lung Adenocarcinoma With Epidermal Growth Factor Receptor Mutation. <i>Frontiers in Oncology</i> , 2021, 11, 731429.	1.3	5
7017	Immune PET Imaging. <i>Radiologic Clinics of North America</i> , 2021, 59, 875-886.	0.9	2
7018	Is Rechallenge Appropriate in Patients that Develop Immune Checkpoint Inhibitor-Associated AKI?: PRO. <i>Kidney360</i> , 2022, 3, 799-802.	0.9	8
7019	Trastuzumab Deruxtecan in <i>HER2</i> -Mutant Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 241-251.	13.9	393
7020	¹⁸ F-BMS986192 PET Imaging of PD-L1 in Metastatic Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors: A Pilot Study. <i>Journal of Nuclear Medicine</i> , 2022, 63, 899-905.	2.8	36

#	ARTICLE	IF	CITATIONS
7021	Current Immunotherapeutic Strategies for the Treatment of Glioblastoma. <i>Cancers</i> , 2021, 13, 4548.	1.7	16
7022	Molecular mechanisms and functions of pyroptosis in inflammation and antitumor immunity. <i>Molecular Cell</i> , 2021, 81, 4579-4590.	4.5	127
7023	Estimating tumor mutational burden across multiple cancer types using whole-exome sequencing. <i>Annals of Translational Medicine</i> , 2021, 9, 1437-1437.	0.7	8
7024	PD-1 inhibition in advanced myeloproliferative neoplasms. <i>Blood Advances</i> , 2021, 5, 5086-5097.	2.5	16
7025	A Radiomic Approach to Assess Tumor Immune Status by CD8+TRMs on Surgically Resected Non-Small-Cell Lung Cancer. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 4921-4931.	1.0	4
7026	Role of the PD-1/PD-L1 Signaling in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis: Recent Insights and Future Directions. <i>Molecular Neurobiology</i> , 2021, 58, 6249-6271.	1.9	15
7027	A Novel Tool for the Risk Assessment and Personalized Chemo-/Immunotherapy Response Prediction of Adenocarcinoma and Squamous Cell Carcinoma Lung Cancer. <i>International Journal of General Medicine</i> , 2021, Volume 14, 5771-5785.	0.8	2
7028	Nephrotoxicity of cancer therapeutic drugs: Focusing on novel agents. <i>Kidney Research and Clinical Practice</i> , 2021, 40, 344-354.	0.9	5
7029	Short-term outcome of neoadjuvant immunotherapy and chemotherapy in non-small cell lung cancer: A systematic review and meta-analysis. <i>JTCVS Open</i> , 2021, , .	0.2	2
7030	Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic Melanoma. <i>Frontiers in Oncology</i> , 2021, 11, 741993.	1.3	9
7031	Outcomes of Patients With Interstitial Lung Disease Receiving Programmed Cell Death 1 Inhibitors: A Retrospective Case Series. <i>Clinical Lung Cancer</i> , 2021, 22, e738-e744.	1.1	14
7032	Cost-effectiveness of pembrolizumab versus docetaxel as second-line treatment of non-small cell lung cancer in China. <i>Annals of Translational Medicine</i> , 2021, 9, 1480-1480.	0.7	7
7033	Losartan Blocks Osteosarcoma-Elicited Monocyte Recruitment, and Combined With the Kinase Inhibitor Toceranib, Exerts Significant Clinical Benefit in Canine Metastatic Osteosarcoma. <i>Clinical Cancer Research</i> , 2022, 28, 662-676.	3.2	38
7034	Efficacy and Safety of Regorafenib Combined with Toripalimab in the Third-Line and beyond Treatment of Advanced Colorectal Cancer. <i>Journal of Oncology</i> , 2021, 2021, 1-7.	0.6	10
7035	A review of research progress on mechanisms and overcoming strategies of acquired osimertinib resistance. <i>Anti-Cancer Drugs</i> , 2022, 33, e76-e83.	0.7	9
7036	The Prognostic Significance of the Continuous Administration of Anti-PD-1 Antibody via Continuation or Rechallenge After the Occurrence of Immune-Related Adverse Events. <i>Frontiers in Oncology</i> , 2021, 11, 704475.	1.3	7
7037	White Blood Cells in Patients Treated with Programmed Cell Death-1 Inhibitors for Non-small Cell Lung Cancer. <i>Lung</i> , 2021, 199, 549-557.	1.4	6
7038	Impact of KRAS mutation status on the efficacy of immunotherapy in lung cancer brain metastases. <i>Scientific Reports</i> , 2021, 11, 18174.	1.6	15

#	ARTICLE	IF	CITATIONS
7039	Protein Signatures of NK Cell-Mediated Melanoma Killing Predict Response to Immunotherapies. <i>Cancer Research</i> , 2021, 81, 5540-5554.	0.4	5
7040	Association of HLA class I homozygosity with unfavorable clinical outcomes in patients with non-small cell lung cancer treated with chemo-immunotherapy or immunotherapy as first-line therapy. <i>Heliyon</i> , 2021, 7, e07916.	1.4	4
7041	A Novel Nine-lncRNA Risk Signature Correlates With Immunotherapy in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 706915.	1.3	8
7042	Imaging CAR T-cell kinetics in solid tumors: Translational implications. <i>Molecular Therapy - Oncolytics</i> , 2021, 22, 355-367.	2.0	20
7043	Crosstalk between the B7/CD28 and EGFR pathways: Mechanisms and therapeutic opportunities. <i>Genes and Diseases</i> , 2022, 9, 1181-1193.	1.5	8
7044	Mouse resources at the RIKEN BioResource Research Center and the National BioResource Project core facility in Japan. <i>Mammalian Genome</i> , 2021, , 1.	1.0	2
7045	Acute kidney injury in cancer patients. <i>Clinical and Experimental Nephrology</i> , 2022, 26, 103-112.	0.7	3
7046	Patterns of Failure in Patients With Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors. <i>Frontiers in Oncology</i> , 2021, 11, 724722.	1.3	3
7047	PD-1/PD-L1 expression in pancreatic cancer and its implication in novel therapies. <i>Medicine and Pharmacy Reports</i> , 0, , .	0.2	10
7048	Tumor microenvironment is associated with clinical and genetic properties of diffuse gliomas and predicts overall survival. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 953-966.	2.0	8
7049	STC1 is a Novel Biomarker Associated with Immune Characteristics and Prognosis of Bladder Cancer. <i>International Journal of General Medicine</i> , 2021, Volume 14, 5505-5516.	0.8	12
7050	The Combination of Radiotherapy With Immunotherapy and Potential Predictive Biomarkers for Treatment of Non-Small Cell Lung Cancer Patients. <i>Frontiers in Immunology</i> , 2021, 12, 723609.	2.2	17
7051	MRTF-A-NF- κ B/p65 axis-mediated PDL1 transcription and expression contributes to immune evasion of non-small-cell lung cancer via TGF- β 2. <i>Experimental and Molecular Medicine</i> , 2021, 53, 1366-1378.	3.2	22
7052	Comparison of Tumor Microenvironments Between Primary Tumors and Brain Metastases in Patients With NSCLC. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100230.	0.6	8
7053	Effect of mesenchymal-epithelial transition amplification on immune microenvironment and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer. <i>Annals of Translational Medicine</i> , 2021, 9, 1475-1475.	0.7	3
7054	Combination strategies to maximize the benefits of cancer immunotherapy. <i>Journal of Hematology and Oncology</i> , 2021, 14, 156.	6.9	202
7055	Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 37-50.	12.5	350
7056	Pembrolizumab Plus Chemotherapy for Chinese Patients With Metastatic Squamous Non-Small-Cell Lung Cancer in KEYNOTE-407. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100225.	0.6	13

#	ARTICLE	IF	CITATIONS
7057	The promise and perils of immunotherapy. <i>Blood Advances</i> , 2021, 5, 3709-3725.	2.5	23
7058	Tumor immune microenvironment in epidermal growth factor receptor-mutated non-small cell lung cancer before and after epidermal growth factor receptor tyrosine kinase inhibitor treatment: a narrative review. <i>Translational Lung Cancer Research</i> , 2021, 10, 3823-3839.	1.3	13
7059	Simultaneously Combined Cancer Cell- and CTLA4-Targeted NIR-PIT Causes a Synergistic Treatment Effect in Syngeneic Mouse Models. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2262-2273.	1.9	20
7060	Chemotherapy, targeted therapy and immunotherapy: Which drugs can be safely used in the solid organ transplant recipients?. <i>Transplant International</i> , 2021, 34, 2442-2458.	0.8	2
7061	Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma. , 2021, 9, e003521.		56
7062	Cholecystokinin Receptor Antagonist Improves Efficacy of Chemotherapy in Murine Models of Pancreatic Cancer by Altering the Tumor Microenvironment. <i>Cancers</i> , 2021, 13, 4949.	1.7	7
7063	Nab-paclitaxel plus S-1 with or without PD-1 inhibitor in pancreatic ductal adenocarcinoma with only hepatic metastases: a retrospective cohort study. <i>Langenbeck's Archives of Surgery</i> , 2021, , 1.	0.8	3
7064	CCR2 and PTPRC are regulators of tumor microenvironment and potential prognostic biomarkers of lung adenocarcinoma. <i>Annals of Translational Medicine</i> , 2021, 9, 1419-1419.	0.7	14
7065	Abemaciclib in Combination With Pembrolizumab for Stage IV KRAS-Mutant or Squamous NSCLC: A Phase 1b Study. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100234.	0.6	10
7066	Resident memory CD8+ T cells in regional lymph nodes mediate immunity to metastatic melanoma. <i>Immunity</i> , 2021, 54, 2117-2132.e7.	6.6	50
7067	Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2021, 7, 1351.	3.4	113
7068	Combination therapy for hepatocellular carcinoma with diacylglycerol kinase alpha inhibition and anti-programmed cell death-1 ligand blockade. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 889-903.	2.0	8
7069	Nivolumab-induced membranous nephropathy in a patient with stage IV lung adenocarcinoma. <i>CEN Case Reports</i> , 2022, 11, 171-176.	0.5	8
7070	Targeting immune checkpoints in gynecologic cancer: updates & perspectives for pathologists. <i>Modern Pathology</i> , 2022, 35, 142-151.	2.9	7
7071	Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study. <i>Frontiers in Oncology</i> , 2021, 11, 696512.	1.3	22
7072	Efficacy and safety of PD-1/PD-L1 plus CTLA-4 antibodies ± other therapies in lung cancer: a systematic review and meta-analysis. <i>European Journal of Hospital Pharmacy</i> , 2023, 30, 3-8.	0.5	9
7073	Discontinuation of anti-PD-1 monotherapy in advanced melanoma—Outcomes of daily clinical practice. <i>International Journal of Cancer</i> , 2022, 150, 317-326.	2.3	12
7074	Critically ill patients with severe immune checkpoint inhibitor related neurotoxicity: A multi-center case series. <i>Journal of Critical Care</i> , 2021, 65, 126-132.	1.0	6

#	ARTICLE	IF	CITATIONS
7075	Expression of programmed death ligand 1 in drug-resistant osteosarcoma: An exploratory study. <i>Surgery Open Science</i> , 2021, 6, 10-14.	0.5	4
7076	Research Progress and Challenges in the Treatment of Central Nervous System Metastasis of Non-Small Cell Lung Cancer. <i>Cells</i> , 2021, 10, 2620.	1.8	10
7077	Nivolumab-associated DRESS in a genetic susceptible individual. , 2021, 9, e002879.		16
7078	Development of poly(ADP-ribose) polymerase inhibitor and immunotherapy combinations: progress, pitfalls, and promises. <i>Trends in Cancer</i> , 2021, 7, 958-970.	3.8	18
7079	Predicting immune checkpoint inhibitor response with mathematical modeling. <i>Immunotherapy</i> , 2021, 13, 1151-1155.	1.0	2
7080	First-in-Class Anti-immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 57-70.	3.2	30
7081	Immune checkpoint inhibitor induced thyroid dysfunction is a frequent event post-treatment in NSCLC. <i>Lung Cancer</i> , 2021, 161, 34-41.	0.9	7
7082	Intra- and inter-reader agreement of iRECIST and RECIST 1.1 criteria for the assessment of tumor response in patients receiving checkpoint inhibitor immunotherapy for lung cancer. <i>Lung Cancer</i> , 2021, 161, 60-67.	0.9	2
7083	Low sodium and tolvaptan have opposite effects in human small cell lung cancer cells. <i>Molecular and Cellular Endocrinology</i> , 2021, 537, 111419.	1.6	10
7084	New insights into exosome mediated tumor-immune escape: Clinical perspectives and therapeutic strategies. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188624.	3.3	29
7085	Immune checkpoint inhibitors: An emergency medicine focused review. <i>American Journal of Emergency Medicine</i> , 2021, 50, 335-344.	0.7	5
7086	Follow-up Care for Patients Receiving Immune Checkpoint Inhibitors. <i>Asia-Pacific Journal of Oncology Nursing</i> , 2021, 8, 596-603.	0.7	6
7087	Is an Immunosuppressive Microenvironment a Characteristic of Both Intra- and Extraparenchymal Central Nervous Tumors?. <i>Pathophysiology</i> , 2021, 28, 34-49.	1.0	2
7088	Immunotherapy in non-small cell lung cancer: update and new insights. <i>Journal of Clinical and Translational Research</i> , 0, , .	0.3	23
7089	Identification of Immune-Related lncRNA Signature to Predict Prognosis and Immunotherapeutic Efficiency in Bladder Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 542140.	1.3	21
7090	A stratified phase I dose escalation trial of hypofractionated radiotherapy followed by ipilimumab in metastatic melanoma: long-term follow-up and final outcomes. <i>Onc Immunology</i> , 2021, 10, 1863631.	2.1	16
7091	Biomarker Discovery in Patients with Immunotherapy-Treated Melanoma with Imaging Mass Cytometry. <i>Clinical Cancer Research</i> , 2021, 27, 1987-1996.	3.2	38
7092	Prognostic impact of primary cancer adjoining emphysematous bullae in non-small cell lung cancer patients treated with immune checkpoint inhibitors. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1745-1753.	2.0	1

#	ARTICLE	IF	CITATIONS
7093	Favorable clinical outcomes of checkpoint inhibitor-based combinations after progression with immunotherapy in advanced non-small cell lung cancer. , 2021, 4, 728-739.		1
7094	Clinical sequencing to assess tumor mutational burden as a useful biomarker to immunotherapy in various solid tumors. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592199299.	1.4	20
7095	Targeting the ubiquitination/deubiquitination process to regulate immune checkpoint pathways. Signal Transduction and Targeted Therapy, 2021, 6, 28.	7.1	28
7096	Synthesis and Preclinical Evaluation of a ⁶⁸ Ga-Labeled Adnectin, ⁶⁸ Ga-BMS-986192, as a PET Agent for Imaging PD-L1 Expression. Journal of Nuclear Medicine, 2021, 62, 1228-1234.	2.8	21
7097	Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma. International Journal of Molecular Sciences, 2021, 22, 593.	1.8	35
7098	Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer. Signal Transduction and Targeted Therapy, 2021, 6, 26.	7.1	112
7099	Antitumour immunity regulated by aberrant ERBB family signalling. Nature Reviews Cancer, 2021, 21, 181-197.	12.8	141
7100	Spectrum and Management of Immune Related Adverse Events Due to Immune Checkpoint Inhibitors. Current Cancer Research, 2021, , 139-173.	0.2	0
7101	Sequential Treatment with an Immune Checkpoint Inhibitor Followed by a Small-Molecule Targeted Agent Increases Drug-Induced Pneumonitis. Cancer Research and Treatment, 2021, 53, 77-86.	1.3	8
7102	Expression of programmed death-ligand 1 and programmed death-1 in patients with extramammary paget's disease. Indian Journal of Dermatology, 2021, 66, 169.	0.1	4
7103	Anorectal Mucosal Melanoma in the Era of Immune Checkpoint Inhibition: Should We Change Our Surgical Management Paradigm?. Diseases of the Colon and Rectum, 2021, 64, 555-562.	0.7	8
7104	A mathematical model for the quantification of a patient's sensitivity to checkpoint inhibitors and long-term tumour burden. Nature Biomedical Engineering, 2021, 5, 297-308.	11.6	28
7105	Simultaneous high PD-L1 and low VEGFR2 expression is associated with better overall survival in rectal cancer. Translational Cancer Research, 2021, 10, 499-508.	0.4	0
7106	Synthesis of Libraries and Multi-Site Mutagenesis using a PCR derived, dU-containing Template. Synthetic Biology, 2021, 6, ysaa030.	1.2	0
7107	Comparison of Different Methods for Defining Hyperprogressive Disease in NSCLC. JTO Clinical and Research Reports, 2021, 2, 100115.	0.6	3
7109	The efficacy and safety of the combination of axitinib and pembrolizumab-activated autologous DC-IC cell immunotherapy for patients with advanced renal cell carcinoma: a phase 2 study. Clinical and Translational Immunology, 2021, 10, e1257.	1.7	4
7110	Residue substitution enhances the immunogenicity of neoepitopes from gastric cancers. Cancer Biology and Medicine, 2021, 18, 0-0.	1.4	1
7111	IL-2 regulates tumor-reactive CD8+ T cell exhaustion by activating the aryl hydrocarbon receptor. Nature Immunology, 2021, 22, 358-369.	7.0	170

#	ARTICLE	IF	CITATIONS
7112	Network for Biomarker Immunoprofiling for Cancer Immunotherapy: Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC). <i>Clinical Cancer Research</i> , 2021, 27, 5038-5048.	3.2	13
7113	Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) $\geq 50\%$: real-world data. <i>Oncology</i> , 2021, 10, 1865653.	2.1	24
7114	Immune regulation in renal inflammation. <i>Cell and Tissue Research</i> , 2021, 385, 305-322.	1.5	7
7115	Immune checkpoint inhibitor-induced aseptic meningitis and encephalitis: a case-series and narrative review. <i>Therapeutic Advances in Drug Safety</i> , 2021, 12, 204209862110047.	1.0	20
7116	The association of transcription factor Prox1 with the proliferation, migration, and invasion of lung cancer. <i>Open Life Sciences</i> , 2021, 16, 602-610.	0.6	2
7117	Hyperprogression: A novel response pattern under immunotherapy. <i>Clinical and Translational Medicine</i> , 2020, 10, e167.	1.7	22
7118	Model-Based Population Pharmacokinetic Analysis of Nivolumab in Patients With Solid Tumors. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017, 6, 58-66.	1.3	195
7119	Managing Checkpoint Inhibitor Symptoms and Toxicity for Metastatic Melanoma. , 2020, , 1187-1214.		2
7120	Immune-Related Adverse Events: Pneumonitis. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1244, 255-269.	0.8	38
7121	High PD-1 expression level is associated with an unfavorable prognosis in patients with cervical adenocarcinoma. <i>Archives of Gynecology and Obstetrics</i> , 2020, 302, 209-218.	0.8	12
7122	Particular findings on lung CT in patients undergoing immunotherapy for bronchogenic carcinoma. <i>Wiener Klinische Wochenschrift</i> , 2020, 132, 467-474.	1.0	8
7123	Cardiotoxicity of Novel Targeted Chemotherapeutic Agents. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2018, 20, 53.	0.4	17
7124	SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019). <i>Clinical and Translational Oncology</i> , 2020, 22, 213-222.	1.2	14
7125	The Role of Anti-PD-1/PD-L1 in the Treatment of Skin Cancer. <i>BioDrugs</i> , 2020, 34, 495-503.	2.2	15
7126	Immune checkpoint inhibitors: a narrative review of considerations for the anaesthesiologist. <i>British Journal of Anaesthesia</i> , 2020, 124, 251-260.	1.5	35
7127	Metabolic consequences of immune checkpoint inhibitors: A new challenge in clinical practice. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 151, 102979.	2.0	5
7128	Immune checkpoint inhibitors to treat cutaneous malignancies. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1239-1253.	0.6	56
7129	Complete pathologic response of metastatic cutaneous squamous cell carcinoma and allograft rejection after treatment with combination immune checkpoint blockade. <i>JAAD Case Reports</i> , 2017, 3, 412-415.	0.4	40

#	ARTICLE	IF	CITATIONS
7130	Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule. <i>Cell Reports Medicine</i> , 2020, 1, 100163.	3.3	27
7131	Cellular senescence in gastrointestinal diseases: from pathogenesis to therapeutics. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 81-95.	8.2	62
7132	Suppression of Sirt1 sensitizes lung cancer cells to WEE1 inhibitor MK-1775-induced DNA damage and apoptosis. <i>Oncogene</i> , 2017, 36, 6863-6872.	2.6	53
7133	Expression patterns of programmed death ligand 1 correlate with different microenvironments and patient prognosis in hepatocellular carcinoma. <i>British Journal of Cancer</i> , 2018, 119, 80-88.	2.9	74
7134	Dramatic enhancement of the detection limits of bioassays via ultrafast deposition of polydopamine. <i>Nature Biomedical Engineering</i> , 2017, 1, .	11.6	93
7135	The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 775-784.	1.1	268
7136	Single versus combined immunoregulatory approach using PD-1 and CTLA-4 modulators in controlling sepsis. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 907-919.	1.3	14
7137	Glycosylation-independent binding of monoclonal antibody toripalimab to FG loop of PD-1 for tumor immune checkpoint therapy. <i>MAbs</i> , 2019, 11, 681-690.	2.6	30
7138	Management of checkpoint inhibitor-associated renal toxicities. <i>Expert Review of Quality of Life in Cancer Care</i> , 2017, 2, 215-223.	0.6	6
7139	Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkaa115.	1.4	14
7140	Hyponatremia and other electrolyte abnormalities in patients receiving immune checkpoint inhibitors. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 2241-2247.	0.4	33
7141	An open-label, single-arm, phase II trial of buparlisib in patients with melanoma brain metastases not eligible for surgery or radiosurgeryâ€”the BUMPER study. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa140.	0.4	6
7142	Incidence and Prediction of Immune Checkpoint Inhibitor-related Nephrotoxicity. <i>Journal of Immunotherapy</i> , 2021, 44, 127-131.	1.2	19
7143	Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218). <i>Melanoma Research</i> , 2021, 31, 67-75.	0.6	15
7144	Clinical Characteristics and Treatment Response With Checkpoint Inhibitors in Malignant Melanoma of the Vulva and Vagina. <i>Journal of Lower Genital Tract Disease</i> , 2021, 25, 146-151.	0.9	12
7145	Risk of Toxicity After Initiating Immune Checkpoint Inhibitor Treatment in Patients With Rheumatoid Arthritis. <i>Journal of Clinical Rheumatology</i> , 2021, 27, 267-271.	0.5	23
7146	CD20 ⁺ tumorâ€”infiltrating immune cells and CD204 ⁺ M2 macrophages are associated with prognosis in thymic carcinoma. <i>Cancer Science</i> , 2020, 111, 1921-1932.	1.7	28
7147	Fiveâ€”year safety and efficacy data from a phase Ib study of nivolumab and chemotherapy in advanced nonâ€”smallâ€”cell lung cancer. <i>Cancer Science</i> , 2020, 111, 1933-1942.	1.7	13

#	ARTICLE	IF	CITATIONS
7148	Uptake of positron emission tomography tracers reflects the tumor immune status in esophageal squamous cell carcinoma. <i>Cancer Science</i> , 2020, 111, 1969-1978.	1.7	13
7149	Immune-checkpoint molecules on regulatory T-cells as a potential therapeutic target in head and neck squamous cell cancers. <i>Cancer Science</i> , 2020, 111, 1943-1957.	1.7	24
7150	Resolution of ipilimumab induced severe hepatotoxicity with triple immunosuppressants therapy. <i>BMJ Case Reports</i> , 2015, 2015, bcr2014208102.	0.2	38
7151	Nivolumab causing painless thyroiditis in a patient with adenocarcinoma of the lung. <i>BMJ Case Reports</i> , 2016, 2016, bcr2015213692.	0.2	14
7152	Immunotherapy in a rare case of primary pelvic retroperitoneal melanoma. <i>BMJ Case Reports</i> , 2016, 2016, bcr2016216450.	0.2	2
7153	Glucocorticoids did not reverse type 1 diabetes mellitus secondary to pembrolizumab in a patient with metastatic melanoma. <i>BMJ Case Reports</i> , 2016, 2016, bcr2016217454.	0.2	56
7154	Anti-PD-L1 therapy and the onset of diabetes mellitus with positive pancreatic autoantibodies. <i>BMJ Case Reports</i> , 2017, 2017, bcr-2017-220415.	0.2	17
7155	New onset diabetes after nivolumab treatment. <i>BMJ Case Reports</i> , 2018, 2018, bcr-2017-220999.	0.2	19
7156	Rare side effect of adjuvant ipilimumab after surgical resection of melanoma: Guillain-Barré syndrome. <i>BMJ Case Reports</i> , 2017, 2017, bcr-2017-221318.	0.2	6
7157	Autoimmune haemolytic anaemia in a patient with advanced lung adenocarcinoma and chronic lymphocytic leukaemia receiving nivolumab and intravenous immunoglobulin. <i>BMJ Case Reports</i> , 2018, 2018, bcr-2017-221801.	0.2	11
7158	Pneumonitis: a serious adverse effect of PD-L1 inhibitors including pembrolizumab. <i>BMJ Case Reports</i> , 2018, 2018, bcr-2018-224485.	0.2	6
7159	IgA nephropathy after pembrolizumab therapy for mesothelioma. <i>BMJ Case Reports</i> , 2020, 13, e237008.	0.2	5
7160	Non-thermal histotripsy tumor ablation promotes abscopal immune responses that enhance cancer immunotherapy. , 2020, 8, e000200.		99
7161	The Case of a Zebra That Was Misdiagnosed as a Horse: Pulmonary Tumor Thrombotic Microangiopathy, a New Paraneoplastic Syndrome, Mimicking PD-1-Induced Pneumonitis. <i>Case Reports in Oncology</i> , 2016, 9, 68-75.	0.3	6
7162	Personalized therapy for lung cancer: Striking a moving target. <i>JCI Insight</i> , 2018, 3, .	2.3	114
7163	Combination anti-PD-1 and antiretroviral therapy provides therapeutic benefit against SIV. <i>JCI Insight</i> , 2018, 3, .	2.3	83
7164	PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. <i>JCI Insight</i> , 2019, 4, .	2.3	345
7165	Urine TNF- α and IL-9 for clinical diagnosis of acute interstitial nephritis. <i>JCI Insight</i> , 2019, 4, .	2.3	89

#	ARTICLE	IF	CITATIONS
7166	Titin mutation associated with responsiveness to checkpoint blockades in solid tumors. JCI Insight, 2019, 4, .	2.3	104
7167	Metronomic capecitabine as an immune modulator in glioblastoma patients reduces myeloid-derived suppressor cells. JCI Insight, 2019, 4, .	2.3	82
7168	Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLC. JCI Insight, 2019, 4, .	2.3	113
7169	Combination of host immune metabolic biomarkers for the PD-1 blockade cancer immunotherapy. JCI Insight, 2020, 5, .	2.3	58
7170	Clinical implications of monitoring nivolumab immunokinetics in nonâ€“small cell lung cancer patients. JCI Insight, 2018, 3, .	2.3	156
7171	Lymphocyte activation gene 3 and coronary artery disease. JCI Insight, 2016, 1, e88628.	2.3	32
7172	Multiparametric profiling of nonâ€“small-cell lung cancers reveals distinct immunophenotypes. JCI Insight, 2016, 1, e89014.	2.3	110
7173	Transcriptional dissection of melanoma identifies a high-risk subtype underlying TP53 family genes and epigenome deregulation. JCI Insight, 2017, 2, .	2.3	48
7174	Partially exhausted tumor-infiltrating lymphocytes predict response to combination immunotherapy. JCI Insight, 2017, 2, .	2.3	62
7175	CTLA4 methylation predicts response to antiâ€“PD-1 and antiâ€“CTLA-4 immunotherapy in melanoma patients. JCI Insight, 2018, 3, .	2.3	67
7176	CSF1R-dependent myeloid cells are required for NKâ€“mediated control of metastasis. JCI Insight, 2018, 3, .	2.3	38
7177	Emerging strategies for combination checkpoint modulators in cancer immunotherapy. Journal of Clinical Investigation, 2018, 128, 3209-3218.	3.9	170
7178	DNA repair defects and implications for immunotherapy. Journal of Clinical Investigation, 2018, 128, 4236-4242.	3.9	59
7179	Proximal tubule ATR regulates DNA repair to prevent maladaptive renal injury responses. Journal of Clinical Investigation, 2019, 129, 4797-4816.	3.9	73
7180	Reparative T lymphocytes in organ injury. Journal of Clinical Investigation, 2019, 129, 2608-2618.	3.9	51
7181	Immunotherapy transforms cancer treatment. Journal of Clinical Investigation, 2018, 129, 46-47.	3.9	34
7182	U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation. Journal of Clinical Investigation, 2019, 130, 374-388.	3.9	43
7183	cGAS/STING axis mediates a topoisomerase II inhibitorâ€“induced tumor immunogenicity. Journal of Clinical Investigation, 2019, 129, 4850-4862.	3.9	136

#	ARTICLE	IF	CITATIONS
7184	The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis. <i>Journal of Clinical Investigation</i> , 2019, 129, 4305-4315.	3.9	100
7185	Activation and inhibition of lymphocytes by costimulation. <i>Journal of Clinical Investigation</i> , 2002, 109, 295-299.	3.9	140
7186	Costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis. <i>Journal of Clinical Investigation</i> , 2003, 111, 363-370.	3.9	164
7187	Tregs and rethinking cancer immunotherapy. <i>Journal of Clinical Investigation</i> , 2007, 117, 1167-1174.	3.9	464
7188	DC-based cancer vaccines. <i>Journal of Clinical Investigation</i> , 2007, 117, 1195-1203.	3.9	502
7189	Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade. <i>Journal of Clinical Investigation</i> , 2015, 125, 3377-3383.	3.9	146
7190	IL-34 mediates acute kidney injury and worsens subsequent chronic kidney disease. <i>Journal of Clinical Investigation</i> , 2015, 125, 3198-3214.	3.9	108
7191	Metabolic regulation of immune responses: therapeutic opportunities. <i>Journal of Clinical Investigation</i> , 2016, 126, 2031-2039.	3.9	78
7192	Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. <i>Journal of Clinical Investigation</i> , 2016, 126, 3130-3144.	3.9	773
7193	TAP-independent self-peptides enhance T cell recognition of immune-escaped tumors. <i>Journal of Clinical Investigation</i> , 2016, 126, 784-794.	3.9	60
7194	Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer. <i>Journal of Clinical Investigation</i> , 2016, 126, 2334-2340.	3.9	312
7195	Overcoming therapeutic resistance in glioblastoma: the way forward. <i>Journal of Clinical Investigation</i> , 2017, 127, 415-426.	3.9	354
7196	Egress of sperm autoantigen from seminiferous tubules maintains systemic tolerance. <i>Journal of Clinical Investigation</i> , 2017, 127, 1046-1060.	3.9	93
7197	Pyruvate controls the checkpoint inhibitor PD-L1 and suppresses T cell immunity. <i>Journal of Clinical Investigation</i> , 2017, 127, 2725-2738.	3.9	75
7198	Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy. <i>Journal of Clinical Investigation</i> , 2018, 128, 1338-1354.	3.9	64
7199	Resisting fatal attraction: a glioma oncometabolite prevents CD8+ T cell recruitment. <i>Journal of Clinical Investigation</i> , 2017, 127, 1218-1220.	3.9	15
7200	Dinaciclib induces immunogenic cell death and enhances anti-PD1-mediated tumor suppression. <i>Journal of Clinical Investigation</i> , 2018, 128, 644-654.	3.9	144
7201	Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression. <i>Journal of Clinical Investigation</i> , 2018, 128, 805-815.	3.9	423

#	ARTICLE	IF	CITATIONS
7202	Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy. <i>Journal of Clinical Investigation</i> , 2018, 128, 5137-5149.	3.9	269
7203	Early B cell changes predict autoimmunity following combination immune checkpoint blockade. <i>Journal of Clinical Investigation</i> , 2018, 128, 715-720.	3.9	298
7204	Antigen delivery targeted to tumor-associated macrophages overcomes tumor immune resistance. <i>Journal of Clinical Investigation</i> , 2019, 129, 1278-1294.	3.9	102
7205	Pro-resolving lipid mediators in vascular disease. <i>Journal of Clinical Investigation</i> , 2018, 128, 3727-3735.	3.9	58
7206	CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms. <i>Journal of Clinical Investigation</i> , 2018, 128, 2613-2625.	3.9	91
7207	B cells as biomarkers: predicting immune checkpoint therapy adverse events. <i>Journal of Clinical Investigation</i> , 2018, 128, 577-579.	3.9	39
7208	Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade. <i>Journal of Clinical Investigation</i> , 2018, 128, 4654-4668.	3.9	591
7209	Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme. <i>BMC Cancer</i> , 2019, 19, 117.	1.1	37
7210	Cerenkov luminescence imaging is an effective preclinical tool for assessing colorectal cancer PD-L1 levels in vivo. <i>EJNMMI Research</i> , 2020, 10, 64.	1.1	8
7212	Influence on [18F]FDG uptake by cancer cells after anti-PD-1 therapy in an enforced-immune activated mouse tumor. <i>EJNMMI Research</i> , 2020, 10, 24.	1.1	10
7213	Metachronous rectal metastasis from pulmonary adenocarcinoma after 11 years of chemo-, immuno-, and radiotherapy for recurrent lesions: a case report. <i>Surgical Case Reports</i> , 2019, 5, 151.	0.2	2
7214	Multimodal therapy with surgery and adjuvant nivolumab for late-onset multiple liver metastases of choroidal malignant melanoma: a case report. <i>Surgical Case Reports</i> , 2020, 6, 187.	0.2	3
7215	Undifferentiated carcinoma of the transverse colon with rhabdoid features that developed during treatment of non-small cell lung carcinoma with pembrolizumab: a case report. <i>Surgical Case Reports</i> , 2020, 6, 196.	0.2	3
7216	The use of patient-reported outcomes to detect adverse events in metastatic melanoma patients receiving immunotherapy: a randomized controlled pilot trial. <i>Journal of Patient-Reported Outcomes</i> , 2020, 4, 88.	0.9	19
7217	Nivolumab-Induced Severe Akathisia in an Advanced Lung Cancer Patient. <i>American Journal of Case Reports</i> , 2016, 17, 880-882.	0.3	13
7218	Resolution of Infliximab-Refractory Nivolumab-Induced Acute Severe Enterocolitis After Cyclosporine Treatment in a Patient with Non-Small Cell Lung Cancer. <i>American Journal of Case Reports</i> , 2018, 19, 360-364.	0.3	34
7219	A Case of Acute Exacerbation of Chronic Adrenal Insufficiency Due to Ipilimumab Treatment for Advanced Melanoma. <i>American Journal of Case Reports</i> , 2019, 20, 106-110.	0.3	7
7220	Febrile Neutropenia in a Patient with Non-Small Cell Lung Cancer Treated with the Immune-Checkpoint Inhibitor Nivolumab. <i>American Journal of Case Reports</i> , 2020, 21, e920809.	0.3	8

#	ARTICLE	IF	CITATIONS
7221	TRAF2 is a Valuable Prognostic Biomarker in Patients with Prostate Cancer. <i>Medical Science Monitor</i> , 2017, 23, 4192-4204.	0.5	15
7222	Bibliometric Analysis of Tumor Immunotherapy Studies. <i>Medical Science Monitor</i> , 2018, 24, 3405-3414.	0.5	34
7223	Expression of B7 Homolog 1 (B7H1) Is Associated with Clinicopathologic Features in Urothelial Bladder Cancer. <i>Medical Science Monitor</i> , 2018, 24, 7303-7308.	0.5	5
7224	LINC00922 Accelerates the Proliferation, Migration and Invasion of Lung Cancer Via the miRNA-204/CXCR4 Axis. <i>Medical Science Monitor</i> , 2019, 25, 5075-5086.	0.5	25
7225	Harnessing the immune response to target tumors. <i>F1000Research</i> , 2017, 6, 710.	0.8	2
7226	Natural killer cells in herpesvirus infections. <i>F1000Research</i> , 2017, 6, 1231.	0.8	9
7227	Recent advances in understanding immune phenotypes of thyroid carcinomas: prognostication and emerging therapies. <i>F1000Research</i> , 2019, 8, 227.	0.8	20
7228	Recent advances in understanding and managing chordomas: an update. <i>F1000Research</i> , 2020, 9, 713.	0.8	10
7229	Tissue-resident lymphocytes: weaponized sentinels at barrier surfaces. <i>F1000Research</i> , 2020, 9, 691.	0.8	8
7230	Current clinical immunotherapeutic approaches for head and neck cancer. <i>F1000Research</i> , 2016, 5, 803.	0.8	5
7231	Recent advances in molecular genetics of melanoma progression: implications for diagnosis and treatment. <i>F1000Research</i> , 2016, 5, 1529.	0.8	4
7232	Recent advances in understanding antitumor immunity. <i>F1000Research</i> , 2016, 5, 2545.	0.8	29
7233	Biomarkers for immune therapy in melanoma. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2018, 37, 120-126.	1.6	2
7234	Immune checkpoint inhibitor-induced colitis: A comprehensive review. <i>World Journal of Clinical Cases</i> , 2019, 7, 405-418.	0.3	171
7235	Acute myelomonocytic leukemia during pembrolizumab treatment for non-small cell lung cancer: A case report. <i>World Journal of Clinical Cases</i> , 2020, 8, 2833-2840.	0.3	3
7236	Significant benefits of pembrolizumab in treating refractory advanced pulmonary sarcomatoid carcinoma: A case report. <i>World Journal of Clinical Cases</i> , 2020, 8, 2876-2884.	0.3	6
7237	Management of cancer patients during COVID-19 pandemic at developing countries. <i>World Journal of Clinical Cases</i> , 2020, 8, 3390-3404.	0.3	16
7238	Management of pembrolizumab-induced steroid refractory mucositis with infliximab: A case report. <i>World Journal of Clinical Cases</i> , 2020, 8, 4100-4108.	0.3	4

#	ARTICLE	IF	CITATIONS
7239	Camrelizumab (SHR-1210) leading to reactive capillary hemangioma in the gingiva: A case report. <i>World Journal of Clinical Cases</i> , 2020, 8, 624-629.	0.3	8
7240	Avelumab for the treatment of metastatic Merkel cell carcinoma. <i>Drugs of Today</i> , 2017, 53, 377.	0.7	6
7241	Immunotherapy in the Precision Medicine Era: Melanoma and Beyond. <i>PLoS Medicine</i> , 2016, 13, e1002196.	3.9	21
7242	<i>Schistosoma mansoni</i> Soluble Egg Antigens Induce Expression of the Negative Regulators SOCS1 and SHP1 in Human Dendritic Cells via Interaction with the Mannose Receptor. <i>PLoS ONE</i> , 2015, 10, e0124089.	1.1	34
7243	Corticosteroids Augment BRAF Inhibitor Vemurafenib Induced Lymphopenia and Risk of Infection. <i>PLoS ONE</i> , 2015, 10, e0124590.	1.1	9
7244	Pre-Vaccination Frequencies of Th17 Cells Correlate with Vaccine-Induced T-Cell Responses to Survivin-Derived Peptide Epitopes. <i>PLoS ONE</i> , 2015, 10, e0131934.	1.1	11
7245	The PD-1/B7-H1 Pathway Modulates the Natural Killer Cells versus Mouse Glioma Stem Cells. <i>PLoS ONE</i> , 2015, 10, e0134715.	1.1	83
7246	Investigation of FOXM1 as a Potential New Target for Melanoma. <i>PLoS ONE</i> , 2015, 10, e0144241.	1.1	35
7247	Characterization of FGFR1 Locus in sqNSCLC Reveals a Broad and Heterogeneous Amplicon. <i>PLoS ONE</i> , 2016, 11, e0149628.	1.1	23
7248	Elevated Levels of SOX10 in Serum from Vitiligo and Melanoma Patients, Analyzed by Proximity Ligation Assay. <i>PLoS ONE</i> , 2016, 11, e0154214.	1.1	4
7249	Correlation of PD-L1 Expression of Tumor Cells with Survival Outcomes after Radical Intensity-Modulated Radiation Therapy for Non-Metastatic Nasopharyngeal Carcinoma. <i>PLoS ONE</i> , 2016, 11, e0157969.	1.1	54
7250	Immune-Modulation by Epidermal Growth Factor Receptor Inhibitors: Implication on Anti-Tumor Immunity in Lung Cancer. <i>PLoS ONE</i> , 2016, 11, e0160004.	1.1	33
7251	Brother of the regulator of the imprinted site (BORIS) variant subfamily 6 is a novel target of lung cancer stem-like cell immunotherapy. <i>PLoS ONE</i> , 2017, 12, e0171460.	1.1	18
7252	Hepatitis C virus impairs natural killer cell activity via viral serine protease NS3. <i>PLoS ONE</i> , 2017, 12, e0175793.	1.1	12
7253	Loss of function JAK1 mutations occur at high frequency in cancers with microsatellite instability and are suggestive of immune evasion. <i>PLoS ONE</i> , 2017, 12, e0176181.	1.1	86
7254	Low-dose glucocorticoids suppresses ovarian tumor growth and metastasis in an immunocompetent syngeneic mouse model. <i>PLoS ONE</i> , 2017, 12, e0178937.	1.1	23
7255	Genome-wide association analysis identifies genetic correlates of immune infiltrates in solid tumors. <i>PLoS ONE</i> , 2017, 12, e0179726.	1.1	216
7256	Development of an automated size-based filtration system for isolation of circulating tumor cells in lung cancer patients. <i>PLoS ONE</i> , 2017, 12, e0179744.	1.1	33

#	ARTICLE	IF	CITATIONS
7257	Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors. PLoS ONE, 2017, 12, e0182665.	1.1	54
7258	Distribution of circulating T follicular helper cell subsets is altered in immunoglobulin A vasculitis in children. PLoS ONE, 2017, 12, e0189133.	1.1	18
7259	Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma. PLoS ONE, 2017, 12, e0189848.	1.1	190
7260	Late-Developing Metastatic Malignant Melanoma in the Thoracic Spine Originating from Choroidal Melanoma. Korean Journal of Spine, 2017, 14, 53-56.	0.9	3
7261	A Case of Acute Heart Failure due to Immune Checkpoint Blocker Nivolumab. Cardiology Research, 2019, 10, 120-123.	0.5	11
7262	An Unusual Case of Gastritis in One Patient Receiving PD-1 Blocking Therapy: Coexisting Immune-Related Gastritis and Cytomegaloviral Infection. Gastroenterology Research, 2018, 11, 383-387.	0.4	19
7263	Novel Drugs and Combination Therapies for the Treatment of Metastatic Melanoma. Journal of Clinical Medicine Research, 2016, 8, 63-75.	0.6	49
7264	Isolated Adrenocorticotrophic Hormone Deficiency and Severe Hypercalcemia After Destructive Thyroiditis in a Patient on Nivolumab Therapy With a Malignant Melanoma. Journal of Clinical Medicine Research, 2018, 10, 358-362.	0.6	23
7265	Autoimmune Diabetes Associated With Pembrolizumab: A Review of Published Case Reports. World Journal of Oncology, 2018, 9, 1-4.	0.6	34
7266	Sarcopenia and Visceral Adiposity Did Not Affect Efficacy of Immune-Checkpoint Inhibitor Monotherapy for Pretreated Patients With Advanced Non-Small Cell Lung Cancer. World Journal of Oncology, 2020, 11, 9-22.	0.6	36
7267	Onconephrology: An Evolving Field. Methodist DeBakey Cardiovascular Journal, 2021, 15, 305.	0.5	3
7268	PD-1 pathway-mediated regulation of islet-specific CD4+ T cell subsets in autoimmune diabetes. Immunoendocrinology (Houston, Tex), 2016, 3, .	1.0	14
7269	Urgent need to define Pretreatment predictors of immune check point inhibitors related endocrinopathies: A case report and review of literature. Journal of Translational Internal Medicine, 2017, 5, 235-239.	1.0	1
7270	A prospective highlight on exosomal nanoshuttles and cancer immunotherapy and vaccination. Biolmpacts, 2015, 5, 117-122.	0.7	16
7271	The actin modulator hMENA regulates GAS 6-AXL axis and tumor cancer/stromal cell cooperation. EMBO Reports, 2020, 21, e50078.	2.0	20
7272	Elevated levels of soluble PD-L1 are associated with reduced recurrence in papillary thyroid cancer. Endocrine Connections, 2019, 8, 1040-1051.	0.8	23
7273	PD-1 and PD-L1 expression in pulmonary carcinoid tumors and their association to tumor spread. Endocrine Connections, 2019, 8, 1168-1175.	0.8	19
7274	Hyponatraemia secondary to nivolumab-induced primary adrenal failure. Endocrinology, Diabetes and Metabolism Case Reports, 2016, 2016, .	0.2	60

#	ARTICLE	IF	CITATIONS
7275	Combination immune checkpoint inhibitor therapy nivolumab and ipilimumab associated with multiple endocrinopathies. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2018, 2018, .	0.2	26
7276	New-onset insulin-dependent diabetes due to nivolumab. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2018, 2018, .	0.2	14
7277	Rapid-onset diabetic ketoacidosis secondary to nivolumab therapy. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2018, 2018, .	0.2	19
7278	Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review. <i>European Journal of Endocrinology</i> , 2019, 181, 363-374.	1.9	154
7279	French Endocrine Society Guidance on endocrine side effects of immunotherapy. <i>Endocrine-Related Cancer</i> , 2019, 26, G1-G18.	1.6	95
7280	Cancer and Heart Failure: Understanding the Intersection. <i>Cardiac Failure Review</i> , 2017, 03, 66-70.	1.2	10
7281	T lymphocytes against solid malignancies: winning ways to defeat tumours. <i>Cell Stress</i> , 2018, 2, 200-212.	1.4	22
7282	Evolution in the management of non-small cell lung cancer in Brazil. <i>Jornal Brasileiro De Pneumologia</i> , 2017, 43, 403-404.	0.4	6
7283	RKIP-Mediated Chemo-Immunosensitization of Resistant Cancer Cells via Disruption of the NF- κ B/Snail/YY1/RKIP Resistance-Driver Loop. <i>Critical Reviews in Oncogenesis</i> , 2014, 19, 431-445.	0.2	31
7284	Liquid Biopsies for Assessing Metastatic Melanoma Progression. <i>Critical Reviews in Oncogenesis</i> , 2016, 21, 141-154.	0.2	15
7285	Pancreatic Cancer: An Emphasis on Current Perspectives in Immunotherapy. <i>Critical Reviews in Oncogenesis</i> , 2019, 24, 105-118.	0.2	8
7286	Clinical Trials in Non-Small Cell Lung Cancer with Biomarker-Driven Treatment Allocation: Ready or Not, Here We Come. <i>Critical Reviews in Oncogenesis</i> , 2015, 20, 339-347.	0.2	6
7287	Large-scale analysis reveals the specific clinical and immune features of CD155 in glioma. <i>Aging</i> , 2019, 11, 5463-5482.	1.4	20
7288	FAM83A signaling induces epithelial-mesenchymal transition by the PI3K/AKT/Snail pathway in NSCLC. <i>Aging</i> , 2019, 11, 6069-6088.	1.4	48
7289	Relationship between PD-L1 expression and 18F-FDG uptake in gastric cancer. <i>Aging</i> , 2019, 11, 12270-12277.	1.4	11
7290	Predictive biomarkers for dasatinib treatment in melanoma. <i>Oncoscience</i> , 2014, 1, 158-166.	0.9	8
7291	Comprehensive immunohistochemical analysis of tumor microenvironment immune status in esophageal squamous cell carcinoma. <i>Oncotarget</i> , 2016, 7, 47252-47264.	0.8	79
7292	Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib. <i>Oncotarget</i> , 2018, 9, 12408-12417.	0.8	11

#	ARTICLE	IF	CITATIONS
7293	Fatal gastrointestinal toxicity with ipilimumab after BRAF/MEK inhibitor combination in a melanoma patient achieving pathological complete response. <i>Oncotarget</i> , 2016, 7, 56619-56627.	0.8	16
7294	Discovery of peptide inhibitors targeting human programmed death 1 (PD-1) receptor. <i>Oncotarget</i> , 2016, 7, 64967-64976.	0.8	42
7295	Î²BÎ¶: an emerging player in cancer. <i>Oncotarget</i> , 2016, 7, 66310-66322.	0.8	48
7296	Characterizing the immune microenvironment of malignant peripheral nerve sheath tumor by PD-L1 expression and presence of CD8+ tumor infiltrating lymphocytes. <i>Oncotarget</i> , 2016, 7, 64300-64308.	0.8	44
7297	Expressions of CD8+TILs, PD-L1 and Foxp3+TILs in stage I NSCLC guiding adjuvant chemotherapy decisions. <i>Oncotarget</i> , 2016, 7, 64318-64329.	0.8	40
7298	Addressing intra-tumoral heterogeneity and therapy resistance. <i>Oncotarget</i> , 2016, 7, 72322-72342.	0.8	67
7299	Phenotypic screening reveals TNFR2 as a promising target for cancer immunotherapy. <i>Oncotarget</i> , 2016, 7, 68278-68291.	0.8	48
7300	Combination treatment including targeted therapy for advanced hepatocellular carcinoma. <i>Oncotarget</i> , 2016, 7, 71036-71051.	0.8	44
7301	The anti-fibrotic effect of GV1001 combined with gemcitabine on treatment of pancreatic ductal adenocarcinoma. <i>Oncotarget</i> , 2016, 7, 75081-75093.	0.8	11
7302	PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma. <i>Oncotarget</i> , 2016, 7, 72961-72977.	0.8	258
7303	CD8+/FOXP3+ ratio and PD-L1 expression associated with survival in pT3N0M0 stage esophageal squamous cell cancer. <i>Oncotarget</i> , 2016, 7, 71455-71465.	0.8	42
7304	Near infrared photoimmunotherapy with avelumab, an anti-programmed death-ligand 1 (PD-L1) antibody. <i>Oncotarget</i> , 2017, 8, 8807-8817.	0.8	68
7305	Programmed death-ligand 1 expression in gastric adenocarcinoma is a poor prognostic factor in a high CD8+ tumor infiltrating lymphocytes group. <i>Oncotarget</i> , 2016, 7, 80426-80434.	0.8	42
7306	Pharmacological interventions for melanoma: Comparative analysis using bayesian meta-analysis. <i>Oncotarget</i> , 2016, 7, 80855-80871.	0.8	2
7307	Correlation between anti-PD-L1 tumor concentrations and tumor-specific and nonspecific biomarkers in a melanoma mouse model. <i>Oncotarget</i> , 2016, 7, 76891-76901.	0.8	9
7308	Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy. <i>Oncotarget</i> , 2016, 7, 76604-76612.	0.8	93
7309	SCIB1, a hulgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors. <i>Oncotarget</i> , 2016, 7, 83088-83100.	0.8	16
7310	Targeted depletion of PIK3R2 induces regression of lung squamous cell carcinoma. <i>Oncotarget</i> , 2016, 7, 85063-85078.	0.8	16

#	ARTICLE	IF	CITATIONS
7311	The evaluation of immunotherapy and chemotherapy treatment on melanoma: a network meta-analysis. <i>Oncotarget</i> , 2016, 7, 81493-81511.	0.8	14
7312	Magic year for multiple myeloma therapeutics: Key takeaways from the ASH 2015 annual meeting. <i>Oncotarget</i> , 2017, 8, 10748-10759.	0.8	15
7313	Antitumor effect of combination of the inhibitors of two new oncotargets: proton pumps and reverse transcriptase. <i>Oncotarget</i> , 2017, 8, 4147-4155.	0.8	12
7314	T lymphocyte SHP2-deficiency triggers anti-tumor immunity to inhibit colitis-associated cancer in mice. <i>Oncotarget</i> , 2017, 8, 7586-7597.	0.8	23
7315	Potent CD4+ T cell-associated antitumor memory responses induced by trifunctional bispecific antibodies in combination with immune checkpoint inhibition. <i>Oncotarget</i> , 2017, 8, 4520-4529.	0.8	9
7316	Autologous reconstitution of human cancer and immune system <i>in vivo</i> . <i>Oncotarget</i> , 2017, 8, 2053-2068.	0.8	20
7317	Prognostic value and clinicopathological features of PD-1/PD-L1 expression with mismatch repair status and desmoplastic stroma in Chinese patients with pancreatic cancer. <i>Oncotarget</i> , 2017, 8, 9354-9365.	0.8	32
7318	Independent prognostic role of PD-L1 expression in patients with esophageal squamous cell carcinoma. <i>Oncotarget</i> , 2017, 8, 8315-8329.	0.8	19
7319	Therapeutic potential of the metabolic modulator phenformin in targeting the stem cell compartment in melanoma. <i>Oncotarget</i> , 2017, 8, 6914-6928.	0.8	38
7320	Immunotherapy: incorporation in the evolving paradigm of renal cancer management and future prospects. <i>Oncotarget</i> , 2017, 8, 17313-17327.	0.8	31
7321	Distinct patterns of infiltrating CD8+ T cells in HPV+ and CD68 macrophages in HPV- oropharyngeal squamous cell carcinomas are associated with better clinical outcome but PD-L1 expression is not prognostic. <i>Oncotarget</i> , 2017, 8, 14416-14427.	0.8	70
7322	A meta-analysis of HLA peptidome composition in different hematological entities: entity-specific dividing lines and <i>pan-leukemia</i> antigens. <i>Oncotarget</i> , 2017, 8, 43915-43924.	0.8	12
7323	PD-1 mRNA expression in peripheral blood cells and its modulation characteristics in cancer patients. <i>Oncotarget</i> , 2017, 8, 50782-50791.	0.8	10
7324	Targeting growth hormone receptor in human melanoma cells attenuates tumor progression and epithelial mesenchymal transition via suppression of multiple oncogenic pathways. <i>Oncotarget</i> , 2017, 8, 21579-21598.	0.8	36
7325	The miR-25-93-106b cluster regulates tumor metastasis and immune evasion via modulation of CXCL12 and PD-L1. <i>Oncotarget</i> , 2017, 8, 21609-21625.	0.8	72
7326	Synergistic effects of the immune checkpoint inhibitor CTLA-4 combined with the growth inhibitor lycorine in a mouse model of renal cell carcinoma. <i>Oncotarget</i> , 2017, 8, 21177-21186.	0.8	20
7327	Prognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma. <i>Oncotarget</i> , 2017, 8, 30175-30189.	0.8	69
7328	The correlation between programmed death-ligand 1 expression and driver gene mutations in NSCLC. <i>Oncotarget</i> , 2017, 8, 23517-23528.	0.8	26

#	ARTICLE	IF	CITATIONS
7329	Efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in targeted therapy of lung squamous cell carcinoma patients with EGFR mutation: a pooled analysis. <i>Oncotarget</i> , 2017, 8, 53675-53683.	0.8	9
7330	PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC). <i>Oncotarget</i> , 2017, 8, 26845-26857.	0.8	55
7331	The antitumor activity and preliminary modeling on the potential mechanism of action of human peroxiredoxin-5. <i>Oncotarget</i> , 2017, 8, 27189-27198.	0.8	5
7332	Tumor-derived IL-18 induces PD-1 expression on immunosuppressive NK cells in triple-negative breast cancer. <i>Oncotarget</i> , 2017, 8, 32722-32730.	0.8	73
7333	Combination GITR targeting/PD-1 blockade with vaccination drives robust antigen-specific antitumor immunity. <i>Oncotarget</i> , 2017, 8, 39117-39130.	0.8	21
7334	Breaking the crosstalk of the cellular tumorigenic network: Hypothesis for addressing resistances to targeted therapies in advanced NSCLC. <i>Oncotarget</i> , 2017, 8, 43555-43570.	0.8	10
7335	Phase I study of nivolumab combined with IFN- γ for patients with advanced melanoma. <i>Oncotarget</i> , 2017, 8, 71181-71187.	0.8	21
7336	Survival benefit of immune checkpoint inhibitors according to the histology in non-small-cell lung cancer: A meta-analysis and review. <i>Oncotarget</i> , 2017, 8, 51779-51785.	0.8	13
7337	Expression of glucose transporter 1 and prognosis in non-small cell lung cancer: a pooled analysis of 1665 patients. <i>Oncotarget</i> , 2017, 8, 60954-60961.	0.8	29
7338	Immune signature of metastatic breast cancer: Identifying predictive markers of immunotherapy response. <i>Oncotarget</i> , 2017, 8, 47400-47411.	0.8	21
7339	Genetic defects of the IRF1-mediated major histocompatibility complex class I antigen presentation pathway occur prevalently in the <i>JAK2</i> gene in non-small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 60975-60986.	0.8	15
7340	Accumulation of prohibitin is a common cellular response to different stressing stimuli and protects melanoma cells from ER stress and chemotherapy-induced cell death. <i>Oncotarget</i> , 2017, 8, 43114-43129.	0.8	19
7341	Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2017, 8, 44418-44433.	0.8	95
7342	Strategies targeting angiogenesis in advanced non-small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 53854-53872.	0.8	57
7343	PD-L1/PD-1 expression and tumor-infiltrating lymphocytes in conjunctival melanoma. <i>Oncotarget</i> , 2017, 8, 54722-54734.	0.8	39
7344	Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN. <i>Oncotarget</i> , 2017, 8, 53068-53083.	0.8	19
7345	Cancer and the kidney: dangerous liaisons or price paid for the progress in medicine?. <i>Oncotarget</i> , 2017, 8, 66601-66619.	0.8	22
7346	Interleukin-15 stimulates natural killer cell-mediated killing of both human pancreatic cancer and stellate cells. <i>Oncotarget</i> , 2017, 8, 56968-56979.	0.8	59

#	ARTICLE	IF	CITATIONS
7347	Promoter hypomethylation of NY-ESO-1, association with clinicopathological features and PD-L1 expression in non-small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 74036-74048.	0.8	13
7348	Regulation of human glioblastoma cell death by combined treatment of cannabidiol, ^{13}C -radiation and small molecule inhibitors of cell signaling pathways. <i>Oncotarget</i> , 2017, 8, 74068-74095.	0.8	34
7349	Prognostic significance of PD-L1 expression and 18F-FDG PET/CT in surgical pulmonary squamous cell carcinoma. <i>Oncotarget</i> , 2017, 8, 51630-51640.	0.8	54
7350	Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer. <i>Oncotarget</i> , 2017, 8, 97671-97682.	0.8	254
7351	Effectiveness and safety of PD-1/PD-L1 inhibitors in the treatment of solid tumors: a systematic review and meta-analysis. <i>Oncotarget</i> , 2017, 8, 59901-59914.	0.8	64
7352	<i>Cblb</i> -deficient T cells are less susceptible to PD-L1-mediated inhibition. <i>Oncotarget</i> , 2017, 8, 41841-41853.	0.8	19
7353	Pseudoprogression in microsatellite instability-high colorectal cancer during treatment with combination T cell mediated immunotherapy: a case report and literature review. <i>Oncotarget</i> , 2017, 8, 57889-57897.	0.8	26
7354	Tumor reductive therapies and antitumor immunity. <i>Oncotarget</i> , 2017, 8, 55736-55749.	0.8	11
7355	HNSCC subverts PBMCs to secrete soluble products that promote tumor cell proliferation. <i>Oncotarget</i> , 2017, 8, 60860-60874.	0.8	9
7356	Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2017, 8, 97920-97927.	0.8	69
7357	Chemosensitivity-directed therapy compared to dacarbazine in chemo-naive advanced metastatic melanoma: a multicenter randomized phase-3 DeCOG trial. <i>Oncotarget</i> , 2017, 8, 76029-76043.	0.8	7
7358	Analyses of selected safety endpoints in phase 1 and late-phase clinical trials of anti-PD-1 and PD-L1 inhibitors: prediction of immune-related toxicities. <i>Oncotarget</i> , 2017, 8, 67782-67789.	0.8	18
7359	Significant benefit of Nivolumab treating PD-L1 positive metastatic pulmonary carcinosarcoma: a case report and literature review. <i>Oncotarget</i> , 2017, 8, 96453-96459.	0.8	8
7360	Radiation alters PD-L1/NKG2D ligand levels in lung cancer cells and leads to immune escape from NK cell cytotoxicity via IL-6-MEK/Erk signaling pathway. <i>Oncotarget</i> , 2017, 8, 80506-80520.	0.8	59
7361	Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism. <i>Oncotarget</i> , 2017, 8, 91841-91859.	0.8	28
7362	The immune checkpoint molecule V-set Ig domain-containing 4 is an independent prognostic factor for multiple myeloma. <i>Oncotarget</i> , 2017, 8, 58122-58132.	0.8	13
7363	Secreted protein acidic and rich in cysteine (SPARC) induces cell migration and epithelial mesenchymal transition through WNK1/snail in non-small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 63691-63702.	0.8	52
7364	Characterization and functional analysis of a slow-cycling subpopulation in colorectal cancer enriched by cell cycle inducer combined chemotherapy. <i>Oncotarget</i> , 2017, 8, 78466-78479.	0.8	17

#	ARTICLE	IF	CITATIONS
7365	PD-1/PD-L1 antibodies efficacy and safety versus docetaxel monotherapy in advanced NSCLC patients after first-line treatment option: systems assessment. <i>Oncotarget</i> , 2017, 8, 59677-59689.	0.8	7
7366	Effective antitumor peptide vaccines can induce severe autoimmune pathology. <i>Oncotarget</i> , 2017, 8, 70317-70331.	0.8	12
7367	Immunohistochemical assays incorporating SP142 and 22C3 monoclonal antibodies for detection of PD-L1 expression in NSCLC patients with known status of EGFR and ALK genes. <i>Oncotarget</i> , 2017, 8, 64283-64293.	0.8	9
7368	Excellent response to chemotherapy post immunotherapy. <i>Oncotarget</i> , 2017, 8, 91795-91802.	0.8	51
7369	Impact of mismatch-repair deficiency on the colorectal cancer immune microenvironment. <i>Oncotarget</i> , 2017, 8, 85526-85536.	0.8	21
7370	Concordance of programmed death-ligand 1 expression between primary and metastatic non-small cell lung cancer by immunohistochemistry and RNA <i>in situ</i> hybridization. <i>Oncotarget</i> , 2017, 8, 87234-87243.	0.8	17
7371	Radiotherapy prolongs the survival of advanced non-small-cell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEBev). <i>Oncotarget</i> , 2017, 8, 75904-75913.	0.8	23
7372	Hitting the nail on the head: combining oncolytic adenovirus-mediated virotherapy and immunomodulation for the treatment of glioma. <i>Oncotarget</i> , 2017, 8, 89391-89405.	0.8	25
7373	PD-L1 expression and CD8+ tumor-infiltrating lymphocytes are associated with ALK rearrangement and clinicopathological features in inflammatory myofibroblastic tumors. <i>Oncotarget</i> , 2017, 8, 89465-89474.	0.8	13
7374	The role of weekly nanoparticle albumin bound paclitaxel monotherapy as second line or later treatment for advanced NSCLC in China. <i>Oncotarget</i> , 2017, 8, 87442-87454.	0.8	6
7375	Harness the synergy between targeted therapy and immunotherapy: what have we learned and where are we headed?. <i>Oncotarget</i> , 2017, 8, 86969-86984.	0.8	5
7376	<i>Solanum incanum</i> extract (SR-T100) induces melanoma cell apoptosis and inhibits established lung metastasis. <i>Oncotarget</i> , 2017, 8, 103509-103517.	0.8	30
7377	Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer. <i>Oncotarget</i> , 2017, 8, 103117-103128.	0.8	84
7378	Functions of pancreatic stellate cell-derived soluble factors in the microenvironment of pancreatic ductal carcinoma. <i>Oncotarget</i> , 2017, 8, 102721-102738.	0.8	41
7379	Expression of PD-1/PD-L1 and PD-L2 in peripheral T-cells from non-small cell lung cancer patients. <i>Oncotarget</i> , 2017, 8, 101994-102005.	0.8	72
7380	Radiotherapy: the key to immunotherapy ignition?. <i>Oncotarget</i> , 2017, 8, 93307-93308.	0.8	3
7381	Clinical characteristics and programmed cell death ligand-1 expression in adenocarcinoma <i>in situ</i> and minimally invasive adenocarcinoma of lung. <i>Oncotarget</i> , 2017, 8, 97801-97810.	0.8	7
7382	The sexist behaviour of immune checkpoint inhibitors in cancer therapy?. <i>Oncotarget</i> , 2017, 8, 99336-99346.	0.8	76

#	ARTICLE	IF	CITATIONS
7383	PD-L1 expression in tumor tissue and peripheral blood of patients with oral squamous cell carcinoma. <i>Oncotarget</i> , 2017, 8, 112584-112597.	0.8	37
7384	Checkpoint inhibitor induced cardiotoxicity: managing the drawbacks of our newest agents against cancer. <i>Oncotarget</i> , 2017, 8, 106165-106166.	0.8	10
7385	Changes in PD-L1 expression according to tumor infiltrating lymphocytes of acquired EGFR-TKI resistant EGFR-mutant non-small-cell lung cancer. <i>Oncotarget</i> , 2017, 8, 107630-107639.	0.8	16
7386	Clinical significance of YAP1 activation in head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2017, 8, 111130-111143.	0.8	34
7387	Programmed death-ligand 1 expression according to epidermal growth factor receptor mutation status in pretreated non-small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 113807-113816.	0.8	8
7388	Comprehensive immunohistochemical analysis of PD-L1 shows scarce expression in castration-resistant prostate cancer. <i>Oncotarget</i> , 2018, 9, 10284-10293.	0.8	44
7389	Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors. <i>Oncotarget</i> , 2017, 8, 114268-114280.	0.8	169
7390	Clinical and molecular features of innate and acquired resistance to anti-PD-1/PD-L1 therapy in lung cancer. <i>Oncotarget</i> , 2018, 9, 4375-4384.	0.8	26
7391	The anti-rheumatic drug, leflunomide, synergizes with MEK inhibition to suppress melanoma growth. <i>Oncotarget</i> , 2018, 9, 3815-3829.	0.8	17
7392	Implications of KRAS mutations in acquired resistance to treatment in NSCLC. <i>Oncotarget</i> , 2018, 9, 6630-6643.	0.8	42
7393	Prognostic value of PD -L1 expression in patients with primary solid tumors. <i>Oncotarget</i> , 2018, 9, 5058-5072.	0.8	47
7394	Targeted drugs for systemic therapy of lung cancer with brain metastases. <i>Oncotarget</i> , 2018, 9, 5459-5472.	0.8	47
7395	Current status and perspectives in immunotherapy for metastatic melanoma. <i>Oncotarget</i> , 2018, 9, 12452-12470.	0.8	73
7396	Cancer immunogenomic approach to neoantigen discovery in a checkpoint blockade responsive murine model of oral cavity squamous cell carcinoma. <i>Oncotarget</i> , 2018, 9, 4109-4119.	0.8	34
7397	Microsatellite instability is a biomarker for immune checkpoint inhibitors in endometrial cancer. <i>Oncotarget</i> , 2018, 9, 5652-5664.	0.8	105
7398	Prognostic value of PD-L1 in esophageal squamous cell carcinoma: a meta-analysis. <i>Oncotarget</i> , 2018, 9, 13920-13933.	0.8	60
7399	T cell infiltration into Ewing sarcomas is associated with local expression of immune-inhibitory HLA-G. <i>Oncotarget</i> , 2018, 9, 6536-6549.	0.8	37
7400	Determinants of variability of five programmed death ligand-1 immunohistochemistry assays in non-small cell lung cancer samples. <i>Oncotarget</i> , 2018, 9, 6841-6851.	0.8	17

#	ARTICLE	IF	CITATIONS
7401	A comparative study of PD-L1 immunohistochemical assays with four reliable antibodies in thymic carcinoma. <i>Oncotarget</i> , 2018, 9, 6993-7009.	0.8	31
7402	Efficacy of PD-1/PD-L1 inhibitors against pretreated advanced cancer: a systematic review and meta-analysis. <i>Oncotarget</i> , 2018, 9, 11846-11857.	0.8	2
7403	Effectiveness of anti-PD-1/PD-L1 antibodies in urothelial carcinoma patients with different PD-L1 expression levels: a meta-analysis. <i>Oncotarget</i> , 2018, 9, 12400-12407.	0.8	13
7404	Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancer. <i>Oncotarget</i> , 2018, 9, 14268-14284.	0.8	12
7405	Molecular and clinical features of the <i>TP53</i> signature gene expression profile in early-stage breast cancer. <i>Oncotarget</i> , 2018, 9, 14193-14206.	0.8	11
7406	Correlation of <i>MET</i> gene amplification and <i>TP53</i> mutation with PD-L1 expression in non-small cell lung cancer. <i>Oncotarget</i> , 2018, 9, 13682-13693.	0.8	39
7407	PD-L1 expression and presence of TILs in small intestinal neuroendocrine tumours. <i>Oncotarget</i> , 2018, 9, 14922-14938.	0.8	29
7408	Affinity-purified DNA-based mutation profiles of endometriosis-related ovarian neoplasms in Japanese patients. <i>Oncotarget</i> , 2018, 9, 14754-14763.	0.8	19
7409	Immunotherapy in mucosal melanoma: a case report and review of the literature. <i>Oncotarget</i> , 2018, 9, 17971-17977.	0.8	19
7410	A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancer. <i>Oncotarget</i> , 2018, 9, 18985-18996.	0.8	83
7411	PD-L1 expression in medulloblastoma: an evaluation by subgroup. <i>Oncotarget</i> , 2018, 9, 19177-19191.	0.8	45
7412	Clinical characteristics of non-small cell lung cancer harboring mutations in exon 20 of <i>EGFR</i> or <i>HER2</i> . <i>Oncotarget</i> , 2018, 9, 21132-21140.	0.8	24
7413	Prognostic impact of programmed cell death ligand 1 (PD-L1) expression and its association with epithelial-mesenchymal transition in extrahepatic cholangiocarcinoma. <i>Oncotarget</i> , 2018, 9, 20034-20047.	0.8	32
7414	Four immunohistochemical assays to measure the PD-L1 expression in malignant pleural mesothelioma. <i>Oncotarget</i> , 2018, 9, 20769-20780.	0.8	20
7415	A pilot study of peptide vaccines for VEGF receptor 1 and 2 in patients with recurrent/progressive high grade glioma. <i>Oncotarget</i> , 2018, 9, 21569-21579.	0.8	20
7416	Indoleamine 2,3-dioxygenase 1 and overall survival of patients diagnosed with esophageal cancer. <i>Oncotarget</i> , 2018, 9, 23482-23493.	0.8	17
7417	Cofilin-1 levels and intracellular localization are associated with melanoma prognosis in a cohort of patients. <i>Oncotarget</i> , 2018, 9, 24097-24108.	0.8	11
7418	Quantitative monitoring of circulating tumor DNA predicts response of cutaneous metastatic melanoma to anti-PD1 immunotherapy. <i>Oncotarget</i> , 2018, 9, 25265-25276.	0.8	46

#	ARTICLE	IF	CITATIONS
7419	PD-L1 is expressed on human platelets and is affected by immune checkpoint therapy. <i>Oncotarget</i> , 2018, 9, 27460-27470.	0.8	53
7420	An NFÎB-dependent mechanism of tumor cell plasticity and lateral transmission of aggressive features. <i>Oncotarget</i> , 2018, 9, 26679-26700.	0.8	14
7421	Docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte-colony stimulating factor for pretreated non-small cell lung cancer. <i>Oncotarget</i> , 2018, 9, 27789-27796.	0.8	9
7422	Real world experience in low-dose ipilimumab in combination with PD-1 blockade in advanced melanoma patients. <i>Oncotarget</i> , 2018, 9, 28903-28909.	0.8	37
7423	The inhibition of malignant melanoma cell invasion of bone by the TLR7 agonist R848 is dependent upon pro-inflammatory cytokines produced by bone marrow macrophages. <i>Oncotarget</i> , 2018, 9, 29934-29943.	0.8	8
7424	PD-L1 expression comparison between primary and relapsed non-small cell lung carcinoma using whole sections and clone SP263. <i>Oncotarget</i> , 2018, 9, 30465-30471.	0.8	26
7425	A potential novel option for cancer immunotherapy - TLR7 stimulation inhibits malignant melanoma bone invasion. <i>Oncotarget</i> , 2018, 9, 31792-31792.	0.8	2
7426	Immune checkpoint inhibitor re-challenge in patients with advanced non-small cell lung cancer. <i>Oncotarget</i> , 2018, 9, 32298-32304.	0.8	53
7427	CDK4/6 inhibition stabilizes disease in patients with p16-null non-small cell lung cancer and is synergistic with mTOR inhibition. <i>Oncotarget</i> , 2018, 9, 37352-37366.	0.8	33
7428	STAT1 deficiency supports PD-1/PD-L1 signaling resulting in dysfunctional TNFÎ± mediated immune responses in a model of NSCLC. <i>Oncotarget</i> , 2018, 9, 37157-37172.	0.8	10
7429	Inhibition of ATM kinase upregulates levels of cell death induced by cannabidiol and Î³-irradiation in human glioblastoma cells. <i>Oncotarget</i> , 2019, 10, 825-846.	0.8	21
7430	Reliable evaluation of tumor-infiltrating lymphocytes in pancreatic cancer tissue biopsies. <i>Oncotarget</i> , 2019, 10, 1149-1159.	0.8	10
7431	Why is immunotherapy for glioblastoma "lagging". <i>Oncotarget</i> , 2019, 10, 1228-1229.	0.8	2
7432	Co-inhibitory T cell receptor KLRG1: human cancer expression and efficacy of neutralization in murine cancer models. <i>Oncotarget</i> , 2019, 10, 1399-1406.	0.8	35
7433	Next generation sequencing driven successful combined treatment with laparoscopic surgery and immunotherapy for relapsed stage IVB cervical and synchronous stage IV lung cancer. <i>Oncotarget</i> , 2019, 10, 2012-2021.	0.8	3
7434	Sustained partial remission of a metastatic NEN using off-label immunotherapy with pembrolizumab. <i>Oncotarget</i> , 2019, 10, 3302-3311.	0.8	6
7435	Evaluation of a ConvitVax/anti-PD-1 combined immunotherapy for breast cancer treatment. <i>Oncotarget</i> , 2019, 10, 6546-6560.	0.8	2
7436	Tumor mutational burden in lung cancer: a systematic literature review. <i>Oncotarget</i> , 2019, 10, 6604-6622.	0.8	72

#	ARTICLE	IF	CITATIONS
7437	Clinicopathological relevance of tumor expression of NK group 2 member D ligands in resected non-small cell lung cancer. <i>Oncotarget</i> , 2019, 10, 6805-6815.	0.8	8
7438	The impact of systemic precision medicine and immunotherapy treatments on brain metastases. <i>Oncotarget</i> , 2019, 10, 6739-6753.	0.8	13
7439	Adoptive cell therapy in combination with checkpoint inhibitors in ovarian cancer. <i>Oncotarget</i> , 2020, 11, 2092-2105.	0.8	64
7440	Rapid onset type 1 diabetes with anti-PD-1 directed therapy. <i>Oncotarget</i> , 2020, 11, 2740-2746.	0.8	17
7441	A novel format for recombinant antibody-interleukin-2 fusion proteins exhibits superior tumor-targeting properties <i>in vivo</i> . <i>Oncotarget</i> , 2020, 11, 3698-3711.	0.8	8
7442	A comprehensive analysis of clinical trials in pancreatic cancer: what is coming down the pike?. <i>Oncotarget</i> , 2020, 11, 3489-3501.	0.8	30
7443	Biomarkers and novel therapeutic approaches for diffuse large B-cell lymphoma in the era of precision medicine. <i>Oncotarget</i> , 2020, 11, 4045-4073.	0.8	12
7444	PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma. <i>Oncotarget</i> , 2015, 6, 3479-3492.	0.8	146
7445	A direct plasma assay of circulating microRNA-210 of hypoxia can identify early systemic metastasis recurrence in melanoma patients. <i>Oncotarget</i> , 2015, 6, 7053-7064.	0.8	72
7446	Active secretion of CXCL10 and CCL5 from colorectal cancer microenvironments associates with GranzymeB+ CD8+ T-cell infiltration. <i>Oncotarget</i> , 2015, 6, 2981-2991.	0.8	128
7447	Inhibition of tumor growth by a newly-identified activator for epidermal fatty acid binding protein. <i>Oncotarget</i> , 2015, 6, 7815-7827.	0.8	23
7448	Attenuated mutant strain of <i>Salmonella</i> Typhimurium lacking the ZnuABC transporter contrasts tumor growth promoting anti-cancer immune response. <i>Oncotarget</i> , 2015, 6, 17648-17660.	0.8	27
7449	Genomic amplification of 9p24.1 targeting <i>JAK2</i> , <i>PD-L1</i> , and <i>PD-L2</i> is enriched in high-risk triple negative breast cancer. <i>Oncotarget</i> , 2015, 6, 26483-26493.	0.8	118
7450	Analysis of SDHD promoter mutations in various types of melanoma. <i>Oncotarget</i> , 2015, 6, 25868-25882.	0.8	9
7451	PD-L1 is remarkably over-expressed in EBV-associated pulmonary lymphoepithelioma-like carcinoma and related to poor disease-free survival. <i>Oncotarget</i> , 2015, 6, 33019-33032.	0.8	69
7452	Extracting tumor tissue immune status from expression profiles: correlating renal cancer prognosis with tumor-associated immunome. <i>Oncotarget</i> , 2015, 6, 33191-33205.	0.8	3
7453	The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients. <i>Oncotarget</i> , 2015, 6, 19393-19404.	0.8	61
7454	Vesicular stomatitis virus expressing interferon- β is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer. <i>Oncotarget</i> , 2015, 6, 33165-33177.	0.8	87

#	ARTICLE	IF	CITATIONS
7455	Morphometric analysis of immunoselection against hyperploid cancer cells. <i>Oncotarget</i> , 2015, 6, 41204-41215.	0.8	13
7456	Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases. <i>Oncotarget</i> , 2015, 6, 40836-40849.	0.8	106
7457	Phase 1b study of lenvatinib (E7080) in combination with temozolomide for treatment of advanced melanoma. <i>Oncotarget</i> , 2015, 6, 43127-43134.	0.8	19
7458	Intra-tumor AvidinOX allows efficacy of low dose systemic biotinylated Cetuximab in a model of head and neck cancer. <i>Oncotarget</i> , 2016, 7, 914-928.	0.8	5
7459	Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma. <i>Oncotarget</i> , 2016, 7, 1486-1499.	0.8	212
7460	Adenomatous polyposis coli genotype-dependent toll-like receptor 4 activity in colon cancer. <i>Oncotarget</i> , 2016, 7, 7761-7772.	0.8	2
7461	Expression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomas. <i>Oncotarget</i> , 2016, 7, 8944-8955.	0.8	60
7462	Human melanoma immunotherapy using tumor antigen-specific T cells generated in humanized mice. <i>Oncotarget</i> , 2016, 7, 6448-6459.	0.8	38
7463	PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2016, 7, 15901-15914.	0.8	125
7464	PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis. <i>Oncotarget</i> , 2016, 7, 19738-19747.	0.8	134
7465	The prevalence and clinicopathological features of programmed death-ligand 1 (PD-L1) expression: a pooled analysis of literatures. <i>Oncotarget</i> , 2016, 7, 15033-15046.	0.8	24
7466	<i>CD274/PD-L1</i> gene amplification and PD-L1 protein expression are common events in squamous cell carcinoma of the oral cavity. <i>Oncotarget</i> , 2016, 7, 12024-12034.	0.8	141
7467	CD40-activated B cells induce anti-tumor immunity <i>in vivo</i> . <i>Oncotarget</i> , 2017, 8, 27740-27753.	0.8	43
7468	Squamous cell carcinomas of the lung and of the head and neck: new insights on molecular characterization. <i>Oncotarget</i> , 2016, 7, 25050-25063.	0.8	6
7469	The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status. <i>Oncotarget</i> , 2016, 7, 35803-35812.	0.8	9
7470	From kinetics and cellular cooperations to cancer immunotherapies. <i>Oncotarget</i> , 2016, 7, 44779-44789.	0.8	3
7471	Signal transducer and activator of transcription 3 in myeloid-derived suppressor cells: an opportunity for cancer therapy. <i>Oncotarget</i> , 0, 7, 42698-42715.	0.8	34
7472	Neuraminidase-1: A novel therapeutic target in multistage tumorigenesis. <i>Oncotarget</i> , 2016, 7, 40860-40881.	0.8	60

#	ARTICLE	IF	CITATIONS
7473	B7-H3 as a promising target for cytotoxicity T cell in human cancer therapy. <i>Oncotarget</i> , 2016, 7, 29480-29491.	0.8	49
7474	Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells. <i>Oncotarget</i> , 2016, 7, 33350-33362.	0.8	56
7475	Programmed death-ligand-1 expression in advanced gastric cancer detected with RNA <i>in situ</i> hybridization and its clinical significance. <i>Oncotarget</i> , 2016, 7, 39671-39679.	0.8	37
7476	Using lymph node swelling as a potential biomarker for successful vaccination. <i>Oncotarget</i> , 2016, 7, 35655-35669.	0.8	11
7477	Profiling the dynamic expression of checkpoint molecules on cytokine-induced killer cells from non-small-cell lung cancer patients. <i>Oncotarget</i> , 2016, 7, 43604-43615.	0.8	45
7478	Treatment with the nitric oxide synthase inhibitor L-NAME provides a survival advantage in a mouse model of <i>Kras</i> mutation-positive, non-small cell lung cancer. <i>Oncotarget</i> , 0, 7, 42385-42392.	0.8	16
7479	Medical management of malignant melanoma. <i>Australian Prescriber</i> , 2015, 38, 74-78.	0.5	24
7480	New drugs: Pembrolizumab. <i>Australian Prescriber</i> , 2015, 38, 180-182.	0.5	2
7481	Refractory hypotension due to Nivolumab-induced adrenal insufficiency. <i>Nagoya Journal of Medical Science</i> , 2018, 80, 285-288.	0.6	9
7482	Costimulation and Pancreatic Autoimmunity: The PD-1/PD-L Conundrum. <i>Review of Diabetic Studies</i> , 2006, 3, 6-6.	0.5	10
7483	Linking tyrosine kinase inhibitor-mediated inflammation with normal epithelial cell homeostasis and tumor therapeutic responses. , 2018, 1, 118-125.		13
7484	Resistance mechanisms in melanoma to immuneoncologic therapy with checkpoint inhibitors. , 2019, 2, 744-761.		3
7485	Drug resistance in cancer immunotherapy: new strategies to improve checkpoint inhibitor therapies. , 2019, 2, 980-993.		9
7486	Cell-mediated immune resistance in cancer. , 2020, 3, 232-251.		9
7487	Resistance to chemoimmunotherapy in non-small-cell lung cancer. , 2020, 3, 445-453.		3
7488	A review of mechanisms of resistance to immune checkpoint inhibitors and potential strategies for therapy. , 2020, 3, 252-275.		18
7489	Biomarkers of resistance to immune checkpoint inhibitors in non-small-cell lung cancer: myth or reality?. , 2020, 3, 276-286.		3
7490	Decoding cancer's camouflage: epithelial-mesenchymal plasticity in resistance to immune checkpoint blockade. , 2020, 3, 832-853.		7

#	ARTICLE	IF	CITATIONS
7491	Use of biologics and chemotherapy in patients with inflammatory bowel diseases and cancer. <i>Annals of Gastroenterology</i> , 2016, 29, 127-36.	0.4	8
7492	Current applications and future prospects of nanotechnology in cancer immunotherapy. <i>Cancer Biology and Medicine</i> , 2019, 16, 487-497.	1.4	40
7493	The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy. <i>Cancer Biology and Medicine</i> , 2019, 16, 655-670.	1.4	95
7494	Tobacco, air pollution, environmental carcinogenesis, and thoughts on conquering strategies of lung cancer. <i>Cancer Biology and Medicine</i> , 2019, 16, 700-713.	1.4	33
7495	The correlation and overlaps between PD-L1 expression and classical genomic aberrations in Chinese lung adenocarcinoma patients: a single center case series. <i>Cancer Biology and Medicine</i> , 2019, 16, 811-821.	1.4	14
7496	T Cell Metabolism in Cancer Immunotherapy. <i>Immunometabolism</i> , 2020, 2, .	0.7	16
7497	Comparative expression analysis of PD-1, PD-L1, and CD8A in lung adenocarcinoma. <i>Annals of Translational Medicine</i> , 2020, 8, 1478-1478.	0.7	17
7498	Neferine induces p38 MAPK/JNK1/2 activation to modulate melanoma proliferation, apoptosis, and oxidative stress. <i>Annals of Translational Medicine</i> , 2020, 8, 1643-1643.	0.7	12
7499	What does the future hold for immunotherapy in cancer?. <i>Annals of Translational Medicine</i> , 2016, 4, 177-177.	0.7	9
7500	Revisiting of cancer vaccine?â€”Specific immunotherapy comes to field with the biomarker. <i>Annals of Translational Medicine</i> , 2016, 4, 179-179.	0.7	1
7501	Uveal melanoma as a target for immune-therapy. <i>Annals of Translational Medicine</i> , 2016, 4, 172-172.	0.7	63
7502	Nivolumab for advanced non-small cell lung cancer: an immunologically-mediated tumor checkout. <i>Annals of Translational Medicine</i> , 2016, 4, 201-201.	0.7	5
7503	Elderly selection on geriatric index assessment. <i>Annals of Translational Medicine</i> , 2016, 4, 245-245.	0.7	1
7504	The European Organization for Research and Treatment of Cancer perspective on designing clinical trials with immune therapeutics. <i>Annals of Translational Medicine</i> , 2016, 4, 267-267.	0.7	17
7505	Melanoma immunotherapy dominates the field. <i>Annals of Translational Medicine</i> , 2016, 4, 269-269.	0.7	19
7506	DNA damage, tumor mutational load and their impact on immune responses against cancer. <i>Annals of Translational Medicine</i> , 2016, 4, 264-264.	0.7	35
7507	Immunotherapy in small-cell lung cancer: at what point are we?. <i>Annals of Translational Medicine</i> , 2016, 4, S5-S5.	0.7	3
7508	Tumor vaccines and cellular immunotherapies. <i>Annals of Translational Medicine</i> , 2016, 4, S24-S24.	0.7	3

#	ARTICLE	IF	CITATIONS
7509	Acquired resistance mechanisms to immunotherapy. <i>Annals of Translational Medicine</i> , 2016, 4, 547-547.	0.7	2
7510	Going into BATTLE: umbrella and basket clinical trials to accelerate the study of biomarker-based therapies. <i>Annals of Translational Medicine</i> , 2016, 4, 529-529.	0.7	11
7511	The KEY to the end of chemotherapy in non-small cell lung cancer?. <i>Annals of Translational Medicine</i> , 2017, 5, 166-166.	0.7	4
7512	Novel immunotherapy clinical trials in malignant pleural mesothelioma. <i>Annals of Translational Medicine</i> , 2017, 5, 245-245.	0.7	6
7513	Atezolizumab in non-small cell lung cancer: the era of precision immuno-oncology. <i>Annals of Translational Medicine</i> , 2017, 5, 265-265.	0.7	5
7514	Neopterin as a biomarker of immune response in cancer patients. <i>Annals of Translational Medicine</i> , 2017, 5, 280-280.	0.7	42
7515	Beyond PD-L1 testing-emerging biomarkers for immunotherapy in non-small cell lung cancer. <i>Annals of Translational Medicine</i> , 2017, 5, 376-376.	0.7	79
7516	PD-L1 as a biomarker in NSCLC: challenges and future directions. <i>Annals of Translational Medicine</i> , 2017, 5, 375-375.	0.7	35
7517	EGFR mutation positive non-small cell lung cancer: can we identify predictors of benefit from immune checkpoint inhibitors. <i>Annals of Translational Medicine</i> , 2017, 5, 424-424.	0.7	5
7518	Immune checkpoint pathways in non-small cell lung cancer. <i>Annals of Translational Medicine</i> , 2018, 6, 88-88.	0.7	13
7519	The emerging treatment landscape of advanced non-small cell lung cancer. <i>Annals of Translational Medicine</i> , 2018, 6, 138-138.	0.7	29
7520	Breakthroughs in the treatment of advanced squamous-cell NSCLC: not the neglected sibling anymore?. <i>Annals of Translational Medicine</i> , 2018, 6, 143-143.	0.7	13
7521	Emerging application of genomics-guided therapeutics in personalized lung cancer treatment. <i>Annals of Translational Medicine</i> , 2018, 6, 160-160.	0.7	22
7522	Third-generation tyrosine kinase inhibitor in the treatment of epidermal growth factor receptor mutated squamous cell lung cancer: a tailored therapy approach. <i>Annals of Translational Medicine</i> , 2019, 7, 14-14.	0.7	11
7523	Is the onset of adverse effects of immunotherapy always bad news for the patients? "certainly not!". <i>Annals of Translational Medicine</i> , 2019, 7, S5-S5.	0.7	5
7524	Is an immune checkpoint inhibitor really a hopeless therapeutic choice for EGFR-mutant non-small cell lung cancer (NSCLC) patients?. <i>Annals of Translational Medicine</i> , 2019, 7, S32-S32.	0.7	1
7525	Systemic therapy of elderly patients with advanced non-small cell lung cancer "individualized treatment is key. <i>Annals of Translational Medicine</i> , 2019, 7, S48-S48.	0.7	3
7526	The role of endobronchial ultrasound transbronchial needle aspiration for programmed death ligand 1 testing and next generation sequencing in advanced non-small cell lung cancer. <i>Annals of Translational Medicine</i> , 2019, 7, 351-351.	0.7	14

#	ARTICLE	IF	CITATIONS
7527	Combining immunotherapy and epidermal growth factor receptor kinase inhibitors: worth the risk?. <i>Annals of Translational Medicine</i> , 2019, 7, S76-S76.	0.7	5
7528	Pembrolizumab plus ipilimumab or pegylated interferon alfa-2b for patients with melanoma or renal cell carcinoma: take new drugs but keep the old?. <i>Annals of Translational Medicine</i> , 2019, 7, S95-S95.	0.7	2
7529	Immunotherapy for mucosal melanoma. <i>Annals of Translational Medicine</i> , 2019, 7, S118-S118.	0.7	23
7530	Pembrolizumab monotherapy for PD-L1 $\geq 50\%$ non-small cell lung cancer, undisputed first choice?. <i>Annals of Translational Medicine</i> , 2019, 7, S140-S140.	0.7	11
7531	Are we facing a cure in lung cancer? KEYNOTE-001 insights. <i>Annals of Translational Medicine</i> , 2019, 7, S215-S215.	0.7	7
7532	JS001, an anti-PD-1 mAb for advanced triple negative breast cancer patients after multi-line systemic therapy in a phase I trial. <i>Annals of Translational Medicine</i> , 2019, 7, 435-435.	0.7	17
7533	Pre-treatment systemic immune-inflammation represents a prognostic factor in patients with advanced non-small cell lung cancer. <i>Annals of Translational Medicine</i> , 2019, 7, 572-572.	0.7	28
7534	Resistance patterns to anti-PD-1 therapy in metastatic melanoma. <i>Chinese Clinical Oncology</i> , 2016, 5, 75-75.	0.4	3
7535	Rational combinations of immunotherapy for pancreatic ductal adenocarcinoma. <i>Chinese Clinical Oncology</i> , 2017, 6, 31-31.	0.4	12
7536	Challenges of PD-L1 testing in non-small cell lung cancer and beyond. <i>Journal of Thoracic Disease</i> , 2020, 12, 4541-4548.	0.6	13
7537	High CCR4 expression in the tumor microenvironment is a poor prognostic indicator in lung adenocarcinoma. <i>Journal of Thoracic Disease</i> , 2018, 10, 4741-4750.	0.6	20
7538	Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 $\geq 50\%$ who progress on first-line immunotherapy: real-world data from a European cohort. <i>Journal of Thoracic Disease</i> , 2019, 11, 4972-4981.	0.6	35
7539	Tissue-specific tumour microenvironments are an emerging determinant of immunotherapy responses. <i>Journal of Thoracic Disease</i> , 2020, 12, 4504-4509.	0.6	3
7540	ERH overexpression is associated with decreased cell migration and invasion and a good prognosis in gastric cancer. <i>Translational Cancer Research</i> , 2020, 9, 5281-5291.	0.4	6
7541	Epigenetic regulation of PD-L1 expression and pancreatic cancer response to checkpoint immunotherapy. <i>Translational Cancer Research</i> , 2017, 6, S652-S654.	0.4	8
7542	Smooth sailing for immunotherapy for unresectable stage III non-small cell lung cancer: the PACIFIC study. <i>Translational Cancer Research</i> , 2018, 7, S16-S20.	0.4	4
7543	Application of Bayesian predictive probability for interim futility analysis in single-arm phase II trial. <i>Translational Cancer Research</i> , 2019, 8, S404-S420.	0.4	5
7544	Predictive values of genomic variation, tumor mutational burden, and PD-L1 expression in advanced lung squamous cell carcinoma treated with immunotherapy. <i>Translational Lung Cancer Research</i> , 2020, 9, 2367-2367.	1.3	20

#	ARTICLE	IF	CITATIONS
7545	Immunotherapy beyond progression in patients with advanced non-small cell lung cancer. Translational Lung Cancer Research, 2020, 9, 2391-2400.	1.3	19
7546	Integrating immune checkpoint inhibitors and targeted therapies in the treatment of early stage non-small cell lung cancer: a narrative review. Translational Lung Cancer Research, 2020, 9, 2656-2673.	1.3	16
7547	Is there any place for immune-checkpoint inhibitors in the treatment algorithm of fusion-driven non-small cell lung cancer? a literature review. Translational Lung Cancer Research, 2020, 9, 2674-2685.	1.3	2
7548	Expert consensus on neoadjuvant immunotherapy for non-small cell lung cancer. Translational Lung Cancer Research, 2020, 9, 2696-2715.	1.3	43
7549	Harnessing the potential synergy of combining radiation therapy and immunotherapy for thoracic malignancies. Translational Lung Cancer Research, 2007, 6, 109-112.	1.3	10
7550	A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel. Translational Lung Cancer Research, 2018, 7, 428-436.	1.3	7
7551	Characterization of PD-L1 protein expression and CD8+ tumor-infiltrating lymphocyte density, and their associations with clinical outcome in small-cell lung cancer. Translational Lung Cancer Research, 2019, 8, 748-759.	1.3	22
7552	Nivolumab resulting in persistently elevated troponin levels despite clinical remission of myocarditis and myositis in a patient with malignant pleural mesothelioma: case report. Translational Lung Cancer Research, 2020, 9, 360-365.	1.3	13
7553	Challenges of evaluating immunotherapy efficacy in solid tumors. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2019, 31, 853-861.	0.7	8
7554	Integration of stereotactic radiosurgery or whole brain radiation therapy with immunotherapy for treatment of brain metastases. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2020, 32, 448-466.	0.7	6
7555	Association of programmed death ligand 1 expression with prognosis among patients with ten uncommon advanced cancers. Future Science OA, 2020, 6, FSO616.	0.9	10
7556	<p>Economic Evaluation of Single versus Combination Immuno-Oncology Therapies: Application of a Novel Modelling Approach in Metastatic Melanoma</p>. ClinicoEconomics and Outcomes Research, 2020, Volume 12, 241-252.	0.7	4
7557	<p>Advanced Squamous Cell Carcinoma of the Lung: Current Treatment Approaches and the Role of Afatinib</p>. OncoTargets and Therapy, 2020, Volume 13, 9305-9321.	1.0	16
7558	Effective Treatment of NSCLC with Surgery After Nivolumab Combined with Chemotherapy: A Case Report and Brief Review of the Literature. OncoTargets and Therapy, 2020, Volume 13, 13307-13313.	1.0	3
7559	<p>PD-1/PD-L1 Inhibitor Combined with Chemotherapy Can Improve the Survival of Non-Small Cell Lung Cancer Patients with Brain Metastases</p>. OncoTargets and Therapy, 2020, Volume 13, 12777-12786.	1.0	7
7560	Osteoclast-like Giant Cell-type Pancreatic Anaplastic Carcinoma Presenting with a Duodenal Polypoid Lesion. Internal Medicine, 2019, 58, 3545-3550.	0.3	5
7561	Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy. Current Medicinal Chemistry, 2019, 26, 3026-3041.	1.2	142
7562	Immunomodulatory Drugs: Immune Checkpoint Agents in Acute Leukemia. Current Drug Targets, 2017, 18, 315-331.	1.0	39

#	ARTICLE	IF	CITATIONS
7563	From Biology to Therapy: Improvements of Therapeutic Options in Lung Cancer. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2019, 18, 1235-1240.	0.9	9
7564	Cancer Site and Adverse Events Induced by Immune Checkpoint Inhibitors: A Retrospective Analysis of Real-life Experience at a Single Institution. <i>Anticancer Research</i> , 2019, 39, 781-790.	0.5	25
7565	Rebiopsy of Histological Samples in Pretreated Non-small Cell Lung Cancer: Comparison Among Rebiopsy Procedures. <i>In Vivo</i> , 2017, 31, 475-479.	0.6	7
7566	The Positive Relationship Between γ H2AX and PD-L1 Expression in Lung Squamous Cell Carcinoma. <i>In Vivo</i> , 2018, 32, 171-177.	0.6	10
7567	Mobile Phone App-Based Pulmonary Rehabilitation for Chemotherapy-Treated Patients With Advanced Lung Cancer: Pilot Study. <i>JMIR MHealth and UHealth</i> , 2019, 7, e11094.	1.8	37
7568	Patient-Reported Outcomes During Immunotherapy for Metastatic Melanoma: Mixed Methods Study of Patients' and Clinicians' Experiences. <i>Journal of Medical Internet Research</i> , 2020, 22, e14896.	2.1	24
7569	Detecting and Filtering Immune-Related Adverse Events Signal Based on Text Mining and Observational Health Data Sciences and Informatics Common Data Model: Framework Development Study. <i>JMIR Medical Informatics</i> , 2020, 8, e17353.	1.3	6
7570	Follow-Up of Cancer Patients Receiving Anti-PD-(L)1 Therapy Using an Electronic Patient-Reported Outcomes Tool (KISS): Prospective Feasibility Cohort Study. <i>JMIR Formative Research</i> , 2020, 4, e17898.	0.7	17
7571	Real-World Treatment Sequences and Outcomes Among Patients With Non-Small Cell Lung Cancer (RESOUNDS) in the United States: Study Protocol. <i>JMIR Research Protocols</i> , 2017, 6, e195.	0.5	5
7572	The Prognostic Value of Pre-Treatment Leukocytosis in Patients with Previously Treated, Stage IIIB/IV Non-Small Cell Lung Cancer Treated with the IGF-1R Pathway Modulator AXL1717 or Docetaxel; a Retrospective Analysis of a Phase II Trial. <i>Asian Pacific Journal of Cancer Prevention</i> , 2017, 18, 1555-1560.	0.5	9
7573	Distribution of tumor-infiltrating immune cells in glioblastoma. <i>CNS Oncology</i> , 2018, 7, CNS21.	1.2	42
7574	Patient Preferences in Adjuvant and Palliative Treatment of Advanced Melanoma: A Discrete Choice Experiment. <i>Acta Dermato-Venereologica</i> , 2020, 100, adv00083-9.	0.6	17
7575	Soluble sPD-L1 and serum amyloid A1 as potential biomarkers for lung cancer. <i>Journal of Medical Biochemistry</i> , 2019, 38, 332-341.	0.7	21
7576	Long-term survival of locally advanced stage III non-small cell lung cancer patients treated with chemoradiotherapy and perspectives for the treatment with immunotherapy. <i>Radiology and Oncology</i> , 2018, 52, 281-288.	0.6	22
7577	Tumor-intrinsic response to IFN γ shapes the tumor microenvironment and anti-PD-1 response in NSCLC. <i>Life Science Alliance</i> , 2019, 2, e201900328.	1.3	38
7578	The immunomodulating roles of glycoproteins in epithelial ovarian cancer. <i>Frontiers in Bioscience - Elite</i> , 2012, E4, 631.	0.9	4
7579	Changing the paradigm: the potential for targeted therapy in laryngeal squamous cell carcinoma. <i>Cancer Biology and Medicine</i> , 2016, 13, 87-100.	1.4	21
7580	Immune checkpoint inhibitor-induced musculoskeletal manifestations. A multicentre prospective study. <i>Mediterranean Journal of Rheumatology</i> , 2020, 31, 239.	0.3	2

#	ARTICLE	IF	CITATIONS
7581	Observational Molecular Case-Control Study of Genetic Polymorphisms 1 in Programmed Cell Death Protein-1 in Patients with Oral Lichen Planus. <i>Asian Pacific Journal of Cancer Prevention</i> , 2019, 20, 421-424.	0.5	3
7582	The Systemic Treatment of Melanoma: The Place of Immune Checkpoint Inhibitors and the Suppression of Intracellular Signal Transduction. <i>Deutsches A&#x0308;rzteblatt International</i> , 2019, 116, 497-504.	0.6	15
7583	Immune Checkpoint Molecules in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System. <i>Basic and Clinical Neuroscience</i> , 2020, 11, 491-498.	0.3	7
7584	Characterization and Prognostic Significance of Cutaneous Adverse Events to Anti-Programmed Cell Death-1 Therapy. <i>Journal of Korean Medical Science</i> , 2019, 34, e186.	1.1	8
7585	Role of Immunosuppressive Microenvironment in Acquiring Immunotolerance Post-Photothermal Therapy. <i>Journal of Korean Medical Science</i> , 2019, 34, e272.	1.1	8
7586	Real-World Experience with Pembrolizumab Treatment in Patients with Heavily Treated Recurrent Gynecologic Malignancies. <i>Yonsei Medical Journal</i> , 2020, 61, 844.	0.9	7
7587	A Novel Probe for Spliceosomal Proteins that Induces Autophagy and Death of Melanoma Cells Reveals New Targets for Melanoma Drug Discovery. <i>Cellular Physiology and Biochemistry</i> , 2019, 53, 656-686.	1.1	12
7588	Innate Lymphoid Cells in Colorectal Cancers: A Double-Edged Sword. <i>Frontiers in Immunology</i> , 2019, 10, 3080.	2.2	14
7589	PCOLCE Is Potent Prognostic Biomarker and Associates With Immune Infiltration in Gastric Cancer. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 544895.	1.6	16
7590	Combined Anti-Cancer Strategies Based on Anti-Checkpoint Inhibitor Antibodies. <i>Antibodies</i> , 2020, 9, 17.	1.2	14
7591	Novel Nuclear Medicine Imaging Applications in Immuno-Oncology. <i>Cancers</i> , 2020, 12, 1303.	1.7	6
7592	Understanding the Effects of Radiotherapy on the Tumour Immune Microenvironment to Identify Potential Prognostic and Predictive Biomarkers of Radiotherapy Response. <i>Cancers</i> , 2020, 12, 2835.	1.7	8
7593	The Role of Regional Therapies for in-Transit Melanoma in the Era of Improved Systemic Options. <i>Cancers</i> , 2015, 7, 1154-1177.	1.7	20
7594	The Role of Immune Checkpoint Blockade in Uveal Melanoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 879.	1.8	57
7595	Viruses Teaching Immunology: Role of LCMV Model and Human Viral Infections in Immunological Discoveries. <i>Viruses</i> , 2019, 11, 106.	1.5	16
7596	Kidney Biopsy Should Be Performed to Document the Cause of Immune Checkpoint Inhibitorâ€™ Associated Acute Kidney Injury: CON. <i>Kidney360</i> , 2020, 1, 162-165.	0.9	10
7597	Acute Interstitial Nephritis and Checkpoint Inhibitor Therapy. <i>Kidney360</i> , 2020, 1, 16-24.	0.9	42
7598	Kidney Biopsy Should Be Performed to Document the Cause of Immune Checkpoint Inhibitorâ€™ Associated Acute Kidney Injury: PRO. <i>Kidney360</i> , 2020, 1, 158-161.	0.9	12

#	ARTICLE	IF	CITATIONS
7599	Perspectives on Treatment Advances for Stage III Locally Advanced Unresectable Non-Small-Cell Lung Cancer. <i>Current Oncology</i> , 2019, 26, 37-42.	0.9	56
7600	Potentiality of immunotherapy against hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2015, 21, 10314.	1.4	32
7601	Promises and paradoxes of regulatory T cells in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2015, 21, 11236.	1.4	48
7602	Viro-immune therapy: A new strategy for treatment of pancreatic cancer. <i>World Journal of Gastroenterology</i> , 2016, 22, 748.	1.4	16
7603	Immunotherapy in human colorectal cancer: Challenges and prospective. <i>World Journal of Gastroenterology</i> , 2016, 22, 6362.	1.4	41
7604	Progress in systemic therapy of advanced hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2016, 22, 6582.	1.4	43
7605	Immune checkpoint and inflammation as therapeutic targets in pancreatic carcinoma. <i>World Journal of Gastroenterology</i> , 2016, 22, 7440.	1.4	15
7606	Thiopurines and inflammatory bowel disease: Current evidence and a historical perspective. <i>World Journal of Gastroenterology</i> , 2016, 22, 10103.	1.4	42
7607	Colonic ulcerations may predict steroid-refractory course in patients with ipilimumab-mediated enterocolitis. <i>World Journal of Gastroenterology</i> , 2017, 23, 2023.	1.4	68
7608	Checkpoint inhibitors in gastrointestinal cancers: Expectations and reality. <i>World Journal of Gastroenterology</i> , 2017, 23, 3017.	1.4	9
7609	Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?. <i>World Journal of Gastroenterology</i> , 2018, 24, 2137-2151.	1.4	99
7610	Advances in immuno-oncology biomarkers for gastroesophageal cancer: Programmed death ligand 1, microsatellite instability, and beyond. <i>World Journal of Gastroenterology</i> , 2018, 24, 2686-2697.	1.4	23
7611	Checkpoint inhibitors: What gastroenterologists need to know. <i>World Journal of Gastroenterology</i> , 2018, 24, 5433-5438.	1.4	14
7612	Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas. <i>World Journal of Gastroenterology</i> , 2019, 25, 1684-1696.	1.4	29
7613	Programmed cell death-1 inhibitor-related sclerosing cholangitis: A systematic review. <i>World Journal of Gastroenterology</i> , 2020, 26, 353-365.	1.4	54
7617	Investigating the role of immunotherapy in advanced/recurrent female genital tract melanoma: a preliminary experience. <i>Journal of Gynecologic Oncology</i> , 2019, 30, e94.	1.0	29
7618	Radiotherapy and immune checkpoint blockades: a snapshot in 2016. <i>Radiation Oncology Journal</i> , 2016, 34, 250-259.	0.7	26
7619	Extracranial systemic antitumor response through the abscopal effect induced by brain radiation in a patient with metastatic melanoma. <i>Radiation Oncology Journal</i> , 2019, 37, 302-308.	0.7	11

#	ARTICLE	IF	CITATIONS
7620	Local ablative radiotherapy for oligometastatic non-small cell lung cancer. <i>Radiation Oncology Journal</i> , 2019, 37, 149-155.	0.7	12
7621	Reader-free ELISPOT assay for immuno-monitoring in peptide-based cancer vaccine immunotherapy. <i>Biomedical Reports</i> , 2020, 12, 244-250.	0.9	5
7622	M2 tumor-associated macrophages promote tumor progression in non-small cell lung cancer. <i>Experimental and Therapeutic Medicine</i> , 2019, 18, 4490-4498.	0.8	83
7623	Downregulation of PD-L1 via amide analogues of brefelamide: Alternatives to antibody-based cancer immunotherapy. <i>Experimental and Therapeutic Medicine</i> , 2020, 19, 3150-3158.	0.8	5
7624	Adoptive immunotherapy combined with FP treatment for head and neck cancer: An in vitro study. <i>International Journal of Oncology</i> , 2017, 51, 1471-1481.	1.4	6
7625	Nivolumab-induced cholangitis in patients with non-small cell lung cancer: Case series and a review of literature. <i>Molecular and Clinical Oncology</i> , 2019, 11, 439-446.	0.4	16
7626	Relapse of aseptic meningitis induced by ipilimumab and nivolumab therapy for metastatic renal cell carcinoma: A case report. <i>Molecular and Clinical Oncology</i> , 2019, 11, 590-594.	0.4	8
7627	Guillain-Barre syndrome induced by pembrolizumab and sunitinib: A case report. <i>Molecular and Clinical Oncology</i> , 2020, 13, 38-42.	0.4	8
7628	Large cell neuroendocrine carcinoma of the lung that responded to nivolumab: A case report. <i>Molecular and Clinical Oncology</i> , 2020, 13, 43-47.	0.4	12
7629	Value of TTF-1 expression in non-squamous non-small cell lung cancer for assessing docetaxel monotherapy after chemotherapy failure. <i>Molecular and Clinical Oncology</i> , 2020, 13, 9.	0.4	6
7630	Combination of checkpoint inhibitors with radiotherapy in esophageal squamous cell carcinoma treatment: A novel strategy (Review). <i>Oncology Letters</i> , 2019, 18, 5011-5021.	0.8	11
7631	Identification of key genes and evaluation of clinical outcomes in lung squamous cell carcinoma using integrated bioinformatics analysis. <i>Oncology Letters</i> , 2019, 18, 5859-5870.	0.8	13
7632	Use of immunotherapy in the treatment of gastric cancer (Review). <i>Oncology Letters</i> , 2019, 18, 5681-5690.	0.8	31
7633	A subset of patients with MSS/MSI-low colorectal cancer showed increased CD8(+) TILs together with up-regulated IFN- γ . <i>Oncology Letters</i> , 2019, 18, 5977-5985.	0.8	33
7634	BATF acts as an oncogene in non-small cell lung cancer. <i>Oncology Letters</i> , 2020, 19, 205-210.	0.8	13
7635	Significant function and research progress of biomarkers in gastric cancer (Review). <i>Oncology Letters</i> , 2020, 19, 17-29.	0.8	26
7636	Nomogram construction for predicting survival of patients with non-small cell lung cancer with malignant pleural or pericardial effusion based on SEER analysis of 10,268 $\frac{1}{2}$ patients. <i>Oncology Letters</i> , 2020, 19, 449-459.	0.8	8
7637	POLR1B is upregulated and promotes cell proliferation in non-small cell lung cancer. <i>Oncology Letters</i> , 2020, 19, 671-680.	0.8	11

#	ARTICLE	IF	CITATIONS
7638	Radiomics predicts survival of patients with advanced non-small cell lung cancer undergoing PD-1 blockade using Nivolumab. <i>Oncology Letters</i> , 2020, 19, 1559-1566.	0.8	46
7639	Cardamonin as a potential treatment for melanoma induces human melanoma cell apoptosis. <i>Oncology Letters</i> , 2020, 19, 1393-1399.	0.8	10
7640	Gene expression profiling identified TP53MutPIK3CAWild as a potential biomarker for patients with triple-negative breast cancer treated with immune checkpoint inhibitors. <i>Oncology Letters</i> , 2020, 19, 2817-2824.	0.8	13
7641	The daily practice reality of PD-L1 (CD274) evaluation in non-small cell lung cancer: A retrospective study. <i>Oncology Letters</i> , 2020, 19, 3400-3410.	0.8	6
7642	Gene silencing of indoleamine 2,3-dioxygenase 1 inhibits lung cancer growth by suppressing T-cell exhaustion. <i>Oncology Letters</i> , 2020, 19, 3827-3838.	0.8	7
7643	Clinical significance of CD38 and CD101 expression in PD-1+CD8+ T cells in patients with epithelial ovarian cancer. <i>Oncology Letters</i> , 2020, 20, 724-732.	0.8	10
7644	Analysis of immune-related signatures of colorectal cancer identifying two different immune phenotypes: Evidence for immune checkpoint inhibitor therapy. <i>Oncology Letters</i> , 2020, 20, 517-524.	0.8	12
7645	Elevated levels of IL-17A and IL-35 in plasma and bronchoalveolar lavage fluid are associated with checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer. <i>Oncology Letters</i> , 2020, 20, 611-622.	0.8	34
7646	Early response of bone metastases can predict tumor response in patients with non-small cell lung cancer with bone metastases in the treatment with nivolumab. <i>Oncology Letters</i> , 2020, 20, 2977-2986.	0.8	11
7647	Safety and tolerability of PD-1/PD-L1 inhibitors in elderly and frail patients with advanced malignancies. <i>Oncology Letters</i> , 2020, 20, 14.	0.8	10
7648	Biomarkers of immunotherapy in non-small cell lung cancer (Review). <i>Oncology Letters</i> , 2020, 20, 1-1.	0.8	8
7649	Profiling of inhibitory immune checkpoints in glioblastoma: Potential pathogenetic players. <i>Oncology Letters</i> , 2020, 20, 332.	0.8	8
7650	Association between the gut microbiota and patient responses to cancer immune checkpoint inhibitors (Review). <i>Oncology Letters</i> , 2020, 20, 1-1.	0.8	11
7651	Mechanism of intrinsic resistance of lung squamous cell carcinoma to epithelial growth factor receptor-tyrosine kinase inhibitors revealed by high-throughput RNA interference screening. <i>Oncology Letters</i> , 2020, 20, 1-1.	0.8	3
7652	Early palliative care of non-small cell lung cancer in the context of immunotherapy. <i>Oncology Letters</i> , 2020, 20, 396.	0.8	1
7653	Plasma plastin-3: A tumor marker in patients with non-small cell lung cancer treated with nivolumab. <i>Oncology Letters</i> , 2020, 21, 1-1.	0.8	4
7654	Histone deacetylase 6 inhibition in urothelial cancer as a potential new strategy for cancer treatment. <i>Oncology Letters</i> , 2020, 21, 64.	0.8	10
7655	HHLA2 is a novel prognostic predictor and potential therapeutic target in malignant glioma. <i>Oncology Reports</i> , 2019, 42, 2309-2322.	1.2	14

#	ARTICLE	IF	CITATIONS
7656	The neutrophil-to-lymphocyte ratio prechemotherapy and postchemotherapy as a prognostic marker in metastatic gastric cancer. Korean Journal of Internal Medicine, 2018, 33, 990-999.	0.7	10
7657	Current status of immune checkpoint inhibitors in treatment of non-small cell lung cancer. Korean Journal of Internal Medicine, 2019, 34, 50-59.	0.7	14
7658	Rheumatic complications in cancer patients treated with immune checkpoint inhibitors. Korean Journal of Internal Medicine, 2019, 34, 1197-1209.	0.7	11
7659	Immunotherapy for pancreatic ductal adenocarcinoma: an overview of clinical trials. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2015, 27, 376-91.	0.7	16
7660	Impact of the immune system and immunotherapy in colorectal cancer. Journal of Gastrointestinal Oncology, 2015, 6, 208-23.	0.6	142
7661	Immunotherapy for advanced gastric and esophageal cancer: preclinical rationale and ongoing clinical investigations. Journal of Gastrointestinal Oncology, 2015, 6, 561-9.	0.6	61
7662	New therapeutic strategies for BRAF mutant colorectal cancers. Journal of Gastrointestinal Oncology, 2015, 6, 650-9.	0.6	21
7663	A phase I study of MEDI4736, NNT-PD-L1 antibody in patients with advanced solid tumors. Translational Lung Cancer Research, 2014, 3, 406-7.	1.3	19
7664	Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced non-small cell lung cancer. Translational Lung Cancer Research, 2014, 3, 403-5.	1.3	21
7665	A new addition to the PD-1 checkpoint inhibitors for non-small cell lung cancer-the anti-PDL1 antibody-MEDI4736. Translational Lung Cancer Research, 2014, 3, 408-10.	1.3	19
7666	Surrogate clinical endpoints to predict overall survival in non-small cell lung cancer trials-are we in a new era?. Translational Lung Cancer Research, 2015, 4, 804-8.	1.3	15
7667	Lung cancer biomarkers, targeted therapies and clinical assays. Translational Lung Cancer Research, 2015, 4, 503-14.	1.3	23
7668	New strategies in immunotherapy for non-small cell lung cancer. Translational Lung Cancer Research, 2015, 4, 553-9.	1.3	35
7669	Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. Translational Lung Cancer Research, 2015, 4, 560-75.	1.3	303
7670	Treatment of advanced squamous cell carcinoma of the lung: a review. Translational Lung Cancer Research, 2015, 4, 524-32.	1.3	74
7671	Lung cancer diagnosis and staging in the minimally invasive age with increasing demands for tissue analysis. Translational Lung Cancer Research, 2015, 4, 392-403.	1.3	24
7672	Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancer. Translational Lung Cancer Research, 2015, 4, 584-97.	1.3	52
7673	Novel radiotherapy approaches for lung cancer: combining radiation therapy with targeted and immunotherapies. Translational Lung Cancer Research, 2015, 4, 545-52.	1.3	70

#	ARTICLE	IF	CITATIONS
7674	Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicity. <i>Translational Lung Cancer Research</i> , 2015, 4, 721-7.	1.3	26
7675	Afatinib in the treatment of squamous non-small cell lung cancer: a new frontier or an old mistake?. <i>Translational Lung Cancer Research</i> , 2016, 5, 110-4.	1.3	9
7676	Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta role. <i>Translational Lung Cancer Research</i> , 2015, 4, 728-42.	1.3	48
7677	Results of clinical trials with anti-programmed death 1/programmed death ligand 1 inhibitors in lung cancer. <i>Translational Lung Cancer Research</i> , 2015, 4, 756-62.	1.3	8
7678	Predictive factors of activity of anti-programmed death-1/programmed death ligand-1 drugs: immunohistochemistry analysis. <i>Translational Lung Cancer Research</i> , 2015, 4, 743-51.	1.3	31
7679	Cellular and molecular biology of small cell lung cancer: an overview. <i>Translational Lung Cancer Research</i> , 2016, 5, 2-15.	1.3	52
7680	Overall survival in non-small cell lung cancer-what is clinically meaningful?. <i>Translational Lung Cancer Research</i> , 2016, 5, 115-9.	1.3	23
7681	Predictive factors for immunotherapy in melanoma. <i>Annals of Translational Medicine</i> , 2015, 3, 208.	0.7	27
7682	Melanoma: oncogenic drivers and the immune system. <i>Annals of Translational Medicine</i> , 2015, 3, 265.	0.7	19
7683	Immune checkpoint inhibitors: therapeutic advances in melanoma. <i>Annals of Translational Medicine</i> , 2015, 3, 267.	0.7	47
7684	Current Status of Immunotherapy for Lung Cancer and Future Perspectives. <i>Tuberculosis and Respiratory Diseases</i> , 2020, 83, 14.	0.7	19
7685	Concordance of Programmed Death-Ligand 1 Expression between SP142 and 22C3/SP263 Assays in Triple-Negative Breast Cancer. <i>Journal of Breast Cancer</i> , 2020, 23, 303.	0.8	25
7686	Analysis of the Expression and Regulation of PD-1 Protein on the Surface of Myeloid-Derived Suppressor Cells (MDSCs). <i>Biomolecules and Therapeutics</i> , 2019, 27, 63-70.	1.1	43
7687	Tumour Regression via Integrative Regulation of Neurological, Inflammatory, and Hypoxic Tumour Microenvironment. <i>Biomolecules and Therapeutics</i> , 2020, 28, 119-130.	1.1	13
7688	Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm. <i>Oncology Reviews</i> , 2020, 14, 490.	0.8	36
7689	Immune based therapy for melanoma. <i>Indian Journal of Medical Research</i> , 2016, 143, 135.	0.4	19
7690	Nivolumab-induced new-onset seronegative rheumatoid arthritis in a patient with advanced metastatic melanoma: A case report and literature review. <i>Avicenna Journal of Medicine</i> , 2018, 8, 34-36.	0.3	18
7691	Saudi lung cancer management guidelines 2017. <i>Annals of Thoracic Medicine</i> , 2017, 12, 221.	0.7	16

#	ARTICLE	IF	CITATIONS
7692	Comparison of programmed death-ligand 1 (PD-L1) immunostain for nonsmall cell lung carcinoma between paired cytological and surgical specimens. <i>CytoJournal</i> , 2018, 15, 29.	0.8	14
7693	Transthoracic fine-needle aspiration diagnosis of solid, subsolid, and partially calcified lung nodules: A retrospective study from a single academic center. <i>CytoJournal</i> , 2019, 16, 16.	0.8	5
7694	Acute hypophysitis secondary to nivolumab immunotherapy in a patient with metastatic melanoma. <i>International Journal of Critical Illness and Injury Science</i> , 2017, 7, 177.	0.2	13
7695	Expression of programmed death-ligand 1 in cutaneous squamous cell carcinoma arising in sun-exposed and nonsun-exposed skin. <i>Indian Journal of Dermatology</i> , 2020, 65, 506.	0.1	4
7696	Nivolumab â€“ Pearls of evidence. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2017, 38, 520.	0.1	7
7697	Comparison of laboratory-developed test & validated assay of programmed death ligand-1 immunohistochemistry in non-small-cell lung carcinoma. <i>Indian Journal of Medical Research</i> , 2019, 150, 376.	0.4	5
7698	Conjunctival melanoma with orbital invasion and liver metastasis managed with systemic immune checkpoint inhibitor therapy. <i>Indian Journal of Ophthalmology</i> , 2019, 67, 2071.	0.5	15
7699	Immunotherapy in oral cancer. <i>Journal of Pharmacy and Bioallied Sciences</i> , 2019, 11, 107.	0.2	37
7700	Multi-Field-of-View Deep Learning Model Predicts Nonsmall Cell Lung Cancer Programmed Death-Ligand 1 Status from Whole-Slide Hematoxylin and Eosin Images. <i>Journal of Pathology Informatics</i> , 2019, 10, 24.	0.8	70
7701	Immune checkpoint inhibitors: Real-world experience from India in advanced solid cancers that have progressed on chemotherapy. <i>South Asian Journal of Cancer</i> , 2019, 08, 65-68.	0.2	4
7702	Treatment of advanced nonsmall cell lung cancer: First line, maintenance and second line â€“ Indian consensus statement update. <i>South Asian Journal of Cancer</i> , 2019, 08, 01-17.	0.2	8
7703	Immune checkpoint inhibitors: Advances and impact in neuro-oncology. , 2019, 10, 9.		18
7704	NK Cell-Based Immunotherapies in Cancer. <i>Immune Network</i> , 2020, 20, e14.	1.6	79
7705	Baseline Serum Interleukin-6 Levels Predict the Response of Patients with Advanced Non-small Cell Lung Cancer to PD-1/PD-L1 Inhibitors. <i>Immune Network</i> , 2020, 20, e27.	1.6	36
7706	Far Beyond Cancer Immunotherapy: Reversion of Multi-Malignant Phenotypes of Immunotherapeutic-Resistant Cancer by Targeting the NANOG Signaling Axis. <i>Immune Network</i> , 2020, 20, e7.	1.6	12
7707	Peripheral blood immune cell-based biomarkers in anti-PD-1/PD-L1 therapy. <i>Immune Network</i> , 2020, 20, e8.	1.6	19
7708	Programmed Death-Ligand 1 Expression and Its Correlation with Lymph Node Metastasis in Papillary Thyroid Carcinoma. <i>Journal of Pathology and Translational Medicine</i> , 2018, 52, 9-13.	0.4	16
7709	PD-L1 Testing in Non-small Cell Lung Cancer: Past, Present, and Future. <i>Journal of Pathology and Translational Medicine</i> , 2019, 53, 199-206.	0.4	51

#	ARTICLE	IF	CITATIONS
7710	Immune landscape and biomarkers for immuno-oncology in colorectal cancers. <i>Journal of Pathology and Translational Medicine</i> , 2020, 54, 351-360.	0.4	9
7711	Association between PD-L1 and HPV Status and the Prognostic Value of PD-L1 in Oropharyngeal Squamous Cell Carcinoma. <i>Cancer Research and Treatment</i> , 2016, 48, 527-536.	1.3	104
7712	Efficacy and Safety of First-Line Nectinumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in East Asian Patients with Stage IV Squamous Non-small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-Label, Randomized SQUIRE Study. <i>Cancer Research and Treatment</i> , 2017, 49, 937-946.	1.3	7
7713	Retrospective Molecular Epidemiology Study of PD-L1 Expression in Patients with EGFR-Mutant Non-small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2018, 50, 95-102.	1.3	22
7714	EGFR Mutation Is Associated with Short Progression-Free Survival in Patients with Stage III Non-squamous Cell Lung Cancer Treated with Concurrent Chemoradiotherapy. <i>Cancer Research and Treatment</i> , 2019, 51, 493-501.	1.3	30
7715	Alterations in PD-L1 Expression Associated with Acquisition of Resistance to ALK Inhibitors in ALK-Rearranged Lung Cancer. <i>Cancer Research and Treatment</i> , 2019, 51, 1231-1240.	1.3	20
7716	Higher Age Puts Lung Cancer Patients at Risk for Not Receiving Anti-cancer Treatment. <i>Cancer Research and Treatment</i> , 2019, 51, 1241-1248.	1.3	7
7717	Effect of Platinum-Based Chemotherapy on PD-L1 Expression on Tumor Cells in Non-small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2019, 51, 1086-1097.	1.3	59
7718	High-Throughput Multiplex Immunohistochemical Imaging of the Tumor and Its Microenvironment. <i>Cancer Research and Treatment</i> , 2020, 52, 98-108.	1.3	18
7719	Clinical Outcomes of Immune Checkpoint Blocker Therapy for Malignant Melanoma in Korean Patients: Potential Clinical Implications for a Combination Strategy Involving Radiotherapy. <i>Cancer Research and Treatment</i> , 2020, 52, 730-738.	1.3	7
7720	Real World Experience of Nivolumab in Non-Small Cell Lung Cancer in Korea. <i>Cancer Research and Treatment</i> , 2020, 52, 1112-1119.	1.3	10
7721	Identification of genomic features associated with immunotherapy response in gastrointestinal cancers. <i>World Journal of Gastrointestinal Oncology</i> , 2019, 11, 270-280.	0.8	8
7722	Immune cell interplay in colorectal cancer prognosis. <i>World Journal of Gastrointestinal Oncology</i> , 2015, 7, 221.	0.8	27
7723	Novel therapy for advanced gastric cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2015, 7, 263.	0.8	6
7724	Gastric cancer: The times they are a-changinâ€™™. <i>World Journal of Gastrointestinal Oncology</i> , 2015, 7, 303.	0.8	16
7725	Is metastatic pancreatic cancer an untargetable malignancy?. <i>World Journal of Gastrointestinal Oncology</i> , 2016, 8, 297.	0.8	8
7726	Association of a PD-L2 Gene Polymorphism with Chronic Lymphatic Filariasis in a South Indian Cohort. <i>American Journal of Tropical Medicine and Hygiene</i> , 2019, 100, 344-350.	0.6	3
7727	Immune checkpoint inhibitor-induced diarrhea/colitis: Endoscopic and pathologic findings. <i>World Journal of Gastrointestinal Pathophysiology</i> , 2019, 10, 17-28.	0.5	26

#	ARTICLE	IF	CITATIONS
7728	Surviving Cancer without a Broken Heart. Rambam Maimonides Medical Journal, 2019, 10, e0012.	0.4	5
7729	Novel therapies for advanced skin carcinomas. Postepy Dermatologii I Alergologii, 2020, 37, 660-670.	0.4	3
7730	Treatment After First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in Non- Small-Cell Lung Cancer. Turkish Thoracic Journal, 2017, 18, 66-71.	0.2	7
7731	Immune Checkpoint Inhibitors in Advanced-Stage Non-small Cell Lung Cancer. Turkish Thoracic Journal, 2017, 18, 101-107.	0.2	2
7732	Nephrotoxicity in cancer treatment: An overview. World Journal of Clinical Oncology, 2020, 11, 190-204.	0.9	64
7733	Immunotherapy – new perspective in lung cancer. World Journal of Clinical Oncology, 2020, 11, 250-259.	0.9	10
7734	Advanced oropharyngeal squamous cell carcinoma: Pathogenesis, treatment, and novel therapeutic approaches. World Journal of Clinical Oncology, 2016, 7, 15.	0.9	14
7735	Off-label use of targeted therapies in oncology. World Journal of Clinical Oncology, 2016, 7, 253.	0.9	25
7736	Immunotherapy in pancreatic cancer: Unleash its potential through novel combinations. World Journal of Clinical Oncology, 2017, 8, 230.	0.9	52
7737	Use of programmed cell death protein ligand 1 assay to predict the outcomes of non-small cell lung cancer patients treated with immune checkpoint inhibitors. World Journal of Clinical Oncology, 2017, 8, 320.	0.9	8
7738	Interleukin-32: Frenemy in cancer?. BMB Reports, 2019, 52, 165-174.	1.1	16
7739	A primer on tumour immunology and prostate cancer immunotherapy. Canadian Urological Association Journal, 2016, 10, 60.	0.3	10
7740	Immune Checkpoint Blockade: A New Paradigm in Treating Advanced Cancer. Journal of the Advanced Practitioner in Oncology, 2014, 5, 418-31.	0.2	48
7741	Pembrolizumab: First in Class for Treatment of Metastatic Melanoma. Journal of the Advanced Practitioner in Oncology, 2015, 6, 234-8.	0.2	3
7742	Understanding and Managing Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Patients With Advanced Melanoma. Journal of the Advanced Practitioner in Oncology, 2017, 8, 58-72.	0.2	7
7743	Clinical Management of Pneumonitis in Patients Receiving Anti-PD-1/PD-L1 Therapy. Journal of the Advanced Practitioner in Oncology, 2018, 9, .	0.2	5
7744	Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 255-289.	2.3	393
7745	Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma. Cancer Biology and Medicine, 2014, 11, 237-46.	1.4	64

#	ARTICLE	IF	CITATIONS
7746	Assays for predicting and monitoring responses to lung cancer immunotherapy. <i>Cancer Biology and Medicine</i> , 2015, 12, 87-95.	1.4	35
7747	Understanding the function and dysfunction of the immune system in lung cancer: the role of immune checkpoints. <i>Cancer Biology and Medicine</i> , 2015, 12, 79-86.	1.4	28
7748	Epigenetic modification of the PD-1 (Pdcd1) promoter in effector CD4+ T cells tolerized by peptide immunotherapy. <i>ELife</i> , 2014, 3, .	2.8	52
7749	TGF β -dependent expression of PD-1 and PD-L1 controls CD8+ T cell anergy in transplant tolerance. <i>ELife</i> , 2016, 5, e08133.	2.8	105
7750	Combination checkpoint inhibitors for treatment of non-small-cell lung cancer: an update on dual anti-CTLA-4 and anti-PD-1/PD-L1 therapies. <i>Drugs in Context</i> , 2020, 9, 1-11.	1.0	34
7751	Metastatic squamous cell non-small-cell lung cancer (NSCLC): disrupting the drug treatment paradigm with immunotherapies. <i>Drugs in Context</i> , 2015, 4, 1-7.	1.0	32
7752	Evaluating cost benefits of combination therapies for advanced melanoma. <i>Drugs in Context</i> , 2016, 5, 1-14.	1.0	19
7753	Classification of ovarian cancer associated with BRCA1 mutations, immune checkpoints, and tumor microenvironment based on immunogenomic profiling. <i>PeerJ</i> , 2020, 8, e10414.	0.9	12
7754	Anti-Programmed Cell Death Protein 1 (PD-1) Immunotherapy for Metastatic Hepatocellular Carcinoma After Liver Transplantation: A Report of Three Cases. <i>Cureus</i> , 2020, 12, e11150.	0.2	16
7755	Nephrotoxicity of Immune Checkpoint Inhibitors: Acute Kidney Injury and Beyond. <i>Cureus</i> , 2020, 12, e12204.	0.2	8
7756	The Most Recent Oncologic Emergency: What Emergency Physicians Need to Know About the Potential Complications of Immune Checkpoint Inhibitors. <i>Cureus</i> , 2017, 9, e1774.	0.2	17
7757	Complete Response of Metastatic Melanoma to Local Radiation and Immunotherapy: 6.5 Year Follow-Up. <i>Cureus</i> , 2018, 10, e3723.	0.2	7
7758	The Abscopal Effect Exists in Non-small Cell Lung Cancer: A Case Report and Review of the Literature. <i>Cureus</i> , 2019, 11, e4118.	0.2	18
7759	High-Dose Radiation as a Dramatic, Immunological Primer in Locally Advanced Melanoma. <i>Cureus</i> , 2015, 7, e417.	0.2	17
7760	Incidence and Risk of Thyroid Dysfunction in Advanced or Metastatic Non-small Cell Lung Cancer Patients Treated with Pembrolizumab: A Meta-analysis. <i>Cureus</i> , 2019, 11, e5997.	0.2	5
7761	Immune-mediated Colitis from Dual Checkpoint Inhibitors. <i>Cureus</i> , 2019, 11, e6233.	0.2	2
7762	Immune Checkpoint Inhibitor-induced Fanconi Syndrome. <i>Cureus</i> , 2020, 12, e7686.	0.2	9
7763	Immune Checkpoint Inhibitors in Lung Cancer: Role of Biomarkers and Combination Therapies. <i>Cureus</i> , 2020, 12, e8095.	0.2	19

#	ARTICLE	IF	CITATIONS
7764	A Rare Case of Immune-Mediated Primary Adrenal Insufficiency With Cytotoxic T-Lymphocyte Antigen-4 Inhibitor Ipilimumab in Metastatic Melanoma of Lung and Neck of Unknown Primary. <i>Cureus</i> , 2020, 12, e8602.	0.2	6
7765	The Association of Radiation Dose-Fractionation and Immunotherapy Use With Overall Survival in Metastatic Melanoma Patients. <i>Cureus</i> , 2020, 12, e8767.	0.2	7
7766	Mucosal Melanoma: A Rare Entity and Review of the Literature. <i>Cureus</i> , 2020, 12, e9483.	0.2	5
7767	Immune-Mediated Toxic Epidermal Necrolysis. <i>Cureus</i> , 2020, 12, e9587.	0.2	6
7768	Natural Killer Cells - Their Role in Tumour Immunosurveillance. <i>Journal of Clinical and Diagnostic Research JCDR</i> , 2017, 11, BE01-BE05.	0.8	25
7769	Targeting PD-L1 (Programmed death-ligand 1) and inhibiting the expression of IGF2BP2 (Insulin-like) Tj ETQq1 1 0.784314 rgBT /Overbo carcinoma cells. <i>Bioengineered</i> , 2021, 12, 7755-7764.	1.4	10
7770	Therapeutic and Systemic Adverse Events of Immune Checkpoint Inhibitors Targeting the PD-1/PD-L1 axis for Clinical Management of NSCLC. <i>Cell Transplantation</i> , 2021, 30, 096368972110415.	1.2	3
7771	Construction of a competing endogenous RNA network related to the prognosis of cholangiocarcinoma and comprehensive analysis of the immunological correlation. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 2287-2309.	0.6	3
7772	Analysis of the efficacy and prognostic factors of PD-1 inhibitors in advanced gallbladder cancer. <i>Annals of Translational Medicine</i> , 2021, 9, 1568-1568.	0.7	5
7773	Treatment Toxicity. <i>UNIPA Springer Series</i> , 2021, , 291-308.	0.1	0
7774	The safety and efficacy of immunotherapy with anti-programmed cell death 1 monoclonal antibody for lung cancer complicated with Mycobacterium tuberculosis infection. <i>Translational Lung Cancer Research</i> , 2021, 10, 3929-3942.	1.3	6
7775	A sporadic case of CTLA4 haploinsufficiency manifesting as Epstein-Barr virus-positive diffuse large B-cell lymphoma. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2021, , .	0.3	1
7776	Gestion des toxicités de l'immunothérapie. <i>Revue Des Maladies Respiratoires Actualites</i> , 2021, 13, 2S258-2S265.	0.0	0
7777	Digital pathology and artificial intelligence in translational medicine and clinical practice. <i>Modern Pathology</i> , 2022, 35, 23-32.	2.9	179
7778	Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy. , 2021, 9, e003066.		34
7779	Lysophosphatidic Acid Receptor 6 (LPAR6) Is a Potential Biomarker Associated with Lung Adenocarcinoma. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 11038.	1.2	3
7780	Differential role of residual metabolic tumor volume in inoperable stage III NSCLC after chemoradiotherapy±immune checkpoint inhibition. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1407-1416.	3.3	5
7781	Emerging Bone Marrow Microenvironment-Driven Mechanisms of Drug Resistance in Acute Myeloid Leukemia: Tangle or Chance?. <i>Cancers</i> , 2021, 13, 5319.	1.7	15

#	ARTICLE	IF	CITATIONS
7782	Immuno-oncologic care during COVID-19: Challenges and opportunities for improving clinical care and investigation. , 2021, 2, 75-82.		1
7783	Improved Immunotherapy Efficacy by Vascular Modulation. <i>Cancers</i> , 2021, 13, 5207.	1.7	12
7784	Clinical Efficacy of Immune Checkpoint Inhibitors in Non-“Small Cell Lung Cancer Patients with Liver Metastases: A Network Meta-Analysis of Nine Randomized Controlled Trials. <i>Cancer Research and Treatment</i> , 2022, 54, 803-816.	1.3	5
7785	Acute kidney injury in patients treated with immune checkpoint inhibitors. , 2021, 9, e003467.		103
7786	Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types. , 2021, 9, e003499.		23
7787	Infections due to dysregulated immunity: an emerging complication of cancer immunotherapy. <i>Thorax</i> , 2022, 77, 304-311.	2.7	44
7788	Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC. <i>BMC Medicine</i> , 2021, 19, 239.	2.3	11
7789	Alloantigen-activated (AAA) CD4+ T cells reinvigorate host endogenous T cell immunity to eliminate pre-established tumors in mice. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 314.	3.5	1
7790	Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES). , 2021, 9, e002995.		18
7791	Association of PD-1/PD-L1 Co-location with Immunotherapy Outcomes in Non-“Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 360-367.	3.2	14
7792	Immune Checkpoint Inhibitors and Kidney Toxicity: Advances in Diagnosis and Management. <i>Kidney Medicine</i> , 2021, 3, 1074-1081.	1.0	26
7793	Safety of immune checkpoint inhibitors in non-small-cell lung cancer patients with idiopathic interstitial pneumonia: a matched case-“control study. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 21-30.	1.1	7
7794	Risk of Pneumonitis Associated With Immune Checkpoint Inhibitors in Melanoma: A Systematic Review and Network Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 651553.	1.3	3
7795	Association of the Geriatric Nutritional Risk Index With the Survival of Patients With Non-“Small Cell Lung Cancer After Nivolumab Therapy. <i>Journal of Immunotherapy</i> , 2022, 45, 125-131.	1.2	17
7796	Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy. <i>Nature Communications</i> , 2021, 12, 6071.	5.8	44
7797	A Research Agenda for Precision Medicine in Sepsis and Acute Respiratory Distress Syndrome: An Official American Thoracic Society Research Statement. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 891-901.	2.5	38
7798	Fibrin gel enhances the antitumor effects of chimeric antigen receptor T cells in glioblastoma. <i>Science Advances</i> , 2021, 7, eabg5841.	4.7	35
7799	Multiplexed imaging reveals an IFN-“3-driven inflammatory state in nivolumab-associated gastritis. <i>Cell Reports Medicine</i> , 2021, 2, 100419.	3.3	9

#	ARTICLE	IF	CITATIONS
7800	Predictive Value of Multiparametric MRI for Response to Single-Cycle Induction Chemo-Immunotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 734872.	1.3	9
7801	The injury response to DNA damage in live tumor cells promotes antitumor immunity. <i>Science Signaling</i> , 2021, 14, eabc4764.	1.6	32
7802	Intestinal flora characteristics of advanced non-small cell lung cancer in China and their role in chemotherapy based on metagenomics: A prospective exploratory cohort study. <i>Thoracic Cancer</i> , 2021, 12, 3293-3303.	0.8	8
7803	Effect of Immune Checkpoint Blockade on Myeloid-Derived Suppressor Cell Populations in Patients With Melanoma. <i>Frontiers in Immunology</i> , 2021, 12, 740890.	2.2	15
7804	CD137 agonist potentiates the abscopal efficacy of nanoparticle-based photothermal therapy for melanoma. <i>Nano Research</i> , 2022, 15, 2300-2314.	5.8	12
7805	Inhibition of estrogen signaling in myeloid cells increases tumor immunity in melanoma. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	40
7806	Prognostic implication of PD-L1 polymorphisms in non-small cell lung cancer treated with radiotherapy. <i>Cancer Medicine</i> , 2021, 10, 8071-8078.	1.3	3
7807	Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. <i>Cell</i> , 2021, 184, 5309-5337.	13.5	588
7808	Nanomedicines in B cell-targeting therapies. <i>Acta Biomaterialia</i> , 2022, 137, 1-19.	4.1	9
7809	Differential expression of programmed cell death ligand 1 (PD-L1) and inflammatory cells in basal cell carcinoma subtypes. <i>Archives of Dermatological Research</i> , 2021, , 1.	1.1	3
7810	Novel classes of immunotherapy for breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 191, 15-29.	1.1	8
7811	Recent advances in primary resistance mechanisms against immune checkpoint inhibitors. <i>Current Opinion in Oncology</i> , 2022, 34, 95-106.	1.1	9
7812	3p Arm Loss and Survival in Head and Neck Cancer: An Analysis of TCGA Dataset. <i>Cancers</i> , 2021, 13, 5313.	1.7	3
7813	Acute Diffuse Renal Tubulopathy in a Patient With Lung Cancer: A Case Report. <i>Frontiers in Medicine</i> , 2021, 8, 742489.	1.2	2
7814	Hematologic complications of immune checkpoint inhibitors. <i>Blood</i> , 2022, 139, 3594-3604.	0.6	30
7815	Serological assessment of collagen fragments and tumor fibrosis may guide immune checkpoint inhibitor therapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 326.	3.5	19
7816	High-Dimensional Single-Cell Transcriptomics in Melanoma and Cancer Immunotherapy. <i>Genes</i> , 2021, 12, 1629.	1.0	8
7817	The Frequency of DNA Mismatch Repair Deficiency Is Very Low in Surgically Resected Lung Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 752005.	1.3	9

#	ARTICLE	IF	CITATIONS
7818	Nanomedicine for Immunotherapy Targeting Hematological Malignancies: Current Approaches and Perspective. <i>Nanomaterials</i> , 2021, 11, 2792.	1.9	8
7820	Gene editing to enhance the efficacy of cancer cell therapies. <i>Molecular Therapy</i> , 2021, 29, 3153-3162.	3.7	5
7821	PET Imaging of VLA-4 in a New BRAFV600E Mouse Model of Melanoma. <i>Molecular Imaging and Biology</i> , 2022, 24, 425-433.	1.3	3
7822	Progression-free survival assessed per immune-related or conventional response criteria, which is the better surrogate endpoint for overall survival in trials of immune-checkpoint inhibitors in lung cancer: A systematic review and meta-analysis. <i>Cancer Medicine</i> , 2021, 10, 8272-8287.	1.3	5
7823	Immunotherapy in Cancer Management: A Literature Review of Clinical Efficacy of Pembrolizumab in the Non-small Cell Lung Cancer Treatment. <i>Advanced Pharmaceutical Bulletin</i> , 2021, , .	0.6	3
7824	Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition – A Descriptive Observational Retrospective Multicenter Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 765608.	1.3	10
7825	Safety of thoracic radiotherapy after PD-(L)1 inhibitor treatment in patients with lung cancer. <i>Cancer Medicine</i> , 2021, 10, 8518-8529.	1.3	3
7826	Nanobody-based CTLA4 inhibitors for immune checkpoint blockade therapy of canine cancer patients. <i>Scientific Reports</i> , 2021, 11, 20763.	1.6	10
7827	CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer. <i>Scientific Reports</i> , 2021, 11, 20059.	1.6	53
7828	Pharmacokinetic Simulation Analysis of Less Frequent Nivolumab and Pembrolizumab Dosing: Pharmacoeconomic Rationale for Dose Deescalation. <i>Journal of Clinical Pharmacology</i> , 2022, 62, 532-540.	1.0	14
7829	The Abscopal Effect: A Review of Pre-Clinical and Clinical Advances. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11061.	1.8	49
7830	Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 355.	7.1	45
7831	PD-1 blockade therapy augments the antitumor effects of lymphodepletion and adoptive T cell transfer. <i>Cancer Immunology, Immunotherapy</i> , 2021, , 1.	2.0	1
7832	Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2021, 22, 1530-1540.	5.1	130
7833	Progress on Ras/MAPK Signaling Research and Targeting in Blood and Solid Cancers. <i>Cancers</i> , 2021, 13, 5059.	1.7	39
7834	Tumour burden and efficacy of immune-checkpoint inhibitors. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 75-90.	12.5	111
7835	Genomic and transcriptomic correlates of immunotherapy response within the tumor microenvironment of leptomeningeal metastases. <i>Nature Communications</i> , 2021, 12, 5955.	5.8	25
7836	Is there a role for neoadjuvant anti-PD-1 therapies in glioma?. <i>Current Opinion in Neurology</i> , 2021, Publish Ahead of Print, 834-839.	1.8	0

#	ARTICLE	IF	CITATIONS
7837	Conditional PD-1/PD-L1 Probody Therapeutics Induce Comparable Antitumor Immunity but Reduced Systemic Toxicity Compared with Traditional Anti-PD-1/PD-L1 Agents. <i>Cancer Immunology Research</i> , 2021, 9, 1451-1464.	1.6	15
7838	Immune checkpoint inhibitors for cancer and venous thromboembolic events. <i>European Journal of Cancer</i> , 2021, 158, 99-110.	1.3	35
7839	Drug-eluting immune checkpoint blockade antibody-nanoparticle conjugate enhances locoregional and systemic combination cancer immunotherapy through T lymphocyte targeting. <i>Biomaterials</i> , 2021, 279, 121184.	5.7	10
7840	Immunotherapy in Melanoma, Gastrointestinal (GI), and Pulmonary Malignancies. <i>AIMS Public Health</i> , 2015, 2, 86-114.	1.1	1
7841	Nivolumab in Metastatic Non-Small Cell Lung Cancer. <i>Journal of the Advanced Practitioner in Oncology</i> , 2016, 7, .	0.2	0
7842	TG4010 immunotherapy: a novel weapon against advanced non-small cell lung cancer?. <i>Annals of Translational Medicine</i> , 2016, 4, 185-185.	0.7	0
7843	2015 Review of Newly Approved Oncologic Therapies. <i>Journal of the Advanced Practitioner in Oncology</i> , 2016, 7, 268-270.	0.2	0
7844	Evolving Paradigms in Melanoma Therapy. <i>Journal of the Advanced Practitioner in Oncology</i> , 2016, 7, 291-294.	0.2	1
7845	Value and Financial Toxicity of New Cancer Drugs. <i>Journal of the Advanced Practitioner in Oncology</i> , 2016, 7, .	0.2	0
7846	Advances in lung cancer with a focus on ATS 2016 updates. <i>Journal of Thoracic Disease</i> , 2016, 8, S566-S568.	0.6	0
7848	Biomarkers/Molecular Targets, Immunotherapy, and Treatments for Non-Small Cell Lung Cancer. <i>Journal of the Advanced Practitioner in Oncology</i> , 2016, 7, 514-524.	0.2	1
7849	How Checkpoint Inhibitors Are Changing the Treatment Paradigm in Solid Tumors: What Advanced Practitioners in Oncology Need to Know. <i>Journal of the Advanced Practitioner in Oncology</i> , 2016, 7, .	0.2	3
7850	Immunotherapy in Cancer: Incremental Gain or a Quantum Leap?. <i>Oman Medical Journal</i> , 2017, 32, 1-2.	0.3	0
7851	Saudi lung cancer management guidelines 2017: Improving lung cancer care in Saudi region. <i>Annals of Thoracic Medicine</i> , 2017, 12, 219.	0.7	0
7852	What Can We Save for the First-Line Treatment of NSCLC in 2016?. <i>World Journal of Oncology</i> , 2017, 8, 31-33.	0.6	4
7853	Moving the mountain in advanced non-small-cell lung cancer: evolving immunotherapies for a dire disease. <i>Translational Cancer Research</i> , 2017, 6, S151-S157.	0.4	2
7854	A T cell equation as a conceptual model of T cell responses for maximizing the efficacy of cancer immunotherapy. <i>SOJ Immunology</i> , 2017, 5, 1-5.	0.2	0
7855	Advances in the Use of Immunotherapy in Oncology. <i>Journal of the Advanced Practitioner in Oncology</i> , 2017, 8, 221-225.	0.2	0

#	ARTICLE	IF	CITATIONS
7856	Management of Patients With Skin Cancers: Basal Cell Carcinoma and Melanoma. <i>Journal of the Advanced Practitioner in Oncology</i> , 2017, 8, 244-248.	0.2	0
7857	Vitamin D receptor activation reduces VCaP xenograft tumor growth and counteracts ERG activity despite induction of TMPRSS2:ERG. <i>Oncotarget</i> , 2017, 8, 44447-44464.	0.8	1
7858	Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience. <i>Oncotarget</i> , 2017, 8, 87163-87173.	0.8	0
7859	Co-inhibitory receptor programmed cell death protein 1 targets co-stimulatory CD28. <i>Translational Cancer Research</i> , 2017, 6, S1080-S1083.	0.4	2
7860	Immunotherapy Through the Years. <i>Journal of the Advanced Practitioner in Oncology</i> , 2017, 8, .	0.2	14
7861	Programmed death 1 (PD-1) and PD-1 ligand (PD-L1) expression in chronic apical periodontitis. <i>European Endodontic Journal</i> , 2018, 4, 3-8.	0.4	3
7862	Expression and Comparison of Cbl-b in Lung Squamous Cell Carcinoma and Adenocarcinoma. <i>Medical Science Monitor</i> , 2018, 24, 623-635.	0.5	3
7864	Cardiovascular and Cancer Risk: The Role of Cardio-oncology. <i>Journal of the Advanced Practitioner in Oncology</i> , 2018, 9, .	0.2	9
7865	5. Nephrotoxicity of Chemotherapy Agents. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2018, 107, 865-871.	0.0	2
7866	Implications of the HDAC6-ERK1 feed forward loop in immunotherapy. <i>Journal of Immunological Sciences</i> , 2018, 2, 59-68.	0.5	2
7867	Advances in radiation therapy for thoracic malignancies. <i>Journal of Thoracic Disease</i> , 2018, 10, S2431-S2436.	0.6	0
7868	Are lung adenocarcinoma mutations shaping the immune microenvironment?. <i>Translational Cancer Research</i> , 2018, 7, S740-S742.	0.4	2
7869	Docetaxel increases the risk of severe infections in the treatment of non-small cell lung cancer: a meta-analysis. <i>Oncoscience</i> , 2018, 5, 220-238.	0.9	6
7870	Gut Microbiome and the Response to Immunotherapy in Cancer. <i>Discoveries</i> , 2018, 6, e84.	1.5	4
7871	Treatment of induction in resectable NSCLC with chemotherapy, followed by surgery and erlotinib. <i>Annals of Translational Medicine</i> , 2018, 6, S31-S31.	0.7	0
7872	Genomic biomarker of checkpoint efficacy, highways for precision medicine in lung cancer. <i>Oncotarget</i> , 2018, 9, 36547-36548.	0.8	0
7873	Pneumonitis in Combined Anti-programmed Death-1 Immunotherapy and Radiation Therapy for Renal Cell Carcinoma. <i>Cureus</i> , 2018, 10, e3748.	0.2	0
7874	Managing Checkpoint Inhibitor Symptoms and Toxicity. , 2019, , 1-28.		0

#	ARTICLE	IF	CITATIONS
7875	Immunotherapy with subcutaneous injection of immunomodulatory agent (OK-432) elicits durable response in locally advanced or relapsed cervical cancer. <i>Gynecology and Minimally Invasive Therapy</i> , 2019, 8, 80.	0.2	2
7876	Relationship between Programmed Cell Death Protein Ligand 1 Expression and Immune-related Adverse Events in Non-small-cell Lung Cancer Patients Treated with Pembrolizumab. <i>JMA Journal</i> , 2019, 3, 58-66.	0.6	13
7877	Targeting the "undruggable" RAS - new strategies - new hope?. , 2019, 2, 813-826.		2
7878	A case of sudden renal dysfunction caused by pembrolizumab for malignant melanoma on the left heel and successfully treated with steroid. <i>Skin Cancer</i> , 2019, 33, 201-205.	0.1	0
7879	Mechanism of resistance to immune checkpoint inhibitors. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2019, 2, 178-188.	0.9	3
7880	Opportunities and challenges of implementing Pharmacogenomics in cancer drug development. , 2019, 2, 43-52.		4
7881	The Kidney in Patients with Cancer. , 2019, , 337-346.		0
7882	Human Leukocyte Antigen Class I and Programmed Death-Ligand 1 Coexpression Is an Independent Poor Prognostic Factor in Adenocarcinoma of the Lung. <i>Journal of Pathology and Translational Medicine</i> , 2019, 53, 86-93.	0.4	3
7883	Chronic obstructive pulmonary disease alters immune cell composition and immune checkpoint inhibitor efficacy in non-small cell lung cancer. <i>Annals of Translational Medicine</i> , 2019, 7, S42-S42.	0.7	3
7884	Checkpoint Inhibitor Immunotherapy for Head and Neck Cancer: Incorporating Care Step Pathways for Effective Side-Effect Management. <i>Journal of the Advanced Practitioner in Oncology</i> , 2019, 10, 37-46.	0.2	5
7885	Immune-Related Adverse Events From Immunotherapy: Incorporating Care Step Pathways to Improve Management Across Tumor Types. <i>Journal of the Advanced Practitioner in Oncology</i> , 2019, 10, 47-62.	0.2	8
7886	An extended overall survival analysis of pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced non-squamous non-small cell lung cancer. <i>Annals of Translational Medicine</i> , 2019, 7, S53-S53.	0.7	5
7887	Management of Adverse Events Induced by Immune Checkpoint Inhibitors in Lung Cancer Treatment. <i>Japanese Journal of Lung Cancer</i> , 2019, 59, 231-237.	0.0	0
7888	Nivolumab-induced Third Degree Atrioventricular Block in a Patient with Stage IV Squamous Cell Lung Carcinoma. <i>Cureus</i> , 2019, 11, e4869.	0.2	7
7889	Programmed death ligand 1 (PD-L1) expression in parathyroid tumors. <i>Endocrine Connections</i> , 2019, 8, 887-897.	0.8	7
7890	Chronic nicotine exposure affects programmed death-ligand 1 expression and sensitivity to epidermal growth factor receptor-tyrosine kinase inhibitor in lung cancer. <i>Translational Cancer Research</i> , 2019, 8, S378-S388.	0.4	3
7891	Extended follow-up on KEYNOTE-024 suggests significant survival benefit for pembrolizumab in patients with PD-L1 ≥50%, but unanswered questions remain. <i>Annals of Translational Medicine</i> , 2019, 7, S127-S127.	0.7	7
7892	Combined Immunotherapy in Metastatic Melanoma with Unknown Primary. <i>Cureus</i> , 2019, 11, e5324.	0.2	1

#	ARTICLE	IF	CITATIONS
7893	Patterns of Radiotherapy Utilization for Lung Cancer Patients with Brain Metastases: A Population-based Analysis. <i>Cureus</i> , 2019, 11, e5591.	0.2	1
7894	The dark side of immunotherapy: challenges facing the new hope in cancer treatment. <i>Annals of Translational Medicine</i> , 2019, 7, S183-S183.	0.7	5
7895	Clinicopathological characteristics with EGFR, ALK, ROS1 genetic alternation and prognostic analysis of primary lymphoepithelioma-like carcinoma. <i>Translational Cancer Research</i> , 2019, 8, 2350-2356.	0.4	0
7896	The role of immune checkpoint inhibitors (ICI) in the treatment of metastatic non-small cell lung carcinoma in the elderly. <i>Annals of Translational Medicine</i> , 2019, 7, S383-S383.	0.7	2
7897	Immune-related adverse events associated with cancer immunotherapy. <i>Practical Oncology</i> , 2019, 2, 24-44.	0.1	0
7899	Manipulation of the immune system by non-small cell lung cancer and possible therapeutic interference. , 2020, 3, 710-725.		2
7900	Timing of changing therapy from gemcitabine and cisplatin chemotherapy based on real-world data of advanced urothelial carcinoma. <i>Oncology Letters</i> , 2020, 19, 2943-2949.	0.8	4
7901	Combination of pembrolizumab and 125I attenuates the aggressiveness of non-small cell lung cancer. <i>Oncology Letters</i> , 2020, 19, 4142-4150.	0.8	1
7902	Long-term response to ipilimumab after nivolumab failure in a case of anorectal melanoma with an intermediate tumor mutation burden and negative for PD-L1 expression. <i>Molecular and Clinical Oncology</i> , 2020, 13, 175-178.	0.4	2
7903	A Case of Acute Heart Failure Following Immunotherapy for Metastatic Lung Cancer. <i>Cureus</i> , 2020, 12, e8093.	0.2	7
7904	In vitro and in vivo synergistic efficacy of ceritinib combined with programmed cell death ligand-1 inhibitor in anaplastic lymphoma kinase-rearranged non-small cell lung cancer. <i>Cancer Science</i> , 2020, 111, 1887-1898.	1.7	8
7905	Checkpoint Inhibitor in a Melanoma Patient With Polyendocrinopathy and Gangrenous Gall Bladder With a Mass. <i>Cureus</i> , 2020, 12, e8786.	0.2	0
7906	Endobronchial Malignant Melanoma: An Exceedingly Rare Occurrence. <i>Cureus</i> , 2020, 12, e8619.	0.2	0
7907	Cellular heterogeneity map of diverse immune and stromal phenotypes within breast tumor microenvironment. <i>PeerJ</i> , 2020, 8, e9478.	0.9	5
7908	Radio-Immunotherapy: A Case Report of "Abscopal Hyper-Progression"? <i>Cureus</i> , 2020, 12, e10117.	0.2	2
7909	Tumor Genotype Is Shaping Immunophenotype and Responses to Immune Checkpoint Inhibitors in Solid Tumors. <i>Journal of Immunotherapy and Precision Oncology</i> , 2020, 3, 121-127.	0.6	1
7910	A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG) <i>TJ ETQq0.0 0 rgBT4/Overlock</i>	0.2	0
7911	4-(N)-Docosahexaenoyl 2 TM , 2 TM -difluorodeoxycytidine induces immunogenic cell death in colon and pancreatic carcinoma models as a single agent. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 59-69.	1.1	3

#	ARTICLE	IF	CITATIONS
7912	<scp>NKG2A</scp> is a late immune checkpoint on <scp>CD8</scp> T cells and marks repeated stimulation and cell division. International Journal of Cancer, 2022, 150, 688-704.	2.3	22
7913	Nivolumab-Induced Crescentic Immunoglobulin A Nephropathy With Henoch-Schonlein Purpura Features in a Patient Diagnosed With Hepatocellular Carcinoma. Cureus, 2021, 13, e19110.	0.2	1
7914	Replication stress response defects are associated with response to immune checkpoint blockade in nonhypermuted cancers. Science Translational Medicine, 2021, 13, eabe6201.	5.8	19
7915	Mechanisms of Immune Checkpoint Inhibitor-Mediated Colitis. Frontiers in Immunology, 2021, 12, 768957.	2.2	22
7916	The Potential Advantage of Targeting Both PD-L1/PD-L2/PD-1 and IL-10â€“IL-10R Pathways in Acute Myeloid Leukemia. Pharmaceuticals, 2021, 14, 1105.	1.7	6
7917	Immune Checkpoint Inhibitors for Genitourinary Cancers: Treatment Indications, Investigational Approaches and Biomarkers. Cancers, 2021, 13, 5415.	1.7	13
7918	p21 produces a bioactive secretome that places stressed cells under immunosurveillance. Science, 2021, 374, eabb3420.	6.0	112
7919	Long-term outcomes in patients with advanced and/or metastatic nonâ€“small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real-world data (KCSG LU20â€“1). Cancer, 2022, 128, 778-787.	2.0	23
7920	Rescue liver re-transplantation after graft loss due to severe rejection in the setting of pre-transplant nivolumab therapy. Clinical Journal of Gastroenterology, 2021, 14, 1718-1724.	0.4	16
7921	Programmed Cell Death Protein Ligand 2 Is a Potential Biomarker That Predicts the Efficacy of Immunotherapy. Disease Markers, 2021, 2021, 1-10.	0.6	2
7922	Enhancing T Cell Chemotaxis and Infiltration in Glioblastoma. Cancers, 2021, 13, 5367.	1.7	10
7923	Dynamics of Early Serum Tumour Markers and Neutrophil-to-Lymphocyte Ratio Predict Response to PD-1/PD-L1 Inhibitors in Advanced Non-Small-Cell Lung Cancer. Cancer Management and Research, 2021, Volume 13, 8241-8255.	0.9	11
7924	TCF-1+ PD-1+ CD8+T cells are associated with the response to PD-1 blockade in non-small cell lung cancer patients. Journal of Cancer Research and Clinical Oncology, 2022, 148, 2653-2660.	1.2	4
7925	Elimination of acquired resistance to PD-1 blockade via the concurrent depletion of tumour cells and immunosuppressive cells. Nature Biomedical Engineering, 2021, 5, 1306-1319.	11.6	21
7926	Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. Journal of Clinical Oncology, 2021, 39, 4073-4126.	0.8	580
7927	Synergy between <i>Toxoplasma gondii</i> type IÎ” <i>GRA17</i> immunotherapy and PD-L1 checkpoint inhibition triggers the regression of targeted and distal tumors. , 2021, 9, e002970.		19
7928	MicroRNA-889-3p restrains the proliferation and epithelialâ€“mesenchymal transformation of lung cancer cells via down-regulation of Homeodomain-interacting protein kinase 1. Bioengineered, 2021, 12, 10945-10958.	1.4	7
7929	Immune-related Adverse Effects Associated with Programmed Death-1 Inhibitor Therapy in the Treatment of Non-Small Cell Lung Cancer: Incidence, Management, and Effect on Outcomes. , 2021, 25, 1-1.		4

#	ARTICLE	IF	CITATIONS
7930	Onco-Nephrology: Acute Kidney Injury in Critically Ill Cancer Patients. Annual Update in Intensive Care and Emergency Medicine, 2020, , 531-539.	0.1	0
7931	The tumor microenvironment of pancreatic adenocarcinoma and immune checkpoint inhibitor resistance: a perplex relationship. , 2020, 3, 699-709.		0
7932	Platinum versus immunotherapy for unresectable esophageal cancer. Medicine (United States), 2020, 99, e23537.	0.4	0
7933	Gene modification strategies using AOâ€mediated exon skipping and CRISPR/Cas9 as potential therapies for Duchenne muscular dystrophy patients. Engineering Biology, 2020, 4, 37-42.	0.8	0
7934	Is hyperprogressive disease a specific phenomom of immunotherapy?. Exploration of Targeted Anti-tumor Therapy, 2020, 1, .	0.5	1
7935	Response evaluation after immunotherapy in NSCLC. Medicine (United States), 2020, 99, e23815.	0.4	8
7936	Manejo de las toxicidades inmunomediadas en los pacientes con melanoma. Piel, 2020, 35, 649-660.	0.0	0
7937	Effects of Clinicopathological Characteristics on the Survival of Patients Treated with PD-1/PD-L1 Inhibitor Monotherapy or Combination Therapy for Advanced Cancer: A Systemic Review and Meta-Analysis. Journal of Immunology Research, 2020, 2020, 1-11.	0.9	8
7938	Tumor immune microenvironment lncRNAs. Briefings in Bioinformatics, 2022, 23, .	3.2	77
7939	The Simultaneous Onset of Pancreatitis and Colitis as Immune-related Adverse Events in a Patient Receiving Nivolumab Treatment for Renal Cell Carcinoma. Internal Medicine, 2022, 61, 1485-1490.	0.3	3
7940	Cancer Treatment Response to Checkpoint Inhibitors Is Associated with Cytomegalovirus Infection. Cureus, 2020, 12, e6670.	0.2	3
7941	The prevalence of tumour markers in malignant pleural effusions associated with primary pulmonary adenocarcinoma: a retrospective study. European Clinical Respiratory Journal, 2021, 8, 1984375.	0.7	0
7942	Randomized phase 3 open label study of quality of life of patients on Pemetrexed versus Erlotinib as maintenance therapy for advanced non squamous non EGFR mutated non small cell lung cancer. Oncotarget, 2019, 10, 6297-6307.	0.8	1
7943	Acute Renal Failure in Critically Ill Cancer Patients. , 2020, , 921-936.		0
7944	Renal Toxicity. Advances in Experimental Medicine and Biology, 2020, 1244, 287-293.	0.8	0
7945	elearning for cancer immunotherapy. Ecancermedalscience, 2020, 14, ed94.	0.6	0
7946	PDâ€™L1 expression in malignant melanomas of the skin and gastrointestinal tract. Oncology Letters, 2020, 19, 2481-2488.	0.8	4
7947	NephrotoxitÃt onkologischer Therapien. , 2020, , 205-220.		0

#	ARTICLE	IF	CITATIONS
7948	Current Status and Future Perspectives of Immunotherapy in Middle-Income Countries: A Single-Center Early Experience. <i>World Journal of Oncology</i> , 2020, 11, 150-157.	0.6	3
7949	CD4/CD8 ratio is a prognostic factor in IgG nonresponders among peptide vaccine-treated ovarian cancer patients. <i>Cancer Science</i> , 2020, 111, 1124-1131.	1.7	10
7950	Immune Checkpoint Inhibitor for Non-small Cell Lung Cancer With Negative or Low Tumor PD-L1 Expression. <i>Cancer Diagnosis & Prognosis</i> , 2021, 1, 173-177.	0.3	2
7951	Safety and Effectiveness of Immune Checkpoint Inhibitors in Older Patients with Cancer: A Systematic Review of 48 Real-World Studies. <i>Drugs and Aging</i> , 2021, 38, 1055-1065.	1.3	8
7952	Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell response. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	15
7953	Immunotherapy in the First-Line Setting in Wild-Type NSCLC. <i>Current Oncology</i> , 2021, 28, 4457-4470.	0.9	10
7954	BDNF Acts as a Prognostic Factor Associated with Tumor-Infiltrating Th2 Cells in Pancreatic Adenocarcinoma. <i>Disease Markers</i> , 2021, 2021, 1-22.	0.6	6
7955	Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer. <i>Molecular Cancer</i> , 2021, 20, 143.	7.9	117
7956	Advances in Pancreatic Ductal Adenocarcinoma Treatment. <i>Cancers</i> , 2021, 13, 5510.	1.7	28
7957	Unravelling Checkpoint Inhibitor Associated Autoimmune Diabetes: From Bench to Bedside. <i>Frontiers in Endocrinology</i> , 2021, 12, 764138.	1.5	22
7958	Comparison of programmed death ligand 1 immunostaining for pancreatic ductal adenocarcinoma between paired cytological and surgical samples. <i>CytoJournal</i> , 2021, 18, 28.	0.8	1
7959	Robust immune response stimulated by in situ injection of CpG/±OX40/cGAMP in ±PD-1-resistant malignancy. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1597-1609.	2.0	2
7960	Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy. <i>BMC Cancer</i> , 2021, 21, 1187.	1.1	6
7961	AMPD1 Is Associated With the Immune Response and Serves as a Prognostic Marker in HER2-Positive Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 749135.	1.3	6
7962	Cost-utility analysis of evolocumab in patients with ASCVD in Italy. <i>Global & Regional Health Technology Assessment</i> , 0, 8, 155-167.	0.2	0
7963	Prognostic Value of Baseline Medications Plus Neutrophil-to-Lymphocyte Ratio in the Effectiveness of Nivolumab and Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer: A Retrospective Study. <i>Frontiers in Oncology</i> , 2021, 11, 770268.	1.3	2
7964	Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose-escalation phase 1 trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 93-103.	1.1	12
7965	The Price of Success: Immune-Related Adverse Events from Immunotherapy in Lung Cancer. <i>Current Oncology</i> , 2021, 28, 4392-4407.	0.9	4

#	ARTICLE	IF	CITATIONS
7966	Risk of colitis in immune checkpoint inhibitors and in chemotherapy/placebo for solid tumors: a systematic review and meta-analysis. <i>Translational Cancer Research</i> , 2020, 9, 4173-4187.	0.4	2
7967	Association of histologic subtypes with genetic alteration and PD-L1 expression in pulmonary adenocarcinoma. <i>Molecular and Clinical Oncology</i> , 2020, 13, 12.	0.4	1
7968	The lymphocyte-to-monocyte ratio could predict the efficacy of PD-1 inhibitors in patients with advanced cancer. <i>Translational Cancer Research</i> , 2020, 9, 4111-4120.	0.4	5
7969	Successful treatment of gastric cancer after complete response of lung cancer by nivolumab: a case report. <i>Surgical Case Reports</i> , 2020, 6, 276.	0.2	0
7970	A novel dual MEK/PDK1 inhibitor 9za retards the cell cycle at G ₀ /G ₁ phase and induces mitochondrial apoptosis in non-small cell lung cancer cells. <i>PeerJ</i> , 2020, 8, e9981.	0.9	2
7971	Postapproval trials versus patient registries: comparability of advanced melanoma patients with brain metastases. <i>Melanoma Research</i> , 2021, 31, 58-66.	0.6	6
7972	Immunotherapy Use in Patients With Lung Cancer and Comorbidities. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 525-536.	1.0	12
7973	Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitor Therapy. <i>Anesthesia and Analgesia</i> , 2021, 132, 374-383.	1.1	8
7974	Lung cancer in HIV-infected patients in the combination antiretroviral treatment era. <i>Translational Lung Cancer Research</i> , 2015, 4, 678-88.	1.3	16
7976	Development and external validation of a diagnostic model for biopsy-proven acute interstitial nephritis using electronic health record data. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 2214-2222.	0.4	11
7977	Gastrointestinal adverse events of immunotherapy. <i>BJR Open</i> , 2021, 3, .	0.4	0
7978	Coexisting opportunities and challenges: In which scenarios can minimal/measurable residual disease play a role in advanced non-small cell lung cancer?. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2021, 33, 574-582.	0.7	5
7979	Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382110396.	0.8	4
7980	IgA Nephropathy that Developed as an Immune-related Adverse Event of Pembrolizumab Complicated with Interstitial Nephritis: A Case Study. <i>Internal Medicine</i> , 2022, , .	0.3	2
7981	Disparities in Tumor Mutational Burden, Immunotherapy Use, and Outcomes Based on Genomic Ancestry in Non-Small-Cell Lung Cancer. <i>JCO Global Oncology</i> , 2021, 7, 1537-1546.	0.8	8
7982	When Should Neuroendovascular Care for Patients With Acute Stroke Be Palliative?. <i>AMA Journal of Ethics</i> , 2021, 23, E783-793.	0.4	7
7983	The Effect of Albumin-Binding Moiety on Tumor Targeting and Biodistribution Properties of ⁶⁷ Ga-Labeled Albumin Binder-Conjugated Alpha-Melanocyte-Stimulating Hormone Peptides. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2022, 37, 47-55.	0.7	1
7984	Complete and Durable Response to Nivolumab in Recurrent Poorly Differentiated Pancreatic Neuroendocrine Carcinoma with High Tumor Mutational Burden. <i>Current Oncology</i> , 2021, 28, 4587-4596.	0.9	4

#	ARTICLE	IF	CITATIONS
7985	Pembrolizumab-Induced Type 1 Diabetes in a 95-Year-Old Veteran With Metastatic Melanoma. , 2021, 38, 520-523.		1
7986	Prediction of Survival Outcome in Lower-Grade Glioma Using a Prognostic Signature with 33 Immune-Related Gene Pairs. International Journal of General Medicine, 2021, Volume 14, 8149-8160.	0.8	7
7987	Efficacy and Safety of Adding Immune Checkpoint Inhibitors to Neoadjuvant Chemotherapy Against Triple-Negative Breast Cancer: A Meta-Analysis of Randomized Controlled Trials. Frontiers in Oncology, 2021, 11, 657634.	1.3	7
7988	The Immune Landscape of Human Primary Lung Tumors Is Th2 Skewed. Frontiers in Immunology, 2021, 12, 764596.	2.2	31
7989	Study on Horizon Scanning by Citation Network Analysis and Text Mining: A Focus on Drug Development Related to T Cell Immune Response. Therapeutic Innovation and Regulatory Science, 2021, , 1.	0.8	3
7990	Current Strategies for Tumor Photodynamic Therapy Combined With Immunotherapy. Frontiers in Oncology, 2021, 11, 738323.	1.3	24
7991	The Role of Neutrophil-to-Lymphocyte Ratio in Predicting Pathological Response for Resectable Nonâ€“Small Cell Lung Cancer Treated with Neoadjuvant Chemotherapy Combined with PD-1 Checkpoint Inhibitors. Cancer Research and Treatment, 2022, 54, 1017-1029.	1.3	7
7992	IgA Nephropathy Secondary to Ipilimumab Use. Case Reports in Nephrology and Dialysis, 2022, 11, 327-333.	0.3	3
7993	New challenges in the combination of radiotherapy and immunotherapy in non-small cell lung cancer. World Journal of Clinical Oncology, 2021, 12, 983-999.	0.9	2
7994	Chemokine level predicts the therapeutic effect of anti-PD-1 antibody (nivolumab) therapy for malignant melanoma. Archives of Dermatological Research, 2021, , 1.	1.1	1
7995	Identification of an Innate Immune-Related Prognostic Signature in Early-Stage Lung Squamous Cell Carcinoma. International Journal of General Medicine, 2021, Volume 14, 9007-9022.	0.8	2
7996	Panâ€“cancer analyses reveal that increased Hedgehog activity correlates with tumor immunosuppression and resistance to immune checkpoint inhibitors. Cancer Medicine, 2021, , .	1.3	10
7997	Plasma complement C7 as a target in non-small cell lung cancer patients to implement 3P medicine strategies. EPMA Journal, 2021, 12, 629-645.	3.3	0
7998	A high OXPHOS CD8 T cell subset is predictive of immunotherapy resistance in melanoma patients. Journal of Experimental Medicine, 2022, 219, .	4.2	37
7999	Neurosurgery at the crossroads of immunology and nanotechnology. New reality in the COVID-19 pandemic. Advanced Drug Delivery Reviews, 2022, 181, 114033.	6.6	5
8000	Melanoma Immunotherapy and Precision Medicine in the Era of Tumor Micro-Tissue Engineering: Where Are We Now and Where Are We Going?. Cancers, 2021, 13, 5788.	1.7	3
8001	CDK4/6 inhibitors: A potential therapeutic approach for triple negative breast cancer. MedComm, 2021, 2, 514-530.	3.1	12
8002	Immunotherapy: A Case Series. Cureus, 2021, 13, e19726.	0.2	2

#	ARTICLE	IF	CITATIONS
8003	Vitamin C, From Supplement to Treatment: A Re-Emerging Adjunct for Cancer Immunotherapy?. <i>Frontiers in Immunology</i> , 2021, 12, 765906.	2.2	12
8004	Checkpoint Inhibition Reduces the Threshold for Drug-Specific T-Cell Priming and Increases the Incidence of Sulfasalazine Hypersensitivity. <i>Toxicological Sciences</i> , 2022, 186, 58-69.	1.4	13
8005	Identification of a novel tumour microenvironmentâ€based prognostic biomarker in skin cutaneous melanoma. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 10990-11001.	1.6	8
8006	Current Progress and Future Perspectives of Immune Checkpoint in Cancer and Infectious Diseases. <i>Frontiers in Genetics</i> , 2021, 12, 785153.	1.1	28
8007	BIPSE: A biomarkerâ€based phase I/II design for immunotherapy trials with progressionâ€free survival endpoint. <i>Statistics in Medicine</i> , 2022, 41, 1205-1224.	0.8	4
8008	Real-world effectiveness of second-line Afatinib versus chemotherapy for the treatment of advanced lung squamous cell carcinoma in immunotherapy-naïve patients. <i>BMC Cancer</i> , 2021, 21, 1225.	1.1	0
8009	The prospect of immunotherapy combined with chemotherapy in patients with advanced non-small cell lung cancer: a narrative review. <i>Annals of Translational Medicine</i> , 2021, 9, 1703-1703.	0.7	9
8010	Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by singleâ€cell transcriptomics. <i>Nature Communications</i> , 2021, 12, 6960.	5.8	53
8011	Natural killer cells and immune-checkpoint inhibitor therapy: Current knowledge and new challenges. <i>Molecular Therapy - Oncolytics</i> , 2022, 24, 26-42.	2.0	26
8012	Avoiding Absolute Quantification Trap: A Novel Predictive Signature of Clinical Benefit to Anti-PD-1 Immunotherapy in Non-Small Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 782106.	2.2	0
8013	Drug eruptions with novel targeted therapies â€ immune checkpoint and EGFR inhibitors. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 1621-1643.	0.4	6
8014	Development and validation of a supervised deep learning algorithm for automated wholeâ€slide programmed deathâ€ligand 1 tumour proportion score assessment in nonâ€small cell lung cancer. <i>Histopathology</i> , 2022, 80, 635-647.	1.6	21
8015	Sudden and severe cardiotoxicity induced with pembrolizumab, its clinical course, therapeutic intervention, and outcome. <i>International Cancer Conference Journal</i> , 2022, 11, 81-86.	0.2	2
8016	Melanoma Targeted Therapies beyond BRAF-Mutant Melanoma: Potential Druggable Mutations and Novel Treatment Approaches. <i>Cancers</i> , 2021, 13, 5847.	1.7	16
8017	A novel model based on liquidâ€liquid phase separationâ€Related genes correlates immune microenvironment profiles and predicts prognosis of lung squamous cell carcinoma. <i>Journal of Clinical Laboratory Analysis</i> , 2021, 36, e24135.	0.9	4
8018	Checkpoint inhibitors: literature review of new treatments for hepatocellular carcinoma. <i>Stem Cell Investigation</i> , 2021, 8, 22-22.	1.3	1
8019	Results of Radiation Therapy as Local Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer. <i>Cancers</i> , 2021, 13, 5773.	1.7	0
8020	Lymphocyte cytosolic protein 2 is a novel prognostic marker in lung adenocarcinoma. <i>Journal of International Medical Research</i> , 2021, 49, 030006052110596.	0.4	7

#	ARTICLE	IF	CITATIONS
8021	Combination Therapy in Renal Cell Carcinoma: the Best Choice for Every Patient?. <i>Current Oncology Reports</i> , 2021, 23, 147.	1.8	15
8022	Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: limitations and prospects: a systematic review. <i>Cell Communication and Signaling</i> , 2021, 19, 117.	2.7	25
8023	Correlation between immune-related adverse events and the efficacy of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: systematic review and meta-analysis. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 1-9.	1.1	10
8024	KRAS mutation: from undruggable to druggable in cancer. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 386.	7.1	255
8025	BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor Microenvironment. <i>Cancer Research</i> , 2022, 82, 264-277.	0.4	8
8026	Overexpression of PD-1 on T cells promotes tolerance in cardiac transplantation via ICOS-dependent mechanisms. <i>JCI Insight</i> , 2021, 6, .	2.3	11
8027	DI-3-N-Butylphthalide Presents Anti-Cancer Activity in Lung Cancer by Targeting PD-1/PD-L1 Signaling. <i>Cancer Management and Research</i> , 2021, Volume 13, 8513-8524.	0.9	3
8028	Advanced Imaging Techniques for Differentiating Pseudoprogression and Tumor Recurrence After Immunotherapy for Glioblastoma. <i>Frontiers in Immunology</i> , 2021, 12, 790674.	2.2	14
8029	Metabolic Reprogramming in the Tumor Microenvironment With Immunocytes and Immune Checkpoints. <i>Frontiers in Oncology</i> , 2021, 11, 759015.	1.3	13
8030	Emerging Approaches for Solid Tumor Treatment Using CAR-T Cell Therapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12126.	1.8	8
8031	Front-Line ICI-Based Combination Therapy Post-TKI Resistance May Improve Survival in NSCLC Patients With EGFR Mutation. <i>Frontiers in Oncology</i> , 2021, 11, 739090.	1.3	19
8032	Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation. <i>BMC Cancer</i> , 2021, 21, 1216.	1.1	8
8033	Complete and durable response of pulmonary large-cell neuroendocrine carcinoma to pembrolizumab. <i>Cancer Reports</i> , 2022, 5, e1589.	0.6	5
8034	CSNK2 in cancer: pathophysiology and translational applications. <i>British Journal of Cancer</i> , 2022, 126, 994-1003.	2.9	20
8035	<i>Fusobacterium nucleatum</i> enhances the efficacy of PD-L1 blockade in colorectal cancer. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 398.	7.1	84
8036	Combination of epigenetic regulation with gene therapy-mediated immune checkpoint blockade induces anti-tumour effects and immune response in vivo. <i>Nature Communications</i> , 2021, 12, 6742.	5.8	45
8037	H4K9me3 is increased in lung adenocarcinoma harboring EGFR-activating mutations and contributes to immunosuppression. <i>Oncogene</i> , 2022, 41, 704-717.	2.6	15
8038	Diabetes and Cancer: Risk, Challenges, Management and Outcomes. <i>Cancers</i> , 2021, 13, 5735.	1.7	40

#	ARTICLE	IF	CITATIONS
8039	Efficacy of single-site radiotherapy plus PD-1 inhibitors vs PD-1 inhibitors for oligometastatic non-small cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 1253-1261.	1.2	11
8040	T Cell Bispecific Antibodies: An Antibody-Based Delivery System for Inducing Antitumor Immunity. <i>Pharmaceuticals</i> , 2021, 14, 1172.	1.7	13
8041	Inhibition of FGFR Reactivates IFN γ Signaling in Tumor Cells to Enhance the Combined Antitumor Activity of Lenvatinib with Anti-PD-1 Antibodies. <i>Cancer Research</i> , 2022, 82, 292-306.	0.4	58
8042	The prognostic impact of mild and severe immune-related adverse events in non-small cell lung cancer treated with immune checkpoint inhibitors: a multicenter retrospective study. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1693-1703.	2.0	18
8043	Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 127-137.	0.8	446
8044	CXCL13 in Cancer and Other Diseases: Biological Functions, Clinical Significance, and Therapeutic Opportunities. <i>Life</i> , 2021, 11, 1282.	1.1	18
8045	PD-1 inhibitors versus chemotherapy as second-line treatment for advanced esophageal squamous cell carcinoma: a meta-analysis. <i>BMC Cancer</i> , 2021, 21, 1195.	1.1	6
8046	Identifying phenotype-associated subpopulations by integrating bulk and single-cell sequencing data. <i>Nature Biotechnology</i> , 2022, 40, 527-538.	9.4	128
8047	Development of a Flow Cytometry Assay to Predict Immune Checkpoint Blockade-Related Complications. <i>Frontiers in Immunology</i> , 2021, 12, 765644.	2.2	5
8048	LncRNA MEG3 promotes chemosensitivity of osteosarcoma by regulating antitumor immunity via miR-21-5p/p53 pathway and autophagy. <i>Genes and Diseases</i> , 2021, , .	1.5	2
8049	Distinct roles but cooperative effect of TLR3/9 agonists and PD-1 blockade in converting the immunotolerant microenvironment of irreversible electroporation-ablated tumors. <i>Cellular and Molecular Immunology</i> , 2021, 18, 2632-2647.	4.8	17
8050	Immune Checkpoints and Innate Lymphoid Cells—New Avenues for Cancer Immunotherapy. <i>Cancers</i> , 2021, 13, 5967.	1.7	11
8051	Effect of targeted therapy and immunotherapy on advanced nonsmall cell lung cancer outcomes in the real world. <i>Cancer Medicine</i> , 2022, 11, 86-93.	1.3	19
8052	The Role of the Tumor Microenvironment and Treatment Strategies in Colorectal Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 792691.	2.2	39
8053	Predictive value of mRNA expression and dynamic changes from immune related biomarkers in liquid biopsies before and after start of pembrolizumab in stage IV non-small cell lung cancer (NSCLC). <i>Translational Lung Cancer Research</i> , 2021, 10, 4106-4119.	1.3	4
8054	Dual inhibition of TGF β 2 and PD-L1: a novel approach to cancer treatment. <i>Molecular Oncology</i> , 2022, 16, 2117-2134.	2.1	53
8055	Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. <i>Lancet Oncology</i> , The, 2021, 22, 1692-1704.	5.1	129
8056	A Phase I/IIa Randomized Trial Evaluating the Safety and Efficacy of SNK01 Plus Pembrolizumab in Patients with Stage IV Non-Small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2021, , .	1.3	5

#	ARTICLE	IF	CITATIONS
8057	Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer. <i>Nature Communications</i> , 2021, 12, 7005.	5.8	66
8058	Neoantigen-Reactive T Cells: The Driving Force behind Successful Melanoma Immunotherapy. <i>Cancers</i> , 2021, 13, 6061.	1.7	5
8059	Tumor metastasis: Mechanistic insights and therapeutic interventions. <i>MedComm</i> , 2021, 2, 587-617.	3.1	42
8060	A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 760737.	2.2	8
8061	Immunotherapy for Melanoma. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 81-111.	0.8	7
8062	Immune System in Action. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 1-43.	0.8	0
8063	An Update on Immune Based Therapies in Acute Myeloid Leukemia: 2021 and Beyond!. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 273-295.	0.8	1
8064	Analysis of human glioma-associated co-inhibitory immune checkpoints in glioma microenvironment and peripheral blood. <i>International Journal of Immunopathology and Pharmacology</i> , 2021, 35, 205873842110565.	1.0	5
8065	Hepatobiliary and Pancreatic Adverse Events. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 339-355.	0.8	6
8066	Pulmonary Toxicities of Immunotherapy. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 357-375.	0.8	4
8067	Interacting Genetic Lesions of Melanoma in the Tumor Microenvironment: Defining a Viable Therapy. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1350, 123-143.	0.8	0
8068	Immunotherapy in Lung Cancer: Are the Promises of Long-Term Benefit Finally Met?. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 113-142.	0.8	5
8069	BDNF expression in GISTs predicts poor prognosis when associated with PD-L1 positive tumor-infiltrating lymphocytes. <i>Oncolmmunology</i> , 2021, 10, 2003956.	2.1	3
8070	Efficacy and Safety of Apatinib in Patients with Recurrent or Refractory Melanoma. <i>Oncologist</i> , 2022, 27, e463-e470.	1.9	7
8071	Immune checkpoint inhibitor rechallenge in advanced or metastatic non-small cell lung cancer: a retrospective cohort study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 3081-3089.	1.2	9
8072	Cancer Immunotherapy with Immune Checkpoint Inhibitors-Biomarkers of Response and Toxicity; Current Limitations and Future Promise. <i>Diagnostics</i> , 2022, 12, 124.	1.3	12
8073	Immune-related lncRNA pairs as novel signature to predict prognosis and immune landscape in melanoma patients. <i>Medicine (United States)</i> , 2022, 101, e28531.	0.4	2
8074	Elevated Baseline Serum PD-L1 Level May Predict Poor Outcomes from Breast Cancer in African-American and Hispanic Women. <i>Journal of Clinical Medicine</i> , 2022, 11, 283.	1.0	2

#	ARTICLE	IF	CITATIONS
8075	Successful immune checkpoint inhibitor-based rechallenge in a patient with advanced esophageal squamous cell cancer: A case report. <i>Thoracic Cancer</i> , 2022, , .	0.8	2
8076	Digital gene expression analysis of NSCLC-patients reveals strong immune pressure, resulting in an immune escape under immunotherapy. <i>BMC Cancer</i> , 2022, 22, 46.	1.1	6
8077	Immunotherapy toxicity: identification and management. <i>Breast Cancer Research and Treatment</i> , 2022, 192, 1-17.	1.1	24
8078	A Combined-Radiomics Approach of CT Images to Predict Response to Anti-PD-1 Immunotherapy in NSCLC: A Retrospective Multicenter Study. <i>Frontiers in Oncology</i> , 2021, 11, 688679.	1.3	13
8079	Insights Into the Prognostic Value and Immunological Role of NAAA in Pan-Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 812713.	2.2	3
8080	Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 752-761.	0.8	189
8081	TGF β 2 Induces the Soluble Isoform of CTLA-4 – Implications for CTLA-4 Based Checkpoint Inhibitor Antibodies in Malignant Melanoma. <i>Frontiers in Immunology</i> , 2021, 12, 763877.	2.2	5
8082	Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency. <i>Nature Medicine</i> , 2022, 28, 125-135.	15.2	53
8083	OUP accepted manuscript. <i>Oncologist</i> , 2022, , .	1.9	1
8084	Immune Checkpoint Inhibitor-related New-onset Thyroid Dysfunction: A Retrospective Analysis Using the US FDA Adverse Event Reporting System. <i>Oncologist</i> , 2022, 27, e126-e132.	1.9	8
8085	Immune-related Thyroid Dysfunction (irTD) in Non-small Cell Lung Cancer (NSCLC) Correlates With Response and Survival. <i>Cancer Diagnosis & Prognosis</i> , 2022, 2, 55-63.	0.3	2
8086	Integrative analysis of CRISPR screening data uncovers new opportunities for optimizing cancer immunotherapy. <i>Molecular Cancer</i> , 2022, 21, 2.	7.9	14
8087	Soluble PD-L1 works as a decoy in lung cancer immunotherapy via alternative polyadenylation. <i>JCI Insight</i> , 2022, 7, .	2.3	20
8088	Antitumor Peptide-Based Vaccine in the Limelight. <i>Vaccines</i> , 2022, 10, 70.	2.1	10
8089	Intratumorally injected alum-tethered cytokines elicit potent and safer local and systemic anticancer immunity. <i>Nature Biomedical Engineering</i> , 2022, 6, 129-143.	11.6	56
8090	Factors Determining Long-Term Antitumor Responses to Immune Checkpoint Blockade Therapy in Melanoma. <i>Frontiers in Immunology</i> , 2021, 12, 810388.	2.2	9
8091	Integrating Quality of Life in the Care Pathway of Cancer Patients Undergoing Immunotherapy Treatment: Descriptive, Cross-sectional Survey of an Online Patient Community's Experiences and Expectations. <i>Journal of Medical Internet Research</i> , 2022, 24, e25792.	2.1	0
8092	A lepidic gene signature predicts patient prognosis and sensitivity to immunotherapy in lung adenocarcinoma. <i>Genome Medicine</i> , 2022, 14, 5.	3.6	25

#	ARTICLE	IF	CITATIONS
8093	Prognostic value of immune related genes in lung adenocarcinoma. <i>Oncology Letters</i> , 2020, 20, 1-1.	0.8	5
8094	Phase I trial of nedaplatin and Sâ€1 in patients with advanced squamous cell lung cancer. <i>Molecular and Clinical Oncology</i> , 2020, 13, 1-1.	0.4	1
8095	Intracranial radiotherapy with or without immune checkpoint inhibition for brain metastases: a systematic review and meta-analysis. <i>Translational Cancer Research</i> , 2020, 9, 5909-5924.	0.4	4
8096	Enumeration and molecular characterization of circulating tumor cells enriched by microcavity array from stage III non-small cell lung cancer patients. <i>Translational Lung Cancer Research</i> , 2020, 9, 1974-1985.	1.3	7
8097	CD204â€positive macrophages accumulate in breast cancer tumors with high levels of infiltrating lymphocytes and programmed death ligandâ€1 expression. <i>Oncology Letters</i> , 2020, 21, 1-1.	0.8	5
8098	Current Trends in Anti-Cancer Molecular Targeted Therapies: Renal Complications and Their Histological Features. <i>Journal of Nippon Medical School</i> , 2022, 89, 128-138.	0.3	4
8099	Adverse events of different PD-1 inhibitors in lung cancer patients: a real-world study. <i>Annals of Translational Medicine</i> , 2022, 10, 183-183.	0.7	7
8100	Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study. <i>Frontiers in Oncology</i> , 2021, 11, 683502.	1.3	21
8101	NephrotoxizitÄt von Krebsmedikamenten: Supportive Strategien zum Schutz der Nieren. , 0, , .		0
8102	Immunotherapy of cancer in the era of checkpoint inhibitor. <i>Clinical and Experimental Metastasis</i> , 2021, 39, 231.	1.7	1
8103	Immunotherapy plus chemotherapy showed superior clinical benefit to chemotherapy alone in advanced NSCLC patients after progression on osimertinib. <i>Thoracic Cancer</i> , 2022, 13, 394-403.	0.8	7
8104	Treatment with immune checkpoint inhibitors after EGFRâ€TKIs in EGFR â€mutated lung cancer. <i>Thoracic Cancer</i> , 2022, 13, 386-393.	0.8	8
8105	Signal pathways of melanoma and targeted therapy. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 424.	7.1	115
8106	Prognostic Value and Correlation With Tumor Immune Infiltration of a Novel Metabolism-Related Gene Signature in Pancreatic Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 757791.	1.3	4
8107	Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects. <i>Cells</i> , 2022, 11, 320.	1.8	43
8108	Analysis of PD-1, PD-L1, and T-cell infiltration in angiosarcoma pathogenetic subgroups. <i>Immunologic Research</i> , 2022, 70, 256-268.	1.3	4
8109	Epigenetic Modification of PD-1/PD-L1-Mediated Cancer Immunotherapy against Melanoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1119.	1.8	10
8110	Clinical research in oncology: in memory of Professor Gordon McVie. <i>Ecancelmedicalscience</i> , 2022, 16, 1340.	0.6	1

#	ARTICLE	IF	CITATIONS
8111	Peripheral lymphocyte count as a surrogate marker of immune checkpoint inhibitor therapy outcomes in patients with non-small-cell lung cancer. <i>Scientific Reports</i> , 2022, 12, 626.	1.6	14
8112	Senescence induction dictates response to chemo- and immunotherapy in preclinical models of ovarian cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	33
8113	Preclinical Pharmacokinetics and Dosimetry of an ⁸⁹ Zr Labelled Anti-PDL1 in an Orthotopic Lung Cancer Murine Model. <i>Frontiers in Medicine</i> , 2021, 8, 741855.	1.2	2
8114	Low-Dose Nivolumab with or without Ipilimumab as Adjuvant Therapy Following the Resection of Melanoma Metastases: A Sequential Dual Cohort Phase II Clinical Trial. <i>Cancers</i> , 2022, 14, 682.	1.7	6
8115	Correlation between Programmed Death Ligand-1 (PD-L1) Expression and Driver Gene Mutations in Non-Small Cell Lung Carcinoma- Adenocarcinoma Phenotype. <i>Asian Pacific Journal of Cancer Prevention</i> , 2022, 23, 131-142.	0.5	0
8116	CD73 and PD-L1 as Potential Therapeutic Targets in Gallbladder Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1565.	1.8	7
8117	Immune checkpoint-targeted antibodies: a room for dose and schedule optimization?. <i>Journal of Hematology and Oncology</i> , 2022, 15, 6.	6.9	17
8118	Tumor-Infiltrating Lymphocytes in Colorectal Cancer: The Fundamental Indication and Application on Immunotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 808964.	2.2	53
8119	Neurotoxicity of Tumor Immunotherapy: The Emergence of Clinical Attention. <i>Journal of Oncology</i> , 2022, 2022, 1-12.	0.6	1
8120	Paraneoplastic Autoimmune Neurological Syndromes and the Role of Immune Checkpoint Inhibitors. <i>Neurotherapeutics</i> , 2022, 19, 848-863.	2.1	10
8121	Tumor-endogenous PD-1 promotes cell proliferation and predicts poor survival in non-small cell lung cancer. <i>Translational Cancer Research</i> , 2022, 11, 3-13.	0.4	3
8122	Active Humoral Response Reverts Tumorigenicity through Disruption of Key Signaling Pathway. <i>Vaccines</i> , 2022, 10, 163.	2.1	3
8123	Regulation of activated T cell survival in rheumatic autoimmune diseases. <i>Nature Reviews Rheumatology</i> , 2022, 18, 232-244.	3.5	21
8124	Electrolyte and Acid-Base Disorders Associated with Cancer Immunotherapy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 922-933.	2.2	15
8125	Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses. , 2022, 10, e003853.		16
8126	Vitamin D can reduce severity in COVID-19 through regulation of PD-L1. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2022, 395, 487-494.	1.4	9
8127	The MITRE trial protocol: a study to evaluate the microbiome as a biomarker of efficacy and toxicity in cancer patients receiving immune checkpoint inhibitor therapy. <i>BMC Cancer</i> , 2022, 22, 99.	1.1	14
8128	Metal-based anticancer agents as immunogenic cell death inducers: the past, present, and future. <i>Chemical Society Reviews</i> , 2022, 51, 1212-1233.	18.7	107

#	ARTICLE	IF	CITATIONS
8129	Pyroptosis-related lncRNAs are potential biomarkers for predicting prognoses and immune responses in patients with UCEC. <i>Molecular Therapy - Nucleic Acids</i> , 2022, 27, 1036-1055.	2.3	41
8130	A Need for More Molecular Profiling in Brain Metastases. <i>Frontiers in Oncology</i> , 2021, 11, 785064.	1.3	1
8131	XP-524 is a dual-BET/EP300 inhibitor that represses oncogenic KRAS and potentiates immune checkpoint inhibition in pancreatic cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	16
8132	Identification of potential key molecular biomarkers in lung adenocarcinoma by bioinformatics analysis. <i>Translational Cancer Research</i> , 2022, 11, 227-241.	0.4	0
8133	Nintedanib enhances the efficacy of PD-L1 blockade by upregulating MHC-I and PD-L1 expression in tumor cells. <i>Theranostics</i> , 2022, 12, 747-766.	4.6	28
8134	Breast Cancer Tumor Microenvironment and Molecular Aberrations Hijack Tumoricidal Immunity. <i>Cancers</i> , 2022, 14, 285.	1.7	12
8135	In vitro characterization of a small molecule PD-1 inhibitor that targets the PD-I/PD-L1 interaction. <i>Scientific Reports</i> , 2022, 12, 303.	1.6	6
8136	Effect of prior antibiotic or chemotherapy treatment on immunotherapy response in non-small cell lung cancer. <i>BMC Cancer</i> , 2022, 22, 101.	1.1	11
8137	PET/CT Imaging of Activated Cancer-Associated Fibroblasts Predict Response to PD-1 Blockade in Gastric Cancer Patients. <i>Frontiers in Oncology</i> , 2021, 11, 802257.	1.3	9
8138	OUP accepted manuscript. <i>Oncologist</i> , 2022, 27, e244-e250.	1.9	1
8139	Perspectives of future lung toxicology studies using human pluripotent stem cells. <i>Archives of Toxicology</i> , 2022, 96, 389-402.	1.9	8
8140	Volume of Disease as a Predictor for Clinical Outcomes in Patients With Melanoma Brain Metastases Treated With Stereotactic Radiosurgery and Immune Checkpoint Therapy. <i>Frontiers in Oncology</i> , 2021, 11, 794615.	1.3	2
8141	Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China. <i>Frontiers in Immunology</i> , 2021, 12, 730666.	2.2	31
8142	Enhancement of interleukin-2 production by bovine peripheral blood mononuclear cells treated with the combination of anti-programmed death-ligand 1 and cytotoxic T lymphocyte antigen 4 chimeric monoclonal antibodies. <i>Journal of Veterinary Medical Science</i> , 2022, 84, 6-15.	0.3	2
8143	T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma. <i>Nature Medicine</i> , 2022, 28, 353-362.	15.2	132
8144	Comprehensive analysis of a TNF family based-signature in diffuse gliomas with regard to prognosis and immune significance. <i>Cell Communication and Signaling</i> , 2022, 20, 6.	2.7	15
8145	Immunomodulatory potential of natural products from herbal medicines as immune checkpoints inhibitors: Helping to fight against cancer via multiple targets. <i>Medicinal Research Reviews</i> , 2022, 42, 1246-1279.	5.0	38
8146	Lower baseline autoantibody levels are associated with immune-related adverse events from immune checkpoint inhibition. , 2022, 10, e004008.		28

#	ARTICLE	IF	CITATIONS
8147	Circulating CD137+ T Cells Correlate with Improved Response to Anti-PD1 Immunotherapy in Patients with Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1027-1037.	3.2	10
8148	Combination strategies with PD-1/PD-L1 blockade: current advances and future directions. <i>Molecular Cancer</i> , 2022, 21, 28.	7.9	393
8149	NLRP4 negatively regulates type I interferon response and influences the outcome in anti-programmed cell death protein (PD)-1/PD-L1 therapy. <i>Cancer Science</i> , 2021, , .	1.7	7
8150	Targeting Protein Tyrosine Phosphatase 22 Does Not Enhance the Efficacy of Chimeric Antigen Receptor T Cells in Solid Tumors. <i>Molecular and Cellular Biology</i> , 2022, 42, MCB0044921.	1.1	8
8151	Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC). <i>Annals of Surgical Oncology</i> , 2022, 29, 3694-3708.	0.7	21
8152	Anti-Programmed Death Ligand-1 Induced Acute Vision Loss in a Patient With Cancer-Associated Retinopathy. <i>Cureus</i> , 2022, 14, e21709.	0.2	2
8153	Blocking the inhibitory receptor programmed cell death 1 prevents allergic immune response and anaphylaxis in mice. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 150, 178-191.e9.	1.5	5
8154	Continuation of Pembrolizumab with Additional Chemotherapy after Progression with PD-1/PD-L1 Inhibitor Monotherapy in Patients with Advanced NSCLC: A Randomized, Placebo-Controlled Phase II Study. <i>Clinical Cancer Research</i> , 2022, 28, 2321-2328.	3.2	7
8155	Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. <i>New England Journal of Medicine</i> , 2022, 386, 24-34.	13.9	766
8156	Pre- and on-treatment lactate dehydrogenase as a prognostic and predictive biomarker in advanced non-small cell lung cancer. <i>Cancer</i> , 2022, 128, 1574-1583.	2.0	14
8157	Loss of SMAD4 Is Associated With Poor Tumor Immunogenicity and Reduced PD-L1 Expression in Pancreatic Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 806963.	1.3	14
8158	Exosome application in tumorigenesis: diagnosis and treatment of melanoma. <i>Medical Oncology</i> , 2022, 39, 19.	1.2	7
8159	Autoimmune retinopathy with associated anti-retinal antibodies as a potential immune-related adverse event associated with immunotherapy in patients with advanced cutaneous melanoma: case series and systematic review. <i>BMJ Open Ophthalmology</i> , 2022, 7, e000889.	0.8	10
8160	Clinical features as potential prognostic factors in patients treated with nivolumab for highly pretreated metastatic gastric cancer: a multicenter retrospective study. <i>BMC Cancer</i> , 2022, 22, 22.	1.1	6
8161	Preferences for Renal Cell Carcinoma Pharmacological Treatment: A Discrete Choice Experiment in Patients and Oncologists. <i>Frontiers in Oncology</i> , 2021, 11, 773366.	1.3	5
8162	Clinical efficacy of nivolumab is associated with tertiary lymphoid structures in surgically resected primary tumors of recurrent gastric cancer. <i>PLoS ONE</i> , 2022, 17, e0262455.	1.1	12
8163	Exploring the synergistic effects of cabozantinib and a programmed cell death protein 1 inhibitor in metastatic renal cell carcinoma with machine learning. <i>Oncotarget</i> , 2022, 13, 237-256.	0.8	2
8164	OUP accepted manuscript. <i>Oncologist</i> , 2022, 27, 245-250.	1.9	1

#	ARTICLE	IF	CITATIONS
8165	GBE1 Is an Independent Prognostic Marker and Associated With CD163+ Tumor-Associated Macrophage Infiltration in Lung Adenocarcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 781344.	1.3	4
8166	<scp>PD‑</scp> and <scp>PD‒</scp> expression in pancreatic ductal adenocarcinoma and their correlation with immune infiltrates and <scp>DNA</scp> damage response molecules. <i>Journal of Pathology: Clinical Research</i> , 2022, 8, 257-267.	1.3	9
8167	Prognostic implication of CTLA-4, PD-1, and PD-L1 expression in aggressive adult T-cell leukemia—lymphoma. <i>Annals of Hematology</i> , 2022, 101, 799.	0.8	2
8168	Efficacy and predictors of rechallenge with immune checkpoint inhibitors in non–small cell lung cancer. <i>Thoracic Cancer</i> , 2022, 13, 624-630.	0.8	9
8169	Prognostic and Predictive Value of BGN in Colon Cancer Outcomes and Response to Immunotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 761030.	1.3	6
8170	Limitations and opportunities of technologies for the analysis of cell-free DNA in cancer diagnostics. <i>Nature Biomedical Engineering</i> , 2022, 6, 232-245.	11.6	56
8171	A Ferroptosis-Related Gene Prognostic Index to Predict Temozolomide Sensitivity and Immune Checkpoint Inhibitor Response for Glioma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 812422.	1.8	5
8172	PD1/PD-L1 immune checkpoint as a potential target for preventing brain tumor progression. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2067-2075.	2.0	24
8173	Phase I Trial of Definitive Concurrent Chemoradiotherapy and Trametinib for KRAS-Mutated Non-Small Cell Lung Cancer. <i>Cancer Treatment and Research Communications</i> , 2022, 30, 100514.	0.7	5
8174	PDL-1 Expression and Survival in Metastatic Non-small Cell Lung Cancer Patients Who Received Chemotherapy as First-Line Treatment. , 2022, 23, 45-51.		0
8175	Identification of Epithelial Mesenchymal Transition-Related lncRNAs Associated with Prognosis and Tumor Immune Microenvironment of Hepatocellular Carcinoma. <i>Disease Markers</i> , 2022, 2022, 1-17.	0.6	2
8176	Expression of Immunomodulatory Checkpoint Molecules in Drug-Resistant Neuroblastoma: An Exploratory Study. <i>Cancers</i> , 2022, 14, 751.	1.7	5
8177	T cell subtype profiling measures exhaustion and predicts anti-PD-1 response. <i>Scientific Reports</i> , 2022, 12, 1342.	1.6	7
8178	Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies. , 2022, 10, e003024.		15
8179	Induction chemoimmunotherapy followed by CD8+ immune cell-based patient selection for chemotherapy-free radioimmunotherapy in locally advanced head and neck cancer. , 2022, 10, e003747.		23
8180	Combination of genetically engineered T cells and immune checkpoint blockade for the treatment of cancer. <i>Immunotherapy Advances</i> , 2022, 2, .	1.2	8
8181	Histone Acetylation Regulator-Mediated Acetylation Patterns Define Tumor Malignant Pathways and Tumor Microenvironment in Hepatocellular Carcinoma. <i>Frontiers in Immunology</i> , 2022, 13, 761046.	2.2	19
8182	Associations between immune-related thyroid dysfunction and efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1795-1812.	2.0	31

#	ARTICLE	IF	CITATIONS
8183	Real-world survival analysis by tumor mutational burden in non-small cell lung cancer: a multisite U.S. study. <i>Oncotarget</i> , 2022, 13, 257-270.	0.8	0
8184	Novel Molecular Determinants of Response or Resistance to Immune Checkpoint Inhibitor Therapies in Melanoma. <i>Frontiers in Immunology</i> , 2021, 12, 798474.	2.2	10
8185	GPR182 limits antitumor immunity via chemokine scavenging in mouse melanoma models. <i>Nature Communications</i> , 2022, 13, 97.	5.8	15
8186	Pembrolizumab-induced Focal Pancreatitis Diagnosed by Endoscopic Ultrasound-guided Fine-needle Aspiration. <i>Internal Medicine</i> , 2022, 61, 2463-2469.	0.3	4
8187	Inflammatory Thoracic Aortic Aneurysm in a Patient with Advanced Lung Adenocarcinoma Treated with Pembrolizumab. <i>Internal Medicine</i> , 2022, 61, 2339-2341.	0.3	4
8188	Insights into Modern Therapeutic Approaches in Pediatric Acute Leukemias. <i>Cells</i> , 2022, 11, 139.	1.8	6
8189	Cancer cell-expressed BTNL2 facilitates tumour immune escape via engagement with IL-17A-producing $\hat{I}^3\hat{I}^T$ cells. <i>Nature Communications</i> , 2022, 13, 231.	5.8	14
8190	Safety and activity of pembrolizumab in combination with rituximab in relapsed or refractory follicular lymphoma. <i>Blood Advances</i> , 2022, 6, 1143-1151.	2.5	21
8191	Risk factors for pneumonitis in patients with non-small cell lung cancer treated with immune checkpoint inhibitors plus chemotherapy: A retrospective analysis. <i>Thoracic Cancer</i> , 2022, 13, 724-731.	0.8	10
8192	Predictable Clinical Benefits without Evidence of Synergy in Trials of Combination Therapies with Immune-Checkpoint Inhibitors. <i>Clinical Cancer Research</i> , 2022, 28, 368-377.	3.2	40
8193	Combining Analysis of Tumor-infiltrating Lymphocytes (TIL) and PD-L1 Refined the Prognostication of Breast Cancer Subtypes. <i>Oncologist</i> , 2022, 27, e313-e327.	1.9	14
8194	Recalibration and validation of the Charlson Comorbidity Index in acute kidney injury patients underwent continuous renal replacement therapy. <i>Kidney Research and Clinical Practice</i> , 2022, , .	0.9	2
8195	A New Trend in Cancer Treatment: The Combination of Epigenetics and Immunotherapy. <i>Frontiers in Immunology</i> , 2022, 13, 809761.	2.2	29
8196	Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2169-2181.	2.0	16
8197	Anti-PD-L1 F(ab) Conjugated PEG-PLGA Nanoparticle Enhances Immune Checkpoint Therapy. <i>Nanotheranostics</i> , 2022, 6, 243-255.	2.7	17
8198	Hepatotoxicity Induced by Biological Agents: Clinical Features and Current Controversies. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 000, 000-000.	0.7	6
8199	Identification and validation of an epithelial mesenchymal transition-related gene pairs signature for prediction of overall survival in patients with skin cutaneous melanoma. <i>PeerJ</i> , 2022, 10, e12646.	0.9	1
8200	Immunotherapy for glioblastoma: the promise of combination strategies. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 35.	3.5	85

#	ARTICLE	IF	CITATIONS
8201	Metabolic and Nutritional Disorders Following the Administration of Immune Checkpoint Inhibitors: A Pharmacovigilance Study. <i>Frontiers in Endocrinology</i> , 2021, 12, 809063.	1.5	0
8202	Comparison of Laboratory Methods for the Clinical Follow Up of Checkpoint Blockade Therapies in Leukemia: Current Status and Challenges Ahead. <i>Frontiers in Oncology</i> , 2022, 12, 789728.	1.3	2
8203	A clinical nomogram for predicting tumor regression grade in esophageal squamous-cell carcinoma treated with immune neoadjuvant immunotherapy. <i>Annals of Translational Medicine</i> , 2022, 10, 102-102.	0.7	4
8204	Gene therapy of prostate cancer using liposomes containing perforin expression vector driven by the promoter of prostate-specific antigen gene. <i>Scientific Reports</i> , 2022, 12, 1442.	1.6	6
8205	Identification of tumor microenvironmentâ€based genes associated with acquired resistance to EGFR Tyrosine Kinase Inhibitor in Lung Adenocarcinoma. <i>Journal of Cancer</i> , 2022, 13, 877-889.	1.2	1
8206	Immune-checkpoint inhibitors: long-term implications of toxicity. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 254-267.	12.5	360
8207	Analysis of a novel immune checkpoint, Siglecâ€15, in pancreatic ductal adenocarcinoma. <i>Journal of Pathology: Clinical Research</i> , 2022, 8, 268-278.	1.3	12
8208	Bullous Pemphigoid Associated With Pembrolizumab Therapy for Non-Small-Cell Lung Cancer: A Case Report. <i>Cureus</i> , 2022, 14, e21770.	0.2	5
8209	Pan-Cancer Study on Protein Kinase C Family as a Potential Biomarker for the Tumors Immune Landscape and the Response to Immunotherapy. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 798319.	1.8	7
8210	Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors. , 2022, 10, e003091.		67
8211	New Therapeutic Approaches for Conjunctival Melanomaâ€”What We Know So Far and Where Therapy Is Potentially Heading: Focus on Lymphatic Vessels and Dendritic Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1478.	1.8	4
8212	Pembrolizumab-Related Side Effects: Acute Renal Failure and Severe Neurological Toxicity. <i>Medicina (Lithuania)</i> , 2022, 58, 209.	0.8	6
8213	A Phase II Study of Pembrolizumab in Combination with Capecitabine and Oxaliplatin with Molecular Profiling in Patients with Advanced Biliary Tract Carcinoma. <i>Oncologist</i> , 2022, 27, e273-e285.	1.9	22
8214	Construction and validation of a pyroptosis-related gene signature associated with the tumor microenvironment in uveal melanoma. <i>Scientific Reports</i> , 2022, 12, 1640.	1.6	6
8215	Current Perspectives in the Treatment of Locally Advanced Basal Cell Carcinoma. <i>Drug Design, Development and Therapy</i> , 2022, Volume 16, 183-190.	2.0	4
8216	Safety and efficacy of sintilimab combination therapy for the treatment of 48 patients with advanced malignant tumors. <i>Translational Cancer Research</i> , 2022, 11, 252-261.	0.4	6
8217	Adenosine 2A receptor and TIM3 suppress cytolytic killing of tumor cells via cytoskeletal polarization. <i>Communications Biology</i> , 2022, 5, 9.	2.0	4
8218	Predicting treatment outcomes using ¹⁸ F-FDG PET biomarkers in patients with non-small-cell lung cancer receiving chemoimmunotherapy. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592110687.	1.4	7

#	ARTICLE	IF	CITATIONS
8219	Safety Related to the Timing of Radiotherapy and Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer: A Single Institutional Experience. <i>Current Oncology</i> , 2022, 29, 221-230.	0.9	2
8220	Association of Baseline and Pharmacodynamic Biomarkers With Outcomes in Patients Treated With the PD-1 Inhibitor Budigalimab. <i>Journal of Immunotherapy</i> , 2022, 45, 167-179.	1.2	7
8221	Taxane/gemcitabine-containing chemotherapy plus locoregional IMRT for patients with de novo metastatic nasopharyngeal carcinoma: the treatment outcomes and prognostic factors analysis. <i>European Archives of Oto-Rhino-Laryngology</i> , 2022, 279, 3947-3956.	0.8	4
8222	Immune checkpoint inhibitors, endocrine adverse events, and outcomes of melanoma. <i>Endocrine Connections</i> , 2022, 11, .	0.8	4
8223	Local consolidative therapy for synchronous oligometastatic non-small cell lung cancer treated with first-line pembrolizumab: A retrospective observational study. <i>Thoracic Cancer</i> , 2022, , .	0.8	6
8224	Carboplatin and nab-paclitaxel chemotherapy with or without atezolizumab as front-line management for treatment-naïve metastatic nonsquamous non-small cell lung cancer with PD-L1 staining: a retrospective study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, , 1.	1.2	2
8225	PD-L1 overexpression correlates with JAK2-mediated mutational burden and is associated with 9p uniparental disomy in myeloproliferative neoplasms. <i>American Journal of Hematology</i> , 2022, 97, 390-400.	2.0	8
8226	Metabolic Implications of Immune Checkpoint Proteins in Cancer. <i>Cells</i> , 2022, 11, 179.	1.8	15
8227	Retrospective analysis of long-term survival factors in patients with advanced non-small cell lung cancer treated with nivolumab. <i>Thoracic Cancer</i> , 2022, , .	0.8	4
8228	Real-world data prognostic model of overall survival in patients with advanced NSCLC receiving anti-PD-1/PD-L1 immune checkpoint inhibitors as second-line monotherapy. <i>Cancer Reports</i> , 2022, 5, e1578.	0.6	8
8229	Impact of Thyroid Incidentaloma on Liver Transplant: A Study of 1010 Recipients at a Single Center. <i>Annals of Transplantation</i> , 2022, 27, e934988.	0.5	0
8230	Inborn Errors of Immunity and Their Phenocopies: CTLA4 and PD-1. <i>Frontiers in Immunology</i> , 2021, 12, 806043.	2.2	7
8231	Identification and Characterization of Immunogene-Related Alternative Splicing Patterns and Tumor Microenvironment Infiltration Patterns in Breast Cancer. <i>Cancers</i> , 2022, 14, 595.	1.7	2
8232	Integrative Modeling of Multiomics Data for Predicting Tumor Mutation Burden in Patients with Lung Cancer. <i>BioMed Research International</i> , 2022, 2022, 1-14.	0.9	7
8233	Vectorized Treg-depleting CTLA-4 elicits antigen cross-presentation and CD8 ⁺ T cell immunity to reject cold tumors. , 2022, 10, e003488.		14
8234	Immunogenic cell death and its therapeutic or prognostic potential in high-grade glioma. <i>Genes and Immunity</i> , 2022, 23, 1-11.	2.2	24
8235	Unraveling the Role of STK11/LKB1 in Non-small Cell Lung Cancer. <i>Cureus</i> , 2022, 14, e21078.	0.2	3
8236	Latest Advances in the Use of Therapeutic Focused Ultrasound in the Treatment of Pancreatic Cancer. <i>Cancers</i> , 2022, 14, 638.	1.7	16

#	ARTICLE	IF	CITATIONS
8237	Loss of STING expression is prognostic in non-small cell lung cancer. <i>Journal of Surgical Oncology</i> , 2022, 125, 1042-1052.	0.8	8
8238	Plasma Thymidine Kinase Activity as a Novel Biomarker in Metastatic Melanoma Patients Treated with Immune Checkpoint Inhibitors. <i>Cancers</i> , 2022, 14, 702.	1.7	3
8239	Present and Emerging Biomarkers in Immunotherapy for Metastatic Non-Small Cell Lung Cancer: A Review. <i>Current Oncology</i> , 2022, 29, 479-489.	0.9	6
8240	Predictive Factors Correlated with the Development of Immune-Related Adverse Events in Patients with Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors. <i>Cancer Management and Research</i> , 2022, Volume 14, 427-435.	0.9	6
8241	Suppressive effects of the obese tumor microenvironment on CD8 T cell infiltration and effector function. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	33
8242	Prognostic Value of Programmed Death Ligand-1 Expression in Solid Tumors Irrespective of Immunotherapy Exposure: A Systematic Review and Meta-Analysis. <i>Molecular Diagnosis and Therapy</i> , 2022, , 1.	1.6	2
8243	Insignificant effects of loss of heterozygosity in HLA in the efficacy of immune checkpoint blockade treatment. <i>Genes and Genomics</i> , 2022, 44, 509-515.	0.5	2
8244	Novel Therapies for the Treatment of Drug-Induced Liver Injury: A Systematic Review. <i>Frontiers in Pharmacology</i> , 2021, 12, 785790.	1.6	12
8245	Biomarkers and risk factors for the early prediction of immune-related adverse events: a review. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-12.	1.4	11
8246	Characterization of Interplay Between Autophagy and Ferroptosis and Their Synergistical Roles on Manipulating Immunological Tumor Microenvironment in Squamous Cell Carcinomas. <i>Frontiers in Immunology</i> , 2021, 12, 739039.	2.2	35
8247	Immune checkpoint blockade in HIV. <i>EBioMedicine</i> , 2022, 76, 103840.	2.7	15
8248	Mechanisms of immune activation and regulation: lessons from melanoma. <i>Nature Reviews Cancer</i> , 2022, 22, 195-207.	12.8	101
8249	Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study). , 2022, 10, e004025.		22
8250	Loss of TET reprograms Wnt signaling through impaired demethylation to promote lung cancer development. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	14
8251	Intravesical immunotherapy with a GM-CSF armed oncolytic vesicular stomatitis virus improves outcome in bladder cancer. <i>Molecular Therapy - Oncolytics</i> , 2022, 24, 507-521.	2.0	7
8252	Targeting the NANOG/HDAC1 axis reverses resistance to PD-1 blockade by reinvigorating the antitumor immunity cycle. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	7
8253	Selective delivery of low-affinity IL-2 to PD-1+ T cells rejuvenates antitumor immunity with reduced toxicity. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	38
8254	Influence of DNA Mismatch Repair (MMR) System in Survival and Response to Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC): Retrospective Analysis. <i>Biomedicines</i> , 2022, 10, 360.	1.4	17

#	ARTICLE	IF	CITATIONS
8255	A Real-World Study on the Effectiveness and Safety of Pembrolizumab Plus Chemotherapy for Nonsquamous NSCLC. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100265.	0.6	15
8256	Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes. , 2022, 10, e003082.		11
8257	PD-1 inhibitor causes pathological injury to multiple organs in a Lewis lung cancer mouse model. <i>International Immunopharmacology</i> , 2022, 105, 108551.	1.7	4
8258	The immune modifying effects of chemotherapy and advances in chemo-immunotherapy. , 2022, 236, 108111.		25
8259	Immunotherapy resistance of lung cancer. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2022, 5, 114-128.	0.9	0
8260	Immunolocalization of CD80 and CD86 in Non-Small Cell Lung Carcinoma: CD80 as a Potent Prognostic Factor. <i>Acta Histochemica Et Cytochemica</i> , 2022, 55, 25-35.	0.8	4
8261	Targeted Next-Generation Sequencing Reveals Exceptionally High Rates of Molecular Driver Mutations in Never-Smokers With Lung Adenocarcinoma. <i>Oncologist</i> , 2022, 27, 476-486.	1.9	15
8262	Adverse events induced by nivolumab and ipilimumab combination regimens. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592110583.	1.4	11
8263	Monitoring tumor growth rate to predict immune checkpoint inhibitorsâ€™ treatment outcome in advanced NSCLC. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592110583.	1.4	2
8264	Myeloidâ€™derived suppressor cell infiltration is associated with a poor prognosis in patients with hepatocellular carcinoma. <i>Oncology Letters</i> , 2022, 23, 93.	0.8	11
8265	Current Immunotherapeutic Approaches for Malignant Gliomas. <i>Brain Tumor Research and Treatment</i> , 2022, 10, 1.	0.4	5
8266	Effectiveness of fourth-line dual immunotherapy in hepatocellular carcinoma with simultaneous steroid administration for immune-related hepatitis. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482110510.	1.4	2
8267	Association of Personal Characteristics and Effectiveness of Immunotherapy in Late-Stage Non-Small Cell Lung Cancer: A Systematic Review. <i>JNCI Cancer Spectrum</i> , 2022, 6, .	1.4	1
8268	Resistance to immune checkpoint inhibitors in KRAS-mutant non-small cell lung cancer. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2022, 5, 129-146.	0.9	4
8269	Antiâ€™PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC. <i>JCI Insight</i> , 2022, 7, .	2.3	42
8270	Emerging drug targets for colon cancer: A preclinical assessment. <i>Expert Opinion on Therapeutic Targets</i> , 2022, 26, 207-216.	1.5	4
8271	Landscape of Immunotherapy Options for Colorectal Cancer: Current Knowledge and Future Perspectives beyond Immune Checkpoint Blockade. <i>Life</i> , 2022, 12, 229.	1.1	15
8272	Extremity risk factors of sepsis for gastrointestinal endoscopy in patients with liver cirrhosis. <i>BMC Gastroenterology</i> , 2022, 22, 54.	0.8	2

#	ARTICLE	IF	CITATIONS
8273	Single-cell analysis of human glioma and immune cells identifies S100A4 as an immunotherapy target. <i>Nature Communications</i> , 2022, 13, 767.	5.8	128
8274	<i>cfTrack</i> : A Method of Exome-Wide Mutation Analysis of Cell-free DNA to Simultaneously Monitor the Full Spectrum of Cancer Treatment Outcomes Including MRD, Recurrence, and Evolution. <i>Clinical Cancer Research</i> , 2022, 28, 1841-1853.	3.2	4
8275	Advances in CAR-T Cell Genetic Engineering Strategies to Overcome Hurdles in Solid Tumors Treatment. <i>Frontiers in Immunology</i> , 2022, 13, 830292.	2.2	24
8276	Disrupting cancer angiogenesis and immune checkpoint networks for improved tumor immunity. <i>Seminars in Cancer Biology</i> , 2022, 86, 981-996.	4.3	15
8277	Combining Hepatic Percutaneous Perfusion with Ipilimumab plus Nivolumab in advanced uveal melanoma (CHOPIN): study protocol for a phase Ib/randomized phase II trial. <i>Trials</i> , 2022, 23, 137.	0.7	10
8278	A Guide to Implementing Immune Checkpoint Inhibitors within a Cancer Program: Experience from a Large Canadian Community Centre. <i>Current Oncology</i> , 2022, 29, 869-880.	0.9	2
8279	First-Line Treatment of Advanced Non-Small-Cell Lung Cancer with Immune-Checkpoint Inhibitors: New Combinations and Long-Term Data. <i>BioDrugs</i> , 2022, 36, 137-151.	2.2	6
8280	Understanding the Critical Role of Glycolysis-Related lncRNAs in Lung Adenocarcinoma Based on Three Molecular Subtypes. <i>BioMed Research International</i> , 2022, 2022, 1-36.	0.9	3
8281	The War Is on: The Immune System against Glioblastoma—How Can NK Cells Drive This Battle?. <i>Biomedicines</i> , 2022, 10, 400.	1.4	5
8282	Immune checkpoint inhibitors for the treatment of melanoma. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 563-576.	1.4	10
8283	Cognitive adverse effects of chemotherapy and immunotherapy: are interventions within reach?. <i>Nature Reviews Neurology</i> , 2022, 18, 173-185.	4.9	31
8284	Resolving the Heterogeneous Tumor-Centric Cellular Neighborhood through Multiplexed, Spatial Paracrine Interactions in the Setting of Immune Checkpoint Blockade. <i>Cancer Research Communications</i> , 2022, 2, 78-89.	0.7	2
8285	Oral Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors: Salivary Gland Dysfunction and Mucosal Diseases. <i>Cancers</i> , 2022, 14, 792.	1.7	8
8286	Cilengitide, an $\alpha_3\beta_1$ -integrin inhibitor, enhances the efficacy of anti-programmed cell death-1 therapy in a murine melanoma model. <i>Bioengineered</i> , 2022, 13, 4557-4572.	1.4	6
8287	The Predictive Potential of the Baseline C-Reactive Protein Levels for the Efficiency of Immune Checkpoint Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis. <i>Frontiers in Immunology</i> , 2022, 13, 827788.	2.2	15
8288	PD-1 agonism by anti-CD80 inhibits T cell activation and alleviates autoimmunity. <i>Nature Immunology</i> , 2022, 23, 399-410.	7.0	36
8289	The Potential Cardiotoxicity of Immune Checkpoint Inhibitors. <i>Journal of Clinical Medicine</i> , 2022, 11, 865.	1.0	8
8290	Interleukin-10 Is a Promising Marker for Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer Receiving Immunotherapy. <i>Frontiers in Immunology</i> , 2022, 13, 840313.	2.2	19

#	ARTICLE	IF	CITATIONS
8291	Checkpoint: Inspecting the barriers in glioblastoma immunotherapies. <i>Seminars in Cancer Biology</i> , 2022, 86, 473-481.	4.3	9
8292	Sintilimab with chemotherapy as first-line treatment for locally advanced or metastatic squamous non-small-cell lung cancer: a real-world data study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 757-764.	1.2	4
8293	Immunotherapy in Lung Cancer: Current Landscape and Future Directions. <i>Frontiers in Immunology</i> , 2022, 13, 823618.	2.2	105
8294	Managing Metastatic Melanoma in 2022: A Clinical Review. <i>JCO Oncology Practice</i> , 2022, 18, 335-351.	1.4	91
8295	Massive digital gene expression analysis reveals different predictive profiles for immune checkpoint inhibitor therapy between adenocarcinoma and squamous cell carcinoma of advanced lung cancer. <i>BMC Cancer</i> , 2022, 22, 154.	1.1	1
8296	Intestinal <i>Akkermansia muciniphila</i> predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer. <i>Nature Medicine</i> , 2022, 28, 315-324.	15.2	225
8297	Predictive Efficacy of Blood-Based Tumor Mutation Burden Assay for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2022, 12, 795933.	1.3	4
8298	Potentials of Non-Invasive 18F-FDG PET/CT in Immunotherapy Prediction for Non-Small Cell Lung Cancer. <i>Frontiers in Genetics</i> , 2021, 12, 810011.	1.1	10
8299	Predictive value of tumor mutational burden for immunotherapy in non-small cell lung cancer: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2022, 17, e0263629.	1.1	11
8300	Colorectal cancer development is affected by the ECM molecule EMILIN-2 hinging on macrophage polarization via the TLR-4/MyD88 pathway. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 60.	3.5	9
8301	The PD-L1/4-1BB Bispecific Antibody-Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner. <i>Clinical Cancer Research</i> , 2022, 28, 3387-3399.	3.2	24
8302	IKK β -deficient lung adenocarcinomas generate an immunosuppressive microenvironment by overproducing Treg-inducing cytokines. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	7
8303	Current therapy and development of therapeutic agents for lung cancer. , 2022, 1, 100015.		8
8304	Accumulation of dysfunctional tumor-infiltrating PD-1+ DCs links PD-1/PD-L1 blockade immunotherapeutic response in cervical cancer. <i>Oncolimmunology</i> , 2022, 11, 2034257.	2.1	11
8305	Combination therapy for pancreatic cancer: anti-PD-(L)1-based strategy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 56.	3.5	20
8306	Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy. , 2022, 10, e004089.		50
8307	Recent insights into the use of immune checkpoint inhibitors in gastric cancer. <i>Porto Biomedical Journal</i> , 2022, 7, e162.	0.4	3
8308	Rare Adverse Events Related to Nivolumab, an Immune Checkpoint Inhibitor: A Case Series. <i>Cureus</i> , 2022, 14, e22070.	0.2	2

#	ARTICLE	IF	CITATIONS
8309	Immune Checkpoint Therapies and Atherosclerosis: Mechanisms and Clinical Implications. <i>Journal of the American College of Cardiology</i> , 2022, 79, 577-593.	1.2	34
8310	Emerging Molecular Dependencies of Mutant EGFR-Driven Non-Small Cell Lung Cancer. <i>Cells</i> , 2021, 10, 3553.	1.8	5
8311	T cell receptor (TCR) signaling in health and disease. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 412.	7.1	127
8312	A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma. <i>Nature Medicine</i> , 2021, 27, 2212-2223.	15.2	88
8313	A Randomized Phase II Study Comparing Nivolumab with Carboplatin + Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L). <i>Clinical Cancer Research</i> , 2022, 28, 893-902.	3.2	35
8314	Efficacy of Plasmapheresis in Nivolumab-Associated ANCA Glomerulonephritis: A Case Report and Pathophysiology Discussion. <i>Case Reports in Nephrology and Dialysis</i> , 2022, 11, 376-383.	0.3	7
8315	Role of PD-L1 in licensing immunoregulatory function of dental pulp mesenchymal stem cells. <i>Stem Cell Research and Therapy</i> , 2021, 12, 598.	2.4	21
8316	Adaptive Dosing of Nivolumab + Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (The ADAPT-IT Study). <i>Journal of Clinical Oncology</i> , 2022, 40, 1059-1067.	0.8	26
8317	Association of Brain Metastases With Immune Checkpoint Inhibitors Efficacy in Advanced Lung Cancer: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 721760.	1.3	4
8319	Immuno-PET imaging of PD-L1 expression in patient-derived lung cancer xenografts with [⁶⁸ Ga]Ga-NOTA-Nb109. <i>Quantitative Imaging in Medicine and Surgery</i> , 2022, 12, 3300-3313.	1.1	5
8320	Efficacy and safety of camrelizumab plus apatinib as second-line treatment for advanced squamous non-small cell lung cancer. <i>Annals of Translational Medicine</i> , 2022, 10, 441-441.	0.7	11
8321	Immunotherapy in Bladder Cancer: Present and Future. <i>Revista Mexicana De Urologia</i> , 2021, 80, 1-19.	0.0	0
8322	Overall Survival Prediction of Docetaxel-based Second-line Treatment for Advanced Non-small Cell Lung Cancer: A Systematic Review and Meta-analysis. <i>Oman Medical Journal</i> , 2022, 37, e419-e419.	0.3	2
8323	Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy. <i>Immune Network</i> , 2022, 22, e2.	1.6	53
8324	Effects of PD-1 Signaling on Immunometabolic Reprogramming. <i>Immunometabolism</i> , 2022, 4, .	0.7	10
8326	OUP accepted manuscript. <i>Oncologist</i> , 2022, , .	1.9	3
8327	BET inhibitor JQ1 enhances anti-tumor immunity and synergizes with PD-1 blockade in CRC. <i>Journal of Cancer</i> , 2022, 13, 2126-2137.	1.2	15
8328	Neoadjuvant therapy for melanoma: rationale for neoadjuvant therapy and pivotal clinical trials. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210830.	1.4	13

#	ARTICLE	IF	CITATIONS
8329	Monoclonal Antibodies to CTLA-4 with Focus on Ipilimumab. <i>Experientia Supplementum</i> (2012), 2022, 113, 295-350.	0.5	3
8330	Commensal Microbiota and Cancer Immunotherapy: Harnessing Commensal Bacteria for Cancer Therapy. <i>Immune Network</i> , 2022, 22, e3.	1.6	11
8332	Evaluation of Pembrolizumab Monotherapy Efficacy in Advanced Non-Small-Cell Lung Cancer by Serial Monitoring of Circulating Tumor DNA Using Next-Generation Sequencing. <i>Clinical Medicine Insights: Oncology</i> , 2022, 16, 117955492210753.	0.6	1
8333	Melanoma therapeutics: a literature review. <i>Journal of Biomedical Research</i> , 2022, 36, 77.	0.7	16
8334	Immunogenetics of Lupus Erythematosus. <i>Advances in Experimental Medicine and Biology</i> , 2022, 1367, 213-257.	0.8	1
8335	The Immunogenetics of Melanoma. <i>Advances in Experimental Medicine and Biology</i> , 2022, 1367, 383-396.	0.8	0
8336	Prognostic and Immunological Role of FAT Family Genes in Non-Small Cell Lung Cancer. <i>Cancer Control</i> , 2022, 29, 107327482210766.	0.7	11
8337	Expression of DNA Mismatch Repair Proteins, PD1 and PDL1 in Barrett's Neoplasia. <i>Cancer Genomics and Proteomics</i> , 2022, 19, 145-150.	1.0	2
8338	Combination immunotherapy of nivolumab plus ipilimumab in a lung cancer patient with Werner syndrome; a case report. <i>Respiratory Medicine Case Reports</i> , 2022, 37, 101642.	0.2	1
8340	Current Status and Future Directions of Immunotherapies in Soft Tissue Sarcomas. <i>Biomedicines</i> , 2022, 10, 573.	1.4	8
8341	Biochanin A Suppresses Tumor Progression and PD-L1 Expression via Inhibiting ZEB1 Expression in Colorectal Cancer. <i>Journal of Oncology</i> , 2022, 2022, 1-12.	0.6	7
8342	Biomarkers of response to PD-1 pathway blockade. <i>British Journal of Cancer</i> , 2022, 126, 1663-1675.	2.9	52
8343	Somatostatin Receptor 2: A Potential Predictive Biomarker for Immune Checkpoint Inhibitor Treatment. <i>Pathology and Oncology Research</i> , 2022, 28, 1610196.	0.9	1
8344	Immunotherapy Outcomes in Individuals With Non-Small Cell Lung Cancer and Poor Performance Status. <i>JNCI Cancer Spectrum</i> , 2022, 6, .	1.4	2
8345	Vedolizumab Attenuates Immune-Checkpoint-Therapy-Induced Infliximab-Refractory Colitis. <i>Diagnostics</i> , 2022, 12, 480.	1.3	3
8346	Controlling Cell Trafficking: Addressing Failures in CAR T and NK Cell Therapy of Solid Tumours. <i>Cancers</i> , 2022, 14, 978.	1.7	12
8347	Molecular Mechanisms and Biomarkers Associated with Chemotherapy-Induced AKI. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2638.	1.8	7
8348	Differences in tumor-infiltrating lymphocyte density and prognostic factors for breast cancer by patient age. <i>World Journal of Surgical Oncology</i> , 2022, 20, 38.	0.8	5

#	ARTICLE	IF	CITATIONS
8349	Brain metastases, patterns of intracranial progression, and the clinical value of upfront cranial radiotherapy in patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors. <i>Translational Lung Cancer Research</i> , 2022, 11, 173-187.	1.3	6
8350	Review of Therapeutic Strategies for Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer. <i>Cancers</i> , 2022, 14, 1184.	1.7	16
8351	Identification and validation of a twelve immune infiltration-related lncRNA prognostic signature for bladder cancer. <i>Aging</i> , 2022, 14, 1492-1507.	1.4	12
8352	A Patient With Failed Liver Transplantation After the Use of PD-1 Blockade Combined With Lenvaxen. <i>Frontiers in Medicine</i> , 2022, 9, 712466.	1.2	2
8353	Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma. , 2022, 10, e003026.		38
8354	Safety and Efficacy of Ipilimumab plus Nivolumab and Sequential Selective Internal Radiation Therapy in Hepatic and Extrahepatic Metastatic Uveal Melanoma. <i>Cancers</i> , 2022, 14, 1162.	1.7	9
8355	Triple Negative Breast Cancer: Updates on Classification and Treatment in 2021. <i>Cancers</i> , 2022, 14, 1253.	1.7	69
8356	Safety and efficacy of nivolumab plus recombinant human endostatin in previously treated advanced non-small-cell lung cancer. <i>Translational Lung Cancer Research</i> , 2022, 11, 201-212.	1.3	10
8357	RAS pathway regulation in melanoma. <i>DMM Disease Models and Mechanisms</i> , 2022, 15, .	1.2	11
8358	Identification of the Expression Patterns and Potential Prognostic Role of 5-Methylcytosine Regulators in Hepatocellular Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 842220.	1.8	8
8359	Safety of Immune Checkpoint Inhibitor Resumption after Interruption for Immune-Related Adverse Events, a Narrative Review. <i>Cancers</i> , 2022, 14, 955.	1.7	9
8360	What Is the Status of Immunotherapy in Neuroendocrine Neoplasms?. <i>Current Oncology Reports</i> , 2022, 24, 451-461.	1.8	1
8361	High farnesoid X receptor expression predicts favorable clinical outcomes in PD-L1 ^{low/negative} non-small cell lung cancer patients receiving anti-PD-1-based chemo-immunotherapy. <i>International Journal of Oncology</i> , 2022, 60, .	1.4	2
8362	Gut Microbiota: A Promising Milestone in Enhancing the Efficacy of PD1/PD-L1 Blockade Therapy. <i>Frontiers in Oncology</i> , 2022, 12, 847350.	1.3	6
8363	Immunotherapeutic Approaches for the Treatment of HPV-Associated (Pre-)Cancer of the Cervix, Vulva and Penis. <i>Journal of Clinical Medicine</i> , 2022, 11, 1101.	1.0	9
8364	The New Era of Immunotherapy in Gastric Cancer. <i>Cancers</i> , 2022, 14, 1054.	1.7	68
8365	Integration of liquid biopsy and pharmacogenomics for precision therapy of EGFR mutant and resistant lung cancers. <i>Molecular Cancer</i> , 2022, 21, 61.	7.9	6
8366	Immune Checkpoint Inhibitors' Associated Cardiotoxicity. <i>Cancers</i> , 2022, 14, 1145.	1.7	25

#	ARTICLE	IF	CITATIONS
8367	Nivolumab-DTPA-Based PD-1 Imaging Reveals Structural and Pathological Changes in Colorectal Carcinoma. <i>Frontiers in Bioengineering and Biotechnology</i> , 2022, 10, 839756.	2.0	2
8368	Diagnostic Performance of PD-L1 versus PD-1 Expression in Circulating CD20 Cells in Diffuse Large B-Cell Lymphoma. <i>Antibodies</i> , 2022, 11, 15.	1.2	3
8369	Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma. <i>Nature Medicine</i> , 2022, 28, 535-544.	15.2	158
8370	Differential expression of PD-L1 and PD-L2 is associated with the tumor microenvironment of TILs and M2 TAMs and tumor differentiation in non-small cell lung cancer. <i>Oncology Reports</i> , 2022, 47, .	1.2	9
8371	Navigational bronchoscopy specimens and PD-L1 expression: a retrospective study. <i>Journal of Thoracic Disease</i> , 2022, 14, 295-305.	0.6	0
8372	Analysis of Gene Co-Expression Network to Identify the Role of CD8 + T Cell Infiltration-Related Biomarkers in High-Grade Glioma. <i>International Journal of General Medicine</i> , 2022, Volume 15, 1879-1890.	0.8	4
8373	Oncolytic viruses in melanoma. <i>Frontiers in Bioscience</i> , 2022, 27, 063.	0.8	12
8374	Prognostic Value of Radiotherapy and Chemotherapy in Stage III Merkel Cell Carcinoma. <i>Frontiers in Medicine</i> , 2022, 9, 845905.	1.2	2
8375	Impact of Glucocorticoid Use in Oncology in the Immunotherapy Era. <i>Cells</i> , 2022, 11, 770.	1.8	26
8376	A Bayesian phase I/II biomarker-based design for identifying subgroup-specific optimal dose for immunotherapy. <i>Statistical Methods in Medical Research</i> , 2022, 31, 1104-1119.	0.7	5
8377	An Immune-Related Gene Pair Index Predicts Clinical Response and Survival Outcome of Immune Checkpoint Inhibitors in Melanoma. <i>Frontiers in Immunology</i> , 2022, 13, 839901.	2.2	1
8378	Characterization of Desmoglein 3 (DSG3) as a Sensitive and Specific Marker for Esophageal Squamous Cell Carcinoma. <i>Gastroenterology Research and Practice</i> , 2022, 2022, 1-7.	0.7	1
8379	Cancer patient survival can be parametrized to improve trial precision and reveal time-dependent therapeutic effects. <i>Nature Communications</i> , 2022, 13, 873.	5.8	13
8380	Role of Base Excision Repair in Innate Immune Cells and Its Relevance for Cancer Therapy. <i>Biomedicines</i> , 2022, 10, 557.	1.4	1
8381	Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis. , 2022, 10, e004036.		24
8382	Palliative Systemic Therapy Given near the End of Life for Metastatic Non-Small Cell Lung Cancer. <i>Current Oncology</i> , 2022, 29, 1316-1325.	0.9	3
8383	Current Limitations and Novel Perspectives in Pancreatic Cancer Treatment. <i>Cancers</i> , 2022, 14, 985.	1.7	25
8384	Time-Dependent Efficacy of Checkpoint Inhibitor Nivolumab: Results from a Pilot Study in Patients with Metastatic Non-Small-Cell Lung Cancer. <i>Cancers</i> , 2022, 14, 896.	1.7	36

#	ARTICLE	IF	CITATIONS
8385	Comparison of Immune Checkpoint Molecules PD-1 and PD-L1 in Paired Primary and Recurrent Glioma: Increasing Trend When Recurrence. <i>Brain Sciences</i> , 2022, 12, 266.	1.1	0
8386	Case Report: Opportunities and Challenges of Immunotherapy in Heavily-Treated EGFR-Mutant Advanced Squamous Cell Lung Carcinoma After Progression on EGFR-TKIs and Chemotherapy. <i>Frontiers in Oncology</i> , 2022, 12, 820408.	1.3	1
8387	Pembrolizumab Plus Chemotherapy Versus Chemotherapy Monotherapy as a First-Line Treatment in Elderly Patients (≥75 Years Old) With Non-Small-Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2022, 13, 807575.	2.2	4
8388	Advanced Pancreatic Cancer Patient Benefit From Personalized Neoantigen Nanovaccine Based Immunotherapy: A Case Report. <i>Frontiers in Immunology</i> , 2022, 13, 799026.	2.2	4
8389	Immune checkpoint silencing using RNAi-incorporated nanoparticles enhances antitumor immunity and therapeutic efficacy compared with antibody-based approaches. , 2022, 10, e003928.		10
8390	Association of computed tomography screening with lung cancer stage shift and survival in the United States: quasi-experimental study. <i>BMJ</i> , The, 2022, 376, e069008.	3.0	44
8391	Long-Term Outcomes of Immune Checkpoint Inhibition in Metastatic Melanoma. <i>American Journal of Clinical Dermatology</i> , 2022, 23, 331-338.	3.3	16
8392	Reduced FEV1 as Prognostic Factors in Patients With Advanced NSCLC Receiving Immune Checkpoint Inhibitors. <i>Frontiers in Medicine</i> , 2022, 9, 860733.	1.2	2
8393	Non-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology. <i>Current Oncology</i> , 2022, 29, 1828-1839.	0.9	72
8394	DNA-PK Inhibition and Radiation Promote Antitumoral Immunity through RNA Polymerase III in Pancreatic Cancer. <i>Molecular Cancer Research</i> , 2022, 20, 1137-1150.	1.5	8
8395	Lenvatinib plus pembrolizumab for systemic therapy-naïve and -experienced unresectable hepatocellular carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2631-2643.	2.0	23
8396	Protein-Protein Binding Free Energy Predictions with the MM/PBSA Approach Complemented with the Gaussian-Based Method for Entropy Estimation. <i>ACS Omega</i> , 2022, 7, 11057-11067.	1.6	9
8397	Acute Liver Failure following a Single Dose of Atezolizumab, as Assessed for Causality Using the Updated RUCAM. <i>Case Reports in Gastrointestinal Medicine</i> , 2022, 2022, 1-4.	0.2	3
8398	Graded Prognostic Assessment (GPA) for Patients With Lung Cancer and Brain Metastases: Initial Report of the Small Cell Lung Cancer GPA and Update of the Non-Small Cell Lung Cancer GPA Including the Effect of Programmed Death Ligand 1 and Other Prognostic Factors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 114, 60-74.	0.4	33
8399	Treatment of Resectable Gallbladder Cancer. <i>Cancers</i> , 2022, 14, 1413.	1.7	11
8400	Human Leukocyte Antigen Class I Antigen-Processing Machinery Upregulation by Anticancer Therapies in the Era of Checkpoint Inhibitors. <i>JAMA Oncology</i> , 2022, 8, 462.	3.4	22
8401	Treatment of Metastatic Melanoma in the Elderly. <i>Current Oncology Reports</i> , 2022, 24, 825-833.	1.8	5
8402	High Intensity Aerobic exercise training and Immune cell Mobilization in patients with lung cancer (HI Tj ETQq1 1 0,784314 rgBT /Overl FO	1.1	10

#	ARTICLE	IF	CITATIONS
8403	Immunomodulatory Properties of Immune Checkpoint Inhibitorsâ€”More than Boosting T-Cell Responses?. <i>Cancers</i> , 2022, 14, 1710.	1.7	13
8404	Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation. <i>Journal of Hematology and Oncology</i> , 2022, 15, 24.	6.9	136
8405	First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 499-514.	1.1	7
8406	The Role of Immune Checkpoint Molecules on Macrophages in Cancer, Infection, and Autoimmune Pathologies. <i>Frontiers in Immunology</i> , 2022, 13, 837645.	2.2	16
8407	Ipilimumab, Pembrolizumab, or Nivolumab in Combination with BBI608 in Patients with Advanced Cancers Treated at MD Anderson Cancer Center. <i>Cancers</i> , 2022, 14, 1330.	1.7	0
8408	Regulation of the antigen presentation machinery in cancer and its implication for immune surveillance. <i>Biochemical Society Transactions</i> , 2022, 50, 825-837.	1.6	14
8409	Entinostat Decreases Immune Suppression to Promote Antitumor Responses in a HER2+ Breast Tumor Microenvironment. <i>Cancer Immunology Research</i> , 2022, 10, 656-669.	1.6	26
8410	Review of Immune-Related Adverse Events (irAEs) in Non-Small-Cell Lung Cancer (NSCLC)â€”Their Incidence, Management, Multiorgan irAEs, and Rechallenge. <i>Biomedicines</i> , 2022, 10, 790.	1.4	17
8411	Immunostimulatory Cancer-Associated Fibroblast Subpopulations Can Predict Immunotherapy Response in Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 2094-2109.	3.2	60
8412	Efficacy and Safety of Nivolumab for Advanced Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. <i>Journal of Oncology</i> , 2022, 2022, 1-5.	0.6	0
8413	An Oxidative Stress-Related Genes Signature for Predicting Survival in Bladder Cancer: Based on TCGA Database and Bioinformatics. <i>International Journal of General Medicine</i> , 2022, Volume 15, 2645-2667.	0.8	9
8414	Strategies for Manipulating T Cells in Cancer Immunotherapy. <i>Biomolecules and Therapeutics</i> , 2022, , .	1.1	0
8415	A prognostic classification based on the International Association for the Study of Lung Cancer histologic grading and immunoscore in <sc> <i>KRAS</i> </sc> â€”mutant invasive nonâ€”mucinous adenocarcinoma. <i>Thoracic Cancer</i> , 2022, 13, 1050-1058.	0.8	5
8417	Optimizing the tumor shrinkage threshold for evaluating immunotherapy efficacy for advanced non-small-cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 1103-1113.	1.2	1
8418	Utilization of Immunotherapy for the Treatment of Hepatocellular Carcinoma in the Peri-Transplant Setting: Transplant Oncology View. <i>Cancers</i> , 2022, 14, 1760.	1.7	20
8419	TIGIT Blockade Exerts Synergistic Effects on Microwave Ablation Against Cancer. <i>Frontiers in Immunology</i> , 2022, 13, 832230.	2.2	13
8420	Incidence, predictorsÂ”and 6-month overall outcome of acute kidney injury in Chinese patients receiving PD-1 inhibitors. <i>Future Oncology</i> , 2022, 18, 1951-1962.	1.1	9
8421	Immuneâ€”related gene signature predicts clinical outcomes and immunotherapy response in acute myeloid leukemia. <i>Cancer Medicine</i> , 2022, 11, 3364-3380.	1.3	3

#	ARTICLE	IF	CITATIONS
8422	The Current State of Treatment and Future Directions in Cutaneous Malignant Melanoma. <i>Biomedicines</i> , 2022, 10, 822.	1.4	18
8423	Alternative medicine: therapeutic effects on gastric original signet ring carcinoma via ascorbate and combination with sodium alpha lipoate. <i>BMC Complementary Medicine and Therapies</i> , 2022, 22, 58.	1.2	1
8424	Targeting the PSGL-1 Immune Checkpoint Promotes Immunity to PD-1-Resistant Melanoma. <i>Cancer Immunology Research</i> , 2022, 10, 612-625.	1.6	12
8425	MER4 endogenous retrovirus correlated with better efficacy of anti-PD1/PD-L1 therapy in non-small cell lung cancer. , 2022, 10, e004241.		11
8426	Agonistic CD27 antibody potency is determined by epitope-dependent receptor clustering augmented through Fc-engineering. <i>Communications Biology</i> , 2022, 5, 229.	2.0	8
8427	Characterization of Somatic Mutations That Affect Neoantigens in Non-Small Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 749461.	2.2	11
8428	Liquid biopsy at the frontier of detection, prognosis and progression monitoring in colorectal cancer. <i>Molecular Cancer</i> , 2022, 21, 86.	7.9	72
8429	Neutrophil Extracellular Traps in Cancer Therapy Resistance. <i>Cancers</i> , 2022, 14, 1359.	1.7	30
8430	Primary Small Bowel Melanoma: A Case Report and Review of Literature. <i>Frontiers in Surgery</i> , 2022, 9, 792243.	0.6	0
8431	A Bayesian Network Meta-Analysis of First-Line Treatments for Non-Small Cell Lung Cancer with High Programmed Death Ligand-1 Expression. <i>Journal of Clinical Medicine</i> , 2022, 11, 1492.	1.0	3
8432	Frequency of Immune Checkpoint Inhibitor-Induced Vasculitides: An Observational Study Using Data From the Japanese Adverse Drug Event Report Database. <i>Frontiers in Pharmacology</i> , 2022, 13, 803706.	1.6	6
8433	Anti-PD-1: When to Stop Treatment. <i>Current Oncology Reports</i> , 2022, 24, 905-915.	1.8	5
8434	Is Timing of Steroid Exposure Prior to Immune Checkpoint Inhibitor Initiation Associated with Treatment Outcomes in Melanoma? A Population-Based Study. <i>Cancers</i> , 2022, 14, 1296.	1.7	8
8435	Association between clinical outcomes and local treatment in stage IV non-small cell lung cancer patients with single extrathoracic metastasis. <i>Thoracic Cancer</i> , 2022, 13, 1349-1360.	0.8	4
8436	ITGAL as a Prognostic Biomarker Correlated With Immune Infiltrates in Gastric Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 808212.	1.8	19
8437	Predictive Simulations in Preclinical Oncology to Guide the Translation of Biologics. <i>Frontiers in Pharmacology</i> , 2022, 13, 836925.	1.6	4
8438	Effect and Tolerability of Immunotherapy in Patients with NSCLC with or without Brain Metastasis. <i>Cancers</i> , 2022, 14, 1682.	1.7	2
8439	Mortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy. , 2022, 10, e004421.		19

#	ARTICLE	IF	CITATIONS
8440	Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in trans. <i>Cell Death and Disease</i> , 2022, 13, 274.	2.7	11
8441	Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer. <i>Frontiers in Immunology</i> , 2022, 13, 827921.	2.2	43
8442	Synchronous glioblastoma and brain metastases: illustrative case. <i>Journal of Neurosurgery Case Lessons</i> , 2022, 3, .	0.1	0
8443	Identification of New m6A Methylation Modification Patterns and Tumor Microenvironment Infiltration Landscape that Predict Clinical Outcomes for Papillary Renal Cell Carcinoma Patients. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 818194.	1.8	1
8444	Trends in treatment patterns and survival outcomes in advanced non-small cell lung cancer: a Canadian population-based real-world analysis. <i>BMC Cancer</i> , 2022, 22, 255.	1.1	11
8445	Current Clinical Trial Landscape of OX40 Agonists. <i>Current Oncology Reports</i> , 2022, 24, 951-960.	1.8	15
8446	Evolution of Molecular Targeted Cancer Therapy: Mechanisms of Drug Resistance and Novel Opportunities Identified by CRISPR-Cas9 Screening. <i>Frontiers in Oncology</i> , 2022, 12, 755053.	1.3	12
8447	Pan-cancer analysis of ARID family members as novel biomarkers for immune checkpoint inhibitor therapy. <i>Cancer Biology and Therapy</i> , 2022, 23, 104-111.	1.5	19
8448	NeoScore Integrates Characteristics of the Neoantigen:MHC Class I Interaction and Expression to Accurately Prioritize Immunogenic Neoantigens. <i>Journal of Immunology</i> , 2022, 208, 1813-1827.	0.4	4
8449	Polyamine Immunometabolism: Central Regulators of Inflammation, Cancer and Autoimmunity. <i>Cells</i> , 2022, 11, 896.	1.8	23
8450	Systematic review and meta-analysis of genomic alterations in acral melanoma. <i>Pigment Cell and Melanoma Research</i> , 2022, 35, 369-386.	1.5	6
8451	The key to immunotherapy: how to choose better therapeutic biomarkers for patients with non-small cell lung cancer. <i>Biomarker Research</i> , 2022, 10, 9.	2.8	28
8452	Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events. <i>Frontiers in Immunology</i> , 2022, 13, 804597.	2.2	27
8453	MD2 Is a Potential Biomarker Associated with Immune Cell Infiltration in Gliomas. <i>Frontiers in Oncology</i> , 2022, 12, 854598.	1.3	3
8454	Correlation of KRAS G12C Mutation and High PD-L1 Expression with Clinical Outcome in NSCLC Patients Treated with Anti-PD1 Immunotherapy. <i>Journal of Clinical Medicine</i> , 2022, 11, 1627.	1.0	14
8455	Non-negative Independent Factor Analysis disentangles discrete and continuous sources of variation in scRNA-seq data. <i>Bioinformatics</i> , 2022, 38, 2749-2756.	1.8	1
8456	Discovery and pharmacological characterization of cetrelimab (JNJ-63723283), an anti-programmed cell death protein-1 (PD-1) antibody, in human cancer models. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 515-527.	1.1	7
8457	Identification of Biomarkers Related to Regulatory T Cell Infiltration in Oral Squamous Cell Carcinoma Based on Integrated Bioinformatics Analysis. <i>International Journal of General Medicine</i> , 2022, Volume 15, 2361-2376.	0.8	3

#	ARTICLE	IF	CITATIONS
8458	Effect of CRISPR/Cas9-Edited PD-1/PD-L1 on Tumor Immunity and Immunotherapy. <i>Frontiers in Immunology</i> , 2022, 13, 848327.	2.2	11
8459	Survival Prediction of Patients Treated With Immune Checkpoint Inhibitors via KRAS/TP53/EGFR-Single Gene Mutation. <i>Frontiers in Pharmacology</i> , 2022, 13, 878540.	1.6	2
8460	CMTM6 as a master regulator of PD-L1. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2325-2340.	2.0	7
8461	Targeting Cancer Cell Ferroptosis to Reverse Immune Checkpoint Inhibitor Therapy Resistance. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 818453.	1.8	14
8462	PRMT7 ablation stimulates anti-tumor immunity and sensitizes melanoma to immune checkpoint blockade. <i>Cell Reports</i> , 2022, 38, 110582.	2.9	24
8463	CRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T cell-mediated cytotoxicity. <i>Nature Communications</i> , 2022, 13, 1606.	5.8	40
8464	Safety and Efficacy of Avelumab in Small Bowel Adenocarcinoma. <i>Clinical Colorectal Cancer</i> , 2022, 21, 236-243.	1.0	6
8465	Associations of Clinical and Molecular Characteristics with the Response to Immune Checkpoint Blockade in Advanced Gastric Cancers. <i>Journal of Oncology</i> , 2022, 2022, 1-10.	0.6	0
8466	Langerhans Cells, T Cells, and B Cells in Oral Lichen Planus and Oral Leukoplakia. <i>International Journal of Dentistry</i> , 2022, 2022, 1-8.	0.5	3
8467	Spectrum of DNA mismatch repair failures viewed through the lens of cancer genomics and implications for therapy. <i>Clinical Science</i> , 2022, 136, 383-404.	1.8	8
8468	Angiogenesis Inhibitors and Immunomodulation in Renal Cell Cancers: The Past, Present, and Future. <i>Cancers</i> , 2022, 14, 1406.	1.7	13
8469	The spectrum of renal diseases with lupus-like features: a single-center study. <i>Renal Failure</i> , 2022, 44, 581-593.	0.8	1
8470	Metastatic urothelial carcinoma harboring ERBB2/3 mutations dramatically respond to chemotherapy plus anti-PD-1 antibody: A case report. <i>World Journal of Clinical Cases</i> , 2022, 10, 2497-2503.	0.3	1
8471	Association of Blood Biochemical Indexes and Antibiotic Exposure With Severe Immune-related Adverse Events in Patients With Advanced Cancers Receiving PD-1 Inhibitors. <i>Journal of Immunotherapy</i> , 2022, 45, 210-216.	1.2	15
8472	Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma. , 2022, 10, e004316.		45
8473	A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer. <i>Gastric Cancer</i> , 2022, 25, 619-628.	2.7	18
8474	Clinicopathologic and molecular characteristics of EGFR-mutant lung adenocarcinomas that transform to small cell lung cancer after TKI therapy. <i>Translational Lung Cancer Research</i> , 2022, 11, 452-461.	1.3	10
8475	The Predictive Individual Effect for Survival Data. <i>Therapeutic Innovation and Regulatory Science</i> , 2022, 56, 492-500.	0.8	1

#	ARTICLE	IF	CITATIONS
8476	Advanced Biomaterials for Cell-Specific Modulation and Restore of Cancer Immunotherapy. <i>Advanced Science</i> , 2022, 9, e2200027.	5.6	26
8477	Context-dependent activation of p53 target genes and induction of apoptosis by actinomycin D in aerodigestive tract cancers. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2022, 27, 342-353.	2.2	3
8478	Predictive Markers for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. <i>Journal of Clinical Medicine</i> , 2022, 11, 1855.	1.0	11
8479	Clinical Applications of Circulating Tumour Cells and Circulating Tumour DNA in Non-Small Cell Lung Cancer—An Update. <i>Frontiers in Oncology</i> , 2022, 12, 859152.	1.3	15
8480	Discovery of efficacy biomarkers for non-small cell lung cancer with first-line anti-PD-1 immunotherapy by data-independent acquisition mass spectrometry. <i>Clinical and Experimental Immunology</i> , 2022, , .	1.1	1
8481	Recent Advances of Immune Checkpoint Inhibition and Potential for (Combined) TIGIT Blockade as a New Strategy for Malignant Pleural Mesothelioma. <i>Biomedicines</i> , 2022, 10, 673.	1.4	4
8482	Integrative Analysis of Multi-Omics Data-Identified Key Genes With KLRC3 as the Core in a Gene Regulatory Network Related to Immune Phenotypes in Lung Adenocarcinoma. <i>Frontiers in Genetics</i> , 2022, 13, 810193.	1.1	1
8483	A retrospective cohort study of sintilimab and pembrolizumab as first-line treatments for advanced non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2022, 14, 679-688.	0.6	1
8484	Tim-3 mediates T cell trogocytosis to limit antitumor immunity. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	25
8485	Reduced CCR2 Can Improve the Prognosis of Sarcoma by Remodeling the Tumor Microenvironment. <i>International Journal of General Medicine</i> , 2022, Volume 15, 3043-3053.	0.8	4
8486	Impact of Histotripsy on Development of Intrahepatic Metastases in a Rodent Liver Tumor Model. <i>Cancers</i> , 2022, 14, 1612.	1.7	19
8487	Everolimus and/or Nivolumab-Associated Cytomegalovirus Colitis in a Patient with Metastatic Renal Cell Carcinoma. , 2022, 54, 77-79.		0
8488	Deleterious AHNAK2 Mutation as a Novel Biomarker for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 798401.	1.3	4
8489	Heterogeneity induced GZMA-F2R communication inefficient impairs antitumor immunotherapy of PD-1 mAb through JAK2/STAT1 signal suppression in hepatocellular carcinoma. <i>Cell Death and Disease</i> , 2022, 13, 213.	2.7	18
8490	Immune-Related Adverse Events After Immune Checkpoint Inhibitors for Melanoma Among Older Adults. <i>JAMA Network Open</i> , 2022, 5, e223461.	2.8	16
8491	Immunosuppressive Signaling Pathways as Targeted Cancer Therapies. <i>Biomedicines</i> , 2022, 10, 682.	1.4	8
8492	TP53 mutations upregulate RCP expression via Sp1/3 to drive lung cancer progression. <i>Oncogene</i> , 2022, 41, 2357-2371.	2.6	4
8493	Computer-assisted three-dimensional quantitation of programmed death-ligand 1 in non-small cell lung cancer using tissue clearing technology. <i>Journal of Translational Medicine</i> , 2022, 20, 131.	1.8	11

#	ARTICLE	IF	CITATIONS
8494	Targeting the tumor mutanome for personalized vaccination in a TMB low non-small cell lung cancer. , 2022, 10, e003821.		12
8495	Treatment Equity in the Immunotherapy Era: Options for Patients with Both Autoimmune Disease and GU Cancers. <i>Life</i> , 2022, 12, 360.	1.1	1
8496	Prediction of Early Response to Immunotherapy: DCE-US as a New Biomarker. <i>Cancers</i> , 2022, 14, 1337.	1.7	0
8497	Rate and risk factors of recurrent immune checkpoint inhibitor-related pneumonitis in patients with lung cancer. <i>Translational Lung Cancer Research</i> , 2022, 11, 381-392.	1.3	7
8498	The Role of PDGFRA in Predicting Oncological and Immune Characteristics in Pancreatic Ductal Adenocarcinoma. <i>Journal of Oncology</i> , 2022, 2022, 1-16.	0.6	0
8499	HLA-G and Other Immune Checkpoint Molecules as Targets for Novel Combined Immunotherapies. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2925.	1.8	19
8500	Microtube Array Membrane Hollow Fiber Assay (MTAM-HFA)â€”An Accurate and Rapid Potential Companion Diagnostic and Pharmacological Interrogation Solution for Cancer Immunotherapy (PD-1/PD-L1). <i>Biomolecules</i> , 2022, 12, 480.	1.8	4
8501	Component with abundant immuneâ€related cells in combined hepatocellular cholangiocarcinoma identified by cluster analysis. <i>Cancer Science</i> , 2022, , .	1.7	3
8502	Bispecific Antibodies Progression in Malignant Melanoma. <i>Frontiers in Pharmacology</i> , 2022, 13, 837889.	1.6	0
8503	Characterization of aging tumor microenvironment with drawing implications in predicting the prognosis and immunotherapy response in low-grade gliomas. <i>Scientific Reports</i> , 2022, 12, 5457.	1.6	3
8504	Serum exosomal <sc>miR</sc>â€16â€5p functions as a tumor inhibitor and a new biomarker for <sc>PDâ€1</sc> inhibitorâ€dependent immunotherapy in lung adenocarcinoma by regulating <sc>PDâ€1</sc> expression. <i>Cancer Medicine</i> , 2022, 11, 2627-2643.	1.3	9
8505	Variation of Immune Cell Responses in Humans Reveals Sex-Specific Coordinated Signaling Across Cell Types. <i>Frontiers in Immunology</i> , 2022, 13, 867016.	2.2	4
8506	Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas. <i>Nature Communications</i> , 2022, 13, 1325.	5.8	31
8507	Immunotherapy of glioblastoma: Recent advances and future prospects. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-16.	1.4	29
8508	Immune Checkpoint Inhibitor-Induced Hypophysitis and Patterns of Loss of Pituitary Function. <i>Frontiers in Oncology</i> , 2022, 12, 836859.	1.3	25
8509	Strategies to overcome the main challenges of the use of CRISPR/Cas9 as a replacement for cancer therapy. <i>Molecular Cancer</i> , 2022, 21, 64.	7.9	45
8510	Soluble Programmed Cell Death Protein 1 and Its Ligand: Potential Biomarkers to Predict Acute Kidney Injury After Surgery in Critically Ill Patients. <i>Journal of Inflammation Research</i> , 2022, Volume 15, 1995-2008.	1.6	2
8511	Immune Landscape and an RBM38-Associated Immune Prognostic Model with Laboratory Verification in Malignant Melanoma. <i>Cancers</i> , 2022, 14, 1590.	1.7	2

#	ARTICLE	IF	CITATIONS
8512	Firstâ€line <sc>PD</sc>â€1</sc> inhibitors plus chemotherapy versus bevacizumab plus chemotherapy for advanced nonâ€squamous nonâ€small cell lung cancer: A Bayesian network metaâ€analysis of randomized controlled trials. <i>Cancer Medicine</i> , 2022, 11, 2043-2055.	1.3	5
8513	5-methylcytosine RNA methylation regulators affect prognosis and tumor microenvironment in lung adenocarcinoma. <i>Annals of Translational Medicine</i> , 2022, 10, 259-259.	0.7	15
8514	AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1+ CD8 T cells. <i>Cell Reports Medicine</i> , 2022, 3, 100554.	3.3	29
8515	Artificial Intelligenceâ€Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Nonâ€Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 1916-1928.	0.8	94
8516	Urinary detection of early responses to checkpoint blockade and of resistance to it via protease-cleaved antibody-conjugated sensors. <i>Nature Biomedical Engineering</i> , 2022, 6, 310-324.	11.6	16
8517	Comprehensive Characterization of Human Lung Large Cell Carcinoma Identifies Transcriptomic Signatures with Potential Implications in Response to Immunotherapy. <i>Journal of Clinical Medicine</i> , 2022, 11, 1500.	1.0	3
8518	Case Report: Immune Checkpoint Inhibitors Successfully Controlled Asymptomatic Brain Metastasis in Esophageal Squamous Cell Carcinoma. <i>Frontiers in Immunology</i> , 2022, 13, 746869.	2.2	2
8519	AllergoOncology: Role of immune cells and immune proteins. <i>Clinical and Translational Allergy</i> , 2022, 12, e12133.	1.4	7
8520	Vitiligo-specific soluble biomarkers as early indicators of response to immune checkpoint inhibitors in metastatic melanoma patients. <i>Scientific Reports</i> , 2022, 12, 5448.	1.6	5
8521	Exploring the Mechanisms Underlying the Cardiotoxic Effects of Immune Checkpoint Inhibitor Therapies. <i>Vaccines</i> , 2022, 10, 540.	2.1	8
8522	Local Ablative Therapy Associated with Immunotherapy in Locally Advanced Pancreatic Cancer: A Solution to Overcome the Double Trouble?â€A Comprehensive Review. <i>Journal of Clinical Medicine</i> , 2022, 11, 1948.	1.0	7
8523	Advances in Knowledge and Management of Immune-Related Adverse Events in Cancer Immunotherapy. <i>Frontiers in Endocrinology</i> , 2022, 13, 779915.	1.5	15
8524	Checkpoint Inhibitors and Induction of Celiac Disease-like Condition. <i>Biomedicines</i> , 2022, 10, 609.	1.4	5
8525	Population pharmacokinetics and exposureâ€response of antiâ€programmed cell death proteinâ€1 monoclonal antibody dostarlimab in advanced solid tumours. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 4142-4154.	1.1	11
8526	Assessing the Future of Solid Tumor Immunotherapy. <i>Biomedicines</i> , 2022, 10, 655.	1.4	34
8527	Simultaneous Genetic Ablation of PD-1, LAG-3, and TIM-3 in CD8 T Cells Delays Tumor Growth and Improves Survival Outcome. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3207.	1.8	7
8528	Association of the Microbiota and Pancreatic Cancer: Opportunities and Limitations. <i>Frontiers in Immunology</i> , 2022, 13, 844401.	2.2	15
8529	The clinical and prognostic significance of CMTM6/PD-L1 in oncology. <i>Clinical and Translational Oncology</i> , 2022, 24, 1478-1491.	1.2	2

#	ARTICLE	IF	CITATIONS
8530	Three-Year Follow-Up and Responseâ€œSurvival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3). <i>Clinical Cancer Research</i> , 2022, 28, 3277-3286.	3.2	27
8531	Targeting HIF-1 α abrogates PD-L1-mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	42
8532	PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases. <i>Frontiers in Pharmacology</i> , 2022, 13, 854967.	1.6	10
8533	Impact of chronic lymphocytic leukaemia on melanoma outcomes: A retrospective caseâ€œcontrol study. <i>British Journal of Haematology</i> , 2022, 197, 320-325.	1.2	5
8534	Hyperprogressive Disease in Malignant Carcinoma With Immune Checkpoint Inhibitor Use: A Review. <i>Frontiers in Nutrition</i> , 2022, 9, 810472.	1.6	5
8535	Evaluation of autoantibodies as predictors of treatment response and immune-related adverse events during the treatment with immune checkpoint inhibitors: A prospective longitudinal panâ€œcancer study. <i>Cancer Medicine</i> , 2022, 11, 3074-3083.	1.3	16
8536	Association of Elevated Expression Levels of COL4A1 in Stromal Cells with an Immunosuppressive Tumor Microenvironment in Low-Grade Glioma, Pancreatic Adenocarcinoma, Skin Cutaneous Melanoma, and Stomach Adenocarcinoma. <i>Journal of Personalized Medicine</i> , 2022, 12, 534.	1.1	3
8537	Immune checkpoints related-LncRNAs can identify different subtypes of lung cancer and predict immunotherapy and prognosis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, , 1.	1.2	2
8538	Secondary Adrenal Insufficiency in a Patient with Metastatic Melanoma Treated with Nivolumab. <i>Case Reports in Dermatology</i> , 2022, 14, 55-60.	0.3	1
8539	Novel Immunotherapies for Osteosarcoma. <i>Frontiers in Oncology</i> , 2022, 12, 830546.	1.3	25
8540	Ex vivo anchored <sc>PD-1</sc> functionally prevent in vivo renal allograft rejection. <i>Bioengineering and Translational Medicine</i> , 2022, 7, .	3.9	3
8541	Development and Validation of Ferroptosis- and Immune-Related lncRNAs Signatures for Breast Infiltrating Duct and Lobular Carcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 844642.	1.3	4
8542	Bronchoalveolar lavage fluid reveals factors contributing to the efficacy of PD-1 blockade in lung cancer. <i>JCI Insight</i> , 2022, 7, .	2.3	10
8543	Efficacy of Cytokine-Induced Killer Cell Immunotherapy for Patients With Pathologically Pure Glioblastoma. <i>Frontiers in Oncology</i> , 2022, 12, 851628.	1.3	4
8544	Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma. <i>Journal of Translational Medicine</i> , 2022, 20, 159.	1.8	12
8545	The prevalence and realâ€œworld therapeutic analysis of Chinese patients with KRASâ€œMutant Nonâ€œSmall Cell lung cancer. <i>Cancer Medicine</i> , 2022, 11, 3581-3592.	1.3	10
8546	Ovarian Endometrioid and Clear Cell Carcinomas with Low Prevalence of Microsatellite Instability: A Unique Subset of Ovarian Carcinomas Could Benefit from Combination Therapy with Immune Checkpoint Inhibitors and Other Anticancer Agents. <i>Healthcare (Switzerland)</i> , 2022, 10, 694.	1.0	4
8547	Heterogeneous Outcomes of Immune Checkpoint Inhibitor Rechallenge in Patients With NSCLC: A Systematic Review and Meta-Analysis. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100309.	0.6	8

#	ARTICLE	IF	CITATIONS
8548	Dual Relationship Between Stromal Cells and Immune Cells in the Tumor Microenvironment. <i>Frontiers in Immunology</i> , 2022, 13, 864739.	2.2	40
8549	Immune checkpoint inhibitor-related endocrinopathies. <i>Journal of Translational Internal Medicine</i> , 2022, 10, 9-14.	1.0	7
8550	The Therapeutic Effect and Clinical Outcome of Immune Checkpoint Inhibitors on Bone Metastasis in Advanced Non-Small-Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 871675.	1.3	9
8551	ZNF143 Expression is Associated with COPD and Tumor Microenvironment in Non-Small Cell Lung Cancer. <i>International Journal of COPD</i> , 2022, Volume 17, 685-700.	0.9	2
8552	Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 2323-2341.	3.3	48
8553	A Toolkit for Profiling the Immune Landscape of Pediatric Central Nervous System Malignancies. <i>Frontiers in Immunology</i> , 2022, 13, 864423.	2.2	2
8554	Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. <i>Cell Communication and Signaling</i> , 2022, 20, 44.	2.7	109
8555	Ubiquitin ligase STUB1 destabilizes IFN γ -receptor complex to suppress tumor IFN γ signaling. <i>Nature Communications</i> , 2022, 13, 1923.	5.8	18
8556	KRAS: A Druggable Target in Colon Cancer Patients. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4120.	1.8	13
8557	Enhanced T-Cell Priming and Improved Anti-Tumor Immunity through Lymphatic Delivery of Checkpoint Blockade Immunotherapy. <i>Cancers</i> , 2022, 14, 1823.	1.7	4
8558	Acute Kidney Injury Induced by Immune Checkpoint Inhibitors. <i>Kidney Diseases (Basel, Switzerland)</i> , 2022, 8, 190-201.	1.2	11
8559	Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany. <i>Cancers</i> , 2022, 14, 1804.	1.7	4
8560	Pretreatment body mass index predicts survival among patients administered nivolumab monotherapy for pretreated non-small cell lung cancer. <i>Thoracic Cancer</i> , 2022, 13, 1479-1489.	0.8	6
8561	CAR-T Cells for the Treatment of Lung Cancer. <i>Life</i> , 2022, 12, 561.	1.1	8
8562	Predictive biomarkers for the efficacy of nivolumab as 3rd-line therapy in patients with advanced gastric cancer: a subset analysis of ATTRACTION-2 phase III trial. <i>BMC Cancer</i> , 2022, 22, 378.	1.1	16
8563	Neoadjuvant Immune Checkpoint Inhibitor Therapy in Melanoma: Efficacy, Safety and Timing. <i>BioDrugs</i> , 2022, 36, 373-380.	2.2	2
8564	Immunological and nutritional predictive factors in patients receiving pembrolizumab for the first-line treatment of non-small cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 1893-1901.	1.2	8
8565	GINS4 might be a novel prognostic immune-related biomarker of not only esophageal squamous cell carcinoma and other cancers. <i>BMC Medical Genomics</i> , 2022, 15, 75.	0.7	1

#	ARTICLE	IF	CITATIONS
8566	Checkpoint Inhibitor Pneumonitis Induced by Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer: Occurrence and Mechanism. <i>Frontiers in Immunology</i> , 2022, 13, 830631.	2.2	28
8567	TP53 Co-Mutations in Advanced EGFR-Mutated Non-Small Cell Lung Cancer: Prognosis and Therapeutic Strategy for Cancer Therapy. <i>Frontiers in Oncology</i> , 2022, 12, 860563.	1.3	12
8568	Association between the type of thyroid dysfunction induced by immune checkpoint inhibitors and prognosis in cancer patients. <i>BMC Endocrine Disorders</i> , 2022, 22, 89.	0.9	14
8569	Durvalumab with or without tremelimumab combined with particle therapy for advanced hepatocellular carcinoma with macrovascular invasion: protocol for the DEPARTURE phase Ib trial. <i>BMJ Open</i> , 2022, 12, e059779.	0.8	1
8570	The Role of Tissue Biopsy in the Management of Immune Checkpoint Inhibitor Toxicity. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 417-425.	2.3	2
8571	Balancing the good and the bad: controlling immune-related adverse events versus anti-tumor responses in cancer patients treated with immune checkpoint inhibitors. <i>Immunotherapy Advances</i> , 2022, 2, .	1.2	5
8572	Imaging immunity in patients with cancer using positron emission tomography. <i>Npj Precision Oncology</i> , 2022, 6, 24.	2.3	13
8573	New evaluation of the tumor immune microenvironment of non-small cell lung cancer and its association with prognosis. , 2022, 10, e003765.		10
8574	Biomarkers of systemic inflammation predict survival with first-line immune checkpoint inhibitors in non-small-cell lung cancer. <i>ESMO Open</i> , 2022, 7, 100445.	2.0	26
8575	Inhibition of renalase drives tumour rejection by promoting T cell activation. <i>European Journal of Cancer</i> , 2022, 165, 81-96.	1.3	2
8576	Pancreatic Adverse Events Associated With Immune Checkpoint Inhibitors: A Large-Scale Pharmacovigilance Analysis. <i>Frontiers in Pharmacology</i> , 2022, 13, 817662.	1.6	8
8577	Remodeling tumor immunosuppressive microenvironment via a novel bioactive nanovaccines potentiates the efficacy of cancer immunotherapy. <i>Bioactive Materials</i> , 2022, 16, 107-119.	8.6	24
8578	Research Trends in Immune Checkpoint Blockade for Melanoma: Visualization and Bibliometric Analysis. <i>Journal of Medical Internet Research</i> , 2022, 24, e32728.	2.1	7
8579	Long-term Changes in the Premature Death Rate in Lung Cancer in a Developed Region of China: Population-based Study. <i>JMIR Public Health and Surveillance</i> , 2022, 8, e33633.	1.2	5
8580	Convection-enhanced delivery for high-grade glioma. <i>Neuro-Oncology Practice</i> , 2022, 9, 24-34.	1.0	6
8581	The multi-specific VH-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity. <i>British Journal of Cancer</i> , 2022, 126, 1168-1177.	2.9	9
8582	Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13311.	1.8	54
8583	The Role of Circulating Biomarkers in the Oncological Management of Metastatic Renal Cell Carcinoma: Where Do We Stand Now?. <i>Biomedicines</i> , 2022, 10, 90.	1.4	6

#	ARTICLE	IF	CITATIONS
8584	The circular RNA circDLG1 promotes gastric cancer progression and anti-PD-1 resistance through the regulation of CXCL12 by sponging miR-141-3p. <i>Molecular Cancer</i> , 2021, 20, 166.	7.9	60
8585	Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer. , 2021, 9, e002780.		15
8586	Association of the Geriatric Nutritional Risk Index with the survival of patients with non-small-cell lung cancer after platinum-based chemotherapy. <i>BMC Pulmonary Medicine</i> , 2021, 21, 409.	0.8	9
8587	B7-1 and programmed cell death ligand 1 in primary and lymph node metastasis lesions of non-small cell lung carcinoma. <i>Cancer Medicine</i> , 2022, 11, 479-491.	1.3	5
8588	A Novel Kinase Inhibitor AX-0085 Inhibits Interferon- β -Mediated Induction of PD-L1 Expression and Promotes Immune Reaction to Lung Adenocarcinoma Cells. <i>Cells</i> , 2022, 11, 19.	1.8	3
8589	Correlation Between Immune-Related Adverse Events and Prognosis in Hepatocellular Carcinoma Patients Treated With Immune Checkpoint Inhibitors. <i>Frontiers in Immunology</i> , 2021, 12, 794099.	2.2	34
8590	Relationship of the lung microbiome with PD-L1 expression and immunotherapy response in lung cancer. <i>Respiratory Research</i> , 2021, 22, 322.	1.4	26
8591	What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy?. <i>Frontiers in Immunology</i> , 2021, 12, 773168.	2.2	18
8592	Identification of a novel immune signature for optimizing prognosis and treatment prediction in colorectal cancer. <i>Aging</i> , 2021, 13, 25518-25549.	1.4	3
8593	Integrative Molecular Analyses of an Individual Transcription Factor-Based Genomic Model for Lung Cancer Prognosis. <i>Disease Markers</i> , 2021, 2021, 1-18.	0.6	2
8594	Immune landscape of advanced gastric cancer tumor microenvironment identifies immunotherapeutic relevant gene signature. <i>BMC Cancer</i> , 2021, 21, 1324.	1.1	8
8595	Improvement of PD-1 Blockade Efficacy and Elimination of Immune-Related Gastrointestinal Adverse Effect by mTOR Inhibitor. <i>Frontiers in Immunology</i> , 2021, 12, 793831.	2.2	16
8596	Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges. <i>Cancers</i> , 2022, 14, 109.	1.7	21
8597	Protein phosphatase 2A inactivation induces microsatellite instability, neoantigen production and immune response. <i>Nature Communications</i> , 2021, 12, 7297.	5.8	25
8598	Sulfisoxazole Elicits Robust Antitumour Immune Response Along with Immune Checkpoint Therapy by Inhibiting Exosomal PD-L1. <i>Advanced Science</i> , 2022, 9, e2103245.	5.6	22
8599	Study on PD-L1 Expression in NSCLC Patients and Related Influencing Factors in the Real World. <i>Computational and Mathematical Methods in Medicine</i> , 2021, 2021, 1-10.	0.7	5
8600	Therapeutic advances in non-small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy. <i>MedComm</i> , 2021, 2, 692-729.	3.1	38
8601	Deep Learning to Predict EGFR Mutation and PD-L1 Expression Status in Non-Small-Cell Lung Cancer on Computed Tomography Images. <i>Journal of Oncology</i> , 2021, 2021, 1-11.	0.6	20

#	ARTICLE	IF	CITATIONS
8602	Clinicopathological implications of lncRNAs, immunotherapy and DNA methylation in lung squamous cell carcinoma: a narrative review. <i>Translational Cancer Research</i> , 2021, 10, 5406-5429.	0.4	4
8603	Frequency of Mismatch Repair Deficiency/High Microsatellite Instability and Its Role as a Predictive Biomarker of Response to Immune Checkpoint Inhibitors in Gynecologic Cancers. <i>Cancer Research and Treatment</i> , 2022, 54, 1200-1208.	1.3	11
8604	Management of acute kidney injury in gastrointestinal tumor: An overview. <i>World Journal of Clinical Cases</i> , 2021, 9, 10746-10764.	0.3	0
8605	Melanoma trials that defined surgical management: Overview of trials that established NCCN margin guidelines. <i>Journal of Surgical Oncology</i> , 2022, 125, 28-33.	0.8	1
8606	A Pan-Cancer Analysis of Predictive Methylation Signatures of Response to Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 796647.	2.2	16
8607	In Vitro Antineoplastic and Antiviral Activity and In Vivo Toxicity of <i>Geum urbanum</i> L. Extracts. <i>Molecules</i> , 2022, 27, 245.	1.7	5
8608	Combination Immune Checkpoint Blockade Enhances IL-2 and CD107a Production from HIV-Specific T Cells Ex Vivo in People Living with HIV on Antiretroviral Therapy. <i>Journal of Immunology</i> , 2022, 208, 54-62.	0.4	16
8609	Cisplatin and gemcitabine exert opposite effects on immunotherapy with PD-1 antibody in K-ras-driven cancer. <i>Journal of Advanced Research</i> , 2022, 40, 109-124.	4.4	10
8610	Assessment of sarcopenia as a predictor of poor overall survival for advanced non-small-cell lung cancer patients receiving salvage anti-PD-1 immunotherapy. <i>Annals of Translational Medicine</i> , 2021, 9, 1801-1801.	0.7	11
8611	The foundations of immune checkpoint blockade and the ipilimumab approval decennial. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 509-528.	21.5	201
8612	E-cadherin on epithelial-mesenchymal transition in thyroid cancer. <i>Cancer Cell International</i> , 2021, 21, 695.	1.8	12
8613	NKG7 Is a T-cell Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy. <i>Cancer Immunology Research</i> , 2022, 10, 162-181.	1.6	26
8614	Prognostic Value of Neoantigen Load in Immune Checkpoint Inhibitor Therapy for Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 689076.	2.2	21
8615	Multicellular Effects of STAT3 in Non-small Cell Lung Cancer: Mechanistic Insights and Therapeutic Opportunities. <i>Cancers</i> , 2021, 13, 6228.	1.7	33
8616	Nivolumab in Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck: A Tertiary Cancer Center Experience. <i>South Asian Journal of Cancer</i> , 2022, 11, 058-061.	0.2	1
8617	Depletion of central memory CD8+ T cells might impede the antitumor therapeutic effect of Mogamulizumab. <i>Nature Communications</i> , 2021, 12, 7280.	5.8	11
8618	Chamaejasmenin B, an Inhibitor for Metastatic Outgrowth, Reversed M2-Dominant Macrophage Polarization in Breast Tumor Microenvironment. <i>Frontiers in Immunology</i> , 2021, 12, 774230.	2.2	1
8619	Treatment patterns and clinical outcomes for patients with melanoma and central nervous system metastases: A real-world study. <i>Cancer Medicine</i> , 2022, 11, 139-150.	1.3	6

#	ARTICLE	IF	CITATIONS
8620	Prognostic significance of natural killer cell-associated markers in gastric cancer: quantitative analysis using multiplex immunohistochemistry. <i>Journal of Translational Medicine</i> , 2021, 19, 529.	1.8	8
8621	Lymphocyte-activation gene 3 in non-small-cell lung carcinomas: correlations with clinicopathologic features and prognostic significance. <i>Modern Pathology</i> , 2022, 35, 615-624.	2.9	7
8622	Efficacy and Safety of Immune Checkpoint Blockades in the Treatment of Ocular Melanoma: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 781162.	1.3	3
8623	Epstein-Barr Virus Epithelial Cancers: A Comprehensive Understanding to Drive Novel Therapies. <i>Frontiers in Immunology</i> , 2021, 12, 734293.	2.2	24
8624	Not so "rare" an example of malignant melanoma in India: report from a tertiary cancer centre. <i>E-cancermedicalscience</i> , 2021, 15, 1335.	0.6	1
8625	Interleukin-8 in Melanoma Pathogenesis, Prognosis and Therapy: An Integrated View into Other Neoplasms and Chemokine Networks. <i>Cells</i> , 2022, 11, 120.	1.8	14
8626	Efficacy and Safety of Immune Checkpoint Inhibitor in Advanced Esophageal Squamous Cell Carcinoma: A Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 777686.	1.3	5
8627	Differential diagnosis and management of immune checkpoint inhibitor-induced colitis: A comprehensive review. <i>World Journal of Experimental Medicine</i> , 2021, 11, 79-92.	0.9	8
8628	Expression signature, prognosis value and immune characteristics of cathepsin F in non-small cell lung cancer identified by bioinformatics assessment. <i>BMC Pulmonary Medicine</i> , 2021, 21, 420.	0.8	7
8629	Dramatic response to immunochemotherapy followed by salvage surgery in an elderly lung cancer patient. <i>Thoracic Cancer</i> , 2022, 13, 510-513.	0.8	2
8630	Tumor Endothelial Marker TEM7 is a Prognostic Biomarker and Correlating with Immune Infiltrates in Gastric Cancer. <i>International Journal of General Medicine</i> , 2021, Volume 14, 10155-10171.	0.8	1
8631	Pan-Cancer Analyses of the Tumor Microenvironment Reveal That Ubiquitin-Conjugating Enzyme E2C Might Be a Potential Immunotherapy Target. <i>Journal of Immunology Research</i> , 2021, 2021, 1-27.	0.9	5
8632	Cardiovascular Safety Assessment in Cancer Drug Development. <i>Journal of the American Heart Association</i> , 2021, 10, e024033.	1.6	5
8633	Prognostic Role of Soluble Programmed Death Ligand 1 in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 774131.	1.3	13
8634	pH Low Insertion Peptide-Modified Programmed Cell Death-Ligand 1 Potently Suppresses T-Cell Activation Under Acidic Condition. <i>Frontiers in Immunology</i> , 2021, 12, 794226.	2.2	2
8635	The Intriguing Thyroid Hormones-Lung Cancer Association as Exemplification of the Thyroid Hormones-Cancer Association: Three Decades of Evolving Research. <i>International Journal of Molecular Sciences</i> , 2022, 23, 436.	1.8	8
8636	Discovery of Spiro-azaindoline Inhibitors of Hematopoietic Progenitor Kinase 1 (HPK1). <i>ACS Medicinal Chemistry Letters</i> , 2022, 13, 84-91.	1.3	17
8637	Chemokines in the Landscape of Cancer Immunotherapy: How They and Their Receptors Can Be Used to Turn Cold Tumors into Hot Ones?. <i>Cancers</i> , 2021, 13, 6317.	1.7	17

#	ARTICLE	IF	CITATIONS
8638	Natural killer cells in liver transplantation: Can we harness the power of the immune checkpoint to promote tolerance?. <i>Clinical and Translational Science</i> , 2022, 15, 1091-1103.	1.5	4
8639	Immunotherapy in non-small cell lung cancer: rationale, recent advances and future perspectives. <i>Precision Clinical Medicine</i> , 2021, 4, 258-270.	1.3	18
8640	Optimizing Immuno-PET Imaging of Tumor PD-L1 Expression: Pharmacokinetic, Biodistribution, and Dosimetric Comparisons of ⁸⁹ Zr-Labeled Anti-PD-L1 Antibody Formats. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1259-1265.	2.8	11
8641	Clinical and prognostic implications of an immune-related risk model based on TP53 status in lung adenocarcinoma. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 436-448.	1.6	3
8642	ENPEP as a potential predictor of immune checkpoint inhibitor efficacy. <i>Cancer Medicine</i> , 2022, 11, 880-887.	1.3	5
8645	Immune checkpoint inhibitor-related interstitial lung disease in patients with advanced non-small cell lung cancer: systemic review of characteristics, incidence, risk factors, and management. <i>Journal of Thoracic Disease</i> , 2021, .	0.6	4
8646	OUP accepted manuscript. <i>Oncologist</i> , 2022, , .	1.9	1
8647	The relationship between different subtypes of KRAS and PD-L1 & tumor mutation burden (TMB) based on next-generation sequencing (NGS) detection in Chinese lung cancer patients. <i>Translational Lung Cancer Research</i> , 2022, 11, 213-223.	1.3	6
8648	Cerebral nocardiosis in a patient treated with pembrolizumab: a first case report. <i>BMC Infectious Diseases</i> , 2022, 22, 306.	1.3	3
8649	Glioma and the gut-brain axis: opportunities and future perspectives. <i>Neuro-Oncology Advances</i> , 2022, 4, vda054.	0.4	10
8650	The Effect of Anlotinib Combined with anti-PD-1 in the Treatment of Gastric Cancer. <i>Frontiers in Surgery</i> , 2022, 9, 895982.	0.6	1
8651	The Implication of Gastric Microbiome in the Treatment of Gastric Cancer. <i>Cancers</i> , 2022, 14, 2039.	1.7	12
8652	Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma. <i>Nature Communications</i> , 2022, 13, 1935.	5.8	37
8653	Prognostic and predictive impact of neutrophil-lymphocyte ratio and HLA genotyping in advanced esophageal squamous cell carcinoma patients receiving immune checkpoint inhibitor monotherapy. <i>Thoracic Cancer</i> , 2022, 13, 1631-1641.	0.8	8
8654	Different subpopulations of regulatory T cells in human autoimmune disease, transplantation, and tumor immunity. <i>MedComm</i> , 2022, 3, e137.	3.1	11
8655	Evaluation of radio-immunotherapy sequence on immunological responses and clinical outcomes in patients with melanoma brain metastases (ELEKTRA). <i>Oncolimmunology</i> , 2022, 11, 2066609.	2.1	13
8656	The Role of Myeloid Cells in Hepatotoxicity Related to Cancer Immunotherapy. <i>Cancers</i> , 2022, 14, 1913.	1.7	7
8657	Bipartite network models to design combination therapies in acute myeloid leukaemia. <i>Nature Communications</i> , 2022, 13, 2128.	5.8	15

#	ARTICLE	IF	CITATIONS
8658	The IFN γ -PDL1 Pathway Enhances CD8T-DCT Interaction to Promote Hypertension. <i>Circulation Research</i> , 2022, 130, 1550-1564.	2.0	15
8659	Cutaneous Adverse Events Associated with Immune Checkpoint Inhibitors: A Review Article. <i>Current Oncology</i> , 2022, 29, 2871-2886.	0.9	24
8660	Role of <i>STK11</i> in <i>ALK</i> -positive non-small cell lung cancer (Review). <i>Oncology Letters</i> , 2022, 23, 181.	0.8	2
8661	Prognostic and Predictive Role of PD-L1 Expression in Stage III Non-small Cell Lung Cancer Treated With Definitive Chemoradiation and Adjuvant Durvalumab. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 752-758.	0.4	5
8662	Mechanisms of Immunotherapy Resistance in Cutaneous Melanoma: Recognizing a Shapeshifter. <i>Frontiers in Oncology</i> , 2022, 12, 880876.	1.3	21
8663	Cost-Effectiveness of Nivolumab Plus Chemotherapy vs. Chemotherapy as First-Line Treatment for Advanced Gastric Cancer/Gastroesophageal Junction Cancer/Esophageal Adenocarcinoma in China. <i>Frontiers in Oncology</i> , 2022, 12, 851522.	1.3	12
8664	Role of immunohistochemistry in the diagnosis and staging of cutaneous squamous cell carcinomas (Review). <i>Experimental and Therapeutic Medicine</i> , 2022, 23, 383.	0.8	4
8665	A Cancer Associated Fibroblasts-Related Six-Gene Panel for Anti-PD-1 Therapy in Melanoma Driven by Weighted Correlation Network Analysis and Supervised Machine Learning. <i>Frontiers in Medicine</i> , 2022, 9, 880326.	1.2	9
8666	Platycodon grandiflorum Triggers Antitumor Immunity by Restricting PD-1 Expression of CD8+ T Cells in Local Tumor Microenvironment. <i>Frontiers in Pharmacology</i> , 2022, 13, 774440.	1.6	5
8667	A diversity outbred F1 mouse model identifies host-intrinsic genetic regulators of response to immune checkpoint inhibitors. <i>OncImmunology</i> , 2022, 11, 2064958.	2.1	10
8668	Gut microbiota correlates with antitumor activity in patients with <i>mCRC</i> and <i>NSCLC</i> treated with cetuximab plus avelumab. <i>International Journal of Cancer</i> , 2022, 151, 473-480.	2.3	24
8669	Inhibitors of PD-1 in Non-Small Cell Lung Cancer: A Meta-Analysis of Clinical and Molecular Features. <i>Frontiers in Immunology</i> , 2022, 13, 875093.	2.2	10
8670	Revisiting the melanomagenic pathways and current therapeutic approaches. <i>Molecular Biology Reports</i> , 2022, 49, 9651-9671.	1.0	2
8671	Role of the cGAS-STING pathway in regulating the tumor-immune microenvironment in dMMR/MSI colorectal cancer. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2765-2776.	2.0	7
8672	Classification of colorectal carcinoma subtypes based on ferroptosis-associated molecular markers. <i>World Journal of Surgical Oncology</i> , 2022, 20, 117.	0.8	6
8673	Novel phthalimides regulating PD-1/PD-L1 interaction as potential immunotherapy agents. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 4446-4457.	5.7	15
8674	Targeting Acquired and Intrinsic Resistance Mechanisms in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer. <i>Drugs</i> , 2022, 82, 649-662.	4.9	15
8675	Association of pre-existing lung interstitial changes with immune-related pneumonitis in patients with non-small lung cancer receiving immunotherapy. <i>Supportive Care in Cancer</i> , 2022, 30, 6515-6524.	1.0	4

#	ARTICLE	IF	CITATIONS
8676	Research Trends and Most Influential Clinical Studies on Anti-PD1/PDL1 Immunotherapy for Cancers: A Bibliometric Analysis. <i>Frontiers in Immunology</i> , 2022, 13, 862084.	2.2	18
8677	Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML Blasts. <i>Cancer Discovery</i> , 2022, 12, 1760-1781.	7.7	15
8678	Incidence of Elevated Aminotransferases With or Without Bilirubin Elevation During Treatment With Immune Checkpoint Inhibitors: A Retrospective Study of Patients From Community Oncology Clinics in the United States. <i>Cureus</i> , 2022, 14, e24053.	0.2	1
8679	Effectiveness and Cost-Effectiveness Profile of Second-Line Treatments with Nivolumab, Pembrolizumab and Atezolizumab in Patients with Advanced Non-Small Cell Lung Cancer. <i>Pharmaceuticals</i> , 2022, 15, 489.	1.7	6
8680	Endothelial Cells Activated by Extracellular Histones Promote Foxp3+ Suppressive Treg Cells In Vitro. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4527.	1.8	2
8681	Expression of CD39 Identifies Activated Intratumoral CD8+ T Cells in Mismatch Repair Deficient Endometrial Cancer. <i>Cancers</i> , 2022, 14, 1924.	1.7	5
8682	When killers become thieves: Trogocytosed PD-1 inhibits NK cells in cancer. <i>Science Advances</i> , 2022, 8, eabj3286.	4.7	35
8683	SEMA6A/RhoA/YAP axis mediates tumor-stroma interactions and prevents response to dual BRAF/MEK inhibition in BRAF-mutant melanoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 148.	3.5	10
8684	Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. <i>Lancet Oncology</i> , The, 2022, 23, 659-670.	5.1	282
8685	Frailty and checkpoint inhibitor toxicity in older patients with melanoma. <i>Cancer</i> , 2022, 128, 2746-2752.	2.0	12
8686	Improved Survival Prediction by Combining Radiological Imaging and S-100B Levels Into a Multivariate Model in Metastatic Melanoma Patients Treated With Immune Checkpoint Inhibition. <i>Frontiers in Oncology</i> , 2022, 12, 830627.	1.3	2
8687	LAG3-PD-1 Combo Overcome the Disadvantage of Drug Resistance. <i>Frontiers in Oncology</i> , 2022, 12, 831407.	1.3	10
8688	The role of cellular proteostasis in antitumor immunity. <i>Journal of Biological Chemistry</i> , 2022, 298, 101930.	1.6	6
8689	Targeting the gut and tumor microbiota in cancer. <i>Nature Medicine</i> , 2022, 28, 690-703.	15.2	159
8690	Emerging role of RNA sensors in tumor microenvironment and immunotherapy. <i>Journal of Hematology and Oncology</i> , 2022, 15, 43.	6.9	11
8691	Immunotherapy of Neuroblastoma: Facts and Hopes. <i>Clinical Cancer Research</i> , 2022, 28, 3196-3206.	3.2	29
8692	Association of Immune Checkpoint Inhibitors With Neurologic Adverse Events. <i>JAMA Network Open</i> , 2022, 5, e227722.	2.8	25
8693	PD-L1 signaling selectively regulates T cell lymphatic transendothelial migration. <i>Nature Communications</i> , 2022, 13, 2176.	5.8	18

#	ARTICLE	IF	CITATIONS
8694	Primary Pulmonary Malignant Melanoma Successfully Treated with Immunotherapy in a 90-Year-Old Patient. <i>Case Reports in Oncology</i> , 0, , 394-398.	0.3	0
8695	Association of a novel 27-gene immuno-oncology assay with efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer. <i>BMC Cancer</i> , 2022, 22, 407.	1.1	9
8696	Analysis of Molecular Biomarkers in Resected Early-Stage Non-Small Cells Lung Cancer: A Narrative Review. <i>Cancers</i> , 2022, 14, 1949.	1.7	2
8697	Targeting Mutant Kirsten Rat Sarcoma Viral Oncogene Homolog in Non-Small Cell Lung Cancer: Current Difficulties, Integrative Treatments and Future Perspectives. <i>Frontiers in Pharmacology</i> , 2022, 13, 875330.	1.6	4
8698	High Levels of Circulating Monocytic Myeloid-Derived Suppressive-Like Cells Are Associated With the Primary Resistance to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: An Exploratory Analysis. <i>Frontiers in Immunology</i> , 2022, 13, 866561.	2.2	15
8699	A Review of the Effects of Cervical Cancer Standard Treatment on Immune Parameters in Peripheral Blood, Tumor Draining Lymph Nodes, and Local Tumor Microenvironment. <i>Journal of Clinical Medicine</i> , 2022, 11, 2277.	1.0	5
8700	Cytokine Based Immunotherapy for Cancer and Lymphoma: Biology, Challenges and Future Perspectives. <i>Frontiers in Immunology</i> , 2022, 13, 872010.	2.2	23
8701	Identification of Tumor Mutation Burden, Microsatellite Instability, and Somatic Copy Number Alteration Derived Nine Gene Signatures to Predict Clinical Outcomes in STAD. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 793403.	1.6	4
8702	PD-1 cooperates with AIRE-mediated tolerance to prevent lethal autoimmune disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2120149119.	3.3	8
8703	The Spatial Landscape of Progression and Immunoediting in Primary Melanoma at Single-Cell Resolution. <i>Cancer Discovery</i> , 2022, 12, 1518-1541.	7.7	87
8704	CXCL13 as a Novel Immune Checkpoint for Regulatory B Cells and Its Role in Tumor Metastasis. <i>Journal of Immunology</i> , 2022, 208, 2425-2435.	0.4	9
8705	Clinical Characteristics of ICI-Related Pancreatitis and Cholangitis Including Radiographic and Endoscopic Findings. <i>Healthcare (Switzerland)</i> , 2022, 10, 763.	1.0	8
8706	Pulmonary Lymphangitis Poses a Major Challenge for Radiologists in an Oncological Setting during the COVID-19 Pandemic. <i>Journal of Personalized Medicine</i> , 2022, 12, 624.	1.1	9
8707	Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial. , 2022, 10, e004424.		54
8708	Analysis of patient reported outcomes included in the registrational clinical trials of nivolumab for advanced non-small cell lung cancer. <i>Translational Oncology</i> , 2022, 20, 101418.	1.7	3
8709	Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis. <i>ESMO Open</i> , 2022, 7, 100465.	2.0	17
8710	Prognostic significance and therapeutic potentials of immune checkpoints in osteosarcoma.. <i>EXCLI Journal</i> , 2022, 21, 250-268.	0.5	10
8711	Sex differences in immune-related adverse events with immune checkpoint inhibitors: data mining of the FDA adverse event reporting system. <i>International Journal of Clinical Pharmacy</i> , 2022, 44, 689-697.	1.0	9

#	ARTICLE	IF	CITATIONS
8712	Development of an immunohistochemical assay for Siglec-15. <i>Laboratory Investigation</i> , 2022, 102, 771-778.	1.7	8
8713	Decitabine increases neoantigen and cancer testis antigen expression to enhance T-cell-mediated toxicity against glioblastoma. <i>Neuro-Oncology</i> , 2022, 24, 2093-2106.	0.6	18
8714	Phase II trial of nivolumab monotherapy and biomarker screening in patients with chemo-refractory germ cell tumors. <i>International Journal of Urology</i> , 2022, 29, 741-747.	0.5	6
8715	Promoting antibody-dependent cellular phagocytosis for effective macrophage-based cancer immunotherapy. <i>Science Advances</i> , 2022, 8, eabl9171.	4.7	30
8716	Genomic Correlates of Outcome in Tumor-Infiltrating Lymphocyte Therapy for Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2022, 28, 1911-1924.	3.2	3
8717	The Challenging Management of Cancer: An Immunonephrologist's Perspective. <i>Kidney and Blood Pressure Research</i> , 2021, 46, 114-120.	0.9	2
8718	Association between plasma somatic copy number variations and response to immunotherapy in patients with programmed death-ligand 1-negative non-small cell lung cancer. <i>Journal of International Medical Research</i> , 2022, 50, 030006052210932.	0.4	3
8719	Squamous cell carcinoma of the lung presenting as a fungating ulcerated skin lesion: a case report. <i>Journal of Medical Case Reports</i> , 2022, 16, 172.	0.4	0
8725	Design of a new multi-epitope peptide vaccine for non-small cell Lung cancer via vaccinology methods: an study.. <i>Molecular Biology Research Communications</i> , 2022, 11, 55-66.	0.2	1
8726	PSA-IgM and iXip in the diagnosis and management of prostate cancer: clinical relevance and future potential. A review.. <i>Acta Biomedica</i> , 2022, 92, e2021344.	0.2	4
8777	The side effects of immune checkpoint inhibitor therapy on the endocrine system. <i>Indian Journal of Medical Research</i> , 2021, 154, 559.	0.4	7
8782	Case Report: Primary Duodenal Melanoma with Brain Metastasis. , 2021, 25, 1-5.		2
8783	Tumor heterogeneity reshapes the tumor microenvironment to influence drug resistance. <i>International Journal of Biological Sciences</i> , 2022, 18, 3019-3033.	2.6	54
8784	Melanoma: An immunotherapy journey from bench to bedside. <i>Cancer Treatment and Research</i> , 2022, 183, 49-89.	0.2	0
8785	Nephrotoxicity in cancer treatment: An update. <i>Advances in Cancer Research</i> , 2022, , 77-129.	1.9	4
8786	Expression and Prognostic Significance of c-Myc, ALK, ROS1, BRAF, and PD-L1 Among Patients With Non-Small Cell Lung Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2022, 16, 117955492210927.	0.6	1
8787	Optimized mobilization of MHC class I- and II- restricted immunity by dendritic cell vaccine potentiates cancer therapy. <i>Theranostics</i> , 2022, 12, 3488-3502.	4.6	7
8788	Combination targeted and immune therapy in the treatment of advanced melanoma: a valid treatment option for patients?. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210903.	1.4	4

#	ARTICLE	IF	CITATIONS
8789	Current status and advances of immunotherapy in nasopharyngeal carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210962.	1.4	23
8790	The Single-Cell Level Perspective of the Tumor Microenvironment and Its Remodeling by CAR-T Cells. <i>Cancer Treatment and Research</i> , 2022, 183, 275-285.	0.2	1
8791	Management of Acral and Mucosal Melanoma: Medical Oncology Perspective. <i>Oncologist</i> , 2022, 27, 703-710.	1.9	8
8792	Gastrointestinal Toxicities of Immune Checkpoint Inhibitors Are Associated With Enhanced Tumor Responsiveness and Improved Survival. <i>Gastroenterology Research</i> , 2022, 15, 56-66.	0.4	2
8793	Deep learning for predicting immunotherapeutic efficacy in advanced non-small cell lung cancer patients: a retrospective study combining progression-free survival risk and overall survival risk. <i>Translational Lung Cancer Research</i> , 2022, 11, 670-685.	1.3	13
8794	CDC25C as a Predictive Biomarker for Immune Checkpoint Inhibitors in Patients With Lung Adenocarcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 867788.	1.3	3
8795	PD-L1/CTLA-1 co-localization: A novel biomarker for immunotherapy response in non-small cell lung cancer. <i>Thoracic Cancer</i> , 2022, , .	0.8	0
8796	Predicting Durable Responses to Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer Using a Multi-Feature Model. <i>Frontiers in Immunology</i> , 2022, 13, 829634.	2.2	7
8797	Real-World Analysis of Nivolumab and Atezolizumab Efficacy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer. <i>Pharmaceuticals</i> , 2022, 15, 533.	1.7	5
8798	A Machine Learning Model Based on PET/CT Radiomics and Clinical Characteristics Predicts Tumor Immune Profiles in Non-Small Cell Lung Cancer: A Retrospective Multicohort Study. <i>Frontiers in Immunology</i> , 2022, 13, 859323.	2.2	25
8799	Immune Checkpoint Inhibitors in Peripheral T-Cell Lymphoma. <i>Frontiers in Pharmacology</i> , 2022, 13, 869488.	1.6	8
8800	Integrative Analysis Constructs an Extracellular Matrix-Associated Gene Signature for the Prediction of Survival and Tumor Immunity in Lung Adenocarcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 835043.	1.8	4
8801	Advanced Immune Cell Profiling by Multiparameter Flow Cytometry in Humanized Patient-Derived Tumor Mice. <i>Cancers</i> , 2022, 14, 2214.	1.7	5
8802	Novel Therapeutic Approaches with DNA Damage Response Inhibitors for Melanoma Treatment. <i>Cells</i> , 2022, 11, 1466.	1.8	6
8803	Dose Finding in Oncology: What is Impeding Coming of Age?. <i>Pharmaceutical Research</i> , 2022, , 1.	1.7	1
8804	Risk factors associated with immune checkpoint inhibitor-induced acute kidney injury compared with other immune-related adverse events: a case-control study. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 1881-1887.	1.4	12
8805	The NOD Mouse Beyond Autoimmune Diabetes. <i>Frontiers in Immunology</i> , 2022, 13, 874769.	2.2	20
8806	Cutaneous immune-related adverse events among Taiwanese cancer patients receiving immune checkpoint inhibitors link to a survival benefit. <i>Scientific Reports</i> , 2022, 12, 7021.	1.6	8

#	ARTICLE	IF	CITATIONS
8807	Feasibility of immunotherapy in cancer patients with persistent or past hepatitis B or C virus infection. <i>JGH Open</i> , 2022, 6, 309-316.	0.7	6
8808	Efficacy and safety of sintilimab plus docetaxel in patients with previously treated advanced non-small cell lung cancer: a prospective, single-arm, phase II study in China. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, , 1.	1.2	3
8809	Paraneoplastic Neurological Syndromes: Transitioning Between the Old and the New. <i>Current Oncology Reports</i> , 2022, 24, 1237-1249.	1.8	2
8810	Identification of sSIGLEC5 and sLAG3 as New Relapse Predictors in Lung Cancer. <i>Biomedicines</i> , 2022, 10, 1047.	1.4	3
8811	DNA Hypermethylation-Regulated CX3CL1 Reducing T Cell Infiltration Indicates Poor Prognosis in Wilms Tumour. <i>Frontiers in Oncology</i> , 2022, 12, 882714.	1.3	7
8812	Identification of Novel Prognostic Biomarkers Relevant to Immune Infiltration in Lung Adenocarcinoma. <i>Frontiers in Genetics</i> , 2022, 13, 863796.	1.1	0
8813	Hematological and Extra-Hematological Autoimmune Complications after Checkpoint Inhibitors. <i>Pharmaceuticals</i> , 2022, 15, 557.	1.7	3
8814	In vivo labeling reveals continuous trafficking of TCF-1+ T cells between tumor and lymphoid tissue. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	42
8815	Exploring the educational needs for severe immune-related adverse events of PD-1/PD-L1 inhibitors in advanced lung cancer: A single-center observational study. <i>Asia-Pacific Journal of Oncology Nursing</i> , 2022, 9, 100076.	0.7	2
8816	Immune Checkpoint Inhibitors in Cancer Therapy. <i>Current Oncology</i> , 2022, 29, 3044-3060.	0.9	239
8817	Targeting nucleotide metabolism: a promising approach to enhance cancer immunotherapy. <i>Journal of Hematology and Oncology</i> , 2022, 15, 45.	6.9	43
8818	Temporal and sex-dependent gene expression patterns in a renal ischemia/reperfusion injury and recovery pig model. <i>Scientific Reports</i> , 2022, 12, 6926.	1.6	4
8819	Dermatological Aspects of Nursing Oncology: Meaningful Observations Ensuring Better Quality of Life. <i>Indian Journal of Palliative Care</i> , 0, .	1.0	0
8820	A State-of-the-Art Roadmap for Biomarker-Driven Drug Development in the Era of Personalized Therapies. <i>Journal of Personalized Medicine</i> , 2022, 12, 669.	1.1	1
8821	The cure from within? a review of the microbiome and diet in melanoma. <i>Cancer and Metastasis Reviews</i> , 2022, 41, 261-280.	2.7	8
8822	Combinatorial Herpes Simplex Vaccine Strategies: From Bedside to Bench and Back. <i>Frontiers in Immunology</i> , 2022, 13, 849515.	2.2	15
8823	Immune Checkpoint Protein Expression Defines the Prognosis of Advanced Thyroid Carcinoma. <i>Frontiers in Endocrinology</i> , 2022, 13, 859013.	1.5	10
8824	A Novel Risk Score Model Based on Eleven Extracellular Matrix-Related Genes for Predicting Overall Survival of Glioma Patients. <i>Journal of Oncology</i> , 2022, 2022, 1-20.	0.6	3

#	ARTICLE	IF	CITATIONS
8825	Novel Al ¹⁸ F-NOTA-Conjugated Lactam-Cyclized α -Melanocyte-Stimulating Hormone Peptides with Enhanced Melanoma Uptake. <i>Bioconjugate Chemistry</i> , 2022, 33, 982-990.	1.8	1
8826	Novel ⁶⁴ Cu-Labeled NOTA-Conjugated Lactam-Cyclized Alpha-Melanocyte-Stimulating Hormone Peptides with Enhanced Tumor to Kidney Uptake Ratios. <i>Molecular Pharmaceutics</i> , 2022, 19, 2535-2541.	2.3	6
8827	What Zebrafish and Nanotechnology Can Offer for Cancer Treatments in the Age of Personalized Medicine. <i>Cancers</i> , 2022, 14, 2238.	1.7	6
8828	Biomarkers of Response and Resistance to Immunotherapy in Microsatellite Stable Colorectal Cancer: Toward a New Personalized Medicine. <i>Cancers</i> , 2022, 14, 2241.	1.7	26
8829	COMMD2 Upregulation Mediated by an ncRNA Axis Correlates With an Unfavorable Prognosis and Tumor Immune Infiltration in Liver Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 853026.	1.3	1
8830	The Cellular Tumor Immune Microenvironment of Childhood Solid Cancers: Informing More Effective Immunotherapies. <i>Cancers</i> , 2022, 14, 2177.	1.7	2
8831	Treatment-Related Adverse Events of Combination EGFR Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor in EGFR-Mutant Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2022, 14, 2157.	1.7	7
8832	Engineered nanomedicines block the PD-1/PD-L1 axis for potentiated cancer immunotherapy. <i>Acta Pharmacologica Sinica</i> , 2022, 43, 2749-2758.	2.8	16
8833	Renal Function Outcomes in Metastatic Non-Small-Cell Lung Carcinoma Patients Treated with Chemotherapy or Immune Checkpoint Inhibitors: An Unexpected Scenario. <i>Vaccines</i> , 2022, 10, 679.	2.1	4
8834	Oxidative Stress in Cancer Immunotherapy: Molecular Mechanisms and Potential Applications. <i>Antioxidants</i> , 2022, 11, 853.	2.2	10
8835	A Novel Immune-Prognosis Index Predicts the Benefit of Lung Adenocarcinoma Patients. <i>Frontiers in Pharmacology</i> , 2022, 13, .	1.6	1
8836	Combination with Toll-like receptor 4 (TLR4) agonist reverses G1TR agonism mediated M2 polarization of macrophage in Hepatocellular carcinoma. <i>Oncolmmunology</i> , 2022, 11, 2073010.	2.1	6
8837	Systematic analysis of IL-6 as a predictive biomarker and desensitizer of immunotherapy responses in patients with non-small cell lung cancer. <i>BMC Medicine</i> , 2022, 20, 187.	2.3	28
8838	Cost-Effectiveness of Tislelizumab Versus Docetaxel for Previously Treated Advanced Non-Small-Cell Lung Cancer in China. <i>Frontiers in Pharmacology</i> , 2022, 13, .	1.6	13
8839	Association Between Immune-Related Adverse Events and Efficacy and Changes in the Relative Eosinophil Count Among Patients with Advanced Urothelial Carcinoma Treated by Pembrolizumab. <i>Cancer Management and Research</i> , 2022, Volume 14, 1641-1651.	0.9	6
8840	ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors. <i>BMC Medicine</i> , 2022, 20, 170.	2.3	15
8841	A Conceptual Framework for Inducing T Cell-Mediated Immunity Against Glioblastoma. <i>Seminars in Immunopathology</i> , 2022, 44, 697-707.	2.8	5
8842	HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	44

#	ARTICLE	IF	CITATIONS
8843	<sc>Real-World</sc> longitudinal practice patterns in the use of <sc>PD-1</sc> and <sc>PD-L1</sc> inhibitors as <sc>First-Line</sc> therapy in patients with <sc>Non-Small</sc> cell lung cancer in the United States. Cancer Medicine, 2022, , .	1.3	2
8844	Molecular Pathology of Skin Melanoma: Epidemiology, Differential Diagnostics, Prognosis and Therapy Prediction. International Journal of Molecular Sciences, 2022, 23, 5384.	1.8	28
8845	Multiparameter Longitudinal Imaging of Immune Cell Activity in Chimeric Antigen Receptor T Cell and Checkpoint Blockade Therapies. ACS Central Science, 2022, 8, 590-602.	5.3	15
8846	Effect of Concomitant Use of Analgesics on Prognosis in Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Frontiers in Immunology, 2022, 13, .	2.2	6
8847	Immunotherapy in Penile Squamous Cell Carcinoma: Present or Future? Multi-Target Analysis of Programmed Cell Death Ligand 1 Expression and Microsatellite Instability. Frontiers in Medicine, 2022, 9, 874213.	1.2	11
8848	Association of Rare Immune-Related Adverse Events to Survival in Advanced Cancer Patients Treated with Immune Checkpoint Inhibitors: A Real-World Single-Center Cohort Study. Cancers, 2022, 14, 2276.	1.7	4
8849	Isolated Renal Calyceal Urothelial Carcinoma Effectively Treated With PD-1 Inhibitor Alone: A Case Report And Literature Review. Frontiers in Oncology, 2022, 12, .	1.3	0
8850	Nuclear focal adhesion kinase induces APC/C activator protein CDH1-mediated cyclin-dependent kinase 4/6 degradation and inhibits melanoma proliferation. Journal of Biological Chemistry, 2022, 298, 102013.	1.6	2
8851	Metastatic Urothelial Carcinoma: Have We Take the Road to the Personalized Medicine?. Cells, 2022, 11, 1614.	1.8	1
8852	OX40 and 4-1BB delineate distinct immune profiles in sarcoma. OncoImmunology, 2022, 11, 2066050.	2.1	6
8853	Interpatient Heterogeneity in Drug Response and Protein Biomarker Expression of Recurrent Ovarian Cancer. Cancers, 2022, 14, 2279.	1.7	5
8854	Development of a Clinically Oriented Model to Predict Antitumor Effects after PD-1/PD-L1 Inhibitor Therapy. Journal of Oncology, 2022, 2022, 1-11.	0.6	2
8855	Hyaluronidase Enhances Targeting of Hydrogel-Encapsulated Anti-CTLA-4 to Tumor Draining Lymph Nodes and Improves Anti-Tumor Efficacy. Gels, 2022, 8, 284.	2.1	3
8856	Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma. Cancers, 2022, 14, 2300.	1.7	6
8857	Cardio-oncology in Austria: cardiotoxicity and surveillance of anti-cancer therapies. Wiener Klinische Wochenschrift, 2022, 134, 654-674.	1.0	7
8858	Macrophage Differentiation and Polarization Regulate the Release of the Immune Checkpoint Protein V-Domain Ig Suppressor of T Cell Activation. Frontiers in Immunology, 2022, 13, .	2.2	10
8859	LAG-3xPD-L1 bispecific antibody potentiates antitumor responses of T cells through dendritic cell activation. Molecular Therapy, 2022, 30, 2800-2816.	3.7	29
8860	Inhibiting Histone and DNA Methylation Improves Cancer Vaccination in an Experimental Model of Melanoma. Frontiers in Immunology, 2022, 13, .	2.2	2

#	ARTICLE	IF	CITATIONS
8861	Autoimmunity and Cancer—Two Sides of the Same Coin. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	16
8862	Response to immunotherapy in KRAS G12C mutated NSCLC: a single-centre retrospective observational study. <i>Oncotarget</i> , 2022, 13, 686-693.	0.8	4
8863	Stimulating TAM-mediated anti-tumor immunity with mannose-decorated nanoparticles in ovarian cancer. <i>BMC Cancer</i> , 2022, 22, 497.	1.1	13
8864	Neuropilin-1 cooperates with PD-1 in CD8+ T cells predicting outcomes in melanoma patients treated with anti-PD1. <i>IScience</i> , 2022, 25, 104353.	1.9	3
8865	The immune checkpoint B7x expands tumor-infiltrating Tregs and promotes resistance to anti-CTLA-4 therapy. <i>Nature Communications</i> , 2022, 13, 2506.	5.8	18
8866	Hematological Prognostic Scoring System Can Predict Overall Survival and Can Indicate Response to Immunotherapy in Patients With Osteosarcoma. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	3
8867	Multifunctional Nanosystems Powered Photodynamic Immunotherapy. <i>Frontiers in Pharmacology</i> , 2022, 13, .	1.6	11
8868	Complementary roles of surgery and systemic treatment in clear cell renal cell carcinoma. <i>Nature Reviews Urology</i> , 2022, 19, 391-418.	1.9	20
8869	Tumor-Associated Macrophages Regulate PD-1/PD-L1 Immunosuppression. <i>Frontiers in Immunology</i> , 2022, 13, 874589.	2.2	71
8870	A Pilot Study of Durvalumab (MEDI4736) with Tremelimumab in Combination with Image-Guided Stereotactic Body Radiotherapy in the Treatment of Metastatic Anaplastic Thyroid Cancer. <i>Thyroid</i> , 2022, 32, 799-806.	2.4	4
8871	Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. <i>Cancer Cell</i> , 2022, 40, 509-523.e6.	7.7	115
8872	Recent Advances in Solid Tumor CAR-T Cell Therapy: Driving Tumor Cells From Hero to Zero?. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	31
8873	Role of T cells in ischemic acute kidney injury and repair. <i>Korean Journal of Internal Medicine</i> , 2022, 37, 534-550.	0.7	6
8874	Intratumoral therapies and in-situ vaccination for melanoma. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1890512.	1.4	8
8875	Neoadjuvant chemoradiation alters the immune microenvironment in pancreatic ductal adenocarcinoma. <i>OncImmunology</i> , 2022, 11, 2066767.	2.1	9
8876	Characterization and function of biomarkers in sunitinib-resistant renal carcinoma cells. <i>Gene</i> , 2022, 832, 146514.	1.0	4
8877	Prognostic value of the platelet-to-lymphocyte ratio in lung cancer patients receiving immunotherapy: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2022, 17, e0268288.	1.1	8
8878	Efficacy and safety of anlotinib with and without EGFR-TKIs or immunotherapy in the treatment of elder patients with non-small-cell lung cancer: a retrospective study. <i>BMC Pulmonary Medicine</i> , 2022, 22, 179.	0.8	5

#	ARTICLE	IF	CITATIONS
8879	Small Molecule Agents Targeting PD-1 Checkpoint Pathway for Cancer Immunotherapy: Mechanisms of Action and Other Considerations for Their Advanced Development. <i>Frontiers in Immunology</i> , 2022, 13, 752065.	2.2	21
8880	Thrombotic microangiopathy (TMA) in adult patients with solid tumors: a challenging complication in the era of emerging anticancer therapies. <i>Supportive Care in Cancer</i> , 2022, 30, 8599-8609.	1.0	5
8881	Vaccine Therapy in Non-Small Cell Lung Cancer. <i>Vaccines</i> , 2022, 10, 740.	2.1	4
8882	Disinfection By-Products in Drinking Water and Bladder Cancer: Evaluation of Risk Modification by Common Genetic Polymorphisms in Two Caseâ€“Control Studies. <i>Environmental Health Perspectives</i> , 2022, 130, 57006.	2.8	5
8883	Serum parameters as prognostic biomarkers in a real world cancer patient population treated with anti PD-1/PD-L1 therapy. <i>Annals of Medicine</i> , 2022, 54, 1339-1349.	1.5	8
8884	Intratumoral delivery of a novel oncolytic adenovirus encoding human antibody against PD-1 elicits enhanced antitumor efficacy. <i>Molecular Therapy - Oncolytics</i> , 2022, 25, 236-248.	2.0	9
8885	Access to early-phase clinical trials in older patients with cancer in France: the EGALICAN-2 study. <i>ESMO Open</i> , 2022, 7, 100468.	2.0	3
8886	Primary malignant melanoma in gastroesophageal junction with 36 monthsâ€™ recurrence-free: a case report. <i>AME Case Reports</i> , 0, .	0.2	0
8887	High GILT Expression Is Associated with Improved Survival in Metastatic Melanoma Patients Treated with Immune Checkpoint Inhibition. <i>Cancers</i> , 2022, 14, 2200.	1.7	1
8888	Meta-Analysis of Efficacy From CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients. <i>Frontiers in Oncology</i> , 2022, 12, 876098.	1.3	2
8889	High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC. , 2022, 10, e004197.		5
8890	Different In Situ Immune Patterns between Primary Tumor and Lymph Node in Non-Small-Cell Lung Cancer: Potential Impact on Neoadjuvant Immunotherapy. <i>Journal of Immunology Research</i> , 2022, 2022, 1-14.	0.9	2
8891	Treatment of patients with cancer using PDâ€™1/PDâ€™L1 antibodies: Adverse effects and management strategies (Review). <i>International Journal of Oncology</i> , 2022, 60, .	1.4	9
8892	Modified-Dose Pembrolizumab and Prognostic Outcomes among Non-Small Cell Lung Cancer Patients: A Chart Review Study. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 5999.	1.2	3
8893	Cost-Effectiveness of PD-L1 Testing in Non-Small Cell Lung Cancer (NSCLC) Using In Vitro Diagnostic (IVD) Versus Laboratory-Developed Test (LDT). <i>Oncology and Therapy</i> , 2022, , 1.	1.0	0
8894	Association of the gut microbiome with cancer immunotherapy. <i>International Journal of Clinical Oncology</i> , 2022, , 1.	1.0	0
8895	Prognostic value of immunotherapy-induced organ inflammation assessed on 18FDG PET in patients with metastatic non-small cell lung cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 3878-3891.	3.3	3
8896	Tumor-Derived Lactate Creates a Favorable Niche for Tumor via Supplying Energy Source for Tumor and Modulating the Tumor Microenvironment. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, .	1.8	14

#	ARTICLE	IF	CITATIONS
8897	Incidence of fatigue associated with immune checkpoint inhibitors in patients with cancer: a meta-analysis. <i>ESMO Open</i> , 2022, 7, 100474.	2.0	3
8898	Analysis of DNA Repair-Related Prognostic Function and Mechanism in Gastric Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, .	1.8	0
8899	Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Nonâ€“Small-Cell Lung Cancer (NADIM phase II trial). <i>Journal of Clinical Oncology</i> , 2022, 40, 2924-2933.	0.8	127
8900	A pathological complete response after nivolumab plus ipilimumab therapy for DNA mismatch repairâ€“deficient/microsatellite instabilityâ€“high metastatic colon cancer: A case report. <i>Oncology Letters</i> , 2022, 24, .	0.8	4
8901	The Strategies and Mechanisms of Immune Checkpoint Inhibitors for Brain Metastases in NSCLC. <i>Frontiers in Pharmacology</i> , 2022, 13, .	1.6	3
8902	Increased PD-L1 Restricts Liver Injury in Nonalcoholic Fatty Liver Disease. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-18.	1.9	8
8903	Mechanism and Management of Checkpoint Inhibitor-Related Toxicities in Genitourinary Cancers. <i>Cancers</i> , 2022, 14, 2460.	1.7	2
8904	Cancer vaccines: past, present and future; a review article. <i>Discover Oncology</i> , 2022, 13, 31.	0.8	24
8905	Evolution of Medical Approaches and Prominent Therapies in Breast Cancer. <i>Cancers</i> , 2022, 14, 2450.	1.7	4
8906	Risk factors for pneumonitis in advanced extrapulmonary cancer patients treated with immune checkpoint inhibitors. <i>BMC Cancer</i> , 2022, 22, 551.	1.1	4
8907	Outcome of Elective Checkpoint Inhibitor Discontinuation in Patients with Metastatic Melanoma Who Achieved a Complete Remission: Real-World Data. <i>Biomedicines</i> , 2022, 10, 1144.	1.4	7
8908	An immune gene signature to predict prognosis and immunotherapeutic response in lung adenocarcinoma. <i>Scientific Reports</i> , 2022, 12, 8230.	1.6	9
8909	A tumor metastasisâ€“associated molecule <i>TWIST1</i> is a favorable target for cancer immunotherapy due to its immunogenicity. <i>Cancer Science</i> , 2022, 113, 2526-2535.	1.7	4
8910	Intra-tumoral angiogenesis correlates with immune features and prognosis in glioma. <i>Aging</i> , 2022, 14, 4402-4424.	1.4	1
8911	Artificial intelligence for the prevention and clinical management of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2022, 76, 1348-1361.	1.8	75
8912	A novel fourâ€“gene signature predicts immunotherapy response of patients with different cancers. <i>Journal of Clinical Laboratory Analysis</i> , 2022, , e24494.	0.9	2
8913	Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial. <i>Nature Medicine</i> , 2022, 28, 1256-1268.	15.2	105
8914	Role of radiomics in predicting immunotherapy response. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2022, 66, 575-591.	0.9	10

#	ARTICLE	IF	CITATIONS
8915	Evolution of preclinical characterization and insights into clinical pharmacology of checkpoint inhibitors approved for cancer immunotherapy. <i>Clinical and Translational Science</i> , 2022, 15, 1818-1837.	1.5	4
8916	Validity of data extraction in evidence synthesis practice of adverse events: reproducibility study. <i>BMJ, The</i> , 2022, 377, e069155.	3.0	16
8917	Albendazole induces immunotherapy response by facilitating ubiquitin-mediated PD-L1 degradation. , 2022, 10, e003819.		13
8918	CD4 ⁺ T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy. , 2022, 10, e004022.		7
8919	Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade. , 2022, 10, e004076.		30
8920	Paired primary and metastatic lesions of patients with ipilimumab-treated melanoma: high variation in lymphocyte infiltration and HLA-ABC expression whereas tumor mutational load is similar and correlates with clinical outcome. , 2022, 10, e004329.		15
8921	Clinical activity of PD-1 inhibition in the treatment of locally advanced or metastatic basal cell carcinoma. , 2022, 10, e004839.		4
8922	The role of biomarkers in personalized immunotherapy. <i>Biomarker Research</i> , 2022, 10, 32.	2.8	27
8923	Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors. <i>Frontiers in Immunology</i> , 2022, 13, 779691.	2.2	100
8926	Molecular Signatures of KRAS-Mutated Lung Adenocarcinoma: Analysis of Concomitant EGFR, ALK, STK11, and PD-L1 Status. <i>BMC Clinical Pathology</i> , 2022, 15, 2632010X2211020.	0.7	2
8927	Emerging Concepts in Managing Malignancy in Kidney Transplant Patients. <i>Seminars in Nephrology</i> , 2022, 42, 63-75.	0.6	4
8928	An analysis report on the application of immune checkpoint inhibitors after liver transplantation. <i>Therapeutic Advances in Chronic Disease</i> , 2022, 13, 204062232210993.	1.1	3
8929	Development and Validation of a Combined Hypoxia and Immune Prognostic Classifier for Lung Adenocarcinoma. <i>Journal of Cancer</i> , 2022, 13, 2631-2643.	1.2	1
8930	Safety and effectiveness of nivolumab in Japanese patients with malignant melanoma: Final analysis of a post-marketing surveillance. <i>Journal of Dermatology</i> , 2022, 49, 862-871.	0.6	6
8931	Resection of Noncontrast-Enhancing Regions Deteriorated the Immunotherapeutic Efficacy of HSPPC-96 Vaccination in Treating Glioblastoma. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	0
8932	Post-radiation neutrophil-to-lymphocyte ratio is a prognostic marker in patients with localized pancreatic adenocarcinoma treated with anti-PD-1 antibody and stereotactic body radiation therapy. <i>Radiation Oncology Journal</i> , 2022, 40, 111-119.	0.7	6
8933	Targeting RAS-RAF-MEK-ERK signaling pathway in human cancer: Current status in clinical trials. <i>Genes and Diseases</i> , 2023, 10, 76-88.	1.5	34
8934	Combination Strategies Involving Immune Checkpoint Inhibitors and Tyrosine Kinase or BRAF Inhibitors in Aggressive Thyroid Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5731.	1.8	9

#	ARTICLE	IF	CITATIONS
8935	Pilot Trial of Arginine Deprivation Plus Nivolumab and Ipilimumab in Patients with Metastatic Uveal Melanoma. <i>Cancers</i> , 2022, 14, 2638.	1.7	12
8936	Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head&neck cancer. <i>Cancer Medicine</i> , 2022, 11, 2550-2560.	1.3	25
8937	Efficacy of PD-1/PD-L1 Inhibitors versus Chemotherapy in Lung Cancer with Brain Metastases: A Systematic Review and Meta-Analysis. <i>Journal of Immunology Research</i> , 2022, 2022, 1-14.	0.9	3
8938	Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy. <i>Biomedicines</i> , 2022, 10, 1181.	1.4	8
8939	Efficacy and safety of maintenance immune checkpoint inhibitors with or without pemetrexed in advanced non-squamous non-small cell lung cancer: a retrospective study. <i>BMC Cancer</i> , 2022, 22, .	1.1	2
8940	PTBP1 as a Promising Predictor of Poor Prognosis by Regulating Cell Proliferation, Immunosuppression, and Drug Sensitivity in SARC. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-26.	1.9	9
8941	The Long-Term and Short-Term Efficacy of Immunotherapy in Non-Small Cell Lung Cancer Patients With Brain Metastases: A Systematic Review and Meta-Analysis. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	13
8942	Individualized Treatment for Advanced Non-Small Cell Lung Cancer: A Case Report and Literature Review. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	2
8943	Multi-Omics Approaches for the Prediction of Clinical Endpoints after Immunotherapy in Non-Small Cell Lung Cancer: A Comprehensive Review. <i>Biomedicines</i> , 2022, 10, 1237.	1.4	7
8944	Immunoexpression of Programmed Death-1 Receptor (PD-1) and Programmed Death-Ligand 1 (PD-L1) in Non-Small-Cell Lung Carcinoma and Its Correlation With Other Clinicopathological Parameters: A Cross-Sectional Study From North India. <i>Cureus</i> , 2022, , .	0.2	0
8945	Illness perception profiles and psychological and physical symptoms in newly diagnosed advanced non-small cell lung cancer.. <i>Health Psychology</i> , 2022, 41, 379-388.	1.3	10
8947	Recent advances, patient selection & challenges in managing cancer patients undergoing treatment with immune checkpoint inhibitors. <i>Indian Journal of Medical Research</i> , 2022, .	0.4	0
8948	Comprehensive Analysis of the Function, Immune Profiles, and Clinical Implication of m1A Regulators in Lung Adenocarcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
8949	High-throughput virtual screening of small-molecule inhibitors targeting immune cell checkpoints to discover new immunotherapeutics for human diseases. <i>Molecular Diversity</i> , 2023, 27, 729-751.	2.1	14
8950	Building Efficient CNN Architectures for Histopathology Images Analysis: A Case-Study in Tumor-Infiltrating Lymphocytes Classification. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	1
8951	Efficient multiple treatments including molecular targeting agents in a case of recurrent hepatocellular carcinoma, post-living donor liver transplantation. <i>Clinical Journal of Gastroenterology</i> , 2022, 15, 755-764.	0.4	3
8952	Transcriptomic datasets of cancer patients treated with immune-checkpoint inhibitors: a systematic review. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	27
8953	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma. , 2022, 10, e003956.		16

#	ARTICLE	IF	CITATIONS
8954	Comprehensive Evaluation of Anti-PD-1, Anti-PD-L1, Anti-CTLA-4 and Their Combined Immunotherapy in Clinical Trials: A Systematic Review and Meta-analysis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	12
8955	Exposed and Sequestered Antigens in Testes and Their Protection by Regulatory T Cell-Dependent Systemic Tolerance. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	0
8956	Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
8957	Peptide nano-blanket impedes fibroblasts activation and subsequent formation of pre-metastatic niche. <i>Nature Communications</i> , 2022, 13, .	5.8	10
8958	Experiences of resuming life after immunotherapy and associated survivorship care needs: a qualitative study among patients with metastatic melanoma. <i>British Journal of Dermatology</i> , 2022, 187, 381-391.	1.4	14
8959	<sc>NKG2A</sc>â€checkpoin inhibition and its blockade critically depends on peptides presented by its ligand <sc>HLAâ€E</sc>. <i>Immunology</i> , 2022, 166, 507-521.	2.0	15
8960	Simple <sc>IHC</sc> reveals complex <sc>MMR</sc> alternations than <sc>PCR</sc> assays: Validation by <sc>LCM</sc> and nextâ€generation sequencing. <i>Cancer Medicine</i> , 2022, 11, 4479-4490.	1.3	6
8961	Understanding Tricky Cellular and Molecular Interactions in Pancreatic Tumor Microenvironment: New Food for Thought. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	7
8962	Lung Inflammation Predictors in Combined Immune Checkpoint-Inhibitor and Radiation Therapyâ€Proof-of-Concept Animal Study. <i>Biomedicines</i> , 2022, 10, 1173.	1.4	3
8963	Platelets Increase the Expression of PD-L1 in Ovarian Cancer. <i>Cancers</i> , 2022, 14, 2498.	1.7	12
8964	Rescue Surgery after Immunotherapy/Tyrosine Kinase Inhibitors for Initially Unresectable Lung Cancer. <i>Cancers</i> , 2022, 14, 2661.	1.7	6
8965	Emerging Blood-Based Biomarkers for Predicting Immunotherapy Response in NSCLC. <i>Cancers</i> , 2022, 14, 2626.	1.7	7
8966	Case Report: PTEN Mutation Induced by anti-PD-1 Therapy in Stage IV Lung Adenocarcinoma. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	4
8967	Realâ€world outcomes of pembrolizumab monotherapy in <sc>nonâ€small</sc> cell lung cancer in Japan: A postâ€marketing surveillance. <i>Cancer Science</i> , 2022, 113, 3110-3119.	1.7	5
8968	Exploring Real World Outcomes with Nivolumab Plus Ipilimumab in Patients with Metastatic Extra-Pulmonary Neuroendocrine Carcinoma (EP-NEC). <i>Cancers</i> , 2022, 14, 2695.	1.7	3
8969	Classification of <sc>PDâ€L1</sc> expression in various cancers and macrophages based on immunohistocytological analysis. <i>Cancer Science</i> , 2022, 113, 3255-3266.	1.7	8
8970	Overcoming Resistance to Checkpoint Inhibitors: Natural Killer Cells in Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	12
8971	Locally advanced rectal cancer receiving total neoadjuvant therapy combined with nivolumab: a case report and literature review. <i>World Journal of Surgical Oncology</i> , 2022, 20, .	0.8	7

#	ARTICLE	IF	CITATIONS
8972	Immunotherapy toxicities: An SGO clinical practice statement. <i>Gynecologic Oncology</i> , 2022, , .	0.6	1
8973	Prosaposin, tumorâ€secreted protein, promotes pancreatic cancer progression by decreasing tumorâ€infiltrating lymphocytes. <i>Cancer Science</i> , 2022, 113, 2548-2559.	1.7	7
8974	An integrated biomarker of ^{PDâ€1} expression and intraepithelial ^{CD8} T cell infiltration was associated with the prognosis of lung cancer patients after intracranial resection of brain metastases. <i>Thoracic Cancer</i> , 0, , .	0.8	3
8975	Relationship between Patientsâ€™ Baseline Characteristics and Survival Benefits in Immunotherapy-Treated Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. <i>Journal of Oncology</i> , 2022, 2022, 1-14.	0.6	2
8976	^{TIGIT} / ^{CD47} dual high expression predicts prognosis and is associated with immunotherapy response in lung squamous cell carcinoma. <i>Thoracic Cancer</i> , 0, , .	0.8	4
8977	PD-1/PD-L1, MDSC Pathways, and Checkpoint Inhibitor Therapy in Ph(-) Myeloproliferative Neoplasm: A Review. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5837.	1.8	7
8978	Nanodrugs Targeting T Cells in Tumor Therapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	13
8979	Development of Two Diagnostic Prediction Models for Leptomeningeal Metastasis in Patients With Solid Tumors. <i>Frontiers in Neurology</i> , 2022, 13, .	1.1	0
8980	Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials. <i>World Journal of Clinical Oncology</i> , 2022, 13, 388-411.	0.9	13
8981	The V2 receptor antagonist tolvaptan counteracts proliferation and invasivity in human cancer cells. <i>Journal of Endocrinological Investigation</i> , 0, , .	1.8	1
8982	Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Nonâ€Small-Cell Lung Cancer Previously Treated With Immunotherapyâ€Lung-MAP S1800A. <i>Journal of Clinical Oncology</i> , 2022, 40, 2295-2307.	0.8	84
8983	Evaluating the tumor immune profile based on a three-gene prognostic risk model in HER2 positive breast cancer. <i>Scientific Reports</i> , 2022, 12, .	1.6	6
8984	Case Report: First-Line Immune Checkpoint Inhibitor Plus Chemotherapy for Oral Metastasis in a Patient with Ultra High-Risk Gestational Choriocarcinoma. <i>Cancer Management and Research</i> , 0, Volume 14, 1867-1875.	0.9	2
8985	Immune checkpoint inhibitors for solid organ transplant recipients: clinical updates. <i>Korean Journal of Transplantation</i> , 2022, 36, 82-98.	0.0	9
8986	Brain metastases and immune checkpoint inhibitors in non-small cell lung cancer: a systematic review and meta-analysis. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 3071-3085.	2.0	5
8987	Characterization of m6A Methylation Modification Patterns in Colorectal Cancer Determines Prognosis and Tumor Microenvironment Infiltration. <i>Journal of Immunology Research</i> , 2022, 2022, 1-17.	0.9	1
8988	Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with Non-small cell lung cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	39
8989	Prediction of Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors With a Panel of Autoantibodies: Protocol of a Multicenter, Prospective, Observational Cohort Study. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	7

#	ARTICLE	IF	CITATIONS
8990	The microRNA-183/96/182 cluster inhibits lung cancer progression and metastasis by inducing an interleukin-2-mediated antitumor CD8 ⁺ cytotoxic T-cell response. <i>Genes and Development</i> , 2022, 36, 582-600.	2.7	9
8991	Pembrolizumab-induced aseptic meningitis in a patient with non-small cell lung cancer: A case report and literature review of aseptic meningitis as an immune-related adverse event. <i>Molecular and Clinical Oncology</i> , 2022, 17, .	0.4	2
8992	Challenges in glioblastoma immunotherapy: mechanisms of resistance and therapeutic approaches to overcome them. <i>British Journal of Cancer</i> , 2022, 127, 976-987.	2.9	26
8993	Immunotherapy and Antivascular Targeted Therapy in Patients' Treatment with Concurrent Malignant Tumors after Organ Transplantation: Opportunity or Challenge. <i>Journal of Immunology Research</i> , 2022, 2022, 1-13.	0.9	0
8994	Pyroptosis is related to immune infiltration and predictive for survival of colon adenocarcinoma patients. <i>Scientific Reports</i> , 2022, 12, .	1.6	5
8995	Current Evidence on Immunotherapy for Gestational Trophoblastic Neoplasia (GTN). <i>Cancers</i> , 2022, 14, 2782.	1.7	11
8996	Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer. , 2022, 10, e004440.		49
8997	Image analysis reveals molecularly distinct patterns of TILs in NSCLC associated with treatment outcome. <i>Npj Precision Oncology</i> , 2022, 6, .	2.3	20
8998	Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial. <i>Nature Medicine</i> , 2022, 28, 1167-1177.	15.2	112
8999	KCNN4 is a Potential Biomarker for Predicting Cancer Prognosis and an Essential Molecule that Remodels Various Components in the Tumor Microenvironment: A Pan-Cancer Study. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, .	1.6	7
9000	Multi-Omics Integrative Analysis of Lung Adenocarcinoma: An in silico Profiling for Precise Medicine. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	4
9001	Plasmablastic myeloma in Taiwan frequently presents with extramedullary and extranodal mass mimicking plasmablastic lymphoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 481, 283-293.	1.4	3
9002	Efficacy of Immune Checkpoint Inhibitor With or Without Chemotherapy for Nonsquamous NSCLC With Malignant Pleural Effusion: A Retrospective Multicenter Cohort Study. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100355.	0.6	5
9003	Safety evaluation of fixed-dose nivolumab in patients with gastric cancer. <i>Health Science Reports</i> , 2022, 5, .	0.6	4
9004	Donor Derived Cell Free DNA in Kidney Transplantation: The Circa 2020-2021 Update. <i>Transplant International</i> , 0, 35, .	0.8	15
9005	A cohort study of the efficacy and safety of immune checkpoint inhibitors plus anlotinib versus immune checkpoint inhibitors alone as the treatment of advanced non-small cell lung cancer in the real world. <i>Translational Lung Cancer Research</i> , 2022, 11, 1051-1068.	1.3	10
9006	Clinical significance of ALKBH4 expression in non-small cell lung cancer. <i>Translational Cancer Research</i> , 2022, 11, 2040-2049.	0.4	2
9007	A bioinformatics-based immune-related prognostic index for lung adenocarcinoma that predicts patient response to immunotherapy and common treatments. <i>Journal of Thoracic Disease</i> , 2022, 14, 2131-2146.	0.6	2

#	ARTICLE	IF	CITATIONS
9008	Efficacy and safety of camrelizumab plus apatinib in previously treated patients with advanced non-small cell lung cancer harboring EGFR or ALK genetic aberration. <i>Translational Lung Cancer Research</i> , 2022, 11, 964-974.	1.3	9
9009	A Brief Introduction to Current Cancer Gene Therapy. <i>Methods in Molecular Biology</i> , 2022, , 1-21.	0.4	3
9010	Current State of Knowledge on the Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer Treatment: Approaches, Efficacy, and Challenges. <i>Clinical Medicine Insights: Oncology</i> , 2022, 16, 117955492210998.	0.6	10
9011	Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression $\geq 45\%$. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211050.	1.4	1
9012	VEGF/VEGFR-Targeted Therapy and Immunotherapy in Non-small Cell Lung Cancer: Targeting the Tumor Microenvironment. <i>International Journal of Biological Sciences</i> , 2022, 18, 3845-3858.	2.6	64
9013	Overlap of Thrombotic Microangiopathy and Mesangial Proliferative Glomerulonephritis Caused by Combination Therapy with Atezolizumab and Bevacizumab. <i>Internal Medicine</i> , 2023, 62, 91-94.	0.3	3
9014	Generation of molecular-targeting helix-loop-helix peptides for inhibition of the interaction between cytotoxic T-lymphocyte-associated protein 4 and B7 in the dog. <i>Journal of Veterinary Medical Science</i> , 2022, 84, 1101-1107.	0.3	0
9015	PD-1/L1 With or Without CTLA-4 Inhibitors Versus Chemotherapy in Advanced Non-Small Cell Lung Cancer. <i>Cancer Control</i> , 2022, 29, 107327482211075.	0.7	1
9016	A degran system targeting endogenous PD-1 inhibits the growth of tumor cells in mice. <i>NAR Cancer</i> , 2022, 4, .	1.6	4
9017	Plasma exchange for severe immune-related adverse events from checkpoint inhibitors: an early window of opportunity?. <i>Immunotherapy Advances</i> , 2022, 2, .	1.2	15
9018	Prevention and Treatment of Side Effects of Immunotherapy for Bladder Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
9019	Liquid Biopsy Assessment of Circulating Tumor Cell PD-L1 and IRF-1 Expression in Patients with Advanced Solid Tumors Receiving Immune Checkpoint Inhibitor. <i>Targeted Oncology</i> , 2022, 17, 329-341.	1.7	2
9020	Treatment Approaches for Melanomas That Relapse After Adjuvant or Neoadjuvant Therapy. <i>Current Oncology Reports</i> , 2022, 24, 1273-1280.	1.8	5
9021	When Less May Be Enough: Dose Selection Strategies for Immune Checkpoint Inhibitors Focusing on AntiPD-(L)1 Agents. <i>Targeted Oncology</i> , 2022, 17, 253-270.	1.7	5
9022	Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade. , 2022, 10, e004762.		19
9023	Adjuvant Anti-PD-1 Antibody Therapy for Advanced Melanoma: A Multicentre Study of 78 Japanese Cases. <i>Acta Dermato-Venereologica</i> , 0, 102, adv00756.	0.6	8
9024	The Applicability of the Results in the Asian Population of ORIENT-11 to a Western Population According to the ICH-E5 Framework. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
9025	“Prevention is better than cure” warning for comedication in patients receiving immune check-point inhibitors to avoid acute kidney injury. <i>CKJ: Clinical Kidney Journal</i> , 0, , .	1.4	0

#	ARTICLE	IF	CITATIONS
9026	Epigenetic priming enhances antitumor immunity in platinum-resistant ovarian cancer. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	28
9027	Safety of sequential immune checkpoint inhibitors after prior immune therapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 2375-2382.	1.2	2
9028	MERTK activation drives osimertinib resistance in EGFR-mutant nonâ€“small cell lung cancer. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	12
9029	Compartmentalization of Intrarenal Programmed Cell Death Protein 1-Ligand 1 and Its Receptor in Kidney Injury Related to Immune Checkpoint Inhibitor Nephrotoxicity. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	5
9030	The Treatment of Advanced Melanoma: Therapeutic Update. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6388.	1.8	41
9031	Next-generation sequencing in advanced Chinese melanoma reveals therapeutic targets and prognostic biomarkers for immunotherapy. <i>Scientific Reports</i> , 2022, 12, .	1.6	7
9032	Current Status and Future Directions of Bacteria-Based Immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
9033	Radiopharmaceuticals as Novel Immune System Tracers. <i>Advances in Radiation Oncology</i> , 2022, , 100936.	0.6	1
9034	Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer. <i>Molecules</i> , 2022, 27, 3798.	1.7	29
9035	Pan-Cancer Pyroptosis Analyses Identified Novel Immunology and Chemotherapy-Related Prognostic Signatures in Cancer Subtypes. <i>Journal of Oncology</i> , 2022, 2022, 1-16.	0.6	0
9036	Targeting Triple Negative Breast Cancer With Oncolytic Adenoviruses. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	0
9037	Recent advances and clinical pharmacology aspects of Chimeric Antigen Receptor (CAR) Tâ€“cellular therapy development. <i>Clinical and Translational Science</i> , 2022, 15, 2057-2074.	1.5	9
9038	Patient-Derived Tumor Organoids for Guidance of Personalized Drug Therapies in Recurrent Glioblastoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6572.	1.8	9
9039	Prognostic Nutritional Index Predicts Outcome of PD-L1 Negative and MSS Advanced Cancer Treated with PD-1 Inhibitors. <i>BioMed Research International</i> , 2022, 2022, 1-9.	0.9	1
9040	Successful Treatment with Short-Term Steroid Against Severe Hepatitis Confirmed by Liver Biopsy in a Patient with Advanced Squamous-Cell Lung Cancer Receiving a Combination of Pembrolizumab, Carboplatin, and Nab-Paclitaxel: A Case Report. <i>OncoTargets and Therapy</i> , 0, Volume 15, 637-642.	1.0	2
9041	PD-1/PD-L Axis in Neuroinflammation: New Insights. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	16
9042	First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 3452-3463.	3.2	21
9043	Real-world progression-free survival (rwPFS) and the impact of PD-L1 and smoking in driver-mutated non-small cell lung cancer (NSCLC) treated with immunotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 1755-1763.	1.2	5

#	ARTICLE	IF	CITATIONS
9044	Novel CD8 ⁺ T cell-based prognostic signature to estimate risk and aid therapy in hepatocellular carcinoma. <i>BMC Cancer</i> , 2022, 22, .	1.1	2
9045	Population Pharmacokinetics of Nivolumab in Japanese Patients with Non-Small Cell Lung Cancer. <i>Therapeutic Drug Monitoring</i> , 2022, Publish Ahead of Print, .	1.0	0
9046	Development of Radiotracers for Imaging of the PD-1/PD-L1 Axis. <i>Pharmaceuticals</i> , 2022, 15, 747.	1.7	18
9047	Therapeutic Targeting of Macrophage Plasticity Remodels the Tumor-Immune Microenvironment. <i>Cancer Research</i> , 2022, 82, 2593-2609.	0.4	5
9048	Immune checkpoint inhibitors and potential risk of thromboembolic events: Analysis of the WHO global database of individual case safety reports. <i>Saudi Pharmaceutical Journal</i> , 2022, 30, 1193-1199.	1.2	1
9049	The current state of molecular profiling in gastrointestinal malignancies. <i>Biology Direct</i> , 2022, 17, .	1.9	5
9050	Symptom clusters and their predictors in patients with lung cancer and treated with programmed cell death protein 1 immunotherapy. <i>Asia-Pacific Journal of Oncology Nursing</i> , 2022, 9, 100103.	0.7	3
9051	PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naïve advanced EGFR-mutant non-small cell lung cancer patients. <i>Scientific Reports</i> , 2022, 12, .	1.6	13
9052	Blood Biomarkers of Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. <i>Journal of Clinical Medicine</i> , 2022, 11, 3245.	1.0	8
9053	Challenging Dermatologic Considerations Associated with Immune Checkpoint Inhibitors. <i>American Journal of Clinical Dermatology</i> , 0, , .	3.3	3
9054	Novel Insights Into Mesothelioma Therapy: Emerging Avenues and Future Prospects. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	11
9055	Clinical Patterns and Follow-Up of Inflammatory Arthritis and Other Immune-Related Adverse Events Induced by Checkpoint Inhibitors. A Multicenter Study. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	9
9056	Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 529-540.	21.5	134
9057	Correlation of PD-L1 expression on tumour cells between diagnostic biopsies and surgical specimens of lung cancer in real life with respect to biopsy techniques and neoadjuvant treatment. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 1747-1754.	1.2	2
9058	Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition. <i>Cancer Immunology Research</i> , 2022, 10, 996-1012.	1.6	18
9059	Pembrolizumab-induced Stevens-Johnson syndrome in advanced squamous cell carcinoma of the lung: A case report and review of literature. <i>World Journal of Clinical Cases</i> , 2022, 10, 6110-6118.	0.3	3
9060	Differential Engraftment of Parental A20 PD-L1 WT and PD-L1 KO Leukemia Cells in Semiallogeneic Recipients in the Context of PD-L1/PD-1 Interaction and NK Cell-Mediated Hybrid Resistance. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
9061	Dosing Regimens of Immune Checkpoint Inhibitors: Attempts at Lower Dose, Less Frequency, Shorter Course. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	13

#	ARTICLE	IF	CITATIONS
9062	Programmed Cell Death Protein 1/Programmed Cell Death Protein Ligand 1 Immunosuppressants in Advanced Non-Small Cell Lung Cancer Research Progress in Treatment. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	0
9063	Immune checkpoint inhibitors unleash pathogenic immune responses against the microbiota. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	21
9064	Combination of two novel blocking antibodies, anti-PD-1 antibody ezabenlimab (BI 754091) and anti-LAG-3 antibody BI 754111, leads to increased immune cell responses. <i>Oncolimmunology</i> , 2022, 11, .	2.1	6
9065	Identifying Candidates for Immunotherapy among Patients with Non-Melanoma Skin Cancer: A Review of the Potential Predictors of Response. <i>Journal of Clinical Medicine</i> , 2022, 11, 3364.	1.0	20
9066	Immunotherapy and the Spectrum of Kidney Disease: Should We Individualize the Treatment?. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	6
9067	Next-generation sequencing: unraveling genetic mechanisms that shape cancer immunotherapy efficacy. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	9
9068	PD-1 Immune Checkpoint Blockade and PSGL-1 Inhibition Synergize to Reinvigorate Exhausted T Cells. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
9069	Peripheral Blood Mononuclear Cells Predict Therapeutic Efficacy of Immunotherapy in NSCLC. <i>Cancers</i> , 2022, 14, 2898.	1.7	5
9070	Two-year efficacy of <sc>SNK01</sc> plus pembrolizumab for non-small cell lung cancer: Expanded observations from a phase <sc>IIIa</sc> randomized controlled trial. <i>Thoracic Cancer</i> , 0, , .	0.8	3
9071	Comprehensive analyses indicated the association between <sc>m6A</sc> related long non-coding <sc>RNAs</sc> and various pathways in glioma. <i>Cancer Medicine</i> , 0, , .	1.3	1
9072	Spontaneous xenogeneic <sc>GvHD</sc> in Wilms' tumor <sc>Patient-Derived</sc> xenograft models and potential solutions. <i>Animal Models and Experimental Medicine</i> , 2022, 5, 389-396.	1.3	3
9073	Absolute lymphocyte count and C-reactive protein/albumin ratio can predict prognosis and adverse events in patients with recurrent esophageal cancer treated with nivolumab therapy. <i>Oncology Letters</i> , 2022, 24, .	0.8	9
9074	Adjuvant Treatments of Adult Melanoma: A Systematic Review and Network Meta-Analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
9075	Increased Circulating Levels of CRP and IL-6 and Decreased Frequencies of T and B Lymphocyte Subsets Are Associated With Immune-Related Adverse Events During Combination Therapy With PD-1 Inhibitors for Liver Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	15
9076	Mutations in KMT2C, BCOR and KDM5C Predict Response to Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer. <i>Cancers</i> , 2022, 14, 2816.	1.7	3
9077	BCG hydrogel promotes CTSS-mediated antigen processing and presentation, thereby suppressing metastasis and prolonging survival in melanoma. , 2022, 10, e004133.		8
9078	Over-Expression of GUSB Leads to Primary Resistance of Anti-PD1 Therapy in Hepatocellular Carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
9079	Clinical significance of signal regulatory protein alpha and T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibition motif domain expression in undifferentiated pleomorphic sarcoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	2

#	ARTICLE	IF	CITATIONS
9080	Safety and tumour-specific immunological responses of combined dendritic cell vaccination and anti-CD40 agonistic antibody treatment for patients with metastatic pancreatic cancer: protocol for a phase I, open-label, single-arm, dose-escalation study (REACTiVe-2 trial). <i>BMJ Open</i> , 2022, 12, e060431.	0.8	4
9081	Immunotherapy for advanced hepatocellular carcinoma: From clinical trials to real-world data and future advances. <i>World Journal of Clinical Oncology</i> , 2022, 13, 448-472.	0.9	6
9082	Tumor Microenvironmentâ€™A Short Review of Cellular and Interaction Diversity. <i>Biology</i> , 2022, 11, 929.	1.3	22
9083	iRECIST and atypical patterns of response to immuno-oncology drugs. , 2022, 10, e004849.		12
9084	Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. <i>Nature Medicine</i> , 2022, 28, 1599-1611.	15.2	185
9085	Immunotherapy in Advanced Non-Small Cell Lung Cancers: Current Status and Updates. <i>Cancer Management and Research</i> , 0, Volume 14, 2079-2090.	0.9	3
9086	Kidney organoids: a pioneering model for kidney diseases. <i>Translational Research</i> , 2022, 250, 1-17.	2.2	12
9087	Contribution of the Skinâ€™Gut Axis to Immune-Related Adverse Events with Multi-System Involvement. <i>Cancers</i> , 2022, 14, 2995.	1.7	5
9088	Pharmacological Treatments Available for Immune-Checkpoint-Inhibitor-Induced Colitis. <i>Biomedicines</i> , 2022, 10, 1334.	1.4	5
9089	Co-Inhibitory Molecules â€™ Their Role in Health and Autoimmunity; Highlighted by Immune Related Adverse Events. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9
9090	Predicting Tumor Mutational Burden From Lung Adenocarcinoma Histopathological Images Using Deep Learning. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	9
9091	EGFR-Mutated Non-Small Cell Lung Cancer and Resistance to Immunotherapy: Role of the Tumor Microenvironment. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6489.	1.8	45
9092	Novel Hypoxia-Associated Gene Signature Depicts Tumor Immune Microenvironment and Predicts Prognosis of Colon Cancer Patients. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	4
9093	IGF1R acts as a cancer-promoting factor in the tumor microenvironment facilitating lung metastasis implantation and progression. <i>Oncogene</i> , 2022, 41, 3625-3639.	2.6	26
9094	Therapeutic cancer vaccines: From biological mechanisms and engineering to ongoing clinical trials. <i>Cancer Treatment Reviews</i> , 2022, 109, 102429.	3.4	30
9095	Integrative pharmacogenomics revealed three subtypes with different immune landscapes and specific therapeutic responses in lung adenocarcinoma. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 3449-3460.	1.9	3
9096	Sensitivity and specificity of amide proton transfer-weighted imaging for assessing programmed death-ligand 1 status in non-small cell lung cancer: a comparative study with intravoxel incoherent motion and 18F-FDG PET. <i>Quantitative Imaging in Medicine and Surgery</i> , 2022, 12, 4474-4487.	1.1	5
9097	The presence and size of intrahepatic tumors determine the therapeutic efficacy of nivolumab in advanced hepatocellular carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211132.	1.4	10

#	ARTICLE	IF	CITATIONS
9098	Chronic Obstructive Pulmonary Disease and Lung Cancer: A Review for Clinicians. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 0, , 454-476.	0.5	3
9099	Nonsurgical Approach to Isolated Pancreatic Metastatic Malignant Melanoma: A Case Report and Review of the Literature. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2022, 10, 232470962211117.	0.3	0
9100	Evolving landscape of first-line combination therapy in advanced renal cancer: a systematic review. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211086.	1.4	15
9101	Trends and costs of stereotactic body radiation therapy in metastatic non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2022, .	0.6	4
9102	Transplant Onconephrology in Patients With Kidney Transplants. <i>Advances in Chronic Kidney Disease</i> , 2022, 29, 188-200.e1.	0.6	4
9103	Long Term Administration of Nivolumab for Metastatic Melanoma: A Case Report. <i>Cureus</i> , 2022, , .	0.2	1
9104	ICIs-Related Cardiotoxicity in Different Types of Cancer. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 203.	0.8	11
9105	Network-based machine learning approach to predict immunotherapy response in cancer patients. <i>Nature Communications</i> , 2022, 13, .	5.8	56
9106	Immune checkpoint inhibitorsâ€™ combination therapy as first-line treatment in advanced esophageal squamous cell carcinoma: a meta-analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	4
9107	Successful electrochemotherapy treatment of a large bleeding lymph node melanoma metastasis. <i>Melanoma Management</i> , 2022, 9, .	0.1	1
9108	Whole-Exome Sequencing Uncovers Specific Genetic Variation Difference Based on Different Modes of Drug Resistance in Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
9109	Spectrum of Immune Checkpoint Inhibitor Anemias: Results From a Single Center, Early-Phase Clinical Trials Case Series Experience. <i>Journal of Hematology (Brossard, Quebec)</i> , 2022, 11, 113-120.	0.4	3
9110	Vaginal Malignant Melanoma: Case Report and Review of the Literature. <i>European Journal of Case Reports in Internal Medicine</i> , 0, , .	0.2	2
9111	Prognostic significance of PD-L1 expression and CD8+ TILs density for disease-free survival in surgically resected lung squamous cell carcinoma: a retrospective study. <i>Journal of Thoracic Disease</i> , 2022, 14, 2224-2234.	0.6	3
9112	Charting roadmaps towards novel and safe synergistic immunotherapy combinations. <i>Nature Cancer</i> , 2022, 3, 665-680.	5.7	18
9113	Dynamic and Flexible Survival Models for Extrapolation of Relative Survival: A Case Study and Simulation Study. <i>Medical Decision Making</i> , 2022, 42, 945-955.	1.2	1
9114	Identification of the Key miRNAs and Genes Associated with the Regulation of Non-Small Cell Lung Cancer: A Network-Based Approach. <i>Genes</i> , 2022, 13, 1174.	1.0	4
9115	Comprehensive Analysis of Cuproptosis-Related Genes in Immune Infiltration and Prognosis in Melanoma. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	134

#	ARTICLE	IF	CITATIONS
9116	Atlas of PD-L1 for Pathologists: Indications, Scores, Diagnostic Platforms and Reporting Systems. <i>Journal of Personalized Medicine</i> , 2022, 12, 1073.	1.1	36
9117	Ferroptosis in Glioma Immune Microenvironment: Opportunity and Challenge. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
9118	Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant. <i>Journal of Clinical Oncology</i> , 2022, 40, 3808-3816.	0.8	19
9119	Dendritic Cell-Based Immunotherapy in Hot and Cold Tumors. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7325.	1.8	7
9120	Nanotechnology-Based siRNA Delivery Systems to Overcome Tumor Immune Evasion in Cancer Immunotherapy. <i>Pharmaceutics</i> , 2022, 14, 1344.	2.0	8
9121	Immune-Mediated Hepatitis During Immune Checkpoint Inhibitor cancer Immunotherapy: Lessons From Autoimmune Hepatitis and Liver Immunology. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	16
9122	Clinical Efficacy and Safety Analysis of PD-1/PD-L1 Inhibitor vs. Chemotherapy in the Treatment of Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. <i>BioMed Research International</i> , 2022, 2022, 1-9.	0.9	2
9123	Comprehensive Comparison of 22C3 and SP263 PD-L1 Expression in Non-Small-Cell Lung Cancer Using Routine Clinical and Conditioned Archives. <i>Cancers</i> , 2022, 14, 3138.	1.7	0
9124	Novel Inflammasome-Based Risk Score for Predicting Survival and Efficacy to Immunotherapy in Early-Stage Non-Small Cell Lung Cancer. <i>Biomedicines</i> , 2022, 10, 1539.	1.4	2
9125	A Novel Defined Endoplasmic Reticulum Stress-Related lncRNA Signature for Prognosis Prediction and Immune Therapy in Glioma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
9126	The Cognitive Effects of Radiotherapy for Brain Metastases. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	18
9127	TNFRSF9 Suppressed the Progression of Breast Cancer via the p38MAPK/PAX6 Signaling Pathway. <i>Journal of Oncology</i> , 2022, 2022, 1-16.	0.6	1
9128	Leveraging structural and 2D-QSAR to investigate the role of functional group substitutions, conserved surface residues and desolvation in triggering the small molecule-induced dimerization of hPD-L1. <i>BMC Chemistry</i> , 2022, 16, .	1.6	3
9129	Stage 4 Cytokine Release Syndrome Caused by the First Dose of Nivolumab and Ipilimumab Combination Therapy in a Patient with Metastatic Melanoma Successfully Treated with Methylprednisolone, Tocilizumab, and Etanercept. <i>Case Reports in Oncology</i> , 2022, 15, 648-653.	0.3	7
9130	Hepatitis B virus reactivation in patients undergoing immune checkpoint inhibition: systematic review with meta-analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 1993-2008.	1.2	5
9131	Clinical outcomes of PD-1/PD-L1 inhibitors in patients with advanced hepatocellular carcinoma: a systematic review and meta-analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 969-978.	1.2	9
9132	A Novel Computational Framework for Predicting the Survival of Cancer Patients With PD-1/PD-L1 Checkpoint Blockade Therapy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
9133	Will We Unlock the Benefit of Metformin for Patients with Lung Cancer? Lessons from Current Evidence and New Hypotheses. <i>Pharmaceutics</i> , 2022, 15, 786.	1.7	8

#	ARTICLE	IF	CITATIONS
9134	The Role of the Immune System in the Development of Endometriosis. <i>Cells</i> , 2022, 11, 2028.	1.8	40
9135	Albumin Paclitaxel Combined with Intrapleural Infusion of Bevacizumab+Lobaplatin for the Second-Line Treatment of Patients with Non-Squamous Non-Small Cell Lung Cancer. <i>Journal of Oncology</i> , 2022, 2022, 1-11.	0.6	2
9136	Research progress on immunotherapy in triple-negative breast cancer (Review). <i>International Journal of Oncology</i> , 2022, 61, .	1.4	9
9137	Penpulimab, an Fc-Engineered IgG1 Anti-PD-1 Antibody, With Improved Efficacy and Low Incidence of Immune-Related Adverse Events. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	10
9138	Upregulation of CCT3 predicts poor prognosis and promotes cell proliferation via inhibition of ferroptosis and activation of AKT signaling in lung adenocarcinoma. <i>BMC Molecular and Cell Biology</i> , 2022, 23, .	1.0	9
9139	Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	23
9140	Case Report: Complete Remission of a Patient With Metastatic Gastric Cancer Treated With Nivolumab Combined With Chemotherapy After Palliative Surgery. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
9141	Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Psoriasis: A Systematic Review and Meta-Analysis of Observational Studies. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
9142	DNA methyltransferase-1 in acute myeloid leukaemia: beyond the maintenance of DNA methylation. <i>Annals of Medicine</i> , 2022, 54, 2011-2023.	1.5	6
9143	Racial and Ethnic Trends and Disparities in NSCLC. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100374.	0.6	1
9144	High Expression of TACC3 Is Associated with the Poor Prognosis and Immune Infiltration in Lung Adenocarcinoma Patients. <i>Disease Markers</i> , 2022, 2022, 1-22.	0.6	1
9145	Updated Efficacy Outcomes of Anti-PD-1 Antibodies plus Multikinase Inhibitors for Patients with Advanced Gastric Cancer with or without Liver Metastases in Clinical Trials. <i>Clinical Cancer Research</i> , 2022, 28, 3480-3488.	3.2	8
9146	Multi-modal molecular programs regulate melanoma cell state. <i>Nature Communications</i> , 2022, 13, .	5.8	9
9147	Prospective assessment using 18F-FDG PET/CT as a novel predictor for early response to PD-1 blockade in non-small-cell lung cancer. <i>Scientific Reports</i> , 2022, 12, .	1.6	3
9148	Correlation between the Treg/Th17 Index and the Efficacy of PD-1 Monoclonal Antibody in Patients with Advanced Non-Small-Cell Lung Cancer Complicated with Chronic Obstructive Pulmonary Disease. <i>Computational and Mathematical Methods in Medicine</i> , 2022, 2022, 1-11.	0.7	0
9149	Single-Cell Sequencing Reveals Trajectory of Tumor-Infiltrating Lymphocyte States in Pancreatic Cancer. <i>Cancer Discovery</i> , 2022, 12, 2330-2349.	7.7	22
9150	Histological changes associated with laser interstitial thermal therapy for radiation necrosis: illustrative cases. <i>Journal of Neurosurgery Case Lessons</i> , 2022, 4, .	0.1	0
9151	NK cell dysfunction is linked with disease severity in SARS-CoV-2 patients. <i>Cell Biochemistry and Function</i> , 2022, 40, 559-568.	1.4	5

#	ARTICLE	IF	CITATIONS
9152	Insights Into the Host Contribution of Endocrine Associated Immune-Related Adverse Events to Immune Checkpoint Inhibition Therapy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	9
9153	Dendritic cell-mediated cross presentation of tumor-derived peptides is biased against plasma membrane proteins. , 2022, 10, e004159.		5
9154	CpG ODN (K3)â€”toll-like receptor 9 agonistâ€”induces Th1-type immune response and enhances cytotoxic activity in advanced lung cancer patients: a phase I study. <i>BMC Cancer</i> , 2022, 22, .	1.1	7
9155	Aging-associated and CD4 T-cellâ€”dependent ectopic CXCL13 activation predisposes to antiâ€”PD-1 therapy-induced adverse events. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	21
9156	The rest period between chemotherapy and immunotherapy influences the efficacy of immune checkpoint inhibitors in lung cancer. <i>Thoracic Cancer</i> , 2022, 13, 2346-2354.	0.8	5
9157	Immunotherapy approaches for malignant pleural mesothelioma. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 573-584.	12.5	21
9158	Artificial Intelligence-Assisted Score Analysis for Predicting the Expression of the Immunotherapy Biomarker PD-L1 in Lung Cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	11
9159	Thyroid Dysfunction as a Predictive Indicator in Camrelizumab of Advanced Esophageal Squamous Cell Carcinoma. <i>Journal of Immunology Research</i> , 2022, 2022, 1-8.	0.9	3
9160	Antioxidative Role of <i>Hygrophila erecta</i> (Brum. F.) Hochr. on UV-Induced Photoaging of Dermal Fibroblasts and Melanoma Cells. <i>Antioxidants</i> , 2022, 11, 1317.	2.2	5
9161	Immunologic Strategies in Pancreatic Cancer: Making <i>Cold</i> Tumors <i>Hot</i>. <i>Journal of Clinical Oncology</i> , 2022, 40, 2789-2805.	0.8	69
9162	Advanced non-small-cell lung cancer: how to manage non-oncogene disease. <i>Drugs in Context</i> , 0, 11, 1-14.	1.0	2
9163	Systematic evaluation of the predictive gene expression signatures of immune checkpoint inhibitors in metastatic melanoma. <i>Molecular Carcinogenesis</i> , 0, , .	1.3	8
9164	Risk of Rash in PD-1 or PD-L1-Related Cancer Clinical Trials: A Systematic Review and Meta-Analysis. <i>Journal of Oncology</i> , 2022, 2022, 1-27.	0.6	5
9165	Development of Lymphopenia during Therapy with Immune Checkpoint Inhibitors Is Associated with Poor Outcome in Metastatic Cutaneous Melanoma. <i>Cancers</i> , 2022, 14, 3282.	1.7	4
9166	<sc>Nonâ€”small</sc> cell lung cancer with tumor proportion scoreâ€”>â€”90% could increase the risk of severe <sc>immuneâ€”related</sc> adverse events in <sc>firstâ€”line</sc> treatments with immune checkpoint inhibitors: A retrospective <sc>singleâ€”center</sc> study. <i>Thoracic Cancer</i> , 2022, 13, 2450-2458.	0.8	4
9167	Association of artificial intelligence-powered and manual quantification of programmed death-ligand 1 (PD-L1) expression with outcomes in patients treated with nivolumab Â± ipilimumab. <i>Modern Pathology</i> , 2022, 35, 1529-1539.	2.9	14
9168	SYK Is Associated With Malignant Phenotype and Immune Checkpoints in Diffuse Glioma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	3
9169	Ferroptosis-Related lncRNA Signature Correlates with the Prognosis, Tumor Microenvironment, and Therapeutic Sensitivity of Esophageal Squamous Cell Carcinoma. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-29.	1.9	8

#	ARTICLE	IF	CITATIONS
9170	CCDC69 is a prognostic marker of breast cancer and correlates with tumor immune cell infiltration. <i>Frontiers in Surgery</i> , 0, 9, .	0.6	6
9171	Age-dependent genomic characteristics and their impact on immunotherapy in lung adenocarcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	3
9172	Economic Evaluation of a Tumour-Agnostic Therapy: Dutch Economic Value of Larotrectinib in TRK Fusion-Positive Cancers. <i>Applied Health Economics and Health Policy</i> , 2022, 20, 717-729.	1.0	4
9173	The Neonatal Innate Immune Response to Sepsis: Checkpoint Proteins as Novel Mediators of This Response and as Possible Therapeutic/Diagnostic Levers. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
9174	Metastasis of Melanoma to the Adrenal Glands: A Case Report and Literature Review. <i>Cureus</i> , 2022, , .	0.2	1
9175	A Dramatic Response to Toripalimab With Chemotherapy and Antiangiogenic Agent Followed by Surgery in a Stage IIIB Lung Adenocarcinoma Patient With an Uncommon EGFR Mutation: A Case Report. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
9176	Real-World Data on Pembrolizumab for Pretreated Non-Small-Cell Lung Cancer: Clinical Outcome and Relevance of the Lung Immune Prognostic Index. <i>Targeted Oncology</i> , 2022, 17, 453-465.	1.7	4
9177	Inflammatory and autoimmune predictive markers of response to anti-PD-1/PD-L1 therapy in NSCLC and melanoma. <i>Experimental and Therapeutic Medicine</i> , 2022, 24, .	0.8	5
9178	Immune Checkpoint Inhibitors: The Unexplored Landscape of Geriatric Oncology. <i>Oncologist</i> , 2022, 27, 778-789.	1.9	2
9179	The benefit of concurrent chemotherapy with radiotherapy for esophageal cancer is limited in Asian patients aged 80 years or older: a SEER database analysis. <i>Esophagus</i> , 2022, 19, 653-659.	1.0	2
9180	Immunotherapy-related renal toxicity causes reversible renal enlargement. <i>Abdominal Radiology</i> , 2022, 47, 3301-3307.	1.0	2
9181	Primary pulmonary lymphoepithelioma-like carcinoma treated with immunotherapy: A case report and literature review. <i>Thoracic Cancer</i> , 0, , .	0.8	4
9182	High expression of fibroblast-activating protein is a prognostic marker in non-small cell lung carcinoma. <i>Thoracic Cancer</i> , 2022, 13, 2377-2384.	0.8	4
9183	Emerging roles of circular RNAs in gastric cancer metastasis and drug resistance. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	17
9184	Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma. , 2022, 10, e004610.		6
9185	Identification of a cytokine-dominated immunosuppressive class in squamous cell lung carcinoma with implications for immunotherapy resistance. <i>Genome Medicine</i> , 2022, 14, .	3.6	20
9186	Mechanisms of resistance to immune checkpoint inhibitors. <i>Cancer Science</i> , 2022, 113, 3303-3312.	1.7	12
9187	Comprehensive Analysis Identifies and Validates the Tumor Microenvironment Subtypes to Predict Anti-Tumor Therapy Efficacy in Hepatocellular Carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1

#	ARTICLE	IF	CITATIONS
9188	Changes of Immune Cell Fractions in Patients Treated with Immune Checkpoint Inhibitors. <i>Cancers</i> , 2022, 14, 3440.	1.7	1
9189	TP53 and LRP1B Co-Wild Predicts Improved Survival for Patients with LUSC Receiving Anti-PD-L1 Immunotherapy. <i>Cancers</i> , 2022, 14, 3382.	1.7	4
9190	The Multi-Dimensional Biomarker Landscape in Cancer Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7839.	1.8	13
9191	Safety and Efficacy of Programmed Cell Death 1 and Programmed Death Ligand-1 Inhibitors in the Treatment of Cancer: An Overview of Systematic Reviews. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	11
9192	Antibody-Based Approaches to Target Pancreatic Tumours. <i>Antibodies</i> , 2022, 11, 47.	1.2	7
9193	DOCK4 as a Potential Biomarker Associated with Immune Infiltration in Stomach Adenocarcinoma: A Database Analysis. <i>International Journal of General Medicine</i> , 0, Volume 15, 6127-6143.	0.8	1
9194	Targeting the CD47-SIRPÎ± Innate Immune Checkpoint to Potentiate Antibody Therapy in Cancer by Neutrophils. <i>Cancers</i> , 2022, 14, 3366.	1.7	13
9195	Tumor antigens and immune subtypes of glioblastoma: the fundamentals of mRNA vaccine and individualized immunotherapy development. <i>Journal of Big Data</i> , 2022, 9, .	6.9	21
9196	Real-world data analysis of immune checkpoint inhibitors in stage III-IV adenocarcinoma and squamous cell carcinoma. <i>BMC Cancer</i> , 2022, 22, .	1.1	4
9197	A Proposed Link Between Acute Thymic Involution and Late Adverse Effects of Chemotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
9198	HLA class II molecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC. <i>BMC Cancer</i> , 2022, 22, .	1.1	7
9199	Early Response Assessment in Advanced Stage Melanoma Treated with Combination Ipilimumab/Nivolumab. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
9200	Fruquintinib in Combination With PD-1 Inhibitors in Patients With Refractory Non-MSI-H/pMMR Metastatic Colorectal Cancer: A Real-World Study in China. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
9201	Routine Screening for Central and Primary Adrenal Insufficiency during Immune-Checkpoint Inhibitor Therapy: An Endocrinology Perspective for Oncologists. <i>Current Oncology</i> , 2022, 29, 4665-4677.	0.9	7
9202	Management of cutaneous melanoma: radiologists challenging and risk assessment. <i>Radiologia Medica</i> , 2022, 127, 899-911.	4.7	20
9203	Correlation Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Programmed Death-Ligand 1 Expression as Prognostic Markers in Non-Small Cell Lung Cancer. <i>Cureus</i> , 2022, , .	0.2	1
9204	Multi-organ perioperative immune-related adverse events and postoperative bronchial anastomotic fistula in a patient receiving neoadjuvant immunotherapy with NSCLC. <i>Thoracic Cancer</i> , 2022, 13, 2340-2345.	0.8	5
9205	Radiation therapy enhances systemic antitumor efficacy in PD-L1 therapy regardless of sequence of radiation in murine osteosarcoma. <i>PLoS ONE</i> , 2022, 17, e0271205.	1.1	4

#	ARTICLE	IF	CITATIONS
9206	Association of thyroid transcription factor-1 with the efficacy of immune-checkpoint inhibitors in patients with advanced lung adenocarcinoma. <i>Thoracic Cancer</i> , 2022, 13, 2309-2317.	0.8	7
9207	Association between Nutritional Status and Treatment Response and Survival in Patients Treated with Immunotherapy for Lung Cancer: A Retrospective French Study. <i>Cancers</i> , 2022, 14, 3439.	1.7	7
9208	Limited Benefit from the Addition of Immunotherapy to Chemotherapy in TKI-Refractory EGFR-Mutant Lung Adenocarcinoma. <i>Cancers</i> , 2022, 14, 3473.	1.7	5
9209	Exploring immunotherapy in colorectal cancer. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	104
9210	Prognostic value of integrating circulating tumour cells and cell-free DNA in non-small cell lung cancer. <i>Heliyon</i> , 2022, 8, e09971.	1.4	4
9211	Clinical Significance of Transient Asymptomatic Elevations in Aminotransferase (TAEAT) in Oncology. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 0, Publish Ahead of Print, .	0.6	3
9212	Cardiovascular Toxicity With PD-1/PD-L1 Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	10
9213	Facts and Hopes for Immunotherapy in Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 5013-5020.	3.2	8
9214	AP3S1 is a Novel Prognostic Biomarker and Correlated With an Immunosuppressive Tumor Microenvironment in Pan-Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	3
9215	Resistance to TKIs in EGFR-Mutated Non-Small Cell Lung Cancer: From Mechanisms to New Therapeutic Strategies. <i>Cancers</i> , 2022, 14, 3337.	1.7	21
9216	Emerging Role of Deubiquitinating Enzymes (DUBs) in Melanoma Pathogenesis. <i>Cancers</i> , 2022, 14, 3371.	1.7	4
9217	Sarcoma Common MHC-I Haplotype Restricts Tumor-Specific CD8+ T Cell Response. <i>Cancers</i> , 2022, 14, 3414.	1.7	7
9218	Interaction of immune checkpoint PD-1 and chemokine receptor 4 (CXCR4) promotes a malignant phenotype in pancreatic cancer cells. <i>PLoS ONE</i> , 2022, 17, e0270832.	1.1	4
9219	Generation, secretion and degradation of cancer immunotherapy target PD-L1. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, .	2.4	5
9220	Increased Soluble PD-1 Predicts Response to Nivolumab plus Ipilimumab in Melanoma. <i>Cancers</i> , 2022, 14, 3342.	1.7	9
9221	PDL1Binder: Identifying programmed cell death ligand 1 binding peptides by incorporating next-generation phage display data and different peptide descriptors. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	5
9222	Mapping the Immune Landscape in Metastatic Melanoma Reveals Localized Cell-Cell Interactions That Predict Immunotherapy Response. <i>Cancer Research</i> , 2022, 82, 3275-3290.	0.4	17
9223	The Predictive Value of Pretreatment Lactate Dehydrogenase and Derived Neutrophil-to-Lymphocyte Ratio in Advanced Non-Small Cell Lung Cancer Patients Treated With PD-1/PD-L1 Inhibitors: A Meta-Analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	9

#	ARTICLE	IF	CITATIONS
9224	Identification of the KCNQ1OT1/ miR-378a-3p/ RBMS1 Axis as a Novel Prognostic Biomarker Associated With Immune Cell Infiltration in Gastric Cancer. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	5
9225	TNF- α Inhibitors and Other Biologic Agents for the Treatment of Immune Checkpoint Inhibitor-Induced Myocarditis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	11
9226	Mixed Response to Cancer Immunotherapy is Driven by Intratumor Heterogeneity and Differential Interlesion Immune Infiltration. <i>Cancer Research Communications</i> , 2022, 2, 739-753.	0.7	2
9227	Splenic volume as a predictor of treatment response in patients with non-small cell lung cancer receiving immunotherapy. <i>PLoS ONE</i> , 2022, 17, e0270950.	1.1	5
9228	Patients deriving long-term benefit from immune checkpoint inhibitors demonstrate conserved patterns of site-specific mutations. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
9229	Immunotherapies and renal injury. <i>Current Opinion in Toxicology</i> , 2022, 31, 100362.	2.6	0
9230	Cellular kinetics: A clinical and computational review of CAR-T cell pharmacology. <i>Advanced Drug Delivery Reviews</i> , 2022, 188, 114421.	6.6	18
9231	Complications in the Oncologic Patient: Abdomen and Pelvis. , 2023, , 692-703.		0
9232	The gut microbiome, immune check point inhibition and immune-related adverse events in non-small cell lung cancer. <i>Cancer and Metastasis Reviews</i> , 2022, 41, 347-366.	2.7	11
9233	Analysis of the OX40/OX40L immunoregulatory axis combined with alternative immune checkpoint molecules in pancreatic ductal adenocarcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
9234	Immune Checkpoint Inhibitor Rechallenge After Prior Immune Toxicity. <i>Current Treatment Options in Oncology</i> , 2022, 23, 1153-1168.	1.3	7
9235	Comprehensive Analysis of HMCN1 Somatic Mutation in Clear Cell Renal Cell Carcinoma. <i>Genes</i> , 2022, 13, 1282.	1.0	2
9236	Evaluation of T-cell aging-related immune phenotypes in the context of biological aging and multimorbidity in the Health and Retirement Study. <i>Immunity and Ageing</i> , 2022, 19, .	1.8	18
9237	Case report: Two novel intergenic region-ALK fusions in non-small-cell lung cancer resistant to alectinib: A report of two cases. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
9238	Techniques for Profiling the Cellular Immune Response and Their Implications for Interventional Oncology. <i>Cancers</i> , 2022, 14, 3628.	1.7	4
9239	Effect of depression disorder on the efficacy and quality of life of first-line chemotherapy combined with immunotherapy in oncogene-driver negative NSCLC patients. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
9240	A ferroptosis-related gene signature for overall survival prediction and immune infiltration in lung squamous cell carcinoma. <i>Bioscience Reports</i> , 2022, 42, .	1.1	7
9241	Immunotherapy-induced Hepatotoxicity: A Review. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 000, 000-000.	0.7	3

#	ARTICLE	IF	CITATIONS
9242	Mesoporous Silica Materials as an Emerging Tool for Cancer Immunotherapy. <i>Advanced Science</i> , 2022, 9, .	5.6	18
9243	Nomogram Prediction Model Analysis of Risk Factors for Conversion to Thoracotomy after Thoracoscopic Resection of Lung Cancer and Prognostic Value of Lung Cancer. <i>Computational and Mathematical Methods in Medicine</i> , 2022, 2022, 1-10.	0.7	1
9244	Somatic mutations in DCC are associated with genomic instability and favourable outcomes in melanoma patients treated with immune checkpoint inhibitors. <i>British Journal of Cancer</i> , 0, , .	2.9	0
9245	Sex-Biased Immune Responses to Antibiotics during Anti-PD-L1 Treatment in Mice with Colon Cancer. <i>Journal of Immunology Research</i> , 2022, 2022, 1-26.	0.9	3
9246	Proliferation and Immune Response Gene Signatures Associated with Clinical Outcome to Immunotherapy and Targeted Therapy in Metastatic Cutaneous Malignant Melanoma. <i>Cancers</i> , 2022, 14, 3587.	1.7	6
9247	Right ventricular and atrial strain in patients with advanced melanoma undergoing immune checkpoint inhibitor therapy. <i>ESC Heart Failure</i> , 2022, 9, 3533-3542.	1.4	3
9248	The expression pattern of Immune checkpoints after chemo/radiotherapy in the tumor microenvironment. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
9249	Interferon- β predicts the treatment efficiency of immune checkpoint inhibitors in cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	1
9250	Anaplastic lymphoma kinase-special immunity and immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
9251	Baseline and post-treatment biomarkers of resistance to anti-PD-1 therapy in acral and mucosal melanoma: an observational study. , 2022, 10, e004879.		14
9252	The Multi-Omics Landscape and Clinical Relevance of the Immunological Signature of Phagocytosis Regulators: Implications for Risk Classification and Frontline Therapies in Skin Cutaneous Melanoma. <i>Cancers</i> , 2022, 14, 3582.	1.7	0
9253	Prognostic value of the controlling nutritional status score in patients with myelodysplastic syndromes. <i>Frontiers in Nutrition</i> , 0, 9, .	1.6	2
9254	Host-Related Factors as Targetable Drivers of Immunotherapy Response in Non-Small Cell Lung Cancer Patients. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
9255	Long non-coding RNA PART1: dual role in cancer. <i>Human Cell</i> , 2022, 35, 1364-1374.	1.2	6
9256	Nivolumab Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	8
9257	Peripheral gene signatures reveal distinct cancer patient immunotypes with therapeutic implications for autologous DC-based vaccines. <i>Oncimmunology</i> , 2022, 11, .	2.1	9
9258	Gene Identification and Potential Drug Therapy for Drug-Resistant Melanoma with Bioinformatics and Deep Learning Technology. <i>Disease Markers</i> , 2022, 2022, 1-13.	0.6	1
9259	Allotinib combined with TQB2450 in patients with platinum-resistant or -refractory ovarian cancer: A multi-center, single-arm, phase 1b trial. <i>Cell Reports Medicine</i> , 2022, 3, 100689.	3.3	12

#	ARTICLE	IF	CITATIONS
9260	Real-world safety and effectiveness of pembrolizumab in Japanese patients with radically unresectable melanoma: An all-case postmarketing surveillance in Japan. <i>Journal of Dermatology</i> , 2022, 49, 1096-1105.	0.6	4
9261	Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes. <i>Cells</i> , 2022, 11, 2249.	1.8	23
9262	Persistent Ethnicity-Associated Disparity in Antitumor Effectiveness of Immune Checkpoint Inhibitors Despite Equal Access. <i>Cancer Research Communications</i> , 2022, 2, 806-813.	0.7	7
9263	Treatment reality of patients with BRAF-mutant advanced/metastatic melanoma in Switzerland in the era of choice. <i>Melanoma Research</i> , 0, Publish Ahead of Print, .	0.6	1
9264	PD-1 TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC. <i>Clinical Cancer Research</i> , 2022, 28, 4893-4906.	3.2	18
9265	The role of obesity and bariatric surgery-induced weight loss in breast cancer. <i>Cancer and Metastasis Reviews</i> , 2022, 41, 673-695.	2.7	7
9266	Necessity of neutrophil-to-lymphocyte ratio monitoring for hypothyroidism using nivolumab in patients with cancer. <i>World Journal of Clinical Oncology</i> , 2022, 13, 641-651.	0.9	2
9267	Immune Checkpoint Inhibitors in Cancer Therapy—How to Overcome Drug Resistance?. <i>Cancers</i> , 2022, 14, 3575.	1.7	18
9268	Positive Correlation of Peripheral CD8+ T Lymphocytes with Immune-Related Adverse Events and Combinational Prognostic Value in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors. <i>Cancers</i> , 2022, 14, 3568.	1.7	2
9269	Effectiveness and Safety of PD-1 Inhibitor Monotherapy for Elderly Patients with Advanced Non-Small Cell Lung Cancer: A Real-World Exploratory Study. <i>Journal of Oncology</i> , 2022, 2022, 1-10.	0.6	2
9270	Immunotherapy combined with antiangiogenic agents in patients with advanced malignant pleural mesothelioma: A case report. <i>World Journal of Clinical Cases</i> , 2022, 10, 8284-8290.	0.3	1
9271	Splenic irradiation contributes to grade 3 lymphopenia after adjuvant chemoradiation for stomach cancer. <i>Clinical and Translational Radiation Oncology</i> , 2022, 36, 83-90.	0.9	3
9272	Imaging features of toxicities associated with immune checkpoint inhibitors. <i>European Journal of Radiology Open</i> , 2022, 9, 100434.	0.7	6
9273	Salmonella-induced immune response reduces recurrence and tumor dissemination in preclinical melanoma model. <i>Current Research in Immunology</i> , 2022, 3, 159-166.	1.2	0
9274	Immune Checkpoint Inhibitors Induced Hepatotoxicity; Gastroenterologists' Perspectives. <i>Middle East Journal of Digestive Diseases</i> , 2022, 14, 244-253.	0.2	1
9275	State of affairs regarding targeted pharmacological therapy of cancers metastasized to the brain. <i>Neurosurgical Review</i> , 2022, 45, 3119-3138.	1.2	1
9276	Immune-Checkpoint-Inhibitor-Related Lung Toxicity: A Multicentre Real-Life Retrospective Portrait from Six Italian Centres. <i>Life</i> , 2022, 12, 1149.	1.1	2
9277	Case Report: Successful treatment of late-onset immune checkpoint inhibitor-associated membranous nephropathy in a patient with advanced renal cell carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5

#	ARTICLE	IF	CITATIONS
9278	Renal Toxicities in Cancer Patients Receiving Immune-Checkpoint Inhibitors: A Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2022, 11, 4373.	1.0	1
9279	Enhanced Inhibitory Effect of DC-CIK Cells on Lung Adenocarcinoma via Anti-Tim-3 Antibody and Antiprogrammed Cell Death-1 Antibody and Possible Mechanism. <i>Evidence-based Complementary and Alternative Medicine</i> , 2022, 2022, 1-11.	0.5	2
9280	Editorial: Decoding checkpoint inhibitor-induced endocrinopathies. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	1
9281	Body mass index and serum markers associated with progression-free survival in lung cancer patients treated with immune checkpoint inhibitors. <i>BMC Cancer</i> , 2022, 22, .	1.1	7
9282	Anti-PD-1 Monotherapy in Advanced Melanoma—Real-World Data from a 77-Month-Long Retrospective Observational Study. <i>Biomedicines</i> , 2022, 10, 1737.	1.4	8
9283	Evaluating the utility of an immune checkpoint-related lncRNA signature for identifying the prognosis and immunotherapy response of lung adenocarcinoma. <i>Scientific Reports</i> , 2022, 12, .	1.6	1
9284	Nanomedicine approaches for treatment of hematologic and oncologic malignancies. <i>World Journal of Clinical Oncology</i> , 2022, 13, 553-566.	0.9	2
9285	Serum immunoglobulins might be useful predictors of immune-related adverse events after immune checkpoint inhibitor usage in lung cancer. <i>Thoracic Cancer</i> , 0, , .	0.8	3
9286	Comorbidities involving parasitic diseases: A look at the benefits and complications. <i>Experimental Biology and Medicine</i> , 2022, 247, 1819-1826.	1.1	2
9287	Chemotherapy and Physical Therapeutics Modulate Antigens on Cancer Cells. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
9288	Safety and efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients with preexisting antinuclear antibodies: a retrospective cohort study. <i>Translational Lung Cancer Research</i> , 2022, 11, 1420-1433.	1.3	7
9289	Chemoradiation-induced alteration of programmed death-ligand 1, CD8+ tumor-infiltrating lymphocytes and mucin expression in rectal cancer. <i>Oncotarget</i> , 2022, 13, 907-917.	0.8	1
9290	A Fc-VEGF chimeric fusion enhances PD-L1 immunotherapy via inducing immune reprogramming and infiltration in the immunosuppressive tumor microenvironment. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 351-369.	2.0	6
9291	Pilot Study: Immune Checkpoints Polymorphisms in Greek Primary Breast Cancer Patients. <i>Biomedicines</i> , 2022, 10, 1827.	1.4	3
9292	Overexpression of 14-3-3 η primes disease recurrence, metastasis and resistance to chemotherapy by inducing epithelial-mesenchymal transition in NSCLC. <i>Aging</i> , 2022, 14, 5838-5854.	1.4	3
9293	Cutting-Edge: Preclinical and Clinical Development of the First Approved Lag-3 Inhibitor. <i>Cells</i> , 2022, 11, 2351.	1.8	29
9294	Therapeutic Strategies to Enhance Tumor Antigenicity: Making the Tumor Detectable by the Immune System. <i>Biomedicines</i> , 2022, 10, 1842.	1.4	5
9295	Comparison of perioperative outcomes among non-small cell lung cancer patients with neoadjuvant immune checkpoint inhibitor plus chemotherapy, EGFR-TKI, and chemotherapy alone: a real-world evidence study. <i>Translational Lung Cancer Research</i> , 2022, 11, 1468-1478.	1.3	3

#	ARTICLE	IF	CITATIONS
9296	Characteristics and usefulness of transabdominal ultrasonography in immune-mediated colitis. <i>Intestinal Research</i> , 2023, 21, 126-136.	1.0	1
9297	Advantages of organ-sparing treatment approaches in metastatic kidney cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 3131-3137.	1.2	1
9298	A randomized phase 2 trial of nivolumab, gemcitabine, and cisplatin or nivolumab and ipilimumab in previously untreated advanced biliary cancer: <sc>BiT</sc>â€œ1. <i>Cancer</i> , 2022, 128, 3523-3530.	2.0	22
9299	Powering single-cell genomics to unravel circulating tumour cell subpopulations in non-small cell lung cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 1941-1950.	1.2	1
9300	The promising immune checkpoint LAG-3 in cancer immunotherapy: from basic research to clinical application. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	44
9301	Radiotherapy combined with immunotherapy: the dawn of cancer treatment. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	142
9302	Applications of Liquid Biopsies in Non-Small-Cell Lung Cancer. <i>Diagnostics</i> , 2022, 12, 1799.	1.3	7
9303	Cancer chemotherapy: insights into cellular and tumor microenvironmental mechanisms of action. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	31
9304	Immunotherapy for EGFR-mutant advanced non-small-cell lung cancer: Current status, possible mechanisms and application prospects. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
9305	Immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer: A review. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
9306	Noncoding RNAs in pyroptosis and cancer progression: Effect, mechanism, and clinical application. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
9307	Grade 3â€œ4 Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer (NSCLC) Patients Are Correlated with Better Outcome: A Real-Life Observational Study. <i>Cancers</i> , 2022, 14, 3878.	1.7	7
9308	Pulmonary Lymphangitis Carcinomatosa Mimicking Immunotherapy-Related Interstitial Pneumonitis: A Case Report. <i>Case Reports in Oncology</i> , 0, , 732-737.	0.3	0
9309	Bayesian sparse modeling to identify highâ€œrisk subgroups in metaâ€œanalysis of safety data. <i>Research Synthesis Methods</i> , 0, , .	4.2	0
9310	Use of First-Line Immune Checkpoint Inhibitors and Association With Overall Survival Among Patients With Metastatic Melanoma in the Antiâ€œPD-1 Era. <i>JAMA Network Open</i> , 2022, 5, e2225459.	2.8	14
9311	Emerging Biomarkers and the Changing Landscape of Small Cell Lung Cancer. <i>Cancers</i> , 2022, 14, 3772.	1.7	11
9312	Synergistic effects of radiotherapy and targeted immunotherapy in improving tumor treatment efficacy: a review. <i>Clinical and Translational Oncology</i> , 2022, 24, 2255-2271.	1.2	6
9313	Recent Advances and Challenges in Cancer Immunotherapy. <i>Cancers</i> , 2022, 14, 3972.	1.7	26

#	ARTICLE	IF	CITATIONS
9314	Bias and inconsistency in the estimation of tumour mutation burden. <i>BMC Cancer</i> , 2022, 22, .	1.1	8
9315	Immunotherapy in non-small cell lung cancer: Past, present, and future directions. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	32
9316	Neutrophils: Musketeers against immunotherapy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	12
9317	PD-1 inhibitor-associated type 1 diabetes: A case report and systematic review. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	10
9318	AZD4625 is a Potent and Selective Inhibitor of KRASG12C. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 1535-1546.	1.9	2
9319	Growth hormone associated with treatment efficacy of immune checkpoint inhibitors in gastric cancer patients. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
9320	A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-Naïve Non-Small Cell Lung Cancer: TORG1630. <i>Clinical Cancer Research</i> , 2022, 28, 4402-4409.	3.2	11
9321	Whole transcriptome and proteome analyses identify potential targets and mechanisms underlying tumor treating fields against glioblastoma. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	5
9322	Efficacy of immune checkpoint inhibitors in non-small cell lung cancer: A systematic review and meta-analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
9323	Value-Based Care in Systemic Therapy: The Way Forward. <i>Current Oncology</i> , 2022, 29, 5792-5799.	0.9	3
9324	Development of a human phage display-derived anti-PD-1 scFv antibody: an attractive tool for immune checkpoint therapy. <i>BMC Biotechnology</i> , 2022, 22, .	1.7	10
9325	Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2023, 41, 528-540.	0.8	62
9326	The gamble between oncolytic virus therapy and IFN. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	10
9327	Ferroptosis-related lncRNAs signature to predict the survival and immune evasion for lung squamous cell carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	0
9328	Cost-effectiveness analysis of tislelizumab, nivolumab and docetaxel as second- and third-line for advanced or metastatic non-small cell lung cancer in China. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	6
9329	Patient-reported tolerability of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III-IV melanoma in phase III trial E1609. <i>Quality of Life Research</i> , 0, , .	1.5	0
9330	Secretory co-factors in next-generation cellular therapies for cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
9331	Analysis of Cancer Survival Associated With Immune Checkpoint Inhibitors After Statistical Adjustment. <i>JAMA Network Open</i> , 2022, 5, e2227211.	2.8	8

#	ARTICLE	IF	CITATIONS
9332	Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	89
9333	Cyclophosphamide depletes tumor infiltrating T regulatory cells and combined with anti-PD-1 therapy improves survival in murine neuroblastoma. <i>IScience</i> , 2022, 25, 104995.	1.9	5
9334	Immunotherapy in Ovarian Cancer. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2022, 70, .	1.0	8
9335	Comparison of Efficacy and Safety Between Immunotherapy and Docetaxel Monotherapy in NSCLC Patients. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
9336	Efficacy and safety of combined immunotherapy and antiangiogenesis with or without chemotherapy for advanced non-small-cell lung cancer: A systematic review and pooled analysis from 23 prospective studies. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	4
9337	Biologic Therapy for Refractory Immune Checkpoint Inhibitor Colitis. <i>Biologics: Targets and Therapy</i> , 0, Volume 16, 119-127.	3.0	1
9338	PD-L1 expression, tumor mutational burden, and immune cell infiltration in non-small cell lung cancer patients with epithelial growth factor receptor mutations. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
9339	Emerging Immune-Monitoring System for Immune Checkpoint Inhibitors. <i>Life</i> , 2022, 12, 1229.	1.1	4
9340	Interleukin-17D promotes lung cancer progression by inducing tumor-associated macrophage infiltration via the p38 MAPK signaling pathway. <i>Aging</i> , 2022, 14, 6149-6168.	1.4	4
9341	Comprehensive circular RNA expression profile of lung adenocarcinoma with bone metastasis: Identification of potential biomarkers. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	2
9342	Stocky/Packed Pancreas: A Case of Focal Drug-Induced Acute Pancreatitis Mimicking Cancer. <i>Tomography</i> , 2022, 8, 2073-2082.	0.8	1
9343	Association of PD-L1 Expression and Other Variables With Benefit From Immune Checkpoint Inhibition in Advanced Gastroesophageal Cancer. <i>JAMA Oncology</i> , 2022, 8, 1456.	3.4	60
9344	Computational identification of immune-related lncRNA signature for predicting the prognosis and immune landscape of human glioblastoma multiforme. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
9345	Development and validation of the potential biomarkers based on m6A-related lncRNAs for the predictions of overall survival in the lung adenocarcinoma and differential analysis with cuproptosis. <i>BMC Bioinformatics</i> , 2022, 23, .	1.2	4
9346	Imaging Findings in Patients with Immune Checkpoint Inhibitor-Induced Arthritis. <i>Diagnostics</i> , 2022, 12, 1961.	1.3	7
9347	Upregulated PD-1 signaling antagonizes glomerular health in aged kidneys and disease. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	20
9348	Regulatory T Cell Depletion Using a CRISPR Fc-Optimized CD25 Antibody. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8707.	1.8	3
9349	TNF- α inhibitor ameliorates immune-related arthritis and pneumonitis in humanized mice. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4

#	ARTICLE	IF	CITATIONS
9350	KRAS-Mutant Non-Small-Cell Lung Cancer: From Past Efforts to Future Challenges. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9391.	1.8	13
9351	Emerging PD-1/PD-L1 targeting immunotherapy in non-small cell lung cancer: Current status and future perspective in Japan, US, EU, and China. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	8
9352	Clinical Features, Survival, and Burden of Toxicities in Survivors More Than One Year After Lung Cancer Immunotherapy. <i>Oncologist</i> , 2022, 27, 971-981.	1.9	9
9353	Adverse Renal Effects of Anticancer Immunotherapy: A Review. <i>Cancers</i> , 2022, 14, 4086.	1.7	3
9354	A Paradoxical Role for Regulatory T Cells in the Tumor Microenvironment of Pancreatic Cancer. <i>Cancers</i> , 2022, 14, 3862.	1.7	8
9355	EMT-Related Gene Signature Predicts the Prognosis in Uveal Melanoma Patients. <i>Journal of Oncology</i> , 2022, 2022, 1-19.	0.6	5
9356	Immune-checkpoint inhibitor-associated grade 3 hepatotoxicity managed with enteric-coated budesonide monotherapy: A case report. <i>Medicine (United States)</i> , 2022, 101, e29473.	0.4	2
9357	Progress in programmed cell death-1/programmed cell death-ligand 1 pathway inhibitors and binding mode analysis. <i>Molecular Diversity</i> , 0, .	2.1	1
9358	Sex-specific differences in immunogenomic features of response to immune checkpoint blockade. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
9359	Injectable Nanoparticle-Based Hydrogels Enable the Safe and Effective Deployment of Immunostimulatory CD40 Agonist Antibodies. <i>Advanced Science</i> , 2022, 9, .	5.6	11
9360	Metastatic ovarian tumor from pancreatic cancer treated with combined immunotherapy: A case report. <i>Oncology Letters</i> , 2022, 24, .	0.8	3
9361	Immune checkpoint inhibitors for PD-1/PD-L1 axis in combination with other immunotherapies and targeted therapies for non-small cell lung cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
9362	Neoadjuvant immunotherapy and chemoimmunotherapy for stage II-III muscle invasive bladder cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	12
9363	Glucose-Thymidine Ratio as a Metabolism Index Using ¹⁸ F-FDG and ¹⁸ F-FLT PET Uptake as a Potential Imaging Biomarker for Evaluating Immune Checkpoint Inhibitor Therapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9273.	1.8	1
9364	Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial. , 2022, 10, e004761.		15
9365	Anti-PD-1 for the treatment of advanced cutaneous squamous cell carcinoma in elderly patients: a French multicenter retrospective survey. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 3549-3562.	1.2	5
9366	Immune Checkpoint Inhibitors™ Associated Renal Toxicity: A Series of 12 Cases. <i>Journal of Clinical Medicine</i> , 2022, 11, 4786.	1.0	4
9367	Insomnia in patients treated with checkpoint inhibitors for cancer: A meta-analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4

#	ARTICLE	IF	CITATIONS
9368	Assessing the robustness of radiomics/deep learning approach in the identification of efficacy of anti-PD-1 treatment in advanced or metastatic non-small cell lung carcinoma patients. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
9369	An immunotherapy response prediction model derived from proliferative CD4+ T cells and antigen-presenting monocytes in ccRCC. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
9370	Non-invasive early prediction of immune checkpoint inhibitor efficacy in non-small-cell lung cancer patients using on-treatment serum CRP and NLR. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	2
9371	The changes in peripheral blood Th17 and Treg ratios in Hashimoto's thyroiditis are accompanied by differential PD-1/PD-L1 expression. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	1
9372	Clinical and Biological Activity of Chemoimmunotherapy in Advanced Endometrial Adenocarcinoma: A Phase II Trial of the Big Ten Cancer Research Consortium. <i>Cancer Research Communications</i> , 2022, 2, 1293-1303.	0.7	2
9373	Real-World Efficacy and Safety of Sintilimab-Based Regimens against Advanced Esophageal Cancer: A Single-Center Retrospective Observational Study. <i>BioMed Research International</i> , 2022, 2022, 1-9.	0.9	3
9374	Features of patients with advanced EGFR-mutated non-small cell lung cancer benefiting from immune checkpoint inhibitors. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
9375	The time window for the reversal of depigmentation from aggravation to recovery in a non-small-cell lung cancer patient with pre-existing vitiligo using anti-programmed cell death-1 therapy: A case report. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
9376	PD-L1 Expression in Endometrial Cancer and Its Association with Clinicopathological Features: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2022, 14, 3911.	1.7	15
9377	T-Cell Receptor Repertoire Sequencing and Its Applications: Focus on Infectious Diseases and Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8590.	1.8	12
9378	Successful immune checkpoint inhibitor rechallenge after immune-related pericarditis: Clinical case series. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	2
9379	Construction of a predictive model for immunotherapy efficacy in lung squamous cell carcinoma based on the degree of tumor-infiltrating immune cells and molecular typing. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	9
9380	Core immune cell infiltration signatures identify molecular subtypes and promote precise checkpoint immunotherapy in cutaneous melanoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
9381	Ocular Inflammation Induced by Immune Checkpoint Inhibitors. <i>Journal of Clinical Medicine</i> , 2022, 11, 4993.	1.0	12
9382	What is the status of immunotherapy in thyroid neoplasms?. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	12
9383	The epiphany derived from T-cell-inflamed profiles: Pan-cancer characterization of CD8A as a biomarker spanning clinical relevance, cancer prognosis, immunosuppressive environment, and treatment responses. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	4
9384	Choosing the optimal immunotherapeutic strategies for non-small cell lung cancer based on clinical factors. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
9385	The role of kidney biopsy in immune checkpoint inhibitor nephrotoxicity. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	2

#	ARTICLE	IF	CITATIONS
9386	Single-cell RNA sequencing reveals the cellular and molecular changes that contribute to the progression of lung adenocarcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	1
9387	Fibroblast activation protein in the tumor microenvironment predicts outcomes of PD-1 blockade therapy in advanced non-small cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 3469-3483.	1.2	9
9388	Current therapeutic strategies and perspectives in refractory ITP: What have we learned recently?. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
9389	Activation Markers on B and T Cells and Immune Checkpoints in Autoimmune Rheumatic Diseases. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8656.	1.8	4
9390	An Immunogenic Model of KRAS-Mutant Lung Cancer Enables Evaluation of Targeted Therapy and Immunotherapy Combinations. <i>Cancer Research</i> , 2022, 82, 3435-3448.	0.4	25
9391	Expression of PD1 and PDL1 as immune-checkpoint inhibitors in mantle cell lymphoma. <i>BMC Cancer</i> , 2022, 22, .	1.1	3
9392	Comparison of real-world data (RWD) analysis on efficacy and post-progression outcomes with pembrolizumab plus chemo vs chemo alone in metastatic non-squamous non-small cell lung cancer with PD-L1 $\geq 50\%$. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
9393	PD-L1+ neutrophils as novel biomarkers for stage IV melanoma patients treated with nivolumab. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
9394	Polygenic autoimmune disease risk alleles impacting B cell tolerance act in concert across shared molecular networks in mouse and in humans. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
9395	Impact of intratumoural $CD96$ expression on clinical outcome and therapeutic benefit in gastric cancer. <i>Cancer Science</i> , 2022, 113, 4070-4081.	1.7	7
9396	Differential distribution and prognostic value of CD4+ T cell subsets before and after radioactive iodine therapy in differentiated thyroid cancer with varied curative outcomes. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
9397	Global research trends on precision cancer medicine-related rashes (2008-2021): A bibliographic study. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
9398	Lipid Nanoparticle Delivery of Fas Plasmid Restores Fas Expression to Suppress Melanoma Growth <i>In Vivo</i> . <i>ACS Nano</i> , 2022, 16, 12695-12710.	7.3	11
9399	COVID-19 vaccination in advanced skin cancer patients receiving systemic anticancer treatment: A prospective singlecenter study investigating seroconversion rates. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
9400	Solving the puzzle of what makes immunotherapies work. <i>Trends in Cancer</i> , 2022, 8, 890-900.	3.8	7
9401	Cost-Utility of Nivolumab Plus Ipilimumab in First-Line Treatment of Advanced Melanoma in the United States: An Analysis Using Long-Term Overall Survival Data from Checkmate 067. <i>PharmacoEconomics - Open</i> , 2022, 6, 697-710.	0.9	3
9402	Discoidin Domain Receptor-Driven Gene Signatures as Markers of Patient Response to Anti-PD-L1 Immune Checkpoint Therapy. <i>Journal of the National Cancer Institute</i> , 2022, 114, 1380-1391.	3.0	4
9403	Correlation between the Immune Checkpoint Inhibitors Prognostic Index and Outcomes in Nonsmall Cell Lung Cancer: A Multicentre Analysis. <i>Journal of Oncology</i> , 2022, 2022, 1-15.	0.6	1

#	ARTICLE	IF	CITATIONS
9404	The Efficacy of Immune Checkpoint Inhibitors vs. Chemotherapy for KRAS-Mutant or EGFR-Mutant Non-Small-Cell Lung Cancers: A Meta-Analysis Based on Randomized Controlled Trials. <i>Disease Markers</i> , 2022, 2022, 1-11.	0.6	3
9405	Preclinical Characterization of Relatlimab, a Human LAG-3-Blocking Antibody, Alone or in Combination with Nivolumab. <i>Cancer Immunology Research</i> , 2022, 10, 1175-1189.	1.6	21
9406	Inflammatory landscape in Xeroderma pigmentosum patients with cutaneous melanoma. <i>Scientific Reports</i> , 2022, 12, .	1.6	0
9407	EGFR Inhibition Strongly Modulates the Tumour Immune Microenvironment in EGFR-Driven Non-Small-Cell Lung Cancer. <i>Cancers</i> , 2022, 14, 3943.	1.7	9
9408	Regulation of PD-L1 through direct binding of cholesterol to CRAC motifs. <i>Science Advances</i> , 2022, 8, .	4.7	16
9409	Computational design of PD-L1 small molecule inhibitors for cancer therapy. <i>Molecular Diversity</i> , 2023, 27, 1633-1644.	2.1	7
9410	Spatial Positioning and Matrix Programs of Cancer-Associated Fibroblasts Promote T-cell Exclusion in Human Lung Tumors. <i>Cancer Discovery</i> , 2022, 12, 2606-2625.	7.7	69
9411	Loss of MHC-I antigen presentation correlated with immune checkpoint blockade tolerance in MAPK inhibitor-resistant melanoma. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	5
9412	Expression, correlation, and prognostic significance of different nicotinic acetylcholine receptors, programmed death ligand 1, and dopamine receptor D2 in lung adenocarcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
9413	Serum cytokine levels for predicting immune-related adverse events and the clinical response in lung cancer treated with immunotherapy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
9414	SAAL1, a novel oncogene, is associated with prognosis and immunotherapy in multiple types of cancer. <i>Aging</i> , 2022, 14, 6316-6337.	1.4	6
9415	The role of ferroptosis in esophageal cancer. <i>Cancer Cell International</i> , 2022, 22, .	1.8	8
9416	A Real-World Analysis of Immune Checkpoint Inhibitor-Based Therapy After Osimertinib Treatment in Patients With EGFR-Mutant NSCLC. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100388.	0.6	4
9417	The immune-related role of beta-2-microglobulin in melanoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	12
9418	Model established based on blood markers predicts overall survival in patients after radical resection of types II and III adenocarcinoma of the esophagogastric junction. <i>World Journal of Gastrointestinal Surgery</i> , 2022, 14, 788-798.	0.8	0
9419	Chemotherapy reinforces anti-tumor immune response and enhances clinical efficacy of immune checkpoint inhibitors. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
9420	HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
9421	Efficacy of immune checkpoint inhibitors in EGFR-Mutant NSCLC patients with EGFR-TKI resistance: A systematic review and meta-analysis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3

#	ARTICLE	IF	CITATIONS
9422	Bystander LECT2 amyloidosis in tumor nephrectomy. <i>CEN Case Reports</i> , 2023, 12, 104-109.	0.5	1
9423	Phase I study of envafolelimab (KN035), a novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2022, 40, 1021-1031.	1.2	10
9424	Clinical utility of tumour mutational burden on efficacy of immune checkpoint inhibitors in malignant solid tumours: protocol for a systematic review and meta-analysis. <i>BMJ Open</i> , 2022, 12, e058692.	0.8	3
9425	High IGC-Expressing Intratumoral Plasma Cells Predict Response to Immune Checkpoint Blockade. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9124.	1.8	7
9426	Unexpected favorable outcome to sintilimab monotherapy in a relapse pancreatic ductal adenocarcinoma patient with high tumor mutational burden: a case report. <i>Anti-Cancer Drugs</i> , 0, Publish Ahead of Print, .	0.7	1
9427	PD-L1 Over-Expression Varies in Different Subtypes of Lung Cancer: Will This Affect Future Therapies?. <i>Clinics and Practice</i> , 2022, 12, 653-671.	0.6	8
9428	Targeting <i>KRAS</i> : Crossroads of Signaling and Immune Inhibition. <i>Journal of Immunotherapy and Precision Oncology</i> , 2022, 5, 68-78.	0.6	6
9429	Evolutions in the management of non-small cell lung cancer: A bibliometric study from the 100 most impactful articles in the field. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
9430	Pneumocystis pneumonia in patient with lung adenocarcinoma: early side effects from pembrolizumab. <i>Radiology Case Reports</i> , 2022, 17, 3979-3981.	0.2	3
9431	Cardiac fibrosis in oncologic therapies. <i>Current Opinion in Physiology</i> , 2022, 29, 100575.	0.9	6
9432	Pathophysiology of Immune Checkpoint Inhibitor-Induced Myocarditis. <i>Cancers</i> , 2022, 14, 4494.	1.7	16
9433	Eight gene mutation-based polygenic hazard score as a potential predictor for immune checkpoint inhibitor therapy outcome in metastatic melanoma. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	1
9434	Dexamethasone and compliance affect TFields efficacy to glioblastoma patients: a systematic review and meta-analysis. <i>Chinese Neurosurgical Journal</i> , 2022, 8, .	0.3	4
9435	STAT3 and PD-L1 are negatively correlated with ATM and have impact on the prognosis of triple-negative breast cancer patients with low ATM expression. <i>Breast Cancer Research and Treatment</i> , 2022, 196, 45-56.	1.1	2
9436	Programmed cell death ligand 1 measurement study in granulocyte colony-stimulating factor-producing lung cancer: an observational study. <i>BMC Cancer</i> , 2022, 22, .	1.1	5
9437	Expression of immune checkpoint regulators, programmed death-ligand 1 (PD-L1/PD-1), cytotoxic T lymphocyte antigen 4 (CTLA-4), and indoleamine-2, 3-deoxygenase (IDO) in uterine mesenchymal tumors. <i>Diagnostic Pathology</i> , 2022, 17, .	0.9	1
9438	Deciphering the immune landscape dominated by cancer-associated fibroblasts to investigate their potential in indicating prognosis and guiding therapeutic regimens in high grade serous ovarian carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
9439	Plasma autoantibodies IgG and IgM to PD1/PDL1 as potential biomarkers and risk factors of lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	0

#	ARTICLE	IF	CITATIONS
9440	<i>EGFR</i> Mutations and PD-L1 Expression in Early-Stage Non-Small Cell Lung Cancer: A Real-World Data From a Single Center in Brazil. <i>Oncologist</i> , 0, , .	1.9	1
9441	Association between germ-line HLA and immune-related adverse events. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
9442	PD-1 expression on mouse intratumoral NK cells and its effects on NK cell phenotype. <i>IScience</i> , 2022, 25, 105137.	1.9	6
9443	The efficacy of immune checkpoint inhibitors in elderly patients: a meta-analysis and meta-regression. <i>ESMO Open</i> , 2022, 7, 100577.	2.0	11
9444	Vedolizumab in the treatment of immune checkpoint inhibitor-induced colitis: Two case reports. <i>World Journal of Clinical Cases</i> , 0, 10, 10550-10558.	0.3	1
9445	Immune checkpoint blockade in pancreatic cancer: Trudging through the immune desert. <i>Seminars in Cancer Biology</i> , 2022, 86, 14-27.	4.3	21
9446	First-line nivolumab plus ipilimumab or chemotherapy <i>versus</i> chemotherapy alone for advanced esophageal cancer: a cost-effectiveness analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211227.	1.4	10
9447	Immunotherapy in soft tissue and bone sarcoma: unraveling the barriers to effectiveness. <i>Theranostics</i> , 2022, 12, 6106-6129.	4.6	14
9449	Microneedle Transdermal Drug Delivery Systems for Allergen-Specific Immunotherapy, Skin Disease Treatment, and Vaccine Development. <i>Yonsei Medical Journal</i> , 2022, 63, 881.	0.9	4
9450	<i>Nephrology (Kidney)</i> . , 2022, , 197-214.		0
9451	Polyglutamate-based nanoconjugates for image-guided surgery and post-operative melanoma metastases prevention. <i>Theranostics</i> , 2022, 12, 6339-6362.	4.6	0
9452	Multi-omics analysis to identify lung squamous carcinoma lactate metabolism-related subtypes and establish related index to predict prognosis and guide immunotherapy. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 4756-4770.	1.9	2
9453	Efficacy and Safety of Immune Checkpoint Inhibitors for Advanced Malignant Melanoma: A Meta-Analysis on Monotherapy Vs Combination Therapy. <i>Journal of Cancer</i> , 2022, 13, 3091-3102.	1.2	4
9454	EZH2 inhibition activates dsRNA-interferon axis stress and promotes response to PD-1 checkpoint blockade in NSCLC. <i>Journal of Cancer</i> , 2022, 13, 2893-2904.	1.2	5
9455	Rational development of molecularly imprinted nanoparticles for blocking PD-1/PD-L1 axis. <i>Chemical Science</i> , 2022, 13, 10897-10903.	3.7	8
9456	Clinical outcomes of Atezolizumab Therapy for Previously-Treated Advanced-Stage Non-Small Cell Lung Cancer: A Real-World Study in Taiwan. <i>Journal of Cancer</i> , 2022, 13, 2922-2932.	1.2	0
9457	Tislelizumab: A Modified Anti-tumor Programmed Death Receptor 1 Antibody. <i>Cancer Control</i> , 2022, 29, 107327482211112.	0.7	17
9458	Emerging approaches for preventing cytokine release syndrome in CAR-T cell therapy. <i>Journal of Materials Chemistry B</i> , 2022, 10, 7491-7511.	2.9	8

#	ARTICLE	IF	CITATIONS
9459	T-Cell Density at the Invasive Margin and Immune Phenotypes Predict Outcome in Vulvar Squamous Cell Cancer. <i>Cancers</i> , 2022, 14, 4246.	1.7	4
9460	Immune-Related Uncommon Adverse Events in Patients with Cancer Treated with Immunotherapy. <i>Diagnostics</i> , 2022, 12, 2091.	1.3	5
9461	High dose androgen suppresses natural killer cytotoxicity of castration-resistant prostate cancer cells via altering AR/circFKBP5/miRNA-513a-5p/PD-L1 signals. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	7
9462	Homodimerized cytoplasmic domain of PD-L1 regulates its complex glycosylation in living cells. <i>Communications Biology</i> , 2022, 5, .	2.0	7
9463	Safety and efficacy of retreatment with immune checkpoint inhibitors in non-small cell lung cancer: a systematic review and meta-analysis. <i>Translational Lung Cancer Research</i> , 2022, 11, 1555-1566.	1.3	8
9464	Combination high-dose interleukin-2 and nivolumab for programmed cell death-1 refractory metastatic melanoma: a case series. <i>Journal of Medical Case Reports</i> , 2022, 16, .	0.4	1
9465	Cost-Effectiveness of Pembrolizumab for the treatment of Non-“Small-Cell lung cancer: A systematic review. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
9466	CC Chemokine Ligand-2: A Promising Target for Overcoming Anticancer Drug Resistance. <i>Cancers</i> , 2022, 14, 4251.	1.7	4
9467	Prognostic and immune-related value of complement C1Q (C1QA, C1QB, and C1QC) in skin cutaneous melanoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	11
9468	Clinical trial design in the era of precision medicine. <i>Genome Medicine</i> , 2022, 14, .	3.6	68
9469	Disrupting the Interplay between Programmed Cell Death Protein 1 and Programmed Death Ligand 1 with Spherical Nucleic Acids in Treating Cancer. <i>ACS Central Science</i> , 2022, 8, 1299-1305.	5.3	8
9470	The association between acute kidney injury and outcomes in cancer patients receiving immune checkpoint inhibitor therapy: a systematic review and meta-analysis. <i>CKJ: Clinical Kidney Journal</i> , 2023, 16, 817-826.	1.4	5
9471	Tobacco Use and Response to Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer. <i>Current Oncology</i> , 2022, 29, 6260-6276.	0.9	6
9472	A retrospective study for prognostic significance of type II diabetes mellitus and hemoglobin A1c levels in non-small cell lung cancer patients treated with pembrolizumab. <i>Translational Lung Cancer Research</i> , 2022, 11, 1619-1630.	1.3	3
9473	Paving the Way to Solid Tumors: Challenges and Strategies for Adoptively Transferred Transgenic T Cells in the Tumor Microenvironment. <i>Cancers</i> , 2022, 14, 4192.	1.7	6
9474	Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancer. <i>Nature Cancer</i> , 2022, 3, 1151-1164.	5.7	79
9475	MS4A6A is a new prognostic biomarker produced by macrophages in glioma patients. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
9476	Photodynamic therapy of lung cancer, where are we?. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	13

#	ARTICLE	IF	CITATIONS
9477	A robust CD8+ T cell-related classifier for predicting the prognosis and efficacy of immunotherapy in stage III lung adenocarcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
9478	Clinical Strategies Targeting the Tumor Microenvironment of Pancreatic Ductal Adenocarcinoma. <i>Cancers</i> , 2022, 14, 4209.	1.7	9
9479	Anti-PD-1 sintilimab-induced bilateral optic neuropathy in non-small cell lung cancer: A case report and literature review. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
9480	Immunochemotherapy - A Missed Opportunity for Metastasized Malignant Melanoma? Reporting a Therapeutic Success with Checkpoint Inhibitor Rechallenge after Cytotoxic Immuno-Priming in a Heavily Pretreated Patient. <i>Case Reports in Dermatology</i> , 2022, 14, 243-248.	0.3	1
9481	What does radiomics do in <sc>PD-L1</sc> blockade therapy of <sc>NSCLC</sc> patients?. <i>Thoracic Cancer</i> , 2022, 13, 2669-2680.	0.8	2
9482	Urinary T cells are detected in patients with immune checkpoint inhibitor-associated immune nephritis that are clonotypically identical to kidney T cell infiltrates. <i>Oncolimmunology</i> , 2022, 11, .	2.1	4
9483	Efficacy and Safety of Combined Brain Stereotactic Radiotherapy and Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with Brain Metastases. <i>Biomedicines</i> , 2022, 10, 2249.	1.4	3
9484	Dynamic host immunity and PD-L1/PD-1 blockade efficacy: developments after α IFN- β from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. <i>British Journal of Cancer</i> , 2023, 128, 461-467.	2.9	9
9485	Conversion therapy from unresectable stage IIIC non-small-cell lung cancer to radical surgery via anti-PD-1 immunotherapy combined with chemotherapy and anti-angiogenesis: A case report and literature review. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
9486	Wnt2b and Wnt5a expression is highly associated with M2 TAMs in non-small cell lung cancer. <i>Oncology Reports</i> , 2022, 48, .	1.2	6
9487	Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	97
9488	An acetonic extract and secondary metabolites from the endolichenic fungus <i>Nemania</i> sp. ELO06872 exhibit immune checkpoint inhibitory activity in lung cancer cell. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	6
9489	Immune status for monitoring and treatment of bladder cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
9490	Editorial: Beyond chemotherapy and immunotherapy in thoracic malignancies: Overcoming resistance by tackling new molecular pathways. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
9491	Overcoming the cardiac toxicities of cancer therapy immune checkpoint inhibitors. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
9492	Comprehensive analysis of somatic mutator-derived and immune infiltrates related lncRNA signatures of genome instability reveals potential prognostic biomarkers involved in non-small cell lung cancer. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	0
9493	The Crosstalk between Microbiome and Immunotherapeutics: Myth or Reality. <i>Cancers</i> , 2022, 14, 4641.	1.7	1
9494	Recent advances in immune checkpoint inhibitors for non-small lung cancer treatment. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6

#	ARTICLE	IF	CITATIONS
9495	Utility of periodic medical questionnaires and examinations for immune-related adverse event screening: A prospective observational study. <i>PLoS ONE</i> , 2022, 17, e0274451.	1.1	1
9496	Association of Oncologist Participation in Medicare's Oncology Care Model With Patient Receipt of Novel Cancer Therapies. <i>JAMA Network Open</i> , 2022, 5, e2234161.	2.8	0
9497	Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites. , 2022, 10, e004884.		15
9498	Molecular Characteristics and the Effect of KRAS Mutation on the Prognosis of Immunotherapy in Non-Small Cell Lung Cancer in Xinjiang, China. <i>OncoTargets and Therapy</i> , 0, Volume 15, 1021-1032.	1.0	1
9499	Establishing a Novel Gene Signature Related to Histone Modifications for Predicting Prognosis in Lung Adenocarcinoma. <i>Journal of Oncology</i> , 2022, 2022, 1-19.	0.6	0
9500	Positron Emission Tomography Probes for Imaging Cytotoxic Immune Cells. <i>Pharmaceutics</i> , 2022, 14, 2040.	2.0	1
9501	Immune Checkpoint Inhibitor-Induced Myositis/Myocarditis with Myasthenia Gravis-like Misleading Presentation: A Case Series in Intensive Care Unit. <i>Journal of Clinical Medicine</i> , 2022, 11, 5611.	1.0	5
9502	Corneal Transplant Rejections in Patients Receiving Immune Checkpoint Inhibitors. <i>Journal of Clinical Medicine</i> , 2022, 11, 5647.	1.0	3
9503	Transient Systemic Autophagy Inhibition Is Selectively and Irreversibly Deleterious to Lung Cancer. <i>Cancer Research</i> , 2022, 82, 4429-4443.	0.4	10
9504	ELEVATE â€“ evaluating Temozolomide and Nivolumab in patients with advanced unresectable previously treated oesophagogastric adenocarcinoma with MGMT methylation: study protocol for a single arm phase II trial. <i>BMC Cancer</i> , 2022, 22, .	1.1	1
9505	Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: a phase II efficacy and biomarker study. <i>BMC Cancer</i> , 2022, 22, .	1.1	6
9506	Evaluating Antibody Pharmacokinetics as Prerequisite for Determining True Efficacy as Shown by Dual Targeting of PD-1 and CD96. <i>Biomedicines</i> , 2022, 10, 2146.	1.4	0
9507	Understanding the functional inflammatory factors involved in therapeutic response to immune checkpoint inhibitors for pan-cancer. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	4
9508	Boosting the Immune Responseâ€”Combining Local and Immune Therapy for Prostate Cancer Treatment. <i>Cells</i> , 2022, 11, 2793.	1.8	3
9509	Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
9510	Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome. <i>Nature Medicine</i> , 2022, 28, 2344-2352.	15.2	79
9511	Current Landscape of Therapeutic Resistance in Lung Cancer and Promising Strategies to Overcome Resistance. <i>Cancers</i> , 2022, 14, 4562.	1.7	15
9512	The expression pattern of immune-related genes and characterization of tumor immune microenvironment: predicting prognosis and immunotherapeutic effects in cutaneous melanoma. <i>World Journal of Surgical Oncology</i> , 2022, 20, .	0.8	1

#	ARTICLE	IF	CITATIONS
9513	Systemic Sclerosis Association with Malignancy. <i>Clinical Reviews in Allergy and Immunology</i> , 2022, 63, 398-416.	2.9	7
9514	Novel macrophage-related gene prognostic index for glioblastoma associated with M2 macrophages and T cell dysfunction. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
9515	Identification of cervical squamous cell carcinoma feature genes and construction of a prognostic model based on immune-related features. <i>BMC Women's Health</i> , 2022, 22, .	0.8	1
9516	Case report: Pneumonia with clinical symptoms precedes imaging evidence after immune checkpoint inhibitors combined with radiotherapy in lung squamous cell cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
9517	Shorter versus longer corticosteroid duration and recurrent immune checkpoint inhibitor-associated AKI. , 2022, 10, e005646.		12
9518	Regulation of autoimmune disease progression by Pik3ip1 through metabolic reprogramming in T cells and therapeutic implications. <i>Science Advances</i> , 2022, 8, .	4.7	3
9519	Efficacy of immune checkpoint inhibitor as maintenance therapy for advanced or metastatic cancers: A meta-analysis of randomized controlled trials. <i>Medicine (United States)</i> , 2022, 101, e30830.	0.4	0
9520	Steven-Johnson Syndrome: A Rare but Serious Adverse Event of Nivolumab Use in a Patient With Metastatic Gastric Adenocarcinoma. <i>Journal of Medical Cases</i> , 2022, 13, 449-455.	0.4	2
9521	New Insights into SARS-CoV-2 and Cancer Cross-Talk: Does a Novel Oncogenesis Driver Emerge?. <i>Vaccines</i> , 2022, 10, 1607.	2.1	5
9522	A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLC. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100416.	0.6	1
9523	Recent Advances in Glioma Cancer Treatment: Conventional and Epigenetic Realms. <i>Vaccines</i> , 2022, 10, 1448.	2.1	3
9524	Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	20
9525	Pembrolizumab monotherapy for untreated PD-L1-Positive non-small cell lung cancer in the elderly or those with poor performance status: A prospective observational study. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
9526	Intratumoral CD73: An immune checkpoint shaping an inhibitory tumor microenvironment and implicating poor prognosis in Chinese melanoma cohorts. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
9527	Clinical implications of immune checkpoint markers and immune infiltrates in patients with thymic neuroendocrine neoplasms. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
9528	Safety and efficacy of nivolumab compared with other regimens in patients with melanoma: A network meta-analysis. <i>Medicine (United States)</i> , 2022, 101, e29390.	0.4	0
9529	Immune checkpoint inhibitors and their impact on liver enzymes and attenuation. <i>BMC Cancer</i> , 2022, 22, .	1.1	2
9530	Mutated processes predict immune checkpoint inhibitor therapy benefit in metastatic melanoma. <i>Nature Communications</i> , 2022, 13, .	5.8	16

#	ARTICLE	IF	CITATIONS
9531	Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline. <i>European Journal of Endocrinology</i> , 2022, 187, G1-G21.	1.9	35
9532	Restoration of p53 activity via intracellular protein delivery sensitizes triple negative breast cancer to anti-PD-1 immunotherapy. , 2022, 10, e005068.		6
9533	Case report: A persistently expanded T cell response in an exceptional responder to radiation and atezolizumab for metastatic non-small cell lung cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
9534	Thyroid-related adverse events induced by immune checkpoint inhibitors. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	9
9535	The immune landscape of hepatocellular carcinoma—where we are? (Review). <i>Oncology Letters</i> , 2022, 24, .	0.8	6
9536	Stromal Reprogramming by FAK Inhibition Overcomes Radiation Resistance to Allow for Immune Priming and Response to Checkpoint Blockade. <i>Cancer Discovery</i> , 2022, 12, 2774-2799.	7.7	22
9537	Checkpoint Inhibitors Immunotherapy in Metastatic Melanoma: When to Stop Treatment?. <i>Biomedicines</i> , 2022, 10, 2424.	1.4	4
9538	Radiation Recall Pneumonitis: A Rare Syndrome That Should Be Recognized. <i>Cancers</i> , 2022, 14, 4642.	1.7	5
9539	Risk factors and prognostic role of renal adverse event in patients receiving immune checkpoint inhibitor therapy: analysis of data from a retrospective cohort study. <i>Annals of Translational Medicine</i> , 2022, 10, 967-967.	0.7	3
9540	Clinical impact of amrubicin monotherapy in patients with relapsed small cell lung cancer: a multicenter retrospective study. <i>Translational Lung Cancer Research</i> , 2022, 11, 1847-1857.	1.3	1
9541	A single-center analysis of 71 patients with thymic carcinoma: the chronological changes in the surgical procedure and prognosis. <i>Journal of Thoracic Disease</i> , 2022, 14, 3211-3220.	0.6	0
9542	Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC). , 2022, 10, e005413.		6
9543	Immune checkpoint inhibitors for non-small cell lung cancer patients on steroid or non-steroidal anti-inflammatory drugs treatment—therapeutic indication or therapeutic efficacy?. <i>Translational Cancer Research</i> , 2022, 11, 3003-3005.	0.4	0
9544	The therapeutic effect of an autologous and allogenic mixed glioma cell lysate vaccine in a rat model. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	0
9545	A vicious circle in breast cancer: The interplay between inflammation, reactive oxygen species, and microRNAs. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	8
9546	USP14 promotes tryptophan metabolism and immune suppression by stabilizing IDO1 in colorectal cancer. <i>Nature Communications</i> , 2022, 13, .	5.8	30
9547	Pancreatic involvement due to immune checkpoint inhibitors: a proposed classification. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 895-901.	2.0	2
9548	Immune cells and their inflammatory mediators modify β cells and cause checkpoint inhibitor—induced diabetes. <i>JCI Insight</i> , 2022, 7, .	2.3	17

#	ARTICLE	IF	CITATIONS
9549	Serological biomarkers predict immune-related adverse events and clinical benefit in patients with advanced gastrointestinal cancers. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	10
9550	Sex difference in response to non-small cell lung cancer immunotherapy: an updated meta-analysis. <i>Annals of Medicine</i> , 2022, 54, 2605-2615.	1.5	7
9551	Evaluating the Combined Anticancer Response of Checkpoint Inhibitor Immunotherapy and FAP-Targeted Molecular Radiotherapy in Murine Models of Melanoma and Lung Cancer. <i>Cancers</i> , 2022, 14, 4575.	1.7	5
9552	Prostaglandin E ₂ -Induced Immune Suppression via Cytotoxic T-Lymphocyte Antigen 4 in Paratuberculosis. <i>Infection and Immunity</i> , 2022, 90, .	1.0	3
9553	Effectiveness of pembrolizumab in trial-ineligible patients with metastatic urothelial carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 841-849.	2.0	2
9554	Real-world data analysis of pembrolizumab monotherapy for non-small cell lung cancer utilizing Japanese post-marketing all-case surveillance data. <i>JTO Clinical and Research Reports</i> , 2022, , 100404.	0.6	0
9555	Manufacturingâ€dependent change in biological activity of the <scp>TLR4</scp> agonist <scp>GSK1795091</scp> and implications for lipid Aâ€analog development. <i>Clinical and Translational Science</i> , 2022, 15, 2625-2639.	1.5	6
9556	Effects of tumor-infiltrating CD8+ T cells, PD1/PD-L1 axis, and expression patterns of HLA class I on the prognosis of patients with malignant pleural mesothelioma who underwent extra-pleural pneumonectomy. <i>Cancer Immunology, Immunotherapy</i> , 0, , .	2.0	2
9557	Advanced Acral Melanoma Therapies: Current Status and Future Directions. <i>Current Treatment Options in Oncology</i> , 2022, 23, 1405-1427.	1.3	9
9558	Novel Therapies and Strategies to Overcome Resistance to Anti-HER2-Targeted Drugs. <i>Cancers</i> , 2022, 14, 4543.	1.7	9
9559	Therapeutic strategies for post-transplant recurrence of hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2022, 28, 4929-4942.	1.4	5
9560	PD-1 inhibitor therapy causes multisystem immune adverse reactions: a case report and literature review. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
9561	Signature based on RNA-binding protein-related genes for predicting prognosis and guiding therapy in non-small cell lung cancer. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	3
9562	Myocarditis Induced by Immunotherapy in Metastatic Melanomaâ€Review of Literature and Current Guidelines. <i>Journal of Clinical Medicine</i> , 2022, 11, 5182.	1.0	2
9563	Soluble programmed cell death-ligand 1 as a new potential biomarker associated with acute coronary syndrome. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	2
9564	Real-World Outcomes and Treatments Patterns Prior and after the Introduction of First-Line Immunotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer. <i>Cancers</i> , 2022, 14, 4481.	1.7	3
9565	Tipping the scales: Immunotherapeutic strategies that disrupt immunosuppression and promote immune activation. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
9566	Editorial: Tumor microenvironment signaling networks in pathophysiology and therapeutics. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0

#	ARTICLE	IF	CITATIONS
9567	Neurology of cancer immunotherapy. <i>Neurological Sciences</i> , 2023, 44, 137-148.	0.9	3
9568	Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survival. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 2235-2242.	1.2	4
9569	Tobacco carcinogen induces tryptophan metabolism and immune suppression via induction of indoleamine 2,3-dioxygenase 1. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	10
9570	The Interaction of the IFN γ /JAK/STAT1 and JAK/STAT3 Signalling Pathways in EGFR-Mutated Lung Adenocarcinoma Cells. <i>Journal of Oncology</i> , 2022, 2022, 1-16.	0.6	1
9571	Is Melanoma Progression Affected by Thyroid Diseases?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10036.	1.8	3
9572	Does treating with anti-PD-1 to improve glomerular health come without a cost? Reply.. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	2
9573	Combination of Tumor Mutational Burden and DNA Damage Repair Gene Mutations with Stromal/Immune Scores Improved Prognosis Stratification in Patients with Lung Adenocarcinoma. <i>Journal of Oncology</i> , 2022, 2022, 1-12.	0.6	2
9574	Induction immune-checkpoint inhibitors for resectable oncogene-mutant NSCLC: A multicenter pooled analysis. <i>Npj Precision Oncology</i> , 2022, 6, .	2.3	10
9575	Antifungal immunity mediated by C-type lectin receptors may be a novel target in immunotherapy for urothelial bladder cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
9576	Wild-type IDH1 inhibition enhances chemotherapy response in melanoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	6
9577	The efficacy of immune checkpoint inhibitors in advanced EGFR-Mutated non-small cell lung cancer after resistance to EGFR-TKIs: Real-World evidence from a multicenter retrospective study. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
9578	The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	83
9579	V-Set and immunoglobulin domain containing (VSIG) proteins as emerging immune checkpoint targets for cancer immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
9580	Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	11
9581	Long response duration to pembrolizumab in metastatic, castration-resistant prostate cancer with microsatellite instability-high and neuroendocrine differentiation: A case report. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
9582	Phase I/II clinical trial of a helper peptide vaccine plus PD-1 blockade in PD-1 antibody-naïve and PD-1 antibody-experienced patients with melanoma (MEL64)., 2022, 10, e005424.		7
9583	The influence of baseline characteristics on the efficacy of immune checkpoint inhibitors for advanced lung cancer: A systematic review and meta-analysis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
9584	Effect of Cancer Stage on Adverse Kidney Outcomes in Patients Receiving Immune Checkpoint Inhibitors for Melanoma. <i>Kidney International Reports</i> , 2022, 7, 2517-2521.	0.4	2

#	ARTICLE	IF	CITATIONS
9585	On-Target Side Effects of Targeted Therapeutics of Cancer. <i>Pathology and Oncology Research</i> , 0, 28, .	0.9	9
9586	Sphingosine kinase 1 promotes tumor immune evasion by regulating the MTA3-PD-L1 axis. , 2022, 19, 1153-1167.		6
9587	Neoadjuvant Radiation Therapy and Surgery Improves Metastasis-Free Survival over Surgery Alone in a Primary Mouse Model of Soft Tissue Sarcoma. <i>Molecular Cancer Therapeutics</i> , 2023, 22, 112-122.	1.9	3
9588	Immune Checkpoint Inhibitor-Induced Hepatic Injury: A Clinicopathologic Review. , 2022, 000, 000-000.		1
9589	A Bayesian phase I/scp>II</scp> design to determine <scp>subgroupâ€specific</scp> optimal dose for immunotherapy sequentially combined with radiotherapy. <i>Pharmaceutical Statistics</i> , 2023, 22, 143-161.	0.7	2
9590	The DPY30-H3K4me3 Axis-Mediated PD-L1 Expression in Melanoma. <i>Journal of Inflammation Research</i> , 0, Volume 15, 5595-5609.	1.6	1
9591	Construction of a nomogram to predict the survival of metastatic gastric cancer patients that received immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
9592	Mass Cytometry Reveals Classical Monocytes, NK Cells, and ICOS+ CD4+ T Cells Associated with Pembrolizumab Efficacy in Patients with Lung Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 5136-5148.	3.2	8
9593	Potassium channel-related genes are a novel prognostic signature for the tumor microenvironment of renal clear cell carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
9594	Carotenoids from Marine Microalgae as Antimelanoma Agents. <i>Marine Drugs</i> , 2022, 20, 618.	2.2	4
9595	High Quality Performance of Novel Immunoassays for the Sensitive Quantification of Soluble PD-1, PD-L1 and PD-L2 in Blood. <i>Biomedicines</i> , 2022, 10, 2405.	1.4	5
9596	Telomere-Associated Changes in Nuclear Architecture of Cancer-Associated Macrophage-like Cells in Liquid Biopsies from Melanoma Patients. <i>Biomedicines</i> , 2022, 10, 2391.	1.4	0
9597	Evaluating the role of IDO1 macrophages in immunotherapy using scRNA-seq and bulk-seq in colorectal cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
9598	Programmed Death-Ligand 1 Expression in Lung Cancer and Paired Brain Metastasesâ€”a Single-Center Study in 190 Patients. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100413.	0.6	1
9599	Immunochemotherapy includes pembrolizumab for stage IIIB lung squamous cell carcinoma: a case report. <i>Annals of Translational Medicine</i> , 2022, 10, 1028-1028.	0.7	1
9600	Distinct pretreatment innate immune landscape and posttreatment T cell responses underlie immunotherapy-induced colitis. <i>JCI Insight</i> , 2022, 7, .	2.3	7
9601	An immunogold single extracellular vesicular RNA and protein (^{Au}SERP) biochip to predict responses to immunotherapy in nonâ€small cell lung cancer patients. <i>Journal of Extracellular Vesicles</i> , 2022, 11, .	5.5	16
9602	Regulation Networks of Non-Coding RNA-Associated ceRNAs in Cisplatin-Induced Acute Kidney Injury. <i>Cells</i> , 2022, 11, 2971.	1.8	2

#	ARTICLE	IF	CITATIONS
9603	Pancreatic injury following immune checkpoint inhibitors: A systematic review and meta-analysis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	5
9604	NAD/NAMPT and mTOR Pathways in Melanoma: Drivers of Drug Resistance and Prospective Therapeutic Targets. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9985.	1.8	11
9605	Identification of macrophage correlated biomarkers to predict the prognosis in patients with intrahepatic cholangiocarcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
9606	Central nervous systemic efficacy of immune checkpoint inhibitors and concordance between intra/extracranial response in non-small cell lung cancer patients with brain metastasis. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	1
9607	Investigation of the efficacy and safety of cryoablation and intra-arterial PD-1 inhibitor in patients with advanced disease not responding to checkpoint inhibitors: An exploratory study. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
9608	The predictive value of total-body PET/CT in non-small cell lung cancer for the PD-L1 high expression. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
9609	Diagnosis and management of immune checkpoint inhibitor-associated acute kidney injury. <i>Nature Reviews Nephrology</i> , 2022, 18, 794-805.	4.1	20
9610	Cytokines as an important player in the context of CAR-T cell therapy for cancer: Their role in tumor immunomodulation, manufacture, and clinical implications. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	12
9611	TNFR2 antagonist and agonist: a potential therapeutics in cancer immunotherapy. , 2022, 39, .		3
9612	Neoantigens and their clinical applications in human gastrointestinal cancers. <i>World Journal of Surgical Oncology</i> , 2022, 20, .	0.8	1
9613	Plasma-Based microRNA Expression Analysis in Advanced Stage NSCLC Patients Treated with Nivolumab. <i>Cancers</i> , 2022, 14, 4739.	1.7	8
9614	Circulating CD81-expressing extracellular vesicles as biomarkers of response for immune-checkpoint inhibitors in advanced NSCLC. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
9615	Anti-“PD”1 immune checkpoint inhibitor inducing endocrine toxicity in a patient with advanced lung cancer: A case report and literature review. <i>Experimental and Therapeutic Medicine</i> , 2022, 24, .	0.8	3
9616	Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915). <i>Journal of Clinical Oncology</i> , 2023, 41, 517-527.	0.8	59
9617	Hospitalized cancer patients with comorbidities and low lymphocyte counts had poor clinical outcomes to immune checkpoint inhibitors. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
9618	Immunomodulatory effects of regorafenib: Enhancing the efficacy of anti-PD-1/PD-L1 therapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
9619	Definition of a new blood cell count score for early survival prediction for non-small cell lung cancer patients treated with atezolizumab: Integrated analysis of four multicenter clinical trials. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
9620	A change of PD-1/PD-L1 expression on peripheral T cell subsets correlates with the different stages of Alzheimer's Disease. <i>Cell and Bioscience</i> , 2022, 12, .	2.1	6

#	ARTICLE	IF	CITATIONS
9621	Treatment of Brain Metastases: The Synergy of Radiotherapy and Immune Checkpoint Inhibitors. <i>Biomedicines</i> , 2022, 10, 2211.	1.4	2
9622	Emerging Trends in Immunotherapy for Cancer. <i>Diseases (Basel, Switzerland)</i> , 2022, 10, 60.	1.0	17
9623	Harnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
9624	Quantitative Spatial Profiling of TILs as the Next Step beyond PD-L1 Testing for Immune Checkpoint Blockade. <i>Clinical Cancer Research</i> , 2022, 28, 4835-4837.	3.2	3
9625	Hepcidin is upregulated and is a potential therapeutic target associated with immunity in glioma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
9626	Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial. <i>Lancet, The</i> , 2022, 400, 1008-1019.	6.3	48
9627	Exploiting the Innate Plasticity of the Programmed Cell Death-1 (PD1) Receptor to Design Pembrolizumab H3 Loop Mimics**. <i>ChemBioChem</i> , 2022, 23, .	1.3	4
9628	Impact of gender on response to immune checkpoint inhibitors in patients with non-small cell lung cancer undergoing second- or later-line treatment. <i>Translational Lung Cancer Research</i> , 2022, 11, 1866-1876.	1.3	1
9629	Identification of Immuno-Targeted Combination Therapies Using Explanatory Subgroup Discovery for Cancer Patients with EGFR Wild-Type Gene. <i>Cancers</i> , 2022, 14, 4759.	1.7	1
9630	Intratumoral administration of CD1c (BDCA-1) and CD141 (BDCA-3) myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients: a phase I clinical trial. , 2022, 10, e005141.		11
9631	Impact of treatment line on risks and benefits of immune checkpoint inhibitor in patients with advanced non-small cell lung cancer and interstitial lung disease: a systematic review and meta-analysis of cohort studies. <i>Translational Lung Cancer Research</i> , 2022, 11, 1835-1846.	1.3	2
9632	Dysregulation of SNHG16(lncRNA)-Hsa-Let-7b-5p(miRNA)-TUBB4A (mRNA) Pathway Fuels Progression of Skin Cutaneous Melanoma. <i>Current Protein and Peptide Science</i> , 2022, 23, 791-809.	0.7	4
9633	Tumor immune microenvironment and systemic response in breast cancer. , 2022, 39, .		6
9634	Is immunotherapy at reduced dose and radiotherapy for older patients with locally advanced non-small lung cancer feasible?â€”a narrative review by the international geriatric radiotherapy group. <i>Translational Cancer Research</i> , 2022, 11, 3298-3308.	0.4	2
9635	Protocol of the TREASURE study: Thoracic Radiotherapy with Atezolizumab in Small cell Lung cancer Extensive disease â€” a randomized, open-label, multicenter phase II trial. <i>BMC Cancer</i> , 2022, 22, .	1.1	7
9636	Dynamic monitoring of PD-L1 and Ki67 in circulating tumor cells of metastatic non-small cell lung cancer patients treated with pembrolizumab. <i>Molecular Oncology</i> , 2023, 17, 792-809.	2.1	8
9637	A Therapy-Terminating Event: Programmed Death-1 Inhibitor-Induced Mucositis. <i>Cureus</i> , 2022, , .	0.2	0
9638	Protein Profiling of Breast Carcinomas Reveals Expression of Immune-Suppressive Factors and Signatures Relevant for Patient Outcome. <i>Cancers</i> , 2022, 14, 4542.	1.7	0

#	ARTICLE	IF	CITATIONS
9639	Indirect Clinical Validation of a Programmed Death-Ligand 1 Laboratory-Developed Test for Gastric/Gastroesophageal Junction Adenocarcinoma with 22C3 Antibody Concentrate. <i>Molecular Diagnosis and Therapy</i> , 2022, 26, 679-688.	1.6	3
9640	Clinical significance for diagnosis and prognosis of POP1 and its potential role in breast cancer: a comprehensive analysis based on multiple databases. <i>Aging</i> , 2022, 14, 6936-6956.	1.4	3
9641	First-in-human study of ONO4578, an antagonist of prostaglandin E_2 receptor 4, alone and with nivolumab in solid tumors. <i>Cancer Science</i> , 2023, 114, 211-220.	1.7	4
9642	Extracellular vesicle-based checkpoint regulation and immune state in cancer. , 2022, 39, .		10
9643	Efficacy of bivalent CEACAM6/4-1BBL genetic vaccine combined with anti-PD1 antibody in MC38 tumor model of mice. <i>Heliyon</i> , 2022, 8, e10775.	1.4	0
9644	MiR-223-3p attenuates the migration and invasion of NSCLC cells by regulating NLRP3. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
9645	Nanocarriers for cancer nano-immunotherapy. <i>Drug Delivery and Translational Research</i> , 2023, 13, 1936-1954.	3.0	17
9646	Overview and clinical significance of multiple mutations in individual genes in hepatocellular carcinoma. <i>BMC Cancer</i> , 2022, 22, .	1.1	2
9647	Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	33
9648	Monoclonal antibodies in cervical malignancy-related HPV. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	7
9649	Bibliometric analysis of research on immunogenic cell death in cancer. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	6
9650	Development of OX40 agonists for canine cancer immunotherapy. <i>IScience</i> , 2022, 25, 105158.	1.9	3
9651	MTAP deficiency contributes to immune landscape remodeling and tumor evasion. <i>Immunology</i> , 0, , .	2.0	1
9652	The role of immune checkpoints in cardiovascular disease. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	10
9653	Delta radiomics model for the prediction of progression-free survival time in advanced non-small-cell lung cancer patients after immunotherapy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	9
9654	The immune system in multiple myeloma and precursor states: Lessons and implications for immunotherapy and interception. <i>American Journal of Hematology</i> , 2023, 98, .	2.0	10
9655	Comparison of next-generation sequencing and cobas EGFR mutation test v2 in detecting EGFR mutations. <i>Thoracic Cancer</i> , 2022, 13, 3217-3224.	0.8	6
9656	<i>Bifidobacterium breve</i> predicts the efficacy of anti-PD1 immunotherapy combined with chemotherapy in Chinese NSCLC patients. <i>Cancer Medicine</i> , 2023, 12, 6325-6336.	1.3	10

#	ARTICLE	IF	CITATIONS
9657	Immune checkpoint inhibitors as mediators for immunosuppression by cancer-associated fibroblasts: A comprehensive review. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	11
9658	Case report: A successful re-challenge report of GLS-010 (Zimberelimab), a novel fully humanized mAb to PD-1, in a case of recurrent endometrial cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
9659	Toripalimab Plus Chemotherapy for Patients With Treatment-Naïve Advanced Non-“Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01). <i>Journal of Clinical Oncology</i> , 2023, 41, 651-663.	0.8	45
9660	Anlotinib Benefits the ±PDL1 Immunotherapy by Activating ROS/JNK/AP-1 Pathway to Upregulate PDL1 Expression in Colorectal Cancer. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-18.	1.9	3
9661	Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases. <i>Nature Reviews Rheumatology</i> , 2022, 18, 641-656.	3.5	37
9662	Pulsed radiotherapy to mitigate high tumor burden and generate immune memory. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
9663	Optimizing the dose and schedule of immune checkpoint inhibitors in cancer to allow global access. <i>Nature Medicine</i> , 2022, 28, 2236-2237.	15.2	24
9664	TIMM8A is associated with dysfunction of immune cell in BRCA and UCEC for predicting anti-PD-L1 therapy efficacy. <i>World Journal of Surgical Oncology</i> , 2022, 20, .	0.8	2
9665	From simplicity to complexity in current melanoma models. <i>Experimental Dermatology</i> , 2022, 31, 1818-1836.	1.4	3
9666	Demonstration of the Antitumor Activity of the iNKT Agonist ABX196, a Novel Enhancer of Cancer Immunotherapy, in Melanoma and Hepatocarcinoma Mouse Models. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 1788-1797.	1.9	0
9667	The Programmed Death-1 Signaling Axis Modulates Inflammation and LV Structure/Function in a Stress-Induced Cardiomyopathy Model. <i>JACC Basic To Translational Science</i> , 2022, 7, 1120-1139.	1.9	8
9668	Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	7
9669	Ferroptosis regulator FANCD2 is associated with immune infiltration and predicts worse prognosis in lung adenocarcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	5
9670	Prognostic value of cuproptosis-related genes signature and its impact on the reshaped immune microenvironment of glioma. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	2
9671	PD-1/PD-L1 combined with LAG3 is associated with clinical activity of immune checkpoint inhibitors in metastatic primary pulmonary lymphoepithelioma-like carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
9672	Onco-biome in pharmacotherapy for lung cancer: a narrative review. <i>Translational Lung Cancer Research</i> , 2022, 11, 2332-2345.	1.3	1
9673	Association of thyroid transcription factor-1 (TTF-1) expression with efficacy of PD-1/PD-L1 inhibitors plus pemetrexed and platinum chemotherapy in advanced non-squamous non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2022, 11, 2208-2215.	1.3	5
9674	Clinical implications of the interaction between PD-1/PD-L1 and PI3K/AKT/mTOR pathway in progression and treatment of non-small cell lung cancer. <i>Journal of Cancer</i> , 2022, 13, 3434-3443.	1.2	16

#	ARTICLE	IF	CITATIONS
9675	Systemic adjuvant therapy for high-risk cutaneous melanoma. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211340.	1.4	7
9676	NMR-Based Metabolomics to Evaluate Individual Response to Treatments. <i>Handbook of Experimental Pharmacology</i> , 2022, , 209-245.	0.9	4
9677	Real-world treatment patterns and outcomes among patients with advanced non-small-cell lung cancer with spindle cell and/or giant cell carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211338.	1.4	1
9678	Diabetes induced by checkpoint inhibition in nonobeseÂdiabetic mice can be prevented or reversed by a <sc>JAK1</sc>/<sc>JAK2</sc> inhibitor. <i>Clinical and Translational Immunology</i> , 2022, 11, .	1.7	6
9679	AKT Isoforms in the Immune Response in Cancer. <i>Current Topics in Microbiology and Immunology</i> , 2022, , 349-366.	0.7	0
9680	A case of crescentic glomerulonephritis and acute tubulointerstitial nephritis requiring temporary hemodialysis during nivolumab treatment for renal cell carcinoma. <i>Nihon Toseki Igakkai Zasshi</i> , 2022, 55, 595-601.	0.2	0
9681	Epitope Mapping of Therapeutic Antibodies Targeting Human LAG3. <i>Journal of Immunology</i> , 2022, 209, 1586-1594.	0.4	4
9682	Differences and Similarities in the Pattern of Early Metabolic and Morphologic Response after Induction Chemo-Immunotherapy versus Induction Chemotherapy Alone in Locally Advanced Squamous Cell Head and Neck Cancer. <i>Cancers</i> , 2022, 14, 4811.	1.7	1
9683	Advances in sex disparities for cancer immunotherapy: unveiling the dilemma of Yin and Yang. <i>Biology of Sex Differences</i> , 2022, 13, .	1.8	9
9684	Early Effects of Nivolumab and Ipilimumab Combined Immunotherapy in the Treatment of Metastatic Melanoma in Poland: A Multicenter Experience. <i>Biomedicines</i> , 2022, 10, 2528.	1.4	2
9685	Bioengineering and computational analysis of programmed cell death ligand-1 monoclonal antibody. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
9686	The Roles of RUNX Proteins in Lymphocyte Function and Anti-Tumor Immunity. <i>Cells</i> , 2022, 11, 3116.	1.8	1
9687	Nivolumabâ€induced radiation recall pneumonitis in nonâ€small cell lung cancer patients with thoracic radiation therapy. <i>Cancer Science</i> , 0, , .	1.7	3
9688	An exploration of <sc>LAFâ€bTMB</sc> as a predictor for the efficacy of immunotherapy combined with chemotherapy in <sc>nonâ€small cell lung cancer</sc>. <i>Thoracic Cancer</i> , 0, , .	0.8	1
9689	Myasthenia Gravis in the Setting of Immune Checkpoint Inhibitor Therapy: Practical Considerations and Opinion-Based Approach to Acute Management. <i>Cureus</i> , 2022, , .	0.2	1
9690	Immune checkpoints inhibitors and its link to acute kidney injury and renal prognosis. <i>International Urology and Nephrology</i> , 2023, 55, 1025-1032.	0.6	3
9691	The gut microbiota modulates responses to antiâ€PD-1 and chemotherapy combination therapy and related adverse events in patients with advanced solid tumors. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
9692	Current status of immunotherapy for non-small cell lung cancer. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	11

#	ARTICLE	IF	CITATIONS
9693	Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	35
9694	The Role of Chemotherapy Plus Immune Checkpoint Inhibitors in Oncogenic-Driven NSCLC: A University of California Lung Cancer Consortium Retrospective Study. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100427.	0.6	3
9695	Health Care Utilization and Costs in Systemic Therapies for Metastatic Melanoma from 2016 to 2020. <i>Oncologist</i> , 0, , .	1.9	1
9696	Impact of Bone Metastases on Patients with Renal Cell Carcinoma or Melanoma Treated with Combotherapy Ipilimumab Plus Nivolumab. <i>Biomedicines</i> , 2022, 10, 2758.	1.4	4
9697	Decreased Tertiary Lymphoid Structures in Lung Adenocarcinomas with ALK Rearrangements. <i>Journal of Clinical Medicine</i> , 2022, 11, 5935.	1.0	1
9698	Is There a Role for Exercise When Treating Patients with Cancer with Immune Checkpoint Inhibitors? A Scoping Review. <i>Cancers</i> , 2022, 14, 5039.	1.7	4
9699	NLRP1 in Cutaneous SCCs: An Example of the Complex Roles of Inflammasomes in Cancer Development. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12308.	1.8	2
9700	A Metabolism-Related Gene Prognostic Index for Prediction of Response to Immunotherapy in Lung Adenocarcinoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12143.	1.8	2
9701	Pathologic Predictors of Response to Treatment of Immune Checkpoint Inhibitorâ€“Induced Kidney Injury. <i>Cancers</i> , 2022, 14, 5267.	1.7	2
9702	Trends in immune-related adverse events for colorectal cancer: A bibliometric analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
9703	Preclinical models of radiation-induced cardiac toxicity: Potential mechanisms and biomarkers. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
9704	Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma. <i>JHEP Reports</i> , 2023, 5, 100620.	2.6	13
9705	Tripartite antigen-agnostic combination immunotherapy cures established poorly immunogenic tumors. , 2022, 10, e004781.		2
9706	Immune-infiltrating signature-based classification reveals CD103+CD39+ T cells associate with colorectal cancer prognosis and response to immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
9707	ARID1A deficiency reverses the response to anti-PD(L)1 therapy in EGFR-mutant lung adenocarcinoma by enhancing autophagy-inhibited type I interferon production. <i>Cell Communication and Signaling</i> , 2022, 20, .	2.7	4
9708	Influence of chemoradiation on the immune microenvironment of cervical cancer patients. <i>Strahlentherapie Und Onkologie</i> , 2023, 199, 121-130.	1.0	7
9709	Predictive Risk Factors Associated with Severe Radiation-Induced Mucositis in Nasopharyngeal or Oropharyngeal Cancer Patients: A Retrospective Study. <i>Biomedicines</i> , 2022, 10, 2661.	1.4	5
9710	Targeting FGL2 in glioma immunosuppression and malignant progression. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2

#	ARTICLE	IF	CITATIONS
9711	Case Report: Anlotinib combined with PD-1 inhibitor and sequential GA regimen or FOLFIRINOX Chemotherapy in treatment of KRAS G12V mutated pancreatic ductal adenocarcinoma with liver metastasis: A case and literature review. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
9712	CXCR5+CD8 T cells: Potential immunotherapy targets or drivers of immune-mediated adverse events?. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	4
9713	Effects of microenvironment in osteosarcoma on chemoresistance and the promise of immunotherapy as an osteosarcoma therapeutic modality. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	11
9714	Incidence and factors associated with cutaneous immune-related adverse events to immune check point inhibitors: An ambispective cohort study. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
9715	Prognostic value of hematologic parameters in advanced non-small cell lung cancer patients receiving anti-PD-1 inhibitors. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
9716	Clinical determinants impacting overall survival of patients with operable brain metastases from non-small cell lung cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
9717	Liver metastases and the efficacy of immune checkpoint inhibitors in advanced lung cancer: A systematic review and meta-analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	7
9718	Development of a salivary autoantibody biomarker panel for diagnosis of oral cavity squamous cell carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
9719	Targeting breast and pancreatic cancer metastasis using a dual-cadherin antibody. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	6
9720	A cutting-edge immunomodulatory interlinkage between HOTAIR and MALAT1 in tumor-associated macrophages in breast cancer: A personalized immunotherapeutic approach. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	7
9721	Clinical utility of liquid biopsy-based companion diagnostics in the non-small-cell lung cancer treatment. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , 630-642.	0.5	7
9722	Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	59
9723	lncRNAs AC156455.1 and AC104532.2 as Biomarkers for Diagnosis and Prognosis in Colorectal Cancer. <i>Disease Markers</i> , 2022, 2022, 1-13.	0.6	2
9724	Cutaneous Melanoma versus Vulvovaginal Melanoma – Risk Factors, Pathogenesis and Comparison of Immunotherapy Efficacy. <i>Cancers</i> , 2022, 14, 5123.	1.7	7
9725	Immunotherapy in Non-Small-Cell Lung Cancer Patients with Driver Alterations: A New Strategy?. <i>Cells</i> , 2022, 11, 3280.	1.8	6
9726	Targeted Cancer Immunotherapy: Nanoformulation Engineering and Clinical Translation. <i>Advanced Science</i> , 2022, 9, .	5.6	20
9727	Modified hollow mesoporous silica nanoparticles as immune adjuvant-nanocarriers for photodynamically enhanced cancer immunotherapy. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	2
9728	HTLV-1 persistence and leukemogenesis: A game of hide-and-seek with the host immune system. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3

#	ARTICLE	IF	CITATIONS
9729	Potential new applications of immunotherapy for neuroendocrine neoplasms: immune landscape, current status and future perspectives. <i>Cancer Biology and Medicine</i> , 0, , 1-13.	1.4	0
9730	Checkpoint Inhibitors in Cancer Therapy: Clinical Benefits for Head and Neck Cancers. <i>Cancers</i> , 2022, 14, 4985.	1.7	5
9731	Immune Checkpoint Inhibitors and RAS-ERK Pathway-Targeted Drugs as Combined Therapy for the Treatment of Melanoma. <i>Biomolecules</i> , 2022, 12, 1562.	1.8	5
9732	Metastatic pancreatic neuroendocrine tumors feature elevated T cell infiltration. <i>JCI Insight</i> , 2022, 7, .	2.3	2
9733	The impact of herbal medicine in regulating intestinal flora on female reproductive disorders. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	1
9734	Immunosenescence is a therapeutic target for frailty in older adults: a narrative review. <i>Annals of Translational Medicine</i> , 2022, 10, 1142-1142.	0.7	3
9735	Lymphocytic Hypophysitis in a Patient With Suspected Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH). <i>Cureus</i> , 2022, , .	0.2	0
9736	Prognostic and clinicopathological significance of CD155 expression in cancer patients: a meta-analysis. <i>World Journal of Surgical Oncology</i> , 2022, 20, .	0.8	4
9737	Peripheral blood markers predict immunotherapeutic efficacy in patients with advanced non-small cell lung cancer: A multicenter study. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1
9738	Chimeric immune checkpoint protein vaccines inhibit the tumorigenesis and growth of rat cholangiocarcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
9739	Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13241.	1.8	9
9740	Review on Advanced Cancer Modeling for a Cancer Study. <i>Current Issues in Molecular Biology</i> , 2022, 44, 5352-5362.	1.0	0
9741	Prognostic Value of Bone Marrow Uptake Using 18F-FDG PET/CT Scans in Solid Neoplasms. <i>Journal of Imaging</i> , 2022, 8, 297.	1.7	0
9742	Efficacy of PD-1/PD-L1 inhibitors in patients with advanced gastroesophageal cancer: An updated meta-analysis based on randomized controlled trials. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
9743	Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor. <i>Thoracic Cancer</i> , 2022, 13, 3420-3430.	0.8	5
9744	Reprogramming of myeloid cells and their progenitors in patients with non-medullary thyroid carcinoma. <i>Nature Communications</i> , 2022, 13, .	5.8	4
9745	PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way. , 2022, 10, e004590.		12
9746	Clinical cancer immunotherapy: Current progress and prospects. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	39

#	ARTICLE	IF	CITATIONS
9747	Meta-analysis of the efficacy and safety of sintilimab for treating advanced non-small cell lung cancer. <i>Oncology Letters</i> , 2022, 24, .	0.8	0
9748	Biomarker-Targeted Therapies in Non-Small Cell Lung Cancer: Current Status and Perspectives. <i>Cells</i> , 2022, 11, 3200.	1.8	15
9749	The intracellular cation channel TMEM176B as a dual immunoregulator. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	2
9750	Efficacy and safety of anti-PD-1/PD-L1 therapy in the treatment of advanced colorectal cancer: a meta-analysis. <i>BMC Gastroenterology</i> , 2022, 22, .	0.8	12
9751	Phase I/II study of nedaplatin and nab-paclitaxel for patients with previously untreated advanced squamous cell lung cancer: Kanto Respiratory Disease Study Group (KRSG) 1302. <i>International Journal of Clinical Oncology</i> , 0, , .	1.0	0
9752	The PD-1/PD-L1 Pathway: A Perspective on Comparative Immuno-Oncology. <i>Animals</i> , 2022, 12, 2661.	1.0	2
9753	Nintedanib plus docetaxel after progression on first-line immunochemotherapy in patients with lung adenocarcinoma: Cohort C of the non-interventional study, VARGADO. <i>Translational Lung Cancer Research</i> , 2022, 11, 2010-2021.	1.3	6
9754	Imaging features of immune checkpoint inhibitor-related nephritis with clinical correlation: a retrospective series of biopsy-proven cases. <i>European Radiology</i> , 2023, 33, 2227-2238.	2.3	2
9755	Immune checkpoint inhibitor-mediated colitis is associated with cancer overall survival. <i>World Journal of Gastroenterology</i> , 0, 28, 5750-5763.	1.4	1
9756	Prognostic value of plasma D-dimer levels in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: a retrospective study. <i>Journal of Thoracic Disease</i> , 2022, 14, 4125-4135.	0.6	3
9757	Immune checkpoint inhibitors in osteosarcoma: A hopeful and challenging future. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	11
9758	Knowledge mapping and current trends of immunotherapy for prostate cancer: A bibliometric study. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	10
9759	Clinical implications of T cell exhaustion for cancer immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 775-790.	12.5	182
9760	Interaction between gut microbiota and immune checkpoint inhibitor-related colitis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
9761	Macrophage Reprogramming with Anti-miR223-Loaded Artificial Protocells Enhances In Vivo Cancer Therapeutic Potential. <i>Advanced Science</i> , 2022, 9, .	5.6	2
9762	Nanotherapeutics Plus Immunotherapy in Oncology: Who Brings What to the Table?. <i>Pharmaceutics</i> , 2022, 14, 2326.	2.0	2
9763	The Lung Microbiota and Lung Cancer: A Growing Relationship. <i>Cancers</i> , 2022, 14, 4813.	1.7	6
9764	The emerging role of pyroptosis in pediatric cancers: from mechanism to therapy. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	13

#	ARTICLE	IF	CITATIONS
9765	The Role of Genomics and Proteomics in Lung Cancer Early Detection and Treatment. <i>Cancers</i> , 2022, 14, 5144.	1.7	8
9766	Immunophenotyping of pulmonary sarcomatoid carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
9767	Peripheral absolute eosinophil count identifies the risk of serious immune-related adverse events in non-small cell lung cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
9768	Anlotinib Hydrochloride and PD-1 Blockade as a Salvage Second-Line Treatment in Patients with Progress of Local Advanced Non-Small Cell Lung Cancer in Half a Year After Standard Treatment. <i>OncoTargets and Therapy</i> , 0, Volume 15, 1221-1228.	1.0	4
9769	Clinical and Molecular Features of KRAS-Mutated Lung Cancer Patients Treated with Immune Checkpoint Inhibitors. <i>Cancers</i> , 2022, 14, 4933.	1.7	5
9770	Changes in the Immune Cell Repertoire for the Treatment of Malignant Melanoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12991.	1.8	3
9771	Immune checkpoint inhibitor related nephrotoxicity: Advances in clinicopathologic features, noninvasive approaches, and therapeutic strategy and rechallenge. , 0, 2, .		2
9772	Genomic landscape of the immunogenicity regulation in skin melanomas with diverse tumor mutation burden. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
9773	Immunotherapy and Modern Radiotherapy Technique for Older Patients with Locally Advanced Head and Neck Cancer: A Proposed Paradigm by the International Geriatric Radiotherapy Group. <i>Cancers</i> , 2022, 14, 5285.	1.7	2
9774	The efficacy and safety of immune checkpoint inhibitors combined with chemotherapy or anti-angiogenic therapy as a second-line or later treatment option for advanced non-small cell lung cancer: a retrospective comparative cohort study. <i>Translational Lung Cancer Research</i> , 2022, 11, 2111-2124.	1.3	2
9775	Enhanced antitumor immune responses via a new agent [131I]-labeled dual-target immunosuppressant. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2023, 50, 275-286.	3.3	6
9776	Clinical predictors of treatment efficacy and a prognostic nomogram in patients with lung adenocarcinoma receiving immune checkpoint inhibitors: a retrospective study. <i>Journal of Thoracic Disease</i> , 2022, 14, 4096-4112.	0.6	2
9777	Effectiveness of immunological agents in non-small cell lung cancer. <i>Cancer Reports</i> , 2023, 6, .	0.6	3
9778	More than one-third of advanced non-small-cell lung cancer patients do not receive immunochemotherapy due to intolerance. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 4933-4938.	1.2	1
9779	Trends in Melanoma Phase 3 Clinical Trials since 2010: Is there Hope for Advanced Melanoma Therapies beyond Approved Treatment Mechanisms?. <i>Cancers</i> , 2022, 14, 5184.	1.7	7
9780	Observational study to predict the efficacy and optimal duration of nivolumab treatment in patients with previously treated advanced or recurrent non-small cell lung cancer. <i>Japanese Journal of Clinical Oncology</i> , 0, , .	0.6	1
9781	Light at the end of the tunnel: Clinical features and therapeutic prospects of KRAS mutant subtypes in non-small-cell lung cancer. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	4
9782	PD-1-mAb Plus Regimen in the First and Second Lines of Advanced and Unresectable Biliary Tract Carcinoma: A Real-World, Multicenter Retrospective Analysis. <i>Journal of Inflammation Research</i> , 0, Volume 15, 6031-6046.	1.6	0

#	ARTICLE	IF	CITATIONS
9783	Limitations of Immunotherapy in Cancer. <i>Cureus</i> , 2022, , .	0.2	2
9784	Editorial: Improvement of melanoma immune checkpoint blockade therapy with potential combinatorial regimens. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
9785	Rs10204525 Polymorphism of the Programmed Death (PD-1) Gene Is Associated with Increased Risk in a Saudi Arabian Population with Colorectal Cancer. <i>Medicina (Lithuania)</i> , 2022, 58, 1439.	0.8	2
9786	KRAS mutation predict response and outcome in advanced non-small cell lung carcinoma without driver alterations receiving PD-1 blockade immunotherapy combined with platinum-based chemotherapy: a retrospective cohort study from China. <i>Translational Lung Cancer Research</i> , 2022, 11, 2136-2147.	1.3	4
9787	Tumor microenvironment shows an immunological abscopal effect in patients with NSCLC treated with pembrolizumab-radiotherapy combination. , 2022, 10, e005248.		8
9788	Hazard Function Analysis of Recurrence in Patients with Curatively Resected Lung Cancer: Results from the Japanese Lung Cancer Registry in 2010. <i>Cancers</i> , 2022, 14, 5119.	1.7	0
9789	Molecular subtypes based on cuproptosis-related genes and immune profiles in lung adenocarcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	3
9790	Intratumoral Treatment with 5-Androstene-3Î², 17Î±-Diol Reduces Tumor Size and Lung Metastasis in a Triple-Negative Experimental Model of Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11944.	1.8	0
9791	Tumor Organoids as a Research Tool: How to Exploit Them. <i>Cells</i> , 2022, 11, 3440.	1.8	4
9792	Exploring Gut Microbiome in Predicting the Efficacy of Immunotherapy in Non-Small Cell Lung Cancer. <i>Cancers</i> , 2022, 14, 5401.	1.7	7
9793	Tbc1d10c is a selective, constitutive suppressor of the CD8 T-cell anti-tumor response. <i>Oncolmmunology</i> , 2022, 11, .	2.1	3
9794	Selection of a <sc>PD</sc>-blocking antibody from a novel fully human phage display library. <i>Protein Science</i> , 2022, 31, .	3.1	7
9795	Immune Checkpoint Inhibitors Related to Cardiotoxicity. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 378.	0.8	3
9796	Virtual clinical trials of anti-PD-1 and anti-CTLA-4 immunotherapy in advanced hepatocellular carcinoma using a quantitative systems pharmacology model. , 2022, 10, e005414.		18
9797	A promising research direction for colorectal cancer immunotherapy: The regulatory mechanism of CCL5 in colorectal cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
9798	Genopathomic profiling identifies signatures for immunotherapy response of lung adenocarcinoma via confounder-aware representation learning. <i>IScience</i> , 2022, 25, 105382.	1.9	0
9799	Complete response to nivolumab in Kirsten rat sarcoma virus oncogene KRAS-G12C mutant metastatic lung adenocarcinoma: a case report. <i>Journal of Medical Case Reports</i> , 2022, 16, .	0.4	1
9800	Leverage biomaterials to modulate immunity for type 1 diabetes. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1

#	ARTICLE	IF	CITATIONS
9801	Hormonal therapies up-regulate MANF and overcome female susceptibility to immune checkpoint inhibitor myocarditis. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	13
9802	Prognosis prediction and tumor immune microenvironment characterization based on tryptophan metabolism-related genes signature in brain glioma. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
9803	BTN3A: A Promising Immune Checkpoint for Cancer Prognosis and Treatment. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13424.	1.8	4
9804	Acute kidney injury in advanced lung cancer patients treated with PD-1 inhibitors: a single center observational study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 5061-5070.	1.2	7
9805	Validation of E1L3N antibody for PD-L1 detection and prediction of pembrolizumab response in non-small-cell lung cancer. <i>Communications Medicine</i> , 2022, 2, .	1.9	5
9806	The Influence of the Gut Microbiome in Paediatric Cancer Origin and Treatment. <i>Antibiotics</i> , 2022, 11, 1521.	1.5	1
9807	A novel senescence-related lncRNA signature that predicts prognosis and the tumor microenvironment in patients with lung adenocarcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	3
9808	Retrospective analysis: checkpoint inhibitor accessibility for thoracic and head and neck cancers and factors influencing it in a tertiary centre in India. <i>Ecancermedicalsecience</i> , 0, 16, .	0.6	3
9809	Microsatellite instability detection in breast cancer using drop-off droplet digital PCR. <i>Oncogene</i> , 2022, 41, 5289-5297.	2.6	7
9810	Tumor-intrinsic SIRPA promotes sensitivity to checkpoint inhibition immunotherapy in melanoma. <i>Cancer Cell</i> , 2022, 40, 1324-1340.e8.	7.7	11
9811	Transportability of Overall Survival Estimates From US to Canadian Patients With Advanced Non-small Cell Lung Cancer With Implications for Regulatory and Health Technology Assessment. <i>JAMA Network Open</i> , 2022, 5, e2239874.	2.8	7
9812	Immune checkpoint inhibitor monotherapy is associated with less cardiac toxicity than combination therapy. <i>PLoS ONE</i> , 2022, 17, e0272022.	1.1	4
9813	Patterns of renal toxicity from the combination of pemetrexed and pembrolizumab for advanced nonsquamous non-small-cell lung cancer (NSCLC): A single-center experience. <i>Lung Cancer</i> , 2022, 174, 91-96.	0.9	6
9814	Dostarlimab an Inhibitor of PD-1/PD-L1: A New Paradigm for the Treatment of Cancer. <i>Medicina (Lithuania)</i> , 2022, 58, 1572.	0.8	5
9815	Comparative analysis of PD-1 target engagement of dostarlimab and pembrolizumab in advanced solid tumours using <i>ex vivo</i> IL-2 stimulation data. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 0, .	1.3	3
9816	Acute kidney injury associated with immune checkpoint inhibitors: A pharmacovigilance study. <i>International Immunopharmacology</i> , 2022, 113, 109350.	1.7	5
9817	A Review of Immune Checkpoint Blockade for the General Surgeon. <i>Journal of Surgical Research</i> , 2023, 281, 289-298.	0.8	3
9818	Emerging therapies for non-small cell lung cancer harboring EGFR exon 20 insertion mutations: narrative review. <i>Annals of Translational Medicine</i> , 2022, .	0.7	0

#	ARTICLE	IF	CITATIONS
9819	Adjunctive PD-1 inhibitor <i>versus</i> standard chemotherapy in recurrent or metastatic nasopharyngeal carcinoma: a systematic review and meta-analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211374.	1.4	0
9820	NKG2D-mediated cytotoxicity improves after primary surgery for high-grade serous ovarian cancer. <i>American Journal of Reproductive Immunology</i> , 0, , .	1.2	2
9821	NKp44-Derived Peptide Used in Combination Stimulates Antineoplastic Efficacy of Targeted Therapeutic Drugs. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14054.	1.8	1
9822	Ewing Sarcoma Meets Epigenetics, Immunology and Nanomedicine: Moving Forward into Novel Therapeutic Strategies. <i>Cancers</i> , 2022, 14, 5473.	1.7	4
9823	The mechanisms on evasion of anti-tumor immune responses in gastric cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
9824	Filling the Gap: The Immune Therapeutic Armamentarium for Relapsed/Refractory Hodgkin Lymphoma. <i>Journal of Clinical Medicine</i> , 2022, 11, 6574.	1.0	4
9825	Cabozantinib sensitizes microsatellite stable colorectal cancer to immune checkpoint blockade by immune modulation in human immune system mouse models. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	7
9826	Systematic assessment and optimizing algorithm of tumor mutational burden calculation and their implications in clinical decision-making. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
9827	Development and validation of immunogenic cell death-related signature for predicting the prognosis and immune landscape of uveal melanoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
9828	Prognostic value of 18F-FDG PET/CT in patients with advanced or metastatic non-small-cell lung cancer treated with immune checkpoint inhibitors: A systematic review and meta-analysis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
9829	Are anti-PD-1-associated immune related adverse events a harbinger of favorable clinical prognosis in patients with gastric cancer?. <i>BMC Cancer</i> , 2022, 22, .	1.1	2
9830	PA-MSHA induces inflamed tumor microenvironment and sensitizes tumor to anti-PD-1 therapy. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	2
9831	Impact of primary site on survival in patients with nasopharyngeal carcinoma from 2004 to 2015. <i>Frontiers in Surgery</i> , 0, 9, .	0.6	1
9832	A case of long-term survival treated with three metastasectomies and two subsequent adjuvant nivolumab therapies for recurrent malignant melanoma of the esophagus. <i>Surgical Case Reports</i> , 2022, 8, .	0.2	0
9833	Incidence, risk factors and prognosis of acute kidney injury in patients treated with immune checkpoint inhibitors: a retrospective study. <i>Scientific Reports</i> , 2022, 12, .	1.6	7
9834	Characterization of the Immune Microenvironmental Landscape of Lung Squamous Cell Carcinoma with Immune Cell Infiltration. <i>Disease Markers</i> , 2022, 2022, 1-15.	0.6	2
9835	A single center analysis of first-line treatment in advanced KRAS mutant non-small cell lung cancer: real-world practice. <i>BMC Cancer</i> , 2022, 22, .	1.1	1
9836	PD-L1 expression and association with genetic background in pheochromocytoma and paraganglioma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4

#	ARTICLE	IF	CITATIONS
9837	Myocardial Protection and Current Cancer Therapy: Two Opposite Targets with Inevitable Cost. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14121.	1.8	4
9838	CD8+ T cell/cancer-associated fibroblast ratio stratifies prognostic and predictive responses to immunotherapy across multiple cancer types. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
9839	Translating the evolving molecular landscape of tumors to biomarkers of response for cancer immunotherapy. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	14
9840	Immune checkpoint inhibitors for unresectable or metastatic pleomorphic dermal sarcomas. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
9841	Molecular subtypes identified by pyroptosis-related genes are associated with tumor microenvironment cell infiltration in colon cancer. <i>Aging</i> , 0, , .	1.4	0
9842	Histomorphological transformation from non-small cell lung carcinoma to small cell lung carcinoma after targeted therapy or immunotherapy: A report of two cases. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
9843	Targeted Therapies for Hepatocellular Carcinoma Treatment: A New Era Ahead—A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14117.	1.8	7
9844	Microfluidics guided by deep learning for cancer immunotherapy screening. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	16
9845	Egr2 and 3 maintain anti-tumour responses of exhausted tumour infiltrating CD8 ⁺ T cells. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 1139-1151.	2.0	1
9846	Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small cell lung cancer: an open-label, randomized controlled phase 3 trial (ORIENT-3). <i>Cancer Communications</i> , 2022, 42, 1314-1330.	3.7	14
9847	A Novel Glycolysis-Related Long Noncoding RNA Signature for Predicting Overall Survival in Gastric Cancer. <i>Pathology and Oncology Research</i> , 0, 28, .	0.9	3
9848	Scope and Consistency of Cancer Outcomes Reported in Randomized Trials in Kidney Transplant Recipients. <i>Kidney International Reports</i> , 2023, 8, 274-281.	0.4	1
9849	Tumor factors stimulate lysosomal degradation of tumor antigens and undermine their cross-presentation in lung cancer. <i>Nature Communications</i> , 2022, 13, .	5.8	7
9850	Ferroptosis: a double-edged sword mediating immune tolerance of cancer. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	20
9851	Predictive performance of PD-L1 tumor proportion score for nivolumab response evaluated using archived specimens in patients with non-small cell lung cancer experiencing a postoperative recurrence. <i>Investigational New Drugs</i> , 0, , .	1.2	0
9852	Targeting the CD47-SIRP α Axis: Present Therapies and the Future for Cutaneous T-cell Lymphoma. <i>Cells</i> , 2022, 11, 3591.	1.8	4
9853	Characterization of immune checkpoint inhibitor-associated fulminant type 1 diabetes associated with autoantibody status and ethnic origin. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
9854	Serine and glycine metabolism-related gene expression signature stratifies immune profiles of brain gliomas, and predicts prognosis and responses to immunotherapy. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	4

#	ARTICLE	IF	CITATIONS
9855	Tissue-resident memory T cells in the era of (Neo) adjuvant melanoma management. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
9856	Granulomatous interstitial nephritis with CTLA-4 haploinsufficiency: a case report. <i>BMC Nephrology</i> , 2022, 23, .	0.8	2
9857	Nanomaterials: small particles show huge possibilities for cancer immunotherapy. <i>Journal of Nanobiotechnology</i> , 2022, 20, .	4.2	14
9858	The effect of organ-specific tumor microenvironments on response patterns to immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
9859	Atezolizumab and stereotactic body radiotherapy in patients with advanced nonâ€small cell lung cancer: safety, clinical activity and <scp>ctDNA</scp> responsesâ€the <scp>ComIT</scp>â€a trial. <i>Molecular Oncology</i> , 2023, 17, 487-498.	2.1	2
9860	Heparin binding epidermal growth factorâ€like growth factor is a prognostic marker correlated with levels of macrophages infiltrated in lung adenocarcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
9861	Prognostic Analysis of Spinal Metastasis Secondary to Lung Cancer after Surgeries: A Unicentric, Largeâ€Cohort, Retrospective Study. <i>Orthopaedic Surgery</i> , 0, , .	0.7	2
9862	Selfâ€Cooperative Prodrug Nanovesicles Migrate Immune Evasion to Potentiate Chemoradiotherapy in Head and Neck Cancer. <i>Advanced Science</i> , 2022, 9, .	5.6	5
9863	Disparity in checkpoint inhibitor utilization among commercially insured adult patients with metastatic lung cancer. <i>Journal of the National Cancer Institute</i> , 2023, 115, 295-302.	3.0	3
9864	Development of an adenosquamous carcinoma histo pathology-selective lung metastasis model. <i>Biology Open</i> , 0, , .	0.6	0
9865	A bibliometric and visualization-based analysis of temozolomide research hotspots and frontier evolution. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
9866	CAR T-cells for colorectal cancer immunotherapy: Ready to go?. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	11
9867	Immune checkpoint gene <scp><i>VSIR</i></scp> predicts patient prognosis in acute myeloid leukemia and myelodysplastic syndromes. <i>Cancer Medicine</i> , 2023, 12, 5590-5602.	1.3	3
9868	Chromomycin A5 induces bona fide immunogenic cell death in melanoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
9869	CNS and CNS diseases in relation to their immune system. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
9870	Immune-related adverse events in patients with pre-existing autoimmune rheumatologic disease on immune checkpoint inhibitor therapy. <i>BMC Rheumatology</i> , 2022, 6, .	0.6	12
9871	Immune Checkpoint Molecules and Glucose Metabolism in HIV-Induced T Cell Exhaustion. <i>Biomedicines</i> , 2022, 10, 2809.	1.4	8
9872	Proteogenomic analysis of lung adenocarcinoma reveals tumor heterogeneity, survival determinants, and therapeutically relevant pathways. <i>Cell Reports Medicine</i> , 2022, 3, 100819.	3.3	15

#	ARTICLE	IF	CITATIONS
9873	Effect of histology on the efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer: A systematic review and meta-analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
9874	Molecular Events in the Melanogenesis Cascade as Novel Melanoma-Targeted Small Molecules: Principle and Development. <i>Cancers</i> , 2022, 14, 5588.	1.7	2
9875	Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration. <i>Journal of Experimental Medicine</i> , 2023, 220, .	4.2	20
9876	Abemaciclib in combination with pembrolizumab for HR+, HER2 ⁺ metastatic breast cancer: Phase 1b study. <i>Npj Breast Cancer</i> , 2022, 8, .	2.3	14
9877	Editorial: Impact of immunotherapy in lung cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
9878	Purine metabolism-related gene expression signature predicts survival outcome and indicates immune microenvironment profile of gliomas. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	1
9879	Comparison between immunotherapy efficacy in early non-small cell lung cancer and advanced non-small cell lung cancer: a systematic review. <i>BMC Medicine</i> , 2022, 20, .	2.3	8
9880	Transcriptomic characterization and construction of M2 macrophage-related prognostic and immunotherapeutic signature in ovarian metastasis of gastric cancer. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 1121-1138.	2.0	6
9881	ImmunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: a phase 0/1 study characterising PD-L1 with ⁸⁹ Zr-durvalumab (MEDI4736) PET/CT in stage III NSCLC patients receiving chemoradiation study protocol. <i>BMJ Open</i> , 2022, 12, e056708.	0.8	8
9882	Anti-glomerular basement membrane glomerulonephritis concurrent with membranous nephropathy and acute tubular interstitial nephritis in a lung cancer patient treated with pembrolizumab. <i>CEN Case Reports</i> , 2023, 12, 230-236.	0.5	2
9884	Gut microbiota diversity and composition in predicting immunotherapy response and immunotherapy-related colitis in melanoma patients: A systematic review. <i>World Journal of Clinical Oncology</i> , 0, 13, 929-942.	0.9	6
9885	Immune checkpoint inhibitor-related adverse cardiac events in patients with lung cancer: a systematic review and meta-analysis. <i>Cancer Cell International</i> , 2022, 22, .	1.8	5
9886	BRAF activation by metabolic stress promotes glycolysis sensitizing NRASQ61-mutated melanomas to targeted therapy. <i>Nature Communications</i> , 2022, 13, .	5.8	7
9887	Identification of Immunogenic Cell Death-Related Signature for Glioma to Predict Survival and Response to Immunotherapy. <i>Cancers</i> , 2022, 14, 5665.	1.7	1
9888	Conversion therapy for advanced penile cancer with tislelizumab combined with chemotherapy: A case report and review of literature. <i>World Journal of Clinical Cases</i> , 0, 10, 12305-12312.	0.3	2
9889	Pembrolizumab in advanced non-small cell lung cancer: safety implications of dose adjustments. <i>Translational Cancer Research</i> , 2021, .	0.4	0
9890	SP142 evaluation contributes to the prediction of immune checkpoint inhibitor efficacy in non-small cell lung cancer with high PD-L1 expression assessed by 22C3. <i>Translational Lung Cancer Research</i> , 2022, 11, 2438-2451.	1.3	1
9891	An open label, safety study of Asian patients with advanced non-small-cell lung cancer receiving second-line nivolumab monotherapy (CheckMate 870). <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211383.	1.4	2

#	ARTICLE	IF	CITATIONS
9892	Effects of postoperative radiotherapy and docetaxel and PD-1 inhibitors on the survival and safety of glioblastoma patients: a systematic review and meta-analysis. <i>Annals of Translational Medicine</i> , 2022, 10, 1326-1326.	0.7	1
9893	Proteomic analysis of brain metastatic lung adenocarcinoma reveals intertumoral heterogeneity and specific alterations associated with the timing of brain metastases. <i>ESMO Open</i> , 2023, 8, 100741.	2.0	4
9894	An Updated Focus on Immune Checkpoint Inhibitors and Tubulointerstitial Nephritis. , 2023, , 157-184.		0
9895	Combatting acquired resistance to osimertinib in EGFR-mutant lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211440.	1.4	7
9896	The Tri-iodothyronine (T3) Level Is a Prognostic Factor for Patients With Advanced NSCLC: Receiving Immune Checkpoint Inhibitors and Is Associated With Liver Metastasis. <i>Clinical Medicine Insights: Oncology</i> , 2022, 16, 117955492211395.	0.6	2
9897	Multiomomic analysis for optimization of combined focal and immunotherapy protocols in murine pancreatic cancer. <i>Theranostics</i> , 2022, 12, 7884-7902.	4.6	3
9899	Late-onset acute type 1 diabetes mellitus 7 months after discontinuation of pembrolizumab against lung cancer. <i>Thoracic Cancer</i> , 0, , .	0.8	2
9900	Immune biology of NSCLC revealed by single-cell technologies: implications for the development of biomarkers in patients treated with immunotherapy. <i>Seminars in Immunopathology</i> , 0, , .	2.8	2
9901	Short-course pembrolizumab and continuous afatinib therapy for recurrent or metastatic head and neck squamous cell carcinoma: a real-world data analysis. <i>BMC Cancer</i> , 2022, 22, .	1.1	3
9902	Immune landscape and immunotherapy for penile cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
9903	Comparison of the efficacy and safety in the treatment strategies between chemotherapy combined with antiangiogenic and with immune checkpoint inhibitors in advanced non-small cell lung cancer patients with negative PD-L1 expression: A network meta-analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
9904	Prevalence of immune-related adverse events and anti-tumor efficacy following immune checkpoint inhibitor therapy in Japanese patients with various solid tumors. <i>BMC Cancer</i> , 2022, 22, .	1.1	6
9905	Immune profile analysis of peripheral blood and tumors of lung cancer patients treated with immune checkpoint inhibitors. <i>Translational Lung Cancer Research</i> , 2022, 11, 2192-2207.	1.3	1
9906	Epigenetic Mechanisms Underlying Melanoma Resistance to Immune and Targeted Therapies. <i>Cancers</i> , 2022, 14, 5858.	1.7	2
9907	Improvements in survival for patients with stage IV adenocarcinoma in the lung, diagnosed between 2010 and 2020 - A population-based registry study from Norway. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
9908	Anlotinib enhances the antitumor immunity of radiotherapy by activating cGAS/STING in non-small cell lung cancer. <i>Cell Death Discovery</i> , 2022, 8, .	2.0	6
9909	How to Manage a Patient with Ocular Metastases?. <i>Biomedicines</i> , 2022, 10, 3044.	1.4	2
9910	Design and reporting of phase III oncology trials with prospective biomarker validation. <i>Journal of the National Cancer Institute</i> , 0, , .	3.0	1

#	ARTICLE	IF	CITATIONS
9911	Development of Radiomic-Based Model to Predict Clinical Outcomes in Non-Small Cell Lung Cancer Patients Treated with Immunotherapy. <i>Cancers</i> , 2022, 14, 5931.	1.7	6
9912	Activated Eosinophils Predict Longer Progression-Free Survival under Immune Checkpoint Inhibition in Melanoma. <i>Cancers</i> , 2022, 14, 5676.	1.7	3
9913	DNA and mRNA Vaccines for Chronic Viral Infections and Cancer: Rationale, Mechanisms, and Progress. <i>Cancers</i> , 2022, 14, 5874.	1.7	1
9914	Initial clinical and experimental analyses of ALDOA in gastric cancer, as a novel prognostic biomarker and potential therapeutic target. <i>Clinical and Experimental Medicine</i> , 0, , .	1.9	1
9915	An EGFR L858R mutation identified in 1862 Chinese NSCLC patients can be a promising neoantigen vaccine therapeutic strategy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
9916	Comparative efficacy and toxicity of immune checkpoint inhibitors in combination with or without chemotherapy treatment for advanced esophageal squamous cell carcinoma: A systematic review and meta-analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
9917	Targeting the CD47/thrombospondin-1 signaling axis regulates immune cell bioenergetics in the tumor microenvironment to potentiate antitumor immune response. , 2022, 10, e004712.		11
9918	Increased tumor glycolysis is associated with decreased immune infiltration across human solid tumors. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
9919	Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma: a multicenter study of the prospective skin cancer registry ADOREG. , 2022, 10, e005930.		10
9920	Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity. , 2022, 10, e005517.		5
9921	Positive regulators of T cell proliferation as biomarkers for predicting prognosis and characterizing the immune landscape in lung adenocarcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	0
9922	Cost-Effectiveness Analysis of Sequential Treatment Strategies for Advanced Melanoma in Real Life in France. <i>Current Oncology</i> , 2022, 29, 9255-9270.	0.9	1
9923	Oncogenic alterations reveal key strategies for precision oncology in melanoma treatment. <i>Annals of Translational Medicine</i> , 2022, 10, 1246-1246.	0.7	0
9924	Immune checkpoint inhibitors alone or in combination with chemotherapy for treatment of advanced non-small cell lung cancer after first-line platinum-based chemotherapy: A propensity score matching analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
9925	A Review of the Role of Stereotactic Radiosurgery and Immunotherapy in the Management of Primary Central Nervous System Tumors. <i>Biomedicines</i> , 2022, 10, 2977.	1.4	2
9926	The Role of 8-oxoG Repair Systems in Tumorigenesis and Cancer Therapy. <i>Cells</i> , 2022, 11, 3798.	1.8	9
9927	Therapeutic Antibodies in Cancer Treatment in the UK. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14589.	1.8	1
9928	Anti-programmed death-1 inhibitor nivolumab-induced immune-related adverse events: hepatitis, renal insufficiency, myositis, vitiligo, and hypothyroidism: a case-based review. <i>Rheumatology International</i> , 2023, 43, 559-565.	1.5	1

#	ARTICLE	IF	CITATIONS
9929	Efficacy and safety of immune checkpoint inhibitors in advanced pancreatic cancer: A real world study in Chinese cohort. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	3
9930	Advances in the Lung Cancer Immunotherapy Approaches. <i>Vaccines</i> , 2022, 10, 1963.	2.1	6
9931	Chemo-Immunotherapy in First Line Extensive Stage Small Cell Lung Cancer (ES-SCLC): A Systematic Review and Meta-Analysis. <i>Current Oncology</i> , 2022, 29, 9046-9065.	0.9	6
9932	Harnessing NK Cells to Control Metastasis. <i>Vaccines</i> , 2022, 10, 2018.	2.1	4
9933	Experimental in vitro, exÂvivo and in vivo models in prostate cancer research. <i>Nature Reviews Urology</i> , 2023, 20, 158-178.	1.9	11
9934	Glomerular diseases after immune checkpoint inhibitors use: What do We know so far?. <i>Renal Failure</i> , 2022, 44, 2058-2067.	0.8	1
9935	Immunogenomic correlates of immune-related adverse events for antiâ€“programmed cell death 1 therapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
9936	Prognostic Hematologic Biomarkers Following Immune Checkpoint Inhibition in Metastatic Uveal Melanoma. <i>Cancers</i> , 2022, 14, 5789.	1.7	3
9937	A tumor vasculatureâ€“based imaging biomarker for predicting response and survival in patients with lung cancer treated with checkpoint inhibitors. <i>Science Advances</i> , 2022, 8, .	4.7	6
9938	Targeting the STAT5A/IDO1 axis overcomes radioresistance and reverses the immunosuppressive tumor microenvironment in NSCLC. <i>International Journal of Oncology</i> , 2022, 62, .	1.4	2
9939	Radiotherapy of the Primary Disease for Synchronous Metastatic Cancer: A Systematic Review. <i>Cancers</i> , 2022, 14, 5929.	1.7	4
9940	Allogeneic natural killer cell therapy. <i>Blood</i> , 2023, 141, 856-868.	0.6	33
9941	<i>SERPINB9</i> is commonly amplified and high expression in cancer cells correlates with poor immune checkpoint blockade response. <i>Oncolimmunology</i> , 2022, 11, .	2.1	10
9942	Development of therapeutic antibodies for the treatment of diseases. <i>Molecular Biomedicine</i> , 2022, 3, .	1.7	19
9943	Final results from TAIL: updated long-term efficacy of atezolizumab in a diverse population of patients with previously treated advanced non-small cell lung cancer. , 2022, 10, e005581.		2
9944	Histology-Agnostic Drugs: A Paradigm Shiftâ€“A Narrative Review. <i>Advances in Therapy</i> , 2023, 40, 1379-1392.	1.3	3
9945	The Roles of MiRNAs (MicroRNAs) in Melanoma Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14775.	1.8	3
9946	Cutaneous adverse events in patients treated with PD-1/PD-L1 checkpoint inhibitors and their association with survival: a systematic review and meta-analysis. <i>Scientific Reports</i> , 2022, 12, .	1.6	4

#	ARTICLE	IF	CITATIONS
9947	Assessing the efficacy of immunotherapy in lung squamous carcinoma using artificial intelligence neural network. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
9948	Bronchoalveolar Lavage Fluid-Isolated Biomarkers for the Diagnostic and Prognostic Assessment of Lung Cancer. <i>Diagnostics</i> , 2022, 12, 2949.	1.3	4
9949	Prognostic and predictive value of YTHDF1 and YTHDF2 and their correlation with tumor-infiltrating immune cells in non-small cell carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
9950	Soluble PD-L1 as a Prognostic Factor for Immunotherapy Treatment in Solid Tumors: Systematic Review and Meta-Analysis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14496.	1.8	13
9951	Metabolic determinants of tumour initiation. <i>Nature Reviews Endocrinology</i> , 2023, 19, 134-150.	4.3	16
9952	Next-generation immunotherapy for solid tumors: combination immunotherapy with crosstalk blockade of TGF β 2 and PD-1/PD-L1. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 1187-1202.	1.9	1
9953	PET/CT radiomics for prediction of hyperprogression in metastatic melanoma patients treated with immune checkpoint inhibitors. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
9954	<sc>RASA3</sc> predicts overall survival and <sc>CD8</sc> + T lymphocyte infiltration in lung adenocarcinoma. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 6056-6065.	1.6	1
9955	Divergent roles of PD-L1 in immune regulation during ischemiaâ€“reperfusion injury. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
9956	Role of cytotoxic T cells and PD-1 immune checkpoint pathway in papillary thyroid carcinoma. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	6
9957	RT-based combination therapy for brain metastasis from NSCLC with non-EGFR mutation/ALK gene rearrangement: A network meta-analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
9958	The Safety and Efficacy of Preoperative Immunotherapy Combined with Chemotherapy in Patients with Stage IIIA-III B Lung Squamous Cell Carcinoma. <i>Thoracic and Cardiovascular Surgeon</i> , 0, , .	0.4	0
9959	Re-administration of immune checkpoint inhibitors for patients with non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2022, 11, 2170-2174.	1.3	0
9960	DDX1 is a prognostic biomarker and correlates with immune infiltrations in hepatocellular carcinoma. <i>BMC Immunology</i> , 2022, 23, .	0.9	3
9961	Immunological and Genomic Analysis Reveals Clinically Relevant Distinctions between Angiosarcoma Subgroups. <i>Cancers</i> , 2022, 14, 5938.	1.7	4
9962	Nonsurgical Treatment Strategies for Elderly Head and Neck Cancer Patients: An Emerging Subject Worldwide. <i>Cancers</i> , 2022, 14, 5689.	1.7	0
9963	Effects of BRAF V600E and NRAS mutational status on the progressionâ€“free survival and clinicopathological characteristics of patients with melanoma. <i>Oncology Letters</i> , 2022, 25, .	0.8	9
9964	Hypermetabolic lymphadenopathy following the administration of COVID-19 vaccine and immunotherapy in a lung cancer patient: a case report. <i>Journal of Medical Case Reports</i> , 2022, 16, .	0.4	2

#	ARTICLE	IF	CITATIONS
9965	Management of Lung Cancer in the Patient with Interstitial Lung Disease. <i>Oncologist</i> , 2023, 28, 12-22.	1.9	4
9966	A case of acute lymphocytic gastritis related to treatment with pembrolizumab for metastatic urothelial carcinoma. <i>IJU Case Reports</i> , 0, , .	0.1	0
9967	A Comparison of Patientsâ€™ and Physiciansâ€™ Knowledge and Expectations Regarding Precision Oncology Tests. <i>Current Oncology</i> , 2022, 29, 9916-9927.	0.9	1
9968	The traditional chinese medicine monomer Ailanthone improves the therapeutic efficacy of anti-PD-L1 in melanoma cells by targeting c-Jun. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	6
9969	Triggering of lymphocytes by CD28, 4-1BB, and PD-1 checkpoints to enhance the immune response capacities. <i>PLoS ONE</i> , 2022, 17, e0275777.	1.1	5
9970	Imaging of Activated T Cells. <i>Journal of Nuclear Medicine</i> , 2023, 64, 30-33.	2.8	1
9971	Reprogramming immune cells activity by furin-like enzymes as emerging strategy for enhanced immunotherapy in cancer. <i>British Journal of Cancer</i> , 0, , .	2.9	0
9972	Case report: Durable response after pembrolizumab in combination with radiation - induced abscopal effect in platinum - refractory metastatic endometrial clear cell carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
9973	The Path to Personalized Treatment in KRAS-Mutant Non-Small Cell Lung Cancer: A Review of Targeted Therapies and Immunotherapy. <i>Cancer Management and Research</i> , 0, Volume 14, 3485-3492.	0.9	2
9974	Integrated investigation of the prognostic role of HLA LOH in advanced lung cancer patients with immunotherapy. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	4
9975	Activating transcription factor 3 inhibits NF- κ B p65 signaling pathway and mediates apoptosis and cell cycle arrest in cervical cancer cells. <i>Infectious Agents and Cancer</i> , 2022, 17, .	1.2	2
9976	Extremely high infiltration of CD8+PD-L1+ cells detected in a stage III non-small cell lung cancer patient exhibiting hyperprogression during anti-PD-L1 immunotherapy after chemoradiation: A case report. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
9977	Comprehensive assessment on the applications of oncolytic viruses for cancer immunotherapy. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	4
9978	Acetylcholine receptor binding antibody-associated myasthenia gravis, myocarditis, and rhabdomyolysis induced by tislelizumab in a patient with colon cancer: A case report and literature review. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
9979	<i>ACTA2</i> Expression Predicts Survival and Is Associated with Response to Immune Checkpoint Inhibitors in Gastric Cancer. <i>Clinical Cancer Research</i> , 2023, 29, 1077-1085.	3.2	9
9980	3-Bromopyruvate Suppresses the Malignant Phenotype of Vemurafenib-Resistant Melanoma Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15650.	1.8	4
9981	Predictive Value of Baseline FDG-PET/CT for the Durable Response to Immune Checkpoint Inhibition in NSCLC Patients Using the Morphological and Metabolic Features of Primary Tumors. <i>Cancers</i> , 2022, 14, 6095.	1.7	8
9982	Immunotherapy for Melanoma: The Significance of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15720.	1.8	13

#	ARTICLE	IF	CITATIONS
9983	Advanced diagnostic and therapeutic strategies in nanotechnology for lung cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
9984	PD-1/PD-L1 inhibitors plus anti-angiogenic agents with or without chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy as second or later-line treatment for patients with advanced non-small cell lung cancer: A real-world retrospective cohort study. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
9985	Nivolumab Hypersensitivity Reactions a Myth or Reality in Solid Tumors? A Systematic Review of the Literature. <i>Current Oncology</i> , 2022, 29, 9428-9436.	0.9	4
9986	Reproducible and opposing gut microbiome signatures distinguish autoimmune diseases and cancers: a systematic review and meta-analysis. <i>Microbiome</i> , 2022, 10, .	4.9	8
9987	Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: the phase 1b MITCI study. , 2022, 10, e005224.		3
9988	Checkpoint inhibitors are a basic science-based, transformative new treatment for lung cancer. <i>Respirology</i> , 2023, 28, 101-106.	1.3	2
9989	Interleukin-10 induces expression of CD39 on CD8+T cells to potentiate anti-PD1 efficacy in EGFR-mutated non-small cell lung cancer. , 2022, 10, e005436.		3
9990	An individualized causal framework for learning intercellular communication networks that define microenvironments of individual tumors. <i>PLoS Computational Biology</i> , 2022, 18, e1010761.	1.5	3
9991	Establishing a whole blood CD4+ T cell immunity measurement to predict response to anti-PD-1. <i>BMC Cancer</i> , 2022, 22, .	1.1	1
9992	Prognostic value of RILPL2 and its correlation with tumor immune microenvironment and glycolysis in non-small cell lung cancer. <i>Cell Cycle</i> , 2023, 22, 841-857.	1.3	5
9993	Encouraging probiotics for the prevention and treatment of immune-related adverse events in novel immunotherapies against malignant glioma. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , 817-827.	0.5	2
9994	Pre-Existing Interstitial Lung Abnormalities Are Independent Risk Factors for Interstitial Lung Disease during Durvalumab Treatment after Chemoradiotherapy in Patients with Locally Advanced Non-Small-Cell Lung Cancer. <i>Cancers</i> , 2022, 14, 6236.	1.7	5
9995	Potential Role of Tumor-Derived Exosomes in Non-Small-Cell Lung Cancer in the Era of Immunotherapy. <i>Life</i> , 2022, 12, 2104.	1.1	5
9996	Attenuated Salmonella potentiate PD-L1 blockade immunotherapy in a preclinical model of colorectal cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
9997	TGF- β 2: A novel predictor and target for anti-PD-1/PD-L1 therapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	22
9998	Genome-wide gain-of-function screening characterized lncRNA regulators for tumor immune response. <i>Science Advances</i> , 2022, 8, .	4.7	3
9999	Comparative risk of acute kidney injury among cancer patients treated with immune checkpoint inhibitors. <i>Cancer Communications</i> , 2023, 43, 214-224.	3.7	5
10000	Programmed Cell Death-Ligand 1 in Head and Neck Squamous Cell Carcinoma: Molecular Insights, Preclinical and Clinical Data, and Therapies. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15384.	1.8	12

#	ARTICLE	IF	CITATIONS
10001	Bioactive Glasses as Carriers of Cancer-Targeted Drugs: Challenges and Opportunities in Bone Cancer Treatment. <i>Materials</i> , 2022, 15, 9082.	1.3	5
10002	CHI3L1 enhances melanoma lung metastasis via regulation of T cell co-stimulators and CTLA-4/B7 axis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
10003	Solid Organ Transplantation Is Associated with an Increased Rate of Mismatch Repair Deficiency and PIK3CA Mutations in Colorectal Cancer. <i>Current Oncology</i> , 2023, 30, 75-84.	0.9	1
10004	Cancer Immunotherapy Beyond Checkpoint Blockade. <i>JACC: CardioOncology</i> , 2022, 4, 563-578.	1.7	1
10005	Immune Checkpoint Inhibitor Therapy in Oncology. <i>JACC: CardioOncology</i> , 2022, 4, 579-597.	1.7	25
10006	Clinical potential of PD-1/PD-L1 blockade therapy for renal cell carcinoma (RCC): a rapidly evolving strategy. <i>Cancer Cell International</i> , 2022, 22, .	1.8	3
10007	Local therapy treatment conditions for oligometastatic non-small cell lung cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
10008	Incidence and severity of immune-related hepatitis after dual checkpoint therapy is linked to younger age independent of herpes virus immunity. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	0
10009	Immune Checkpoint Inhibitors and Endocrine Disorders: A Position Statement from the Korean Endocrine Society. <i>Endocrinology and Metabolism</i> , 2022, 37, 839-850.	1.3	3
10010	Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF- β 2 and PD-L1, in Patients with Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors. <i>Oncologist</i> , 2023, 28, 258-267.	1.9	7
10011	Clinical characteristics of adrenal insufficiency induced by pembrolizumab in non-small cell lung cancer. <i>Thoracic Cancer</i> , 2023, 14, 442-449.	0.8	5
10012	EGFR is a master switch between immunosuppressive and immunoactive tumor microenvironment in inflammatory breast cancer. <i>Science Advances</i> , 2022, 8, .	4.7	14
10013	Lung Cancer Clinical Trials with a Seamless Phase II/III Design: Systematic Review. <i>Journal of Clinical Medicine</i> , 2022, 11, 7176.	1.0	0
10014	A novel diagnostic model for predicting immune microenvironment subclass based on costimulatory molecules in lung squamous carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	0
10015	Anti-Programmed Cell Death-1 Antibody and Dasatinib Combination Therapy Exhibits Efficacy in Metastatic Colorectal Cancer Mouse Models. <i>Cancers</i> , 2022, 14, 6146.	1.7	3
10016	Clinical outcomes and risk factor of immune checkpoint inhibitors-related pneumonitis in non-small cell lung cancer patients with chronic obstructive pulmonary disease. <i>BMC Pulmonary Medicine</i> , 2022, 22, .	0.8	3
10017	Rational combinations of targeted cancer therapies: background, advances and challenges. <i>Nature Reviews Drug Discovery</i> , 2023, 22, 213-234.	21.5	69
10018	Assessing the risk of cardiovascular events in patients receiving immune checkpoint inhibitors. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	2

#	ARTICLE	IF	CITATIONS
10019	Primary esophageal malignant melanoma without recurrence after surgery and adjuvant therapy with nivolumab. <i>International Cancer Conference Journal</i> , 0, , .	0.2	1
10020	In vivo genome-wide CRISPR screening identifies ZNF24 as a negative NF- κ B modulator in lung cancer. <i>Cell and Bioscience</i> , 2022, 12, .	2.1	2
10021	Treatment of rheumatic adverse events of cancer immunotherapy. <i>Best Practice and Research in Clinical Rheumatology</i> , 2022, 36, 101805.	1.4	9
10022	Evolutionary Characteristics and Immunologic Divergence of Lung and Brain Metastasis Lesions in NSCLC. <i>Molecular Cancer Research</i> , 2023, 21, 374-385.	1.5	0
10023	Immune checkpoint inhibitor induced nephrotoxicity: An ongoing challenge. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	1
10024	Regulatory T cells infiltrate the tumor-induced tertiary lymphoid structures and are associated with poor clinical outcome in NSCLC. <i>Communications Biology</i> , 2022, 5, .	2.0	17
10025	Protocol for mathematical prediction of patient response and survival to immune checkpoint inhibitor immunotherapy. <i>STAR Protocols</i> , 2022, 3, 101886.	0.5	0
10026	BCL-xL inhibition potentiates cancer therapies by redirecting the outcome of p53 activation from senescence to apoptosis. <i>Cell Reports</i> , 2022, 41, 111826.	2.9	7
10027	Small-molecule PTPN2 Inhibitors Sensitize Resistant Melanoma to Anti-PD-1 Immunotherapy. <i>Cancer Research Communications</i> , 2023, 3, 119-129.	0.7	3
10028	Estimated Costs of the Ipilimumabâ€“Nivolumab Therapy and Related Adverse Events in Metastatic Melanoma. <i>Cancers</i> , 2023, 15, 31.	1.7	1
10029	Early on-treatment tumor growth rate (EOT-TGR) determines treatment outcomes of advanced non-small-cell lung cancer patients treated with programmed cell death protein 1 axis inhibitor. <i>ESMO Open</i> , 2022, 7, 100630.	2.0	1
10030	Approach to the Patient With Immune Checkpoint Inhibitorâ€“Associated Endocrine Dysfunction. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2023, 108, 1514-1525.	1.8	8
10031	Cytokines and Immune Cell Phenotype in Acute Kidney Injury Associated With Immune Checkpoint Inhibitors. <i>Kidney International Reports</i> , 2023, 8, 628-641.	0.4	11
10032	Biomaterials for enhanced immunotherapy. <i>APL Bioengineering</i> , 2022, 6, .	3.3	7
10033	Immunoregulatory framework and the role of miRNA in the pathogenesis of NSCLC â€“ A systematic review. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
10034	The potential of PARP inhibitors in targeted cancer therapy and immunotherapy. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	12
10035	The High-Resolution Structure Reveals Remarkable Similarity in PD-1 Binding of Cemiplimab and Dostarlimab, the FDA-Approved Antibodies for Cancer Immunotherapy. <i>Biomedicines</i> , 2022, 10, 3154.	1.4	4
10036	Current status and challenges of immunotherapy in ALK rearranged NSCLC. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0

#	ARTICLE	IF	CITATIONS
10037	Case report: Eosinophilic fasciitis induced by pembrolizumab with high FDG uptake on 18F-FDG-PET/CT. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	2
10038	Acute Kidney Injury in Cancer Immunotherapy Recipients. <i>Cells</i> , 2022, 11, 3991.	1.8	4
10039	MOVIE: a phase I, open-label, multicenter study to evaluate the safety and tolerability of metronomic vinorelbine combined with durvalumab plus tremelimumab in patients with advanced solid tumors. <i>ESMO Open</i> , 2022, 7, 100646.	2.0	7
10040	Anti-TGF- β 2/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer. , 2022, 10, e005543.		53
10041	Genomic Immune Evasion: Diagnostic and Therapeutic Opportunities in Head and Neck Squamous Cell Carcinomas. <i>Journal of Clinical Medicine</i> , 2022, 11, 7259.	1.0	3
10042	Biologic Impact of Green Synthesized Magnetic Iron Oxide Nanoparticles on Two Different Lung Tumorigenic Monolayers and a 3D Normal Bronchial Modelâ€™EpiAirwayTM Microtissue. <i>Pharmaceutics</i> , 2023, 15, 2.	2.0	4
10043	Identifying Patients at Risk of Acute Kidney Injury among Patients Receiving Immune Checkpoint Inhibitors: A Machine Learning Approach. <i>Diagnostics</i> , 2022, 12, 3157.	1.3	6
10044	Single-cell RNA sequencing reveals distinct T cell populations in immune-related adverse events of checkpoint inhibitors. <i>Cell Reports Medicine</i> , 2023, 4, 100868.	3.3	16
10045	Monitoring PD-L1 Expression on Circulating Tumorâ€™Associated Cells in Recurrent Metastatic Nonâ€™Small-Cell Lung Carcinoma Predicts Response to Immunotherapy With Radiation Therapy. <i>JCO Precision Oncology</i> , 2022, , .	1.5	10
10046	Combination of immune checkpoint inhibitors with radiation therapy in cancer: A hammer breaking the wall of resistance. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	7
10047	Effectiveness of Nivolumab in Second-Line and Later in Patients with Advanced Non-Small Cell Lung Cancer in Real-Life Practice in France and Germany: Analysis of the ESME-AMLC and CRISP Cohorts. <i>Cancers</i> , 2022, 14, 6148.	1.7	0
10048	Lung Cancer Immunotherapy: Beyond Common Immune Checkpoints Inhibitors. <i>Cancers</i> , 2022, 14, 6145.	1.7	10
10049	Association of Body Mass Index With the Safety Profile of Nivolumab With or Without Ipilimumab. <i>JAMA Oncology</i> , 2023, 9, 102.	3.4	11
10050	Immune-based combination therapy for esophageal cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
10051	Predictive value of PD-L1 expression in response to immune checkpoint inhibitors for esophageal cancer treatment: A systematic review and meta-analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	7
10052	Rhâ€™endostatin plus camrelizumab and chemotherapy in firstâ€™line treatment of advanced nonâ€™small cell lung cancer: A multicenter retrospective study. <i>Cancer Medicine</i> , 2023, 12, 7724-7733.	1.3	7
10053	Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer. <i>Molecular Biomedicine</i> , 2022, 3, .	1.7	8
10054	Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	46

#	ARTICLE	IF	CITATIONS
10055	Evolving landscape of PD-L2: bring new light to checkpoint immunotherapy. <i>British Journal of Cancer</i> , 2023, 128, 1196-1207.	2.9	28
10056	MEK inhibition enhances presentation of targetable MHC-I tumor antigens in mutant melanomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	7
10057	Cognitive assessment in patients treated by immunotherapy: the prospective Cog-Immuno trial. <i>BMC Cancer</i> , 2022, 22, .	1.1	2
10058	MYCBP2 expression correlated with inflammatory cell infiltration and prognosis immunotherapy in thyroid cancer patients. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
10059	Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study. , 2022, 10, e005755.		34
10060	Two Cases of Subsequent Hepatocellular Carcinoma in ICI-Responsive Non-Small Cell Lung Cancer. <i>JTO Clinical and Research Reports</i> , 2022, , 100448.	0.6	0
10061	The Nephrotoxicity of Drugs Used in Causal Oncological Therapies. <i>Current Oncology</i> , 2022, 29, 9681-9694.	0.9	4
10062	Characterization of the high-affinity anti-CTLA-4 monoclonal antibody JS007 for immune checkpoint therapy of cancer. <i>MAbs</i> , 2023, 15, .	2.6	0
10063	Global research landscape and trends of lung cancer immunotherapy: A bibliometric analysis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
10064	Attempting to Identify Bacterial Allies in Immunotherapy of NSCLC Patients. <i>Cancers</i> , 2022, 14, 6250.	1.7	6
10065	Immunotherapeutics in lung cancers: from mechanistic insight to clinical implications and synergistic perspectives. <i>Molecular Biology Reports</i> , 0, , .	1.0	0
10066	Targeting the EGF receptor family in non-small cell lung cancerâ€™increased complexity and future perspectives. <i>Cancer Biology and Medicine</i> , 2022, 19, 1543-1564.	1.4	12
10067	Clinical Benefit of First-Line Programmed Death-1 Antibody Plus Chemotherapy in Low Programmed Cell Death Ligand 1â€™Expressing Esophageal Squamous Cell Carcinoma: A Post Hoc Analysis of JUPITER-06 and Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2023, 41, 1735-1746.	0.8	19
10068	Melanoma Treatments and Mortality Rate Trends in the US, 1975 to 2019. <i>JAMA Network Open</i> , 2022, 5, e2245269.	2.8	19
10069	T-cell repertoire diversity: friend or foe for protective antitumor response?. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	11
10070	Serum albumin: a pharmacokinetic marker for optimizing treatment outcome of immune checkpoint blockade. , 2022, 10, e005670.		5
10071	ANK2 as a novel predictive biomarker for immune checkpoint inhibitors and its correlation with antitumor immunity in lung adenocarcinoma. <i>BMC Pulmonary Medicine</i> , 2022, 22, .	0.8	0
10072	IMAGENE trial: multicenter, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy of niraparib with PD-1 inhibitor in solid cancer patients with homologous recombination repair genes mutation. <i>BMC Cancer</i> , 2022, 22, .	1.1	0

#	ARTICLE	IF	CITATIONS
10073	Comparison of the Impact of Immune-Related Adverse Events Due to Immune Checkpoint Inhibitor Dual Combination Therapy and Immune Checkpoint Inhibitor Plus Tyrosine Kinase Inhibitor Combination Therapy in Patients with Advanced Renal Cell Carcinoma. <i>Targeted Oncology</i> , 0, , .	1.7	1
10074	In or out of control: Modulating regulatory T cell homeostasis and function with immune checkpoint pathways. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
10075	Melanogenesis and the Targeted Therapy of Melanoma. <i>Biomolecules</i> , 2022, 12, 1874.	1.8	9
10076	The Effect of Pleural Effusion on Prognosis in Patients with Non-Small Cell Lung Cancer Undergoing Immunochemotherapy: A Retrospective Observational Study. <i>Cancers</i> , 2022, 14, 6184.	1.7	3
10077	A Novel Immune Gene-Related Prognostic Score Predicts Survival and Immunotherapy Response in Glioma. <i>Medicina (Lithuania)</i> , 2023, 59, 23.	0.8	1
10078	Efficacy and Safety of the PD-1 Inhibitor Combined with Albumin-Bound Paclitaxel and Nedaplatin in Preoperative Neoadjuvant Therapy of Unresectable Stage III Lung Squamous Cell Carcinoma. <i>Drug Design, Development and Therapy</i> , 0, Volume 16, 4269-4277.	2.0	4
10079	A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer. <i>ESMO Open</i> , 2022, 7, 100639.	2.0	21
10080	Allograft rejection following immune checkpoint inhibitors in solid organ transplant recipients: A safety analysis from a literature review and a pharmacovigilance system. <i>Cancer Medicine</i> , 2023, 12, 5181-5194.	1.3	3
10081	Anti-4-1BB immunotherapy enhances systemic immune effects of radiotherapy to induce B and T cell-dependent anti-tumor immune activation and improve tumor control at unirradiated sites. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 1445-1460.	2.0	5
10082	Identification of comutation in signaling pathways to predict the clinical outcomes of immunotherapy. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	2
10083	Investigating the Quality of Life for Cancer Patients and Estimating the Cost of Immunotherapy in Selected Cases. <i>Cureus</i> , 2022, , .	0.2	0
10084	Radiopharmaceuticals heat anti-tumor immunity. <i>Theranostics</i> , 2023, 13, 767-786.	4.6	4
10085	Efficacy and safety of gemcitabine and capecitabine combination for patients with previously treated advanced primary pulmonary lymphoepithelioma-like carcinoma: a retrospective single-arm cohort study. <i>Translational Lung Cancer Research</i> , 2023, 12, 96-108.	1.3	1
10086	CAR T-Cell Immunotherapy Treating T-ALL: Challenges and Opportunities. <i>Vaccines</i> , 2023, 11, 165.	2.1	9
10087	Application of individualized multimodal radiotherapy combined with immunotherapy in metastatic tumors. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
10088	Investigation of racial differences in survival from non-small cell lung cancer with immunotherapy use: A Texas study. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
10089	Clinical outcomes of immune checkpoint inhibitor therapy for advanced lung adenosquamous carcinoma. <i>Journal of Thoracic Disease</i> , 2023, .	0.6	1
10090	Traditional Herbal Medicine: A Potential Therapeutic Approach for Adjuvant Treatment of Non-small Cell Lung Cancer in the Future. <i>Integrative Cancer Therapies</i> , 2022, 21, 153473542211443.	0.8	6

#	ARTICLE	IF	CITATIONS
10091	Evolution of treatment patterns and survival outcomes in patients with advanced non-small cell lung cancer treated at Frankfurt University Hospital in 2012–2018. <i>BMC Pulmonary Medicine</i> , 2023, 23, .	0.8	0
10092	Immunotherapy Assessment: A New Paradigm for Radiologists. <i>Diagnostics</i> , 2023, 13, 302.	1.3	1
10093	Comprehensive Analysis of Clinicopathological and Molecular Features to Predict Anti-PD-1-Based Therapy Efficacy in Patients with Advanced Gastric Signet Ring Cell Carcinoma. <i>Journal of Personalized Medicine</i> , 2023, 13, 115.	1.1	0
10094	IP-score correlated to endogenous tumour antigen peptide processing: A candidate clinical response score algorithm of immune checkpoint inhibitors therapy in multiple cohorts. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
10095	⁶⁸ Ga-HBED-CC-WL-12 PET in Diagnosing and Differentiating Pancreatic Cancers in Murine Models. <i>Pharmaceuticals</i> , 2023, 16, 80.	1.7	3
10096	Drastic transformation of visceral adipose tissue and peripheral CD4 T cells in obesity. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
10097	Immune-related ureteritis and cystitis induced by immune checkpoint inhibitors: Case report and literature review. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
10098	BCAT2 Shapes a Noninflamed Tumor Microenvironment and Induces Resistance to Anti-PD-1/PD-L1 Immunotherapy by Negatively Regulating Proinflammatory Chemokines and Anticancer Immunity. <i>Advanced Science</i> , 2023, 10, .	5.6	23
10099	Postoperative adjuvant therapy for hepatocellular carcinoma with microvascular invasion. <i>World Journal of Gastrointestinal Surgery</i> , 0, 15, 19-31.	0.8	4
10100	Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 1365-1379.	2.0	93
10101	High-Dose Ascorbate in Combination with Anti-PD1 Checkpoint Inhibition as Treatment Option for Malignant Melanoma. <i>Cells</i> , 2023, 12, 254.	1.8	1
10102	Risk of diabetes mellitus among users of immune checkpoint inhibitors: A population-based cohort study. <i>Cancer Medicine</i> , 2023, 12, 8144-8153.	1.3	2
10103	Neoadjuvant treatment for stage III and IV cutaneous melanoma. <i>The Cochrane Library</i> , 2023, 2023, .	1.5	1
10104	Configuring Therapeutic Aspects of Immune Checkpoints in Lung Cancer. <i>Cancers</i> , 2023, 15, 543.	1.7	8
10105	Signaling pathways in brain tumors and therapeutic interventions. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	13
10106	Recombinant GM-CSF for diseases of GM-CSF insufficiency: Correcting dysfunctional mononuclear phagocyte disorders. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
10107	Immunotherapy for Triple-Negative Breast Cancer: Combination Strategies to Improve Outcome. <i>Cancers</i> , 2023, 15, 321.	1.7	21
10108	Immune Pathways with Aging Characteristics Improve Immunotherapy Benefits and Drug Prediction in Human Cancer. <i>Cancers</i> , 2023, 15, 342.	1.7	0

#	ARTICLE	IF	CITATIONS
10109	Development of a Novel Predictive-Prognostic Scoring Index for Immune Checkpoint Inhibitors in Advanced Non-small Cell Lung Cancer. <i>Cureus</i> , 2023, , .	0.2	1
10110	Fundamentals to therapeutics: Epigenetic modulation of CD8+ T Cell exhaustion in the tumor microenvironment. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	4
10111	A Subset of PD-1-Expressing CD56bright NK Cells Identifies Patients with Good Response to Immune Checkpoint Inhibitors in Lung Cancer. <i>Cancers</i> , 2023, 15, 329.	1.7	8
10112	When cancer drug resistance meets metabolomics (bulk, single-cell and/or spatial): Progress, potential, and perspective. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
10113	Biparatopic antibody BA7208/7125 effectively neutralizes SARS-CoV-2 variants including Omicron BA.1-BA.5. <i>Cell Discovery</i> , 2023, 9, .	3.1	11
10114	Pembrolizumab for first-line treatment of advanced unresectable or metastatic esophageal or gastroesophageal junction cancer. <i>Therapeutic Advances in Gastroenterology</i> , 2023, 16, 175628482211482.	1.4	1
10115	Epigenetic modification-related mechanisms of hepatocellular carcinoma resistance to immune checkpoint inhibition. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9
10116	Caspase-8 contributes to an immuno-hot microenvironment by promoting phagocytosis via an ecto-calreticulin-dependent mechanism. <i>Experimental Hematology and Oncology</i> , 2023, 12, .	2.0	0
10117	Sorting Transcriptomics Immune Information from Tumor Molecular Features Allows Prediction of Response to Anti-PD1 Therapy in Patients with Advanced Melanoma. <i>International Journal of Molecular Sciences</i> , 2023, 24, 801.	1.8	0
10118	Dexamethasone and OLT1177 Cooperate in the Reduction of Melanoma Growth by Inhibiting STAT3 Functions. <i>Cells</i> , 2023, 12, 294.	1.8	3
10119	Combination therapy with oncolytic viruses and immune checkpoint inhibitors in head and neck squamous cell carcinomas: an approach of complementary advantages. <i>Cancer Cell International</i> , 2023, 23, .	1.8	5
10120	At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC. <i>Nature Reviews Clinical Oncology</i> , 2023, 20, 143-159.	12.5	29
10121	The Tumor Microenvironment in Tumorigenesis and Therapy Resistance Revisited. <i>Cancers</i> , 2023, 15, 376.	1.7	46
10122	Knowledge atlas of antibody-drug conjugates on CiteSpace and clinical trial visualization analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
10123	Advances in artificial intelligence to predict cancer immunotherapy efficacy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	23
10124	Immune Checkpoint Inhibitors: Changing the Treatment Landscape in Esophagogastric Adenocarcinoma. <i>Pharmaceuticals</i> , 2023, 16, 102.	1.7	0
10125	Nintedanib in an elderly non-small-cell lung cancer patient with severe steroid-refractory checkpoint inhibitor-related pneumonitis: A case report and literature review. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
10126	Impact of mouse model tumor implantation site on acquired resistance to anti-PD-1 immune checkpoint therapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5

#	ARTICLE	IF	CITATIONS
10127	Research landscape and trends of melanoma immunotherapy: A bibliometric analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
10128	Case report: Pharmacokinetics of pembrolizumab in a patient with stage IV non-â€‘small cell lung cancer after a single 200 mg administration. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
10129	Trends, Changes, and Disruptions: The Fragile Economics of Cancer Treatments. <i>Oncologist</i> , 0, , .	1.9	1
10130	Narrative review: blood and tumor biomarker testing in non-small cell lung cancer without an oncogenic driver. <i>Translational Lung Cancer Research</i> , 2023, 12, 158-167.	1.3	2
10131	DNA methylation-based patterns for early diagnostic prediction and prognostic evaluation in colorectal cancer patients with high tumor mutation burden. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
10132	A Three-â€‘in-â€‘One Nanoscale Coordination Polymer for Potent Chemo-â€‘immunotherapy. <i>Small Methods</i> , 2023, 7, .	4.6	5
10133	Cost-effectiveness of immune checkpoint inhibition and targeted treatment in combination as adjuvant treatment of patient with BRAF-mutant advanced melanoma. <i>BMC Health Services Research</i> , 2023, 23, .	0.9	3
10134	Inhibition of IL-12 heterodimers impairs TLR9-mediated prevention of early mouse plasmacytoma cell growth. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	0
10135	Tumor-infiltrating lymphocyte enrichment predicted by CT radiomics analysis is associated with clinical outcomes of non-small cell lung cancer patients receiving immune checkpoint inhibitors. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
10136	Editorial: Immune modulation in tumor microenvironment: New perspectives for cancer immunotherapy. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	1
10137	Shaping the Future of Immunotherapy Targets and Biomarkers in Melanoma and Non-Melanoma Cutaneous Cancers. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1294.	1.8	6
10138	Phytochemical Constituents and Derivatives of <i>Cannabis sativa</i> ; Bridging the Gap in Melanoma Treatment. <i>International Journal of Molecular Sciences</i> , 2023, 24, 859.	1.8	8
10139	CRISPR/Cas9 therapeutics: progress and prospects. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	73
10140	AXL antibody and AXL-ADC mediate antitumor efficacy via targeting AXL in tumor-intrinsic epithelial-mesenchymal transition and tumor-associated M2-like macrophage. <i>Acta Pharmacologica Sinica</i> , 2023, 44, 1290-1303.	2.8	3
10141	Molecular characterization based on tumor microenvironment-related signatures for guiding immunotherapy and therapeutic resistance in lung adenocarcinoma. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	1
10142	Case report: Identification of acute promyelocytic leukemia during osimertinib resistance followed by granulocyte colony-stimulating factor and pembrolizumab. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
10143	Upregulation of complement proteins in lung cancer cells mediates tumor progression. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
10144	Association between pre-treatment chest imaging and pulmonary function abnormalities and immune checkpoint inhibitor pneumonitis. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 1727-1735.	2.0	2

#	ARTICLE	IF	CITATIONS
10145	Updated Views in Targeted Therapy in the Patient with Non-Small Cell Lung Cancer. <i>Journal of Personalized Medicine</i> , 2023, 13, 167.	1.1	5
10146	Circulating exosomal immuno-oncological checkpoints and cytokines are potential biomarkers to monitor tumor response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
10147	The value of the multidisciplinary team in metastatic renal cell carcinoma: Paving the way for precision medicine in toxicities management. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
10148	Case Report: Chemotherapy-free treatment with camrelizumab and anlotinib for elderly patients with KRAS and TP53 mutated advanced lung cancer. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	2
10149	Gradient differences of immunotherapy efficacy in metastatic melanoma related to sunlight exposure pattern: A population-based study. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
10150	Wnt/ β -Catenin Signaling and Resistance to Immune Checkpoint Inhibitors: From Non-Small-Cell Lung Cancer to Other Cancers. <i>Biomedicines</i> , 2023, 11, 190.	1.4	9
10151	Application of Immune Checkpoint Inhibitors in Gynecological Cancers: What Do Gynecologists Need to Know before Using Immune Checkpoint Inhibitors?. <i>International Journal of Molecular Sciences</i> , 2023, 24, 974.	1.8	3
10152	The development of a tumor-associated autoantibodies panel to predict clinical outcomes for immune checkpoint inhibitor-based treatment in patients with advanced non-small cell lung cancer. <i>Thoracic Cancer</i> , 2023, 14, 497-505.	0.8	1
10153	The impact of combined PD-L1 positive score on clinical response to nivolumab in patients with advanced esophageal squamous cell carcinoma. <i>Esophagus</i> , 2023, 20, 524-532.	1.0	5
10154	Canine oral squamous cell carcinoma as a spontaneous, translational model for radiation and immunology research. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
10155	Avelumab in Combination With Cetuximab and Chemotherapy as First-Line Treatment for Patients With Advanced Squamous Non-Small Cell Lung Cancer. <i>JTO Clinical and Research Reports</i> , 2023, , 100461.	0.6	0
10156	Peripheral and tumor-infiltrating immune cells are correlated with patient outcomes in ovarian cancer. <i>Cancer Medicine</i> , 2023, 12, 10045-10061.	1.3	1
10157	Combined Hypophysitis and Type 1 Diabetes Mellitus Related to Immune Checkpoint Inhibitors. <i>Journal of the Endocrine Society</i> , 2023, 7, .	0.1	1
10158	CMTM6 is highly expressed in lung adenocarcinoma and can be used as a biomarker of a poor diagnosis. <i>PeerJ</i> , 0, 11, e14668.	0.9	0
10159	Thyroid dysfunction in Chinese nasopharyngeal carcinoma after anti-PD-1 therapy and its association with treatment response. <i>BMC Medicine</i> , 2023, 21, .	2.3	0
10160	Immunopathogenesis of Immune Checkpoint Inhibitor Induced Myocarditis: Insights from Experimental Models and Treatment Implications. <i>Biomedicines</i> , 2023, 11, 107.	1.4	4
10161	Investigating silver nanoparticles and resiquimod as a local melanoma treatment. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2023, 183, 1-12.	2.0	3
10162	The Outcomes of Surgical and Nonsurgical Treatment in Patients With Spinal Metastases of Lung Cancer: Protocol for a Prospective Cohort Study. <i>JMIR Research Protocols</i> , 0, 12, e38273.	0.5	0

#	ARTICLE	IF	CITATIONS
10163	Immune checkpoint inhibitors in kidney transplantation. <i>Current Opinion in Organ Transplantation</i> , 2023, 28, 46-54.	0.8	4
10164	Crescentic Fibrillary Glomerulonephritis in the Setting of Immune Checkpoint Inhibitor Therapy: A Report of Two Cases. <i>Glomerular Diseases</i> , 2023, 3, 69-74.	0.2	1
10165	Emerging Biomarkers in Immune Oncology to Guide Lung Cancer Management. <i>Targeted Oncology</i> , 0, , .	1.7	1
10166	Long Non-Coding RNAs as Epigenetic Regulators of Immune Checkpoints in Cancer Immunity. <i>Cancers</i> , 2023, 15, 184.	1.7	3
10167	Intrinsic and Extrinsic Transcriptional Profiles That Affect the Clinical Response to PD-1 Inhibitors in Patients with Non-“Small Cell Lung Cancer. <i>Cancers</i> , 2023, 15, 197.	1.7	1
10168	Aerosolized immunotherapeutic nanoparticle inhalation potentiates PD-L1 blockade for locally advanced lung cancer. <i>Nano Research</i> , 2023, 16, 5300-5310.	5.8	2
10169	Advancements in Cancer Immunotherapies. <i>Vaccines</i> , 2023, 11, 59.	2.1	8
10170	Establishment and validation of an aging-related risk signature associated with prognosis and tumor immune microenvironment in breast cancer. <i>European Journal of Medical Research</i> , 2022, 27, .	0.9	4
10171	Atypical Response in Metastatic Non-Small Cell Lung Cancer Treated with PD-1/PD-L1 Inhibitors: Radiographic Patterns and Clinical Value of Local Therapy. <i>Cancers</i> , 2023, 15, 180.	1.7	0
10172	Stereotactic Body Radiotherapy and Immunotherapy for Older Patients with Oligometastases: A Proposed Paradigm by the International Geriatric Radiotherapy Group. <i>Cancers</i> , 2023, 15, 244.	1.7	3
10173	Penetrating Exploration of Prognostic Correlations of the FKBP Gene Family with Lung Adenocarcinoma. <i>Journal of Personalized Medicine</i> , 2023, 13, 49.	1.1	2
10174	The Role of Immune Checkpoint Inhibitors in Cancer Therapy. <i>Clinics and Practice</i> , 2023, 13, 22-40.	0.6	14
10175	Management of Endocrine and Metabolic Toxicities of Immune-Checkpoint Inhibitors: From Clinical Studies to a Real-Life Scenario. <i>Cancers</i> , 2023, 15, 246.	1.7	8
10176	Impact of Liver Metastases and Number of Metastatic Sites on Immune-Checkpoint Inhibitors Efficacy in Patients with Different Solid Tumors: A Retrospective Study. <i>Biomedicines</i> , 2023, 11, 83.	1.4	3
10177	Serum CCL22 Increased in Advanced Melanoma Patients with Liver Metastases: Report of 5 Cases. <i>Case Reports in Oncology</i> , 2022, 15, 1114-1120.	0.3	0
10178	Preoperative immunochemotherapy for locally advanced non-small cell lung cancer: an analysis of the clinical outcomes, optimal number of cycles, and peripheral immune markers. <i>Translational Lung Cancer Research</i> , 2022, 11, 2364-2381.	1.3	5
10179	Cutaneous Melanoma and Hormones: Focus on Sex Differences and the Testis. <i>International Journal of Molecular Sciences</i> , 2023, 24, 599.	1.8	5
10180	The Latest Approach of Immunotherapy with Endosomal TLR Agonists Improving NK Cell Function: An Overview. <i>Biomedicines</i> , 2023, 11, 64.	1.4	2

#	ARTICLE	IF	CITATIONS
10181	Telomere Status of Advanced Non-Small-Cell Lung Cancer Offers a Novel Promising Prognostic and Predictive Biomarker. <i>Cancers</i> , 2023, 15, 290.	1.7	2
10182	PD-L1 Expression is not a Predictive Factor for Recurrence in Resected Non-small Cell Lung Cancer. <i>Lung</i> , 2023, 201, 95-101.	1.4	1
10183	Efficacy of Immunotherapy in Second-Line Treatment of KRAS-Mutated Patients with Non-Small-Cell Lung Cancer—Data from Daily Practice. <i>Current Oncology</i> , 2023, 30, 462-475.	0.9	2
10184	Lymphocytes from B-acute lymphoblastic leukemia patients present differential regulation of the adenosinergic axis depending on risk stratification. <i>Discover Oncology</i> , 2022, 13, .	0.8	1
10185	Molecular characterization of feline immune checkpoint molecules and establishment of PD-L1 immunohistochemistry for feline tumors. <i>PLoS ONE</i> , 2023, 18, e0281143.	1.1	4
10186	IFN γ signaling in cytotoxic T cells restricts anti-tumor responses by inhibiting the maintenance and diversity of intra-tumoral stem-like T cells. <i>Nature Communications</i> , 2023, 14, .	5.8	12
10187	Gastric adenocarcinoma with high level microsatellite instability: A case report. <i>Molecular and Clinical Oncology</i> , 2023, 18, .	0.4	0
10188	A combination therapy of bortezomib, CXCR4 inhibitor, and checkpoint inhibitor is effective in cholangiocarcinoma in vivo. <i>iScience</i> , 2023, 26, 106095.	1.9	2
10189	Construction and Verification of the Molecular Subtype and a Novel Prognostic Signature Based on Inflammatory Response-Related Genes in Uveal Melanoma. <i>Journal of Clinical Medicine</i> , 2023, 12, 861.	1.0	1
10190	Incidence of adverse cardiovascular events associated with immune checkpoint inhibitors and risk factors for left ventricular dysfunction: A single-center prospective clinical study. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	1.1	6
10191	Syngeneic N1-S1 Orthotopic Hepatocellular Carcinoma in Sprague Dawley Rat for the Development of Interventional Oncology-Based Immunotherapy: Survival Assay and Tumor Immune Microenvironment. <i>Cancers</i> , 2023, 15, 913.	1.7	3
10192	Bevacizumab-Induced Thrombotic Microangiopathy (TMA) in Metastatic Lung Adenocarcinoma Patients Receiving Nivolumab Combined with Bevacizumab, Carboplatin and Paclitaxel: Two Case Reports. <i>Clinics and Practice</i> , 2023, 13, 200-205.	0.6	2
10193	Neoadjuvant therapy with immunoagent (nivolumab) or placebo plus chemotherapy followed by surgery and adjuvant treatment in subjects with resectable esophageal squamous cell carcinoma: study protocol of a randomized, multicenter, double blind, phase II trial (NATION-2203 trial). <i>Journal of Thoracic Disease</i> , 2023, .	0.6	1
10194	Evaluating Pneumonitis Incidence in Patients with Non-small Cell Lung Cancer Treated with Immunotherapy and/or Chemotherapy Using Real-world and Clinical Trial Data. <i>Cancer Research Communications</i> , 2023, 3, 258-266.	0.7	0
10195	Efficacy and safety of immune checkpoint inhibitors with or without radiotherapy in metastatic non-small cell lung cancer: A systematic review and meta-analysis. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	2
10196	A Review of the Pharmacokinetic Characteristics of Immune Checkpoint Inhibitors and Their Clinical Impact Factors. <i>Pharmacogenomics and Personalized Medicine</i> , 0, Volume 16, 29-36.	0.4	0
10197	Combining targeted DNA repair inhibition and immune-oncology approaches for enhanced tumor control. <i>Molecular Cell</i> , 2023, 83, 660-680.	4.5	10
10198	Targeting ULK1 Decreases IFN γ -Mediated Resistance to Immune Checkpoint Inhibitors. <i>Molecular Cancer Research</i> , 2023, 21, 332-344.	1.5	4

#	ARTICLE	IF	CITATIONS
10199	Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy. , 2023, 11, e005924.		24
10200	Impact of Immune-Related Adverse Events on Immune Checkpoint Inhibitors Treated Cancer Patientsâ€™ Survival: Single Center Experience and Literature Review. <i>Cancers</i> , 2023, 15, 888.	1.7	5
10201	Using EGFR amplification to stratify recurrent glioblastoma treated with immune checkpoint inhibitors. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 1893-1901.	2.0	4
10202	PD-L1, CD4+, and CD8+ Tumor-Infiltrating Lymphocytes (TILs) Expression Profiles in Melanoma Tumor Microenvironment Cells. <i>Journal of Personalized Medicine</i> , 2023, 13, 221.	1.1	8
10203	Duration of Immunotherapy in Non-Small Cell Lung Cancer Survivors: A Lifelong Commitment?. <i>Cancers</i> , 2023, 15, 689.	1.7	5
10204	An Immunogenic Cell Death-Related Gene Signature Reflects Immune Landscape and Predicts Prognosis in Melanoma Independently of BRAF V600E Status. <i>BioMed Research International</i> , 2023, 2023, 1-21.	0.9	2
10205	Efficacy and Safety of PD-1/PD-L1 Checkpoint Inhibitors versus Anti-PD-1/PD-L1 Combined with Other Therapies for Tumors: A Systematic Review. <i>Cancers</i> , 2023, 15, 682.	1.7	2
10206	Fucosylation of HLA-DRB1 regulates CD4+ T cell-mediated anti-melanoma immunity and enhances immunotherapy efficacy. <i>Nature Cancer</i> , 2023, 4, 222-239.	5.7	15
10207	Data mining combines bioinformatics discover immunoinfiltration-related gene SERPINE1 as a biomarker for diagnosis and prognosis of stomach adenocarcinoma. <i>Scientific Reports</i> , 2023, 13, .	1.6	7
10208	Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 1381-1394.	2.0	3
10209	Oligometastatic disease and visceral resections in advanced malignant melanoma: a propensity-matched analysis. <i>Langenbeck's Archives of Surgery</i> , 2023, 408, .	0.8	1
10210	Phytochemicals as Immunomodulatory Agents in Melanoma. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2657.	1.8	4
10211	Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Cocksackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors. , 2023, 11, e005007.		3
10212	DNA methylation and transcriptome signatures of the PDCD1 gene in ankylosing spondylitis. <i>Genes and Immunity</i> , 2023, 24, 46-51.	2.2	2
10213	Outcome following nivolumab treatment in patients with advanced non-small cell lung cancer and comorbid interstitial lung disease in a real-world setting. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592311528.	1.4	1
10214	Peripheral blood lymphocytes differentiation patterns in responses / outcomes to immune checkpoint blockade therapies in non-small cell lung cancer: a retrospective study. <i>BMC Cancer</i> , 2023, 23, .	1.1	3
10215	Targeting the cMET pathway to enhance immunotherapeutic approaches for mUM patients. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
10216	Chromatin Regulator-Related Gene Signature for Predicting Prognosis and Immunotherapy Efficacy in Breast Cancer. <i>Journal of Oncology</i> , 2023, 2023, 1-12.	0.6	1

#	ARTICLE	IF	CITATIONS
10217	Whole-Transcriptome Sequencing Combined with High-Dimensional Proteomic Technologies Reveals the Potential Value of miR-135b-5p as a Biomarker for Hepatocellular Carcinoma. <i>BioMed Research International</i> , 2023, 2023, 1-22.	0.9	0
10218	MicroRNAs with Multiple Targets of Immune Checkpoints, as a Potential Sensitizer for Immune Checkpoint Inhibitors in Breast Cancer Treatment. <i>Cancers</i> , 2023, 15, 824.	1.7	3
10219	ITA-IMMUNO-PET: The Role of [18F]FDG PET/CT for Assessing Response to Immunotherapy in Patients with Some Solid Tumors. <i>Cancers</i> , 2023, 15, 878.	1.7	6
10220	A signature-based classification of lung adenocarcinoma that stratifies tumor immunity. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
10221	The application of patient-derived organoid in the research of lung cancer. <i>Cellular Oncology (Dordrecht)</i> , 2023, 46, 503-519.	2.1	9
10222	Rapid disease progression on immune checkpoint inhibitors in young patients with stage IV melanoma. <i>Frontiers in Medicine</i> , 0, 10, .	1.2	2
10223	High PD-L2 Predicts Early Recurrence of ER-Positive Breast Cancer. <i>JCO Precision Oncology</i> , 2023, , .	1.5	6
10224	Head and Neck Cancer Immunotherapy: Molecular Biological Aspects of Preclinical and Clinical Research. <i>Cancers</i> , 2023, 15, 852.	1.7	6
10225	Predicting PD-L1 expression status in patients with non-small cell lung cancer using [18F]FDG PET/CT radiomics. <i>EJNMMI Research</i> , 2023, 13, .	1.1	6
10226	Soluble and cell-based markers of immune checkpoint inhibitor-associated nephritis. , 2023, 11, e006222.		9
10227	Caregivers with Cancer Patients: Focus on Hispanics. <i>Cancers</i> , 2023, 15, 626.	1.7	4
10228	Injectable Polypeptide Hydrogel Depots Containing Dual Immune Checkpoint Inhibitors and Doxorubicin for Improved Tumor Immunotherapy and Post-Surgical Tumor Treatment. <i>Pharmaceutics</i> , 2023, 15, 428.	2.0	4
10229	Rapidly Progressive Pauci-Immune Glomerulonephritis with Aberrant Fibrinoid Necrosis Associated with Atezolizumab, an Immune Check Point Inhibitor: A Case Report and Review of Literature. <i>Antibodies</i> , 2023, 12, 10.	1.2	2
10230	Impact of Frailty on Outcomes of First-Line Pembrolizumab Monotherapy in a Real-World Population with Advanced Non-Small Cell Lung Cancer. <i>Biology</i> , 2023, 12, 191.	1.3	0
10231	Leading Edge: Intratumor Delivery of Monoclonal Antibodies for the Treatment of Solid Tumors. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2676.	1.8	6
10232	Immunotherapy in oncology and the kidneys: a clinical review of the evaluation and management of kidney immune-related adverse events. <i>CKJ: Clinical Kidney Journal</i> , 2023, 16, 939-951.	1.4	5
10233	A Novel Humanized PD-1/PD-L1 Mouse Model Permits Direct Comparison of Antitumor Immunity Generated by Food and Drug Administration-Approved PD-1 and PD-L1 Inhibitors. <i>ImmunoHorizons</i> , 2023, 7, 125-139.	0.8	1
10234	Associated Factors of Spontaneous Hemorrhage in Brain Metastases in Patients with Lung Adenocarcinoma. <i>Cancers</i> , 2023, 15, 619.	1.7	2

#	ARTICLE	IF	CITATIONS
10235	Microenvironment and the progress of immunotherapy in clinical practice of NSCLC brain metastasis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
10236	Immune-Related Thyroiditis in Patients with Advanced Lung Cancer Treated with Immune Checkpoint Inhibitors: Imaging Features and Clinical Implications. <i>Cancers</i> , 2023, 15, 649.	1.7	1
10237	Immune-Related Adverse Events of the Gastrointestinal System. <i>Cancers</i> , 2023, 15, 691.	1.7	1
10238	BASP1 is a prognostic biomarker associated with immunotherapeutic response in head and neck squamous cell carcinoma. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	3
10239	Immunogenic cell death: The cornerstone of oncolytic viro-immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
10240	Immune checkpoint inhibitors as first-line therapy for non-small cell lung cancer: A systematic evaluation and meta-analysis. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .	1.4	3
10241	Association between <sc>PD</sc> inhibitor-related adverse events and frailty assessed by frailty index in lung cancer patients. <i>Cancer Medicine</i> , 0, , .	1.3	1
10242	Upregulated SSB Is Involved in Hepatocellular Carcinoma Progression and Metastasis through the Epithelial-Mesenchymal Transition, Antiapoptosis, and Altered ROS Level Pathway. <i>Oxidative Medicine and Cellular Longevity</i> , 2023, 2023, 1-16.	1.9	0
10244	The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitors. <i>Anti-Cancer Drugs</i> , 2023, 34, 783-790.	0.7	2
10245	Treatments for brain metastases from EGFR/ALK-negative/unselected NSCLC: A network meta-analysis. <i>Open Medicine (Poland)</i> , 2023, 18, .	0.6	0
10246	Prognostic significance of lymph node dissection for lung cancer surgery: a narrative review. <i>Journal of Thoracic Disease</i> , 2023, 15, 2253-2260.	0.6	1
10247	Emerging Nano-/Biotechnology Drives Oncolytic Virus-Activated and Combined Cancer Immunotherapy. <i>Research</i> , 2023, 6, .	2.8	12
10248	Prognostic role of soluble PD-1 and BTN2A1 in overweight melanoma patients treated with nivolumab or pembrolizumab: finding the missing links in the symbiotic immune-metabolic interplay. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592311518.	1.4	6
10249	A pathway-based mutation signature to predict the clinical outcomes and response to CTLA-4 inhibitors in melanoma. <i>Computational and Structural Biotechnology Journal</i> , 2023, 21, 2536-2546.	1.9	4
10250	Pyroptosis-based risk score predicts prognosis and drug sensitivity in lung adenocarcinoma. <i>Open Medicine (Poland)</i> , 2023, 18, .	0.6	0
10251	Treatment strategies based on different oligoprogressive patterns after immunotherapy failure in metastatic NSCLC. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592311563.	1.4	1
10252	Integration of transcriptomics data into agent-based models of solid tumor metastasis. <i>Computational and Structural Biotechnology Journal</i> , 2023, 21, 1930-1941.	1.9	0
10253	Editorial: Factors that impact the survival of non-small cell lung cancer. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0

#	ARTICLE	IF	CITATIONS
10254	Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T. <i>Molecular Cancer</i> , 2023, 22, .	7.9	14
10255	Classic and new strategies for the treatment of advanced melanoma and non-melanoma skin cancer. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	6
10256	Long-term persistence and functionality of adoptively transferred antigen-specific T cells with genetically ablated PD-1 expression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2023, 120, .	3.3	9
10257	Immune Checkpoint Inhibitors for Solid Tumors in the Adjuvant Setting: Current Progress, Future Directions, and Role in Transplant Oncology. <i>Cancers</i> , 2023, 15, 1433.	1.7	3
10258	Association of Computed Tomography Measures of Muscle and Adipose Tissue and Progressive Changes throughout Treatment with Clinical Endpoints in Patients with Advanced Lung Cancer Treated with Immune Checkpoint Inhibitors. <i>Cancers</i> , 2023, 15, 1382.	1.7	1
10259	Immune checkpoint inhibitor-induced vitiligo in cancer patients: characterization and management. <i>Archives of Dermatological Research</i> , 2023, 315, 1697-1703.	1.1	1
10260	Predictive value of 18F-FDG PET/CT for evaluating the response to hypofractionated radiotherapy combined with PD-1 blockade in non-small cell lung cancer. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
10261	The ratio of adaptive to innate immune cells differs between genders and associates with improved prognosis and response to immunotherapy. <i>PLoS ONE</i> , 2023, 18, e0281375.	1.1	0
10262	Cardiovascular, Renal and Pulmonary Toxicity of Immune Checkpoint Inhibitors in Cancer: What the GP Should Know. <i>Praxis</i> , 2023, 112, 160-171.	0.2	1
10263	A text-mining approach to study the real-world effectiveness and potentially fatal immune-related adverse events of PD-1 and PD-L1 inhibitors in older patients with stage III/IV non-small cell lung cancer. <i>BMC Cancer</i> , 2023, 23, .	1.1	0
10264	Germline genetic variants are associated with development of insulin-dependent diabetes in cancer patients treated with immune checkpoint inhibitors. , 2023, 11, e006570.		8
10265	PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma. <i>Journal of Biomedical Science</i> , 2023, 30, .	2.6	4
10266	Combating pancreatic cancer with ovarian cancer cells. <i>Aging</i> , 2023, 15, 2189-2207.	1.4	0
10267	Blockade of trans PD-L1 interaction with CD80 augments antitumor immunity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2023, 120, .	3.3	5
10268	Diagnosis and Management of Pembrolizumab-Associated Pericardial Effusion in a Non-small Cell Lung Cancer Patient. <i>Cureus</i> , 2023, , .	0.2	0
10269	Overcoming anti-PD-1/PD-L1 immune checkpoint blockade resistance: the role of macrophage, neutrophils and mast cells in the tumor microenvironment. <i>Clinical and Experimental Medicine</i> , 2023, 23, 3077-3091.	1.9	7
10270	Immunotherapy of thymic epithelial tumors: molecular understandings and clinical perspectives. <i>Molecular Cancer</i> , 2023, 22, .	7.9	3
10271	Efficacy and safety of combined immunotherapy and stereotactic radiosurgery in NSCLCBM patients and a novel prognostic nomogram: A real-world study. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1

#	ARTICLE	IF	CITATIONS
10272	Machine learning-based integration develops an immune-related risk model for predicting prognosis of high-grade serous ovarian cancer and providing therapeutic strategies. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
10273	Impact of extended interval dosing of immune checkpoint inhibitors in lung cancer patients during the COVID-19 pandemic. <i>Respiratory Medicine and Research</i> , 2023, 83, 101004.	0.4	0
10274	Ionizable polymeric nanocarriers for the codelivery of bi-adjuvant and neoantigens in combination tumor immunotherapy. <i>Bioactive Materials</i> , 2023, 26, 169-180.	8.6	3
10275	Organoids as an Enabler of Precision Immuno-Oncology. <i>Cells</i> , 2023, 12, 1165.	1.8	2
10276	Ipilimumab-related uveitis and refractory hypotony with a flat chamber in a trabeculectomized eye with exfoliation glaucoma: A case report. <i>American Journal of Ophthalmology Case Reports</i> , 2023, 29, 101807.	0.4	2
10277	SECTM1 is upregulated in immuno-hot tumors and predicts immunotherapeutic efficacy in multiple cancers. <i>IScience</i> , 2023, 26, 106027.	1.9	6
10278	Immunology and immunotherapy of cholangiocarcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2023, 20, 349-365.	8.2	28
10279	Advances in the Molecular Landscape of Lung Cancer Brain Metastasis. <i>Cancers</i> , 2023, 15, 722.	1.7	6
10280	Adjuvant immunotherapy in early-stage resectable non-small cell lung cancer: A new milestone. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	4
10281	Immune-related adverse events in checkpoint blockade: Observations from human tissue and therapeutic considerations. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	8
10282	Monitoring and Modulating Diet and Gut Microbes to Enhance Response and Reduce Toxicity to Cancer Treatment. <i>Cancers</i> , 2023, 15, 777.	1.7	3
10283	Targets of Immune Escape Mechanisms in Cancer: Basis for Development and Evolution of Cancer Immune Checkpoint Inhibitors. <i>Biology</i> , 2023, 12, 218.	1.3	27
10284	TSC2 regulates tumor susceptibility to TRAIL-mediated T cell killing by orchestrating mTOR signaling. <i>EMBO Journal</i> , 2023, 42, .	3.5	2
10285	Agonistic and antagonistic targeting of immune checkpoint molecules differentially regulate osteoclastogenesis. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
10286	Phosphoinositide acyl chain saturation drives CD8+ effector T cell signaling and function. <i>Nature Immunology</i> , 2023, 24, 516-530.	7.0	9
10287	The CTLA-4 immune checkpoint protein regulates PD-L1:PD interaction via transendocytosis of its ligand CD80. <i>EMBO Journal</i> , 2023, 42, .	3.5	7
10288	The role of potential probiotic strains <i>Lactobacillus reuteri</i> in various intestinal diseases: New roles for an old player. <i>Frontiers in Microbiology</i> , 0, 14, .	1.5	11
10289	Management of papillary thyroid cancer with tracheal invasion and lung cancer: A case report. <i>Oncology Letters</i> , 2023, 25, .	0.8	0

#	ARTICLE	IF	CITATIONS
10290	Persistent response of furmonertinib plus anlotinib in a lung adenocarcinoma patient with an EGFR exon 20 insertion mutation: A case report. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	1
10291	Association between Loss of Immune Checkpoint Programmed Cell Death Protein 1 and Active ANCA-Associated Renal Vasculitis. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2975.	1.8	3
10292	A narrative review of genetic biomarkers in non-small cell lung cancer: an update and future perspectives. <i>AME Medical Journal</i> , 0, 8, 6-6.	0.4	1
10293	Targeted Therapy of Interleukin-34 as a Promising Approach to Overcome Cancer Therapy Resistance. <i>Cancers</i> , 2023, 15, 971.	1.7	3
10294	A case of hepatocellular carcinoma with "pseudoprogression" followed by complete response to atezolizumab plus bevacizumab. <i>Clinical Journal of Gastroenterology</i> , 2023, 16, 392-396.	0.4	1
10295	Modulation of oxidative phosphorylation and mitochondrial biogenesis by cigarette smoke influence the response to immune therapy in NSCLC patients. <i>Lung Cancer</i> , 2023, 178, 37-46.	0.9	0
10296	Re-Irradiation by Stereotactic Radiotherapy of Brain Metastases in the Case of Local Recurrence. <i>Cancers</i> , 2023, 15, 996.	1.7	1
10297	COVID-19 vaccination in patients with cancer receiving immune checkpoint inhibitors: a systematic review and meta-analysis. , 2023, 11, e006246.		10
10298	Regulation of immunological tolerance by the p53-inhibitor iASPP. <i>Cell Death and Disease</i> , 2023, 14, .	2.7	3
10299	Proto-Oncogene FAM50A Can Regulate the Immune Microenvironment and Development of Hepatocellular Carcinoma In Vitro and In Vivo. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3217.	1.8	2
10300	Effectiveness and safety of pembrolizumab for patients with advanced non-small cell lung cancer in real-world studies and randomized controlled trials: A systematic review and meta-analysis. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
10301	Autoantibody profiles in patients with immune checkpoint inhibitor-induced neurological immune related adverse events. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	11
10302	Clinicopathological Features of Kidney Injury Related to Immune Checkpoint Inhibitors: A Systematic Review. <i>Journal of Clinical Medicine</i> , 2023, 12, 1349.	1.0	1
10303	Prognostic RNA-editing signature predicts immune functions and therapy responses in gliomas. <i>Frontiers in Genetics</i> , 0, 14, .	1.1	0
10304	Characterization of the immune cell landscape in CRC: Clinical implications of tumour-infiltrating leukocytes in early- and late-stage CRC. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
10305	Extracellular Vesicles in Cancer Drug Resistance: Implications on Melanoma Therapy. <i>Cancers</i> , 2023, 15, 1074.	1.7	2
10306	Radiotherapy, PARP Inhibition, and Immune-Checkpoint Blockade: A Triad to Overcome the Double-Edged Effects of Each Single Player. <i>Cancers</i> , 2023, 15, 1093.	1.7	4
10307	<sc>CD70</sc> and <sc>PD-1</sc> (<sc>CD274</sc>) co-expression predicts poor clinical outcomes in patients with pleural mesothelioma. <i>Journal of Pathology: Clinical Research</i> , 2023, 9, 195-207.	1.3	2

#	ARTICLE	IF	CITATIONS
10308	Echinacea purpurea-derived homogeneous polysaccharide exerts anti-tumor efficacy via facilitating M1 macrophage polarization. <i>Innovation(China)</i> , 2023, 4, 100391.	5.2	4
10309	Effect of Cancer-Related Cachexia and Associated Changes in Nutritional Status, Inflammatory Status, and Muscle Mass on Immunotherapy Efficacy and Survival in Patients with Advanced Non-Small Cell Lung Cancer. <i>Cancers</i> , 2023, 15, 1076.	1.7	13
10310	Development and validation of a decision model for the evaluation of novel lung cancer treatments in the Netherlands. <i>Scientific Reports</i> , 2023, 13, .	1.6	1
10311	Immunotherapy in Melanoma: Recent Advances and Future Directions. <i>Cancers</i> , 2023, 15, 1106.	1.7	39
10312	Efficacy of PD-1/PD-L1 inhibitors in gastric or gastro-oesophageal junction cancer based on clinical characteristics: a meta-analysis. <i>BMC Cancer</i> , 2023, 23, .	1.1	4
10313	Activated CTLA-4-independent immunosuppression of Treg cells disturbs CTLA-4 blockade-mediated antitumor immunity. <i>Cancer Science</i> , 2023, 114, 1859-1870.	1.7	6
10314	Long-Term Response of Pembrolizumab in a Patient with Metastatic Squamous Non-Small Cell Lung Cancer on Hemodialysis: Case Report and Review of the Literature. <i>Medicina (Lithuania)</i> , 2023, 59, 325.	0.8	3
10315	Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 immunotherapy for solid cancers. <i>Molecular Cancer</i> , 2023, 22, .	7.9	36
10316	Circulating Biomarkers for Prediction of Immunotherapy Response in NSCLC. <i>Biomedicines</i> , 2023, 11, 508.	1.4	3
10317	Clinical Characteristics and Pharmacokinetics Change of Long-Term Responders to Antiprogrammed Cell Death Protein 1 Inhibitor Among Patients With Advanced NSCLC. <i>JTO Clinical and Research Reports</i> , 2023, 4, 100474.	0.6	0
10318	Identification and characterization of a novel molecular classification incorporating oxidative stress and metabolism-related genes for stomach adenocarcinoma in the framework of predictive, preventive, and personalized medicine. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	8
10319	Immunotherapy for Prostate Cancer: A Current Systematic Review and Patient Centric Perspectives. <i>Journal of Clinical Medicine</i> , 2023, 12, 1446.	1.0	7
10320	Prediction of CD3 T cells and CD8 T cells expression levels in non-small cell lung cancer based on radiomic features of CT images. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1
10321	Systemic Inflammation/Nutritional Status Scores Are Prognostic but Not Predictive in Metastatic Non-Small-Cell Lung Cancer Treated with First-Line Immune Checkpoint Inhibitors. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3618.	1.8	6
10322	Is the combination of immunotherapy with conventional chemotherapy the key to increase the efficacy of colorectal cancer treatment?. <i>World Journal of Gastrointestinal Oncology</i> , 0, 15, 251-267.	0.8	6
10323	The efficacy and safety of PD-1 inhibitors for EGFR-mutant non-small cell lung cancer after tyrosine kinase inhibitor failure: a retrospective real-world cohort study. <i>Annals of Translational Medicine</i> , 2023, 11, 157-157.	0.7	2
10324	TNFR2 expression predicts the responses to immune checkpoint inhibitor treatments. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	3
10325	Toripalimab plus chemotherapy vs. chemotherapy in patients with advanced non-small-cell lung cancer: A cost-effectiveness analysis. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	0

#	ARTICLE	IF	CITATIONS
10326	Impact of the immune molecular profile of the tumor microenvironment on the prognosis of NSCLC. <i>Oncology Letters</i> , 2023, 25, .	0.8	0
10327	<italic>Salmonella typhimurium</italic> may support cancer treatment: a review. <i>Acta Biochimica Et Biophysica Sinica</i> , 2023, 55, 331-342.	0.9	2
10328	The Gut Microbiome and Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Medicine</i> , 2023, 12, 1502.	1.0	3
10329	Neoadjuvant PD-1 Blockade in Non-Small Cell Lung Cancer: Current perspectives and Moving Forward. <i>OncoTargets and Therapy</i> , 0, Volume 16, 99-108.	1.0	4
10330	Evaluation and management of acute high-grade immunotherapy-related neurotoxicity. <i>Heliyon</i> , 2023, 9, e13725.	1.4	0
10331	Efficacy and safety of mycophenolate mofetil in treating immune-related hepatitis induced by immune checkpoint inhibitor use: A retrospective study. <i>JGH Open</i> , 2023, 7, 87-97.	0.7	4
10332	Changes in circulating tumor DNA and outcomes in solid tumors treated with immune checkpoint inhibitors: a systematic review. , 2023, 11, e005854.		8
10333	Progression patterns and site-specific responses in advanced gastric cancer patients treated with nivolumab. <i>Cancer Medicine</i> , 0, , .	1.3	1
10334	Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers. <i>Current Oncology</i> , 2023, 30, 2366-2387.	0.9	5
10335	The Prognostic Impact of Gender, Therapeutic Strategies, Molecular Background, and Tumor-Infiltrating Lymphocytes in Glioblastoma: A Still Unsolved Jigsaw. <i>Genes</i> , 2023, 14, 501.	1.0	5
10336	Recent advances and applications of CRISPR-Cas9 in cancer immunotherapy. <i>Molecular Cancer</i> , 2023, 22, .	7.9	14
10337	Unexpected curative effect of PD-1 inhibitor in gastric cancer with brain metastasis: A case report. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
10338	ALK-positive lung cancer: a moving target. <i>Nature Cancer</i> , 2023, 4, 330-343.	5.7	24
10339	Monocyte chemoattractant protein 1 as a potential biomarker for immune checkpoint inhibitor-associated neurotoxicity. <i>Cancer Medicine</i> , 2023, 12, 9373-9383.	1.3	7
10340	Development and validation of a radiomics-based nomogram for predicting a major pathological response to neoadjuvant immunochemotherapy for patients with potentially resectable non-small cell lung cancer. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	4
10341	Immunotherapy for hepatocellular carcinoma recurrence after liver transplantation, can we harness the power of immune checkpoint inhibitors?. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	5
10342	The immunotherapy advancement targeting malignant blastomas in early childhood. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
10343	Immunotherapy associated central nervous system complications in primary brain tumors. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	2

#	ARTICLE	IF	CITATIONS
10344	Serum cytokine levels and other associated factors as possible immunotherapeutic targets and prognostic indicators for lung cancer. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1
10345	Prospects and feasibility of synergistic therapy with radiotherapy, immunotherapy, and DNA methyltransferase inhibitors in non-small cell lung cancer. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
10346	Exosomal microRNAs in cancer: Potential biomarkers and immunotherapeutic targets for immune checkpoint molecules. <i>Frontiers in Genetics</i> , 0, 14, .	1.1	6
10347	Precision immunointerception of EGFR-driven tumorigenesis for lung cancer prevention. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
10348	The past, present, and future of immunotherapy for colorectal cancer. , 2023, 40, .		3
10349	TIGIT signaling and its influence on T cell metabolism and immune cell function in the tumor microenvironment. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	3
10350	Inhibition of myeloperoxidase enhances immune checkpoint therapy for melanoma. , 2023, 11, e005837.		11
10351	The Efficacy and Hemorheological Indexes of Ginseng and Its Active Components for Patients with Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. <i>Journal of Oncology</i> , 2023, 2023, 1-15.	0.6	0
10352	Enhanced antitumor activity of a novel, oral, helper epitope-containing WT1 protein vaccine in a model of murine leukemia. <i>BMC Cancer</i> , 2023, 23, .	1.1	1
10353	Prognostic significance of epidermal growth factor receptor and programmed cell death-ligand 1 co-expression in esophageal squamous cell carcinoma. <i>Aging</i> , 0, , .	1.4	0
10354	NLRC3 is a potential prognostic biomarker that is correlated with immune cell infiltration in lung adenocarcinoma. <i>Scientific Reports</i> , 2023, 13, .	1.6	0
10355	Angiogenic inhibitor preadministration improves the therapeutic effects of immunotherapy. <i>Cancer Medicine</i> , 2023, 12, 9760-9773.	1.3	3
10356	VISTA expression and patient selection for immune-based anticancer therapy. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	6
10357	The prognostic value of tumor mutation burden (TMB) and its relationship with immune infiltration in breast cancer patients. <i>European Journal of Medical Research</i> , 2023, 28, .	0.9	1
10358	MTSS1 curtails lung adenocarcinoma immune evasion by promoting AIP4-mediated PD-L1 monoubiquitination and lysosomal degradation. <i>Cell Discovery</i> , 2023, 9, .	3.1	5
10359	Cell adhesion molecules and immunotherapy in advanced non-small cell lung cancer: Current process and potential application. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
10360	The role of LncRNAs in tumor immunotherapy. <i>Cancer Cell International</i> , 2023, 23, .	1.8	11
10361	Cutaneous manifestations associated with immune checkpoint inhibitors. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	12

#	ARTICLE	IF	CITATIONS
10362	The role of macrophages in non-small cell lung cancer and advancements in 3D co-cultures. <i>ELife</i> , 0, 12, .	2.8	4
10363	Using deep learning to predict tumor mutational burden from scans of H&E-stained multicenter slides of lung squamous cell carcinoma. <i>Journal of Medical Imaging</i> , 2023, 10, .	0.8	1
10364	Economic burden of locoregional and metastatic relapses in resectable early-stage non-small cell lung cancer in Spain. <i>BMC Pulmonary Medicine</i> , 2023, 23, .	0.8	1
10365	Lung cancer immunotherapy: progress, pitfalls, and promises. <i>Molecular Cancer</i> , 2023, 22, .	7.9	104
10366	Current Trends in Mucosal Melanomas: An Overview. <i>Cancers</i> , 2023, 15, 1356.	1.7	5
10367	Case series: Immune checkpoint inhibitor-induced transverse myelitis. <i>Frontiers in Neurology</i> , 0, 14, .	1.1	1
10368	Association Between Survival and Metastatic Site in Mismatch Repair-Deficient Metastatic Colorectal Cancer Treated With First-line Pembrolizumab. <i>JAMA Network Open</i> , 2023, 6, e230400.	2.8	15
10369	Ocular adverse events associated with immune checkpoint inhibitors, a scoping review. <i>Journal of Ophthalmic Inflammation and Infection</i> , 2023, 13, .	1.2	8
10370	Acquired radioresistance in EMT6 mouse mammary carcinoma cell line is mediated by CTLA-4 and PD-1 through JAK/STAT/PI3K pathway. <i>Scientific Reports</i> , 2023, 13, .	1.6	1
10371	Killer to cure: Expression and production costs calculation of tobacco plant-made cancer-immune checkpoint inhibitors. <i>Plant Biotechnology Journal</i> , 2023, 21, 1254-1269.	4.1	4
10372	Developing an m5C regulator-mediated RNA methylation modification signature to predict prognosis and immunotherapy efficacy in rectal cancer. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
10373	Advances in immune checkpoint inhibitors induced-cardiotoxicity. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
10374	Imaging assessment of toxicity related to immune checkpoint inhibitors. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	6
10375	Predictive biomarkers for PD-1/PD-L1 checkpoint inhibitor response in NSCLC: an analysis of clinical trial and real-world data. , 2023, 11, e006464.		4
10376	An arginase1- and PD-L1-derived peptide-based vaccine for myeloproliferative neoplasms: A first-in-man clinical trial. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	3
10377	Circulating immune index predicting the prognosis of patients with hepatocellular carcinoma treated with lenvatinib and immunotherapy. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1
10378	Predictive and Prognostic Implications of Circulating CX3CR1+ CD8+ T Cells in Non-Small Cell Lung Cancer Patients Treated with Chemo-Immunotherapy. <i>Cancer Research Communications</i> , 2023, 3, 510-520.	0.7	2
10379	Unobvious Neutrophil Extracellular Traps Signification in the Course of Oral Squamous Cell Carcinoma: Current Understanding and Future Perspectives. <i>Cancer Control</i> , 2023, 30, 107327482311593.	0.7	1

#	ARTICLE	IF	CITATIONS
10380	Advances in Intralesional Therapy for Locoregionally Advanced and Metastatic Melanoma: Five Years of Progress. <i>Cancers</i> , 2023, 15, 1404.	1.7	0
10381	MicroRNA in lung cancer—a novel potential way for early diagnosis and therapy. <i>Journal of Applied Genetics</i> , 2023, 64, 459-477.	1.0	3
10382	Identification of tumor mutation burden-associated molecular and clinical features in cancer by analyzing multi-omics data. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	9
10383	Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	15
10384	Changes and correlations of T-cell coinhibitory molecule programmed death-1 and interferon- β in pediatric immune thrombocytopenia. <i>Clinical and Experimental Pediatrics</i> , 2023, 66, 127-133.	0.9	0
10385	Blocking CD47-SIRP α Signal Axis as Promising Immunotherapy in Ovarian Cancer. <i>Cancer Control</i> , 2023, 30, 107327482311597.	0.7	5
10386	Molecular phenotypic linkage between N6-methyladenosine methylation and tumor immune microenvironment in hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, .	1.2	0
10387	Effectiveness and Safety of Atezolizumab Monotherapy in Previously Treated Japanese Patients With Unresectable Advanced or Recurrent NSCLC: A Multicenter, Prospective, Observational Study (J-TAIL). <i>JTO Clinical and Research Reports</i> , 2023, 4, 100484.	0.6	1
10388	Bronchiolitis obliterans syndrome associated with an immune checkpoint inhibitor in a patient with non-small cell lung cancer. <i>Respiratory Medicine Case Reports</i> , 2023, 42, 101824.	0.2	1
10389	The Usefulness of Nanotechnology in Improving the Prognosis of Lung Cancer. <i>Biomedicines</i> , 2023, 11, 705.	1.4	1
10390	^{CD169} sinus macrophages in regional lymph nodes do not predict mismatch repair status of patients with colorectal cancer. <i>Cancer Medicine</i> , 2023, 12, 10199-10211.	1.3	5
10391	Narrative review: immunotherapy in anaplastic lymphoma kinase (ALK)+ lung cancer—current status and future directions. <i>Translational Lung Cancer Research</i> , 2023, 12, 322-336.	1.3	1
10392	Safety and efficacy of autologous cell vaccines in solid tumors: a systematic review and meta-analysis of randomized control trials. <i>Scientific Reports</i> , 2023, 13, .	1.6	6
10393	Pembrolizumab plus pemetrexed-carboplatin combination in first-line treatment of advanced non-squamous non-small cell lung cancer: a multicenter real-life study (CAP29). <i>Translational Lung Cancer Research</i> , 2023, 12, 266-276.	1.3	2
10394	New biomarkers exploration and nomogram construction of prognostic and immune-related adverse events of advanced non-small cell lung cancer patients receiving immune checkpoint inhibitors. <i>Respiratory Research</i> , 2023, 24, .	1.4	2
10395	Current status and future perspectives of bispecific antibodies in the treatment of lung cancer. <i>Chinese Medical Journal</i> , 2023, 136, 379-393.	0.9	1
10396	Case report: Spontaneous remission in lung carcinoma with a late relapse after adjuvant immunotherapy: Exceptional tumor micro-environment. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
10397	Molecular and functional imaging in cancer-targeted therapy: current applications and future directions. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	25

#	ARTICLE	IF	CITATIONS
10398	Myeloid cells in the immunosuppressive microenvironment in glioblastoma: The characteristics and therapeutic strategies. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
10399	Differential organ-specific tumor response to first-line immune checkpoint inhibitor therapy in non-small cell lung cancer—a retrospective cohort study. <i>Translational Lung Cancer Research</i> , 2023, 12, 312-321.	1.3	1
10400	Immunotherapy in Elderly Patients Affected by Non-Small Cell Lung Cancer: A Narrative Review. <i>Journal of Clinical Medicine</i> , 2023, 12, 1833.	1.0	4
10401	Pharmacodynamic activity of BMS-986156, a glucocorticoid-induced TNF receptor-related protein agonist, alone or in combination with nivolumab in patients with advanced solid tumors. <i>ESMO Open</i> , 2023, 8, 100784.	2.0	1
10402	3D Spheroid Configurations Are Possible Indicators for Evaluating the Pathophysiology of Melanoma Cell Lines. <i>Cells</i> , 2023, 12, 759.	1.8	8
10403	A Novel Prognostic Marker and Therapeutic Target Associated with Glioma Progression in a Tumor Immune Microenvironment. <i>Journal of Inflammation Research</i> , 0, Volume 16, 895-916.	1.6	0
10404	A real-world retrospective study of incidence and associated factors of endocrine adverse events related to PD-1/PD-L1 inhibitors. <i>Annals of Translational Medicine</i> , 2023, 11, 164-164.	0.7	0
10405	The characteristics of oncological clinical trials investigating the synergistic effect of radiotherapy and immune checkpoint inhibitors: a cross-sectional study. <i>Translational Cancer Research</i> , 2023, 12, 558-571.	0.4	0
10406	Insight into the Crosstalk between Photodynamic Therapy and Immunotherapy in Breast Cancer. <i>Cancers</i> , 2023, 15, 1532.	1.7	6
10407	Efficacy of stereotactic ablative radiotherapy (SABR) during anti-PD-1 in oligoprogressive non-small cell lung cancer and melanoma—a prospective multicenter observational study pointing out new unmet needs. <i>Translational Cancer Research</i> , 2023, 12, 688-691.	0.4	1
10408	Future therapeutic strategies in the treatment of extrapulmonary neuroendocrine carcinoma: a review. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592311568.	1.4	2
10409	Hemophagocytic Lymphohistiocytosis Associated with Immunological Checkpoint Inhibitors: A Pharmacovigilance Study. <i>Journal of Clinical Medicine</i> , 2023, 12, 1985.	1.0	7
10410	Downregulation of KEAP1 in melanoma promotes resistance to immune checkpoint blockade. <i>Npj Precision Oncology</i> , 2023, 7, .	2.3	3
10411	Acral Melanoma Is Infiltrated with cDC1s and Functional Exhausted CD8 T Cells Similar to the Cutaneous Melanoma of Sun-Exposed Skin. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4786.	1.8	0
10412	Immune-related toxicity and soluble profile in patients affected by solid tumors: a network approach. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 2217-2231.	2.0	2
10413	Treatment of Unresectable Cutaneous Squamous Cell Carcinoma with Cemiplimab in a Patient on Dialysis. <i>Case Reports in Oncology</i> , 0, , 143-148.	0.3	0
10414	Precision Surgery in NSCLC. <i>Cancers</i> , 2023, 15, 1571.	1.7	5
10415	Immune checkpoint blockade induces gut microbiota translocation that augments extraintestinal antitumor immunity. <i>Science Immunology</i> , 2023, 8, .	5.6	18

#	ARTICLE	IF	CITATIONS
10416	Antitumor Therapy Targeting the Tumor Microenvironment. <i>Journal of Oncology</i> , 2023, 2023, 1-16.	0.6	4
10417	Opportunities and challenges related to ferroptosis in glioma and neuroblastoma. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	3
10418	Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancer. <i>ESMO Open</i> , 2023, 8, 101160.	2.0	3
10419	Immunotherapy Resumption/Rechallenge in Melanoma Patients after Toxicity: Do We Have Another Chance?. <i>Pharmaceutics</i> , 2023, 15, 823.	2.0	1
10420	Identifying tumour microenvironment-related signature that correlates with prognosis and immunotherapy response in breast cancer. <i>Scientific Data</i> , 2023, 10, .	2.4	4
10421	Stuttering as a signal of encephalopathy associated with toripalimab in a pancreatic ductal adenocarcinoma patient: a case report. <i>BMC Neurology</i> , 2023, 23, .	0.8	1
10422	Nidogen-2 (NID2) is a Key Factor in Collagen Causing Poor Response to Immunotherapy in Melanoma. <i>Pharmacogenomics and Personalized Medicine</i> , 0, Volume 16, 153-172.	0.4	0
10423	CDK4/6 inhibition triggers ICAM1-driven immune response and sensitizes LKB1 mutant lung cancer to immunotherapy. <i>Nature Communications</i> , 2023, 14, .	5.8	14
10424	An Immunological Perspective on the Mechanism of Drug Induced Liver Injury: Focused on Drugs for Treatment of Hepatocellular Carcinoma and Liver Transplantation. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5002.	1.8	6
10425	Immune checkpoint inhibitor-associated toxicity in advanced non-small cell lung cancer: An updated understanding of risk factors. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
10426	Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity. <i>MAbs</i> , 2023, 15, .	2.6	25
10427	The Renewal of Cancer Immunotherapy. <i>Vaccines</i> , 2023, 11, 592.	2.1	0
10428	Immune checkpoint inhibitors related respiratory disorders in patients with lung cancer: A meta-analysis of randomized controlled trials. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
10429	Progression in immunotherapy for advanced prostate cancer. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	3
10430	Changes of tumor microenvironment in non-small cell lung cancer after TKI treatments. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	8
10431	IFN γ is a central node of cancer immune equilibrium. <i>Cell Reports</i> , 2023, 42, 112219.	2.9	6
10432	Neoadjuvant immunotherapy for colorectal cancer: Right regimens, right patients, right directions?. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	7
10433	Current landscape and tailored management of immune-related adverse events. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	1

#	ARTICLE	IF	CITATIONS
10434	Pneumonitis associated with pembrolizumab plus chemotherapy for non-squamous non-small cell lung cancer. <i>Scientific Reports</i> , 2023, 13, .	1.6	2
10435	TTF-1 Expression and Clinical Outcomes of Combined Chemoimmunotherapy in Patients With Advanced Lung Adenocarcinoma: A Prospective Observational Study. <i>JTO Clinical and Research Reports</i> , 2023, 4, 100494.	0.6	1
10436	Diversity of immune checkpoints in cancer immunotherapy. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	11
10437	Hepatotoxicity in immune checkpoint inhibitors: A pharmacovigilance study from 2014â€“2021. <i>PLoS ONE</i> , 2023, 18, e0281983.	1.1	1
10438	Collectin-11 promotes cancer cell proliferation and tumor growth. <i>JCI Insight</i> , 2023, 8, .	2.3	4
10439	Emerging phagocytosis checkpoints in cancer immunotherapy. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	32
10440	Prognostic Role of Soluble and Extracellular Vesicle-Associated PD-L1, B7-H3 and B7-H4 in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors. <i>Cells</i> , 2023, 12, 832.	1.8	10
10441	Pexidartinib synergize PD-1 antibody through inhibiting treg infiltration by reducing TAM-derived CCL22 in lung adenocarcinoma. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	1
10442	Incorporating risk preferences of patients in the valuation of immune checkpoint inhibitors for non-small cell lung cancer. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
10443	Status and prognostic value of immunological biomarkers of breast cancer. <i>Oncology Letters</i> , 2023, 25, .	0.8	1
10444	Systemic inflammation shapes clinical outcomes in response to immune checkpoint blockade treatment: moving toward optimizing antitumor immunity. , 2023, 11, e006462.		3
10445	Diagnostic criteria and proposed management of immune-related endocrinopathies following immune checkpoint inhibitor therapy for cancer. <i>Endocrine Connections</i> , 2023, 12, .	0.8	3
10446	The effect of combining PD-1 agonist and low-dose Interleukin-2 on treating systemic lupus erythematosus. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	3
10447	Discontinuation of Immune Checkpoint Inhibitor due to irAEs in NSCLC Patients With EGFR Mutation. <i>Cancer Diagnosis & Prognosis</i> , 2023, 3, 244-250.	0.3	1
10448	Treatment of Recurrent Melanoma Following Adjuvant Therapy. <i>American Journal of Clinical Dermatology</i> , 0, , .	3.3	0
10449	MC38 colorectal tumor cell lines from two different sources display substantial differences in transcriptome, mutanome and neoantigen expression. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	5
10450	Nivolumabâ€“induced acute tubular <sc>injury: A</sc> case report. <i>Clinical Case Reports (discontinued)</i> , 2023, 11, .	0.2	1
10451	Immune selection determines tumor antigenicity and influences response to checkpoint inhibitors. <i>Nature Genetics</i> , 2023, 55, 451-460.	9.4	16

#	ARTICLE	IF	CITATIONS
10452	Effect of BIM expression on the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs. <i>Scientific Reports</i> , 2023, 13, .	1.6	0
10453	Comprehensive bioinformatic analysis constructs a CXCL model for predicting survival and immunotherapy effectiveness in ovarian cancer. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	1
10454	Immune checkpoint inhibitors associated granulomatous small vessel vasculitis accompanied with tubulointerstitial nephritis: a case report. <i>BMC Nephrology</i> , 2023, 24, .	0.8	4
10455	PD-L1 Tumor Expression as a Predictive Biomarker of Immune Checkpoint Inhibitorsâ€™ Response and Survival in Advanced Melanoma Patients in Brazil. <i>Diagnostics</i> , 2023, 13, 1041.	1.3	1
10456	Characterisation of tumor microenvironment and prevalence of CD274/PD-L1 genetic alterations difference in colorectal Cancer. <i>BMC Cancer</i> , 2023, 23, .	1.1	1
10457	Comparative evaluation of PD-L1 expression in cytology imprints, circulating tumour cells and tumour tissue in non-small cell lung cancer patients. <i>Molecular Oncology</i> , 2023, 17, 737-746.	2.1	3
10458	Economic Evaluation of Nivolumab Versus Docetaxel for the Treatment of Advanced Squamous and Non-squamous Non-small Cell Lung Cancer After Prior Chemotherapy in China. <i>PharmacoEconomics - Open</i> , 2023, 7, 273-284.	0.9	1
10459	Efficacy of immune checkpoint inhibitors in patients with KRAS-mutant advanced non-small cell lung cancer: A retrospective analysis. <i>Open Medicine (Poland)</i> , 2023, 18, .	0.6	1
10460	Emerging Trends in Immunotherapy for Adult Sarcomas. <i>Oncologist</i> , 0, , .	1.9	2
10461	Immune gene patterns and characterization of the tumor immune microenvironment associated with cancer immunotherapy efficacy. <i>Heliyon</i> , 2023, 9, e14450.	1.4	1
10462	Comparison of sequential and joint nonlinear mixed effects modeling of tumor kinetics and survival following Durvalumab treatment in patients with metastatic urothelial carcinoma. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2023, 50, 251-265.	0.8	1
10463	A degradome-based prognostic signature that correlates with immune infiltration and tumor mutation burden in breast cancer. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
10464	Invasive margin tissue-resident macrophages of high CD163 expression impede responses to T cell-based immunotherapy. , 2023, 11, e006433.		4
10465	Novel Nanotherapeutics for Cancer Immunotherapy by PD-L1-Aptamer-Functionalized and Fexofenadine-Loaded Albumin Nanoparticles. <i>Molecules</i> , 2023, 28, 2556.	1.7	5
10466	Immune Checkpoint Inhibitor Related Rheumatological Complications: Cooperation between Rheumatologists and Oncologists. <i>International Journal of Environmental Research and Public Health</i> , 2023, 20, 4926.	1.2	0
10467	Anti-PD-(L)1 therapy of non-small cell lung cancerâ€“A summary of clinical trials and current progresses. <i>Heliyon</i> , 2023, 9, e14566.	1.4	2
10468	Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapy. <i>Theranostics</i> , 2023, 13, 1520-1544.	4.6	19
10469	Immune Checkpoint Inhibitorâ€“Associated Sarcoidosis Reaction in the Kidney: Case Report. <i>Kidney Medicine</i> , 2023, 5, 100626.	1.0	4

#	ARTICLE	IF	CITATIONS
10470	Descriptive Analysis of First-Line Non-Small Cell Lung Cancer Treatment with Pembrolizumab in Tumors Expressing PD-L1 ≥ 50% in Patients Treated in Quebec's University Teaching Hospitals (DALP-First Study). <i>Current Oncology</i> , 2023, 30, 3251-3262.	0.9	0
10471	Safety and efficacy of radiotherapy/chemoradiotherapy combined with immune checkpoint inhibitors for non-small cell lung cancer: A systematic review and meta-analysis. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	3
10472	Effect of neoadjuvant chemotherapy combined with arterial chemoembolization on short-term clinical outcome of locally advanced gastric cancer. <i>BMC Cancer</i> , 2023, 23, .	1.1	0
10473	Turning a Tumor Microenvironment Pitfall into Opportunity: Discovery of Benzamidoxime as PD-L1 Ligand with pH-Dependent Potency. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5535.	1.8	3
10474	I kappa B kinase interacting protein as a promising biomarker in pan-cancer: A multi-omics analysis. <i>Frontiers in Genetics</i> , 0, 14, .	1.1	0
10475	Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors. , 2023, 11, e005921.		6
10476	Association of Glycosylation-Related Genes with Different Patterns of Immune Profiles and Prognosis in Cervical Cancer. <i>Journal of Personalized Medicine</i> , 2023, 13, 529.	1.1	1
10477	Nontoxic Fluorescent Nanoprobes for Multiplexed Detection and 3D Imaging of Tumor Markers in Breast Cancer. <i>Pharmaceutics</i> , 2023, 15, 946.	2.0	2
10478	Intrinsic RIG-I restrains STAT5 activation to modulate antitumor activity of CD8+ T cells. <i>Journal of Clinical Investigation</i> , 2023, 133, .	3.9	3
10479	Trends in Survival Rates of Non-Small Cell Lung Cancer With Use of Molecular Testing and Targeted Therapy in Korea, 2010-2020. <i>JAMA Network Open</i> , 2023, 6, e232002.	2.8	7
10480	Rheumatic Immune-Related Adverse Events due to Immune Checkpoint Inhibitors—A 2023 Update. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5643.	1.8	7
10481	Could S-1-based non-platinum doublet chemotherapy be a new option as a second-line treatment for advanced non-small cell lung cancer patients? A multicenter retrospective study. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
10482	Associations of immune checkpoint inhibitor therapy efficacy with clinical parameters and tumor-infiltrating CD68-positive cell counts in patients with EGFR-mutant non-small cell lung cancer. <i>Molecular and Clinical Oncology</i> , 2023, 18, .	0.4	1
10483	Efficacy of immunotherapy in oncogene-driven non-small-cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592311614.	1.4	8
10484	Sarcomatoid urothelial carcinoma of the renal pelvis treated with immunotherapy. <i>BMC Urology</i> , 2023, 23, .	0.6	3
10485	Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling T-cells, myeloid derived suppressor and NK cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2023, 42, .	3.5	4
10486	Peripheral lymphocyte fluctuation as an indicator of severe immune-related adverse events in patients treated with immune checkpoint inhibitors. <i>Cancer Medicine</i> , 2023, 12, 10636-10646.	1.3	3
10487	Theranostic applications of selenium nanomedicines against lung cancer. <i>Journal of Nanobiotechnology</i> , 2023, 21, .	4.2	10

#	ARTICLE	IF	CITATIONS
10488	The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	23
10489	Melanoma Brain Metastases: A Systematic Review of Opportunities for Earlier Detection, Diagnosis, and Treatment. <i>Life</i> , 2023, 13, 828.	1.1	3
10490	Immune Checkpoint Inhibitor Associated Myocarditis and Cardiomyopathy: A Translational Review. <i>Biology</i> , 2023, 12, 472.	1.3	2
10491	Current literature review on the tumor immune micro-environment, its heterogeneity and future perspectives in treatment of advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2023, .	1.3	1
10492	Immunotherapies for advanced hepatocellular carcinoma. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	4
10493	Long-Lasting Therapeutic Response following Treatment with Pembrolizumab in Patients with Non-Small Cell Lung Cancer: A Real-World Experience. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5938.	1.8	9
10494	Interactive process mining of cancer treatment sequences with melanoma real-world data. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
10495	Aging microenvironment and antitumor immunity for geriatric oncology: the landscape and future implications. <i>Journal of Hematology and Oncology</i> , 2023, 16, .	6.9	5
10496	Leptomeningeal Disease (LMD) in Patients with Melanoma Metastases. <i>Cancers</i> , 2023, 15, 1884.	1.7	4
10497	Nivolumab or Atezolizumab in the Second-Line Treatment of Advanced Non-Small Cell Lung Cancer? A Prognostic Index Based on Data from Daily Practice. <i>Journal of Clinical Medicine</i> , 2023, 12, 2409.	1.0	0
10498	FoxP3 Expression in Tumor-Infiltrating Lymphocytes as Potential Predictor of Response to Immune Checkpoint Inhibitors in Patients with Advanced Melanoma and Non-Small Cell Lung Cancer. <i>Cancers</i> , 2023, 15, 1901.	1.7	1
10499	Examination of the Functional Relationship between PD-L1 DNA Methylation and mRNA Expression in Non-Small-Cell Lung Cancer. <i>Cancers</i> , 2023, 15, 1909.	1.7	4
10500	Refining the Treatment of Pancreatic Cancer From Big Data to Improved Individual Survival. <i>Function</i> , 2023, 4, .	1.1	6
10501	Systemic LRG1 Expression in Melanoma is Associated with Disease Progression and Recurrence. <i>Cancer Research Communications</i> , 2023, 3, 672-683.	0.7	4
10502	Towards a consensus definition of immune exclusion in cancer. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	6
10503	Immune Checkpoint Inhibitors and the Kidney: A Focus on Diagnosis and Management for Personalised Medicine. <i>Cancers</i> , 2023, 15, 1891.	1.7	2
10504	Global trends in the health economics field of PD-1/PD-L1 inhibitors: A bibliometric and visualized study. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	1
10505	Immunotherapy combined with rh-endostatin improved clinical outcomes over immunotherapy plus chemotherapy for second-line treatment of advanced NSCLC. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	2

#	ARTICLE	IF	CITATIONS
10506	Tumors evade immune cytotoxicity by altering the surface topology of NK cells. <i>Nature Immunology</i> , 2023, 24, 802-813.	7.0	17
10507	The Gut Microbiome and Pancreatic Cancer Development and Treatment. <i>Cancer Journal (Sudbury, Tj ETQq1 1 0.784314 rgBT /Overload</i>	1.0	3
10508	Prioritizing exhausted T cell marker genes highlights immune subtypes in pan-cancer. <i>IScience</i> , 2023, 26, 106484.	1.9	1
10509	Onionin A inhibits small-cell lung cancer proliferation through suppressing STAT3 activation induced by macrophages-derived IL-6 and cell-cell interaction with tumor-associated macrophage. <i>Human Cell</i> , 2023, 36, 1068-1080.	1.2	2
10510	Immune profiles according to EGFR mutant subtypes and correlation with PD-1/PD-L1 inhibitor therapies in lung adenocarcinoma. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
10511	Tumor intrinsic and extrinsic functions of CD73 and the adenosine pathway in lung cancer. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
10512	Application status and future prospects of the PDX model in lung cancer. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	3
10513	Ganglioglioma deep transcriptomics reveals primitive neuroectoderm neural precursor-like population. <i>Acta Neuropathologica Communications</i> , 2023, 11, .	2.4	0
10514	Clinicopathological classification of immune checkpoint inhibitor-associated myocarditis: possible refinement by measuring macrophage abundance. <i>Cardio-Oncology</i> , 2023, 9, .	0.8	1
10515	Immunogenicity in renal cell carcinoma: shifting focus to alternative sources of tumour-specific antigens. <i>Nature Reviews Nephrology</i> , 2023, 19, 440-450.	4.1	4
10516	A phase I prospective, non-randomized trial of autologous dendritic cell-based cryoimmunotherapy in patients with metastatic castration-resistant prostate cancer. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 2357-2373.	2.0	3
10517	Deep-learning-based survival prediction of patients with cutaneous malignant melanoma. <i>Frontiers in Medicine</i> , 0, 10, .	1.2	3
10518	Rheumatic Diseases Development in Patients Treated by Anti-PD1 Immune Checkpoint Inhibitors: A Single-Centre Descriptive Study. <i>Life</i> , 2023, 13, 877.	1.1	3
10519	Infectious Complications of Targeted Therapies for Solid Cancers or Leukemias/Lymphomas. <i>Cancers</i> , 2023, 15, 1989.	1.7	2
10520	Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Strategies and Biomarkers Predicting Response and/or Resistance. <i>Biomedicines</i> , 2023, 11, 1020.	1.4	6
10521	Neoadjuvant Immunotherapy for Head and Neck Squamous Cell Carcinoma: Expecting Its Application in Temporal Bone Squamous Cell Carcinoma. <i>Current Medical Science</i> , 2023, 43, 213-222.	0.7	2
10522	Efficacy and outcome of extensive intraoperative peritoneal lavage plus surgery <i>vs</i> surgery alone with advanced gastric cancer patients. <i>World Journal of Gastrointestinal Surgery</i> , 0, 15, 430-439.	0.8	2
10523	Radiomics and Delta-Radiomics Signatures to Predict Response and Survival in Patients with Non-Small-Cell Lung Cancer Treated with Immune Checkpoint Inhibitors. <i>Cancers</i> , 2023, 15, 1968.	1.7	7

#	ARTICLE	IF	CITATIONS
10524	Low-Dose Immunotherapy: Is It Just an Illusion?. <i>Biomedicines</i> , 2023, 11, 1032.	1.4	1
10525	APC mutation correlated with poor response of immunotherapy in colon cancer. <i>BMC Gastroenterology</i> , 2023, 23, .	0.8	1
10526	Immunogenic hypofractionated radiotherapy sensitising head and neck squamous cell carcinoma to anti-PD-L1 therapy in MDSC-dependent manner. <i>British Journal of Cancer</i> , 2023, 128, 2126-2139.	2.9	5
10527	LRP1B mutation is associated with tumor immune microenvironment and progression-free survival in lung adenocarcinoma treated with immune checkpoint inhibitors. <i>Translational Lung Cancer Research</i> , 2023, 12, 510-529.	1.3	2
10528	Immunotherapy efficacy predictive tool for lung adenocarcinoma based on neural network. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
10529	Oncogenic epidermal growth factor receptor signal-induced histone deacetylation suppresses chemokine gene expression in human lung adenocarcinoma. <i>Scientific Reports</i> , 2023, 13, .	1.6	1
10530	Association between response to anti-PD-1 treatment and blood soluble PD-L1 and IL-8 changes in patients with NSCLC. <i>Discover Oncology</i> , 2023, 14, .	0.8	2
10531	Chemotherapy in Cutaneous Melanoma: Is There Still a Role?. <i>Current Oncology Reports</i> , 2023, 25, 609-621.	1.8	8
10532	Peripheral PD-1 and Tim-3 percentages are associated with primary sites and pathological types of peritoneal neoplasms. <i>BMC Cancer</i> , 2023, 23, .	1.1	2
10533	Pancreatic Ductal Adenocarcinoma and Immune Checkpoint Inhibitors: The Gray Curtain of Immunotherapy and Spikes of Lights. <i>Current Oncology</i> , 2023, 30, 3871-3885.	0.9	4
10534	7,8-Dihydroxyflavone induces mitochondrial apoptosis and down-regulates the expression of ganglioside GD3 in malignant melanoma cells. <i>Discover Oncology</i> , 2023, 14, .	0.8	1
10535	RNF31 promotes tumorigenesis via inhibiting RIPK1 kinase-dependent apoptosis. <i>Oncogene</i> , 0, , .	2.6	1
10536	Sequencing Targeted and Immune Therapy in BRAF-Mutant Melanoma: Lessons Learned. <i>Current Oncology Reports</i> , 2023, 25, 623-634.	1.8	3
10537	Hyperprogressive disease after immune checkpoint inhibitor therapy in a patient with non-small cell lung cancer who harbors a TGFBR2 mutation: A case report. <i>Experimental and Therapeutic Medicine</i> , 2023, 25, .	0.8	4
10538	Liquid biopsy on the horizon in immunotherapy of non-small cell lung cancer: current status, challenges, and perspectives. <i>Cell Death and Disease</i> , 2023, 14, .	2.7	14
10539	Kidney Adverse Events Associated with Immune Checkpoint Inhibitor Therapy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2023, 18, 843-849.	2.2	3
10540	Biomarkers predicting clinical outcomes in nasopharyngeal cancer patients receiving immune checkpoint inhibitors: A systematic review and meta-analysis. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
10541	Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice. <i>BMC Gastroenterology</i> , 2023, 23, .	0.8	0

#	ARTICLE	IF	CITATIONS
10542	The Role of the Gut Microbiome in Cancer Immunotherapy: Current Knowledge and Future Directions. <i>Cancers</i> , 2023, 15, 2101.	1.7	3
10543	Engineering of a Bispecific Nanofitin with Immune Checkpoint Inhibitory Activity Conditioned by the Cross-Arm Binding to EGFR and PDL1. <i>Biomolecules</i> , 2023, 13, 636.	1.8	1
10544	Spending, Utilization, and Price Trends for Immune Checkpoint Inhibitors in US Medicaid Programs: An Empirical Analysis from 2011 to 2021. <i>Clinical Drug Investigation</i> , 2023, 43, 289-298.	1.1	5
10545	High expression of Talin-1 is associated with tumor progression and recurrence in melanoma skin cancer patients. <i>BMC Cancer</i> , 2023, 23, .	1.1	1
10546	The Latest Option: Nivolumab and Relatlimab in Advanced Melanoma. <i>Current Oncology Reports</i> , 2023, 25, 647-657.	1.8	7
10547	Potential therapeutic effects of Chinese materia medica in mitigating drug-induced acute kidney injury. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	1
10548	Immune checkpoint inhibitor-associated acute kidney injury in patients with cancer: a systematic review and meta-analysis of risk factors. <i>Clinical and Experimental Nephrology</i> , 2023, 27, 603-612.	0.7	2
10549	Newly developed 3D in vitro models to study tumor-immune interaction. <i>Journal of Experimental and Clinical Cancer Research</i> , 2023, 42, .	3.5	11
10550	Drug target therapy and emerging clinical relevance of exosomes in meningeal tumors. <i>Molecular and Cellular Biochemistry</i> , 2024, 479, 127-170.	1.4	1
10551	Integrative analysis of a novel super-enhancer-associated lncRNA prognostic signature and identifying LINC00945 in aggravating glioma progression. <i>Human Genomics</i> , 2023, 17, .	1.4	1
10552	Machine learning-based construction of immunogenic cell death-related score for improving prognosis and response to immunotherapy in melanoma. <i>Aging</i> , 2023, 15, 2667-2688.	1.4	2
10553	Immunotherapy resistance in non-small-cell lung cancer: From mechanism to clinical strategies. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	8
10554	Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer. <i>Nature Genetics</i> , 2023, 55, 807-819.	9.4	18
10555	Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG. , 2023, 11, e005828.		3
10556	The influence of antibody CD166 on the treatment of tumor and the immunological mechanism in mice bearing oral squamous cell carcinoma. <i>Translational Cancer Research</i> , 2023, .	0.4	0
10558	Promising Therapeutic Impact of Immune Checkpoint Inhibitors in Type II Endometrial Cancer Patients with Deficient Mismatch Repair Status. <i>Healthcare (Switzerland)</i> , 2023, 11, 1073.	1.0	0
10559	Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired. <i>Cancer Cell International</i> , 2023, 23, .	1.8	24
10560	Autoimmunity and Carcinogenesis: Their Relationship under the Umbrella of Autophagy. <i>Biomedicines</i> , 2023, 11, 1130.	1.4	3

#	ARTICLE	IF	CITATIONS
10561	Navigating approval pathways for immunotherapy in NSCLC: should criteria be revised?. <i>Nature Reviews Clinical Oncology</i> , 0, , .	12.5	0
10562	Recent Advancement of PD-L1 Detection Technologies and Clinical Applications in the Era of Precision Cancer Therapy. <i>Journal of Cancer</i> , 2023, 14, 850-873.	1.2	5
10563	Involvement of the kynurenine pathway in breast cancer: updates on clinical research and trials. <i>British Journal of Cancer</i> , 2023, 129, 185-203.	2.9	6
10564	Cuproptosis-related molecular subtypes direct T cell exhaustion phenotypes and therapeutic strategies for patients with lung adenocarcinoma. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	2
10565	Prognostic effect of cachexia in patients with non-small cell lung cancer receiving immune checkpoint inhibitors. <i>Thoracic Cancer</i> , 2023, 14, 1362-1367.	0.8	6
10566	Monoclonal antibodies for the treatment of squamous cell carcinoma: A literature review. <i>Cancer Reports</i> , 2023, 6, .	0.6	4
10567	Cross-platform comparison of immune signatures in immunotherapy-treated patients with advanced melanoma using a rank-based scoring approach. <i>Journal of Translational Medicine</i> , 2023, 21, .	1.8	1
10568	Interaction between Radiation Therapy and Targeted Therapies in HER2-Positive Breast Cancer: Literature Review, Levels of Evidence for Safety and Recommendations for Optimal Treatment Sequence. <i>Cancers</i> , 2023, 15, 2278.	1.7	7
10569	Current Progress on Predictive Biomarkers for Response to Immune Checkpoint Inhibitors in Gastric Cancer: How to Maximize the Immunotherapeutic Benefit?. <i>Cancers</i> , 2023, 15, 2273.	1.7	2
10570	Sintilimab Plus Modified FOLFIRINOX in Metastatic or Recurrent Pancreatic Cancer: The Randomized Phase II CISP3 Trial. <i>Annals of Surgical Oncology</i> , 2023, 30, 5071-5080.	0.7	3
10571	Inflammatory Cells Can Alter the Levels of H3K9ac and H2AX in Dysplastic Cells and Favor Tumor Phenotype. <i>Journal of Personalized Medicine</i> , 2023, 13, 662.	1.1	1
10572	Novel strategies for cancer immunotherapy: counter-immunoediting therapy. <i>Journal of Hematology and Oncology</i> , 2023, 16, .	6.9	14
10573	Predictive biomarkers of immunotherapy response with pharmacological applications in solid tumors. <i>Acta Pharmacologica Sinica</i> , 2023, 44, 1879-1889.	2.8	15
10574	CircSCUBE3 Reduces the Anti-gastric Cancer Activity of Anti-PD-L1. <i>Molecular Biotechnology</i> , 2024, 66, 123-137.	1.3	1
10575	Malignancy diseases and kidneys: A nephrologist prospect and updated review. <i>Medicine (United Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50</i>	0.4	2
10576	Cardiotoxicity of lung cancer-related immunotherapy versus chemotherapy: a systematic review and network meta-analysis of randomized controlled trials. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
10577	HIF1 α -dependent and independent pathways regulate the expression of PD-L1 in prostate cancer. , 2023, 40, .		1
10578	Enhanced anti-tumor efficacy through a combination of intramuscularly expressed DNA vaccine and plasmid-encoded PD-1 antibody. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1

#	ARTICLE	IF	CITATIONS
10579	Clinical Relevance of Targeted Therapy and Immune-Checkpoint Inhibition in Lung Cancer. <i>Pharmaceutics</i> , 2023, 15, 1252.	2.0	7
10580	Immunomodulators for Non-Melanoma Skin Cancers: Updated Perspectives. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 0, Volume 16, 1025-1045.	0.8	0
10581	Amyloidoses in Onco-Nephrology Practice: A Multidisciplinary Case-Based Conference Report. <i>Canadian Journal of Kidney Health and Disease</i> , 2023, 10, 205435812311657.	0.6	0
10582	A review of recent advances in the novel therapeutic targets and immunotherapy for lung cancer. , 2023, 40, .		4
10583	Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancer. <i>Nature Communications</i> , 2023, 14, .	5.8	8
10584	Intratumoral tertiary lymphoid structure (TLS) maturation is influenced by draining lymph nodes of lung cancer. , 2023, 11, e005539.		7
10585	Improving Selection for Sentinel Lymph Node Biopsy Among Patients With Melanoma. <i>JAMA Network Open</i> , 2023, 6, e236356.	2.8	3
10586	Mortality associated with the development of acute liver failure after a single dose of nivolumab. <i>Clinical Journal of Gastroenterology</i> , 0, , .	0.4	1
10587	Regression and Eradication of Triple-Negative Breast Carcinoma in 4T1 Mouse Model by Combination Immunotherapies. <i>Cancers</i> , 2023, 15, 2366.	1.7	3
10588	A perspective of immunotherapy for acute myeloid leukemia: Current advances and challenges. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	0
10589	Tumor Area Positivity (TAP) score of programmed death-ligand 1 (PD-L1): a novel visual estimation method for combined tumor cell and immune cell scoring. <i>Diagnostic Pathology</i> , 2023, 18, .	0.9	3
10590	Drawbacks of immune checkpoint inhibition and rigorous management for immune-related adverse events along with a mathematical model to assess therapy success and optimum therapy duration and a strategy against tumor plasticity. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	0
10591	Correlation of preclinical and clinical biomarkers with efficacy and toxicity of cancer immunotherapy. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592311638.	1.4	0
10592	Sema4D silencing increases the sensitivity of nivolumab to B16-F10 resistant melanoma via inhibiting the PI3K/AKT signaling pathway. <i>PeerJ</i> , 0, 11, e15172.	0.9	1
10593	CodeBreak 200: Sotorasib (AMG510) Has Broken the KRAS G12C+ NSCLC Enigma Code. <i>Lung Cancer: Targets and Therapy</i> , 0, Volume 14, 31-39.	1.3	0
10594	Immunotherapy in glioblastoma treatment: Current state and future prospects. <i>World Journal of Clinical Oncology</i> , 0, 14, 138-159.	0.9	13
10595	High VISTA expression is linked to a potent epithelial-mesenchymal transition and is positively correlated with PD1 in breast cancer. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	2
10596	A bibliometric and visualized research on global trends of immune checkpoint inhibitors related complications in melanoma, 2011â€“2021. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	0

#	ARTICLE	IF	CITATIONS
10597	TIGIT in Lung Cancer: Potential Theranostic Implications. <i>Life</i> , 2023, 13, 1050.	1.1	0
10598	Anti-PD-1 therapy achieves favorable outcomes in HBV-positive non-liver cancer. <i>Oncogenesis</i> , 2023, 12, .	2.1	1
10599	Prognostic and Predictive Biomarkers in the Era of Immunotherapy for Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7577.	1.8	2
10600	Regulation of early diagnosis and prognostic markers of lung adenocarcinoma in immunity and hypoxia. <i>Scientific Reports</i> , 2023, 13, .	1.6	1
10601	Operative management of immune checkpoint colitis following in-transit melanoma: Case report. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1
10602	Exome-Based Genomic Markers Could Improve Prediction of Checkpoint Inhibitor Efficacy Independently of Tumor Type. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7592.	1.8	1
10603	Tumor-infiltrating CD36+CD8+T cells determine exhausted tumor microenvironment and correlate with inferior response to chemotherapy in non-small cell lung cancer. <i>BMC Cancer</i> , 2023, 23, .	1.1	2
10604	Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database. <i>EClinicalMedicine</i> , 2023, 59, 101967.	3.2	11
10605	Baseline neutrophil-to- ratio combined with the change during treatment provides risk stratification for metastatic malignant melanoma patients treated with PD-1 inhibitors in a Chinese population. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1
10606	The abscopal effect: inducing immunogenicity in the treatment of brain metastases secondary to lung cancer and melanoma. <i>Journal of Neuro-Oncology</i> , 2023, 163, 1-14.	1.4	2
10607	Could Inhibiting the DNA Damage Repair Checkpoint Rescue Immune-Checkpoint-Inhibitor-Resistant Endometrial Cancer?. <i>Journal of Clinical Medicine</i> , 2023, 12, 3014.	1.0	0
10608	Comparison Between Simultaneous and Sequential Utilization of Safety and Efficacy for Optimal Dose Determination in Bayesian Model-Assisted Designs. <i>Therapeutic Innovation and Regulatory Science</i> , 0, , .	0.8	0
10609	Evaluating the effect of PD-1 inhibitors on left ventricular function in lung cancer with noninvasive myocardial work. <i>Quantitative Imaging in Medicine and Surgery</i> , 2023, .	1.1	1
10610	Single-cell analysis of immune cells on gingiva-derived mesenchymal stem cells in experimental autoimmune uveitis. <i>IScience</i> , 2023, 26, 106729.	1.9	3
10611	Therapeutic potential of tucidinostat, a subtype-selective HDAC inhibitor, in cancer treatment. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	15
10631	Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma. <i>Nature Reviews Clinical Oncology</i> , 2023, 20, 408-422.	12.5	9
10643	Safety, Regulation and Clinical Translation. , 2023, , 265-284.		0
10645	Development of pauci-immune necrotizing glomerulonephritis during pembrolizumab treatment. <i>Clinical and Experimental Nephrology</i> , 0, , .	0.7	0

#	ARTICLE	IF	CITATIONS
10649	Immune Checkpoint Inhibition. , 2024, , 1-91.		0